Androgen B-CHEMICAL
antagonistic O
effect O
of O
estramustine B-CHEMICAL
phosphate I-CHEMICAL
(EMP) B-CHEMICAL
metabolites O
on O
wild-type O
and O
mutated O
androgen B-GENE-Y
receptor. I-GENE-Y
Estramustine B-CHEMICAL
phosphate I-CHEMICAL
is O
used O
frequently, O
alone O
or O
in O
combination O
with O
other O
antitumor O
agents, O
for O
the O
treatment O
of O
hormone-refractory O
prostate O
cancer. O
Estramustine B-CHEMICAL
phosphate I-CHEMICAL
is O
metabolically O
activated O
in O
vivo, O
and O
its O
metabolites, O
estramustine, B-CHEMICAL
estromustine, B-CHEMICAL
estrone, B-CHEMICAL
and O
beta-estradiol B-CHEMICAL
inhibit O
the O
assembly O
of O
microtubules O
[for O
review O
see: O
Kreis O
W, O
In: O
Concepts, O

Mechanisms, O
and O
New O
Targets O
for O
Chemotherapy O
(Ed. O
Muggia O
FM), O
pp. O
163-184. O
Kluwer O
Academic O
Publishers, O
Boston, O
1995]. O
We O
investigated, O
by O
displacement O
of O
[3H]methyltrienolone B-CHEMICAL
in O
the O
presence O
of O
2.5 O
mM O
of O
triamcinolone B-CHEMICAL
acetonide, I-CHEMICAL
the O
binding O
of O
estramustine B-CHEMICAL
phosphate I-CHEMICAL
and O
its O
metabolites, O
estramustine, B-CHEMICAL
estromustine, B-CHEMICAL
estrone, B-CHEMICAL
and O
beta-estradiol, B-CHEMICAL
as O
well O
as O
other O
antiandrogen O
agents O
including O
alpha-estradiol, B-CHEMICAL

bicalutamide, B-CHEMICAL
and O
hydroxyflutamide, B-CHEMICAL
to O
the O
mutated O
androgen B-GENE-Y
receptor I-GENE-Y
(m-AR) B-GENE-Y
in O
LNCaP O
cells O
and O
to O
the O
wild-type O
androgen B-GENE-Y
receptor I-GENE-Y
in O
wild-type O
AR B-GENE-Y
cDNA O
expression O
plasmid O
(w-pAR0) O
cDNA-transfected O
HeLa O
cells. O
Analogous O
to O
the O
antiandrogens, O
bicalutamide B-CHEMICAL
and O
hydroxyflutamide, B-CHEMICAL
binding O
of O
estramustine B-CHEMICAL
phosphate I-CHEMICAL
metabolites O
to O
the O
androgen B-CHEMICAL
receptor I-GENE-Y
was O
observed. O
The O
EC50 O
values O
(in O
microM) O

were: O
estramustine B-CHEMICAL
phosphate, I-CHEMICAL
> O
10; O
estramustine, B-CHEMICAL
3.129 O
+/- O
0.312; O
estromustine; B-CHEMICAL
2.612 O
+/- O
0.584; O
estrone, B-CHEMICAL
0.800 O
+/- O
0.090; O
alpha-estradiol, B-CHEMICAL
1.051 O
+/- O
0.096; O
beta-estradiol, B-CHEMICAL
0.523 O
+/- O
0.028; O
bicalutamide, B-CHEMICAL
4.920 O
+/- O
0.361; O
and O
hydroxyflutamide, B-CHEMICAL
0.254 O
+/- O

0.012. O
The O
transactivation O
assay O
demonstrated O
that, O
analogous O
to O
bicalutamide, B-CHEMICAL
estramustine B-CHEMICAL
could O
not O
induce O
luciferase O
activity O
in O
either O
w-pAR0 O
or O
m-pARL O
transfected O
HeLa O
cells. O
In O
contrast, O
a O
strong O
induction O
of O
the O
reporter O
activity O
by O
dihydrotestosterone B-CHEMICAL
was O
observed. O
Down-regulation O
of O
prostate-specific B-GENE-Y
antigen I-GENE-Y
(PSA) B-GENE-Y
expression, O
an O
AR-target B-GENE-Y
gene, O
by O
estramustine B-CHEMICAL
and O
bicalutamide B-CHEMICAL
was O
accompanied O
by O
the O
blockade O
of O
the O
mutated O
androgen B-GENE-Y
receptor. I-GENE-Y
Exposure O
of O

LNCaP O
cells O
to O
estramustine B-CHEMICAL
for O
24 O
hr O
caused O
transcriptional O
inhibition O
of O
PSA B-GENE-Y
in O
a O
concentration-dependent O
manner. O
The O
levels O
of O
PSA B-GENE-Y
mRNA O
decreased O
56 O
and O
90% O
when O
LNCaP O
cells O
were O
treated O
with O
5 O
and O
10 O
microM O
of O
estramustine, B-CHEMICAL
respectively O
(IC50 O
= O
10.97 O
+/- O
1.68 O
microM). O
Binding O
of O
hydroxyflutamide B-CHEMICAL
to O
m-AR B-GENE-Y
in O
LNCaP O
cells O
resulted O
in O
a O
concentration-dependent O
stimulation O
of O
PSA B-GENE-Y
expression, O
suggesting O
that O
hydroxyflutamide B-CHEMICAL
acted O
as O
an O
agonist O

of O
the O
m-AR. B-GENE-Y
Our O
data O
indicate O
that O
estramustine B-CHEMICAL
phosphate I-CHEMICAL
metabolites O
perform O
as O
androgen B-CHEMICAL
antagonists O
of O
AR, B-GENE-Y
an O
additional O
mechanism O
involved O
in O
the O
therapeutic O
effect O
of O
estramustine B-CHEMICAL
phosphate I-CHEMICAL
in O
patients O
with O
prostate O
cancer. O
Static O
Laue O
diffraction O
studies O
on O
acetylcholinesterase. B-GENE-Y
Acetylcholinesterase B-GENE-Y
(AChE) B-GENE-Y
is O
one O
of O
nature's O
fastest O
enzymes, O
despite O
the O
fact O
that O
its O
three-dimensional O
structure O
reveals O
its O
active O
site O
to O
be O
deeply O
sequestered O
within O
the O
molecule. O
This O
raises O
questions O
with O
respect O
to O
traffic O
of O
substrate O
to, O
and O
products O
from, O
the O
active O

site, O
which O
may O
be O
investigated O
by O
time-resolved O
crystallography. O
In O
order O
to O
address O
one O
aspect O
of O
the O
feasibility O
of O
performing O
time-resolved O
studies O
on O
AChE, B-GENE-Y
a O
data O
set O
has O
been O
collected O
using O
the O
Laue O
technique O
on O
a O
trigonal O
crystal O
of O
Torpedo B-GENE-Y
californica I-GENE-Y
AChE I-GENE-Y
soaked O
with O
the O
reversible O
inhibitor O
edrophonium, B-CHEMICAL
using O
a O
total O
X-ray O
exposure O
time O
of O
24 O
ms. O
Electron-density O
maps O
obtained O
from O
the O
Laue O
data, O
which O
are O
of O
surprisingly O
good O
quality O
compared O
with O
similar O
maps O
from O
monochromatic O
data, O
show O
essentially O
the O
same O
features. O
They O
clearly O

reveal O
the O
bound O
ligand, O
as O
well O
as O
a O
structural O
change O
in O
the O
conformation O
of O
the O
active-site O
Ser200 O
induced O
upon O
binding. O
Synthesis O
of O
thrombin-inhibiting B-GENE-Y
heparin O
mimetics O
without O
side O
effects. O
Unwanted O
side O
effects O
of O
pharmacologically O
active O
compounds O
can O
usually O
be O
eliminated O
by O
structural O
modifications. O
But O
the O
complex O
heterogeneous O
structure O
of O
the O
polysaccharide O
heparin O
has O
limited O
this O
approach O
to O
fragmentation, O
leading O
to O
slightly O
better-tolerated O
heparin O
preparations O
of O
low O
molecular O
mass. O
Despite O
this O
improvement, O
heparin-induced O

thrombocytopaenia O
(HIT), O
related O
to O
an O
interaction O
with O
platelet B-GENE-Y
factor I-GENE-Y
4 I-GENE-Y
(PF4) B-GENE-Y
and, O
to O
a O
lesser O
extent, O
haemorrhages, O
remain O
significant O
side O
effects O
of O
heparinotherapy. O
Breakthroughs O
in O
oligosaccharide O
chemistry O
made O
possible O
the O
total O
synthesis O
of O
the O
pentasaccharide O
antithrombin-binding B-GENE-Y
site O
of O
heparin. O
This O
pentasaccharide O
represents O
a O
new O
family O
of O
potential O
antithrombotic O
drugs, O
devoid O
of O
thrombin B-GENE-Y
inhibitory O
properties, O
and O
free O
of O
undesired O
interactions O
with O
blood O
and O

vessel O
components. O
To O
obtain O
more O
potent O
and O
well-tolerated O
antithrombotic O
drugs, O
we O
wished O
to O
synthesize O
heparin O
mimetics O
able O
to O
inhibit O
thrombin, B-GENE-Y
that O
is, O
longer O
oligosaccharides. O
Like O
thrombin B-GENE-Y
inhibition, O
undesired O
interactions O
are O
directly O
correlated O
to O
the O
charge O
and O
the O
size O
of O
the O
molecules, O
so O
we O
had O
to O
design O
structures O
that O
were O
able O
to O
discriminate O
between O
thrombin B-GENE-Y
and O
other O
proteins, O
particularly O
PF4. B-GENE-Y
Here O
we O
describe O
the O
use O
of O
multistep O
converging O
synthesis O
to O
obtain O
sulphated O

oligosaccharides O
that O
meet O
these O
requirements. O
Selective O
inhibition O
of O
cyclooxygenase B-GENE-Y
2 I-GENE-Y
spares O
renal O
function O
and O
prostaglandin B-CHEMICAL
synthesis O
in O
cirrhotic O
rats O
with O
ascites. O
BACKGROUND O
& O
AIMS: O
The O
critical O
role O
of O
cyclooxygenase B-GENE-N
(COX) B-GENE-N
products O
in O
maintenance O
of O
renal O
function O
in O
cirrhosis O
with O
ascites O
discourages O
the O
use O
of O
nonsteroidal O
anti-inflammatory O
drugs O
in O
this O
disease. O
The O
recent O
development O
of O
selective O
COX-2 B-GENE-Y
inhibitors O
opens O
new O

avenues O
for O
the O
use O
of O
these O
compounds O
in O
decompensated O
cirrhosis. O
The O
current O
study O
evaluates O
the O
effects O
of O
a O
selective O
COX-2 B-GENE-Y
inhibitor O
(SC-236) B-CHEMICAL
on O
renal O
function O
in O
cirrhotic O
rats O
with O
ascites. O
METHODS: O
In O
protocol O
1, O
urine O
volume, O
urinary O
excretion O
of O
sodium B-CHEMICAL
and O
prostaglandins, B-CHEMICAL
glomerular O
filtration O
rate, O
and O
renal O
plasma O
flow O
were O
measured O
before O
and O
after O
administration O
of O
SC-236 B-CHEMICAL
(n O
= O
12) O
or O
ketorolac B-CHEMICAL
(n O
= O
10) O
to O
rats O
with O

cirrhosis. O
Protocol O
2 O
was O
aimed O
at O
assessing O
the O
effects O
of O
COX B-GENE-N
inhibitors O
on O
renal O
water O
metabolism O
in O
28 O
cirrhotic O
rats. O
RESULTS: O
Administration O
of O
SC-236 B-CHEMICAL
to O
cirrhotic O
animals O
did O
not O
produce O
significant O
renal O
effects, O
whereas O
administration O
of O
the O
nonselective O
COX-1/COX-2 B-GENE-Y
inhibitor, O
ketorolac, B-CHEMICAL
resulted O
in O
a O
marked O
reduction O
in O
urine O
volume, O
urinary O
excretion O
of O
prostaglandins, B-CHEMICAL
and O
glomerular O
filtration O
rate O
and O
in O
a O
significant O
impairment O
in O
renal O
water O
metabolism. O

CONCLUSIONS: O
These O
findings O
indicate O
that O
SC-236 B-CHEMICAL
does O
not O
significantly O
impair O
renal O
function O
in O
rats O
with O
cirrhosis. O
Inhibition O
of O
cPLA2 B-GENE-Y
translocation O
and O
leukotriene B-CHEMICAL
C4 I-CHEMICAL
secretion O
by O
fluticasone B-CHEMICAL
propionate I-CHEMICAL
in O
exogenously O
activated O
human O
eosinophils. O
We O
examined O
the O
effect O
of O
the O
highly O
lipophilic O
corticosteroid, O
fluticasone B-CHEMICAL
propionate I-CHEMICAL
(FP), B-CHEMICAL
in O
causing O
(1) O
inhibition O
of O
nuclear O
translocation O
of O
cytosolic B-GENE-Y
phospholipase I-GENE-Y
A2 I-GENE-Y

(cPLA2), B-GENE-Y
and O
(2) O
blockade O
of O
leukotriene B-CHEMICAL
C4 I-CHEMICAL
(LTC4) B-CHEMICAL
synthesis O
in O
isolated O
human O
eosinophils O
in O
vitro. O
Eosinophils O
were O
isolated O
from O
peripheral O
blood, O
treated O
with O
either O
buffer O
or O
10(-)10 O
M O
to O
10(-)6 O
M O
FP B-CHEMICAL
in O
the O
presence O
of O
10 O
pg/ml O
human B-GENE-Y
recombinant I-GENE-Y
interleukin-5 I-GENE-Y
(rhIL-5) B-GENE-Y
and O
activated O
with O
formyl-met-leu-phe B-CHEMICAL
(FMLP) B-CHEMICAL
+ O
cytochalasin B-CHEMICAL
B I-CHEMICAL
(CB). B-CHEMICAL

At O
24 O
h, O
stimulated O
LTC4 B-CHEMICAL
secretion O
from O
eosinophils O
was O
unchanged; O
however, O
when O
corrected O
for O
cell O
viability, O
LTC4 B-CHEMICAL
secretion O
decreased O
from O
1,429 O
+/- O
327 O
pg/10(6) O
cells O
to O
762 O
+/- O
113 O
pg/10(6) O
cells O
for O
eosinophils O
treated O
for O
48 O
h O
with O
>/= O
10(-)8 O
M O
FP B-CHEMICAL
(p O
< O
0.003). O
FMLP/CB-stimulated B-CHEMICAL
translocation O
of O
cPLA2 B-GENE-Y
to O
the O
nuclear O
envelope O
assessed O
by O
specific O
immunohistochemical O

staining O
also O
was O
blocked O
by O
FP. B-CHEMICAL
By O
contrast, O
membrane O
expression O
of O
annexin-1, B-GENE-Y
which O
was O
not O
minimal O
at O
30 O
min, O
was O
substantial O
at O
48 O
h O
for O
eosinophils O
treated O
with O
> O
10(-)10 O
M O
FP, B-CHEMICAL
and O
inhibition O
of O
LTC4 B-CHEMICAL
synthesis O
was O
reversed O
by O
exogenous O
arachidonic B-CHEMICAL
acid I-CHEMICAL
(AA). B-CHEMICAL
We O
find O
that O
FP B-CHEMICAL
causes O
a O
decrease O
in O
stimulated O
eosinophil O
secretion O
of O
LTC4 B-CHEMICAL
that O
is O
regulated O
by O
phospholipase B-GENE-Y
A2 I-GENE-Y
(PLA2). B-GENE-Y
Inhibition O
of O
LTC4 B-CHEMICAL
synthesis O
precedes O
the O

global O
cytotoxic O
effects O
of O
FP B-CHEMICAL
as O
indicated O
by O
the O
simultaneous O
upregulation O
of O
annexin-1 B-GENE-Y
expression. O
Inhibited O
stimulated O
secretion O
corresponds O
to O
inhibited O
translocation O
of O
cPLA2 B-GENE-Y
to O
the O
nuclear O
envelope O
during O
cellular O
activation. O
Desipramine B-CHEMICAL
treatment O
decreases O
3H-nisoxetine B-CHEMICAL
binding O
and O
norepinephrine B-CHEMICAL
transporter I-GENE-Y
mRNA O
in O
SK-N-SHSY5Y O
cells. O
The O
antidepressant O
desipramine B-CHEMICAL
has O
been O
shown O
to O
decrease O
synaptic O
membrane O
concentrations O
of O
the O
norepinephrine B-CHEMICAL
re-uptake I-GENE-Y
transporter I-GENE-Y
(NET) B-GENE-Y

in O
vivo O
and O
in O
vitro, O
on O
both O
an O
acute O
and O
a O
chronic O
basis. O
The O
possible O
contribution O
of O
decreased O
NET B-GENE-Y
synthesis O
to O
the O
chronic O
downregulation O
of O
the O
NETs B-GENE-Y
has O
not O
been O
definitively O
established. O
In O
this O
study, O
we O
treated O
SK-N-SHSY5Y O
cells O
with O
100 O
nM O
desipramine B-CHEMICAL
for O
24 O
or O
72 O
h, O
and O
measured O
3H-nisoxetine B-CHEMICAL
binding O
(as O
an O
estimate O
of O
NETs) B-GENE-Y
and O
NET B-GENE-Y
mRNA O
by O
quantitative O
reverse O
transcription O
polymerase O
chain O
reaction. O
Similar O
to O
what O
has O
been O
reported O
previously, O
membrane O
3H-nisoxetine B-CHEMICAL
binding O
was O

significantly O
decreased O
at O
both O
24 O
and O
72 O
h O
(approximately O
50% O
at O
both O
time O
points). O
However, O
a O
significant O
decrease O
(64 O
+/- O
8% O
of O
paired O
control) O
of O
NET B-GENE-Y
mRNA O
was O
observed O
only O
at O
the O
72-h O
time O
point. O
We O
conclude O
that O
decreased O
NET B-GENE-Y
synthesis O
may O
contribute O
to O
the O
chronic, O
but O
not O
acute, O
effect O
of O
desipramine B-CHEMICAL
to O
downregulate O
the O
NET. B-GENE-Y
Inhibition O
of O
the O
human B-GENE-Y
ether-a-go-go-related I-GENE-Y
gene I-GENE-Y
(HERG) I-GENE-Y
potassium I-GENE-Y
channel I-GENE-Y
by O
cisapride: B-CHEMICAL
affinity O
for O
open O
and O
inactivated O
states. O
1 O
Cisapride B-CHEMICAL
is O
a O

prokinetic O
agent O
which O
has O
been O
associated O
with O
QT O
prolongation, O
torsades O
de O
pointes O
and O
cardiac O
arrest. O
The O
cellular O
mechanism O
for O
these O
observations O
is O
high O
affinity O
blockade O
of O
IKr B-GENE-N
(encoded O
by O
HERG). B-GENE-Y
2 O
In O
a O
chronic O
transfection O
model O
using O
CHO-K1 O
cells, O
cisapride B-CHEMICAL
inhibited O
HERG B-GENE-Y
tail O
currents O
after O
a O
step O
to O
+25 O
mV O
with O
similar O
potency O
at O
room O
and O
physiological O
temperatures O
(IC50 O
16. O
4 O
nM O
at O
20-22 O
degrees O
C O
and O
23.6 O
nM O
at O
37 O
degrees O
C). O
3 O
Channel O
inhibition O
exhibited O

time-, O
voltage- O
and O
frequency-dependence. O
In O
an O
envelope O
of O
tails O
test, O
channel O
blockade O
increased O
from O
27+/-8% O
after O
a O
120 O
ms O
depolarizing O
step O
to O
50+/-4% O
after O
a O
1.0 O
s O
step. O
These O
findings O
suggested O
affinity O
for O
open O
and/or O
inactivated O
channel O
states. O
4 O
Inactivation O
was O
significantly O
accelerated O
by O
cisapride B-CHEMICAL
in O
a O
concentration-dependent O
manner O
and O
there O
was O
a O
small O
(-7 O
mV) O
shift O
in O
the O
voltage O
dependence O
of O
steady O
state O
inactivation. O
5 O
Channel O
blockade O
by O
cisapride B-CHEMICAL
was O
modulated O
by O
[K+]o, B-CHEMICAL
with O

a O
26% O
reduction O
in O
the O
potency O
of O
channel O
blockade O
when O
[K+]o B-CHEMICAL
was O
increased O
from O
1 O
to O
10 O
mM. O
6 O
In O
conclusion, O
HERG B-GENE-Y
channel O
inhibition O
by O
cisapride B-CHEMICAL
exhibits O
features O
consistent O
with O
open O
and O
inactivated O
state O
binding O
and O
is O
sensitive O
to O
external O
potassium B-CHEMICAL
concentration. O
These O
features O
may O
have O
significant O
clinical O
implications O
with O
regard O
to O
the O
mechanism O
and O
treatment O
of O
cisapride-induced B-CHEMICAL
proarrhythmia. O
Comparison O
of O
the O
novel O
antipsychotic O
ziprasidone B-CHEMICAL
with O
clozapine B-CHEMICAL
and O
olanzapine: B-CHEMICAL
inhibition O
of O
dorsal O
raphe O
cell O
firing O
and O
the O
role O
of O

5-HT1A B-GENE-Y
receptor I-GENE-Y
activation. O
Ziprasidone B-CHEMICAL
is O
a O
novel O
antipsychotic O
agent O
which O
binds O
with O
high O
affinity O
to O
5-HT1A B-GENE-Y
receptors I-GENE-Y
(Ki O
= O
3.4 O
nM), O
in O
addition O
to O
5-HT1D, B-GENE-Y
5-HT2, B-GENE-Y
and O
D2 B-GENE-Y
sites. O
While O
it O
is O
an O
antagonist O
at O
these O
latter O
receptors, O
ziprasidone B-CHEMICAL
behaves O
as O
a O
5-HT1A B-GENE-Y
agonist O
in O
vitro O
in O
adenylate B-GENE-N
cyclase I-GENE-N
measurements. O
The O
goal O
of O
the O
present O
study O
was O
to O
examine O
the O
5-HT1A B-GENE-Y
properties O
of O

ziprasidone B-CHEMICAL
in O
vivo O
using O
as O
a O
marker O
of O
central O
5-HT1A B-GENE-Y
activity O
the O
inhibition O
of O
firing O
of O
serotonin-containing B-CHEMICAL
neurons O
in O
the O
dorsal O
raphe O
nucleus. O
In O
anesthetized O
rats, O
ziprasidone B-CHEMICAL
dose-dependently O
slowed O
raphe O
unit O
activity O
(ED50 O
= O
300 O
micrograms/kg O
i.v.) O
as O
did O
the O
atypical O
antipsychotics O
clozapine B-CHEMICAL
(ED50 O
= O
250 O
micrograms/kg O
i.v.) O
and O
olanzapine B-CHEMICAL
(ED50 O
= O
1000 O
micrograms/kg O

i.v.). O
Pretreatment O
with O
the O
5-HT1A B-GENE-Y
antagonist O
WAY-100,635 B-CHEMICAL
(10 O
micrograms/kg O
i.v.) O
prevented O
the O
ziprasidone-induced B-CHEMICAL
inhibition; O
the O
same O
dose O
of O
WAY-100,635 B-CHEMICAL
had O
little O
effect O
on O
the O
inhibition O
produced O
by O
clozapine B-CHEMICAL
and O
olanzapine. B-CHEMICAL
Because O
all O
three O
agents O
also O
bind O
to O
alpha B-GENE-N
1 I-GENE-N
receptors, I-GENE-N
antagonists O
of O
which O
inhibit O
serotonin B-CHEMICAL
neuronal O
firing, O
this O
aspect O
of O
their O
pharmacology O
was O
assessed O
with O
desipramine B-CHEMICAL
(DMI), B-CHEMICAL

a O
NE B-CHEMICAL
re-uptake O
blocker O
previously O
shown O
to O
reverse O
the O
effects O
of O
alpha O
1 O
antagonists O
on O
raphe O
unit O
activity. O
DMI B-CHEMICAL
(5 O
mg/kg O
i.v.) O
failed O
to O
reverse O
the O
inhibitory O
effect O
of O
ziprasidone B-CHEMICAL
but O
produced O
nearly O
complete O
reversal O
of O
that O
of O
clozapine B-CHEMICAL
and O
olanzapine. B-CHEMICAL
These O
profiles O
suggest O
a O
mechanism O
of O
action O
for O
each O
agent, O
5-HT1A B-GENE-Y
agonism O
for O
ziprasidone B-CHEMICAL
and O
alpha O
1 O
antagonism O
for O
clozapine B-CHEMICAL
and O
olanzapine. B-CHEMICAL
The O
5-HT1A B-GENE-Y
agonist O
activity O
reported O
here O
clearly O
distinguishes O

ziprasidone B-CHEMICAL
from O
currently O
available O
antipsychotic O
agents O
and O
suggests O
that O
this O
property O
may O
play O
a O
significant O
role O
in O
its O
pharmacologic O
actions. O
Reduction O
of O
oral O
ethanol B-CHEMICAL
self-administration O
in O
rats O
by O
monoamine B-GENE-N
oxidase I-GENE-N
inhibitors. O
Evidence O
for O
a O
role O
of O
dopamine B-CHEMICAL
and O
serotonin B-CHEMICAL
in O
the O
control O
of O
ethanol B-CHEMICAL
intake O
in O
animals O
suggests O
that O
monoamine B-CHEMICAL
oxidase I-GENE-N
(MAO) B-GENE-N
inhibitors, O
which O
increase O
the O
synaptic O
availability O
of O
serotonin B-CHEMICAL
and O
dopamine B-CHEMICAL
by O
blocking O
their O
metabolism, O
might O
have O
efficacy O
in O
the O
treatment O
of O
alcohol B-CHEMICAL
dependence. O
The O
aim O
of O
the O

present O
study O
was, O
therefore, O
to O
evaluate O
several O
MAO B-GENE-N
inhibitors O
for O
their O
capacity O
to O
affect O
ethanol B-CHEMICAL
self-administration O
in O
rats O
trained O
to O
self-administer O
ethanol B-CHEMICAL
(10% O
v/v) O
orally O
in O
a O
free-choice O
two-lever O
operant O
task. O
The O
nonselective O
and O
irreversible O
MAO B-GENE-N
inhibitors, O
phenelzine B-CHEMICAL
(3-10 O
mg/kg), O
tranylcypromine B-CHEMICAL
(1-3 O
mg/kg), O
and O
nialamide B-CHEMICAL
(30 O
mg/kg), O
decreased O
rates O
of O
responding O
maintained O
by O
ethanol B-CHEMICAL
reinforcement. O
The O
reversible O
MAO-A B-GENE-Y
inhibitor, O

befloxatone B-CHEMICAL
(0.3-3 O
mg/kg), O
and O
the O
irreversible O
MAO-A B-GENE-Y
inhibitor, O
clorgyline B-CHEMICAL
(10-30 O
mg/kg), O
also O
reduced O
ethanol B-CHEMICAL
self-administration. O
However, O
befloxatone-induced B-CHEMICAL
effects O
leveled O
off O
at O
a O
50% O
decrease. O
The O
irreversible O
MAO-B B-GENE-Y
inhibitors, O
pargyline B-CHEMICAL
(30 O
mg/kg) O
and O
l-deprenyl B-CHEMICAL
(3-10 O
mg/kg) O
also O
decreased O
responding O
maintained O
by O
ethanol B-CHEMICAL
reinforcement; O
these O
results O
are O
consistent O
with O
previous O
findings O
that O
both O
drugs O
decreased O
ethanol B-CHEMICAL
intake O
in O
mice. O
In O

conclusion, O
the O
present O
results O
showing O
that O
several O
MAO B-GENE-N
inhibitors O
decreased O
ethanol B-CHEMICAL
self-administration O
in O
rats O
are O
consistent O
with O
previous O
findings O
that O
synaptic O
levels O
of O
serotonin B-CHEMICAL
and O
dopamine B-CHEMICAL
play O
a O
critical O
role O
in O
the O
control O
of O
ethanol B-CHEMICAL
self-administration. O
Decreased O
intracellular O
proteolysis O
correlates O
with O
the O
maintenance O
of O
a O
specific O
isoenzyme O
of O
cytochrome B-GENE-N
P-450. I-GENE-N
The O
rates O
of O
intracellular O
protein O
degradation, O
of O
identically O
labelled O
populations O
of O
proteins, O
were O
compared O
in O
hepatocytes O
cultured O
at O
37 O
degrees O
(on O
an O
adsorbed O
collagen O
layer) O
and O
in O
cells O

preserved O
on O
gelatin O
gels O
at O
10 O
degrees O
C. O
The O
half-lives O
of O
the O
long-lived O
proteins O
were O
35.4+/-8.6 O
h O
(N=4) O
and O
692.9+/-216.9 O
h O
(N=4) O
respectively. O
Proteolysis O
was O
substantially O
decreased O
at O
10 O
degrees O
C O
but O
the O
rate O
of O
decrease O
remained O
constant. O
Hepatocytes O
rapidly O
removed O
resorufin B-CHEMICAL
from O
the O
culture O
medium. O
The O
resorufin B-CHEMICAL
was O
not O
being O
conjugated O
or O
accumulated O
within O
the O
cells. O
Dicumarol, B-CHEMICAL
a O
potent O
inhibitor O
of O
quinone B-GENE-N

oxidoreductase, I-GENE-N
at O
high O
concentration O
(500 O
microm O
) O
caused O
only O
a O
72% O
decrease O
in O
the O
utilization O
of O
resorufin. B-CHEMICAL
The O
microsomal O
detoxifying O
enzyme, O
cytochrome B-GENE-Y
P-450 I-GENE-Y
1A1 I-GENE-Y
remained O
at O
a O
constant O
level O
in O
the O
preserved O
hepatocyte O
monolayers. O
The O
results O
of O
this O
study O
strongly O
favour O
storing O
hepatocytes O
at O
10 O
degrees O
C O
rather O
than O
at O
4 O
degrees O
or O
37 O
degrees O
C. O
A O
novel O
mutation O
of O
the O
erythroid-specific B-GENE-N
gamma-Aminolevulinate B-CHEMICAL
synthase I-GENE-N
gene O
in O
a O
patient O
with O
non-inherited O

pyridoxine-responsive B-CHEMICAL
sideroblastic O
anemia. O
A O
novel O
missense O
mutation, O
G663A, B-GENE-N
in O
exon O
5 O
of O
the O
erythroid-specific B-GENE-Y
delta-aminolevulinate B-CHEMICAL
synthase I-GENE-Y
gene O
(ALAS2) B-GENE-Y
was O
identified O
in O
a O
Japanese O
male O
with O
pyridoxine-responsive B-CHEMICAL
sideroblastic O
anemia. O
Activity O
of O
the O
mutant O
delta-aminolevulinate B-GENE-Y
synthase I-GENE-Y
protein O
expressed O
in O
vitro O
was O
15.1% O
compared O
with O
the O
normal O
control, O
but O
was O
increased O
up O
to O
34.5% O
by O
the O
addition O
of O

pyridoxal B-CHEMICAL
5'-phosphate, I-CHEMICAL
consistent O
with O
the O
clinical O
response O
of O
the O
patient O
to O
pyridoxine B-CHEMICAL
treatment. O
The O
same O
mutation O
was O
also O
detected O
in O
genomic O
DNa O
from O
the O
oral O
mucosal O
membrane O
of O
the O
patiet; O
however, O
it O
was O
not O
detected O
in O
other O
family O
member. O
These O
findings O
suggest O
that O
this O
G663A B-GENE-N
mutation O
is O
responsible O
for O
sideroblastic O
anemia O
in O
the O
proband, O
and O
may O
be O
an O
index O
mutation O
in O
this O
pedigree. O
Preferential O
cerebrospinal O
fluid O
acetylcholinesterase B-GENE-Y
inhibition O
by O
rivastigmine B-CHEMICAL
in O

humans. O
This O
study O
sought O
to O
examine O
the O
feasibility O
of O
prolonged O
assessment O
of O
acetylcholinesterase B-GENE-Y
(AChE) B-GENE-Y
activity O
in O
the O
cerebrospinal O
fluid O
(CSF) O
of O
volunteers O
and O
to O
test O
the O
hypothesis O
that O
rivastigmine B-CHEMICAL
(ENA-713; B-CHEMICAL
Exelon, B-CHEMICAL
Novartis O
Pharma O
AG, O
Basel, O
Switzerland) O
selectively O
inhibits O
AChE B-GENE-Y
in O
CSF O
in O
humans O
at O
a O
dose O
producing O
minimal O
inhibition O
of O
the O
peripheral O
enzyme. O
Lumbar O
CSF O
samples O
were O
collected O
continuously O
(0.1 O
mL O
x O
min(-1)) O
for O
49 O
hours O
from O

eight O
healthy O
volunteers O
who O
took O
either O
placebo O
or O
a O
single O
oral O
dose O
of O
rivastigmine B-CHEMICAL
(3 O
mg). O
CSF O
specimens O
and O
samples O
of O
blood O
cells O
and O
blood O
plasma O
were O
analyzed O
at O
intervals O
for O
rivastigmine B-CHEMICAL
and O
its O
metabolite O
NAP B-CHEMICAL
226-90 I-CHEMICAL
([-] B-CHEMICAL
[3-([1-dimethylaminolethyl)-phenol]), I-CHEMICAL
erythrocyte O
AChE B-GENE-Y
activity, O
CSF O
AChE B-GENE-Y
activity, O
and O
plasma O
and O
CSF O
butyrylcholinesterase B-GENE-Y
(BuChE) B-GENE-Y
activity. O
Safety O
evaluations O
were O
performed O
23 O
hours O

after O
drug O
dosing O
and O
at O
the O
end O
of O
the O
study. O
Evaluable O
data O
were O
obtained O
from O
six O
subjects. O
The O
mean O
time O
to O
maximal O
rivastigmine B-CHEMICAL
plasma O
concentration O
(tmax) O
was O
0.83 O
+/- O
0.26 O
hours, O
the O
mean O
maximal O
plasma O
concentration O
(Cmax) O
was O
4.88 O
+/- O
3.82 O
ng O
x O
mL(-1), O
the O
mean O
plasma O
area O
under O
the O
concentration O
versus O
time O
curve O
(AUC0-infinity) O
was O
7.43 O
+/- O
4.74 O
ng O
x O
hr O
x O
mL(-1), O
and O
the O
mean O
plasma O

t1/2 O
was O
0.85 O
+/- O
0.115 O
hours. O
The O
concentration O
of O
rivastigmine B-CHEMICAL
in O
CSF O
was O
lower O
than O
the O
quantification O
limit O
for O
assay O
(0.65 O
ng O
x O
mL(-1)), O
but O
NAP B-CHEMICAL
226-90 I-CHEMICAL
reached O
a O
mean O
Cmax O
of O
3.14 O
+/- O
0.57 O
ng O
x O
mL(-1). O
Only O
minimal O
inhibition O
of O
erythrocyte O
AChE B-GENE-Y
activity O
(approximately O
3%) O
was O
observed. O
Inhibition O
of O
AChE B-GENE-Y
in O
the O
CSF O
after O
rivastigmine B-CHEMICAL
administration O
was O
significantly O
greater O
than O
after O

placebo O
for O
up O
to O
8.4 O
hours O
after O
the O
dose O
and O
was O
maximal O
(40%) O
at O
2.4 O
hours. O
Plasma O
BuChE B-GENE-Y
activity O
was O
significantly O
lower O
after O
rivastigmine B-CHEMICAL
than O
after O
placebo, O
but O
this O
was O
not O
clinically O
relevant. O
BuChE B-GENE-Y
activity O
in O
CSF O
was O
significantly O
lower O
after O
rivastigmine B-CHEMICAL
than O
after O
placebo O
for O
up O
to O
3.6 O
hours O
after O
dosing, O
but O
this O
difference O
was O
not O
sustained. O
This O
study O
confirms O
the O
feasibility O
of O
using O
continuous O
measurement O
of O
AChE B-GENE-Y
activity O
in O
CSF O
over O
prolonged O
periods, O
that O
rivastigmine B-CHEMICAL

markedly O
inhibits O
CSF O
AChE B-GENE-Y
after O
a O
single O
oral O
dose O
of O
3 O
mg, O
and O
that O
the O
inhibition O
of O
central O
AChE B-GENE-Y
is O
substantially O
greater O
than O
that O
of O
peripheral O
AChE B-GENE-Y
or O
BuChE. B-GENE-Y
Identification O
of O
amino B-CHEMICAL
acids I-CHEMICAL
in O
the O
factor B-GENE-N
XI I-GENE-N
apple I-GENE-N
3 I-GENE-N
domain I-GENE-N
required O
for O
activation O
of O
factor B-GENE-Y
IX. I-GENE-Y
Activated B-GENE-Y
coagulation I-GENE-Y
factor I-GENE-Y
XI I-GENE-Y
(factor B-GENE-Y
XIa) I-GENE-Y
proteolytically O
cleaves O
its O
substrate, O
factor B-GENE-Y
IX, I-GENE-Y
in O
an O
interaction O
requiring O
the O
factor B-GENE-N
XI I-GENE-N
A3 I-GENE-N
domain I-GENE-N
(Sun, O
Y., O
and O
Gailani, O
D. O
(1996) O
J. O
Biol. O
Chem. O

271, O
29023-29028). O
To O
identify O
key O
amino B-CHEMICAL
acids I-CHEMICAL
involved O
in O
factor B-GENE-Y
IX I-GENE-Y
activation, O
recombinant O
factor B-GENE-Y
XIa I-GENE-Y
proteins O
containing O
alanine B-CHEMICAL
substitutions O
for O
wild-type O
sequence O
were O
expressed O
in O
293 O
fibroblasts O
and O
tested O
in O
a O
plasma O
clotting O
assay. O
Substitutions O
for O
Ile(183)-Val(191) O
and O
Ser(195)-Ile(197) O
at O
the O
N B-CHEMICAL
terminus O
and O
for O
Ser(258)-Ser(264) O
at O
the O
C B-CHEMICAL
terminus O
of O
the O
A3 B-GENE-N
domain I-GENE-N
markedly O
decreased O
factor B-GENE-Y
XI I-GENE-Y
coagulant O
activity. O
The O
plasma B-GENE-N
protease I-GENE-N

prekallikrein B-GENE-Y
is O
structurally O
homologous O
to O
factor B-GENE-Y
XI, I-GENE-Y
but O
activated O
factor B-GENE-Y
IX I-GENE-Y
poorly. O
A O
chimeric O
factor B-GENE-Y
XIa I-GENE-Y
molecule O
with O
the O
A3 B-GENE-N
domain I-GENE-N
replaced O
with O
A3 O
from O
prekallikrein B-GENE-Y
(FXI/PKA3) B-GENE-Y
activated B-GENE-Y
factor I-GENE-Y
IX I-GENE-Y
with O
a O
K(m) O
35-fold O
greater O
than O
that O
of O
wild-type O
factor B-GENE-Y
XI. I-GENE-Y
FXI/PKA3 B-GENE-Y
was O
used O
as O
a O
template O
for O
a O
series O
of O
proteins O
in O
which O
prekallikrein B-GENE-Y
A3 O
sequence O
was O
replaced O
with O
factor B-GENE-Y
XI I-GENE-Y
sequence O
to O
restore O
factor B-GENE-Y
IX I-GENE-Y
activation. O
Clotting O
and O
kinetics O
studies O
using O
these O
chimeras O
confirmed O

the O
results O
obtained O
with O
alanine B-CHEMICAL
mutants. O
Amino B-CHEMICAL
acids I-CHEMICAL
between O
Ile(183) O
and O
Val(191) O
are O
necessary O
for O
proper O
factor B-GENE-Y
IX I-GENE-Y
activation, O
but O
additional O
sequence O
between O
Ser(195) O
and O
Ile(197) O
or O
between O
Phe(260) O
and O
Ser(265) O
is O
required O
for O
complete O
restoration O
of O
activation. O
Agonist O
and O
antagonist O
actions O
of O
yohimbine B-CHEMICAL
as O
compared O
to O
fluparoxan B-CHEMICAL
at O
alpha(2)-adrenergic B-GENE-N
receptors I-GENE-N
(AR)s, B-GENE-N
serotonin B-CHEMICAL
(5-HT)(1A), B-GENE-Y
5-HT(1B), B-GENE-Y

5-HT(1D) B-GENE-Y
and O
dopamine B-GENE-N
D(2) I-GENE-N
and I-GENE-N
D(3) I-GENE-N
receptors. I-GENE-N
Significance O
for O
the O
modulation O
of O
frontocortical O
monoaminergic O
transmission O
and O
depressive O
states. O
Herein, O
we O
evaluate O
the O
interaction O
of O
the O
alpha(2)-AR B-GENE-N
antagonist, I-GENE-N
yohimbine, B-CHEMICAL
as O
compared O
to O
fluparoxan, B-CHEMICAL
at O
multiple O
monoaminergic B-GENE-N
receptors I-GENE-N
and O
examine O
their O
roles O
in O
the O
modulation O
of O
adrenergic, O
dopaminergic O
and O
serotonergic O
transmission O
in O
freely-moving O
rats. O
Yohimbine B-CHEMICAL
displays O
marked O
affinity O
at O
human B-GENE-N

(h)alpha(2A)-, I-GENE-N
halpha(2B)- I-GENE-N
and I-GENE-N
halpha(2C)-ARs, I-GENE-N
significant O
affinity O
for O
h5-HT(1A), B-GENE-Y
h5-HT(1B), B-GENE-Y
h5-HT(1D), B-GENE-Y
and O
hD(2) B-GENE-Y
receptors I-GENE-Y
and O
weak O
affinity O
for O
hD(3) B-GENE-Y
receptors. I-GENE-Y
In O
[(35)S]GTPgammaS B-CHEMICAL
binding O
protocols, O
yohimbine B-CHEMICAL
exerts O
antagonist O
actions O
at O
halpha(2A)-AR, B-GENE-Y
h5-HT(1B), B-GENE-Y

h5-HT(1D), B-GENE-Y
and O
hD(2) B-GENE-Y
sites, O
yet O
partial O
agonist O
actions O
at O
h5-HT(1A) B-GENE-Y
sites. O
In O
vivo, O
agonist O
actions O
of O
yohimbine B-CHEMICAL
at O
5-HT(1A) B-GENE-Y
sites O
are O
revealed O
by O
WAY100,635-reversible B-CHEMICAL
induction O
of O
hypothermia O
in O
the O
rat. O
In O
guinea O
pigs, O
antagonist O
actions O
of O
yohimbine B-CHEMICAL
at O
5-HT(1B) B-GENE-Y
receptors O
are O
revealed O
by O
blockade O
of O
hypothermia O
evoked O
by O
the O
5-HT(1B) B-GENE-Y
agonist, O

GR46,611. B-CHEMICAL
In O
distinction O
to O
yohimbine, B-CHEMICAL
fluparoxan B-CHEMICAL
shows O
only O
modest O
partial O
agonist O
actions O
at O
h5-HT(1A) B-GENE-Y
sites O
versus O
marked O
antagonist O
actions O
at O
halpha(2)-ARs. B-GENE-N
While O
fluparoxan B-CHEMICAL
selectively O
enhances O
hippocampal O
noradrenaline B-CHEMICAL
(NAD) B-CHEMICAL
turnover, O
yohimbine B-CHEMICAL
also O
enhances O
striatal O
dopamine B-CHEMICAL
(DA) B-CHEMICAL
turnover O
and O
suppresses O
striatal O
turnover O
of O
5-HT. B-CHEMICAL
Further, O
yohimbine B-CHEMICAL
decreases O
firing O
of O
serotonergic O
neurones O
in O
raphe O
nuclei, O

an O
action O
reversed O
by O
WAY100,635. B-CHEMICAL
Fluparoxan B-CHEMICAL
increases O
extracellular O
levels O
of O
DA B-CHEMICAL
and O
NAD, B-CHEMICAL
but O
not O
5-HT, B-CHEMICAL
in O
frontal O
cortex. O
In O
analogy, O
yohimbine B-CHEMICAL
enhances O
FCX O
levels O
of O
DA B-CHEMICAL
and O
NAD, B-CHEMICAL
yet O
suppresses O
those O
of O
5-HT, B-CHEMICAL
the O
latter O
effect O
being O
antagonized O
by O
WAY100,635. B-CHEMICAL
The O
induction O
by O
fluoxetine O
of O
FCX O
levels O
of O
5-HT, B-CHEMICAL
DA, B-CHEMICAL
and O
NAD B-CHEMICAL
is O
potentiated O
by O
fluparoxan. B-CHEMICAL
Yohimbine B-CHEMICAL
likewise O
facilitates O
the O
influence O
of O
fluoxetine B-CHEMICAL

upon O
DA B-CHEMICAL
and O
NAD B-CHEMICAL
levels, O
but O
not O
those O
of O
5-HT. B-CHEMICAL
In O
conclusion, O
the O
alpha(2)-AR B-GENE-N
antagonist O
properties O
of O
yohimbine B-CHEMICAL
increase O
DA B-CHEMICAL
and O
NAD B-CHEMICAL
levels O
both O
alone O
and O
in O
association O
with O
fluoxetine. O
However, O
in O
contrast O
to O
the O
selective O
alpha(2)-AR B-GENE-N
antagonist, O
fluparoxan, B-CHEMICAL
the O
5-HT(1A) B-GENE-Y
agonist O
actions O
of O
yohimbine B-CHEMICAL
suppress O
5-HT B-CHEMICAL
levels O
alone O
and O
underlie O
its O
inability O
to O
augment O
the O
influence O
of O
fluoxetine B-CHEMICAL
upon O
5-HT B-CHEMICAL
levels. O
The O
antitussive O
activity O
of O
delta-opioid B-GENE-Y

receptor I-GENE-Y
stimulation O
in O
guinea O
pigs. O
In O
this O
study, O
the O
activity O
of O
the O
delta-opioid B-GENE-Y
receptor I-GENE-Y
subtype-selective O
agonist, O
SB B-CHEMICAL
227122, I-CHEMICAL
was O
investigated O
in O
a O
guinea O
pig O
model O
of O
citric B-CHEMICAL
acid-induced I-CHEMICAL
cough. O
Parenteral O
administration O
of O
selective O
agonists O
of O
the O
delta-opioid B-GENE-Y
receptor I-GENE-Y
(SB B-CHEMICAL
227122), I-CHEMICAL
mu-opioid B-GENE-Y
receptor I-GENE-Y
(codeine B-CHEMICAL
and O
hydrocodone), B-CHEMICAL
and O
kappa-opioid B-GENE-Y
receptor I-GENE-Y
(BRL B-CHEMICAL
52974) I-CHEMICAL
produced O
dose-related O
inhibition O
of O
citric B-CHEMICAL
acid-induced I-CHEMICAL
cough O

with O
ED(50) O
values O
of O
7.3, O
5.2, O
5.1, O
and O
5.3 O
mg/kg, O
respectively. O
The O
nonselective O
opioid B-GENE-N
receptor I-GENE-N
antagonist, O
naloxone B-CHEMICAL
(3 O
mg/kg, O
i.m.), O
attenuated O
the O
antitussive O
effects O
of O
codeine B-CHEMICAL
or O
SB B-CHEMICAL
227122, I-CHEMICAL
indicating O
that O
the O
antitussive O
activity O
of O
both O
compounds O
is O
opioid B-GENE-N
receptor-mediated. I-GENE-N
The O
delta-receptor B-GENE-Y
antagonist, O
SB B-CHEMICAL
244525 I-CHEMICAL
(10 O
mg/kg, O
i.p.), O
inhibited O
the O
antitussive O
effect O
of O

SB B-CHEMICAL
227122 I-CHEMICAL
(20 O
mg/kg, O
i.p.). O
In O
contrast, O
combined O
pretreatment O
with O
beta-funaltrexamine B-CHEMICAL
(mu-receptor B-GENE-Y
antagonist; O
20 O
mg/kg, O
s.c.) O
and O
norbinaltorphimine B-CHEMICAL
(kappa-receptor B-GENE-Y
antagonist; O
20 O
mg/kg, O
s.c.), O
at O
doses O
that O
inhibited O
the O
antitussive O
activity O
of O
mu- B-GENE-N
and I-GENE-N
kappa-receptor I-GENE-N
agonists, O
respectively, O
was O
without O
effect O
on O
the O
antitussive O
response O
of O
SB B-CHEMICAL
227122 I-CHEMICAL
(20 O
mg/kg, O

i.p.). O
The O
sigma-receptor B-GENE-N
antagonist O
rimcazole B-CHEMICAL
(3 O
mg/kg, O
i.p.) O
inhibited O
the O
antitussive O
effect O
of O
dextromethorphan B-CHEMICAL
(30 O
mg/kg, O
i.p.), O
a O
sigma-receptor O
agonist, O
but O
not O
that O
of O
SB B-CHEMICAL
227122. I-CHEMICAL
These O
studies O
provide O
compelling O
evidence O
that O
the O
antitussive O
effects O
of O
SB B-CHEMICAL
227122 I-CHEMICAL
in O
this O
guinea O
pig O
cough O
model O
are O
mediated O
by O
agonist O
activity O
at O
the O
delta-opioid B-GENE-Y
receptor. I-GENE-Y
COX-2-specific B-GENE-Y
inhibition: O
implications O
for O
clinical O

practice. O
Although O
conventional O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
have O
long O
been O
a O
major O
therapeutic O
choice O
for O
the O
management O
of O
arthritic O
conditions, O
the O
potential O
adverse O
effects O
of O
these O
agents O
sometimes O
compromise O
their O
clinical O
utility. O
New O
modes O
of O
therapy O
have O
recently O
been O
introduced, O
and O
data O
on O
the O
cyclooxygenase-2 B-GENE-Y
(COX-2)-specific B-GENE-Y
inhibitors O
celecoxib B-CHEMICAL
and O
rofecoxib B-CHEMICAL
suggest O
that O
these O
agents O
will O
meet O
the O
need O
for O
safe O
and O
effective O
therapeutic O
alternatives O
to O
conventional O
NSAIDs. O
Kinetics O
of O
inhibition O
of O
human B-GENE-N
and I-GENE-N
rat I-GENE-N
dihydroorotate I-GENE-N

dehydrogenase I-GENE-N
by O
atovaquone, B-CHEMICAL
lawsone B-CHEMICAL
derivatives, O
brequinar B-CHEMICAL
sodium I-CHEMICAL
and O
polyporic B-CHEMICAL
acid. I-CHEMICAL
Mitochondrially-bound O
dihydroorotate B-GENE-Y
dehydrogenase I-GENE-Y
(EC B-GENE-Y
1.3.99.11) I-GENE-Y
catalyzes O
the O
fourth O
sequential O
step O
in O
the O
de O
novo O
synthesis O
of O
uridine B-CHEMICAL
monophosphate. I-CHEMICAL
The O
enzyme O
has O
been O
identified O
as O
or O
surmised O
to O
be O
the O
pharmacological O
target O
for O
isoxazol, B-CHEMICAL
triazine, B-CHEMICAL
cinchoninic B-CHEMICAL
acid I-CHEMICAL
and O
(naphtho)quinone B-CHEMICAL
derivatives, O
which O

exerted O
antiproliferative, O
immunosuppressive, O
and O
antiparasitic O
effects. O
Despite O
this O
broad O
spectrum O
of O
biological O
and O
clinical O
relevance, O
there O
have O
been O
no O
comparative O
studies O
on O
drug-dihydroorotate B-GENE-Y
dehydrogenase I-GENE-Y
interactions. O
Here, O
we O
describe O
a O
study O
of O
the O
inhibition O
of O
the O
purified O
recombinant O
human B-GENE-N
and I-GENE-N
rat I-GENE-N
dihydroorotate I-GENE-N
dehydrogenase I-GENE-N
by O
ten O
compounds. O
1,4-Naphthoquinone, B-CHEMICAL
5,8-hydroxy-naphthoquinone B-CHEMICAL
and O
the O
natural O
compounds O
juglon, B-CHEMICAL
plumbagin B-CHEMICAL

and O
polyporic B-CHEMICAL
acid I-CHEMICAL
(quinone B-CHEMICAL
derivative) O
were O
found O
to O
function O
as O
alternative O
electron O
acceptors O
with O
10-30% O
of O
control O
enzyme O
activity. O
The O
human O
and O
rat O
enzyme O
activity O
was O
decreased O
by O
50% O
by O
the O
natural O
compound O
lawsone B-CHEMICAL
( O
> O
500 O
and O
49 O
microM, O
respectively) O
and O
by O
the O
derivatives O
dichloroally-lawsone B-CHEMICAL
(67 O
and O
10 O
nM), O
lapachol B-CHEMICAL
(618 O
and O
61 O
nM) O
and O
atovaquone B-CHEMICAL
(15 O
microM O
and O
698 O
nM). O
With O
respect O
to O
the O
quinone B-CHEMICAL
co-substrate O
of O
the O
dihydroorotate B-CHEMICAL

dehydrogenase, I-GENE-Y
atovaquone B-CHEMICAL
(Kic O
= O
2.7 O
microM) O
and O
dichloroally-lawsone B-CHEMICAL
(Kic O
= O
9.8 O
nM) O
were O
shown O
to O
be O
competitive O
inhibitors O
of O
human B-GENE-Y
dihydroorotate B-CHEMICAL
dehydrogenase. I-GENE-Y
Atovaquone B-CHEMICAL
(Kic O
= O
60 O
nM) O
was O
also O
acompetitive O
inhibitor O
of O
the O
rat O
enzyme. O
Dichloroally]-lawsone B-CHEMICAL
was O
found O
to O
be O
a O
time-dependent O
inhibitor O
of O
the O
rat O
enzyme, O
with O
the O
lowest O
inhibition O
constant O
(Ki* O
= O
0.77 O
nM) O
determined O

so O
far O
for O
mammalian B-GENE-N
dihydroorotate I-GENE-N
dehydrogenases. I-GENE-N
Another O
inhibitor, O
brequinar B-CHEMICAL
was O
previously O
reported O
to O
be O
a O
slow-binding O
inhibitor O
of O
the O
human B-GENE-Y
dihydroorotate I-GENE-Y
dehydrogenase I-GENE-Y
[W. O
Knecht, O
M. O
Loffler, O
Species-related O
inhibition O
of O
human B-GENE-N
and I-GENE-N
rat I-GENE-N
dihyroorotate I-GENE-N
dehydrogenase I-GENE-N
by O
immunosuppressive O
isoxazol B-CHEMICAL
and O
cinchoninic B-CHEMICAL
acid I-CHEMICAL
derivatives, O
Biochem. O
Pharmacol. O
56 O
(1998) O
1259-1264]. O
The O
slow O
binding O
features O
of O

this O
potent O
inhibitor O
(Ki* O
= O
1.8 O
nM) O
with O
the O
human O
enzyme, O
were O
verified O
and O
seen O
to O
be O
one O
of O
the O
reasons O
for O
the O
narrow O
therapeutic O
window O
(efficacy O
versus O
toxicity) O
reported O
from O
clinical O
trials O
on O
its O
antiproliferative O
and O
immunosuppressive O
action. O
With O
respect O
to O
the O
substrate O
dihydroorotate, B-CHEMICAL
atovaquone B-CHEMICAL
was O
an O
uncompetitive O
inhibitor O
of O
human B-GENE-Y
dihydroorotate I-GENE-Y
dehydrogenase I-GENE-Y
(Kiu O
= O
11.6 O
microM) O
and O
a O
non-competitive O
inhibitor O
of O
the O
rat O
enzyme O
(Kiu O
= O
905/ O
Kic O
= O

1,012 O
nM). O
1.5 O
mM O
polyporic B-CHEMICAL
acid, I-CHEMICAL
a O
natural O
quinone B-CHEMICAL
from O
fungi, O
influenced O
the O
activity O
of O
the O
human O
enzyme O
only O
slightly; O
the O
activity O
of O
the O
rat O
enzyme O
was O
decreased O
by O
30%. O
Sodium B-GENE-N
channel I-GENE-N
blockers O
identify O
risk O
for O
sudden O
death O
in O
patients O
with O
ST-segment O
elevation O
and O
right O
bundle O
branch O
block O
but O
structurally O
normal O
hearts. O
BACKGROUND: O
A O
mutation O
in O
the O
cardiac B-GENE-N
sodium B-CHEMICAL
channel I-GENE-N
gene O
(SCN5A) B-GENE-Y
has O
been O
described O
in O
patients O
with O
the O
syndrome O
of O
right O
bundle O
branch O
block, O
ST-segment O
elevation O
in O
leads O
V1 O
to O
V3, O
and O

sudden O
death O
(Brugada O
syndrome). O
These O
electrocardiographic O
manifestations O
are O
transient O
in O
many O
patients O
with O
the O
syndrome. O
The O
present O
study O
examined O
arrhythmic O
risk O
in O
patients O
with O
overt O
and O
concealed O
forms O
of O
the O
disease O
and O
the O
effectiveness O
of O
sodium B-CHEMICAL
channel I-GENE-N
blockers O
to O
unmask O
the O
syndrome O
and, O
thus, O
identify O
patients O
at O
risk. O
METHODS O
AND O
RESULTS: O
The O
effect O
of O
intravenous O
ajmaline B-CHEMICAL
(1 O
mg/kg), O
procainamide B-CHEMICAL
(10 O
mg/kg), O
or O
flecainide B-CHEMICAL
(2 O
mg/kg) O
on O
the O
ECG O

was O
studied O
in O
34 O
patients O
with O
the O
syndrome O
and O
transient O
normalization O
of O
the O
ECG O
(group O
A), O
11 O
members O
of O
3 O
families O
in O
whom O
a O
SCN5A B-GENE-Y
mutation O
was O
associated O
with O
the O
syndrome O
and O
8 O
members O
in O
whom O
it O
was O
not O
(group O
B), O
and O
53 O
control O
subjects O
(group O
C). O
Ajmaline, B-CHEMICAL
procainamide, B-CHEMICAL
or O
flecainide B-CHEMICAL
administration O
resulted O
in O
ST-segment O
elevation O
and O
right O
bundle O
branch O
block O
in O
all O
patients O
in O
group O
A O
and O
in O
all O
11 O
patients O
with O
the O
mutation O
in O
group O
B. O
A O
similar O
pattern O
could O
not O
be O
elicited O
in O
the O
8 O
patients O
in O
group O
B O
who O
lacked O

the O
mutation O
or O
in O
any O
person O
in O
group O
C. O
The O
follow-up O
period O
(37+/-33 O
months) O
revealed O
no O
differences O
in O
the O
incidence O
of O
arrhythmia O
between O
the O
34 O
patients O
in O
whom O
the O
phenotypic O
manifestation O
of O
the O
syndrome O
was O
transient O
and O
the O
24 O
patients O
in O
whom O
it O
was O
persistent O
(log-rank, O
0.639). O
CONCLUSIONS: O
The O
data O
demonstrated O
a O
similar O
incidence O
of O
potentially O
lethal O
arrhythmias O
in O
patients O
displaying O
transient O
versus O
persistent O
ST-segment O
elevation O
and O
right O
bundle O
branch O
block, O
as O
well O
as O
the O
effectiveness O
of O
sodium B-CHEMICAL
channel I-GENE-N
blockers O
to O
unmask O

the O
syndrome O
and, O
thus, O
identify O
patients O
at O
risk. O
Determinants O
of O
voltage-dependent O
inactivation O
affect O
Mibefradil B-CHEMICAL
block O
of O
calcium B-GENE-N
channels. I-GENE-N
The O
voltage B-GENE-N
gated I-GENE-N
calcium B-CHEMICAL
channel I-GENE-N
family O
is O
a O
major O
target O
for O
a O
range O
of O
therapeutic O
drugs. O
Mibefradil B-CHEMICAL
(Ro B-CHEMICAL
40-5967) I-CHEMICAL
belongs O
to O
a O
new O
chemical O
class O
of O
these O
molecules O
which O
differs O
from O
other O
Ca2+ B-CHEMICAL
antagonists O
by O
its O
ability O
to O
potently O
block O
T-type B-GENE-N
Ca2+ B-CHEMICAL
channels. I-GENE-N
However, O
this O
molecule O
has O
also O
been O
shown O
to O
inhibit O
other O
Ca2+ B-CHEMICAL
channel I-GENE-N
subtypes. O
To O
further O
analyze O
the O
mechanism O

governing O
the O
Ca2+ B-CHEMICAL
channel-Mibefradil I-GENE-N
interaction, O
we O
examined O
the O
effect O
of O
Mibefradil B-CHEMICAL
on O
various O
recombinant O
Ca2+ B-GENE-N
channels I-GENE-N
expressed O
in O
mammalian O
cells O
from O
their O
cloned O
cDNAs, O
using O
Ca2+ B-CHEMICAL
as O
the O
permeant O
ion O
at O
physiological O
concentration. O
Expression O
of O
alpha1A, O
alpha1C, O
and O
alpha1E O
in O
tsA O
201 O
cells O
resulted O
in O
Ca2+ B-CHEMICAL
currents O
with O
functional O
characteristics O
closely O
related O
to O
those O
of O
their O
native O
counterparts. O
Mibefradil B-CHEMICAL
blocked O
alpha1A O
and O
alpha1E O
with O
a O
Kd O
comparable O
to O
that O

reported O
for O
T-type B-GENE-N
channels, I-GENE-N
but O
had O
a O
lower O
affinity O
(approximately O
30-fold) O
for O
alpha1C. O
For O
each O
channel, O
inhibition O
by O
Mibefradil B-CHEMICAL
was O
consistent O
with O
high-affinity O
binding O
to O
the O
inactivated O
state. O
Modulation O
of O
the O
voltage-dependent O
inactivation O
properties O
by O
the O
nature O
of O
the O
coexpressed O
beta O
subunit O
or O
the O
alpha1 O
splice O
variant O
altered O
block O
at O
the O
Mibefradil B-CHEMICAL
receptor O
site. O
Therefore, O
we O
conclude O
that O
the O
tissue O
and O
sub-cellular O
localization O
of O
calcium B-CHEMICAL
channel I-GENE-N
subunits O
as O
well O
as O
their O
specific O
associations O
are O
essential O
parameters O
to O
understand O
the O
in O
vivo O
effects O
of O

Mibefradil. B-CHEMICAL
Use O
of O
tranexamic B-CHEMICAL
acid I-CHEMICAL
for O
an O
effective O
blood O
conservation O
strategy O
after O
total O
knee O
arthroplasty. O
We O
have O
investigated O
the O
effect O
of O
treatment O
with O
tranexamic B-CHEMICAL
acid, I-CHEMICAL
an O
inhibitor O
of O
fibrinolysis, O
on O
blood O
loss, O
blood O
transfusion O
requirements O
and O
blood O
coagulation O
in O
a O
randomized, O
double-blind, O
placebo-controlled O
study O
of O
42 O
patients O
after O
total O
knee O
arthroplasty. O
Tranexamic B-CHEMICAL
acid I-CHEMICAL
15 O
mg O
kg-1 O
(n O
= O
21) O
or O
an O
equivalent O
volume O
of O
normal O
saline O
(n O
= O
21) O
was O
given O
30 O
min O
before O
surgery O
and O
subsequently O
every O

8 O
h O
for O
3 O
days. O
Coagulation O
and O
fibrinolysis O
values, O
blood O
loss O
and O
blood O
units O
administered O
were O
measured O
before O
administration O
of O
tranexamic B-CHEMICAL
acid, I-CHEMICAL
8 O
h O
after O
the O
end O
of O
surgery O
and O
at O
24 O
and O
72 O
h O
after O
operation. O
Coagulation O
profile O
was O
examined O
(bleeding O
time, O
platelet O
count, O
prothrombin B-GENE-Y
time O
(PT), O
activated O
partial O
thromboplastin B-GENE-Y
time O
(aPTT), O
plasminogen, B-GENE-Y
beta-thromboglobulin B-GENE-Y
and O
fibrinogen). B-GENE-N
Fibrinolysis O
was O
evaluated O
by O
measurement O
of O
concentrations O
of O
D-dimer O
and O

fibrinogen B-GENE-N
degradation I-GENE-N
products I-GENE-N
(FDP). B-GENE-N
Total O
blood O
loss O
in O
the O
tranexamic B-CHEMICAL
acid I-CHEMICAL
group O
was O
678 O
(SD O
352) O
ml O
compared O
with O
1419 O
(607) O
ml O
in O
the O
control O
group O
(P O
< O
0.001), O
and O
occurred O
primarily O
during O
the O
first O
24 O
h O
after O
surgery. O
Thirteen O
patients O
received O
1-5 O
u. O
of O
packed O
red O
blood O
cells O
in O
the O
control O
group O
compared O
with O
two O
patients O
in O
the O
tranexamic B-CHEMICAL
acid I-CHEMICAL
group, O
who O
received O
3 O
u. O
(P O
< O
0.001). O
Postoperative O
packed O
cell O
volume O
values O
were O
higher O
in O
the O
tranexamic B-CHEMICAL
acid I-CHEMICAL

group O
despite O
fewer O
blood O
transfusions. O
Postoperative O
concentrations O
of O
plasminogen B-GENE-Y
were O
decreased O
significantly O
in O
the O
tranexamic B-CHEMICAL
acid I-CHEMICAL
group O
(P O
< O
0.001). O
Platelet O
count, O
PT, O
aPTT, O
bleeding O
time, O
beta-thromboglobulin, B-GENE-Y
fibrinogen B-GENE-N
and O
FDP B-GENE-N
concentrations O
did O
not O
differ O
between O
groups, O
but O
D-dimer O
concentrations O
were O
increased O
in O
the O
control O
group. O
Thromboembolic O
complications O
occurred O
in O
two O
patients O
in O
the O
control O
group O
compared O
with O
none O
in O
the O
tranexamic B-CHEMICAL
acid I-CHEMICAL
group. O
Correlations O
between O
serotonin B-CHEMICAL
level O
and O

single-cell O
firing O
in O
the O
rat's O
nucleus O
raphe O
magnus. O
The O
relation O
between O
serotonin B-CHEMICAL
release O
and O
electrical O
activity O
was O
examined O
in O
the O
nucleus O
raphe O
magnus O
of O
rats O
anesthetized O
with O
pentobarbital. B-CHEMICAL
Serotonin B-CHEMICAL
levels O
were O
monitored O
through O
a O
carbon-fiber B-CHEMICAL
microelectrode O
by O
fast O
cyclic O
voltammetry O
(usually O
at O
1 O
Hz). O
Single-cell O
firing O
was O
recorded O
through O
the O
same O
microelectrode, O
except O
during O
the O
voltammetry O
waveform O
and O
associated O
electrical O
artifact O
(totaling O
about O
30 O
ms). O
Multi-barrel O
micropipettes O
incorporating O
the O
voltammetry O

electrode O
were O
used O
for O
iontophoresis O
of O
drugs. O
Cells O
were O
inhibited, O
excited O
or O
unaffected O
by O
noxious O
mechanical O
skin O
stimulation. O
These O
were O
respectively O
designated O
as O
off(M) O
cells, O
on(M) O
cells O
and O
neutral(M) O
cells, O
M O
denoting O
mechanical. O
During O
3 O
min O
of O
pinching, O
serotonin B-CHEMICAL
slowly O
rose O
near O
seven O
of O
14 O
on(M) O
cells O
and O
26 O
of O
46 O
off(M) O
cells; O
it O
fell O
near O
two O
off(M) O
cells; O
it O
was O
unchanged O
near O
all O
other O
cells, O
including O
six O
neutral(M) O
cells. O
On O
a O
finer O
spatiotemporal O

scale, O
near O
four O
of O
seven O
on(M) O
cells, O
10 O
of O
14 O
off(M) O
cells O
and O
0 O
of O
four O
neutral(M) O
cells, O
average O
serotonin B-CHEMICAL
levels O
fell O
significantly O
within O
+/- O
100 O
ms O
of O
spontaneous O
spikes. O
Lower O
serotonin B-CHEMICAL
may O
have O
caused O
the O
higher O
spike O
probability; O
the O
converse O
is O
theoretically O
unlikely, O
since O
delays O
between O
release O
and O
detection O
are O
estimated O
to O
exceed O
100 O
ms. O
Increased O
serotonin B-CHEMICAL
and O
decreased O
firing O
were O
always O
seen O
following O
iontophoresis O
or O
intravenous O
injection O
(1 O
mg/kg) O
of O
the O
serotonin B-CHEMICAL
re-uptake O
inhibitor O

clomipramine B-CHEMICAL
(n O
= O
7). O
Iontophoresis O
of O
+/- B-CHEMICAL
propranolol, I-CHEMICAL
whose O
serotonergic O
actions O
include O
antagonism O
and O
partial O
agonism O
at O
5-HT1 B-GENE-N
receptors, O
also O
increased O
serotonin B-CHEMICAL
and O
decreased O
firing O
(n=4). O
Methiothepin B-CHEMICAL
(intravenous, O
1 O
mg/kg), O
whose O
serotonergic O
actions O
include O
5-HT1 B-GENE-N
and O
5-HT2 B-GENE-N
antagonism, O
typically O
raised O
serotonin B-CHEMICAL
levels O
(four O
of O
five O
cells) O
and O
always O
blocked O
inhibition O
by O

clomipramine B-CHEMICAL
(n O
= O
3). O
Iontophoresis O
of O
glutamate B-CHEMICAL
always O
lowered O
serotonin B-CHEMICAL
and O
increased O
firing O
(n O
= O
4). O
Since O
serotonin B-CHEMICAL
levels O
and O
firing O
were O
usually O
inversely O
correlated, O
except O
near O
on(M) O
cells O
during O
pinch, O
we O
propose O
that O
serotonin B-CHEMICAL
is O
released O
from O
terminals O
of O
incoming O
nociceptive O
afferents. O
Prior O
neuroanatomical O
knowledge O
favors O
a O
midbrain O
origin O
for O
these O
afferents, O
while O
some O
of O
the O
drug O
findings O
suggest O
that O
their O
terminals O
possess O
inhibitory O
serotonergic O
autoreceptors, O
possibly O
of O

5-HT1b B-GENE-Y
subtype. O
The O
released O
serotonin B-CHEMICAL
could O
contribute O
to O
the O
inhibition O
of O
off(M) O
cells O
and O
excitation O
of O
on(M) O
cells O
by O
noxious O
stimulation, O
since O
inhibitory O
5-HT1a B-GENE-Y
receptors O
and O
excitatory O
5-HT2 B-GENE-N
receptors, O
respectively, O
have O
previously O
been O
shown O
to O
dominate O
their O
serotonergic O
responses. O
The O
Hsp90-specific B-GENE-N
inhibitor O
geldanamycin B-CHEMICAL
selectively O
disrupts O
kinase-mediated B-GENE-N
signaling O
events O
of O
T-lymphocyte O
activation. O
The O
90-kDa B-GENE-N
heat I-GENE-N
shock I-GENE-N
protein I-GENE-N
(Hsp90) B-GENE-N
is O
the O
most O

abundant O
molecular B-GENE-N
chaperone I-GENE-N
of O
eukaryotic O
cells. O
Its O
chaperone O
function O
in O
folding O
nascent O
proteins O
seems O
to O
be O
restricted O
to O
a O
subset O
of O
proteins O
including O
major O
components O
of O
signal O
transduction O
pathways O
(eg, O
nuclear B-GENE-N
hormone I-GENE-N
receptors, I-GENE-N
transcription O
factors, O
and O
protein B-GENE-N
kinases). I-GENE-N
Improper O
function O
of O
these O
proteins O
can O
be O
induced O
by O
selective O
disruption O
of O
their O
complexes O
with O
Hsp90 B-GENE-N
using O
the O
benzoquinonoid B-CHEMICAL
ansamycin I-CHEMICAL
geldanamycin. B-CHEMICAL
In O
this O
study, O
we O
demonstrate O
that O
geldanamycin B-CHEMICAL
treatment O
blocks O
interleukin B-GENE-Y
(IL)-2 I-GENE-Y
secretion, O
IL-2 B-GENE-N
receptor I-GENE-N
expression, O
and O

proliferation O
of O
stimulated O
T-lymphocytes. O
Moreover, O
geldanamycin B-CHEMICAL
decreases O
the O
amount O
and O
phosphorylation O
of O
Lck B-GENE-Y
and O
Raf-1 B-GENE-Y
kinases B-GENE-N
and O
prevents O
activation O
of O
the O
extracellular B-GENE-Y
signal I-GENE-Y
regulated I-GENE-Y
kinase I-GENE-Y
(ERK)-2 I-GENE-Y
kinase. B-GENE-N
Geldanamycin B-CHEMICAL
also O
disrupts O
the O
T-cell B-GENE-N
receptor-mediated I-GENE-N
activation O
of O
nuclear B-GENE-N
factor I-GENE-N
of I-GENE-N
activated I-GENE-N
T-cells I-GENE-N
(NF-AT). B-GENE-N
Treatment O
with O
geldanamycin, B-CHEMICAL
however, O
does O
not O
affect O
the O
activation O
of O
lysophosphatide B-GENE-N
acyltransferase, I-GENE-N
which O
is O
a O
plasma O
membrane O
enzyme O
coupled O
to O
the O

T-cell B-GENE-N
receptor I-GENE-N
after O
T-cell O
stimulation. O
Through O
demonstrating O
the O
selective O
inhibition O
of O
kinase-related B-GENE-N
T-lymphocyte O
responses O
by O
geldanamycin, B-CHEMICAL
our O
results O
emphasize O
the O
substantial O
role O
of O
Hsp90-kinase B-GENE-N
complexes O
in O
T-cell O
activation. O
Carnitine B-CHEMICAL
biosynthesis. O
Purification O
of O
gamma-butyrobetaine B-GENE-Y
hydroxylase I-GENE-Y
from O
rat O
liver. O
gamma-Butyrobetaine B-CHEMICAL
hydroxylase I-GENE-Y
catalyse O
the O
last O
step O
in O
carnitine B-CHEMICAL
biosynthesis, O
the O
formation O
of O
L-carnitine B-CHEMICAL
from O
gamma-butyrobetaine, B-CHEMICAL
a O
reaction O
dependent O

on O
Fe2+, B-CHEMICAL
alpha-ketoglutarate, B-CHEMICAL
ascorbate B-CHEMICAL
and O
oxygen. B-CHEMICAL
Initial O
attempts O
to O
purify O
the O
protein O
from O
rat O
liver O
showed O
that O
gamma-butyrobetaine B-CHEMICAL
hydroxylase I-GENE-Y
is O
unstable. O
We, O
therefore, O
determined O
the O
influence O
of O
various O
compounds O
on O
the O
stability O
of O
gamma-butyrobetaine B-CHEMICAL
hydroxylase I-GENE-Y
at O
different O
storage O
temperatures. O
The O
enzyme O
activity O
was O
best O
conserved O
by O
storing O
the O
protein O
at O
4 O
degrees O
C O
in O
the O
presence O
of O
200 O
g/l O
glycerol B-CHEMICAL
and O
10 O
mM O
DTT. B-CHEMICAL
We O
subsequently O
purified O
the O
enzyme O
from O
rat O
liver O
to O
apparent O
homogeneity O
by O
liquid O

chromatography. O
Aspirin B-CHEMICAL
and O
sodium B-CHEMICAL
salicylate I-CHEMICAL
inhibit O
endothelin O
ETA B-GENE-Y
receptors I-GENE-Y
by O
an O
allosteric O
type O
of O
mechanism. O
Aspirin B-CHEMICAL
is O
a O
commonly O
used O
drug O
with O
a O
wide O
pharmacological O
spectrum O
including O
antiplatelet, O
anti-inflammatory, O
and O
neuroprotective O
actions. O
This O
study O
shows O
that O
aspirin B-CHEMICAL
and O
sodium B-CHEMICAL
salicylate, I-CHEMICAL
its O
major O
blood O
metabolite, O
reverse O
contractile O
actions O
of O
endothelin-1 B-GENE-N
(ET-1) B-GENE-N
in O
isolated O
rat O
aorta O
and O
human O
mammary O
arteries. O
They O
also O
prevent O
the O
intracellular O
Ca(2+) B-CHEMICAL

mobilizing O
action O
of O
ET-1 B-GENE-Y
in O
cultured O
endothelial O
cells O
but O
not O
those O
of O
neuromedin B-GENE-Y
B I-GENE-Y
or O
UTP. O
Inhibition O
of O
the O
actions O
of O
ET-1 B-GENE-Y
by O
salicylates B-CHEMICAL
is O
apparently O
competitive. O
Salicylates B-CHEMICAL
inhibit O
(125)I-ET-1 B-CHEMICAL
binding O
to O
recombinant O
rat B-GENE-Y
ETA I-GENE-Y
receptors. I-GENE-Y
Salicylic B-CHEMICAL
acid I-CHEMICAL
promotes O
dissociation O
of O
(125)I-ET-1 B-CHEMICAL
ETA B-GENE-Y
receptor I-GENE-Y
complexes O
both O
in O
the O
absence O
and O
the O
presence O
of O
unlabeled O
ET-1. B-GENE-Y
It O
has O
no O
influence O
on O
the O
rate O
of O
association O
of O

(125)I-ET-1 B-CHEMICAL
to O
ETA B-GENE-Y
receptors. I-GENE-Y
Salicylates B-CHEMICAL
do O
not O
promote O
dissociation O
of O
(125)I-ET-1 B-CHEMICAL
ETB B-GENE-Y
receptor I-GENE-Y
complexes. O
Salicylates B-CHEMICAL
potentiate O
relaxing O
actions O
of O
receptor O
antagonists O
such O
as O
bosentan. B-CHEMICAL
It O
is O
concluded O
that O
salicylates B-CHEMICAL
are O
allosteric O
inhibitors O
of O
ETA B-GENE-Y
receptors. I-GENE-Y
The O
results O
also O
suggest O
that: O
1) O
irreversible O
ET-1 B-GENE-Y
binding O
probably O
limits O
actions O
of O
receptor O
antagonists O
in O
vivo, O
and O
2) O
an O
association O
of O
salicylates B-CHEMICAL
and O
ETA B-GENE-Y
receptor I-GENE-Y
antagonists O
should O
be O
used O
to O
evaluate O
the O

physiopathological O
role O
of O
ET-1 B-GENE-Y
and O
may O
be O
of O
therapeutic O
interest O
in O
the O
treatment O
of O
ischemic O
heart O
disease. O
A O
unique O
cytosolic O
activity O
related O
but O
distinct O
from O
NQO1 B-GENE-N
catalyses O
metabolic O
activation O
of O
mitomycin B-CHEMICAL
C. I-CHEMICAL
Mitomycin B-CHEMICAL
C I-CHEMICAL
(MMC) B-CHEMICAL
is O
a O
prototype O
bioreductive O
drug O
employed O
to O
treat O
a O
variety O
of O
cancers O
including O
head O
and O
neck O
cancer. O
Among O
the O
various O
enzymes, O
dicoumarol B-CHEMICAL
inhibitable O
cytosolic O
NAD(P)H:quinone B-CHEMICAL
oxidoreductase1 I-GENE-N
(NQO1) B-GENE-N
was O
shown O
to O

catalyse O
bioreductive O
activation O
of O
MMC B-CHEMICAL
leading O
to O
cross-linking O
of O
the O
DNA O
and O
cytotoxicity. O
However, O
the O
role O
of O
NQO1 B-GENE-N
in O
metabolic O
activation O
of O
MMC B-CHEMICAL
has O
been O
disputed. O
In O
this O
report, O
we O
present O
cellular O
and O
animal O
models O
to O
demonstrate O
that O
NQO1 B-GENE-N
may O
play O
only O
a O
minor O
role O
in O
metabolic O
activation O
of O
MMC. B-CHEMICAL
We O
further O
demonstrate O
that O
bioreductive O
activation O
of O
MMC B-CHEMICAL
is O
catalysed O
by O
a O
unique O
cytosolic O
activity O
which O
is O
related O
but O
distinct O
from O
NQO1. B-GENE-N
Chinese O
hamster O
ovary O
(CHO) O
cells O
were O
developed O
that O
permanently O
express O
higher O
levels O

of O
cDNA-derived O
NQO1. B-GENE-N
These O
cells O
showed O
significantly O
increased O
protection O
against O
menadione B-CHEMICAL
toxicity. O
However, O
they O
failed O
to O
demonstrate O
higher O
cytotoxicity O
due O
to O
exposure O
to O
MMC B-CHEMICAL
under O
oxygen B-CHEMICAL
(normal O
air) O
or O
hypoxia, O
as O
compared O
to O
the O
wild-type O
control O
CHO O
cells. O
Disruption O
of O
the O
NQO1 B-GENE-N
gene O
by O
homologous O
recombination O
generated O
NQO1-/- B-GENE-N
mice O
that O
do O
not O
express O
the O
NQO1 B-GENE-N
gene O
resulting O
in O
the O
loss O
of O
NQO1 B-GENE-N
protein O
and O
activity. O
The O
cytosolic O
fractions O
from O
liver O
and O

colon O
tissues O
of O
NQO1-/- B-GENE-N
mice O
showed O
similar O
amounts O
of O
DNA O
cross-linking O
upon O
exposure O
to O
MMC, B-CHEMICAL
as O
observed O
in O
NQO1+/+ B-GENE-N
mice. O
The O
unique O
cytosolic O
activity O
that O
activated O
MMC B-CHEMICAL
in O
cytosolic O
fractions O
of O
liver O
and O
colon O
tissues O
of O
NQO1-/- B-GENE-N
mice O
was O
designated O
as O
cytosolic O
MMC B-CHEMICAL
reductase. I-GENE-N
This O
activity, O
like O
NQO1, B-GENE-N
was O
inhibited O
by O
dicoumarol B-CHEMICAL
and O
immunologically O
related O
to O
NQO1. B-GENE-N
Troglitazone B-CHEMICAL
reduces O
plasminogen B-GENE-Y

activator I-GENE-Y
inhibitor-1 I-GENE-Y
expression O
and O
secretion O
in O
cultured O
human O
adipocytes. O
AIMS/HYPOTHESIS: O
Increased O
plasma B-GENE-Y
plasminogen I-GENE-Y
activator I-GENE-Y
inhibitor-1 I-GENE-Y
(PAI-1) B-GENE-Y
concentrations O
are O
characteristic O
for O
subjects O
with O
insulin B-GENE-Y
resistance O
and O
could O
contribute O
to O
the O
increased O
cardiovascular O
risk O
in O
this O
state. O
In O
this O
study, O
we O
investigated O
the O
effect O
of O
troglitazone, B-CHEMICAL
a O
ligand O
of O
the O
nuclear B-GENE-N
receptor I-GENE-N
peroxisome B-GENE-Y
proliferator I-GENE-Y
activated I-GENE-Y
receptor-gamma, I-GENE-Y
on O
PAI-1 B-GENE-Y
expression O
and O
secretion O
in O
human O
adipocytes. O
METHODS: O
We O
used O
two O

models: O
in O
vitro O
differentiated O
subcutaneous O
and O
omental O
adipocytes O
cultured O
under O
serum-free O
conditions O
and O
isolated O
subcutaneous O
and O
omental O
fat O
cells O
kept O
in O
suspension O
culture. O
Plasminogen B-GENE-Y
activator I-GENE-Y
inhibitor-1 I-GENE-Y
protein O
was O
measured O
by O
ELISA, O
PAI-1 B-GENE-Y
mRNA O
by O
a O
semiquantitative O
RT-PCR O
technique. O
RESULTS: O
Exposure O
of O
in O
vitro O
differentiated O
subcutaneous O
adipocytes O
from O
young O
normal-weight O
females O
to O
1 O
microgram/ml O
troglitazone B-CHEMICAL
for O
72 O
h O
caused O
a O
reduction O
of O
both O
PAI-1 B-GENE-Y

secretion O
(by O
29 O
+/- O
5%; O
p O
< O
0.01) O
and O
PAI-1 B-GENE-Y
mRNA O
expression O
(by O
26 O
+/- O
3%; O
p O
< O
0.05). O
In O
cultures O
from O
severely O
obese O
subjects, O
troglitazone B-CHEMICAL
induced O
a O
decrease O
of O
PAI-1 B-GENE-Y
antigen O
secretion O
from O
newly O
differentiated O
omental O
adipocytes O
by O
49 O
+/- O
8% O
(p O
< O
0.01) O
and O
from O
subcutaneous O
adipocytes O
by O
30 O
+/- O
7% O
(p O
< O
0.05). O
Exposure O
of O
freshly O
isolated O
subcutaneous O
and O
omental O
adipocytes O

in O
suspension O
culture O
to O
troglitazone B-CHEMICAL
induced O
a O
similar O
reduction O
of O
PAI-1 B-GENE-Y
concentration O
in O
the O
culture O
medium O
(by O
35 O
+/- O
11%, O
p O
< O
0.05, O
and O
33 O
+/- O
8%, O
p O
< O
0.05 O
compared O
with O
control, O
respectively). O
CONCLUSION/INTERPRETATION: O
This O
study O
provides O
evidence O
that O
troglitazone B-CHEMICAL
reduces O
PAI-1 B-GENE-Y
production O
in O
human O
adipocytes, O
probably O
at O
the O
transcriptional O
level. O
This O
observation O
could O
point O
to O
a O
new O
beneficial O
effect O
of O
troglitazone, B-CHEMICAL
particularly O
in O
obese O
subjects, O
which O
could O

be O
associated O
with O
a O
reduced O
cardiovascular O
risk. O
Effect O
of O
JTH-601, O
a O
novel O
alpha(1)-adrenoceptor B-GENE-N
antagonist, O
on O
prostate O
function O
in O
dogs. O
We O
examined O
the O
effect O
of O
JTH-601 B-CHEMICAL
(3- O
inverted O
question O
markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom B-CHEMICAL
ethyl B-CHEMICAL
inverted O
question O
mark-4-methoxy-2,5,6-trimethylphenol B-CHEMICAL
hemifumarate), I-CHEMICAL
a O
new O

alpha(1L)-adrenoceptor B-GENE-N
antagonist, O
on O
prostatic O
function O
in O
isolated O
canine O
prostate O
and O
in O
anesthetized O
dogs. O
In O
the O
contraction O
study, O
phenylephrine B-CHEMICAL
and O
noradrenaline B-CHEMICAL
produced O
concentration-dependent O
contractions O
in O
canine O
prostate O
and O
carotid O
artery, O
respectively. O
In O
these O
tissues, O
JTH-601, B-CHEMICAL
prazosin B-CHEMICAL
(a O
non-selective O
alpha(1)-adrenoceptor B-GENE-N
antagonist), O
and O
tamsulosin B-CHEMICAL
(an O
alpha(1A)-adrenoceptor B-GENE-Y
antagonist) O
competitively O
antagonized O
contraction O
in O
a O

concentration-dependent O
manner. O
The O
pA(2) O
(pK(B)) O
values O
with O
prostate O
were O
8.49+/-0.07 O
for O
JTH-601, O
7.94+/-0.04 O
for O
prazosin B-CHEMICAL
and O
9.42+/-0.22 O
for O
tamsulosin. B-CHEMICAL
The O
ratio O
of O
pA(2) O
(carotid O
artery/prostate), O
i.e. O
prostatic O
selectivity, O
was O
10.471 O
for O
JTH-601, B-CHEMICAL
0.008 O
for O
prazosin B-CHEMICAL
and O
0.371 O
for O

tamsulosin, B-CHEMICAL
respectively. O
In O
anesthetized O
dogs, O
JTH-601 B-CHEMICAL
(1 O
mg/kg, O
i.d.) O
significantly O
decreased O
urethral O
pressure O
by O
15% O
without O
affecting O
blood O
pressure O
or O
heart O
rate. O
Tamsulosin B-CHEMICAL
(0.1 O
mg/kg, O
i.d.) O
decreased O
urethral O
pressure O
to O
the O
same O
extent O
as O
did O
JTH-601, B-CHEMICAL
but O
with O
a O
significant O
effect O
on O
blood O
pressure O
and O
heart O
rate. O
JTH-601 B-CHEMICAL
showed O
higher O
selectivity O
for O
canine O
prostate O
both O
in O
vitro O
and O
in O
vivo. O
In O
prostate, O
an O
important O
role O

of O
the O
alpha(1L)-adrenoceptor B-GENE-N
is O
suggested O
in O
the O
smooth O
muscle O
contraction O
mediated O
by O
alpha(1)-adrenoceptors. B-GENE-N
JTH-601 B-CHEMICAL
is O
expected O
to O
be O
an O
effective O
alpha(1)-adrenoceptor B-GENE-N
antagonist O
for O
the O
treatment O
of O
urinary O
outlet O
obstruction O
by O
benign O
prostatic O
hypertrophy O
with O
a O
minimum O
effect O
on O
the O
cardiovascular O
system. O
Severe O
impairment O
of O
salivation O
in O
Na+/K+/2Cl- B-GENE-N
cotransporter I-GENE-N
(NKCC1)-deficient B-GENE-Y
mice. O
The O
salivary O
fluid O

secretory O
mechanism O
is O
thought O
to O
require O
Na(+)/K(+)/2Cl(-) B-GENE-N
cotransporter-mediated I-GENE-N
Cl(-) B-CHEMICAL
uptake. O
To O
directly O
test O
this O
possibility O
we O
studied O
the O
in O
vivo O
and O
in O
vitro O
functioning O
of O
acinar O
cells O
from O
the O
parotid O
glands O
of O
mice O
with O
targeted O
disruption O
of O
Na(+)/K(+)/2Cl(-) B-GENE-Y
cotransporter I-GENE-Y
isoform I-GENE-Y
1 I-GENE-Y
(Nkcc1), B-GENE-Y
the O
gene O
encoding O
the O
salivary O

Na(+)/K(+)/2Cl(-) B-GENE-N
cotransporter. I-GENE-N
In O
wild-type O
mice O
NKCC1 B-GENE-Y
was O
localized O
to O
the O
basolateral O
membranes O
of O
parotid O
acinar O
cells, O
whereas O
expression O
was O
not O
detected O
in O
duct O
cells. O
The O
lack O
of O
functional O
NKCC1 B-GENE-Y
resulted O
in O
a O
dramatic O
reduction O
(>60%) O
in O
the O
volume O
of O
saliva O
secreted O
in O
response O
to O
a O
muscarinic O
agonist, O
the O
primary O
in O
situ O
salivation O
signal. O
Consistent O
with O
defective O
Cl(-) B-CHEMICAL
uptake, O
a O
loss O
of O

bumetanide-sensitive B-CHEMICAL
Cl(-) B-CHEMICAL
influx O
was O
observed O
in O
parotid O
acinar O
cells O
from O
mice O
lacking O
NKCC1. B-GENE-Y
Cl(-)/ B-GENE-N
HCO(3)(-) I-GENE-N
exchanger I-GENE-N
activity O
was O
increased O
in O
parotid O
acinar O
cells O
isolated O
from O
knockout O
mice O
suggesting O
that O
the O
residual O
saliva O
secreted O
by O
mice O
lacking O
NKCC1 B-GENE-Y
is O
associated O
with O
anion O
exchanger-dependent O
Cl(-) B-CHEMICAL
uptake. O
Indeed, O
expression O
of O
the O
Cl(-)/ B-CHEMICAL
HCO(3)(-) B-CHEMICAL
exchanger I-GENE-N
AE2 B-GENE-N
was O
enhanced O
suggesting O
that O
this O
transporter O
compensates O

for O
the O
loss O
of O
functional O
Na(+)/K(+)/2Cl(-) B-CHEMICAL
cotransporter. I-GENE-N
Furthermore, O
the O
ability O
of O
the O
parotid O
gland O
to O
conserve O
NaCl B-CHEMICAL
was O
abolished O
in O
NKCC1-deficient B-GENE-Y
mice. O
This O
deficit O
was O
not O
associated O
with O
changes O
in O
the O
morphology O
of O
the O
ducts, O
but O
transcript O
levels O
for O
the O
alpha-, O
beta-, O
and O
gamma-subunits O
of O
the O
epithelial O
Na(+) B-CHEMICAL
channel O
were O
reduced. O
These O
data O
directly O
demonstrate O
that O
NKCC1 B-GENE-Y
is O
the O
major O
Cl(-) B-CHEMICAL
uptake O
mechanism O
across O
the O

basolateral O
membrane O
of O
acinar O
cells O
and O
is O
critical O
for O
driving O
saliva O
secretion O
in O
vivo. O
Evaluation O
of O
in O
vivo O
binding O
properties O
of O
3H-NMPB B-CHEMICAL
and O
3H-QNB B-CHEMICAL
in O
mouse O
brain. O
UNLABELLED: O
Apparent O
muscarinic B-GENE-N
acetylcholine I-GENE-N
(mAch) I-GENE-N
receptor I-GENE-N
occupancy O
in O
mouse O
cerebral O
cortex, O
hippocampus, O
and O
striatum O
by O
scopolamine, B-CHEMICAL
an O
antagonist, O
and O
biperiden, B-CHEMICAL
a O
relatively O
selective O
M1 B-GENE-Y
antagonist, O
was O
estimated O
with O
competitive O
binding O
studies O
using O
two O
different O
radioligands: O

3H-N-methyl B-CHEMICAL
piperidyl I-CHEMICAL
benzilate I-CHEMICAL
(3H-NMPB) B-CHEMICAL
and O
3H-quinuclidinyl B-CHEMICAL
benzilate I-CHEMICAL
(3H-QNB). B-CHEMICAL
Both O
radioligands O
labeled O
mAch B-GENE-N
receptors I-GENE-N
in O
these O
brain O
regions, O
and O
the O
relative O
regional O
distributions O
of O
the O
specific O
binding O
of O
3H-NMPB B-CHEMICAL
in O
vivo O
paralleled O
the O
distribution O
of O
mAch B-GENE-N
receptors. I-GENE-N
3H-NMPB B-CHEMICAL
binding O
in O
vivo O
was O
much O
more O
sensitive O
to O
direct O
competitive O
inhibition O
by O
scopolamine B-CHEMICAL
than O
was O
3H-QNB. B-CHEMICAL
A O
similar O
discrepancy O
in O

sensitivity O
to O
competitors O
between O
3H-NMPB B-CHEMICAL
and O
3H-QNB B-CHEMICAL
was O
also O
observed O
when O
biperiden B-CHEMICAL
was O
used O
as O
a O
competitor, O
indicating O
that O
binding O
to O
different O
subtypes O
of O
the O
mAch B-GENE-N
receptor I-GENE-N
could O
not O
account O
for O
the O
observed O
differences O
in O
sensitivity O
to O
competition. O
An O
in O
vivo O
saturation O
study O
suggested O
that O
the O
apparent O
association O
rate O
constant O
(k O
on) O
of O
3H-QNB B-CHEMICAL
binding O
might O
be O
changed O
by O
ligand O
concentration. O
The O
heterogeneity O
of O
the O
free O
ligand O
concentration O
in O
intact O
brain O
was O
assessed O
in O
relation O
to O
the O
ligand O
concentration O
dependency O
of O
the O
apparent O
association O
rate O
constant O
(k O

on) O
of O
3H-QNB B-CHEMICAL
binding. O
This O
finding, O
together O
with O
the O
more O
favorable O
accumulation O
of O
3H-NMPB B-CHEMICAL
in O
cerebral O
cortex, O
hippocampus, O
and O
striatum, O
leads O
us O
to O
conclude O
that O
3H-NMPB, B-CHEMICAL
or O
its O
positron O
emitting O
counterpart, O
should O
be O
the O
more O
favorable O
radiotracer O
for O
the O
estimation O
of O
mAch B-GENE-N
receptor I-GENE-N
occupancy O
by O
cholinergic O
drugs O
in O
the O
brain. O
KEYWORDS: O
mAch B-GENE-N
receptor, I-GENE-N
QNB, B-CHEMICAL
NMPB, B-CHEMICAL
in O
vivo, O
mouse. O
Impaired O
expression O
of O

the O
uncoupling B-GENE-Y
protein-3 I-GENE-Y
gene O
in O
skeletal O
muscle O
during O
lactation: O
fibrates O
and O
troglitazone B-CHEMICAL
reverse O
lactation-induced O
downregulation O
of O
the O
uncoupling B-GENE-Y
protein-3 I-GENE-Y
gene. O
The O
expression O
of O
uncoupling B-GENE-Y
protein I-GENE-Y
(UCP)-3 I-GENE-Y
mRNA O
in O
skeletal O
muscle O
is O
dramatically O
reduced O
during O
lactation O
in O
mice. O
The O
reduction O
in O
UCP-3 B-GENE-Y
mRNA O
levels O
lowers O
the O
amount O
of O
the O
UCP-3 B-GENE-Y
protein O
in O
skeletal O
muscle O
mitochondria O
during O
lactation. O
Spontaneous O
or O
abrupt O
weaning O
reverses O
the O
downregulation O
of O
the O

UCP-3 B-GENE-Y
mRNA O
but O
not O
the O
reduction O
in O
UCP-3 B-GENE-Y
protein O
levels. O
In O
lactating O
and O
virgin O
mice, O
however, O
fasting O
increases O
UCP-3 B-GENE-Y
mRNA O
levels. O
Changes O
in O
UCP-3 B-GENE-Y
mRNA O
occur O
in O
parallel O
with O
modifications O
in O
the O
levels O
of O
free O
fatty B-CHEMICAL
acids, I-CHEMICAL
which O
are O
reduced O
in O
lactation O
and O
are O
upregulated O
due O
to O
weaning O
or O
fasting. O
Modifications O
in O
the O
energy O
nutritional O
stress O
of O
lactating O
dams O
achieved O
by O
manipulating O
litter O
sizes O
do O
not O
influence O
UCP-3 B-GENE-Y
mRNA O
levels O
in O
skeletal O
muscle. O
Conversely, O
when O
mice O
are O
fed O
a O

high-fat O
diet O
after O
parturition, O
the O
downregulation O
of O
UCP-3 B-GENE-Y
mRNA O
and O
UCP-3 B-GENE-Y
protein O
levels O
due O
to O
lactation O
is O
partially O
reversed, O
as O
is O
the O
reduction O
in O
serum O
free O
fatty B-CHEMICAL
acid I-CHEMICAL
levels. O
Treatment O
of O
lactating O
mice O
with O
a O
single O
injection O
of O
bezafibrate, B-CHEMICAL
an O
activator O
of O
the O
peroxisome B-GENE-N
proliferator-activated I-GENE-N
receptor I-GENE-N
(PPAR), B-GENE-N
raises O
UCP-3 B-GENE-Y
mRNA O
in O
skeletal O
muscle O
to O
levels O
similar O
to O
those O
in O
virgin O
mice. O

4-chloro-6-[(2,3-xylidine)-pirimidinylthio] B-CHEMICAL
acetic I-CHEMICAL
acid I-CHEMICAL
(WY-14,643), B-CHEMICAL
a O
specific O
ligand O
of O
the O
PPAR-alpha B-GENE-Y
subtype, O
causes O
the O
most O
dramatic O
increase O
in O
UCP-3 B-GENE-Y
mRNA, O
whereas O
troglitazone, B-CHEMICAL
a O
specific O
activator O
of O
PPAR-gamma, B-GENE-Y
also O
significantly O
increases O
UCP-3 B-GENE-Y
mRNA O
abundance O
in O
skeletal O
muscle O
of O
lactating O
mice. O
However, O
in O
virgin O
mice, O
bezafibrate B-CHEMICAL
and O
WY-14,643 B-CHEMICAL
do O
not O

significantly O
affect O
UCP-3 B-GENE-Y
mRNA O
expression, O
whereas O
troglitazone B-CHEMICAL
is O
at O
least O
as O
effective O
as O
it O
is O
in O
lactating O
dams. O
It O
is O
proposed O
that O
the O
UCP-3 B-GENE-Y
gene O
is O
regulated O
in O
skeletal O
muscle O
during O
lactation O
in O
response O
to O
changes O
in O
circulating O
free O
fatty B-CHEMICAL
acids I-CHEMICAL
by O
mechanisms O
involving O
activation O
of O
PPARs. B-GENE-N
The O
impaired O
expression O
of O
the O
UCP-3 B-GENE-Y
gene O
is O
consistent O
with O
the O
involvement O
of O
UCP-3 B-GENE-Y
gene O
regulation O
in O
the O
reduction O
of O
the O
use O
of O
fatty B-CHEMICAL
acids I-CHEMICAL
as O
fuel O
by O
the O
skeletal O
muscle O
and O
in O
impaired O
adaptative O
thermogenesis, O
both O
of O
which O
are O
major O
metabolic O
adaptations O
that O
occur O
during O

lactation. O
The O
apoptosome: O
heart O
and O
soul O
of O
the O
cell O
death O
machine. O
Apoptosis O
is O
a O
fundamental O
biologic O
process O
by O
which O
metazoan O
cells O
orchestrate O
their O
own O
self-demise. O
Genetic O
analyses O
of O
the O
nematode O
C O
elegans O
identified O
three O
core O
components O
of O
the O
suicide O
apparatus O
which O
include O
CED-3, B-GENE-Y
CED-4, B-GENE-Y
and O
CED-9. B-GENE-Y
An O
analogous O
set O
of O
core O
constituents O
exists O
in O
mammalian O
cells O
and O
includes O
caspase-9, B-GENE-Y
Apaf-1, B-GENE-Y
and O
bcl-2/xL, B-GENE-N
respectively. O
CED-3 B-GENE-Y
and O

CED-4, B-GENE-Y
along O
with O
their O
mammalian O
counterparts, O
function O
to O
kill O
cells, O
whereas O
CED-9 B-GENE-Y
and O
its O
mammalian O
equivalents O
protect O
cells O
from O
death. O
These O
central O
components O
biochemically O
intermingle O
in O
a O
ternary O
complex O
recently O
dubbed O
the O
"apoptosome." O
The O
C O
elegans O
protein O
EGL-1 B-GENE-Y
and O
its O
mammalian O
counterparts, O
pro-apoptotic O
members O
of O
the O
bcl-2 B-GENE-N
family, O
induce O
cell O
death O
by O
disrupting O
apoptosome O
interactions. O
Thus, O
EGL-1 B-GENE-Y
may O
represent O
a O
primordial O
signal O
integrator O
for O

the O
apoptosome. O
Various O
biochemical O
processes O
including O
oligomerization, O
adenosine B-CHEMICAL
triphosphate I-CHEMICAL
ATP/dATP B-CHEMICAL
binding, O
and O
cytochrome B-GENE-Y
c I-GENE-Y
interaction O
play O
a O
role O
in O
regulating O
the O
ternary O
death O
complex. O
Recent O
studies O
suggest O
that O
cell O
death B-GENE-N
receptors, I-GENE-N
such O
as O
CD95, B-GENE-Y
may O
amplify O
their O
suicide O
signal O
by O
activating O
the O
apoptosome. O
These O
mutual O
associations O
by O
core O
components O
of O
the O
suicide O
apparatus O
provide O
a O
molecular O
framework O
in O
which O
diverse O
death O
signals O
likely O
interface. O
Understanding O
the O
apoptosome O
and O
its O
cellular O
connections O
will O
facilitate O
the O
design O
of O
novel O
therapeutic O
strategies O
for O
cancer O
and O
other O
disease O
states O

in O
which O
apoptosis O
plays O
a O
pivotal O
role. O
Retigabine, B-CHEMICAL
a O
novel O
anti-convulsant, O
enhances O
activation O
of O
KCNQ2/Q3 B-GENE-N
potassium B-GENE-N
channels. I-GENE-N
Retigabine B-CHEMICAL
[N-(2-amino-4-[fluorobenzylamino]-phenyl) B-CHEMICAL
carbamic I-CHEMICAL
acid; I-CHEMICAL
D-23129] B-CHEMICAL
is O
a O
novel O
anticonvulsant, O
unrelated O
to O
currently O
available O
antiepileptic O
agents, O
with O
activity O
in O
a O
broad O
range O
of O
seizure O
models. O
In O
the O
present O
study, O
we O
sought O
to O
determine O
whether O
retigabine O
could O
enhance O
current O
through O
M-like O
currents O

in O
PC12 O
cells O
and O
KCNQ2/Q3 B-GENE-N
K(+) B-CHEMICAL
channels I-GENE-N
expressed O
in O
Chinese O
hamster O
ovary O
cells O
(CHO-KCNQ2/Q3). B-GENE-N
In O
differentiated O
PC12 O
cells, O
retigabine O
enhanced O
a O
linopirdine-sensitive B-CHEMICAL
current. O
The O
effect O
of O
retigabine B-CHEMICAL
was O
associated O
with O
a O
slowing O
of O
M-like O
tail O
current O
deactivation O
in O
these O
cells. O
Retigabine B-CHEMICAL
(0.1 O
to O
10 O
microM) O
induced O
a O
potassium B-CHEMICAL
current O
and O
hyperpolarized O
CHO O
cells O
expressing O
KCNQ2/Q3 B-GENE-N
cells O
but O
not O
in O
wild-type O

cells. O
Retigabine-induced B-CHEMICAL
currents O
in O
CHO-KCNQ2/Q3 B-GENE-N
cells O
were O
inhibited O
by O
60.6 O
+/- O
11% O
(n O
= O
4) O
by O
the O
KCNQ2/Q3 B-GENE-N
blocker, O
linopirdine B-CHEMICAL
(10 O
microM), O
and O
82.7 O
+/- O
5.4% O
(n O
= O
4) O
by O
BaCl(2) B-CHEMICAL
(10 O
mM). O
The O
mechanism O
by O
which O
retigabine B-CHEMICAL
enhanced O
KCNQ2/Q3 B-GENE-N
currents O
involved O
large, O
drug-induced, O
leftward O
shifts O
in O
the O
voltage O
dependence O
of O
channel O
activation O

(-33.1 O
+/- O
2.6 O
mV, O
n O
= O
4, O
by O
10 O
microM O
retigabine). B-CHEMICAL
Retigabine B-CHEMICAL
shifted O
the O
voltage O
dependence O
of O
channel O
activation O
with O
an O
EC(50) O
value O
of O
1.6 O
+/- O
0.3 O
microM O
(slope O
factor O
was O
1.2 O
+/- O
0.1, O
n O
= O
4 O
to O
5 O
cells O
per O
concentration). O
Retigabine B-CHEMICAL
(0.1 O
to O
10 O
microM) O
also O
slowed O
the O
rate O
of O
channel O
deactivation, O
predominantly O
by O
increasing O
the O
contribution O
of O
a O
slowly O
deactivating O
tail O
current O
component. O
Our O
findings O
identify O

KCNQ2/Q3 B-GENE-N
channels O
as O
a O
molecular O
target O
for O
retigabine B-CHEMICAL
and O
suggest O
that O
activation O
of O
KCNQ2/Q3 B-GENE-N
channels O
may O
be O
responsible O
for O
at O
least O
some O
of O
the O
anticonvulsant O
activity O
of O
this O
agent. O
Serotonin B-GENE-Y
transporter I-GENE-Y
gene O
regulatory O
region O
polymorphism O
(5-HTTLPR), B-GENE-Y
[3H]paroxetine B-CHEMICAL
binding O
in O
healthy O
control O
subjects O
and O
alcohol-dependent O
patients O
and O
their O
relationships O
to O
impulsivity. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
[3H]paroxetine B-CHEMICAL
binding O
and O
impulsivity O
in O
alcohol-dependent B-CHEMICAL
and O

age-matched O
control O
subjects O
in O
relation O
to O
a O
5'-promoter O
region O
serotonin B-CHEMICAL
transporter I-GENE-Y
(5-HTT) B-GENE-Y
polymorphism O
(5-HTTLPR). B-GENE-Y
Alcohol-dependent O
subjects O
were O
hypothesized O
to O
show O
a O
decreased O
number O
of O
bindings O
sites O
and O
a O
lower O
dissociation O
constant. O
5-HTTLPR B-GENE-Y
S-genotype O
carriers O
in O
both O
alcohol-dependent B-CHEMICAL
and O
control O
subjects O
were O
expected O
to O
show O
significantly O
fewer O
binding O
sites O
and O
a O
lower O
dissociation O
constant. O
Influences O
of O
impulsive O
traits, O
chronic O
daily O
alcohol B-CHEMICAL
intake, O
duration O
of O
alcohol B-CHEMICAL
dependence, O
age O
of O

onset O
and O
age O
on O
[3H]paroxetine B-CHEMICAL
binding O
were O
also O
investigated. O
Inpatients O
meeting O
DSM O
IV O
alcohol B-CHEMICAL
dependence O
criteria O
and O
of O
German O
descent O
were O
recruited O
to O
avoid O
ethnic O
stratification O
effects. O
One O
hundred O
and O
seventeen O
control O
subjects O
of O
similar O
social O
status O
were O
recruited O
from O
a O
town O
community. O
Blood O
samples O
were O
taken O
from O
both O
alcohol-dependent B-CHEMICAL
and O
control O
subjects O
to O
determine O
5-HTTLPR B-GENE-Y
genotypes O
using O
PCR O
of O
lymphocyte O
DNA, O
and O
to O
perform O
platelet O
[3H]paroxetine B-CHEMICAL
binding O
(binding O
capacity: O
B(max); O
and O
dissociation O
constant: O

K(D)). O
Impulsivity O
was O
assessed O
using O
the O
Barratt O
impulsiveness O
scale O
version O
5 O
(BIS-5) O
in O
alcohol-dependent B-CHEMICAL
subjects O
only. O
Alcohol-dependent B-CHEMICAL
subjects O
were O
subdivided O
into O
low O
or O
high O
impulsivity O
groups O
using O
a O
median-split O
of O
the O
BIS-5 O
scale. O
The O
control O
group O
was O
slightly O
older O
than O
the O
alcohol-dependent O
group O
(not O
statistically O
significant). O
[3H]paroxetine B-CHEMICAL
binding O
was O
investigated O
in O
72 O
control O
subjects O
and O
72 O
patients, O
of O
which O
five O
patients O
met O
type O
2 O
alcohol B-CHEMICAL
dependence O
criteria. O
Genotyping O
was O
carried O
out O
in O
all O
patients O

and O
control O
subjects. O
A O
significant O
influence O
of O
duration O
of O
alcohol B-CHEMICAL
dependence O
was O
found O
on O
the O
[3H]paroxetine B-CHEMICAL
binding O
K(D) O
but O
not O
B(max.) O
Neither O
alcohol-dependent B-CHEMICAL
nor O
control O
subjects O
showed O
any O
differences O
in O
B(max) O
or O
K(D). O
S-allele O
carriers O
did O
not O
show O
a O
decreased O
binding O
or O
lower O
dissociation O
constant. O
Furthermore, O
no O
significant O
interaction O
between O
B(max) O
and O
K(D) O
with O
either O
5-HTTLPR B-GENE-Y
genotype O
or O
impulsivity O
was O
revealed. O
This O
was O
the O
first O
study O
to O
investigate O
platelet O

[3H]paroxetine B-CHEMICAL
binding O
in O
alcohol-dependent B-CHEMICAL
and O
age-matched O
control O
subjects O
in O
relation O
to O
the O
5-HTTLPR B-GENE-Y
genotype. O
No O
differences O
concerning O
5-HTTLPR-alleles B-GENE-Y
were O
found O
in O
these O
groups O
Furthermore, O
no O
significant O
interaction O
between O
these O
parameters O
and O
impulsivity O
was O
shown O
in O
alcohol-dependent B-CHEMICAL
subjects. O
These O
results O
do O
not O
support O
previous O
results O
of O
altered O
[3H]paroxetine B-CHEMICAL
binding O
sites O
in O
alcohol-dependent O
subjects O
or O
5-HTTLPR B-GENE-Y
S-allele O
carriers. O
K(D) O
might O
be O
influenced O
by O
duration O
of O
alcohol B-CHEMICAL
dependence, O
but O
not O
sufficiently O
to O

yield O
differences O
between O
alcohol-dependent B-CHEMICAL
and O
control O
subjects. O
Arachidonic B-CHEMICAL
acid I-CHEMICAL
and O
nonsteroidal O
anti-inflammatory O
drugs O
induce O
conformational O
changes O
in O
the O
human B-GENE-Y
prostaglandin I-GENE-Y
endoperoxide I-GENE-Y
H2 I-GENE-Y
synthase-2 I-GENE-Y
(cyclooxygenase-2). B-GENE-Y
By O
using O
the O
technique O
of O
site-directed O
spin O
labeling O
combined O
with O
EPR O
spectroscopy, O
we O
have O
observed O
that O
binding O
of O
arachidonic B-CHEMICAL
acid I-CHEMICAL
and O
nonsteroidal O
anti-inflammatory O
drugs O
induces O
conformational O
changes O
in O
the O
human B-GENE-N
prostaglandin B-CHEMICAL
endoperoxide I-CHEMICAL
H(2) I-CHEMICAL
synthase I-GENE-N
enzyme I-GENE-N

(PGHS-2). B-GENE-Y
Line O
shape O
broadening O
resulting O
from O
spin-spin O
coupling O
of O
nitroxide B-CHEMICAL
pairs O
introduced O
into O
the O
membrane-binding O
helices O
of O
PGHS-2 B-GENE-Y
was O
used O
to O
calculate O
the O
inter-helical O
distances O
and O
changes O
in O
these O
distances O
that O
occur O
in O
response O
to O
binding O
various O
ligands. O
The O
inter-residue O
distances O
determined O
for O
the O
PGHS-2 B-GENE-Y
holoenzyme O
using O
EPR O
were O
1-7.9 O
A O
shorter O
than O
those O
of O
the O
crystal O
structure O
of O
the O
PGHS-2 B-GENE-Y
holoenzyme. O
However, O
inter-helical O
distances O
calculated O
and O
determined O
by O

EPR O
for O
PGHS-2 B-GENE-Y
complexed O
with O
arachidonic B-CHEMICAL
acid, I-CHEMICAL
flurbiprofen, B-CHEMICAL
and O
SC-58125 B-CHEMICAL
were O
in O
close O
agreement O
with O
those O
obtained O
from O
the O
cognate O
crystal O
structures. O
These O
results O
indicate O
that O
the O
structure O
of O
the O
solubilized O
PGHS-2 B-GENE-Y
holoenzyme O
measured O
in O
solution O
differs O
from O
the O
crystal O
structure O
of O
PGHS-2 B-GENE-Y
holoenzyme O
obtained O
by O
x-ray O
analysis. O
Furthermore, O
binding O
of O
ligands O
induces O
a O
conformational O
change O
in O
the O
holo-PGHS-2, B-GENE-Y
converting O
it O
to O
a O
structure O
similar O
to O
those O
obtained O
by O

x-ray O
analysis. O
Proteolysis O
protection O
assays O
had O
previously O
provided O
circumstantial O
evidence O
that O
binding O
of O
heme O
and O
non-steroidal B-CHEMICAL
anti-inflammatory O
drugs O
alters O
the O
conformation O
of O
PGHS, B-GENE-N
but O
the O
present O
experiments O
are O
the O
first O
to O
directly O
measure O
such O
changes. O
The O
finding O
that O
arachidonate B-CHEMICAL
can O
also O
induce O
a O
conformational O
change O
in O
PGHS-2 B-GENE-Y
was O
unexpected, O
and O
the O
magnitude O
of O
changes O
suggests O
this O
structural O
flexibility O
may O
be O
integral O
to O
the O
cyclooxygenase B-GENE-N
catalytic O
mechanism. O
Suppression O
of O
NF-kappaB B-GENE-N
activity O
by O
sulfasalazine B-CHEMICAL

is O
mediated O
by O
direct O
inhibition O
of O
IkappaB B-GENE-N
kinases I-GENE-N
alpha I-GENE-N
and I-GENE-N
beta. I-GENE-N
BACKGROUND O
& O
AIMS: O
Activation O
of O
NF-kappaB/Rel B-GENE-N
has O
been O
implicated O
in O
the O
pathogenesis O
of O
inflammatory O
bowel O
disease O
(IBD). O
Various O
drugs O
used O
in O
the O
treatment O
of O
IBD, O
such O
as O
glucocorticoids, O
5-aminosalicylic B-CHEMICAL
acid, I-CHEMICAL
and O
sulfasalazine, B-CHEMICAL
interfere O
with O
NF-kappaB/Rel B-GENE-N
signaling. O
The O
aim O
of O
this O
study O
was O
to O
define O
the O
molecular O
mechanism O
by O
which O
sulfasalazine B-CHEMICAL

inhibits O
NF-kappaB B-GENE-N
activation. O
METHODS: O
The O
effects O
of O
sulfasalazine B-CHEMICAL
and O
its O
moieties O
on O
NF-kappaB B-GENE-N
signaling O
were O
evaluated O
using O
electromobility O
shift, O
transfection, O
and O
immune O
complex O
kinase O
assays. O
The O
direct O
effect O
of O
sulfasalazine B-CHEMICAL
on O
IkappaB B-GENE-N
kinase I-GENE-N
(IKK) B-GENE-N
activity O
was O
investigated O
using O
purified O
recombinant O
IKK-alpha B-GENE-N
and I-GENE-N
-beta I-GENE-N
proteins. O
RESULTS: O
NF-kappaB/Rel B-GENE-N
activity O
induced O
by O
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
alpha, I-GENE-Y

12-O-tetradecanoylphorbol-13-acetate, B-CHEMICAL
or O
overexpression O
of O
NF-kappaB-inducing B-GENE-Y
kinase, I-GENE-Y
IKK-alpha, B-GENE-Y
IKK-beta, B-GENE-Y
or O
constitutively O
active O
IKK-alpha B-GENE-Y
and O
IKK-beta B-GENE-Y
mutants O
was O
inhibited O
dose O
dependently O
by O
sulfasalazine. B-CHEMICAL
Sulfasalazine B-CHEMICAL
inhibited O
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
alpha-induced I-GENE-Y
activation O
of O
endogenous O
IKK B-GENE-N
in O
Jurkat O
T O
cells O
and O
SW620 O
colon O
cells, O
as O
well O
as O
the O
catalytic O

activity O
of O
purified O
IKK-alpha B-GENE-Y
and O
IKK-beta B-GENE-Y
in O
vitro. O
In O
contrast, O
the O
moieties O
of O
sulfasalazine, B-CHEMICAL
5-aminosalicylic B-CHEMICAL
acid, I-CHEMICAL
and O
sulfapyridine B-CHEMICAL
or O
4-aminosalicylic B-CHEMICAL
acid I-CHEMICAL
had O
no O
effect. O
Activation O
of O
extracellular B-GENE-N
signal-related I-GENE-N
kinase I-GENE-N
(ERK) I-GENE-N
1 I-GENE-N
and I-GENE-N
2, I-GENE-N
c-Jun-N-terminal B-GENE-Y
kinase I-GENE-Y
(JNK) I-GENE-Y
1, I-GENE-Y
and O
p38 B-GENE-N
was O
unaffected O
by O
sulfasalazine. B-CHEMICAL
The O
decrease O
in O
substrate O
phosphorylation O
by O
IKK-alpha B-GENE-N
and I-GENE-N

-beta I-GENE-N
is O
associated O
with O
a O
decrease O
in O
autophosphorylation O
of O
IKKs B-GENE-N
and O
can O
be O
antagonized O
by O
excess O
adenosine B-CHEMICAL
triphosphate. I-CHEMICAL
CONCLUSIONS: O
These O
data O
identify O
sulfasalazine B-CHEMICAL
as O
a O
direct O
inhibitor O
of O
IKK-alpha B-GENE-N
and I-GENE-N
-beta I-GENE-N
by O
antagonizing O
adenosine B-CHEMICAL
triphosphate I-CHEMICAL
binding. O
The O
suppression O
of O
NF-kappaB B-GENE-N
activation O
by O
inhibition O
of O
the O
IKKs B-GENE-N
contributes O
to O
the O
well-known O
anti-inflammatory O
and O
immunosuppressive O
effects O
of O
sulfasalazine. B-CHEMICAL
Biochemistry O
of O

cyclooxygenase B-GENE-Y
(COX)-2 I-GENE-Y
inhibitors O
and O
molecular O
pathology O
of O
COX-2 B-GENE-Y
in O
neoplasia. O
Several O
types O
of O
human O
tumors O
overexpress O
cyclooxygenase B-GENE-Y
(COX) I-GENE-Y
-2 I-GENE-Y
but O
not O
COX-1, B-GENE-Y
and O
gene O
knockout O
transfection O
experiments O
demonstrate O
a O
central O
role O
of O
COX-2 B-GENE-Y
in O
experimental O
tumorigenesis. O
COX-2 B-GENE-Y
produces O
prostaglandins B-CHEMICAL
that O
inhibit O
apoptosis O
and O
stimulate O
angiogenesis O
and O
invasiveness. O
Selective O
COX-2 B-GENE-Y
inhibitors O
reduce O
prostaglandin B-CHEMICAL
synthesis, O
restore O

apoptosis, O
and O
inhibit O
cancer O
cell O
proliferation. O
In O
animal O
studies O
they O
limit O
carcinogen-induced O
tumorigenesis. O
In O
contrast, O
aspirin-like B-CHEMICAL
nonselective O
NSAIDs O
such O
as O
sulindac B-CHEMICAL
and O
indomethacin B-CHEMICAL
inhibit O
not O
only O
the O
enzymatic O
action O
of O
the O
highly O
inducible, O
proinflammatory O
COX-2 B-GENE-Y
but O
the O
constitutively O
expressed, O
cytoprotective O
COX-1 B-GENE-Y
as O
well. O
Consequently, O
nonselective O
NSAIDs O
can O
cause O
platelet O
dysfunction, O
gastrointestinal O
ulceration, O
and O

kidney O
damage. O
For O
that O
reason, O
selective O
inhibition O
of O
COX-2 B-GENE-Y
to O
treat O
neoplastic O
proliferation O
is O
preferable O
to O
nonselective O
inhibition. O
Selective O
COX-2 B-GENE-Y
inhibitors, O
such O
as O
meloxicam, B-CHEMICAL
celecoxib B-CHEMICAL
(SC-58635), B-CHEMICAL
and O
rofecoxib B-CHEMICAL
(MK-0966), B-CHEMICAL
are O
NSAIDs O
that O
have O
been O
modified O
chemically O
to O
preferentially O
inhibit O
COX-2 B-GENE-Y
but O
not O
COX-1. B-GENE-Y
For O
instance, O
meloxicam B-CHEMICAL
inhibits O
the O
growth O
of O
cultured O
colon O
cancer O
cells O

(HCA-7 O
and O
Moser-S) O
that O
express O
COX-2 B-GENE-Y
but O
has O
no O
effect O
on O
HCT-116 O
tumor O
cells O
that O
do O
not O
express O
COX-2. B-GENE-Y
NS-398 B-CHEMICAL
induces O
apoptosis O
in O
COX-2 B-GENE-Y
expressing O
LNCaP O
prostate O
cancer O
cells O
and, O
surprisingly, O
in O
colon O
cancer O
S/KS O
cells O
that O
does O
not O
express O
COX-2. B-GENE-Y
This O
effect O
may O
due O
to O
induction O
of O
apoptosis O
through O
uncoupling O
of O
oxidative O
phosphorylation O
and O
down-regulation O
of O
Bcl-2, B-GENE-Y
as O
has O
been O
demonstrated O
for O
some O

nonselective O
NSAIDs, O
for O
instance, O
flurbiprofen. B-CHEMICAL
COX-2 B-GENE-Y
mRNA O
and O
COX-2 B-GENE-Y
protein O
is O
constitutively O
expressed O
in O
the O
kidney, O
brain, O
spinal O
cord, O
and O
ductus O
deferens, O
and O
in O
the O
uterus O
during O
implantation. O
In O
addition, O
COX-2 B-GENE-Y
is O
constitutively O
and O
dominantly O
expressed O
in O
the O
pancreatic O
islet O
cells. O
These O
findings O
might O
somewhat O
limit O
the O
use O
of O
presently O
available O
selective O
COX-2 B-GENE-Y
inhibitors O
in O
cancer O
prevention O
but O
will O
probably O
not O
deter O
their O
successful O
application O
for O
the O
treatment O
of O
human O
cancers. O

The O
aromatic-L-amino B-GENE-Y
acid I-GENE-Y
decarboxylase I-GENE-Y
inhibitor O
carbidopa O
is O
selectively O
cytotoxic O
to O
human O
pulmonary O
carcinoid O
and O
small O
cell O
lung O
carcinoma O
cells. O
The O
carcinoid O
tumor O
is O
an O
uncommon O
neuroendocrine O
neoplasm O
the O
hallmark O
of O
which O
is O
excessive O
serotonin B-CHEMICAL
production. O
In O
studying O
kinetics O
of O
tryptophan B-CHEMICAL
hydroxylase I-GENE-N
and O
aromatic-L-amino B-CHEMICAL
acid I-CHEMICAL
decarboxylase I-GENE-Y
(AAAD) B-GENE-Y
in O
human O
carcinoid O
hepatic O
metastases O
and O
adjacent O
normal O
liver O
(J. O
A. O
Gilbert O
et O
al, O

Biochem. O
Pharmacol., O
50: O
845-850, O
1995), O
we O
identified O
one O
significant O
difference: O
the O
Vmax O
of O
carcinoid O
AAAD B-GENE-Y
was O
50-fold O
higher O
than O
that O
in O
normal O
liver. O
Here, O
we O
report O
Western O
and O
Northern O
analyses O
detecting O
large O
quantities O
of O
AAAD B-GENE-Y
polypeptide O
and O
mRNA O
in O
human O
carcinoid O
primary O
as O
well O
as O
metastatic O
tumors O
compared O
with O
normal O
surrounding O
tissues. O
To O
assess O
the O
feasibility O
of O
targeting O
these O
high O
AAAD B-GENE-Y
levels O
for O
chemotherapy, O
AAAD B-GENE-Y
inhibitors O
carbidopa B-CHEMICAL

(alpha-methyl-dopahydrazine), B-CHEMICAL
alpha-monofluoromethyldopa B-CHEMICAL
(MFMD), B-CHEMICAL
and O
3-hydroxybenzylhydrazine B-CHEMICAL
(NSD-1015) B-CHEMICAL
were O
incubated O
(72 O
h) O
with O
NCI-H727 O
human O
lung O
carcinoid O
cells. O
Carbidopa B-CHEMICAL
and O
MFMD B-CHEMICAL
were O
lethal O
(IC50 O
= O
29 O
+/- O
2 O
microM O
and O
56 O
+/- O
6 O
microM, O
respectively); O
NSD-1015 B-CHEMICAL
had O
no O
effect O
on O
proliferation. O
On O
exposure O
to O
other O
human O
tumor O
lines, O

carbidopa B-CHEMICAL
was O
lethal O
only O
to O
NCI-H146 O
and O
NCI-H209 O
small O
cell O
lung O
carcinoma O
(SCLC) O
lines O
(IC50 O
= O
12 O
+/- O
1 O
microM O
and O
22 O
+/- O
5 O
microM, O
respectively). O
Carbidopa B-CHEMICAL
(100 O
microM) O
decreased O
growth O
of O
(but O
did O
not O
kill) O
SK-N-SH O
neuroblastoma O
and O
A204 O
rhabdomyosarcoma O
cells O
and O
did O
not O
affect O
proliferation O
of O
DU O
145 O
prostate, O
MCF7 O
breast, O
or O
NCI-H460 O
large O
cell O
lung O
carcinoma O

lines. O
The O
rank O
order O
of O
lines O
by O
AAAD B-GENE-Y
activity O
was O
NCI-H146 O
> O
NCI-H209 O
> O
SK-N-SH O
> O
NCI-H727, O
whereas O
A204, O
DU O
145, O
MCF7, O
and O
NCI-H460 O
had O
no O
measurable O
activity. O
For O
lung O
tumor O
lines O
(carcinoid, O
two O
SCLC, O
and O
one O
large O
cell O
lung O
carcinoma), O
AAAD B-GENE-Y
activity O
was O
correlated O
with O
the O
potency O
of O
carbidopa-induced B-CHEMICAL
cytotoxicity. O
However, O
carcinoid O
cell O
death O
was O
not O
solely O
attributable O
to O

complete O
inhibition O
of O
either O
AAAD B-GENE-Y
activity O
or O
the O
serotonin B-CHEMICAL
synthetic O
pathway. O
In O
further O
evaluating O
potential O
applications O
of O
these O
findings O
with O
carbidopa, B-CHEMICAL
we O
determined O
that O
sublethal O
doses O
of O
carbidopa B-CHEMICAL
produced O
additive O
cytotoxic O
effects O
in O
carcinoid O
cells O
in O
combination O
with O
etoposide O
and O
cytotoxic O
synergy O
in O
SCLC O
cells O
when O
coincubated O
with O
topotecan. B-CHEMICAL
Hexahydrochromeno[4,3-b]pyrrole B-CHEMICAL
derivatives O
as O
acetylcholinesterase B-GENE-Y
inhibitors. O
In O
a O
search O
for O
less O
flexible O
analogues O
of O

caproctamine B-CHEMICAL
(1), O
a O
diamine B-CHEMICAL
diamide B-CHEMICAL
endowed O
with O
an O
interesting O
AChE B-GENE-Y
affinity O
profile, O
we O
discovered O
compound O
2, O
in O
which O
the O
terminal O
2-methoxybenzyl B-CHEMICAL
groups O
of O
1 O
have O
been O
incorporated O
into O
a O
tricyclic B-CHEMICAL
system. O
Since O
this O
compound O
retains O
good O
AChE B-GENE-Y
inhibitory O
activity O
and O
its O
hexahydrochromeno[4,3-b]pyrrole B-CHEMICAL
moiety O
is O
reminiscent O
of O
the O
hexahydropyrrolo[2,3-b]indole B-CHEMICAL
of I-CHEMICAL
physostigmine I-CHEMICAL
(3), O
we O
have O
designed O
and O
synthesized O

carbamates B-CHEMICAL
4-6, O
and O
their O
biological O
evaluation O
has O
been O
assessed O
in O
vitro O
against O
human B-GENE-Y
AChE I-GENE-Y
and O
BChE. B-GENE-Y
The O
6-carbamate B-CHEMICAL
4 O
was O
almost O
as O
potent O
as O
physostigmine B-CHEMICAL
and O
was O
60- O
and O
550-fold O
more O
potent O
than O
the O
7-carbamate O
5 O
and O
the O
8-carbamate O
6, O
respectively. O
The O
two O
enantiomers O
of O
4, O
(-)-4 O
and O
(+)-4, O
did O
not O
show O
a O
marked O
enantioselectivity. O
Finally, O
a O
similar O
time-dependent O
pattern O
of O
inhibition O
of O
AChE B-GENE-Y
was O
observed O
for O
3 O

and O
4. O
Brugada O
syndrome O
without O
mutation O
of O
the O
cardiac B-GENE-Y
sodium B-CHEMICAL
channel I-GENE-Y
gene O
in O
a O
Taiwanese O
patient. O
We O
describe O
a O
45-year-old O
Taiwanese O
man O
with O
specific O
features O
of O
Brugada O
syndrome O
but O
no O
clinical O
features O
of O
structural O
heart O
disease. O
He O
was O
successfully O
treated O
with O
an O
implantable O
cardioverter-defibrillator. O
His O
electrocardiogram O
(ECG) O
patterns O
changed O
intermittently. O
Alpha-adrenoceptor B-GENE-N
stimulation O
and O
beta-adrenoceptor B-GENE-N
blockade O
augmented O
the O
characteristic O
ST-segment O
elevation, O
whereas O
alpha-adrenoceptor B-GENE-N
blockade O
and O
beta-adrenoceptor B-GENE-N
stimulation O
mitigated O

the O
ST-segment O
elevation. O
Intravenous O
procainamide B-CHEMICAL
administration O
did O
not O
aggravate O
ST-segment O
elevation O
when O
ECG O
had O
shown O
coved O
ST O
elevation O
in O
the O
right O
precordial O
leads. O
Molecular O
study O
did O
not O
reveal O
the O
same O
mutations O
in O
the O
cardiac B-GENE-Y
sodium I-GENE-Y
channel I-GENE-Y
gene O
(SCN5A) B-GENE-Y
as O
previously O
reported O
in O
Brugada O
syndrome. O
This O
case O
demonstrates O
the O
genetic O
heterogeneity O
of O
SCN5A B-GENE-Y
in O
Brugada O
syndrome. O
Breakdown O
of O
Th O
cell O
immune O
responses O
and O
steroidogenic O
CYP11A1 B-GENE-Y
expression O
in O
CD4+ O
T O
cells O
in O
a O
murine O
model O
implanted O
with O

B16 O
melanoma. O
The O
association O
between O
the O
balance O
of O
Th1/Th2 O
cell O
responses O
and O
CYP11A1 B-GENE-Y
expression O
in O
CD4+ O
T O
cells O
was O
investigated O
in O
a O
murine O
model O
implanted O
with O
highly O
metastatic O
B16F10 O
melanoma O
cells O
(B16F10 O
mice). O
When O
2 O
x O
10(5) O
cells/mouse O
of O
B16F10 O
cells O
were O
inoculated O
into O
C57BL/6 O
mice, O
Th2 O
cell O
responses O
and O
pulmonary O
metastasis O
were O
increased. O
In O
addition, O
corticosterone B-CHEMICAL
levels O
in O
splenic O
tissue O
or O
serum O
and O

CYP11A1 B-GENE-Y
mRNA O
expression O
(mRNA O
encoding O
cholesterol B-CHEMICAL
side-chain I-GENE-Y
cleavage I-GENE-Y
p450 I-GENE-Y
enzyme) I-GENE-Y
in O
CD4+ O
T O
cells O
were O
increased O
in O
these O
mice. O
When O
the O
anti-corticosterone O
drug O
aminoglutethimide B-CHEMICAL
(CYP11A1 B-GENE-Y
inhibitor) O
was O
administered O
to O
B16F10 O
mice, O
corticosterone B-CHEMICAL
levels O
in O
splenic O
tissue O
or O
serum O
and O
CYP11A1 B-GENE-Y
mRNA O
expression O
were O
decreased O
at O
14 O
days O
after O
tumor O
inoculation. O
In O
addition, O
Th1 O
cell O
responses O
were O
restored O
and O
pulmonary O
metastasis O
was O
reduced O
by O

aminoglutethimide. B-CHEMICAL
These O
results O
indicated O
that O
the O
breakdown O
of O
Th O
cell O
responses O
and O
increase O
of O
pulmonary O
metastasis O
were O
due O
to O
an O
increase O
in O
steroidogenic O
CYP11A1 B-GENE-Y
mRNA O
expression O
in O
CD4+ O
T O
cells. O
Moreover, O
it O
was O
suggested O
that O
promotion O
of O
CYP11A1 B-GENE-Y
mRNA O
expression O
in O
Th2 O
cells O
was O
partially O
involved O
due O
to O
an O
increase O
in O
level O
of O
corticosterone B-CHEMICAL
in O
splenic O
tissue O
and O
the O
breakdown O
of O
Th O
cell O
responses O
locally O
in O
the O
splenic O
tissue, O
which O
then O
affected O
the O
maintenance O
of O
Th2 O
cell O
functions O
in O
the O
microenvironment O
of O

tumor-bearing O
mice. O
A O
nonsense O
mutation O
in O
the O
NDUFS4 B-GENE-Y
gene O
encoding O
the O
18 B-GENE-Y
kDa I-GENE-Y
(AQDQ) I-GENE-Y
subunit I-GENE-Y
of I-GENE-Y
complex I-GENE-Y
I I-GENE-Y
abolishes O
assembly O
and O
activity O
of O
the O
complex O
in O
a O
patient O
with O
Leigh-like O
syndrome. O
Sequence O
analysis O
of O
mitochondrial O
and O
nuclear O
candidate O
genes O
of O
complex B-GENE-N
I I-GENE-N
in O
children O
with O
deficiency O
of O
this O
complex O
and O
exhibiting O
Leigh-like O
syndrome O
has O
revealed, O
in O
one O
of O
them, O
a O
novel O
mutation O
in O
the O
NDUFS4 B-GENE-Y
gene O
encoding O
the O
18 O
kDa O
subunit. O
Phosphorylation O
of O
this O
subunit O
by O
cAMP-dependent B-GENE-N
protein I-GENE-N
kinase I-GENE-N
has O
previously O
been O
found O
to O
activate O
the O

complex. O
The O
present O
mutation O
consists O
of O
a O
homozygous O
G-->A O
transition O
at O
nucleotide O
position O
+44 O
of O
the O
coding O
sequence O
of O
the O
gene, O
resulting O
in O
the O
change O
of O
a O
tryptophan B-CHEMICAL
codon O
to O
a O
stop O
codon. O
Such O
mutation O
causes O
premature O
termination O
of O
the O
protein O
after O
only O
14 O
amino B-CHEMICAL
acids I-CHEMICAL
of O
the O
putative O
mitochondrial O
targeting O
peptide. O
Fibroblast O
cultures O
from O
the O
patient O
exhibited O
severe O
reduction O
of O
the O
rotenone-sensitive O
NADH-->UQ B-CHEMICAL
oxidoreductase I-GENE-N
activity O
of O
complex B-GENE-N
I, I-GENE-N
which O
was O
insensitive O
to O
cAMP B-CHEMICAL
stimulation. O
Two-dimensional O

electrophoresis O
showed O
the O
absence O
of O
detectable O
normally O
assembled O
complex B-GENE-N
I I-GENE-N
in O
the O
inner O
mitochondrial O
membrane. O
These O
findings O
show O
that O
the O
expression O
of O
the O
NDUFS4 B-GENE-Y
gene O
is O
essential O
for O
the O
assembly O
of O
a O
functional O
complex B-GENE-N
I. I-GENE-N
Glucagon-like B-GENE-Y
peptide I-GENE-Y
(GLP)-2 I-GENE-Y
reduces O
chemotherapy-associated O
mortality O
and O
enhances O
cell O
survival O
in O
cells O
expressing O
a O
transfected O
GLP-2 B-GENE-Y
receptor. I-GENE-Y
Chemotherapeutic O
agents O
produce O
cytotoxicity O
via O
induction O
of O
apoptosis O
and O
cell O
cycle O
arrest. O
Rapidly O
proliferating O
cells O
in O
the O
bone O
marrow O
and O
intestinal O
crypts O
are O

highly O
susceptible O
to O
chemotherapy, O
and O
damage O
to O
these O
cellular O
compartments O
may O
preclude O
maximally O
effective O
chemotherapy O
administration. O
Glucagon-like B-GENE-Y
peptide I-GENE-Y
(GLP)-2 I-GENE-Y
is O
an O
enteroendocrine-derived O
regulatory O
peptide O
that O
inhibits O
crypt O
cell O
apoptosis O
after O
administration O
of O
agents O
that O
damage O
the O
intestinal O
epithelium. O
We O
report O
here O
that O
a O
human O
degradation-resistant O
GLP-2 B-GENE-Y
analogue, O
h[Gly2]-GLP-2 B-CHEMICAL
significantly O
improves O
survival, O
reduces O
bacteremia, O
attenuates O
epithelial O
injury, O
and O

inhibits O
crypt O
apoptosis O
in O
the O
murine O
gastrointestinal O
tract O
after O
administration O
of O
topoisomerase B-GENE-Y
I I-GENE-Y
inhibitor O
irinotecan B-CHEMICAL
hydrochloride I-CHEMICAL
or O
the O
antimetabolite O
5-fluorouracil. B-CHEMICAL
h[Gly2]-GLP-2 B-CHEMICAL
significantly O
improved O
survival O
and O
reduced O
weight O
loss O
but O
did O
not O
impair O
chemotherapy O
effectiveness O
in O
tumor-bearing O
mice O
treated O
with O
cyclical O
irinotecan. O
Furthermore, O
h[Gly2]-GLP-2 B-CHEMICAL
reduced O
chemotherapy-induced O
apoptosis, O
decreased O
activation O
of O
caspase-8 B-GENE-N
and I-GENE-N

-3, I-GENE-N
and O
inhibited O
poly(ADP-ribose) B-GENE-N
polymerase I-GENE-N
cleavage O
in O
heterologous O
cells O
transfected O
with O
the O
GLP-2 B-GENE-Y
receptor. I-GENE-Y
These O
observations O
demonstrate O
that O
the O
antiapoptotic O
effects O
of O
GLP-2 B-GENE-Y
on O
intestinal O
crypt O
cells O
may O
be O
useful O
for O
the O
attenuation O
of O
chemotherapy-induced O
intestinal O
mucositis. O
On O
the O
relationship O
between O
the O
dopamine B-GENE-N
transporter I-GENE-N
and O
the O
reinforcing O
effects O
of O
local O
anesthetics O
in O
rhesus O
monkeys: O
practical O
and O
theoretical O
concerns. O
RATIONALE: O
Drugs O
that O
are O

self-administered O
appear O
to O
vary O
in O
their O
potency O
and O
effectiveness O
as O
positive O
reinforcers. O
Understanding O
mechanisms O
that O
determine O
relative O
effectiveness O
of O
drugs O
as O
reinforcers O
will O
enhance O
our O
understanding O
of O
drug O
abuse. O
OBJECTIVES: O
The O
hypothesis O
of O
the O
present O
study O
was O
that O
differences O
among O
dopamine B-GENE-N
transporter I-GENE-N
(DAT) B-GENE-N
ligands O
in O
potency O
and O
effectiveness O
as O
a O
positive O
reinforcers O
were O
related O
to O
potency O
and O
effectiveness O
as O
DA B-CHEMICAL
uptake O
inhibitors. O
Accordingly, O
self-administration O
of O
a O
group O
of O
local O
anesthetics O
that O
are O
DAT B-GENE-N
ligands O
was O
compared O
to O
their O
effects O
as O
DA B-CHEMICAL
uptake O
blockers O
in O

vitro O
in O
brain O
tissue. O
METHODS: O
Rhesus O
monkeys O
were O
allowed O
to O
self-administer O
cocaine B-CHEMICAL
and O
other O
local O
anesthetics O
i.v. O
under O
a O
progressive-ratio O
schedule. O
The O
same O
compounds O
were O
compared O
in O
standard O
in O
vitro O
DA B-CHEMICAL
uptake O
assays O
using O
monkey O
caudate O
tissue. O
RESULTS: O
The O
rank O
order O
of O
both O
potency O
and O
effectiveness O
as O
reinforcers O
was O
cocaine B-CHEMICAL
> O
dimethocaine B-CHEMICAL
> O
procaine B-CHEMICAL
> O
chloroprocaine. B-CHEMICAL
Tetracaine B-CHEMICAL
did O
not O
maintain O
self-administration. O
For O
inhibiting O
DA B-CHEMICAL
uptake, O
the O
potency O
order O

was O
cocaine B-CHEMICAL
> O
dimethocaine B-CHEMICAL
> O
tetracaine B-CHEMICAL
> O
procaine B-CHEMICAL
> O
chloro-procaine. B-CHEMICAL
At O
maximum, O
these O
compounds O
were O
equally O
effective O
in O
blocking O
DA B-CHEMICAL
uptake. O
Lidocaine B-CHEMICAL
did O
not O
inhibit O
DA B-CHEMICAL
uptake. O
CONCLUSIONS: O
The O
potency O
of O
local O
anesthetics O
as O
positive O
reinforcers O
is O
likely O
related O
to O
their O
potency O
as O
DA B-CHEMICAL
uptake O
inhibitors. O
Variation O
in O
their O
effectiveness O
as O
positive O
reinforcers O
was O
not O
a O
function O
of O
differences O
in O
effectiveness O
as O
DA B-CHEMICAL
uptake O
blockers, O
but O
may O
be O
related O
to O
relative O
potency O
over O
the O
concentrations O
that O

are O
achieved O
in O
vivo. O
Effects O
at O
sodium B-GENE-N
channels I-GENE-N
may O
limit O
the O
reinforcing O
effects O
of O
local O
anesthetics. O
Contribution O
of O
the O
Na+-K+-2Cl- B-GENE-N
cotransporter I-GENE-N
NKCC1 B-GENE-Y
to O
Cl- B-CHEMICAL
secretion O
in O
rat O
OMCD. O
In O
rat O
kidney O
the O
"secretory" O
isoform O
of O
the O
Na+-K+-2Cl- B-GENE-N
cotransporter I-GENE-N
(NKCC1) B-GENE-Y
localizes O
to O
the O
basolateral O
membrane O
of O
the O
alpha-intercalated O
cell. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
rat O
outer O
medullary O
collecting O

duct O
(OMCD) O
secretes O
Cl- B-CHEMICAL
and O
whether O
transepithelial O
Cl- B-CHEMICAL
transport O
occurs, O
in O
part, O
through O
Cl- B-CHEMICAL
uptake O
across O
the O
basolateral O
membrane O
mediated O
by O
NKCC1 B-GENE-Y
in O
series O
with O
Cl- B-CHEMICAL
efflux O
across O
the O
apical O
membrane. O
OMCD O
tubules O
from O
rats O
treated O
with O
deoxycorticosterone B-CHEMICAL
pivalate I-CHEMICAL
were O
perfused O
in O
vitro O
in O
symmetrical O
HCO/CO2-buffered B-CHEMICAL
solutions. O
Cl- B-CHEMICAL
secretion O
was O
observed O
in O
this O
segment, O
accompanied O
by O
a O
lumen O
positive O
transepithelial O
potential. O

Bumetanide B-CHEMICAL
(100 O
microM), O
when O
added O
to O
the O
bath, O
reduced O
Cl- B-CHEMICAL
secretion O
by O
78%, O
although O
the O
lumen O
positive O
transepithelial O
potential O
and O
fluid O
flux O
were O
unchanged. O
Bumetanide-sensitive B-CHEMICAL
Cl- B-CHEMICAL
secretion O
was O
dependent O
on O
extracellular O
Na+ B-CHEMICAL
and O
either O
K+ B-CHEMICAL
or O
NH, B-CHEMICAL
consistent O
with O
the O
ion O
dependency O
of O
NKCC1-mediated B-GENE-Y
Cl- B-CHEMICAL
transport. O
In O
conclusion, O
OMCD O
tubules O
from O
deoxycorticosterone B-CHEMICAL
pivalate-treated I-CHEMICAL
rats O
secrete O
Cl- B-CHEMICAL
into O
the O
luminal O
fluid O
through O
NKCC1-mediated B-GENE-Y

Cl- B-CHEMICAL
uptake O
across O
the O
basolateral O
membrane O
in O
series O
with O
Cl- B-CHEMICAL
efflux O
across O
the O
apical O
membrane. O
The O
physiological O
role O
of O
NKCC1-mediated B-GENE-Y
Cl- B-CHEMICAL
uptake O
remains O
to O
be O
determined. O
However, O
the O
role O
of O
NKCC1 B-GENE-Y
in O
the O
process O
of O
fluid O
secretion O
could O
not O
be O
demonstrated. O
Evidence O
for O
genetic O
heterogeneity O
of O
pseudohypoaldosteronism O
type O
1: O
identification O
of O
a O
novel O
mutation O
in O
the O
human B-GENE-Y
mineralocorticoid I-GENE-Y
receptor I-GENE-Y
in O
one O
sporadic O
case O
and O
no O
mutations O
in O
two O
autosomal O
dominant O
kindreds. O

Pseudohypoaldosteronism O
type O
1 O
(PHA1) O
is O
characterized O
by O
neonatal O
salt O
wasting O
resistant O
to O
mineralocorticoids. O
There O
are O
2 O
forms O
of O
PHA1: O
the O
autosomal O
recessive O
form O
with O
symptoms O
persisting O
into O
adulthood, O
caused O
by O
mutations O
in O
the O
amiloride-sensitive B-GENE-N
luminal I-GENE-N
sodium I-GENE-N
channel, I-GENE-N
and O
the O
autosomal O
dominant O
or O
sporadic O
form, O
which O
shows O
milder O
symptoms O
that O
remit O
with O
age. O
Mutations O
in O
the O
gene O
encoding O
the O
human B-GENE-Y
mineralocorticoid I-GENE-Y
receptor I-GENE-Y
(hMR) B-GENE-Y
are, O
at O
least O
in O
some O
patients, O
responsible O
for O
the O
latter O
form O

of O
PHA1. O
We O
here O
report O
the O
results O
of O
a O
genetic O
study O
in O
a O
sporadic O
case O
and O
in O
5 O
affected O
patients O
from O
2 O
families O
with O
autosomal O
dominant O
PHA1. O
In O
the O
sporadic O
case O
we O
identified O
a O
new O
frameshift O
mutation, O
Ins2871C, B-GENE-N
in O
exon O
9 O
of O
the O
hMR B-GENE-Y
gene. O
Family O
members O
were O
asymptomatic O
and O
had O
no O
mutation. O
This O
mutation O
is O
the O
first O
described O
in O
exon O
9 O
and O
impairs O
the O
last O
27 O
amino B-CHEMICAL
acids I-CHEMICAL
of O
the O
hormone-binding B-GENE-N
domain. I-GENE-N
In O
2 O
kindreds O
with O
autosomal O
dominant O
PHA1 O
we O
found O
no O
mutation O
of O
the O

hMR B-GENE-Y
gene. O
Our O
results O
confirm O
the O
hypothesis O
that O
autosomal O
dominant O
or O
sporadic O
PHA1 O
is O
a O
genetically O
heterogeneous O
disease O
involving O
other, O
as O
yet O
unidentified, O
genes. O
The O
broad-spectrum O
anti-emetic O
activity O
of O
AS-8112, B-CHEMICAL
a O
novel O
dopamine B-GENE-N
D2, I-GENE-N
D3 I-GENE-N
and O
5-HT3 B-GENE-Y
receptors I-GENE-Y
antagonist. O
The O
anti-emetic O
and O
pharmacological O
profile O
of O
AS-8112 B-CHEMICAL

((R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy B-CHEMICAL
lamino-3-pyridinecarboxamide.2 I-CHEMICAL
fumarate), I-CHEMICAL
a O
novel O
and O
potent O
dopamine B-GENE-N
D2, I-GENE-N
D3 I-GENE-N
and O
5-hydroxytryptamine-3 B-GENE-Y
(5-HT3) I-GENE-Y
receptors I-GENE-Y
ligand, O
was O
investigated O
in O
the O
present O
study. O
In O
guinea-pig O
isolated O

colon, O
AS-8112 B-CHEMICAL
produced O
a O
rightward O
shift O
of O
the O
concentration-response O
curves O
of O
2-methyl-5HT, B-CHEMICAL
a O
5-HT3 B-GENE-Y
receptor I-GENE-Y
agonist O
(pA2 O
value O
of O
7.04). O
Other O
5-HT3 B-GENE-Y
receptor I-GENE-Y
antagonists O
also O
produced O
such O
a O
shift O
in O
the O
following O
antagonistic-potency O
order: O
granisetron> B-CHEMICAL
ondansetron=AS-8112>>metoclopramide. B-CHEMICAL
In O
mice, O
AS-8112 B-CHEMICAL
(1.0 O
- O
3.0 O
mg O
kg(-1) O
s.c.) O
potently O
inhibited O

hypothermia O
induced O
by O
the O
dopamine B-GENE-Y
D3 I-GENE-Y
receptor I-GENE-Y
agonist; O
R(+)-7-OH-DPAT B-CHEMICAL
(R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) B-CHEMICAL
(0.3 O
mg O
kg(-1) O
s.c.). O
Domperidone B-CHEMICAL
and O
haloperidol, B-CHEMICAL
which O
have O
affinity O
for O
dopamine B-GENE-Y
D3 I-GENE-Y
receptor, I-GENE-Y
also O
inhibited O
R(+)-7-OH-DPAT-induced B-CHEMICAL
hypothermia. O
In O

ferrets O
or O
dogs, O
AS-8112 B-CHEMICAL
dose-dependently O
inhibited O
emesis O
induced O
by O
R(+)-7-OH-DPAT, B-CHEMICAL
apomorphine, B-CHEMICAL
morphine B-CHEMICAL
or O
cisplatin B-CHEMICAL
with O
ID50 O
values O
of O
2.22 O
microg O
kg(-1) O
s.c., O
10.5 O
microg O
kg(-1) O
s.c., O
14.2 O
microg O
kg(-1) O
i.v. O
and O
17.6 O
microg O
kg(-1) O
i.v., O
respectively. O
Moreover, O
oral O
administration O
of O
AS-8112 B-CHEMICAL
significantly O

inhibited O
emesis O
induced O
by O
these O
emetogens. O
AS-8112 B-CHEMICAL
(0.3 O
mg O
kg(-1) O
i.v.) O
significantly O
inhibited O
emesis O
induced O
by O
cyclophosphamide B-CHEMICAL
and O
doxorubicin. B-CHEMICAL
In O
conclusion, O
AS-8112 B-CHEMICAL
is O
a O
potent O
dopamine B-GENE-N
D2, I-GENE-N
D3 I-GENE-N
and O
5-HT3 B-GENE-Y
receptors I-GENE-Y
antagonist, O
and O
a O
novel O
anti-emetic O
agent O
with O
a O
broad-spectrum O
of O
anti-emetic O
activity. O
These O
results O
suggest O
that O
this O
compound O
is O
worthy O
of O
clinical O
investigation. O
Heparin-binding O
exosite O
of O
factor B-GENE-Y
Xa. I-GENE-Y

Recent O
studies O
have O
indicated O
that O
the O
basic O
residues O
Arg(93), B-CHEMICAL
Lys(96), B-CHEMICAL
Arg(125), B-CHEMICAL
Arg(165), B-CHEMICAL
Lys(169), B-CHEMICAL
Lys(236), B-CHEMICAL
and O
Arg(240) B-CHEMICAL
(chymotrypsin B-GENE-N
numbering) O
constitute O
an O
exosite O
in O
the O
catalytic O
domain O
of O
factor B-GENE-Y
Xa I-GENE-Y
that O
can O
effectively O
bind O
heparin O
only O
if O
the O
acidic O
N-terminal B-CHEMICAL
Gla I-GENE-N
domain I-GENE-N
of O
the O
proteinase B-GENE-N
was O
neutralized O
by O
physiological O
levels O
of O
calcium. B-CHEMICAL
Binding O
of O
a O
full-length O
heparin O
chain O
to O
this O
site O
of O
factor B-GENE-Y
Xa I-GENE-Y
in O
the O
presence O
of O
calcium B-CHEMICAL

makes O
a O
significant O
contribution O
to O
acceleration O
of O
the O
proteinase B-GENE-N
inhibition O
by O
antithrombin B-GENE-Y
through O
a O
ternary O
complex O
bridging O
or O
template O
mechanism. O
Moreover, O
certain O
basic O
residues O
of O
this O
site, O
particularly O
Arg(165) B-CHEMICAL
and O
Lys(169), B-CHEMICAL
play O
a O
key O
role O
in O
factor B-GENE-Y
Va I-GENE-Y
and/or O
prothrombin B-GENE-Y
recognition O
by O
factor B-GENE-Y
Xa I-GENE-Y
in O
the O
prothrombinase O
complex. O
This O
article O
reviews O
recent O
structural, O
mutagenesis O
and O
kinetic O
data O
that O
lead O
to O
identification O
of O
this O
exosite O
and O
discusses O
how O
the O
binding O
of O
protein O
or O
polysaccharide O
cofactors O
to O
this O
site O
of O
factor B-GENE-Y
Xa I-GENE-Y

can O
modulate O
the O
specificity O
and O
physiological O
function O
of O
this O
key O
coagulant O
enzyme O
in O
plasma. O
Rofecoxib: B-CHEMICAL
a O
review O
of O
its O
use O
in O
the O
management O
of O
osteoarthritis, O
acute O
pain O
and O
rheumatoid O
arthritis. O
Rofecoxib B-CHEMICAL
is O
a O
selective O
cyclo-oxygenase B-GENE-Y
(COX)-2 I-GENE-Y
inhibitor O
which O
has O
little O
or O
no O
effect O
on O
the O
COX-1 B-GENE-Y
isoenzyme O
at O
doses O
up O
to O
1000 O
mg/day. O
Rofecoxib B-CHEMICAL
has O
greater O
selectivity O
for O
COX-2 B-GENE-Y
than O
celecoxib, B-CHEMICAL

meloxicam, B-CHEMICAL
diclofenac B-CHEMICAL
and O
indomethacin. B-CHEMICAL
In O
well-controlled O
clinical O
trials, O
rofecoxib B-CHEMICAL
12.5 O
to O
500 O
mg/day O
has O
been O
evaluated O
for O
its O
efficacy O
in O
the O
treatment O
of O
osteoarthritis, O
acute O
pain O
and O
rheumatoid O
arthritis O
[lower O
dosages O
(5 O
to O
125 O
mg/day) O
were O
generally O
used O
in O
the O
chronic O
pain O
indications]. O
In O
the O
treatment O
of O
patients O
with O
osteoarthritis, O
rofecoxib B-CHEMICAL
was O
more O
effective O
in O
providing O
symptomatic O
relief O
than O
placebo, O
paracetamol B-CHEMICAL

(acetaminophen) B-CHEMICAL
and O
celecoxib B-CHEMICAL
and O
was O
similar O
in O
efficacy O
to O
ibuprofen, B-CHEMICAL
diclofenac, B-CHEMICAL
naproxen B-CHEMICAL
and O
nabumetone. B-CHEMICAL
Overall, O
both O
the O
physician's O
assessment O
of O
disease O
status O
and O
the O
patient's O
assessment O
of O
response O
to O
therapy O
tended O
to O
favour O
rofecoxib. B-CHEMICAL
In O
patients O
with O
postsurgical O
dental O
pain, O
pain O
after O
spinal O
fusion O
or O
orthopaedic O
surgery, O
or O
primary O
dysmenorrhoea, O
rofecoxib B-CHEMICAL
provided O
more O
rapid O
and O
more O
sustained O
pain O
relief O
and O
reduced O
requirements O
for O
supplemental O
morphine O
use O
after O
surgery O

than O
placebo. O
Rofecoxib B-CHEMICAL
was O
more O
efficacious O
than O
celecoxib B-CHEMICAL
in O
patients O
with O
acute O
dental O
pain O
and O
pain O
after O
spinal O
fusion O
surgery, O
although O
celecoxib B-CHEMICAL
may O
have O
been O
used O
at O
a O
subtherapeutic O
dose. O
In O
comparison O
with O
traditional O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ibuprofen, B-CHEMICAL
diclofenac B-CHEMICAL
and O
naproxen B-CHEMICAL
sodium, I-CHEMICAL
rofecoxib B-CHEMICAL
was O
similar O
in O
efficacy O
in O
the O
treatment O
of O
acute O
pain. O
Although O
naproxen B-CHEMICAL
sodium I-CHEMICAL
provided O
more O
rapid O
pain O
relief O
than O
rofecoxib B-CHEMICAL
in O
patients O
with O
primary O

dysmenorrhoea, O
the O
reverse O
was O
true O
after O
orthopaedic O
surgery: O
rofecoxib B-CHEMICAL
provided O
more O
rapid O
pain O
relief O
and O
less O
supplemental O
morphine B-CHEMICAL
was O
needed. O
Rofecoxib B-CHEMICAL
was O
as O
effective O
as O
naproxen B-CHEMICAL
in O
providing O
symptomatic O
relief O
for O
over O
8700 O
patients O
with O
rheumatoid O
arthritis. O
Compared O
with O
traditional O
NSAID O
therapy, O
rofecoxib B-CHEMICAL
had O
a O
significantly O
lower O
incidence O
of O
endoscopically O
confirmed O
gastroduodenal O
ulceration O
and, O
in O
approximately O
13,000 O
patients O
with O
osteoarthritis O
and O

rheumatoid O
arthritis, O
a O
lower O
incidence O
of O
gastrointestinal O
(GI) O
adverse O
events. O
Rofecoxib B-CHEMICAL
was O
generally O
well O
tolerated O
in O
all O
indications O
with O
an O
overall O
tolerability O
profile O
similar O
to O
traditional O
NSAIDs. O
The O
most O
common O
adverse O
events O
in O
rofecoxib B-CHEMICAL
recipients O
were O
nausea, O
dizziness O
and O
headache. O
In O
conclusion, O
rofecoxib B-CHEMICAL
is O
at O
least O
as O
effective O
as O
traditional O
NSAID O
therapy O
in O
providing O
pain O
relief O
for O
both O
chronic O
and O
acute O
pain O
conditions. O
Rofecoxib B-CHEMICAL
provides O
an O
alternative O
treatment O
option O
to O
traditional O
NSAID O
therapy O
in O
the O
management O
of O

symptomatic O
pain O
relief O
in O
patients O
with O
osteoarthritis. O
Initial O
data O
from O
patients O
with O
primary O
dysmenorrhoea O
and O
postoperative O
pain O
are O
promising O
and O
further O
trials O
may O
confirm O
its O
place O
in O
the O
treatment O
of O
these O
indications. O
Rofecoxib B-CHEMICAL
has O
also O
shown O
promising O
results O
in O
patients O
with O
rheumatoid O
arthritis O
and O
is O
likely O
to O
become O
a O
valuable O
addition O
to O
current O
drug O
therapy O
for O
this O
patient O
population. O
Importantly, O
rofecoxib B-CHEMICAL
is O
associated O
with O
a O
lower O
incidence O
of O
GI O
adverse O
events O
than O
traditional O
NSAIDs O
making O
it O
a O
primary O
treatment O
option O
in O
patients O
at O
risk O
of O
developing O

GI O
complications O
or O
patients O
with O
chronic O
conditions O
requiring O
long O
term O
treatment. O
Clinical, O
biochemical O
and O
molecular O
genetic O
data O
in O
five O
children O
with O
Gitelman's O
syndrome. O
Gitelman's O
variant O
of O
Bartter's O
syndrome, O
inherited O
hypokalemic O
alkalosis, O
is O
caused O
by O
mutation O
in O
the O
thiazide-sensitive B-GENE-Y
NaCl I-GENE-Y
co-transporter I-GENE-Y
(NCCT). B-GENE-Y
The O
main O
clinical O
symptoms O
are: O
muscular O
weakness, O
carpopedal O
spasm, O
constipation O
and O
short O
stature. O
The O
diagnosis O
was O
suspected O
in O
five O
children O
according O
to O
clinical O
criteria. O
All O
patients O
exhibited O
carpopedal O
spasm O
during O

febrile O
illness, O
three O
patients O
had O
short O
stature. O
Biochemical O
features O
were: O
metabolic O
alkalosis, O
hypokalemia, O
hypomagnesemia, O
low O
IGF-I B-GENE-Y
levels, O
hyperkaliuria, O
hypernatriuria, O
hypocalciuria O
and O
normoprostaglandinuria. O
Three O
patients O
had O
elevated O
plasma O
renin B-GENE-Y
activity O
and O
hyperaldosteronism. O
Mutational O
analysis O
of O
the O
NCCT B-GENE-Y
gene O
confirmed O
the O
diagnosis O
in O
all O
five O
patients. O
Different O
forms O
of O
therapy, O
potassium B-CHEMICAL
and O
magnesium B-CHEMICAL
substitution, O
spironolactone B-CHEMICAL
and O

indomethacin B-CHEMICAL
failed O
to O
fully O
correct O
hypokalemia O
and O
hypomagnesemia, O
but O
markedly O
improved O
growth O
velocity O
and O
normalized O
IGF-I B-GENE-Y
levels O
in O
the O
three O
patients O
with O
short O
stature. O
During O
therapy, O
clinical O
symptoms O
disappeared. O
We O
conclude O
that O
Gitelman's O
syndrome O
is O
a O
disorder O
with O
a O
variable O
symptom O
profile, O
but O
can O
be O
suspected O
on O
clinical O
signs O
already O
in O
early O
childhood. O
The O
early O
diagnosis O
is O
essential O
in O
preventing O
complications. O
Peroxisome B-GENE-N
proliferator-activated I-GENE-N
receptor I-GENE-N
subtype-specific O
regulation O
of O
hepatic O
and O
peripheral O
gene O
expression O
in O
the O
Zucker O
diabetic O

fatty O
rat. O
Fibrates B-CHEMICAL
and O
thiazolidinediones B-CHEMICAL
are O
used O
clinically O
to O
treat O
hypertriglyceridemia O
and O
hyperglycemia, O
respectively. O
Fibrates B-CHEMICAL
bind O
to O
the O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
(PPAR)-alpha, I-GENE-Y
and O
thiazolidinediones B-CHEMICAL
are O
ligands O
of O
PPAR-gamma. B-GENE-Y
These O
intracellular O
receptors O
form O
heterodimers O
with O
retinoid B-CHEMICAL
X I-GENE-N
receptor I-GENE-N
to O
modulate O
gene O
transcription. O
To O
elucidate O
the O
target O
genes O
regulated O
by O
these O
compounds, O
we O
treated O
Zucker O
diabetic O
fatty O
rats O

(ZDF) O
for O
15 O
days O
with O
a O
PPAR-alpha-specific B-GENE-Y
compound, O
fenofibrate, B-CHEMICAL
a O
PPAR-gamma-specific B-GENE-Y
ligand, O
rosiglitazone, B-CHEMICAL
and O
a O
PPAR-alpha/-gamma B-GENE-N
coagonist, O
GW2331, B-CHEMICAL
and O
measured O
the O
levels O
of O
several O
messenger O
RNAs O
(mRNAs) O
in O
liver O
by O
real-time O
polymerase O
chain O
reaction. O
All O
3 O
compounds O
decreased O
serum O
glucose B-CHEMICAL
and O
triglyceride B-CHEMICAL
levels. O
Fenofibrate B-CHEMICAL
and O
GW2331 B-CHEMICAL
induced O
expression O
of O
acyl-coenzyme B-GENE-N
A I-GENE-N
(CoA) I-GENE-N

oxidase I-GENE-N
and O
enoyl-CoA B-GENE-Y
hydratase I-GENE-Y
and O
reduced O
apolipoprotein B-GENE-Y
C-III I-GENE-Y
and O
phosphoenolpyruvate B-GENE-N
carboxykinase I-GENE-N
mRNAs. O
Rosiglitazone B-CHEMICAL
modestly O
increased O
apolipoprotein B-GENE-Y
C-III I-GENE-Y
mRNA O
and O
had O
no O
effect O
on O
expression O
of O
the O
other O
2 O
genes O
in O
the O
liver O
but O
increased O
the O
expression O
of O
glucose B-CHEMICAL
transporter I-GENE-Y
4 I-GENE-Y
and O
phosphoenolpyruvate B-CHEMICAL
carboxykinase I-GENE-N
in O
adipose O
tissue. O
We O
identified O
a O
novel O
target O
in O
liver, O
mitogen-activated B-GENE-Y
phosphokinase I-GENE-Y

phosphatase I-GENE-Y
1, I-GENE-Y
whose O
down-regulation O
by O
PPAR-alpha B-GENE-Y
agonists O
may O
improve O
insulin B-GENE-N
sensitivity O
in O
that O
tissue O
by O
prolonging O
insulin B-GENE-N
responses. O
The O
results O
of O
these O
studies O
suggest O
that O
activation O
of O
PPAR-alpha B-GENE-Y
as O
well O
as O
PPAR-gamma B-GENE-Y
in O
therapy O
for O
type O
2 O
diabetes O
will O
enhance O
glucose B-CHEMICAL
and O
triglyceride B-CHEMICAL
control O
by O
combining O
actions O
in O
hepatic O
and O
peripheral O
tissues. O
Serotonergic O
effects O
and O
extracellular O
brain O
levels O
of O
eletriptan, B-CHEMICAL
zolmitriptan B-CHEMICAL
and O
sumatriptan B-CHEMICAL
in O
rat O
brain. O
In O
vivo O
microdialysis O
was O
used O
to O
assess O
the O
central O

serotonergic O
effects O
and O
extracellular O
brain O
levels O
of O
the O
5-HT(1B/1D) B-GENE-N
receptor O
agonists O
eletriptan, B-CHEMICAL
zolmitriptan B-CHEMICAL
and O
sumatriptan B-CHEMICAL
in O
rats O
after O
intravenous O
and O
intracerebral O
administration, O
while O
their O
binding O
affinities O
and O
functional O
potencies O
were O
determined O
at O
5-HT(1B), B-GENE-Y
5-HT(1D) B-GENE-Y
and O
5-HT(1A) B-GENE-Y
receptors. O
In O
vitro O
studies O
showed O
that O
all O
three O
triptans B-CHEMICAL
are O
high O
affinity, O
full O
agonists O
at O

5-HT(1B/1D) B-GENE-N
receptors, O
but O
that O
sumatriptan B-CHEMICAL
is O
functionally O
less O
potent O
as O
a O
5-HT(1B/1D) B-GENE-N
agonist O
than O
zolmitriptan B-CHEMICAL
and O
eletriptan. B-CHEMICAL
Local O
intracortical O
perfusion O
with O
the O
compounds O
via O
the O
dialysis O
probe O
decreased O
cortical O
5-HT B-CHEMICAL
(5-hydroxytryptamine, B-CHEMICAL
serotonin) B-CHEMICAL
release O
with O
ED(50) O
values O
of O
approximately O
0.1 O
microM O
for O
eletriptan B-CHEMICAL
and O
zolmitriptan B-CHEMICAL
and O
0.5 O
microM O
for O

sumatriptan. B-CHEMICAL
At O
3.2 O
mg/kg O
i.v., O
both O
eletriptan B-CHEMICAL
and O
zolmitriptan B-CHEMICAL
decreased O
5-HT B-CHEMICAL
levels O
by O
about O
35%, O
while O
sumatriptan B-CHEMICAL
had O
no O
effect, O
despite O
the O
fact O
that O
maximal O
sumatriptan B-CHEMICAL
concentrations O
in O
cortical O
dialysates O
were O
higher O
(8.8 O
nM O
at O
20 O
min) O
than O
those O
of O
zolmitriptan B-CHEMICAL
(5.9 O
nM O
at O
20 O
min) O
and O
eletriptan B-CHEMICAL
(2.6 O
nM O
at O
40 O
min). O
The O
observation O
that O
eletriptan B-CHEMICAL
and O
zolmitriptan B-CHEMICAL
produce O

almost O
identical O
central O
serotonergic O
effects, O
after O
intracerebral O
as O
well O
as O
after O
systemic O
administration, O
is O
in O
agreement O
with O
their O
comparable O
functional O
5-HT(1B/1D) B-GENE-N
receptor O
agonist O
potencies O
and O
their O
free O
levels O
in O
cortical O
dialysates O
after O
3.2 O
mg/kg O
i.v. O
On O
the O
other O
hand, O
the O
lack O
of O
central O
serotonergic O
effects O
of O
3.2 O
mg/kg O
i.v. O
sumatriptan B-CHEMICAL
is O
likely O
due O
to O
its O
weaker O
functional O
5-HT(1B/1D) B-GENE-N
receptor O
agonist O
potency O
than O
eletriptan B-CHEMICAL

and O
zolmitriptan, B-CHEMICAL
rather O
than O
lower O
brain O
levels, O
consistent O
with O
sumatriptan's O
fivefold O
lower O
potency O
after O
intracerebral O
administration. O
Urokinase B-GENE-Y
plasminogen I-GENE-Y
activator I-GENE-Y
and O
plasmin B-GENE-Y
efficiently O
convert O
hemofiltrate B-GENE-Y
CC I-GENE-Y
chemokine I-GENE-Y
1 I-GENE-Y
into O
its O
active. O
We O
have O
previously O
isolated O
from O
human O
hemofiltrate O
an O
N-terminally B-CHEMICAL
truncated O
form O
of O
the O
hemofiltrate B-GENE-Y
CC I-GENE-Y
chemokine I-GENE-Y
1 I-GENE-Y
(HCC-1), B-GENE-Y
and O
characterized O
HCC-1[9-74] B-GENE-Y
as O
a O
strong O
agonist O
of O
CCR1, B-GENE-Y

CCR5, B-GENE-Y
and O
to O
a O
lower O
extent O
CCR3. B-GENE-Y
In O
this O
study, O
we O
show O
that O
conditioned O
media O
from O
human O
tumor O
cell O
lines O
PC-3 O
and O
143B O
contain O
proteolytic O
activities O
that O
convert O
HCC-1 B-GENE-Y
into O
the O
[9-74] O
form. O
This O
activity O
was O
fully O
inhibited O
by O
inhibitors O
of O
urokinase-type B-GENE-Y
plasminogen I-GENE-Y
activator I-GENE-Y
(uPA), B-GENE-Y
including O
PA B-GENE-Y
inhibitor-1, I-GENE-Y
an O
anti-uPA B-GENE-Y
mAb, O
and O
amiloride. O
Pure O
preparations O
of O
uPA B-GENE-Y
processed O
HCC-1 B-GENE-Y
with O
high O
efficiency, O
without O
further O
degrading O

HCC-1[9-74]. B-GENE-Y
Plasmin B-GENE-Y
could O
also O
generate O
HCC-1[9-74], B-GENE-Y
but O
degraded O
the O
active O
product O
as O
well. O
The O
kinetics O
of O
HCC-1 B-GENE-Y
cleavage O
by O
uPA B-GENE-Y
and O
plasmin B-GENE-Y
(Michaelis O
constant, O
K(m), O
of O
0.76 O
+/- O
0.4 O
microM O
for O
uPA, B-GENE-Y
and O
0.096 O
+/- O
0.05 O
microM O
for O
plasmin; B-GENE-Y
catalytic O
rate O
constant, O
k(cat): O
3.36 O
+/- O
0.96 O
s(-1) O
for O
uPA B-GENE-Y
and O
6 O

+/- O
3.6 O
s(-1) O
for O
plasmin) B-GENE-Y
are O
fully O
compatible O
with O
a O
role O
in O
vivo. O
The O
activation O
of O
an O
abundant O
inactive O
precursor O
into O
a O
broad-spectrum O
chemokine O
by O
uPA B-GENE-Y
and O
plasmin B-GENE-Y
directly O
links O
the O
production O
of O
uPA B-GENE-Y
by O
numerous O
tumors O
and O
their O
ability O
to O
recruit O
mononuclear O
leukocytes, O
without O
the O
need O
for O
the O
transcriptional O
activation O
of O
chemokine B-GENE-N
genes. O
Cembranoid B-CHEMICAL
and O
long-chain B-CHEMICAL
alkanol I-CHEMICAL
sites O
on O
the O
nicotinic B-GENE-N
acetylcholine I-GENE-N
receptor I-GENE-N
and O
their O
allosteric O
interaction. O
Long-chain B-CHEMICAL
alkanols I-CHEMICAL
are O

general O
anesthetics O
which O
can O
also O
act O
as O
uncharged O
noncompetitive O
inhibitors O
of O
the O
peripheral O
nicotinic B-GENE-N
acetylcholine B-CHEMICAL
receptor I-GENE-N
(AChR) B-GENE-N
by O
binding O
to O
one O
or O
more O
specific O
sites O
on O
the O
AChR. B-GENE-N
Cembranoids B-CHEMICAL
are O
naturally O
occurring, O
uncharged O
noncompetitive O
inhibitors O
of O
peripheral O
and O
neuronal O
AChRs, B-GENE-N
which O
have O
no O
demonstrable O
general O
anesthetic O
activity O
in O
vivo. O
In O
this O
study, O
[3H]tenocyclidine B-CHEMICAL
([3H]TCP), B-CHEMICAL
an O
analogue O
of O
the O
cationic O
noncompetitive O

inhibitor O
phencyclidine B-CHEMICAL
(PCP), B-CHEMICAL
was O
used O
to O
characterize O
the O
cembranoid B-CHEMICAL
and O
long-chain B-CHEMICAL
alkanol I-CHEMICAL
sites O
on O
the O
desensitized O
Torpedo O
californica O
AChR B-GENE-N
and O
to O
investigate O
if O
these O
sites O
interact. O
These O
studies O
confirm O
that O
there O
is O
a O
single O
cembranoid O
site O
which O
sterically O
overlaps O
the O
[3H]TCP B-CHEMICAL
channel O
site. O
This O
cembranoid B-CHEMICAL
site O
probably O
also O
overlaps O
the O
sites O
for O
the O
cationic O
noncompetitive O
inhibitors, O
procaine B-CHEMICAL
and O
quinacrine. B-CHEMICAL
Evidence O
is O
also O
presented O
for O
one O

or O
more O
allosteric O
cembranoid O
sites O
which O
negatively O
modulate O
cembranoid B-CHEMICAL
affinity O
for O
the O
inhibitory O
site. O
In O
contrast, O
long-chain B-CHEMICAL
alkanols I-CHEMICAL
inhibit O
[3H]TCP B-CHEMICAL
binding O
through O
an O
allosteric O
mechanism O
involving O
two O
or O
more O
alkanol B-CHEMICAL
sites O
which O
display O
positive O
cooperativity O
toward O
each O
other. O
Double O
inhibitor O
studies O
show O
that O
the O
cembranoid B-CHEMICAL
inhibitory O
site O
and O
the O
alkanol B-CHEMICAL
sites O
are O
not O
independent O
of O
each O
other O
but O
interfere O
allosterically O
with O
each O
other's O
inhibition O
of O
[3H]TCP B-CHEMICAL
binding. O
The O
simplest O
models O
consistent O
with O
the O
observed O

data O
are O
presented O
and O
discussed. O
Sulfasalazine, B-CHEMICAL
a O
potent O
suppressor O
of O
lymphoma O
growth O
by O
inhibition O
of O
the O
x(c)- B-GENE-Y
cystine I-GENE-Y
transporter: I-GENE-Y
a O
new O
action O
for O
an O
old O
drug. O
Although O
cyst(e)ine B-CHEMICAL
is O
nutritionally O
a O
non-essential B-CHEMICAL
amino I-CHEMICAL
acid, I-CHEMICAL
lymphoid O
cells O
cannot O
synthesize O
it, O
rendering O
their O
growth O
dependent O
on O
uptake O
of O
cyst(e)ine B-CHEMICAL
from O
their O
microenvironment. O
Accordingly, O
we O
previously O
suggested O
that O
the O
x(c)- B-GENE-Y
plasma I-GENE-Y
membrane I-GENE-Y
cystine B-CHEMICAL
transporter I-GENE-Y
provided O
a O
target O
for O
lymphoid O
cancer O

therapy. O
Its O
inhibition O
could O
lead O
to O
cyst(e)ine B-CHEMICAL
deficiency O
in O
lymphoma O
cells O
via O
reduction O
of O
both O
their O
cystine B-CHEMICAL
uptake O
and O
cysteine B-CHEMICAL
supply O
by O
somatic O
cells. O
In O
this O
study, O
using O
rat O
Nb2 O
lymphoma O
cultures, O
drugs O
were O
screened O
for O
growth O
arrest O
based O
on O
x(c)- B-GENE-Y
inhibition. O
Sulfasalazine B-CHEMICAL
was O
fortuitously O
found O
to O
be O
a O
novel, O
potent O
inhibitor O
of O
the O
x(c)- B-GENE-Y
transporter. I-GENE-Y
It O
showed O
high O
rat O
lymphoma O
growth-inhibitory O
and O
lytic O
activity O
in O
vitro O
(IC50 O
= O

0.16 O
mM), O
based O
specifically O
on O
inhibition O
of O
x(c)--mediated B-GENE-Y
cystine B-CHEMICAL
uptake, O
in O
contrast O
to O
its O
colonic O
metabolites, O
sulfapyridine B-CHEMICAL
and O
5-aminosalicylic B-CHEMICAL
acid. I-CHEMICAL
Sulfasalazine B-CHEMICAL
was O
even O
more O
effective O
against O
human O
non-Hodgkin's O
lymphoma O
(DoHH2) O
cultures. O
In O
rats O
(n O
= O
13), O
sulfasalazine B-CHEMICAL
(i.p.) O
markedly O
inhibited O
growth O
of O
well-developed, O
rapidly O
growing O
rat O
Nb2 O
lymphoma O
transplants O
without O
apparent O

side-effects. O
Reduced, O
macrophage-mediated O
supply O
of O
cysteine B-CHEMICAL
was O
probably O
involved. O
In O
five O
rats, O
90-100% O
tumor O
growth O
suppression, O
relative O
to O
controls, O
was O
obtained. O
The O
x(c)- B-GENE-Y
cystine B-CHEMICAL
transporter I-GENE-Y
represents O
a O
novel O
target O
for O
sulfasalazine-like B-CHEMICAL
drugs O
with O
high O
potential O
for O
application O
in O
therapy O
of O
lymphoblastic O
and O
other O
malignancies O
dependent O
on O
extracellular O
cyst(e)ine. B-CHEMICAL
Advances O
in O
antihypertensive O
combination O
therapy: O
benefits O
of O
low-dose O
thiazide B-CHEMICAL
diuretics O
in O
conjunction O
with O

omapatrilat, B-CHEMICAL
a O
vasopeptidase B-GENE-N
inhibitor. O
The O
preferred O
initial O
agents O
for O
the O
treatment O
of O
high O
blood O
pressure O
are O
low-dose O
thiazide B-CHEMICAL
diuretics, O
beta O
blockers, O
calcium B-CHEMICAL
antagonists, O
and O
angiotensin-converting B-CHEMICAL
enzyme I-GENE-Y
(ACE) B-GENE-Y
inhibitors. O
In O
high-risk O
patients, O
including O
those O
with O
diabetes, O
renal O
insufficiency, O
left O
ventricular O
dysfunction, O
and O
atherosclerosis, O
ACE B-GENE-Y
inhibitors O
may O
have O
specific O
benefit O
in O
reducing O
cardiovascular O
morbidity O
and O
mortality. O
Omapatrilat, B-CHEMICAL
the O
prototypical O

vasopeptidase B-GENE-N
inhibitor, O
inhibits O
not O
only O
ACE B-GENE-Y
but O
also O
neutral B-GENE-Y
endopeptidase. I-GENE-Y
Like O
conventional O
ACE B-GENE-Y
inhibitors, O
omapatrilat B-CHEMICAL
causes O
extracellular O
volume O
reduction O
and O
vasodilatation; O
moreover, O
it O
increases O
levels O
of O
atrial B-GENE-N
and I-GENE-N
brain I-GENE-N
natriuretic I-GENE-N
peptides I-GENE-N
and O
bradykinin. B-GENE-Y
Effective O
blood O
pressure O
control, O
especially O
in O
the O
high-risk O
patient, O
usually O
necessitates O
combination O
therapy. O
A O
recent O
study O
randomized O
274 O
subjects O
with O
mild O
to O
severe O
hypertension O
(stages O
1-3 O
diastolic O
blood O
pressure O
elevation) O
and O
confirmed O
the O
benefits O

of O
omapatrilat B-CHEMICAL
combined O
with O
hydrochlorothiazide B-CHEMICAL
in O
patients O
not O
controlled O
on O
hydrochlorothiazide B-CHEMICAL
alone. O
The O
frequencies O
of O
adverse O
events, O
serious O
adverse O
events, O
and O
discontinuation O
attributed O
to O
adverse O
events O
were O
similar O
for O
omapatrilat B-CHEMICAL
and O
placebo. O
Furthermore, O
there O
were O
no O
clinically O
significant O
changes O
in O
serum O
creatinine, B-CHEMICAL
potassium, B-CHEMICAL
or O
other O
laboratory O
parameters. O
Adding O
omapatrilat B-CHEMICAL
to O
the O
background O
of O
hydrochlorothiazide B-CHEMICAL
treatment O
produced O
statistically O
significant O
additional O
reductions O
in O
trough O
diastolic O
and O
systolic O
blood O
pressures O
at O
weeks O

4 O
and O
8. O
Neonatal O
red O
blood O
cells: O
amiloride-insensitive B-CHEMICAL
Na+-H+ B-CHEMICAL
transport O
isoform O
would O
express O
Na+-Li+ B-CHEMICAL
exchange. O
Neonatal O
red O
cells O
(umbilical O
cord O
blood) O
were O
in O
vitro O
incubated O
in O
isotonic O
media O
(thiocyanate B-CHEMICAL
as O
predominant O
anion). O
This O
experimental O
condition O
was O
selected O
as O
it O
was O
known O
that O
this O
chaotropic O
anion O
induced O
activation O
of O
Na+-H+ B-CHEMICAL
exchange. O
The O
transport O
amiloride-sensitive B-CHEMICAL
mechanism, O
that O
decreased O
the O
acidic O
intracellular O
pH O
change O
occurring O
in O
this O
medium, O
would O
correspond O

to O
Na+-H+ B-CHEMICAL
exchange O
(NHE1 B-GENE-Y
isoform). O
However, O
the O
Na+-Li+ B-CHEMICAL
exchange, O
also O
determined O
in O
the O
cells O
in O
the O
above-mentioned O
medium O
was O
not O
affected O
by O
amiloride. B-CHEMICAL
The O
present O
data O
suggest O
that O
an O
amiloride B-CHEMICAL
insensitive O
Na+-H+ B-CHEMICAL
exchange O
isoform O
would O
express O
Na+-Li+ B-CHEMICAL
countertransport O
in O
these O
cells. O
Aspirin B-CHEMICAL
and O
salicylate B-CHEMICAL
bind O
to O
immunoglobulin B-GENE-Y
heavy I-GENE-Y
chain I-GENE-Y
binding I-GENE-Y
protein I-GENE-Y
(BiP) B-GENE-Y
and O
inhibit O
its O
ATPase B-GENE-N
activity O
in O
human O
fibroblasts. O
Salicylic B-CHEMICAL
acid I-CHEMICAL

(SA), B-CHEMICAL
an O
endogenous O
signaling O
molecule O
of O
plants, O
possesses O
anti-inflammatory O
and O
anti-neoplastic O
actions O
in O
human. O
Its O
derivative, O
aspirin, O
is O
the O
most O
commonly O
used O
anti-inflammatory O
and O
analgesic O
drug. O
Aspirin B-CHEMICAL
and O
sodium B-CHEMICAL
salicylate I-CHEMICAL
(salicylates) B-CHEMICAL
have O
been O
reported O
to O
have O
multiple O
pharmacological O
actions. O
However, O
it O
is O
unclear O
whether O
they O
bind O
to O
a O
cellular O
protein. O
Here, O
we O
report O
for O
the O
first O
time O
the O
purification O
from O
human O
fibroblasts O
of O
a O
approximately O
78 O
kDa O
salicylate B-GENE-N
binding I-GENE-N
protein I-GENE-N
with O
sequence O
identity O
to O

immunoglobulin B-GENE-Y
heavy I-GENE-Y
chain I-GENE-Y
binding I-GENE-Y
protein I-GENE-Y
(BiP). B-GENE-Y
The O
Kd O
values O
of O
SA B-CHEMICAL
binding O
to O
crude O
extract O
and O
to O
recombinant O
BiP B-GENE-Y
were O
45.2 O
and O
54.6 O
microM, O
respectively. O
BiP B-GENE-Y
is O
a O
chaperone B-GENE-N
protein I-GENE-N
containing O
a O
polypeptide O
binding O
site O
recognizing O
specific O
heptapeptide B-GENE-N
sequence I-GENE-N
and O
an O
ATP B-CHEMICAL
binding I-GENE-N
site. I-GENE-N
A O
heptapeptide O
with O
the O
specific O
sequence O
displaced O
SA B-CHEMICAL
binding O
in O
a O
concentration-dependent O
manner O
whereas O
a O
control O
heptapeptide O
did O
not. O
Salicylates B-CHEMICAL
inhibited O
ATPase B-GENE-N
activity O
stimulated O
by O
this O
specific O

heptapeptide O
but O
did O
not O
block O
ATP B-CHEMICAL
binding O
or O
induce O
BiP B-GENE-Y
expression. O
These O
results O
indicate O
that O
salicylates B-CHEMICAL
bind O
specifically O
to O
the O
polypeptide O
binding O
site O
of O
BiP B-GENE-Y
in O
human O
cells O
that O
may O
interfere O
with O
folding O
and O
transport O
of O
proteins O
important O
in O
inflammation. O
Compensatory O
changes O
in O
enzymes O
of O
arginine B-CHEMICAL
metabolism O
during O
renal O
hypertrophy O
in O
mice. O
The O
present O
study O
investigates O
enzyme O
activities O
of O
the O
urea O
cycle, O
transamidinase B-GENE-Y
and O
ornithine-proline B-CHEMICAL
inter-conversion O
in O
the O
hypertrophied O
kidney O
after O
unilateral O
nephrectomy O
in O

mice. O
Surgical O
removal O
of O
the O
left O
kidney O
in O
mice O
led O
to O
compensatory O
enlargement O
of O
the O
right O
kidney O
after O
1 O
and O
14 O
days. O
This O
renal O
growth O
was O
associated O
with O
an O
increase O
in O
glomerular O
volume O
(but O
not O
number) O
and O
enlargement O
of O
the O
proximal O
convoluted O
tubules. O
The O
total O
renal O
protein O
content O
increased O
in O
proportion O
to O
the O
increase O
in O
kidney O
weight, O
but O
the O
protein O
per O
gram O
weight O
of O
kidney O
did O
not O
change. O
The O
specific O
activity O
of O
only O
ornithine B-GENE-Y
aminotransferase I-GENE-Y
(OAT), B-GENE-Y
the O
rate-limiting O
enzyme O
in O
the O
conversion O
of O
ornithine B-CHEMICAL
to O

proline, B-CHEMICAL
increased O
in O
2 O
weeks O
of O
hypertrophy. O
The O
specific O
activity O
of O
all O
other O
enzymes O
was O
unchanged. O
However, O
the O
total O
enzyme O
activity O
per O
kidney O
of O
all O
the O
enzymes, O
without O
exception, O
was O
elevated O
in O
the O
hypertrophied O
kidney. O
While O
the O
increase O
in O
total O
OAT B-GENE-Y
activity O
was O
much O
more O
than O
the O
increase O
in O
kidney O
weight, O
all O
other O
enzymes O
increased O
more O
or O
less O
in O
proportion O
to O
the O
increase O
in O
renal O
mass. O
The O
results O
suggest O
that O
compensation O
in O
OAT B-GENE-Y
activity O
to O
chronic O
reduction O
in O
renal O
mass O
was O
complete, O
but O
only O
partial O
in O
the O
case O
of O
other O
enzymes. O
Analgesia O
and O
COX-2 B-GENE-Y
inhibition. O
While O

non-steroidal B-CHEMICAL
anti-inflammatory O
drugs O
(NSAIDs) O
are O
the O
mainstay O
of O
therapy O
for O
the O
management O
of O
acute O
pain O
and O
rheumatoid O
arthritis, O
toxicity O
associated O
with O
chronic O
administration O
limits O
their O
benefit-to-risk O
relationship O
in O
many O
patients. O
A O
series O
of O
studies O
is O
reviewed O
that O
assesses O
the O
relationship O
between O
cytokines B-GENE-N
released O
at O
the O
site O
of O
tissue O
injury O
and O
NSAID O
analgesia, O
and O
the O
in O
vivo O
selectivity O
of O
a O
selective O
cyclooxygenase B-GENE-Y
(COX)-2 I-GENE-Y
inhibitor O
(celecoxib) B-CHEMICAL
in O
comparison O
to O
a O
dual O

COX-1/COX-2 B-GENE-Y
inhibitor O
(ketorolac). B-CHEMICAL
Three O
replicate O
studies O
in O
the O
oral O
surgery O
model O
of O
acute O
pain O
used O
submucosal O
microdialysis O
sample O
collection O
for O
the O
measurement O
of O
prostaglandin B-CHEMICAL
E2 I-CHEMICAL
(PGE2; B-CHEMICAL
a O
product O
of O
both O
COX-1 B-GENE-Y
and O
COX-2) B-GENE-Y
and O
thromboxane B-CHEMICAL
B2 I-CHEMICAL
(as O
a O
biomarker O
for O
COX-1 B-GENE-Y
activity) O
with O
parallel O
assessments O
of O
pain. O
The O
time O
course O
of O
PGE2 B-CHEMICAL
production O
was O
consistent O
with O
early O
release O
due O
to O
COX-1 B-GENE-Y
activity O
followed O
by O
increased O
production O
2-3 O
hours O
after O

surgery, O
consistent O
with O
COX-2 B-GENE-Y
expression. O
Ketorolac B-CHEMICAL
30 O
mg O
at O
pain O
onset O
suppressed O
both O
pain O
and O
peripheral O
PGE2 B-CHEMICAL
levels. O
Ketorolac B-CHEMICAL
1 O
mg O
either O
at O
the O
site O
of O
injury O
or O
intramuscularly O
also O
produced O
analgesia O
but O
without O
any O
effect O
on O
peripheral O
PGE2 B-CHEMICAL
levels. O
Celecoxib B-CHEMICAL
selectively O
suppressed O
PGE2 B-CHEMICAL
but O
not O
TxB2 B-CHEMICAL
at O
time O
points O
consistent O
with O
COX-2 B-GENE-Y
activity, O
while O
producing O
analgesia. O
These O
studies O
demonstrate O
the O
ability O
to O
assess O
the O
time O
course O
and O
selective O
effects O
of O
COX-2 B-GENE-Y
inhibitors O
in O
vivo O
and O
suggest O
that O
suppression O
of O

COX-2 B-GENE-Y
mediated O
PGE2 B-CHEMICAL
is O
temporally O
related O
to O
NSAID O
analgesia. O
[3H]dofetilide B-CHEMICAL
binding O
to O
HERG B-GENE-Y
transfected O
membranes: O
a O
potential O
high O
throughput O
preclinical O
screen. O
The O
pharmacological O
characteristics O
of O
[3H]dofetilide B-CHEMICAL
binding O
were O
examined O
in O
membranes O
prepared O
from O
human O
embryonic O
kidney O
(HEK293) O
cells O
stably O
expressing O
human B-GENE-Y
ether-a-go-go B-CHEMICAL
related I-GENE-Y
gene I-GENE-Y
(HERG) I-GENE-Y
K+ B-CHEMICAL
channels. I-GENE-Y
The O
classIII O
antiarrhythmic O
compounds O
dofetilide, B-CHEMICAL

clofilium, B-CHEMICAL
4'-[[1-[2-(6-methyl-2-pyridyl)ethyl]-4-piperidyl]carbonyl]methanesulfonanilide B-CHEMICAL
(E-4031), B-CHEMICAL
N-methyl-N-[2-[methyl-(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]-4-[(methylsulfo B-CHEMICAL
nyl)amino]benzene-sulfonamide I-CHEMICAL

(WAY-123,398) B-CHEMICAL
and O
d-sotalol B-CHEMICAL
all O
inhibited O
[3H]dofetilide B-CHEMICAL
binding. O
In O
addition, O
the O
structurally O
unrelated O
compounds O
pimozide, B-CHEMICAL
terfenadine B-CHEMICAL
and O
haloperidol, B-CHEMICAL
all O
of O
which O
prolong O
the O
QT O
interval O
in O
man, O
also O
inhibited O
binding. O
These O
data O
indicate O
that O
a O
[3H]dofetilide B-CHEMICAL
binding O
assay O
using O
HERG B-GENE-Y
membranes O
may O
help O
identify O
compounds O
that O
prolong O
the O
QT O
interval. O
Effects O
of O
the O
antidepressant/antipanic O
drug O
phenelzine B-CHEMICAL
on O
alanine B-CHEMICAL
and O

alanine B-GENE-N
transaminase I-GENE-N
in O
rat O
brain. O
1. O
Phenelzine B-CHEMICAL
(PLZ) B-CHEMICAL
is O
an O
antidepressant O
with O
anxiolytic O
properties. O
Acute O
and O
chronic O
PLZ B-CHEMICAL
administration O
increase O
brain O
GABA B-CHEMICAL
levels, O
an O
effect O
due, O
at O
least O
in O
part, O
to O
an O
inhibition O
of O
the O
activity O
of O
the O
GABA B-CHEMICAL
metabolizing O
enzyme, O
GABA B-GENE-Y
transaminase I-GENE-Y
(GABA-T). B-GENE-Y
2. O
Previous O
preliminary O
reports O
have O
indicated O
that O
acute O
PLZ B-CHEMICAL
treatment O
also O
elevates O
brain O
alanine B-CHEMICAL
levels. O
As O
with O
GABA, B-CHEMICAL
the O
metabolism O
of O
alanine B-CHEMICAL
involves O
a O

pyridoxal B-GENE-N
phosphate-dependent I-GENE-N
transaminase. I-GENE-N
3. O
In O
the O
study O
reported O
here, O
the O
effects O
of O
acute O
PLZ B-CHEMICAL
treatment O
on O
the O
levels O
of O
various O
amino B-CHEMICAL
acids, I-CHEMICAL
some O
of O
which O
are O
also O
metabolized O
by O
pyridoxal B-GENE-N
phosphate-dependent I-GENE-N
transaminases I-GENE-N
were O
compared O
in O
rat O
whole O
brain. O
Of O
the O
6 O
amino B-CHEMICAL
acids I-CHEMICAL
investigated, O
only O
GABA B-CHEMICAL
and O
alanine B-CHEMICAL
levels O
were O
elevated O
(in O
a O
time- O
and O
dose-dependent O
manner). O
4. O
The O
elevation O
in O
brain O
alanine B-CHEMICAL
levels O
could O
be O
explained, O
at O
least O
in O
part, O
by O
a O
time- O
and O
dose-dependent O
inhibitory O
effect O
of O

PLZ B-CHEMICAL
on O
alanine B-GENE-N
transaminase I-GENE-N
(ALA-T), B-GENE-N
although O
as O
with O
GABA B-CHEMICAL
the O
increases O
are O
higher O
than O
expected O
from O
the O
degree O
of O
enzyme O
inhibition O
produced. O
In O
addition, O
we O
also O
showed O
that O
the O
elevation O
in O
alanine B-CHEMICAL
levels O
and O
the O
inhibition O
of O
alanine B-GENE-N
transaminase I-GENE-N
in O
the O
brain O
are O
retained O
after O
14 O
days O
of O
PLZ B-CHEMICAL
treatment, O
and O
that O
PLZ B-CHEMICAL
produces O
a O
marked O
increase O
in O
extracellular O
levels O
of O
alanine. B-CHEMICAL
5. O
These O
results O
are O
discussed O
in O
terms O
of O
their O
relevance O
to O
synaptic O
function O
and O
to O
the O
pharmacological O
profile O
of O
PLZ. B-CHEMICAL

Nicotine-induced B-CHEMICAL
contraction O
in O
the O
rat O
coronary O
artery: O
possible O
involvement O
of O
the O
endothelium, O
reactive O
oxygen B-CHEMICAL
species O
and O
COX-1 B-GENE-Y
metabolites. O
Nicotine B-CHEMICAL
caused O
a O
contraction O
of O
the O
rat O
coronary O
artery O
in O
the O
presence O
of O
Nomega-nitro-L-arginine B-CHEMICAL
methyl I-CHEMICAL
ester I-CHEMICAL
(L-NAME) B-CHEMICAL
and O
arachidonic B-CHEMICAL
acid, I-CHEMICAL
and O
did O
not O
in O
the O
absence O
of O
these O
agents. O
The O
present O
experiments O
were O
undertaken O
to O
pharmacologically O
characterize O
the O
nicotine-induced B-CHEMICAL
contraction O
in O
ring O
preparations O
of O
the O
rat O
coronary O
artery. O
The O
contraction O
was O

abolished O
by O
chemical O
removal O
of O
endothelium O
saponin. B-CHEMICAL
Oxygen B-CHEMICAL
radical O
scavengers, O
superoxide B-GENE-N
dismutase I-GENE-N
and O
catalase, B-GENE-Y
significantly O
attenuated O
the O
contraction. O
Cyclooxygenase-1 B-GENE-Y
(COX-1) B-GENE-Y
inhibitors O
(flurbiprofen, B-CHEMICAL
ketoprofen B-CHEMICAL
and O
ketrolack) B-CHEMICAL
attenuated O
the O
nicotine-induced B-CHEMICAL
contraction O
in O
a O
concentration-dependent O
manner, O
and O
cyclooxygenase-2 B-GENE-Y
(COX-2) B-GENE-Y
inhibitors O
at O
high O
concentrations O
(nimesulide B-CHEMICAL
and O
NS-389) B-CHEMICAL

slightly O
attenuated O
the O
contraction. O
A O
TXA2 B-GENE-Y
synthetase I-GENE-Y
inhibitor O
(OKY-046) B-CHEMICAL
attenuated O
the O
contraction O
to O
a O
small O
extent O
only O
at O
high O
concentrations. O
A O
TXA2 B-GENE-Y
receptor I-GENE-Y
antagonist O
(S-1452) B-CHEMICAL
attenuated O
the O
contraction O
in O
a O
concentration-dependent O
manner. O
A O
nicotinic B-GENE-N
receptor I-GENE-N
antagonist O
(hexamethonium) B-CHEMICAL
attenuated O
the O
contraction O
in O
part O
and O
an O
alpha-adrenoceptor B-GENE-N
antagonist O
(prazosin) B-CHEMICAL
nearly O
abolished O
the O
contraction. O
From O
these O
results, O
it O
was O
suggested O
that O
the O
contraction O
induced O
by O
nicotine B-CHEMICAL
in O
the O
rat O
coronary O
artery O
in O

the O
presence O
of O
L-NAME B-CHEMICAL
and O
arachidonic B-CHEMICAL
acid I-CHEMICAL
is O
endothelium O
dependent, O
and O
involves O
reactive O
oxygen B-CHEMICAL
species O
and O
endothelial O
COX-1 B-GENE-Y
metabolites O
of O
arachidonic B-CHEMICAL
acid. I-CHEMICAL
Part O
of O
the O
contraction O
is O
probably O
due O
to O
release O
of O
norepinephrine. B-CHEMICAL
Efficacy O
and O
safety O
of O
the O
factor B-GENE-Y
VIII/von I-GENE-Y
Willebrand I-GENE-Y
factor I-GENE-Y
concentrate, O
haemate-P/humate-P: O
ristocetin B-CHEMICAL
cofactor O
unit O
dosing O
in O
patients O
with O
von O
Willebrand O
disease. O
The O
present O
study O
was O
initiated O
to O
evaluate O
the O
safety O
and O
efficacy O
of O

Haemate-P O
(Humate-P O
in O
North O
America) O
(anti-hemophilic O
FVIII/VWF B-GENE-Y
complex O
[human] O
dried, O
pasteurized) O
dosed O
in O
ristocetin B-CHEMICAL
cofactor O
units O
(VWF:RCo) O
in O
the O
treatment O
of O
von O
Willebrand O
disease O
(VWD) O
patients O
in O
Canada. O
This O
retrospective O
data O
collection O
reviewed O
the O
medical O
records O
of O
VWD O
patients O
treated O
under O
the O
Canadian O
Emergency O
Drug O
Release O
Program O
from O
November O
22, O
1991, O
to O
April O
30, O
1996. O
Data O
collection O
was O
accomplished O
by O
on-site O
retrieval O
from O
source O
data O
for O
97 O
patients. O

Dosing O
was O
based O
on O
the O
German O
package O
insert, O
which O
lists O
only O
Factor B-GENE-Y
VIII:C I-GENE-Y
(FVIII:C) B-GENE-Y
units, O
which O
were O
converted O
in O
the O
study O
analysis O
to O
VWF:RCo O
units O
based O
on O
the O
analysis O
of O
the O
individual O
manufactured O
lots O
of O
product O
used O
in O
these O
patients O
(average O
ratio O
of O
2.6 O
IU O
VWF:RCo O
per O
IU O
FVIII:C). B-GENE-Y
Twenty O
five O
different O
lots O
of O
Haemate-P/Humate-P O
were O
used O
to O
treat O
437 O
different O
events O
in O
the O
97 O
study O
patients O
(344 O
hemorrhagic O
events, O
73 O
surgical O
interventions O
and O
20 O

prophylactic O
infusion O
cycles). O
Overall, O
the O
median O
dose O
of O
concentrate O
per O
infusion O
used O
to O
treat O
surgical O
events O
was O
69.1 O
IU O
VWF:RCo/kg O
(range O
11.9-222.8); O
bleeding O
events O
55.3 O
IU O
VWF:RCo/kg O
(range O
17.1-227.5) O
and O
prophylaxis O
41.6 O
IU O
VWF:RCo/kg O
(range O
34.6-81.0). O
Treatment O
periods O
varied, O
with O
the O
majority O
of O
events O
treated O
for O
< O
or O
= O
10 O
days O
(91%). O
Fifty O
percent O
of O

events O
that O
were O
treated O
longer O
than O
10 O
days O
were O
given O
for O
prophylactic O
reasons. O
Efficacy O
was O
determined O
in O
a O
standardized O
manner O
by O
the O
physician, O
based O
on O
dosing O
in O
VWF:RCo O
activity. O
An O
overall O
clinical O
result O
of O
"excellent" O
or O
"good" O
was O
reported O
in O
97% O
(424/437) O
of O
treatment O
events. O
A O
pediatric O
sub-population O
analysis O
of O
the O
patient O
population O
reported O
"excellent/good" O
efficacy O
in O
100% O
(17/17) O
of O
treatment O
events O
in O
infants, O
95% O
(155/164) O
in O
children, O
and O
94% O
(76/81) O
in O
adolescent O
patients. O

Related O
adverse O
events O
(AEs) O
were O
observed O
in O
only O
4 O
(4%) O
patients O
and O
were O
not O
deemed O
to O
be O
serious. O
The O
findings O
in O
this O
study O
confirm O
the O
safety O
and O
efficacy O
of O
Haemate-P/Humate-P O
using O
VWF:RCo B-GENE-Y
dosing O
in O
pediatric O
and O
adult O
patients O
with O
various O
types O
of O
VWD. O
Differential O
binding O
mode O
of O
diverse O
cyclooxygenase B-GENE-N
inhibitors. O
Non-steroidal B-CHEMICAL
anti-inflammatory O
drugs O
(NSAIDs) O
are O
competitive O
inhibitors O
of O
cyclooxygenase B-GENE-N
(COX), B-GENE-N
the O
enzyme O
that O
mediates O

biosynthesis O
of O
prostaglandins B-CHEMICAL
and O
thromboxanes B-CHEMICAL
from O
arachidonic B-CHEMICAL
acid. I-CHEMICAL
There O
are O
at O
least O
two O
different O
isoforms O
of O
the O
enzyme O
known O
as O
COX-1 B-GENE-N
and I-GENE-N
-2. I-GENE-N
Site O
directed O
mutagenesis O
studies O
suggest O
that O
non-selective O
COX B-GENE-N
inhibitors O
of O
diverse O
chemical O
families O
exhibit O
differential O
binding O
modes O
to O
the O
two O
isozymes. O
These O
results O
cannot O
clearly O
be O
explained O
from O
the O
sole O
analysis O
of O
the O
crystal O
structures O
of O
COX B-GENE-N
available O
from O
X-ray O
diffraction O
studies. O
With O
the O
aim O
to O
elucidate O
the O
structural O
features O
governing O
the O
differential O
inhibitory O
binding O
behavior O
of O
these O

inhibitors, O
molecular O
modeling O
studies O
were O
undertaken O
to O
generate O
atomic O
models O
compatible O
with O
the O
experimental O
data O
available. O
Accordingly, O
docking O
of O
different O
COX B-GENE-N
inhibitors, O
including O
selective O
and O
non-selective O
ligands: O
rofecoxib, B-CHEMICAL
ketoprofen, B-CHEMICAL
suprofen, B-CHEMICAL
carprofen, B-CHEMICAL
zomepirac, B-CHEMICAL
indomethacin, B-CHEMICAL
diclofenac B-CHEMICAL
and O
meclofenamic B-CHEMICAL
acid I-CHEMICAL
were O
undertaken O
using O
the O
AMBER O
program. O
The O
results O
of O
the O
present O
study O
provide O
new O
insights O
into O
a O
better O
understanding O
of O
the O
differential O
binding O
mode O
of O
diverse O
families O
of O
COX B-GENE-N
inhibitors, O
and O
are O
expected O
to O

contribute O
to O
the O
design O
of O
new O
selective O
compounds. O
Pure O
antiestrogens O
and O
breast O
cancer. O
Tamoxifen, B-CHEMICAL
which O
is O
the O
most O
commonly O
used O
drug O
for O
treatment O
of O
breast O
cancer, O
has O
both O
estrogen B-CHEMICAL
agonist O
and O
antagonist O
actions. O
Pure O
antiestrogens O
are O
devoid O
of O
any O
estrogen B-CHEMICAL
agonist O
effects. O
ICI B-CHEMICAL
182,780 I-CHEMICAL
(fulvestrant) B-CHEMICAL
(Faslodex) B-CHEMICAL
and O
ICI B-CHEMICAL
164,384 I-CHEMICAL
are O
competitive O
inhibitors O
of O
estrogen B-CHEMICAL
by O
binding O
to O
the O
estrogen B-GENE-Y
receptor I-GENE-Y
(ER). B-GENE-Y
Preclinical O
and O
clinical O
studies O
show O
that O
fulvestrant B-CHEMICAL
and O
ICI B-CHEMICAL

164,384 I-CHEMICAL
are O
more O
potent O
than O
tamoxifen B-CHEMICAL
in O
inhibiting O
the O
growth O
of O
breast O
cancer O
cells. O
They O
are O
devoid O
of O
any O
estrogen-agonist B-CHEMICAL
action O
on O
the O
uterus O
and O
vagina O
but O
lack O
the O
beneficial O
effects O
of O
tamoxifen B-CHEMICAL
on O
the O
bone O
and O
serum O
lipid O
profile. O
Fulvestrant B-CHEMICAL
is O
the O
first O
pure O
antiestrogen B-CHEMICAL
to O
complete O
phase O
III O
clinical O
trials. O
Such O
studies O
have O
shown O
that O
fulvestrant B-CHEMICAL
is O
at O
least O
as O
good O
as O
anastrozole B-CHEMICAL
in O
the O
treatment O
of O
post-menopausal O
women O
with O
advanced O
breast O
cancer O
who O
had O
relapsed O
or O
progressed O
on O
prior O

endocrine O
therapy. O
The O
drug O
was O
well O
tolerated O
and O
only O
minor O
side-effects O
were O
reported. O
Its O
potential O
role O
in O
the O
adjuvant O
setting O
will O
be O
determined O
by O
its O
adverse O
effects O
on O
bone O
mass O
and O
serum O
lipids. O
EM-800 B-CHEMICAL
and O
EM-652 B-CHEMICAL
are O
the O
most O
potent O
pure O
antiestrogens O
and O
EM-652 B-CHEMICAL
has O
the O
highest O
affinity O
of O
all O
antiestrogens O
to O
ER. B-GENE-Y
They O
have O
no O
stimulatory O
effects O
on O
the O
uterus O
or O
vagina. O
It O
seems O
reasonable O
to O
expect O
that O
pure O
antiestrogens O
will O
be O
good O
alternatives O
to O
tamoxifen B-CHEMICAL
and O
aromatase O

inhibitors O
in O
the O
treatment O
of O
breast O
cancer. O
Hepatotoxicity O
of O
commonly O
used O
drugs: O
nonsteroidal O
anti-inflammatory O
drugs, O
antihypertensives, O
antidiabetic O
agents, O
anticonvulsants, O
lipid-lowering O
agents, O
psychotropic O
drugs. O
Hepatotoxic O
adverse O
drug O
reactions O
have O
contributed O
to O
the O
decline O
of O
many O
promising O
therapies, O
even O
among O
mainstream O
medication O
classes O
(bromfenac B-CHEMICAL
and O
troglitazone B-CHEMICAL
are O
recent O
examples). O
The O
spectrum O
of O
nonsteroidal O
anti-inflammatory O
drug-related O
liver O
toxicity O
continues O
to O
expand, O
with O
reports O
in O
children, O
interactive O

toxicity O
in O
persons O
with O
hepatitis O
C, O
and O
recognition O
of O
the O
toxicity O
of O
both O
the O
preferential O
and O
selective O
cyclooxygenase-2 B-GENE-Y
inhibitors. O
Of O
the O
antihypertensive O
agents, O
methyldopa O
is O
now O
rarely O
prescribed O
and O
adverse O
effects O
are O
reported O
infrequently, O
whereas O
cases O
of O
liver O
injury O
associated O
with O
the O
angiotensin B-GENE-N
receptor I-GENE-N
and O
converting B-GENE-Y
enzyme I-GENE-Y
inhibitors O
are O
increasingly O
reported. O
Of O
the O
antidiabetic O
agents, O
acarbose, B-CHEMICAL
gliclazide, B-CHEMICAL
metformin, B-CHEMICAL
and O
human B-GENE-Y
insulin I-GENE-Y
have O
been O
implicated O
in O
causing O
liver O
injury. O
To O
date, O
the O
newer O

thiazolidinediones B-CHEMICAL
do O
not O
appear O
to O
share O
the O
hepatotoxic O
potential O
of O
troglitazone, B-CHEMICAL
although O
a O
few O
reports O
of O
acute O
hepatitis O
have O
accrued. O
Although O
liver O
injury O
has O
been O
associated O
with O
the O
"statins," O
the O
frequency O
of O
such O
toxicity O
is O
lower O
than O
that O
of O
the O
background O
population O
and O
the O
value O
of O
biochemical O
monitoring O
remains O
unproved. O
Newer O
concepts O
in O
anticonvulsant O
hepatotoxicity O
have O
been O
the O
recognition O
of O
the O
reactive O
metabolite O
syndrome, O
delineation O
of O
the O
risk O
factors O
for O
valproic B-CHEMICAL
acid I-CHEMICAL
toxicity, O
the O
potential O

role O
of O
carnitine B-CHEMICAL
in O
preventing O
valproic B-CHEMICAL
acid I-CHEMICAL
hepatotoxicity, O
and O
the O
toxicity O
of O
second-line O
antiepileptic O
drugs. O
Liver O
injury O
associated O
with O
newer O
psychotropic O
agents, O
particularly O
the O
selective O
serotonin B-CHEMICAL
reuptake O
inhibitors, O
is O
also O
discussed. O
The O
focus O
of O
the O
review O
is O
the O
hepatotoxicity O
of O
commonly O
used O
drugs O
with O
particular O
reference O
to O
recent O
and O
novel O
reports O
of O
toxicity. O
Well-known O
causes O
of O
liver O
injury O
such O
as O
chlorpromazine, B-CHEMICAL
phenytoin, B-CHEMICAL
and O
methyldopa B-CHEMICAL
are O
not O
discussed. O
Pharmacological, O

pharmacokinetic O
and O
clinical O
properties O
of O
olopatadine B-CHEMICAL
hydrochloride, I-CHEMICAL
a O
new O
antiallergic O
drug. O
Olopatadine B-CHEMICAL
hydrochloride I-CHEMICAL
(olopatadine, B-CHEMICAL
11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic B-CHEMICAL
acid I-CHEMICAL
monohydrochloride) I-CHEMICAL
is O
a O
novel O
antiallergic/histamine B-CHEMICAL
H1-receptor I-GENE-Y
antagonistic O
drug O
that O
was O
synthesized O
and O
evaluated O
in O
our O
laboratories. O
Oral O
administration O
of O

olopatadine B-CHEMICAL
at O
doses O
of O
0.03 O
mg/kg O
or O
higher O
inhibited O
the O
symptoms O
of O
experimental O
allergic O
skin O
responses, O
rhinoconjunctivitis O
and O
bronchial O
asthma O
in O
sensitized O
guinea O
pigs O
and O
rats. O
Olopatadine B-CHEMICAL
is O
a O
selective O
histamine B-GENE-Y
H1-receptor I-GENE-Y
antagonist O
possessing O
inhibitory O
effects O
on O
the O
release O
of O
inflammatory O
lipid O
mediators O
such O
as O
leukotriene B-CHEMICAL
and O
thromboxane B-CHEMICAL
from O
human O
polymorphonuclear O
leukocytes O
and O
eosinophils. O
Olopatadine B-CHEMICAL
also O
inhibited O
the O
tachykininergic O
contraction O

in O
the O
guinea O
pig O
bronchi O
by O
prejunctional O
inhibition O
of O
peripheral O
sensory O
nerves. O
Olopatadine B-CHEMICAL
exerted O
no O
significant O
effects O
on O
action O
potential O
duration O
in O
isolated O
guinea O
pig O
ventricular O
myocytes, O
myocardium O
and O
human B-GENE-Y
ether-a-go-go-related I-GENE-Y
gene I-GENE-Y
channel. I-GENE-Y
Olopatadine B-CHEMICAL
was O
highly O
and O
rapidly O
absorbed O
in O
healthy O
human O
volunteers. O
The O
urinary O
excretion O
of O
olopatadine B-CHEMICAL
accounted O
for O
not O
less O
than O
58% O
and O
the O
contribution O
of O
metabolism O
was O
considerably O
low O
in O
the O
clearance O
of O
olopatadine B-CHEMICAL
in O
humans. O
Olopatadine B-CHEMICAL
is O
one O
of O
the O
few O

renal O
clearance O
drugs O
in O
antiallergic O
drugs. O
Olopatadine B-CHEMICAL
was O
shown O
to O
be O
useful O
for O
the O
treatment O
of O
allergic O
rhinitis O
and O
chronic O
urticaria O
in O
double-blind O
clinical O
trials. O
Olopatadine B-CHEMICAL
was O
approved O
in O
Japan O
for O
the O
treatment O
of O
allergic O
rhinitis, O
chronic O
urticaria, O
eczema O
dermatitis, O
prurigo, O
pruritus O
cutaneous, O
psoriasis O
vulgaris O
and O
erythema O
exsudativum O
multiforme O
in O
December, O
2000. O
Ophthalmic O
solution O
of O
olopatadine B-CHEMICAL
was O
also O
approved O
in O
the O

United O
States O
for O
the O
treatment O
of O
seasonal O
allergic O
conjunctivitis O
in O
December, O
1996 O
(Appendix: O
also O
in O
the O
European O
Union, O
it O
was O
approved O
in O
February O
2002). O
Serotonin B-CHEMICAL
transporter I-GENE-Y
polymorphisms O
and O
measures O
of O
impulsivity, O
aggression, O
and O
sensation O
seeking O
among O
African-American O
cocaine-dependent B-CHEMICAL
individuals. O
Considerable O
evidence O
indicates O
that O
serotonergic O
mechanisms, O
particularly O
the O
serotonin B-CHEMICAL
transporter I-GENE-Y
(5HTT), B-GENE-Y
may O
mediate O
central O
effects O
of O
cocaine B-CHEMICAL
and O
may O
also O
be O
involved O
in O
impulsive O
and O
aggressive O
behavior. O
We O
investigated O
whether O
polymorphisms O
in O
the O

5HTT B-GENE-Y
gene O
were O
related O
to O
traits O
of O
impulsivity, O
sensation O
seeking, O
and O
aggression O
among O
cocaine B-CHEMICAL
abusers. O
Standardized O
measures O
of O
these O
personality O
traits O
were O
obtained O
in O
a O
sample O
of O
105 O
severely O
affected O
cocaine-dependent B-CHEMICAL
African-American O
subjects O
and O
44 O
African-American O
controls. O
Two O
polymorphisms O
of O
the O
5HTT B-GENE-Y
gene O
were O
examined O
involving O
the O
5' O
promoter O
(5HTTLPR) B-GENE-N
region O
and O
a O
17 O
base O
pair O
variable-number-tandem-repeat B-GENE-N
(VNTR) B-GENE-N
marker O
among O
cocaine B-CHEMICAL
patients. O
No O
significant O
relationships O
were O
observed O
between O
polymorphic O
variants O
of O
the O
5HTTLPR B-GENE-N
and O
VNTR B-GENE-N
regions O
and O
scores O
on O

any O
of O
the O
trait O
measures. O
Similarly, O
demographic O
variables O
and O
measures O
of O
severity O
of O
substance O
use O
and O
depression O
were O
unrelated O
to O
allele O
frequencies O
or O
genotype O
distributions O
of O
the O
variants O
among O
cocaine B-CHEMICAL
patients. O
As O
expected, O
cocaine B-CHEMICAL
patients O
scored O
significantly O
higher O
on O
total O
scores O
of O
impulsivity, O
aggression, O
and O
sensation O
seeking O
compared O
to O
controls. O
The O
findings O
do O
not O
seem O
to O
support O
an O
association O
between O
these O
polymorphisms O
in O
the O
5HTT B-GENE-Y
gene O
and O
impulsive-aggressive O
traits O
among O
cocaine-dependent B-CHEMICAL
African-American O
individuals. O
A O
molecular O
mechanism O
of O
action O
of O
theophylline: B-CHEMICAL
Induction O
of O
histone B-GENE-N
deacetylase I-GENE-N
activity O
to O
decrease O
inflammatory O
gene O

expression. O
The O
molecular O
mechanism O
for O
the O
anti-inflammatory O
action O
of O
theophylline B-CHEMICAL
is O
currently O
unknown, O
but O
low-dose O
theophylline B-CHEMICAL
is O
an O
effective O
add-on O
therapy O
to O
corticosteroids O
in O
controlling O
asthma. O
Corticosteroids B-CHEMICAL
act, O
at O
least O
in O
part, O
by O
recruitment O
of O
histone B-GENE-N
deacetylases I-GENE-N
(HDACs) B-GENE-N
to O
the O
site O
of O
active O
inflammatory O
gene O
transcription. O
They O
thereby O
inhibit O
the O
acetylation O
of O
core O
histones O
that O
is O
necessary O
for O
inflammatory O
gene O
transcription. O
We O
show O
both O
in O
vitro O
and O
in O
vivo O
that O
low-dose O
theophylline B-CHEMICAL
enhances O
HDAC B-GENE-N

activity O
in O
epithelial O
cells O
and O
macrophages. O
This O
increased O
HDAC B-GENE-N
activity O
is O
then O
available O
for O
corticosteroid B-CHEMICAL
recruitment O
and O
predicts O
a O
cooperative O
interaction O
between O
corticosteroids B-CHEMICAL
and O
theophylline. B-CHEMICAL
This O
mechanism O
occurs O
at O
therapeutic O
concentrations O
of O
theophylline B-CHEMICAL
and O
is O
dissociated O
from O
phosphodiesterase B-GENE-N
inhibition O
(the O
mechanism O
of O
bronchodilation) O
or O
the O
blockade O
of O
adenosine B-GENE-N
receptors, I-GENE-N
which O
are O
partially O
responsible O
for O
its O
side O
effects. O
Thus O
we O
have O
shown O
that O
low-dose O
theophylline B-CHEMICAL
exerts O
an O
anti-asthma O
effect O
through O
increasing O
activation O

of O
HDAC B-GENE-N
which O
is O
subsequently O
recruited O
by O
corticosteroids B-CHEMICAL
to O
suppress O
inflammatory O
genes. O
Interactions O
of O
rifamycin B-CHEMICAL
SV I-CHEMICAL
and O
rifampicin B-CHEMICAL
with O
organic O
anion O
uptake O
systems O
of O
human O
liver. O
The O
antibiotics O
rifamycin B-CHEMICAL
SV I-CHEMICAL
and O
rifampicin B-CHEMICAL
substantially O
reduce O
sulfobromophthalein B-CHEMICAL
(BSP) B-CHEMICAL
elimination O
in O
humans. O
In O
rats, O
rifamycin B-CHEMICAL
SV I-CHEMICAL
and O
rifampicin B-CHEMICAL
were O
shown O
to O
interfere O
with O
hepatic O
organic O
anion O
uptake O
by O
inhibition O
of O
the O
organic B-GENE-N
anion I-GENE-N
transporting I-GENE-N
polypeptides I-GENE-N
Oatp1 B-GENE-Y
and O

Oatp2. B-GENE-Y
Therefore, O
we O
investigated O
the O
effects O
of O
rifamycin B-CHEMICAL
SV I-CHEMICAL
and O
rifampicin B-CHEMICAL
on O
the O
OATPs B-GENE-N
of O
human O
liver O
and O
determined O
whether O
rifampicin B-CHEMICAL
is O
a O
substrate O
of O
1 O
or O
several O
of O
these O
carriers. O
In O
complementary O
RNA O
(cRNA)-injected O
Xenopus O
laevis O
oocytes, O
rifamycin B-CHEMICAL
SV I-CHEMICAL
(10 O
micromol/L) O
cis-inhibited O
human B-GENE-Y
organic I-GENE-Y
anion I-GENE-Y
transporting I-GENE-Y
polypeptide I-GENE-Y
C I-GENE-Y
(SLC21A6) B-GENE-Y
(OATP-C), B-GENE-Y
human B-GENE-Y
organic I-GENE-Y
anion I-GENE-Y
transporting I-GENE-Y
polypeptide I-GENE-Y
8 I-GENE-Y

(SLC21A8) B-GENE-Y
(OATP8), B-GENE-Y
human B-GENE-Y
organic I-GENE-Y
anion I-GENE-Y
transporting I-GENE-Y
polypeptide I-GENE-Y
B I-GENE-Y
(SLC21A9) B-GENE-Y
(OATP-B), B-GENE-Y
and O
human B-GENE-Y
organic I-GENE-Y
anion I-GENE-Y
transporting I-GENE-Y
polypeptide I-GENE-Y
A I-GENE-Y
(SLC21A3) B-GENE-Y
(OATP-A) B-GENE-Y
mediated O
BSP O
uptake O
by O
69%, O
79%, O
89%, O
and O
57%, O
respectively, O
as O
compared O
with O
uptake O
into O
control O
oocytes. O
In O
the O
presence O
of O
100 O
micromol/L O
rifamycin B-CHEMICAL
SV, I-CHEMICAL
BSP B-CHEMICAL
uptake O
was O
almost O
completely O
abolished. O

Approximate O
K(i) O
values O
were O
2 O
micromol/L O
for O
OATP-C, B-GENE-Y
3 O
micromol/L O
for O
OATP8, B-GENE-Y
3 O
micromol/L O
for O
OATP-B B-GENE-Y
and O
11 O
micromol/L O
for O
OATP-A. B-GENE-Y
Rifampicin B-CHEMICAL
(10 O
micromol/L) O
inhibited O
OATP8-mediated B-GENE-Y
BSP B-CHEMICAL
uptake O
by O
50%, O
whereas O
inhibition O
of O
OATP-C-, B-GENE-Y
OATP-B-, B-GENE-Y
and O
OATP-A-mediated B-GENE-Y
BSP B-CHEMICAL
transport O
was O
below O
15%. O

100 O
micromol/L O
rifampicin B-CHEMICAL
inhibited O
OATP-C- B-GENE-Y
and O
OATP8-, B-GENE-Y
OATP-B- B-GENE-Y
and O
OATP-A-mediated B-GENE-Y
BSP B-CHEMICAL
uptake O
by O
66%, O
96%, O
25%, O
and O
49%, O
respectively. O
The O
corresponding O
K(i) O
values O
were O
17 O
micromol/L O
for O
OATP-C, B-GENE-Y
5 O
micromol/L O
for O
OATP8, B-GENE-Y
and O
51 O
micromol/L O
for O
OATP-A. B-GENE-Y
Direct O
transport O
of O
rifampicin B-CHEMICAL
could O
be O
shown O
for O
OATP-C B-GENE-Y

(apparent O
K(m) O
value O
13 O
micromol/L) O
and O
OATP8 B-GENE-Y
(2.3 O
micromol/L). O
In O
conclusion, O
these O
results O
show O
that O
rifamycin B-CHEMICAL
SV I-CHEMICAL
and O
rifampicin B-CHEMICAL
interact O
with O
OATP-mediated B-GENE-N
substrate O
transport O
to O
different O
extents. O
Inhibition O
of O
human B-GENE-N
liver I-GENE-N
OATPs I-GENE-N
can O
explain O
the O
previously O
observed O
effects O
of O
rifamycin B-CHEMICAL
SV I-CHEMICAL
and O
rifampicin B-CHEMICAL
on O
hepatic O
organic O
anion O
elimination. O
Metformin B-CHEMICAL
increases O
AMP-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
activity O
in O
skeletal O
muscle O
of O
subjects O
with O
type O
2 O
diabetes. O
Metformin B-CHEMICAL
is O
an O
effective O

hypoglycemic O
drug O
that O
lowers O
blood O
glucose B-CHEMICAL
concentrations O
by O
decreasing O
hepatic O
glucose B-CHEMICAL
production O
and O
increasing O
glucose B-CHEMICAL
disposal O
in O
skeletal O
muscle; O
however, O
the O
molecular O
site O
of O
metformin B-CHEMICAL
action O
is O
not O
well O
understood. O
AMP-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
(AMPK) B-GENE-N
activity O
increases O
in O
response O
to O
depletion O
of O
cellular O
energy O
stores, O
and O
this O
enzyme O
has O
been O
implicated O
in O
the O
stimulation O
of O
glucose B-CHEMICAL
uptake O
into O
skeletal O
muscle O
and O
the O
inhibition O
of O
liver O
gluconeogenesis. O
We O
recently O
reported O
that O
AMPK B-GENE-N
is O
activated O
by O
metformin B-CHEMICAL
in O
cultured O
rat O
hepatocytes, O
mediating O
the O
inhibitory O
effects O
of O
the O

drug O
on O
hepatic O
glucose B-CHEMICAL
production. O
In O
the O
present O
study, O
we O
evaluated O
whether O
therapeutic O
doses O
of O
metformin B-CHEMICAL
increase O
AMPK B-GENE-N
activity O
in O
vivo O
in O
subjects O
with O
type O
2 O
diabetes. O
Metformin B-CHEMICAL
treatment O
for O
10 O
weeks O
significantly O
increased O
AMPK B-GENE-Y
alpha2 I-GENE-Y
activity O
in O
the O
skeletal O
muscle, O
and O
this O
was O
associated O
with O
increased O
phosphorylation O
of O
AMPK B-GENE-N
on O
Thr172 O
and O
decreased O
acetyl-CoA B-GENE-Y
carboxylase-2 I-GENE-Y
activity. O
The O
increase O
in O
AMPK B-GENE-Y
alpha2 I-GENE-Y
activity O
was O
likely O
due O
to O
a O
change O
in O
muscle O
energy O
status O
because O
ATP B-CHEMICAL
and O
phosphocreatine B-CHEMICAL
concentrations O
were O
lower O
after O

metformin B-CHEMICAL
treatment. O
Metformin-induced B-CHEMICAL
increases O
in O
AMPK B-GENE-N
activity O
were O
associated O
with O
higher O
rates O
of O
glucose B-CHEMICAL
disposal O
and O
muscle O
glycogen O
concentrations. O
These O
findings O
suggest O
that O
the O
metabolic O
effects O
of O
metformin O
in O
subjects O
with O
type O
2 O
diabetes O
may O
be O
mediated O
by O
the O
activation O
of O
AMPK B-GENE-Y
alpha2. I-GENE-Y
Thalidomide B-CHEMICAL
prevents O
alcoholic B-CHEMICAL
liver O
injury O
in O
rats O
through O
suppression O
of O
Kupffer O
cell O
sensitization O
and O
TNF-alpha B-GENE-Y
production. O
BACKGROUND O
& O
AIMS: O
Sensitization O
of O
Kupffer O
cells O
(KCs) O
to O
lipopolysaccharide O
(LPS) O

and O
overproduction O
of O
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
(TNF) I-GENE-Y
alpha I-GENE-Y
are O
critical O
for O
progression O
of O
alcoholic B-CHEMICAL
liver O
injury. O
Thalidomide B-CHEMICAL
has O
been O
shown O
to O
suppress O
TNF-alpha B-GENE-Y
production O
from O
macrophages. O
Accordingly, O
the O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
thalidomide B-CHEMICAL
could O
prevent O
alcohol-induced B-CHEMICAL
liver O
injury. O
METHODS: O
Rats O
were O
given O
ethanol B-CHEMICAL
(5 O
g/kg O
body O
wt) O
and O
thalidomide B-CHEMICAL
(5 O
mg/kg) O
once O
every O
24 O
hours O
intragastrically. O
To O
assess O
the O
sensitization O
of O
Kupffer O
cells, O
LPS O
(5 O

mg/kg O
intravenously) O
was O
administered O
and O
liver O
histology O
was O
evaluated O
24 O
hours O
later. O
KCs O
were O
isolated O
after O
4 O
weeks O
of O
ethanol B-CHEMICAL
treatment O
and O
intracellular O
Ca2+ B-CHEMICAL
([Ca2+]i) B-CHEMICAL
was O
measured O
using O
fura-2, O
whereas O
TNF-alpha B-GENE-Y
was O
evaluated O
by O
reverse-transcription O
polymerase O
chain O
reaction O
and O
enzyme-linked O
immunosorbent O
assay. O
CD14 B-GENE-Y
was O
determined O
by O
Western O
and O
fluorescence O
staining. O
RESULTS: O
Treatment O
with O
ethanol B-CHEMICAL
for O
8 O
weeks O
caused O
marked O
steatosis, O
necrosis, O
and O
inflammation O
in O
the O
liver. O
These O

pathologic O
parameters O
were O
diminished O
markedly O
by O
treatment O
with O
thalidomide. B-CHEMICAL
In O
the O
4-week O
ethanol B-CHEMICAL
group, O
the O
LPS-induced O
liver O
damage O
was O
aggravated O
and O
KCs O
were O
sensitized O
to O
LPS. O
Coadministration O
of O
thalidomide B-CHEMICAL
with O
ethanol B-CHEMICAL
prevented O
the O
KC O
sensitization O
completely. O
Furthermore, O
thalidomide B-CHEMICAL
abolished O
the O
LPS-induced O
increase O
in O
CD14 B-GENE-Y
expression O
and O
[Ca2+]i B-CHEMICAL
elevation O
in O
KCs. O
Gut O
permeability O
was O
increased O
about O
10-fold O
after O
4 O
weeks O
of O
ethanol B-CHEMICAL
exposure, O
which O
was O
not O
affected O
by O

thalidomide. B-CHEMICAL
Moreover, O
thalidomide B-CHEMICAL
reduced O
the O
LPS-induced O
TNF-alpha B-GENE-Y
production O
by O
KCs O
by O
decreasing O
TNF-alpha B-GENE-Y
messenger O
RNA. O
CONCLUSIONS: O
These O
results O
collectively O
indicate O
that O
thalidomide B-CHEMICAL
prevents O
alcoholic O
liver O
injury O
through O
suppression O
of O
TNF-alpha B-GENE-Y
production O
and O
abolishment O
of O
KC O
sensitization. O
Identification O
and O
characterization O
of O
a O
novel O
flavin-containing B-CHEMICAL
spermine B-GENE-N
oxidase I-GENE-N
of O
mammalian O
cell O
origin. O
During O
polyamine B-CHEMICAL
catabolism, O
spermine B-CHEMICAL
and O
spermidine B-CHEMICAL
are O
first O
acetylated O
by O

spermidine/spermine B-GENE-Y
N(1)-acetyltransferase I-GENE-Y
(SSAT) B-GENE-Y
and O
subsequently O
oxidized O
by O
polyamine B-CHEMICAL
oxidase I-GENE-Y
(PAO) B-GENE-Y
to O
produce O
spermidine B-CHEMICAL
and O
putrescine, B-CHEMICAL
respectively. O
In O
attempting O
to O
clone O
the O
PAO B-GENE-Y
involved O
in O
this O
back-conversion O
pathway, O
we O
encountered O
an O
oxidase B-GENE-N
that O
preferentially O
cleaves O
spermine B-CHEMICAL
in O
the O
absence O
of O
prior O
acetylation O
by O
SSAT. B-GENE-Y
A O
BLAST O
search O
using O
maize B-GENE-Y
PAO I-GENE-Y
sequences O
identified O
homologous O
mammalian O
cDNAs O
derived O
from O
human O
hepatoma O
and O
mouse O

mammary O
carcinoma: O
the O
encoded O
proteins O
differed O
by O
20 O
amino B-CHEMICAL
acids. I-CHEMICAL
When O
either O
cDNA O
was O
transiently O
transfected O
into O
HEK-293 O
cells, O
intracellular O
spermine B-CHEMICAL
pools O
decreased O
by O
75% O
while O
spermidine B-CHEMICAL
and O
N B-CHEMICAL
(1)-acetylspermidine I-CHEMICAL
pools O
increased, O
suggesting O
that O
spermine B-CHEMICAL
was O
selectively O
and O
directly O
oxidized O
by O
the O
enzyme. O
Substrate O
specificity O
using O
lysates O
of O
oxidase-transfected B-GENE-N
HEK-293 O
cells O
revealed O
that O
the O
newly O
identified O
oxidase B-GENE-N
strongly O
favoured O
spermine B-CHEMICAL
over O
N B-CHEMICAL

(1)-acetylspermine I-CHEMICAL
and O
that O
it O
failed O
to O
act O
on O
N B-CHEMICAL
(1)-acetylspermidine, I-CHEMICAL
spermidine B-CHEMICAL
or O
the O
preferred O
PAO B-GENE-Y
substrate, O
N B-CHEMICAL
(1), I-CHEMICAL
N I-CHEMICAL
(12)-diacetylspermine. I-CHEMICAL
The O
PAO B-GENE-Y
inhibitor, O
MDL-72,527, B-CHEMICAL
only O
partially O
blocked O
oxidation O
of O
spermine B-CHEMICAL
while O
a O
previously O
reported O
PAO B-GENE-Y
substrate, O
N B-CHEMICAL
(1)-( I-CHEMICAL
n I-CHEMICAL
-octanesulphonyl)spermine, I-CHEMICAL
potently O
inhibited O
the O
reaction. O
Overall, O
the O
data O
indicate O
that O
the O
enzyme O
represents O
a O
novel O
mammalian B-GENE-N

oxidase I-GENE-N
which, O
on O
the O
basis O
of O
substrate O
specificity, O
we O
have O
designated O
spermine B-CHEMICAL
oxidase I-GENE-N
in O
order O
to O
distinguish O
it O
from O
the O
PAO B-GENE-N
involved O
in O
polyamine B-CHEMICAL
back-conversion. O
The O
identification O
of O
an O
enzyme O
capable O
of O
directly O
oxidizing O
spermine B-CHEMICAL
to O
spermidine B-CHEMICAL
has O
important O
implications O
for O
understanding O
polyamine O
homoeostasis O
and O
for O
interpreting O
metabolic O
and O
cellular O
responses O
to O
clinically O
relevant O
polyamine B-CHEMICAL
analogues O
and O
inhibitors. O
Low O
incidence O
of O
paradoxical O
platelet O
activation O
by O
glycoprotein B-GENE-N
IIb/IIIa I-GENE-N
inhibitors. O
The O
human B-GENE-N
platelet I-GENE-N
antigen-1 I-GENE-N

(HPA-1, B-GENE-N
Pl(A)) B-GENE-N
polymorphism O
has O
been O
proposed O
to O
influence O
the O
inhibitory O
actions O
of O
abciximab. O
Thus, O
we O
hypothesized O
that O
this O
polymorphism O
might O
also O
be O
the O
cause O
for O
paradoxical O
activation O
of O
platelets O
by O
GPIIb/IIIa B-GENE-N
inhibitors. O
The O
effects O
of O
abciximab O
(1-10 O
microg/ml), O
tirofiban B-CHEMICAL
(3-30 O
nM), O
or O
eptifibatide B-CHEMICAL
(0.3-3 O
microg/ml) O
on O
basal O
and O
ADP B-CHEMICAL

(3 O
microM)-induced O
CD62P B-GENE-Y
externalization O
were O
measured O
in O
n=62 O
healthy O
blood O
donors O
and O
n=177 O
patients O
with O
stable O
coronary O
artery O
disease. O
All O
subjects O
were O
genotyped O
for O
the O
human B-GENE-N
platelet I-GENE-N
antigen-1 I-GENE-N
(HPA-1, B-GENE-N
Pl(A)) B-GENE-N
polymorphism O
by O
GALIOS(R) O
and O
fluorescence O
correlation O
spectroscopy. O
Although O
a O
significant O
platelet O
hyperreactivity O
was O
observed O
in O
the O
patients, O
the O
HPA-1 B-GENE-N
genotype O
did O
not O
influence O
basal O
or O
ADP-induced B-CHEMICAL
CD62P B-GENE-Y
expression. O
A O
moderate O

(twofold) O
stimulation O
of O
CD62P B-GENE-Y
expression O
by O
abciximab O
but O
not O
by O
tirofiban B-CHEMICAL
or O
eptifibatide B-CHEMICAL
was O
observed O
in O
one O
patient. O
Interestingly, O
this O
patient O
carried O
the O
HPA-1 B-GENE-N
b/b O
genotype. O
In O
no O
other O
subject O
any O
activation O
of O
platelets O
by O
GP B-GENE-N
IIb/IIIa I-GENE-N
inhibitors O
was O
observed O
and O
there O
were O
no O
statistically O
significant O
differences O
between O
HPA-1 B-GENE-N
genotypes O
with O
respect O
to O
the O
effects O
of O
GP B-GENE-N
IIb/IIIa I-GENE-N
inhibitors O
on O
basal O
or O
ADP-stimulated B-CHEMICAL
CD62P B-GENE-Y
expression. O
It O
is O
concluded O
that O

paradoxical O
platelet O
activation O
by O
abciximab O
is O
a O
rare O
(<2%) O
phenomenon. O
HPA-1 B-GENE-N
b/b O
genotype O
might O
be O
a O
contributing O
factor O
but O
clearly O
does O
not O
predict O
platelet O
activation O
by O
GP B-GENE-N
IIb/IIIa I-GENE-N
inhibitors. O
Toxic, O
halogenated O
cysteine B-CHEMICAL
S-conjugates I-CHEMICAL
and O
targeting O
of O
mitochondrial O
enzymes O
of O
energy O
metabolism. O
Several O
haloalkenes B-CHEMICAL
are O
metabolized O
in O
part O
to O
nephrotoxic O
cysteine B-CHEMICAL
S-conjugates; I-CHEMICAL
for O
example, O
trichloroethylene B-CHEMICAL
and O

tetrafluoroethylene B-CHEMICAL
are O
converted O
to O
S-(1,2-dichlorovinyl)-L-cysteine B-CHEMICAL
(DCVC) B-CHEMICAL
and O
S-(1,1,2,2-tetrafluoroethyl)-L-cysteine B-CHEMICAL
(TFEC), B-CHEMICAL
respectively. O
Although O
DCVC-induced B-CHEMICAL
toxicity O
has O
been O
investigated O
since O
the O
1950s, O
the O
toxicity O
of O
TFEC B-CHEMICAL
and O
other O
haloalkene-derived B-CHEMICAL
cysteine I-CHEMICAL
S-conjugates I-CHEMICAL
has O
been O
studied O
more O
recently. O
Some O
segments O
of O
the O
US O
population O
are O
exposed O
to O

haloalkenes B-CHEMICAL
either O
through O
drinking O
water O
or O
in O
the O
workplace. O
Therefore, O
it O
is O
important O
to O
define O
the O
toxicological O
consequences O
of O
such O
exposures. O
Most O
halogenated O
cysteine B-CHEMICAL
S-conjugates I-CHEMICAL
are O
metabolized O
by O
cysteine B-CHEMICAL
S-conjugate I-CHEMICAL
beta-lyases B-GENE-N
to O
pyruvate, B-CHEMICAL
ammonia, B-CHEMICAL
and O
an O
alpha-chloroenethiolate B-CHEMICAL
(with O
DCVC) B-CHEMICAL
or O
an O
alpha-difluoroalkylthiolate B-CHEMICAL
(with O
TFEC) B-CHEMICAL
that O
may O
eliminate O
halide B-CHEMICAL
to O
give O
a O
thioacyl B-CHEMICAL
halide, I-CHEMICAL
which O
reacts O
with O

epsilon-amino B-CHEMICAL
groups O
of O
lysine B-CHEMICAL
residues O
in O
proteins. O
Nine O
mammalian O
pyridoxal B-CHEMICAL
5'-phosphate I-CHEMICAL
(PLP)-containing B-CHEMICAL
enzymes O
catalyze O
cysteine B-CHEMICAL
S-conjugate I-CHEMICAL
beta-lyase B-GENE-N
reactions, O
including O
mitochondrial B-GENE-Y
aspartate I-GENE-Y
aminotransferase I-GENE-Y
(mitAspAT), B-GENE-Y
and O
mitochondrial B-GENE-Y
branched-chain I-GENE-Y
amino I-GENE-Y
acid I-GENE-Y
aminotransferase I-GENE-Y
(BCAT(m)). B-GENE-Y
Most O
of O
the O
cysteine B-CHEMICAL
S-conjugate I-CHEMICAL
beta-lyases B-GENE-N
are O
syncatalytically O
inactivated. O
TFEC-induced B-CHEMICAL
toxicity O
is O
associated O
with O
covalent O

modification O
of O
several O
mitochondrial O
enzymes O
of O
energy O
metabolism. O
Interestingly, O
the O
alpha-ketoglutarate- B-CHEMICAL
and I-GENE-N
branched-chain B-CHEMICAL
alpha-keto I-CHEMICAL
acid I-CHEMICAL
dehydrogenase I-GENE-N
complexes I-GENE-N
(KGDHC B-GENE-N
and O
BCDHC), B-GENE-N
but O
not O
the O
pyruvate B-CHEMICAL
dehydrogenase I-GENE-N
complex I-GENE-N
(PDHC), B-GENE-N
are O
susceptible O
to O
inactivation. O
mitAspAT B-GENE-Y
and O
BCAT(m) B-GENE-Y
may O
form O
metabolons O
with O
KGDHC B-GENE-N
and O
BCDHC, B-GENE-N
respectively, O
but O
no O
PLP B-GENE-N
enzyme I-GENE-N
is O
known O
to O
associate O
with O
PDHC. B-GENE-N
Consequently, O
we O
hypothesize O
that O
not O
only O
do O
these O

metabolons O
facilitate O
substrate O
channeling, O
but O
they O
also O
facilitate O
toxicant O
channeling, O
thereby O
promoting O
the O
inactivation O
of O
proximate O
mitochondrial O
enzymes O
and O
the O
induction O
of O
mitochondrial O
dysfunction. O
A O
heterozygote O
phenotype O
is O
present O
in O
the O
jvs O
+/- O
mutant O
mouse O
livers. O
The O
juvenile O
visceral O
steatosis O
(jvs) O
mouse, O
having O
a O
mutation O
in O
the O
carnitine B-CHEMICAL
transporter O
gene O
Octn2, B-GENE-Y
is O
a O
model O
of O
primary O
systemic O
carnitine B-CHEMICAL
deficiency O
in O
humans O
(SCD, O
OMIM O
212140). O
Like O
humans O
with O
SCD, O

homozygous O
jvs O
-/- O
mice O
have O
hepatic O
and O
cardiac O
steatoses, O
reduced O
plasma O
and O
tissue O
carnitines, B-CHEMICAL
and O
increased O
urinary O
carnitine B-CHEMICAL
clearance. O
Because O
symptomatic O
heterozygotes O
have O
been O
reported O
for O
some O
fatty B-CHEMICAL
acid I-CHEMICAL
oxidation O
disorders, O
including O
SCD, O
we O
compared O
the O
jvs O
heterozygotes O
to O
normal O
control O
mice. O
We O
measured O
the O
free O
and O
esterified O
carnitine, B-CHEMICAL
total O
cholesterol, B-CHEMICAL
and O
triglycerides B-CHEMICAL
in O
adult O
liver O
samples, O
myocardium, O
and O
skeletal O
muscle. O
Our O
results O
indicate O
significant O
differences O

between O
the O
livers O
of O
nonfasting O
adult O
normal O
(n O
= O
8) O
vs O
jvs O
heterozygotes O
(n O
= O
8) O
(means O
+/- O
SEM, O
p O
< O
0.01) O
for O
the O
following O
parameters: O
free O
carnitine, B-CHEMICAL
2.28 O
+/- O
0.36 O
nmol/mg O
protein O
vs O
0.41 O
+/- O
0.13; O
total O
carnitine, B-CHEMICAL
3.48 O
+/- O
0.36 O
vs O
1.27 O
+/- O
0.25; O
triglycerides, B-CHEMICAL
0.14 O
+/- O
0.04 O
vs O
0.39 O
+/- O

0.02; O
and O
total O
cholesterol, B-CHEMICAL
0.21 O
+/- O
0.02 O
vs O
0.39 O
+/- O
0.04, O
but O
not O
for O
esterified O
carnitine, B-CHEMICAL
1.18 O
+/- O
0.17 O
vs O
0.90 O
+/- O
0.17 O
(p O
> O
0.05). O
There O
is O
also O
a O
negative O
correlation O
between O
hepatic O
free O
carnitine B-CHEMICAL
and O
triglycerides B-CHEMICAL
from O
jvs O
heterozygotes O
(p O
< O
0.05). O
Similar O
results O
were O
obtained O
with O
myocardium O
and O
skeletal O
muscle. O
We O
conclude O
that O
free O
and O
total O

carnitine B-CHEMICAL
levels O
are O
significantly O
lower O
in O
the O
heterozygote O
mouse O
liver O
and O
heart O
while O
triglyceride B-CHEMICAL
and O
total O
cholesterol B-CHEMICAL
levels O
are O
significantly O
higher. O
We O
speculate O
that O
in O
situations O
of O
lipolytic O
stress, O
some O
SCD O
heterozygotes O
might O
develop O
clinical O
symptoms O
of O
carnitine B-CHEMICAL
deficiency. O
Organic B-GENE-N
cation I-GENE-N
transporter I-GENE-N
mRNA O
and O
function O
in O
the O
rat O
superior O
cervical O
ganglion. O
Reuptake O
of O
extracellular O
noradrenaline B-CHEMICAL
(NA) B-CHEMICAL
into O
superior O
cervical O
ganglion O
(SCG) O
neurones O
is O
mediated O
by O
means O
of O
the O
noradrenaline B-CHEMICAL

transporter I-GENE-Y
(NAT, B-GENE-Y
uptake O
1). O
We O
now O
demonstrate O
by O
single-cell O
RT-PCR O
that O
mRNA O
of O
the O
organic B-GENE-Y
cation I-GENE-Y
transporter I-GENE-Y
3 I-GENE-Y
(OCT3, B-GENE-Y
uptake O
2) O
occurs O
in O
rat O
SCG O
neurones O
as O
well. O
Furthermore, O
our O
RT-PCR O
analyses O
reveal O
the O
presence O
of O
mRNA O
for O
novel B-GENE-N
organic I-GENE-N
cation I-GENE-N
transporters I-GENE-N
1 I-GENE-N
and I-GENE-N
2 I-GENE-N
(OCTN1 B-GENE-Y
and O
OCTN2), B-GENE-Y
but O
not O
for O
OCT1 B-GENE-Y
or O
OCT2 B-GENE-Y
in O
the O
ganglion. O
Making O
use O
of O
the O
NAT B-GENE-Y
as O
a O
powerful, O
neurone-specific O
transporter O
system, O
we O

loaded[3H]-N-methyl-4-phenylpyridinium B-CHEMICAL
([3H]-MPP+) B-CHEMICAL
into O
cultured O
rat O
SCG O
neurones. O
The O
ensuing O
radioactive O
outflow O
from O
these O
cultures O
was O
enhanced O
by O
desipramine B-CHEMICAL
and O
reserpine, B-CHEMICAL
but O
reduced O
(in O
the O
presence O
of O
desipramine) B-CHEMICAL
by O
the O
OCT3 B-GENE-Y
inhibitors O
cyanine O
863, O
oestradiol B-CHEMICAL
and O
corticosterone. B-CHEMICAL
In O
contrast, O
cyanine O
863 O
enhanced O
the O
radioactive O
outflow O
from O
cultures O
preloaded O
with O
[3H]-NA. B-CHEMICAL
Two O
observations O
suggest O
that O

a O
depletion O
of O
storage O
vesicles O
by O
cyanine O
863 O
accounts O
for O
the O
latter O
phenomenon: O
first, O
the O
primary O
radioactive O
product O
isolated O
from O
supernatants O
of O
cultures O
loaded O
with O
[3H]-NA B-CHEMICAL
was O
the O
metabolite O
[3H]-DHPG; B-CHEMICAL
and O
second, O
inhibition O
of O
MAO B-GENE-N
significantly O
reduced O
the O
radioactive O
outflow O
in O
response O
to O
cyanine O
863. O
The O
outflow O
of O
[3H]-MPP+ B-CHEMICAL
was O
significantly O
enhanced O
by O
MPP+, B-CHEMICAL
guanidine, B-CHEMICAL
choline B-CHEMICAL
and O
amantadine B-CHEMICAL
as O
potential O
substrates O
for O
OCT-related B-GENE-N
transmembrane B-GENE-N

transporters. I-GENE-N
However, O
desipramine B-CHEMICAL
at O
a O
low O
concentration O
essentially O
blocked O
the O
radioactive O
outflow O
induced O
by O
all O
of O
these O
substances O
with O
the O
exception O
of O
MPP+, B-CHEMICAL
indicating O
the O
NAT B-GENE-Y
and O
not O
an O
OCT B-GENE-N
as O
their O
primary O
site O
of O
action. O
The O
MPP+-induced B-CHEMICAL
release O
of O
[3H]-MPP+ B-CHEMICAL
was O
fully O
prevented O
by O
a O
combined O
application O
of O
desipramine B-CHEMICAL
and O
cyanine O
863. O
No O
trans-stimulation O
of O
[3H]-MPP+ B-CHEMICAL
outflow O
was O
observed O
by O
the O
OCTN1 B-GENE-Y
and O
OCTN2 B-GENE-Y
substrate O
carnitine O
at O
100 O
microM. O
Our O
observations O
indicate O
an O

OCT-mediated B-GENE-N
transmembrane O
transport O
of O
[3H]-MPP+. B-CHEMICAL
Amongst O
the O
three O
OCTs B-GENE-N
expressed O
in O
the O
SCG, O
OCT3 B-GENE-Y
best O
fits O
the O
profile O
of O
substrates O
and O
antagonists O
that O
cause O
trans-stimulation O
and O
trans-inhibition, O
respectively, O
of O
[3H]-MPP+ B-CHEMICAL
release. O
Neuroprotection O
by O
propargylamines B-CHEMICAL
in O
Parkinson's O
disease: O
suppression O
of O
apoptosis O
and O
induction O
of O
prosurvival O
genes. O
In O
Parkinson's O
disease O
(PD), O
therapies O
to O
delay O
or O
suppress O
the O
progression O
of O
cell O
death O
in O
nigrostriatal O

dopamine B-CHEMICAL
neurons O
have O
been O
proposed O
by O
use O
of O
various O
agents. O
An O
inhibitor O
of O
type B-GENE-Y
B I-GENE-Y
monoamine B-CHEMICAL
oxidase I-GENE-Y
(MAO-B), B-GENE-Y
(-)deprenyl B-CHEMICAL
(selegiline), B-CHEMICAL
was O
reported O
to O
have O
neuroprotective O
activity, O
but O
clinical O
trials O
failed O
to O
confirm O
it. O
However, O
the O
animal O
and O
cellular O
models O
of O
PD O
proved O
that O
selegiline B-CHEMICAL
protects O
neurons O
from O
cell O
death. O
Among O
selegiline-related B-CHEMICAL
propargylamines, B-CHEMICAL
(R)(+)-N-propargyl-1-aminoindan B-CHEMICAL
(rasagiline) B-CHEMICAL
was O
the O

most O
effective O
to O
suppress O
the O
cell O
death O
in O
in O
vivo O
and O
in O
vitro O
experiments. O
In O
this O
paper, O
the O
mechanism O
of O
the O
neuroprotection O
by O
rasagiline B-CHEMICAL
was O
examined O
using O
human O
dopaminergic O
SH-SY5Y O
cells O
against O
cell O
death O
induced O
by O
an O
endogenous O
dopaminergic O
neurotoxin O
N-methyl(R)salsolinol B-CHEMICAL
(NM(R)Sal). B-CHEMICAL
NM(R)Sal B-CHEMICAL
induced O
apoptosis O
(but O
not O
necrosis) O
in O
SH-SY5Y O
cells, O
and O
the O
apoptotic O
cascade O
was O

initiated O
by O
mitochondrial O
permeability O
transition O
(PT) O
and O
activated O
by O
stepwise O
reactions. O
Rasagiline B-CHEMICAL
prevented O
the O
PT O
in O
mitochondria O
directly O
and O
also O
indirectly O
through O
induction O
of O
antiapoptotic O
Bcl-2 B-GENE-Y
and O
a O
neurotrophic B-GENE-N
factor, I-GENE-N
glial B-GENE-Y
cell I-GENE-Y
line-derived I-GENE-Y
neurotrophic I-GENE-Y
factor I-GENE-Y
(GDNF). B-GENE-Y
Long-term O
administration O
of O
propargylamines B-CHEMICAL
to O
rats O
increased O
the O
activities O
of O
antioxidative O
enzymes O
superoxide B-CHEMICAL
dismutase I-GENE-N
(SOD) B-GENE-N
and O
catalase B-GENE-Y
in O
the O
brain O
regions O
containing O
dopamine B-CHEMICAL
neurons. O
Rasagiline B-CHEMICAL
and O
related O

propargylamines B-CHEMICAL
may O
rescue O
degenerating O
dopamine B-CHEMICAL
neurons O
through O
inhibiting O
death O
signal O
transduction O
initiated O
by O
mitochondria O
PT. O
Pharmacodynamics O
and O
pharmacokinetics O
of O
phenylbutazone B-CHEMICAL
in O
calves. O
Phenylbutazone B-CHEMICAL
(PBZ) B-CHEMICAL
was O
administered O
to O
six O
calves O
intravenously O
(i.v.) O
and O
orally O
at O
a O
dose O
rate O
of O
4.4 O
mg/kg O
in O
a O
three-period O
cross-over O
study O
incorporating O
a O
placebo O
treatment O
to O
establish O
its O
pharmacokinetic O
and O
pharmacodynamic O
properties. O

Extravascular O
distribution O
was O
determined O
by O
measuring O
penetration O
into O
tissue O
chamber O
fluid O
in O
the O
absence O
of O
stimulation O
(transudate) O
and O
after O
stimulation O
of O
chamber O
tissue O
with O
the O
mild O
irritant O
carrageenan O
(exudate). O
PBZ B-CHEMICAL
pharmacokinetics O
after O
i.v. O
dosage O
was O
characterized O
by O
slow O
clearance O
(1.29 O
mL/kg/h), O
long-terminal O
half-life O
(53.4 O
h), O
low O
distribution O
volume O
(0.09 O
L/kg) O
and O
low O
concentrations O
in O
plasma O
of O
the O
metabolite O
oxyphenbutazone B-CHEMICAL
(OPBZ), B-CHEMICAL
confirming O

previously O
published O
data O
for O
adult O
cattle. O
After O
oral O
dosage O
bioavailability O
(F) O
was O
66%. O
Passage O
into O
exudate O
was O
slow O
and O
limited, O
and O
penetration O
into O
transudate O
was O
even O
slower O
and O
more O
limited; O
area O
under O
curve O
values O
for O
plasma, O
exudate O
and O
transudate O
after O
i.v. O
dosage O
were O
3604, O
1117 O
and O
766 O
microg O
h/mL O
and O
corresponding O
values O
after O
oral O
dosage O
were O
2435, O
647 O
and O
486 O
microg O
h/mL. O
These O
concentrations O
were O
approximately O
15-20 O
(plasma) O
and O
nine O
(exudate) O
times O
greater O
than O
those O
previously O

reported O
in O
horses O
(receiving O
the O
same O
dose O
rate O
of O
PBZ). B-CHEMICAL
In O
the O
horse, O
the O
lower O
concentrations O
had O
produced O
marked O
inhibition O
of O
eicosanoid O
synthesis O
and O
suppressed O
the O
inflammatory O
response. O
The O
higher O
concentrations O
in O
calves O
were O
insufficient O
to O
inhibit O
significantly O
exudate O
prostaglandin B-CHEMICAL
E2 I-CHEMICAL
(PGE2), B-CHEMICAL
leukotriene B-CHEMICAL
B4 I-CHEMICAL
(LTB4) B-CHEMICAL
and O
beta-glucuronidase B-GENE-Y
concentrations O
and O
exudate O
leucocyte O
numbers, O
serum O
thromboxane B-CHEMICAL
B2 I-CHEMICAL
(TxB2), B-CHEMICAL
and O
bradykinin-induced B-GENE-Y
skin O
swelling. O
These O
differences O

from O
the O
horse O
might O
be O
the O
result O
of: O
(a) O
the O
presence O
in O
equine O
biological O
fluids O
of O
higher O
concentrations O
than O
in O
calves O
of O
the O
active O
PBZ B-CHEMICAL
metabolite, O
OPBZ; B-CHEMICAL
(b) O
a O
greater O
degree O
of O
binding O
of O
PBZ B-CHEMICAL
to O
plasma O
protein O
in O
calves; O
(c) O
species O
differences O
in O
the O
sensitivity O
to O
PBZ B-CHEMICAL
of O
the O
cyclo-oxygenase B-GENE-N
(COX) B-GENE-N
isoenzymes, O
COX-1 B-GENE-Y
and O
COX-2 B-GENE-Y
or; O
(d) O
a O
combination O
of O
these O
factors. O
To O
achieve O
clinical O
efficacy O
with O
single O
doses O
of O
PBZ B-CHEMICAL
in O

calves, O
higher O
dosages O
than O
4.4 O
mg/kg O
will O
be O
probably O
required. O
Practical O
asymmetric O
synthesis O
of O
aprepitant, B-CHEMICAL
a O
potent O
human O
NK-1 B-GENE-Y
receptor I-GENE-Y
antagonist, O
via O
a O
stereoselective O
Lewis O
acid-catalyzed O
trans O
acetalization O
reaction. O
A O
streamlined O
and O
high-yielding O
synthesis O
of O
aprepitant B-CHEMICAL
(1), O
a O
potent O
substance B-CHEMICAL
P I-CHEMICAL
(SP) I-GENE-Y
receptor I-GENE-Y
antagonist, O
is O
described. O
The O
enantiopure O
oxazinone B-CHEMICAL
16 O
starting O
material O
was O
synthesized O
via O
a O
novel O
crystallization-induced O
dynamic O
resolution O
process. O
Conversion O
of O
16 O
to O
the O
penultimate O
intermediate O

cis-sec-amine B-CHEMICAL
9 O
features O
a O
highly O
stereoselective O
Lewis O
acid-catalyzed O
trans O
acetalization O
of O
chiral B-CHEMICAL
alcohol I-CHEMICAL
3 O
with O
trichloroacetimidate B-CHEMICAL
18 O
followed O
by O
inversion O
of O
the O
adjacent O
chiral O
center O
on O
the O
morpholine B-CHEMICAL
ring. O
The O
six-step O
process O
for O
the O
synthesis O
of O
9 O
was O
accomplished O
in O
extremely O
high O
overall O
yield O
(81%) O
and O
with O
only O
two O
isolations. O
Signaling O
through O
Gi B-GENE-N
family O
members O
in O
platelets. O
Redundancy O
and O
specificity O
in O
the O
regulation O
of O
adenylyl B-GENE-N
cyclase I-GENE-N
and O
other O
effectors. O
Platelet O

responses O
at O
sites O
of O
vascular O
injury O
are O
regulated O
by O
intracellular O
cAMP B-CHEMICAL
levels, O
which O
rise O
rapidly O
when O
prostacyclin B-CHEMICAL
(PGI(2)) B-CHEMICAL
is O
released O
from O
endothelial O
cells. O
Platelet O
agonists O
such O
as O
ADP B-CHEMICAL
and O
epinephrine O
suppress O
PGI(2)-stimulated B-CHEMICAL
cAMP B-CHEMICAL
formation O
by O
activating O
receptors O
coupled O
to O
G(i) B-GENE-N
family O
members, O
four O
of O
which O
are O
present O
in O
platelets. O
To O
address O
questions O
about O
the O
specificity O
of O
receptor:G B-GENE-N
protein I-GENE-N
coupling, O
the O
regulation O
of O
cAMP B-CHEMICAL
formation O
in O
vivo O
and O
the O
contribution O
of O
G(i)-mediated B-GENE-N
pathways O

that O
do O
not O
involve O
adenylyl B-GENE-N
cyclase, I-GENE-N
we O
studied O
platelets O
from O
mice O
that O
lacked O
the O
alpha O
subunits O
of O
one O
or O
more O
of O
the O
three O
most O
abundantly O
expressed O
G(i) B-GENE-N
family O
members O
and O
compared O
the O
results O
with O
platelets O
from O
mice O
that O
lacked O
the O
PGI(2) B-GENE-Y
receptor, I-GENE-Y
IP. B-GENE-Y
As O
reported O
previously, O
loss O
of O
G(i2)alpha B-GENE-Y
or O
G(z)alpha B-GENE-Y
inhibited O
aggregation O
in O
response O
to O
ADP B-CHEMICAL
and O
epinephrine, B-CHEMICAL
respectively, O
producing O
defects O
that O
could O
not O
be O
reversed O
by O
adding O
an O
adenylyl B-GENE-N
cyclase I-GENE-N
inhibitor. O
Platelets O
that O
lacked O
both O

G(i2)alpha B-GENE-Y
and O
G(z)alpha B-GENE-Y
showed O
impaired O
responses O
to O
both O
agonists, O
but O
the O
impairment O
was O
no O
greater O
than O
in O
the O
individual O
knockouts. O
Loss O
of O
G(i3)alpha B-GENE-Y
had O
no O
effect O
either O
alone O
or O
in O
combination O
with O
G(z)alpha. B-GENE-Y
Loss O
of O
either O
G(z)alpha B-GENE-Y
or O
G(i2)alpha B-GENE-Y
impaired O
the O
ability O
of O
ADP B-CHEMICAL
and O
epinephrine B-CHEMICAL
to O
inhibit O
PGI(2)-stimulated B-CHEMICAL
adenylyl B-CHEMICAL
cyclase I-GENE-N
activity O
and O
caused O
a O
40%-50% O
rise O
in O
basal O
cAMP B-CHEMICAL
levels, O
whereas O
loss O
of O

G(i3)alpha B-GENE-Y
did O
not. O
Conversely, O
deletion O
of O
IP B-GENE-Y
abolished O
responses O
to O
PGI(2) B-CHEMICAL
and O
caused O
cAMP B-CHEMICAL
levels O
to O
fall O
by O
30%, O
effects O
that O
did O
not O
translate O
into O
enhanced O
responsiveness O
to O
agonists O
ex O
vivo. O
From O
these O
results O
we O
conclude O
that O
1) O
cAMP B-CHEMICAL
levels O
in O
circulating O
platelets O
reflect O
ongoing O
signaling O
through O
G(i2), B-GENE-N
G(z), B-GENE-N
and O
IP, B-GENE-Y
but O
not O
G(i3); B-GENE-N
2) O
platelet O
epinephrine B-CHEMICAL
(alpha(2A)-adrenergic) B-GENE-Y
and O
ADP B-CHEMICAL

(P2Y12) B-GENE-Y
receptors O
display O
strong O
preferences O
among O
G(i) B-GENE-N
family O
members O
with O
little O
evidence O
of O
redundancy; O
and O
3) O
these O
receptor O
preferences O
do O
not O
extend O
to O
G(i3). B-GENE-N
Finally, O
the O
failure O
of O
ADP B-CHEMICAL
and O
epinephrine B-CHEMICAL
to O
inhibit O
basal, O
as O
opposed O
to O
PGI(2)-stimulated, B-CHEMICAL
cAMP B-CHEMICAL
formation O
highlights O
the O
need O
during O
platelet O
activation O
for O
G(i) B-GENE-N
signaling O
pathways O
that O
involve O
effectors O
other O
than O
adenylyl B-GENE-N
cyclase. I-GENE-N
Effects O
of O
pentosan O
polysulfate O
sodium B-CHEMICAL
on O
the O
estrogen-induced B-CHEMICAL
pituitary O

prolactinoma O
in O
Fischer O
344 O
rats. O
The O
development O
of O
estrogen-induced B-CHEMICAL
pituitary O
prolactinoma O
in O
Fischer O
344 O
(F344) O
rats O
is O
associated O
with O
enhanced O
neovascularization. O
This O
type O
of O
tumor O
is O
a O
rich O
source O
of O
basic B-GENE-Y
fibroblast I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(bFGF), B-GENE-Y
which O
possesses O
strong O
mitogenic O
and O
angiogenic O
properties. O
Pentosan O
polysulfate O
sodium B-CHEMICAL
(PPS) O
has O
been O
shown O
to O
exert O
antitumor O
activity O
by O
antagonizing O
the O
binding O
of O
bFGF B-GENE-Y
to O
cell O
surface O
receptors. O
We O
have O
examined O
the O
effects O
of O
pentosan O

on O
tumor O
growth, O
hyperprolactinemia O
and O
angiogenesis O
in O
diethylstilbestrol-induced B-CHEMICAL
anterior O
pituitary O
adenoma O
in O
F344 O
rats. O
Chronic O
treatment O
with O
PPS O
did O
not O
cause O
any O
changes O
in O
the O
pituitary O
weight O
and O
serum O
prolactin O
concentration O
in O
comparison O
with O
untreated O
animals. O
The O
density O
of O
microvessels O
identified O
by O
CD-31 O
was O
also O
not O
affected O
by O
the O
tested O
drug. O
On O
the O
other O
hand, O
pentosan O
has O
been O
found O
to O
decrease O
cell O
proliferation O
evaluated O
by O
a O
number O
of O
PCNA-positive O
stained O
cell O
nuclei. O
Moreover, O
the O
TUNEL O
method O

has O
revealed O
an O
increased O
number O
of O
apoptotic O
bodies O
within O
the O
anterior O
pituitary O
after O
treatment O
with O
PPS. O
Despite O
the O
antiproliferative O
and O
proapoptotic O
activity O
of O
pentosan, O
the O
drug O
failed O
to O
inhibit O
tumor O
growth. O
This O
fact O
might O
be O
due O
to O
the O
lack O
of O
antiangiogenic O
activity O
of O
PPS O
in O
this O
experimental O
design. O
Localization O
of O
the O
ammonium B-CHEMICAL
transporter I-GENE-N
proteins I-GENE-N
RhBG B-GENE-Y
and O
RhCG B-GENE-Y
in O
mouse O
kidney. O
Ammonia B-CHEMICAL
is O
both O
produced O
and O
transported O
by O
renal O
epithelial O
cells, O
and O
it O
regulates O
renal O
ion O
transport. O
Recent O
studies O
have O
identified O
a O

family O
of O
putative O
ammonium B-CHEMICAL
transporters; I-GENE-N
mRNA O
for O
two O
members O
of O
this O
family, O
Rh B-GENE-Y
B-glycoprotein I-GENE-Y
(RhBG) B-GENE-Y
and O
Rh B-GENE-Y
C-glycoprotein I-GENE-Y
(RhCG), B-GENE-Y
is O
expressed O
in O
the O
kidney. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
cellular O
location O
of O
RhBG B-GENE-Y
and O
RhCG B-GENE-Y
protein O
in O
the O
mouse O
kidney. O
We O
generated O
RhBG- B-GENE-Y
and O
RhCG-specific B-GENE-Y
anti-peptide O
antibodies. O
Immunoblot O
analysis O
confirmed O
that O
both O
proteins O
were O
expressed O
in O
the O
mouse O
kidney. O

RhBG B-GENE-Y
localization O
with O
immunohistochemistry O
revealed O
discrete O
basolateral O
labeling O
in O
the O
connecting O
segment O
(CNT) O
and O
in O
the O
majority O
of O
initial O
collecting O
tubule O
(ICT) O
and O
cortical O
collecting O
duct O
(CCD) O
cells. O
In O
the O
outer O
medullary O
collecting O
duct O
(OMCD) O
and O
inner O
medullary O
collecting O
duct O
(IMCD) O
only O
a O
subpopulation O
of O
cells O
exhibited O
basolateral O
immunoreactivity. O
Colocalization O
of O
RhBG B-GENE-Y
with O
carbonic B-GENE-Y
anhydrase I-GENE-Y
II, I-GENE-Y
the O
thiazide-sensitive B-CHEMICAL

transporter, O
and O
the O
anion B-GENE-N
exchangers I-GENE-N
AE1 B-GENE-Y
and O
pendrin B-GENE-Y
demonstrated O
RhBG B-GENE-Y
immunoreactivity O
in O
all O
CNT O
cells O
and O
all O
CCD O
and O
ICT O
principal O
cells. O
In O
the O
ICT O
and O
CCD, O
basolateral O
RhBG B-GENE-Y
immunoreactivity O
is O
also O
present O
in O
A-type O
intercalated O
cells O
but O
not O
in O
pendrin-positive B-GENE-Y
CCD O
intercalated O
cells. O
In O
the O
OMCD O
and O
IMCD, O
only O
intercalated O
cells O
exhibit O
RhBG B-GENE-Y
immunoreactivity. O
Immunoreactivity O
for O
a O
second O
putative O

ammonium B-CHEMICAL
transporter, I-GENE-N
RhCG, B-GENE-Y
was O
present O
in O
the O
apical O
region O
of O
cells O
with O
almost O
the O
same O
distribution O
as O
RhBG. B-GENE-Y
However, O
RhCG B-GENE-Y
immunoreactivity O
was O
present O
in O
all O
CCD O
cells, O
and O
it O
was O
present O
in O
outer O
stripe O
OMCD O
principal O
cells, O
in O
addition O
to O
OMCD O
and O
IMCD O
intercalated O
cells. O
Thus O
the O
majority O
of O
RhBG B-GENE-Y
and O
RhCG B-GENE-Y
protein O
expression O
is O
present O
in O
the O
same O
epithelial O
cell O
types O
in O
the O
CNT O
and O
collecting O
duct O
but O
with O
opposite O
polarity. O
These O
findings O
suggest O
that O
RhBG B-GENE-Y
and O

RhCG B-GENE-Y
may O
play O
important O
and O
cell-specific O
roles O
in O
ammonium B-CHEMICAL
transport O
and O
signaling O
in O
these O
regions O
of O
the O
kidney. O
Phosphodiesterase B-GENE-Y
type I-GENE-Y
5 I-GENE-Y
as O
a O
pharmacologic O
target O
in O
erectile O
dysfunction. O
The O
scientific O
rationale O
of O
pharmacologically O
inhibiting O
phosphodiesterase B-GENE-Y
type I-GENE-Y
5 I-GENE-Y
(PDE5) B-GENE-Y
in O
the O
treatment O
of O
erectile O
dysfunction O
(ED) O
is O
reviewed. O
Published O
literature O
on O
the O
nitric B-CHEMICAL
oxide-cyclic I-CHEMICAL
guanosine I-CHEMICAL
monophosphate I-CHEMICAL
(cGMP) B-CHEMICAL
pathway O
for O
penile O
erection O
and O
on O
PDE5 B-GENE-Y

inhibition O
using O
sildenafil O
as O
the O
model O
for O
pharmacologic O
PDE5 B-GENE-Y
inhibition O
are O
assessed. O
The O
key O
second O
messenger O
in O
the O
mediation O
of O
penile O
erection O
is O
cGMP. O
PDE5 B-GENE-Y
is O
the O
predominant O
PDE B-GENE-N
in O
the O
corpus O
cavernosum, O
and O
cGMP B-CHEMICAL
is O
its O
primary O
substrate. O
Therefore, O
in O
men O
with O
ED, O
elevation O
of O
cGMP B-CHEMICAL
in O
corpus O
cavernosal O
tissue O
via O
selective O
inhibition O
of O
cGMP-specific B-CHEMICAL
PDE5 B-GENE-Y
is O
a O
means O
of O
improving O
erectile O
function O
at O
minimal O
risk O
of O
adverse O
events. O
This O
approach O
is O
validated O
by O
the O
clinical O
efficacy O
and O
safety O
of O

sildenafil, B-CHEMICAL
the O
pioneering O
drug O
for O
selective O
PDE5 B-GENE-Y
inhibitor O
therapy O
for O
ED. O
Sildenafil B-CHEMICAL
exhibits O
inhibitory O
potency O
against O
PDE5 B-GENE-Y
and O
a O
10-fold O
lower O
dose-related O
inhibitory O
potency O
against O
rod O
outer O
segment O
PDE6, B-GENE-N
the O
predominant O
PDE B-GENE-N
in O
the O
phototransduction O
cascade O
in O
rods. O
Thus, O
its O
pharmacologic O
profile O
is O
predictable, O
with O
close O
correlation O
between O
pharmacodynamic O
and O
pharmacokinetic O
properties. O
Clinically, O
sildenafil B-CHEMICAL
improves O
erectile O
function O
in O
a O
large O
percentage O
of O
men O
with O
ED. O
The O

most O
common O
adverse O
events O
are O
due O
to O
PDE5 B-GENE-Y
inhibition O
in O
vascular O
and O
visceral O
smooth O
muscle; O
similar O
adverse O
events O
are O
expected O
during O
therapeutic O
use O
of O
all O
PDE5 B-GENE-Y
inhibitors. O
As O
free O
sildenafil B-CHEMICAL
plasma O
concentrations O
approach O
concentrations O
sufficient O
to O
inhibit O
retinal O
PDE6, B-GENE-N
usually O
at O
higher O
therapeutic O
doses, O
transient, O
reversible O
visual O
adverse O
events O
can O
occur, O
albeit O
infrequently. O
Selective O
inhibition O
of O
PDE5 B-GENE-Y
is O
a O
rational O
therapeutic O
approach O
in O
ED, O
as O
proved O
by O
the O
clinical O
success O
of O
sildenafil. B-CHEMICAL
Study O
of O
the O
nematode O
putative O
GABA B-GENE-N

type-A I-GENE-N
receptor I-GENE-N
subunits: O
evidence O
for O
modulation O
by O
ivermectin. B-CHEMICAL
Two O
alleles O
of O
the O
HG1 B-GENE-Y
gene, O
which O
encodes O
a O
putative O
GABA B-GENE-N
receptor I-GENE-N
alpha/gamma I-GENE-N
subunit, O
were O
isolated O
from O
Haemonchus O
contortus. O
These O
two O
alleles O
were O
shown O
previously O
to O
be O
associated O
with O
ivermectin B-CHEMICAL
susceptibility O
(HG1A) B-GENE-Y
and O
resistance O
(HG1E), B-GENE-Y
respectively. O
Sequence O
analysis O
indicates O
that O
they O
differ O
in O
four O
amino B-CHEMICAL
acids. I-CHEMICAL
To O
explore O
the O
functional O
properties O
of O
the O
two O
alleles, O
a O
full-length O
cDNA O
encoding O
the O

beta O
subunit, O
a O
key O
functional O
component O
of O
the O
GABA B-GENE-N
receptor, I-GENE-N
was O
isolated O
from O
Caenorhabditis O
elegans O
(gab-1, B-GENE-Y
corresponding O
to O
the O
GenBank B-GENE-Y
locus I-GENE-Y
ZC482.1) I-GENE-Y
and O
coexpressed O
in O
Xenopus O
oocytes O
with O
the O
HG1 B-GENE-Y
alleles. O
When O
gab-1 B-GENE-Y
was O
coexpressed O
with O
either O
the O
HG1A B-GENE-Y
allele O
or O
the O
HG1E B-GENE-Y
allele O
in O
Xenopus O
oocytes, O
gamma-aminobutyric B-GENE-N
acid I-GENE-N
(GABA)-responsive I-GENE-N
channels I-GENE-N
with O
different O
sensitivity O
to O
the O
agonist O
were O
formed. O
The O

effects O
of O
ivermectin B-CHEMICAL
on O
the O
hetero-oligomeric O
receptors O
were O
determined. O
Application O
of O
ivermectin B-CHEMICAL
alone O
had O
no O
effect O
on O
the O
receptors. O
However, O
when O
coapplied O
with O
10 O
micro O
m O
GABA, B-CHEMICAL
ivermectin B-CHEMICAL
potentiated O
the O
GABA-evoked B-CHEMICAL
current O
of O
the O
GAB-1/HG1A B-GENE-Y
receptor, O
but O
attenuated O
the O
GABA B-CHEMICAL
response O
of O
the O
GAB-1/HG1E B-GENE-Y
receptor. O
We O
demonstrated O
that O
the O
coexpressed O
HG1 B-GENE-Y
and O
GAB-1 B-GENE-Y
receptors O
are O
GABA-responsive, B-CHEMICAL
and O
provide O
evidence O
for O

the O
possible O
involvement O
of O
GABA B-CHEMICAL
receptors I-GENE-N
in O
the O
mechanism O
of O
ivermectin B-CHEMICAL
resistance. O
Yohimbine B-CHEMICAL
dimers O
exhibiting O
selectivity O
for O
the O
human B-GENE-Y
alpha I-GENE-Y
2C-adrenoceptor I-GENE-Y
subtype. O
Yohimbine B-CHEMICAL
is O
a O
potent O
and O
selective O
alpha2- B-GENE-N
versus I-GENE-N
alpha1-adrenoceptor I-GENE-N
antagonist. O
To O
date, O
drugs O
with O
high O
specificity O
for O
the O
alpha2-adrenoceptor B-GENE-N
show O
marginal O
selectivity O
among O
the O
three O
alpha2-adrenoceptor B-GENE-N
subtypes. O
Initial O
studies O
showed O
that O
yohimbine B-CHEMICAL
was O
about O
4- O
and O
15-fold O
more O
selective O
for O
the O
human B-GENE-Y

alpha2C-adrenoceptor I-GENE-Y
in O
comparison O
with O
the O
alpha2A- B-GENE-N
and I-GENE-N
alpha2B-adrenoceptors, I-GENE-N
respectively. O
To O
improve O
on O
this O
alpha2-adrenoceptor B-GENE-N
subtype O
selectivity, O
a O
series O
of O
yohimbine B-CHEMICAL
dimers O
(varying O
from O
n O
= O
2 O
to O
24 O
spacer O
atoms) O
were O
prepared O
and O
evaluated O
for O
receptor O
binding O
on O
human B-GENE-N
alpha2-adrenoceptor I-GENE-N
subtypes O
expressed O
in O
Chinese O
hamster O
ovary O
cells. O
Each O
dimeric O
analog O
showed O
higher O
affinities O
for O
alpha2A- B-GENE-N
and I-GENE-N
alpha2C-adrenoceptor I-GENE-N
versus O
the O

alpha2B-adrenoceptor; B-GENE-Y
and O
yohimbine B-CHEMICAL
dimers O
with O
spacers O
of O
n O
= O
2, O
3, O
4, O
18, O
and O
24 O
exhibited O
selectivity O
for O
the O
alpha2C-adrenoceptor. B-GENE-Y
The O
yohimbine B-CHEMICAL
dimers O
n O
= O
3 O
and O
n O
= O
24 O
showed O
the O
highest O
potency O
and O
selectivity O
(32- O
and O
82-fold. O
respectively) O
for O
the O
alpha2C-adrenoceptor B-GENE-Y
in O
receptor O
binding O
and O
in O
functional O
studies O
(42- O
and O
29-fold, O
respectively) O
measuring O
cAMP B-CHEMICAL
changes O
using O
a O
cell-based O
luciferase O
reporter O
gene O
assay. O
The O

dimers O
(n O
= O
3 O
and O
n O
= O
24) O
had O
high O
selectivity O
(>1000-fold) O
for O
the O
alpha2C-adrenoceptor B-GENE-Y
compared O
with O
the O
three O
alpha1-adrenoceptor B-GENE-N
subtypes. O
These O
findings O
demonstrate O
that O
the O
addition O
of O
spacer O
linkages O
to O
bivalent O
yohimbine B-CHEMICAL
molecules O
provides O
a O
successful O
approach O
to O
the O
development O
of O
ligands O
that O
are O
potent O
and O
highly O
selective O
for O
the O
alpha2C-adrenoceptor. B-GENE-Y
Plasmacytoid O
dendritic O
cells O
produce O
cytokines B-GENE-N
and O
mature O
in O
response O
to O
the O
TLR7 B-GENE-Y
agonists, O

imiquimod B-CHEMICAL
and O
resiquimod. B-CHEMICAL
The O
immune O
response O
modifiers, O
imiquimod B-CHEMICAL
and O
resiquimod, B-CHEMICAL
are O
TLR7 B-GENE-Y
agonists O
that O
induce O
type B-GENE-N
I I-GENE-N
interferon I-GENE-N
in O
numerous O
species, O
including O
humans. O
Recently, O
it O
was O
shown O
that O
plasmacytoid O
dendritic O
cells O
(pDC) O
are O
the O
primary O
interferon-producing B-GENE-N
cells O
in O
the O
blood O
in O
response O
to O
viral O
infections. O
Here, O
we O
characterize O
the O
activation O
of O
human O
pDC O
with O
the O
TLR7 B-GENE-Y
agonists O
imiquimod B-CHEMICAL
and O
resiquimod. B-CHEMICAL
Results O
indicate O
that O

imiquimod B-CHEMICAL
and O
resiquimod B-CHEMICAL
induce O
IFN-alpha B-GENE-N
and O
IFN-omega B-GENE-N
from O
purified O
pDC, O
and O
pDC O
are O
the O
principle O
IFN-producing B-GENE-N
cells O
in O
the O
blood. O
Resiquimod-stimulated B-CHEMICAL
pDC O
also O
produce O
a O
number O
of O
other O
cytokines B-GENE-N
including O
TNF-alpha B-GENE-Y
and O
IP-10. B-GENE-Y
Resiquimod B-CHEMICAL
enhances O
co-stimulatory O
marker O
expression, O
CCR7 B-GENE-Y
expression, O
and O
pDC O
viability. O
Resiquimod B-CHEMICAL
was O
compared O
throughout O
the O
study O
to O
the O
pDC O
survival O
factors, O
IL-3 B-GENE-Y
and O

IFN-alpha; B-GENE-N
resiquimod B-CHEMICAL
more O
effectively O
matures O
pDC O
than O
either O
IL-3 B-GENE-Y
or O
IFN-alpha B-GENE-N
alone. O
These O
results O
demonstrate O
that O
imidazoquinoline B-CHEMICAL
molecules O
directly O
induce O
pDC O
maturation O
as O
determined O
by O
cytokine B-GENE-N
induction, O
CCR7 B-GENE-Y
and O
co-stimulatory O
marker O
expression O
and O
prolonging O
viability. O
Induction O
of O
heat B-GENE-N
shock I-GENE-N
proteins I-GENE-N
(HSPs) B-GENE-N
by O
sodium B-CHEMICAL
arsenite I-CHEMICAL
in O
cultured O
astrocytes O
and O
reduction O
of O
hydrogen B-CHEMICAL
peroxide-induced I-CHEMICAL
cell O
death. O
Induction O
of O
heat B-GENE-N
shock I-GENE-N
proteins I-GENE-N
(HSPs) B-GENE-N
protects O
cells O
from O
oxidative O

injury. O
Here O
Hsp72, B-GENE-Y
Hsp27 B-GENE-Y
and O
heme B-GENE-Y
oxygenase-1 I-GENE-Y
(HO-1) B-GENE-Y
were O
induced O
in O
cultured O
rat O
astrocytes, O
and O
protection O
against O
oxidative O
stress O
was O
investigated. O
Astrocytes O
were O
treated O
with O
sodium B-CHEMICAL
arsenite I-CHEMICAL
(20-50 O
micro O
m) O
for O
1 O
h, O
which O
was O
non-toxic O
to O
cells, O
24 O
h O
later O
they O
were O
exposed O
to O
400 O
micro O
m O
H2O2 B-CHEMICAL
for O
1 O
h, O
and O
cell O
death O
was O
evaluated O
at O
different O
time O
points. O
Arsenite B-CHEMICAL
triggered O
strong O
induction O
of O
HSPs, B-GENE-N
which O
was O
prevented O
by O
1 O
micro O
g/mL O

cycloheximide B-CHEMICAL
(CXH). B-CHEMICAL
H2O2 B-CHEMICAL
caused O
cell O
loss O
and O
increased O
cell O
death O
with O
features O
of O
apoptosis, O
i.e. O
TdT-mediated O
dUTP O
nick-end O
labelling O
(TUNEL) O
reaction O
and O
caspase-3 B-GENE-Y
activation. O
These O
features O
were O
abrogated O
by O
pre-treatment O
with O
arsenite, B-CHEMICAL
which O
prevented O
cell O
loss O
and O
significantly O
reduced O
the O
number O
of O
dead O
cells. O
The O
protective O
effect O
of O
arsenite B-CHEMICAL
was O
not O
detected O
in O
the O
presence O
of O
CHX. B-CHEMICAL
Pre-treatment O
with O
arsenite O
increased O
protein B-GENE-N
kinase I-GENE-N
B I-GENE-N
(Akt) B-GENE-N
and O

extracellular B-GENE-N
signal I-GENE-N
regulated I-GENE-N
kinase I-GENE-N
1/2 I-GENE-N
(ERK1/2) B-GENE-N
phosphorylation O
after O
H2O2. B-CHEMICAL
However, O
while O
Akt B-GENE-N
phosphorylation O
was O
prevented O
by O
CHX, O
Erk1/2 B-GENE-N
phosphorylation O
was O
further O
enhanced O
by O
CHX. B-CHEMICAL
The O
results O
show O
that O
transient O
arsenite B-CHEMICAL
pre-treatment O
induces O
Hsp72, B-GENE-Y
HO-1 B-GENE-Y
and, O
to O
a O
lesser O
extent, O
Hsp27; B-GENE-Y
it O
reduces O
H2O2-induced B-CHEMICAL
astrocyte O
death; O
and O
it O
causes O
selective O
activation O
of O
Akt B-GENE-N
following O
H2O2. B-CHEMICAL
It O
is O
suggested O
that O

HSP B-GENE-N
expression O
at O
the O
time O
of O
H2O2 B-CHEMICAL
exposure O
protects O
astrocytes O
from O
oxidative O
injury O
and O
apoptotic O
cell O
death O
by O
means O
of O
pro-survival O
Akt. B-GENE-N
Investigation O
of O
bradykinin B-GENE-N
metabolism O
in O
human O
and O
rat O
plasma O
in O
the O
presence O
of O
the O
dual O
ACE/NEP B-GENE-N
inhibitors O
GW660511X B-CHEMICAL
and O
omapatrilat. B-CHEMICAL
Several O
studies O
have O
suggested O
that O
the O
accumulation O
of O
bradykinin, B-GENE-Y
or O
that O
of O
one O
its O
metabolites O
BK1-8, O
is O
involved O
in O
the O
occurrence O
of O
side O
effects O
such O
as O
AE O
associated O
with O
the O
use O
of O
various O

ACEi. B-GENE-Y
In O
this O
work O
a O
novel O
approach O
combining O
HPLC-UV O
on-line O
with O
oaTOF-MS O
and O
ICPMS O
was O
applied O
to O
investigate O
in O
human O
and O
rat O
plasma O
the O
metabolism O
of O
labelled O
BK B-GENE-N
(79/81 B-GENE-N
Br-Phe5) I-GENE-N
BrBK B-GENE-N
in O
the O
presence O
of O
two O
new O
dual O
ACE/NEP B-GENE-N
inhibitors O
(GW660511X B-CHEMICAL
and O
omapatrilat) B-CHEMICAL
currently O
under O
clinical O
trial. O
In O
human O
plasma O
the O
BrBK B-GENE-Y
half-life O
values O
in O
the O
absence O
or O
in O
the O
presence O
of O
GW660511X B-CHEMICAL
(3.8 O

microM) O
or O
omapatrilat B-CHEMICAL
(32 O
nM) O
were O
38.7 O
+/- O
2.4, O
51.2 O
+/- O
4.7 O
and O
114.7 O
+/- O
9.3 O
min, O
respectively O
and O
BrBK B-GENE-Y
was O
degraded O
into O
BrBK1-8, B-GENE-Y
BrBK1-7, B-GENE-Y
BrBK1-5 B-GENE-Y
and O
Br-Phe. B-GENE-Y
In O
the O
presence O
of O
inhibitors, O
however, O
the O
levels O
of O
these O
resultant O
metabolites O
were O
different. O
Unlike O
GW660511X, B-CHEMICAL
omapatrilat B-CHEMICAL
abolished O
the O
production O
of O

BrBK1-5 B-GENE-Y
and O
BrBK1-7, B-GENE-Y
suggesting O
a O
better O
ACE B-GENE-Y
inhibition O
effect O
over O
GW660511X B-CHEMICAL
as O
no O
NEP B-GENE-Y
activity O
was O
found. O
In O
addition O
the O
production O
of O
BrBK1-8 B-GENE-Y
was O
enhanced O
in O
the O
presence O
of O
these O
inhibitors O
with O
a O
greater O
accumulation O
being O
observed O
with O
omapatrilat. B-CHEMICAL
The O
production O
of O
Br-Phe5 B-GENE-Y
was O
reduced O
with O
GW660511X B-CHEMICAL
while O
no O
significant O
change O
was O
observed O
with O
omapatrilat B-CHEMICAL
after O
4 O
h O
of O
incubation. O
In O
rat O
plasma O
the O
BrBK B-CHEMICAL
half-life O
values O
in O

the O
absence O
or O
in O
the O
presence O
of O
GW660511X B-CHEMICAL
(530 O
nM) O
or O
omapatrilat B-CHEMICAL
(50 O
nM) O
were O
9.31 O
+/- O
1.7, O
22.06 O
+/- O
3.1 O
and O
25.3 O
+/- O
1.7 O
min, O
respectively O
and O
BrBK B-CHEMICAL
was O
degraded O
into O
BrBK1-8, B-GENE-Y
BrBK1-7, B-GENE-Y
BrBK1-5 B-GENE-Y
and O
Br-Phe5 B-GENE-Y
plus O
BrBK2-9, B-GENE-Y
BrBK4-8 B-GENE-Y
and O
BrBK2-8 B-GENE-N

metabolites O
not O
found O
in O
human O
plasma. O
GW660511X B-CHEMICAL
and O
omapatrilat B-CHEMICAL
reduced O
the O
production O
of O
BrBK1-5 B-GENE-Y
and O
BrBK1-7 B-GENE-Y
with O
more O
effect O
being O
observed O
with O
omapatrilat. B-CHEMICAL
GW660511X B-CHEMICAL
and O
omapatrilat B-CHEMICAL
increased O
the O
production O
of O
both O
BrBK1-8 B-GENE-N
and O
Br-Phe5 B-GENE-N
but O
not O
that O
of O
BrBK4-8 B-GENE-N
and O
BrBK2-8. B-GENE-N
This O
study O
shows O
that O
the O
potency O
of O
GW660511X B-CHEMICAL
in O
comparison O
with O

omapatrilat B-CHEMICAL
is O
more O
than O
100-fold O
lower O
in O
human, O
but O
less O
than O
10-fold O
lower O
in O
rat O
plasma, O
suggesting O
that O
rat O
may O
not O
be O
a O
suitable O
in O
vivo O
model O
for O
the O
evaluation O
of O
ACE/NEP B-GENE-Y
inhibition O
in O
relation O
to O
effects O
in O
humans. O
Activity O
of O
opioid O
ligands O
in O
cells O
expressing O
cloned O
mu B-GENE-Y
opioid I-GENE-Y
receptors. I-GENE-Y
BACKGROUND: O
The O
aim O
of O
the O
present O
study O
was O
to O
describe O
the O
activity O
of O
a O
set O
of O
opioid O
drugs, O
including O
partial O
agonists, O
in O
a O
cell O
system O
expressing O
only O
mu B-GENE-Y
opioid I-GENE-Y
receptors. I-GENE-Y
Receptor O

activation O
was O
assessed O
by O
measuring O
the O
inhibition O
of O
forskolin-stimulated B-CHEMICAL
cyclic B-CHEMICAL
adenosine I-CHEMICAL
mono I-CHEMICAL
phosphate I-CHEMICAL
(cAMP) B-CHEMICAL
production. O
Efficacies O
and O
potencies O
of O
these O
ligands O
were O
determined O
relative O
to O
the O
endogenous O
ligand O
beta-endorphin B-GENE-Y
and O
the O
common O
mu O
agonist, O
morphine. B-CHEMICAL
RESULTS: O
Among O
the O
ligands O
studied O
naltrexone, B-CHEMICAL
WIN B-CHEMICAL
44,441 I-CHEMICAL
and O
SKF B-CHEMICAL
10047, I-CHEMICAL
were O
classified O
as O
antagonists, O
while O
the O
remaining O
ligands O
were O
agonists. O
Agonist O
efficacy O
was O
assessed O
by O

determining O
the O
extent O
of O
inhibition O
of O
forskolin-stimulated B-CHEMICAL
cAMP B-CHEMICAL
production. O
The O
rank O
order O
of O
efficacy O
of O
the O
agonists O
was O
fentanyl B-CHEMICAL
= O
hydromorphone B-CHEMICAL
= O
beta-endorphin O
> O
etorphine B-CHEMICAL
= O
lofentanil B-CHEMICAL
= O
butorphanol B-CHEMICAL
= O
morphine B-CHEMICAL
= O
nalbuphine B-CHEMICAL
= O
nalorphine B-CHEMICAL
> O
cyclazocine B-CHEMICAL
= O
dezocine B-CHEMICAL
= O
metazocine B-CHEMICAL
>or= O
xorphanol. B-CHEMICAL
The O
rank O
order O
of O
potency O
of O
these O
ligands O
was O
different O
from O
that O
of O
their O
efficacies; O
etorphine B-CHEMICAL
> O

hydromorphone B-CHEMICAL
> O
dezocine B-CHEMICAL
> O
xorphanol B-CHEMICAL
= O
nalorphine B-CHEMICAL
= O
butorphanol B-CHEMICAL
= O
lofentanil B-CHEMICAL
> O
metazocine B-CHEMICAL
> O
nalbuphine B-CHEMICAL
> O
cyclazocine B-CHEMICAL
> O
fentanyl B-CHEMICAL
> O
morphine B-CHEMICAL
>>>> O
beta-endorphin. O
CONCLUSION: O
These O
results O
elucidate O
the O
relative O
activities O
of O
a O
set O
of O
opioid O
ligands O
at O
mu B-GENE-Y
opioid I-GENE-Y
receptor I-GENE-Y
and O
can O
serve O
as O
the O
initial O
step O
in O
a O
systematic O
study O
leading O
to O
understanding O
of O
the O
mode O
of O
action O
of O
opioid O
ligands O
at O
this O

receptor. O
Furthermore, O
these O
results O
can O
assist O
in O
understanding O
the O
physiological O
effect O
of O
many O
opioid O
ligands O
acting O
through O
mu B-GENE-Y
opioid I-GENE-Y
receptors. I-GENE-Y
Ventricular O
tachyarrhythmias O
in O
a O
canine O
model O
of O
LQT3: O
arrhythmogenic O
effects O
of O
sympathetic O
activity O
and O
therapeutic O
effects O
of O
mexiletine. B-CHEMICAL
The O
ventricular O
tachyarrhythmias O
associated O
with O
the O
LQT3 O
syndrome O
are O
typically O
bradycardia-dependent. O
However, O
some O
episodes O
can O
be O
associated O
with O
exercise O
or O
emotional O
stress, O
suggesting O
a O
different O
arrhythmogenic O
mechanism O
when O
sympathetic O

activity O
predominates. O
This O
study O
examined O
the O
potential O
arrhythmogenic O
mechanisms O
during O
periods O
of O
autonomically O
mediated O
transient O
heart O
rate O
acceleration O
in O
a O
canine O
anthopleurin-A B-GENE-Y
model O
of O
LQT3 O
syndrome. O
Using O
plunge O
needle O
electrodes, O
transmural O
unipolar O
electrograms O
of O
the O
left O
ventricle O
were O
recorded O
from O
endocardial O
(Endo), O
mid-myocardial O
(Mid) O
and O
epicardial O
(Epi) O
sites. O
The O
activation-recovery O
interval O
(ARI) O
was O
measured O
to O
estimate O
local O
refractoriness. O
The O
cardiac O
cycle O

length O
was O
gradually O
shortened O
by O
cessation O
of O
vagal O
stimulation O
(vagal O
stimulation O
protocol O
(VSP)), O
and O
intramural O
electrograms O
and O
onset O
mode O
of O
ventricular O
tachyarrhythmias O
were O
analyzed O
in O
7 O
experiments. O
The O
VSP O
was O
performed O
8 O
times O
before O
and O
5 O
times O
after O
administration O
of O
mexiletine B-CHEMICAL
in O
each O
experiment. O
Before O
mexiletine, B-CHEMICAL
vagal O
stimulation O
slowed O
the O
heart O
rate O
and O
created O
large O
transmural O
ARI O
dispersion O
because O
of O
a O
greater O
ARI O
prolongation O
at O
Mid O
rather O
than O
Epi/Endo O
sites. O
After O
cessation O
of O

vagal O
stimulation, O
unipolar O
electrograms O
started O
to O
show O
ARI O
alternans O
and O
ventricular O
premature O
beats O
developed O
sporadically. O
Sustained O
ventricular O
tachyarrhythmias O
were O
induced O
in O
12 O
of O
the O
56 O
trials O
of O
the O
VSP. O
Initiation O
of O
ventricular O
tachyarrhythmias O
was O
associated O
with O
delayed O
conduction O
at O
Mid/Endo O
sites. O
Mexiletine B-CHEMICAL
attenuated O
transmural O
ARI O
dispersion, O
and O
neither O
ARI O
alternans O
nor O
ventricular O
tachyarrhythmias O
was O
observed O
during O
all O
35 O
trials O

of O
the O
VSP O
after O
mexiletine B-CHEMICAL
administration. O
Heart O
rate O
acceleration O
induced O
by O
an O
abrupt O
shift O
to O
a O
state O
of O
predominant O
sympathetic O
activity O
enhances O
arrhythmias O
in O
this O
LQT3 O
model. O
Mexiletine B-CHEMICAL
homogenizes O
ventricular O
repolarization, O
suppresses O
premature O
complexes O
and O
was O
antiarrhythmic O
during O
ventricular O
tachyarrhythmias O
induced O
by O
the O
VSP. O
Butyrylcholinesterase: B-GENE-Y
an O
important O
new O
target O
in O
Alzheimer's O
disease O
therapy. O
Acetylcholinesterase B-GENE-Y
(AChE) B-GENE-Y
predominates O
in O
the O
healthy O

brain, O
with O
butyrylcholinesterase B-GENE-Y
(BuChE) B-GENE-Y
considered O
to O
play O
a O
minor O
role O
in O
regulating O
brain O
acetylcholine B-CHEMICAL
(ACh) B-CHEMICAL
levels. O
However, O
BuChE B-GENE-Y
activity O
progressively O
increases O
in O
patients O
with O
Alzheimer's O
disease O
(AD), O
while O
AChE B-GENE-Y
activity O
remains O
unchanged O
or O
declines. O
Both O
enzymes O
therefore O
represent O
legitimate O
therapeutic O
targets O
for O
ameliorating O
the O
cholinergic O
deficit O
considered O
to O
be O
responsible O
for O
the O
declines O
in O
cognitive, O
behavioral O
and O
global O
functioning O
characteristic O
of O
AD. O
The O
two O
enzymes O
differ O
in O
substrate O
specificity, O
kinetics O
and O
activity O
in O
different O
brain O
regions. O
Experimental O
evidence O
from O

the O
use O
of O
agents O
with O
enhanced O
selectivity O
for O
BuChE B-GENE-Y
(cymserine B-CHEMICAL
analogues, O
MF-8622) B-CHEMICAL
and O
the O
dual O
inhibitor O
of O
both O
AChE B-GENE-Y
and O
BuChE, B-GENE-Y
rivastigmine, B-CHEMICAL
indicates O
potential O
therapeutic O
benefits O
of O
inhibiting O
both O
AChE B-GENE-Y
and O
BuChE B-GENE-Y
in O
AD O
and O
related O
dementias. O
Recent O
evidence O
suggests O
that O
both O
AChE B-GENE-Y
and O
BuChE B-GENE-Y
may O
have O
roles O
in O
the O
aetiology O
and O
progression O
of O
AD O
beyond O
regulation O
of O
synaptic O
ACh O
levels. O
The O
development O
of O
specific O
BuChE B-GENE-Y
inhibitors O
and O
further O
experience O

with O
the O
dual O
enzyme O
inhibitor O
rivastigmine B-CHEMICAL
will O
improve O
understanding O
of O
the O
aetiology O
of O
AD O
and O
should O
lead O
to O
a O
wider O
variety O
of O
potent O
treatment O
options. O
A O
low O
toxicity O
maintenance O
regime, O
using O
eicosapentaenoic B-CHEMICAL
acid I-CHEMICAL
and O
readily O
available O
drugs, O
for O
mantle O
cell O
lymphoma O
and O
other O
malignancies O
with O
excess O
cyclin B-GENE-Y
D1 I-GENE-Y
levels. O
Mantle O
cell O
lymphoma O
is O
a O
difficult O
to O
treat O
non-Hodgkin's O
lymphoma O
(NHL) O
whose O
biochemistry O
is O
unusually O
well O
characterised. O
Almost O
all O
and O
perhaps O
all O
patients O
overexpress O
the O
cyclin B-GENE-Y
D1 I-GENE-Y
protein O
which O
is O

crucial O
in O
driving O
cells O
from O
the O
G1 O
to O
the O
S O
phase. O
This O
overexpression O
may O
be O
responsible O
for O
the O
refractoriness. O
Despite O
this O
understanding, O
treatments O
for O
mantle O
cell O
lymphoma O
are O
based O
on O
standard O
NHL O
regimes O
of O
cyclophosphamide, B-CHEMICAL
doxorubicin, B-CHEMICAL
vincristine B-CHEMICAL
and O
prednisone, B-CHEMICAL
perhaps O
supplemented O
with O
the O
monoclonal O
antibody O
rituximab. O
There O
has O
never O
been O
any O
attempt O
to O
direct O
treatment O
to O
the O
cyclin B-GENE-Y
D1 I-GENE-Y
mechanism O
or O
to O
angiogenesis O
which O
is O
now O
known O
to O
be O
important O
in O
all O
lymphomas. O

Both O
these O
targets O
lend O
themselves O
to O
long-term O
maintenance O
regimes O
of O
relatively O
low O
toxicity O
which O
can O
be O
used O
as O
adjuvants O
to O
standard O
therapy. O
Agents O
which O
have O
recently O
been O
shown O
to O
block O
cyclin B-GENE-Y
D1 I-GENE-Y
translation O
by O
regulating O
calcium O
levels O
are O
the O
unsaturated B-CHEMICAL
essential I-CHEMICAL
fatty I-CHEMICAL
acid, I-CHEMICAL
eicosapentaenoic B-CHEMICAL
acid I-CHEMICAL
(EPA), B-CHEMICAL
the O
antidiabetic O
thiazolidinediones, B-CHEMICAL
and O
the O
antifungal O
agent, O
clotrimazole. B-CHEMICAL
Two O
types O
of O
agent O
which O
have O
been O
shown O
to O
inhibit O
angiogenesis O
are O
the O
teratogen, O
thalidomide, B-CHEMICAL
and O
the O
selective O

inhibitors O
of O
cyclo-oxygenase B-GENE-Y
2 I-GENE-Y
(COX-2). B-GENE-Y
Retinoids B-CHEMICAL
exert O
synergistic O
effects O
with O
EPA B-CHEMICAL
and O
have O
been O
shown O
to O
inhibit O
both O
tumour O
growth O
and O
angiogenesis. O
The O
mechanisms O
of O
action O
of O
these O
various O
agents O
are O
discussed, O
and O
specific O
suggestions O
are O
made O
for O
low O
toxicity O
maintenance O
therapy O
of O
mantle O
cell O
lymphoma O
and O
of O
other O
tumours O
which O
overexpress O
cyclin B-GENE-Y
D1. I-GENE-Y
Angiotensin B-CHEMICAL
AT1 I-GENE-Y
receptor I-GENE-Y
antagonist O
losartan B-CHEMICAL
and O
the O
defence O
reaction O
in O
the O
anaesthetised O
rat. O
Effect O
on O
the O
carotid O
chemoreflex. O

Modulation O
at O
the O
level O
of O
the O
nucleus O
tractus O
solitarii O
(NTS) O
appears O
to O
be O
an O
effective O
way O
of O
controlling O
cardiovascular O
reflexes. O
Angiotensin B-GENE-Y
II I-GENE-Y
acting O
on O
angiotensin B-GENE-Y
AT1 I-GENE-Y
receptors I-GENE-Y
at O
the O
central O
nervous O
system O
appears O
to O
have O
an O
important O
role O
in O
these O
modulatory O
processes. O
The O
hypothalamic O
defence O
area O
(HDA) O
is O
a O
potential O
source O
of O
descending O
fibres O
containing O
angiotensin B-GENE-Y
II I-GENE-Y
that O
innervate O
the O
NTS. O
We O
investigated O
the O
effect O
of O
AT1 B-GENE-Y
receptor I-GENE-Y
blockade O
in O
the O
NTS O
on O
the O
response O
to O
stimulation O
of O
HDA O
in O
anaesthetised O
rats O
treated O

with O
the O
neuromuscular O
blocking O
agent O
pancuronium B-CHEMICAL
bromide. I-CHEMICAL
The O
characteristic O
increase O
in O
heart O
rate, O
blood O
pressure O
and O
phrenic O
nerve O
activity O
evoked O
by O
electrical O
stimulation O
of O
HDA O
is O
decreased O
by O
the O
microinjection O
of O
the O
AT1 B-GENE-Y
receptor I-GENE-Y
antagonist O
losartan O
into O
the O
NTS O
and O
the O
cardiovascular O
response O
to O
carotid O
body O
chemical O
stimulation O
is O
also O
reduced. O
These O
results O
support O
the O
hypothesis O
that O
AT1 B-GENE-Y
receptors I-GENE-Y
in O
the O
NTS O
play O
a O
role O
in O
the O
modulation O
of O
cardiovascular O
reflexes, O
and O
modify O
the O
influence O
exerted O
on O
the O
processing O
of O
these O
reflexes O
by O
other O
areas O
of O
the O
central O
nervous O
system. O

Defective O
processing O
of O
the O
transforming B-GENE-Y
growth I-GENE-Y
factor-beta1 I-GENE-Y
in O
azoxymethane-induced B-CHEMICAL
mouse O
colon O
tumors. O
High O
levels O
of O
the O
cell O
growth O
inhibitor O
transforming B-GENE-Y
growth I-GENE-Y
factor-beta1 I-GENE-Y
(TGF-beta1) B-GENE-Y
are O
often O
found O
in O
a O
variety O
of O
human O
cancers. O
However, O
the O
physiological O
significance O
of O
this O
overexpression O
depends O
on O
the O
availability O
of O
the O
biologically O
active O
form O
of O
TGF-beta1 B-GENE-Y
within O
the O
extracellular O
matrix O
of O
the O
tumor O
microenvironment. O
To O
determine O
the O
expression O
and O
activation O
status O
of O
TGF-beta1 B-GENE-Y
in O
chemically O
induced O
tumors, O
6-wk-old O

A/J O
mice O
were O
injected O
intraperitoneally O
with O
either O
azoxymethane B-CHEMICAL
(AOM) B-CHEMICAL
(10 O
mg/kg O
body O
weight, O
once O
a O
week O
for O
6 O
wk) O
or O
normal O
saline O
solution, O
and O
colon O
tumors O
were O
isolated O
24 O
wk O
following O
the O
last O
injection. O
An O
enzyme-linked O
immunosorbent O
assay O
for O
TGF-beta1 B-GENE-Y
revealed O
a O
significant O
increase O
(1.7-fold, O
P O
< O
0.05) O
in O
total O
TGF-beta1 B-GENE-Y
protein O
in O
tumors. O
Interestingly, O
while O
80% O
of O
the O
total O
TGF-beta1 B-GENE-Y
in O
the O
control O
colon O

tissues O
was O
in O
the O
active O
form, O
only O
50% O
was O
found O
to O
be O
active O
in O
tumors. O
Together O
with O
our O
earlier O
observations O
that O
TGF-beta1 B-GENE-Y
mRNA O
levels O
are O
unchanged O
in O
A/J O
tumors, O
these O
data O
further O
support O
a O
mechanism O
whereby O
elevated O
TGF-beta1 B-GENE-Y
levels O
result O
from O
a O
defective O
activation O
and O
turnover O
of O
this O
protein. O
Because O
plasmin B-GENE-Y
is O
known O
to O
be O
a O
major O
activator O
of O
TGF-beta1 B-GENE-Y
in O
vivo, O
we O
hypothesized O
that O
reduced O
plasmin B-GENE-Y
activity O
may O
be O
responsible O
for O
the O
observed O
dysregulation O
of O
TGF-beta1 B-GENE-Y
processing O
in O
these O

behaviorally O
benign O
tumors. O
With O
a O
fluorogenic O
peptide O
substrate O
for O
serine B-CHEMICAL
proteases, I-GENE-N
a O
deficiency O
in O
plasmin B-GENE-Y
activity O
was O
found O
in O
the O
tumors. O
Furthermore, O
semiquantitative O
reverse O
transcription O
(RT)-polymerase O
chain O
reaction O
(PCR) O
analysis O
of O
a O
panel O
of O
genes O
involved O
in O
the O
plasminogen B-GENE-Y
activation O
system, O
including O
plasminogen B-GENE-Y
activator I-GENE-Y
inhibitor-1 I-GENE-Y
(PAI-1), B-GENE-Y
urokinase-plasminogen B-GENE-Y
activator I-GENE-Y
(u-PA), B-GENE-Y
and O
urokinase-receptor B-GENE-Y
(u-PAR-1), B-GENE-Y
demonstrated O
a O
significant O

upregulation O
(approximately O
fourfold O
to O
sixfold, O
P O
< O
0.05) O
in O
the O
expression O
of O
each O
of O
these O
genes O
in O
the O
tumor O
tissue. O
In O
addition, O
no O
significant O
changes O
were O
observed O
in O
the O
expression O
levels O
of O
thrombospondin-1 B-GENE-Y
(TSP-1) B-GENE-Y
and O
insulin-like B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
type I-GENE-Y
II I-GENE-Y
receptor I-GENE-Y
(IGF-IIR), B-GENE-Y
which O
also O
mediate O
the O
activation O
of O
latent O
TGF-beta1. B-GENE-Y
To O
gain O
further O
insight O
into O
the O
functionality O
of O
the O
TGF-beta1 B-GENE-Y
pathway, O
cDNA O
microarrays O
were O
performed O
and O
the O
expression O
levels O
of O
a O
panel O
of O
21 O

TGF-beta1-specific B-GENE-Y
target O
genes O
were O
determined O
in O
AOM-induced B-CHEMICAL
tumors O
that O
overexpress O
the O
ligand. O
A O
significant O
dysregulation O
in O
the O
expression O
of O
each O
of O
these O
targets O
was O
observed, O
providing O
evidence O
of O
aberrant O
TGF-beta1 B-GENE-Y
signaling O
in O
tumors. O
Overall, O
the O
present O
study O
demonstrates O
a O
very O
low O
plasmin B-GENE-Y
activity O
in O
A/J O
colon O
tumors, O
possibly O
as O
a O
result O
of O
the O
potent O
inhibitory O
effect O
of O
PAI-1 B-GENE-Y
on O
the O
plasminogen B-GENE-Y
activation O
cascade. O
The O
observed O
deficiency O
in O
plasmin B-GENE-Y
activity O
may O
not O
be O
sufficiently O
compensated O
for O
by O
other O
mechanisms O

of O
latent O
TGF-beta1 B-GENE-Y
activation, O
including O
TSP-1 B-GENE-Y
and O
IGF-IIR, B-GENE-Y
thereby O
resulting O
in O
a O
decreased O
fraction O
of O
the O
biologically O
active O
form O
of O
TGF-beta1 B-GENE-Y
and O
subsequent O
aberration O
in O
TGF-beta1-specific B-GENE-Y
gene O
regulation O
in O
A/J O
tumors. O
Inhibition O
by O
pentosan O
polysulfate O
(PPS) O
of O
heparin-binding B-GENE-N
growth I-GENE-N
factors I-GENE-N
released O
from O
tumor O
cells O
and O
blockage O
by O
PPS O
of O
tumor O
growth O
in O
animals. O
BACKGROUND: O
In O
a O
proliferating O
tumor, O
locally O
secreted O

polypeptide O
growth O
factors, O
which O
have O
autocrine O
and O
paracrine O
functions, O
induce O
vascularization O
essential O
for O
tumor O
growth O
and O
metastasis. O
These O
growth O
factors O
may O
serve O
as O
targets O
for O
tumor O
therapy. O
We O
have O
shown O
that O
the O
heparinoid O
pentosan O
polysulfate O
(PPS) O
can O
block O
growth O
of O
subcutaneous O
human O
tumor O
xenografts O
in O
nude O
mice O
and O
angiogenesis O
induced O
by O
the O
heparin-binding, O
Kaposi's B-GENE-N
sarcoma-derived I-GENE-N
fibroblast I-GENE-N
growth I-GENE-N
factor I-GENE-N
(K-FGF). B-GENE-N
PURPOSE: O
The O
purpose O
of O
this O
study O
was O

to O
determine O
whether O
PPS O
might O
also O
interfere O
with O
stimulation O
of O
endothelial O
cells O
by O
other O
growth O
factors O
released O
from O
tumor O
cells O
and O
whether O
the O
promising O
antitumor O
effects O
of O
PPS O
extend O
to O
other O
human O
tumor O
cell O
lines. O
We O
studied O
the O
effects O
of O
PPS O
on O
stimulation O
by O
heparin-binding B-GENE-N
growth I-GENE-N
factors I-GENE-N
released O
from O
seven O
human O
tumor O
cell O
lines O
in O
vitro O
and O
on O
tumors O
growing O
from O
these O
cell O
lines O
in O
athymic O
nude O
mice. O
METHODS: O
Seven O
human O
cell O
lines O
established O
from O
breast, O
prostate, O
epidermoid, O
and O
lung O
carcinomas O
and O
rhabdomyosarcoma O
were O
used O
in O
in O

vivo O
as O
well O
as O
in O
vitro O
studies O
of O
the O
effects O
of O
PPS. O
We O
also O
studied O
in O
vitro O
the O
effects O
of O
PPS O
on O
growth O
factor-induced O
colony O
formation O
of O
normal O
rat O
kidney O
fibroblasts O
and O
human O
adrenal O
carcinoma O
cells. O
RESULTS: O
The O
tumor O
cell O
lines O
released O
growth O
factors O
into O
their O
media O
that O
stimulated O
growth O
of O
endothelial O
and O
epithelial O
cells O
as O
well O
as O
fibroblasts. O
Heparin-affinity O
chromatography O
showed O
that O
heparin-binding B-GENE-N
growth I-GENE-N
factors I-GENE-N
contributed O
substantially O
to O
this O
paracrine O
activity O
and O
that O
PPS O
inhibited O
this O

stimulus. O
Six O
of O
the O
seven O
tumor O
cell O
lines O
were O
resistant O
to O
PPS O
in O
soft-agar O
cloning O
assays O
and O
hence O
did O
not O
appear O
to O
depend O
on O
autocrine O
stimulation O
by O
the O
heparin-binding B-GENE-N
growth I-GENE-N
factors. I-GENE-N
In O
contrast O
to O
this O
in O
vitro O
resistance, O
subcutaneous O
growth O
of O
tumors O
from O
all O
cell O
lines O
in O
athymic O
nude O
mice O
was O
inhibited O
in O
a O
dose-dependent O
fashion O
by O
daily O
intraperitoneal O
injections O
of O
PPS. O
CONCLUSIONS: O
We O
conclude O
that O
heparin-binding B-GENE-N
growth I-GENE-N
factors I-GENE-N
contribute O
substantially O
to O
tumor O
growth O
in O
vivo O
and O
that O
PPS O
acts O

by O
blocking O
the O
paracrine O
effects O
of O
heparin-binding B-GENE-N
growth I-GENE-N
factors I-GENE-N
released O
from O
the O
tumor O
cells. O
IMPLICATION: O
PPS O
could O
become O
a O
novel O
treatment O
tool O
targeting O
tumor O
growth O
factors. O
Binding O
and O
GTPgammaS B-CHEMICAL
autoradiographic O
analysis O
of O
preproorphanin B-GENE-N
precursor I-GENE-N
peptide I-GENE-N
products O
at O
the O
ORL1 B-GENE-Y
and O
opioid B-GENE-N
receptors. I-GENE-N
Utilizing O
agonist-stimulated O
GTPgammaS B-CHEMICAL
autoradiography, O
we O
analyzed O
the O
ability O
of O
preproorphanin B-GENE-N
FQ I-GENE-N
(ppOFQ) I-GENE-N
peptides I-GENE-N
to O
stimulate O

[35S]-GTPgammaS B-CHEMICAL
binding O
in O
adult O
rat O
brain. O
Orphanin B-GENE-Y
FQ I-GENE-Y
(OFQ) B-GENE-Y
stimulated O
[35S]-GTPgammaS B-CHEMICAL
binding O
in O
a O
pattern O
similar O
to O
that O
described O
for O
[125I]-OFQ B-CHEMICAL
at O
the O
endogenous O
opioid B-GENE-Y
receptor-like I-GENE-Y
(ORL1) I-GENE-Y
receptor. I-GENE-Y
The O
ppOFQ B-GENE-N
peptides O
nocistatin O
and O
orphanin B-GENE-Y
FQ2 I-GENE-Y
(OFQ B-GENE-Y
II(1-17)) I-GENE-Y
had O
no O
effect, O
suggesting O
that O
they O
do O
not O
mediate O
their O
reported O
analgesic O
effects O
via O
a O
G(i/o)-coupled B-GENE-N

receptor I-GENE-N
(i.e. O
opioid O
or O
ORL1). B-GENE-Y
Unlike O
OFQ B-GENE-Y
II(1-17), I-GENE-Y
high O
concentrations O
of O
its O
C-terminal B-CHEMICAL
extension, O
OFQ B-GENE-Y
II(1-28), I-GENE-Y
stimulated O
[35S]-GTPgammaS B-CHEMICAL
binding O
in O
a O
mu B-GENE-Y
(mu) I-GENE-Y
opioid I-GENE-Y
receptor-like I-GENE-Y
distribution O
and O
the O
effect O
was O
blocked O
by O
naloxone. B-CHEMICAL
To O
explore O
these O
observations, O
we O
evaluated O
the O
receptor O
binding O
profile O
of O
OFQ B-GENE-Y
II(1-28) I-GENE-Y
at O
the O
cloned O
ORL1 B-GENE-Y
and O
mu B-GENE-Y
opioid I-GENE-Y
receptors. I-GENE-Y
OFQ B-GENE-Y
II(1-28) I-GENE-Y
had O

no O
specific O
binding O
at O
either O
ORL1 B-GENE-Y
or O
mu B-GENE-Y
opioid I-GENE-Y
receptors I-GENE-Y
at O
concentrations O
up O
to O
50 O
microM. O
This O
lack O
of O
affinity O
was O
not O
consistent O
with O
a O
mu-mediated O
effect, O
as O
suggested O
by O
preliminary O
observation O
using O
functional O
autoradiography O
in O
rat O
brain O
sections. O
Although O
behavioral O
studies O
suggest O
that O
OFQ B-GENE-Y
II(1-28) I-GENE-Y
possesses O
analgesic O
activity, O
this O
effect O
does O
not O
appear O
to O
be O
mediated O
via O
direct O
binding O
at O
the O
mu B-GENE-Y
opioid I-GENE-Y
receptor. I-GENE-Y
Taken O
together, O
these O
findings O
support O
the O
view O
that O
(1) O
OFQ B-GENE-Y
is O
the O
only O
ppOFQ B-GENE-N
peptide O
that O
binds O
to O
and O
activates O
the O

ORL1 B-GENE-N
receptor O
and O
(2) O
OFQ B-GENE-Y
II(1-28) I-GENE-Y
does O
not O
bind O
or O
stimulate O
[35S]-GTPgammaS B-CHEMICAL
binding O
in O
cells O
expressing O
the O
mu B-GENE-Y
opioid I-GENE-Y
receptor. I-GENE-Y
Tethered O
dimers O
as O
NAD B-CHEMICAL
synthetase I-GENE-N
inhibitors O
with O
antibacterial O
activity. O
The O
solution-phase O
parallel O
synthesis O
of O
tethered O
dimers O
was O
employed O
to O
identify O
lead O
inhibitors O
of O
bacterial B-GENE-N
NAD I-GENE-N
synthetase. I-GENE-N
Active O
dimers O
contained O
two O
aromatic O
end O
groups O
joined O
by O
a O
polymethylene O
linker, O
with O
one O
end O
group O
containing O
a O
permanent O
positive O
charge. O
Effective O
inhibitors O

of O
NAD B-GENE-N
synthetase I-GENE-N
also O
inhibited O
the O
growth O
of O
Gram-positive O
(but O
not O
Gram-negative) O
bacteria, O
including O
antibiotic-resistant O
strains. O
The O
desmethyl O
precursors O
of O
active O
inhibitors O
lacked O
a O
permanent O
positive O
charge O
and O
were O
inactive O
as O
either O
enzyme O
inhibitors O
or O
antibacterial O
agents. O
Similarly, O
a O
close O
structural O
analogue O
of O
the O
most O
active O
inhibitors O
contained O
two O
additional O
ether O
oxygens B-CHEMICAL
in O
the O
tether O
and O
was O
inactive O
in O
both O
assays. O
These O
results O
are O
consistent O
with O
the O
premise O
that O
NAD B-GENE-N
synthetase I-GENE-N
inhibition O
is O
responsible O
for O
the O
antibacterial O
actions O
and O
support O
further O
studies O
on O
NAD B-CHEMICAL

synthetase I-GENE-N
as O
a O
new O
target O
for O
antibacterial O
agents. O
Blockade O
of O
LTC4 B-CHEMICAL
synthesis O
caused O
by O
additive O
inhibition O
of O
gIV-PLA2 B-GENE-N
phosphorylation: O
Effect O
of O
salmeterol B-CHEMICAL
and O
PDE4 B-GENE-N
inhibition O
in O
human O
eosinophils. O
BACKGROUND: O
Prior O
investigations O
have O
demonstrated O
that O
beta(2)-adrenoceptor B-GENE-Y
stimulation O
is O
ineffective O
in O
inhibiting O
synthesis O
of O
eicosanoids O
in O
human O
eosinophils. O
This O
effect O
has O
been O
postulated O
to O
relate O
to O
density O
or O
structural O
differences O
in O
the O

beta(2)-adrenoceptor B-GENE-Y
or O
its O
coupled O
G-protein. B-GENE-N
However, O
recent O
reports O
indicate O
that O
cAMP-specific B-GENE-N
PDE4 I-GENE-N
activity O
in O
eosinophils O
is O
10-fold O
that O
of O
other O
inflammatory O
cells. O
We O
postulated O
that O
selective O
blockade O
of O
PDE4 B-GENE-N
in O
eosinophils O
would O
unmask O
the O
inhibitory O
effect O
of O
beta(2)-adrenoceptor B-GENE-Y
stimulation O
and O
that O
this O
inhibition O
would O
result O
from O
decreased O
phosphor-ylation O
of O
cytosolic B-GENE-N
group I-GENE-N
IV-PLA(2) I-GENE-N
(gIV-PLA(2)). B-GENE-N

OBJECTIVE: O
To O
determine O
(a) O
whether O
PDE4 B-GENE-N
inhibition O
alone O
with O
rolipram B-CHEMICAL
blocked O
secretions O
of O
arachidonic B-CHEMICAL
acid I-CHEMICAL
(AA) B-CHEMICAL
and O
leukotriene B-CHEMICAL
C(4) I-CHEMICAL
(LTC(4)) B-CHEMICAL
caused O
by O
activation O
of O
eosinophils O
with O
formyl-met-leu-phe B-CHEMICAL
plus O
cytochalasin B-CHEMICAL
B I-CHEMICAL
(FMLP/B), O
(b) O
to O
determine O
if O
PDE4 B-GENE-N
inhibition O
plus O
beta(2)-adrenoceptor B-GENE-Y
agonist O
act O
additively O
to O
augment O
endogenous O
cAMP B-CHEMICAL

concentration, O
and O
(c) O
to O
determine O
the O
mechanism O
by O
which O
additive O
inhibition O
of O
AA B-CHEMICAL
and O
LTC(4) B-CHEMICAL
synthesis O
is O
regulated O
by O
cAMP. B-CHEMICAL
METHODS: O
Human O
eosinophils O
were O
pretreated O
with O
buffer, O
salmeterol B-CHEMICAL
or O
rolipram B-CHEMICAL
(singly O
or O
combination) O
before O
FMLP/B O
activation. O
Release O
of O
AA B-CHEMICAL
and O
LTC(4), B-CHEMICAL
intracellular O
cAMP B-CHEMICAL
concentration, O
and O
phosphorylation O
and O
activation O
of O
gIV-PLA(2) B-GENE-N
were O
determined. O
RESULTS: O
Rolipram B-CHEMICAL
unmasked O
the O

inhibitory O
effect O
of O
beta(2)-adrenoceptor B-GENE-N
stimulation O
with O
salmeterol B-CHEMICAL
and O
significantly O
attenuated O
the O
stimulated O
release O
of O
AA B-CHEMICAL
and O
subsequent O
LTC(4). B-CHEMICAL
Inhibition O
corresponded O
to O
increased O
cAMP B-CHEMICAL
production O
caused O
by O
rolipram B-CHEMICAL
alone O
or O
rolipram B-CHEMICAL
plus O
salmeterol B-CHEMICAL
and O
blocked O
proportionately O
the O
phosphorylation O
and O
activation O
of O
gIV-PLA(2) B-GENE-N
in O
FMLP/B-activated O
eosinophils. O
CONCLUSIONS: O
Inhibition O
of O
PDE4 B-GENE-N
by O
rolipram B-CHEMICAL
unmasks O

beta(2)-adrenergic B-GENE-Y
blockade O
of O
LTC(4) B-CHEMICAL
synthesis O
caused O
by O
FMLP/B. O
A O
phase O
1 O
study O
of O
tazarotene B-CHEMICAL
in O
adults O
with O
advanced O
cancer. O
Tazarotene B-CHEMICAL
is O
an O
acetylenic B-CHEMICAL
retinoid I-CHEMICAL
which O
is O
metabolised O
to O
tazarotenic B-CHEMICAL
acid I-CHEMICAL
and O
which O
binds O
selectively O
to O
the O
retinoid B-CHEMICAL
receptors I-GENE-N
RARbeta B-GENE-Y
and O
RARgamma. B-GENE-Y
The O
safety, O
toxicity O
and O
pharmacokinetics O
of O
oral O
tazarotene B-CHEMICAL
were O
determined O
over O
12 O
weeks O
of O
treatment O
in O
34 O
patients O
with O
advanced O
cancer. O
Commonly O
seen O
toxicities O
were O

mucocutaneous O
symptoms, O
musculoskeletal O
pain O
and O
headache. O
Dose-limiting O
toxicities O
were O
hypercalcaemia, O
hypertriglyceridaemia O
and O
musculoskeletal O
pain. O
The O
maximum O
tolerated O
dose O
of O
tazarotene B-CHEMICAL
in O
this O
schedule O
is O
25.2 O
mg O
day(-1). O
Plasma O
concentrations O
of O
tazarotenic B-CHEMICAL
acid I-CHEMICAL
were O
found O
to O
peak O
rapidly O
within O
1-3 O
h O
of O
dosing O
and O
thereafter O
declined O
quickly. O
The O
C(max) O
and O
AUC O
values O
on O
day O
0, O
and O
weeks O
2 O
and O
4 O
were O
similar O
indicating O
no O
drug O
accumulation. O
The O

dose-normalised O
C(max) O
and O
AUC O
values O
at O
different O
dose O
levels O
and O
different O
study O
days O
appeared O
to O
be O
similar O
indicating O
linear O
pharmacokinetics. O
No O
objective O
responses O
were O
seen, O
although O
stable O
disease O
was O
seen O
in O
six O
out O
of O
eight O
evaluable O
patients O
receiving O
the O
three O
highest O
dose O
levels O
of O
tazarotene B-CHEMICAL
(16.8, O
25.2 O
or O
33.4 O
mg O
day(-1)). O
We O
conclude O
that O
oral O
tazarotene B-CHEMICAL
is O
well O
tolerated O
when O
administered O
daily O
for O
12 O
weeks, O
has O
a O
favourable O
toxicity O
profile O
compared O
with O
other O
retinoids B-CHEMICAL
and O
merits O
further O
investigation O
as O
an O
anticancer O

therapy. O
Anabolic O
effects O
of O
clenbuterol B-CHEMICAL
on O
skeletal O
muscle O
are O
mediated O
by O
beta B-GENE-Y
2-adrenoceptor I-GENE-Y
activation. O
The O
potent O
anabolic O
effects O
of O
the O
beta B-GENE-Y
2-adrenoceptor I-GENE-Y
agonist O
clenbuterol B-CHEMICAL
on O
skeletal O
muscle O
have O
been O
reported O
to O
be O
independent O
of O
actions O
on O
beta-adrenoceptors. B-GENE-N
In O
the O
present O
study O
clenbuterol, B-CHEMICAL
presented O
to O
rats O
in O
the O
diet O
(4 O
mg/kg), O
caused O
significant O
increases O
in O
gastrocnemius O
muscle O
mass, O
protein, O
and O
RNA O
content O
and O
a O
decrease O
in O
epididymal O
fat O
pad O
mass. O
These O
effects O
were O

not O
mimicked O
by O
oral O
administration O
of O
the O
beta B-GENE-Y
2-adrenoceptor I-GENE-Y
agonist O
salbutamol B-CHEMICAL
even O
at O
high O
dose O
(52 O
mg/kg O
diet), O
and O
the O
effects O
of O
clenbuterol B-CHEMICAL
were O
not O
inhibited O
by O
addition O
of O
DL-propranolol B-CHEMICAL
(200 O
mg/kg O
diet). O
However, O
the O
selective O
beta O
2-antagonist O
ICI-118,551 B-CHEMICAL
(200 O
mg/kg O
diet) O
reversed O
the O
anabolic O
effects O
of O
clenbuterol, B-CHEMICAL
and O
a O
high O
dose O
of O
DL-propranolol B-CHEMICAL
(1,000 O
mg/kg O
diet) O
also O
inhibited O
these O

actions O
of O
clenbuterol. B-CHEMICAL
Furthermore, O
continuous O
infusion O
of O
salbutamol B-CHEMICAL
(1.15 O
mg.kg O
body O
wt-1.day-1) O
via O
miniosmotic O
pumps O
did O
cause O
significant O
increases O
in O
muscle O
mass, O
protein, O
and O
RNA O
content. O
These O
results O
indicate O
that O
the O
anabolic O
effects O
of O
clenbuterol B-CHEMICAL
are O
dependent O
on O
interaction O
with O
the O
beta B-GENE-Y
2-adrenoceptor. I-GENE-Y
However, O
a O
long O
duration O
of O
action O
appears O
to O
be O
required O
to O
induce O
the O
anabolic O
effects O
of O
beta O
2-agonists. O
Evidence O
that O
an O
alpha B-GENE-Y
2A-adrenoceptor I-GENE-Y
subtype O

mediates O
antinociception O
in O
mice. O
In O
the O
hot-plate O
test O
in O
mice, O
the O
antinociceptive O
action O
of O
the O
alpha B-GENE-N
2-adrenoceptor I-GENE-N
agonist, O
UK B-CHEMICAL
14,304, I-CHEMICAL
was O
abolished O
by O
the O
alpha B-GENE-N
2-adrenoceptor I-GENE-N
antagonist, O
idazoxan, B-CHEMICAL
the O
potent O
alpha B-GENE-Y
2A-adrenoceptor I-GENE-Y
antagonist, O
RX B-CHEMICAL
821002 I-CHEMICAL
and O
the O
preferential O
alpha B-GENE-Y
2A-adrenoceptor I-GENE-Y
antagonist, O
BRL B-CHEMICAL
44408. I-CHEMICAL
In O
contrast, O
the O
preferential O
alpha B-GENE-N
2B- I-GENE-N
(and I-GENE-N
alpha I-GENE-N
2C)-adrenoceptor I-GENE-N
ligands O

('antagonists'), O
ARC-239, B-CHEMICAL
BRL B-CHEMICAL
41992 I-CHEMICAL
and O
prazosin B-CHEMICAL
were O
inactive. O
The O
preferential O
alpha B-GENE-Y
2A-adrenoceptor I-GENE-Y
partial O
agonist, O
guanfacine, B-CHEMICAL
partially O
inhibited O
UK B-CHEMICAL
14,304-induced I-CHEMICAL
antinociception. O
Further, O
guanfacine B-CHEMICAL
BRL B-CHEMICAL
44408 I-CHEMICAL
reversibly O
elicited O
submaximal O
antinociception. O
It O
is O
concluded O
that O
alpha B-GENE-Y
2A-adrenoceptors I-GENE-Y
mediate O
antinociception O
in O
mice. O
Crystal O
structure O
of O
serine B-GENE-Y
dehydratase I-GENE-Y
from O
rat O
liver. O
SDH B-GENE-Y

(L-serine B-GENE-Y
dehydratase, I-GENE-Y
EC B-GENE-Y
4.3.1.17) I-GENE-Y
catalyzes O
the O
pyridoxal B-CHEMICAL
5'-phosphate I-CHEMICAL
(PLP)-dependent B-CHEMICAL
dehydration O
of O
L-serine B-CHEMICAL
to O
yield O
pyruvate B-CHEMICAL
and O
ammonia. B-CHEMICAL
Liver O
SDH B-GENE-Y
plays O
an O
important O
role O
in O
gluconeogenesis. O
Formation O
of O
pyruvate B-CHEMICAL
by O
SDH B-GENE-Y
is O
a O
two-step O
reaction O
in O
which O
the O
hydroxyl B-CHEMICAL
group O
of O
serine B-CHEMICAL
is O
cleaved O
to O
produce O
aminoacrylate, B-CHEMICAL
and O
then O
the O
aminoacrylate B-CHEMICAL
is O
deaminated O
by O
nonenzymatic O

hydrolysis O
to O
produce O
pyruvate. B-CHEMICAL
The O
crystal O
structure O
of O
rat B-GENE-Y
liver I-GENE-Y
apo-SDH I-GENE-Y
was O
determined O
by O
single O
isomorphous O
replacement O
at O
2.8 O
A O
resolution. O
The O
holo-SDH B-GENE-Y
crystallized O
with O
O-methylserine B-CHEMICAL
(OMS) B-CHEMICAL
was O
also O
determined O
at O
2.6 O
A O
resolution O
by O
molecular O
replacement. O
SDH B-GENE-Y
is O
composed O
of O
two O
domains, O
and O
each O
domain O
has O
a O
typical O
alphabeta-open O
structure. O
The O
active O
site O
is O
located O
in O
the O
cleft O
between O
the O
two O
domains. O
The O
holo-SDH B-GENE-Y
contained O
PLP-OMS O
aldimine B-CHEMICAL
in O
the O
active O
site, O

indicating O
that O
OMS B-CHEMICAL
can O
form O
the O
Schiff B-CHEMICAL
base I-CHEMICAL
linkage O
with O
PLP, B-CHEMICAL
but O
the O
subsequent O
dehydration O
did O
not O
occur. O
Apo-SDH B-GENE-Y
forms O
a O
dimer O
by O
inserting O
the O
small O
domain O
into O
the O
catalytic O
cleft O
of O
the O
partner O
subunit O
so O
that O
the O
active O
site O
is O
closed. O
Holo-SDH B-GENE-Y
also O
forms O
a O
dimer O
by O
making O
contacts O
at O
the O
back O
of O
the O
clefts O
so O
that O
the O
dimerization O
does O
not O
close O
the O
catalytic O
cleft. O
The O
phosphate O
group O
of O
PLP B-CHEMICAL
is O
surrounded O
by O
a O
characteristic O
G-rich B-GENE-N
sequence I-GENE-N

((168)GGGGL(172)) B-CHEMICAL
and O
forms O
hydrogen B-CHEMICAL
bonds O
with O
the O
amide B-CHEMICAL
groups O
of O
those O
amino B-CHEMICAL
acid I-CHEMICAL
residues, O
suggesting O
that O
the O
phosphate B-CHEMICAL
group O
can O
be O
protonated. O
N(1) O
of O
PLP B-CHEMICAL
participates O
in O
a O
hydrogen B-CHEMICAL
bond O
with O
Cys303, O
and O
similar O
hydrogen B-CHEMICAL
bonds O
with O
N(1) O
participating O
are O
seen O
in O
other O
beta-elimination O
enzymes. O
These O
hydrogen B-CHEMICAL
bonding O
schemes O
indicate O
that O
N(1) O
is O
not O
protonated, O
and O
thus, O
the O
pyridine B-CHEMICAL
ring O
cannot O
take O
a O
quinone-like B-CHEMICAL
structure. O
These O
characteristics O
of O
the O
bound O
PLP B-CHEMICAL
suggest O
that O
SDH B-GENE-Y
catalysis O
is O

not O
facilitated O
by O
forming O
the O
resonance-stabilized O
structure O
of O
the O
PLP-Ser B-CHEMICAL
aldimine I-CHEMICAL
as O
seen O
in O
aminotransferases. B-GENE-N
A O
possible O
catalytic O
mechanism O
involves O
the O
phosphate B-CHEMICAL
group, O
surrounded O
by O
the O
characteristic O
sequence, O
acting O
as O
a O
general O
acid O
to O
donate O
a O
proton O
to O
the O
leaving O
hydroxyl B-CHEMICAL
group O
of O
serine. B-CHEMICAL
Epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
autocrine O
signaling O
in O
RIE-1 O
cells O
transformed O
by O
the O
Ras B-GENE-N
oncogene O
enhances O
radiation O
resistance. O
Oncogenic O
forms O
of O
the O
small O
GTPase B-GENE-N
Ras B-GENE-N
increase O
the O
resistance O
of O
cells O
to O
killing O
by O
ionizing O
radiation O
(IR). O
Although O
not O

all O
of O
the O
signaling O
pathways O
for O
radioresistance O
are O
well O
defined, O
it O
is O
now O
clear O
that O
Ras-dependent B-GENE-N
signaling O
pathways O
involved O
in O
radioresistance O
include O
those O
mediated O
by O
phosphatidylinositol B-CHEMICAL
3'-kinase I-GENE-N
(PI3-K) B-GENE-N
and O
Raf. B-GENE-N
Nevertheless, O
PI3-K B-GENE-N
and O
Raf B-GENE-N
together O
are O
not O
sufficient O
to O
reconstitute O
all O
of O
the O
resistance O
conferred O
by O
Ras, B-GENE-N
indicating O
that O
other O
effectors O
must O
also O
contribute. O
We O
show O
here O
that O
Ras-driven B-GENE-N
autocrine O
signaling O
through O
the O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(EGFR) B-GENE-Y
also O
contributes O

to O
radioresistance O
in O
Ras-transformed B-GENE-N
cells. O
Conditioned O
media O
(CM) O
collected O
from O
RIE-1 O
rat O
intestinal O
epithelial O
cells O
expressing O
oncogenic O
Ras B-GENE-N
increased O
the O
survival O
of O
irradiated O
cells. O
Ras-CM B-GENE-N
contains O
elevated O
levels O
of O
the O
EGFR B-GENE-Y
ligand O
transforming B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
alpha I-GENE-Y
(TGF-alpha). B-GENE-Y
Both O
Ras-CM B-GENE-N
and O
TGF-alpha B-GENE-Y
stimulated O
EGFR B-GENE-Y
phosphorylation, O
and O
exogenous O
TGF-alpha B-GENE-Y
mimicked O
the O
effects O
of O
Ras-CM B-GENE-N
to O
increase O

radioresistance. O
Blocking O
EGFR B-GENE-Y
signaling O
with O
the O
EGFR/HER-2 B-GENE-Y
kinase O
inhibitor O
(KI) O
GW572016 B-CHEMICAL
decreased O
the O
postradiation O
survival O
of O
irradiated O
Ras-transformed B-GENE-N
cells O
and O
normal O
cells O
but O
had O
no O
effect O
on O
the O
survival O
of O
unirradiated O
cells. O
Ras-CM B-GENE-N
and O
TGF-alpha B-GENE-Y
also O
increase O
PI3-K B-GENE-N
activity O
downstream O
of O
the O
EGFR B-GENE-Y
and O
increase O
postradiation O
survival, O
both O
of O
which O
are O
abrogated O
by O
GW572016. B-CHEMICAL
Thus, O
Ras B-GENE-N
utilizes O
autocrine O
signaling O
through O

EGFR B-GENE-Y
to O
increase O
radioresistance, O
and O
the O
EGFR B-GENE-Y
KI O
GW572016 B-CHEMICAL
acts O
as O
a O
radiosensitizer. O
The O
observation O
that O
Ras-transformed B-GENE-N
cells O
can O
be O
sensitized O
to O
killing O
by O
ionizing O
radiation O
with O
GW572016 B-CHEMICAL
demonstrates O
that O
EGFR B-GENE-Y
KIs O
could O
potentially O
be O
used O
to O
radiosensitize O
tumors O
in O
which O
radioresistance O
is O
dependent O
on O
Ras-driven B-GENE-N
autocrine O
signaling O
through O
EGFR. B-GENE-Y
Characterization O
of O
beta B-GENE-Y
3-adrenoceptor-mediated I-GENE-Y
relaxation O
in O
rat O
abdominal O
aorta O
smooth O
muscle. O
The O

present O
study O
was O
carried O
out O
to O
characterize O
beta-adrenoceptor B-GENE-N
subtypes O
mediating O
relaxation O
of O
rat O
abdominal O
aorta O
smooth O
muscle. O
(-)-Isoprenaline B-CHEMICAL
and O
a O
nonconventional O
beta(3)-adrenoceptor B-GENE-Y
agonist, O
(+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida B-CHEMICAL
zol-2-one] I-CHEMICAL
hydrochloride I-CHEMICAL

((+/-)-CGP12177A), B-CHEMICAL
induced O
concentration-dependent O
relaxation O
of O
(-)-phenylephrine B-CHEMICAL
(0.3 O
microM) O
preconstricted O
spiral O
preparations. O
Pretreatment O
with O
a O
combination O
of O
(+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 B-CHEMICAL

-yl]phenoxy]propyl]amino]ethoxy]-benzamide I-CHEMICAL
methanesulfonate I-CHEMICAL
(CGP20712A, B-CHEMICAL
a O
selective O
beta(1)-adrenoceptor B-GENE-Y
antagonist) O
and O
(+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta B-CHEMICAL
nol I-CHEMICAL
hydrochloride I-CHEMICAL
(ICI-118,5511, B-CHEMICAL
a O
selective O

beta(2)-adrenoceptor B-GENE-Y
antagonist) O
(0.1 O
microM O
for O
each) O
produced O
a O
14-fold O
rightward O
shift O
of O
the O
concentration-response O
curve O
for O
(-)-isoprenaline; B-CHEMICAL
however, O
the O
relaxation O
in O
response O
to O
(+/-)-CGP12177A B-CHEMICAL
was O
unaffected O
by O
the O
blockade O
of O
beta(1)- B-GENE-N
and I-GENE-N
beta(2)-adrenoceptors. I-GENE-N
In O
the O
presence O
of O
CGP20712A B-CHEMICAL
and O
ICI-118,551 B-CHEMICAL
(0.1 O
microM O
for O
each), O
the O
concentration-response O
curves O
for O

(-)-isoprenaline B-CHEMICAL
and O
(+/-)-CGP12177A B-CHEMICAL
were O
shifted O
to O
the O
right O
by O
a O
nonselective O
beta(1)-, B-GENE-N
beta(2)- I-GENE-N
and I-GENE-N
beta(3)-adrenoceptor I-GENE-N
antagonist, O
(+/-)-bupranolol B-CHEMICAL
(3 O
and O
10 O
microM). O
These O
results O
clearly O
suggest O
that O
beta(3)-adrenoceptors B-GENE-Y
are O
involved O
in O
beta-adrenoceptor-mediated B-GENE-N
relaxation O
of O
rat O
abdominal O
aorta O
smooth O
muscle. O
Use O
of O
the O
norepinephrine B-GENE-Y
transporter I-GENE-Y
as O
a O
reporter O
gene O

for O
non-invasive O
imaging O
of O
genetically O
modified O
cells. O
BACKGROUND: O
The O
norepinephrine B-CHEMICAL
transporter I-GENE-Y
(NET) B-GENE-Y
is O
a O
high-affinity O
transporter O
for O
catecholamines. B-CHEMICAL
Its O
expression O
is O
almost O
exclusively O
restricted O
to O
the O
sympathetic O
nervous O
system. O
In O
this O
study O
we O
evaluated O
whether O
the O
NET B-GENE-Y
can O
be O
used O
as O
a O
reporter O
gene O
for O
non-invasive O
imaging O
of O
genetically O
modified O
cells O
with O
radiolabeled O
probes. O
METHODS: O
Human O
A431, O
HT1080 O
and O
murine O
CMS-5 O
cells O
were O
retrovirally O
transduced O
with O
bovine B-GENE-Y
NET I-GENE-Y

cDNA. O
Transduced O
and O
parental O
cells O
were O
incubated O
in O
vitro O
with O
[(131)I]meta-iodobenzylguanidine B-CHEMICAL
([(131)I]MIBG). B-CHEMICAL
The O
specificity O
of O
tracer O
uptake O
was O
determined O
by O
adding O
the O
NET B-GENE-Y
inhibitor O
imipramine. B-CHEMICAL
Rat O
PC12 O
cells O
served O
as O
positive O
controls. O
Parental O
and O
A431NET B-GENE-Y
cells O
were O
xenotransplanted O
into O
nude O
mice O
and O
tumor O
uptake O
of O
[(123)I]MIBG B-CHEMICAL
in O
vivo O
was O
determined O
after O
tracer O
administration. O

RESULTS: O
In O
vitro O
stably O
transduced O
cells O
showed O
a O
66- O
to O
120-fold O
higher O
[(131)I]MIBG B-CHEMICAL
uptake O
than O
parental O
cells. O
Incubation O
with O
imipramine B-CHEMICAL
reduced O
[(131)I]MIBG B-CHEMICAL
uptake O
of O
transduced O
cells O
to O
the O
level O
found O
in O
parental O
cells. O
More O
than O
70% O
of O
the O
initial O
radioactivity O
was O
retained O
in O
all O
transduced O
cell O
lines O
after O
2 O
h O
incubation O
with O
tracer-free O
medium. O
[(131)I]MIBG B-CHEMICAL
uptake O
in O
PC12 O
cells, O
which O
express O
the O
NET B-GENE-Y

endogenously, O
was O
20- O
to O
28-fold O
lower O
than O
in O
transduced O
cells. O
In O
vivo, O
A431NET B-GENE-Y
tumors O
demonstrated O
a O
33-fold O
higher O
[(123)I]MIBG B-CHEMICAL
uptake O
than O
parental O
tumors. O
Gamma O
camera O
images O
24 O
h O
after O
tracer O
injection O
showed O
no O
tracer O
uptake O
in O
parental O
A431 O
tumors, O
but O
clear O
images O
of O
A431NET B-GENE-Y
tumors. O
CONCLUSIONS: O
Transduction O
of O
tumor O
cells O
with O
NET B-GENE-Y
cDNA O
causes O
highly O
specific O
uptake O
and O
significant O
retention O
of O
catecholamine B-CHEMICAL
analogs O
in O
vitro O
and O
in O
vivo. O
These O
characteristics O

make O
the O
NET B-GENE-Y
suitable O
as O
a O
reporter O
gene O
for O
non-invasive O
monitoring O
of O
gene O
transfer. O
Comparative O
pharmacology O
of O
human B-GENE-N
beta-adrenergic I-GENE-N
receptor I-GENE-N
subtypes--characterization O
of O
stably O
transfected O
receptors O
in O
CHO O
cells. O
Although O
many O
beta1-receptor B-GENE-Y
antagonists O
and O
beta2-receptor B-GENE-Y
agonists O
have O
been O
used O
in O
pharmacotherapy O
for O
many O
years O
their O
pharmacological O
properties O
at O
all O
three O
known O
subtypes O
of O
beta-adrenergic B-GENE-N
receptors I-GENE-N
are O
not O
always O
well O
characterized. O
The O
aim O
of O
this O
study O
was, O
therefore, O
to O
provide O
comparative O
binding O
characteristics O
of O
agonists O

(epinephrine, B-CHEMICAL
norepinephrine, B-CHEMICAL
isoproterenol, B-CHEMICAL
fenoterol, B-CHEMICAL
salbutamol, B-CHEMICAL
salmeterol, B-CHEMICAL
terbutalin, B-CHEMICAL
formoterol, B-CHEMICAL
broxaterol) B-CHEMICAL
and O
antagonists O
(propranolol, B-CHEMICAL
alprenolol, B-CHEMICAL
atenolol, B-CHEMICAL
metoprolol, B-CHEMICAL
bisoprolol, B-CHEMICAL
carvedilol, B-CHEMICAL
pindolol, B-CHEMICAL
BRL B-CHEMICAL
37344, I-CHEMICAL
CGP B-CHEMICAL
20712, I-CHEMICAL
SR B-CHEMICAL
59230A, I-CHEMICAL
CGP B-CHEMICAL
12177, I-CHEMICAL
ICI B-CHEMICAL
118551) I-CHEMICAL
at O
all O
three O
subtypes O
of O
human B-GENE-N

beta-adrenergic I-GENE-N
receptors I-GENE-N
in O
an O
identical O
cellular O
background. O
We O
generated O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
the O
three O
beta-adrenergic B-GENE-N
receptor I-GENE-N
subtypes O
at O
comparable O
levels. O
We O
characterized O
these O
receptor O
subtypes O
and O
analyzed O
the O
affinity O
of O
routinely O
used O
drugs O
as O
well O
as O
experimental O
compounds O
in O
competition O
binding O
studies, O
using O
the O
non-selective O
antagonist O
125I-cyanopindolol B-CHEMICAL
as O
a O
radioligand. O
Furthermore, O
we O
analyzed O
the O
beta-receptor-mediated B-GENE-N
adenylyl B-CHEMICAL
cyclase I-GENE-N
activity O
in O
isolated O
membranes O
from O
these O
cell O
lines. O
The O
results O
from O
our O
experiments O
show O
that O

all O
compounds O
exhibit O
distinct O
patterns O
of O
selectivity O
and O
activity O
at O
the O
three O
beta-receptor B-GENE-N
subtypes. O
In O
particular, O
a O
number O
of O
beta2- B-GENE-N
or I-GENE-N
beta3-receptor I-GENE-N
agonists O
that O
are O
inverse O
agonists O
at O
the O
other O
subtypes O
were O
identified. O
In O
addition, O
beta1-receptor B-GENE-Y
antagonists O
with O
agonistic O
activity O
at O
beta2- B-GENE-N
and I-GENE-N
beta3-receptors I-GENE-N
were O
found. O
These O
specific O
mixtures O
of O
agonism, O
antagonism, O
and O
inverse O
agonism O
at O
different O
subtypes O
may O
have O
important O
implications O
for O
the O
therapeutic O
use O
of O
the O
respective O
compounds. O
Ocular O
hypotensive O
FP O

prostaglandin B-CHEMICAL
(PG) B-CHEMICAL
analogs: O
PG B-GENE-N
receptor I-GENE-N
subtype O
binding O
affinities O
and O
selectivities, O
and O
agonist O
potencies O
at O
FP B-GENE-Y
and O
other O
PG B-GENE-N
receptors I-GENE-N
in O
cultured O
cells. O
Natural O
prostaglandins B-CHEMICAL
(PGs) B-CHEMICAL
such O
as O
PGD2, B-CHEMICAL
PGE2, B-CHEMICAL
PGF2(2alpha), B-CHEMICAL
and O
PGI2 B-CHEMICAL
exhibited O
the O
highest O
affinity O
for O
their O
respective O
cognate O
receptors, O
but O
were O
the O
least O
selective O
agents O
when O
tested O
in O
receptor O
binding O
assays. O
Travoprost B-CHEMICAL
acid I-CHEMICAL
([+]-fluprostenol) B-CHEMICAL
was O
the O
most O

FP-receptor-selective B-GENE-Y
compound, O
exhibiting O
a O
high O
affinity O
(Ki O
= O
35 O
+/- O
5 O
nM) O
for O
the O
FP B-GENE-Y
receptor, I-GENE-Y
and O
minimal O
affinity O
for O
DP B-GENE-N
(Ki O
= O
52,000 O
nM), O
EP1 B-GENE-Y
(Ki O
= O
9540 O
nM), O
EP3 B-GENE-Y
(Ki O
= O
3501 O
nM), O
EP4 B-GENE-Y
(Ki O
= O
41,000 O
nM), O
IP B-GENE-Y
(Ki O
> O
90,000 O
nM), O
and O
TP B-GENE-Y
(Ki O
= O
121,000 O
nM) O
receptors. O
Travoprost B-CHEMICAL
acid I-CHEMICAL
was O
the O
most O
potent O
PG B-CHEMICAL
analog O
tested O
in O
FP B-GENE-Y
receptor I-GENE-Y
functional O

phosphoinositide B-CHEMICAL
turnover O
assays O
in O
the O
following O
cell O
types: O
human O
ciliary O
muscle O
(EC50 O
= O
1.4 O
nM), O
human O
trabecular O
meshwork O
(EC50 O
= O
3.6 O
nM), O
and O
mouse O
fibroblasts O
and O
rat O
aortic O
smooth O
muscle O
cells O
(EC50 O
= O
2.6 O
nM). O
Although O
latanoprost B-CHEMICAL
acid I-CHEMICAL
exhibited O
a O
relatively O
high O
affinity O
for O
the O
FP B-GENE-Y
receptor I-GENE-Y
(Ki O
= O
98 O
nM), O
it O
had O
significant O
functional O
activity O
at O
FP B-GENE-Y
(EC50 O
= O
32-124 O
nM) O
and O
EP1 B-GENE-Y
(EC50 O
= O
119 O

nM) O
receptors. O
Bimatoprost B-CHEMICAL
acid I-CHEMICAL
was O
less O
selective, O
exhibiting O
a O
relatively O
high O
affinity O
for O
the O
FP B-GENE-Y
(Ki O
= O
83 O
nM), O
EP1 B-GENE-Y
(Ki O
= O
95 O
nM), O
and O
EP3 B-GENE-Y
(Ki O
= O
387 O
nM) O
receptors. O
Bimatoprost B-CHEMICAL
acid I-CHEMICAL
exhibited O
functional O
activity O
at O
the O
EP1 B-GENE-N
(EC50 O
= O
2.7 O
nM) O
and O
FP B-GENE-Y
(EC50 O
= O
2.8-3.8 O
nM O
in O
most O
cells) O
receptors. O
Bimatoprost B-CHEMICAL
(nonhydrolyzed O
amide) O
also O
behaved O
as O
an O
FP B-GENE-Y
agonist O
at O
the O

cloned O
human B-GENE-Y
FP I-GENE-Y
receptor I-GENE-Y
(EC50 O
= O
681 O
nM), O
in O
h-TM O
(EC50 O
= O
3245 O
nM) O
and O
other O
cell O
types. O
Unoprostone B-CHEMICAL
and O
S-1033 B-CHEMICAL
bound O
with O
low O
affinity O
(Ki O
= O
5.9 O
microM O
to O
> O
22 O
microM) O
to O
the O
FP B-GENE-Y
receptor, I-GENE-Y
were O
not O
selective, O
but O
activated O
the O
FP B-GENE-Y
receptor. I-GENE-Y
In O
conclusion, O
travoprost B-CHEMICAL
acid I-CHEMICAL
has O
the O
highest O
affinity, O
the O
highest O
FP-receptor-selectivity, B-GENE-Y
and O
the O
highest O
potency O
at O
the O
FP B-GENE-Y
receptor I-GENE-Y
as O
compared O
to O
the O
other O
ocular O
hypotensive O

PG O
analogs O
known O
so O
far, O
including O
free B-CHEMICAL
acids I-CHEMICAL
of I-CHEMICAL
latanoprost, I-CHEMICAL
bimatoprost, I-CHEMICAL
and I-CHEMICAL
unoprostone I-CHEMICAL
isopropyl I-CHEMICAL
ester. I-CHEMICAL
Loss O
of O
beta-adrenoceptor B-GENE-N
response O
in O
myocytes O
overexpressing O
the O
Na+/Ca(2+)-exchanger. B-CHEMICAL
Increased O
Na+/Ca(2+)-exchanger B-GENE-N
(NCX) B-GENE-N
and O
altered O
beta-adrenoceptor B-GENE-N
(betaAR) B-GENE-N
responses O
are O
observed O
in O
failing O
human O
heart. O
To O
determine O
the O
possible O
interaction O
between O
these O
changes, O
we O
investigated O
the O
effect O
of O
NCX B-GENE-N
overexpression O
on O

responses O
to O
isoproterenol O
in O
adult O
rat O
ventricular O
myocytes. O
Responses O
to O
isoproterenol B-CHEMICAL
were O
largely O
mediated O
through O
the O
beta1AR B-GENE-Y
in O
control O
myocytes. O
Adenovirally-mediated O
overexpression O
of O
NCX, B-GENE-N
at O
levels, O
which O
did O
not O
alter O
basal O
contraction O
of O
myocytes, O
markedly O
depressed O
the O
isoproterenol B-CHEMICAL
concentration-response O
curve. O
Responses O
to O
isoproterenol B-CHEMICAL
could O
be O
restored O
to O
normal O
by O
beta2AR B-GENE-Y
blockade, O
suggesting O
a O
beta2AR-mediated B-GENE-Y
inhibition O
of O
beta1AR B-GENE-Y
signalling. O
Pertussis B-GENE-N
toxin I-GENE-N
normalised O
isoproterenol B-CHEMICAL
responses O
in O

NCX B-GENE-N
cells, O
indicating O
that O
beta2AR B-GENE-Y
effects O
were O
mediated O
by O
Gi. B-GENE-N
Negative-inotropic O
effects O
of O
high O
concentrations O
of O
ICI O
118,551, O
previously O
shown O
to O
be O
due O
to O
beta2AR-Gi B-GENE-Y
coupling, O
were O
increased O
in O
NCX B-GENE-N
cells. O
We O
conclude O
that O
NCX B-GENE-N
upregulation O
can O
markedly O
alter O
the O
consequences O
of O
betaAR B-GENE-N
stimulation O
and O
that O
this O
may O
contribute O
to O
the O
alterations O
in O
betaAR B-GENE-N
response O
seen O
in O
failing O
human O
heart. O
Manipulation O
of O
kinetic O
profiles O
in O
2-aryl B-CHEMICAL
propionic I-CHEMICAL
acid I-CHEMICAL
cyclooxygenase B-GENE-N
inhibitors. O
The O
nonsteroidal O

anti-inflammatory O
drugs O
flurbiprofen B-CHEMICAL
and O
ibuprofen B-CHEMICAL
were O
modified O
in O
an O
attempt O
to O
alter O
the O
kinetics O
of O
inhibitor O
binding O
by O
COX-1. B-GENE-Y
Contrary O
to O
prior O
predictions, O
a O
halogen B-CHEMICAL
substituent O
is O
not O
sufficient O
to O
confer O
slow O
tight-binding O
behavior. O
Conversion O
of O
the O
carboxylate B-CHEMICAL
moiety O
of O
flurbiprofen B-CHEMICAL
to O
an O
ester B-CHEMICAL
or O
amide B-CHEMICAL
abolishes O
slow O
tight-binding O
behavior, O
regardless O
of O
halogenation O
state. O
Effects O
of O
the O
EGFR/HER2 B-GENE-Y
kinase B-GENE-N
inhibitor O
GW572016 B-CHEMICAL
on O

EGFR- B-GENE-Y
and O
HER2-overexpressing B-GENE-Y
breast O
cancer O
cell O
line O
proliferation, O
radiosensitization, O
and O
resistance. O
PURPOSE: O
Two O
members O
of O
the O
epidermal O
growth O
factor O
receptor O
family, O
EGFR B-GENE-Y
and O
HER2, B-GENE-Y
have O
been O
implicated O
in O
radioresistance O
in O
breast O
cancer O
and O
other O
malignancies. O
To O
gauge O
the O
potential O
clinical O
utility O
of O
targeting O
both O
EGFR B-GENE-Y
and O
HER2 B-GENE-Y
to O
control O
growth O
and O
radiosensitize O
human O
breast O
cancers, O
we O
examined O
the O
effect O
of O
a O
dual O
EGFR/HER2 B-GENE-Y
inhibitor, O
GW572016, B-CHEMICAL

on O
the O
proliferation O
and O
radiation O
response O
of O
either O
EGFR- B-GENE-Y
or O
HER2-overexpressing B-GENE-Y
human O
breast O
cancer O
cell O
lines. O
METHODS O
AND O
MATERIALS: O
Primary O
human O
breast O
cancer O
cell O
lines O
that O
endogenously O
overexpress O
EGFR B-GENE-Y
or O
HER2 B-GENE-Y
and O
luminal O
mammary O
epithelial O
H16N2 O
cells O
stably O
transfected O
with O
HER2 B-GENE-Y
were O
evaluated O
for O
the O
effect O
of O
GW572016 B-CHEMICAL
on O
inhibition O
of O
ligand-induced O
or O
constitutive B-GENE-N
receptor I-GENE-N
phosphorylation, O
proliferation, O
radiosensitization, O
and O
inhibition O

of O
downstream O
signaling. O
RESULTS: O
GW572016 B-CHEMICAL
inhibited O
constitutive O
and/or O
ligand-induced O
EGFR B-GENE-Y
or O
HER2 B-GENE-Y
tyrosine B-CHEMICAL
phosphorylation O
of O
all O
five O
cell O
lines, O
which O
correlated O
with O
the O
antiproliferative O
response O
in O
all O
but O
one O
cell O
line. O
GW572016 B-CHEMICAL
radiosensitized O
EGFR-overexpressing B-GENE-Y
cell O
lines, O
but O
HER2-overexpressing B-GENE-Y
cells O
were O
unable O
to O
form O
colonies O
after O
brief O
exposure O
to O
GW572016 B-CHEMICAL
even O
in O
the O
absence O
of O
radiation, O
and O
thus O
could O

not O
be O
evaluated O
for O
radiosensitization. O
One O
cell O
line O
was O
resistant O
to O
the O
antiproliferative O
and O
radiosensitizing O
effects O
of O
GW572016, B-CHEMICAL
despite O
receptor O
inhibition. O
Exploration O
of O
potential O
mechanisms O
of O
resistance O
in O
SUM185 O
cells O
revealed O
failure O
of O
GW572016 B-CHEMICAL
to O
inhibit O
downstream O
ERK B-GENE-N
and O
Akt B-GENE-N
activation, O
despite O
inhibition O
of O
HER2 B-GENE-Y
phosphorylation. O
In O
contrast, O
sensitive O
HER2-overexpressing B-GENE-Y
cell O
lines O
demonstrated O
inhibition O
of O
both O
ERK B-GENE-N
and O
Akt B-GENE-N
phosphorylation. O
CONCLUSION: O
GW572016 B-CHEMICAL

potently O
inhibits O
receptor O
phosphorylation O
in O
either O
EGFR- B-GENE-Y
or O
HER2-overexpressing B-GENE-Y
cell O
lines O
and O
has O
both O
antiproliferative O
and O
radiosensitizing O
effects. O
Resistance O
to O
GW572016 B-CHEMICAL
was O
not O
due O
to O
a O
lack O
of O
receptor O
inhibition, O
but O
rather O
with O
a O
lack O
of O
inhibition O
of O
ERK B-GENE-N
and O
Akt, B-GENE-N
suggesting O
that O
measurement O
of O
inhibition O
of O
crucial O
signaling O
pathways O
may O
better O
predict O
response O
than O
inhibition O
of O
receptor O
phosphorylation. O
The O
SUM185 O
cell O
line O
provides O
a O
valuable O
model O
for O
studying O
mechanisms O
of O
resistance O
of O

EGFR/HER2 B-GENE-Y
inhibitor O
therapy. O
Aquaporin-1 B-GENE-Y
deletion O
reduces O
osmotic O
water O
permeability O
and O
cerebrospinal O
fluid O
production. O
Aquaporin-1 B-GENE-Y
(AQP1) B-GENE-Y
is O
a O
water B-GENE-N
channel I-GENE-N
that O
is O
strongly O
expressed O
at O
the O
ventricular-facing O
surface O
of O
choroid O
plexus O
epithelium. O
Using O
wildtype O
and O
AQP1 B-GENE-Y
null O
mice, O
we O
developed O
novel O
methods O
to O
compare O
the O
water O
permeability O
in O
isolated O
choroid O
plexus, O
and O
cerebrospinal O
fluid O
(CSF) O
production O
in O
living O
mice. O

Osmotically-induced O
water O
transport O
was O
rapid O
in O
freshly O
isolated O
choroid O
plexus O
from O
wildtype O
mice O
as O
measured O
by O
a O
spatial-filtering O
optical O
method, O
and O
reduced O
by O
5-fold O
by O
AQP1 B-GENE-Y
deletion. O
CSF O
production, O
an O
isosmolar O
fluid O
secretion O
process, O
was O
measured O
by O
a O
dye O
dilution O
method O
involving O
fluid O
collections O
using O
a O
second O
microneedle O
introduced O
into O
the O
cisterna O
magna. O
CSF O
production O
in O
wildtype O
mice O
was O
(in O
microl/min) O
0.37 O
+/- O
0.04 O
microl/min O
(control), O
0.16 O
+/- O

0.03 O
microl/min O
(acetazolamide-treated) B-CHEMICAL
and O
1.14 O
+/- O
0.15 O
microl/min O
(forskolin-treated), B-CHEMICAL
and O
reduced O
by O
up O
to O
25% O
in O
AQP1 B-GENE-Y
null O
mice. O
The O
impaired O
CSF O
production O
in O
AQP1 B-GENE-Y
null O
mice O
provides O
direct O
functional O
evidence O
for O
the O
involvement O
of O
AQP1 B-GENE-Y
in O
CSF O
formation. O
Metformin, B-CHEMICAL
but O
not O
leptin, O
regulates O
AMP-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
in O
pancreatic O
islets: O
impact O
on O
glucose-stimulated B-CHEMICAL
insulin B-GENE-N
secretion. O
Metformin, B-CHEMICAL
a O
drug O
widely O
used O
in O

the O
treatment O
of O
type O
2 O
diabetes, O
has O
recently O
been O
shown O
to O
act O
on O
skeletal O
muscle O
and O
liver O
in O
part O
through O
the O
activation O
of O
AMP-activated B-CHEMICAL
protein I-GENE-N
kinase I-GENE-N
(AMPK). B-GENE-N
Whether O
metformin B-CHEMICAL
or O
the O
satiety O
factor O
leptin, O
which O
also O
stimulates O
AMPK B-GENE-N
in O
muscle, O
regulates O
this O
enzyme O
in O
pancreatic O
islets O
is O
unknown. O
We O
have O
recently O
shown O
that O
forced O
increases O
in O
AMPK B-GENE-N
activity O
inhibit O
insulin B-GENE-N
secretion O
from O
MIN6 O
cells O
(da O
Silva O
Xavier O
G, O
Leclerc O
I, O
Varadi O
A, O
Tsuboi O
T, O
Moule O
SK, O
and O
Rutter O
GA. O

Biochem O
J O
371: O
761-774, O
2003). O
Here, O
we O
explore O
whether O
1) O
glucose, B-CHEMICAL
metformin, B-CHEMICAL
or O
leptin O
regulates O
AMPK B-GENE-N
activity O
in O
isolated O
islets O
from O
rodent O
and O
human O
and O
2) O
whether O
changes O
in O
AMPK B-GENE-N
activity O
modulate O
insulin B-GENE-Y
secretion O
from O
human O
islets. O
Increases O
in O
glucose B-CHEMICAL
concentration O
from O
0 O
to O
3 O
and O
from O
3 O
to O
17 O
mM O
inhibited O
AMPK B-GENE-N
activity O
in O
primary O
islets O
from O
mouse, O
rat, O
and O
human, O
confirming O
previous O
findings O
in O
insulinoma O
cells. O
Incubation O
with O
metformin B-CHEMICAL

(0.2-1 O
mM) O
activated O
AMPK B-GENE-N
in O
both O
human O
islets O
and O
MIN6 O
beta-cells O
in O
parallel O
with O
an O
inhibition O
of O
insulin B-GENE-N
secretion, O
whereas O
leptin O
(10-100 O
nM) O
was O
without O
effect O
in O
MIN6 O
cells. O
These O
studies O
demonstrate O
that O
AMPK B-GENE-N
activity O
is O
subject O
to O
regulation O
by O
both O
glucose B-CHEMICAL
and O
metformin B-CHEMICAL
in O
pancreatic O
islets O
and O
clonal O
beta-cells. O
The O
inhibitory O
effects O
of O
metformin B-CHEMICAL
on O
insulin B-GENE-N
secretion O
may O
therefore O
need O
to O
be O
considered O
with O
respect O
to O
the O
use O
of O
this O
drug O
for O
the O
treatment O
of O
type O
2 O
diabetes. O
A O
novel O

retinoic B-GENE-N
acid-responsive I-GENE-N
element I-GENE-N
regulates O
retinoic B-CHEMICAL
acid-induced I-CHEMICAL
BLR1 B-GENE-N
expression. O
The O
mechanism O
of O
action O
of O
retinoic B-CHEMICAL
acid I-CHEMICAL
(RA) B-CHEMICAL
is O
of O
broad O
relevance O
to O
cell O
and O
developmental O
biology, O
nutrition, O
and O
cancer O
chemotherapy. O
RA B-CHEMICAL
is O
known O
to O
induce O
expression O
of O
the O
Burkitt's B-GENE-Y
lymphoma I-GENE-Y
receptor I-GENE-Y
1 I-GENE-Y
(BLR1) B-GENE-Y
gene O
which O
propels O
RA-induced B-CHEMICAL
cell O
cycle O
arrest O
and O
differentiation O
of O
HL-60 O
human O
myeloblastic O
leukemia O
cells, O
motivating O
the O
present O
analysis O
of O
transcriptional O
regulation O
of O
blr1 B-GENE-Y
expression O
by O
RA. B-CHEMICAL
The O

RA-treated B-CHEMICAL
HL-60 O
cells O
used O
here O
expressed O
all O
RA B-GENE-N
receptor I-GENE-N
(RAR) B-GENE-N
and O
retinoid B-GENE-N
X I-GENE-N
receptor I-GENE-N
(RXR) B-GENE-N
subtypes O
(as O
detected O
by O
Northern O
analysis) O
except O
RXRgamma. B-GENE-Y
Treatment O
with O
RAR- B-GENE-N
and O
RXR-selective B-GENE-N
ligands O
showed O
that O
RARalpha B-GENE-Y
synergized O
with O
RXRalpha B-GENE-Y
to O
transcriptionally O
activate O
blr1 B-GENE-Y
expression. O
A O
5'-flanking O
region O
capable O
of O
supporting O
RA-induced B-CHEMICAL
blr1 B-GENE-Y
activation O
in O
HL-60 O
cells O
was O
found O
to O
contain O
a O
205-bp O
sequence O
in O
the O
distal O
portion O
that O

was O
necessary O
for O
transcriptional O
activation O
by O
RA. B-CHEMICAL
Within O
this O
sequence O
DNase B-GENE-Y
I I-GENE-Y
footprinting O
revealed O
that O
RA B-CHEMICAL
induced O
binding O
of O
a O
nuclear B-GENE-N
protein I-GENE-N
complex I-GENE-N
to O
an O
element O
containing O
two O
GT B-GENE-N
boxes. I-GENE-N
Electromobility O
shift O
assays O
(EMSAs) O
and O
supershift O
assays O
showed O
that O
this O
element O
bound O
recombinant O
RARalpha B-GENE-Y
and O
RXRalpha. B-GENE-Y
Without O
RA B-CHEMICAL
there O
was O
neither O
complex O
binding O
nor O
transcriptional O
activation. O
Both O
GT B-GENE-N
boxes I-GENE-N
were O
needed O
for O
binding O
the O
complex, O
and O
mutation O
of O
either O
GT B-GENE-N
box I-GENE-N
caused O
the O
loss O
of O
transcriptional O
activation O
by O
RA. B-CHEMICAL
The O
ability O
of O
this O
cis-acting O

RAR-RXR B-GENE-N
binding I-GENE-N
element I-GENE-N
to O
activate O
transcription O
in O
response O
to O
RA B-CHEMICAL
also O
depended O
on O
downstream O
sequences O
where O
an O
octamer B-GENE-Y
transcription I-GENE-Y
factor I-GENE-Y
1 I-GENE-Y
(Oct1) B-GENE-Y
site O
and O
a O
nuclear B-GENE-Y
factor I-GENE-Y
of I-GENE-Y
activated I-GENE-Y
T I-GENE-Y
cells I-GENE-Y
(NFATc) B-GENE-Y
site O
between O
this O
element O
and O
the O
transcriptional O
start, O
as O
well O
as O
a O
cyclic B-CHEMICAL
AMP I-CHEMICAL
response I-GENE-N
element I-GENE-N
binding I-GENE-N
factor I-GENE-N
(CREB) B-GENE-N
site O
between O
the O
transcriptional O
start O
and O
first O
exon O
of O
the O
blr1 B-GENE-Y
gene, O
were O
necessary. O
Each O
of O
these O
sites O
bound O
its O
corresponding O
transcription O
factor. O
A O
transcription O
factor-transcription O
factor O
binding O
array O
analysis O
of O
nuclear O
lysate O
from O
RA-treated B-CHEMICAL
cells O
indicated O

several O
prominent O
RARalpha B-GENE-Y
binding O
partners; O
among O
these, O
Oct1, B-GENE-Y
NFATc3, B-GENE-Y
and O
CREB2 B-GENE-Y
were O
identified O
by O
competition O
EMSA O
and O
supershift O
and O
chromatin O
immunoprecipitation O
assays O
as O
components O
of O
the O
complex. O
RA B-CHEMICAL
upregulated O
expression O
of O
these O
three O
factors. O
In O
sum O
the O
results O
of O
the O
present O
study O
indicate O
that O
RA-induced B-CHEMICAL
expression O
of O
blr1 B-GENE-Y
expression O
depends O
on O
a O
novel O
RA B-GENE-N
response I-GENE-N
element. I-GENE-N
This O
cis-acting O
element O
approximately O
1 O
kb O
upstream O
of O
the O
transcriptional O
start O
consists O
of O
two O
GT B-GENE-N
boxes I-GENE-N
that O
bind O
RAR B-GENE-N
and O
RXR B-GENE-N
in O

a O
nuclear B-GENE-N
protein I-GENE-N
complex I-GENE-N
that O
also O
contains O
Oct1, B-GENE-Y
NFATc3, B-GENE-Y
and O
CREB2 B-GENE-Y
bound O
to O
their O
cognate O
downstream O
consensus O
binding O
sites. O
The O
persistent O
membrane O
retention O
of O
desipramine B-CHEMICAL
causes O
lasting O
inhibition O
of O
norepinephrine B-GENE-Y
transporter I-GENE-Y
function. O
The O
present O
study O
examined O
the O
potential O
membrane O
retention O
of O
desipramine B-CHEMICAL
(DMI) B-CHEMICAL
following O
exposures O
of O
293-hNET B-GENE-Y
cells O
to O
DMI, B-CHEMICAL
and O
its O
effect O
on O
[3H]NE B-CHEMICAL
uptake. O
Incubation O
of O
cells O
with O
500 O
nM O
DMI B-CHEMICAL
for O
1 O
h O
or O
1 O
day O
persistently O
inhibited O
the O
uptake O
of O

[3H]NE B-CHEMICAL
up O
to O
7 O
days, O
despite O
daily O
repeated O
washing O
of O
cells O
with O
drug-free O
medium. O
Uptake O
inhibition O
was O
paralleled O
by O
persistent O
retention O
of O
DMI B-CHEMICAL
associated O
with O
cells, O
as O
determined O
by O
HPLC O
and O
by O
radiotracer O
experiments O
using O
[3H]DMI. B-CHEMICAL
[3H]DMI B-CHEMICAL
trapped O
in O
membranes O
was O
displaceable O
by O
the O
structurally O
unrelated O
NET B-GENE-Y
inhibitor, O
nisoxetine, B-CHEMICAL
in O
a O
concentration-dependent O
manner, O
implying O
interaction O
of O
retained O
[3H]DMI B-CHEMICAL
with O
the O
NET. B-GENE-Y
A O
similar O
cellular O
retention O
was O
observed O
following O
incubation O
of O
cells O
with O

nisoxetine. B-CHEMICAL
The O
results O
demonstrate O
that O
DMI B-CHEMICAL
and O
nisoxetine B-CHEMICAL
are O
persistently O
retained O
in O
cell O
membranes, O
at O
least O
partly O
in O
association O
with O
the O
NET. B-GENE-Y
The O
retention O
and O
slow O
diffusion O
of O
DMI B-CHEMICAL
and O
nisoxetine B-CHEMICAL
from O
membranes O
may O
contribute O
to O
their O
pharmacological O
and O
modulatory O
action O
on O
NET. B-GENE-Y
AT1-receptor B-GENE-Y
antagonism O
in O
hypertension: O
what O
has O
been O
learned O
with O
irbesartan? B-CHEMICAL
Irbesartan B-CHEMICAL
is O
a O
long-acting O
angiotensin B-CHEMICAL
II I-CHEMICAL
antagonist O
acting O
specifically O
at O
the O
level O
of O
the O
Type O
1-receptor O
subtype O

(AT1-receptor). B-GENE-Y
This O
compound O
lowers O
blood O
pressure O
dose-dependently O
in O
hypertensive O
patients O
and O
has O
a O
placebo-like O
tolerability. O
The O
antihypertensive O
efficacy O
of O
irbesartan B-CHEMICAL
is O
greatly O
enhanced O
by O
the O
coadministration O
of O
a O
diuretic, O
and O
fixed-dose O
combinations O
of O
irbesartan B-CHEMICAL
and O
hydrochlorothiazide B-CHEMICAL
are O
now O
available. O
Irbesartan-based B-CHEMICAL
treatment O
appears O
especially O
effective O
for O
high-risk O
patients, O
such O
as O
those O
with O
diabetes, O
renal O
disease O
and O
cardiac O
hypertrophy. O
In O
patients O
with O
Type O
2 O
diabetes, O

irbesartan B-CHEMICAL
delays O
the O
development O
of O
nephropathy O
as O
well O
as O
the O
progression O
of O
renal O
failure. O
Irbesartan B-CHEMICAL
may O
have O
antiatherosclerotic O
properties O
beyond O
those O
expected O
from O
blood O
pressure O
lowering O
per O
se: O
this O
AT1-blocker B-GENE-Y
decreases O
the O
vascular O
oxidative O
stress O
and O
prevents O
the O
procoagulant O
as O
well O
as O
the O
pro-inflammatory O
effects O
of O
angiotensin B-CHEMICAL
II. I-CHEMICAL
Irbesartan O
given O
alone O
or O
in O
combination O
with O
a O
diuretic O
therefore O
represents O
a O
rational O
approach O
to O
treat O
hypertensive O
patients. O
Binding O
of O

(-)-[3H]-CGP12177 B-CHEMICAL
at O
two O
sites O
in O
recombinant O
human B-GENE-Y
beta I-GENE-Y
1-adrenoceptors I-GENE-Y
and O
interaction O
with O
beta-blockers. O
To O
verify O
the O
hypothesis O
that O
the O
non-conventional O
partial O
agonist O
(-)-CGP12177 B-CHEMICAL
binds O
at O
two O
beta(1)-adrenoceptor B-GENE-Y
sites, O
human B-GENE-Y
beta(1)-adrenoceptors, I-GENE-Y
expressed O
in O
CHO O
cells, O
were O
labelled O
with O
(-)-[(3)H]-CGP12177. B-CHEMICAL
We O
compared O
the O
binding O
affinity O
and O
antagonist O
potency O
of O
12 O
clinically O

used O
beta-blockers O
against O
the O
cyclic B-CHEMICAL
AMP-enhancing I-CHEMICAL
effects O
of O
(-)-isoprenaline B-CHEMICAL
and O
(-)-CGP12177.(-)-[(3)H]-CGP12177 B-CHEMICAL
bound O
to O
a O
high O
affinity O
site O
(H; O
K(H)=0.47 O
nM) O
and O
low O
affinity O
site O
(L); O
K(L)=235 O
nM). O
(-)-[(3)H]-CGP12177 B-CHEMICAL
dissociated O
from O
the O
beta(1)-adrenoceptors B-GENE-Y
with O
a O
fast O
component O

(k(off)=0.45 O
min(-1)), O
consistent O
with O
the O
L-site, O
and O
a O
slow O
component O
(k(off)=0.017-0.033 O
min(-1)), O
consistent O
with O
the O
H-site. O
(-)-Isoprenaline B-CHEMICAL
and O
(-)-CGP12177 B-CHEMICAL
caused O
96-fold O
and O
12-fold O
maximal O
increases O
in O
cyclic B-CHEMICAL
AMP I-CHEMICAL
levels O
with O
-logEC(50)M O
of O
8.2 O
and O
7.6. O
(-)-CGP12177 B-CHEMICAL
antagonised O
the O
effects O
of O

(-)-isoprenaline B-CHEMICAL
with O
a O
pK(B) O
of O
9.9. O
The O
beta-blockers O
antagonised O
the O
effects O
of O
(-)-isoprenaline B-CHEMICAL
more O
than O
the O
effects O
of O
(-)-CGP12177 B-CHEMICAL
with O
potency O
ratios: O
(-)-atenolol B-CHEMICAL
1,000, O
(+/-)-metropolol B-CHEMICAL
676, O
(-)-pindolol B-CHEMICAL
631, O
(-)-timolol B-CHEMICAL
589, O
(+/-)-carvedilol B-CHEMICAL
204, O

(+/-)-oxprenolol B-CHEMICAL
138, O
(+/-)-sotalol B-CHEMICAL
132, O
(-)-propranolol B-CHEMICAL
120, O
(+/-)-bisoprolol B-CHEMICAL
95, O
(+/-)-alprenolol B-CHEMICAL
81, O
(+/-)-nadolol B-CHEMICAL
68 O
and O
(-)-bupranolol B-CHEMICAL
56. O
In O
intact O
cells O
the O
binding O
constants O
of O
beta-blockers, O
estimated O
from O
competition O
with O
3-5 O
nM O
(-)-[(3)H]-CGP12177 B-CHEMICAL
(binding O
to O
the O

H-site), O
correlated O
with O
the O
corresponding O
affinities O
estimated O
from O
antagonism O
of O
the O
(-)-isoprenaline B-CHEMICAL
effects. O
We O
conclude O
that O
(-)-[(3)H]-CGP12177 B-CHEMICAL
binds O
at O
two O
sites O
in O
the O
recombinant O
beta(1)-adrenoceptor. B-GENE-Y
(-)-CGP12177 B-CHEMICAL
is O
an O
antagonist O
of O
catecholamine B-CHEMICAL
effects O
through O
the O
H-site O
and O
a O
non-conventional O
partial O
agonist O
through O
the O
L-site. O
beta-blockers O
are O
more O
potent O
antagonists O
through O
the O
H-site O
than O
the O
L-site. O

Imiquimod, B-CHEMICAL
a O
Toll-like B-GENE-Y
receptor-7 I-GENE-Y
agonist, O
induces O
perforin B-GENE-Y
in O
cytotoxic O
T O
lymphocytes O
in O
vitro. O
Imiquimod B-CHEMICAL
(IMQ), B-CHEMICAL
an O
activator O
of O
Toll-like B-GENE-Y
receptor-7 I-GENE-Y
(TLR-7), B-GENE-Y
induces O
by O
several O
routes O
a O
profound O
anti-viral O
and O
anti-tumor O
effect O
in O
vivo. O
Physiologically, O
the O
immune O
system O
is O
using O
perforin-containing B-GENE-Y
granules O
of O
cytotoxic O
T O
lymphocytes O
(CTL) O
towards O
the O
same O
biological O
purpose. O
This O

functional O
synergism O
prompted O
our O
current O
experiments O
addressing O
the O
question O
whether O
IMQ B-CHEMICAL
may O
influence O
perforin-release B-GENE-Y
and/or O
induce O
perforin B-GENE-Y
in O
CTLs O
in O
vitro. O
In O
peripheral O
lymphocytes O
of O
healthy O
and O
diseased O
subjects, O
IMQ B-CHEMICAL
induced O
a O
significant O
increase O
of O
perforin(+) B-GENE-Y
CTLs O
within O
12h O
in O
all O
experiments O
performed. O
This O
effect O
was O
most O
pronounced O
in O
CTLs O
of O
patients O
suffering O
from O
atopic O
dermatitis, O
a O
model O
disorder O
for O
subnormal O
perforin B-GENE-Y
expression: O
as O
compared O
to O
perforin(+) B-GENE-Y
CTLs O
detected O
at O
time O
point O
zero O

(100%), O
up O
to O
270% O
of O
perforin(+) B-GENE-Y
CTLs O
were O
induced O
by O
2.5 O
microg/ml O
[corrected] O
IMQ. B-CHEMICAL
Perforin B-GENE-Y
release O
from O
peripheral O
blood O
CTLs O
after O
PMA/ionomycin-stimulation O
was O
not O
influenced O
significantly O
by O
IMQ. B-CHEMICAL
Thus, O
the O
biological O
activity O
of O
IMQ B-CHEMICAL
appears O
to O
exceed O
its O
previously O
known O
functions, O
inasmuch O
as O
it O
boosts O
up O
significantly O
the O
perforin-granule B-GENE-Y
system. O
Caffeine B-CHEMICAL
as O
a O
psychomotor O
stimulant: O
mechanism O
of O
action. O
The O
popularity O
of O

caffeine B-CHEMICAL
as O
a O
psychoactive O
drug O
is O
due O
to O
its O
stimulant O
properties, O
which O
depend O
on O
its O
ability O
to O
reduce O
adenosine B-CHEMICAL
transmission O
in O
the O
brain. O
Adenosine B-CHEMICAL
A(1) I-GENE-N
and I-GENE-N
A(2A) I-GENE-N
receptors I-GENE-N
are O
expressed O
in O
the O
basal O
ganglia, O
a O
group O
of O
structures O
involved O
in O
various O
aspects O
of O
motor O
control. O
Caffeine B-CHEMICAL
acts O
as O
an O
antagonist O
to O
both O
types O
of O
receptors. O
Increasing O
evidence O
indicates O
that O
the O
psychomotor O
stimulant O
effect O
of O
caffeine B-CHEMICAL
is O
generated O
by O
affecting O
a O
particular O
group O
of O
projection O
neurons O
located O
in O
the O
striatum, O
the O
main O
receiving O
area O

of O
the O
basal O
ganglia. O
These O
cells O
express O
high O
levels O
of O
adenosine B-CHEMICAL
A(2A) I-GENE-Y
receptors, I-GENE-Y
which O
are O
involved O
in O
various O
intracellular O
processes, O
including O
the O
expression O
of O
immediate O
early O
genes O
and O
regulation O
of O
the O
dopamine- B-CHEMICAL
and I-GENE-Y
cyclic B-CHEMICAL
AMP-regulated I-CHEMICAL
32-kDa I-GENE-Y
phosphoprotein I-GENE-Y
DARPP-32. B-GENE-Y
The O
present O
review O
focuses O
on O
the O
effects O
of O
caffeine B-CHEMICAL
on O
striatal O
signal O
transduction O
and O
on O
their O
involvement O
in O
caffeine-mediated B-CHEMICAL
motor O
stimulation. O
Mesenteric O
artery O
remodeling O
and O
effects O
of O
imidapril B-CHEMICAL
and O
irbesartan B-CHEMICAL
on O

it O
in O
spontaneously O
hypertensive O
rats. O
AIM: O
To O
investigate O
the O
remodeling O
of O
mesenteric O
artery O
and O
the O
expression O
of O
TGF-beta1, B-GENE-Y
c-Jun B-GENE-Y
in O
mesenteric O
artery O
and O
effects O
of O
imidapril B-CHEMICAL
and O
irbesartan B-CHEMICAL
on O
the O
remodeling O
in O
spontaneously O
hypertensive O
rats O
(SHR). O
METHODS: O
Thirty O
SHR O
(male/female, O
21/9), O
aged O
13 O
wk, O
were O
randomly O
divided O
into O
3 O
groups O
(7 O
male O
rats O
and O
3 O
female O
rats O
each O
group): O
SHR O
group, O
imidapril B-CHEMICAL
group O

(imidapril B-CHEMICAL
3 O
mg/kg.d O
was O
given O
in O
drinking O
water O
for O
14 O
wk), O
and O
irbesartan B-CHEMICAL
group O
(irbesartan B-CHEMICAL
50 O
mg/kg.d O
was O
given O
in O
drinking O
water O
foe O
14 O
wk). O
Ten O
homogeneous O
Wistar O
Kyoto O
rats, O
5 O
males O
and O
5 O
females, O
weighing O
206+/-49 O
g, O
were O
selected O
as O
normal O
control O
group O
(WKY O
group). O
Systolic O
pressure O
was O
measured O
on O
d O
1, O
2, O
4, O
6, O
8, O
10, O
12 O
and O
14 O
during O
the O
experiment O
and O
the O
rats O
were O
killed O
at O
the O
end O
of O
the O

experiment. O
Angiotensin B-GENE-Y
II I-GENE-Y
(Ang B-GENE-Y
II) I-GENE-Y
level O
in O
plasma O
and O
mesenteric O
arteries O
was O
measured O
by O
radioimmunoassay. O
The O
morphology O
of O
the O
secondary O
branches O
of O
mesenteric O
artery O
were O
examined O
by O
light O
microscopy O
and O
electron O
microscopy. O
Reverse O
transcription O
polymerase O
chain O
reaction O
(RT-PCR) O
was O
used O
to O
detect O
the O
expression O
of O
transforming B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
TGF-beta1 B-GENE-Y
and O
c-Jun B-GENE-Y
mRNA. O
RESULTS: O
Compared O
with O
imidapril B-CHEMICAL
group O
and O
irbesartan B-CHEMICAL
group, O
the O
blood O
pressure O
was O
remarkably O
increased O
in O
SHR O
group. O
Ang B-CHEMICAL
II I-CHEMICAL
level O

in O
plasma O
and O
mesenteric O
arteries O
in O
SHR O
group O
was O
the O
same O
or O
lower O
than O
that O
in O
WKY O
group, O
and O
was O
higher O
in O
irbesartan B-CHEMICAL
group O
and O
lower O
in O
imidapril B-CHEMICAL
group. O
The O
remodeling O
of O
mesenteric O
arteries O
in O
SHR O
group O
was O
mostly O
obvious O
among O
the O
4 O
groups. O
The O
ratio O
of O
TGF-beta1 B-GENE-Y
absorbed O
light O
value O
to O
GAPDH B-GENE-Y
absorbed O
light O
value O
in O
the O
SHR O
group O
was O
0.887+/-0.019, O
which O
was O
significantly O
higher O
than O
that O
in O
WKY O
group, O
imidapril B-CHEMICAL
group, O
and O

irbesartan B-CHEMICAL
group O
with O
the O
ratios O
of O
0.780+/-0.018, O
0.803+/-0.005, O
and O
0.847+/-0.017, O
respectively O
(P<0.01). O
Ang B-GENE-Y
II I-GENE-Y
level O
in O
plasma O
and O
mesenteric O
arteries O
in O
imidapril B-CHEMICAL
group O
was O
significantly O
lower O
than O
that O
in O
irbesartan B-CHEMICAL
group O
(P<0.05). O
The O
c-Jun B-GENE-Y
absorbed O
light O
value/GAPDH B-GENE-Y
absorbed O
light O
value O
of O
mesenteric O
arteries O
in O
the O
SHR O
group O
was O

0.850+/-0.015, O
which O
was O
significantly O
higher O
than O
that O
in O
the O
WKY, O
imidapril, B-CHEMICAL
and O
irbesartan B-CHEMICAL
groups O
(0.582+/-0.013, O
0.743+/-0.012, O
and O
0.789+/-0.013, O
respectively, O
P<0.01), O
and O
was O
significantly O
lower O
in O
imidapril B-CHEMICAL
group O
than O
in O
irbesartan B-CHEMICAL
group O
(P<0.05). O
CONCLUSION: O
Imidapril B-CHEMICAL
and O
irbesartan B-CHEMICAL
can O

not O
only O
control O
blood O
pressure O
but O
also O
inhibit O
mesenteric O
arteries O
remodeling O
and O
mRNA O
expression O
of O
TGF-beta1, B-GENE-Y
c-Jun B-GENE-Y
in O
SHR. O
Imidapril B-CHEMICAL
is O
more O
effective O
than O
irbesartan. B-CHEMICAL
Clinical O
assessment O
of O
norepinephrine B-GENE-Y
transporter I-GENE-Y
blockade O
through O
biochemical O
and O
pharmacological O
profiles. O
BACKGROUND: O
To O
assess O
the O
sensitivity O
of O
biochemical, O
physiological, O
and O
pharmacological O
markers O
of O
peripheral O
norepinephrine B-CHEMICAL
(NE) I-GENE-Y
transporter I-GENE-Y
(NET) B-GENE-Y
function, O
we O
chronically O
antagonized O
NET B-GENE-Y
by O
a O
range O

of O
doses O
of O
duloxetine B-CHEMICAL
[(+)-N-methyl-3-(1-naphthalenyloxy)-2 B-CHEMICAL
thiophenepropanamine], I-CHEMICAL
which O
blocks O
the O
NE B-CHEMICAL
reuptake O
process. O
METHODS O
AND O
RESULTS: O
Duloxetine B-CHEMICAL
was O
administered O
in O
a O
randomized, O
placebo-controlled O
study O
in O
15 O
healthy O
volunteers. O
Plasma O
from O
duloxetine-treated B-CHEMICAL
subjects O
(ex O
vivo O
effect) O
dose-dependently O
decreased O
radioligand O
binding O
to O
human B-GENE-Y
NET I-GENE-Y
(maximum O
inhibition O
was O
60%) O

(P=0.02). O
The O
dose O
of O
intravenous O
tyramine O
required O
to O
raise O
systolic O
blood O
pressure O
by O
30 O
mm O
Hg O
(PD30) O
increased O
dose-dependently O
with O
duloxetine O
and O
was O
significant O
at O
the O
end O
of O
the O
120-mg/d O
dosage O
(P<0.001). O
The O
plasma O
dihydoxyphenylglycol B-CHEMICAL
to O
NE B-CHEMICAL
(DHPG/NE) B-CHEMICAL
ratio O
was O
reduced O
significantly O
at O
2 O
weeks O
of O
treatment O
with O
80 O
mg/d O
duloxetine B-CHEMICAL
(11.3 O
at O
baseline, O
3.4 O
at O
240 O
mg/d, O

P<0.001). O
Plasma O
NE B-CHEMICAL
was O
significantly O
increased O
starting O
at O
120 O
mg/d O
duloxetine. B-CHEMICAL
Urine O
results O
(corrected O
for O
24-hour O
creatinine B-CHEMICAL
excretion) O
showed O
a O
dose-dependent O
change O
from O
the O
baseline O
urinary O
excretion O
for O
NE, B-CHEMICAL
DHPG, B-CHEMICAL
and O
the O
DHPG/NE B-CHEMICAL
ratio. O
The O
most O
sensitive O
measure, O
the O
DHPG/NE B-CHEMICAL
ratio, O
was O
significant O
at O
the O
80-mg O
dose. O
Urinary O
NE B-CHEMICAL
excretion O
was O
significantly O
raised O
after O
2 O
weeks O
of O
treatment O
with O
80 O
mg/d O
duloxetine B-CHEMICAL

(P<0.001), O
the O
lowest O
dose O
used O
in O
the O
study. O
CONCLUSIONS: O
These O
findings O
suggest O
that O
the O
degree O
of O
NET B-GENE-Y
blockade O
can O
be O
assessed O
with O
the O
plasma O
or O
urine O
DHPG/NE B-CHEMICAL
ratio O
and O
the O
pressor O
effect O
of O
tyramine. O
Also, O
the O
DHPG/NE B-CHEMICAL
ratio O
is O
more O
sensitive O
at O
the O
lower O
end O
of O
NET B-GENE-Y
inhibition, O
whereas O
tyramine O
exhibits O
a O
linear O
relation, O
with O
NET B-GENE-Y
inhibition O
commencing O
at O
a O
higher O
dose. O
Auranofin B-CHEMICAL
increases O
apoptosis O
and O
ischaemia-reperfusion O
injury O
in O
the O
rat O
isolated O
heart. O

Auranofin, B-CHEMICAL
an O
antirheumatic O
gold O
compound, O
is O
an O
inhibitor O
of O
selenocysteine B-CHEMICAL
enzymes, I-GENE-N
such O
as O
thioredoxin B-GENE-Y
reductase I-GENE-Y
and O
glutathione B-CHEMICAL
peroxidase. I-GENE-N
These O
enzymes O
play O
an O
important O
role O
in O
protecting O
cardiac O
tissue O
from O
oxidative O
stress O
generated O
during O
ischaemia-reperfusion. O
Auranofin B-CHEMICAL
(100 O
mg/kg) O
was O
administered O
to O
rats O
and O
their O
hearts O
were O
subjected O
to O
an O
in O
vitro O
model O
of O
ischaemia-reperfusion. O
The O
activity O
of O
thioredoxin B-GENE-Y
reductase I-GENE-Y
and O
glutathione B-CHEMICAL
peroxidase I-GENE-N
was O
determined O

in O
liver O
and O
heart O
tissues O
in O
an O
attempt O
to O
correlate O
enzymatic O
activity O
with O
heart O
recovery O
after O
ischaemia-reperfusion. O
There O
was O
significantly O
less O
thioredoxin B-GENE-Y
reductase I-GENE-Y
activity O
in O
rat O
liver O
extracts, O
whereas O
the O
level O
of O
glutathione B-CHEMICAL
activity O
remained O
unchanged, O
demonstrating O
that O
the O
dose O
of O
auranofin B-CHEMICAL
used O
was O
able O
to O
selectively O
inhibit O
one O
of O
these O
enzyme O
systems. O
Rats O
administered O
auranofin B-CHEMICAL
displayed O
significantly O
impaired O
recovery O
from O
ischaemic O
insult. O
The O
end O
diastolic O
pressure O
was O
increased, O
whereas O
the O
rate O
pressure O
product O
was O
significantly O
decreased. O
The O
level O
of O
postischaemic O
apoptosis O

was O
also O
assessed O
by O
examining O
caspase-3 B-GENE-Y
activity O
in O
tissue O
homogenates. O
Auranofin B-CHEMICAL
significantly O
increased O
the O
degree O
of O
postischaemic O
apoptosis, O
leading O
to O
poor O
postischaemic O
recovery. O
Gallium B-CHEMICAL
and O
other O
main O
group O
metal O
compounds O
as O
antitumor O
agents. O
Gallium B-CHEMICAL
has O
been O
the O
second O
metal O
to O
show O
activity O
against O
malignant O
tumors O
in O
humans O
soon O
after O
the O
establishment O
of O
platinum B-CHEMICAL
drugs O
in O
routine O
clinical O
practice. O
It O
has O
the O
unique O
property O
of O
inhibiting O
tumor O
growth O
as O
a O
simple O
cation, O
mainly O
because O
of O
its O
close O
resemblance O
to O
ferric B-CHEMICAL
iron. I-CHEMICAL
Even O
though O
its O
inability O
to O
shift O
between O
the O

trivalent O
and O
a O
divalent O
oxidation O
state O
precludes O
that O
gallium B-CHEMICAL
behaves O
as O
an O
iron B-CHEMICAL
analogue O
in O
every O
respect, O
it O
strongly O
interferes O
with O
cellular O
acquisition O
of O
iron O
from O
blood O
by O
competitive O
interaction O
with O
transferrin B-GENE-Y
and O
transferrin B-GENE-N
receptor-mediated I-GENE-N
endocytosis. O
Furthermore, O
gallium B-CHEMICAL
also O
seems O
to O
affect O
intracellular O
availability O
of O
iron B-CHEMICAL
already O
taken O
up O
via O
this O
pathway, O
probably O
due O
to O
its O
inhibitory O
activity O
on O
vacuolar-type B-GENE-N
H(+)-ATPases. I-GENE-N
Apart O
from O
the O
consequences O
of O
iron B-CHEMICAL
deprivation, O
gallium B-CHEMICAL
exerts O
cytotoxic O
effects O
by O
direct O
interaction O
with O
the O

iron-dependent B-CHEMICAL
enzyme O
ribonucleotide B-GENE-N
reductase, I-GENE-N
resulting O
in O
reduced O
dNTP O
pools O
and O
inhibition O
of O
DNA O
synthesis. O
Both O
the O
abundance O
of O
transferrin B-GENE-N
receptors I-GENE-N
and O
upregulation O
of O
ribonucleotide B-GENE-N
reductase I-GENE-N
render O
tumors O
susceptible O
to O
gallium-induced B-CHEMICAL
cytotoxicity. O
However, O
some O
experimental O
findings O
raise O
the O
question O
whether O
these O
effects O
resulting O
from O
the O
iron-mimicking B-CHEMICAL
properties O
of O
gallium B-CHEMICAL
are O
solely O
responsible O
for O
its O
antineoplastic O
activity O
or O
whether O
additional O
mechanisms O
are O
involved, O
such O
as O
antimitotic O
effects O
which O
result O
from O
its O
capability O
of O
inhibiting O
tubulin B-GENE-N
polymerization. O
The O
limitations O
experienced O
with O

gallium B-CHEMICAL
nitrate I-CHEMICAL
and O
gallium B-CHEMICAL
chloride, I-CHEMICAL
which O
call O
for O
a O
prolonged O
exposure O
to O
low O
steady-state O
gallium B-CHEMICAL
levels O
in O
blood O
in O
order O
to O
adequately O
exploit O
the O
affinity O
of O
gallium B-CHEMICAL
to O
tumor O
tissues O
and O
to O
avoid O
severe O
toxic O
effects, O
may O
be O
overcome O
by O
oral O
gallium B-CHEMICAL
complexes O
such O
as O
tris(3-hydroxy-2-methyl-4H-pyran-4-onato)gallium(III) B-CHEMICAL
(gallium B-CHEMICAL
maltolate) I-CHEMICAL
or O
tris(8-quinolinolato)gallium(III) B-CHEMICAL
(KP46), B-CHEMICAL
which O
are O
currently O
being O
evaluated O
in O
clinical O
trials O
and O
show O

promise O
to O
initiate O
a O
revival O
of O
gallium B-CHEMICAL
in O
the O
clinical O
setting. O
These O
two O
investigational O
drugs, O
albeit O
differing O
in O
their O
complex O
stability, O
have O
both O
been O
developed O
with O
the O
intention O
of O
providing O
gallium B-CHEMICAL
in O
a O
form O
which O
allows O
sufficient O
intestinal O
absorption, O
but O
without O
altering O
its O
pharmacodynamic O
effects. O
Gallium B-CHEMICAL
complexes O
based O
on O
other O
rationales O
are O
scarce O
and, O
with O
regard O
to O
the O
well-known O
antineoplastic O
potential O
of O
this O
metal, O
noticeably O
under-explored. O
With O
the O
recent O
approval O
of O
arsenic O
trioxide B-CHEMICAL
for O
the O
second-line O
treatment O
of O
acute O
promyelocytic O
leukemia, O
the O
clinical O
revival O
of O

arsenic B-CHEMICAL
compounds, O
which O
have O
been O
the O
mainstay O
of O
antileukemic O
therapy O
before O
the O
age O
of O
modern O
cancer O
chemotherapy, O
has O
already O
begun. O
Currently, O
strong O
efforts O
are O
being O
made O
to O
explore O
the O
activity O
spectrum O
in O
other O
(less O
rare) O
malignancies O
and O
to O
gain O
a O
deeper O
insight O
into O
the O
mode O
of O
action. O
Although O
this O
development O
is O
currently O
focusing O
on O
arsenic B-CHEMICAL
trioxide, I-CHEMICAL
it O
should O
be O
suited O
to O
stimulate O
investigations O
into O
the O
therapeutic O
potential O
of O
other O
arsenic B-CHEMICAL
compounds O
as O
well. O
The O
synaptic B-GENE-Y
vesicle I-GENE-Y
protein I-GENE-Y
SV2A I-GENE-Y
is O
the O
binding O
site O
for O
the O
antiepileptic O
drug O

levetiracetam. B-CHEMICAL
Here, O
we O
show O
that O
the O
synaptic B-GENE-Y
vesicle I-GENE-Y
protein I-GENE-Y
SV2A I-GENE-Y
is O
the O
brain O
binding O
site O
of O
levetiracetam B-CHEMICAL
(LEV), B-CHEMICAL
a O
new O
antiepileptic O
drug O
with O
a O
unique O
activity O
profile O
in O
animal O
models O
of O
seizure O
and O
epilepsy. O
The O
LEV-binding B-CHEMICAL
site O
is O
enriched O
in O
synaptic O
vesicles, O
and O
photoaffinity O
labeling O
of O
purified O
synaptic O
vesicles O
confirms O
that O
it O
has O
an O
apparent O
molecular O
mass O
of O
approximately O
90 O
kDa. O
Brain O
membranes O
and O
purified O
synaptic O
vesicles O
from O
mice O
lacking O

SV2A B-GENE-Y
do O
not O
bind O
a O
tritiated O
LEV B-CHEMICAL
derivative, O
indicating O
that O
SV2A B-GENE-Y
is O
necessary O
for O
LEV B-CHEMICAL
binding. O
LEV B-CHEMICAL
and O
related O
compounds O
bind O
to O
SV2A B-GENE-Y
expressed O
in O
fibroblasts, O
indicating O
that O
SV2A B-GENE-Y
is O
sufficient O
for O
LEV B-CHEMICAL
binding. O
No O
binding O
was O
observed O
to O
the O
related O
isoforms O
SV2B B-GENE-Y
and O
SV2C. B-GENE-Y
Furthermore, O
there O
is O
a O
high O
degree O
of O
correlation O
between O
binding O
affinities O
of O
a O
series O
of O
LEV B-CHEMICAL
derivatives O
to O
SV2A B-GENE-Y
in O
fibroblasts O
and O
to O
the O
LEV-binding B-CHEMICAL
site O
in O
brain. O
Finally, O
there O
is O
a O
strong O

correlation O
between O
the O
affinity O
of O
a O
compound O
for O
SV2A B-GENE-Y
and O
its O
ability O
to O
protect O
against O
seizures O
in O
an O
audiogenic O
mouse O
animal O
model O
of O
epilepsy. O
These O
experimental O
results O
suggest O
that O
SV2A B-GENE-Y
is O
the O
binding O
site O
of O
LEV B-CHEMICAL
in O
the O
brain O
and O
that O
LEV B-CHEMICAL
acts O
by O
modulating O
the O
function O
of O
SV2A, B-GENE-Y
supporting O
previous O
indications O
that O
LEV B-CHEMICAL
possesses O
a O
mechanism O
of O
action O
distinct O
from O
that O
of O
other O
antiepileptic O
drugs. O
Further, O
these O
results O
indicate O
that O
proteins O
involved O
in O
vesicle O
exocytosis, O
and O
SV2 B-GENE-N
in O
particular, O
are O
promising O
targets O
for O
the O
development O
of O
new O
CNS O
drug O

therapies. O
Electrophysiological O
properties O
of O
mouse O
horizontal O
cell O
GABAA B-GENE-N
receptors. I-GENE-N
GABA-induced B-CHEMICAL
currents O
have O
been O
characterized O
in O
isolated O
horizontal O
cells O
from O
lower O
vertebrates O
but O
not O
in O
mammalian O
horizontal O
cells. O
Therefore O
horizontal O
cells O
were O
isolated O
after O
enzymatical O
and O
mechanical O
dissociation O
of O
the O
adult O
mouse O
retina O
and O
visually O
identified. O
We O
recorded O
from O
horizontal O
cell O
bodies O
using O
the O
whole O
cell O
and O
outside-out O
configuration O
of O
the O
patch-clamp O
technique. O
Extracellular O
application O
of O
GABA B-CHEMICAL
induced O
inward O
currents O
carried O
by O
chloride B-CHEMICAL
ions. O
GABA-evoked B-CHEMICAL
currents O
were O
completely O
and O
reversibly O
blocked O
by O
the O
competitive O

GABAA B-GENE-N
receptor I-GENE-N
antagonist O
bicuculline B-CHEMICAL
(IC50 O
= O
1.7 O
microM), O
indicating O
expression O
of O
GABAA B-GENE-N
but O
not O
GABAC B-GENE-N
receptors. I-GENE-N
Their O
affinity O
for O
GABA B-CHEMICAL
was O
moderate O
(EC50 O
= O
30 O
microM), O
and O
the O
Hill O
coefficient O
was O
1.3, O
corresponding O
to O
two O
GABA B-GENE-N
binding I-GENE-N
sites. I-GENE-N
GABA B-CHEMICAL
responses O
were O
partially O
reduced O
by O
picrotoxin B-CHEMICAL
with O
differential O
effects O
on O
peak O
and O
steady-state O
current O
values. O
Zinc B-CHEMICAL
blocked O
the O
GABA B-CHEMICAL
response O
with O
an O
IC50 O
value O
of O
7.3 O
microM O
in O
a O
noncompetitive O
manner. O
Furthermore, O
GABA B-CHEMICAL
receptors I-GENE-N
of O

horizontal O
cells O
were O
modulated O
by O
extracellular O
application O
of O
diazepam, B-CHEMICAL
zolpidem, B-CHEMICAL
methyl B-CHEMICAL
6,7-dimethoxy-4-ethyl-beta-carboxylate, I-CHEMICAL
pentobarbital, B-CHEMICAL
and O
alphaxalone, B-CHEMICAL
thus O
showing O
typical O
pharmacological O
properties O
of O
CNS O
GABAA B-GENE-N
receptors. I-GENE-N
GABA-evoked B-CHEMICAL
single-channel O
currents O
were O
characterized O
by O
a O
main O
conductance O
state O
of O
29.8 O
pS O
and O
two O
subconductance O
states O
(20.2 O
and O
10.8 O
pS, O
respectively). O
Kinetic O
analysis O
of O
single-channel O
events O
within O
bursts O

revealed O
similar O
mean O
open O
and O
closed O
times O
for O
the O
main O
conductance O
and O
the O
20.2-pS O
subconductance O
state, O
resulting O
in O
open O
probabilities O
of O
44.6 O
and O
42.7%, O
respectively. O
The O
ratio O
of O
open O
to O
closed O
times, O
however, O
was O
significantly O
different O
for O
the O
10.8-pS O
subconductance O
state O
with O
an O
open O
probability O
of O
57.2%. O
Decreased O
histamine B-CHEMICAL
H1 I-GENE-Y
receptor I-GENE-Y
binding O
in O
the O
brain O
of O
depressed O
patients. O
The O
central O
histaminergic O
neuron O
system O
modulates O
the O
wakefulness, O
sleep-awake O
cycle, O
appetite O
control, O
learning O
and O
memory, O
and O
emotion. O

Previous O
studies O
have O
reported O
changes O
in O
neuronal O
histamine B-CHEMICAL
release O
and O
its O
metabolism O
under O
stress O
conditions O
in O
the O
mammalian O
brain. O
In O
this O
study, O
we O
examined, O
using O
positron O
emission O
tomography O
(PET) O
and O
[(11)C]-doxepin, B-CHEMICAL
whether O
the O
histaminergic O
neuron O
system O
is O
involved O
in O
human O
depression. O
Cerebral O
histamine B-CHEMICAL
H1 I-GENE-Y
receptor I-GENE-Y
(H(1)R) B-GENE-Y
binding O
was O
measured O
in O
10 O
patients O
with O
major O
depression O
and O
in O
10 O
normal O
age-matched O
subjects O
using O
PET O
and O
[(11)C]-doxepin. B-CHEMICAL
Data O
were O
calculated O
by O
a O
graphical O

analysis O
on O
voxel-by-voxel O
and O
ROI O
(region O
of O
interests) O
basis. O
Binding O
potential O
(BP) O
values O
for O
[(11)C]-doxepin B-CHEMICAL
binding O
in O
the O
frontal O
and O
prefrontal O
cortices, O
and O
cingulate O
gyrus O
were O
significantly O
lower O
in O
the O
depressed O
patients O
than O
those O
in O
the O
normal O
control O
subjects. O
There O
was O
no O
area O
of O
the O
brain O
where O
[(11)C]-doxepin B-CHEMICAL
binding O
was O
significantly O
higher O
in O
the O
depressed O
patients O
than O
in O
the O
controls. O
ROI-based O
analysis O
also O
revealed O
that O
BP O
values O
for O

[(11)C]-doxepin B-CHEMICAL
binding O
in O
the O
frontal O
cortex O
and O
cingulate O
gyrus O
decreased O
in O
proportion O
to O
self-rating O
depressive O
scales O
scores. O
The O
results O
of O
this O
study O
demonstrate O
that O
depressed O
patients O
have O
decreased O
brain O
H(1)R B-GENE-Y
binding O
and O
that O
this O
decrease O
correlates O
with O
the O
severity O
of O
depression O
symptoms. O
It O
is O
therefore O
suggested O
that O
the O
histaminergic O
neuron O
system O
plays O
an O
important O
role O
in O
the O
pathophysiology O
of O
depression O
and O
that O
its O
modulation O
may O
prove O
to O
be O
useful O
in O
the O
treatment O
of O
depression. O
Central O
effects O
of O
fexofenadine B-CHEMICAL
and O
cetirizine: B-CHEMICAL
measurement O
of O

psychomotor O
performance, O
subjective O
sleepiness, O
and O
brain O
histamine B-GENE-Y
H1-receptor I-GENE-Y
occupancy O
using O
11C-doxepin B-CHEMICAL
positron O
emission O
tomography. O
Histamine B-GENE-Y
H1-receptor I-GENE-Y
(H1R) B-GENE-Y
antagonists, O
or O
antihistamines, B-CHEMICAL
often O
induce O
sedative O
side O
effects O
when O
used O
for O
the O
treatment O
of O
allergic O
disorders. O
This O
study O
compared O
the O
sedative O
profiles O
of O
the O
second-generation O
antihistamines, B-CHEMICAL
fexofenadine B-CHEMICAL
and O
cetirizine, B-CHEMICAL
using O
3 O
different O
criteria: O
subjective O
sleepiness O
evaluated O
by O
the O
Stanford O
Sleepiness O
Scale, O
objective O
psychomotor O
tests O

(simple O
and O
choice O
reaction O
time O
tests O
and O
visual O
discrimination O
tests O
at O
4 O
different O
exposure O
durations), O
and O
measurement O
of O
histamine B-GENE-Y
H1-receptor I-GENE-Y
occupancy O
(H1RO) O
in O
the O
brain. O
Subjective O
sleepiness O
and O
psychomotor O
performance O
were O
measured O
in O
20 O
healthy O
Japanese O
volunteers O
at O
baseline O
and O
90 O
min O
after O
administration O
of O
fexofenadine B-CHEMICAL
120 O
mg O
or O
cetirizine B-CHEMICAL
20 O
mg O
in O
a O
double-blind, O
placebo-controlled O
crossover O
study. O
Hydroxyzine B-CHEMICAL
30 O
mg O
was O
included O
as O
a O
positive O
control. O
H1RO O
was O
measured O
using O
positron O
emission O
tomography O
(PET) O
with O

(11)C-doxepin B-CHEMICAL
in O
12 O
of O
the O
20 O
subjects, O
and O
a O
further O
11 O
volunteers O
were O
recruited O
to O
act O
as O
controls. O
In O
psychomotor O
tests, O
fexofenadine B-CHEMICAL
was O
not O
significantly O
different O
from O
placebo O
and O
significantly O
less O
impairing O
than O
cetirizine B-CHEMICAL
on O
some O
tasks, O
as O
well O
as O
significantly O
less O
impairing O
than O
hydroxyzine B-CHEMICAL
on O
all O
tasks. O
For O
subjective O
sleepiness, O
fexofenadine B-CHEMICAL
was O
not O
significantly O
different O
from O
placebo, O
whereas O
cetirizine B-CHEMICAL
showed O
a O
trend O
toward O
increased O
sleepiness O
compared O
with O
fexofenadine B-CHEMICAL
and O
placebo. O
H1RO O
was O
negligible O

with O
fexofenadine B-CHEMICAL
(-0.1%) O
but O
moderately O
high O
with O
cetirizine B-CHEMICAL
(26.0%). O
In O
conclusion, O
fexofenadine B-CHEMICAL
120 O
mg O
is O
distinguishable O
from O
cetirizine B-CHEMICAL
20 O
mg, O
as O
assessed O
by O
H1RO O
and O
psychomotor O
testing. O
A O
novel O
membrane O
sensor O
for O
histamine B-GENE-Y
H1-receptor I-GENE-Y
antagonist O
"fexofenadine". B-CHEMICAL
The O
construction O
and O
general O
performance O
of O
thirteen O
new O
polymeric O
membrane O
sensors O
for O
the O
determination O
of O
fexofenadine B-CHEMICAL
hydrochloride I-CHEMICAL
based O
on O
its O
ion O
exchange O
with O
reineckate, O
tetraphenylborate B-CHEMICAL

and O
tetraiodomercurate B-CHEMICAL
have O
been O
studied. O
The O
effects O
of O
membrane O
composition, O
type O
of O
plasticizer, O
pH O
value O
of O
sample O
solution O
and O
concentration O
of O
the O
analyte O
in O
the O
sensor O
internal O
solution O
have O
been O
thoroughly O
investigated. O
The O
novel O
sensor O
based O
on O
reineckate O
exchanger O
shows O
a O
stable, O
potentiometric O
response O
for O
fexofenadine B-CHEMICAL
in O
the O
concentration O
range O
of O
1 O
x O
10(-2) O
- O
2.5 O
x O
10(-6) O
M O
at O
25 O
degrees O
C O
that O
is O
independent O
of O
pH O
in O
the O
range O
of O
2.0 O
- O
4.5. O
The O
sensor O
possesses O
a O
Nernstian O
cationic O
slope O
of O

62.3+/-0.7 O
mV/concentration O
decade O
and O
a O
lower O
detection O
limit O
of O
1.3 O
x O
10(-6) O
M O
with O
a O
fast O
response O
time O
of O
20 O
- O
40 O
s. O
Selectivity O
coefficients O
for O
a O
number O
of O
interfering O
ions O
and O
excipients O
relative O
to O
fexofenadine B-CHEMICAL
were O
investigated. O
There O
is O
negligible O
interference O
from O
almost O
all O
studied O
cations, O
anions, O
and O
pharmaceutical O
excipients, O
however, O
citrizine B-CHEMICAL
that O
has O
a O
structure O
homologous O
to O
that O
of O
fexofenadine B-CHEMICAL
was O
found O
to O
interfere. O
The O
determination O
of O
fexofenadine B-CHEMICAL
in O

aqueous O
solution O
shows O
an O
average O
recovery O
of O
99.83% O
with O
a O
mean O
relative O
standard O
deviation O
(RSD) O
of O
0.5%. O
Direct O
potentiometric O
determination O
of O
fexofenadine B-CHEMICAL
in O
tablets O
gave O
results O
that O
compare O
favorably O
with O
those O
obtained O
by O
standard O
spectrophotometric O
methods. O
Potentiometric O
titration O
of O
fexofenadine B-CHEMICAL
with O
phosphomolybdic B-CHEMICAL
acid I-CHEMICAL
as O
a O
titrant O
has O
been O
monitored O
with O
the O
proposed O
sensor O
as O
an O
end O
point O
indicator O
electrode. O
Thymidylate B-GENE-Y
synthase: I-GENE-Y
a O
critical O
target O
in O
cancer O
therapy? O
For O
the O
last O
four O
decades, O
synthesis O

and O
testing O
of O
potentially O
active O
drugs O
(e.g., O
antimetabolites) O
have O
focused O
on O
structural O
modification O
of O
existing O
metabolites O
as O
precursors O
of O
DNA O
and O
RNA O
synthesis. O
In O
recent O
years, O
the O
focus O
has O
shifted O
to O
synthesis O
of O
target-specific O
agents. O
Thus, O
the O
current O
emphasis O
of O
drug O
development O
is O
directed O
at O
inhibiting O
specific O
target(s) O
expressed O
preferentially, O
if O
not O
exclusively, O
in O
tumor O
tissues, O
with O
the O
ultimate O
goal O
of O
improving O
the O
therapeutic O
efficacy O
and O
selectivity O
of O
these O
new O
agents. O
Preclinically, O
proof-of-principle O
studies O
were O
carried O
out O
in O
tumors O
with O
specific O
expression O
of O
the O
intended O

target. O
With O
the O
hope O
of O
translating O
preclinical O
findings O
to O
the O
design O
of O
implementation O
of O
clinical O
trials. O
Thymidylate B-GENE-Y
synthase I-GENE-Y
(TS) B-GENE-Y
continues O
to O
be O
a O
critical O
target O
for O
5-fluorouracil B-CHEMICAL
(5-FU) B-CHEMICAL
and O
its O
prodrugs, O
UFT/LV B-CHEMICAL
(Orzel), B-CHEMICAL
capecitabine B-CHEMICAL
(Xeloda), B-CHEMICAL
and O
S-1, B-CHEMICAL
primarily O
because O
this O
enzyme O
is O
essential O
for O
the O
synthesis O
of O
2-deoxythymidine-5-monophosphate, B-CHEMICAL
a O
precursor O
for O
DNA O
synthesis. O
While O
fluoropyrimidine B-CHEMICAL

antimetabolites O
have O
other O
sites O
of O
action, O
antifolates O
ZD1694 B-CHEMICAL
(raltitrexed, B-CHEMICAL
Tomudex) B-CHEMICAL
and O
AG337 B-CHEMICAL
(Thymitag) B-CHEMICAL
are O
more O
specific O
and O
potent O
TS B-GENE-Y
inhibitors. O
Thus, O
it O
is O
hoped O
that O
pronounced O
and O
sustained O
inhibition O
of O
this O
enzyme O
could O
result O
in O
downstream O
regulation O
of O
molecular O
markers O
associated O
with O
sensitivity O
and O
resistance O
to O
these O
agents. O
It O
is O
also O
critical O
to O
recognize O
that O
the O
degree O
and O
duration O
of O
inhibition O
of O
the O
target O
enzyme O
may O
depend O
on O
the O
expression O
level O
of O
the O
target O
enzyme, O
thymidylate B-GENE-Y
synthase. I-GENE-Y
Correlative O
studies O
in O

preclinical O
and O
clinical O
systems O
demonstrated O
a O
close O
relationship O
between O
the O
enzyme O
level O
(mRNA O
and O
protein) O
and O
response O
to O
therapy O
of O
colorectal O
cancer O
patients O
treated O
with O
fluoropyrimidine B-CHEMICAL
or O
Tomudex. B-CHEMICAL
However, O
significant O
overlap O
was O
demonstrated O
between O
responders O
and O
non-responders. O
These O
data O
are O
consistent O
with O
the O
hypothesis O
that O
prediction O
of O
response O
to O
anticancer O
drugs O
is O
multifactorial, O
and O
TS B-GENE-Y
is O
one O
target. O
Clinically, O
although O
overall O
response O
of O
colorectal O
cancer O
patients O
to O
a O
variety O
of O
TS B-GENE-Y
inhibitors O
is O
similar, O
toxicity O
profiles O
are O
different. O
The O
availability O
of O
the O
5-FU B-CHEMICAL

prodrugs O
offers O
the O
possibility O
of O
greater O
therapeutic O
selectivity O
based O
on O
the O
demonstration O
that O
thymidine B-GENE-Y
phosphorylase, I-GENE-Y
the O
activating O
enzyme O
for O
5-FU, B-CHEMICAL
is O
expressed O
at O
a O
higher O
level O
in O
tumor O
tissue O
compared O
with O
normal O
tissue O
counterparts. O
It O
is O
likely O
that O
successful O
application O
of O
TS B-GENE-Y
inhibitors O
will O
not O
only O
be O
based O
on O
measurement O
of O
the O
TS B-GENE-Y
level O
in O
tumors O
vs. O
normal O
tissues, O
but O
on O
the O
delineation O
of O
the O
consequences O
of O
this O
inhibition O
on O
molecular O
markers O
associated O
with O
cellular O
proliferation, O
apoptosis O
and O
cell O
cycle O
regulation. O
[Pharmacological O
treatment O
of O
obesity]. O
The O
pharmacological O
treatment O
of O

obesity O
should O
be O
considered O
when O
cannot O
be O
achieved O
a O
10% O
weight O
loss O
with O
diet O
therapy O
and O
physical O
activity. O
The O
drugs O
effective O
in O
obesity O
treatment O
may O
act O
by O
different O
mechanisms O
such O
as O
reduction O
in O
food O
intake, O
inhibition O
of O
fat O
absorption, O
increase O
of O
thermogenesis O
and O
stimulation O
of O
adipocyte O
apoptosis. O
At O
present, O
we O
only O
have O
two O
marketed O
drugs O
for O
obesity O
treatment. O
Sibutramine B-CHEMICAL
is O
an O
inhibitor O
of O
norepinephrine, B-CHEMICAL
dopamine B-CHEMICAL
and O
serotonina O
reuptake O
which O
inhibits O
food O
intake O
and O
increases O
thermogenesis. O
Sibutramine B-CHEMICAL
administration O
for O
a O
year O
can O
induce O
a O

weight O
loss O
of O
4-7%. O
Its O
main O
side O
effects O
are O
hypertension, O
headache, O
insomnia O
and O
constipation. O
Orlistat B-CHEMICAL
is O
an O
inhibitor O
of O
pancreatic B-GENE-N
lipase I-GENE-N
which O
is O
able O
to O
block O
the O
absorption O
of O
30% O
of O
ingested O
fat. O
Its O
administration O
induces O
weight O
loss O
and O
reduction O
of O
ulterior O
weight O
regain. O
Also, O
this O
drug O
improves O
hypertension O
dyslipdaemia O
and O
helps O
to O
prevent O
diabetes O
in O
52% O
of O
cases O
when O
administered O
over O
four O
years. O
The O
increase O
in O
frequency O
of O
stools O
and O
interference O
with O
vitamin O
absorption O
are O
its O
main O
side O
effects. O
Glucagon-like B-GENE-Y

peptide I-GENE-Y
1, I-GENE-Y
which O
increases O
insulin B-GENE-Y
sensitivity O
and O
satiety, O
adiponectin B-GENE-Y
and O
PPAR-gamma B-GENE-Y
agonists O
which O
reduce O
insulin B-GENE-Y
resistance O
and O
modulates O
adipocyte O
generation O
are O
the O
basis O
for O
future O
therapeutic O
approaches O
of O
obesity. O
Phosphatase B-GENE-N
inhibitors O
induce O
PPAR-gamma B-GENE-Y
phosphorylation O
and O
UCP-1 B-GENE-Y
expression O
leading O
to O
an O
increase O
in O
thermogenesis O
and O
reduction O
in O
appetite. O
Viability O
assessment O
in O
sandwich-cultured O
rat O
hepatocytes O
after O
xenobiotic O
exposure. O
Troglitazone, B-CHEMICAL
bosentan B-CHEMICAL
and O
glibenclamide B-CHEMICAL
inhibit O
the O

bile B-GENE-Y
salt I-GENE-Y
export I-GENE-Y
pump I-GENE-Y
(Bsep) B-GENE-Y
which O
transports O
taurocholate B-CHEMICAL
into O
bile. O
Sandwich-cultured O
rat O
hepatocytes O
maintain O
functional O
sodium B-CHEMICAL
taurocholate I-CHEMICAL
co-transporting I-GENE-Y
polypeptide I-GENE-Y
and O
Bsep B-GENE-Y
transport O
proteins, O
and O
may O
be O
useful O
to O
study O
inhibition O
of O
transport O
by O
xenobiotics O
at O
concentrations O
below O
the O
lowest O
observable O
adverse O
effect O
level O
(LOAEL). O
The O
purpose O
of O
this O
study O
was O
to O
compare O
viability O
assessments O
determined O
with O
the O
neutral O
red, O
lactate B-GENE-N
dehydrogenase I-GENE-N
(LDH), B-GENE-N
alamar B-CHEMICAL
blue, I-CHEMICAL

3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium B-CHEMICAL
bromide I-CHEMICAL
(MTT) B-CHEMICAL
and O
propidium B-CHEMICAL
iodide I-CHEMICAL
assays O
in O
sandwich-cultured O
rat O
hepatocytes O
following O
exposure O
to O
xenobiotics O
known O
to O
inhibit O
Bsep, B-GENE-Y
and O
to O
define O
the O
LOAEL O
for O
these O
xenobiotics O
in O
this O
system. O
The O
neutral O
red O
assay O
was O
not O
amenable O
to O
use O
in O
this O
model O
due O
to O
crystal O
formation O
on O
the O
collagen. B-GENE-N
Troglitazone B-CHEMICAL
decreased O
viability O
in O
every O
assay O

examined, O
with O
a O
LOAEL O
approximately O
100 O
microM. O
Bosentan B-CHEMICAL
also O
decreased O
viability O
as O
measured O
by O
the O
LDH, B-GENE-N
MTT B-CHEMICAL
and O
propidium B-CHEMICAL
iodide I-CHEMICAL
assays, O
with O
a O
LOAEL O
approximately O
200 O
microM; O
however, O
a O
significant O
decrease O
in O
viability O
was O
not O
observed O
with O
the O
alamar B-CHEMICAL
blue I-CHEMICAL
assay. O
Glibenclamide B-CHEMICAL
did O
not O
decrease O
viability O
with O
any O
assay O
at O
the O
xenobiotic O
concentrations O
examined O
in O
this O
study. O
Based O
on O
the O
results O
of O
this O
study, O
the O
LDH B-GENE-N
or O
propidium B-CHEMICAL
iodide I-CHEMICAL
assays O
would O
be O
the O
methods O
of O
choice O
to O
assess O
viability O

in O
sandwich-cultured O
rat O
hepatocytes O
after O
xenobiotic O
exposure. O
Valdecoxib: B-CHEMICAL
assessment O
of O
cyclooxygenase-2 B-GENE-Y
potency O
and O
selectivity. O
The O
discovery O
of O
a O
second B-GENE-Y
isoform I-GENE-Y
of I-GENE-Y
cyclooxygenase I-GENE-Y
(COX) B-GENE-N
led O
to O
the O
search O
for O
compounds O
that O
could O
selectively O
inhibit O
COX-2 B-GENE-Y
in O
humans O
while O
sparing O
prostaglandin B-CHEMICAL
formation O
from O
COX-1. B-GENE-Y
Celecoxib B-CHEMICAL
and O
rofecoxib B-CHEMICAL
were O
among O
the O
molecules O
developed O
from O
these O
efforts. O
We O
report O
here O
the O
pharmacological O
properties O
of O
a O

third O
selective O
COX-2 B-GENE-Y
inhibitor, O
valdecoxib, B-CHEMICAL
which O
is O
the O
most O
potent O
and O
in O
vitro O
selective O
of O
the O
marketed O
COX-2 B-GENE-Y
inhibitors O
that O
we O
have O
studied. O
Recombinant O
human B-GENE-Y
COX-1 I-GENE-Y
and O
COX-2 B-GENE-Y
were O
used O
to O
screen O
for O
new O
highly O
potent O
and O
in O
vitro O
selective O
COX-2 B-GENE-Y
inhibitors O
and O
compare O
kinetic O
mechanisms O
of O
binding O
and O
enzyme O
inhibition O
with O
other O
COX B-GENE-N
inhibitors. O
Valdecoxib B-CHEMICAL
potently O
inhibits O
recombinant O
COX-2, B-GENE-Y
with O
an O
IC(50) O
of O
0.005 O
microM; O
this O
compares O

with O
IC O
values O
of O
0.05 O
microM O
for O
celecoxib, B-CHEMICAL
0.5 O
microM O
for O
rofecoxib, B-CHEMICAL
and O
5 O
microM O
for O
etoricoxib. B-CHEMICAL
Unique O
binding O
interactions O
of O
valdecoxib B-CHEMICAL
with O
COX-2 B-GENE-Y
translate O
into O
a O
fast O
rate O
of O
inactivation O
of O
COX-2 B-GENE-Y
(110,000 O
M/s O
compared O
with O
7000 O
M/s O
for O
rofecoxib B-CHEMICAL
and O
80 O
M/s O
for O
etoricoxib). B-CHEMICAL
The O
overall O
saturation O
binding O
affinity O
for O
COX-2 B-GENE-Y
of O
valdecoxib B-CHEMICAL
is O
2.6 O
nM O

(compared O
with O
1.6 O
nM O
for O
celecoxib, B-CHEMICAL
51 O
nM O
for O
rofecoxib, B-CHEMICAL
and O
260 O
nM O
for O
etoricoxib), B-CHEMICAL
with O
a O
slow O
off-rate O
(t(1/2) O
approximately O
98 O
min). O
Valdecoxib B-CHEMICAL
inhibits O
COX-1 B-GENE-Y
in O
a O
competitive O
fashion O
only O
at O
very O
high O
concentrations O
(IC(50) O
= O
150 O
microM). O
Collectively, O
these O
data O
provide O
a O
mechanistic O
basis O
for O
the O
potency O
and O
in O
vitro O
selectivity O
of O
valdecoxib B-CHEMICAL
for O
COX-2. B-GENE-Y

Valdecoxib B-CHEMICAL
showed O
similar O
activity O
in O
the O
human B-GENE-N
whole-blood I-GENE-N
COX I-GENE-N
assay O
(COX-2 B-GENE-Y
IC(50) O
= O
0.24 O
microM; O
COX-1 B-GENE-Y
IC(50) O
= O
21.9 O
microM). O
We O
also O
determined O
whether O
this O
in O
vitro O
potency O
and O
selectivity O
translated O
to O
significant O
potency O
in O
vivo. O
In O
rats, O
valdecoxib B-CHEMICAL
demonstrated O
marked O
potency O
in O
acute O
and O
chronic O
models O
of O
inflammation O
(air O
pouch O
ED(50) O
= O
0.06 O
mg/kg; O
paw O
edema O
ED(50) O
= O
5.9 O

mg/kg; O
adjuvant O
arthritis O
ED(50) O
= O
0.03 O
mg/kg). O
In O
these O
same O
animals, O
COX-1 B-GENE-Y
was O
spared O
at O
doses O
greater O
than O
200 O
mg/kg. O
These O
data O
provide O
a O
basis O
for O
the O
observed O
potent O
anti-inflammatory O
activity O
of O
valdecoxib B-CHEMICAL
in O
humans. O
An O
angiotensin B-CHEMICAL
II I-CHEMICAL
AT1 I-GENE-Y
receptor I-GENE-Y
antagonist, O
telmisartan B-CHEMICAL
augments O
glucose B-CHEMICAL
uptake O
and O
GLUT4 B-GENE-Y
protein O
expression O
in O
3T3-L1 O
adipocytes. O
Evidence O
has O
accumulated O
that O
some O
of O
the O
angiotensin B-CHEMICAL
II I-CHEMICAL
AT1 I-GENE-Y
receptor I-GENE-Y
antagonists O
have O

insulin-sensitizing B-GENE-N
property. O
We O
thus O
examined O
the O
effect O
of O
telmisartan B-CHEMICAL
on O
insulin B-GENE-N
action O
using O
3T3-L1 O
adipocytes. O
With O
standard O
differentiation O
inducers, O
a O
higher O
dose O
of O
telmisartan B-CHEMICAL
effectively O
facilitated O
differentiation O
of O
3T3-L1 O
preadipocytes. O
Treatment O
of O
both O
differentiating O
adipocytes O
and O
fully O
differentiated O
adipocytes O
with O
telmisartan B-CHEMICAL
caused O
a O
dose-dependent O
increase O
in O
mRNA O
levels O
for O
PPARgamma B-GENE-Y
target O
genes O
such O
as O
aP2 B-GENE-Y
and O
adiponectin. B-GENE-Y
By O
contrast, O
telmisartan B-CHEMICAL
attenuated O

11beta-hydroxysteroid B-CHEMICAL
dehydrogenase I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
mRNA O
level O
in O
differentiated O
adipocytes. O
Of O
note, O
we O
demonstrated O
for O
the O
first O
time O
that O
telmisartan B-CHEMICAL
augmented O
GLUT4 B-GENE-Y
protein O
expression O
and O
2-deoxy B-CHEMICAL
glucose I-CHEMICAL
uptake O
both O
in O
basal O
and O
insulin-stimulated B-GENE-N
state O
of O
adipocytes, O
which O
may O
contribute, O
at O
least O
partly, O
to O
its O
insulin-sensitizing B-GENE-N
ability. O
Pharmacogenetic O
differences O
in O
response O
to O
albuterol B-CHEMICAL
between O
Puerto O
Ricans O
and O
Mexicans O
with O
asthma. O
BACKGROUND: O
In O
the O
United O
States, O

Puerto O
Ricans O
and O
Mexicans O
have O
the O
highest O
and O
lowest O
asthma O
prevalence, O
morbidity, O
and O
mortality, O
respectively. O
Ethnic-specific O
differences O
in O
the O
response O
to O
drug O
treatment O
may O
contribute O
to O
differences O
in O
disease O
outcomes. O
Genetic O
variants O
at O
the O
beta(2)-adrenergic B-GENE-Y
receptor I-GENE-Y
(beta(2)AR) B-GENE-Y
may O
modify O
asthma O
severity O
and O
albuterol B-CHEMICAL
responsiveness. O
We O
tested O
the O
association O
of O
beta(2)AR B-GENE-Y
genotypes O
with O
asthma O
severity O
and O
bronchodilator O
response O
to O
albuterol B-CHEMICAL
in O
Puerto O
Ricans O
and O
Mexicans O
with O
asthma. O

METHODS: O
We O
used O
both O
family-based O
and O
cross-sectional O
tests O
of O
association O
with O
8 O
beta(2)AR B-GENE-Y
single O
nucleotide B-CHEMICAL
polymorphisms O
in O
684 O
Puerto O
Rican O
and O
Mexican O
families. O
Regression O
analyses O
were O
used O
to O
determine O
the O
interaction O
between O
genotype, O
asthma O
severity, O
and O
bronchodilator O
drug O
responsiveness. O
RESULTS: O
Among O
Puerto O
Ricans O
with O
asthma, O
the O
arginine B-CHEMICAL
(Arg) B-CHEMICAL
16 O
allele O
was O
associated O
with O
greater O
bronchodilator O
response O
using O
both O
family-based O
and O
cross-sectional O
tests O

(p O
= O
0.00001-0.01). O
We O
found O
a O
strong O
interaction O
of O
baseline O
FEV(1) O
with O
the O
Arg16Glycine B-GENE-N
(Gly) B-CHEMICAL
polymorphism O
in O
predicting O
bronchodilator O
response. O
Among O
Puerto O
Ricans O
with O
asthma O
with O
baseline O
FEV(1) O
< O
80% O
of O
predicted, O
but O
not O
in O
those O
with O
FEV(1) O
> O
80%, O
there O
was O
a O
very O
strong O
association O
between O
the O
Arg16 O
genotype O
and O
greater O
bronchodilator O
responsiveness. O
No O
association O
was O
observed O
between O

Arg16Gly B-GENE-N
genotypes O
and O
drug O
responsiveness O
among O
Mexicans O
with O
asthma. O
CONCLUSIONS: O
Ethnic-specific O
pharmacogenetic O
differences O
exist O
between O
Arg16Gly B-GENE-N
genotypes, O
asthma O
severity, O
and O
bronchodilator O
response O
in O
Puerto O
Ricans O
and O
Mexicans O
with O
asthma. O
These O
findings O
underscore O
the O
need O
for O
additional O
research O
on O
racial/ethnic O
differences O
in O
asthma O
morbidity O
and O
drug O
responsiveness. O
Tyrosinase B-GENE-Y
inhibitors O
from O
Rhododendron O
collettianum O
and O

their O
structure-activity O
relationship O
(SAR) O
studies. O
A O
new O
coumarinolignoid B-CHEMICAL
8'-epi-cleomiscosin B-CHEMICAL
A I-CHEMICAL
(1) O
together O
with O
the O
new O
glycoside O
8-O-beta-D-glucopyranosyl-6-hydroxy-2-methyl-4H-1-benzopyrane-4-one B-CHEMICAL
(2) O
have O
been O
isolated O
from O
the O
aerial O
parts O
of O
Rhododendron O
collettianum O
and O
their O
structures O
determined O
on O
the O
basis O
of O
spectroscopic O
evidences. O
Tyrosinase B-GENE-Y
inhibition O
study O
of O
these O

compounds O
and O
their O
structure-activity O
relationship O
(SAR) O
were O
also O
investigated. O
The O
compounds O
exhibited O
potent O
to O
mild O
inhibition O
activity O
against O
the O
enzyme. O
Especially, O
the O
compound O
1 O
showed O
strong O
inhibition O
(IC50=1.33 O
microM) O
against O
the O
enzyme O
tyrosinase, B-GENE-Y
as O
compared O
to O
the O
standard O
tyrosinase O
inhibitors O
kojic B-CHEMICAL
acid I-CHEMICAL
(IC50=16.67 O
microM) O
and O
L-mimosine B-CHEMICAL
(IC50=3.68 O
microM), O
indicating O
its O
potential O
used O
for O
the O
treatment O
of O
hyperpigmentation O
associated O
with O
the O
high O
production O
of O
melanocytes. O

In O
vivo O
activity O
of O
the O
potent O
oxytocin B-GENE-Y
antagonist O
on O
uterine O
activity O
in O
the O
rat. O
Oxytocin B-GENE-Y
antagonist O
(OTA), O
TT-235, B-CHEMICAL
was O
developed O
by O
our O
group O
and O
shown O
to O
inhibit O
either O
spontaneous O
or O
oxytocin-induced B-CHEMICAL
uterine O
contractions O
in O
primates. O
The O
purpose O
of O
the O
present O
study O
was O
to O
confirm O
the O
duration O
of O
TT-235 B-CHEMICAL
to O
block O
oxytocin-induced B-GENE-Y
uterine O
contractions O
in O
estrous O
rats. O
In O
Experiment O
1, O
the O
time-response O
of O
the O
three O
OTAs O
on O
uterine O
contractility O
was O
examined. O
The O
rats O
were O

anesthetized O
and O
cannulas O
were O
placed O
in O
the O
jugular O
vein O
for O
infusing O
vehicle O
(sterile O
saline), O
Antag B-CHEMICAL
I, I-CHEMICAL
Antag B-CHEMICAL
II I-CHEMICAL
and O
TT-235. B-CHEMICAL
The O
uterine O
activity O
was O
monitored O
through O
a O
water-filled O
balloon-tipped O
cannula O
placed O
in O
the O
uterine O
horn. O
The O
uterine O
contractile O
activity O
was O
determined O
as O
the O
integrated O
area O
for O
10 O
minutes. O
Each O
OTA O
was O
administered O
as O
a O
single O
bolus O
injection O
of O
5 O
microg, O
followed O
by O
100 O
mU O
of O
oxytocin B-GENE-Y
5 O
minutes O
later, O
also O
done O
as O
a O
single O
bolus. O

Oxytocin B-GENE-Y
injection O
of O
the O
same O
dosage O
was O
repeated O
every O
hour O
for O
5 O
hours. O
Experiment O
2 O
determined O
the O
effect O
of O
the O
three O
OTAs O
on O
uterine O
oxytocin B-GENE-Y
receptor I-GENE-Y
number O
(Rn) O
and O
binding O
affinity O
(Kd). O
Rats O
treated O
with O
either O
OTA O
or O
vehicle O
were O
sacrificed O
at O
0.5 O
and O
4 O
hours O
for O
receptor O
assay. O
In O
Experiment O
1, O
Antag B-CHEMICAL
I, I-CHEMICAL
Antag B-CHEMICAL
II I-CHEMICAL
and O
TT-235 B-CHEMICAL
inhibited O
the O
integrated O
uterine O
response O
to O
oxytocin B-CHEMICAL
at O
5 O
minutes O
by O
76%, O
77% O
and O
80%, O
respectively, O
compared O
to O
controls O

(p<0.05). O
Two O
hours O
after O
injecting O
Antag B-CHEMICAL
I, I-CHEMICAL
inhibition O
of O
uterine O
contractility O
was O
55% O
lower O
than O
controls O
(p<0.05). O
At O
3 O
hours, O
uterine O
contractility O
was O
no O
longer O
affected O
in O
rats O
treated O
with O
Antag B-CHEMICAL
I I-CHEMICAL
compared O
with O
controls. O
The O
suppressive O
uterine O
activity O
with O
Antag B-CHEMICAL
II I-CHEMICAL
continued O
up O
to O
3 O
hours. O
However, O
uterine O
contractility O
remained O
lower O
(53%) O
in O
rats O
treated O
with O
TT-235 B-CHEMICAL
5 O
hours O
later. O
In O
Experiment O
2, O
TT-235 B-CHEMICAL
induced O
a O
significant O
decrease O
(p<0.05) O
in O

oxytocin B-GENE-Y
receptor I-GENE-Y
number O
and O
binding O
affinity O
at O
both O
0.5 O
and O
4 O
hours O
compared O
with O
controls. O
Antag B-CHEMICAL
I I-CHEMICAL
and O
Antag B-CHEMICAL
II I-CHEMICAL
did O
not O
alter O
oxytocin B-GENE-Y
receptor I-GENE-Y
number O
or O
binding O
affinity O
significantly O
at O
each O
time O
point O
studied O
compared O
with O
controls. O
In O
conclusion, O
TT-235 B-CHEMICAL
may O
inhibit O
the O
uterine O
response O
to O
oxytocin B-GENE-Y
by O
decreasing O
oxytocin B-GENE-Y
receptor I-GENE-Y
numbers O
and O
oxytocin B-GENE-Y
binding O
affinity, O
which O
might O
explain O
the O
prolonged O
oxytocin B-GENE-Y
antagonist O
activity O
of O
TT-235. B-CHEMICAL
Preclinical O
pharmacology O
of O
lumiracoxib: B-CHEMICAL
a O
novel O
selective O
inhibitor O
of O

cyclooxygenase-2. B-GENE-Y
1. O
This O
manuscript O
presents O
the O
preclinical O
profile O
of O
lumiracoxib, B-CHEMICAL
a O
novel O
cyclooxygenase-2 B-GENE-Y
(COX-2) B-GENE-Y
selective O
inhibitor. O
2. O
Lumiracoxib B-CHEMICAL
inhibited O
purified O
COX-1 B-GENE-Y
and O
COX-2 B-GENE-Y
with O
K(i) O
values O
of O
3 O
and O
0.06 O
microM, O
respectively. O
In O
cellular O
assays, O
lumiracoxib B-CHEMICAL
had O
an O
IC(50) O
of O
0.14 O
microM O
in O
COX-2-expressing B-GENE-Y
dermal O
fibroblasts, O
but O

caused O
no O
inhibition O
of O
COX-1 B-GENE-Y
at O
concentrations O
up O
to O
30 O
microM O
(HEK O
293 O
cells O
transfected O
with O
human B-GENE-N
COX-1). I-GENE-N
3. O
In O
a O
human O
whole O
blood O
assay, O
IC(50) O
values O
for O
lumiracoxib B-CHEMICAL
were O
0.13 O
microM O
for O
COX-2 B-GENE-Y
and O
67 O
microM O
for O
COX-1 B-GENE-Y
(COX-1/COX-2 B-GENE-Y
selectivity O
ratio O
515). O
4. O
Lumiracoxib B-CHEMICAL
was O
rapidly O
absorbed O
following O
oral O
administration O
in O
rats O
with O
peak O
plasma O
levels O
being O
reached O
between O
0.5 O
and O
1 O
h. O
5. O
Ex O

vivo, O
lumiracoxib B-CHEMICAL
inhibited O
COX-1-derived B-GENE-Y
thromboxane B-CHEMICAL
B(2) I-CHEMICAL
(TxB(2)) B-CHEMICAL
generation O
with O
an O
ID(50) O
of O
33 O
mg O
kg(-1), O
whereas O
COX-2-derived B-GENE-Y
production O
of O
prostaglandin B-CHEMICAL
E(2) I-CHEMICAL
(PGE(2)) B-CHEMICAL
in O
the O
lipopolysaccharide-stimulated O
rat O
air O
pouch O
was O
inhibited O
with O
an O
ID(50) O
value O
of O
0.24 O
mg O
kg(-1). O
6. O
Efficacy O
of O
lumiracoxib B-CHEMICAL
in O
rat O
models O

of O
hyperalgesia, O
oedema, O
pyresis O
and O
arthritis O
was O
dose-dependent O
and O
similar O
to O
diclofenac. B-CHEMICAL
However, O
consistent O
with O
its O
low O
COX-1 B-GENE-Y
inhibitory O
activity, O
lumiracoxib B-CHEMICAL
at O
a O
dose O
of O
100 O
mg O
kg(-1) O
orally O
caused O
no O
ulcers O
and O
was O
significantly O
less O
ulcerogenic O
than O
diclofenac B-CHEMICAL
(P<0.05). O
7. O
Lumiracoxib B-CHEMICAL
is O
a O
highly O
selective O
COX-2 B-GENE-Y
inhibitor O
with O
anti-inflammatory, O
analgesic O
and O
antipyretic O
activities O
comparable O
with O

diclofenac, B-CHEMICAL
the O
reference O
NSAID, O
but O
with O
much O
improved O
gastrointestinal O
safety. O
Cloning, O
sequencing, O
structural O
and O
molecular O
biological O
characterization O
of O
placental B-GENE-Y
protein I-GENE-Y
20 I-GENE-Y
(PP20)/human B-GENE-Y
thiamin B-CHEMICAL
pyrophosphokinase I-GENE-Y
(hTPK). B-GENE-Y
Full-length O
cDNAs O
of O
placental B-GENE-Y
protein I-GENE-Y
20 I-GENE-Y
(PP20) B-GENE-Y
were O
cloned O
by O
screening O
a O
human O
placental O
cDNA O
library, O
which O
encode O
a O
243 O
amino O
acid O
protein, O
identical O
to O
human B-GENE-Y
thiamin B-CHEMICAL
pyrophosphokinase I-GENE-Y
(hTPK) B-GENE-Y
as O
confirmed O
by O
protein O
sequence O

analysis. O
Genomic O
alignment O
showed O
that O
the O
PP20/hTPK B-GENE-Y
gene O
contains O
9 O
exons. O
It O
is O
abundantly O
expressed O
in O
placenta, O
as O
numerous O
EST O
clones O
were O
identified. O
As O
thiamine B-CHEMICAL
metabolism O
deficiencies O
have O
been O
seen O
in O
placental O
infarcts O
previously, O
these O
indicate O
that O
PP20/hTPK B-GENE-Y
may O
have O
a O
role O
in O
placental O
diseases. O
Analysis O
of O
the O
1kb O
promoter O
region O
showed O
numerous O
putative O
transcription O
factor O
binding O
sites, O
which O
might O
be O
responsible O
for O
the O
ubiquitous O
PP20/hTPK B-GENE-Y
expression. O
This O
may O
also O
be O
in O
accordance O
with O
the O
presence O
of O
the O
protein O
in O
tissues O
responsible O

for O
the O
regulation O
of O
the O
exquisite O
balance O
between O
cell O
division, O
differentiation O
and O
survival. O
TPK B-GENE-Y
activity O
of O
the O
purified O
and O
recombinant O
protein O
was O
proved O
by O
mass O
spectrometry O
with O
electrospray O
ionization. O
By O
Western O
blot, O
PP20/hTPK B-GENE-Y
was O
found O
in O
all O
human O
normal O
and O
tumorous O
adult O
and O
fetal O
tissues O
in O
nearly O
equal O
amounts, O
but O
not O
in O
sera. O
By O
immunohistochemical O
and O
immunofluorescent O
confocal O
imaging O
methods, O
diffuse O
labelling O
in O
the O
cytoplasm O
of O
the O
syncytiotrophoblasts O
and O
weak O

staining O
of O
the O
trophoblasts O
were O
observed, O
and O
the O
amount O
of O
PP20/hTPK B-GENE-Y
decreased O
from O
the O
first O
trimester O
to O
the O
end O
of O
gestation. O
A O
3D O
model O
of O
PP20/hTPK B-GENE-Y
was O
computed O
(PDB O
No.: O
1OLY) O
by O
homology O
modelling. O
A O
high O
degree O
of O
structural O
homology O
showed O
that O
the O
thiamin B-CHEMICAL
binding O
site O
was O
highly O
similar O
to O
that O
of O
the O
mouse O
enzyme, O
but O
highly O
different O
from O
the O
bacterial O
ones. O
Comparison O
of O
the O
catalytic O
centre O
sequences O
revealed O
differences, O
raising O
the O
possibility O
of O
designing O
new O
drugs O
which O
specifically O
inhibit O
bacterial O
and O
fungal O
enzymes O

without O
affecting O
PP20/hTPK B-GENE-Y
and O
offering O
the O
possibility O
for O
safe O
antimicrobial O
therapy O
during O
pregnancy. O
Safety O
and O
tolerability O
of O
denufosol B-CHEMICAL
tetrasodium I-CHEMICAL
inhalation O
solution, O
a O
novel O
P2Y2 B-GENE-Y
receptor I-GENE-Y
agonist: O
results O
of O
a O
phase O
1/phase O
2 O
multicenter O
study O
in O
mild O
to O
moderate O
cystic O
fibrosis. O
Denufosol B-CHEMICAL
tetrasodium I-CHEMICAL
(INS37217) B-CHEMICAL
is O
a O
selective O
P2Y(2) B-GENE-Y
agonist O
that O
stimulates O
ciliary O
beat O
frequency O
and O
Cl(-) B-CHEMICAL
secretion O
in O
normal O
and O
cystic O
fibrosis O

(CF) O
airway O
epithelia, O
and O
is O
being O
investigated O
as O
an O
inhaled O
treatment O
for O
CF. O
The O
Cl(-) B-CHEMICAL
secretory O
response O
is O
mediated O
via O
a O
non-CFTR B-GENE-Y
pathway, O
and O
the O
driving O
force O
for O
Cl(-) B-CHEMICAL
secretion O
is O
enhanced O
by O
the O
effect O
of O
P2Y(2) B-GENE-Y
activation O
to O
also O
inhibit O
epithelial O
Na(+) B-CHEMICAL
transport. O
Denufosol B-CHEMICAL
is O
metabolically O
more O
stable O
and O
better O
tolerated, O
and O
may O
enhance O
mucociliary O
clearance O
for O
a O
longer O
period O
of O
time O
than O
previously O
investigated O
P2Y(2) B-GENE-Y
agonists. O
The O
goal O
of O
this O
phase O

1/phase O
2 O
study O
was O
to O
assess O
the O
safety O
and O
tolerability O
of O
single O
and O
repeated O
doses O
of O
aerosolized O
denufosol B-CHEMICAL
in O
subjects O
with O
CF. O
The O
study O
was O
a O
double-blind, O
placebo-controlled, O
multicenter O
comparison O
of O
ascending O
single O
doses O
of O
denufosol B-CHEMICAL
(10, O
20, O
40, O
and O
60 O
mg, O
administered O
by O
inhalation O
via O
the O
Pari O
LC O
Star O
nebulizer) O
vs. O
placebo O
(normal O
saline), O
followed O
by O
a O
comparison O
of O
twice-daily O
administration O
of O
the O
maximum O
tolerated O
dose O
(MTD) O
of O
denufosol B-CHEMICAL
or O
placebo O
for O
5 O

days. O
Thirty-seven O
adult O
(18 O
years O
of O
age O
or O
older) O
and O
24 O
pediatric O
(5-17 O
years O
of O
age) O
subjects O
with O
CF O
were O
evaluated O
in O
five O
cohorts. O
Subjects O
were O
randomized O
in O
a O
3:1 O
ratio O
to O
receive O
either O
denufosol B-CHEMICAL
or O
placebo O
within O
each O
cohort. O
The O
percent O
of O
subjects O
experiencing O
adverse O
events O
was O
similar O
between O
the O
denufosol B-CHEMICAL
and O
placebo O
groups. O
The O
most O
common O
adverse O
event O
in O
subjects O
receiving O
denufosol B-CHEMICAL
was O
chest O
tightness O
in O
adult O
subjects O
(39%) O
and O
cough O
in O
pediatric O
subjects O
(56%). O
Three O
(7%) O
subjects O
receiving O

denufosol B-CHEMICAL
and O
one O
(7%) O
subject O
receiving O
placebo O
experienced O
a O
serious O
adverse O
event. O
Forced O
expiratory O
volume O
in O
1 O
sec O
(FEV(1)) O
profiles O
following O
dosing O
were O
similar O
across O
treatment O
groups, O
with O
some O
acute, O
reversible O
decline O
seen O
in O
both O
groups, O
most O
notably O
in O
subjects O
with O
lower O
lung O
function O
at O
baseline. O
In O
conclusion, O
doses O
up O
to O
60 O
mg O
of O
denufosol B-CHEMICAL
inhalation O
solution O
were O
well-tolerated O
in O
most O
subjects. O
Some O
intolerability O
was O
noted O
among O
subjects O
with O
lower O
baseline O
lung O
function. O
Based O
on O
the O
results O
of O
this O
phase O
1/phase O
2 O

study, O
the O
Therapeutics O
Development O
Network O
(TDN) O
of O
the O
Cystic O
Fibrosis O
Foundation O
(CFF) O
and O
Inspire O
Pharmaceuticals, O
Inc., O
recently O
completed O
a O
multicenter, O
28-day, O
phase O
2 O
safety O
and O
efficacy O
clinical O
trial O
of O
denufosol B-CHEMICAL
inhalation O
solution O
in O
CF O
subjects O
with O
mild O
lung O
disease. O
The O
dextromethorphan B-CHEMICAL
analog O
dimemorfan B-CHEMICAL
attenuates O
kainate-induced O
seizures O
via O
sigma1 B-GENE-Y
receptor I-GENE-Y
activation: O
comparison O
with O
the O
effects O
of O
dextromethorphan. B-CHEMICAL
In O
a O
previous O
study, O
we O
demonstrated O
that O
a O

dextromethorphan B-CHEMICAL
analog, O
dimemorfan, B-CHEMICAL
has O
neuroprotective O
effects. O
Dextromethorphan B-CHEMICAL
and O
dimemorfan B-CHEMICAL
are O
high-affinity O
ligands O
at O
sigma1 B-GENE-Y
receptors. I-GENE-Y
Dextromethorphan B-CHEMICAL
has O
moderate O
affinities O
for O
phencyclidine B-CHEMICAL
sites, O
while O
dimemorfan B-CHEMICAL
has O
very O
low O
affinities O
for O
such O
sites, O
suggesting O
that O
these O
sites O
are O
not O
essential O
for O
the O
anticonvulsant O
actions O
of O
dimemorfan. B-CHEMICAL
Kainate B-CHEMICAL
(KA) B-CHEMICAL
administration O
(10 O
mg O
kg(-1), O
i.p.) O
produced O
robust O

convulsions O
lasting O
4-6 O
h O
in O
rats. O
Pre-treatment O
with O
dimemorfan B-CHEMICAL
(12 O
or O
24 O
mg O
kg(-1)) O
reduced O
seizures O
in O
a O
dose-dependent O
manner. O
Dimemorfan B-CHEMICAL
pre-treatment O
also O
attenuated O
the O
KA-induced B-CHEMICAL
increases O
in O
c-fos/c-jun B-GENE-Y
expression, O
activator B-GENE-Y
protein I-GENE-Y
(AP)-1 I-GENE-Y
DNA-binding O
activity, O
and O
loss O
of O
cells O
in O
the O
CA1 O
and O
CA3 O
fields O
of O
the O
hippocampus. O
These O
effects O
of O
dimemorfan B-CHEMICAL
were O
comparable O
to O
those O
of O
dextromethorphan. B-CHEMICAL
The O

anticonvulsant O
action O
of O
dextromethorphan B-CHEMICAL
or O
dimemorfan B-CHEMICAL
was O
significantly O
counteracted O
by O
a O
selective O
sigma1 B-GENE-Y
receptor I-GENE-Y
antagonist O
BD B-CHEMICAL
1047, I-CHEMICAL
suggesting O
that O
the O
anticonvulsant O
action O
of O
dextromethorphan B-CHEMICAL
or O
dimemorfan B-CHEMICAL
is, O
at O
least O
in O
part, O
related O
to O
sigma1 B-GENE-Y
receptor-activated I-GENE-Y
modulation O
of O
AP-1 B-GENE-Y
transcription O
factors. O
We O
asked O
whether O
dimemorfan B-CHEMICAL
produces O
the O
behavioral O
side O
effects O
seen O
with O
dextromethorphan B-CHEMICAL
or O
dextrorphan B-CHEMICAL
(a O
phencyclidine-like B-CHEMICAL
metabolite O
of O

dextromethorphan). B-CHEMICAL
Conditioned O
place O
preference O
and O
circling O
behaviors O
were O
significantly O
increased O
in O
mice O
treated O
with O
phencyclidine, B-CHEMICAL
dextrorphan B-CHEMICAL
or O
dextromethorphan, B-CHEMICAL
while O
mice O
treated O
with O
dimemorfan O
showed O
no O
behavioral O
side O
effects. O
Our O
results O
suggest O
that O
dimemorfan B-CHEMICAL
is O
equipotent O
to O
dextromethorphan B-CHEMICAL
in O
preventing O
KA-induced B-CHEMICAL
seizures, O
while O
it O
may O
lack O
behavioral O
effects, O
such O
as O
psychotomimetic O
reactions. O
Binding O
domains O
of O
the O
oxytocin B-GENE-Y
receptor I-GENE-Y
for O
the O
selective O
oxytocin B-GENE-Y
receptor I-GENE-Y
antagonist O

barusiban B-CHEMICAL
in O
comparison O
to O
the O
agonists O
oxytocin B-GENE-Y
and O
carbetocin. B-CHEMICAL
We O
have O
analyzed O
binding O
domains O
of O
the O
oxytocin B-GENE-Y
receptor I-GENE-Y
for O
barusiban, B-CHEMICAL
a O
highly O
selective O
oxytocin B-GENE-Y
receptor I-GENE-Y
antagonist, O
in O
comparison O
to O
the O
combined O
vasopressin B-GENE-N
V1A/oxytocin I-GENE-N
receptor I-GENE-N
antagonist O
atosiban B-CHEMICAL
and O
the O
agonists O
oxytocin B-GENE-Y
and O
carbetocin. B-CHEMICAL
For O
this O
purpose, O
chimeric O
'gain-in O
function' O
oxytocin/vasopressin B-GENE-N
V2 I-GENE-N
receptors I-GENE-N
were O
expressed O
in O
COS-7 O
cells. O
These O

recombinant O
receptors O
have O
been O
produced O
by O
transfer O
of O
domains O
from O
the O
oxytocin B-GENE-Y
receptor I-GENE-Y
into O
the O
related O
vasopressin B-GENE-Y
V2 I-GENE-Y
receptor I-GENE-Y
and O
have O
already O
been O
successfully O
employed O
for O
the O
identification O
of O
ligand O
binding O
domains O
at O
the O
oxytocin B-GENE-Y
receptor I-GENE-Y
(Postina, O
R., O
Kojro, O
E., O
Fahrenholz, O
F., O
1996. O
Separate O
agonist O
and O
peptide O
antagonist O
binding O
sites O
of O
the O
oxytocin B-GENE-Y
receptor I-GENE-Y
defined O
by O
their O
transfer O
into O
the O
V2 B-GENE-Y
vasopressin I-GENE-Y
receptor. I-GENE-Y
J. O
Biol. O
Chem. O
271, O

31593-31601). O
In O
displacement O
studies O
with O
10 O
chimeric O
receptor O
constructs, O
the O
binding O
profile O
of O
barusiban B-CHEMICAL
was O
compared O
with O
the O
binding O
profiles O
of O
the O
ligands O
oxytocin, B-GENE-Y
[Arg8]vasopressin, B-CHEMICAL
carbetocin, B-CHEMICAL
and O
atosiban. B-CHEMICAL
The O
binding O
profiles O
for O
the O
agonists O
oxytocin B-GENE-Y
and O
carbetocin B-CHEMICAL
were O
found O
to O
be O
similar. O
For O
both O
agonists, O
important O
binding O
domains O
were O
the O
extracellular O
N-terminus B-CHEMICAL
(=E1) O
and O
the O
extracellular O
loops O
E2 O
and O
E3 O
from O
the O
oxytocin B-CHEMICAL

receptor. I-GENE-Y
For O
the O
vasopressin B-CHEMICAL
V1A/oxytocin I-GENE-N
receptor I-GENE-N
antagonist O
atosiban, B-CHEMICAL
none O
of O
the O
receptor O
constructs O
were O
able O
to O
provide O
a O
binding O
with O
higher O
affinity O
than O
the O
starting O
vasopressin B-GENE-Y
V2 I-GENE-Y
receptor. I-GENE-Y
In O
contrast, O
the O
binding O
of O
barusiban B-CHEMICAL
was O
significantly O
improved O
when O
the O
transmembrane O
domains O
1 O
and O
2 O
were O
transferred O
from O
the O
oxytocin B-CHEMICAL
receptor O
to O
the O
vasopressin B-GENE-Y
V2 I-GENE-Y
receptor. I-GENE-Y
The O
binding O
domain O
of O
barusiban B-CHEMICAL
differs O
from O
the O
binding O
domain O
of O
the O
agonists O
and O
the O
nonselective O
oxytocin B-GENE-Y
receptor I-GENE-Y
antagonist O

d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin B-CHEMICAL
that O
has O
been O
used O
in O
previous O
studies. O
Overall, O
the O
data O
supported O
the O
concept O
of O
a O
central O
pocket O
site O
within O
the O
oxytocin B-GENE-Y
receptor. I-GENE-Y
Neonatal O
epileptic O
encephalopathy O
caused O
by O
mutations O
in O
the O
PNPO B-GENE-Y
gene O
encoding O
pyridox(am)ine B-GENE-Y
5'-phosphate I-GENE-Y
oxidase. I-GENE-Y
In O
the O
mouse, O
neurotransmitter O
metabolism O
can O
be O
regulated O
by O
modulation O
of O
the O
synthesis O
of O
pyridoxal B-CHEMICAL

5'-phosphate I-CHEMICAL
and O
failure O
to O
maintain O
pyridoxal B-CHEMICAL
phosphate I-CHEMICAL
(PLP) B-CHEMICAL
levels O
results O
in O
epilepsy. O
This O
study O
of O
five O
patients O
with O
neonatal O
epileptic O
encephalopathy O
suggests O
that O
the O
same O
is O
true O
in O
man. O
Cerebrospinal O
fluid O
and O
urine O
analyses O
indicated O
reduced O
activity O
of O
aromatic B-CHEMICAL
L-amino I-CHEMICAL
acid I-CHEMICAL
decarboxylase I-GENE-Y
and O
other O
PLP-dependent B-CHEMICAL
enzymes. O
Seizures O
ceased O
with O
the O
administration O
of O
PLP, B-CHEMICAL
having O
been O
resistant O
to O
treatment O
with O
pyridoxine, O
suggesting O
a O
defect O
of O
pyridox(am)ine B-CHEMICAL
5'-phosphate I-CHEMICAL

oxidase I-GENE-Y
(PNPO). B-GENE-Y
Sequencing O
of O
the O
PNPO B-GENE-Y
gene O
identified O
homozygous O
missense, O
splice O
site O
and O
stop O
codon O
mutations. O
Expression O
studies O
in O
Chinese O
hamster O
ovary O
cells O
showed O
that O
the O
splice O
site O
(IVS3-1g>a) B-GENE-N
and O
stop O
codon O
(X262Q) O
mutations O
were O
null O
activity O
mutations O
and O
that O
the O
missense O
mutation O
(R229W) B-GENE-N
markedly O
reduced O
pyridox(am)ine B-CHEMICAL
phosphate I-CHEMICAL
oxidase I-GENE-Y
activity. O
Maintenance O
of O
optimal O
PLP B-CHEMICAL
levels O
in O
the O
brain O
may O
be O
important O
in O
many O

neurological O
disorders O
in O
which O
neurotransmitter O
metabolism O
is O
disturbed O
(either O
as O
a O
primary O
or O
as O
a O
secondary O
phenomenon). O
Effect O
of O
5-azacytidine B-CHEMICAL
and O
procainamide B-CHEMICAL
on O
CD3-zeta B-GENE-Y
chain I-GENE-Y
expression O
in O
Jurkat O
T O
cells. O
It O
has O
been O
observed O
that O
decrease O
of O
DNA B-GENE-Y
methyltransferase I-GENE-Y
1 I-GENE-Y
(DNMT1) B-GENE-Y
activity O
is O
associated O
with O
low O
content O
of O
the O
CD3-zeta B-GENE-Y
(zeta) I-GENE-Y
chain I-GENE-Y
in O
T B-GENE-N
cell I-GENE-N
receptor I-GENE-N
(TCR)/CD3 B-GENE-N
complex O
of O
T O
cells O
in O
systemic O
lupus O
erythematosus O
(SLE) O

patients. O
The O
CD3-zeta B-GENE-Y
chain I-GENE-Y
plays O
a O
pivotal O
role O
in O
intracellular O
signal O
transmission O
between O
TCR/CD3 B-GENE-N
complex O
and O
nuclei. O
The O
compounds O
5'-azacytidine B-CHEMICAL
(AZC) B-CHEMICAL
and O
procainamide B-CHEMICAL
(PCA) B-CHEMICAL
belong O
to O
inhibitors O
of O
DNMT1, B-GENE-Y
whose O
low O
activity O
correlates O
with O
increase O
in O
transcription O
of O
various O
genes. O
Using O
the O
reverse-transcription O
and O
real-time O
quantitative O
PCR O
(RQ-PCR) O
analysis, O
we O
indicated O
that O
AZC B-CHEMICAL
and O
PCA B-CHEMICAL
did O
not O
profoundly O
affect O
on O
CD3-zeta B-GENE-Y
chain I-GENE-Y
transcription O
in O
Jurkat O
T O

leukemia O
cells O
clone O
E6-1. O
However, O
the O
flowcytometric O
analysis O
revealed O
that O
AZC B-CHEMICAL
and O
PCA B-CHEMICAL
decreased O
intracellular O
contents O
of O
CD3-zeta B-GENE-Y
chain I-GENE-Y
in O
these O
cells O
in O
dose O
dependent O
manner. O
Our O
results O
suggest O
that O
decrease O
of O
DNMT1 B-GENE-Y
activity O
may O
alter O
intracellular O
signal O
transmission O
without O
effect O
on O
transcription O
level O
of O
CD3-zeta B-GENE-Y
chain. I-GENE-Y
Changes O
in O
gene O
expression O
associated O
with O
loss O
of O
function O
of O
the O
NSDHL B-GENE-Y
sterol B-GENE-N
dehydrogenase I-GENE-N
in O
mouse O
embryonic O
fibroblasts. O
Seven O
human O
disorders O
of O
postsqualene O
cholesterol B-CHEMICAL
biosynthesis O

have O
been O
described. O
One O
of O
these, O
congenital O
hemidysplasia O
with O
ichthyosiform O
nevus O
and O
limb O
defects O
(CHILD) O
syndrome, O
results O
from O
mutations O
in O
the O
X-linked O
gene O
NADH B-CHEMICAL
sterol B-CHEMICAL
dehydrogenase-like I-GENE-Y
(NSDHL) B-GENE-Y
encoding O
a O
sterol B-CHEMICAL
dehydrogenase. I-GENE-N
A O
series O
of O
mutant O
alleles O
of O
the O
murine O
Nsdhl B-GENE-Y
gene O
are O
carried O
by O
bare O
patches O
(Bpa) O
mice, O
with O
Bpa(1H) O
representing O
a O
null O
allele. O
Heterozygous O
Bpa(1H) O
females O
display O

skin O
and O
skeletal O
abnormalities O
in O
a O
distribution O
reflecting O
random O
X O
inactivation, O
whereas O
hemizygous O
male O
embryos O
die O
before O
embryonic O
day O
10.5. O
To O
investigate O
the O
molecular O
basis O
of O
defects O
associated O
with O
perturbations O
in O
cholesterol B-CHEMICAL
biosynthesis, O
microarray O
analysis O
was O
performed O
comparing O
gene O
expression O
in O
embryonic O
fibroblasts O
expressing O
the O
Bpa(1H) O
allele O
versus O
wild-type O
(wt) O
cells. O
Labeled O
cDNAs O
from O
cells O
grown O
in O
normal O
serum O
or O
lipid-depleted O
serum O
(LDS) O
were O
hybridized O
to O
microarrays O

containing O
22,000 O
mouse O
genes. O
Among O
44 O
genes O
that O
showed O
higher O
expression O
in O
the O
Bpa(1H) O
versus O
wt O
cells O
grown O
in O
LDS, O
11 O
function O
in O
cholesterol B-CHEMICAL
biosynthesis, O
7 O
are O
involved O
in O
fatty B-CHEMICAL
acid I-CHEMICAL
synthesis, O
3 O
(Srebp2, B-GENE-Y
Insig1, B-GENE-Y
and O
Orf11) B-GENE-N
encode O
sterol-regulatory B-CHEMICAL
proteins, O
and O
2 O
(Ldlr B-GENE-Y
and O
StarD4) B-GENE-Y
are O
lipid O
transporters. O
Of O
the O
21 O
remaining O
genes, O
16 O
are O
known O
genes, O
some O
of O
which O
have O
been O
implicated O
previously O
in O
cholesterol B-CHEMICAL
homeostasis O
or O
lipid-mediated O
signaling, O

and O
5 O
are O
uncharacterized O
cDNA O
clones. O
Rapid O
quantitation O
of O
plasma O
2'-deoxyuridine B-CHEMICAL
by O
high-performance O
liquid O
chromatography/atmospheric O
pressure O
chemical O
ionization O
mass O
spectrometry O
and O
its O
application O
to O
pharmacodynamic O
studies O
in O
cancer O
patients. O
A O
novel O
method O
employing O
high-performance O
liquid O
chromatograph-mass O
spectrometry O
(LC-MS) O
has O
been O
developed O
and O
validated O
for O
the O
quantitation O
of O
plasma O
2'-deoxyuridine B-CHEMICAL
(UdR). B-CHEMICAL
It O
involves O
a O
plasma O
clean-up O
step O
with O
strong O
anion-exchange O

solid-phase O
extraction O
(SAX-SPE) O
followed O
by O
HPLC O
separation O
and O
atmospheric O
pressure O
chemical O
ionization O
mass O
spectrometry O
detection O
(APCI-MS) O
in O
a O
selected-ion O
monitoring O
(SIM) O
mode. O
The O
ionization O
conditions O
were O
optimised O
in O
negative O
ion O
mode O
to O
give O
the O
best O
intensity O
of O
the O
dominant O
formate B-CHEMICAL
adduct O
[M+HCOO]- B-CHEMICAL
at O
m/z O
273. O
Retention O
times O
were O
7.5 O
and O
12.5 O
min O
for O
2'-deoxyuridine B-CHEMICAL
and O
5-iodo-2'-deoxyuridine, B-CHEMICAL
an O

iodinated O
analogue O
internal O
standard O
(IS), O
respectively. O
Peak O
area O
ratios O
of O
2'-deoxyuridine B-CHEMICAL
to O
IS O
were O
used O
for O
regression O
analysis O
of O
the O
calibration O
curve. O
The O
latter O
was O
linear O
from O
5 O
to O
400 O
nmol/l O
using O
1 O
ml O
sample O
volume O
of O
plasma. O
The O
average O
recovery O
was O
81.5% O
and O
78.6% O
for O
2'-deoxyuridine B-CHEMICAL
and O
5-iodo-deoxyuridine, B-CHEMICAL
respectively. O
The O
method O
provides O
sufficient O
sensitivity, O
precision, O
accuracy O
and O
selectivity O
for O
routine O
analysis O
of O
human O
plasma O
2'-deoxyuridine B-CHEMICAL
concentration O
with O

the O
lowest O
limit O
of O
quantitation O
(LLOQ) O
of O
5 O
nmol/l. O
Clinical O
studies O
in O
cancer O
patients O
treated O
with O
the O
new O
fluoropyrimidine B-CHEMICAL
analogue O
capecitabine B-CHEMICAL
(N4-pentoxycarbonyl-5'-5-fluorocytidine) B-CHEMICAL
have O
shown O
that O
plasma O
2'-deoxyuridine B-CHEMICAL
was O
significantly O
elevated O
after O
1 O
week O
of O
treatment, O
consistent O
with O
inhibition O
of O
thymidylate B-CHEMICAL
synthase I-GENE-Y
(TS). B-GENE-Y
These O
findings O
suggest O
that O
the O
mechanism O
of O
antiproliferative O
toxicity O
of O
capecitabine B-CHEMICAL
is O
at O
least O
partly O
due O
to O
TS B-GENE-Y

inhibitory O
activity O
of O
its O
active O
metabolite O
5-fluoro-2'-deoxyuridine B-CHEMICAL
monophosphate I-CHEMICAL
(FdUMP). B-CHEMICAL
Monitoring O
of O
plasma O
UdR B-CHEMICAL
concentrations O
have O
the O
potential O
to O
help O
clinicians O
to O
guide O
scheduling O
of O
capecitabine B-CHEMICAL
or O
other O
TS B-GENE-Y
inhibitors O
in O
clinical O
trials. O
Marked O
differences O
of O
plasma O
2'-deoxyuridine B-CHEMICAL
between O
human O
and O
rodents O
have O
also O
been O
confirmed. O
In O
conclusion, O
the O
LC-MS O
method O
developed O
is O
simple, O
highly O
selective O
and O
sensitive O
and O
permits O
pharmacodynamic O
studies O
of O
TS B-GENE-N
inhibitors O
in O
several O
species. O
Induction O
of O

heparin-binding B-GENE-Y
EGF-like I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
and O
activation O
of O
EGF B-GENE-Y
receptor I-GENE-Y
in O
imatinib B-CHEMICAL
mesylate-treated I-CHEMICAL
squamous O
carcinoma O
cells. O
Imatinib B-CHEMICAL
mesylate I-CHEMICAL
is O
a O
tyrosine B-CHEMICAL
kinase I-GENE-N
inhibitor O
of O
the O
ABL, B-GENE-Y
platelet-derived B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(PDGFR), B-GENE-Y
and O
c-kit B-GENE-Y
kinases. B-GENE-N
Inhibition O
of O
BCR-ABL B-GENE-Y
and O
c-kit B-GENE-Y
accounts O
for O
its O
clinical O
activity O
in O
leukemia O
and O
sarcoma, O
respectively. O
In O
this O
report, O
we O
describe O
other O
cellular O
targets O
for O
imatinib. B-CHEMICAL
Treatment O
of O
head O
and O
neck O

squamous O
carcinoma O
cells O
with O
clinically O
relevant O
concentrations O
of O
imatinib-induced B-CHEMICAL
changes O
in O
cell O
morphology O
and O
growth O
similar O
to O
changes O
associated O
with O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(EGFR) B-GENE-Y
activation. O
Imatinib-induced B-CHEMICAL
changes O
were O
blocked O
with O
the O
EGFR B-GENE-Y
antagonist O
cetuximab, O
which O
suggested O
direct O
involvement O
of O
EGFR B-GENE-Y
in O
this O
process. O
Western O
blot O
analysis O
of O
cells O
incubated O
with O
imatinib B-CHEMICAL
demonstrated O
activation O
of O
EGFR B-GENE-Y
and O
downstream O
signaling O
that O
was O
reduced O
by O
inhibition O
of O
mitogen-activated B-GENE-Y
protein/extracellular I-GENE-Y
signal-regulated I-GENE-Y
kinase I-GENE-Y
kinase I-GENE-Y
1 I-GENE-Y

(MEK1) B-GENE-Y
and O
EGFR, B-GENE-Y
but O
not O
Her2/ErbB2. B-GENE-Y
An O
in O
vitro O
kinase B-GENE-N
assay O
showed O
that O
imatinib B-CHEMICAL
did O
not O
directly O
affect O
EGFR B-GENE-Y
kinase B-GENE-N
activity, O
suggesting O
involvement O
of O
EGFR-activating B-GENE-Y
molecules. O
Inhibitors O
and O
neutralizing O
antibodies O
against O
heparin-binding B-GENE-Y
epidermal I-GENE-Y
growth I-GENE-Y
factor-like I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(HB-EGF), B-GENE-Y
and O
to O
a O
lesser O
extent O
transforming B-GENE-Y
growth I-GENE-Y
factor-alpha, I-GENE-Y
reduced O
imatinib-mediated B-CHEMICAL
mitogen B-GENE-N
activated I-GENE-N
protein I-GENE-N
kinase I-GENE-N
(MAPK) B-GENE-N
activation. O
Imatinib B-CHEMICAL
stimulated O

the O
rapid O
release O
of O
soluble O
HB-EGF B-GENE-Y
and O
the O
subsequent O
induction O
of O
membrane-bound O
HB-EGF, B-GENE-Y
which O
correlated O
with O
biphasic O
MAPK B-GENE-N
activation. O
Together, O
these O
results O
suggested O
that O
imatinib B-CHEMICAL
affects O
EGFR B-GENE-Y
activation O
and O
signaling O
pathways O
through O
rapid O
release O
and O
increased O
expression O
of O
endogenous O
EGFR-activating B-GENE-Y
ligands. O
Although, O
imatinib B-CHEMICAL
primarily O
inhibits O
tyrosine B-GENE-N
kinases, I-GENE-N
it O
also O
stimulates O
the O
activity O
of O
EGFR B-GENE-Y
tyrosine B-CHEMICAL
kinase I-GENE-N
in O
head O
and O
neck O
squamous O
tumors. O
This O
finding O
demonstrates O
the O
need O
for O

careful O
use O
of O
this O
drug O
in O
cancer O
patients. O
Epithelioid O
gastrointestinal O
stromal O
tumor O
with O
PDGFRA B-GENE-Y
activating O
mutation O
and O
immunoreactivity. O
The O
authors O
report O
a O
unique O
case O
of O
an O
intra-abdominal, O
epithelioid O
mesenchymal O
tumor O
that O
had O
an O
activating O
mutation O
of O
PDGFRA B-GENE-Y
and O
a O
strong O
PDGFRA B-GENE-Y
immunoreactivity O
but O
lacked O
both O
c-kit B-GENE-Y
mutation O
and O
c-kit B-GENE-Y
protein O
(CD117) B-GENE-Y
expression. O
IHC O
study O
showed O
that O
the O
tumor O
cells O
were O
diffusely O
and O
strongly O
positive O
for O

PDGFRA, B-GENE-Y
vimentin, B-GENE-Y
CD34, B-GENE-Y
and O
Bcl-2 B-GENE-Y
but O
completely O
negative O
for O
CD117 B-GENE-Y
as O
well O
as O
for O
muscle, O
epithelial, O
endothelial, O
endocrine, O
mesothelial, O
neural, O
and O
melanocytic O
cell O
markers. O
Molecular O
study O
revealed O
a O
mutation O
at O
the O
juxtamembrane O
domain O
of O
exon O
12 O
in O
PDGFRA B-GENE-Y
gene O
with O
GTC B-GENE-N
to I-GENE-N
GAC I-GENE-N
transition O
at O
codon O
561 O
(V561D), B-GENE-N
as O
shown O
in O
the O
previous O
mutational O
studies O
on O
gastrointestinal O
stromal O
tumor O

(GIST). O
This O
case O
likely O
represents O
an O
example O
of O
GIST O
with O
PDGFRA B-GENE-Y
activating O
mutation O
and O
PDGFRA B-GENE-Y
immunoreactivity O
without O
CD117 B-GENE-Y
positivity, O
which O
has O
not O
been O
documented O
in O
the O
literature. O
STI B-CHEMICAL
571 I-CHEMICAL
(imatinib B-CHEMICAL
mesylate I-CHEMICAL
[Gleevec]) B-CHEMICAL
might O
be O
an O
effective O
therapy O
in O
this O
case, O
since O
Gleevec B-CHEMICAL
targets O
both O
PDGFRA B-GENE-Y
and O
c-kit B-GENE-Y
oncoproteins. O
Genetic O
polymorphism O
and O
activities O
of O
human B-GENE-N
lung I-GENE-N
alcohol I-GENE-N
and I-GENE-N
aldehyde I-GENE-N
dehydrogenases: I-GENE-N
implications O

for O
ethanol B-CHEMICAL
metabolism O
and O
cytotoxicity. O
Alcohol B-CHEMICAL
dehydrogenase I-GENE-N
(ADH) B-GENE-N
and O
aldehyde B-CHEMICAL
dehydrogenase I-GENE-N
(ALDH) B-GENE-N
exhibit O
genetic O
polymorphism O
and O
tissue O
specificity. O
ADH B-GENE-N
and O
ALDH B-GENE-N
isozyme O
phenotypes O
from O
39 O
surgical O
Chinese O
lung O
specimens O
were O
identified O
by O
agarose O
isoelectric O
focusing. O
The O
identity O
of O
the O
lung O
beta-ADHs B-GENE-N
was O
further O
demonstrated O
by O
their O
characteristic O
pH-activity O
profiles O
for O
ethanol B-CHEMICAL
oxidation, O
Km O
values O
for O
NAD O
and O
ethanol, B-CHEMICAL
and O
inhibition O
by O
4-methylpyrazole B-CHEMICAL
or O

1,10-phenanthroline. B-CHEMICAL
The O
beta O
2 O
allele, O
coding O
for O
beta O
2 O
polypeptide, B-CHEMICAL
was O
found O
to O
be O
predominant O
in O
the O
lung O
specimens O
studied. O
The O
ADH B-GENE-N
activities O
in O
the O
lungs O
with O
the O
homozygous O
phenotype O
ADH2 B-GENE-Y
2-2 I-GENE-Y
(exhibiting O
beta O
2 O
beta O
2) O
and O
ADH2 B-GENE-Y
1-1 I-GENE-Y
(exhibiting O
beta O
1 O
beta O
1) O
and O
the O
heterozygous O
phenotype O
ADH2 B-GENE-Y
2-1 I-GENE-Y
(exhibiting O
beta O
2 O
beta O
2, O
beta O
2 O
beta O
1, O
and O
beta O
1 O
beta O
1) O
were O
determined O
to O
be O
999 O
+/- O

77, O
48 O
+/- O
17, O
and O
494 O
+/- O
61 O
nmol/min/g O
tissue, O
respectively. O
Fifty-one O
percent O
of O
the O
specimens O
studied O
lacked O
the O
ALDH2 B-GENE-Y
activity O
band O
on O
the O
isoelectric O
focusing O
gels. O
The O
activities O
in O
the O
lung O
tissues O
with O
the O
ALDH2-active B-GENE-Y
phenotype O
and O
the O
inactive O
phenotype O
were O
determined O
to O
be O
30 O
+/- O
3 O
and O
17 O
+/- O
1 O
nmol/min/g O
tissue, O
respectively. O
These O
findings O
indicate O
that O
human O
pulmonary O
ethanol-metabolizing B-CHEMICAL
activities O
differ O
significantly O
with O
respect O
to O
genetic O
polymorphism O
at O
both O
the O

ADH2 B-GENE-Y
and O
the O
ALDH2 B-GENE-Y
loci. O
The O
results O
suggest O
that O
individuals O
with O
high O
Vmax O
beta B-GENE-Y
2-ADH I-GENE-Y
and O
deficient O
in O
low-Km O
mitochondrial O
ALDH2, B-GENE-Y
accounting O
for O
approximately O
45% O
of O
the O
Chinese O
population, O
may O
end O
up O
with O
acetaldehyde B-CHEMICAL
accumulation O
during O
alcohol B-CHEMICAL
consumption, O
rendering O
them O
vulnerable O
to O
tissue O
injury O
caused O
by O
this O
highly O
reactive O
and O
toxic O
metabolite. O
Simvastatin B-CHEMICAL
induces O
interleukin-18 B-GENE-Y
production O
in O
human O
peripheral O
blood O
mononuclear O
cells. O
The O
effects O
of O
statins O
on O
immune O
response O
depend O
on O
the O
inhibition O
of O

3-hydroxy-3-methylglutaryl B-CHEMICAL
coenzyme-A I-CHEMICAL
(HMG-CoA) I-GENE-Y
reductase I-GENE-Y
and O
leukocyte B-GENE-Y
function-associated I-GENE-Y
antigen I-GENE-Y
(LFA)-1, I-GENE-Y
which O
is O
a O
ligand O
of O
intercellular B-GENE-Y
adhesion I-GENE-Y
molecule I-GENE-Y
(ICAM)-1. I-GENE-Y
Simvastatin, B-CHEMICAL
an O
HMG-CoA B-CHEMICAL
reductase I-GENE-Y
inhibitor O
with O
mild O
inhibition O
of O
LFA-1, B-GENE-Y
induced O
the O
production O
of O
interleukin B-GENE-Y
(IL)-18, I-GENE-Y
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
(TNF)-alpha I-GENE-Y
and O
interferon B-GENE-Y

(IFN)-gamma I-GENE-Y
in O
human O
peripheral O
blood O
mononuclear O
cells O
(PBMC). O
The O
IL-18 B-GENE-Y
production O
is O
located O
upstream O
of O
the O
cytokine B-GENE-N
cascade O
activated O
by O
simvastatin. B-CHEMICAL
Moreover, O
simvastatin B-CHEMICAL
concentration-dependently O
inhibited O
the O
expression O
of O
ICAM-1 B-GENE-Y
and O
induced O
the O
expression O
of O
CD40 B-GENE-Y
on O
monocytes. O
In O
the O
presence O
of O
IL-18, B-GENE-Y
simvastatin B-CHEMICAL
suppressed O
the O
expression O
of O
ICAM-1 B-GENE-Y
and O
CD40 B-GENE-Y
as O
well O
as O
the O
production O
of O
IL-12, B-GENE-N
TNF-alpha B-GENE-Y
and O
IFN-gamma B-GENE-Y
in O

PBMC, O
contributing O
to O
the O
anti-inflammatory O
effect O
of O
simvastatin. B-CHEMICAL
The O
effects O
of O
simvastatin B-CHEMICAL
were O
abolished O
by O
the O
addition O
of O
the O
product O
of O
the O
HMG-CoA B-GENE-Y
reductase, I-GENE-Y
mevalonate, B-CHEMICAL
indicating O
the O
involvement O
of O
HMG-CoA B-CHEMICAL
reductase I-GENE-Y
in O
the O
action O
of O
simvastatin. B-CHEMICAL
COX-1 B-GENE-Y
and O
COX-2 B-GENE-Y
inhibition O
in O
horse O
blood O
by O
phenylbutazone, B-CHEMICAL
flunixin, B-CHEMICAL
carprofen B-CHEMICAL
and O
meloxicam: B-CHEMICAL
an O
in O
vitro O
analysis. O
We O
report O
on O
the O
inhibitory O
activity O
of O
the O

NSAIDs O
meloxicam, B-CHEMICAL
carprofen, B-CHEMICAL
phenylbutazone B-CHEMICAL
and O
flunixin, B-CHEMICAL
on O
blood O
cyclooxygenases B-GENE-N
in O
the O
horse O
using O
in O
vitro O
enzyme-linked O
assays. O
As O
expected, O
comparison O
of O
IC50 O
indicated O
that O
meloxicam B-CHEMICAL
and O
carprofen B-CHEMICAL
are O
more O
selective O
inhibitors O
of O
COX-2 B-GENE-Y
than O
phenylbutazone B-CHEMICAL
and O
flunixin; B-CHEMICAL
meloxicam B-CHEMICAL
was O
the O
most O
advantageous O
for O
horses O
of O
four O
NSAIDs O
examined. O
However O
at O
IC80, O
phenylbutazone B-CHEMICAL
(+134.4%) O

and O
flunixin B-CHEMICAL
(+29.7%) O
had O
greater O
COX-2 B-GENE-Y
selectivity O
than O
at O
IC50, O
and O
meloxicam B-CHEMICAL
(-41.2%) O
and O
carprofen B-CHEMICAL
(-12.9%) O
had O
lower O
COX-2 B-GENE-Y
selectivity O
than O
at O
IC50. O
We O
therefore O
propose O
that O
the O
selectivity O
of O
NSAIDs O
should O
be O
assessed O
at O
the O
80% O
as O
well O
as O
50% O
inhibition O
level. O
Carvedilol B-CHEMICAL
prevents O
cardiac O
hypertrophy O
and O
overexpression O
of O
hypoxia-inducible B-GENE-Y
factor-1alpha I-GENE-Y
and O
vascular B-GENE-Y
endothelial I-GENE-Y
growth I-GENE-Y

factor I-GENE-Y
in O
pressure-overloaded O
rat O
heart. O
The O
use O
of O
beta-blockers O
has O
emerged O
as O
a O
beneficial O
treatment O
for O
cardiac O
hypertrophy. O
Hypoxia-inducible B-GENE-Y
factor-1alpha I-GENE-Y
(HIF-1alpha) B-GENE-Y
is O
tightly O
regulated O
in O
the O
ventricular O
myocardium. O
However, O
the O
expression O
of O
HIF-1alpha B-GENE-Y
in O
cardiac O
hypertrophy O
due O
to O
pressure O
overload O
and O
after O
treatment O
with O
beta-blocker O
is O
little O
known. O
To O
evaluate O
the O
effect O
of O
carvedilol B-CHEMICAL
on O
both O
myocardial O
HIF-1alpha B-GENE-Y
expression O
and O
cardiac O
hypertrophy, O

infra-renal O
aortic O
banding O
was O
performed O
for O
4 O
weeks O
in O
adult O
Sprague-Dawley O
rats O
to O
induce O
cardiac O
hypertrophy. O
Carvedilol B-CHEMICAL
at O
50 O
mg/kg O
body O
weight O
per O
day O
after O
surgery O
was O
given. O
Heart O
weight O
and O
the O
ratio O
of O
heart O
weight O
and O
body O
weight O
increased O
significantly O
after O
aortic O
banding O
for O
4 O
weeks O
in O
the O
absence O
of O
drug O
treatment. O
Mean O
arterial O
pressure O
increased O
from O
80 O
+/- O
9 O
mmHg O
in O
the O
sham O
group O
to O
94 O
+/-5 O
mmHg O
(p O
< O
0.001) O
in O
the O
banding O
group. O
Echocardiography O
showed O

concentric O
hypertrophy O
after O
aortic O
banding. O
Mean O
arterial O
pressure O
decreased O
after O
treatment O
with O
carvedilol. B-CHEMICAL
The O
increased O
wall O
thickness O
and O
heart O
weight O
was O
reversed O
to O
normal O
by O
carvedilol. B-CHEMICAL
Western O
blot O
showed O
that O
HIF-1alpha, B-GENE-Y
vascular B-GENE-Y
endothelial I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(VEGF) B-GENE-Y
and O
brain B-GENE-Y
natriuretic I-GENE-Y
peptide I-GENE-Y
(BNP) B-GENE-Y
proteins O
were O
up-regulated O
and O
nerve B-GENE-Y
growth I-GENE-Y
factor-beta I-GENE-Y
(NGF-beta) B-GENE-Y
down-regulated O
in O
the O
banding O
group. O
Treatment O
with O
valsartan, B-CHEMICAL
doxazosin, B-CHEMICAL
or O
N-acetylcysteine B-CHEMICAL
did O

not O
significantly O
affect O
HIF-1alpha B-GENE-Y
and O
VEGF B-GENE-Y
proteins O
expression O
in O
the O
banding O
groups. O
Real-time O
polymerase O
chain O
reaction O
showed O
that O
mRNA O
of O
HIF-1alpha, B-GENE-Y
VEGF B-GENE-Y
and O
BNP B-GENE-Y
increased O
and O
mRNA O
of O
NGF-beta B-GENE-Y
decreased O
in O
the O
banding O
group. O
Treatment O
with O
carvedilol B-CHEMICAL
reversed O
both O
protein O
and O
mRNA O
of O
HIF-1alpha, B-GENE-Y
VEGF, B-GENE-Y
BNP, B-GENE-Y
and O
NGF-beta B-GENE-Y
to O
the O
baseline O
values. O
Increased O
immunohistochemical O
labeling O
of O
HIF-1alpha, B-GENE-Y
VEGF, B-GENE-Y
and O
BNP B-GENE-Y

in O
the O
ventricular O
myocardium O
was O
observed O
in O
the O
banding O
group O
and O
carvedilol B-CHEMICAL
again O
normalized O
the O
labeling. O
In O
conclusion, O
HIF-1alpha, B-GENE-Y
VEGF, B-GENE-Y
and O
BNP B-GENE-Y
mRNA O
and O
protein O
expression O
were O
up-regulated, O
while O
NGF-beta B-GENE-Y
mRNA O
and O
protein O
was O
downregulated O
in O
the O
rat O
model O
of O
pressure-overloaded O
cardiac O
hypertrophy. O
Treatment O
with O
carvedilol B-CHEMICAL
is O
associated O
with O
a O
reversal O
of O
abnormal O
regulation O
of O
HIF-1alpha, B-GENE-Y
VEGF, B-GENE-Y
BNP, B-GENE-Y
and O
NGF-beta B-GENE-Y
in O
the O
hypertrophic O

myocardium. O
Imatinib B-CHEMICAL
resistance O
in O
gastrointestinal O
stromal O
tumors. O
Conventional O
chemotherapeutic O
drugs O
are O
ineffective O
in O
treatment O
of O
gastrointestinal O
stromal O
tumors O
(GISTs). O
Imatinib B-CHEMICAL
(STI571, B-CHEMICAL
Gleevec, B-CHEMICAL
Glivec; B-CHEMICAL
Novartis O
Pharmaceuticals, O
East O
Hanover, O
NJ), O
a O
selective O
inhibitor O
of O
KIT, B-GENE-Y
ABL, B-GENE-Y
BCR-ABL, B-GENE-Y
PDGFRA, B-GENE-Y
and O
PDGFRB, B-GENE-Y
represents O
a O
new O
paradigm O
of O
targeted O
cancer O
therapy O
and O
has O

revolutionized O
the O
treatment O
of O
patients O
with O
chronic O
myelogenous O
leukemia O
and O
GISTs. O
Unfortunately, O
imatinib B-CHEMICAL
resistance O
has O
emerged. O
The O
reported O
mechanism O
of O
imatinib B-CHEMICAL
resistance O
in O
GISTs O
involves O
missense O
mutation O
in O
the O
kinase B-GENE-N
domain I-GENE-N
of O
KIT, B-GENE-N
including O
Thr670Ile, B-GENE-N
Tyr823Asp, B-GENE-N
and O
Val654Ala. B-GENE-N
The O
established O
mechanisms O
and O
potential O
mechanisms O
of O
imatinib B-CHEMICAL
resistance O
in O
GISTs, O
the O
imaging O
studies O
indicative O
of O
early O
development O
of O
imatinib B-CHEMICAL
resistance, O
and O
the O
management O
of O
imatinib-resistant B-CHEMICAL
GISTs O

are O
discussed. O
Evaluation O
of O
histamine B-GENE-N
H1-, I-GENE-N
H2-, I-GENE-N
and I-GENE-N
H3-receptor I-GENE-N
ligands O
at O
the O
human B-GENE-Y
histamine I-GENE-Y
H4 I-GENE-Y
receptor: I-GENE-Y
identification O
of O
4-methylhistamine B-CHEMICAL
as O
the O
first O
potent O
and O
selective O
H4 B-GENE-Y
receptor I-GENE-Y
agonist. O
The O
histamine B-CHEMICAL
H(4) I-GENE-Y
receptor I-GENE-Y
(H(4)R) B-GENE-Y
is O
involved O
in O
the O
chemotaxis O
of O
leukocytes O
and O
mast O
cells O
to O
sites O
of O
inflammation O
and O
is O
suggested O
to O
be O
a O
potential O
drug O
target O
for O
asthma O
and O
allergy. O
So O
far, O
selective O
H(4)R B-GENE-Y
agonists O
have O
not O
been O
identified. O
In O
the O
present O

study, O
we O
therefore O
evaluated O
the O
human B-GENE-Y
H(4)R I-GENE-Y
(hH(4)R) B-GENE-Y
for O
its O
interaction O
with O
various O
known O
histaminergic O
ligands. O
Almost O
all O
of O
the O
tested O
H(1)R B-GENE-Y
and O
H(2)R B-GENE-Y
antagonists, O
including O
several O
important O
therapeutics, O
displaced O
less O
than O
30% O
of O
specific O
[(3)H]histamine B-CHEMICAL
binding O
to O
the O
hH(4)R B-GENE-Y
at O
concentrations O
up O
to O
10 O
microM. O
Most O
of O
the O
tested O
H(2)R B-GENE-Y
agonists O
and O
imidazole-based B-CHEMICAL
H(3)R B-GENE-Y
ligands O
show O

micromolar-to-nanomolar O
range O
hH(4)R B-GENE-Y
affinity, O
and O
these O
ligands O
exert O
different O
intrinsic O
hH(4)R B-GENE-Y
activities, O
ranging O
from O
full O
agonists O
to O
inverse O
agonists. O
Interestingly, O
we O
identified O
4-methylhistamine B-CHEMICAL
as O
a O
high-affinity O
H(4)R B-GENE-Y
ligand O
(K(i) O
= O
50 O
nM) O
that O
has O
a O
>100-fold O
selectivity O
for O
the O
hH(4)R B-GENE-Y
over O
the O
other O
histamine B-CHEMICAL
receptor I-GENE-N
subtypes. O
Moreover, O
4-methylhistamine B-CHEMICAL
potently O
activated O
the O

hH(4)R B-GENE-Y
(pEC(50) O
= O
7.4 O
+/- O
0.1; O
alpha O
= O
1), O
and O
this O
response O
was O
competitively O
antagonized O
by O
the O
selective O
H(4)R B-GENE-Y
antagonist O
JNJ B-CHEMICAL
7777120 I-CHEMICAL
[1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] B-CHEMICAL
(pA(2) O
= O
7.8). O
The O
identification O
of O
4-methylhistamine B-CHEMICAL
as O
a O
potent O
H(4)R B-GENE-Y
agonist O
is O
of O
major O
importance O
for O

future O
studies O
to O
unravel O
the O
physiological O
roles O
of O
the O
H(4)R. B-GENE-Y
Novel O
agents O
that O
potentially O
inhibit O
irinotecan-induced B-CHEMICAL
diarrhea. O
Irinotecan B-CHEMICAL
(CPT-11, B-CHEMICAL
7-ethyl-10-[4-(1-piperidino)-1-piperidino] B-CHEMICAL
carbonyloxycamptothecin) I-CHEMICAL
has O
exhibited O
clinical O
activities O
against O
a O
broad O
spectrum O
of O
carcinomas O
by O
inhibiting O
DNA B-GENE-Y
topoisomerase I-GENE-Y
I I-GENE-Y
(Topo B-GENE-Y
I). I-GENE-Y
However, O
severe O
and O
unpredictable O
dosing-limiting O
toxicities O
(mainly O
myelosuppression O
and O

severe O
diarrhea) O
hinder O
its O
clinical O
use. O
The O
latter O
consists O
of O
early O
and O
late-onset O
diarrhea, O
occurring O
within O
24 O
hr O
or O
> O
or O
= O
24 O
hr O
after O
CPT-11 B-CHEMICAL
administration, O
respectively. O
This O
review O
highlights O
novel O
agents O
potentially O
inhibiting O
CPT-11-induced B-CHEMICAL
diarrhea, O
which O
are O
designed O
and O
tested O
under O
guidance O
of O
disposition O
pathways O
and O
potential O
toxicity O
mechanisms. O
Early-onset O
diarrhea O
is O
observed O
immediately O
after O
CPT-11 B-CHEMICAL
infusion O
and O
probably O
due O
to O
the O
inhibition O
of O
acetylcholinesterase B-GENE-Y
activity, O
which O
can O
be O
eliminated O
by O
administration O
of O

atropine. B-CHEMICAL
Late-onset O
diarrhea O
appears O
to O
be O
associated O
with O
intestinal O
exposure O
to O
SN-38 B-CHEMICAL
(7-ethyl-10-hydroxycamptothecin), B-CHEMICAL
the O
major O
active O
metabolite O
of O
CPT-11, B-CHEMICAL
which O
may O
bind O
to O
Topo B-GENE-Y
I I-GENE-Y
and O
induce O
apoptosis O
of O
intestinal O
epithelia, O
leading O
to O
the O
disturbance O
in O
the O
absorptive O
and O
secretory O
functions O
of O
mucosa. O
CPT-11 B-CHEMICAL
and O
SN-38 B-CHEMICAL
may O
also O
stimulate O
the O
production O
of O
pro-inflammatory O
cytokines B-GENE-N
and O
prostaglandins B-CHEMICAL

(PGs), B-CHEMICAL
thus O
inducing O
the O
secretion O
of O
Na(+) B-CHEMICAL
and O
Cl(-). B-CHEMICAL
Early O
treatment O
of O
severe O
late-onset O
diarrhea O
with O
oral O
high-dose O
loperamide B-CHEMICAL
has O
decreased O
patient O
morbidity. O
Extensive O
studies O
have O
been O
conducted O
to O
identify O
other O
potential O
agents O
to O
ameliorate O
diarrhea O
in O
preclinical O
and O
clinical O
models. O
These O
include O
intestinal O
alkalizing O
agents, O
oral O
antibiotics, O
enzyme O
inducers, O
P-glycoprotein B-GENE-N
(PgP) B-GENE-N
inhibitors, O
cyclooxygenase-2 B-GENE-Y

(COX-2) B-GENE-Y
inhibitors, O
tumor B-GENE-Y
necrosis I-GENE-Y
factor-alpha I-GENE-Y
(TNF-alpha) B-GENE-Y
inhibitors, O
or O
blockers O
of O
biliary O
excretion O
of O
SN-38. B-CHEMICAL
Further O
studies O
are O
needed O
to O
identify O
the O
molecular O
targets O
associated O
with O
CPT-11 B-CHEMICAL
toxicity O
and O
safe O
and O
effective O
agents O
for O
alleviating O
CPT-11-induced B-CHEMICAL
diarrhea. O
Crystal O
structure O
of O
pyridoxal B-GENE-Y
kinase I-GENE-Y
in O
complex O
with O
roscovitine B-CHEMICAL
and O
derivatives. O
Pyridoxal B-GENE-Y
kinase I-GENE-Y
(PDXK) B-GENE-Y
catalyzes O
the O
phosphorylation O
of O
pyridoxal, B-CHEMICAL

pyridoxamine, B-CHEMICAL
and O
pyridoxine B-CHEMICAL
in O
the O
presence O
of O
ATP B-CHEMICAL
and O
Zn2+. B-CHEMICAL
This O
constitutes O
an O
essential O
step O
in O
the O
synthesis O
of O
pyridoxal B-CHEMICAL
5'-phosphate I-CHEMICAL
(PLP), B-CHEMICAL
the O
active O
form O
of O
vitamin B-CHEMICAL
B6, I-CHEMICAL
a O
cofactor O
for O
over O
140 O
enzymes. O
(R)-Roscovitine B-CHEMICAL
(CYC202, B-CHEMICAL
Seliciclib) B-CHEMICAL
is O
a O
relatively O
selective O
inhibitor O
of O
cyclin-dependent B-GENE-N
kinases I-GENE-N
(CDKs), B-GENE-N
currently O
evaluated O
for O
the O
treatment O
of O
cancers, O
neurodegenerative O
disorders, O
renal O
diseases, O
and O

several O
viral O
infections. O
Affinity O
chromatography O
investigations O
have O
shown O
that O
(R)-roscovitine B-CHEMICAL
also O
interacts O
with O
PDXK. B-GENE-Y
To O
understand O
this O
interaction, O
we O
determined O
the O
crystal O
structure O
of O
PDXK B-GENE-Y
in O
complex O
with O
(R)-roscovitine, B-CHEMICAL
N6-methyl-(R)-roscovitine, B-CHEMICAL
and O
O6-(R)-roscovitine, B-CHEMICAL
the O
two O
latter O
derivatives O
being O
designed O
to O
bind O
to O
PDXK B-GENE-Y
but O
not O
to O
CDKs. B-GENE-N
Structural O
analysis O
revealed O
that O
these O
three O
roscovitines B-CHEMICAL
bind O
similarly O
in O
the O

pyridoxal-binding B-CHEMICAL
site O
of O
PDXK B-GENE-Y
rather O
than O
in O
the O
anticipated O
ATP-binding B-CHEMICAL
site. O
The O
pyridoxal B-CHEMICAL
pocket O
has O
thus O
an O
unexpected O
ability O
to O
accommodate O
molecules O
different O
from O
and O
larger O
than O
pyridoxal. B-CHEMICAL
This O
work O
provides O
detailed O
structural O
information O
on O
the O
interactions O
between O
PDXK B-GENE-Y
and O
roscovitine B-CHEMICAL
and O
analogs. O
It O
could O
also O
aid O
in O
the O
design O
of O
roscovitine B-CHEMICAL
derivatives O
displaying O
strict O
selectivity O
for O
either O
PDXK B-GENE-Y
or O
CDKs. B-GENE-N
Gastric B-GENE-N
mucin I-GENE-N
secretion O
in O
response O
to O
beta-adrenergic B-GENE-N
G I-GENE-N
protein-coupled I-GENE-N
receptor I-GENE-N
activation O
is O
mediated O
by O
SRC B-GENE-Y

kinase-dependent B-GENE-N
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
transactivation. O
In O
many O
systems, O
the O
integration O
of O
converging O
regulatory O
signals O
that O
relay O
on O
G B-GENE-N
protein-coupled I-GENE-N
receptor I-GENE-N
(GPCR) B-GENE-N
activation O
into O
functional O
cellular O
pathways O
requires O
the O
involvement O
of O
receptor B-GENE-N
tyrosine B-CHEMICAL
kinase. I-GENE-N
In O
this O
report, O
we O
provide O
evidence O
that O
activation O
of O
GPCR B-GENE-N
by O
beta-adrenergic O
agonist O
leading O
to O
stimulation O
in O
gastric B-GENE-N
mucin I-GENE-N
secretion O
requires O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(EGFR) B-GENE-Y
participation. O
Using O
[(3)H]glucosamine-labeled B-CHEMICAL
gastric O
mucosal O
cells, O
we O
show O
that O

stimulatory O
effect O
of O
beta-adrenergic O
agonist, O
isoproterenol, O
on O
mucin B-GENE-N
secretion O
was O
inhibited O
by O
EGFR B-GENE-Y
kinase B-GENE-N
inhibitor, O
PD153035, B-CHEMICAL
as O
well O
as O
wortmannin, B-CHEMICAL
a O
specific O
inhibitor O
of O
PI3K. B-GENE-N
Both O
inhibitors, O
moreover, O
blunted O
the O
mucin B-GENE-N
secretory O
responses O
to O
beta-adrenergic O
agonist-generated O
second O
messenger, O
cAMP B-CHEMICAL
as O
well O
as O
adenylate B-CHEMICAL
cyclase I-GENE-N
activator, O
forskolin. B-CHEMICAL
The O
gastric B-GENE-N
mucin I-GENE-N
secretory O
responses O
to O

isoproterenol, B-CHEMICAL
furthermore, O
were O
inhibited O
by O
PP2, B-CHEMICAL
a O
selective O
inhibitor O
of O
tyrosine B-GENE-N
kinase I-GENE-N
Src B-GENE-Y
responsible O
for O
ligand-independent O
EGFR B-GENE-Y
autophosphorylation, O
but O
not O
by O
ERK B-GENE-N
inhibitor, O
PD98059. B-CHEMICAL
The O
inhibition O
of O
ERK, B-GENE-N
moreover, O
did O
not O
cause O
attenuation O
in O
mucin B-GENE-N
secretion O
in O
response O
to O
cAMP B-CHEMICAL
and O
forskolin. B-CHEMICAL
The O
findings O
underline O
the O
role O
of O
EGFR B-GENE-Y
as O
a O
convergence O
point O
in O
gastric B-GENE-N
mucin I-GENE-N
secretion O
triggered O
by O
beta-adrenergic B-GENE-N
GPCR I-GENE-N

activation, O
and O
demonstrate O
the O
requirement O
for O
Src B-GENE-Y
kinase B-GENE-N
in O
EGFR B-GENE-Y
transactivation. O
Losartan: B-CHEMICAL
a O
selective O
angiotensin B-GENE-Y
II I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
(AT1) I-GENE-Y
receptor I-GENE-Y
antagonist O
for O
the O
treatment O
of O
heart O
failure. O
Losartan B-CHEMICAL
(COZAAR) B-CHEMICAL
is O
the O
prototype O
of O
a O
new O
class O
of O
potent O
and O
selective O
angiotensin B-GENE-Y
II I-GENE-Y
(AII) I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
(AT(1)) I-GENE-Y
receptor I-GENE-Y
antagonists O
with O
the O
largest O
published O
preclinical O
and O
clinical O
data O
base. O
Since O
all O
of O
the O
AII B-GENE-Y
antagonists O
are O
selective O
for O
the O
AT(1) B-GENE-Y
receptor, I-GENE-Y
these O
drugs O
should O
exhibit O
similar O
cardiovascular O
effects. O

However, O
since O
the O
pharmacokinetic/pharmacodynamic O
profiles O
of O
these O
agents O
and O
their O
degree O
of O
affinity O
for O
the O
AT(1) B-GENE-Y
receptor I-GENE-Y
differ, O
it O
is O
likely O
that O
differences O
in O
clinical O
profiles O
between O
these O
drugs O
exist O
and O
will O
require O
investigation. O
Losartan B-CHEMICAL
(parent O
compound), O
has O
moderate O
affinity O
for O
the O
AT(1) B-GENE-Y
receptor I-GENE-Y
(competitive O
inhibition). O
Losartan B-CHEMICAL
is O
well-absorbed O
orally O
as O
an O
active O
drug O
and O
is O
rapidly O
converted O
via O
oxidation O
in O
the O
human O
liver O
to O
a O
more O
potent O
metabolite O
(designated O
E3174) O
with O
an O
affinity O
20- O
to O
30-times O
greater O
for O
the O

AT(1) B-GENE-Y
receptor I-GENE-Y
(non-competitive O
inhibition). O
E3174 O
has O
a O
half-life O
of O
6 O
- O
9 O
h; O
elimination O
is O
via O
renal O
and O
hepatic O
routes. O
Antihypertensive O
and, O
in O
heart O
failure O
patients, O
haemodynamic O
activity O
is O
observed O
over O
a O
24 O
h O
period O
with O
once O
daily O
dosing. O
Over O
6 O
million O
patients O
have O
been O
treated O
for O
hypertension O
with O
continued O
excellent O
tolerability. O
Clinical O
experience O
in O
heart O
failure O
is O
growing, O
and O
recent O
data O
suggest O
an O
improved O
survival O
with O
losartan B-CHEMICAL
versus O
captopril, B-CHEMICAL
a O
drug O
from O
the O
angiotensin-converting-enzyme B-CHEMICAL
inhibitor O

class O
with O
proven O
benefit O
in O
this O
population. O
The O
current O
comprehensive O
losartan B-CHEMICAL
clinical O
end-point O
programme O
(4 O
large O
scale O
morbidity/mortality O
trials) O
should O
provide O
evidence O
regarding O
the O
efficacy O
of O
direct O
blockade O
of O
the O
AT(1) B-GENE-Y
receptor I-GENE-Y
with O
losartan B-CHEMICAL
compared O
to O
standard O
therapy: O
1) O
The O
Losartan B-CHEMICAL
Heart O
Failure O
Survival O
Study O
- O
ELITE O
II, O
2) O
The O
Losartan B-CHEMICAL
Post-Myocardial O
Infarction O
Survival O
Study O
- O
OPTIMAAL, O
3) O
The O
Losartan B-CHEMICAL
Hypertension O
Survival O
Study O
- O
LIFE O
and O
4) O
The O
Losartan B-CHEMICAL
Renal O
Protection O
Study O

- O
RENAAL. O
Effect O
of O
amrinone B-CHEMICAL
on O
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
production O
in O
endotoxic O
shock. O
Tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
(TNF) B-GENE-Y
is O
a O
macrophage-derived O
mediator O
responsible O
for O
many O
of O
the O
pathophysiologic O
manifestations O
of O
endotoxic O
shock. O
We O
now O
demonstrate O
that O
amrinone, B-CHEMICAL
a O
noncatechol O
inotrope, O
strongly O
inhibits O
lipopolysaccharide O
(LPS)-induced O
TNF B-GENE-Y
production O
at O
concentrations O
readily O
achieved O
in O
vivo. O
This O
inhibition O
is O
apparent O
in O
murine O
macrophages, O
in O

macrophage O
cell O
lines, O
in O
vivo, O
and O
in O
cell O
lines O
containing O
a O
reporter O
gene O
construct O
that O
substitutes O
the O
chloramphenicol O
acetyl O
transferase O
(CAT) O
coding O
sequence O
for O
the O
TNF B-GENE-Y
coding O
sequence O
and O
introns. O
Inhibition O
by O
amrinone B-CHEMICAL
(like O
inhibition O
by O
pentoxifylline) B-CHEMICAL
is O
manifested O
at O
the O
level O
of O
mRNA O
accumulation, O
in O
contrast O
to O
inhibition O
caused O
by O
dexamethasone. B-CHEMICAL
Combined O
application O
of O
dexamethasone B-CHEMICAL
and O
amrinone B-CHEMICAL
caused O
additive O
inhibition O
of O
TNF B-GENE-Y
biosynthesis O
in O
vitro. O
Furthermore, O
treatment O
of O
mice O

with O
amrinone B-CHEMICAL
immediately O
prior O
to O
endotoxin O
challenge O
led O
to O
significantly O
improved O
survival. O
These O
findings O
suggest O
that O
amrinone B-CHEMICAL
possesses O
antiinflammatory O
as O
well O
as O
inotropic O
properties O
that O
may O
make O
it O
an O
appropriate O
agent O
for O
use O
in O
septic O
shock O
or O
other O
serious O
bacterial O
infections. O
Abrupt O
removal O
of O
amrinone B-CHEMICAL
or O
pentoxifylline B-CHEMICAL
from O
the O
culture O
medium O
prior O
to O
LPS O
stimulation, O
however, O
caused O
significantly O
augmented O
TNF B-GENE-Y
production. O
Therefore, O
amrinone B-CHEMICAL
and O
other O
phosphodiesterase B-GENE-N
inhibitors O
may O
also O
enhance O
sensitivity O
to O
LPS O
during O
a O
period O
of O
time O
following O
discontinuation O
of O
therapy. O

Age-dependent O
changes O
of O
pyridoxal B-CHEMICAL
phosphate I-CHEMICAL
synthesizing O
enzymes O
immunoreactivities O
and O
activities O
in O
the O
gerbil O
hippocampal O
CA1 O
region. O
In O
the O
present O
study, O
age-related O
changes O
of O
pyridoxal B-CHEMICAL
5'-phosphate I-CHEMICAL
(PLP) B-CHEMICAL
synthesizing O
enzymes, O
pyridoxal B-CHEMICAL
kinase I-GENE-N
(PLK) B-GENE-N
and O
pyridoxine B-CHEMICAL
5'-phosphate I-CHEMICAL
oxidase I-GENE-N
(PNPO), B-GENE-N
their O
protein O
contents O
and O
activities O
were O
examined O
in O
the O
gerbil O
hippocampus O
proper. O
Significant O
age-dependent O
changes O
in O
PLK B-GENE-N

and O
PNPO B-GENE-N
immunoreactivities O
were O
found O
in O
the O
CA1 O
region, O
but O
not O
in O
the O
CA2/3 O
region. O
In O
the O
postnatal O
month O
1 O
(PM O
1) O
group, O
PLK B-GENE-N
and O
PNPO B-GENE-N
immunoreactivities O
were O
detected O
mainly O
in O
the O
stratum O
pyramidale O
of O
the O
CA1 O
region. O
PLK B-GENE-N
and O
PNPO B-GENE-N
immunoreactivities O
and O
their O
protein O
contents O
were O
highest O
in O
the O
PM O
6 O
group, O
showing O
that O
many O
CA1 O
pyramidal O
cells O
had O
strong O
PLK B-GENE-N
and O
PNPO B-GENE-N
immunoreactivities. O
Thereafter, O

PLK B-GENE-N
and O
PNPO B-GENE-N
immunoreactivities O
started O
to O
decrease O
and O
were O
very O
low O
at O
PM O
24. O
Alterations O
in O
the O
change O
patterns O
in O
protein O
contents O
and O
total O
activities O
of O
PLK B-GENE-N
and O
PNPO B-GENE-N
corresponded O
to O
the O
immunohistochemical O
data, O
but O
their O
specific O
activities O
were O
not O
altered O
in O
any O
experimental O
group. O
Based O
on O
double O
immunofluorescence O
study, O
PLK B-GENE-N
and O
PNPO B-GENE-N
immunoreactive O
cells O
in O
the O
strata O
oriens O
and O
radiatum O
were O
identified O
as O
GABAergic O
cells. O
Therefore, O
decreases O
of O
PLK B-GENE-N
and O
PNPO B-GENE-N
in O
the O

hippocampal O
CA1 O
region O
of O
aged O
brains O
may O
be O
involved O
in O
aging O
processes O
related O
with O
gamma-aminobutyric B-CHEMICAL
acid I-CHEMICAL
(GABA) B-CHEMICAL
function. O
Functional O
characteristics O
of O
H+ B-CHEMICAL
-dependent O
nicotinate B-CHEMICAL
transport O
in O
primary O
cultures O
of O
astrocytes O
from O
rat O
cerebral O
cortex. O
In O
the O
present O
study, O
we O
report O
the O
characteristics O
of O
H(+)-coupled B-CHEMICAL
nicotinate B-CHEMICAL
transport O
in O
primary O
cultures O
of O
astrocytes O
from O
rat O
cerebral O
cortex. O
The O
[(3)H]nicotinate B-CHEMICAL
transport O
in O
rat O
astrocytes O
increased O
up O
to O
a O
pH O
5.5. O
The O
nicotinic B-CHEMICAL
acid I-CHEMICAL
uptake O
at O
pH O

6.0 O
was O
both O
energy-dependent O
and O
saturable O
with O
a O
Michaelis O
constant O
(K(t)) O
of O
2.8+/-0.4 O
mM O
and O
the O
maximal O
uptake O
rate O
(V(max)) O
of O
31+/-3.2 O
nmol/mg O
protein/10 O
min. O
This O
process O
was O
reduced O
by O
a O
protonophore, O
carbonylcyanide B-CHEMICAL
p-trifluoromethoxyphenylhydrazone, I-CHEMICAL
and O
a O
typical O
monocarboxylate B-GENE-N
transporter I-GENE-N
(MCT) B-GENE-N
inhibitor, O

alpha-cyano-4-hydroxycinnamic B-CHEMICAL
acid, I-CHEMICAL
suggesting O
that O
nicotinate B-CHEMICAL
uptake O
by O
rat O
astrocytes O
is O
mediated O
by O
H(+)-coupled B-CHEMICAL
monocarboxylate B-GENE-N
transport I-GENE-N
system. I-GENE-N
[(3)H]Nicotinate B-CHEMICAL
transport O
in O
rat O
astrocytes O
was O
significantly O
inhibited O
by O
various O
monocarboxylic B-CHEMICAL
acids I-CHEMICAL
such O
as O
l-lactic B-CHEMICAL
acid I-CHEMICAL
and O
pyruvic B-CHEMICAL
acid I-CHEMICAL
with O
a O
relatively O
low O
affinity O
(K(i)>10 O
mM). O
On O
the O
other O
hand, O
the O
uptake O
process O
of O
l-lactic B-CHEMICAL
acid I-CHEMICAL
was O
also O
saturable O
with O

a O
high-affinity O
component O
(K(t)=0.27 O
mM) O
and O
a O
low-affinity O
component O
(K(t)=35.9 O
mM). O
Reverse O
transcription-PCR O
and O
Western O
blot O
analyses O
revealed O
that O
three O
MCT B-GENE-N
subtypes, O
MCT1/Slc16a1, B-GENE-Y
MCT2/Slc16a7, B-GENE-Y
and O
MCT4/Slc16a3, B-GENE-Y
were O
expressed O
in O
these O
cells. O
Because O
l-lactate B-CHEMICAL
reduced O
to O
67% O
of O
the O
nicotinate B-CHEMICAL
uptake O
even O
at O
10mM, O
it O
is O
unlikely O
that O
nicotinate B-CHEMICAL

uptake O
in O
rat O
astrocytes O
is O
mediated O
by O
MCT1 B-GENE-Y
and/or O
MCT2. B-GENE-Y
These O
results O
provide O
biochemical O
evidence O
of O
a O
H(+)-coupled B-CHEMICAL
and O
saturable O
transport O
system, O
presumed O
to O
be O
a O
low-affinity B-GENE-N
monocarboxylate B-CHEMICAL
transporter I-GENE-N
MCT4 B-GENE-Y
or O
other O
unknown O
H(+)-coupled B-CHEMICAL
monocarboxylate B-CHEMICAL
transport I-GENE-N
system, I-GENE-N
for O
nicotinate B-CHEMICAL
in O
rat O
cerebrocortical O
astrocytes. O
A O
review O
of O
the O
structural O
and O
functional O
features O
of O
olmesartan B-CHEMICAL
medoxomil, I-CHEMICAL
an O
angiotensin B-GENE-N
receptor I-GENE-N
blocker. O
The O
angiotensin B-CHEMICAL

II I-CHEMICAL
(A-II) I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
(AT1) I-GENE-Y
receptor-mediated I-GENE-Y
effects O
of O
A-II B-CHEMICAL
play O
a O
key O
role O
in O
the O
pathophysiology O
of O
hypertension. O
Effective O
inhibition O
of O
A-II B-CHEMICAL
is O
provided O
by O
the O
latest O
class O
of O
antihypertensive O
medications, O
the O
AT1 B-GENE-Y
receptor O
blockers O
(ARBs). O
These O
orally O
available O
agents O
were O
developed O
around O
a O
common O
imidazole-based O
structural O
core. O
The O
most O
recent O
member O
of O
this O
drug O
class O
to O
be O
approved O
by O
the O
Food O
and O
Drug O
Administration, O
olmesartan B-CHEMICAL
medoxomil, I-CHEMICAL
contains O
unique O
features O
that O
may O
explain O
its O
clinical O

efficacy. O
Key O
structural O
elements O
of O
olmesartan B-CHEMICAL
medoxomil I-CHEMICAL
include O
a O
hydroxyalkyl O
substituent O
at O
the O
imidazole O
4-position O
and O
a O
hydrolyzable O
ester O
group O
at O
the O
imidazole O
5-position. O
Inter- O
and O
intramolecular O
hydrogen O
bonding O
involving O
these O
groups O
may O
contribute O
to O
the O
potentiation O
of O
antagonist O
activity. O
After O
oral O
administration, O
olmesartan B-CHEMICAL
medoxomil I-CHEMICAL
is O
deesterified O
in O
the O
intestinal O
tract O
to O
produce O
the O
active O
metabolite O
olmesartan, O
which O
undergoes O
no O
additional O
metabolic O
change. O
The O
marked O

antihypertensive O
efficacy O
of O
olmesartan B-CHEMICAL
medoxomil I-CHEMICAL
may O
result O
from O
a O
unique O
pharmacological O
interaction O
of O
the O
drug O
with O
the O
AT1 B-GENE-Y
receptor, O
resulting O
in O
a O
potent, O
long-lasting, O
dose-dependent O
blockade O
of O
A-II. B-CHEMICAL
This O
review O
article O
characterizes O
the O
structural O
features O
of O
olmesartan O
that O
may O
be O
responsible O
for O
its O
clinical O
efficacy. O
Inferential O
pharmacological O
studies O
compare O
and O
contrast O
the O
effects O
of O
olmesartan O
to O
those O
of O
other O
ARBs O
in O
comparable O
preclinical O
animal O
models. O
Effects O
of O
granulocyte B-GENE-Y
colony-stimulating I-GENE-Y
factor I-GENE-Y

(G-CSF) B-GENE-Y
and O
neutrophil B-GENE-Y
elastase I-GENE-Y
inhibitor O
(ONO-5046) B-CHEMICAL
on O
acid-induced O
lung O
injury O
in O
rats. O
It O
has O
been O
suggested O
that O
neutrophils O
play O
an O
important O
role O
in O
acid-aspirated O
lung O
injury. O
We O
examined O
the O
effects O
of O
the O
high O
dose O
of O
granulocyte-colony B-GENE-Y
stimulating I-GENE-Y
factor I-GENE-Y
(G-CSF), B-GENE-Y
which O
is O
capable O
of O
increasing O
peripheral O
neutrophils, O
and O
a O
specific O
neutrophil B-GENE-Y
elastase I-GENE-Y
inhibitor O
(ONO-5046) B-CHEMICAL
on O
acid O
lung O
injury O
in O
rats. O
Animals O
were O
anesthetized O
and O
normal O

saline O
(NS, O
2 O
mL O
kg(-1)) O
or O
hydrochloric B-CHEMICAL
acid I-CHEMICAL
(HCl, B-CHEMICAL
0.1 O
N O
2 O
mL O
kg(-1)) O
was O
then O
instilled O
into O
trachea. O
Thirty O
minutes O
before O
HCl B-CHEMICAL
instillation, O
G-CSF B-GENE-Y
(150 O
microg O
kg(-1)) O
was O
injected O
subcutaneously O
or O
ONO-5046 B-CHEMICAL
(10 O
mg O
kg(-1) O
h(-1)) O
was O
infused O
continuously O
into O
the O
right O
jugular O
vein. O
Animals O
were O
ventilated O
during O
the O
experiments. O
Five O
hours O
after O
HCl B-CHEMICAL
or O
NS O

instillation, O
bronchoalveolar O
lavage O
fluid O
(BALF) O
and O
lung O
tissue O
samples O
were O
obtained. O
Total O
nuclear O
cell O
count, O
absorbance, O
albumin, B-GENE-Y
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
(TNF)-alpha, I-GENE-Y
interleukin B-GENE-Y
(IL)-6, I-GENE-Y
cytokine-induced B-GENE-N
neutrophil I-GENE-N
chemoattractant I-GENE-N
(CINC), B-GENE-N
neutrophil B-GENE-Y
elastase I-GENE-Y
in O
BALF, O
wet-to-dry O
(W/D) O
ratio O
were O
measured. O
HCl B-CHEMICAL
aspiration O
markedly O
increased O
these O
values O
in O
BALF O
and O
W/D O
ratio. O
Both O

ONO-5046 B-CHEMICAL
and O
G-CSF B-GENE-Y
attenuated O
the O
parameters O
increased O
by O
acid-induced O
lung O
injury O
in O
rats. O
The O
data O
suggests O
that O
neutrophils O
play O
an O
important O
role O
in O
acid-induced O
lung O
injury. O
However, O
high-dose O
G-CSF B-GENE-Y
does O
not O
exacerbate O
acid-aspirated O
lung O
injury O
in O
rats, O
although O
this O
agent O
causes O
an O
increase O
in O
peripheral O
neutrophils. O
Guidance O
on O
the O
use O
of O
miglustat B-CHEMICAL
for O
treating O
patients O
with O
type O
1 O
Gaucher O
disease. O
Type O
1 O
Gaucher O
disease O
(GD) O
is O
a O
progressive O
lysosomal O
storage O
disorder O
due O

to O
an O
autosomal O
recessive O
deficiency O
of O
glucocerebrosidase. B-GENE-Y
Clinical O
manifestations O
include O
anemia, O
thrombocytopenia, O
hepatosplenomegaly, O
and O
bone O
and O
pulmonary O
disease. O
Intravenous O
enzyme O
replacement O
(ERT) O
with O
imiglucerase O
is O
the O
accepted O
standard O
for O
treatment O
of O
symptomatic O
patients. O
More O
than O
3,500 O
patients O
worldwide O
have O
received O
ERT O
with O
well-documented O
beneficial O
effects O
on O
the O
hematological, O
visceral, O
skeletal, O
and O
pulmonary O
manifestations, O
and O
with O
resultant O
improvement O
in O
health-related O
quality O
of O
life. O

Miglustat, B-CHEMICAL
an O
imino B-CHEMICAL
sugar I-CHEMICAL
that O
reversibly O
inhibits O
glucosylceramide B-GENE-Y
synthase I-GENE-Y
and O
reduces O
intracellular O
substrate O
burden, O
is O
an O
oral O
treatment O
for O
patients O
with O
type O
1 O
GD O
that O
was O
recently O
approved O
in O
the O
United O
States O
for O
symptomatic O
patients O
with O
mild O
to O
moderate O
clinical O
manifestations O
for O
whom O
ERT O
is O
not O
an O
option. O
Because O
responses O
to O
miglustat B-CHEMICAL
are O
slower O
and O
less O
robust O
than O
those O
observed O
with O
ERT, O
and O
because O
miglustat B-CHEMICAL
is O
associated O
with O
significant O
side O
effects, O
clinicians O
who O
care O
for O
patients O
with O
GD O
should O
become O
familiar O
with O
the O
limited O
indications O
for O

miglustat B-CHEMICAL
use O
and O
the O
circumstances O
when O
it O
may O
be O
prescribed O
appropriately. O
This O
review O
article O
and O
position O
statement O
represents O
the O
current O
opinion O
of O
American O
physicians O
with O
extensive O
expertise O
in O
GD O
regarding O
patient O
management O
in O
the O
context O
of O
the O
availability O
of O
standard O
imiglucerase O
treatment O
and O
the O
recent O
introduction O
of O
miglustat. B-CHEMICAL
Nicotinic-receptor B-GENE-N
potentiator O
drugs, O
huprine O
X O
and O
galantamine, B-CHEMICAL
increase O
ACh B-CHEMICAL
release O
by O
blocking O
AChE B-GENE-Y
activity O
but O
not O
acting O
on O
nicotinic B-GENE-N
receptors. I-GENE-N
The O
main O
goal O
of O
the O
present O
study O
was O
to O
analyse O
the O
effects O
of O
(+/-)-huprine O
X O

((+/-)-HX) O
and O
galantamine O
(GAL), O
with O
potentiating O
action O
on O
nicotinic B-GENE-N
receptors, I-GENE-N
and O
huperzine O
A O
(HPA), O
devoid O
of O
nicotinic O
activity, O
on O
[3H]-acetylcholine B-CHEMICAL
([3H]-ACh) B-CHEMICAL
release O
in O
striatal O
slices O
of O
rat O
brain. O
All O
compounds O
are O
non-covalent O
and O
reversible O
inhibitors O
of O
AChE. B-GENE-Y
Addition O
of O
(+/-)-HX O
(0.01 O
microM), O
GAL O
(10 O
microM) O
and O

HPA O
(0.1 O
microM) O
to O
the O
superfusion O
medium O
decreased O
the O
release O
of O
the O
ACh B-CHEMICAL
neurotransmitter O
to O
a O
similar O
extent: O
36%, O
30% O
and O
34%, O
respectively O
(P<0.01). O
This O
effect O
was O
reverted O
in O
the O
presence O
of O
atropine B-CHEMICAL
(ATR; B-CHEMICAL
0.1 O
microM), O
which O
blocks O
the O
pre-synaptic O
muscarinic B-GENE-Y
M2 I-GENE-Y
receptor. I-GENE-Y
After O
that, O
a O
wide O
range O
of O
concentrations O
of O
drugs, O
concomitantly O
with O
ATR B-CHEMICAL
(0.1 O
microM), O
was O
studied O
in O
the O
presence O
of O
haloperidol B-CHEMICAL

(HAL; B-CHEMICAL
0.01 O
microM), O
a O
dopamine B-GENE-Y
D2 I-GENE-Y
antagonist. O
In O
these O
conditions, O
a O
dose-dependent O
increase O
of O
[3H]-ACh B-CHEMICAL
release O
was O
observed O
in O
the O
presence O
of O
(+/-)-HX, O
GAL O
and O
HPA. O
To O
test O
the O
role O
of O
nicotinic B-GENE-N
receptors I-GENE-N
in O
the O
drugs' O
effects O
on O
[3H]-ACh B-CHEMICAL
release, O
mecamylamine B-CHEMICAL
(MEC) B-CHEMICAL
100 O
microM O
was O
used O
to O
block O
such O
receptors. O
MEC B-CHEMICAL
alone O
significantly O
decreased O
neurotransmitter O
release O
by O
18% O
(P<0.05), O
but O
no O

change O
was O
obtained O
in O
the O
presence O
of O
both O
ATR B-CHEMICAL
and O
MEC. B-CHEMICAL
Under O
these O
conditions, O
(+/-)-HX, O
GAL O
and O
HPA O
increased O
the O
release O
of O
[3H]-ACh B-CHEMICAL
by O
37%, O
25% O
and O
38%, O
respectively O
(P<0.01). O
Taking O
into O
account O
all O
of O
these O
data, O
the O
present O
results O
suggest O
that O
the O
effects O
induced O
by O
(+/-)-HX O
and O
GAL O
nicotinic-receptor B-GENE-N
potentiators O
seem O
to O
be O
mainly O
due O
to O
their O
ability O
in O
inhibiting O
acetylcholinesterase B-GENE-Y
activity, O
but O
not O
by O
interaction O
on O
the O

nicotinic B-GENE-N
receptors. I-GENE-N
Rat O
hepatic O
stellate O
cells O
become O
retinoid B-CHEMICAL
unresponsive O
during O
activation. O
Hepatic O
stellate O
cells O
(HSC) O
play O
an O
essential O
role O
in O
fibrogenesis. O
Many O
stimuli O
cause O
HSC O
to O
activate, O
lose O
their O
Vitamin B-CHEMICAL
A I-CHEMICAL
and O
produce O
collagen. B-GENE-N
It O
is O
unclear O
whether O
Vitamin B-CHEMICAL
A I-CHEMICAL
loss O
causes O
activation, O
potentiates O
it O
or O
is O
simply O
an O
event O
in O
the O
cascade O
of O
activation O
changes. O
We O
determine O
if O
exogenous O
retinoids B-CHEMICAL
prevent O
the O
activation O
of O
freshly O
isolated O
rat O
HSC O
activated O
by O
plating O
on O
plastic. O
We O
also O
determine O
if O

retinoids: B-CHEMICAL
(1) O
reverse O
HSC O
activation; O
(2) O
maintain/restore O
HSC O
intracellular O
retinoid B-CHEMICAL
levels; O
(3) O
maintain O
expression O
of O
HSC O
nuclear B-GENE-N
receptors I-GENE-N
for I-GENE-N
retinoic B-CHEMICAL
acid I-CHEMICAL
(RAR) B-GENE-N
in O
HSC O
that O
are O
becoming O
activated O
or O
are O
chronically O
activated. O
Markers O
of O
activation O
in O
freshly O
isolated O
HSC O
were O
decreased O
by O
either O
retinol B-CHEMICAL
or O
retinoic B-CHEMICAL
acid I-CHEMICAL
without O
increases O
in O
HSC O
retinoid B-CHEMICAL
concentration. O
mRNA O
levels O
for O
RAR-alpha, B-GENE-Y
RAR-beta B-GENE-Y
and O
RAR-gamma, B-GENE-Y
the O
nuclear B-GENE-N
receptors I-GENE-N
for O
retinoic B-CHEMICAL
acid, I-CHEMICAL
decreased O
during O
activation O
of O
freshly O
isolated O

HSC O
even O
with O
retinoid B-CHEMICAL
supplementation. O
RAR-alpha, B-GENE-Y
RAR-beta B-GENE-Y
and O
RAR-gamma B-GENE-Y
mRNA O
and O
RAR-beta B-GENE-N
protein O
was O
undetectable O
in O
chronically O
activated O
HSC O
and O
remained O
absent O
after O
retinoic B-CHEMICAL
acid I-CHEMICAL
supplementation. O
Activation O
markers O
in O
chronically O
activated O
HSC O
were O
only O
slightly O
decreased O
after O
retinoid B-CHEMICAL
exposure. O
We O
conclude O
that O
exposure O
of O
HSC O
to O
extracellular O
retinoids B-CHEMICAL
diminishes O
some O
markers O
of O
activation O
but O
does O
not O
prevent O
HSC O
activation. O
Protein B-GENE-N
kinase I-GENE-N
C I-GENE-N
potentiates O
homologous O
desensitization O
of O
the O
beta2-adrenoceptor B-GENE-Y

in O
bovine O
tracheal O
smooth O
muscle. O
Preincubation O
(30 O
min) O
of O
bovine O
tracheal O
smooth O
muscle O
with O
various O
concentrations O
(0.1, O
1 O
and O
10 O
microM) O
of O
fenoterol B-CHEMICAL
decreased O
isoprenaline-induced B-CHEMICAL
maximal O
relaxation O
(E(max)) O
of O
methacholine-contracted B-CHEMICAL
preparations O
in O
a O
concentration O
dependent O
fashion, O
indicating O
desensitization O
of O
the O
beta(2)-adrenoceptor. B-GENE-Y
Preincubation O
with O
1 O
microM O
of O
the O
protein B-GENE-N
kinase I-GENE-N
C I-GENE-N
(PKC) B-GENE-N
activator O
phorbol B-CHEMICAL
12-myristate I-CHEMICAL

13-acetate I-CHEMICAL
(PMA) B-CHEMICAL
caused O
a O
small O
but O
significant O
decrease O
in O
isoprenaline-induced B-CHEMICAL
E(max), O
indicating O
activated O
PKC-mediated B-GENE-N
heterologous O
beta(2)-adrenoceptor B-GENE-Y
desensitization. O
To O
investigate O
the O
capacity O
of O
activated O
PKC B-GENE-N
to O
regulate O
homologous O
desensitization, O
we O
incubated O
the O
smooth O
muscle O
strips O
with O
the O
combination O
of O
both O
1 O
microM O
PMA O
and O
1 O
microM O
fenoterol. B-CHEMICAL
This O
combined O
treatment O
synergistically O
decreased O
the O
isoprenaline-induced B-CHEMICAL
maximal O
relaxation, O
as O
compared O
to O
the O
individual O

effects O
of O
PMA B-CHEMICAL
and O
fenoterol B-CHEMICAL
alone, O
indicating O
a O
common O
pathway O
for O
heterologous O
and O
homologous O
desensitization. O
Moreover, O
the O
specific O
PKC-inhibitor B-GENE-N
2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) B-CHEMICAL
maleimide I-CHEMICAL
(GF B-CHEMICAL
109203X) I-CHEMICAL
markedly O
increased O
the O
potency O
and O
E(max) O
of O
isoprenaline B-CHEMICAL
for O
all O
conditions O
used, O
including O
control O
conditions, O
and O
the O

synergistic O
effects O
of O
PMA B-CHEMICAL
and O
fenoterol B-CHEMICAL
were O
completely O
prevented. O
In O
conclusion, O
the O
present O
study O
demonstrates O
that O
homologous O
desensitization O
of O
the O
beta(2)-adrenergic B-GENE-Y
receptor I-GENE-Y
can O
be O
enhanced O
by O
PKC B-GENE-N
activation. O
For O
the O
first O
time O
we O
have O
provided O
evidence O
that O
this O
concept O
is O
functionally O
operative O
in O
airway O
smooth O
muscle, O
and O
it O
may O
explain O
the O
reduced O
bronchodilator O
response O
to O
beta(2)-adrenoceptor B-GENE-Y
agonists O
in O
patients O
with O
asthma O
during O
a O
severe O
exacerbation. O
Overview O
of O
monoclonal O
antibodies O
and O
small O
molecules O

targeting O
the O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
pathway O
in O
colorectal O
cancer. O
The O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(EGFR) B-GENE-Y
provides O
survival O
signals O
and O
is O
overexpressed O
in O
the O
majority O
of O
colorectal O
cancers. O
As O
more O
is O
learned O
about O
the O
molecular O
details O
of O
EGFR B-GENE-Y
signaling, O
antibodies O
can O
be O
designed O
to O
interfere O
with O
specific O
domains O
of O
the O
EGFR B-GENE-Y
molecule. O
In O
this O
review, O
we O
analyze O
preclinical O
and O
current O
clinical O
data O
on O
EGFR-targeting B-GENE-Y
molecules O
and O
their O
potential O
role O
in O
the O
treatment O
of O
colorectal O
cancer. O
Cetuximab O
binds O
to O
domain O
III O
of O

EGFR B-GENE-Y
and O
hinders O
ligand O
binding. O
It O
is O
now O
approved O
by O
the O
US O
Food O
and O
Drug O
Administration O
for O
metastatic O
colorectal O
cancer O
treatment. O
Panitumumab O
is O
another O
widely O
studied O
anti-EGFR B-GENE-Y
antibody O
with O
similar O
properties. O
Bispecific O
antibodies O
are O
modified O
immunoglobulin B-GENE-N
molecules O
containing O
2 O
different O
binding O
specificities. O
These O
antibodies O
can O
redirect O
the O
immune O
response O
against O
tumor O
cells O
by O
tethering O
effector O
cells O
such O
as O
CD3e-expressing B-GENE-Y
T O
cells O
or O
CD16-expressing B-GENE-N
natural O
killer O
cells O
and O
granulocytes O
to O
the O
surface O
of O
cancer O
cells. O
Tyrosine B-GENE-N

kinase I-GENE-N
inhibitors O
are O
quinazoline-derived, B-CHEMICAL
low O
molecular O
weight O
synthetic O
molecules O
that O
can O
block O
the O
intracellular O
tyrosine B-GENE-N
kinase I-GENE-N
domain I-GENE-N
of O
several O
receptors, O
including O
EGFR, B-GENE-Y
Erb2, B-GENE-Y
and O
vascular B-GENE-N
endothelial I-GENE-N
growth I-GENE-N
factor I-GENE-N
receptor, I-GENE-N
and O
thereby O
inhibit O
ligand-induced O
receptor O
phosphorylation O
and O
abrogate O
the O
biologic O
effect O
of O
EGFR B-GENE-Y
signaling. O
The O
presence O
of O
skin O
rash O
and O
EGFR B-GENE-Y
gene O
amplification O
have O
been O
advanced O
as O
possible O
predictors O
of O
clinical O
effectiveness O
of O
targeted O
anti-EGFR B-GENE-Y
therapies. O
Isolation O
and O

function O
of O
the O
amino B-GENE-Y
acid I-GENE-Y
transporter I-GENE-Y
PAT1 I-GENE-Y
(slc36a1) B-GENE-Y
from O
rabbit O
and O
discrimination O
between O
transport O
via O
PAT1 B-GENE-Y
and O
system B-GENE-N
IMINO I-GENE-N
in O
renal O
brush-border O
membrane O
vesicles. O
Reabsorption O
of O
amino B-CHEMICAL
acids I-CHEMICAL
is O
an O
important O
function O
of O
the O
renal O
proximal O
tubule. O
pH-dependent O
amino B-CHEMICAL
acid I-CHEMICAL
transport O
has O
been O
measured O
previously O
using O
rabbit O
renal O
brush-border O
membrane O
vesicles O
(BBMV). O
The O
purpose O
of O
this O
investigation O
was O
to O
determine O
whether O
this O
pH-dependent O
uptake O
represents O
H(+)/amino B-CHEMICAL
acid I-CHEMICAL
cotransport O
via O
a O
PAT1-like B-GENE-Y

transport O
system. O
The O
rabbit B-GENE-Y
PAT1 I-GENE-Y
cDNA O
was O
isolated O
(2296bp O
including O
both O
5' O
and O
3' O
untranslated O
regions O
and O
poly(A) B-GENE-N
tail) I-GENE-N
and O
the O
open B-GENE-N
reading I-GENE-N
frame I-GENE-N
codes O
for O
a O
protein O
of O
475 O
amino B-CHEMICAL
acids I-CHEMICAL
(92% O
identity O
to O
human B-GENE-Y
PAT1). I-GENE-Y
Rabbit B-GENE-Y
PAT1 I-GENE-Y
mRNA O
was O
found O
in O
all O
tissues O
investigated O
including O
kidney. O
When O
expressed O
heterologously O
in O
a O
mammalian O
cell O
line, O
rabbit B-GENE-Y
PAT1 I-GENE-Y
mediates O
pH-dependent, O
Na(+)-independent B-CHEMICAL
uptake O
of O
proline, B-CHEMICAL
glycine, B-CHEMICAL
l-alanine B-CHEMICAL
and O

alpha-(methylamino)isobutyric B-CHEMICAL
acid. I-CHEMICAL
Proline B-CHEMICAL
uptake O
was O
maximal O
at O
pH O
5.0 O
(K(m) O
2.2+/-0.7 O
mM). O
A O
transport O
system O
with O
identical O
characteristics O
(ion O
dependency, O
substrate O
specificity) O
was O
detected O
in O
rabbit O
renal O
BBMV O
where O
an O
overshoot O
was O
observed O
in O
the O
absence O
of O
Na+ B-CHEMICAL
but O
in O
the O
presence O
of O
an O
inwardly O
directed O
H+ B-CHEMICAL
gradient. O
In O
the O
presence O
of O
Na+ B-CHEMICAL
and O
under O
conditions O
in O
which O
PAT1 B-GENE-Y
transport O
function O
was O
suppressed, O
a O
second O
proline B-CHEMICAL
uptake O
system O
was O
detected O
that O
exhibited O
functional O
characteristics O
similar O

to O
those O
of O
the O
IMINO B-GENE-N
system. I-GENE-N
The O
functional O
characteristics O
of O
rabbit B-GENE-Y
PAT1 I-GENE-Y
in O
either O
mammalian O
cells O
or O
renal O
BBMV O
suggest O
that O
PAT1 B-GENE-Y
is O
the O
low-affinity O
transporter O
of O
proline, B-CHEMICAL
glycine B-CHEMICAL
and O
hydroxyproline B-CHEMICAL
believed O
to O
be O
defective O
in O
patients O
with O
iminoglycinuria. O
Antidepressants O
suppress O
production O
of O
the O
Th1 O
cytokine B-GENE-N
interferon-gamma, B-GENE-Y
independent O
of O
monoamine B-GENE-N
transporter I-GENE-N
blockade. O
In O
this O
study, O
antidepressants O
with O
selectivity O
for O
the O
noradrenaline B-GENE-Y
transporter I-GENE-Y
(reboxetine B-CHEMICAL
and O

desipramine), B-CHEMICAL
or O
the O
serotonin B-CHEMICAL
transporter I-GENE-Y
(fluoxetine B-CHEMICAL
and O
clomipramine) B-CHEMICAL
were O
examined O
in O
terms O
of O
their O
ability O
to O
promote O
an O
anti-inflammatory O
cytokine B-GENE-N
phenotype O
in O
human O
blood. O
In O
addition, O
we O
examined O
the O
ability O
of O
trimipramine; B-CHEMICAL
a O
tricyclic B-CHEMICAL
antidepressant O
that O
is O
devoid O
of O
monoamine B-CHEMICAL
reuptake O
inhibitory O
properties O
on O
cytokine B-GENE-N
production. O
Lipopolysaccharide O
(LPS) O
was O
used O
to O
stimulate O
monocyte-derived O
pro-inflammatory O
(IL-1beta, B-GENE-Y
TNF-alpha, B-GENE-Y

IL-12) B-GENE-N
and O
anti-inflammatory O
(IL-10) B-GENE-Y
cytokines, B-GENE-N
whilst O
concanavalin O
A O
(Con O
A) O
was O
used O
to O
stimulate O
T-cell O
(Th(1): O
IFN-gamma B-GENE-Y
and O
Th(2/3): O
IL-10) B-GENE-Y
cytokines. B-GENE-N
All O
of O
the O
antidepressants O
suppressed O
IFN-gamma B-GENE-Y
production O
in O
the O
10-50 O
microM O
concentration O
range, O
irrespective O
of O
their O
preference O
for O
serotonin B-GENE-N
or I-GENE-N
noradrenaline I-GENE-N
transporters. I-GENE-N
This O
suppression O
of O
IFN-gamma B-GENE-Y
production O
was O
paralleled O
by O
reduced O
T-cell O
proliferation, O
therefore O
we O

suggest O
that O
the O
ability O
of O
antidepressants O
to O
suppress O
IFN-gamma B-GENE-Y
production O
may O
be O
related O
to O
their O
anti-proliferative O
properties. O
The O
fact O
that O
trimipramine B-CHEMICAL
also O
suppressed O
IFN-gamma B-GENE-Y
production O
and O
T-cell O
proliferation O
indicates O
that O
these O
immunomodulatory O
actions O
of O
antidepressants O
are O
most O
likely O
unrelated O
to O
inhibition O
of O
monoamine B-CHEMICAL
reuptake. O
Interestingly, O
exposure O
to O
a O
lower O
concentration O
(1 O
microM) O
of O
the O
antidepressants O
tended O
to O
increase O
T-cell-derived O
IL-10 B-GENE-Y
production, O
with O
significant O
effects O
elicited O
by O
the O
noradrenaline B-CHEMICAL
reuptake O

inhibitors O
reboxetine B-CHEMICAL
and O
desipramine. B-CHEMICAL
In O
contrast O
to O
the O
robust O
actions O
of O
antidepressants O
on O
T-cell O
derived O
cytokine B-GENE-N
production, O
they O
failed O
to O
induce O
any O
consistent O
change O
in O
LPS-induced O
monocyte O
cytokine B-GENE-N
production. O
Overall, O
our O
results O
indicate O
that O
IFN-gamma B-GENE-Y
producing O
T-cells O
(Th(1) O
cells) O
are O
the O
major O
target O
for O
the O
immunomodulatory O
actions O
of O
antidepressants, O
and O
provide O
evidence O
questioning O
the O
relationship O
between O
the O
monoaminergic O
reuptake O
properties O
of O
antidepressants O
and O
their O

immunomodulatory O
effects. O
The O
potential O
clinical O
significance O
of O
the O
anti-inflammatory O
actions O
of O
antidepressants O
is O
discussed. O
Effect O
of O
cyproheptadine B-CHEMICAL
on O
serum O
leptin B-GENE-Y
levels. O
Leptin B-GENE-Y
is O
a O
167 O
amino B-CHEMICAL
acid I-CHEMICAL
protein O
encoded O
by O
the O
obesity O
gene O
that O
is O
synthesized O
in O
adipose O
tissue O
and O
interacts O
with O
receptors O
in O
the O
hypothalamus O
linked O
to O
the O
regulation O
of O
appetite O
and O
metabolism. O
It O
is O
known O
to O
suppress O
appetite O
and O
increase O
energy O
expenditure. O
Cyproheptadine B-CHEMICAL
is O
a O
piperidine B-CHEMICAL
antihistamine B-CHEMICAL
that O
increases O
appetite O
through O
its O
antiserotonergic O
effect O
on O

5-HT2 B-GENE-Y
receptors O
in O
the O
brain. O
Although O
both O
leptin B-GENE-Y
and O
cyproheptadine B-CHEMICAL
are O
effective O
in O
controlling O
appetite, O
their O
interaction O
has O
not O
been O
addressed O
in O
clinical O
studies. O
This O
study O
evaluated O
serum O
leptin O
concentrations O
in O
patients O
who O
received O
cyproheptadine B-CHEMICAL
to O
treat O
a O
variety O
of O
disorders. O
Sixteen O
patients O
aged O
7 O
to O
71 O
years O
(mean, O
26.25 O
years) O
were O
given O
cyproheptadine B-CHEMICAL
2 O
to O
6 O
mg/day O
for O
a O
minimum O
of O
7 O
days. O
Body O
weight O
was O
measured O
and O
blood O
samples O
were O
obtained O
at O
baseline O
and O
after O
1 O
week O
of O
treatment. O
Serum O
leptin B-GENE-Y

levels O
were O
determined O
by O
leptin B-GENE-Y
radioimmunoassay. O
The O
mean O
body O
weight O
at O
baseline O
(52.59 O
kg) O
did O
not O
differ O
significantly O
from O
that O
at O
1 O
week O
after O
treatment O
(52.84 O
kg; O
P O
> O
.05), O
but O
the O
mean O
leptin B-GENE-Y
level O
after O
1 O
week O
of O
treatment O
with O
cyproheptadine B-CHEMICAL
(3.14 O
ng/mL) O
was O
14.2% O
higher O
than O
that O
at O
baseline O
(2.75 O
ng/mL; O
P O
< O
.05). O
This O
increase O
may O
suggest O
that O
both O
leptin B-GENE-Y
and O
cyproheptadine B-CHEMICAL
may O
affect O
appetite O
via O

similar O
receptors O
and O
that O
cyproheptadine B-CHEMICAL
does O
not O
impair O
leptin O
activity O
through O
these O
receptors. O
Further O
study O
will O
be O
necessary O
to O
clarify O
this O
relationship. O
Comparison O
of O
captopril B-CHEMICAL
and O
enalapril B-CHEMICAL
to O
study O
the O
role O
of O
the O
sulfhydryl-group B-CHEMICAL
in O
improvement O
of O
endothelial O
dysfunction O
with O
ACE B-GENE-Y
inhibitors O
in O
high O
dieted O
methionine B-CHEMICAL
mice. O
To O
examine O
the O
role O
of O
sulfhydryl B-CHEMICAL
(-SH) B-CHEMICAL
group O
in O
improvement O
of O
endothelial O
dysfunction O
with O
angiotensin-converting B-GENE-Y
enzyme I-GENE-Y
(ACE) B-GENE-Y
inhibitors O
in O

experimental O
high O
dose O
of O
methionine B-CHEMICAL
dieted O
rats. O
We O
compared O
the O
effects O
of O
Captopril B-CHEMICAL
(an O
ACE B-GENE-Y
inhibitor O
with O
-SH B-CHEMICAL
group), O
enalapril B-CHEMICAL
(an O
ACE-inhibitor B-GENE-Y
without O
-SH B-CHEMICAL
group), O
N-acetylcysteine B-CHEMICAL
(only O
-SH B-CHEMICAL
group O
not O
ACE B-GENE-Y
inhibitor) O
on O
endothelial O
dysfunction O
injured O
by O
methionine-induced B-CHEMICAL
hyperhomocysteinemia O
(HHcy) O
in O
rats. O
Male O
Sprague-Dawley O
rats O
were O
divided O
randomly O
into O
seven O
groups: O
control O
group, O
L-methionine B-CHEMICAL
group, O
low O
dose O

Captopril B-CHEMICAL
(15 O
mg/kg), O
middle O
dose O
Captopril B-CHEMICAL
(30 O
mg/kg), O
high O
dose O
Captopril B-CHEMICAL
(45 O
mg/kg), O
enalapril B-CHEMICAL
(20 O
mg/kg), O
N-acetylcysteine B-CHEMICAL
(200 O
mg/kg); O
control O
group O
were O
intragastric O
gavaged O
by O
water O
and O
others O
groups O
were O
intragastric O
gavaged O
by O
L-methionine B-CHEMICAL
and O
drugs O
in O
water O
one O
time O
every O
day. O
Acetylcholine B-CHEMICAL
(ACh)-induced B-CHEMICAL
endothelium-dependent O
relaxation O
(EDR), O
sodium B-CHEMICAL

nitroprusside I-CHEMICAL
(SNP)-induced B-CHEMICAL
endothelium-independent O
relaxation O
of O
aortic O
rings O
were O
examined. O
Paraoxonase1 B-GENE-Y
(PON1) B-GENE-Y
and O
ACE B-GENE-Y
activity, O
malondialdehyde B-CHEMICAL
(MDA), B-CHEMICAL
nitric B-CHEMICAL
oxide I-CHEMICAL
(NO), B-CHEMICAL
superoxide B-CHEMICAL
dismutase I-GENE-N
(SOD) B-GENE-N
in O
serum O
were O
analyzed. O
It O
was O
found O
that O
a O
single O
intragastric O
gavage O
by O
L-methionine B-CHEMICAL
resulted O
in O
inhibition O
of O
endothelium-dependent O
relaxation, O
markedly O
increased O
the O
serum O
level O
of O
malondialdehyde B-CHEMICAL
and O
decreased O
the O
activity O
of O

PON1 B-GENE-Y
and O
SOD, B-GENE-N
similarly O
decreased O
the O
level O
of O
NO B-CHEMICAL
in O
the O
serum; O
but O
had O
no O
effects O
on O
endothelium-independent O
relaxation O
and O
angiotensin-converting B-CHEMICAL
enzyme I-GENE-Y
activity O
compared O
with O
the O
control O
group. O
Given O
the O
treatment O
with O
three O
doses O
of O
Captopril B-CHEMICAL
(15 O
approximately O
45 O
mg/kg) O
markedly O
attenuated O
inhibition O
of O
vasodilator O
responses O
to O
ACh, B-CHEMICAL
and O
eliminated O
the O
increased O
level O
of O
malondialdehyde, B-CHEMICAL
the O
decreased O
level O
of O
NO, B-CHEMICAL
activity O
of O
PON1 B-GENE-Y
and O
SOD B-GENE-N
in O
serum O
by O
single O
intragastric O
gavaged O
L-methionine. B-CHEMICAL

However, O
there O
were O
some O
significant O
differences O
among O
Captopril B-CHEMICAL
(30 O
mg/kg O
or O
45 O
mg/kg), O
enalapril B-CHEMICAL
(20 O
mg/kg), O
and O
N-acetylcysteine B-CHEMICAL
particular O
in O
the O
activity O
of O
PON1 B-GENE-Y
and O
ACE. B-GENE-Y
These O
results O
suggested O
that O
Captopril B-CHEMICAL
can O
protect O
the O
vascular O
endothelium O
against O
the O
damages O
induced O
by O
L-methionine B-CHEMICAL
in O
rats, O
and O
the O
beneficial O
effects O
of O
Captopril B-CHEMICAL
may O
be O
related O
to O
attenuating O
the O
decrease O
in O
PON1 B-GENE-Y
activity O
and O
NO B-CHEMICAL
levels. O
Furthermore, O
this O
protective O
effect O
may O
be O
concerned O
with O
the O
sulfhydryl B-CHEMICAL

group. O
Preclinical O
and O
clinical O
development O
of O
the O
oral O
multikinase O
inhibitor O
sorafenib B-CHEMICAL
in O
cancer O
treatment. O
Tumor O
survival, O
growth O
and O
metastasis O
depend O
on O
efficient O
tumor O
cell O
proliferation O
and O
tumor O
angiogenesis, O
and O
targeting O
both O
of O
these O
processes O
simultaneously O
could O
prove O
to O
be O
therapeutically O
relevant. O
The O
RAS/RAF B-GENE-N
signaling O
pathway O
is O
an O
important O
mediator O
of O
tumor O
cell O
proliferation, O
and O
angiogenesis O
and O
is O
often O
aberrantly O
activated O
in O
human O
tumors O
due O
to O
the O
presence O
of O
activated O
Ras B-GENE-N
or O
mutant O
B-Raf, B-GENE-Y
or O
elevation O
of O
growth B-GENE-N
factor I-GENE-N
receptors. I-GENE-N
Sorafenib, B-CHEMICAL
which O
belongs O
chemically O
to O
a O
class O

that O
can O
be O
described O
as O
bis-aryl B-CHEMICAL
ureas, I-CHEMICAL
was O
selected O
for O
further O
pharmacologic O
characterization O
based O
on O
potent O
inhibition O
of O
Raf-1 B-GENE-Y
and O
its O
favorable O
kinase B-GENE-N
selectivity O
profile. O
Further O
characterization O
showed O
that O
sorafenib B-CHEMICAL
suppresses O
both O
wild-type O
and O
V599E B-GENE-N
mutant O
B-Raf B-GENE-Y
activity O
in O
vitro. O
In O
addition, O
sorafenib B-CHEMICAL
demonstrated O
significant O
activity O
against O
several O
receptor B-GENE-N
tyrosine I-GENE-N
kinases I-GENE-N
involved O
in O
neovascularization O
and O
tumor O
progression, O
including O
vascular-endothelial B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(VEGFR)-2, I-GENE-Y

VEGFR-3, B-GENE-Y
platelet-derived B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(PDGFR)-beta I-GENE-Y
Flt-3, B-GENE-Y
and O
c-KIT. B-GENE-Y
Preclinically, O
sorafenib B-CHEMICAL
showed O
broad-spectrum O
antitumor O
activity O
in O
colon, O
breast O
and O
non-small-cell O
lung O
cancer O
xenograft O
models. O
A O
total O
of O
four O
phase O
I O
studies O
using O
oral O
sorafenib B-CHEMICAL
as O
a O
single O
agent O
have O
been O
completed, O
and O
the O
compound O
showed O
a O
favorable O
safety O
profile O
with O
mild O
to O
moderate O
diarrhea O
being O
the O
most O
common O
treatment-related O
adverse O
event. O
The O
maximum O
tolerated O
dose O
was O
400 O
mg O

b.i.d. O
continuous. O
Single-agent O
phase O
II O
trials O
reported O
so O
far O
demonstrated O
antitumor O
activity O
of O
sorafenib B-CHEMICAL
in O
patients O
with O
hepatocellular O
carcinoma, O
sarcoma O
and O
renal O
cell O
cancer O
(RCC). O
Based O
on O
phase O
II O
results O
in O
RCC O
patients, O
a O
placebo-controlled O
phase O
III O
study O
was O
performed, O
which O
randomized O
a O
total O
of O
905 O
patients, O
most O
of O
whom O
were O
treated O
previously. O
The O
partial O
response O
rate O
was O
2% O
for O
sorafenib B-CHEMICAL
and O
0% O
for O
placebo. O
Stable O
disease O
was O
observed O
in O
78% O
and O
55% O
of O
patients O
on O
sorafenib B-CHEMICAL

and O
placebo, O
respectively. O
Sorafenib B-CHEMICAL
significantly O
prolonged O
median O
progression-free O
survival O
(24 O
weeks) O
compared O
with O
placebo O
(12 O
weeks) O
in O
all O
subsets O
of O
patients O
evaluated. O
Approval O
of O
sorafenib B-CHEMICAL
by O
the O
U.S. O
Food O
and O
Drug O
Administration O
for O
this O
indication O
is O
pending. O
A O
first-line O
phase O
III O
study O
in O
RCC O
as O
well O
as O
phase O
III O
studies O
in O
hepatocellular O
carcinoma O
and O
metastatic O
melanoma O
have O
been O
initiated. O
A O
selective O
retinoid B-GENE-N
X I-GENE-N
receptor I-GENE-N
agonist O
bexarotene B-CHEMICAL
(LGD1069, B-CHEMICAL
targretin) B-CHEMICAL
inhibits O

angiogenesis O
and O
metastasis O
in O
solid O
tumours. O
The O
present O
study O
determined O
the O
influence O
of O
a O
retinoid B-CHEMICAL
X I-GENE-N
receptor I-GENE-N
agonist O
bexarotene B-CHEMICAL
on O
angiogenesis O
and O
metastasis O
in O
solid O
tumours. O
In O
the O
experimental O
lung O
metastasis O
xenograft O
models, O
treatment O
with O
bexarotene B-CHEMICAL
inhibited O
the O
development O
of O
the O
lung O
tumour O
nodule O
formation O
compared O
to O
control. O
In O
vivo O
angiogenesis O
assay O
utilising O
gelfoam O
sponges, O
bexarotene B-CHEMICAL
reduced O
angiogenesis O
in O
sponges O
containing O
vascular B-GENE-Y
endothelial I-GENE-Y
growth I-GENE-Y
factor, I-GENE-Y
epidermal B-GENE-Y
growth I-GENE-Y

factor I-GENE-Y
and O
basic O
fibroblast B-GENE-N
growth I-GENE-N
factor I-GENE-N
to O
various O
extent. O
To O
determine O
the O
basis O
of O
these O
observations, O
human O
breast O
and O
non-small-cell O
lung O
cancer O
cells O
were O
subjected O
to O
migration O
and O
invasion O
assays O
in O
the O
presence O
of O
bexarotene. B-CHEMICAL
Our O
data O
showed O
that O
bexarotene B-CHEMICAL
decrease O
migration O
and O
invasiveness O
of O
tumour O
cells O
in O
a O
dose-dependent O
manner. O
Furthermore, O
bexarotene B-CHEMICAL
inhibited O
angiogenesis O
by O
directly O
inhibiting O
human O
umbilical O
vein O
endothelial O
cell O
growth O
and O
indirectly O
inhibiting O
tumour O
cell-mediated O
migration O
of O
human O
umbilical O
vein O
endothelial O
cells O
through O
Matrigel O

matrix. O
Analysis O
of O
tumour-conditioned O
medium O
indicated O
that O
bexarotene B-CHEMICAL
decreased O
the O
secretion O
of O
angiogenic O
factors O
and O
matrix B-GENE-N
metalloproteinases I-GENE-N
and O
increased O
the O
tissue O
inhibitor O
of O
matrix B-GENE-N
metalloproteinases. I-GENE-N
The O
ability O
of O
bexarotene B-CHEMICAL
to O
inhibit O
angiogenesis O
and O
metastasis O
was O
dependent O
on O
activation O
of O
its O
heterodimerisation O
partner O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
gamma. I-GENE-Y
Collectively, O
our O
results O
suggest O
a O
role O
of O
bexarotene B-CHEMICAL
in O
treatment O
of O
angiogenesis O
and O
metastasis O
in O
solid O
tumours. O
DRD2 B-GENE-N
promoter I-GENE-N
region O
variation O
as O
a O
predictor O
of O
sustained O

response O
to O
antipsychotic O
medication O
in O
first-episode O
schizophrenia O
patients. O
OBJECTIVE: O
All O
antipsychotics O
act O
on O
the O
dopamine B-GENE-Y
D(2) I-GENE-Y
receptor. I-GENE-Y
The O
present O
study O
extends O
prior O
pharmacogenetic O
investigations O
of O
the O
D(2) B-GENE-Y
receptor I-GENE-Y
gene O
(DRD2) B-GENE-Y
by O
examining, O
in O
first-episode O
schizophrenia O
patients, O
promoter O
region O
variation O
as O
a O
predictor O
of O
response O
time O
to O
two O
first-line O
atypical O
antipsychotics. O
METHOD: O
Patients O
experiencing O
their O
first O
episode O
of O
schizophrenia O
(N=61) O
were O
genotyped O
for O
two O

DRD2 B-GENE-N
promoter I-GENE-N
region O
polymorphisms O
(A-241G B-GENE-N
and O
-141C O
Ins/Del) O
and O
were O
randomly O
assigned O
to O
receive O
16 O
weeks O
of O
treatment O
with O
either O
risperidone B-CHEMICAL
or O
olanzapine. B-CHEMICAL
Time O
until O
sustained O
response O
(two O
consecutive O
ratings O
without O
significant O
positive O
symptoms) O
for O
rare O
allele O
carriers O
versus O
wild O
types O
was O
examined O
by O
using O
Kaplan-Meier O
curves. O
RESULTS: O
Relative O
to O
wild O
type O
homozygotes, O
G O
carriers O
(A-241G) B-GENE-N
exhibited O
a O
significantly O
faster O
time O
until O
response, O
whereas O
-141C O
Del O
carriers O
took O
a O
significantly O
longer O
time O
to O
respond. O

Diplotype O
analysis O
revealed O
similar O
results. O
CONCLUSIONS: O
These O
findings O
suggest O
that O
variation O
in O
the O
D(2) B-GENE-Y
receptor I-GENE-Y
gene O
can, O
in O
part, O
explain O
variation O
in O
the O
timing O
of O
clinical O
response O
to O
antipsychotics O
in O
patients O
with O
first-episode O
schizophrenia. O
Intrauterine O
pressure, O
ischemia O
markers, O
and O
experienced O
pain O
during O
administration O
of O
a O
vasopressin B-GENE-Y
V1a I-GENE-Y
receptor I-GENE-Y
antagonist O
in O
spontaneous O
and O
vasopressin-induced B-GENE-Y
dysmenorrhea. O
BACKGROUND: O
A O
model O
to O
study O
the O
effect O
of O
vasopressin B-GENE-Y
V1a I-GENE-Y
antagonist O

in O
dysmenorrhea. O
METHODS: O
A O
double-blind, O
randomized, O
placebo-controlled, O
cross-over O
trial O
was O
performed. O
Eight O
patients O
with O
primary O
dysmenorrhea O
and O
eight O
tuballigated, O
healthy O
subjects O
participated O
on O
days O
1-2 O
of O
two O
consecutive O
menstruations. O
At O
each O
menstruation O
a O
bolus O
injection O
of O
10 O
pmol/kg O
of O
vasopressin B-CHEMICAL
was O
administered O
before O
and O
during O
infusion O
of O
either O
300 O
microg/min O
of O
atosiban B-CHEMICAL
or O
placebo. O
Intrauterine O
pressure O
was O
measured O
as O
area O
under O
the O
curve O
throughout O
the O

experiments. O
Ischemia O
markers O
in O
plasma O
and O
pain O
recorded O
by O
a O
visual O
analog O
scale O
were O
measured O
before O
and O
after O
each O
vasopressin B-GENE-Y
injection O
as O
well O
as O
before O
and O
after O
the O
start O
of O
either O
atosiban B-CHEMICAL
or O
placebo O
infusion. O
RESULTS: O
Vasopressin B-GENE-Y
injections O
elevated O
area O
under O
the O
curve O
in O
both O
healthy O
volunteers O
and O
dysmenorrhea O
subjects. O
The O
vasopressin-induced B-CHEMICAL
rise O
in O
area O
under O
the O
curve O
was O
lower O
during O
atosiban B-CHEMICAL
administration O
than O
during O
infusion O
of O
placebo O
in O
both O
groups. O
None O
of O
the O
ischemia O
markers O
differed O
between O
or O
within O
groups O
at O

vasopressin B-CHEMICAL
injections O
or O
atosiban/placebo B-CHEMICAL
infusions. O
In O
subjects O
with O
dysmenorrhea O
the O
increase O
in O
pain O
following O
the O
administration O
of O
vasopressin B-CHEMICAL
was O
significantly O
lower O
during O
atosiban B-CHEMICAL
than O
during O
placebo O
infusion. O
Healthy O
volunteers O
experienced O
only O
slight O
discomfort O
after O
the O
vasopressin B-CHEMICAL
injections. O
CONCLUSIONS: O
Atosiban B-CHEMICAL
reduces O
vasopressin-induced B-CHEMICAL
intrauterine O
pressure O
in O
both O
healthy O
volunteers O
and O
dysmenorrheics, O
and O
reported O
pain O
in O
subjects O
with O
dysmenorrhea. O
The O

ischemia O
markers O
are O
not O
a O
useful O
biomarker O
index O
in O
women O
with O
dysmenorrhea. O
The O
dysmenorrhea O
pain O
evoked O
by O
vasopressin B-CHEMICAL
correlated O
poorly O
with O
area O
under O
the O
curve, O
which O
may O
suggest O
that O
the O
effect O
is O
mediated O
by O
more O
than O
one O
V1a-like B-GENE-Y
receptor. I-GENE-Y
We O
conclude O
that O
this O
model O
with O
recordings O
in O
healthy O
women O
is O
useful O
in O
the O
evaluation O
of O
drug O
candidates O
for O
primary O
dysmenorrhea. O
Thymidylate B-CHEMICAL
synthase I-GENE-Y
expression O
in O
resectable O
and O
unresectable O
pancreatic O
cancer: O
role O
as O
predictive O
or O
prognostic O
marker? O

BACKGROUND O
AND O
AIMS: O
Thymidylate B-CHEMICAL
synthase I-GENE-Y
(TS) B-GENE-Y
is O
an O
important O
enzyme O
for O
DNA O
synthesis O
and O
the O
target O
for O
5-fluorouracil B-CHEMICAL
(5-FU). B-CHEMICAL
Its O
expression O
may O
determine O
the O
outcome O
of O
patients O
with O
gastrointestinal O
cancers. O
We O
examined O
the O
prognostic O
and O
predictive O
value O
of O
TS-protein B-GENE-Y
expression O
in O
patients O
with O
ductal O
adenocarcinoma O
of O
the O
pancreas. O
METHODS: O
TS B-GENE-Y
expression O
from O
131 O
patients O
with O
ductal O
adenocarcinoma O
of O
the O
pancreas O
was O
analyzed O
by O

immunohistochemistry O
in O
paraffin-embedded O
primary O
tumour O
specimens O
or O
biopsies. O
RESULTS: O
The O
median O
disease-specific O
survival O
among O
all O
patients O
(n=131) O
was O
13 O
months. O
The O
invasion O
depth, O
the O
presence O
of O
metastases, O
grading O
and O
Union O
Internationale O
Contre O
le O
Cancer O
[International O
Union O
Against O
Cancer] O
(UICC) O
stage O
were O
associated O
with O
survival. O
Among O
resected O
patients O
(n=98), O
a O
difference O
in O
median O
survival O
was O
seen O
in O
the O
group O
receiving O
postoperative O
adjuvant O
treatment O
(21.1 O
months) O
compared O
with O
the O
group O
treated O
by O
surgery O
alone O

(12.4 O
months) O
(p=0.025). O
Low- O
and O
high-TS B-GENE-Y
immunoreactivity O
was O
present O
in O
74 O
(56%) O
and O
56 O
(43%) O
of O
the O
cancers, O
respectively. O
One O
sample O
was O
not O
evaluable. O
No O
difference O
in O
median O
survival O
was O
observed O
among O
low- O
and O
high-TS-expressing B-GENE-Y
tumours. O
Among O
patients O
undergoing O
resection O
and O
receiving O
postoperative O
intra-arterial O
chemotherapy O
(n=23), O
a O
marked O
trend O
to O
a O
longer O
median O
survival O
was O
seen O
for O
the O
group O
with O
low-TS-expressing B-GENE-Y
tumours O

compared O
with O
the O
corresponding O
high-TS B-GENE-Y
group O
(25.0 O
vs O
16.0 O
months) O
(p=0.3834). O
There O
was O
no O
difference O
in O
survival O
among O
all O
palliative O
treated O
patients O
with O
low- O
and O
high-TS-expressing B-GENE-Y
tumours. O
CONCLUSION: O
Especially O
patients O
undergoing O
tumour O
resection O
with O
low-TS B-GENE-Y
values O
seemed O
to O
have O
taken O
advantage O
from O
an O
intensified O
postoperative O
chemotherapeutic O
protocol. O
However O
due O
to O
the O
heterogeneous O
group O
of O
patients O
in O
the O
present O
report, O
larger O
trials O
of O
more O
homogenous O
patient O
populations O
will O
be O
necessary O
to O
confirm O

this O
hypothesis. O
Enzymatic O
and O
biochemical O
properties O
of O
a O
novel O
human B-GENE-Y
serine B-CHEMICAL
dehydratase I-GENE-Y
isoform. O
A O
cDNA O
clone O
similar O
to O
human B-GENE-Y
serine B-CHEMICAL
dehydratase I-GENE-Y
(SDH) B-GENE-Y
is O
deposited O
in O
the O
GenBank/EMBL O
databases, O
but O
its O
structural O
and O
functional O
bases O
remain O
unknown. O
Despite O
the O
occurrence O
of O
mRNA, O
the O
expected O
protein O
level O
was O
found O
to O
be O
low O
in O
cultured O
cells. O
To O
learn O
about O
physicochemical O
properties O
of O
the O
protein, O
we O
expressed O
the O
cDNA O
in O
Escherichia O
coli, O
and O
compared O
the O
expressed O
protein O
with O
that O
of O
a O
hepatic O

SDH. B-GENE-Y
The O
purified O
protein O
showed O
l-serine B-CHEMICAL
and I-GENE-Y
l-threonine B-CHEMICAL
dehydratase I-GENE-Y
activity, O
demonstrating O
to O
be O
an O
isoform O
of O
SDH. B-GENE-Y
However, O
their O
Km O
and O
Vmax O
constants O
were O
different O
in O
a O
range O
of O
two-order. O
Removal O
of O
Pro128 O
from O
the O
hepatic O
SDH B-GENE-Y
consisting O
of O
328 O
residues, O
which O
is O
missing O
in O
the O
corresponding O
position O
of O
the O
isoform O
consisting O
of O
329 O
residues, O
significantly O
changed O
the O
Michaelis O
constants O
and O
Kd O
value O
for O
pyridoxal B-CHEMICAL
5'-phosphate, I-CHEMICAL
whereas O
addition O
of O
a O
proline B-CHEMICAL
residue O
to O
the O

isoform O
was O
without O
effect. O
These O
findings O
suggest O
the O
difference O
in O
the O
structures O
of O
the O
active O
sites O
of O
the O
two O
enzymes. O
Another O
striking O
feature O
was O
that O
the O
expressed O
level O
of O
the O
isoform O
in O
E. O
coli O
was O
7-fold O
lower O
than O
that O
of O
the O
hepatic O
SDH. B-GENE-Y
Substitution O
of O
Val B-GENE-N
for I-GENE-N
Leu287 I-GENE-N
in O
the O
isoform O
dramatically O
increased O
the O
protein O
level. O
The O
high O
yield O
of O
the O
mutated O
isoform O
was O
also O
confirmed O
by O
the O
in O
vitro O
transcription O
and O
translation O
experiment. O
The O
poor O
expression O
of O
the O
isoform O
could O
be O
explained O
by O
the O
more O
stable O
secondary O
structure O
of O
the O
mRNA O
than O
that O

of O
the O
hepatic O
SDH B-GENE-Y
mRNA. O
The O
present O
findings O
may O
provide O
a O
clue O
as O
to O
why O
the O
protein O
level O
in O
cultured O
cells O
is O
low. O
Multiple O
enzyme O
inhibitions O
by O
histamine B-GENE-Y
H3 I-GENE-Y
receptor I-GENE-Y
antagonists O
as O
potential O
procognitive O
agents. O
Novel O
highly O
affine O
histamine B-CHEMICAL
H3 I-GENE-Y
receptor I-GENE-Y
ligands O
with O
additional O
inhibitory O
effects O
on O
the O
main O
histamine B-CHEMICAL
metabolizing O
enzyme O
in O
the O
brain, O
N-methyltransferase, B-CHEMICAL
chemically O
show O
structural O
elements O
of O
the O
acetylcholinesterase B-GENE-Y
inhibitor O
tacrine. B-CHEMICAL
H3 B-GENE-Y
receptor I-GENE-Y
antagonism, O
inhibition O
of O
metabolisation O
of O

neuronal O
histamine B-CHEMICAL
as O
well O
as O
inhibition O
of O
hydrolysis O
of O
acetylcholine B-CHEMICAL
are O
each O
one O
believed O
to O
improve O
reduced O
cognitive O
functions, O
which O
is O
useful O
for O
symptomatic O
treatment O
of O
Alzheimer's O
disease. O
Some O
of O
the O
new O
compounds O
proved O
in O
a O
slightly O
modified O
colorimetric O
Ellmann's O
assay O
to O
be O
potent O
inhibitors O
of O
acetylcholinesterase B-GENE-Y
and O
of O
butyrylcholinesterase B-GENE-Y
which O
is O
another O
catalytic O
enzyme O
hydrolysing O
acetylcholine. B-CHEMICAL
Some O
compounds O
with O
(sub)nanomolar O
activities O
on O
the O
histamine-related B-CHEMICAL
targets O
are O
also O
active O
in O

the O
nanomolar O
concentration O
range O
on O
both O
cholinesterase B-GENE-N
targets O
being O
5- O
to O
40-times O
more O
potent O
than O
tacrine. B-CHEMICAL
Preliminary O
structure-activity O
relationships O
could O
already O
be O
drawn O
from O
the O
small O
number O
of O
compounds. O
The O
compounds O
acting O
as O
hybrid O
drugs O
simultaneously O
on O
four O
different O
targets O
to O
enhance O
cognitive O
functions O
via O
different O
pathways O
are O
promising O
lead O
structures O
for O
a O
new O
approach O
in O
the O
treatment O
of O
Alzheimer's O
disease. O
Chemotherapy O
and O
targeted O
therapy O
combinations O
in O
advanced O
melanoma. O
For O
three O
decades, O
clinical O
trials O
with O
chemotherapy O
in O
melanoma O
have O
failed O
to O
show O
superiority O
of O
any O
one O
regimen O
over O
another. O
Dacarbazine B-CHEMICAL
remains O
the O
only O

"standard" O
agent. O
With O
response O
rates O
of O
<10% O
and O
median O
progression-free O
survival O
of O
2 O
months O
or O
less O
in O
contemporary O
trials, O
there O
is O
a O
need O
to O
improve O
systemic O
therapy. O
Combination O
chemotherapy O
is O
associated O
with O
higher O
response O
rates O
than O
single-agent O
therapy O
but O
this O
has O
not O
translated O
into O
improved O
survival. O
An O
increasing O
number O
of O
potential O
therapeutic O
targets O
have O
been O
identified. O
For O
some, O
pharmacologic O
inhibitors O
are O
available, O
including O
sorafenib B-CHEMICAL
for O
BRAF, B-GENE-Y
farnesyltransferase B-GENE-N
inhibitors O
for O
NRAS, B-GENE-Y
PD-0325901 B-CHEMICAL
for O
mitogen-activated B-GENE-N
protein I-GENE-N
kinase/extracellular I-GENE-N

signal-regulated I-GENE-N
kinase I-GENE-N
kinase, I-GENE-N
rapamycin B-CHEMICAL
analogues O
for O
mammalian B-GENE-Y
target I-GENE-Y
of I-GENE-Y
rapamycin, B-CHEMICAL
and O
agents O
that O
inhibit O
either O
vascular B-GENE-Y
endothelial I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
or O
its O
receptors. O
Several O
multitargeted O
kinase B-GENE-N
inhibitors O
have O
potency O
against O
the O
fibroblast B-GENE-N
growth I-GENE-N
factor I-GENE-N
receptor, I-GENE-N
c-kit, B-GENE-Y
and O
platelet-derived B-GENE-N
growth I-GENE-N
factor I-GENE-N
receptor. I-GENE-N
Small-molecule O
inhibitors O
of O
c-met B-GENE-Y
and O
Akt B-GENE-N
are O
in O
preclinical O
development. O
Another O
class O
of O
agents O
indirectly O
affect O
aberrant O
signaling, O
including O
inhibitors O
of O
chaperones B-GENE-N
and O
proteasomes. B-GENE-N
Several O
targeted O
agents O
seem O
to O
enhance O
the O

cytotoxicity O
of O
chemotherapy O
in O
preclinical O
models. O
The O
mechanism O
by O
which O
signaling O
inhibition O
might O
synergize O
with O
chemotherapy O
requires O
more O
study O
so O
that O
rational O
combinations O
move O
forward. O
Very O
few O
targeted O
agents O
have O
been O
studied O
rigorously O
in O
this O
fashion. O
Lipid O
specific O
activation O
of O
the O
murine B-GENE-N
P4-ATPase I-GENE-N
Atp8a1 B-GENE-Y
(ATPase B-GENE-Y
II). I-GENE-Y
The O
asymmetric O
transbilayer O
distribution O
of O
phosphatidylserine B-CHEMICAL
(PS) B-CHEMICAL
in O
the O
mammalian O
plasma O
membrane O
and O
secretory O
vesicles O
is O
maintained, O
in O
part, O
by O
an O
ATP-dependent B-CHEMICAL

transporter. O
This O
aminophospholipid O
"flippase" B-GENE-N
selectively O
transports O
PS B-CHEMICAL
to O
the O
cytosolic O
leaflet O
of O
the O
bilayer O
and O
is O
sensitive O
to O
vanadate, B-CHEMICAL
Ca(2+), B-CHEMICAL
and O
modification O
by O
sulfhydryl B-CHEMICAL
reagents. O
Although O
the O
flippase B-GENE-N
has O
not O
been O
positively O
identified, O
a O
subfamily O
of O
P-type B-GENE-N
ATPases I-GENE-N
has O
been O
proposed O
to O
function O
as O
transporters O
of O
amphipaths, O
including O
PS O
and O
other O
phospholipids. O
A O
candidate O
PS B-GENE-Y
flippase I-GENE-Y
ATP8A1 I-GENE-Y
(ATPase B-GENE-Y
II), I-GENE-Y
originally O
isolated O
from O
bovine O
secretory O

vesicles, O
is O
a O
member O
of O
this O
subfamily O
based O
on O
sequence O
homology O
to O
the O
founding O
member O
of O
the O
subfamily, O
the O
yeast B-GENE-Y
protein I-GENE-Y
Drs2, I-GENE-Y
which O
has O
been O
linked O
to O
ribosomal O
assembly, O
the O
formation O
of O
Golgi-coated O
vesicles, O
and O
the O
maintenance O
of O
PS O
asymmetry. O
To O
determine O
if O
ATP8A1 B-GENE-Y
has O
biochemical O
characteristics O
consistent O
with O
a O
PS B-GENE-N
flippase, I-GENE-N
a O
murine O
homologue O
of O
this O
enzyme O
was O
expressed O
in O
insect O
cells O
and O
purified. O
The O
purified O
Atp8a1 B-GENE-Y
is O
inactive O
in O
detergent O
micelles O
or O
in O
micelles O
containing O

phosphatidylcholine, B-CHEMICAL
phosphatidic B-CHEMICAL
acid, I-CHEMICAL
or O
phosphatidylinositol, B-CHEMICAL
is O
minimally O
activated O
by O
phosphatidylglycerol B-CHEMICAL
or O
phosphatidylethanolamine B-CHEMICAL
(PE), B-CHEMICAL
and O
is O
maximally O
activated O
by O
PS. B-CHEMICAL
The O
selectivity O
for O
PS B-CHEMICAL
is O
dependent O
upon O
multiple O
elements O
of O
the O
lipid O
structure. O
Similar O
to O
the O
plasma B-GENE-N
membrane I-GENE-N
PS B-CHEMICAL
transporter, I-GENE-N
Atp8a1 B-GENE-Y
is O
activated O
only O
by O
the O
naturally O
occurring O
sn-1,2-glycerol B-CHEMICAL
isomer O
of O
PS O
and O
not O
the O

sn-2,3-glycerol B-CHEMICAL
stereoisomer. O
Both O
flippase B-GENE-N
and O
Atp8a1 B-GENE-Y
activities O
are O
insensitive O
to O
the O
stereochemistry O
of O
the O
serine O
headgroup. O
Most O
modifications O
of O
the O
PS B-CHEMICAL
headgroup O
structure O
decrease O
recognition O
by O
the O
plasma O
membrane O
PS B-GENE-N
flippase. I-GENE-N
Activation O
of O
Atp8a1 B-GENE-Y
is O
also O
reduced O
by O
these O
modifications; O
phosphatidylserine-O-methyl B-CHEMICAL
ester, I-CHEMICAL
lysophosphatidylserine, B-CHEMICAL
glycerophosphoserine, B-CHEMICAL
and O
phosphoserine, B-CHEMICAL
which O
are O
not O
transported O
by O
the O
plasma O
membrane O

flippase, O
do O
not O
activate O
Atp8a1. B-GENE-Y
Weakly O
translocated O
lipids O
(PE, B-CHEMICAL
phosphatidylhydroxypropionate, B-CHEMICAL
and O
phosphatidylhomoserine) B-CHEMICAL
are O
also O
weak O
Atp8a1 B-GENE-Y
activators. O
However, O
N-methyl-phosphatidylserine, B-CHEMICAL
which O
is O
transported O
by O
the O
plasma O
membrane O
flippase B-GENE-N
at O
a O
rate O
equivalent O
to O
PS, B-CHEMICAL
is O
incapable O
of O
activating O
Atp8a1 B-GENE-Y
activity. O
These O
results O
indicate O
that O
the O
ATPase B-GENE-N
activity O
of O
the O
secretory O
granule O

Atp8a1 B-GENE-Y
is O
activated O
by O
phospholipids O
binding O
to O
a O
specific O
site O
whose O
properties O
(PS B-CHEMICAL
selectivity, O
dependence O
upon O
glycerol B-CHEMICAL
but O
not O
serine, B-CHEMICAL
stereochemistry, O
and O
vanadate O
sensitivity) O
are O
similar O
to, O
but O
distinct O
from, O
the O
properties O
of O
the O
substrate O
binding O
site O
of O
the O
plasma O
membrane O
flippase. B-GENE-N
Pneumocystis O
jiroveci O
pneumonia O
in O
a O
patient O
with O
rheumatoid O
arthritis O
as O
a O
complication O
of O
treatment O
with O
infliximab, O
anti-tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
alpha I-GENE-Y
neutralizing O
antibody. O
We O
report O
that O

a-63-year-old O
woman O
developed O
Pneumocystis O
jiroveci O
pneumonia O
(PCP) O
as O
a O
complication O
from O
treatment O
with O
infliximab O
for O
rheumatoid O
arthritis. O
Although O
there O
was O
neither O
symptoms O
of O
dyspnea O
nor O
typical O
observations O
on O
a O
chest O
X-ray O
examination, O
low O
levels O
of O
oxygen B-CHEMICAL
saturation O
and O
findings O
of O
high-resolution O
chest O
computed O
tomographic O
scanning O
suggested O
a O
possibility O
of O
interstitial O
pneumonia. O
A O
polymerase O
chain O
reaction-based O
detection O
of O
Pneumocystis O
jiroveci O
in O
induced O
sputum O
allowed O
an O
early O
diagnosis O
of O
PCP O
and O

subsequent O
effective O
treatment. O
High-mannose-type B-CHEMICAL
glycan O
modifications O
of O
dihydrofolate B-CHEMICAL
reductase I-GENE-Y
using O
glycan-methotrexate B-CHEMICAL
conjugates. O
Various O
high-mannose-type B-CHEMICAL
glycan O
modifications O
of O
dihydrofolate B-CHEMICAL
reductase I-GENE-Y
(DHFR) B-GENE-Y
were O
achieved O
by O
ligand-based O
approach O
using O
glycan-methotrexate B-CHEMICAL
(MTX) B-CHEMICAL
conjugates O
as O
tight O
binding O
glycan O
bearing O
ligands O
for O
DHFR. B-GENE-Y
The O
resulting O
glycan-MTX B-CHEMICAL
conjugates O
and O
the O
corresponding O
artificial O

glycoproteins O
could O
be O
useful O
as O
oligosaccharide- O
and O
glycoprotein-probes O
to O
perform O
quantitative O
analysis O
of O
glycan B-GENE-N
recognizing I-GENE-N
protein I-GENE-N
such O
as O
lectins, B-GENE-N
glycosyltransferases B-GENE-N
or O
glycosidases. B-GENE-N
Moreover, O
artificial O
glycoproteins O
having O
two O
different O
high-mannose-type B-CHEMICAL
glycans O
were O
developed O
for O
the O
first O
time O
by O
a O
combination O
of O
two O
different O
types O
of O
glycan O
modification O
strategies. O
NMDA B-GENE-N
receptors I-GENE-N
are O
not O
alone: O
dynamic O
regulation O
of O
NMDA B-GENE-N
receptor I-GENE-N
structure O
and O
function O
by O
neuregulins B-GENE-N
and O
transient B-GENE-N

cholesterol-rich I-GENE-N
membrane I-GENE-N
domains I-GENE-N
leads O
to O
disease-specific O
nuances O
of O
glutamate-signalling. B-CHEMICAL
Glutamate B-CHEMICAL
receptors I-GENE-N
of O
the O
N-methyl-D-asparate B-CHEMICAL
(NMDA-) B-CHEMICAL
subtype O
are O
tetrameric O
allosteric O
and O
ligand-gated B-GENE-N
calcium I-GENE-N
channels. I-GENE-N
They O
are O
modulated O
by O
a O
variety O
of O
endogenous O
ligands O
and O
ions O
and O
play O
a O
pivotal O
role O
in O
memory-related O
signal O
transduction O
due O
to O
a O
voltage-dependent O
block O
by O
magnesium, B-CHEMICAL
which O
makes O
them O
Hebbian O
coincidence O
detectors. O
On O
the O
structural O
level O
NMDA B-CHEMICAL
receptors I-GENE-N
have O

an O
enormous O
flexibility O
due O
to O
seven O
genes O
(NR1, B-GENE-Y
NR2A-D B-GENE-N
and O
NR3A-B), B-GENE-N
alternative O
splicing, O
RNA-editing O
and O
extensive O
posttranslational O
modifications, O
like O
phosphorylation O
and O
glycosylation. O
NMDA B-GENE-N
receptors I-GENE-N
are O
thought O
to O
be O
responsible O
for O
excitotoxicity O
and O
subsequent O
downstream O
events O
like O
neuroinflammation O
and O
apoptosis O
and O
thus O
have O
been O
implicated O
in O
many O
important O
human O
pathologies, O
ranging O
from O
amyotrophic O
lateral O
sclerosis, O
Alzheimer's O
and O
Parkinson' O
disease, O
depression, O
epilepsy, O
trauma O

and O
stroke O
to O
schizophrenia. O
This O
fundamental O
significance O
of O
NMDA B-GENE-N
receptor-related I-GENE-N
excitotoxicity O
is O
discussed O
in O
the O
context O
of O
the O
developing O
clinical O
success O
of O
Memantine, B-CHEMICAL
but O
moreover O
set O
into O
relation O
to O
various O
proteomic O
and O
genetic O
markers O
of O
said O
diseases. O
The O
very O
complex O
localisational O
and O
functional O
regulation O
of O
NMDA B-CHEMICAL
receptors I-GENE-N
appears O
to O
be O
dependent O
on O
neuregulins B-GENE-N
and O
receptor B-GENE-N
tyrosine B-CHEMICAL
kinases I-GENE-N
in O
cholesterol-rich B-CHEMICAL
membrane O
domains O
(lipid O
rafts), O
calcium-related B-CHEMICAL
mitochondrial O
feedback-loops O
and O
subsynaptic O
structural O
elements O
like O
PSD-95 B-GENE-Y

(post-synaptic B-GENE-Y
density I-GENE-Y
protein I-GENE-Y
of I-GENE-Y
95 I-GENE-Y
kD). I-GENE-Y
The O
flexibility O
and O
multitude O
of O
interaction O
partners O
and O
possibilities O
of O
these O
highly O
dynamic O
molecular O
systems O
are O
discussed O
in O
terms O
of O
drug O
development O
strategies, O
in O
particular O
comparing O
high O
affinity O
and O
sub-type O
specific O
ligands O
to O
currently O
successful O
or O
promising O
therapies. O
Sorafenib: B-CHEMICAL
recent O
update O
on O
activity O
as O
a O
single O
agent O
and O
in O
combination O
with O
interferon-alpha2 B-GENE-Y
in O
patients O
with O
advanced-stage O
renal O
cell O
carcinoma. O
Metastatic O
renal O
cell O
carcinoma O
does O
not O
respond O
favorably O
to O
conventional O
treatment O
strategies O
and O
is O
not O
very O
responsive O
to O

cytokine O
therapy. O
Therefore, O
novel O
targeted O
treatment O
approaches O
have O
been O
explored O
for O
patients O
with O
renal O
cancer O
who O
have O
chemotherapy-refractory O
disease. O
Sorafenib B-CHEMICAL
(BAY B-CHEMICAL
43-9006) I-CHEMICAL
is O
a O
small-molecule O
inhibitor O
that O
has O
been O
shown O
to O
target O
members O
of O
multiple O
classes O
of O
tyrosine B-GENE-N
kinases I-GENE-N
that O
are O
known O
to O
be O
involved O
in O
tumor O
cell O
proliferation O
and O
tumor O
angiogenesis. O
These O
kinases B-GENE-N
include O
vascular B-GENE-Y
endothelial I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(VEGFR)-1, I-GENE-Y
VEGFR-2, B-GENE-Y
VEGFR-3, B-GENE-Y
platelet-derived B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y

receptor, I-GENE-Y
Flt-3, B-GENE-Y
c-kit, B-GENE-Y
and O
Raf B-GENE-Y
kinases. B-GENE-N
Based O
on O
the O
significant O
improvement O
in O
progression-free O
survival, O
sorafenib B-CHEMICAL
received O
Food O
and O
Drug O
Administration O
approval O
in O
December O
2005 O
for O
the O
treatment O
of O
renal O
cell O
carcinoma. O
In O
combination O
studies, O
sorafenib B-CHEMICAL
with O
other O
antitumor O
agents O
has O
demonstrated O
significant O
clinical O
activity O
in O
patients O
with O
renal O
cell O
carcinoma. O
As O
discussed O
in O
this O
mini-review, O
the O
clinical O
potency O
of O
sorafenib B-CHEMICAL
as O
a O
single O
agent O
or O
in O
combination O
with O
other O
antitumor O
agents O
is O
being O
evaluated O
in O
several O
ongoing O
clinical O
trials O
in O
patients O
with O
renal O

carcinoma. O
Hydrogen B-CHEMICAL
sulfide I-CHEMICAL
inhibits O
nitric B-CHEMICAL
oxide I-CHEMICAL
production O
and O
nuclear B-GENE-N
factor-kappaB I-GENE-N
via O
heme B-GENE-Y
oxygenase-1 I-GENE-Y
expression O
in O
RAW264.7 O
macrophages O
stimulated O
with O
lipopolysaccharide. O
Hydrogen B-CHEMICAL
sulfide I-CHEMICAL
(H(2)S), B-CHEMICAL
a O
regulatory O
gaseous O
molecule O
that O
is O
endogenously O
synthesized O
by O
cystathionine B-GENE-Y
gamma-lyase I-GENE-Y
(CSE) B-GENE-Y
and/or O
cystathionine B-CHEMICAL
beta-synthase I-GENE-Y
(CBS) B-GENE-Y
from O
L-cysteine B-CHEMICAL
(L-Cys) B-CHEMICAL

metabolism, O
is O
a O
putative O
vasodilator, O
and O
its O
role O
in O
nitric B-CHEMICAL
oxide I-CHEMICAL
(NO) B-CHEMICAL
production O
is O
unexplored. O
Here, O
we O
show O
that O
at O
noncytotoxic O
concentrations, O
H(2)S B-CHEMICAL
was O
able O
to O
inhibit O
NO B-CHEMICAL
production O
and O
inducible B-GENE-Y
NO I-GENE-Y
synthase I-GENE-Y
(iNOS) B-GENE-Y
expression O
via O
heme B-GENE-N
oxygenase I-GENE-N
(HO-1) B-GENE-Y
expression O
in O
RAW264.7 O
macrophages O
stimulated O
with O
lipopolysaccharide O
(LPS). O
Both O
H(2)S B-CHEMICAL
solution O
prepared O
by O
bubbling O
pure O
H(2)S B-CHEMICAL

gas O
and O
NaSH, B-CHEMICAL
a O
H(2)S B-CHEMICAL
donor, O
dose O
dependently O
induced O
HO-1 B-GENE-Y
expression O
through O
the O
activation O
of O
the O
extracellular B-GENE-N
signal-regulated I-GENE-N
kinase I-GENE-N
(ERK). B-GENE-N
Pretreatment O
with O
H(2)S B-CHEMICAL
or O
NaHS B-CHEMICAL
significantly O
inhibited O
LPS-induced O
iNOS B-GENE-Y
expression O
and O
NO B-CHEMICAL
production. O
Moreover, O
NO B-CHEMICAL
production O
in O
LPS-stimulated O
macrophages O
that O
are O
expressing O
CSE B-GENE-Y
mRNA O
was O
significantly O
reduced O
by O
the O
addition O
of O
L-Cys, B-CHEMICAL
a O
substrate O
for O
H(2)S, B-CHEMICAL
but O
enhanced O
by O
the O
selective O
CSE B-GENE-Y
inhibitor O

beta-cyano-L-alanine B-CHEMICAL
but O
not O
by O
the O
CBS B-GENE-Y
inhibitor O
aminooxyacetic B-CHEMICAL
acid. I-CHEMICAL
While O
either O
blockage O
of O
HO B-GENE-Y
activity O
by O
the O
HO B-GENE-Y
inhibitor, O
tin O
protoporphyrin O
IX, O
or O
down-regulation O
of O
HO-1 B-GENE-Y
expression O
by O
HO-1 B-GENE-Y
small O
interfering O
RNA O
(siRNA) O
reversed O
the O
inhibitory O
effects O
of O
H(2)S B-CHEMICAL
on O
iNOS B-GENE-Y
expression O
and O
NO B-CHEMICAL
production, O
HO-1 B-GENE-Y
overexpression O
produced O
the O
same O
inhibitory O
effects O
of O
H(2)S. B-CHEMICAL
In O
addition, O
LPS-induced O
nuclear O
factor O
(NF)-kappaB B-GENE-N

activation O
was O
diminished O
in O
RAW264.7 O
macrophages O
preincubated O
with O
H(2)S. B-CHEMICAL
Interestingly, O
the O
inhibitory O
effect O
of O
H(2)S B-CHEMICAL
on O
NF-kappaB B-GENE-N
activation O
was O
reversed O
by O
the O
transient O
transfection O
with O
HO-1 B-GENE-Y
siRNA, O
but O
was O
mimicked O
by O
either O
HO-1 B-GENE-Y
gene O
transfection O
or O
treatment O
with O
carbon B-CHEMICAL
monoxide I-CHEMICAL
(CO), B-CHEMICAL
an O
end O
product O
of O
HO-1. B-GENE-Y
CO B-CHEMICAL
treatment O
also O
inhibited O
LPS-induced O
NO B-CHEMICAL
production O
and O
iNOS B-GENE-Y
expression O
via O
its O
inactivation O
of O

NF-kappaB. B-GENE-N
Collectively, O
our O
results O
suggest O
that O
H(2)S B-CHEMICAL
can O
inhibit O
NO B-CHEMICAL
production O
and O
NF-kappaB B-GENE-N
activation O
in O
LPS-stimulated O
macrophages O
through O
a O
mechanism O
that O
involves O
the O
action O
of O
HO-1/CO. B-GENE-Y
Effect O
of O
chronic O
renal O
failure O
on O
arginase B-GENE-N
and O
argininosuccinate B-GENE-Y
synthetase I-GENE-Y
expression. O
BACKGROUND: O
L-arginine B-CHEMICAL
(L-arg) B-CHEMICAL
participates O
in O
numerous O
biological O
functions O
including O
urea B-CHEMICAL
and O
nitric B-CHEMICAL
oxide I-CHEMICAL
synthesis. O
Sources O
of O
L-arg B-CHEMICAL
include O
dietary O
proteins O
and O

endogenous O
synthesis O
by O
argininosuccinate B-CHEMICAL
synthetase I-GENE-Y
and O
argininosuccinate B-GENE-Y
lyase. I-GENE-Y
L-arg B-CHEMICAL
is O
converted O
to O
urea B-CHEMICAL
by O
arginase B-GENE-Y
I I-GENE-Y
in O
the O
liver O
and O
arginase B-GENE-Y
II I-GENE-Y
in O
the O
kidney. O
Normally, O
the O
liver O
fully O
consumes O
L-arg B-CHEMICAL
for O
urea B-CHEMICAL
generation O
and O
does O
not O
contribute O
to O
its O
circulating O
pool. O
Instead, O
much O
of O
the O
circulating O
L-arg B-CHEMICAL
is O
produced O
by O
the O
kidney. O
If O
true, O
plasma O
L-arg B-CHEMICAL
should O
be O
severely O
reduced O
in O
chronic O
renal O
failure O
(CRF); O
however, O
plasma O
L-arg B-CHEMICAL
is O
frequently O
unchanged O

in O
CRF. O
We O
hypothesized O
that O
preservation O
of O
plasma O
L-arg B-CHEMICAL
in O
CRF O
may O
be, O
partly, O
due O
to O
downregulation/inhibition O
of O
arginase. B-GENE-N
METHODS: O
Argininosuccinate B-GENE-Y
synthetase, I-GENE-Y
arginase B-GENE-N
I I-GENE-N
and I-GENE-N
II I-GENE-N
protein O
abundance O
and O
activity O
were O
measured O
in O
the O
liver O
and O
kidneys O
of O
rats O
6 O
weeks O
after O
5/6 O
nephrectomy O
or O
sham O
operation. O
In O
addition, O
arginase B-GENE-N
activity O
was O
measured O
in O
the O
presence O
of O
different O
urea B-CHEMICAL
concentrations O
to O
simulate O
azotemia O
in O
vitro. O

RESULTS: O
Arginases B-GENE-N
I I-GENE-N
and I-GENE-N
II I-GENE-N
protein O
abundance O
as O
well O
as O
arginase B-GENE-N
activity O
in O
the O
liver, O
measured O
in O
the O
physiological O
buffer, O
were O
similar O
among O
the O
CRF O
and O
control O
groups. O
However, O
in O
vitro O
experiments O
simulating O
a O
uremic O
milieu O
revealed O
a O
marked O
concentration-dependent O
inhibition O
of O
arginase B-GENE-N
activity O
by O
urea B-CHEMICAL
in O
the O
tissue O
lysates. O
CRF O
had O
no O
significant O
effect O
on O
argininosuccinate B-CHEMICAL
synthetase I-GENE-Y
abundance O
in O
the O
kidney, O
liver, O
spleen O
or O
intestine. O
CONCLUSIONS: O
Although O
CRF O
does O

not O
change O
the O
abundance O
or O
intrinsic O
properties O
of O
arginase, B-GENE-N
the O
inherent O
rise O
in O
urea B-CHEMICAL
concentration O
inhibits O
its O
enzymatic O
activity. O
The O
latter, O
in O
turn, O
attenuates O
L-arg B-CHEMICAL
catabolism O
and O
urea O
production O
and, O
thereby, O
mitigates O
the O
fall O
in O
plasma O
L-arg. B-CHEMICAL
Epratuzumab, O
a O
CD22-targeting B-GENE-Y
recombinant O
humanized O
antibody O
with O
a O
different O
mode O
of O
action O
from O
rituximab. O
Epratuzumab O
is O
a O
humanized O
anti-CD22 B-GENE-Y
monoclonal O
antibody O
currently O
in O
clinical O
trials O
for O
treatment O

of O
non-Hodgkin O
lymphoma O
(NHL) O
and O
certain O
autoimmune O
diseases. O
Here O
we O
report O
the O
results O
of O
investigations O
of O
epratuzumab's O
mode O
of O
action O
in O
comparison O
to O
and O
in O
combination O
with O
the O
anti-CD20 B-GENE-Y
mAb, O
rituximab. O
In O
vitro O
cell O
growth O
inhibition, O
induction O
of O
apoptosis, O
and O
the O
ability O
of O
the O
mAbs O
to O
mediate O
complement-dependent B-GENE-N
cytotoxicity O
(CDC) O
and O
antibody-dependent O
cellular O
cytotoxicity O
(ADCC) O
were O
evaluated. O
We O
also O
investigated O
the O
potential O
activity O
of O

epratuzumab O
in O
the O
regulation O
of O
B-cell B-GENE-N
antigen I-GENE-N
receptor I-GENE-N
(BCR) B-GENE-N
activation. O
Epratuzumab O
and O
rituximab O
displayed O
very O
distinct O
modes O
of O
action; O
epratuzumab O
acts O
as O
an O
immunomodulatory O
agent, O
while O
rituximab O
is O
an O
acutely O
cytotoxic O
therapeutic O
antibody. O
Epratuzumab O
has O
distinct O
effects O
on O
cell O
growth O
from O
rituximab. O
For O
example, O
rituximab+anti-human O
IgG B-GENE-N
Fcgamma I-GENE-N
yielded O
marked O
inhibition O
of O
proliferation O
in O
human O
NHL O
cell O

lines, O
while O
epratuzumab O
had O
little O
or O
no O
effect O
in O
this O
assay. O
However, O
when O
cells O
were O
immobilized O
and O
stimulated O
with O
anti-IgM, B-GENE-N
epratuzumab, O
but O
not O
rituximab, O
caused O
a O
significant O
antiproliferative O
effect. O
Unlike O
rituximab, O
no O
CDC O
could O
be O
detected, O
and O
ADCC O
was O
modest O
but O
significant O
with O
epratuzumab. O
Importantly, O
combining O
rituximab O
and O
epratuzumab O
did O
not O
decrease O
rituximab's O
ability O
to O
induce O
apoptosis, O

CDC, O
and O
ADCC. O
In O
fact, O
the O
combination O
is O
more O
effective O
than O
rituximab O
alone O
in O
inhibiting O
proliferation O
of O
Daudi O
Burkitt O
lymphoma O
cells O
in O
the O
presence O
of O
second O
antibody, O
and O
at O
least O
equally O
effective O
to O
rituximab O
in O
the O
absence O
of O
crosslinking. O
These O
observations O
suggest O
that O
it O
may O
be O
possible O
to O
enhance O
clinical O
efficacy O
by O
combination O
therapy O
comprised O
of O
anti-CD20 B-GENE-Y
and O
anti-CD22 B-GENE-Y
mAbs. O
Vasopressin B-GENE-Y
antagonists O
as O
aquaretic O
agents O
for O
the O
treatment O
of O
hyponatremia. O
Hyponatremia O
is O

the O
most O
frequent O
electrolyte O
disorder O
encountered O
in O
hospitalized O
patients. O
It O
is O
a O
state O
of O
relative O
water O
excess O
due O
to O
stimulated O
arginine B-CHEMICAL
vasopressin I-CHEMICAL
(AVP) B-GENE-Y
and O
fluid O
intake O
greater O
than O
obligatory O
losses. O
This O
kind O
of O
hyponatremia O
occurs O
in O
the O
syndrome O
of O
inappropriate O
antidiuretic B-GENE-Y
hormone I-GENE-Y
secretion, O
congestive O
heart O
failure, O
and O
liver O
cirrhosis. O
Fluid O
restriction O
is O
the O
presently O
recommended O
treatment O
for O
hyponatremia. O
However, O
fluid O
restriction O
may O
be O
very O
difficult O
for O
patients O
to O
achieve, O
is O
slow O
to O
work, O
and O
does O
not O
allow O
a O

graded O
therapeutic O
approach. O
More O
efficient O
and O
specific O
treatments O
of O
hyponatremia O
are O
needed. O
In O
this O
respect, O
pharmacologic O
research O
has O
yielded O
a O
number O
of O
compounds O
exhibiting O
antagonistic O
qualities O
at O
the O
vasopressin B-GENE-Y
V2 I-GENE-Y
receptor. I-GENE-Y
Among O
these O
agents, O
peptidic O
derivatives O
of O
AVP B-GENE-Y
turned O
out O
to O
have O
intrinsic O
antidiuretic O
properties O
in O
vivo O
when O
given O
over O
days O
or O
weeks. O
The O
development O
of O
such O
agents O
for O
use O
in O
patients O
has O
not O
been O
pursued. O
However, O
several O
promising O
nonpeptide, O
vasopressin B-GENE-N
receptor I-GENE-N
antagonists O
have O
been O
described; O
these O
agents O
are O
VPA-985 B-CHEMICAL

(lixivaptan), B-CHEMICAL
YM-087 B-CHEMICAL
(conivaptan), B-CHEMICAL
OPC-41061 B-CHEMICAL
(tolvaptan), B-CHEMICAL
and O
SR-121463. B-CHEMICAL
Prospective, O
randomized, O
placebo-controlled O
trials O
performed O
with O
these O
agents O
found O
that O
they O
corrected O
hyponatremia O
efficiently O
and O
safely. O
Most O
of O
the O
studies O
were O
conducted O
over O
a O
4- O
to O
28-day O
period. O
Long-term O
studies O
will O
be O
needed O
in O
the O
future O
to O
address O
such O
issues O
as O
the O
eventual O
benefit O
to O
patients O
and O
the O
effects O
of O
vasopressin B-CHEMICAL
antagonists O
on O
morbidity O
and O
mortality O
of O
patients O

with O
hyponatremia. O
Sedation O
and O
histamine B-GENE-Y
H1-receptor I-GENE-Y
antagonism: O
studies O
in O
man O
with O
the O
enantiomers O
of O
chlorpheniramine B-CHEMICAL
and O
dimethindene. B-CHEMICAL
1. O
The O
effects O
of O
10 O
mg O
(+)- B-CHEMICAL
and I-CHEMICAL
(-)-chlorpheniramine I-CHEMICAL
and O
5 O
mg O
(+)- B-CHEMICAL
and I-CHEMICAL
(-)-dimethindene I-CHEMICAL
on O
daytime O
sleep O
latencies, O
digit O
symbol O
substitution O
and O
subjective O
assessments O
of O
mood O
and O
well-being O
were O
studied O
in O
6 O
healthy O
young O
adult O
humans. O
Each O
subject O
also O
took O
5 O
mg O
triprolidine B-CHEMICAL
hydrochloride I-CHEMICAL
as O
an O
active O
control O
and O

two O
placebos. O
2. O
Daytime O
sleep O
latencies O
were O
reduced O
with O
triprolidine, B-CHEMICAL
(+)-chlorpheniramine B-CHEMICAL
and O
(-)-dimethindene, B-CHEMICAL
and O
subjects O
also O
reported O
that O
they O
felt O
more O
sleepy O
after O
(+)-chlorpheniramine B-CHEMICAL
and O
(-)-dimethindene. B-CHEMICAL
Performance O
on O
digit O
symbol O
substitution O
was O
impaired O
with O
(+)-chlorpheniramine. B-CHEMICAL
3. O
Changes O
in O
measures O
with O
(-)-chlorpheniramine B-CHEMICAL
and O
(+)-dimethindene B-CHEMICAL
were O
not O
different O
from O
changes O
with O
placebo. O
4. O
In O
the O
present O
study, O
changes O

in O
measures O
of O
drowsiness O
and O
performance O
were O
limited O
to O
the O
enantiomers O
with O
high O
affinity O
for O
the O
histamine B-GENE-Y
H1-receptor. I-GENE-Y
These O
findings O
strongly O
suggest O
that O
sedation O
can O
arise O
from O
H1-receptor B-GENE-Y
antagonism O
alone, O
and O
provide O
further O
support O
for O
the O
belief O
that O
the O
histaminergic O
system O
is O
concerned O
with O
the O
regulation O
of O
alertness O
in O
man. O
Anti-clastogenic O
effect O
of O
beta-glucan O
extracted O
from O
barley O
towards O
chemically O
induced O
DNA O
damage O
in O
rodent O
cells. O
beta-Glucan O
(BG) O
was O
tested O
in O
vitro O
to O
determine O
its O
potential O
clastogenic O
and/or O

anti-clastogenic O
activity, O
and O
attempts O
were O
made O
to O
elucidate O
its O
possible O
mechanism O
of O
action O
by O
using O
combinations O
with O
an O
inhibitor O
of O
DNA B-GENE-N
polymerase. I-GENE-N
The O
study O
was O
carried O
out O
on O
cells O
deficient O
(CHO-k1) O
and O
cells O
proficient O
(HTC) O
in O
phases O
I O
and O
II O
enzymes, O
and O
the O
DNA O
damage O
was O
assessed O
by O
the O
chromosomal O
aberration O
assay. O
BG O
did O
not O
show O
a O
clastogenic O
effect, O
but O
was O
anti-clastogenic O
in O
both O
cell O
lines O
used, O
and O
at O
all O
concentrations O
tested O
(2.5, O
5 O
and O
10 O
microg/mL) O
in O
combination O

with O
damage O
inducing O
agents O
(methylmethane B-CHEMICAL
sulfonate I-CHEMICAL
in O
cell O
line O
CHO-k1, O
and O
methylmethane B-CHEMICAL
sulfonate I-CHEMICAL
or O
2-aminoanthracene B-CHEMICAL
in O
cell O
line O
HTC). O
BG O
also O
showed O
a O
protective O
effect O
in O
the O
presence O
of O
a O
DNA B-GENE-Y
polymerase I-GENE-Y
beta I-GENE-Y
inhibitor O
(cytosine B-CHEMICAL
arabinoside-3-phosphate, I-CHEMICAL
Ara-C), B-CHEMICAL
demonstrating O
that O
BG O
does O
not O
act O
through O
an O
anti-mutagenic O
mechanism O
of O
action O
involving O
DNA B-GENE-Y
polymerase I-GENE-Y
beta. I-GENE-Y
Association O
of O
DRD2 B-GENE-Y
polymorphisms O
and O
chlorpromazine-induced B-CHEMICAL

extrapyramidal O
syndrome O
in O
Chinese O
schizophrenic O
patients. O
AIM: O
Extrapyramidal O
syndrome O
(EPS) O
is O
most O
commonly O
affected O
by O
typical O
antipsychotic O
drugs O
that O
have O
a O
high O
affinity O
with O
the O
D2 B-GENE-Y
receptor. I-GENE-Y
Recently, O
many O
research O
groups O
have O
reported O
on O
the O
positive O
relationship O
between O
the O
genetic O
variations O
in O
the O
DRD2 B-GENE-Y
gene O
and O
the O
therapeutic O
response O
in O
schizophrenia O
patients O
as O
a O
result O
of O
the O
role O
of O
variations O
in O
the O
receptor O
in O
modulating O
receptor O
expression. O
In O
this O
study, O
we O
evaluate O
the O
role O
DRD2 B-GENE-Y
plays O
in O
chlorpromazine-induced B-CHEMICAL
EPS O
in O
schizophrenic O

patients. O
METHODS: O
We O
identified O
seven O
SNP(single O
nucleotide B-CHEMICAL
polymorphism) O
(-141Cins>del, O
TaqIB, O
TaqID, O
Ser311Cys, B-GENE-N
rs6275, O
rs6277 O
and O
TaqIA) O
in O
the O
DRD2 B-GENE-Y
gene O
in O
146 O
schizophrenic O
inpatients O
(59 O
with O
EPS O
and O
87 O
without O
EPS O
according O
to O
the O
Simpson-Angus O
Scale) O
treated O
with O
chlorpromazine B-CHEMICAL
after O
8 O
weeks. O
The O
alleles O
of O
all O
loci O
were O
determined O
by O
PCR O
(polymerase O
chain O

reaction). O
RESULTS: O
Polymorphisms O
TaqID, O
Ser311Cys B-GENE-N
and O
rs6277 O
were O
not O
polymorphic O
in O
the O
population O
recruited O
in O
the O
present O
study. O
No O
statistical O
significance O
was O
found O
in O
the O
allele O
distribution O
of O
-141Cins>del, O
TaqIB, O
rs6275 O
and O
TaqIA O
or O
in O
the O
estimated O
haplotypes O
(constituted O
by O
TaqIB, O
rs6275 O
and O
TaqIA) O
in O
linkage O
disequilibrium O
between O
the O
two O
groups. O
CONCLUSION: O
Our O
results O
did O
not O
lend O
strong O

support O
to O
the O
view O
that O
the O
genetic O
variation O
of O
the O
DRD2 B-GENE-Y
gene O
plays O
a O
major O
role O
in O
the O
individually O
variable O
adverse O
effect O
induced O
by O
chlorpromazine, B-CHEMICAL
at O
least O
in O
Chinese O
patients O
with O
schizophrenia. O
Our O
results O
confirmed O
a O
previous O
study O
on O
the O
relationship O
between O
DRD2 B-GENE-Y
and O
EPS O
in O
Caucasians. O
Activity-dependent O
cleavage O
of O
brain O
glutamic B-GENE-Y
acid I-GENE-Y
decarboxylase I-GENE-Y
65 I-GENE-Y
by O
calpain. B-GENE-N
Previously, O
we O
reported O
that O
l-glutamic B-CHEMICAL
acid I-CHEMICAL
decarboxylase I-GENE-Y
isoform I-GENE-Y
65 I-GENE-Y
(GAD65) B-GENE-Y
could O
be O
cleaved O
in O
vitro O
to O
release O
a O

stable O
truncated O
form O
which O
lacks O
amino B-CHEMICAL
acid I-CHEMICAL
1-69 O
from O
the O
N-terminus, B-CHEMICAL
GAD65(Delta1-69). B-GENE-Y
However, O
whether O
such O
a O
truncated O
form O
is O
also O
present O
under O
certain O
physiological O
conditions O
remains O
elusive. O
In O
the O
present O
study, O
we O
showed O
that, O
upon O
sustained O
neuronal O
stimulation, O
GAD65 B-GENE-Y
could O
be O
cleaved O
into O
a O
truncated O
form O
in O
a O
rat O
synaptosomal O
preparation. O
This O
truncated O
form O
had O
similar O
electrophoretic O
mobility O
to O
purified O
recombinant O
human B-GENE-Y
GAD65(Delta1-69). I-GENE-Y
Furthermore, O
we O
demonstrated O
that O
this O
conversion O
was O
calcium B-CHEMICAL
dependent. O

Calcium-chelating B-CHEMICAL
reagents O
such O
as O
EDTA B-CHEMICAL
and O
1,2-bis-(o-aminphenoxy)-ethane-N,N,N',N'-tetra-acetic B-CHEMICAL
acid I-CHEMICAL
tetra-acetoxy-methyl I-CHEMICAL
ester I-CHEMICAL
prevented O
the O
cleavage O
of O
GAD65. B-GENE-Y
In O
addition, O
our O
data O
suggested O
that O
calpain, B-GENE-N
a O
calcium-dependent B-CHEMICAL
cysteine B-CHEMICAL
protease, I-GENE-N
is O
activated O
upon O
neuronal O
stimulation O
and O
could O
be O
responsible O
for O
the O
conversion O
of O
full-length O
GAD65 B-GENE-Y
to O
truncated O
GAD65 B-GENE-Y
in O
the O

brain. O
Moreover, O
calpain B-GENE-N
inhibitors O
such O
as O
calpain O
inhibitor O
I O
or O
calpastatin B-GENE-Y
could O
block O
the O
cleavage. O
Results O
of O
our O
in O
vitro O
cleavage O
assay O
using O
purified O
calpain B-GENE-N
and O
immunopurified O
rat B-GENE-Y
GAD65 I-GENE-Y
also O
supported O
the O
idea O
that O
GAD65 B-GENE-Y
could O
be O
directly O
cleaved O
by O
calpain. B-GENE-N
Therapeutic O
targets O
in O
melanoma: O
map B-GENE-N
kinase I-GENE-N
pathway. O
Recent O
progress O
in O
our O
understanding O
of O
the O
genetic O
alterations O
that O
occur O
in O
the O
pathogenesis O
of O
melanoma O
provides O
exciting O
opportunities O
for O
therapy. O
The O
most O
important O
signaling O
pathways O
in O

melanoma O
lie O
downstream O
of O
NRAS: B-GENE-Y
the O
RAS-BRAF-MAPK B-GENE-N
pathway. O
A O
great O
deal O
of O
attention O
has O
been O
focused O
on O
the O
high O
mutation O
rate O
in O
the O
BRAF B-GENE-Y
oncogene, O
which O
approaches O
60%, O
because O
BRAF B-GENE-Y
itself O
is O
an O
appealing O
drug O
substrate O
and O
because O
of O
the O
central O
contribution O
of O
BRAF B-GENE-Y
function O
to O
melanoma O
development O
that O
the O
mutation O
rate O
signifies. O
Agents O
that O
specifically O
target O
BRAF, B-GENE-Y
such O
as O
sorafenib, B-CHEMICAL
as O
well O
as O
new O
molecules O
that O
function O
both O
upstream O
and O
downstream O
of O
BRAF, B-GENE-Y
are O
being O
actively O
investigated. O
Reduction O
of O
cerebral O
infarct O
size O
by O
the O

AT1-receptor B-GENE-N
blocker O
candesartan, B-CHEMICAL
the O
HMG-CoA B-GENE-Y
reductase I-GENE-Y
inhibitor O
rosuvastatin B-CHEMICAL
and O
their O
combination. O
An O
experimental O
study O
in O
rats. O
Our O
purpose O
was O
to O
test O
the O
impact O
of O
single O
and/or O
combined O
treatment O
with O
the O
AT(1)-receptor B-GENE-N
blocker O
candesartan B-CHEMICAL
and O
the O
HMG-CoA B-CHEMICAL
reductase I-GENE-Y
inhibitor O
rosuvastatin B-CHEMICAL
on O
infarct O
size O
and O
neuroscore O
in O
transient O
cerebral O
ischemia O
in O
rats. O
L-NAME B-CHEMICAL
was O
used O
to O
test O
whether O
any O
potential O
effect O
was O
due O
to O
activation O
of O
endothelial B-GENE-Y
nitric I-GENE-Y

oxide I-GENE-Y
synthase I-GENE-Y
(eNOS). B-GENE-Y
Therefore, O
the O
middle O
cerebral O
artery O
was O
occluded O
for O
1 O
h O
(MCAO) O
followed O
by O
7 O
days O
reperfusion. O
Rats O
received O
candesartan B-CHEMICAL
2h O
before O
and O
daily O
after O
MCAO O
(pretreatment) O
or O
daily O
after O
MCAO O
(posttreatment); O
rosuvastatin B-CHEMICAL
was O
given O
daily O
for O
7 O
days O
before O
MCAO O
without O
or O
with O
candesartan B-CHEMICAL
pre- O
and O
posttreatment. O
In O
addition, O
candesartan B-CHEMICAL
and O
rosuvastatin B-CHEMICAL
were O
combined O
with O
L-NAME. B-CHEMICAL
Infarct O
size O
and O

neuroscore O
at O
day O
7 O
were O
compared O
to O
those O
of O
controls. O
As O
result, O
compared O
to O
controls O
(109+/-12 O
mm(3)) O
infarct O
size O
with O
candesartan B-CHEMICAL
(pretreatment: O
21+/-5 O
mm(3); O
posttreatment: O
68+/-29 O
mm(3); O
P<0.05) O
or O
rosuvastatin B-CHEMICAL
(69+/-14 O
mm(3); O
P<0.05) O
was O
smaller. O
Combined O
treatment O
also O
reduced O
infarct O
size O
(pretreatment: O
37+/-15 O

mm(3); O
posttreatment O
57+/-20mm(3); O
P<0.05); O
but O
there O
was O
no O
benefit O
of O
combined O
treatment O
over O
candesartan B-CHEMICAL
pretreatment O
alone. O
Compared O
to O
controls O
(2.08+/-0.28) O
only O
candesartan B-CHEMICAL
pretreatment O
and O
combined O
treatment O
improved O
the O
neuroscore O
(0.97+/-0.05, O
1.10+/-0.33; O
P<0.05). O
L-NAME B-CHEMICAL
abolished O
the O
reduction O
in O
infarct O
size O
and O
improvement O
in O
neuroscore. O

In O
conclusion, O
both, O
candesartan B-CHEMICAL
or O
rosuvastatin B-CHEMICAL
treatment O
alone O
reduced O
infarct O
size O
in O
transient O
cerebral O
ischemia, O
and O
the O
best O
result O
was O
achieved O
with O
candesartan B-CHEMICAL
pretreatment. O
Combined O
treatment O
was O
superior O
to O
rosuvastatin B-CHEMICAL
alone, O
but O
not O
to O
candesartan. B-CHEMICAL
The O
therapeutic O
benefit O
of O
both O
agents O
was O
at O
least O
in O
parts O
mediated O
by O
eNOS-activation. B-GENE-Y
ABCA12 B-GENE-Y
is O
the O
major O
harlequin O
ichthyosis O
gene. O
Harlequin O
ichthyosis O
(HI) O
is O
the O
most O
severe O
form O
of O

autosomal-recessive, O
congenital O
ichthyosis. O
Affected O
infants O
have O
markedly O
impaired O
barrier O
function O
and O
are O
more O
susceptible O
to O
infection. O
Abnormalities O
in O
the O
localization O
of O
epidermal O
lipids O
as O
well O
as O
abnormal O
lamellar O
granule O
formation O
are O
features O
of O
HI O
skin. O
Previously, O
we O
and O
others O
have O
shown O
that O
mutations O
in O
the O
ABCA12 B-GENE-Y
gene O
encoding O
an O
adenosine B-GENE-N
triphosphate-binding I-GENE-N
cassette I-GENE-N
(ABC) I-GENE-N
transporter I-GENE-N
underlie O
the O
skin O
disease O
HI. O
In O
this O
study, O
we O
have O
sequenced O
the O
ABCA12 B-GENE-Y
gene O
in O
an O
additional O
14 O
patients O
and O
show O

that O
all O
contain O
mutations, O
with O
the O
majority O
being O
either O
nonsense O
substitution O
or O
frameshift O
mutations. O
Eleven O
HI O
patients O
had O
bi-allelic O
ABCA12 B-GENE-Y
mutations, O
whereas O
in O
the O
remaining O
three O
HI O
patients O
in O
this O
study, O
ABCA12 B-GENE-Y
mutations O
were O
detected O
on O
only O
one O
allele O
by O
sequencing. O
In O
addition, O
the O
one O
patient O
from O
the O
previous O
study O
where O
no O
sequence O
mutations O
were O
detected O
was O
screened O
for O
heterozygous O
deletions. O
A O
combination O
of O
oligonucleotide O
arrays, O
multiplex O
PCR O
analysis O
and O
single-nucleotide B-CHEMICAL
polymorphism O
genotyping O
revealed O
a O

heterozygous O
intragenic O
deletion O
in O
exon O
8. O
These O
mutation O
data O
establish O
ABCA12 B-GENE-Y
as O
the O
major O
HI O
gene. O
Phosphorylation O
and O
up-regulation O
of O
diacylglycerol B-GENE-Y
kinase I-GENE-Y
gamma I-GENE-Y
via O
its O
interaction O
with O
protein B-GENE-Y
kinase I-GENE-Y
C I-GENE-Y
gamma. I-GENE-Y
Diacylglycerol B-CHEMICAL
(DAG) B-CHEMICAL
acts O
as O
an O
allosteric O
activator O
of O
protein B-GENE-N
kinase I-GENE-N
C I-GENE-N
(PKC) B-GENE-N
and O
is O
converted O
to O
phosphatidic B-CHEMICAL
acid I-CHEMICAL
by O
DAG B-GENE-N
kinase I-GENE-N
(DGK). B-GENE-N
Therefore, O
DGK B-GENE-N
is O
thought O
to O
be O
a O
negative O
regulator O
of O
PKC B-GENE-N
activation. O
Here O
we O
show O

molecular O
mechanisms O
of O
functional O
coupling O
of O
the O
two O
kinases. B-GENE-N
gammaPKC B-GENE-Y
directly O
associated O
with O
DGKgamma B-GENE-Y
through O
its O
accessory O
domain O
(AD), O
depending O
on O
Ca2+ B-CHEMICAL
as O
well O
as O
phosphatidylserine/diolein B-CHEMICAL
in O
vitro. O
Mass O
spectrometric O
analysis O
and O
mutation O
studies O
revealed O
that O
gammaPKC B-GENE-Y
phosphorylated B-CHEMICAL
Ser-776 I-CHEMICAL
and O
Ser-779 B-CHEMICAL
in O
the O
AD O
of O
DGKgamma. B-GENE-Y
The O
phosphorylation O
by O
gammaPKC B-GENE-Y
resulted O
in O
activation O
of O
DGKgamma B-GENE-Y
because O
a O
DGKgamma B-GENE-Y
mutant O
in O

which O
Ser-776 B-CHEMICAL
and O
Ser-779 B-CHEMICAL
were O
substituted O
with O
glutamic B-CHEMICAL
acid I-CHEMICAL
to O
mimic O
phosphorylation O
exhibited O
significantly O
higher O
activity O
compared O
with O
wild O
type O
DGKgamma B-GENE-Y
and O
an O
unphosphorylatable O
DGKgamma B-GENE-Y
mutant. O
Importantly, O
the O
interaction O
of O
the O
two O
kinases B-GENE-N
and O
the O
phosphorylation O
of O
DGKgamma B-GENE-Y
by O
gammaPKC B-GENE-Y
could O
be O
confirmed O
in O
vivo, O
and O
overexpression O
of O
the O
AD O
of O
DGKgamma B-GENE-Y
inhibited O
re-translocation O
of O
gammaPKC. B-GENE-Y
These O
results O
demonstrate O
that O
localization O
and O
activation O
of O
the O

functionally O
correlated O
kinases, B-GENE-N
gammaPKC B-GENE-Y
and O
DGKgamma, B-GENE-Y
are O
spatio-temporally O
orchestrated O
by O
their O
direct O
association O
and O
phosphorylation, O
contributing O
to O
subtype-specific O
regulation O
of O
DGKgamma B-GENE-Y
and O
DAG O
signaling. O
Differences O
in O
conformational O
stability O
between O
native O
and O
phosphorylated B-GENE-Y
acetylcholinesterase I-GENE-Y
as O
evidenced O
by O
a O
monoclonal O
antibody. O
Monoclonal O
antibody O
25B1 O
generated O
against O
diisopropyl B-CHEMICAL
phosphorofluoridate I-CHEMICAL
inhibited O
fetal O
bovine B-GENE-Y
serum I-GENE-Y
acetylcholinesterase I-GENE-Y

has O
been O
extensively O
characterized O
with O
respect O
to O
its O
anticholinesterase B-GENE-Y
properties. O
This O
antibody O
demonstrated O
considerably O
different O
properties O
from O
previously O
reported O
inhibitory O
antibodies O
raised O
against O
acetylcholinesterase B-GENE-Y
in O
terms O
of O
the O
degree O
of O
inhibition O
(greater O
than O
98%), O
the O
high O
degree O
of O
specificity, O
and O
the O
stability O
of O
the O
antigen-antibody O
complex. O
Monoclonal O
antibody O
25B1 O
appears O
to O
be O
directed O
against O
a O
conformational O
epitope O
located O
in O
close O
proximity O
to O
the O
catalytic O
center O
of O
the O
enzyme O
and O
was O
found O
to O
be O
most O
suitable O
for O
studying O
the O
stabilization O
of O
the O
active O
site O
of O

acetylcholinesterase B-GENE-Y
against O
denaturation O
by O
heat O
or O
guanidine B-CHEMICAL
following O
phosphorylation O
by O
organophosphorus O
anticholinesterase B-GENE-Y
compounds. O
This O
approach O
allowed O
the O
determination O
of O
stability O
rank O
order O
of O
various O
phosphorylated B-GENE-N
acetylcholinesterases. I-GENE-N
Among O
all O
the O
organophosphates B-CHEMICAL
tested, O
the O
combination O
of O
a O
methyl O
group O
and O
a O
negatively O
charged O
oxygen B-CHEMICAL
attached O
to O
the O
P B-CHEMICAL
atom, O
CH3P(O)(O-)-AChE, B-CHEMICAL
conferred O
the O
greatest O
protection O
to O
the O
active O
site O
of O
aged O
or O
nonaged O
organophosphoryl B-CHEMICAL
conjugates O

of O
acetylcholinesterase. B-GENE-Y
Effects O
of O
folic B-CHEMICAL
acid I-CHEMICAL
deficiency O
and O
MTHFR B-GENE-Y
C677T B-GENE-N
polymorphism O
on O
spontaneous O
and O
radiation-induced O
micronuclei O
in O
human O
lymphocytes. O
Folic B-CHEMICAL
acid I-CHEMICAL
plays O
a O
key O
role O
in O
the O
maintenance O
of O
genomic O
stability, O
providing O
methyl O
groups O
for O
the O
conversion O
of O
uracil B-CHEMICAL
to O
thymine B-CHEMICAL
and O
for O
DNA O
methylation. O
Besides O
dietary O
habits, O
folic B-CHEMICAL
acid I-CHEMICAL
metabolism O
is O
influenced O
by O
genetic O
polymorphism. O
The O
C677T B-GENE-N
polymorphism O
of O
the O
methylene-tetrahydrofolate B-GENE-Y
reductase I-GENE-Y

(MTHFR) B-GENE-Y
gene O
is O
associated O
with O
a O
reduction O
of O
catalytic O
activity O
and O
is O
suggested O
to O
modify O
cancer O
risk O
differently O
depending O
on O
folate B-CHEMICAL
status. O
In O
this O
work O
the O
effect O
of O
folic B-CHEMICAL
acid I-CHEMICAL
deficiency O
on O
genome O
stability O
and O
radiosensitivity O
has O
been O
investigated O
in O
cultured O
lymphocytes O
of O
12 O
subjects O
with O
different O
MTHFR B-GENE-Y
genotype O
(four O
for O
each O
genotype). O
Cells O
were O
grown O
for O
9 O
days O
with O
12, O
24 O
and O
120 O
nM O
folic B-CHEMICAL
acid I-CHEMICAL
and O
analyzed O
in O
a O
comprehensive O
micronucleus O
test O
coupled O
with O
centromere O
characterization O
by O
CREST O
immunostaining. O
In O
other O
experiments, O
cells O

were O
grown O
with O
various O
folic B-CHEMICAL
acid I-CHEMICAL
concentrations, O
irradiated O
with O
0.5 O
Gy O
of O
gamma O
rays O
and O
analyzed O
in O
the O
micronucleus O
test. O
The O
results O
obtained O
indicate O
that O
folic B-CHEMICAL
acid I-CHEMICAL
deficiency O
induces O
to O
a O
comparable O
extent O
chromosome O
loss O
and O
breakage, O
irrespective O
of O
the O
MTHFR B-GENE-Y
genotype. O
The O
effect O
of O
folic B-CHEMICAL
acid I-CHEMICAL
was O
highly O
significant O
(P O
< O
0.001) O
and O
explained O
>50% O
of O
variance O
of O
both O
types O
of O
micronuclei. O
Also O
nucleoplasmic O
bridges O
and O
buds O
were O
significantly O
increased O
under O
low O
folate B-CHEMICAL
supply; O
the O
increase O
in O
bridges O
was O
mainly O
observed O

in O
TT O
cells, O
highlighting O
a O
significant O
effect O
of O
the O
MTHFR B-GENE-Y
genotype O
(P O
= O
0.006) O
on O
this O
biomarker. O
Folic B-CHEMICAL
acid I-CHEMICAL
concentration O
significantly O
affected O
radiation-induced O
micronuclei O
(P O
< O
0.001): O
the O
increased O
incidence O
of O
radiation-induced O
micronuclei O
with O
low O
folic B-CHEMICAL
acid I-CHEMICAL
was O
mainly O
accounted O
for O
by O
carriers O
of O
the O
variant O
MTHFR B-GENE-Y
allele O
(both O
homozygotes O
and O
heterozygotes), O
but O
the O
overall O
effect O
of O
genotype O
did O
not O
attain O
statistical O
significance. O
Treatment O
with O
ionizing O
radiations O
also O
increased O
the O
frequency O
of O

nucleoplasmic O
bridges. O
The O
effect O
of O
folic B-CHEMICAL
acid I-CHEMICAL
level O
on O
this O
end-point O
was O
modulated O
by O
the O
MTHFR B-GENE-Y
genotype O
(P O
for O
interaction O
= O
0.02), O
with O
TT O
cells O
grown O
at O
low O
folic B-CHEMICAL
acid I-CHEMICAL
concentration O
apparently O
resistant O
to O
the O
induction O
of O
radiation-induced O
bridges. O
Finally, O
the O
effect O
of O
in O
vitro O
folate B-CHEMICAL
deprivation O
on O
global O
DNA O
methylation O
was O
evaluated O
in O
lymphocytes O
of O
six O
homozygous O
subjects O
(three O
CC O
and O
three O
TT). O
The O
results O
obtained O
suggest O
that, O
under O
the O
conditions O
of O
this O
work, O
folic B-CHEMICAL
acid I-CHEMICAL

deprivation O
is O
associated O
with O
global O
DNA O
hypermethylation. O
Antifungal O
agents: O
mode O
of O
action O
in O
yeast O
cells. O
Different O
kinds O
of O
mycoses, O
especially O
invasive, O
have O
become O
an O
important O
public O
health O
problem O
as O
their O
incidence O
has O
increased O
dramatically O
in O
the O
last O
decades O
in O
relation O
to O
AIDS, O
hematological O
malignancies, O
transplant O
recipients O
and O
other O
immunosuppressed O
individuals. O
Management O
of O
fungal O
infections O
is O
markedly O
limited O
by O
problems O
of O
drug O
safety, O
resistance O
and O
effectiveness O
profile. O
Current O
therapy O
for O
invasive O
mycoses O
uses O
a O
relatively O
reduced O
number O
of O
antifungal O
drugs, O
such O
as O
amphotericin B-CHEMICAL

B, I-CHEMICAL
fluconazole B-CHEMICAL
and O
itraconazole. B-CHEMICAL
Other O
new O
antifungal O
agents O
from O
old O
and O
new O
chemical O
families, O
like O
voriconazole, B-CHEMICAL
posaconazole, B-CHEMICAL
ravuconazole, B-CHEMICAL
caspofungin B-CHEMICAL
and O
micafungin, B-CHEMICAL
have O
been O
introduced O
into O
the O
armamentarium O
for O
fungal O
infections O
management. O
This O
review O
is O
focused O
on O
the O
mode O
of O
action O
of O
those O
antifungal O
drugs O
used O
against O
pathogenic O
yeasts. O
The O
interaction O
of O
amphotericin B-CHEMICAL
B I-CHEMICAL
with O
ergosterol B-CHEMICAL
and O
other O
membrane O
sterols B-CHEMICAL
results O
in O
the O
production O
of O
aqueous O
pores O
of O

drug O
and O
the O
ergosterol B-CHEMICAL
biosynthetic O
pathway O
is O
the O
target O
of O
the O
allylamines, B-CHEMICAL
phenylmorpholines B-CHEMICAL
and O
azole B-CHEMICAL
antifungal O
agents. O
The O
main O
molecular O
target O
of O
azole B-CHEMICAL
antifungals O
is O
the O
cytochrome B-GENE-N
P-450 I-GENE-N
protein O
Erg11p/Cyp51p. B-GENE-N
Echinocandins, O
a O
new O
class O
of O
antifungal O
drugs, O
are O
fungal O
secondary O
metabolites O
that O
act O
against O
beta-1-3-D-glucan O
synthesis. O
The O
phenylmorpholines, B-CHEMICAL
of O
which O
amorolfine B-CHEMICAL
is O
the O

sole O
representative O
in O
human O
therapy, O
affect O
two O
targets O
in O
the O
ergosterol O
pathway: O
Erg24p B-GENE-N
(delta B-GENE-N
14 I-GENE-N
reductase) I-GENE-N
and O
Erg2p B-GENE-N
(delta B-GENE-N
8-delta I-GENE-N
7 I-GENE-N
isomerase). I-GENE-N
The O
sordarins B-CHEMICAL
group O
are O
protein O
synthesis O
inhibitors O
that O
work O
by O
blocking O
the O
function O
of O
fungal B-GENE-N
translation I-GENE-N
elongation I-GENE-N
factor I-GENE-N
2. I-GENE-N
Other O
protein O
inhibitors O
are O
zofimarin, B-CHEMICAL
BE31045, B-CHEMICAL
SCH57504, B-CHEMICAL
xylarin, B-CHEMICAL
hypoxysordarin B-CHEMICAL
and O
GR135402. B-CHEMICAL
In O
order O
to O
overcome O
the O
problems O
derived O
from O
the O
exploitation O
of O

azole B-CHEMICAL
drugs, O
macrolides O
and O
echinocandins, B-CHEMICAL
novel O
targets O
were O
explored. O
Proposed O
antifungal O
drugs O
have O
been O
developed O
against O
potential O
targets O
like O
the O
N-myristylation B-CHEMICAL
of O
fungal O
proteins, O
with O
inhibitors O
like O
myristate B-CHEMICAL
and O
histidine B-CHEMICAL
analogues O
or O
myristoylpeptide O
derivatives, O
aminobenzothiazoles, B-CHEMICAL
quinolines B-CHEMICAL
and O
benzofurans. B-CHEMICAL
Polymerization O
of O
cell O
wall O
carbohydrates O
from O
uridine B-CHEMICAL
di-phospho I-CHEMICAL
sugars I-CHEMICAL
is O
another O
potential O
target. O
D-myo-inositol B-CHEMICAL

1-phosphate I-CHEMICAL
as O
a O
surrogate O
of O
D-myo-inositol B-CHEMICAL
1,4,5-tris I-CHEMICAL
phosphate I-CHEMICAL
to O
monitor O
G B-GENE-N
protein-coupled I-GENE-N
receptor I-GENE-N
activation. O
Phospholipase B-GENE-N
C I-GENE-N
beta I-GENE-N
(PLC-beta)-coupled B-GENE-N
G B-GENE-N
protein-coupled I-GENE-N
receptor I-GENE-N
(GPCR) B-GENE-N
activities O
traditionally O
are O
assessed O
by O
measuring O
Ca2+ B-CHEMICAL
triggered O
by O
D-myo-inositol B-CHEMICAL
1,4,5-trisphosphate I-CHEMICAL
(IP3), B-CHEMICAL
a O
PLC-beta B-GENE-N
hydrolysis O
product, O
or O
by O
measuring O
the O
production O
of O
inositol B-CHEMICAL
phosphate I-CHEMICAL
using O
cumbersome O
radioactive O
assays. O

A O
specific O
detection O
of O
IP3 B-CHEMICAL
production O
was O
also O
established O
using O
IP3 B-CHEMICAL
binding O
proteins. O
The O
short O
lifetime O
of O
IP3 B-CHEMICAL
makes O
this O
detection O
very O
challenging O
in O
measuring O
GPCR B-GENE-N
responses. O
Indeed, O
this O
IP3 B-CHEMICAL
rapidly O
enters O
the O
metabolic O
inositol B-CHEMICAL
phosphate I-CHEMICAL
cascade. O
It O
has O
been O
known O
for O
decades O
that O
lithium B-CHEMICAL
chloride I-CHEMICAL
(LiCl) B-CHEMICAL
leads O
to O
D-myo-inositol B-CHEMICAL
1-phosphate I-CHEMICAL
accumulation O
on O
GPCR B-GENE-N
activation O
by O
inhibiting O
inositol B-GENE-N
monophosphatase, I-GENE-N
the O
final O
enzyme O
of O
the O
IP3 B-CHEMICAL
metabolic O
cascade. O
We O
show O
here O
that O
IP1 B-CHEMICAL
can O
be O
used O
as O
a O
surrogate O
of O

IP3 B-CHEMICAL
to O
monitor O
GPCR B-GENE-N
activation. O
We O
developed O
a O
novel O
homogeneous O
time-resolved O
fluorescence O
(HTRF) O
assay O
that O
correlates O
perfectly O
with O
existing O
methods O
and O
is O
easily O
amenable O
to O
high-throughput O
screening. O
The O
IP-One O
assay O
was O
validated O
on O
various O
GPCR B-GENE-N
models. O
It O
has O
the O
advantage O
over O
the O
traditional O
Ca2+ B-CHEMICAL
assay O
of O
allowing O
the O
measurement O
of O
inverse O
agonist O
activity O
as O
well O
as O
the O
analysis O
of O
PLC-beta B-GENE-N
activity O
in O
any O
nontransfected O
primary O
cultures. O
Finally, O
the O
high O
assay O
specificity O
for O
D-myo-inositol B-CHEMICAL
1 I-CHEMICAL

monophosphate I-CHEMICAL
(IP1(1)) B-CHEMICAL
opens O
new O
possibilities O
in O
developing O
selective O
assays O
to O
study O
the O
functional O
roles O
of O
the O
various O
isoforms O
of O
inositol B-CHEMICAL
phosphates. I-CHEMICAL
Non-enzymatic O
interactions O
of O
glyoxylate B-CHEMICAL
with O
lysine, B-CHEMICAL
arginine, B-CHEMICAL
and O
glucosamine: B-CHEMICAL
a O
study O
of O
advanced O
non-enzymatic O
glycation O
like O
compounds. O
Glyoxylate B-CHEMICAL
is O
a O
2 O
carbon B-CHEMICAL
aldo I-CHEMICAL
acid I-CHEMICAL
that O
is O
formed O
in O
hepatic O
tissue O
from O
glycolate. B-CHEMICAL
Once O
formed, O
the O
molecule O
can O
be O
converted O
to O
glycine B-CHEMICAL
by O

alanine-glyoxylate B-CHEMICAL
aminotransferase I-GENE-Y
(AGAT). B-GENE-Y
In O
defects O
of O
AGAT, B-GENE-Y
glyoxylate B-CHEMICAL
is O
transformed O
to O
oxalate, B-CHEMICAL
resulting O
in O
high O
levels O
of O
oxalate B-CHEMICAL
in O
the O
body. O
The O
objective O
of O
this O
study O
was O
2-fold. O
First, O
it O
was O
to O
determine, O
if O
akin O
to O
D-glucose, B-CHEMICAL
D-fructose B-CHEMICAL
or O
DL-glyceraldehyde, B-CHEMICAL
glyoxylate B-CHEMICAL
was O
susceptible O
to O
non-enzymatic O
attack O
by O
amino B-CHEMICAL
containing O
molecules O
such O
as O
lysine, B-CHEMICAL
arginine B-CHEMICAL
or O
glucosamine. B-CHEMICAL
Second, O

if O
by O
virtue O
of O
its O
molecular O
structure O
and O
size, O
glyoxylate B-CHEMICAL
was O
as O
reactive O
a O
reagent O
in O
non-enzymatic O
reactions O
as O
DL-glyceraldehyde; B-CHEMICAL
i.e., O
a O
glycose B-CHEMICAL
that O
we O
previously O
demonstrated O
to O
be O
a O
more O
effective O
glycating O
agent O
than O
D-glucose B-CHEMICAL
or O
D-fructose. B-CHEMICAL
Using O
capillary O
electrophoresis O
(CE), O
high O
performance O
liquid O
chromatography O
and O
UV O
and O
fluorescence O
spectroscopy, O
glyoxylate B-CHEMICAL
was O
found O
to O
be O
a O
highly O
reactive O
precursor O
of O
advanced O
glycation O
like O
end O
products O

(AGLEs) O
and O
a O
more O
effective O
promoter O
of O
non-enzymatic O
end O
products O
than O
D-glucose, B-CHEMICAL
D-fructose B-CHEMICAL
or O
DL-glyceraldehyde. B-CHEMICAL
Cortisol B-CHEMICAL
metabolism O
in O
hypertension. O
Corticosteroids B-CHEMICAL
are O
critically O
involved O
in O
blood O
pressure O
regulation. O
Lack O
of O
adrenal O
steroids B-CHEMICAL
in O
Addison's O
disease O
causes O
life-threatening O
hypotension, O
whereas O
glucocorticoid O
excess O
in O
Cushing's O
syndrome O
invariably O
results O
in O
high O
blood O
pressure. O
At O
a O
pre-receptor O
level, O
glucocorticoid O
action O
is O

modulated O
by O
11beta-hydroxysteroid B-CHEMICAL
dehydrogenases I-GENE-N
(11beta-HSDs). B-GENE-N
11Beta-HSD1 B-GENE-Y
activates O
cortisone B-CHEMICAL
to O
cortisol B-CHEMICAL
to O
facilitate O
glucocorticoid B-GENE-Y
receptor I-GENE-Y
(GR)-mediated B-GENE-Y
action. O
By O
contrast, O
11beta-HSD2 B-GENE-Y
plays O
a O
pivotal O
role O
in O
aldosterone B-CHEMICAL
target O
tissues O
where O
it O
catalyses O
the O
opposite O
reaction O
(i.e. O
inactivation O
of O
cortisol B-CHEMICAL
to O
cortisone) B-CHEMICAL
to O
prevent O
activation O
of O
the O
mineralocorticoid B-GENE-Y
receptor I-GENE-Y
(MR) B-GENE-Y
by O

cortisol. B-CHEMICAL
Mutations O
in O
the O
11beta-HSD2 B-GENE-Y
gene O
cause O
a O
rare O
form O
of O
inherited O
hypertension, O
the O
syndrome O
of O
apparent O
mineralocorticoid O
excess O
(AME), O
in O
which O
cortisol B-CHEMICAL
activates O
the O
MR B-GENE-Y
resulting O
in O
severe O
hypertension O
and O
hypokalemia. O
Ingestion O
of O
competitive O
inhibitors O
of O
11beta-HSD2 B-GENE-Y
such O
as O
liquorice O
and O
carbenoxolone B-CHEMICAL
result O
in O
a O
similar O
but O
milder O
clinical O
phenotype. O
Epidemiological O
data O
suggests O
that O
polymorphic O
variability O
in O
the O
HSD11B2 B-GENE-Y
gene O
determines O

salt O
sensitivity O
in O
the O
general O
population, O
which O
is O
a O
key O
predisposing O
factor O
to O
adult O
onset O
hypertension O
in O
some O
patients. O
Extrarenal O
sites O
of O
glucocorticoid O
action O
and O
metabolism O
that O
might O
impact O
on O
blood O
pressure O
include O
the O
vasculature O
and O
the O
central O
nervous O
system. O
Intriguingly, O
increased O
exposure O
to O
glucocorticoids O
during O
fetal O
life O
promotes O
high O
blood O
pressure O
in O
adulthood O
suggesting O
an O
early O
programming O
effect. O
Thus, O
metabolism O
and O
action O
in O
many O
peripheral O
tissues O
might O
contribute O
to O
the O
pathophysiology O
of O
human O
hypertension. O
PPARgamma B-GENE-Y
controls O
CD1d B-GENE-Y
expression O
by O
turning O
on O

retinoic B-CHEMICAL
acid I-CHEMICAL
synthesis O
in O
developing O
human O
dendritic O
cells. O
Dendritic O
cells O
(DCs) O
expressing O
CD1d, B-GENE-Y
a O
molecule O
responsible O
for O
lipid O
antigen O
presentation, O
are O
capable O
of O
enhancing O
natural O
killer O
T O
(iNKT) O
cell O
proliferation. O
The O
signals O
controlling O
CD1 B-GENE-N
expression O
and O
lipid O
antigen O
presentation O
are O
poorly O
defined. O
We O
have O
shown O
previously O
that O
stimulation O
of O
the O
lipid-activated B-GENE-N
transcription I-GENE-N
factor, I-GENE-N
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
(PPAR)gamma, I-GENE-Y
indirectly O
regulates O
CD1d B-GENE-Y
expression. O
Here O
we O
demonstrate O
that O
PPARgamma, B-GENE-Y
turns O
on O
retinoic B-CHEMICAL
acid I-CHEMICAL
synthesis O
by O
inducing O

the O
expression O
of O
retinol B-CHEMICAL
and O
retinal B-CHEMICAL
metabolizing O
enzymes O
such O
as O
retinol B-CHEMICAL
dehydrogenase I-GENE-Y
10 I-GENE-Y
and O
retinaldehyde B-CHEMICAL
dehydrogenase I-GENE-Y
type I-GENE-Y
2 I-GENE-Y
(RALDH2). B-GENE-Y
PPARgamma-regulated B-GENE-Y
expression O
of O
these O
enzymes O
leads O
to O
an O
increase O
in O
the O
intracellular O
generation O
of O
all-trans B-CHEMICAL
retinoic I-CHEMICAL
acid I-CHEMICAL
(ATRA) B-CHEMICAL
from O
retinol. B-CHEMICAL
ATRA B-CHEMICAL
regulates O
gene O
expression O
via O
the O
activation O
of O
the O
retinoic B-GENE-Y
acid I-GENE-Y
receptor I-GENE-Y
(RAR)alpha I-GENE-Y
in O
human O
DCs, O
and O
RARalpha B-GENE-Y
acutely O
regulates O
CD1d B-GENE-Y
expression. O
The O
retinoic B-CHEMICAL

acid-induced I-CHEMICAL
elevated O
expression O
of O
CD1d B-GENE-Y
is O
coupled O
to O
enhanced O
iNKT O
cell O
activation. O
Furthermore, O
in O
vivo O
relevant O
lipids O
such O
as O
oxidized O
low-density O
lipoprotein O
can O
also O
elicit O
retinoid B-CHEMICAL
signaling O
leading O
to O
CD1d B-GENE-Y
up-regulation. O
These O
data O
show O
that O
regulation O
of O
retinoid B-CHEMICAL
metabolism O
and O
signaling O
is O
part O
of O
the O
PPARgamma-controlled B-GENE-Y
transcriptional O
events O
in O
DCs. O
The O
uncovered O
mechanisms O
allow O
the O
DCs O
to O
respond O
to O
altered O
lipid O
homeostasis O
by O
changing O
CD1 B-GENE-N
gene O
expression. O
Ramelteon: B-CHEMICAL
a O
novel O
hypnotic O
lacking O
abuse O
liability O
and O

sedative O
adverse O
effects. O
CONTEXT: O
Ramelteon B-CHEMICAL
is O
a O
novel O
MT1 B-GENE-Y
and O
MT2 B-GENE-Y
melatonin I-GENE-Y
receptor I-GENE-Y
selective O
agonist O
recently O
approved O
for O
insomnia O
treatment. O
Most O
approved O
insomnia O
medications O
have O
potential O
for O
abuse O
and O
cause O
motor O
and O
cognitive O
impairment. O
OBJECTIVE: O
To O
evaluate O
the O
potential O
for O
abuse, O
subjective O
effects, O
and O
motor O
and O
cognitive-impairing O
effects O
of O
ramelteon B-CHEMICAL
compared O
with O
triazolam, B-CHEMICAL
a O
classic O
benzodiazepine B-CHEMICAL
sedative-hypnotic O
drug. O
DESIGN: O
In O
this O
double-blind O

crossover O
study, O
each O
participant O
received O
oral O
doses O
of O
ramelteon B-CHEMICAL
(16, O
80, O
or O
160 O
mg), O
triazolam B-CHEMICAL
(0.25, O
0.5, O
or O
0.75 O
mg), O
and O
placebo O
during O
approximately O
18 O
days. O
All O
participants O
received O
each O
treatment O
on O
different O
days. O
Most O
outcome O
measures O
were O
assessed O
at O
0.5 O
hours O
before O
drug O
administration O
and O
repeatedly O
up O
to O
24 O
hours O
after O
drug O
administration. O
SETTING: O
Residential O
research O
facility. O
PARTICIPANTS: O
Fourteen O
adults O
with O
histories O
of O
sedative O
abuse. O
MAIN O
OUTCOME O
MEASURES: O
Subject-rated O
measures O
included O

items O
relevant O
to O
potential O
for O
abuse O
(eg, O
drug O
liking, O
street O
value, O
and O
pharmacological O
classification), O
as O
well O
as O
assessments O
of O
a O
broad O
range O
of O
stimulant O
and O
sedative O
subjective O
effects. O
Observer-rated O
measures O
included O
assessments O
of O
sedation O
and O
impairment. O
Motor O
and O
cognitive O
performance O
measures O
included O
psychomotor O
and O
memory O
tasks O
and O
a O
standing O
balance O
task. O
RESULTS: O
Compared O
with O
placebo, O
ramelteon B-CHEMICAL
(16, O
80, O
and O
160 O
mg) O
showed O
no O
significant O
effect O
on O
any O
of O
the O
subjective O
effect O
measures, O
including O
those O
related O
to O
potential O
for O
abuse. O
In O
the O

pharmacological O
classification, O
79% O
(11/14) O
of O
subjects O
identified O
the O
highest O
dose O
of O
ramelteon B-CHEMICAL
as O
placebo. O
Similarly, O
compared O
with O
placebo, O
ramelteon B-CHEMICAL
had O
no O
effect O
at O
any O
dose O
on O
any O
observer-rated O
or O
motor O
and O
cognitive O
performance O
measure. O
In O
contrast, O
triazolam B-CHEMICAL
showed O
dose-related O
effects O
on O
a O
wide O
range O
of O
subject-rated, O
observer-rated, O
and O
motor O
and O
cognitive O
performance O
measures, O
consistent O
with O
its O
profile O
as O
a O
sedative O
drug O
with O
abuse O
liability. O
CONCLUSION: O
Ramelteon B-CHEMICAL
demonstrated O
no O
significant O
effects O
indicative O
of O
potential O
for O
abuse O
or O
motor O
and O

cognitive O
impairment O
at O
up O
to O
20 O
times O
the O
recommended O
therapeutic O
dose O
and O
may O
represent O
a O
useful O
alternative O
to O
existing O
insomnia O
medications. O
Inhibition O
of O
cardiac O
voltage-gated B-GENE-N
sodium I-GENE-N
channels I-GENE-N
by O
grape O
polyphenols. O
BACKGROUND O
AND O
PURPOSE: O
The O
cardiovascular O
benefits O
of O
red O
wine O
consumption O
are O
often O
attributed O
to O
the O
antioxidant O
effects O
of O
its O
polyphenolic O
constituents, O
including O
quercetin, B-CHEMICAL
catechin B-CHEMICAL
and O
resveratrol. B-CHEMICAL
Inhibition O
of O
cardiac O
voltage-gated B-GENE-N
sodium I-GENE-N
channels I-GENE-N
(VGSCs) B-GENE-N
is O
antiarrhythmic O
and O

cardioprotective. O
As O
polyphenols O
may O
also O
modulate O
ion O
channels, O
and O
possess O
structural O
similarities O
to O
several O
antiarrhythmic O
VGSC B-GENE-N
inhibitors, O
we O
hypothesised O
that O
VGSC B-GENE-N
inhibition O
may O
contribute O
to O
cardioprotection O
by O
these O
polyphenols. O
EXPERIMENTAL O
APPROACH: O
The O
whole-cell O
voltage-clamp O
technique O
was O
used O
to O
record O
peak O
and O
late O
VGSC B-GENE-N
currents O
(INa) O
from O
recombinant O
human B-GENE-Y
heart I-GENE-Y
NaV1.5 I-GENE-Y
channels O
expressed O
in O
tsA201 O
cells. O
Right O
ventricular O

myocytes O
from O
rat O
heart O
were O
isolated O
and O
single O
myocytes O
were O
field-stimulated. O
Either O
calcium B-CHEMICAL
transients O
or O
contractility O
were O
measured O
using O
the O
calcium-sensitive B-CHEMICAL
dye O
Calcium-Green B-CHEMICAL
1AM O
or O
video O
edge O
detection, O
respectively. O
KEY O
RESULTS: O
The O
red O
grape O
polyphenols O
quercetin, B-CHEMICAL
catechin B-CHEMICAL
and O
resveratrol B-CHEMICAL
blocked O
peak O
INa O
with O
IC50s O
of O
19.4 O
microM, O
76.8 O
microM O
and O
77.3 O
microM, O
respectively. O
In O
contrast O
to O
lidocaine, B-CHEMICAL
resveratrol B-CHEMICAL
did O
not O
exhibit O
any O
frequency-dependence O

of O
peak O
INa O
block. O
Late O
INa O
induced O
by O
the O
VGSC B-GENE-N
long O
QT O
mutant O
R1623Q B-GENE-N
was O
reduced O
by O
resveratrol B-CHEMICAL
and O
quercetin. B-CHEMICAL
Resveratrol B-CHEMICAL
and O
quercetin B-CHEMICAL
also O
blocked O
late O
INa O
induced O
by O
the O
toxin, O
ATX O
II, O
with O
IC50s O
of O
26.1 O
microM O
and O
24.9 O
microM, O
respectively. O
In O
field-stimulated O
myocytes, O
ATXII-induced O
increases O
in O
diastolic O
calcium B-CHEMICAL
were O
prevented O
and O
reversed O
by O
resveratrol. B-CHEMICAL
ATXII-induced O
contractile O
dysfunction O
was O
delayed O
and O
reduced O

by O
resveratrol. B-CHEMICAL
CONCLUSIONS O
AND O
IMPLICATIONS: O
Our O
results O
indicate O
that O
several O
red O
grape O
polyphenols O
inhibit O
cardiac O
VGSCs B-GENE-N
and O
that O
this O
effect O
may O
contribute O
to O
the O
documented O
cardioprotective O
efficacy O
of O
red O
grape O
products. O
Enhancement O
of O
radiosensitivity O
by O
topoisomerase B-GENE-Y
II I-GENE-Y
inhibitor, O
amrubicin B-CHEMICAL
and O
amrubicinol, B-CHEMICAL
in O
human O
lung O
adenocarcinoma O
A549 O
cells O
and O
kinetics O
of O
apoptosis O
and O
necrosis O
induction. O
The O
effects O
of O
amrubicin B-CHEMICAL
(AMR) B-CHEMICAL
and O

its O
active O
metabolite, O
amrubicinol B-CHEMICAL
(AMROH), B-CHEMICAL
on O
the O
sensitivity O
of O
human O
lung O
adenocarcinoma O
A549 O
cells O
to O
ionizing O
radiation O
were O
investigated O
in O
vitro. O
Further, O
the O
kinetics O
of O
apoptosis O
and O
necrosis O
induction O
were O
also O
analyzed. O
The O
cytocidal O
effects O
of O
X-ray O
irradiation O
on O
A549 O
cells O
resulted O
in O
a O
low O
level O
of O
radiosensitivity O
with O
a O
D0 O
value O
of O
12 O
Gy. O
The O
slopes O
of O
the O
survival O
curves O
in O
the O
exponential O
phase O
were O
plotted O
on O
semilogarithmic O
paper O
for O
radiation O

combined O
with O
AMR B-CHEMICAL
(2.5 O
microg/ml) O
and O
AMROH B-CHEMICAL
(0.02 O
microg/ml) O
treatment, O
and O
were O
shown O
to O
be O
approximately O
parallel O
to O
treatment O
with O
irradiation O
alone. O
The O
initial O
shoulder-shape O
portion O
of O
the O
survival O
curve O
for O
radiation O
alone, O
indicating O
the O
repair O
of O
sublethal O
damage, O
was O
reduced O
as O
compared O
to O
that O
for O
sequential O
combined O
treatment O
with O
AMR B-CHEMICAL
or O
AMROH. B-CHEMICAL
Sequential O
treatments O
with O
AMR B-CHEMICAL
or O
AMROH B-CHEMICAL
prior O
to O
ionizing O
radiation O
resulted O
in O
an O
additive O
radio-enhancement O
effect O
that O
reduced O
not O
only O
survival, O
but O
also O
the O
shoulder O
width. O

Fractionated O
irradiation O
with O
2 O
Gy O
per O
fraction O
of O
A549 O
cells O
was O
carried O
out O
in O
vitro O
similar O
to O
that O
commonly O
performed O
in O
clinical O
radiotherapy O
and O
the O
radio-resistance O
of O
the O
cells O
was O
shown O
to O
be O
inhibited O
by O
AMR B-CHEMICAL
and O
AMROH. B-CHEMICAL
Similar O
to O
AMR B-CHEMICAL
and O
AMROH, B-CHEMICAL
adriamycin B-CHEMICAL
and O
etoposide B-CHEMICAL
(VP-16) B-CHEMICAL
are O
DNA B-GENE-Y
topoisomerase I-GENE-Y
II I-GENE-Y
inhibitors. O
The O
effects O
of O
these O
4 O
agents O
on O
cells O
that O
received O
X-ray O
irradiation O
were O
compared O
and O
all O
of O
the O
agents O
exhibited O
comparable O
radio-enhancement O
effects. O
The O
induction O
of O

apoptosis O
was O
investigated O
at O
48 O
and O
72 O
h O
after O
administration O
of O
AMROH, B-CHEMICAL
radiation O
or O
combined O
treatment, O
and O
apoptosis O
was O
not O
significantly O
induced O
after O
any O
of O
the O
treatments. O
We O
also O
examined O
the O
induction O
of O
necrosis, O
and O
found O
that O
the O
incidence O
of O
necrosis O
following O
combined O
treatment O
was O
approximately O
2 O
times O
higher O
than O
that O
with O
either O
of O
the O
single O
treatments. O
Interaction O
of O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAID) O
with O
Helicobacter O
pylori O
in O
the O
stomach O
of O
humans O
and O
experimental O
animals. O
Helicobacter O
pylori O
(H. O
pylori) O
and O
non-steroidal B-CHEMICAL

anti-inflammatory O
drugs O
(NSAID) O
are O
major O
pathogenic O
factors O
in O
peptic O
ulcer O
disease O
but O
whether O
these O
two O
factors O
exert O
synergistic O
or O
antagonistic O
action O
on O
the O
gastric O
mucosa O
has O
been O
a O
subject O
of O
controversy. O
The O
classic O
concept O
states O
that O
there O
is O
an O
increased O
ulcer O
occurrence O
and O
bleeding O
in O
patients O
with O
both O
H. O
pylori O
infection O
and O
NSAID O
use. O
However, O
the O
question O
whether O
the O
H. O
pylori O
eradication O
therapy O
in O
NSAID O
users O
reduces O
the O
occurrence O
of O
peptic O
ulcer O
has O
not O
been O
fully O
addressed. O
Studies O
on O
secondary O
prevention O
of O
NSAID-associated O
ulcers O
in O
H. O

pylori O
patients O
have O
indicated O
that O
H. O
pylori O
eradication O
results O
in O
impaired O
ulcer O
healing O
with O
an O
effect O
on O
the O
rate O
of O
peptic O
ulcer O
occurrence. O
On O
the O
other O
hand, O
the O
treatment O
of O
H. O
pylori O
in O
patients O
with O
no O
prior O
history O
of O
chronic O
NSAID O
therapy O
has O
been O
shown O
to O
decrease O
the O
risk O
of O
peptic O
ulcer. O
Studies O
in O
experimental O
animals O
revealed O
for O
instance, O
that O
the O
H. O
pylori O
infection O
augments O
the O
gastric O
mucosal O
damage O
induced O
by O
NSAID O
in O
Mongolian O
gerbils. O
In O
rats O
with O
preexisting O
chromic O
gastric O
ulcers, O

H. O
pylori O
infection O
attenuated O
significantly O
the O
aspirin-induced B-CHEMICAL
inhibition O
of O
ulcer O
healing O
and O
accompanying O
fall O
in O
the O
gastric O
blood O
flow O
at O
the O
margin O
of O
these O
ulcers, O
suggesting O
negative O
interaction O
between O
aspirin B-CHEMICAL
and O
H. O
pylori O
on O
ulcerogenesis. O
Accumulated O
evidence O
in O
humans O
and O
animals O
shows O
that O
both O
aspirin B-CHEMICAL
and O
H. O
pylori O
upregulate O
the O
expression O
of O
cyclooxygenase B-GENE-N
(COX)-2 I-GENE-N
both O
at O
mRNA O
and O
protein O
levels O
at O
the O
ulcer O
margin, O
but O
failed O
to O
influence O
significantly O
that O
of O
COX-1. B-GENE-N

It O
was, O
therefore, O
proposed O
that O
H. O
pylori O
may O
in O
fact, O
antagonize, O
aspirin-induced B-CHEMICAL
delay O
of O
ulcer O
healing O
due O
to O
suppression O
of O
acid O
secretion O
by O
the O
enhancement O
in O
PGE(2) B-CHEMICAL
possibly O
derived O
from O
COX-2 B-GENE-N
expression O
and O
activity O
and O
to O
the O
overexpression O
of O
growth O
factors O
such O
as O
TGF B-GENE-N
alpha I-GENE-N
and O
VEGF. B-GENE-N
The O
present O
review O
summarizes O
and O
further O
addresses O
the O
issue O
of O
the O
interaction O
between O
these O
two O
major O
ulcer O
risk O
factors O
determined O
in O
the O
stomach O
of O
humans O
and O
experimental O
animals. O
The O
effect O
of O
a O
novel O
transition O
state O
inhibitor O
of O
methylthioadenosine B-GENE-Y

phosphorylase I-GENE-Y
on O
pemetrexed B-CHEMICAL
activity. O
Pemetrexed O
is O
a O
new-generation O
antifolate O
inhibitor O
of O
thymidylate B-GENE-Y
synthase I-GENE-Y
(TS) B-GENE-Y
and O
a O
weaker O
inhibitor O
of O
glycinamide B-CHEMICAL
ribonucleotide I-CHEMICAL
transformylase I-GENE-Y
(GARFT) B-GENE-Y
required O
for O
de O
novo O
purine B-CHEMICAL
synthesis. O
Methylthioadenosine B-CHEMICAL
phosphorylase I-GENE-Y
(MTAP) B-GENE-Y
salvages O
purines B-CHEMICAL
by O
releasing O
adenine B-CHEMICAL
from O
methylthioadenosine B-CHEMICAL
and O
is O
often O
deleted O
in O
mesothelioma. O
The O
current O
study O
addresses O
the O
effect O
of O

MTAP B-GENE-Y
on O
pemetrexed B-CHEMICAL
activity O
using O
a O
highly O
potent O
transition O
state O
inhibitor O
of O
MTAP, B-GENE-Y
MT-DADMe-Immucillin O
A O
(ImmA; O
K(i) O
= O
86 O
pmol/L) O
in O
the O
MTAP(+) B-GENE-Y
NCI-H28 O
and O
MTAP(-) B-GENE-Y
NCI-H2052 O
mesothelioma O
cell O
lines. O
Based O
on O
selective O
nucleoside O
protection, O
TS B-GENE-Y
was O
found O
to O
be O
the O
primary O
pemetrexed B-CHEMICAL
target O
in O
both O
cell O
lines O
with O
GARFT B-GENE-Y
inhibition O
requiring O
20- O
to O

30-fold O
higher O
pemetrexed B-CHEMICAL
concentrations. O
ImmA O
had O
no O
effect O
on O
pemetrexed B-CHEMICAL
activity O
but, O
when O
thymidine B-CHEMICAL
was O
added, O
the O
pemetrexed B-CHEMICAL
IC(50) O
decreased O
by O
a O
factor O
of O
approximately O
3 O
in O
MTAP(+) B-GENE-Y
H28 O
cells O
with O
no O
effect O
in O
MTAP(-) B-GENE-Y
H2052 O
cells. O
Conversely, O
the O
transfection O
of O
MTAP B-GENE-Y
into O
H2052 O
cells O
increased O
the O
pemetrexed B-CHEMICAL
IC(50) O
by O
nearly O
3-fold O
but O
only O
in O
the O
presence O
of O
thymidine; B-CHEMICAL
this O
was O
reversed O
by O

ImmA. O
An O
MTAP-specific B-GENE-Y
short O
interfering O
RNA O
produced O
a O
2-fold O
decrease O
in O
pemetrexed B-CHEMICAL
IC(50) O
in O
MTAP(+) B-GENE-Y
HeLa O
cells O
in O
the O
presence O
of O
thymidine. B-CHEMICAL
These O
data O
indicate O
that O
suppression O
of O
constitutive O
MTAP B-GENE-Y
has O
no O
effect O
on O
pemetrexed B-CHEMICAL
activity O
when O
the O
primary O
target O
is O
TS. B-GENE-Y
There O
is O
a O
modest O
salutary O
effect O
when O
the O
pemetrexed B-CHEMICAL
target O
is O
GARFT B-GENE-Y
alone. O
Sulfonylureas B-CHEMICAL
and O
glinides B-CHEMICAL
exhibit O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
gamma I-GENE-Y
activity: O

a O
combined O
virtual O
screening O
and O
biological O
assay O
approach. O
Most O
drugs O
currently O
employed O
in O
the O
treatment O
of O
type O
2 O
diabetes O
either O
target O
the O
sulfonylurea B-GENE-N
receptor I-GENE-N
stimulating O
insulin B-GENE-Y
release O
(sulfonylureas, B-CHEMICAL
glinides), B-CHEMICAL
or O
target O
the O
peroxisome B-GENE-N
proliferator-activated I-GENE-N
receptor I-GENE-N
(PPARgamma) B-GENE-Y
improving O
insulin B-GENE-Y
resistance O
(thiazolidinediones). B-CHEMICAL
Our O
work O
shows O
that O
sulfonylureas B-CHEMICAL
and O
glinides B-CHEMICAL
additionally O
bind O
to O
PPARgamma B-GENE-Y
and O
exhibit O
PPARgamma B-GENE-Y
agonistic O
activity. O
This O
activity O
was O
predicted O
in O
silico O
by O
virtual O
screening O
and O
confirmed O
in O

vitro O
in O
a O
binding O
assay, O
a O
transactivation O
assay, O
and O
by O
measuring O
the O
expression O
of O
PPARgamma B-GENE-Y
target O
genes. O
Among O
the O
measured O
compounds, O
gliquidone B-CHEMICAL
and O
glipizide B-CHEMICAL
(two O
sulfonylureas), B-CHEMICAL
as O
well O
as O
nateglinide B-CHEMICAL
(a O
glinide), B-CHEMICAL
exhibit O
PPARgamma B-GENE-Y
agonistic O
activity O
at O
concentrations O
comparable O
with O
those O
reached O
under O
pharmacological O
treatment. O
The O
most O
active O
of O
these O
compounds, O
gliquidone, B-CHEMICAL
is O
shown O
to O
be O
as O
potent O
as O
pioglitazone B-CHEMICAL
at O
inducing O
PPARgamma B-GENE-Y
target O
gene O
expression. O
This O

dual O
mode O
of O
action O
of O
sulfonylureas B-CHEMICAL
and O
glinides B-CHEMICAL
may O
open O
new O
perspectives O
for O
the O
molecular O
pharmacology O
of O
antidiabetic O
drugs, O
because O
it O
provides O
evidence O
that O
drugs O
can O
be O
designed O
that O
target O
both O
the O
sulfonylurea B-GENE-N
receptor I-GENE-N
and O
PPARgamma. B-GENE-Y
Targeting O
both O
receptors O
could O
increase O
pancreatic O
insulin B-GENE-Y
secretion O
and O
improve O
insulin B-GENE-Y
resistance. O
Glinides, B-CHEMICAL
sulfonylureas, B-CHEMICAL
and O
other O
acidified B-CHEMICAL
sulfonamides I-CHEMICAL
may O
be O
promising O
leads O
in O
the O
development O
of O
new O
PPARgamma B-GENE-Y
agonists. O
In O
addition, O
we O
provide O
a O
unified O
concept O
of O
the O
PPARgamma B-GENE-Y

binding O
ability O
of O
seemingly O
disparate O
compound O
classes. O
PGE(1) B-CHEMICAL
stimulation O
of O
HEK293 O
cells O
generates O
multiple O
contiguous O
domains O
with O
different O
[cAMP]: B-CHEMICAL
role O
of O
compartmentalized O
phosphodiesterases. O
There O
is O
a O
growing O
appreciation O
that O
the O
cyclic B-CHEMICAL
adenosine I-CHEMICAL
monophosphate I-CHEMICAL
(cAMP)-protein B-CHEMICAL
kinase I-GENE-N
A I-GENE-N
(PKA) B-GENE-N
signaling O
pathway O
is O
organized O
to O
form O
transduction O
units O
that O
function O
to O
deliver O
specific O
messages. O
Such O
organization O
results O
in O
the O
local O
activation O
of O
PKA B-GENE-N
subsets O
through O
the O
generation O
of O
confined O
intracellular O
gradients O
of O
cAMP, B-CHEMICAL
but O
the O
mechanisms O
responsible O

for O
limiting O
the O
diffusion O
of O
cAMP B-CHEMICAL
largely O
remain O
to O
be O
clarified. O
In O
this O
study, O
by O
performing O
real-time O
imaging O
of O
cAMP, B-CHEMICAL
we O
show O
that O
prostaglandin B-CHEMICAL
1 I-CHEMICAL
stimulation O
generates O
multiple O
contiguous, O
intracellular O
domains O
with O
different O
cAMP B-CHEMICAL
concentration O
in O
human O
embryonic O
kidney O
293 O
cells. O
By O
using O
pharmacological O
and O
genetic O
manipulation O
of O
phosphodiesterases B-GENE-N
(PDEs), B-GENE-N
we O
demonstrate O
that O
compartmentalized O
PDE4B B-GENE-Y
and O
PDE4D B-GENE-Y
are O
responsible O
for O
selectively O
modulating O
the O
concentration O
of O
cAMP B-CHEMICAL
in O
individual O
subcellular O
compartments. O
We O
propose O
a O

model O
whereby O
compartmentalized O
PDEs, B-GENE-N
rather O
than O
representing O
an O
enzymatic O
barrier O
to O
cAMP B-CHEMICAL
diffusion, O
act O
as O
a O
sink O
to O
drain O
the O
second O
messenger O
from O
discrete O
locations, O
resulting O
in O
multiple O
and O
simultaneous O
domains O
with O
different O
cAMP B-CHEMICAL
concentrations O
irrespective O
of O
their O
distance O
from O
the O
site O
of O
cAMP B-CHEMICAL
synthesis. O
DNA B-GENE-Y
topoisomerase I-GENE-Y
IIalpha I-GENE-Y
(TOP2A) B-GENE-Y
inhibitors O
up-regulate O
fatty B-CHEMICAL
acid I-CHEMICAL
synthase I-GENE-Y
gene O
expression O
in O
SK-Br3 O
breast O
cancer O
cells: O
in O
vitro O
evidence O
for O
a O
'functional O
amplicon' O
involving O
FAS, B-GENE-Y
Her-2/neu B-GENE-Y
and O

TOP2A B-GENE-Y
genes. O
Fatty B-CHEMICAL
acid I-CHEMICAL
synthase I-GENE-Y
(FAS), B-GENE-Y
the O
key O
metabolic O
multi-enzyme O
that O
is O
responsible O
for O
the O
terminal O
catalytic O
step O
in O
the O
de O
novo O
fatty O
acid O
biosynthesis, O
plays O
an O
active O
role O
in O
the O
development, O
maintenance, O
and O
enhancement O
of O
the O
malignant O
phenotype O
in O
a O
subset O
of O
breast O
carcinomas. O
We O
recently O
described O
that O
a O
molecular O
bi-directional O
cross-talk O
between O
FAS B-GENE-Y
and O
the O
Her-2/neu B-GENE-Y
(erbB-2) B-GENE-Y
oncogene O
is O
taking O
place O
at O
the O
level O
of O
transcription, O
translation, O
and O
activity O
in O
breast O
cancer O
cells. O

Because O
Her-2/neu B-GENE-Y
has O
been O
linked O
with O
altered O
sensitivity O
to O
cytotoxic O
drugs, O
we O
envisioned O
that O
FAS B-GENE-Y
gene O
expression O
may O
represent O
a O
novel O
predictive O
molecular O
factor O
for O
breast O
cancer O
response O
to O
chemotherapy O
in O
a O
Her-2/neu-related B-GENE-Y
manner. O
We O
herein O
evaluated O
whether O
chemotherapy-induced O
cell O
damage O
acts O
in O
an O
epigenetic O
fashion O
by O
inducing O
changes O
in O
the O
transcriptional O
activation O
of O
FAS B-GENE-Y
gene O
in O
breast O
cancer O
cells. O
To O
evaluate O
this O
option, O
FAS- B-GENE-Y
and O
Her-2/neu-overexpressing B-GENE-Y
SK-Br3 O
breast O
cancer O
cells O
were O
transiently O

transfected O
with O
a O
FAS B-GENE-N
promoter-reporter I-GENE-N
construct O
(FAS-Luciferase) B-GENE-Y
harboring O
all O
the O
elements O
necessary O
for O
high O
level O
expression O
in O
cancer O
cells. O
SK-Br3 O
cells O
cultured O
in O
the O
presence O
of O
topoisomerase B-GENE-Y
IIalpha I-GENE-Y
(TOP2A) B-GENE-Y
inhibitors O
doxorubicin B-CHEMICAL
and O
etopoxide B-CHEMICAL
(VP-16) B-CHEMICAL
demonstrated O
a O
2- O
to O
3-fold O
increase O
in O
FAS B-GENE-N
promoter I-GENE-N
activity O
when O
compared O
with O
control O
cells O
growing O
in O
drug-free O
culture O
conditions. O
We O
failed O
to O
observe O
any O
significant O
activation O
of O
FAS B-GENE-N
promoter I-GENE-N
following O
exposure O
to O
the O
anti-metabolite O

5-fluorouracil, B-CHEMICAL
the O
alkylating O
drug O
cisplatin, B-CHEMICAL
or O
the O
microtubule O
interfering-agents O
paclitaxel B-CHEMICAL
and O
vincristine. B-CHEMICAL
Moreover, O
the O
up-regulatory O
effects O
of O
TOP2A B-GENE-Y
inhibitors O
on O
the O
transcriptional O
activation O
of O
FAS B-GENE-Y
gene O
expression O
were O
not O
significantly O
decreased O
when O
the O
FAS B-GENE-N
promoter I-GENE-N
was O
damaged O
at O
the O
sterol B-GENE-N
regulatory I-GENE-N
element I-GENE-N
binding I-GENE-N
protein I-GENE-N
(SREBP)-binding B-GENE-N
site. O
Considering O
that O
FAS B-GENE-Y
inhibition O
produces O
profound O
inhibition O
of O
DNA O
replication O
and O
S-phase O
progression O
in O
cancer O
cells, O
we O
finally O
asked O
whether O
a O
cross-talk O
between O

TOP2A B-GENE-Y
and O
FAS B-GENE-Y
could O
exhibit O
a O
Her-2/neu-related B-GENE-Y
bi-directional O
nature. O
TOP2A B-GENE-Y
protein O
levels O
were O
decreased O
during O
treatment O
with O
the O
anti-Her-2/neu B-GENE-Y
antibody O
trastuzumab O
while, O
concomitantly, O
FAS B-GENE-N
promoter I-GENE-N
activity O
and O
FAS B-GENE-Y
protein O
expression O
were O
significantly O
reduced. O
Of O
note, O
when O
the O
expression O
levels O
of O
TOP2A B-GENE-Y
protein O
were O
analyzed O
following O
exposure O
of O
SK-Br3 O
cells O
to O
increasing O
concentrations O
of O
the O
novel O
slow-binding O
FAS B-GENE-Y
inhibitor O
C75, O
a O
dose-dependent O
reduction O
in O
TOP2A B-GENE-Y
expression O
was O
observed. O
Although O

FAS B-GENE-Y
gene O
is O
not O
physically O
located O
in O
the O
Her-2/neu-TOP2A B-GENE-Y
amplicon, O
our O
present O
findings O
strongly O
suggest O
that O
a O
tight O
functional O
association O
between O
FAS, B-GENE-Y
Her-2/neu B-GENE-Y
and O
TOP2A B-GENE-Y
genes O
is O
taking O
place O
in O
a O
subset O
of O
breast O
carcinoma O
cells. O
Mifepristone B-CHEMICAL
alters O
expression O
of O
endometrial O
steroid B-GENE-N
receptors I-GENE-N
and O
their O
cofactors O
in O
new O
users O
of O
medroxyprogesterone B-CHEMICAL
acetate. I-CHEMICAL
OBJECTIVE: O
To O
evaluate O
the O
effect O
of O
mifepristone O
on O
the O
expression O
of O
endometrial O

steroid B-CHEMICAL
receptors I-GENE-N
and O
their O
co-factors O
in O
depot O
medroxyprogesterone B-CHEMICAL
acetate I-CHEMICAL
(DMPA) O
users. O
DESIGN: O
A O
prospective, O
randomized, O
placebo-controlled O
trial. O
SETTING: O
Reproductive O
research O
center. O
PATIENT(S): O
Fifty O
healthy O
women O
with O
regular O
menstrual O
cycle. O
INTERVENTION(S): O
One O
hundred O
fifty O
milligrams O
of O
DMPA O
were O
given O
every O
3 O
months. O
Two O
pills O
(25 O
mg O
each) O
of O
placebo O
or O
mifepristone B-CHEMICAL
were O
administered O
every O
14 O
days O
during O
the O
DMPA O

therapy. O
Four O
endometrial O
biopsy O
specimens O
were O
obtained O
from O
each O
patient. O
MAIN O
OUTCOME O
MEASURE(S): O
The O
expression O
of O
estrogen B-CHEMICAL
receptor I-GENE-N
subtypes I-GENE-N
alpha I-GENE-N
and I-GENE-N
beta I-GENE-N
(ERalpha B-GENE-Y
and O
ERbeta), B-GENE-Y
progesterone B-CHEMICAL
receptors I-GENE-N
A I-GENE-N
and I-GENE-N
B I-GENE-N
(PRAB B-GENE-N
and O
PRB), B-GENE-Y
and O
androgen B-CHEMICAL
receptor I-GENE-N
messenger O
RNA O
and O
protein O
was O
detected O
by O
real-time O
polymerase O
chain O
reaction O
and O
immunohistochemistry, O
respectively. O
Steroid B-GENE-Y
receptor I-GENE-Y
coactivator I-GENE-Y
1 I-GENE-Y
(SRC-1), B-GENE-Y
silencing O
mediator O
for O
retinoid B-GENE-N
and I-GENE-N
thyroid-hormone I-GENE-N

receptors, I-GENE-N
and O
cell O
proliferation O
were O
evaluated O
by O
immunohistochemistry. O
RESULT(S): O
The O
expression O
of O
endometrial O
ERalpha, B-GENE-Y
PRAB, B-GENE-N
PRB, B-GENE-Y
and O
SRC-1 B-GENE-Y
was O
increased O
significantly O
after O
1 O
week O
of O
mifepristone, B-CHEMICAL
but O
the O
increase O
was O
no O
longer O
seen O
after O
10 O
weeks. O
A O
positive O
correlation O
between O
endometrial O
ERalpha, B-GENE-Y
PRAB, B-GENE-N
PRB, B-GENE-Y
and O
SRC-1 B-GENE-Y
production O
and O
proliferation O
was O
demonstrated. O
CONCLUSION(S): O
Short-term O
exposure O
of O
mifepristone B-CHEMICAL
in O
new O
starters O
of O
DMPA O
increases O

the O
expression O
of O
endometrial O
ERalpha, B-GENE-Y
PRAB, B-GENE-N
PRB, B-GENE-Y
and O
SRC-1 B-GENE-Y
and O
promotes O
cell O
proliferation. O
Prolonged O
exposure O
to O
mifepristone B-CHEMICAL
does O
not O
alter O
the O
suppression O
of O
these O
receptors O
that O
are O
caused O
by O
DMPA O
and O
continues O
to O
result O
in O
endometrial O
atrophy. O
Characterization O
of O
the O
molecular O
mechanisms O
involved O
in O
the O
increased O
insulin B-GENE-N
secretion O
in O
rats O
with O
acute O
liver O
failure. O
To O
investigate O
the O
mechanism O
of O
hyperinsulinaemia O
in O
rats O
with O
acute O
liver O
failure O
induced O
by O
the O
administration O
of O
d-galactosamine B-CHEMICAL
(GalN), B-CHEMICAL
we O
focused O
on O
the O
role O
of O

polyprimidine B-GENE-Y
tract-binding I-GENE-Y
protein I-GENE-Y
(PTB) B-GENE-Y
in O
islet O
insulin B-GENE-N
synthesis. O
Recent O
reports O
indicate O
that O
PTB B-GENE-Y
binds O
and O
stabilizes O
mRNA O
encoding O
insulin B-GENE-N
and O
insulin B-GENE-N
secretory I-GENE-N
granule I-GENE-N
proteins, I-GENE-N
including O
islet B-GENE-Y
cell I-GENE-Y
autoantigen I-GENE-Y
512 I-GENE-Y
(ICA512), B-GENE-Y
prohormone B-GENE-N
convertase I-GENE-N
1/3 I-GENE-N
(PC1/3), B-GENE-N
and O
PC2. B-GENE-Y
In O
the O
present O
study, O
glucose-stimulated B-CHEMICAL
insulin B-GENE-N
secretion O
was O
significantly O
increased O
in O
GalN-treated B-CHEMICAL
rats O
compared O
to O
controls. O
Levels O
of O
mRNA O
encoding O
insulin B-GENE-Y
1, I-GENE-Y
ICA512, B-GENE-Y
and O
PC1/3 B-GENE-N
were O
increased O

in O
the O
pancreatic O
islets O
of O
GalN-treated B-CHEMICAL
rats. O
This O
mRNA O
level O
elevation O
was O
not O
prevented O
by O
pretreatment O
with O
actinomycin B-CHEMICAL
D. I-CHEMICAL
When O
the O
PTB-binding B-GENE-N
site I-GENE-N
in O
insulin B-GENE-Y
1 I-GENE-Y
mRNA O
was O
incubated O
with O
the O
islet O
cytosolic O
fraction, O
the O
RNA-protein O
complex O
level O
was O
increased O
in O
the O
cytosolic O
fraction O
obtained O
from O
GalN-treated B-CHEMICAL
rats O
compared O
to O
the O
level O
in O
control O
rats. O
The O
cytosolic O
fraction O
obtained O
from O
pancreatic O
islets O
obtained O
from O
GalN-treated B-CHEMICAL
rats O
had O
an O
increased O
PTB B-GENE-Y
level O
compared O
to O
the O
levels O
obtained O
from O

the O
pancreatic O
islets O
of O
control O
rats. O
These O
findings O
suggest O
that, O
in O
rats O
with O
acute O
liver O
failure, O
cytosolic O
PTB B-GENE-Y
binds O
and O
stabilizes O
mRNA O
encoding O
insulin B-GENE-N
and O
its O
secretory B-GENE-N
granule I-GENE-N
proteins. I-GENE-N
Cysteinyl B-GENE-Y
leukotriene I-GENE-Y
receptor I-GENE-Y
1 I-GENE-Y
is O
involved O
in O
N-methyl-D-aspartate-mediated B-CHEMICAL
neuronal O
injury O
in O
mice. O
AIM: O
To O
determine O
whether O
cysteinyl B-CHEMICAL
leukotriene I-CHEMICAL
receptor I-GENE-Y
1 I-GENE-Y
(CysLT1 B-GENE-Y
receptor) I-GENE-Y
is O
involved O
in O
N-methyl-D-aspartate B-CHEMICAL
(NMDA)-induced B-CHEMICAL

excitotoxic O
injury O
in O
the O
mouse O
brain. O
METHODS: O
Brain O
injury O
was O
induced O
by O
NMDA B-CHEMICAL
microinjection O
(50-150 O
nmol O
in O
0.5 O
microL) O
into O
the O
cerebral O
cortex. O
The O
changes O
in O
CysLT1 B-GENE-Y
receptor I-GENE-Y
expression O
24 O
h O
after O
NMDA B-CHEMICAL
injection O
and O
the O
effects O
of O
a O
CysLT1 B-GENE-Y
receptor I-GENE-Y
antagonist, O
pranlukast B-CHEMICAL
(0.01 O
and O
0.1 O
mg/kg), O
an O
NMDA B-CHEMICAL
receptor I-GENE-N
antagonist, O
ketamine B-CHEMICAL
(30 O
mg/kg), O
and O
an O
antioxidant, O
edaravone B-CHEMICAL
(9 O
mg/kg) O
were O

observed. O
RESULTS: O
In O
the O
NMDA-injured B-CHEMICAL
brain, O
the O
CysLT1 B-GENE-Y
receptor I-GENE-Y
mRNA, O
and O
protein O
expression O
were O
upregulated, O
and O
the O
receptor O
was O
mainly O
localized O
in O
the O
neurons O
and O
not O
in O
the O
astrocytes. O
Pranlukast, B-CHEMICAL
ketamine B-CHEMICAL
and O
edaravone B-CHEMICAL
decreased O
NMDA-induced B-CHEMICAL
injury; O
pranlukast B-CHEMICAL
(0.1 O
mg/kg) O
and O
ketamine B-CHEMICAL
inhibited O
the O
upregulated O
expression O
of O
the O
CysLT1 B-GENE-Y
receptor. I-GENE-Y
CONCLUSION: O
CysLT1 B-GENE-Y
receptor I-GENE-Y
expression O
in O
neurons O
is O
upregulated O

after O
NMDA B-CHEMICAL
injection, O
and O
NMDA-induced B-CHEMICAL
responses O
are O
inhibited O
by O
CysLT1 B-GENE-Y
receptor I-GENE-Y
antagonists, O
indicating O
that O
the O
increased O
CysLT1 B-GENE-Y
receptor I-GENE-Y
is O
involved O
in O
NMDA B-CHEMICAL
excitotoxicity. O
Bcl-2 B-GENE-Y
phosphorylation O
has O
pathological O
significance O
in O
human O
breast O
cancer. O
The O
anti-apoptotic O
molecule, O
Bcl-2, B-GENE-Y
is O
well O
known O
to O
play O
an O
important O
role O
in O
the O
chemoresistance O
of O
breast O
cancer. O
We O
have O
previously O
demonstrated O
that O
phosphorylation O
of O
Fas-associated B-GENE-Y
death I-GENE-Y
domain-containing I-GENE-Y
protein I-GENE-Y
(FADD) B-GENE-Y

at O
194 O
serine B-CHEMICAL
through O
c-jun B-GENE-N
NH2-terminal B-CHEMICAL
kinase I-GENE-N
(JNK) B-GENE-N
activation O
sensitizes O
breast O
cancer O
cells O
to O
chemotherapy O
through O
accelerating O
cell O
cycle O
arrest O
at O
G2/M, O
and O
that O
Bcl-2 B-GENE-Y
phosphorylation O
downstream O
of O
JNK/FADD B-GENE-N
plays O
an O
important O
role O
in O
cell O
growth O
suppression O
by O
paclitaxel. B-CHEMICAL
In O
this O
study, O
the O
clinicopathological O
association O
of O
phosphorylated B-GENE-Y
Bcl-2 I-GENE-Y
(P-Bcl-2) B-GENE-Y
with O
estrogen, B-CHEMICAL
progesterone, B-CHEMICAL

c-erbB-2 I-GENE-N
receptors, I-GENE-N
p53 B-GENE-Y
expressions O
and O
phosphorylated B-GENE-Y
FADD/JNK I-GENE-Y
(P-FADD/JNK) B-GENE-Y
was O
analyzed O
immunohistochemically O
using O
107 O
human O
breast O
cancer O
specimens. O
Expression O
of O
P-Bcl-2 B-GENE-Y
was O
found O
to O
significantly O
correlate O
with O
lymphatic O
invasion, O
lymph O
node O
metastasis, O
but O
not O
histological O
differentiation, O
tumor O
grade O
or O
vascular O
and O
fatty O
invasion. O
The O
positivity O
of O
P-Bcl-2 B-GENE-Y
was O
also O
significantly O
correlated O
to O
that O
of O

P-FADD/JNK. B-GENE-Y
Thus, O
P-Bcl-2 B-GENE-Y
as O
well O
as O
the O
P-FADD/JNK B-GENE-Y
parameter O
might O
be O
useful O
markers O
for O
cancer O
progression, O
independent O
of O
the O
hormone O
receptor O
status, O
in O
human O
breast O
cancers. O
Studies O
on O
the O
mechanism O
of O
arterial O
vasodilation O
produced O
by O
the O
novel O
antihypertensive O
agent, O
carvedilol. B-CHEMICAL
The O
mechanism(s) O
responsible O
for O
arterial O
vasodilation O
observed O
following O
acute O
administration O
of O
racemic B-CHEMICAL
carvedilol, I-CHEMICAL
a O
novel O
vasodilator/beta B-GENE-N
adrenoceptor I-GENE-N
antagonist, O
has O
been O
investigated O
in O
rats. O

In O
conscious O
spontaneously O
hypertensive O
rats, O
carvedilol B-CHEMICAL
(0.03-3.0 O
mg/kg, O
iv) O
produced O
a O
dose-dependent O
reduction O
in O
blood O
pressure O
with O
no O
significant O
effect O
on O
heart O
rate. O
Because O
cardiac O
output O
was O
relatively O
unaffected, O
the O
antihypertensive O
response O
of O
carvedilol B-CHEMICAL
was O
associated O
with O
a O
dose-dependent O
reduction O
in O
total O
peripheral O
vascular O
resistance. O
Submaximal O
antihypertensive O
doses O
of O
carvedilol B-CHEMICAL
were O
chosen O
for O
mechanism O
of O
action O
studies O
in O
pithed O
rats. O
Carvedilol B-CHEMICAL
(0.3 O
mg/kg, O
iv) O
produced O
a O
significant O
inhibition O
of O
the O

beta B-GENE-Y
1 I-GENE-Y
adrenoceptor I-GENE-Y
mediated O
positive O
chronotropic O
response O
to O
isoproterenol. B-CHEMICAL
This O
same O
dose O
of O
carvedilol B-CHEMICAL
also O
inhibited, O
but O
to O
a O
lesser O
degree, O
the O
beta B-GENE-Y
2 I-GENE-Y
adrenoceptor I-GENE-Y
mediated O
vasodepressor O
response O
to O
salbutamol B-CHEMICAL
in O
pithed O
rats O
whose O
blood O
pressure O
was O
elevated O
by O
a O
constant O
intravenous O
infusion O
of O
angiotensin B-GENE-Y
II. I-GENE-Y
Thus, O
carvedilol B-CHEMICAL
blocks O
both O
beta B-GENE-N
1 I-GENE-N
and I-GENE-N
beta I-GENE-N
2 I-GENE-N
adrenoceptors I-GENE-N
at O
antihypertensive O
doses, O
with O
modest O
selectivity O
being O
observed O
for O
the O
beta B-GENE-Y
1 I-GENE-Y
adrenoceptor I-GENE-Y

subtype. O
Carvedilol B-CHEMICAL
produced O
significant O
inhibition O
of O
the O
alpha B-GENE-N
1 I-GENE-N
adrenoceptor I-GENE-N
mediated O
pressor O
response O
to O
cirazoline B-CHEMICAL
in O
the O
pithed O
rat, O
but O
had O
no O
effect O
on O
the O
alpha B-GENE-Y
2 I-GENE-Y
adrenoceptor I-GENE-Y
mediated O
pressor O
response O
to O
B-HT B-CHEMICAL
933, I-CHEMICAL
suggesting O
that O
carvedilol B-CHEMICAL
is O
also O
an O
alpha B-GENE-N
1 I-GENE-N
adrenoceptor I-GENE-N
antagonist O
at O
antihypertensive O
doses. O
Carvedilol B-CHEMICAL
had O
no O
effect O
on O
the O
pressor O
response O
elicited O
by O
angiotensin B-GENE-Y
II, I-GENE-Y
indicating O
a O
lack O
of O
nonspecific O
vasodilator O
activity. O
The O

vasopressor O
response O
to O
the O
calcium B-CHEMICAL
channel I-GENE-N
activator, O
BAY-K-8644, B-CHEMICAL
which O
is O
mediated O
through O
the O
opening O
of O
voltage B-GENE-N
dependent I-GENE-N
calcium B-CHEMICAL
channels I-GENE-N
and O
the O
subsequent O
translocation O
of O
extracellular O
calcium, B-CHEMICAL
was O
significantly O
inhibited O
by O
carvedilol B-CHEMICAL
(1 O
mg/kg, O
iv), O
suggesting O
that O
carvedilol B-CHEMICAL
is O
also O
a O
calcium B-GENE-N
channel I-GENE-N
antagonist, O
consistent O
with O
our O
previous O
in O
vitro O
studies. O
In O
anesthetized O
spontaneously O
hypertensive O
rats, O
the O
antihypertensive O
activity O
of O
carvedilol B-CHEMICAL
was O
nearly O
abolished O
by O
combined O
pretreatment O
of O
the O
rats O
with O
high O
doses O
of O
the O
alpha B-GENE-N
1 I-GENE-N

adrenoceptor I-GENE-N
antagonist, O
prazosin B-CHEMICAL
(1 O
mg/kg, O
iv), O
and O
the O
nonselective O
beta B-GENE-N
adrenoceptor I-GENE-N
antagonist, O
propranolol B-CHEMICAL
(3 O
mg/kg, O
iv), O
suggesting O
that O
the O
majority O
of O
the O
antihypertensive O
response O
produced O
by O
carvedilol B-CHEMICAL
may O
be O
accounted O
for O
by O
blockade O
of O
beta B-GENE-N
and I-GENE-N
alpha I-GENE-N
1 I-GENE-N
adrenoceptors. I-GENE-N
We O
therefore O
conclude O
that O
carvedilol, B-CHEMICAL
at O
antihypertensive O
doses, O
is O
an O
antagonist O
of O
beta B-GENE-N
1, I-GENE-N
beta I-GENE-N
2, I-GENE-N
and I-GENE-N
alpha I-GENE-N
1 I-GENE-N
adrenoceptors, I-GENE-N
and O
also O
of O
calcium B-GENE-N
channels I-GENE-N
in O
vascular O
smooth O

muscle.(ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS) O
Clinical, O
biochemical O
and O
molecular O
diagnosis O
of O
a O
compound O
homozygote O
for O
the O
254 O
bp O
deletion-8 O
bp O
insertion O
of O
the O
APRT B-GENE-Y
gene O
suffering O
from O
severe O
renal O
failure. O
OBJECTIVE: O
To O
determine O
the O
type O
of O
mutation O
in O
a O
patient O
with O
clinical O
diagnosis O
of O
suspected O
APRT B-GENE-Y
deficiency. O
DESIGN O
AND O
METHODS: O
A O
51-year-old O
male O
patient, O
with O
a O
clinical O
history O
of O
two O
prior O
episodes O
of O
renal O
colic O
with O
urinary O
stone O
excretion O
(reported O

as O
uric B-CHEMICAL
acid I-CHEMICAL
stones O
in O
the O
first O
episode O
and O
as O
calcium B-CHEMICAL
oxalate I-CHEMICAL
stones O
in O
the O
second), O
was O
admitted O
to O
the O
hospital O
with O
severe O
non-oliguric O
renal O
failure O
(1.06 O
mmol/L O
serum O
creatinine), B-CHEMICAL
severe O
hyponatremia O
(114 O
mmol/L O
Na(+)), B-CHEMICAL
metabolic O
acidosis O
(14 O
mmol/L O
HCO(3)(-)) B-CHEMICAL
and O
uricemia O
in O
the O
normal O
range. O
Abnormalities O
at O
renal O
scan O
and O
persistency O
of O
severe O
renal O
failure O
required O
to O
start O
haemodialysis. O

Results O
of O
renal O
biopsy O
prompted O
us O
to O
undertake O
a O
biochemical O
and O
molecular O
biological O
evaluation O
of O
the O
patient O
for O
suspected O
adenine B-CHEMICAL
phosphoribosyltransferase I-GENE-Y
(APRT) B-GENE-Y
deficiency. O
RESULTS: O
HPLC O
analysis O
of O
serum O
and O
urine, O
for O
determining O
purine B-CHEMICAL
derivative O
profile, O
showed O
the O
pathological O
presence O
of O
adenine B-CHEMICAL
in O
both O
biological O
fluids O
(3.57 O
micromol/L O
and O
7.11 O
micromol/mmol O
creatinine B-CHEMICAL
in O
serum O
and O
urine, O
respectively; O
not O
detectable O
in O
both O
fluids O
in O
healthy O
controls). O
APRT B-GENE-Y
assay O
in O
a O
sample O
of O
patient O

hemolysate O
showed O
no O
detectable O
activity O
of O
the O
enzyme O
(25.56+/-9.55 O
U/L O
red O
blood O
cells O
in O
control O
healthy O
subjects). O
Molecular O
biological O
analysis O
of O
the O
amplified O
APRT B-GENE-Y
gene O
revealed O
that O
the O
patient O
harboured O
in O
exon O
3 O
a O
homozygous O
254 O
bp O
deletion-8 O
bp O
insertion, O
previously O
described O
only O
once O
in O
a O
compound O
heterozygote. O
Analysis O
of O
the O
patient O
family O
showed O
that O
heterozygotes O
for O
this O
APRT B-GENE-Y
gene O
mutation, O
in O
spite O
of O
a O
69% O
lower O
APRT B-GENE-Y
enzymatic O
activity O
than O
that O
of O
healthy O
subjects, O
had O
no O

detectable O
adenine B-CHEMICAL
concentrations O
in O
both O
serum O
and O
urine. O
CONCLUSIONS: O
Results O
of O
the O
first O
patient O
harbouring O
the O
homozygous O
254 O
bp O
deletion-8 O
bp O
insertion O
of O
the O
APRT B-GENE-Y
gene O
strongly O
indicated O
that O
definitive O
diagnosis O
of O
APRT B-GENE-Y
deficiency O
(often O
under O
or O
misdiagnosed) O
would O
require O
a O
combined O
clinical, O
biochemical O
and O
molecular O
biological O
evaluation. O
Phospholipase B-GENE-Y
Cgamma1 I-GENE-Y
negatively O
regulates O
growth B-GENE-Y
hormone I-GENE-Y
signalling O
by O
forming O
a O
ternary O
complex O
with O
Jak2 B-GENE-Y
and O
protein B-GENE-Y
tyrosine B-CHEMICAL
phosphatase-1B. I-GENE-Y
Growth B-GENE-Y
hormone I-GENE-Y
binds O
to O
its O

membrane O
receptor O
(GHR), B-GENE-Y
whereby O
it O
regulates O
many O
cellular O
functions, O
including O
proliferation, O
differentiation O
and O
chemotaxis. O
However, O
although O
the O
activation O
of O
growth B-GENE-Y
hormone-mediated I-GENE-Y
signalling O
is O
well O
understood, O
the O
precise O
mechanism O
responsible O
for O
its O
regulation O
has O
not O
been O
elucidated. O
Here, O
we O
demonstrate O
that O
phospholipase B-GENE-Y
Cgamma1 I-GENE-Y
(PLCgamma1) B-GENE-Y
modulates O
the O
action O
of O
growth B-GENE-Y
hormone-mediated I-GENE-Y
signalling O
by O
interacting O
with O
tyrosine B-CHEMICAL
kinase I-GENE-Y
Jak2 I-GENE-Y
(janus B-GENE-Y
kinase I-GENE-Y
2) I-GENE-Y
in O
a O
growth B-GENE-Y
hormone-dependent I-GENE-Y
manner. O
In O
the O
absence O
of O
PLCgamma1 B-GENE-Y

(PLCgamma1(-/-)), B-GENE-Y
growth B-GENE-Y
hormone-induced I-GENE-Y
JAK2 B-GENE-Y
and O
STAT5 B-GENE-Y
phosphorylation O
significantly O
increased O
in O
mouse O
embryonic O
fibroblasts O
(MEFs). O
Furthermore, O
the O
re-expression O
of O
PLCgamma1 B-GENE-Y
reduced O
growth B-GENE-Y
hormone-induced I-GENE-Y
Jak2 B-GENE-Y
activation. O
Growth B-GENE-Y
hormone-induced I-GENE-Y
Jak2 B-GENE-Y
phosphorylation O
was O
enhanced O
by O
siRNA-specific O
knockdown O
of O
PLCgamma1. B-GENE-Y
Interestingly, O
PLCgamma1 B-GENE-Y
physically O
linked O
Jak2 B-GENE-Y
and O
protein B-GENE-N
tyrosine I-GENE-N
phosphatase-1B I-GENE-N

(PTP-1B) B-GENE-N
by O
binding O
to O
both O
using O
different O
domains, O
and O
this O
process O
was O
implicated O
in O
the O
modulation O
of O
cytokine B-GENE-N
signalling O
through O
Jak2. B-GENE-Y
In O
addition, O
in O
PLCgamma1(-/-) B-GENE-Y
MEFs, O
growth B-GENE-Y
hormone-dependent I-GENE-Y
c-Fos B-GENE-Y
activation O
was O
upregulated O
and O
growth B-GENE-Y
hormone-induced I-GENE-Y
proliferation O
was O
potentiated. O
These O
results O
suggest O
that O
PLCgamma1 B-GENE-Y
has O
a O
key O
function O
in O
the O
regulation O
of O
growth B-GENE-Y
hormone-mediated I-GENE-Y
signalling O
by O
negatively O
regulating O
Jak2 B-GENE-Y
activation. O
Increased O
responsiveness O
of O
rat O
colonic O
splanchnic O

afferents O
to O
5-HT B-CHEMICAL
after O
inflammation O
and O
recovery. O
5-Hydroxytryptamine B-CHEMICAL
(5-HT) B-CHEMICAL
activates O
colonic O
splanchnic O
afferents, O
a O
mechanism O
by O
which O
it O
has O
been O
implicated O
in O
generating O
symptoms O
in O
postinfectious O
and O
postinflammatory O
states O
in O
humans. O
Here O
we O
compared O
mechanisms O
of O
colonic O
afferent O
activation O
by O
5-HT B-CHEMICAL
and O
mechanical O
stimuli O
in O
normal O
and O
inflamed O
rat O
colon, O
and O
after O
recovery O
from O
inflammation. O
Colonic O
inflammation O
was O
induced O
in O
rats O
by O
dextran B-CHEMICAL
sulphate I-CHEMICAL
sodium. I-CHEMICAL
Single-fibre O
recordings O

of O
colonic O
lumbar O
splanchnic O
afferents O
revealed O
that O
58% O
of O
endings O
responded O
to O
5-HT B-CHEMICAL
(10(-4) O
m) O
in O
controls, O
88% O
in O
acute O
inflammation O
(P<0.05) O
and O
75% O
after O
21 O
days O
recovery O
(P O
< O
0.05 O
versus O
control). O
Maximal O
responses O
to O
5-HT B-CHEMICAL
were O
also O
larger, O
and O
the O
estimated O
EC50 O
was O
reduced O
from O
3.2 O
x O
10(-6) O
to O
8 O
x O
10(-7) O
m O
in O
acute O
inflammation O
and O
recovered O
to O
2 O
x O
10(-6) O
m O
after O
recovery. O

Responsiveness O
to O
mechanical O
stimulation O
was O
unaffected. O
5-HT3 B-GENE-Y
receptor I-GENE-Y
antagonism O
with O
alosetron B-CHEMICAL
reduced O
responses O
to O
5-HT B-CHEMICAL
in O
controls O
but O
not O
during O
inflammation. O
Responses O
to O
the O
mast O
cell O
degranulator O
48/80 O
mimicked O
those O
to O
5-HT B-CHEMICAL
in O
inflamed O
tissue O
but O
not O
in O
controls, O
and O
more O
5-HT-containing B-CHEMICAL
mast O
cells O
were O
seen O
close O
to O
calcitonin B-GENE-N
gene-related I-GENE-N
peptide-containing I-GENE-N
fibres O
in O
inflamed O
serosa. O
We O
conclude O
that O
colonic O
serosal O
and O
mesenteric O
endings O
exhibit O
increased O
sensitivity O

to O
5-HT B-CHEMICAL
in O
inflammation, O
with O
both O
an O
increase O
in O
proportion O
of O
responders O
and O
an O
increase O
in O
sensitivity, O
which O
is O
maintained O
after O
healing O
of O
inflammation. O
This O
is O
associated O
with O
alterations O
in O
the O
roles O
of O
5-HT3 B-GENE-Y
receptors I-GENE-Y
and O
mast O
cells. O
The O
role O
of O
extranuclear O
signaling O
actions O
of O
progesterone B-GENE-Y
receptor I-GENE-Y
in O
mediating O
progesterone B-CHEMICAL
regulation O
of O
gene O
expression O
and O
the O
cell O
cycle. O
Human B-GENE-Y
progesterone B-CHEMICAL
receptor I-GENE-Y
(PR) B-GENE-Y
contains O
a O
motif O
that O
interacts O
with O
the O
SH3 B-GENE-N
domain I-GENE-N
of O
Src B-GENE-Y
and O
mediates O
rapid O
activation O
of O
Src B-GENE-Y
and O
downstream O
MAPK B-GENE-N
(Erk-1/-2) B-GENE-N

without O
relying O
on O
the O
transcriptional O
activity O
of O
the O
receptor. O
Here O
we O
investigated O
the O
role O
and O
intracellular O
location O
of O
this O
nontranscriptional O
activity O
of O
PR. B-GENE-Y
Progestin B-CHEMICAL
activation O
of O
Src/MAPK B-GENE-Y
occurred O
outside O
the O
nucleus O
with O
the O
B B-GENE-Y
isoform I-GENE-Y
of I-GENE-Y
PR I-GENE-Y
that O
was O
distributed O
between O
the O
cytoplasm O
and O
nucleus, O
but O
not O
with O
PR-A B-GENE-Y
that O
was O
predominantly O
nuclear. O
Breast O
cancer O
cells O
stably O
expressing O
wild-type O
PR-B B-GENE-Y
or O
PR-B B-GENE-Y
with O
disrupting O
point O
mutations O
in O
the O
SH3 B-GENE-N
domain I-GENE-N
binding I-GENE-N
motif I-GENE-N
(PR-BDeltaSH3) B-GENE-N
that O
do O
not O
affect O
the O

transcriptional O
activity O
of O
PR, B-GENE-Y
were O
compared O
for O
effects O
of O
progestin B-CHEMICAL
on O
endogenous O
target O
gene O
expression O
and O
cell O
proliferation. O
Progestin B-CHEMICAL
induction O
of O
the O
cyclin B-GENE-Y
D1 I-GENE-Y
gene, O
which O
lacks O
a O
progesterone B-CHEMICAL
response I-GENE-N
element, I-GENE-N
was O
dependent O
on O
PR B-GENE-Y
activation O
of O
the O
Src/MAPK B-GENE-Y
pathway, O
whereas O
induction O
of O
the O
Sgk B-GENE-Y
(serum B-GENE-Y
and I-GENE-Y
glucocorticoid I-GENE-Y
regulated I-GENE-Y
kinase) I-GENE-Y
gene O
that O
contains O
a O
functional O
progesterone B-CHEMICAL
response I-GENE-N
element I-GENE-N
was O
unaffected O
by O
mutations O
that O
interfere O
with O
PR B-GENE-Y
activation O
of O
Src. B-GENE-Y
Progestin B-CHEMICAL
induction O
of O
cell O
cycle O
progression O
was O
also O
abrogated O
in O
cells O
expressing O

PR-BDeltaSH3, B-GENE-N
and O
no O
effect O
of O
progestin B-CHEMICAL
on O
cyclin B-GENE-Y
D1 I-GENE-Y
expression O
and O
cell O
cycle O
was O
observed O
in O
the O
presence O
of O
PR-A. B-GENE-Y
These O
results O
highlight O
the O
importance O
of O
PR B-GENE-Y
activation O
of O
the O
Src/MAPK B-GENE-Y
signaling O
pathway O
for O
progesterone-induced B-CHEMICAL
transcription O
of O
select O
target O
genes O
and O
cell O
cycle O
progression. O
Seizures O
and O
enhanced O
cortical O
GABAergic O
inhibition O
in O
two O
mouse O
models O
of O
human O
autosomal O
dominant O
nocturnal O
frontal O
lobe O
epilepsy. O
Selected O
mutations O
in O
the O
human B-GENE-N
alpha4 I-GENE-N
or I-GENE-N
beta2 I-GENE-N
neuronal I-GENE-N
nicotinic I-GENE-N
acetylcholine I-GENE-N

receptor I-GENE-N
subunit O
genes O
cosegregate O
with O
a O
partial O
epilepsy O
syndrome O
known O
as O
autosomal O
dominant O
nocturnal O
frontal O
lobe O
epilepsy O
(ADNFLE). O
To O
examine O
possible O
mechanisms O
underlying O
this O
inherited O
epilepsy, O
we O
engineered O
two O
ADNFLE O
mutations O
(Chrna4(S252F) B-GENE-Y
and O
Chrna4(+L264)) B-GENE-Y
in O
mice. O
Heterozygous O
ADNFLE O
mutant O
mice O
show O
persistent, O
abnormal O
cortical O
electroencephalograms O
with O
prominent O
delta O
and O
theta O
frequencies, O
exhibit O
frequent O
spontaneous O
seizures, O
and O
show O
an O
increased O
sensitivity O
to O
the O
proconvulsant O
action O
of O

nicotine. B-CHEMICAL
Relative O
to O
WT, O
electrophysiological O
recordings O
from O
ADNFLE O
mouse O
layer O
II/III O
cortical O
pyramidal O
cells O
reveal O
a O
>20-fold O
increase O
in O
nicotine-evoked B-CHEMICAL
inhibitory O
postsynaptic O
currents O
with O
no O
effect O
on O
excitatory O
postsynaptic O
currents. O
i.p. O
injection O
of O
a O
subthreshold O
dose O
of O
picrotoxin, B-CHEMICAL
a O
use-dependent O
gamma-aminobutyric B-CHEMICAL
acid I-CHEMICAL
receptor I-GENE-N
antagonist, O
reduces O
cortical O
electroencephalogram O
delta O
power O
and O
transiently O
inhibits O
spontaneous O
seizure O
activity O
in O
ADNFLE O
mutant O
mice. O
Our O
studies O
suggest O

that O
the O
mechanism O
underlying O
ADNFLE O
seizures O
may O
involve O
inhibitory O
synchronization O
of O
cortical O
networks O
via O
activation O
of O
mutant O
alpha4-containing B-GENE-Y
nicotinic I-GENE-Y
acetylcholine I-GENE-Y
receptors I-GENE-Y
located O
on O
the O
presynaptic O
terminals O
and O
somatodendritic O
compartments O
of O
cortical O
GABAergic O
interneurons. O
Molecular O
recognition O
of O
histidine B-CHEMICAL
tRNA O
by O
histidyl-tRNA B-GENE-Y
synthetase I-GENE-Y
from O
hyperthermophilic O
archaeon, O
Aeropyrum O
pernix O
K1. O
To O
investigate O
the O
recognition O
sites O
of O
histidine B-CHEMICAL
tRNA O
for O

histidyl-tRNA B-GENE-Y
synthetase I-GENE-Y
from O
an O
extreme O
hyperthermophilic O
archaeon, O
Aeropyrum O
pernix O
K1, O
we O
examined O
histidylation O
activities O
by O
using O
overexpressed O
histidyl-tRNA B-GENE-Y
synthetase I-GENE-Y
and O
various O
histidine B-CHEMICAL
tRNA O
transcripts O
that O
were O
prepared O
by O
in O
vitro O
transcription O
system. O
Results O
indicated O
that O
anticodon O
was O
not O
recognized O
by O
the O
histidyl-tRNA B-GENE-Y
synthetase I-GENE-Y
similar O
to O
that O
of O
Escherichia O
coli O
histidine B-CHEMICAL
tRNA O
recognition O
system. O
Discriminator O
base O
C73 O
was O
weekly O
recognized O

and O
an O
additional O
G O
residue O
was O
specifically O
recognized O
by O
the O
enzyme. O
Synthesis, O
radiosynthesis, O
and O
biological O
evaluation O
of O
carbon-11 B-CHEMICAL
labeled I-CHEMICAL
2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: I-CHEMICAL
candidate O
radioligands O
for O
in O
vivo O
imaging O
of O
the O
serotonin B-GENE-Y
transporter I-GENE-Y
with O
positron O
emission O
tomography. O

2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane B-CHEMICAL
(mZIENT, B-CHEMICAL
1) O
and O
2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane B-CHEMICAL
(mZBrENT, B-CHEMICAL
2) O
were O
synthesized O
and O
evaluated O
for O
binding O
to O
the O
human B-GENE-N
serotonin, B-CHEMICAL
dopamine, B-CHEMICAL
and I-GENE-N
norepinephrine B-CHEMICAL
transporters I-GENE-N

(SERT, B-GENE-Y
DAT, B-GENE-Y
and O
NET, B-GENE-Y
respectively) O
using O
transfected O
cells. O
Both O
1 O
and O
2 O
have O
a O
high O
affinity O
for O
the O
SERT B-GENE-Y
(Ki=0.2 O
nM) O
and O
are O
approximately O
160 O
times O
more O
selective O
for O
the O
SERT B-GENE-Y
than O
the O
DAT. B-GENE-Y
Compound O
2 O
has O
a O
significantly O
higher O
affinity O
for O
the O
NET B-GENE-Y
than O
1, O
and O
this O
may O
be O
a O
result O
of O
the O
different O
size O
and O
electronegativity O
of O
the O
halogen B-CHEMICAL
atoms. O
MicroPET O
imaging O
in O
nonhuman O
primates O
with O
[11C]1 B-CHEMICAL
and O
[11C]2 B-CHEMICAL
demonstrated O
that O
both O
tracers O
behave O
similarly O
in O
vivo O
with O

high O
uptake O
being O
observed O
in O
the O
SERT-rich B-GENE-N
brain O
regions O
and O
peak O
uptake O
being O
achieved O
in O
about O
55 O
min O
postinjection. O
Chase O
studies O
with O
citalopram B-CHEMICAL
and O
methylphenidate B-CHEMICAL
demonstrated O
that O
this O
uptake O
is O
the O
result O
of O
preferential O
binding O
to O
the O
SERT. B-GENE-N
Pharmacokinetics O
of O
olmesartan B-CHEMICAL
medoxomil I-CHEMICAL
plus O
hydrochlorothiazide B-CHEMICAL
combination O
in O
healthy O
subjects. O
BACKGROUND: O
Hypertension O
treatment O
guidelines O
recommend O
combination O
therapy O
with O
diuretics O
and O
other O
antihypertensive O
agents, O
including O
angiotensin B-CHEMICAL
II I-CHEMICAL
type I-GENE-Y
1 I-GENE-Y

(AT1) I-GENE-Y
receptor I-GENE-Y
antagonists. O
This O
trial O
investigated O
the O
possibility O
of O
pharmacokinetic O
interactions O
between O
the O
AT1 B-GENE-Y
receptor I-GENE-Y
antagonist O
olmesartan B-CHEMICAL
medoxomil I-CHEMICAL
and O
the O
thiazide B-CHEMICAL
diuretic O
hydrochlorothiazide B-CHEMICAL
in O
healthy O
subjects. O
METHODS: O
Twenty-four O
healthy O
normotensive O
adult O
male O
subjects O
underwent O
three O
consecutive O
7-day O
treatment O
periods O
(A, O
B O
and O
C, O
respectively) O
during O
which O
they O
were O
randomised O
to O
receive: O
olmesartan B-CHEMICAL
medoxomil I-CHEMICAL
20 O
mg O
once O
daily O
(regimen O
A), O
hydrochlorothiazide B-CHEMICAL

25 O
mg O
once O
daily O
(regimen O
B), O
or O
olmesartan B-CHEMICAL
medoxomil I-CHEMICAL
20 O
mg O
once O
daily O
plus O
hydrochlorothiazide B-CHEMICAL
25 O
mg O
once O
daily O
(regimen O
C). O
Treatment O
periods O
were O
separated O
by O
washouts O
of O
7-14 O
days. O
The O
primary O
pharmacokinetic O
parameters O
evaluated O
were: O
the O
area O
under O
the O
plasma O
concentration O
versus O
time O
curve O
at O
steady O
state O
(AUCss,tau), O
the O
maximum O
plasma O
concentration O
at O
steady O
state O
(Css,max), O
and O
the O
time O
at O
which O
Css,max O
occurred O
(tmax). O
RESULTS: O

Complete O
data O
sets O
from O
17 O
subjects O
were O
available O
for O
pharmacokinetic O
analyses. O
Mean O
concentration O
versus O
time O
profiles O
were O
similar O
for O
monotherapy O
and O
combination O
treatment O
for O
both O
olmesartan B-CHEMICAL
(the O
active O
metabolite O
of O
olmesartan B-CHEMICAL
medoxomil) I-CHEMICAL
and O
hydrochlorothiazide. B-CHEMICAL
For O
olmesartan, B-CHEMICAL
comparison O
of O
monotherapy O
with O
combination O
therapy O
showed O
that O
for O
AUCss,tau O
and O
Css,max O
point O
estimates O
were O
close O
to O
unity, O
demonstrating O
bioequivalence. O
For O
hydrochlorothiazide, B-CHEMICAL
combination O
therapy O
resulted O
in O
decreases O
in O

AUCss,tau O
and O
Css,max O
of O
approximately O
10% O
versus O
monotherapy; O
nevertheless, O
since O
90% O
CIs O
were O
within O
the O
acceptance O
range, O
bioequivalence O
was O
proven. O
Median O
tmax O
values O
for O
olmesartan B-CHEMICAL
and O
hydrochlorothiazide B-CHEMICAL
for O
periods O
A, O
B O
and O
C O
were O
identical, O
indicating O
bioequivalence. O
Both O
olmesartan B-CHEMICAL
medoxomil I-CHEMICAL
and O
hydrochlorothiazide B-CHEMICAL
were O
well O
tolerated. O
CONCLUSION: O
These O
results O
show O
that O
there O
is O
little O
or O
no O
potential O
for O
a O
clinically O
relevant O

pharmacokinetic O
interaction O
between O
olmesartan B-CHEMICAL
medoxomil I-CHEMICAL
20 O
mg O
and O
hydrochlorothiazide B-CHEMICAL
25 O
mg, O
and O
therefore O
dosage O
adjustment O
should O
not O
be O
necessary O
when O
they O
are O
co-administered. O
Effect O
of O
cromolyn O
on O
S100P B-GENE-Y
interactions O
with O
RAGE O
and O
pancreatic O
cancer O
growth O
and O
invasion O
in O
mouse O
models. O
BACKGROUND: O
We O
previously O
found O
that O
S100P, B-GENE-Y
a O
member O
of O
the O
S100 B-GENE-N
protein O
family, O
is O
expressed O
in O
more O
than O
90% O
of O
pancreatic O
tumors O
and O
is O
associated O
with O
tumor O
growth O
and O
invasion. O
In O
the O
current O
study, O
we O
investigated O

the O
ability O
of O
the O
antiallergy O
drug, O
cromolyn, O
to O
block O
S100P B-GENE-Y
function. O
METHODS: O
Interactions O
between O
cromolyn O
and O
S100P B-GENE-Y
were O
investigated O
using O
a O
drug O
affinity O
column O
and O
by O
examining O
cromolyn's O
effects O
on O
coimmunoprecipitation O
of O
S100P B-GENE-Y
and O
receptor O
for O
advanced O
glycation O
end-products O
(RAGE). O
The O
effects O
of O
cromolyn O
on O
cell O
growth, O
invasion, O
and O
nuclear B-GENE-N
factor-kappaB I-GENE-N
(NFkappaB) B-GENE-N
activity O
of O
pancreatic O
cancer O
cells O
with O
(BxPC-3 O
and O

MPanc-96) O
and O
without O
(Panc-1) O
endogenous O
S100P B-GENE-Y
were O
investigated O
by O
cell O
proliferation O
assay, O
by O
cell O
invasion O
assay, O
and O
by O
luciferase O
reporter O
gene O
assay, O
respectively. O
The O
effects O
of O
cromolyn O
on O
tumor O
growth O
in O
vivo O
were O
investigated O
in O
three O
orthotopic O
models O
(n O
= O
20 O
mice O
per O
model) O
by O
administration O
of O
cromolyn O
(5 O
mg/kg O
body O
weight, O
daily) O
with O
and O
without O
gemcitabine B-CHEMICAL
(125 O
mg/kg O
body O
weight, O
biweekly), O
the O
drug O
currently O
used O
to O
treat O
pancreatic O
cancer. O

Tumor O
growth O
was O
assayed O
by O
reporter O
gene O
expression. O
All O
statistical O
tests O
were O
two-sided. O
RESULTS: O
S100P B-GENE-Y
was O
retained O
on O
a O
cromolyn O
affinity O
column. O
Cromolyn O
blocked O
the O
coimmunoprecipitation O
of O
S100P B-GENE-Y
and O
RAGE. O
In O
vitro, O
cromolyn O
(100 O
microM) O
inhibited O
S100P-stimulated B-GENE-Y
Panc-1 O
cell O
proliferation O
(S100P, B-GENE-Y
mean O
= O
0.93 O
U, O
versus O
S100P B-GENE-Y
+ O
cromolyn, O
mean O
= O
0.56 O
U, O
difference O
= O
0.37 O

U; O
95% O
confidence O
interval O
[CI] O
= O
0.24 O
to O
0.49 O
U; O
P O
= O
.001, O
n O
= O
3), O
invasion O
(S100P, B-GENE-Y
mean O
= O
58.0%, O
versus O
S100P B-GENE-Y
+ O
cromolyn, O
mean O
= O
9.4%, O
difference O
= O
48.6%; O
95% O
CI O
= O
38.8% O
to O
58.8%; O
P<.001, O
n O
= O
3), O
and O
NFkappaB B-GENE-N
activity O
(S100P, B-GENE-Y
mean O
= O
14,460, O
versus O
S100P B-GENE-Y
+ O
cromolyn, O
mean O
= O
7360 O

photons/s, O
difference O
= O
7100 O
photons/s; O
95% O
CI O
= O
3689 O
to O
10 O
510 O
photons/s; O
P O
= O
.005, O
n O
= O
3). O
In O
vivo, O
cromolyn O
inhibited O
tumor O
growth O
in O
mice O
bearing O
tumor O
with O
endogenous O
S100P B-GENE-Y
(BxPC-3: O
control, O
mean O
= O
1.6 O
x O
10(9) O
photons/s, O
versus O
cromolyn, O
mean O
= O
4.4 O
x O
10(8) O
photons/s, O
difference O
= O
1.2 O
x O
10(9) O
photons/s; O

95% O
CI O
= O
6.2 O
x O
10(8) O
to O
1.6 O
x O
10(9) O
photons/s; O
P<.001, O
n O
= O
5; O
MPanc-96: O
control, O
mean O
= O
1.1 O
x O
10(10) O
photons/s, O
versus O
cromolyn, O
mean O
= O
4.8 O
x O
10(9) O
photons/s, O
difference O
= O
6.2 O
x O
10(9) O
photons/s; O
95% O
CI O
= O
1.9 O
x O
10(9) O
to O
1.0 O
x O
10(10) O
photons/s; O
P O
= O

.009, O
n O
= O
5) O
and O
increased O
the O
effectiveness O
of O
gemcitabine B-CHEMICAL
(BxPC-3: O
gemcitabine, B-CHEMICAL
mean O
= O
9.2 O
x O
10(8) O
photons/s, O
versus O
combination, O
mean O
= O
1.8 O
x O
10(8) O
photons/s, O
difference O
= O
7.4 O
x O
10(8) O
photons/s; O
95% O
CI O
= O
4.5 O
x O
10(8) O
to O
1.0 O
x O
10(9) O
photons/s; O
P<.001; O
MPanc-96: O
gemcitabine, B-CHEMICAL
mean O
= O

4.1 O
x O
10(9) O
photons/s, O
versus O
combination, O
mean O
= O
2.0 O
x O
10(9) O
photons/s, O
difference O
= O
2.1 O
x O
10(9) O
photons/s; O
95% O
CI O
= O
4.4 O
x O
10(8) O
to O
3.8 O
x O
10(9) O
photons/s; O
P<.001). O
However, O
cromolyn O
had O
no O
effect O
on O
growth O
of O
tumors O
lacking O
S100P B-GENE-Y
(Panc-1). O
CONCLUSION: O
Cromolyn O
binds O
S100P, B-GENE-Y
prevents O
activation O
of O
RAGE, O

inhibits O
tumor O
growth, O
and O
increases O
the O
effectiveness O
of O
gemcitabine B-CHEMICAL
in O
experimental O
models. O
Genetic O
polymorphisms O
in O
the O
cyclooxygenase-2 B-GENE-Y
gene, O
use O
of O
nonsteroidal O
anti-inflammatory O
drugs, O
and O
breast O
cancer O
risk. O
INTRODUCTION: O
The O
association O
between O
use O
of O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
and O
breast O
cancer O
risk O
remains O
unclear. O
Inconsistencies O
in O
previously O
reported O
findings O
may O
be O
partly O
due O
to O
differences O
in O
expression O
of O
cyclooxygenase B-GENE-Y
(COX)-2. I-GENE-Y
We O

hypothesized O
that O
genetic O
polymorphisms O
(COX-2 B-GENE-Y
.926, O
COX-2 B-GENE-Y
.5209, O
and O
COX-2 B-GENE-Y
.8473) O
may O
reduce O
overall O
breast O
cancer O
risk O
or O
risk O
for O
subtypes O
of O
breast O
cancer O
by O
modulating O
the O
inflammatory O
response O
and O
may O
interact O
with O
aspirin O
or O
any O
NSAID O
use. O
METHODS: O
We O
conducted O
a O
population-based, O
case-control O
study O
in O
which O
we O
genotyped O
1,067 O
breast O
cancer O
cases O
and O
1,110 O
control O
individuals O
included O
in O
the O
Long O
Island O
Breast O
Cancer O
Study O
Project. O

RESULTS: O
No O
major O
effects O
of O
the O
three O
COX-2 B-GENE-Y
variant O
alleles O
on O
breast O
cancer O
risk O
were O
found. O
A O
total O
of O
eight O
distinct O
haplotypes O
and O
18 O
diplotypes O
were O
observed O
in O
the O
population. O
Overall, O
no O
significant O
associations O
between O
COX-2 B-GENE-N
haplotypes/diplotypes O
and O
breast O
cancer O
risk O
were O
observed. O
Among O
women O
who O
used O
aspirin O
or O
any O
NSAID O
there O
was O
little O
evidence O
for O
an O
interaction O
with O
the O
at-risk O
COX-2 B-GENE-Y
genotypes, O
with O
one O
exception. O
Among O
women O
with O
hormone O
receptor O
positive O
breast O
cancer, O
the O
reduced O
risk O
for O
any O

NSAID O
use O
was O
only O
evident O
among O
those O
who O
had O
at O
least O
one O
variant O
C O
allele O
of O
COX-2 B-GENE-Y
.8473 O
(odds O
ratio O
= O
0.7, O
95% O
confidence O
interval O
= O
0.5 O
to O
1.0; O
P O
for O
the O
interaction O
= O
0.02). O
There O
was O
no O
corresponding O
interaction O
for O
aspirin O
use, O
possibly O
because O
of O
limited O
power. O
CONCLUSION: O
These O
data O
provide O
modest O
evidence O
that O
the O
C O
allele O
of O
COX-2 B-GENE-Y
.8473 O
may O
interact O
with O
NSAIDs O
to O
reduce O
risk O
for O
hormone O
receptor O
positive O
breast O
cancer. O
Biosynthesis O
of O
selenocysteine B-CHEMICAL

on O
its O
tRNA O
in O
eukaryotes. O
Selenocysteine B-CHEMICAL
(Sec) B-CHEMICAL
is O
cotranslationally O
inserted O
into O
protein O
in O
response O
to O
UGA B-GENE-N
codons O
and O
is O
the O
21st O
amino B-CHEMICAL
acid I-CHEMICAL
in O
the O
genetic O
code. O
However, O
the O
means O
by O
which O
Sec B-CHEMICAL
is O
synthesized O
in O
eukaryotes O
is O
not O
known. O
Herein, O
comparative O
genomics O
and O
experimental O
analyses O
revealed O
that O
the O
mammalian B-GENE-Y
Sec B-CHEMICAL
synthase I-GENE-Y
(SecS) B-GENE-Y
is O
the O
previously O
identified O
pyridoxal B-CHEMICAL
phosphate-containing I-CHEMICAL
protein O
known O
as O
the O
soluble B-GENE-Y
liver I-GENE-Y
antigen. I-GENE-Y
SecS B-GENE-Y
required O
selenophosphate B-CHEMICAL
and O

O-phosphoseryl-tRNA([Ser]Sec) B-CHEMICAL
as O
substrates O
to O
generate O
selenocysteyl-tRNA([Ser]Sec). B-CHEMICAL
Moreover, O
it O
was O
found O
that O
Sec B-GENE-Y
was O
synthesized O
on O
the O
tRNA O
scaffold O
from O
selenide, B-CHEMICAL
ATP, B-CHEMICAL
and O
serine B-CHEMICAL
using O
tRNA([Ser]Sec), O
seryl-tRNA B-GENE-Y
synthetase, I-GENE-Y
O-phosphoseryl-tRNA([Ser]Sec) B-GENE-Y
kinase, I-GENE-Y
selenophosphate B-GENE-N
synthetase, I-GENE-N
and O
SecS. B-GENE-Y
By O
identifying O
the O
pathway O
of O

Sec B-CHEMICAL
biosynthesis O
in O
mammals, O
this O
study O
not O
only O
functionally O
characterized O
SecS B-GENE-Y
but O
also O
assigned O
the O
function O
of O
the O
O-phosphoseryl-tRNA([Ser]Sec) B-GENE-Y
kinase. I-GENE-Y
In O
addition, O
we O
found O
that O
selenophosphate B-GENE-Y
synthetase I-GENE-Y
2 I-GENE-Y
could O
synthesize O
monoselenophosphate B-CHEMICAL
in O
vitro O
but O
selenophosphate B-CHEMICAL
synthetase I-GENE-Y
1 I-GENE-Y
could O
not. O
Conservation O
of O
the O
overall O
pathway O
of O
Sec O
biosynthesis O
suggests O
that O
this O
pathway O
is O
also O
active O
in O
other O
eukaryotes O
and O
archaea O
that O
synthesize O

selenoproteins. B-GENE-N
Effects O
of O
triflusal B-CHEMICAL
and O
aspirin B-CHEMICAL
in O
a O
rat O
model O
of O
cerebral O
ischemia. O
BACKGROUND O
AND O
PURPOSE: O
Neuroinflammation O
plays O
a O
critical O
role O
in O
the O
pathogenesis O
of O
cerebral O
ischemia. O
Triflusal, B-CHEMICAL
a O
selective O
cyclooxygenase-2, B-GENE-Y
and O
its O
active O
metabolite O
3-hydroxy-4-trifluoromethylbenzoic B-CHEMICAL
acid I-CHEMICAL
may O
inhibit O
apoptosis O
and O
inflammation O
after O
cerebral O
ischemia. O
An O
in O
vivo O
model O
of O
cerebral O

ischemia O
was O
used O
to O
investigate O
the O
effects O
of O
triflusal B-CHEMICAL
and O
aspirin B-CHEMICAL
treatment O
on O
infarct O
volume, O
and O
inflammation O
after O
cerebral O
ischemia O
in O
the O
rat. O
METHODS: O
Male O
Wistar O
rats O
were O
subjected O
to O
a O
permanent O
right-sided O
middle O
cerebral O
artery O
occlusion. O
Rats O
received O
oral O
administration O
of O
either O
triflusal B-CHEMICAL
or O
aspirin. B-CHEMICAL
After O
3 O
days O
after O
surgery, O
immunostaining O
was O
used O
to O
detect O
neuroinflammatory O
cells O
and O
molecules, O
and O
infarct O
volumes O
were O
measured. O
RESULTS: O
Both O
triflusal B-CHEMICAL
and O

aspirin B-CHEMICAL
at O
a O
dose O
of O
30 O
mg/kg O
but O
not O
10 O
mg/kg O
significantly O
reduced O
infarct O
volume O
compared O
with O
vehicle O
treatment. O
Middle O
cerebral O
artery O
occlusion O
resulted O
in O
increased O
astrocyte O
and O
heat B-GENE-Y
shock I-GENE-Y
protein-27 I-GENE-Y
(Hsp27) B-GENE-Y
immunostaining O
in O
the O
ipsilateral O
cortex. O
Triflusal B-CHEMICAL
(30 O
mg/kg) O
or O
aspirin B-CHEMICAL
treatment O
(30 O
mg/kg) O
did O
not O
reduce O
the O
levels O
of O
GFAP B-GENE-Y
or O
Hsp27 B-GENE-Y
immunostaining. O
Triflusal B-CHEMICAL
(30 O
mg/kg) O
also O
significantly O
decreased O
the O
protein O
levels O
of O
IL-Ibeta B-GENE-Y
but O

not O
nuclear B-GENE-N
factor I-GENE-N
kappa I-GENE-N
B I-GENE-N
or O
tumor B-GENE-Y
necrosis I-GENE-Y
factor-alpha I-GENE-Y
in O
the O
cortex O
ipsilateral O
to O
the O
middle O
cerebral O
artery O
occlusion. O
CONCLUSIONS: O
The O
results O
suggest O
that O
triflusal B-CHEMICAL
and O
aspirin B-CHEMICAL
appear O
to O
be O
equally O
neuroprotective O
against O
middle O
cerebral O
artery O
occlusion-induced O
cerebral O
ischemia. O
Therefore, O
strong O
rationale O
exists O
to O
continue O
the O
neuroprotective O
examination O
of O
triflusal B-CHEMICAL
in O
brain O
injury. O
Differential O
expression O
of O
glycans O
in O
the O
hippocampus O
of O
rats O
trained O
on O
an O
inhibitory O
learning O
paradigm. O
The O
glycan O
chains O

of O
glycoconjugates O
play O
important O
roles O
in O
cell-cell O
and O
cell-matrix O
interactions. O
In O
the O
CNS, O
previous O
studies O
on O
learning O
and O
memory O
suggest O
the O
importance O
of O
oligosaccharides O
attached O
to O
glycoconjugates O
in O
the O
modulation O
of O
synaptic O
connections. O
We O
studied O
the O
hippocampal O
glycan O
distribution O
of O
rats O
subject O
to O
an O
inhibitory O
avoidance O
task. O
The O
expression O
of O
glycans O
was O
examined O
by O
lectin-histochemistry B-GENE-N
using O
Vicia B-GENE-N
villosa I-GENE-N
lectin I-GENE-N
(VVL) B-GENE-N
for O
terminal O
alpha/beta B-CHEMICAL

N-acetylgalactosamine I-CHEMICAL
(alpha/beta B-CHEMICAL
GalNAc); I-CHEMICAL
Galanthus B-GENE-Y
nivalus I-GENE-Y
lectin I-GENE-Y
(GNL) B-GENE-Y
for O
terminal O
mannose B-CHEMICAL
alpha-1,3 I-CHEMICAL
(Man B-CHEMICAL
alpha-1,3); I-CHEMICAL
Peanut B-GENE-Y
agglutinin I-GENE-Y
(PNA) B-GENE-Y
for O
galactose B-CHEMICAL
beta-1,3N-acetylgalactosamine I-CHEMICAL
(Gal B-CHEMICAL
beta-1,3 I-CHEMICAL
GalNAc); I-CHEMICAL
Erythrina B-GENE-Y
cristagalli I-GENE-Y
lectin I-GENE-Y
(ECL) B-GENE-Y
for O
galactose B-CHEMICAL
beta-1,4 I-CHEMICAL
N-acetylglucosamine I-CHEMICAL

(Gal B-CHEMICAL
beta-1,4 I-CHEMICAL
GlcNAc); I-CHEMICAL
Sambucus B-GENE-Y
nigra I-GENE-Y
lectin I-GENE-Y
(SNA) B-GENE-Y
for O
sialic B-CHEMICAL
acid I-CHEMICAL
alpha-2.6 I-CHEMICAL
galactose I-CHEMICAL
(SA B-CHEMICAL
alpha-2,6 I-CHEMICAL
Gal); I-CHEMICAL
Maackia B-GENE-N
amurensis I-GENE-N
lectin I-GENE-N
II I-GENE-N
(MAL B-GENE-N
II) I-GENE-N
for O
sialic B-CHEMICAL
acid I-CHEMICAL
alpha-2,3 I-CHEMICAL
(SA B-CHEMICAL
alpha-2,3); I-CHEMICAL
Wheat B-GENE-N
germ I-GENE-N
agglutinin I-GENE-N
(WGA) B-GENE-N
for O
terminal O
N-acetylglucosamine B-CHEMICAL
with/ O
without O
sialic B-CHEMICAL
acid I-CHEMICAL
(GlcNAc B-CHEMICAL
wo O

SA); B-CHEMICAL
succynilated O
WGA O
(sWGA) O
for O
terminal O
N-acetylglucosamine B-CHEMICAL
without O
sialic B-CHEMICAL
acid I-CHEMICAL
(terminal O
GlcNAc B-CHEMICAL
without O
SA); B-CHEMICAL
Griffonia B-GENE-N
simplicifolia I-GENE-N
lectin I-GENE-N
II I-GENE-N
(GSL B-GENE-N
II) I-GENE-N
for O
terminal O
alpha/beta B-CHEMICAL
N-acetylglucosamine I-CHEMICAL
(alpha/beta B-CHEMICAL
GlcNAc I-CHEMICAL
terminal); O
and O
Lotus B-GENE-Y
tetragonolobus I-GENE-Y
lectin I-GENE-Y
(LTL) B-GENE-Y
alpha-fucose. B-CHEMICAL
Two O
groups O
of O
10 O
animals O
were O
examined: O
non-trained O
(Control) O
and O
Trained O
rats. O
ECL, B-GENE-N

sWGA B-GENE-N
and O
GSL B-GENE-N
II I-GENE-N
were O
negative O
for O
both O
groups O
in O
all O
the O
hippocampal O
subfields O
studied. O
For O
both O
groups, O
VVL O
was O
negative O
in O
CA4 O
and O
granular O
cells O
of O
the O
Dentate O
Gyrus O
(DG) O
and O
LTL O
was O
negative O
in O
the O
CA4 O
subfield. O
Expression O
of O
alpha/beta O
GalNAc, B-CHEMICAL
alpha-fucose B-CHEMICAL
and O
GlcNAc B-CHEMICAL
in O
other O
hippocampal O
subflields O
was O
positive, O
with O
no O
differences O
between O
groups. O
However, O
expression O
of O
Man B-CHEMICAL
alpha-1,3 I-CHEMICAL
was O
significantly O
higher O
in O
the O
CA1, O
CA2, O

CA3, O
and O
CA4 O
subfields O
in O
the O
Trained O
group. O
On O
the O
other O
hand, O
expression O
of O
Gal B-CHEMICAL
beta-1,3 I-CHEMICAL
GalNAc I-CHEMICAL
was O
significantly O
low O
in O
CA4 O
and O
DG O
in O
the O
Trained O
group. O
In O
conclusion, O
the O
results O
here O
presented O
indicate O
that O
the O
exposure O
of O
rats O
to O
an O
associative O
behavioral O
paradigm O
related O
to O
declarative O
memory, O
involves O
some O
regulatory O
mechanism/s O
for O
the O
differential O
patterns O
of O
glycan O
expression. O
Glutamate B-CHEMICAL
stimulates O
glutamate B-GENE-Y
receptor I-GENE-Y
interacting I-GENE-Y
protein I-GENE-Y
1 I-GENE-Y
degradation O
by O
ubiquitin-proteasome B-GENE-N
system O
to O
regulate O
surface O
expression O
of O

GluR2. B-GENE-Y
The O
glutamate B-CHEMICAL
receptor I-GENE-Y
interacting I-GENE-Y
protein I-GENE-Y
1 I-GENE-Y
(GRIP1) B-GENE-Y
is O
a O
scaffolding O
protein O
in O
postsynaptic O
density O
(PSD), O
tethering O
AMPA B-GENE-N
receptors I-GENE-N
to O
other O
signaling O
proteins. O
Here O
we O
report O
that O
glutamate B-CHEMICAL
stimulation O
caused O
a O
rapid O
reduction O
in O
protein O
levels O
of O
GRIP1, B-GENE-Y
but O
not O
that O
of O
glutamate B-CHEMICAL
receptor O
(GluR) B-GENE-Y
1, I-GENE-Y
GluR2 B-GENE-Y
and O
protein B-GENE-Y
interacting I-GENE-Y
with I-GENE-Y
C I-GENE-Y
kinase I-GENE-Y
1 I-GENE-Y
(PICK1) B-GENE-Y
in O
rat O
primary O
cortical O
neuron O
cultures. O
Down-regulation O
of O
GRIP1 B-GENE-Y
by O

glutamate B-CHEMICAL
was O
blocked O
by O
carbobenzoxyl-leucinyl-leucinyl-leucinal B-CHEMICAL
(MG132), B-CHEMICAL
a O
proteasome B-GENE-N
inhibitor O
and O
by O
expression O
of O
K48R-ubiquitin, B-GENE-N
a O
dominant O
negative O
form O
of O
ubiquitin. B-GENE-N
The O
GRIP1 B-GENE-Y
reduction O
was O
inhibited O
by O
MK-801, B-CHEMICAL
an O
N-methyl-d-aspartate B-GENE-N
(NMDA) I-GENE-N
receptor I-GENE-N
antagonist, O
but O
not O
by O
6-cyano-7-nitroquinoxaline-2,3-dione B-CHEMICAL

(CNQX), B-CHEMICAL
an O
AMPA B-GENE-N
receptor I-GENE-N
antagonist. O
EGTA B-CHEMICAL
and O
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra B-CHEMICAL
acetic I-CHEMICAL
acid I-CHEMICAL
tetrakis I-CHEMICAL
(BAPTA), B-CHEMICAL
two O
Ca2+ B-CHEMICAL
chelators, O
but O
not O
nifedipine, B-CHEMICAL
an O
L-type B-GENE-N
Ca2+ I-GENE-N
channel I-GENE-N
blocker, O
prevented O
GRIP1 B-GENE-Y
degradation. O
Furthermore, O
MG132 B-CHEMICAL
prevented O
glutamate-stimulated B-CHEMICAL
reduction O
in O
surface O
amount O
of O
GluR2, B-GENE-Y
and O
knockdown O
of O
GRIP1 B-GENE-Y
by O

RNAi O
against O
GRIP1 B-GENE-Y
reduced O
surface O
GluR2 B-GENE-Y
in O
neurons. O
Our O
results O
suggest O
that O
glutamate B-CHEMICAL
induces O
GRIP1 B-GENE-Y
degradation O
by O
proteasome B-GENE-N
through O
an O
NMDA B-CHEMICAL
receptor-Ca2+ I-GENE-N
pathway O
and O
that O
GRIP1 B-GENE-Y
degradation O
may O
play O
an O
important O
role O
in O
regulating O
GluR2 B-GENE-Y
surface O
expression. O
Transgenic O
expression O
of O
the O
human B-GENE-Y
Vitamin I-GENE-Y
D I-GENE-Y
receptor I-GENE-Y
(hVDR) B-GENE-Y
in O
the O
duodenum O
of O
VDR-null B-GENE-Y
mice O
attenuates O
the O
age-dependent O
decline O
in O
calcium B-CHEMICAL
absorption. O
1,25(OH)(2)D(3) B-CHEMICAL
regulates O
calcium B-CHEMICAL

homeostasis O
through O
its O
actions O
in O
the O
intestine, O
bone, O
and O
kidney. O
These O
actions O
are O
mediated O
through O
the O
VDR. B-GENE-Y
To O
determine O
if O
VDR's B-GENE-Y
actions O
in O
the O
proximal O
small O
intestine O
can O
sufficiently O
restore O
calcium B-CHEMICAL
homeostasis, O
we O
generated O
transgenic O
mice O
expressing O
hVDR B-GENE-Y
exclusively O
in O
the O
duodenum O
of O
mVDR-null B-GENE-Y
mice O
by O
using O
the O
adenosine B-CHEMICAL
deaminase I-GENE-N
enhancer I-GENE-N
(hVDR+/mVDR-null). B-GENE-Y
Unlike O
wild-type O
mice, O
hVDR+/mVDR-null B-GENE-Y
mice O
express O
hVDR B-GENE-Y
and O
VDR B-GENE-Y
target O
genes O
only O
in O

the O
proximal O
small O
intestine. O
Despite O
having O
functional O
hVDR B-GENE-Y
in O
the O
proximal O
small O
intestine, O
hVDR+/mVDR-null B-GENE-Y
mice O
were O
hypocalcaemic O
when O
fed O
a O
normal O
rodent O
diet O
at O
weaning, O
like O
mVDR-null B-GENE-Y
mice O
fed O
the O
same O
diet. O
The O
hypocalcemia O
in O
these O
mice O
is O
prevented O
if O
they O
are O
given O
the O
rescue O
diet O
before O
weaning. O
However, O
when O
90-day-old O
rachitic O
mice O
were O
fed O
a O
rescue O
diet, O
serum O
calcium B-CHEMICAL
improved O
in O
hVDR+/mVDR-null B-GENE-Y
mice, O
but O
not O

in O
mVDR-null B-GENE-Y
mice. O
In O
conclusion, O
transgenic O
hVDR B-GENE-Y
in O
the O
proximal O
small O
intestine O
of O
hVDR+/mVDR-null B-GENE-Y
mice O
was O
transcriptionally O
active O
and O
regulated O
calcium B-CHEMICAL
absorption, O
but O
VDR B-GENE-Y
actions O
elsewhere O
in O
the O
intestine O
are O
probably O
necessary O
to O
support O
adequate O
calcium B-CHEMICAL
homeostasis. O
In O
addition, O
hVDR+/mVDR-null B-GENE-Y
mice O
responded O
better O
to O
the O
late O
rescue O
diet O
suggesting O
that O
expression O
of O
VDR B-GENE-Y
in O
the O
proximal O
small O
intestine O
protected O
the O
calcium B-CHEMICAL
absorbing O
machinery O
from O
age-dependent O
decline. O
The O
inhibitory O
effect O
of O
the O
leukotriene B-GENE-N
receptor I-GENE-N
antagonist O
on O

leukotriene B-CHEMICAL
D4-induced I-CHEMICAL
MUC2/5AC B-GENE-N
gene O
expression O
and O
mucin B-GENE-N
secretion O
in O
human O
airway O
epithelial O
cells. O
OBJECTIVES: O
Mucin B-GENE-N
gene O
expression O
and O
mucin B-GENE-N
production O
are O
markedly O
increased O
in O
inflammatory O
airway O
disorders O
such O
as O
asthma, O
chronic O
bronchitis O
and O
rhinosinusitis. O
Cytokines, B-GENE-N
lipopolysaccharides O
and O
other O
inflammatory O
mediators O
such O
as O
prostaglandin B-CHEMICAL
and O
leukotriene B-CHEMICAL
are O
related O
to O
the O
secretion O
and O
production O
of O
mucin. B-GENE-N
However, O
the O
relationship O
of O

leukotrienes B-CHEMICAL
with O
mucin B-GENE-N
genes O
expression O
is O
not O
clear. O
The O
aim O
of O
this O
study O
is O
to O
evaluate O
MUC2/5AC B-GENE-N
gene O
expression O
and O
mucin B-GENE-N
secretion O
by O
the O
leukotriene B-CHEMICAL
receptor I-GENE-N
in O
human O
airway O
epithelial O
cells. O
METHODS: O
The O
effect O
of O
leukotriene B-CHEMICAL
D(4) I-CHEMICAL
and O
the O
leukotriene B-GENE-N
receptor I-GENE-N
antagonist, O
pranlukast B-CHEMICAL
hydrate I-CHEMICAL
(ONO-1078) B-CHEMICAL
on O
the O
regulation O
of O
MUC2/5AC B-GENE-N
gene O
expression O
and O
mucin B-GENE-N
secretion O
were O
observed O
in O
human O
airway O
NCI-H292 O

epithelial O
cells. O
The O
mRNA O
levels O
of O
MUC2/5AC B-GENE-N
and O
the O
amount O
of O
mucin B-GENE-N
were O
determined O
by O
reverse O
transcription-polymerase O
chain O
reaction O
(RT-PCR) O
and O
immunoassay. O
RESULTS: O
Leukotriene B-CHEMICAL
D(4) I-CHEMICAL
upregulated O
MUC2/5AC B-GENE-N
gene O
expression O
and O
mucin B-GENE-N
secretion O
in O
a O
dose O
dependent O
pattern. O
Pranlukast B-CHEMICAL
hydrate I-CHEMICAL
(ONO-1078, B-CHEMICAL
100 O
microM) O
downregulated O
the O
leukotriene B-CHEMICAL
D(4)-induced I-CHEMICAL

MUC2/5AC B-GENE-N
gene O
expression O
and O
mucin B-GENE-N
secretion. O
CONCLUSION: O
These O
results O
suggest O
that O
the O
leukotriene B-CHEMICAL
receptor I-GENE-N
system O
is O
one O
of O
the O
mechanisms O
related O
to O
MUC2/5AC B-GENE-N
gene O
expression O
and O
mucin B-GENE-N
secretion O
in O
the O
human O
airway O
epithelium. O
Effect O
of O
isolated O
isoflavone B-CHEMICAL
supplementation O
on O
ABCA1-dependent B-GENE-Y
cholesterol B-CHEMICAL
efflux O
potential O
in O
postmenopausal O
women. O
OBJECTIVE: O
Isoflavones B-CHEMICAL
may O
display O
beneficial O
health O
effects O
in O
postmenopausal O
women. O
We O
studied O
in O
a O
clinical O
trial O
whether O

isolated O
isoflavone B-CHEMICAL
treatment O
in O
postmenopausal O
women O
could O
affect O
reverse O
cholesterol B-CHEMICAL
transport O
as O
evaluated O
by O
adenosine B-GENE-Y
triphosphate-binding I-GENE-Y
cassette I-GENE-Y
A1- I-GENE-Y
(ABCA1), B-GENE-Y
dependent O
cholesterol B-CHEMICAL
efflux O
from O
macrophages. O
In O
addition, O
various O
serum O
lipid O
and O
lipoprotein B-GENE-N
parameters O
were O
investigated. O
Furthermore, O
we O
separately O
assessed O
equol-producing O
and O
non-equol-producing O
women. O
DESIGN: O
Postmenopausal O
women O
(n=56) O
were O
treated O
with O
either O
isoflavone B-CHEMICAL
or O
placebo O
tablets O
for O
3 O
months O
in O

a O
crossover O
design, O
separated O
by O
a O
2-month O
washout O
period. O
Fifteen O
women O
were O
classified O
as O
equol O
producers, O
and O
15 O
women O
were O
classified O
as O
non-equol O
producers. O
Serum O
samples O
were O
collected O
before O
and O
after O
each O
treatment O
period. O
[H]-Cholesterol-labeled B-CHEMICAL
J774 O
macrophage O
cells, O
with O
and O
without O
ABCA1 B-GENE-Y
up-regulation, O
were O
incubated O
with O
the O
samples, O
and O
ABCA1-dependent B-GENE-Y
cholesterol B-CHEMICAL
efflux O
and O
serum O
lipid O
and O
lipoprotein B-GENE-N
levels O
were O
assessed. O
RESULTS: O
Serum O
promoted O

3.1%+/-1.1% O
and O
3.2%+/-1.1% O
cholesterol B-CHEMICAL
efflux O
from O
macrophages O
after O
isoflavone B-CHEMICAL
and O
placebo O
treatment, O
respectively. O
Thus, O
isoflavone B-CHEMICAL
supplementation O
did O
not O
affect O
ABCA1-dependent B-GENE-Y
cholesterol B-CHEMICAL
efflux O
to O
serum. O
However, O
as O
a O
novel O
finding, O
isoflavone B-CHEMICAL
treatment O
increased O
a O
subclass O
of O
high-density B-GENE-N
lipoprotein, I-GENE-N
the O
pre-beta B-GENE-N
high-density I-GENE-N
lipoprotein I-GENE-N
levels O
by O
18% O
without O
affecting O
any O
other O
serum O
lipid O
concentrations. O

ABCA1-facilitated B-GENE-Y
cholesterol B-CHEMICAL
efflux O
and O
lipid O
parameters O
did O
not O
differ O
between O
equol-producing B-CHEMICAL
and O
non-equol-producing B-CHEMICAL
women. O
CONCLUSION: O
In O
postmenopausal O
women, O
isolated O
isoflavone B-CHEMICAL
treatment O
does O
not O
affect O
ABCA1-dependent B-GENE-Y
cholesterol B-CHEMICAL
efflux O
potential O
from O
macrophages O
but O
increases O
circulating O
pre-beta B-GENE-N
high-density I-GENE-N
lipoprotein I-GENE-N
level, O
which O
could O
provide O
beneficial O
vascular O
effects. O
The O
ability O
of O
sorafenib B-CHEMICAL
to O
inhibit O
oncogenic O
PDGFRbeta B-GENE-Y
and O
FLT3 B-GENE-Y
mutants O
and O

overcome O
resistance O
to O
other O
small O
molecule O
inhibitors. O
BACKGROUND O
AND O
OBJECTIVES: O
Activated O
tyrosine B-GENE-N
kinases I-GENE-N
are O
implicated O
in O
the O
pathogenesis O
of O
chronic O
and O
acute O
leukemia, O
and O
represent O
attractive O
targets O
for O
therapy. O
Sorafenib B-CHEMICAL
(BAY43-9006, B-CHEMICAL
Nexavar) B-CHEMICAL
is O
a O
small O
molecule O
B-RAF B-GENE-Y
inhibitor O
that O
is O
used O
for O
the O
treatment O
of O
renal O
cell O
carcinoma, O
and O
has O
been O
shown O
to O
have O
activity O
against O
receptor B-GENE-N
tyrosine I-GENE-N
kinases I-GENE-N
from O
the O
platelet-derived B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(PDGFR) B-GENE-Y
and O
vascular B-GENE-N

endothelial I-GENE-N
growth I-GENE-N
factor I-GENE-N
receptor I-GENE-N
(VEGFR) B-GENE-N
families. O
We O
investigated O
the O
efficacy O
of O
sorafenib B-CHEMICAL
at O
inhibiting O
mutants O
of O
the O
receptor B-GENE-N
tyrosine I-GENE-N
kinases I-GENE-N
PDGFRbeta, B-GENE-Y
KIT, B-GENE-Y
and O
FLT3, B-GENE-Y
which O
are O
implicated O
in O
the O
pathogenesis O
of O
myeloid O
malignancies. O
DESIGN O
AND O
METHODS: O
We O
tested O
the O
effect O
of O
sorafenib B-CHEMICAL
on O
the O
proliferation O
of O
hematopoietic O
cells O
transformed O
by O
ETV6-PDGFRbeta, B-GENE-Y
FLT3 B-GENE-Y
with O
an O
internal O
tandem O
duplication O
or O

D835Y B-GENE-N
point O
mutation, O
and O
the O
KIT(D816V) B-GENE-Y
mutant. O
The O
direct O
effect O
of O
sorafenib B-CHEMICAL
on O
the O
activity O
of O
these O
kinases B-GENE-N
and O
their O
downstream O
signaling O
was O
tested O
using O
phospho-specific B-CHEMICAL
antibodies. O
RESULTS: O
We O
show O
that O
sorafenib B-CHEMICAL
is O
a O
potent O
inhibitor O
of O
ETV6-PDGFRbeta B-GENE-Y
and O
FLT3 B-GENE-Y
mutants, O
including O
some O
of O
the O
mutants O
that O
confer O
resistance O
to O
PKC412 O
and O
other O
FLT3 B-GENE-Y
inhibitors. O
Sorafenib B-CHEMICAL
induced O
a O
cell O
cycle O
block O
and O
apoptosis O
in O
the O
acute O

myeloid O
leukemia O
cell O
lines O
MV4-11 O
and O
MOLM-13, O
both O
expressing O
FLT3 B-GENE-Y
with O
an O
internal O
tandem O
duplication, O
whereas O
no O
effect O
was O
observed O
on O
four O
other O
acute O
myeloid O
leukemia O
cell O
lines. O
The O
imatinib-resistant B-CHEMICAL
KIT(D816V) B-GENE-Y
mutant, O
associated O
with O
systemic O
mastocytosis, O
was O
found O
to O
be O
resistant O
to O
sorafenib. B-CHEMICAL
INTERPRETATION O
AND O
CONCLUSIONS: O
These O
results O
warrant O
further O
clinical O
studies O
of O
sorafenib B-CHEMICAL
for O
the O
treatment O
of O
myeloid O
malignancies O
expressing O
activated O
forms O
of O

PDGFRbeta B-GENE-Y
and O
FLT3. B-GENE-Y
Glucocorticoids O
stimulate O
ENaC B-GENE-N
upregulation O
in O
bovine O
mammary O
epithelium. O
Mammary O
epithelia O
produce O
an O
isotonic, O
low-Na(+) B-CHEMICAL
fluid O
that O
is O
rich O
in O
nutrients. O
Mechanisms O
that O
account O
for O
the O
low O
electrolyte O
concentration O
have O
not O
been O
elucidated, O
although O
amiloride-sensitive B-CHEMICAL
ion O
transport O
has O
been O
reported O
in O
some O
situations. O
We O
hypothesized O
that O
corticosteroid O
exposure O
modulates O
epithelial B-GENE-N
Na(+) B-CHEMICAL
channel I-GENE-N

(ENaC) B-GENE-N
expression O
and/or O
activity O
in O
bovine O
mammary O
epithelial O
cells. O
BME-UV O
cells O
were O
grown O
to O
confluent O
monolayers O
on O
permeable O
supports O
with O
a O
standard O
basolateral O
medium O
and O
apical O
medium O
of O
low-electrolyte, O
high-lactose B-CHEMICAL
composition O
that O
resembles O
the O
ionic O
composition O
of O
milk. O
Ion O
transport O
was O
assessed O
in O
modified O
Ussing O
flux O
chambers. O
Exposure O
to O
glucocorticoids O
(dexamethasone, B-CHEMICAL
cortisol, B-CHEMICAL
or O
prednisolone), B-CHEMICAL
but O
not O
aldosterone, B-CHEMICAL
increased O

short-circuit O
current O
(I(sc)), O
a O
sensitive O
measure O
of O
net O
ion O
transport, O
whereas O
apical O
exposure O
to O
amiloride B-CHEMICAL
or O
benzamil B-CHEMICAL
reduced O
corticosteroid-induced O
I(sc) O
close O
to O
basal O
levels. O
Quantitative O
RT-PCR O
indicated O
a O
glucocorticoid-induced O
increase O
in O
mRNA O
for O
beta- B-GENE-N
and I-GENE-N
gamma-ENaC, I-GENE-N
whereas O
alpha-ENaC B-GENE-Y
mRNA O
expression O
was O
only O
mildly O
affected. O
Exposure O
to O
mifepristone B-CHEMICAL
(a O
glucocorticoid B-GENE-Y
receptor I-GENE-Y
antagonist), O
but O
not O
spironolactone B-CHEMICAL

(a O
mineralocorticoid B-GENE-N
receptor I-GENE-N
antagonist), O
precluded O
both O
the O
corticosteroid-induced O
elevation O
in O
amiloride-sensitive B-CHEMICAL
I(sc) O
and O
the O
induced O
changes O
in O
beta- B-GENE-N
and I-GENE-N
gamma-ENaC I-GENE-N
mRNA. O
We O
conclude O
that O
Na(+) B-CHEMICAL
movement O
across O
mammary O
epithelia O
is O
modulated O
by O
corticosteroids O
via O
a O
glucocorticoid B-GENE-Y
receptor-mediated I-GENE-Y
mechanism O
that O
regulates O
the O
expression O
of O
the O
beta- B-GENE-N
and I-GENE-N
gamma-subunits I-GENE-N
of I-GENE-N
ENaC. I-GENE-N
ENaC B-GENE-N
expression O
and O
activity O
could O
account O
for O
the O
low O
Na(+) B-CHEMICAL
concentration O

that O
is O
typical O
of O
milk. O
Salicylate-based B-CHEMICAL
anti-inflammatory O
drugs O
inhibit O
the O
early O
lesion O
of O
diabetic O
retinopathy. O
It O
has O
been O
previously O
reported O
that O
aspirin B-CHEMICAL
inhibited O
the O
development O
of O
diabetic O
retinopathy O
in O
diabetic O
animals, O
raising O
the O
possibility O
that O
anti-inflammatory O
drugs O
may O
have O
beneficial O
effects O
on O
diabetic O
retinopathy. O
To O
further O
explore O
this, O
we O
compared O
effects O
of O
oral O
consumption O
of O
three O
different O
salicylate-based B-CHEMICAL
drugs O
(aspirin, B-CHEMICAL
sodium B-CHEMICAL
salicylate, I-CHEMICAL
and O
sulfasalazine) B-CHEMICAL
on O
the O
development O
of O
early O
stages O
of O
diabetic O

retinopathy O
in O
rats. O
These O
three O
drugs O
differ O
in O
their O
ability O
to O
inhibit O
cyclooxygenase B-GENE-N
but O
share O
an O
ability O
to O
inhibit O
nuclear B-GENE-N
factor-kappaB I-GENE-N
(NF-kappaB). B-GENE-N
Diabetes O
of O
9-10 O
months O
duration O
significantly O
increased O
the O
number O
of O
TUNEL O
(transferase-mediated O
dUTP O
nick-end O
labeling)-positive O
capillary O
cells O
and O
acellular O
(degenerate) O
capillaries O
in O
the O
retinal O
vasculature, O
and O
all O
three O
salicylate-based B-CHEMICAL
drugs O
inhibited O
this O
cell O
death O
and O
formation O
of O

acellular O
capillaries O
without O
altering O
the O
severity O
of O
hyperglycemia. O
In O
short-term O
diabetes O
(2-4 O
months), O
all O
three O
salicylates B-CHEMICAL
inhibited O
the O
diabetes-induced O
loss O
of O
neuronal O
cells O
from O
the O
ganglion O
cell O
layer. O
Oral O
aspirin B-CHEMICAL
(as O
a O
representative O
of O
the O
salicylate B-CHEMICAL
family) O
inhibited O
diabetes-induced O
increase O
in O
NF-kappaB B-GENE-N
DNA-binding O
affinity O
in O
electrophoretic O
mobility O
shift O
assay O
and O
transcription O
factor O
array O
in O
nuclear O
extract O
isolated O
from O
whole O
retina. O
All O
three O
salicylates B-CHEMICAL
inhibited O
the O
diabetes-induced O
translocation O

of O
p50 B-GENE-Y
(a O
subunit O
of O
NF-kappaB) B-GENE-N
into O
nuclei O
of O
retinal O
vascular O
endothelial O
cells O
of O
the O
isolated O
retinal O
vasculature, O
as O
well O
as O
of O
p50 B-GENE-Y
and O
p65 B-GENE-Y
into O
nuclei O
of O
cells O
in O
the O
ganglion O
cell O
layer O
and O
inner O
nuclear O
layer O
on O
whole-retinal O
sections. O
Sulfasalazine B-CHEMICAL
(also O
as O
a O
representative O
of O
the O
salicylates) B-CHEMICAL
inhibited O
the O
diabetes-induced O
upregulation O
of O
several O
inflammatory O
gene O
products, O
which O
are O
regulated O
by O
NF-kappaB, B-GENE-N
including O
vascular O
cell O
adhesion O
molecule, O
intracellular B-GENE-Y
adhesion I-GENE-Y

molecule-1, I-GENE-Y
inducible B-GENE-Y
nitric B-CHEMICAL
oxide I-CHEMICAL
synthase, I-GENE-Y
and O
cyclooxygenase-2 B-GENE-Y
in O
whole-retinal O
lysate. O
Salicylates, B-CHEMICAL
in O
doses O
administrated O
in O
our O
experiments, O
inhibited O
NF-kappaB B-GENE-N
and O
perhaps O
other O
transcription O
factors O
in O
the O
retina, O
were O
well O
tolerated, O
and O
offered O
new O
tools O
to O
investigate O
and O
inhibit O
the O
development O
of O
diabetic O
retinopathy. O
Localization O
of O
an O
11 B-GENE-Y
beta I-GENE-Y
hydroxysteroid I-GENE-Y
dehydrogenase I-GENE-Y
activity O
to O
the O
distal O
nephron. O
Evidence O
for O
the O
existence O
of O
two O
species O
of O

dehydrogenase B-GENE-N
in O
the O
rat O
kidney. O
An O
11 B-GENE-Y
beta I-GENE-Y
hydroxysteroid I-GENE-Y
dehydrogenase I-GENE-Y
(11 B-GENE-Y
beta I-GENE-Y
HSD) I-GENE-Y
activity O
has O
been O
localized O
in O
the O
rat O
kidney O
by O
a O
histochemical O
technique O
which O
links O
steroid B-CHEMICAL
metabolism O
with O
the O
production O
of O
a O
color O
reaction. O
Oxidation O
of O
11 B-CHEMICAL
beta-hydroxyandrostenedione I-CHEMICAL
was O
observed O
in O
cortical O
distal O
convoluted O
tubules O
and O
in O
medullary O
collecting O
ducts. O
Carbenoxolone B-CHEMICAL
abolished O
staining, O
no O
reaction O
was O
obtained O
with O
androstenedione B-CHEMICAL
hydroxylated O
at O
the O
17 O
or O
19 O
position, O

and O
oxidation O
of O
11 B-CHEMICAL
beta-hydroxyandrostenedione I-CHEMICAL
was O
nicotinamide-adenine B-CHEMICAL
dinucleotide I-CHEMICAL
(NAD) B-CHEMICAL
dependent. O
These O
results O
demonstrate O
the O
presence O
of O
a O
dehydrogenase B-GENE-N
activity O
separate O
from O
the O
nicotinamide-adenine B-CHEMICAL
dinucleotide I-CHEMICAL
phosphate I-CHEMICAL
(NADP)-dependent B-CHEMICAL
11 B-GENE-Y
beta I-GENE-Y
hydroxysteroid I-GENE-Y
dehydrogenase I-GENE-Y
recently O
purified O
and O
cloned O
from O
rat O
liver. O
We O
have O
named O
this O
activity O
11 B-GENE-Y
beta I-GENE-Y
HSD2 I-GENE-Y
to O
distinguish O
it O
from O
the O
NADP-dependent B-CHEMICAL
11 B-GENE-Y
beta I-GENE-Y
HSD. I-GENE-Y
Histological O
studies O
showed O
that O
11 B-GENE-Y
beta I-GENE-Y

HSD2 I-GENE-Y
activity O
does O
not O
correlate O
with O
the O
immunocytochemical O
localization O
of O
the O
previously O
defined O
11 B-GENE-Y
beta I-GENE-Y
HSD I-GENE-Y
enzyme, O
but O
rather O
the O
11 B-GENE-Y
beta I-GENE-Y
HSD2 I-GENE-Y
activity O
is O
localized O
in O
the O
distal O
tubules O
of O
the O
rat O
kidney. O
In O
this O
respect O
11 B-GENE-Y
beta I-GENE-Y
HSD2 I-GENE-Y
colocalizes O
with O
the O
mineralocorticoid B-GENE-Y
receptor. I-GENE-Y
No O
reaction O
product O
was O
obtained O
using O
cortisol B-CHEMICAL
or O
corticosterone B-CHEMICAL
as O
substrate O
with O
either O
NAD B-CHEMICAL
or O
NADP B-CHEMICAL
as O
cofactor. O
Furthermore O
incubation O
of O
tissue O
sections O
with O
11 B-CHEMICAL
beta I-CHEMICAL
androstenedione I-CHEMICAL
in O
the O
presence O
of O

deoxycorticosterone B-CHEMICAL
completely O
inhibited O
cytochemical O
staining. O
We O
interpret O
these O
results O
as O
evidence O
of O
20 B-GENE-N
reductase I-GENE-N
activity O
which O
uses O
the O
reduced O
cofactor O
at O
the O
expense O
of O
the O
color O
reaction. O
These O
results O
support O
the O
crucial O
role O
played O
by O
an O
11 B-CHEMICAL
beta I-CHEMICAL
hydroxysteroid I-CHEMICAL
dehydrogenase I-GENE-Y
in O
the O
local O
protection O
of O
type O
I O
receptors O
in O
mineralocorticoid O
selective O
tissues. O
Effect O
of O
long-term O
fluoxetine B-CHEMICAL
treatment O
on O
the O
human B-GENE-Y
serotonin I-GENE-Y
transporter I-GENE-Y
in O
Caco-2 O
cells. O
Fluoxetine B-CHEMICAL
is O
a O
selective O
serotonin B-CHEMICAL
reuptake O
inhibitor O

(SSRI) O
broadly O
used O
in O
the O
treatment O
of O
human O
mood O
disorders O
and O
gastrointestinal O
diseases O
involving O
the O
serotoninergic O
system. O
The O
effectiveness O
of O
this O
therapy O
depends O
on O
repeated O
long-term O
treatment. O
Most O
of O
the O
long-term O
studies O
in O
vivo O
of O
SSRI O
effects O
on O
serotoninergic O
activity O
have O
focused O
on O
their O
effects O
on O
autoreceptors O
or O
postsynaptic O
receptors. O
The O
chronic O
effect O
of O
SSRIs O
on O
the O
activity O
of O
the O
serotonin B-CHEMICAL
transporter I-GENE-Y
(SERT) B-GENE-Y
has O
been O
less O
studied O
and O
the O
results O
have O
been O
contradictory. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
specific O
effect O

of O
long-term O
fluoxetine B-CHEMICAL
treatment O
on O
human B-GENE-Y
serotonin B-CHEMICAL
transporter I-GENE-Y
(hSERT) B-GENE-Y
in O
vitro, O
by O
using O
the O
human O
enterocyte-like O
cell O
line O
Caco-2. O
Results O
show O
that O
fluoxetine B-CHEMICAL
diminished O
the O
5-HT B-CHEMICAL
uptake O
in O
a O
concentration-dependent O
way O
and O
that O
this O
effect O
was O
reversible. O
Fluoxetine B-CHEMICAL
affected O
mainly O
the O
hSERT B-GENE-Y
transport O
rate O
by O
reducing O
the O
availability O
of O
the O
transporter O
in O
the O
membrane O
with O
no O
significant O
alteration O
of O
either O
the O
total O
hSERT B-GENE-Y
protein O
content O
or O
the O
hSERT B-GENE-Y
mRNA O
level. O
These O
results O
suggest O
that O
the O
effect O
of O

fluoxetine B-CHEMICAL
on O
the O
expression O
of O
hSERT B-GENE-Y
is O
post-translational O
and O
has O
shown O
itself O
to O
be O
independent O
of O
PKC B-GENE-N
and O
PKA B-GENE-N
activity. O
This O
study O
may O
be O
useful O
to O
clarify O
the O
effect O
of O
the O
long-term O
fluoxetine B-CHEMICAL
therapy O
in O
both O
gastrointestinal O
and O
central O
nervous O
system O
disorders. O
Roles O
played O
by O
lymphocyte B-GENE-Y
function-associated I-GENE-Y
antigen-1 I-GENE-Y
in O
the O
regulation O
of O
lymphocytic O
cholinergic O
activity. O
Lymphocytes O
possess O
the O
essential O
components O
of O
a O
cholinergic O
system, O
including O
acetylcholine B-CHEMICAL
(ACh); B-CHEMICAL
choline B-CHEMICAL

acetyltransferase I-GENE-Y
(ChAT), B-GENE-Y
its O
synthesizing O
enzyme; O
and O
both O
muscarinic B-GENE-N
and I-GENE-N
nicotinic I-GENE-N
ACh B-CHEMICAL
receptors I-GENE-N
(mAChRs B-GENE-N
and O
nAChRs, B-GENE-N
respectively). O
Stimulation O
of O
lymphocytes O
with O
phytohemagglutinin, B-GENE-N
which O
activates O
T O
cells O
via O
the O
T B-GENE-N
cell I-GENE-N
receptor/CD3 I-GENE-N
complex, O
enhances O
the O
synthesis O
and O
release O
of O
ACh B-CHEMICAL
and O
up-regulates O
expression O
of O
ChAT B-GENE-Y
and O
M(5) B-GENE-Y
mAChR I-GENE-Y
mRNAs. O
In O
addition, O
activation O
of O
protein B-GENE-N
kinase I-GENE-N
C I-GENE-N
and O
increases O
in O

intracellular O
cAMP B-CHEMICAL
also O
enhance O
cholinergic O
activity O
in O
T O
cells, O
and O
lymphocyte B-GENE-Y
function I-GENE-Y
associated I-GENE-Y
antigen-1 I-GENE-Y
(LFA-1; B-GENE-Y
CD11a/CD18) B-GENE-Y
is O
an O
important O
mediator O
of O
leukocyte O
migration O
and O
T O
cell O
activation. O
Anti-CD11a B-GENE-Y
monoclonal O
antibody O
(mAb) O
as O
well O
as O
antithymocyte O
globulin B-GENE-N
containing O
antibodies O
against O
CD2, B-GENE-Y
CD7 B-GENE-Y
and O
CD11a B-GENE-Y
all O
increase O
ChAT B-GENE-Y
activity, O
ACh B-CHEMICAL
synthesis O
and O
release, O
and O
expression O
of O
ChAT B-GENE-Y
and O
M(5) B-GENE-Y
mAChR I-GENE-Y
mRNAs O
in O

T O
cells. O
The O
cholesterol-lowering B-CHEMICAL
drug O
simvastatin O
inhibits O
LFA-1 B-GENE-Y
signaling O
by O
binding O
to O
an O
allosteric O
site O
on O
CD11a B-GENE-Y
(LFA-1 B-GENE-Y
alpha I-GENE-Y
chain), O
which O
leads O
to O
immunomodulation. O
We O
found O
that O
simvastatin B-CHEMICAL
abolishes O
anti-CD11a B-GENE-Y
mAb-induced O
increases O
in O
lymphocytic O
cholinergic O
activity O
in O
a O
manner O
independent O
of O
its O
cholesterol-lowering B-CHEMICAL
activity. O
Collectively O
then, O
these O
results O
indicate O
that O
LFA-1 B-GENE-Y
contributes O
to O
the O
regulation O
of O
lymphocytic O
cholinergic O
activity O
via O

CD11a-mediated B-GENE-Y
pathways O
and O
suggest O
that O
simvastatin B-CHEMICAL
exerts O
its O
immunosuppressive O
effects O
in O
part O
via O
modification O
of O
lymphocytic O
cholinergic O
activity. O
Association O
of O
estrogen B-GENE-Y
receptor-alpha I-GENE-Y
and O
progesterone B-GENE-Y
receptor I-GENE-Y
A O
expression O
with O
hormonal O
mammary O
carcinogenesis: O
role O
of O
the O
host O
microenvironment. O
INTRODUCTION: O
Medroxyprogesterone B-CHEMICAL
acetate I-CHEMICAL
(MPA) B-CHEMICAL
induces O
estrogen B-GENE-Y
receptor I-GENE-Y
(ER)-positive B-GENE-Y
and O
progesterone B-GENE-Y
receptor I-GENE-Y
(PR)-positive B-GENE-Y
ductal O
invasive O
mammary O

carcinomas O
in O
BALB/c O
mice. O
We O
sought O
to O
reproduce O
this O
MPA B-CHEMICAL
cancer O
model O
in O
C57BL/6 O
mice O
because O
of O
their O
widespread O
use O
in O
genetic O
engineering. O
Within O
this O
experimental O
setting, O
we O
studied O
the O
carcinogenic O
effects O
of O
MPA, B-CHEMICAL
the O
morphologic O
changes O
in O
mammary O
glands O
that O
are O
induced O
by O
MPA B-CHEMICAL
and O
progesterone, B-CHEMICAL
and O
the O
levels O
of O
ER B-GENE-Y
and O
PR B-GENE-Y
expression O
in O
MPA-treated B-CHEMICAL
and O
progesterone-treated B-CHEMICAL
mammary O
glands. O
Finally, O
we O
evaluated O
whether O
the O
differences O
found O
between O
BALB/c O
and O
C57BL/6 O
mouse O
strains O

were O
due O
to O
intrinsic O
differences O
in O
epithelial O
cells. O
METHODS: O
The O
carcinogenic O
effect O
of O
MPA B-CHEMICAL
was O
evaluated O
in O
C57BL/6 O
mice O
using O
protocols O
proven O
to O
be O
carcinogenic O
in O
BALB/c O
mice. O
In O
addition, O
BALB/c O
and O
C57BL/6 O
females O
were O
treated O
with O
progesterone B-CHEMICAL
or O
MPA B-CHEMICAL
for O
1 O
or O
2 O
months, O
and O
mammary O
glands O
were O
excised O
for O
histologic O
studies O
and O
for O
immunohistochemical O
and O
Western O
blot O
evaluation O
of O
ER B-GENE-Y
and O
PR. B-GENE-Y
Hormone O
levels O
were O
determined O
by O

radioimmunoassay. O
Isolated O
mammary O
epithelial O
cells O
were O
transplanted O
into O
cleared O
fat O
pads O
of O
21-day-old O
female O
Swiss O
nu/nu O
mice O
or O
control O
congenic O
animals. O
RESULTS: O
MPA B-CHEMICAL
failed O
to O
induce O
mammary O
carcinomas O
or O
significant O
morphologic O
changes O
in O
the O
mammary O
glands O
of O
C57BL/6 O
mice. O
The O
expression O
of O
ER-alpha B-GENE-Y
and O
PR B-GENE-Y
isoform I-GENE-Y
A I-GENE-Y
in O
virgin O
mice O
was O
surprisingly O
much O
higher O
in O
BALB/c O
than O
in O
C57BL/6 O
mammary O
glands, O
and O
both O

receptors O
were O
downregulated O
in O
progestin-treated B-CHEMICAL
BALB/c O
mice O
(P O
< O
0.05). O
PR B-GENE-Y
isoform I-GENE-Y
B I-GENE-Y
levels O
were O
low O
in O
virgin O
control O
mice O
and O
increased O
after O
progestin B-CHEMICAL
treatment O
in O
both O
strains. O
ER-beta B-GENE-Y
expression O
followed O
a O
similar O
trend. O
No O
differences O
in O
hormone O
levels O
were O
found O
between O
strains. O
Surprisingly, O
the O
transplantation O
of O
the O
epithelial O
mammary O
gland O
cells O
of O
both O
strains O
into O
the O
cleared O
fat O
pads O
of O
Swiss O
(nu/nu) O
mice O
abolished O
the O
mammary O
gland O
morphologic O
differences O
and O
the O
ER B-GENE-Y
and O
PR B-GENE-Y
differences O
between O

strains. O
CONCLUSION: O
C57BL/6 O
mammary O
glands O
are O
resistant O
to O
MPA-induced B-CHEMICAL
carcinogenesis O
and O
to O
hormone O
action. O
MPA B-CHEMICAL
and O
progesterone B-CHEMICAL
have O
different O
effects O
on O
mammary O
glands. O
Low O
ER-alpha B-GENE-Y
and O
PR-A B-GENE-Y
levels O
in O
untreated O
mammary O
glands O
may O
be O
associated O
with O
a O
low-risk O
breast O
cancer O
profile. O
Although O
we O
cannot O
at O
this O
time O
rule O
out O
the O
participation O
of O
other, O
untested O
factors, O
our O
findings O
implicate O
the O
stroma O
as O
playing O
a O
crucial O
role O
in O
the O
strain-specific O
differential O
hormone B-GENE-N
receptor I-GENE-N
expression O
and O
hormone O

responsiveness. O
Transplacental O
exposure O
to O
inorganic B-CHEMICAL
arsenic I-CHEMICAL
at O
a O
hepatocarcinogenic O
dose O
induces O
fetal O
gene O
expression O
changes O
in O
mice O
indicative O
of O
aberrant O
estrogen B-CHEMICAL
signaling O
and O
disrupted O
steroid B-CHEMICAL
metabolism. O
Exposure O
to O
inorganic B-CHEMICAL
arsenic I-CHEMICAL
in O
utero O
in O
C3H O
mice O
produces O
hepatocellular O
carcinoma O
in O
male O
offspring O
when O
they O
reach O
adulthood. O
To O
help O
define O
the O
molecular O
events O
associated O
with O
the O
fetal O
onset O
of O
arsenic B-CHEMICAL
hepatocarcinogenesis, O
pregnant O
C3H O
mice O
were O
given O
drinking O
water O
containing O
0 O
(control) O
or O
85 O

ppm O
arsenic B-CHEMICAL
from O
day O
8 O
to O
18 O
of O
gestation. O
At O
the O
end O
of O
the O
arsenic B-CHEMICAL
exposure O
period, O
male O
fetal O
livers O
were O
removed O
and O
RNA O
isolated O
for O
microarray O
analysis O
using O
22K O
oligo O
chips. O
Arsenic B-CHEMICAL
exposure O
in O
utero O
produced O
significant O
(p<0.001) O
alterations O
in O
expression O
of O
187 O
genes, O
with O
approximately O
25% O
of O
aberrantly O
expressed O
genes O
related O
to O
either O
estrogen B-CHEMICAL
signaling O
or O
steroid B-CHEMICAL
metabolism. O
Real-time O
RT-PCR O
on O
selected O
genes O
confirmed O
these O
changes. O
Various O
genes O
controlled O
by O
estrogen, B-CHEMICAL
including O
X-inactive-specific B-GENE-Y

transcript, I-GENE-Y
anterior B-GENE-Y
gradient-2, I-GENE-Y
trefoil B-GENE-Y
factor-1, I-GENE-Y
CRP-ductin, B-GENE-Y
ghrelin, B-GENE-Y
and O
small B-GENE-Y
proline-rich I-GENE-Y
protein-2A, I-GENE-Y
were O
dramatically O
over-expressed. O
Estrogen-regulated B-CHEMICAL
genes O
including O
cytokeratin B-GENE-Y
1-19 I-GENE-Y
and O
Cyp2a4 B-GENE-Y
were O
over-expressed, O
although O
Cyp3a25 B-GENE-Y
was O
suppressed. O
Several O
genes O
involved O
with O
steroid B-CHEMICAL
metabolism O
also O
showed O
remarkable O
expression O
changes, O
including O
increased O
expression O
of O
17beta-hydroxysteroid B-GENE-Y
dehydrogenase-7 I-GENE-Y
(HSD17beta7; B-GENE-Y
involved O
in O
estradiol B-CHEMICAL

production) O
and O
decreased O
expression O
of O
HSD17beta5 B-GENE-Y
(involved O
in O
testosterone B-CHEMICAL
production). O
The O
expression O
of O
key O
genes O
important O
in O
methionine B-CHEMICAL
metabolism, O
such O
as O
methionine B-CHEMICAL
adenosyltransferase-1a, I-GENE-Y
betaine-homocysteine B-CHEMICAL
methyltransferase I-GENE-Y
and O
thioether B-GENE-Y
S-methyltransferase, I-GENE-Y
were O
suppressed. O
Thus, O
exposure O
of O
mouse O
fetus O
to O
inorganic B-CHEMICAL
arsenic I-CHEMICAL
during O
a O
critical O
period O
in O
development O
significantly O
alters O
the O
expression O
of O
various O
genes O
encoding O
estrogen B-CHEMICAL
signaling O
and O
steroid B-CHEMICAL
or O
methionine B-CHEMICAL
metabolism. O

These O
alterations O
could O
disrupt O
genetic O
programming O
at O
the O
very O
early O
life O
stage, O
which O
could O
impact O
tumor O
formation O
much O
later O
in O
adulthood. O
A O
pilot O
study O
of O
IL-1 B-GENE-N
inhibition O
by O
anakinra O
in O
acute O
gout. O
Monosodium B-CHEMICAL
urate I-CHEMICAL
crystals O
stimulate O
monocytes O
and O
macrophages O
to O
release O
IL-1beta B-GENE-Y
through O
the O
NALP3 B-GENE-Y
component O
of O
the O
inflammasome. O
The O
effectiveness O
of O
IL-1 B-GENE-N
inhibition O
in O
hereditary O
autoinflammatory O
syndromes O
with O
mutations O
in O
the O
NALP3 B-GENE-Y
protein O
suggested O
that O
IL-1 B-GENE-N
inhibition O
might O
also O
be O
effective O
in O
relieving O
the O
inflammatory O
manifestations O
of O
acute O

gout. O
The O
effectiveness O
of O
IL-1 B-GENE-N
inhibition O
was O
first O
evaluated O
in O
a O
mouse O
model O
of O
monosodium B-CHEMICAL
urate I-CHEMICAL
crystal-induced O
inflammation. O
IL-1 B-GENE-N
inhibition O
prevented O
peritoneal O
neutrophil O
accumulation O
but O
TNF B-GENE-Y
blockade O
had O
no O
effect. O
Based O
on O
these O
findings, O
we O
performed O
a O
pilot, O
open-labeled O
study O
(trial O
registration O
number O
ISRCTN10862635) O
in O
10 O
patients O
with O
gout O
who O
could O
not O
tolerate O
or O
had O
failed O
standard O
antiinflammatory O
therapies. O
All O
patients O
received O
100 O
mg O
anakinra O
daily O
for O
3 O
days. O
All O
10 O
patients O
with O
acute O
gout O
responded O
rapidly O

to O
anakinra. O
No O
adverse O
effects O
were O
observed. O
IL-1 B-GENE-N
blockade O
appears O
to O
be O
an O
effective O
therapy O
for O
acute O
gouty O
arthritis. O
The O
clinical O
findings O
need O
to O
be O
confirmed O
in O
a O
controlled O
study. O
Structural O
basis O
of O
inhibition O
of O
the O
human B-GENE-Y
NAD+-dependent B-CHEMICAL
deacetylase I-GENE-Y
SIRT5 I-GENE-Y
by O
suramin. B-CHEMICAL
Sirtuins O
are O
NAD(+)-dependent B-CHEMICAL
protein O
deacetylases O
and O
are O
emerging O
as O
molecular O
targets O
for O
the O
development O
of O
pharmaceuticals O
to O
treat O
human O
metabolic O
and O
neurological O
diseases O
and O
cancer. O
To O
date, O
several O
sirtuin B-GENE-N
inhibitors O
and O
activators O
have O
been O

identified, O
but O
the O
structural O
mechanisms O
of O
how O
these O
compounds O
modulate O
sirtuin B-GENE-N
activity O
have O
not O
yet O
been O
determined. O
We O
identified O
suramin B-CHEMICAL
as O
a O
compound O
that O
binds O
to O
human B-GENE-Y
SIRT5 I-GENE-Y
and O
showed O
that O
it O
inhibits O
SIRT5 B-GENE-Y
NAD(+)-dependent B-CHEMICAL
deacetylase I-GENE-Y
activity O
with O
an O
IC(50) O
value O
of O
22 O
microM. O
To O
provide O
insights O
into O
how O
sirtuin O
function O
is O
altered O
by O
inhibitors, O
we O
determined O
two O
crystal O
structures O
of O
SIRT5, B-GENE-Y
one O
in O
complex O
with O
ADP-ribose, B-CHEMICAL
the O
other O
bound O
to O
suramin. B-CHEMICAL
Our O
structural O
studies O
provide O
a O
view O
of O

a O
synthetic O
inhibitory O
compound O
in O
a O
sirtuin B-GENE-N
active O
site O
revealing O
that O
suramin B-CHEMICAL
binds O
into O
the O
NAD(+), B-CHEMICAL
the O
product, O
and O
the O
substrate-binding O
site. O
Finally, O
our O
structures O
may O
enable O
the O
rational O
design O
of O
more O
potent O
inhibitors. O
Metabolic O
derangement O
of O
methionine B-CHEMICAL
and O
folate B-CHEMICAL
metabolism O
in O
mice O
deficient O
in O
methionine B-GENE-Y
synthase I-GENE-Y
reductase. I-GENE-Y
Hyperhomocyst(e)inemia O
is O
a O
metabolic O
derangement O
that O
is O
linked O
to O
the O
distribution O
of O
folate B-CHEMICAL
pools, O
which O
provide O
one-carbon B-CHEMICAL
units O
for O
biosynthesis O
of O
purines B-CHEMICAL
and O

thymidylate B-CHEMICAL
and O
for O
remethylation O
of O
homocysteine B-CHEMICAL
to O
form O
methionine. B-CHEMICAL
In O
humans, O
methionine B-GENE-Y
synthase I-GENE-Y
deficiency O
results O
in O
the O
accumulation O
of O
methyltetrahydrofolate B-CHEMICAL
at O
the O
expense O
of O
folate B-CHEMICAL
derivatives O
required O
for O
purine B-CHEMICAL
and O
thymidylate B-CHEMICAL
biosynthesis. O
Complete O
ablation O
of O
methionine B-GENE-Y
synthase I-GENE-Y
activity O
in O
mice O
results O
in O
embryonic O
lethality. O
Other O
mouse O
models O
for O
hyperhomocyst(e)inemia O
have O
normal O
or O
reduced O
levels O
of O
methyltetrahydrofolate B-CHEMICAL
and O
are O
not O

embryonic O
lethal, O
although O
they O
have O
decreased O
ratios O
of O
AdoMet/AdoHcy B-CHEMICAL
and O
impaired O
methylation. O
We O
have O
constructed O
a O
mouse O
model O
with O
a O
gene O
trap O
insertion O
in O
the O
Mtrr B-GENE-Y
gene O
specifying O
methionine B-GENE-Y
synthase I-GENE-Y
reductase, I-GENE-Y
an O
enzyme O
essential O
for O
the O
activity O
of O
methionine B-GENE-Y
synthase. I-GENE-Y
This O
model O
is O
a O
hypomorph, O
with O
reduced O
methionine B-GENE-Y
synthase I-GENE-Y
reductase I-GENE-Y
activity, O
thus O
avoiding O
the O
lethality O
associated O
with O
the O
absence O
of O
methionine B-GENE-Y
synthase I-GENE-Y
activity. O
Mtrr(gt/gt) B-GENE-Y
mice O
have O
increased O

plasma O
homocyst(e)ine, B-CHEMICAL
decreased O
plasma O
methionine, B-CHEMICAL
and O
increased O
tissue O
methyltetrahydrofolate. B-CHEMICAL
Unexpectedly, O
Mtrr(gt/gt) B-GENE-Y
mice O
do O
not O
show O
decreases O
in O
the O
AdoMet/AdoHcy B-CHEMICAL
ratio O
in O
most O
tissues. O
The O
different O
metabolite O
profiles O
in O
the O
various O
genetic O
mouse O
models O
for O
hyperhomocyst(e)inemia O
may O
be O
useful O
in O
understanding O
biological O
effects O
of O
elevated O
homocyst(e)ine. B-CHEMICAL
Metformin B-CHEMICAL
and O
phenformin B-CHEMICAL
activate O
AMP-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
in O
the O
heart O

by O
increasing O
cytosolic O
AMP B-CHEMICAL
concentration. O
AMP-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
(AMPK) B-GENE-N
acts O
as O
a O
cellular O
energy O
sensor: O
it O
responds O
to O
an O
increase O
in O
AMP B-CHEMICAL
concentration O
([AMP]) B-CHEMICAL
or O
the O
AMP-to-ATP B-CHEMICAL
ratio O
(AMP/ATP). B-CHEMICAL
Metformin B-CHEMICAL
and O
phenformin, B-CHEMICAL
which O
are O
biguanides, B-CHEMICAL
have O
been O
reported O
to O
increase O
AMPK B-GENE-N
activity O
without O
increasing O
AMP/ATP. B-CHEMICAL
This O
study O
tests O
the O
hypothesis O
that O
these O
biguanides B-CHEMICAL
increase O
AMPK B-GENE-N
activity O
in O
the O
heart O
by O
increasing O
cytosolic O
[AMP]. B-CHEMICAL
Groups O
of O
isolated O
rat O
hearts O
(n O

= O
5-7 O
each) O
were O
perfused O
with O
Krebs-Henseleit O
buffer O
with O
or O
without O
0.2 O
mM O
phenformin B-CHEMICAL
or O
10 O
mM O
metformin, B-CHEMICAL
and O
(31)P-NMR-measured B-CHEMICAL
phosphocreatine, B-CHEMICAL
ATP, B-CHEMICAL
and O
intracellular O
pH O
were O
used O
to O
calculate O
cytosolic O
[AMP]. B-CHEMICAL
At O
various O
times, O
hearts O
were O
freeze-clamped O
and O
assayed O
for O
AMPK B-GENE-N
activity, O
phosphorylation O
of O
Thr(172) O
on O
AMPK-alpha, B-GENE-N
and O
phosphorylation O
of O
Ser(79) O
on O

acetyl-CoA B-GENE-N
carboxylase, I-GENE-N
an O
AMPK B-GENE-N
target. O
In O
hearts O
treated O
with O
phenformin B-CHEMICAL
for O
18 O
min O
and O
then O
perfused O
for O
20 O
min O
with O
Krebs-Henseleit O
buffer, O
[AMP] B-CHEMICAL
began O
to O
increase O
at O
26 O
min O
and O
AMPK B-GENE-N
activity O
was O
elevated O
at O
36 O
min. O
In O
hearts O
treated O
with O
metformin, B-CHEMICAL
[AMP] B-CHEMICAL
was O
increased O
at O
50 O
min O
and O
AMPK B-GENE-N
activity, O
phosphorylated O
AMPK, B-GENE-N
and O
phosphorylated B-GENE-N
acetyl-CoA B-CHEMICAL
carboxylase I-GENE-N
were O
elevated O
at O
61 O
min. O
In O

metformin-treated B-CHEMICAL
hearts, O
HPLC-measured O
total O
AMP B-CHEMICAL
content O
and O
total O
AMP/ATP B-CHEMICAL
did O
not O
increase. O
In O
summary, O
phenformin B-CHEMICAL
and O
metformin B-CHEMICAL
increase O
AMPK B-GENE-N
activity O
and O
phosphorylation O
in O
the O
isolated O
heart. O
The O
increase O
in O
AMPK B-GENE-N
activity O
was O
always O
preceded O
by O
and O
correlated O
with O
increased O
cytosolic O
[AMP]. B-CHEMICAL
Total O
AMP B-CHEMICAL
content O
and O
total O
AMP/ATP B-CHEMICAL
did O
not O
change. O
Cytosolic O
[AMP] B-CHEMICAL
reported O
metabolically O
active O
AMP, B-CHEMICAL
which O
triggered O
increased O
AMPK B-GENE-N
activity, O
but O
measures O
of O
total O
AMP B-CHEMICAL
did O
not. O
The O
role O
of O

glutathione B-CHEMICAL
transferases I-GENE-N
M1 I-GENE-N
and I-GENE-N
T1 I-GENE-N
in O
individual O
susceptibility O
to O
bladder O
cancer O
in O
a O
Tunisian O
population. O
BACKGROUND: O
Susceptibility O
to O
bladder O
cancer O
is O
thought O
to O
depend O
on O
interplay O
between O
genetic O
factors O
and O
environmental O
chemical O
carcinogens. O
AIM: O
This O
study O
seeks O
to O
determine O
the O
role O
of O
the O
glutathione B-GENE-N
transferases I-GENE-N
M1 I-GENE-N
and I-GENE-N
T1 I-GENE-N
null O
genotypes O
(GSTM1*0 B-GENE-Y
and O
GSTT1*0) B-GENE-Y
in O
individual O
susceptibility O
to O
bladder O
cancer O
in O
a O
Tunisian O
population. O
METHOD: O
Sixty-two O
patients O
with O

transitional O
cell O
carcinoma O
of O
the O
bladder O
cancer O
and O
79 O
controls O
were O
examined O
with O
respect O
to O
the O
frequency O
of O
GSTM1 B-GENE-Y
and O
GSTT1 B-GENE-Y
null O
genotypes. O
RESULTS: O
The O
frequencies O
of O
the O
GSTT1 B-GENE-Y
null O
in O
the O
total O
group O
of O
bladder O
cancer O
cases O
vs. O
controls O
did O
not O
differ O
statistically. O
The O
proportion O
of O
GSTM1 B-GENE-Y
null O
genotype O
in O
patients O
was O
63% O
compared O
to O
45% O
in O
controls O
group O
(OR O
= O
2.03; O
95% O
CI O
0.97-4.24; O
p O
= O
0.04). O
A O
significantly O
higher O
incidence O
of O
GSTM1 B-GENE-Y

deletion O
genotype O
was O
found O
in O
smokers O
with O
bladder O
cancer O
compared O
to O
the O
controls O
(65.38% O
vs. O
45.5%). O
Smokers O
lacking O
the O
GSTM1 B-GENE-Y
gene O
are O
at O
an O
approximately O
2.2-fold O
higher O
risk O
of O
bladder O
cancer O
(OR= O
2.23, O
95% O
CI O
1-5.15; O
p O
= O
0.03). O
CONCLUSION: O
This O
study O
suggests O
that O
in O
Tunisian O
subjects O
the O
GSTM1 B-GENE-Y
null O
genotype O
may O
be O
associated O
with O
an O
increased O
risk O
of O
bladder O
cancer. O
This O
association O
appears O
to O
depend O
upon O
smoking O
status. O
Characterization O
of O

5-hydroxytryptamine1B B-GENE-Y
receptors O
in O
rat O
spinal O
cord O
via O
[125I]iodocyanopindolol B-CHEMICAL
binding O
and O
inhibition O
of O
[3H]-5-hydroxytryptamine B-CHEMICAL
release. O
The O
aim O
of O
the O
present O
study O
in O
rat O
spinal O
cord O
synaptosomes O
was O
to O
compare O
the O
pharmacological O
characteristics O
of O
the O
serotonin B-GENE-Y
(5-HT)1B I-GENE-Y
receptor I-GENE-Y
defined O
by O
[125I]iodocyanopindolol B-CHEMICAL
[( B-CHEMICAL
125I] I-CHEMICAL
ICYP) I-CHEMICAL
binding O
and O
the O
5-HT B-GENE-Y
autoreceptor I-GENE-Y
defined O
by O
inhibition O
of O

[3H]-5-HT B-CHEMICAL
release. O
In O
Percoll O
gradient O
Fractions O
3 O
and O
4 O
of O
spinal O
cord O
synaptosomes, O
a O
single O
saturable O
binding O
site O
for O
[125I]ICYP B-CHEMICAL
with O
a O
maximum O
binding O
of O
70 O
and O
134 O
fmol/mg, O
respectively, O
was O
demonstrated O
in O
the O
presence O
of O
30 O
microM O
isoproterenol. B-CHEMICAL
The O
Kd O
of O
0.16 O
nM O
did O
not O
vary O
between O
fractions. O
Competition O
for O
[125I]ICYP B-CHEMICAL
binding O
by O
various O
5-HT B-CHEMICAL
agonists O
and O
antagonists O
also O
indicated O
a O
single O
site O
model O
based O
on O
a O
Hill O
coefficient O
of O
approximately O

1.0. O
The O
most O
potent O
compounds O
at O
displacing O
[125I]ICYP B-CHEMICAL
binding O
were O
RU B-CHEMICAL
24969 I-CHEMICAL
(5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), B-CHEMICAL
5-carboxyamidotryptamine B-CHEMICAL
HCl, I-CHEMICAL
5-methoxytryptamine, B-CHEMICAL
5-HT B-CHEMICAL
and O
CGS B-CHEMICAL
12066B I-CHEMICAL
(7-trifluoromethyl-4(4 B-CHEMICAL

methyl-1-pyrolo[1,2-a]-quinoxaline I-CHEMICAL
malate). I-CHEMICAL
[125I]ICYP B-CHEMICAL
binding O
was O
not O
altered O
by O
compounds O
with O
activity O
at O
5-HT1A, B-GENE-Y
5-HT1C, B-GENE-Y
5-HT2, B-GENE-Y
5-HT3 B-GENE-Y
or O
alpha-2 O
receptor O
sites. O
Similar O
to O
the O
pharmacological O
characteristics O
of O
the O
5HT1B B-GENE-Y
site O
defined O
by O
[125I]ICYP, B-CHEMICAL
compounds O
most O
active O
at O
inhibiting O
15 O
mM O
K(+)-stimulated B-CHEMICAL
release O
of O
[3H]-5-HT B-CHEMICAL

were O
RU24969 B-CHEMICAL
= O
5-carboxyamidotryptamine B-CHEMICAL
HCl B-CHEMICAL
= O
CGS B-CHEMICAL
12066B I-CHEMICAL
greater O
than O
5-methoxytryptamine B-CHEMICAL
greater O
than O
5-HT. B-CHEMICAL
Compounds O
with O
activity O
at O
5-HT1A, B-GENE-Y
5-HT1C, B-GENE-Y
5-HT2 B-GENE-Y
or O
5-HT3 B-GENE-Y
sites O
were O
inactive. O
A O
correlation O
analysis O
of O
selective O
5-HT1B B-GENE-Y
compounds O
comparing O
the O
pKD O
for O
displacement O
of O
[125I]ICYP B-CHEMICAL
vs. O
the O
IC50 O
for O
inhibition O
of O
[3H]-5-HT B-CHEMICAL
release O
demonstrated O

the O
pharmacological O
similarity O
of O
the O
presynaptic O
inhibitory O
5-HT B-GENE-Y
autoreceptor I-GENE-Y
and O
the O
5-HT B-GENE-Y
receptor I-GENE-Y
site O
defined O
by O
[125I]ICYP B-CHEMICAL
binding O
in O
spinal O
cord O
synaptosomes O
(r O
= O
0.791, O
P O
= O
.0193). O
Although O
[125I]ICYP B-CHEMICAL
binding O
was O
unaltered, O
alpha-2 O
agonists O
such O
as O
clonidine, B-CHEMICAL
norepinephrine B-CHEMICAL
and O
UK B-CHEMICAL
14304 I-CHEMICAL

[5-bromo-6-[2-imidazolin-2-ylamino]-quinoxaline) B-CHEMICAL
as O
well O
as O
the O
alpha-2 O
antagonists O
rauwolscine B-CHEMICAL
and O
yohimbine B-CHEMICAL
also O
decreased O
the O
K(+)-stimulated B-CHEMICAL
release O
of O
[3H]-5-HT B-CHEMICAL
and O
phentolamine, B-CHEMICAL
an O
alpha-2 O
antagonist O
increased O
release. O
The O
action O
of O
these O
alpha-2 O
compounds O
to O
alter O
[3H]-5-HT B-CHEMICAL
release O
suggests O
the O
presence O
of O
heteroreceptors O
localized O
on O
5-HT B-CHEMICAL
terminals O
in O
the O
spinal O
cord. O
These O
results O

point O
out O
that O
[125I]ICYP B-CHEMICAL
identifies O
the O
5-HT1B B-GENE-Y
receptor, O
and O
affinity O
of O
compounds O
for O
this O
site O
predicts O
action O
at O
the O
5-HT1B B-GENE-Y
autoreceptor.(ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS) O
Histamine B-GENE-Y
H1 I-GENE-Y
receptor I-GENE-Y
involvement O
in O
prepulse O
inhibition O
and O
memory O
function: O
relevance O
for O
the O
antipsychotic O
actions O
of O
clozapine. B-CHEMICAL
Histamine B-GENE-Y
H(1) I-GENE-Y
blockade O
is O
one O
of O
the O
more O
prominent O
actions O
of O
the O
multi-receptor O
acting O
antipsychotic O
clozapine. B-CHEMICAL
It O
is O
currently O
not O
known O
how O
much O

this O
H(1) B-GENE-Y
antagonism O
of O
clozapine B-CHEMICAL
contributes O
to O
the O
therapeutic O
or O
adverse O
side O
effects O
of O
clozapine. B-CHEMICAL
The O
current O
studies O
with O
Sprague-Dawley O
rats O
were O
conducted O
to O
determine O
the O
participation O
of O
histaminergic B-GENE-Y
H(1) I-GENE-Y
receptor I-GENE-Y
subtype O
in O
sensorimotor O
plasticity O
and O
memory O
function O
affected O
by O
clozapine B-CHEMICAL
using O
tests O
of O
prepulse O
inhibition O
(PPI) O
and O
radial-arm O
maze O
choice O
accuracy. O
The O
PPI O
impairment O
caused O
by O
the O
glutamate B-CHEMICAL
antagonist O
dizocilpine B-CHEMICAL
(MK-801) B-CHEMICAL
was O
significantly O
attenuated O
by O

clozapine. B-CHEMICAL
In O
the O
current O
project, O
we O
found O
that O
the O
selective O
H(1) B-GENE-Y
antagonist O
pyrilamine B-CHEMICAL
also O
reversed O
the O
dizocilpine-induced B-CHEMICAL
impairment O
in O
PPI O
of O
tactile O
startle O
with O
an O
auditory O
prepulse. O
In O
the O
radial-arm O
maze O
(RAM), O
pyrilamine, B-CHEMICAL
like O
clozapine, B-CHEMICAL
impaired O
working O
memory O
and O
caused O
a O
significant O
dose-related O
slowing O
of O
response. O
Pyrilamine, B-CHEMICAL
however, O
decreased O
the O
number O
of O
reference O
memory O
errors. O
We O
have O
previously O
shown O
that O
nicotine B-CHEMICAL
effectively O
attenuates O
the O
clozapine-induced B-CHEMICAL
working O

memory O
impairment, O
but O
in O
the O
current O
study, O
nicotine B-CHEMICAL
did O
not O
significantly O
alter O
the O
effects O
of O
pyrilamine B-CHEMICAL
on O
the O
RAM. O
In O
summary, O
the O
therapeutic O
effect O
of O
clozapine B-CHEMICAL
in O
reversing O
PPI O
impairment O
was O
mimicked O
by O
the O
H(1) B-GENE-Y
antagonist O
pyrilamine, B-CHEMICAL
while O
pyrilamine B-CHEMICAL
had O
a O
mixed O
effect O
on O
cognition. O
Pyrilamine B-CHEMICAL
impaired O
working O
memory O
but O
improved O
reference O
memory O
in O
rats. O
Thus, O
H(1) B-GENE-Y
antagonism O
seems O
to O
play O
a O
role O
in O
part O
of O
the O
beneficial O
actions O
of O
antipsychotics, O
such O
as O
clozapine. B-CHEMICAL
Inhibition O
of O

phosphatidylserine O
biosynthesis O
in O
developing O
rat O
brain O
by O
maternal O
exposure O
to O
ethanol. B-CHEMICAL
Phosphatidylserine O
(PtdSer), O
major O
acidic O
phospholipids O
in O
neuronal O
membranes, O
participate O
in O
important O
cell O
signaling O
processes. O
The O
PtdSer O
in O
brain O
is O
highly O
enriched O
with O
docosahexaenoic B-CHEMICAL
acid I-CHEMICAL
(DHA; B-CHEMICAL
22:6n-3), O
and O
the O
DHA B-CHEMICAL
status O
or O
ethanol B-CHEMICAL
exposure O
has O
been O
shown O
to O
influence O
the O
PtdSer O
level. O
This O
study O
shows O
that O
ethanol B-CHEMICAL
exposure O
during O
prenatal O
and O

developmental O
period O
significantly O
attenuates O
microsomal O
PtdSer O
biosynthetic O
activities O
and O
reduces O
PtdSer, O
particularly O
18:0, O
22:6-PtdSer, O
in O
developing O
rat O
brain O
cortices. O
Brain O
microsomes O
were O
incubated O
with O
deuterium B-CHEMICAL
labeled O
exogenous O
substrates O
in O
vitro O
and O
the O
products O
formed O
were O
detected O
by O
reversed O
phase O
HPLC-electrospray O
ionization O
mass O
spectrometry O
(ESI-MS). O
These O
in O
vitro O
bioassays O
showed O
that O

1-stearoyl-2-docosahexaenoyl B-CHEMICAL
(18:0, O
22:6) O
species O
is O
the O
best O
substrate O
for O
PtdSer O
synthesis O
from O
both O
phosphatidylcholine B-CHEMICAL
(PtdCho) B-CHEMICAL
and O
phosphatidylethanolamine B-CHEMICAL
(PtdEtn). B-CHEMICAL
The O
PtdSer O
biosynthetic O
activity O
of O
brain, O
especially O
for O
18:0, O
22:6-PtdSer O
production, O
was O
hampered O
significantly O
by O
maternal O
exposure O
to O
ethanol. B-CHEMICAL
PtdSer O
levels O
were O
consistently O
reduced O
significantly O
in O
brain O

cortices O
of O
the O
pups O
from O
ethanol-exposed B-CHEMICAL
dams, O
due O
mainly O
to O
the O
depletion O
of O
18:0, O
22:6-PtdSer. O
The O
mRNA O
expression O
of O
PtdSer B-GENE-Y
synthase I-GENE-Y
1 I-GENE-Y
(PSS1) B-GENE-Y
and O
PtdSer B-GENE-Y
synthase I-GENE-Y
2 I-GENE-Y
(PSS2) B-GENE-Y
was O
not O
reduced O
by O
ethanol. B-CHEMICAL
Similarly, O
the O
PSS1 B-GENE-Y
enzyme O
level O
did O
not O
change O
after O
ethanol B-CHEMICAL
exposure O
but O
PSS2 B-GENE-Y
could O
not O
be O
probed O
with O
the O
antibody O
available O
currently. O
Degradation O
of O
PtdSer O
by O
mitochondrial O
PtdSer O
decarboxylation O

was O
not O
enhanced O
but O
also O
inhibited. O
Taken O
together, O
attenuated O
PtdSer O
biosynthetic O
activities O
are O
largely O
responsible O
for O
the O
PtdSer O
reduction O
observed O
in O
developing O
rat O
brains O
after O
maternal O
exposure O
to O
ethanol. B-CHEMICAL
Regulation O
of O
gluconeogenesis O
by O
Kruppel-like B-GENE-Y
factor I-GENE-Y
15. I-GENE-Y
In O
the O
postabsorptive O
state, O
certain O
tissues, O
including O
the O
brain, O
require O
glucose B-CHEMICAL
as O
the O
sole O
source O
of O
energy. O
After O
an O
overnight O
fast, O
hepatic O
glycogen O
stores O
are O
depleted, O
and O
gluconeogenesis O
becomes O
essential O
for O
preventing O
life-threatening O
hypoglycemia. O

Mice O
with O
a O
targeted O
deletion O
of O
KLF15, B-GENE-Y
a O
member O
of O
the O
Kruppel-like B-GENE-N
family O
of O
transcription O
factors, O
display O
severe O
hypoglycemia O
after O
an O
overnight O
(18 O
hr) O
fast. O
We O
provide O
evidence O
that O
defective O
amino B-CHEMICAL
acid I-CHEMICAL
catabolism O
promotes O
the O
development O
of O
fasting O
hypoglycemia O
in O
KLF15-/- B-GENE-Y
mice O
by O
limiting O
gluconeogenic O
substrate O
availability. O
KLF15-/- B-GENE-Y
liver O
and O
skeletal O
muscle O
show O
markedly O
reduced O
mRNA O
expression O
of O
amino B-CHEMICAL
acid-degrading I-CHEMICAL
enzymes. O
Furthermore, O
the O
enzymatic O
activity O
of O
alanine B-CHEMICAL

aminotransferase I-GENE-N
(ALT), B-GENE-N
which O
converts O
the O
critical O
gluconeogenic O
amino B-CHEMICAL
acid I-CHEMICAL
alanine B-CHEMICAL
into O
pyruvate, B-CHEMICAL
is O
decreased O
(approximately O
50%) O
in O
KLF15-/- B-GENE-Y
hepatocytes. O
Consistent O
with O
this O
observation, O
intraperitoneal O
injection O
of O
pyruvate, B-CHEMICAL
but O
not O
alanine, B-CHEMICAL
rescues O
fasting O
hypoglycemia O
in O
KLF15-/- B-GENE-Y
mice. O
We O
conclude O
that O
KLF15 B-GENE-Y
plays O
an O
important O
role O
in O
the O
regulation O
of O
gluconeogenesis. O
D-glucose B-CHEMICAL
stimulation O
of O
L-arginine B-CHEMICAL

transport O
and O
nitric B-CHEMICAL
oxide I-CHEMICAL
synthesis O
results O
from O
activation O
of O
mitogen-activated B-GENE-N
protein I-GENE-N
kinases I-GENE-N
p42/44 I-GENE-N
and O
Smad2 B-GENE-Y
requiring O
functional O
type B-GENE-Y
II I-GENE-Y
TGF-beta I-GENE-Y
receptors I-GENE-Y
in O
human O
umbilical O
vein O
endothelium. O
Elevated O
extracellular O
D-glucose B-CHEMICAL
increases O
transforming B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
beta1 I-GENE-Y
(TGF-beta1) B-GENE-Y
release O
from O
human O
umbilical O
vein O
endothelium O
(HUVEC). O
TGF-beta1, B-GENE-Y
via O
TGF-beta B-GENE-Y
receptors I-GENE-Y
I I-GENE-Y
(TbetaRI) B-GENE-Y
and O
TbetaRII, B-GENE-Y
activates O
Smad2 B-GENE-Y
and O
mitogen-activated B-GENE-N
protein I-GENE-N

kinases I-GENE-N
p44 B-GENE-Y
and O
p42 B-GENE-Y
(p42/44(mapk)). B-GENE-N
We O
studied O
whether O
D-glucose-stimulation B-CHEMICAL
of O
L-arginine B-CHEMICAL
transport O
and O
nitric B-CHEMICAL
oxide I-CHEMICAL
synthesis O
involves O
TGF-beta1 B-GENE-Y
in O
primary O
cultures O
of O
HUVEC. O
TGF-beta1 B-GENE-Y
release O
was O
higher O
( O
approximately O
1.6-fold) O
in O
25 O
mM O
(high) O
compared O
with O
5 O
mM O
(normal) O
D-glucose. B-CHEMICAL
TGF-beta1 B-GENE-Y
increases O
L-arginine B-CHEMICAL
transport O
(half O
maximal O
effect O
approximately O
1.6 O
ng/ml) O
in O
normal O
D-glucose, B-CHEMICAL
but O

did O
not O
alter O
high O
D-glucose-increased B-CHEMICAL
L-arginine B-CHEMICAL
transport. O
TGF-beta1 B-GENE-Y
and O
high O
D-glucose B-CHEMICAL
increased O
hCAT-1 B-GENE-Y
mRNA O
expression O
( O
approximately O
8-fold) O
and O
maximal O
transport O
velocity O
(V(max)), O
L-[(3)H]citrulline B-CHEMICAL
formation O
from O
L-[(3)H]arginine B-CHEMICAL
(index O
of O
NO B-CHEMICAL
synthesis) O
and O
endothelial B-GENE-Y
NO I-GENE-Y
synthase I-GENE-Y
(eNOS) B-GENE-Y
protein O
abundance, O
but O
did O
not O
alter O
eNOS B-GENE-Y
phosphorylation. O
TGF-beta1 B-GENE-Y
and O

high O
D-glucose B-CHEMICAL
increased O
p42/44(mapk) B-GENE-N
and O
Smad2 B-GENE-Y
phosphorylation, O
an O
effect O
blocked O
by O
PD-98059 B-CHEMICAL
(MEK1/2 B-GENE-N
inhibitor). O
However, O
TGF-beta1 B-GENE-Y
and O
high O
D-glucose B-CHEMICAL
were O
ineffective O
in O
cells O
expressing O
a O
truncated, O
negative O
dominant O
TbetaRII. B-GENE-Y
High O
D-glucose B-CHEMICAL
increases O
L-arginine B-CHEMICAL
transport O
and O
eNOS B-GENE-Y
expression O
following O
TbetaRII B-GENE-Y
activation O
by O
TGF-beta1 B-GENE-Y
involving O
p42/44(mapk) B-GENE-N
and O
Smad2 B-GENE-Y
in O
HUVEC. O
Thus, O

TGF-beta1 B-GENE-Y
could O
play O
a O
crucial O
role O
under O
conditions O
of O
hyperglycemia, O
such O
as O
gestational O
diabetes O
mellitus, O
which O
is O
associated O
with O
fetal O
endothelial O
dysfunction. O
n-3 B-CHEMICAL
and I-CHEMICAL
n-6 I-CHEMICAL
polyunsaturated I-CHEMICAL
fatty I-CHEMICAL
acids I-CHEMICAL
induce O
the O
expression O
of O
COX-2 B-GENE-Y
via O
PPARgamma B-GENE-Y
activation O
in O
human O
keratinocyte O
HaCaT O
cells. O
Polyunsaturated B-CHEMICAL
fatty I-CHEMICAL
acids I-CHEMICAL
(PUFA) I-CHEMICAL
n-3 I-CHEMICAL
inhibit O
inflammation, O
in O
vivo O
and O
in O
vitro O
in O
keratinocytes. O
We O
examined O
in O

HaCaT O
keratinocyte O
cell O
line O
whether O
eicosapentaenoic B-CHEMICAL
acid I-CHEMICAL
(EPA) B-CHEMICAL
a O
n-3 B-CHEMICAL
PUFA, I-CHEMICAL
gamma-linoleic B-CHEMICAL
acid I-CHEMICAL
(GLA) B-CHEMICAL
a O
n-6 B-CHEMICAL
PUFA, I-CHEMICAL
and O
arachidic B-CHEMICAL
acid I-CHEMICAL
a O
saturated B-CHEMICAL
fatty I-CHEMICAL
acid, I-CHEMICAL
modulate O
expression O
of O
cyclooxygenase-2 B-GENE-Y
(COX-2), B-GENE-Y
an O
enzyme O
pivotal O
to O
skin O
inflammation O
and O
reparation. O
We O
demonstrate O
that O
only O
treatment O
of O
HaCaT O
with O
GLA B-CHEMICAL
and O
EPA B-CHEMICAL
or O
a O
PPARgamma B-GENE-Y
ligand O

(roziglitazone), B-CHEMICAL
induced O
COX-2 B-GENE-Y
expression O
(protein O
and O
mRNA). O
Moreover O
stimulation O
of O
COX-2 B-GENE-N
promoter I-GENE-N
activity O
was O
increased O
by O
those O
PUFAs B-CHEMICAL
or O
rosiglitazone. B-CHEMICAL
The O
inhibitory O
effects O
of O
GW9662 B-CHEMICAL
and O
T0070907 B-CHEMICAL
(PPARgamma B-GENE-Y
antagonists), O
on O
COX-2 B-GENE-Y
expression O
and O
on O
stimulation O
of O
COX-2 B-GENE-N
promoter I-GENE-N
activity O
by O
EPA B-CHEMICAL
and O
GLA B-CHEMICAL
suggest O
that O
PPARgamma B-GENE-Y
is O
implicated O
in O
COX-2 B-GENE-Y
induction. O
Finally, O
PLA2 B-GENE-Y
inhibitor O
methyl O
arachidonyl B-CHEMICAL

fluorophosphonate I-CHEMICAL
blocked O
the O
PUFA B-CHEMICAL
effects O
on O
COX-2 B-GENE-Y
induction, O
promoter O
activity O
and O
arachidonic B-CHEMICAL
acid I-CHEMICAL
mobilization O
suggesting O
involvement O
of O
AA B-CHEMICAL
metabolites O
in O
PPAR B-GENE-N
activation. O
These O
findings O
demonstrate O
that O
n-3 B-CHEMICAL
and I-CHEMICAL
n-6 I-CHEMICAL
PUFA I-CHEMICAL
increased O
PPARgamma B-GENE-Y
activity O
is O
necessary O
for O
the O
COX-2 B-GENE-Y
induction O
in O
HaCaT O
human O
keratinocyte O
cells. O
Given O
the O
anti-inflammatory O
properties O
of O
EPA, B-CHEMICAL
we O
suggest O
that O
induction O
of O
COX-2 B-GENE-Y
in O
keratinocytes O
may O
be O
important O
in O
the O
anti-inflammatory O
and O
protective O
mechanism O
of O
action O
of O
PUFAs B-CHEMICAL

n-3 I-CHEMICAL
or O
n-6. O
Methylation-mediated O
silencing O
of O
genes O
is O
not O
altered O
by O
selenium B-CHEMICAL
treatment O
of O
prostate O
cancer O
cells. O
BACKGROUND: O
The O
role O
of O
selenium B-CHEMICAL
in O
reducing O
the O
risk O
of O
multiple O
cancers O
has O
been O
described O
in O
the O
literature. O
Although O
reports O
have O
described O
the O
antiproliferative O
and O
pro-apoptotic O
function O
of O
selenium B-CHEMICAL
by O
up-regulation O
of O
genes O
in O
these O
pathways, O
information O
is O
lacking O
on O
the O
target O
mechanisms O
of O
selenium B-CHEMICAL
on O
specific O
genes. O
This O
study O
examines O
whether O
selenium B-CHEMICAL
treatment O
alters O
the O
methylation O
status O
of O

epigenetically O
silenced O
genes O
in O
prostate O
cancer O
cells. O
MATERIALS O
AND O
METHODS: O
Methylation O
of O
glutathione B-GENE-Y
sulfotransferase I-GENE-Y
pi I-GENE-Y
(GSTP1) B-GENE-Y
and O
Ras B-GENE-Y
associated I-GENE-Y
family I-GENE-Y
1A I-GENE-Y
(RASSF1A) B-GENE-Y
genes O
was O
studied O
using O
methylation O
sensitive O
PCR O
(MS-PCR). O
Gene O
expression O
was O
studied O
using O
Reverse O
Transcriptase O
PCR O
and O
Western O
Blotting. O
RESULTS O
AND O
CONCLUSION: O
Treatment O
of O
prostate O
cancer O
cells O
with O
selenium B-CHEMICAL
did O
not O
alter O
the O
expression O
of O
genes O
that O
were O

silenced O
by O
DNA O
methylation. O
Furthermore, O
the O
methylation O
status O
of O
these O
genes O
remained O
unaltered O
after O
treatment O
with O
seleno-DL-methionine. B-CHEMICAL
Nebulized O
arformoterol B-CHEMICAL
in O
patients O
with O
COPD: O
a O
12-week, O
multicenter, O
randomized, O
double-blind, O
double-dummy, O
placebo- O
and O
active-controlled O
trial. O
OBJECTIVE: O
The O
aim O
of O
this O
study O
was O
to O
assess O
the O
efficacy O
and O
tolerability O
of O
nebulized O
arformoterol B-CHEMICAL
tartrate I-CHEMICAL
(a O
selective, O
long-acting O

beta(2)-adrenergic B-GENE-Y
agonist O
that O
is O
the O
[R,R] B-CHEMICAL
isomer I-CHEMICAL
of I-CHEMICAL
formoterol) I-CHEMICAL
and O
salmeterol B-CHEMICAL
xinafoate I-CHEMICAL
versus O
placebo O
in O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
(COPD). O
METHODS: O
This O
12-week, O
multicenter, O
randomized, O
double-blind, O
double-dummy, O
placebo- O
and O
active-controlled O
trial O
was O
conducted O
at O
60 O
centers O
across O
the O
United O
States. O
Male O
and O
female O
patients O
aged O
>or=35 O
years O
with O
physician-diagnosed O
COPD O
received O
arformoterol B-CHEMICAL
(15 O
microg O
BID, O

25 O
microg O
BID, O
or O
50 O
microg O
QD O
via O
nebulizer), O
salmeterol B-CHEMICAL
(42 O
microg O
BID O
via O
metered O
dose O
inhaler), O
or O
placebo. O
Pulmonary O
function O
was O
assessed O
by O
spirometry; O
dyspnea, O
by O
the O
Transitional O
Dyspnea O
Index O
(TDI); O
and O
health O
status, O
by O
the O
St. O
George's O
Respiratory O
Questionnaire O
(SGRQ). O
Adverse O
events O
(AEs) O
were O
assessed O
by O
site O
personnel O
at O
all O
clinic O
visits O
(screening, O
first O
dose O
at O
week O
0, O
and O
at O
weeks O
3, O

6, O
9, O
12, O
and O
follow-up). O
COPD O
exacerbations O
were O
defined O
as O
worsening O
respiratory O
status O
requiring O
a O
change O
in O
medication O
or O
an O
unscheduled O
provider O
visit. O
RESULTS: O
A O
total O
of O
717 O
patients O
received O
study O
medication. O
The O
demographic O
composition O
of O
all O
treatment O
arms O
was O
similar. O
The O
mean O
age O
was O
62.9 O
years, O
58% O
were O
men, O
and O
mean O
baseline O
forced O
expiratory O
volume O
in O
1 O
second O
(FEV(1)) O
was O
1.2 O
L O
(41% O
predicted). O
Mean O
improvement O
in O
trough O
FEV(1) O
over O
12 O
weeks O
was O

significantly O
greater O
with O
all O
3 O
arformoterol B-CHEMICAL
doses O
(15 O
microg O
BID, O
+16.9%; O
25 O
microg O
BID, O
+18.9%; O
50 O
microg O
QD, O
+14.9%) O
and O
for O
salmeterol B-CHEMICAL
(+17.4%) O
relative O
to O
placebo O
(+6.0%; O
P O
< O
0.001). O
There O
were O
significantly O
greater O
improvements O
in O
the O
mean O
percentage O
change O
in O
FEV(1) O
AUC(0-12h) O
from O
the O
predose O
value O
over O
12 O
weeks O
(15 O
microg O
BID, O
12.7%, O

25 O
microg O
BID, O
13.9%, O
50 O
microg O
QD, O
18.9%; O
salmeterol, B-CHEMICAL
9.8%) O
versus O
placebo O
(2.7%; O
P O
<or= O
0.001); O
all O
doses O
of O
arformoterol O
were O
statistically O
different O
from O
salmeterol O
for O
this O
end O
point O
(P O
<or= O
0.024). O
At O
week O
12, O
TDI O
focal O
scores O
were O
significantly O
greater O
with O
all O
arformoterol O
doses O
compared O
with O
placebo O
(mean O
[95% O
CI]: O
15 O
microg O
BID, O
0.97 O

[0.25-1.69]; O
25 O
microg O
BID, O
1.08 O
[0.3-1.86]; O
50 O
microg O
QD, O
1.04 O
[0.32-1.771), O
suggesting O
treatment-associated O
improvement O
in O
dyspnea, O
however, O
the O
difference O
between O
salmeterol O
and O
placebo O
was O
not O
statistically O
significant O
(0.36 O
[-0.40 O
to O
1.12]). O
Improvements O
in O
health O
status, O
as O
measured O
using O
SGRQ O
total O
scores, O
were O
-2.6 O
to O
-3.6 O
U O
in O
the O
arformoterol O

groups, O
-4.4 O
U O
for O
salmeterol, O
and O
-1.2 O
U O
for O
placebo; O
95% O
CI O
of O
differences O
versus O
placebo O
suggested O
significant O
improvement O
for O
the O
arformoterol O
25 O
microg O
BID O
and O
salmeterol O
groups. O
There O
was O
a O
similar O
frequency O
of O
AEs O
and O
COPD O
exacerbations O
across O
all O
groups, O
including O
placebo. O
CONCLUSIONS: O
In O
this O
trial, O
patients O
with O
moderate O
to O
severe O
COPD O
administered O
nebulized O
arformoterol O
over O
12 O
weeks O
were O
observed O
to O
have O
significant O
and O
sustained O
improvements O
in O
airway O
function O
and O
dyspnea O
compared O
with O

placebo. O
The O
results O
also O
suggest O
that O
all O
doses O
of O
arformoterol, O
including O
the O
lowest O
dose O
(15 O
microg O
BID), O
were O
effective. O
Overall, O
nebulized O
arformoterol O
was O
well O
tolerated. O
Discovery O
of O
acetyl-coenzyme B-GENE-Y
A I-GENE-Y
carboxylase I-GENE-Y
2 I-GENE-Y
inhibitors: O
comparison O
of O
a O
fluorescence O
intensity-based O
phosphate B-CHEMICAL
assay O
and O
a O
fluorescence O
polarization-based O
ADP B-CHEMICAL
Assay O
for O
high-throughput O
screening. O
Acetyl-coenzyme B-CHEMICAL
A I-CHEMICAL
carboxylase I-GENE-N
(ACC) B-GENE-N
enzymes O
exist O
as O
two O
isoforms, O
ACC1 B-GENE-Y
and O

ACC2, B-GENE-Y
which O
play O
critical O
roles O
in O
fatty B-CHEMICAL
acid I-CHEMICAL
biosynthesis O
and O
oxidation. O
Though O
each O
isoform O
differs O
in O
tissue O
and O
subcellular O
localization, O
both O
catalyze O
the O
biotin- B-CHEMICAL
and O
ATP-dependent B-CHEMICAL
carboxylation O
of O
acetyl-coenzyme B-CHEMICAL
A I-CHEMICAL
to O
generate O
malonyl-coenzyme B-CHEMICAL
A, I-CHEMICAL
a O
key O
metabolite O
in O
the O
control O
of O
fatty B-CHEMICAL
acid I-CHEMICAL
synthesis O
and O
oxidation. O
The O
cytosolic O
ACC1 B-GENE-Y
is O
expressed O
primarily O
in O
liver O
and O
adipose O
tissue, O
and O
uses O
malonyl-coenzyme B-CHEMICAL
A I-CHEMICAL
as O
a O
key O
building O
block O
in O
fatty B-CHEMICAL
acid I-CHEMICAL
biosynthesis. O

The O
mitochondrial O
ACC2 B-GENE-Y
is O
primarily O
expressed O
in O
heart O
and O
skeletal O
muscle, O
where O
it O
is O
involved O
in O
the O
regulation O
of O
fatty B-CHEMICAL
acid I-CHEMICAL
oxidation. O
Inhibitors O
of O
ACC B-GENE-N
enzymes O
may O
therefore O
be O
useful O
therapeutics O
for O
diabetes, O
obesity, O
and O
metabolic O
syndrome. O
Two O
assay O
formats O
for O
these O
ATP-utilizing B-CHEMICAL
enzymes O
amenable O
to O
high-throughput O
screening O
are O
compared: O
a O
fluorescence O
intensity-based O
assay O
to O
detect O
inorganic B-CHEMICAL
phosphate I-CHEMICAL
and O
a O
fluorescence O
polarization-based O
assay O
to O
detect O
ADP. B-CHEMICAL
Acetyl-coenzyme B-CHEMICAL
A I-CHEMICAL
carboxylase I-GENE-N
inhibitors O
were O
identified O
by O
these O
high-throughput O
screening O
methods O

and O
were O
confirmed O
in O
a O
radiometric O
high O
performance O
liquid O
chromatography O
assay O
of O
malonyl-coenzyme B-CHEMICAL
A I-CHEMICAL
production. O
Retinoic B-CHEMICAL
acid I-CHEMICAL
is O
required O
for O
specification O
of O
the O
ventral O
eye O
field O
and O
for O
Rathke's O
pouch O
in O
the O
avian O
embryo. O
We O
have O
investigated O
the O
role O
of O
retinoic B-CHEMICAL
acid I-CHEMICAL
(RA) B-CHEMICAL
in O
eye O
development O
using O
the O
vitamin B-CHEMICAL
A I-CHEMICAL
deficient O
quail O
model O
system, O
which O
overcomes O
problems O
of O
retinoic B-CHEMICAL
acid I-CHEMICAL
synthesising O
enzyme O
redundancy O
in O
the O
embryo. O
In O
the O
absence O
of O
retinoic B-CHEMICAL
acid, I-CHEMICAL
the O
ventral O
optic O
stalk O
and O
ventral O
retina O
are O
missing, O

whereas O
the O
dorsal O
optic O
stalk O
and O
dorsal O
retina O
develop O
appropriately. O
Other O
ocular O
abnormalities O
observed O
were O
a O
thinner O
retina O
and O
the O
lack O
of O
differentiation O
of O
the O
lens. O
In O
an O
attempt O
to O
explain O
this, O
we O
studied O
the O
expression O
of O
various O
dorsally O
and O
ventrally O
expressed O
genes O
such O
as O
Pax2, B-GENE-N
Pax6, B-GENE-Y
Tbx6, B-GENE-N
Vax2, B-GENE-N
Raldh1 B-GENE-N
and O
Raldh3 B-GENE-N
and O
noted O
that O
they O
were O
unchanged O
in O
their O
expression O
patterns. O
In O
contrast, O
the O
RA B-CHEMICAL
catabolising O
enzymes O
Cyp26A1 B-GENE-N
and O
Cyp26B1 B-GENE-N
which O
are O
known O
to O
be O
RA-responsive B-CHEMICAL
were O
not O

expressed O
at O
all O
in O
the O
developing O
eye. O
At O
much O
earlier O
stages, O
the O
expression O
domain O
of O
Shh B-GENE-Y
in O
the O
prechordal O
plate O
was O
reduced, O
as O
was O
Nkx2.1 B-GENE-N
and O
we O
suggest O
a O
model O
whereby O
the O
eye O
field O
is O
specified O
according O
to O
the O
concentration O
of O
SHH B-GENE-Y
protein O
that O
is O
present. O
We O
also O
describe O
another O
organ, O
Rathke's O
pouch O
which O
fails O
to O
develop O
in O
the O
absence O
of O
retinoic B-CHEMICAL
acid. I-CHEMICAL
We O
attribute O
this O
to O
the O
down-regulation O
of O
Bmp2, B-GENE-N
Shh B-GENE-Y
and O
Fgf8 B-GENE-N
which O
are O
known O
to O
be O
involved O
in O
the O
induction O
of O
this O
structure. O
Distinct O
patterns O
of O
mutations O
occurring O
in O

de O
novo O
AML O
versus O
AML O
arising O
in O
the O
setting O
of O
severe O
congenital O
neutropenia. O
Severe O
congenital O
neutropenia O
(SCN) O
is O
an O
inborn O
disorder O
of O
granulopoiesis. O
Like O
most O
other O
bone O
marrow O
failure O
syndromes, O
it O
is O
associated O
with O
a O
marked O
propensity O
to O
transform O
into O
a O
myelodysplastic O
syndrome O
(MDS) O
or O
acute O
leukemia, O
with O
a O
cumulative O
rate O
of O
transformation O
to O
MDS/leukemia O
that O
exceeds O
20%. O
The O
genetic O
(and/or O
epigenetic) O
changes O
that O
contribute O
to O
malignant O
transformation O
in O

SCN O
are O
largely O
unknown. O
In O
this O
study, O
we O
performed O
mutational O
profiling O
of O
14 O
genes O
previously O
implicated O
in O
leukemogenesis O
using O
14 O
MDS/leukemia O
samples O
from O
patients O
with O
SCN. O
We O
used O
high-throughput O
exon-based O
resequencing O
of O
whole-genome-amplified O
genomic O
DNA O
with O
a O
semiautomated O
method O
to O
detect O
mutations. O
The O
sensitivity O
and O
specificity O
of O
the O
sequencing O
pipeline O
was O
validated O
by O
determining O
the O
frequency O
of O
mutations O
in O
these O
14 O
genes O
using O
188 O
de O
novo O
AML O
samples. O
As O
expected, O
mutations O
of O
tyrosine B-GENE-N
kinase I-GENE-N
genes O
(FLT3, B-GENE-Y

KIT, B-GENE-Y
and O
JAK2) B-GENE-Y
were O
common O
in O
de O
novo O
AML, O
with O
a O
cumulative O
frequency O
of O
30%. O
In O
contrast, O
no O
mutations O
in O
these O
genes O
were O
detected O
in O
the O
SCN O
samples; O
instead, O
mutations O
of O
CSF3R, B-GENE-Y
encoding O
the O
G-CSF B-GENE-Y
receptor, I-GENE-Y
were O
common. O
These O
data O
support O
the O
hypothesis O
that O
mutations O
of O
CSF3R B-GENE-Y
may O
provide O
the O
"activated O
tyrosine B-GENE-N
kinase I-GENE-N
signal" O
that O
is O
thought O
to O
be O
important O
for O
leukemogenesis. O
Biology O
of O
incretins: B-GENE-N
GLP-1 B-GENE-Y
and O
GIP. B-GENE-Y
This O
review O
focuses O
on O
the O
mechanisms O
regulating O
the O
synthesis, O
secretion, O

biological O
actions, O
and O
therapeutic O
relevance O
of O
the O
incretin B-GENE-N
peptides O
glucose-dependent B-CHEMICAL
insulinotropic I-GENE-Y
polypeptide I-GENE-Y
(GIP) B-GENE-Y
and O
glucagon-like B-GENE-Y
peptide-1 I-GENE-Y
(GLP-1). B-GENE-Y
The O
published O
literature O
was O
reviewed, O
with O
emphasis O
on O
recent O
advances O
in O
our O
understanding O
of O
the O
biology O
of O
GIP B-GENE-Y
and O
GLP-1. B-GENE-Y
GIP B-GENE-Y
and O
GLP-1 B-GENE-Y
are O
both O
secreted O
within O
minutes O
of O
nutrient O
ingestion O
and O
facilitate O
the O
rapid O
disposal O
of O
ingested O
nutrients. O
Both O
peptides O
share O
common O
actions O
on O
islet O
beta-cells O
acting O
through O
structurally O
distinct O
yet O
related O
receptors. O

Incretin-receptor B-GENE-N
activation O
leads O
to O
glucose-dependent B-CHEMICAL
insulin B-GENE-Y
secretion, O
induction O
of O
beta-cell O
proliferation, O
and O
enhanced O
resistance O
to O
apoptosis. O
GIP B-GENE-Y
also O
promotes O
energy O
storage O
via O
direct O
actions O
on O
adipose O
tissue, O
and O
enhances O
bone O
formation O
via O
stimulation O
of O
osteoblast O
proliferation O
and O
inhibition O
of O
apoptosis. O
In O
contrast, O
GLP-1 B-GENE-Y
exerts O
glucoregulatory O
actions O
via O
slowing O
of O
gastric O
emptying O
and O
glucose-dependent B-CHEMICAL
inhibition O
of O
glucagon B-GENE-Y
secretion. O
GLP-1 B-GENE-Y
also O
promotes O
satiety O
and O
sustained O
GLP-1-receptor B-GENE-N
activation O
is O
associated O
with O
weight O

loss O
in O
both O
preclinical O
and O
clinical O
studies. O
The O
rapid O
degradation O
of O
both O
GIP B-GENE-Y
and O
GLP-1 B-GENE-Y
by O
the O
enzyme O
dipeptidyl B-GENE-Y
peptidase-4 I-GENE-Y
has O
led O
to O
the O
development O
of O
degradation-resistant O
GLP-1-receptor B-GENE-Y
agonists O
and O
dipeptidyl B-GENE-Y
peptidase-4 I-GENE-Y
inhibitors O
for O
the O
treatment O
of O
type O
2 O
diabetes. O
These O
agents O
decrease O
hemoglobin B-GENE-Y
A1c I-GENE-Y
(HbA1c) B-GENE-Y
safely O
without O
weight O
gain O
in O
subjects O
with O
type O
2 O
diabetes. O
GLP-1 B-GENE-Y
and O
GIP B-GENE-Y
integrate O
nutrient-derived O
signals O
to O
control O
food O
intake, O
energy O
absorption, O
and O

assimilation. O
Recently O
approved O
therapeutic O
agents O
based O
on O
potentiation O
of O
incretin B-GENE-N
action O
provide O
new O
physiologically O
based O
approaches O
for O
the O
treatment O
of O
type O
2 O
diabetes. O
[Characteristics O
of O
A-interferon-generated B-GENE-N
dendritic O
cells O
in O
patients O
with O
pulmonary O
tuberculosis]. O
The O
phenotype O
of O
the O
dendritic O
cells O
(DC) O
generated O
from O
the O
adhesion O
fraction O
of O
mononuclear O
cells O
in O
the O
presence O
of O
GM-CSF O
and O
alpha-interferon B-GENE-N
was O
studied O
in O
patients O
with O
pulmonary O
tuberculosis. O
Despite O
the O
absence O
of O
significant O
differences O
in O
the O
count O
of O
mature O
CD83+DCs O
in O
the O
groups O
of O
patients O
(n O

= O
38) O
and O
healthy O
donors O
(n O
= O
30), O
elevated O
CD14(+)-monocyte O
levels O
and O
few O
activated O
CD25(+)-DCs O
were O
indicative O
of O
the O
impaired O
process O
of O
DC O
maturation/generation O
in O
patients O
with O
pulmonary O
tuberculosis, O
particularly O
in O
a O
subgroup O
of O
patients O
with O
a O
low O
T-cell O
proliferative O
response O
against O
PPD O
(PPD-anergy, O
n O
= O
10). O
The O
patients O
with O
tuberculosis O
showed O
the O
lower O
relative O
levels O
of O
CD11c(-)-CD123(+)-DC O
and O
the O
normal O
levels O
of O
myeloid O

CD11c(+)D123(-)DCs. O
However, O
in O
patients O
with O
PPD-anergy, O
the O
content O
of O
myeloid O
CD11c(+)CD123(-)-DCs O
was O
significantly O
higher O
than O
that O
in O
PPD-reactive O
patients. O
Moreover, O
the O
patients O
with O
PPD-anergy O
were O
characterized O
by O
the O
elevated O
peripheral O
blood O
levels O
of O
CD14+CD16(+)-monocytes, O
which O
was O
associated O
with O
the O
high O
suppressive O
activity O
of O
monocytes O
(r(s) O
= O
0.53; O
p O
< O
0.05). O
The O
impaired O
process O
of O
DC O

generation/maturation O
in O
patients O
with O
pulmonary O
tuberculosis O
is O
believed O
to O
be O
associated O
with O
the O
changes O
in O
the O
phenotypic O
and O
functional O
properties O
of O
monocytes O
and O
to O
be O
a O
cause O
of O
an O
inadequate O
antigen-specific O
response O
in O
tuberculous O
infection. O
Aripiprazole O
acts O
as O
a O
selective O
dopamine B-GENE-Y
D2 I-GENE-Y
receptor I-GENE-Y
partial O
agonist. O
Aripiprazole B-CHEMICAL
has O
made O
a O
significant O
contribution O
to O
the O
treatment O
of O
schizophrenia O
and O
related O
disorders O
with O
an O
improved O
safety O
and O
tolerability O
profile, O
which O
has O
been O
attributed O
to O
its O
unique O
pharmacological O
profile. O
It O
has O
been O
claimed O
that O
partial O
agonism O
of O
the O
dopamine B-CHEMICAL

D(2) I-GENE-N
and I-GENE-N
5-HT(1A) I-GENE-N
receptors I-GENE-N
and O
antagonism O
of O
the O
5-HT(2) B-GENE-Y
receptor O
contribute O
to O
the O
clinical O
profile O
of O
aripiprazole, B-CHEMICAL
a O
so-called O
dopamine- B-CHEMICAL
and O
5-HT B-CHEMICAL
stabiliser. O
However, O
recent O
studies O
have O
questioned O
the O
role O
of O
the O
5-HT-mediated B-CHEMICAL
systems O
in O
the O
mechanism O
of O
action O
of O
aripiprazole. B-CHEMICAL
This O
report O
reviews O
published O
and O
unpublished O
data O
that O
suggest O
that O
aripiprazole B-CHEMICAL
acts O
as O
a O
selective O
partial O
agonist O
at O
the O
dopamine B-CHEMICAL
D(2) I-GENE-Y
receptor I-GENE-Y
and O
does O
not O
affect O
5-HT B-GENE-N
receptors I-GENE-N

at O
therapeutic O
doses. O
Pharmacological O
therapy O
of O
Cushing's O
syndrome: O
drugs O
and O
indications. O
OBJECTIVE: O
To O
review O
the O
main O
pharmacological O
properties O
and O
clinical O
applications O
of O
the O
drugs O
used O
in O
the O
medical O
therapy O
of O
Cushing's O
syndrome. O
DATA O
SOURCES: O
Search O
for O
articles O
were O
performed O
in O
the O
following O
dababases: O
MEDLINE, O
EMBASE, O
Cochrane O
Database O
of O
systematic O
Reviews O
and O
The O
Cochrane O
Central O
Register O
of O
Controlled O
Trials O
(CENTRAL). O
Search O
terms O
included O
Cushing's O
syndrome O
and O
drug O
therapy. O
DATA O

SYNTHESIS: O
Available O
data O
suggest O
that O
neuromodulatory O
compounds O
affect O
corticotropin B-GENE-Y
(ACTH) B-GENE-Y
or O
ACTH-releasing B-GENE-Y
hormone I-GENE-Y
(CRH) B-GENE-Y
synthesis O
and O
release. O
They O
include O
serotonin B-CHEMICAL
antagonists, O
dopaminergic O
agonists, O
valproic B-CHEMICAL
acid, I-CHEMICAL
reserpine, B-CHEMICAL
somatostatin B-GENE-Y
analogs O
and O
thiazolidinediones. B-CHEMICAL
These O
agents O
have O
been O
effective O
in O
a O
limited O
number O
of O
patients O
with O
ACTH-dependent B-GENE-Y
Cushing's O
syndrome. O
Inhibitors O
of O
steroidogenesis O
reduce O
cortisol O
production O
by O

blocking O
one O
(metyrapone, B-CHEMICAL
trilostane) B-CHEMICAL
or O
several O
(aminoglutethimide, B-CHEMICAL
ketoconazole, B-CHEMICAL
fluconazole, B-CHEMICAL
etomidate) B-CHEMICAL
enzymes O
involved O
in O
steroid O
biosynthesis. O
Mitotane B-CHEMICAL
is O
a O
steroidogenesis O
inhibitor O
with O
adrenolitic O
properties. O
Mifepriston'e B-CHEMICAL
blocks O
glucocorticoid B-GENE-Y
receptor I-GENE-Y
activation O
without O
modifying O
cortisol B-CHEMICAL
synthesis. O
CONCLUSION: O
Agents O
that O
inhibit O
steroidogenesis O
are O
useful O
in O
all O
forms O
of O
Cushing's O
syndrome O
and O
are O
effective O
in O
about O
70% O
of O

patients. O
Main O
indications O
for O
drug O
therapy O
include O
preparation O
for O
surgery, O
persistence O
or O
recurrence O
after O
surgery, O
while O
awaiting O
for O
the O
effect O
of O
radiation O
therapy, O
occult O
ectopic O
ACTH B-GENE-Y
syndrome, O
severe O
hypercortisolism O
and O
malignancy O
related O
hypercortisolism. O
Cannabinoid B-GENE-Y
CB1 I-GENE-Y
receptors I-GENE-Y
in O
the O
paraventricular O
nucleus O
and O
central O
control O
of O
penile O
erection: O
immunocytochemistry, O
autoradiography O
and O
behavioral O
studies. O

[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] B-CHEMICAL
(SR B-CHEMICAL
141716A), I-CHEMICAL
a O
selective O
cannabinoid B-CHEMICAL
CB1 I-GENE-Y
receptor I-GENE-Y
antagonist, O
injected O
into O
the O
paraventricular O
nucleus O
of O
the O
hypothalamus O
(PVN) O
of O
male O
rats, O
induces O
penile O
erection. O
This O
effect O
is O
mediated O
by O
the O
release O
of O
glutamic B-CHEMICAL
acid, I-CHEMICAL
which O
in O
turn O
activates O
central O
oxytocinergic O
neurons O
mediating O
penile O

erection. O
Double O
immunofluorescence O
studies O
with O
selective O
antibodies O
against O
CB1 B-GENE-Y
receptors, I-GENE-Y
glutamic B-CHEMICAL
acid I-CHEMICAL
transporters I-GENE-N
(vesicular B-GENE-N
glutamate I-GENE-N
transporters I-GENE-N
1 I-GENE-N
and I-GENE-N
2 I-GENE-N
(VGlut1 B-GENE-Y
and O
VGlut2), B-GENE-Y
glutamic B-GENE-Y
acid I-GENE-Y
decarboxylase-67 I-GENE-Y
(GAD67) B-GENE-Y
and O
oxytocin B-GENE-Y
itself, O
have O
shown O
that O
CB1 B-GENE-Y
receptors I-GENE-Y
in O
the O
PVN O
are O
located O
mainly O
in O
GABAergic O
terminals O
and O
fibers O
surrounding O
oxytocinergic O
cell O
bodies. O
As O
GABAergic O
synapses O
in O
the O
PVN O
impinge O
directly O
on O

oxytocinergic O
neurons O
or O
on O
excitatory O
glutamatergic O
synapses, O
which O
also O
impinge O
on O
oxytocinergic O
neurons, O
these O
results O
suggest O
that O
the O
blockade O
of O
CB1 B-GENE-Y
receptors I-GENE-Y
decreases O
GABA B-CHEMICAL
release O
in O
the O
PVN, O
increasing O
in O
turn O
glutamatergic O
neurotransmission O
to O
activate O
oxytocinergic O
neurons O
mediating O
penile O
erection. O
Autoradiography O
studies O
with O
[(3)H](-)-CP B-CHEMICAL
55,940 I-CHEMICAL
show O
that O
chronic O
treatment O
with O
SR B-CHEMICAL
141716A I-CHEMICAL
for O
15 O
days O
twice O
daily O
(1 O
mg/kg O

i.p.) O
significantly O
increases O
the O
density O
of O
CB1 B-GENE-Y
receptors I-GENE-Y
in O
the O
PVN. O
This O
increase O
occurs O
concomitantly O
with O
an O
almost O
twofold O
increase O
in O
the O
pro-erectile O
effect O
of O
SR B-CHEMICAL
141716A I-CHEMICAL
injected O
into O
the O
PVN O
as O
compared O
with O
control O
rats. O
The O
present O
findings O
confirm O
that O
PVN O
CB1 B-GENE-Y
receptors, I-GENE-Y
localized O
mainly O
in O
GABAergic O
synapses O
that O
control O
in O
an O
inhibitory O
fashion O
excitatory O
synapses, O
exert O
an O
inhibitory O
control O
on O
penile O
erection, O
demonstrating O
for O
the O
first O
time O
that O
chronic O
blockade O
of O
CB1 B-GENE-Y
receptors I-GENE-Y
by O
SR B-CHEMICAL
141716A I-CHEMICAL
increases O
the O
density O
of O
these O

receptors O
in O
the O
PVN. O
This O
increase O
is O
related O
to O
an O
enhanced O
pro-erectile O
effect O
of O
SR B-CHEMICAL
141716A, I-CHEMICAL
which O
is O
still O
present O
3 O
days O
after O
the O
end O
of O
the O
chronic O
treatment. O
Activation O
of O
human O
platelets O
by O
misfolded O
proteins. O
OBJECTIVE: O
Protein O
misfolding O
diseases O
result O
from O
the O
deposition O
of O
insoluble O
protein O
aggregates O
that O
often O
contain O
fibrils O
called O
amyloid. B-GENE-Y
Amyloids B-GENE-Y
are O
found O
in O
Alzheimer O
disease, O
atherosclerosis, O
diabetes O
mellitus, O
and O
systemic O
amyloidosis, O
which O
are O
diseases O
where O
platelet O
activation O
might O
be O

implicated. O
METHODS O
AND O
RESULTS: O
We O
induced O
amyloid B-GENE-Y
properties O
in O
6 O
unrelated O
proteins O
and O
found O
that O
all O
induced O
platelet O
aggregation O
in O
contrast O
to O
fresh O
controls. O
Amyloid-induced B-GENE-Y
platelet O
aggregation O
was O
independent O
of O
thromboxane B-CHEMICAL
A2 I-CHEMICAL
formation O
and O
ADP B-CHEMICAL
secretion O
but O
enhanced O
by O
feedback O
stimulation O
through O
these O
pathways. O
Treatments O
that O
raised O
cAMP B-CHEMICAL
(iloprost), B-CHEMICAL
sequestered O
Ca2+ B-CHEMICAL
(BAPTA-AM) B-CHEMICAL
or O
prevented O
amyloid-platelet B-GENE-Y
interaction O
(sRAGE, O
tissue-type B-GENE-Y
plasminogen I-GENE-Y
activator I-GENE-Y

[tPA]) B-GENE-Y
induced O
almost O
complete O
inhibition. O
Modulation O
of O
the O
function O
of O
CD36 B-GENE-N
(CD36-/- O
mice), O
p38(MAPK) B-GENE-N
(SB203580), B-CHEMICAL
COX-1 B-GENE-N
(indomethacin), B-CHEMICAL
and O
glycoprotein B-GENE-N
Ib I-GENE-N
alpha I-GENE-N
(Nk-protease, B-GENE-N
6D1 O
antibody) O
induced O
approximately O
50% O
inhibition. O
Interference O
with O
fibrinogen B-GENE-N
binding O
(RGDS) O
revealed O
a O
major O
contribution O
of O
alphaIIb B-GENE-N
beta3-independent I-GENE-N
aggregation O
(agglutination). O

CONCLUSIONS: O
Protein O
misfolding O
resulting O
in O
the O
appearance O
of O
amyloid B-GENE-N
induces O
platelet O
aggregation. O
Amyloid B-GENE-N
activates O
platelets O
through O
2 O
pathways: O
one O
is O
through O
CD36, B-GENE-N
p38(MAPK), B-GENE-N
thromboxane B-CHEMICAL
A2-mediated I-CHEMICAL
induction O
of O
aggregation; O
the O
other O
is O
through O
glycoprotein B-GENE-N
Ib I-GENE-N
alpha-mediated I-GENE-N
aggregation O
and O
agglutination. O
The O
platelet O
stimulating O
properties O
of O
amyloid O
might O
explain O
the O
enhanced O
platelet O
activation O
observed O
in O
many O
diseases O
accompanied O
by O
the O
appearance O
of O
misfolded O
proteins O
with O

amyloid. O
RDH12, B-GENE-Y
a O
retinol B-CHEMICAL
dehydrogenase I-GENE-N
causing O
Leber's O
congenital O
amaurosis, O
is O
also O
involved O
in O
steroid O
metabolism. O
Three O
retinol B-CHEMICAL
dehydrogenases I-GENE-N
(RDHs) B-GENE-N
were O
tested O
for O
steroid O
converting O
abilities: O
human B-GENE-N
and I-GENE-N
murine I-GENE-N
RDH I-GENE-N
12 I-GENE-N
and O
human B-GENE-Y
RDH13. I-GENE-Y
RDH12 B-GENE-Y
is O
involved O
in O
retinal O
degeneration O
in O
Leber's O
congenital O
amaurosis O
(LCA). O
We O
show O
that O
murine B-GENE-Y
Rdh12 I-GENE-Y
and O
human B-GENE-Y
RDH13 I-GENE-Y
do O
not O
reveal O

activity O
towards O
the O
checked O
steroids, O
but O
that O
human B-GENE-Y
type I-GENE-Y
12 I-GENE-Y
RDH I-GENE-Y
reduces O
dihydrotestosterone O
to O
androstanediol, B-CHEMICAL
and O
is O
thus O
also O
involved O
in O
steroid O
metabolism. O
Furthermore, O
we O
analyzed O
both O
expression O
and O
subcellular O
localization O
of O
these O
enzymes. O
Alteration O
of O
gastric O
functions O
and O
candidate O
genes O
associated O
with O
weight O
reduction O
in O
response O
to O
sibutramine. B-CHEMICAL
BACKGROUND O
& O
AIMS: O
It O
is O
unclear O
whether O
weight O
loss O
with O
the O
noradrenergic O
(norepinephrine) B-CHEMICAL
and O
serotonergic O
(5-hydroxytryptamine) B-CHEMICAL

reuptake O
inhibitor, O
sibutramine, B-CHEMICAL
is O
associated O
with O
altered O
stomach O
functions O
and O
whether O
genetics O
influence O
treatment O
response. O
METHODS: O
Forty-eight O
overweight O
and O
obese O
but O
otherwise O
healthy O
participants O
were O
randomized O
to O
placebo O
or O
sibutramine B-CHEMICAL
(15 O
mg/day O
for O
12 O
weeks). O
At O
baseline O
and O
posttreatment O
we O
measured O
the O
following: O
gastric O
emptying O
for O
solids O
and O
liquids O
by O
scintigraphy, O
gastric O
volumes O
by O
single-photon O
emission O
computed O
tomography, O
maximum O
tolerated O
volume O
and O
30-minute O
postnutrient O
challenge O
symptoms, O
and O
selected O

gastrointestinal O
hormones. O
All O
participants O
received O
structured O
behavior O
therapy O
for O
weight O
management. O
The O
influence O
of O
candidate O
gene O
polymorphisms O
involved O
in O
norepinephrine B-CHEMICAL
and O
5-hydroxytryptamine B-CHEMICAL
or O
receptor O
function O
(phenylethanolamine B-CHEMICAL
N-methyltransferase, B-CHEMICAL
guanine B-GENE-Y
nucleotide I-GENE-Y
binding I-GENE-Y
protein I-GENE-Y
beta I-GENE-Y
polypeptide I-GENE-Y
3, I-GENE-Y
alpha2A B-GENE-Y
adrenoreceptor, I-GENE-Y
and O
solute B-GENE-Y
carrier I-GENE-Y
family I-GENE-Y
6 I-GENE-Y
[neurotransmitter I-GENE-Y
transporter, I-GENE-Y
serotonin] B-CHEMICAL
member I-GENE-Y
4 I-GENE-Y
[homo O
sapiens] O
[SLC6A4]) B-GENE-Y

on O
weight O
loss O
and O
gastric O
functions O
was O
evaluated. O
RESULTS: O
The O
overall O
average O
weight O
loss O
posttreatment O
was O
5.4 O
+/- O
0.8 O
(SEM) O
kg O
with O
sibutramine B-CHEMICAL
and O
0.9 O
+/- O
0.9 O
kg O
with O
placebo O
(P O
< O
.001). O
The O
sibutramine B-CHEMICAL
group O
showed O
significant O
retardation O
in O
gastric O
emptying O
of O
solids O
(P O
= O
.03), O
reduced O
maximum O
tolerated O
volume O
(P O
= O
.03), O
and O
increased O
postprandial O
peptide B-GENE-Y
YY I-GENE-Y
compared O
with O
the O
placebo O
group. O
Obese O
females O

showed O
greater O
effects O
of O
sibutramine B-CHEMICAL
on O
weight O
loss O
and O
gastric O
emptying O
of O
solids O
and O
liquids. O
Gastric O
volumes O
and O
postchallenge O
symptoms O
were O
not O
significantly O
different O
in O
the O
2 O
treatment O
groups. O
The O
LS/SS O
genotype O
of O
the O
promoter O
for O
SLC6A4 B-GENE-Y
was O
associated O
with O
enhanced O
weight O
loss O
with O
sibutramine. B-CHEMICAL
CONCLUSIONS: O
Weight O
reduction O
with O
sibutramine B-CHEMICAL
is O
associated O
with O
altered O
gastric O
functions O
and O
increased O
peptide B-GENE-Y
YY I-GENE-Y
and O
is O
significantly O
associated O
with O
SLC6A4 B-GENE-Y
genotype. O
The O
role O
of O
genetic O
variation O
in O
SLC6A4 B-GENE-Y
on O
weight O
loss O

in O
response O
to O
sibutramine B-CHEMICAL
deserves O
further O
study. O
Multiple O
rat B-GENE-Y
brain I-GENE-Y
calpastatin I-GENE-Y
forms O
are O
produced O
by O
distinct O
starting O
points O
and O
alternative O
splicing O
of O
the O
N-terminal B-CHEMICAL
exons. O
5'-RACE O
was O
performed O
on O
rat B-GENE-Y
brain I-GENE-Y
calpastatin I-GENE-Y
mRNA O
and O
two O
new O
translation O
initiation O
ATG's O
were O
found. O
The O
first O
one O
is O
upstream O
of O
the O
previously O
designed O
initiation O
translation O
site O
localized O
in O
the O
rat B-GENE-N
calpastatin I-GENE-N
L-domain. I-GENE-N
The O
deduced O
protein O
sequence O
of O
this O
region O
is O
highly O
homologous O
to O
the O
XL-domain B-GENE-N
of O
calpastatin B-GENE-N
type I-GENE-N
I I-GENE-N
in O
other O
species. O
The O

other O
ATG O
has O
not O
previously O
been O
reported O
and O
is O
localized O
in O
exon O
8, O
thus O
originating O
a O
calpastatin B-GENE-Y
isoform O
constituted O
only O
by O
four O
repetitive O
inhibitory O
units O
without O
the O
XL-L-domains. B-GENE-N
Transcripts O
from O
the O
rat B-GENE-Y
brain I-GENE-Y
calpastatin I-GENE-Y
gene O
are O
also O
subjected O
to O
multiple O
splicing O
events O
involving O
exons O
4, O
6, O
8 O
in O
different O
combinations. O
A O
series O
of O
recombinant O
calpastatin B-GENE-Y
forms O
was O
produced O
that O
differed O
in O
the O
exons O
present O
in O
the O
L-domain, B-GENE-N
and O
all O
the O
variants O
showed O
comparable O
inhibitory O
efficiency O
against O
calpain. B-GENE-N
It O
was O
concluded O
that O
the O
presence O

of O
the O
XL-domain B-GENE-N
in O
these O
isoforms O
is O
not O
relevant O
for O
the O
formation O
of O
the O
calpain/calpastatin B-GENE-N
complex O
in O
the O
absence O
of O
calcium, B-CHEMICAL
that O
is O
the O
interaction O
of O
calpastatin B-GENE-Y
with O
inactive O
calpain. B-GENE-N
Using O
exon-specific O
antisera, O
specific O
calpastatin B-GENE-Y
protein O
isoforms O
containing O
the O
XL-domain B-GENE-N
have O
been O
detected O
in O
rat O
brain O
homogenates. O
An O
investigation O
of O
the O
absolute O
configuration O
of O
the O
potent O
histamine B-GENE-Y
H3 I-GENE-Y
receptor I-GENE-Y
antagonist O
GT-2331 B-CHEMICAL
using O
vibrational O
circular O
dichroism. O
GT-2331 B-CHEMICAL

[(+)-1] O
is O
one O
of O
the O
most O
potent O
members O
of O
a O
class O
of O
chiral O
drug O
substances O
used O
to O
regulate O
the O
synthesis O
and O
release O
of O
histamine B-CHEMICAL
by O
the O
histamine B-GENE-Y
H3 I-GENE-Y
receptor, I-GENE-Y
and O
as O
such, O
is O
an O
important O
biomarker O
for O
pharmaceutical O
companies O
conducting O
research O
in O
this O
field. O
In O
addition O
to O
overall O
structural O
features, O
the O
bioactivity O
of O
this O
molecule O
has O
also O
been O
found O
to O
be O
highly O
dependent O
on O
absolute O
stereochemistry, O
making O
the O
reliable O
assignment O
of O
this O
property O
a O
necessity. O
X-ray O
diffraction O
studies O
have O
provided O
conflicting O
data, O
leaving O
its O
three-dimensional O
structure O
uncertain. O
In O
view O
of O
this, O
its O
absolute O
configuration O
was O

investigated O
by O
vibrational O
circular O
dichroism. O
Results O
from O
this O
study O
provided O
independent O
assignment O
of O
this O
important O
molecule O
as O
the O
(1S,2S)-enantiomer. O
Allosteric O
interaction O
of O
the O
neuromuscular O
blockers O
vecuronium B-CHEMICAL
and O
pancuronium B-CHEMICAL
with O
recombinant O
human B-GENE-Y
muscarinic I-GENE-Y
M2 I-GENE-Y
receptors. I-GENE-Y
Neuromuscular O
blocking O
drugs O
produce O
muscle O
weakness O
by O
interaction O
with O
nicotinic-acetylcholine B-GENE-N
receptors. I-GENE-N
Cardiovascular O
side O
effects O
have O
been O
reported. O
In O
this O
study O
the O
neuromuscular O
blocking O
drug O
vecuronium B-CHEMICAL
and O
the O
controls O
gallamine B-CHEMICAL
and O

pancuronium B-CHEMICAL
slowed O
the O
rate O
of O
atropine B-CHEMICAL
induced O
[(3)H]N-methylscopolamine B-CHEMICAL
dissociation O
from O
Chinese O
hamster O
ovary O
cells O
expressing O
recombinant O
human B-GENE-Y
muscarinic I-GENE-Y
M2 I-GENE-Y
receptors I-GENE-Y
K(off) O
values O
min(-1); O
vecuronium B-CHEMICAL
(125 O
nM), O
atropine B-CHEMICAL
0.45+/-0.07+blocker O
0.04+/-0.02; O
gallamine B-CHEMICAL
(21 O
nM), O
atropine B-CHEMICAL
0.42+/-0.05+blocker O

0.15+/-0.04; O
pancuronium(21 B-CHEMICAL
nM), O
atropine B-CHEMICAL
0.36+/-0.03+blocker O
0.03+/-0.01). O
These O
data O
indicate O
that O
vecuronium, B-CHEMICAL
gallamine B-CHEMICAL
and O
pancuronium B-CHEMICAL
interact O
with O
an O
allosteric O
site O
on O
the O
muscarinic B-GENE-Y
M2 I-GENE-Y
receptor I-GENE-Y
(located O
on O
the O
heart) O
and O
this O
may O
explain O
some O
of O
their O
cardiac O
side O
effects. O
Hydrogen B-CHEMICAL
peroxide-mediated I-CHEMICAL
oxidative O
stress O
disrupts O
calcium B-CHEMICAL
binding O
on O
calmodulin: B-GENE-Y
more O
evidence O
for O
oxidative O
stress O

in O
vitiligo. O
Patients O
with O
acute O
vitiligo O
have O
low O
epidermal O
catalase B-GENE-Y
expression/activities O
and O
accumulate O
10(-3) O
M O
H(2)O(2). B-CHEMICAL
One O
consequence O
of O
this O
severe O
oxidative O
stress O
is O
an O
altered O
calcium B-CHEMICAL
homeostasis O
in O
epidermal O
keratinocytes O
and O
melanocytes. O
Here, O
we O
show O
decreased O
epidermal O
calmodulin B-GENE-Y
expression O
in O
acute O
vitiligo. O
Since O
10(-3)M O
H(2)O(2) B-CHEMICAL
oxidises O
methionine B-CHEMICAL
and O
tryptophan B-CHEMICAL

residues O
in O
proteins, O
we O
examined O
calcium B-CHEMICAL
binding O
to O
calmodulin B-GENE-Y
in O
the O
presence O
and O
absence O
of O
H(2)O(2) B-CHEMICAL
utilising O
(45)calcium. B-CHEMICAL
The O
results O
showed O
that O
all O
four O
calcium B-CHEMICAL
atoms O
exchanged O
per O
molecule O
of O
calmodulin. B-GENE-Y
Since O
oxidised O
calmodulin B-GENE-Y
looses O
its O
ability O
to O
activate O
calcium B-GENE-N
ATPase, I-GENE-N
enzyme O
activities O
were O
followed O
in O
full O
skin O
biopsies O
from O
lesional O
skin O
of O
patients O
with O
acute O
vitiligo O
(n=6) O
and O
healthy O
controls O
(n=6). O
The O
results O
yielded O
a O
4-fold O
decrease O
of O
ATPase O
activities O
in O
the O
patients. O
Computer O
simulation O
of O
native O
and O

oxidised O
calmodulin B-GENE-Y
confirmed O
the O
loss O
of O
all O
four O
calcium B-CHEMICAL
ions O
from O
their O
specific O
EF-hand B-GENE-N
domains. I-GENE-N
Taken O
together O
H(2)O(2)-mediated B-CHEMICAL
oxidation O
affects O
calcium B-CHEMICAL
binding O
in O
calmodulin B-GENE-Y
leading O
to O
perturbed O
calcium B-CHEMICAL
homeostasis O
and O
perturbed O
l-phenylalanine-uptake B-CHEMICAL
in O
the O
epidermis O
of O
acute O
vitiligo. O
The O
genetic O
interaction O
between O
VKORC1 B-GENE-Y
c1173t B-GENE-N
and O
calumenin B-GENE-Y
a29809g B-GENE-N
modulates O
the O
anticoagulant O
response O
of O
acenocoumarol. O

BACKGROUND: O
The O
efficacy O
of O
oral O
anticoagulant O
therapy O
is O
largely O
conditioned O
by O
both O
environmental O
and O
genetic O
factors. O
OBJECTIVES: O
To O
attempt O
to O
define O
the O
genetic O
profile O
involved O
in O
the O
response O
to O
this O
treatment. O
PATIENTS O
AND O
METHODS: O
We O
selected O
100 O
men O
younger O
than O
75 O
years, O
with O
non-valvular O
atrial O
fibrillation, O
who O
started O
anticoagulation O
with O
acenocoumarol O
following O
the O
same O
protocol: O
3 O
mg O
for O
three O
consecutive O
days. O
Then, O
doses O
were O
individually O
adjusted O
to O
achieve O
a O
steady O
International O
Normalized O
Ratio O

(INR). O
The O
basal O
plasma O
level O
and O
the O
level O
after O
3 O
days O
were O
obtained, O
and O
the O
INR O
was O
determined. O
We O
studied O
five O
functional O
polymorphisms: O
FVII B-GENE-Y
-323 O
Del/Ins, O
CYP2C*9, B-GENE-Y
VKORC1 B-GENE-Y
c1173t, B-GENE-N
calumenin B-GENE-Y
(CALU) B-GENE-Y
R4Q B-GENE-N
and O
CALU B-GENE-Y
a29809g. B-GENE-N
The O
dose O
required O
for O
a O
steady O
INR O
was O
also O
recorded. O
RESULTS: O
Only O
the O
VKORC1 B-GENE-Y
genotype O
had O
significant O
impact O
on O
the O
efficacy O
of O
therapy. O
Carriers O
of O
the O

1173t O
allele O
were O
significantly O
more O
sensitive O
to O
therapy O
for O
3 O
days O
[INR O
2.07 O
(1.59-2.87) O
vs. O
1.74 O
(1.30-2.09); O
P O
= O
0.015] O
and O
they O
needed O
lower O
acenocoumarol O
doses O
to O
stabilize O
their O
INR O
(15.8 O
+/- O
5.6 O
vs. O
19.5 O
+/- O
6.0 O
mg O
week(-1); O
P O
= O
0.004). O
Its O
effect O
was O
exacerbated O
by O
combination O
with O
the O
CALU B-GENE-Y
a29809g B-GENE-N

polymorphism. O
Carriers O
of O
both O
variants O
(27% O
of O
the O
sample) O
achieved O
the O
highest O
INR O
[2.26 O
(1.70-3.32)] O
and O
required O
the O
lowest O
dose O
(14.1 O
+/- O
5.1 O
mg O
week(-1)). O
This O
genetic O
profile O
was O
particularly O
relevant O
in O
patients O
with O
INR O
>or= O
3.5 O
at O
the O
start O
of O
therapy O
(P O
= O
0.005; O
odds O
ratio O
= O
6.67, O
95% O
confidence O
interval O
= O
1.32-37.43). O
CONCLUSIONS: O
Our O
results O
suggest O
that O
CALU B-GENE-Y

a29809g B-GENE-N
might O
be O
a O
new O
genetic O
factor O
involved O
in O
the O
pharmacogenetics O
of O
anticoagulant O
therapy, O
and O
confirm O
that O
specific O
genetic O
profiles O
defined O
by O
different O
polymorphisms O
will O
determine O
the O
initial O
response O
and O
dose O
required O
to O
achieve O
a O
stable O
and O
safe O
INR. O
Characterization O
of O
the O
nitrosyl B-CHEMICAL
adduct O
of O
substrate-bound O
mouse B-GENE-Y
cysteine I-GENE-Y
dioxygenase I-GENE-Y
by O
electron O
paramagnetic O
resonance: O
electronic O
structure O
of O
the O
active O
site O
and O
mechanistic O
implications. O
Mammalian B-GENE-Y
cysteine I-GENE-Y
dioxygenase I-GENE-Y
(CDO) B-GENE-Y
is O
a O
non-heme O
iron B-CHEMICAL

metalloenzyme O
that O
catalyzes O
the O
first O
committed O
step O
in O
oxidative O
cysteine B-CHEMICAL
catabolism. O
The O
active O
site O
coordination O
of O
CDO B-GENE-Y
comprises O
a O
mononuclear O
iron B-CHEMICAL
ligated O
by O
the O
Nepsilon O
atoms O
of O
three O
protein-derived O
histidines, B-CHEMICAL
thus O
representing O
a O
new O
variant O
on O
the O
2-histidine-1-carboxylate B-GENE-N
(2H1C) I-GENE-N
facial I-GENE-N
triad I-GENE-N
motif. I-GENE-N
Nitric B-CHEMICAL
oxide I-CHEMICAL
was O
used O
as O
a O
spectroscopic O
probe O
in O
investigating O
the O
order O
of O
substrate-O2 B-CHEMICAL
binding O
by O
EPR O
spectroscopy. O
In O
these O
experiments, O

CDO B-GENE-Y
exhibits O
an O
ordered O
binding O
of O
l-cysteine B-CHEMICAL
prior O
to O
NO B-CHEMICAL
(and O
presumably O
O2) B-CHEMICAL
similar O
to O
that O
observed O
for O
the O
2H1C B-GENE-N
class I-GENE-N
of I-GENE-N
non-heme I-GENE-N
iron I-GENE-N
enzymes. I-GENE-N
Moreover, O
the O
CDO B-GENE-Y
active O
site O
is O
essentially O
unreactive O
toward O
NO B-CHEMICAL
in O
the O
absence O
of O
substrate, O
suggesting O
an O
obligate O
ordered O
binding O
of O
l-cysteine B-CHEMICAL
prior O
to O
NO. B-CHEMICAL
Typically, O
addition O
of O
NO B-CHEMICAL
to O
a O
mononuclear O
non-heme O
iron B-CHEMICAL
center O
results O
in O
the O
formation O
of O
an O
{FeNO}7 B-CHEMICAL
(S O
= O
3/2) O
species O
characterized O
by O
an O
axial O
EPR O
spectrum O
with O

gx, O
gy, O
and O
gz O
values O
of O
approximately O
4, O
approximately O
4, O
and O
approximately O
2, O
respectively. O
However, O
upon O
addition O
of O
NO B-CHEMICAL
to O
CDO B-GENE-Y
in O
the O
presence O
of O
substrate O
l-cysteine, B-CHEMICAL
a O
low-spin O
{FeNO}7 B-CHEMICAL
(S O
= O
1/2) O
signal O
that O
accounts O
for O
approximately O
85% O
of O
the O
iron B-CHEMICAL
within O
the O
enzyme O
develops. O
Similar O
{FeNO}7 B-CHEMICAL
(S O
= O
1/2) O
EPR O
signals O
have O
been O
observed O
for O
a O
variety O
of O
octahedral O
mononuclear O
iron-nitrosyl B-CHEMICAL
synthetic O
complexes; O
however, O
this O
type O
of O

iron-nitrosyl B-CHEMICAL
species O
is O
not O
commonly O
observed O
for O
non-heme O
iron B-CHEMICAL
enzymes. O
Substitution O
of O
l-cysteine B-CHEMICAL
with O
isosteric O
substrate O
analogues O
cysteamine, B-CHEMICAL
3-mercaptopropionic B-CHEMICAL
acid, I-CHEMICAL
and O
propane B-CHEMICAL
thiol I-CHEMICAL
did O
not O
produce O
any O
analogous O
{FeNO}7 B-CHEMICAL
signals O
(S O
= O
1/2 O
or O
3/2), O
thus O
reflecting O
the O
high O
substrate O
specificity O
of O
the O
enzyme O
observed O
by O
a O
number O
of O
researchers. O
The O
unusual O
{FeNO}7 B-CHEMICAL
(S O
= O
1/2) O
electronic O
configuration O
adopted O
by O
the O
substrate-bound O

iron-nitrosyl B-CHEMICAL
CDO B-GENE-Y
(termed O
{ES-NO}7) B-CHEMICAL
is O
a O
result O
of O
the O
bidentate B-CHEMICAL
thiol/amine I-CHEMICAL
coordination O
of O
l-cysteine B-CHEMICAL
in O
the O
NO-bound B-CHEMICAL
CDO B-GENE-Y
active O
site. O
DFT O
computations O
were O
performed O
to O
further O
characterize O
this O
species. O
The O
DFT-predicted O
geometric O
parameters O
for O
{ES-NO}7 B-CHEMICAL
are O
in O
good O
agreement O
with O
the O
crystallographically O
determined O
substrate-bound O
active O
site O
configuration O
of O
CDO B-GENE-Y
and O
are O
consistent O
with O
known O
iron-nitrosyl B-CHEMICAL
model O
complexes. O
Moreover, O
the O
computed O
EPR O
parameters O
(g O
and O
A O
values) O

are O
in O
excellent O
agreement O
with O
experimental O
results O
for O
this O
CDO B-GENE-Y
species O
and O
those O
obtained O
from O
comparable O
synthetic O
{FeNO}7 B-CHEMICAL
(S O
= O
1/2) O
iron-nitrosyl B-CHEMICAL
complexes. O
Ligand-dependent O
transcriptional O
activities O
of O
four O
torafugu O
pufferfish O
Takifugu O
rubripes O
peroxisome B-GENE-N
proliferator-activated I-GENE-N
receptors. I-GENE-N
Structural O
and O
functional O
properties O
were O
investigated O
for O
four O
peroxisome B-GENE-N
proliferator-activated I-GENE-N
receptors I-GENE-N
(PPARs), B-GENE-N
PPARalpha1, B-GENE-Y
PPARalpha2, B-GENE-Y
PPARbeta, B-GENE-Y
and O
PPARgamma, B-GENE-Y
from O
torafugu O

pufferfish O
Takifugu O
rubripes O
and O
determined O
for O
their O
transcriptional O
activity O
by O
the O
reporter O
assay O
using O
reporter O
plasmids O
containing O
three O
copies O
of O
the O
acyl-CoA B-CHEMICAL
oxidase I-GENE-N
PPAR I-GENE-N
response I-GENE-N
element. I-GENE-N
Although B-GENE-N
torafugu I-GENE-N
PPARs I-GENE-N
showed O
a O
high O
similarity O
in O
the O
primary O
structure O
to O
other O
vertebrate O
counterparts, O
torafugu B-GENE-N
PPARalpha2 I-GENE-N
and I-GENE-N
gamma I-GENE-N
contained O
additional O
sequences O
of O
21 O
and O
28 O
amino B-CHEMICAL
acids, I-CHEMICAL
respectively, O
as O
in O
the O
case O
of O
other O
teleost O
fish O
species O
when O
compared O
with O
African O
clawed O
frog O
counterparts. O
The O
transcriptional O
activity O
of O
torafugu O

PPARalpha1 B-GENE-Y
was O
enhanced O
4.5- O
and O
11.5-fold O
by O
Wy-14643 B-CHEMICAL
and O
5,8,11,14-eicosatetraynoic B-CHEMICAL
acid I-CHEMICAL
(ETYA) B-CHEMICAL
each O
at O
10 O
microM, O
respectively, O
whereas O
that O
of O
PPARalpha2, B-GENE-Y
4.5- O
and O
7.3-fold O
at O
the O
same O
concentration O
of O
the O
respective O
ligands, O
respectively. O
The O
activities O
of O
torafugu O
PPARalpha1 B-GENE-N
and I-GENE-N
alpha2 I-GENE-N
were O
also O
enhanced O
5.6- O
and O
6.3-fold O
by O
ETYA B-CHEMICAL
at O
1 O
microM, O
respectively, O
but O
not O

by O
Wy-14643 B-CHEMICAL
at O
this O
concentration. O
Furthermore, O
the O
activities O
of O
the O
two O
torafugu B-GENE-N
PPARalphas I-GENE-N
were O
enhanced O
4.3- O
and O
7.6-fold O
by O
arachidonic B-CHEMICAL
acid, I-CHEMICAL
4.4- O
and O
5.2-fold O
by O
docosahexaenoic B-CHEMICAL
acid, I-CHEMICAL
and O
6.7- O
and O
8.0-fold O
by O
eicosapentaenoic B-CHEMICAL
acid I-CHEMICAL
each O
at O
50 O
microM, O
respectively. O
On O
the O
other O
hand, O
the O
activities O
of O
torafugu B-GENE-N
PPARbeta I-GENE-N
and I-GENE-N
gamma I-GENE-N
were O
not O
changed O
by O
Wy-14643, B-CHEMICAL
ETYA, B-CHEMICAL

rosiglitazone, B-CHEMICAL
nor O
PUFAs. O
These O
results O
suggest O
that O
the O
activities O
of O
torafugu B-GENE-N
PPARbeta I-GENE-N
and I-GENE-N
gamma I-GENE-N
require O
undefined O
ligands. O
Alternatively, O
the O
molecular O
mechanisms O
involved O
in O
their O
activation O
are O
different O
from O
those O
of O
other O
vertebrates. O
Combination O
chemotherapy O
with O
a O
substance B-GENE-Y
P I-GENE-Y
receptor I-GENE-Y
antagonist O
(aprepitant) B-CHEMICAL
and O
melarsoprol B-CHEMICAL
in O
a O
mouse O
model O
of O
human O
African O
trypanosomiasis. O
Drug O
therapy O
for O
late-stage O
(encephalitic) O
human O
African O
trypanosomiasis O
(HAT) O
is O
currently O
very O

unsatisfactory O
with O
the O
most O
commonly O
used O
drug, O
melarsoprol, B-CHEMICAL
having O
a O
5% O
overall O
mortality. O
There O
is O
evidence O
in O
a O
mouse O
model O
of O
HAT O
that O
Substance B-CHEMICAL
P I-CHEMICAL
(SP) I-GENE-Y
receptor I-GENE-Y
antagonism O
reduces O
the O
neuroinflammatory O
reaction O
to O
CNS O
trypanosome O
infection. O
In O
this O
study O
we O
investigated O
the O
effects O
of O
combination O
chemotherapy O
with O
melarsoprol B-CHEMICAL
and O
a O
humanised B-GENE-Y
SP B-CHEMICAL
receptor I-GENE-Y
antagonist O
aprepitant B-CHEMICAL
(EMEND) B-CHEMICAL
in O
this O
mouse O
model. O
The O
melarsoprol/aprepitant B-CHEMICAL
drug O
combination O
did O
not O
produce O
any O
clinical O
signs O
of O
illness O
in O

mice O
with O
CNS O
trypanosome O
infection. O
This O
lack O
of O
any O
additional O
or O
unexpected O
CNS O
toxicity O
in O
the O
mouse O
model O
of O
CNS O
HAT O
provides O
valuable O
safety O
data O
for O
the O
future O
possible O
use O
of O
this O
drug O
combination O
in O
patients O
with O
late-stage O
HAT. O
Identification O
of O
the O
RLBP1 B-GENE-N
gene I-GENE-N
promoter. I-GENE-N
PURPOSE: O
Cellular B-GENE-Y
retinaldehyde-binding B-CHEMICAL
protein I-GENE-Y
(CRALBP), B-GENE-Y
transcribed O
from O
the O
RLBP1 B-GENE-Y
gene, O
is O
a O
36-kDa B-GENE-N
water-soluble I-GENE-N
protein I-GENE-N
with O
316 O
amino B-CHEMICAL
acids I-CHEMICAL
found O
in O
the O
retinal B-CHEMICAL
pigment O
epithelium O

(RPE) O
and O
in O
retinal B-CHEMICAL
Muller O
cells. O
It O
is O
thought O
to O
play O
a O
critical O
role O
in O
the O
visual O
cycle O
by O
functioning O
as O
an O
acceptor O
of O
11-cis-retinol B-CHEMICAL
from O
the O
isomerohydrolase B-GENE-N
reaction. O
The O
goal O
here O
was O
to O
evaluate O
the O
functional O
promoter O
of O
this O
gene. O
METHODS: O
5' O
RACE O
analysis, O
promoter-reporter O
assays, O
and O
semiquantitative O
PCR O
with O
exon-specific O
primers O
were O
performed O
using O
human-derived O
RPE O
cells O
(ARPE-19 O
and O
D407) O
in O
culture O
to O
evaluate O
the O
5' O
sequence O
flanking O
the O

RLBP1 B-GENE-Y
gene. O
In O
addition, O
the O
murine, B-GENE-N
bovine, I-GENE-N
and I-GENE-N
porcine I-GENE-N
RLBP1 I-GENE-N
genes O
were O
evaluated O
in O
silico O
to O
identify O
likely O
proximal O
promoter/exon O
1 O
sequences O
similar O
to O
the O
human O
gene. O
RESULTS: O
5' O
RACE O
analysis O
revealed O
the O
presence O
of O
a O
previously O
undescribed O
exon O
in O
the O
RLBP1 B-GENE-Y
gene. O
This O
was O
confirmed O
by O
analysis O
of O
the O
GenBank O
Human O
EST O
database, O
which O
revealed O
the O
presence O
of O
18 O
sequences O
matching O
exon O
1. O
Exon-specific O
PCR O
revealed O
that O
most O
CRALBP B-GENE-Y
transcripts O

expressed O
in O
ARPE-19 O
cells O
contain O
both O
exon O
1 O
and O
the O
final O
exon, O
suggesting O
that O
the O
primary O
promoter O
of O
CRALBP B-GENE-Y
exists O
5' O
of O
the O
newly O
identified O
exon O
1. O
Highly O
homologous O
sequences O
in O
the O
murine, O
bovine, O
and O
porcine O
genes O
were O
also O
identified. O
Finally, O
promoter-reporter O
constructs O
revealed O
a O
minimal O
sequence O
necessary O
for O
promoter O
function O
and O
indicated O
significantly O
greater O
promoter O
activity O
compared O
with O
previously O
described O
RLBP1 B-GENE-N
promoters. I-GENE-N
CONCLUSIONS: O
The O
findings O
presented O
here O
suggest O
that O
CRALBP B-GENE-Y
transcripts O
in O
RPE O
cells O
contain O
a O

noncoding O
exon O
in O
addition O
to O
a O
newly O
described O
promoter O
and, O
by O
definition, O
an O
additional O
intron. O
This O
finding O
sets O
the O
stage O
for O
a O
mechanistic O
understanding O
of O
the O
high O
degree O
of O
cell O
type-specific O
expression O
of O
RLBP1. B-GENE-Y
Determination O
of O
dimethylarginine B-GENE-Y
dimethylaminohydrolase I-GENE-Y
activity O
in O
the O
kidney. O
Dimethylarginine B-CHEMICAL
dimethylaminohydrolase I-GENE-Y
(DDAH) B-GENE-Y
metabolizes O
asymmetric O
dimethylarginine B-CHEMICAL
to O
generate O
L-citrulline B-CHEMICAL
and O
is O
present O
in O
large O
quantities O
in O
the O
kidney. O
We O
present O
a O
new O
study O

that O
optimizes O
the O
Prescott-Jones O
colorimetric O
assay O
to O
measure O
DDAH-dependent B-GENE-Y
L-citrulline B-CHEMICAL
generation O
in O
kidney O
homogenates. O
We O
found O
that O
the O
removal O
of O
urea B-CHEMICAL
with O
urease B-GENE-N
is O
necessary O
since O
urea B-CHEMICAL
also O
produces O
a O
positive O
reaction. O
Deproteinization O
with O
sulfosalicylic B-CHEMICAL
acid I-CHEMICAL
was O
found O
to O
be O
optimal O
and O
that O
protease B-GENE-N
inhibitors O
were O
not O
necessary. O
All O
assays O
were O
conducted O
in O
phosphate B-CHEMICAL
buffer, O
since O
other O
common O
additives O
can O
create O
false O
positive O
and O
false O
negative O
reactions. O
Arginase B-GENE-N
or O
nitric B-CHEMICAL
oxide I-CHEMICAL
synthase I-GENE-N

isoenzymes O
were O
not O
found O
to O
influence O
L-citrulline B-CHEMICAL
production. O
Our O
optimized O
L-citrulline B-CHEMICAL
production O
assay O
to O
measure O
DDAH B-GENE-Y
activity O
correlated O
closely O
with O
the O
direct O
measure O
of O
the O
rate O
of O
asymmetric O
dimethylarginine B-CHEMICAL
consumption. O
Using O
this O
assay, O
we O
found O
that O
both O
superoxide B-CHEMICAL
and O
nitric B-CHEMICAL
oxide I-CHEMICAL
inhibit O
renal O
cortical O
DDAH B-GENE-Y
activity O
in O
vitro. O
The O
role O
of O
trastuzumab O
in O
early O
stage O
breast O
cancer: O
current O
data O
and O
treatment O
recommendations. O
OPINION O
STATEMENT: O
Treatment O
of O
early O
stage O

breast O
cancer O
requires O
a O
multimodality O
approach O
in O
order O
to O
eradicate O
residual O
cancer O
and O
prevent O
recurrent O
disease. O
Targeting O
the O
pathways O
that O
promote O
or O
sustain O
cancer O
cell O
growth O
and O
invasion O
is O
critical O
to O
the O
effective O
treatment O
of O
breast O
and O
other O
cancers. O
Overexpression O
of O
the O
family O
of O
HER B-GENE-N
receptors O
have O
been O
associated O
with O
a O
variety O
of O
malignancies; O
the O
first O
and O
best O
studied O
is O
the O
association O
of O
overexpression O
of O
the O
HER2/neu B-GENE-Y
receptor I-GENE-Y
with O
a O
more O
aggressive O
breast O
cancer O
phenotype O
and O
poorer O
survival. O
A O
humanized O
antibody O
to O
HER2/neu, B-GENE-Y

trastuzumab, O
is O
now O
FDA O
approved O
for O
the O
treatment O
of O
early O
stage, O
HER2/neu B-GENE-Y
overexpressing O
breast O
cancer O
sequenced O
with O
chemotherapy O
including O
doxorubicin, B-CHEMICAL
cyclophosphamide, B-CHEMICAL
and O
paclitaxel. B-CHEMICAL
Additional O
international O
and O
national O
studies O
support O
the O
significant O
impact O
of O
trastuzumab O
on O
both O
disease O
free O
and O
overall O
survival O
in O
women O
with O
this O
aggressive O
form O
of O
breast O
cancer. O
Toxicity O
includes O
a O
low O
but O
clear O
risk O
of O
congestive O
heart O
failure, O
and O
the O
large O
phase O
III O
trials O
have O
helped O
to O
determine O
which O
patients O
are O
at O
higher O
risk O
for O
this O

complication. O
Non-anthracycline B-CHEMICAL
containing O
regimens O
are O
an O
alternative O
therapy O
associated O
with O
reduced O
cardiac O
toxicity. O
Trastuzumab O
therapy O
is O
now O
the O
standard O
of O
care O
for O
the O
treatment O
of O
early O
stage, O
HER2/neu B-GENE-Y
positive O
breast O
cancer O
given O
in O
combination O
with O
one O
of O
several O
chemotherapy O
regimens. O
Ongoing O
questions O
include O
the O
appropriate O
duration O
of O
trastuzumab O
treatment O
as O
well O
as O
the O
optimal O
chemotherapy O
regimen O
and O
sequence. O
The O
next O
large O
phase O
III O
adjuvant O
trial O
for O
this O
subset O
of O
breast O
cancer O
is O
an O
international O
collaboration O
designed O
to O
evaluate O
the O
added O
or O
alternative O
benefit O
of O
an O
oral O
tyrosine B-CHEMICAL

kinase O
inhibitor O
targeting O
HER2/neu B-GENE-Y
as O
well O
as O
the O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(EGFR), B-GENE-Y
lapatinib. B-CHEMICAL
Other O
trials O
are O
investigating O
differences O
in O
duration. O
Studies O
in O
the O
neoadjuvant O
setting O
should O
help O
to O
define O
markers O
of O
trastuzumab O
and O
lapatinib B-CHEMICAL
sensitivity O
and O
resistance. O
Preliminary O
data O
combining O
trastuzumab O
with O
the O
antiangiogenic O
antibody O
bevacizumab O
is O
encouraging; O
this O
combination O
will O
be O
tested O
in O
both O
early O
stage O
and O
late O
stage O
disease. O
Stimulation O
of O
N-methyl-D-aspartate B-GENE-N
receptors I-GENE-N

modulates O
Jurkat O
T O
cell O
growth O
and O
adhesion O
to O
fibronectin. B-GENE-Y
The O
aims O
of O
this O
study O
were O
to O
investigate O
the O
expression O
and O
the O
functional O
roles O
of O
N-methyl-d-aspartate B-GENE-N
(NMDA) I-GENE-N
receptors I-GENE-N
in O
leukemic O
Jurkat O
T O
cells. O
RT-PCR O
and O
immunofluorescence/confocal O
microscopy O
analysis O
showed O
that O
Jurkat O
T O
cells O
express O
the O
NR1 B-GENE-Y
and O
NR2B B-GENE-Y
subunits O
of O
the O
NMDA B-CHEMICAL
receptors. I-GENE-N
Exposure O
of O
Jurkat O
cells O
to O
either O

(5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine B-CHEMICAL
[(+)-MK B-CHEMICAL
801] I-CHEMICAL
or O
D-(-)-2-amino-5-phosphonopentanoic B-CHEMICAL
acid I-CHEMICAL
(D-AP5), B-CHEMICAL
two O
selective O
NMDA B-CHEMICAL
receptor I-GENE-N
antagonists, O
limited O
cell O
growth O
by O
inhibiting O
cell O
cycle O
progression O
and O
inducing O
apoptosis, O
whereas O
l-glutamate B-CHEMICAL
(1 O

microM) O
and O
NMDA B-CHEMICAL
(10 O
microM) O
significantly O
increased O
(137.2+/-22.0%; O
P<0.01) O
Jurkat O
T O
cell O
adhesion O
to O
fibronectin. B-GENE-Y
In O
conclusion, O
our O
results O
demonstrate O
that O
Jurkat O
T O
cells O
express O
NMDA B-GENE-N
receptors I-GENE-N
functionally O
active O
in O
controlling O
cell O
growth O
and O
adhesion O
to O
fibronectin. B-GENE-Y
Desvenlafaxine B-CHEMICAL
succinate I-CHEMICAL
identifies O
novel O
antagonist O
binding O
determinants O
in O
the O
human B-GENE-Y
norepinephrine I-GENE-Y
transporter. I-GENE-Y
Desvenlafaxine B-CHEMICAL
succinate I-CHEMICAL
(DVS) B-CHEMICAL
is O
a O
recently O
introduced O
antagonist O
of O
the O

human B-GENE-N
norepinephrine I-GENE-N
and I-GENE-N
serotonin I-GENE-N
transporters I-GENE-N
(hNET B-GENE-Y
and O
hSERT, B-GENE-Y
respectively), O
currently O
in O
clinical O
development O
for O
use O
in O
the O
treatment O
of O
major O
depressive O
disorder O
and O
vasomotor O
symptoms O
associated O
with O
menopause. O
Initial O
evaluation O
of O
the O
pharmacological O
properties O
of O
DVS B-CHEMICAL
(J O
Pharmacol O
Exp O
Ther O
318:657-665, O
2006) O
revealed O
significantly O
reduced O
potency O
for O
the O
hNET B-GENE-Y
expressed O
in O
membranes O
compared O
with O
whole O
cells O
when O
competing O
for O
[(3)H]nisoxetine B-CHEMICAL
(NIS) B-CHEMICAL
binding. O
Using O
hNET B-GENE-Y

in O
transfected O
human O
embryonic O
kidney-293 O
cells, O
this O
difference O
in O
potency O
for O
DVS B-CHEMICAL
at O
sites O
labeled O
by O
[(3)H]NIS B-CHEMICAL
was O
found O
to O
distinguish O
DVS, B-CHEMICAL
the O
DVS B-CHEMICAL
analog O
rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol B-CHEMICAL
(WY-46824), B-CHEMICAL
methylphenidate, B-CHEMICAL
and O
the O
cocaine B-CHEMICAL
analog O

3beta-(4-iodophenyl)tropane-2beta-carboxylic B-CHEMICAL
acid I-CHEMICAL
methyl I-CHEMICAL
ester I-CHEMICAL
(RTI-55) B-CHEMICAL
from O
other O
hNET B-GENE-Y
antagonists, O
such O
as O
NIS, B-CHEMICAL
mazindol, B-CHEMICAL
tricyclic B-CHEMICAL
antidepressants, O
and O
cocaine. B-CHEMICAL
These O
differences O
seem O
not O
to O
arise O
from O
preparation-specific O
perturbations O
of O
ligand O
intrinsic O
affinity O
or O
antagonist-specific O
surface O
trafficking O
but O
rather O
from O
protein O
conformational O
alterations O
that O
perturb O
the O
relationships O
between O
distinct O
hNET B-GENE-Y
binding O
sites. O
In O
an O
initial O
search O
for O
molecular O
features O
that O
differentially O
define O
antagonist O
binding O

determinants, O
we O
document O
that O
Val148 O
in O
hNET B-GENE-N
transmembrane I-GENE-N
domain I-GENE-N
3 I-GENE-N
selectively O
disrupts O
NIS B-CHEMICAL
binding O
but O
not O
that O
of O
DVS. O
[Lipoprotein(a): B-GENE-Y
a O
link O
between O
thrombogenesis O
and O
atherogenesis]. O
INTRODUCTION: O
It O
is O
well O
known O
that O
numerous O
mechanisms O
of O
thrombogenesis O
can O
participate O
in O
every O
stage O
of O
atherosclerotic O
disease. O
The O
discovery O
of O
Lp(a) B-GENE-Y
lipoprotein B-GENE-N
and O
its O
structural O
similarity O
with O
plasminogen B-GENE-Y
suggests O
another O
pathogenic O
link O
between O
atherogenesis O
and O

thrombogenesis. O
SOME O
CHARACTERISTICS O
OF O
LP(A) B-GENE-Y
LIPOPROTEIN: B-GENE-N
This O
lipoprotein O
is O
present O
in O
the O
whole O
human O
population O
in O
a O
wide O
range O
of O
plasma O
concentrations. O
It O
has O
numerous O
different O
isoforms. O
Its O
synthesis O
occurs O
in O
the O
liver, O
but O
it O
is O
practically O
metabolically O
independent O
from O
other O
lipoproteins. B-GENE-N
Today, O
Lp(a) B-GENE-Y
lipoprotein B-GENE-N
is O
considered O
to O
be O
an O
independent O
risk O
factor O
for O
heart O
and O
brain O
ischemic O
disease. O
FIBRINOLYTIC O
MECHANISMS: O
The O
primary O
role O
of O
the O

fibrinolytic O
mechanism O
is O
to O
prevent O
thrombus O
Jormation O
during O
circulation O
and O
to O
remove O
already O
formed O
ones. O
Plasmin B-GENE-Y
has O
a O
central O
role O
in O
this O
process, O
due O
to O
the O
inactive O
proenzyme O
plasminogen. B-GENE-Y
Its O
basic O
activators O
are O
tissue-type B-GENE-Y
plasminogen I-GENE-Y
activator I-GENE-Y
(t-PA) B-GENE-Y
and O
urokinase B-GENE-Y
plasminogen I-GENE-Y
activator I-GENE-Y
(u-PA). B-GENE-Y
The O
most O
important O
inhibitors O
of O
plasminogen B-GENE-Y
are O
alpha2-antiplasmin B-GENE-Y
and O
plasminogen B-GENE-N
activator I-GENE-N
inhibitors I-GENE-N
1 I-GENE-N
and I-GENE-N
2 I-GENE-N
(PA-1 B-GENE-Y
and O

PAI-2). B-GENE-Y
Structural O
similarity O
of O
Lp(a) B-GENE-Y
and O
plasminogen B-GENE-Y
The O
apo(a) B-GENE-N
and O
plasminogen B-GENE-Y
genes O
are O
very O
closely O
linked O
on O
the O
long O
arm O
of O
chromosome O
6. O
Because O
of O
that O
they O
are O
structuraly O
very O
similar O
and O
they O
have O
a O
cross O
immunological O
reactivity. O
Their O
common O
elements O
are O
so-called O
"kringle" O
structures. O
The O
key O
difference O
in O
structure O
of O
Lp(a) B-GENE-Y
and O
plasminogen B-GENE-Y
is O
replacement O
of O
Arg B-CHEMICAL
with O
Ser B-CHEMICAL
at O
position O
560. O
This O
prevents O
splitting O
of O
apo(a) B-GENE-N
by O
plasminogen B-GENE-N
activators. I-GENE-N

LP(A) B-GENE-Y
AND O
FIBRINOLYSIS: O
Lp(a) B-GENE-Y
lipoprotein B-GENE-N
inhibits O
activation O
of O
plasminogen B-GENE-Y
by O
streptokinase. B-GENE-N
It O
is O
also O
a O
competitive O
inhibitor O
of O
plasminogen B-GENE-Y
for O
its O
binding O
to O
plasminogen B-GENE-N
receptors. I-GENE-N
Furthermore, O
it O
successfully O
achieves O
competitive O
inhibition O
of O
plasminogen B-GENE-Y
for O
binding O
to O
tetranectin B-GENE-Y
and O
thrombospondin. B-GENE-Y
Also, O
Lp(a) B-GENE-Y
inhibits O
activation O
of O
transforming B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
alpha I-GENE-Y
(TGF-alpha). B-GENE-Y
It O
positively O
correlates O
with O
PAI-1 B-GENE-Y
and O
it O

is O
assumed O
that O
it O
promotes O
release O
of O
tissue B-GENE-Y
factor I-GENE-Y
pathway O
inhibitor O
(17FPI) O
from O
endothelial O
cell O
surfaces. O
CONCLUSION: O
In O
regulation O
of O
the O
hemostatic O
system O
via O
apolipoprotein(a) B-GENE-N
antifibrinolytic O
effects, O
Lp(a) B-GENE-Y
lipoprotein B-GENE-N
ojfers O
a O
molecular O
solution O
to O
the O
link O
between O
thrombogenesis O
and O
atherogenesis. O
Sunitinib, B-CHEMICAL
sorafenib B-CHEMICAL
and O
mTOR B-GENE-Y
inhibitors O
in O
renal O
cancer. O
Understanding O
the O
alterations O
in O
cellular O
protein O
interactions O
and O
their O
relations O
to O
genetic O
mutations O
that O
cause O
renal O
cell O
carcinoma O

(RCC) O
provides O
a O
unique O
opportunity O
for O
the O
development O
of O
disease-specific O
therapy O
for O
patients O
with O
advanced O
forms O
of O
this O
disease. O
There O
is O
substantial O
evidence O
of O
an O
association O
between O
mutation O
on O
von B-GENE-Y
Hippel-Lindau I-GENE-Y
(VHL) B-GENE-Y
gene O
and O
the O
earliest O
stages O
of O
tumorigenesis O
of O
RCC. O
The O
main O
consequence O
of O
VHL B-GENE-Y
loss O
is O
the O
upregulation O
of O
downstream O
proangiogenic O
factors O
leading O
to O
highly O
vascular O
tumors. O
Overexpression O
of O
hypoxia B-GENE-N
inducible I-GENE-N
factor I-GENE-N
(HIF) B-GENE-N
is O
also O
caused O
by O
the O
mammalian B-GENE-Y
target I-GENE-Y
of I-GENE-Y
rapamycin I-GENE-Y
(mTOR), B-GENE-Y
a O
key O
component O
of O

signaling O
pathways O
inside O
the O
cell, O
involved O
in O
cell O
proliferation. O
The O
inhibition O
of O
proangiogenic O
factors O
and O
mTOR B-GENE-Y
was O
the O
main O
idea O
behind O
the O
development O
of O
new O
targeted O
agents O
in O
advanced O
RCC. O
Since O
December O
2005, O
3 O
targeted O
agents O
have O
been O
approved O
by O
the O
U.S. O
Food O
and O
Drug O
Administration O
(FDA) O
for O
the O
treatment O
of O
advanced O
RCC: O
sorafenib, B-CHEMICAL
sunitinib B-CHEMICAL
and O
temsirolimus. B-CHEMICAL
Sorafenib B-CHEMICAL
and O
sunitinib B-CHEMICAL
are O
synthetic, O
orally O
active O
agents O
shown O
to O
directly O
inhibit O
vascular B-GENE-N
endothelial I-GENE-N
growth I-GENE-N
factor I-GENE-N
receptors I-GENE-N
-2 I-GENE-N
and I-GENE-N
-3 I-GENE-N

(VEGFR-2, B-GENE-Y
VEGFR-3) B-GENE-Y
and O
platelet-derived B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
beta I-GENE-Y
(PDGFR-beta), B-GENE-Y
while O
temsirolimus B-CHEMICAL
is O
an O
mTOR B-GENE-Y
inhibitor. O
Recent O
clinical O
studies O
form O
the O
basis O
for O
new O
guidelines O
for O
the O
treatment O
of O
advanced O
RCC: O
sorafenib B-CHEMICAL
should O
be O
used O
as O
a O
second-line O
treatment, O
sunitinib B-CHEMICAL
as O
the O
first-line O
therapy O
for O
good O
and O
intermediate-risk O
patients, O
and O
temsirolimus B-CHEMICAL
should O
be O
considered O
as O
first-line O
treatment O
for O
poor-risk O
patients. O
Future O
approaches O
to O
targeted O
therapy O
should O
focus O
on O
optimizing O

the O
use O
of O
current O
active O
drugs, O
exploring O
their O
combinations O
or O
investigating O
their O
sequential O
use. O
In O
addition, O
it O
is O
important O
to O
define O
the O
mechanisms O
of O
resistance O
on O
their O
use O
and O
to O
further O
investigate O
biomarkers O
and O
enhance O
treatment O
efficacy O
for O
the O
individual O
patients. O
The O
development O
of O
these O
targeted O
therapies O
represents O
an O
exciting O
step O
forward O
in O
the O
treatment O
of O
advanced O
RCC. O
Management O
of O
psoriasis: O
the O
position O
of O
retinoid B-CHEMICAL
drugs. O
Oral O
synthetic O
retinoids B-CHEMICAL
have O
been O
established O
as O
effective O
systemic O
therapy O
for O
psoriasis O
since O
their O
introduction O
for O
clinical O
use O
in O
the O
1970s; O
a O
compound O
for O
topical O
use, O
tazarotene B-CHEMICAL
has O
been O
recently O
marketed. O
Despite O

the O
demonstrated O
clinical O
success O
of O
retinoid B-CHEMICAL
therapy O
in O
psoriasis, O
its O
mechanism O
of O
action O
has O
not O
been O
fully O
elucidated, O
and O
investigators O
are O
confronted O
with O
two O
paradoxes. O
One O
is O
that O
the O
binding O
of O
retinoids B-CHEMICAL
to O
nuclear O
retinoic B-CHEMICAL
acid I-CHEMICAL
receptors I-GENE-N
(RARs) B-GENE-N
does O
not O
match O
their O
therapeutic O
efficacy: O
acitretin B-CHEMICAL
activates O
the O
three O
receptor O
subtypes, O
RAR-alpha, B-GENE-N
-beta I-GENE-N
and I-GENE-N
-gamma, I-GENE-N
without O
measurable O
receptor O
binding, O
whereas O
tazarotene B-CHEMICAL
preferentially O
binds O
to O
and O
activates O
RAR-beta B-GENE-N
and I-GENE-N
-gamma I-GENE-N
in O
preference O
to O
RAR-alpha. B-GENE-Y
The O
other O
is O

that O
there O
is O
already O
increased O
formation O
of O
retinoic B-CHEMICAL
acid I-CHEMICAL
in O
the O
psoriatic O
lesion. O
Answering O
these O
questions O
should O
result O
in O
better O
use O
of O
these O
drugs O
in O
the O
treatment O
of O
psoriasis. O
Oral O
administration O
of O
acitretin B-CHEMICAL
remains O
one O
of O
the O
first O
therapeutic O
choices O
for O
severe O
psoriasis, O
particularly O
in O
association O
with O
ultraviolet O
light O
therapy, O
of O
which O
it O
may O
decrease O
the O
carcinogenic O
risk. O
Topical O
tazarotene B-CHEMICAL
is O
suitable O
for O
moderate O
plaque O
psoriasis. O
Its O
efficacy O
and O
tolerability O
can O
be O
enhanced O
by O
the O
addition O
of O
topical O
corticosteroids; B-CHEMICAL
its O
irritative O
potential O
is O
counterbalanced O

by O
a O
sustained O
therapeutic O
effect O
after O
the O
treatment O
is O
stopped. O
Comprehensive O
review O
of O
rasagiline, B-CHEMICAL
a O
second-generation O
monoamine B-GENE-N
oxidase I-GENE-N
inhibitor, O
for O
the O
treatment O
of O
Parkinson's O
disease. O
BACKGROUND: O
Inhibitors O
of O
monoamine B-GENE-N
oxidase I-GENE-N
(MAO) B-GENE-N
with O
selectivity O
and O
specificity O
for O
MAO B-GENE-Y
type I-GENE-Y
B I-GENE-Y
(MAO-B) B-GENE-Y
prolong O
the O
duration O
of O
action O
of O
both O
endogenously O
and O
exogenously O
derived O
dopamine. B-CHEMICAL
Rasagiline B-CHEMICAL
[N-propargyl-l(R)-aminoindan] B-CHEMICAL
is O
a O

second-generation O
propargylamine B-CHEMICAL
pharmacophore O
that O
selectively O
and O
irreversibly O
inhibits O
brain O
MAO-B B-GENE-Y
and O
is O
specifically O
designed O
for O
the O
treatment O
of O
Parkinson's O
disease O
(PD). O
OBJECTIVE: O
The O
aim O
of O
this O
study O
was O
to O
review O
the O
pharmacology, O
tolerability, O
and O
clinical O
efficacy O
of O
rasagiline B-CHEMICAL
in O
the O
treatment O
of O
PD. O
METHODS: O
MEDLINE O
(1966-April O
2007), O
the O
Cochrane O
Database O
of O
Systematic O
Reviews, O
and O
International O
Pharmaceutical O
Abstracts O
(1970-April O
2007) O
were O

searched O
for O
original O
research O
and O
review O
articles O
published O
in O
English. O
The O
search O
terms O
were O
monoamine B-GENE-N
oxidase, I-GENE-N
neuroprotection, O
Parkinson O
disease, O
propargylamine, B-CHEMICAL
rasagiline, B-CHEMICAL
and O
selegiline. B-CHEMICAL
The O
reference O
lists O
of O
articles O
were O
also O
consulted, O
as O
was O
information O
provided O
by O
the O
manufacturer O
of O
rasagiline. B-CHEMICAL
RESULTS: O
Data O
from O
63 O
clinical O
and O
laboratory O
studies O
were O
analyzed. O
Based O
on O
the O
results O
from O
those O
studies, O
we O
concluded O
that O
rasagiline B-CHEMICAL
PO O
QD, O
at O
the O
therapeutic O
dosage O
range O
of O
0.5 O
to O
1 O
rag/d, O
is O
effective O
and O

well O
tolerated O
and O
completely, O
selectively, O
and O
specifically O
inhibited O
MAO-B. B-GENE-Y
Pharmacologically, O
rasagiline B-CHEMICAL
was O
found O
to O
be O
< O
or O
=10-fold O
more O
potent O
than O
selegiline B-CHEMICAL
and O
was O
not O
metabolized O
to O
amphetamine B-CHEMICAL
derivatives. O
Rasagiline B-CHEMICAL
was O
effective O
both O
as O
monotherapy O
in O
early O
PD O
and O
as O
adjunctive O
treatment O
in O
patients O
with O
advancing O
PD O
and O
motor O
fluctuations. O
As O
monotherapy, O
rasagiline B-CHEMICAL
provided O
modest O
yet O
clinically O
meaningful O
benefit. O
A O
randomized, O
double-blind, O
placebo-controlled O
study O
found O
that, O
after O
26 O
weeks O
of O
treatment, O
the O

adjusted O
effect O
size O
for O
total O
Unified O
Parkinson's O
Disease O
Rating O
Scale O
score O
was O
-4.20 O
(95% O
CI, O
-5.66 O
to O
-2.73) O
for O
rasagiline O
1 O
mg/d O
versus O
placebo O
(P O
< O
0.001). O
Preliminary O
long-term O
data O
from O
an O
open-label O
study O
suggest O
a O
sustained O
therapeutic O
advantage O
when O
rasagiline O
is O
initiated O
early O
(before O
the O
need O
for O
dopaminergic O
agents) O
rather O
than O
later. O
In O
patients O
with O
more O
advanced O
disease O
who O
received O
treatment O
with O
dopaminergic O
agents, O
rasagiline B-CHEMICAL
and O
entacapone B-CHEMICAL
were O
associated O
with O

reductions O
of O
"off" O
time O
significantly O
greater O
than O
placebo O
(-1.18 O
and O
-1.2 O
vs O
0.4 O
hour; O
both, O
P O
< O
or O
= O
0.001). O
Rasagiline B-CHEMICAL
was O
well O
tolerated O
in O
younger O
(aged O
<;70 O
years) O
and O
older O
(aged O
> O
or O
=70 O
years) O
patients O
with O
early O
or O
advanced O
PD. O
Pharmacologically, O
rasagiline O
has O
the O
potential O
to O
augment O
the O
vasopressor O
effects O
of O
diet-derived O
tyramine B-CHEMICAL
(ie, O
the O
"cheese O
reaction"). O
However, O
clinical O
challenge O
studies O
of O
tyramine B-CHEMICAL
have O
found O
this O

unlikely O
to O
occur O
even O
with O
ingestion O
of O
supraphysiologic O
amounts O
of O
tyramine. B-CHEMICAL
In O
experimental O
models, O
rasagiline B-CHEMICAL
has O
been O
found O
to O
have O
neuroprotective O
properties O
that O
may O
be O
independent O
of O
MAO-B B-GENE-Y
inhibition. O
CONCLUSIONS: O
Based O
on O
this O
review, O
rasagiline B-CHEMICAL
has O
been O
found O
to O
be O
well O
tolerated O
and O
effective O
in O
the O
treatment O
of O
early O
PD O
and O
as O
adjunctive O
treatment O
in O
motor O
fluctuations. O
Whether O
rasagiline O
is O
associated O
with O
clinically O
significant O
neuroprotection O
(ie, O
disease O
modification) O
in O
PD O
is O
the O
subject O
of O
ongoing O

clinical O
trials. O
Mutation O
of O
Gly721 O
alters O
DNA B-GENE-Y
topoisomerase I-GENE-Y
I I-GENE-Y
active O
site O
architecture O
and O
sensitivity O
to O
camptothecin. B-CHEMICAL
DNA B-GENE-Y
topoisomerase I-GENE-Y
I I-GENE-Y
(Top1p) B-GENE-Y
catalyzes O
the O
relaxation O
of O
supercoiled O
DNA O
via O
a O
concerted O
mechanism O
of O
DNA O
strand O
cleavage O
and O
religation. O
Top1p B-GENE-Y
is O
the O
cellular O
target O
of O
the O
anti-cancer O
drug O
camptothecin B-CHEMICAL
(CPT), B-CHEMICAL
which O
reversibly O
stabilizes O
a O
covalent O
enzyme-DNA O
intermediate. O
Top1p B-GENE-Y
clamps O
around O
duplex O
DNA, O
wherein O
the O
core O
and O
C-terminal B-CHEMICAL
domains O
are O
connected O
by O
extended O

alpha-helices B-GENE-N
(linker B-GENE-N
domain), I-GENE-N
which O
position O
the O
active O
site O
Tyr B-CHEMICAL
of O
the O
C-terminal B-CHEMICAL
domain O
within O
the O
catalytic O
pocket. O
The O
physical O
connection O
of O
the O
linker O
with O
the O
Top1p B-GENE-Y
clamp O
as O
well O
as O
linker O
flexibility O
affect O
enzyme O
sensitivity O
to O
CPT. B-CHEMICAL
Crystallographic O
data O
reveal O
that O
a O
conserved O
Gly B-CHEMICAL
residue O
(located O
at O
the O
juncture O
between O
the O
linker O
and O
C-terminal B-CHEMICAL
domains) O
is O
at O
one O
end O
of O
a O
short O
alpha-helix, B-GENE-N
which O
extends O
to O
the O
active O
site O
Tyr B-CHEMICAL
covalently O
linked O
to O
the O
DNA. O
In O
the O
presence O
of O
drug, O
the O
linker O
is O
rigid O
and O
this O

alpha-helix B-GENE-N
extends O
to O
include O
Gly B-CHEMICAL
and O
the O
preceding O
Leu. B-CHEMICAL
We O
report O
that O
mutation O
of O
this O
conserved O
Gly B-CHEMICAL
in O
yeast B-GENE-Y
Top1p I-GENE-Y
alters O
enzyme O
sensitivity O
to O
CPT. B-CHEMICAL
Mutating O
Gly B-CHEMICAL
to O
Asp, B-CHEMICAL
Glu, B-CHEMICAL
Asn, B-CHEMICAL
Gln, B-CHEMICAL
Leu, B-CHEMICAL
or O
Ala B-CHEMICAL
enhanced O
enzyme O
CPT B-CHEMICAL
sensitivity, O
with O
the O
acidic O
residues O
inducing O
the O
greatest O
increase O
in O
drug O
sensitivity O
in O
vivo O
and O
in O
vitro. O
By O
contrast, O
Val B-CHEMICAL
or O
Phe B-CHEMICAL
substituents O
rendered O
the O
enzyme O
CPT-resistant. B-CHEMICAL
Mutation-induced O
alterations O
in O
enzyme O
architecture O
preceding O
the O
active O
site O
Tyr B-CHEMICAL
suggest O
these O
structural O
transitions O

modulate O
enzyme O
sensitivity O
to O
CPT, B-CHEMICAL
while O
enhancing O
the O
rate O
of O
DNA O
cleavage. O
We O
postulate O
that O
this O
conserved O
Gly B-CHEMICAL
residue O
provides O
a O
flexible O
hinge O
within O
the O
Top1p B-GENE-Y
catalytic O
pocket O
to O
facilitate O
linker O
dynamics O
and O
the O
structural O
alterations O
that O
accompany O
drug O
binding O
of O
the O
covalent O
enzyme-DNA O
intermediate. O
Characterization O
of O
the O
substrate O
mimic O
bound O
to O
engineered O
prostacyclin B-GENE-Y
synthase I-GENE-Y
in O
solution O
using O
high-resolution O
NMR O
spectroscopy O
and O
mutagenesis: O
implication O
of O
the O
molecular O
mechanism O
in O
biosynthesis O
of O
prostacyclin. B-CHEMICAL
High-resolution O
NMR O
spectroscopy O
was O
used O

to O
determine O
the O
docking O
of O
a O
substrate O
(prostaglandin B-CHEMICAL
H2) I-CHEMICAL
mimic O
(U46619) B-CHEMICAL
to O
the O
engineered O
prostacyclin B-CHEMICAL
(PGI2) I-GENE-Y
synthase I-GENE-Y
(PGIS) B-GENE-Y
in O
solution. O
The O
binding O
of O
U46619 B-CHEMICAL
to O
the O
PGIS B-GENE-Y
protein O
was O
demonstrated O
by O
1D O
NMR O
titration, O
and O
the O
significant O
perturbation O
of O
the O
chemical O
shifts O
of O
protons O
at O
C-11, B-CHEMICAL
H2C, B-CHEMICAL
and O
H20 B-CHEMICAL
of O
U46619 B-CHEMICAL
were O
observed O
upon O
U46619 B-CHEMICAL
binding O
to O
the O
engineered O
PGIS B-GENE-Y
in O
a O
concentration-dependent O
manner. O
The O
detailed O

conformational O
change O
and O
3D O
structure O
of O
the O
PGIS-bound B-GENE-Y
U46619 B-CHEMICAL
were O
further O
demonstrated O
by O
2D O
1H B-CHEMICAL
NMR O
experiments O
using O
the O
transferred O
NOE O
technique. O
The O
distances O
between O
the O
protons O
H20 B-CHEMICAL
and O
H2, B-CHEMICAL
H18 B-CHEMICAL
and O
H2, B-CHEMICAL
and O
H18 B-CHEMICAL
and O
H4 B-CHEMICAL
are O
shorter O
following O
their O
binding O
to O
the O
PGIS B-GENE-Y
in O
solution-down O
to O
within O
5 O
A. O
These O
shorter O
distances O
resulted O
in O
a O
widely O
open O
conformation, O
where O
the O
triangle O
shape O
of O
the O
unbound O
U46619 B-CHEMICAL
changed O
to O
a O
more O
compact O
conformation O
with O
an O
oval O
shape. O
The O
bound O
conformation O
of O
U46619 B-CHEMICAL
fits O
the O
crystal O
structure O
of O

the O
PGIS B-GENE-Y
substrate O
binding O
pocket O
considerably O
better O
than O
that O
of O
the O
unbound O
U46619. B-CHEMICAL
The O
residues O
important O
to O
the O
substrate O
binding O
in O
the O
active O
site O
pocket O
of O
PGIS B-GENE-Y
were O
also O
predicted. O
For O
example, O
Trp282 O
could O
be O
one O
of O
the O
most O
important O
residues O
and O
is O
suspected O
to O
play O
a O
role O
in O
the O
determination O
of O
specific O
catalytic O
function, O
which O
has O
been O
established O
by O
the O
docking O
studies O
using O
the O
NMR O
structure O
of O
the O
PGIS-bound B-GENE-Y
form O
of O
U46619 B-CHEMICAL
and O
the O
PGIS B-GENE-Y
crystal O
structure. O
These O
studies O
have O
provided O
the O
structural O
information O
for O
the O
interaction O
of O
the O
PGIS B-GENE-Y
with O
its O
substrate O
mimic. O

The O
noted O
conformational O
changes O
where O
the O
C-6 B-CHEMICAL
position O
is O
closer O
to O
the O
C-9 B-CHEMICAL
position O
of O
U46619 B-CHEMICAL
provided O
the O
first O
experimental O
data O
for O
understanding O
the O
molecular O
mechanism O
of O
the O
catalytic O
function O
of O
PGIS B-GENE-Y
in O
the O
isomerization O
of O
PGH2 B-CHEMICAL
to O
prostacyclin. B-CHEMICAL
Type O
2 O
diabetes O
and O
oral O
antihyperglycemic O
drugs. O
Type O
II O
diabetes O
is O
a O
heterogeneous O
disease O
where O
environment O
and O
genetics O
are O
important O
factors O
for O
the O
expression O
of O
the O
disease. O
The O
high O
cost O
for O
treating O
complications O
of O
diabetes O
is O
a O
burden O
for O
public O
health O
systems O
and O
governments O
worldwide. O
Type O
II O
diabetes O
has O
been O
causing O
debilitation O
worldwide O

for O
many O
decades, O
and O
a O
single O
drug O
that O
safely O
treats O
the O
disease O
has O
yet O
to O
be O
discovered. O
Sulfonylureas, B-CHEMICAL
biguanides, B-CHEMICAL
alpha-glucosidase, B-GENE-N
meglitinides, B-CHEMICAL
DPP-4 B-GENE-Y
inhibitors O
and O
thiazolidinediones B-CHEMICAL
are O
among O
the O
classes O
of O
oral O
hypoglycemic O
drugs O
available O
to O
treat O
Type O
II O
diabetes, O
but O
concerns O
exist O
regarding O
safety O
and O
efficacy O
of O
these O
drugs. O
In O
this O
article O
we O
present O
the O
pros O
and O
cons O
of O
the O
six O
classes O
and O
discuss O
some O
of O
the O
latest O
advances O
towards O
the O
development O
of O
new O
drugs O
for O
the O
treatment O
of O
Type O
II O
diabetes. O

Asenapine: B-CHEMICAL
a O
novel O
psychopharmacologic O
agent O
with O
a O
unique O
human O
receptor O
signature. O
Asenapine B-CHEMICAL
is O
a O
novel O
psychopharmacologic O
agent O
under O
development O
for O
the O
treatment O
of O
schizophrenia O
and O
bipolar O
disorder. O
We O
determined O
and O
compared O
the O
human O
receptor O
binding O
affinities O
and O
functional O
characteristics O
of O
asenapine B-CHEMICAL
and O
several O
antipsychotic O
drugs. O
Compounds O
were O
tested O
under O
comparable O
assay O
conditions O
using O
cloned O
human O
receptors. O
In O
comparison O
with O
the O
antipsychotics, O
asenapine O
showed O
high O
affinity O
and O
a O
different O
rank O
order O
of O
binding O
affinities O
(pKi) O
for O

serotonin B-GENE-N
receptors I-GENE-N
(5-HT1A B-GENE-Y
[8.6], O
5-HT1B B-GENE-Y
[8.4], O
5-HT2A B-GENE-Y
[10.2], O
5-HT2B B-GENE-Y
[9.8], O
5-HT2C B-GENE-Y
[10.5], O
5-HT5 B-GENE-Y
[8.8], O
5-HT6 B-GENE-Y
[9.6] O
and O
5-HT7 B-GENE-Y
[9.9]), O
adrenoceptors B-GENE-N
(alpha1 I-GENE-N
[8.9], O
alpha2A B-GENE-Y
[8.9], O
alpha2B B-GENE-Y

[9.5] O
and O
alpha2C B-GENE-Y
[8.9]), O
dopamine B-CHEMICAL
receptors I-GENE-Y
(D1 I-GENE-Y
[8.9], O
D2 B-GENE-Y
[8.9], O
D3 B-GENE-Y
[9.4] O
and O
D4 B-GENE-Y
[9.0]) O
and O
histamine B-CHEMICAL
receptors I-GENE-Y
(H1 I-GENE-Y
[9.0] O
and O
H2 B-GENE-Y
[8.2]). O
It O
had O
much O
lower O
affinity O
(pKi<or=5) O
for O
muscarinic O
receptors O
and O
was O
the O
only O
agent O
with O
affinity O
for O
H2 O
receptors. O
Relative O
to O
its O
D2 O
receptor O
affinity, O
asenapine O
had O
a O
higher O
affinity O
for O

5-HT2C, O
5-HT2A, O
5-HT2B, O
5-HT7, O
5-HT6, O
alpha2B O
and O
D3 O
receptors, O
suggesting O
stronger O
engagement O
of O
these O
targets O
at O
therapeutic O
doses. O
Asenapine O
behaved O
as O
a O
potent O
antagonist O
(pKB) O
at O
5-HT1A O
(7.4), O
5-HT1B O
(8.1), O
5-HT2A O
(9.0), O
5-HT2B O
(9.3), O
5-HT2C O
(9.0), O

5-HT6 O
(8.0), O
5-HT7 O
(8.5), O
D2 O
(9.1), O
D3 O
(9.1), O
alpha2A O
(7.3), O
alpha2B O
(8.3), O
alpha2C O
(6.8) O
and O
H1 O
(8.4) O
receptors. O
These O
functional O
effects O
differed O
from O
those O
of O
risperidone O
(pKB<5 O
for O
5-HT6) O
and O
olanzapine O
(pKB<5 O
for O
5-HT1A O
and O
alpha2). O
Our O
results O
indicate O
that O

asenapine O
has O
a O
unique O
human O
receptor O
signature, O
with O
binding O
affinity O
and O
antagonistic O
properties O
that O
differ O
appreciably O
from O
those O
of O
antipsychotic O
drugs. O
Current O
and O
future O
prospects O
for O
anticoagulant O
therapy: O
inhibitors O
of O
factor B-GENE-Y
Xa I-GENE-Y
and O
factor B-GENE-Y
IIa. I-GENE-Y
Indirect O
systemic O
and O
direct O
oral O
factor O
Xa O
and O
direct O
oral O
factor B-GENE-Y
IIa I-GENE-Y
inhibitors O
with O
improved O
pharmacologic O
profiles O
compared O
with O
heparins O
and O
vitamin B-CHEMICAL
K I-CHEMICAL
antagonists O
are O
currently O
in O
clinical O
development. O
This O
overview O
focuses O
on O
the O
indirect O
antithrombin O
dependent O
pentasaccharide B-CHEMICAL
derivatives O
of O
idraparinux B-CHEMICAL
and O
on O
the O
most O
advanced O

oral O
direct O
inhibitors O
to O
factor B-GENE-Y
Xa I-GENE-Y
(rivaroxaban B-CHEMICAL
and O
apixaban) B-CHEMICAL
and O
IIa O
(dabigatran). B-CHEMICAL
Specifically, O
the O
results O
of O
dose-finding O
studies O
for O
the O
prevention O
of O
venous O
thromboembolism O
after O
elective O
orthopedic O
surgery, O
the O
results O
of O
dose-finding O
studies O
for O
treatment O
of O
acute O
venous O
thromboembolism O
including O
prolonged O
prophylaxis O
of O
recurrent O
events, O
and O
the O
designs O
of O
ongoing O
clinical O
trials O
are O
reviewed. O
Triple O
pharmacological O
blockade O
of O
the O
renin-angiotensin-aldosterone B-GENE-Y
system O
in O
nondiabetic O

CKD: O
an O
open-label O
crossover O
randomized O
controlled O
trial. O
BACKGROUND: O
Agents O
inhibiting O
the O
renin-angiotensin-aldosterone B-GENE-Y
(RAAS) O
system O
have O
an O
important O
role O
in O
slowing O
the O
progression O
of O
chronic O
kidney O
disease. O
We O
evaluated O
the O
hypothesis O
that O
the O
addition O
of O
an O
aldosterone B-CHEMICAL
receptor I-GENE-Y
antagonist O
to O
an O
angiotensin-converting B-GENE-Y
enzyme I-GENE-Y
(ACE) B-GENE-Y
inhibitor O
and O
angiotensin B-CHEMICAL
II I-CHEMICAL
type I-GENE-Y
1 I-GENE-Y
(AT-1) I-GENE-Y
receptor I-GENE-Y
blocker O
(ARB) O
(triple O
RAAS O
blockade) O
may O
provide O
an O
additional O
benefit O
compared O
with O
an O
ACE B-GENE-Y
inhibitor O
and O
ARB O

(double O
RAAS O
blockade). O
DESIGN: O
Randomized O
open O
controlled O
crossover O
study. O
SETTING O
& O
PARTICIPANTS: O
18 O
whites O
(7 O
women, O
11 O
men) O
from O
the O
Outpatient O
Department O
of O
Nephrology O
with O
chronic O
nondiabetic O
proteinuric O
kidney O
diseases, O
mean O
age O
42.4 O
+/- O
1.9 O
years O
(SEM). O
INTERVENTIONS: O
In O
the O
8-week O
run-in O
period, O
all O
participants O
received O
the O
ACE B-GENE-Y
inhibitor O
cilazapril B-CHEMICAL
(5 O
mg), O
the O
ARB O
telmisartan B-CHEMICAL
(80 O
mg), O

and O
the O
diuretic O
hydrochlorothiazide B-CHEMICAL
(12.5 O
mg) O
as O
double O
RAAS O
blockade O
to O
achieve O
the O
target O
blood O
pressure O
of O
less O
than O
130/80 O
mm O
Hg. O
Participants O
were O
then O
randomly O
assigned O
to O
2 O
treatment O
sequences, O
either O
the O
addition O
of O
spironolactone B-CHEMICAL
(25 O
mg) O
(triple O
RAAS O
blockade) O
through O
8 O
weeks O
followed O
by O
double O
RAAS O
blockade O
through O
8 O
weeks O
(sequence O
1) O
or O
double O
RAAS O
blockade O
followed O
by O
triple O
RAAS O
blockade O
(sequence O
2). O
MAIN O
OUTCOME O
MEASURES: O
24-hour O
urine O
protein O
excretion O
(primary O
end O

point) O
and O
markers O
of O
tubular O
injury O
and O
fibrosis O
(secondary O
end O
points). O
Analysis O
was O
performed O
using O
analysis O
of O
variance O
for O
repeated O
measurements. O
RESULTS: O
At O
baseline, O
mean O
serum O
creatinine O
level O
was O
1.16 O
+/- O
0.09 O
mg/dL O
(103 O
+/- O
8 O
micromol/L), O
estimated O
glomerular O
filtration O
rate O
was O
107.8 O
mL/min O
(95% O
confidence O
interval, O
93 O
to O
140.9 O
[1.8 O
mL/s; O
95% O
confidence O
interval, O
1.55 O
to O
2.35; O

Cockcroft-Gault O
formula), O
and O
24-hour O
mean O
proteinuria O
was O
0.97 O
+/- O
0.18 O
g. O
Mean O
urine O
protein O
excretion O
was O
0.7 O
g/24 O
h O
(95% O
confidence O
interval, O
0.48 O
to O
0.92) O
less O
after O
triple O
RAAS O
blockade O
than O
after O
double O
RAAS O
blockade O
(P O
= O
0.01), O
without O
change O
in O
blood O
pressure. O
Urine O
excretion O
of O
N-acetyl-beta-d-glucosaminidase B-GENE-Y
(P O
= O
0.02) O
and O
amino-terminal O
propeptide O
of O
type B-GENE-N
III I-GENE-N
procollagen I-GENE-N

(P O
= O
0.05) O
also O
significantly O
decreased. O
Potassium B-CHEMICAL
levels O
increased O
significantly O
after O
triple O
therapy O
(P O
= O
0.02). O
However, O
no O
patient O
was O
withdrawn O
because O
of O
adverse O
effects. O
LIMITATIONS: O
Absence O
of O
blinding, O
small O
sample O
size, O
short O
treatment O
period, O
absence O
of O
histological O
assessment. O
CONCLUSIONS: O
Administration O
of O
an O
aldosterone B-CHEMICAL
receptor I-GENE-Y
antagonist O
in O
addition O
to O
double O
RAAS O
blockade O
with O
an O
ACE B-GENE-Y
inhibitor O
and O
ARB O
may O
slow O
the O
progression O
of O
chronic O
kidney O
disease. O
Additional O
studies O
are O
necessary O
to O
confirm O
this O
result. O
Porcine O
TLR8 B-GENE-Y
and O
TLR7 B-GENE-Y

are O
both O
activated O
by O
a O
selective O
TLR7 B-GENE-Y
ligand, O
imiquimod. B-CHEMICAL
Toll-like B-GENE-N
receptors I-GENE-N
(TLRs) B-GENE-N
are O
a O
family O
of O
highly O
conserved O
germline-encoded O
pattern-recognition B-GENE-N
receptors I-GENE-N
(PRR), B-GENE-N
which O
are O
utilized O
by O
the O
innate O
immune O
system O
to O
recognize O
microbial O
components, O
known O
as O
pathogen-associated O
molecular O
patterns O
(PAMP). O
We O
cloned O
and O
characterized O
porcine O
TLR7 B-GENE-Y
and O
TLR8 B-GENE-Y
genes O
from O
pig O
lymph O
node O
tissue. O
Sequence O
analysis O
showed O
that O
the O
aa O
sequence O
identities O
of O
porcine B-GENE-Y
TLR7 I-GENE-Y
with O
human, B-GENE-N
mouse I-GENE-N
and I-GENE-N
bovine I-GENE-N

TLR7 I-GENE-N
are O
85, O
78 O
and O
90%, O
respectively, O
whereas O
porcine B-GENE-Y
TLR8 I-GENE-Y
aa O
sequence O
identities O
with O
human, B-GENE-N
mouse I-GENE-N
and I-GENE-N
bovine I-GENE-N
TLR8 I-GENE-N
are O
73, O
69 O
and O
79%, O
respectively. O
Both O
porcine B-GENE-N
TLR7 I-GENE-N
and O
TLR8 B-GENE-N
proteins O
were O
expressed O
in O
cell O
lines O
and O
were O
N-glycosylated. B-CHEMICAL
The O
stimulatory O
activity O
of O
TLR7 B-GENE-Y
and O
TLR8 B-GENE-Y
ligands O
to O
porcine B-GENE-N
and I-GENE-N
human I-GENE-N
TLR7 I-GENE-N
and O
TLR8 B-GENE-N
in O
transiently O
transfected O
Cos-7 O
and O
293T O
cells O
were O
analyzed O
using O
a O

NF-kappaB B-GENE-N
reporter O
assay. O
Two O
imidazoquinoline B-CHEMICAL
molecules, O
imiquimod B-CHEMICAL
and O
gardiquimod, B-CHEMICAL
markedly O
activated O
both O
porcine B-GENE-Y
TLR7 I-GENE-Y
and O
TLR8 B-GENE-Y
whereas O
only O
human B-GENE-Y
TLR7, I-GENE-Y
but O
not O
TLR8, B-GENE-Y
was O
activated O
by O
the O
ligands. O
Therefore, O
receptor O
specificity O
for O
porcine B-GENE-Y
TLR8 I-GENE-Y
is O
clearly O
species O
specific. O
We O
further O
showed O
that O
porcine B-GENE-Y
TLR7 I-GENE-Y
and O
TLR8 B-GENE-Y
are O
located O
intracellularly O
and O
are O
mainly O
within O
the O
endoplasmic O
reticulum. O
Moreover, O
activation O
of O
transfected O
cells O
and O

porcine O
PBMC O
by O
TLR7 B-GENE-Y
ligands O
was O
inhibited O
by O
bafilomycin B-CHEMICAL
A(1) I-CHEMICAL
indicating O
the O
requirement O
of O
endosomal/lysosomal O
acidification O
for O
activation O
of O
the O
receptors. O
High-affinity O
blockade O
of O
voltage-operated B-GENE-N
skeletal I-GENE-N
muscle I-GENE-N
and I-GENE-N
neuronal I-GENE-N
sodium I-GENE-N
channels I-GENE-N
by O
halogenated B-CHEMICAL
propofol I-CHEMICAL
analogues. O
BACKGROUND O
AND O
PURPOSE: O
Voltage-operated B-GENE-N
sodium B-CHEMICAL
channels I-GENE-N
constitute O
major O
target O
sites O
for O
local O
anaesthetic-like O
action. O
The O
clinical O
use O
of O
local O
anaesthetics O
is O
still O
limited O
by O
severe O
side O
effects, O
in O

particular, O
arrhythmias O
and O
convulsions. O
These O
side O
effects O
render O
the O
search O
for O
new O
local O
anaesthetics O
a O
matter O
of O
high O
interest. O
EXPERIMENTAL O
APPROACH: O
We O
have O
investigated O
the O
effects O
of O
three O
halogenated O
structural O
analogues O
of O
propofol B-CHEMICAL
on O
voltage-operated B-GENE-N
human I-GENE-N
skeletal I-GENE-N
muscle I-GENE-N
sodium I-GENE-N
channels I-GENE-N
(Na(V)1.4) B-GENE-Y
and O
the O
effect O
of O
one O
compound O
(4-chloropropofol) B-CHEMICAL
on O
neuronal B-GENE-N
sodium I-GENE-N
channels I-GENE-N
(Na(V)1.2) B-GENE-Y
heterologously O
expressed O
in O
human O
embryonic O
kidney O

cell O
line O
293. O
KEY O
RESULTS: O
4-Iodo-, B-CHEMICAL
4-bromo- B-CHEMICAL
and O
4-chloropropofol B-CHEMICAL
reversibly O
suppressed O
depolarization-induced O
whole-cell O
sodium B-CHEMICAL
inward O
currents O
with O
high O
potency. O
The O
IC(50) O
for O
block O
of O
resting O
channels O
at O
-150 O
mV O
was O
2.3, O
3.9 O
and O
11.3 O
microM O
in O
Na(V)1.4, B-GENE-Y
respectively, O
and O
29.2 O
microM O
for O
4-chloropropofol B-CHEMICAL
in O
Na(V)1.2. B-GENE-Y
Membrane O

depolarization O
inducing O
inactivation O
strongly O
increased O
the O
blocking O
potency O
of O
all O
compounds. O
Estimated O
affinities O
for O
the O
fast-inactivated O
channel O
state O
were O
81 O
nM, O
312 O
nM O
and O
227 O
nM O
for O
4-iodopropofol, B-CHEMICAL
4-bromopropofol B-CHEMICAL
and O
4-chloropropofol B-CHEMICAL
in O
Na(V)1.4, B-GENE-Y
and O
450 O
nM O
for O
4-chloropropofol B-CHEMICAL
in O
Na(V)1.2. B-GENE-Y
Recovery O
from O
fast O
inactivation O
was O
prolonged O
in O
the O
presence O
of O
drug O
leading O
to O
an O
accumulation O
of O
block O
during O
repetitive O
stimulation O
at O
high O

frequencies O
(100 O
Hz). O
CONCLUSIONS O
AND O
IMPLICATIONS: O
Halogenated B-CHEMICAL
propofol I-CHEMICAL
analogues O
constitute O
a O
novel O
class O
of O
sodium B-CHEMICAL
channel-blocking I-GENE-N
drugs O
possessing O
almost O
100-fold O
higher O
potency O
compared O
with O
the O
local O
anaesthetic O
and O
anti-arrhythmic O
drug O
lidocaine. B-CHEMICAL
Preferential O
drug O
binding O
to O
inactivated O
channel O
states O
suggests O
that O
halogenated B-CHEMICAL
propofol I-CHEMICAL
analogues O
might O
be O
especially O
effective O
in O
suppressing O
ectopic O
discharges O
in O
a O
variety O
of O
pathological O
conditions. O
Irbesartan: B-CHEMICAL
a O
review O
of O
its O
use O
in O
hypertension O
and O

diabetic O
nephropathy. O
Irbesartan B-CHEMICAL
(Aprovel, B-CHEMICAL
Avapro, B-CHEMICAL
Irbetan, B-CHEMICAL
Karvea), B-CHEMICAL
an O
angiotensin B-CHEMICAL
II I-CHEMICAL
receptor I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
antagonist, O
is O
approved O
in O
many O
countries O
worldwide O
for O
the O
treatment O
of O
hypertension. O
It O
is O
also O
approved O
in O
some O
regions O
for O
the O
treatment O
of O
nephropathy O
in O
patients O
with O
hypertension O
and O
type O
2 O
diabetes O
mellitus. O
In O
adults O
with O
essential O
hypertension, O
irbesartan B-CHEMICAL
is O
effective O
at O
reducing O
blood O
pressure O
(BP) O
over O
a O
24-hour O
period O
with O
once-daily O
administration. O

Irbesartan B-CHEMICAL
also O
slows O
the O
progression O
of O
renal O
disease O
in O
hypertensive O
patients O
with O
type O
2 O
diabetes, O
with O
this O
effect O
partly O
independent O
of O
its O
BP-lowering O
effect. O
In O
addition, O
irbesartan B-CHEMICAL
was O
generally O
well O
tolerated O
in O
clinical O
trials. O
Thus, O
irbesartan B-CHEMICAL
is O
a O
useful O
treatment O
option O
for O
patients O
with O
hypertension, O
including O
those O
with O
type O
2 O
diabetes O
and O
nephropathy. O
DNA O
damage O
and O
homologous O
recombination O
signaling O
induced O
by O
thymidylate B-CHEMICAL
deprivation. O
DNA O
damage O
is O
accepted O
as O
a O
consequence O
of O
thymidylate B-CHEMICAL
deprivation O
induced O
by O

chemotherapeutic O
inhibitors O
of O
thymidylate B-CHEMICAL
synthase I-GENE-Y
(TS), B-GENE-Y
but O
the O
types O
of O
damage O
and O
signaling O
responses O
remain O
incompletely O
understood. O
Thymidylate B-CHEMICAL
deprivation O
increases O
dUTP O
and O
uracil B-CHEMICAL
in O
DNA, O
which O
is O
removed O
by O
base O
excision O
repair O
(BER). O
Because O
BER O
requires O
a O
synthesis O
step, O
strand O
break O
intermediates O
presumably O
accumulate. O
Thymidylate B-CHEMICAL
deprivation O
also O
induces O
cell O
cycle O
arrest O
during O
replication. O
Homologous O
recombination O
(HR) O
is O
a O
means O
of O
repairing O
persistent O
BER O
intermediates O

and O
collapsed O
replication O
forks. O
There O
are O
also O
intimate O
links O
between O
HR O
and O
S-phase O
checkpoint O
pathways. O
In O
this O
study, O
the O
goals O
were O
to O
determine O
the O
involvement O
of O
HR-associated O
proteins O
and O
DNA O
damage O
signaling O
responses O
to O
thymidylate B-CHEMICAL
deprivation. O
When O
RAD51, B-GENE-Y
which O
is O
a O
central O
component O
of O
HR, O
was O
depleted O
by O
siRNA O
cells O
were O
sensitized O
to O
raltitrexed B-CHEMICAL
(RTX), B-CHEMICAL
which O
specifically O
inhibits O
TS. B-GENE-Y
To O
our O
knowledge, O
this O
is O
the O
first O
demonstration O
in O
mammalian O
cells O
that O
depletion O
of O
RAD51 B-GENE-Y
causes O
sensitivity O
to O

thymidylate B-CHEMICAL
deprivation. O
Activation O
of O
DNA O
damage O
signaling O
responses O
was O
examined O
following O
treatment O
with O
RTX. B-CHEMICAL
Phosphorylation O
of O
replication B-GENE-N
protein I-GENE-N
A I-GENE-N
(RPA2 B-GENE-Y
subunit) O
and O
formation O
of O
damage-induced O
foci O
were O
strikingly O
evident O
following O
IC(50) O
doses O
of O
RTX. B-CHEMICAL
Induction O
was O
much O
more O
striking O
following O
RTX B-CHEMICAL
treatment O
than O
with O
hydroxyurea, B-CHEMICAL
which O
is O
commonly O
used O
to O
inhibit O
replication. O
RTX B-CHEMICAL
treatment O
also O
induced O
foci O
of O
RAD51, B-GENE-Y
gamma-H2AX, B-GENE-Y
phospho-Chk1, B-GENE-Y
and O

phospho-NBS1, B-GENE-Y
although O
the O
extent O
of O
co-localization O
with O
RPA2 B-GENE-Y
foci O
varied. O
Collectively, O
the O
results O
suggest O
that O
HR O
and O
S-phase O
checkpoint O
signaling O
processes O
are O
invoked O
by O
thymidylate B-CHEMICAL
deprivation O
and O
influence O
cellular O
resistance O
to O
thymidylate B-CHEMICAL
deprivation. O
Corticosteroids B-CHEMICAL
and O
human B-GENE-Y
recombinant I-GENE-Y
activated I-GENE-Y
protein I-GENE-Y
C I-GENE-Y
for O
septic O
shock. O
This O
article O
summarizes O
the O
current O
knowledge O
on O
the O
benefit/risk O
profile O
from O
the O
use O
of O
low-dose O
corticosteroids B-CHEMICAL
and O
activated B-GENE-Y
protein I-GENE-Y
C I-GENE-Y
in O
treating O
septic O
shock. O
Physicians O
should O

consider O
using O
low-dose O
corticosteroids B-CHEMICAL
and O
drotrecogin B-GENE-Y
alpha I-GENE-Y
activated O
in O
the O
treatment O
of O
patients O
who O
have O
vasopressor-dependent O
septic O
shock O
with O
persistent O
signs O
of O
hypoperfusion, O
organ O
dysfunction, O
or O
hypotension. O
The O
optimal O
timing O
for O
initiating O
these O
treatments O
is O
from O
6 O
to O
24 O
hours O
from O
onset O
of O
shock. O
When O
patients O
are O
receiving O
these O
drugs, O
physicians O
should O
systematically O
screen O
for O
superinfection O
and O
serious O
bleeding O
events. O
Adipose O
tissue O
as O
a O
source O
of O
nicotinamide B-GENE-Y
N-methyltransferase I-GENE-Y
and O
homocysteine. B-CHEMICAL

Nicotinamide B-CHEMICAL
N-methyltransferase B-CHEMICAL
(NNMT) B-GENE-Y
catalyses O
the O
conversion O
of O
nicotinamide B-CHEMICAL
to O
1-methylnicotinamide B-CHEMICAL
and O
plays O
an O
important O
role O
in O
hepatic O
detoxification O
reactions. O
Here O
we O
show O
that, O
in O
addition O
to O
the O
liver, O
3T3-L1 O
adipocytes O
as O
well O
as O
human O
and O
murine O
adipose O
tissue O
explants O
express O
high O
amounts O
of O
enzymatically O
active O
NNMT. B-GENE-Y
NNMT B-GENE-Y
mRNA O
levels O
and O
enzyme O
activity O
increased O
in O
3T3-L1 O
cells O
in O
a O
differentiation-dependent O
manner. O

Homocysteine, B-CHEMICAL
the O
atherogenic O
product O
of O
the O
NNMT-catalyzed B-GENE-Y
reaction, O
was O
secreted O
from O
3T3-L1 O
cells O
or O
adipose O
tissue O
cultures. O
Homocysteine B-CHEMICAL
release O
increased O
during O
3T3-L1 O
differentiation O
and O
was O
reduced O
when O
adipose O
tissue O
was O
treated O
with O
the O
NNMT B-GENE-Y
inhibitor O
1-methylnicotinamide. B-CHEMICAL
Nicotinic B-CHEMICAL
acid I-CHEMICAL
(NA), B-CHEMICAL
a O
widely O
used O
drug O
to O
lower O
elevated O
plasma O
lipid O
levels, O
induced O
NNMT B-GENE-Y
enzyme O
activity O
in O
white O
adipose O
tissue O
of O
mice. O
In O
tissue O
culture O
nicotinamide B-CHEMICAL
treatment O

led O
to O
an O
increase O
in O
adipose O
tissue O
homocysteine B-CHEMICAL
secretion. O
These O
data O
support O
the O
concept O
that O
adipose O
tissue O
NNMT B-GENE-Y
contributes O
to O
the O
increased O
plasma O
homocysteine B-CHEMICAL
levels O
in O
patients O
treated O
with O
NA. B-CHEMICAL
Expression O
and O
1,4-dihydropyridine-binding B-CHEMICAL
properties O
of O
brain O
L-type B-GENE-N
calcium I-GENE-N
channel I-GENE-N
isoforms. O
The O
L-type B-GENE-N
calcium B-CHEMICAL
channel I-GENE-N
(LTCC) B-GENE-N
isoforms O
Ca(v)1.2 B-GENE-Y
and O
Ca(v)1.3 B-GENE-Y
display O
similar O
1,4-dihydropyridine B-CHEMICAL
(DHP) B-CHEMICAL
binding O
properties O
and O
are O

both O
expressed O
in O
mammalian O
brain. O
Recent O
work O
implicates O
Ca(v)1.3 B-GENE-Y
channels O
as O
interesting O
drug O
targets, O
but O
no O
isoform-selective O
modulators O
exist. O
It O
is O
also O
unknown O
to O
what O
extent O
Ca(v)1.1 B-GENE-Y
and O
Ca(v)1.4 B-GENE-Y
contribute O
to O
L-type-specific O
DHP B-CHEMICAL
binding O
activity O
in O
brain. O
To O
address O
this O
question O
and O
to O
determine O
whether O
DHPs O
can O
discriminate O
between O
Ca(v)1.2 B-GENE-Y
and O
Ca(v)1.3 B-GENE-Y
binding O
pockets, O
we O
combined O
radioreceptor O
assays O
and O
quantitative O
polymerase O
chain O

reaction O
(qPCR). O
We O
bred O
double O
mutants O
(Ca(v)-DM) B-GENE-N
from O
mice O
expressing O
mutant O
Ca(v)1.2 B-GENE-Y
channels O
[Ca(v)1.2DHP(-/-)] B-GENE-Y
lacking O
high O
affinity O
for O
DHPs O
and O
from O
Ca(v)1.3 B-GENE-Y
knockouts O
[Ca(v)1.3(-/-)]. B-GENE-Y
(+)-[(3)H]isradipine B-CHEMICAL
binding O
to O
Ca(v)1.2DHP(-/-) B-GENE-Y
and O
Ca(v)-DM B-GENE-N
brains O

was O
reduced O
to O
15.1 O
and O
4.4% O
of O
wild O
type, O
respectively, O
indicating O
that O
Ca(v)1.3 B-GENE-Y
accounts O
for O
10.7% O
of O
brain O
LTCCs. B-GENE-N
qPCR O
revealed O
that O
Ca(v)1.1 B-GENE-Y
and O
Ca(v)1.4 B-GENE-Y
alpha(1) I-GENE-Y
subunits O
comprised O
0.08% O
of O
the O
LTCC B-GENE-N
transcripts O
in O
mouse O
whole O
brain, O
suggesting O
that O
they O
cannot O
account O
for O
the O
residual O
binding. O
Instead, O
this O
could O
be O
explained O
by O
low-affinity O
binding O
(127-fold O
K(d) O
increase) O
to O
the O
mutated O

Ca(v)1.2 B-GENE-Y
channels. O
Inhibition O
of O
(+)-[(3)H]isradipine B-CHEMICAL
binding O
to O
Ca(v)1.2DHP(-/-) B-GENE-Y
(predominantly O
Ca(v)1.3) B-GENE-Y
and O
wild-type O
(predominantly O
Ca(v)1.2) B-GENE-Y
brain O
membranes O
by O
unlabeled O
DHPs O
revealed O
a O
3- O
to O
4-fold O
selectivity O
of O
nitrendipine B-CHEMICAL
and O
nifedipine B-CHEMICAL
for O
the O
Ca(v)1.2 B-GENE-Y
binding O
pocket, O
a O
finding O
further O
confirmed O
with O
heterologously O
expressed O
channels. O
This O

suggests O
that O
small O
differences O
in O
their O
binding O
pockets O
may O
allow O
development O
of O
isoform-selective O
modulators O
for O
LTCCs B-GENE-N
and O
that, O
because O
of O
their O
very O
low O
expression, O
Ca(v)1.1 B-GENE-Y
and O
Ca(v)1.4 B-GENE-Y
are O
unlikely O
to O
serve O
as O
drug O
targets O
to O
treat O
CNS O
diseases. O
Global O
target O
profile O
of O
the O
kinase B-GENE-N
inhibitor O
bosutinib B-CHEMICAL
in O
primary O
chronic O
myeloid O
leukemia O
cells. O
The O
detailed O
molecular O
mechanism O
of O
action O
of O
second-generation O
BCR-ABL B-GENE-Y
tyrosine B-GENE-N
kinase I-GENE-N
inhibitors, O
including O
perturbed O
targets O
and O
pathways, O
should O
contribute O
to O
rationalized O
therapy O
in O

chronic O
myeloid O
leukemia O
(CML) O
or O
in O
other O
affected O
diseases. O
Here, O
we O
characterized O
the O
target O
profile O
of O
the O
dual O
SRC/ABL B-GENE-Y
inhibitor O
bosutinib B-CHEMICAL
employing O
a O
two-tiered O
approach O
using O
chemical O
proteomics O
to O
identify O
natural O
binders O
in O
whole O
cell O
lysates O
of O
primary O
CML O
and O
K562 O
cells O
in O
parallel O
to O
in O
vitro O
kinase B-GENE-N
assays O
against O
a O
large O
recombinant O
kinase B-GENE-N
panel. O
The O
combined O
strategy O
resulted O
in O
a O
global O
survey O
of O
bosutinib B-CHEMICAL
targets O
comprised O
of O
over O
45 O
novel O
tyrosine B-CHEMICAL
and I-GENE-N
serine/threonine B-CHEMICAL

kinases. I-GENE-N
We O
have O
found O
clear O
differences O
in O
the O
target O
patterns O
of O
bosutinib B-CHEMICAL
in O
primary O
CML O
cells O
versus O
the O
K562 O
cell O
line. O
A O
comparison O
of O
bosutinib B-CHEMICAL
with O
dasatinib B-CHEMICAL
across O
the O
whole O
kinase B-GENE-N
panel O
revealed O
overlapping, O
but O
distinct, O
inhibition O
profiles. O
Common O
among O
those O
were O
the O
SRC, B-GENE-Y
ABL B-GENE-Y
and O
TEC B-GENE-Y
family O
kinases. B-GENE-N
Bosutinib B-CHEMICAL
did O
not O
inhibit O
KIT B-GENE-Y
or O
platelet-derived B-GENE-N
growth I-GENE-N
factor I-GENE-N
receptor, I-GENE-N
but O
prominently O
targeted O
the O
apoptosis-linked O
STE20 B-GENE-N
kinases. I-GENE-N
Although O
in O
vivo O
bosutinib B-CHEMICAL
is O
inactive O
against O
ABL B-GENE-Y

T315I, B-GENE-N
we O
found O
this O
clinically O
important O
mutant O
to O
be O
enzymatically O
inhibited O
in O
the O
mid-nanomolar O
range. O
Finally, O
bosutinib B-CHEMICAL
is O
the O
first O
kinase B-GENE-N
inhibitor O
shown O
to O
target O
CAMK2G, B-GENE-Y
recently O
implicated O
in O
myeloid O
leukemia O
cell O
proliferation. O
The O
effect O
of O
estramustine B-CHEMICAL
derivatives O
on O
microtubule O
assembly O
in O
vitro O
depends O
on O
the O
charge O
of O
the O
substituent. O
Estramustine, B-CHEMICAL
and O
derivatives O
of O
estramustine B-CHEMICAL
with O
a O
charged O
substituent O
at O
position O
17 O
on O
the O
estrogen B-CHEMICAL
moiety, O
have O
been O

investigated O
for O
their O
effects O
on O
bovine O
brain O
microtubules O
in O
vitro. O
The O
negatively O
charged O
estramustine B-CHEMICAL
phosphate I-CHEMICAL
has O
been O
found O
previously O
to O
be O
a O
microtubule-associated B-GENE-N
protein I-GENE-N
(MAP)-dependent B-GENE-N
microtubule O
inhibitor O
[Wallin O
M, O
Deinum O
J O
and O
Friden O
B, O
FEBS O
Lett O
179: O
289-293, O
1985]. O
In O
the O
present O
study O
the O
binding O
of O
estramustine B-CHEMICAL
phosphate I-CHEMICAL
to O
MAP2 B-GENE-Y
and O
tau B-GENE-Y
was O
investigated. O
Both O
these O
MAPs B-GENE-N
were O
found O
to O
have O
two O
to O
three O
binding O
sites O
for O
estramustine B-CHEMICAL
phosphate I-CHEMICAL
which O
is O
compatible O
with O
the O
reported O
number O

of O
basic O
amino B-CHEMICAL
acid I-CHEMICAL
repeats O
of O
these O
MAPs, B-GENE-N
considered O
to O
be O
the O
ultimate O
tubulin B-GENE-N
binding O
domains. O
The O
Kd O
for O
the O
binding O
of O
estramustine B-CHEMICAL
phosphate I-CHEMICAL
to O
MAP2 B-GENE-N
was O
estimated O
to O
be O
20 O
microM O
at O
4 O
degrees, O
and O
for O
the O
binding O
of O
tau, O
200 O
microM. O
The O
rate O
of O
dissociation O
was O
very O
low O
(T1/2 O
greater O
than O
2 O
hr), O
which O
indicates O
that O
the O
binding O
of O
estramustine B-CHEMICAL
phosphate I-CHEMICAL
may O
stabilize O
the O
protein-drug O
complex O
by O
changing O
the O
protein O
conformation. O
Two O
new O
negatively O
charged O
estramustine B-CHEMICAL
derivatives, O
estramustine B-CHEMICAL
sulphate I-CHEMICAL
and O

estramustine B-CHEMICAL
glucuronide, I-CHEMICAL
were O
found O
to O
be O
similar O
MAP-dependent B-GENE-N
microtubule O
inhibitors. O
The O
concentration O
for O
50% O
inhibition O
of O
assembly O
was O
100 O
microM O
for O
the O
sulphate B-CHEMICAL
derivative, O
the O
same O
as O
found O
previously O
for O
estramustine B-CHEMICAL
phosphate, I-CHEMICAL
and O
250 O
microM O
for O
the O
more O
bulky O
estramustine B-CHEMICAL
glucuronide. I-CHEMICAL
A O
positively O
charged O
derivative, O
estramustine B-CHEMICAL
sarcosinate, I-CHEMICAL
did O
not O
inhibit O
microtubule O
assembly O
or O
alter O
the O
composition O
of O
the O
coassembled O
MAPs. B-GENE-N
The O
morphology O
of O
the O
microtubules O
was, O
however, O
affected. O
The O

uncharged O
estramustine B-CHEMICAL
bound O
to O
both O
tubulin B-GENE-N
and O
MAPs, B-GENE-N
but O
no O
effects O
were O
seen O
on O
microtubule O
assembly, O
the O
composition O
of O
coassembled O
MAPs B-GENE-N
or O
the O
microtubule O
morphology. O
Our O
results O
suggest O
that O
only O
negatively O
charged O
estramustine B-CHEMICAL
derivatives O
have O
a O
MAP-dependent B-GENE-N
microtubule O
inhibitory O
effect. O
The O
two O
new O
negatively O
charged O
derivatives O
could O
therefore O
be O
valuable O
tools O
in O
the O
study O
of O
tubulin-MAP B-GENE-N
interactions. O
The O
results O
also O
confirm O
that O
these O
interactions O
between O
tubulin B-GENE-N
and O
MAPs B-GENE-N
are O
mainly O
electrostatic. O
Analysis O
of O
coenzyme O
binding O
by O
human B-GENE-N
placental I-GENE-N
3 I-GENE-N

beta-hydroxy-5-ene-steroid I-GENE-N
dehydrogenase I-GENE-N
and O
steroid B-GENE-N
5----4-ene-isomerase I-GENE-N
using O
5'-[p-(fluorosulfonyl)benzoyl]adenosine, B-CHEMICAL
an O
affinity O
labeling O
cofactor O
analog. O
3 B-GENE-N
beta-Hydroxy-5-ene-steroid I-GENE-N
dehydrogenase I-GENE-N
and O
steroid B-GENE-N
5----4-ene-isomerase I-GENE-N
copurify O
as O
a O
single, O
homogeneous O
protein O
from O
human O
placental O
microsomes. O

Affinity O
alkylation O
with O
2 O
alpha-bromoacetoxyprogesterone B-CHEMICAL
suggests O
that O
the O
dehydrogenase B-GENE-N
and O
isomerase O
substrate O
steroids B-CHEMICAL
bind O
at O
different O
sites O
on O
the O
same O
protein. O
However, O
the O
coenzyme, O
NADH, B-CHEMICAL
completely O
abolishes O
the O
alkylation O
of O
both O
enzyme O
activities O
by O
the O
progestin B-CHEMICAL
analog O
[Thomas O
J O
.L., O
Myers O
R. O
P., O
Rosik O
L. O
O. O
and O
Strickler O
R. O
C., O
J. O
Steroid O
Biochem. O
36 O
(1990) O
117-123]. O
Unlike O
bacterial O

3-keto-5-ene-steroid B-GENE-N
isomerase, I-GENE-N
the O
human O
isomerase O
reaction O
is O
stimulated O
by O
diphosphopyridine B-CHEMICAL
nucleotides I-CHEMICAL
(NADH, B-CHEMICAL
NAD+). B-CHEMICAL
The O
affinity O
labeling O
nucleotide B-CHEMICAL
analog, O
5'-[p-(fluorosulfonyl)benzoyl]adenosine B-CHEMICAL
(FSA), B-CHEMICAL
inactivates O
the O
dehydrogenase B-GENE-N
and O
isomerase O
activities O
at O
similar O
rates O
in O
an O
irreversible O
manner O
which O
follows O
first O
order O
kinetics O
with O
respect O
to O
both O
time O
and O
alkylator O
concentration O

(0.2-0.6 O
mM). O
FSA O
is O
a O
cofactor O
site-directed O
reagent O
that O
binds O
with O
similar O
affinity O
as O
a O
competitive O
inhibitor O
of O
NAD+ B-CHEMICAL
reduction O
by O
dehydrogenase B-GENE-N
(Ki O
= O
162 O
microM) O
or O
as O
a O
stimulator O
of O
isomerase O
(Km O
= O
153 O
microM). O
Parallel O
plots O
derived O
from O
Kitz O
and O
Wilson O
analysis O
indicate O
that O
FSA B-CHEMICAL
inactivates O
the O
two O
enzyme O
activities O
with O
equal O
alkylation O
efficiency O
(k3/Ki O
= O
1/slope O
= O
0.51/mol-s O
for O
both). O
The O
3 B-CHEMICAL

beta-hydroxysteroid I-CHEMICAL
substrate, O
pregnenolone, B-CHEMICAL
protects O
isomerase O
as O
well O
as O
dehydrogenase B-GENE-N
from O
inactivation O
by O
FSA. B-CHEMICAL
These O
observations O
are O
evidence O
for O
a O
single O
cofactor O
binding O
region O
which O
services O
both O
enzyme O
activities. O
Tyrosine B-GENE-N
kinase I-GENE-N
blockers: O
new O
hope O
for O
successful O
cancer O
therapy. O
Tyrosine B-GENE-N
kinases I-GENE-N
(TKs) B-GENE-N
are O
attractive O
targets O
for O
cancer O
therapy, O
as O
quite O
often O
their O
abnormal O
signaling O
has O
been O
linked O
with O
tumor O
development O
and O
growth. O
Constitutive O
activated O
TKs B-GENE-N
stimulate O
multiple O
signaling O
pathways O
responsible O
for O
DNA O
repair, O
apoptosis, O
and O
cell O
proliferation. O
During O
the O
last O

few O
years, O
thorough O
analysis O
of O
the O
mechanism O
underlying O
tyrosine B-GENE-N
kinase's I-GENE-N
activity O
led O
to O
novel O
cancer O
therapy O
using O
TKs B-GENE-N
blockers. O
These O
drugs O
are O
remarkably O
effective O
in O
the O
treatment O
of O
various O
human O
tumors O
including O
head O
and O
neck, O
gastric, O
prostate O
and O
breast O
cancer O
and O
leukemias. O
The O
most O
successful O
example O
of O
kinase B-GENE-N
blockers O
is O
Imatinib B-CHEMICAL
(Imatinib B-CHEMICAL
mesylate, I-CHEMICAL
Gleevec, B-CHEMICAL
STI571), B-CHEMICAL
the O
inhibitor O
of O
Bcr/Abl B-GENE-Y
oncoprotein, O
which O
has O
become O
a O
first-line O
therapy O
for O
chronic O
myelogenous O

leukemia. O
The O
introduction O
of O
STI571 B-CHEMICAL
for O
the O
treatment O
of O
leukemia O
in O
clinical O
oncology O
has O
had O
a O
dramatic O
impact O
on O
how O
this O
disease O
is O
currently O
managed. O
Others O
kinase O
inhibitors O
used O
recently O
in O
cancer O
therapy O
include O
Dasatinib B-CHEMICAL
(BMS-354825) B-CHEMICAL
specific O
for O
ABL B-GENE-Y
non-receptor B-GENE-N
cytoplasmic I-GENE-N
kinase, I-GENE-N
Gefitinib B-CHEMICAL
(Iressa), B-CHEMICAL
Erlotinib B-CHEMICAL
(OSI-774, B-CHEMICAL
Tarceva) B-CHEMICAL
and O
Sunitinib B-CHEMICAL
(SU B-CHEMICAL
11248, I-CHEMICAL
Sutent) B-CHEMICAL
specific O
for O
VEGF B-GENE-N
receptor I-GENE-N
kinase, B-GENE-N
AMN107 B-CHEMICAL

(Nilotinib) B-CHEMICAL
and O
INNO-406 B-CHEMICAL
(NS-187) B-CHEMICAL
specific O
for O
c-KIT B-GENE-Y
kinase. O
The O
following O
TK B-GENE-N
blockers O
for O
treatment O
of O
various O
human O
tumors O
are O
in O
clinical O
development: O
Lapatinib B-CHEMICAL
(Lapatinib B-CHEMICAL
ditosylate, I-CHEMICAL
Tykerb, B-CHEMICAL
GW-572016), B-CHEMICAL
Canertinib B-CHEMICAL
(CI-1033), B-CHEMICAL
Zactima B-CHEMICAL
(ZD6474), B-CHEMICAL
Vatalanib B-CHEMICAL
(PTK787/ZK B-CHEMICAL
222584), I-CHEMICAL
Sorafenib B-CHEMICAL
(Bay B-CHEMICAL
43-9006, I-CHEMICAL

Nexavar), B-CHEMICAL
and O
Leflunomide B-CHEMICAL
(SU101, B-CHEMICAL
Arava). B-CHEMICAL
Herein, O
we O
discuss O
the O
chemistry, O
biological O
activity O
and O
clinical O
potential O
of O
new O
drugs O
with O
tyrosine B-GENE-N
kinase I-GENE-N
blockers O
for O
cancer O
treatment. O
Transdermal O
selegiline B-CHEMICAL
for O
the O
treatment O
of O
major O
depressive O
disorder. O
Non-selective O
inhibition O
of O
monoamine B-CHEMICAL
oxidase I-GENE-N
(MAO) B-GENE-N
enzymes O
(ie, O
isoforms O
A O
and O
B) O
in O
the O
brain O
are O
associated O
with O
clinically O
significant O
antidepressant O
effects. O
In O
the O
US, O
the O
selegiline B-CHEMICAL
transdermal O
system O

(STS; O
EMSAM) O
is O
the O
first O
antidepressant O
transdermal O
delivery O
system O
to O
receive O
Food O
and O
Drug O
Administration O
(FDA) O
approved O
labeling O
for O
the O
treatment O
of O
major O
depressive O
disorder O
(MDD). O
Currently, O
the O
use O
of O
orally O
administered O
MAO B-GENE-N
inhibitor O
antidepressants O
(eg, O
phenelzine, B-CHEMICAL
tranylcypromine) B-CHEMICAL
is O
limited O
by O
the O
risk O
of O
tyramine-provoked B-CHEMICAL
events O
(eg, O
acute O
hypertension O
and O
headache, O
also O
known O
as O
the O
"cheese O
reaction") O
when O
combined O
with O
dietary O
tyramine. B-CHEMICAL
The O
selegiline B-CHEMICAL
transdermal O

system O
is O
the O
only O
MAOI O
available O
in O
the O
US O
for O
the O
treatment O
of O
MDD O
that O
does O
not O
require O
dietary O
restriction O
at O
the O
clinically O
effective O
dose O
of O
6 O
mg/24 O
hours. O
Delivery O
of O
selegiline O
transdermally O
(EMSAM((R))) O
bypasses O
hepatic O
first O
pass O
metabolism, O
thereby O
avoiding O
significant O
inhibition O
of O
gastrointestinal O
and O
hepatic O
MAO-A B-GENE-Y
activity O
(ie, O
reduced O
risk O
of O
tyramine-provoked B-CHEMICAL
events) O
while O
still O
providing O
sufficient O
levels O
of O
selegiline B-CHEMICAL
in O
the O
brain O
to O
produce O
an O
antidepressant O
effect. O
At O

dosages O
of O
6-12 O
mg/24 O
hours, O
EMSAM O
has O
been O
shown O
to O
improve O
symptoms O
of O
depression, O
have O
good O
tolerability, O
and O
have O
high O
rates O
of O
medication O
adherence. O
However, O
at O
higher O
doses O
of O
EMSAM O
(ie, O
9 O
mg/24 O
hours O
or O
more), O
dietary O
restriction O
of O
tyramine B-CHEMICAL
intake O
is O
recommended. O
The O
introduction O
of O
EMSAM O
overcomes O
many O
of O
the O
safety O
concerns O
affiliated O
with O
the O
conventional O
oral O
MAO B-GENE-N
inhibitors O
and O
EMSAM O
may O
be O
considered O
another O
strategy O
for O
the O
treatment O
of O
MDD, O
especially O
in O
patients O
who O
cannot O
tolerate O
oral O
antidepressants, O
are O
poorly O

adherent, O
who O
present O
with O
atypical O
depressive O
symptoms, O
or O
have O
failed O
other O
antidepressants. O
Atomoxetine: B-CHEMICAL
a O
review O
of O
its O
use O
in O
attention-deficit O
hyperactivity O
disorder O
in O
children O
and O
adolescents. O
Atomoxetine B-CHEMICAL
(Strattera(R)) B-CHEMICAL
is O
a O
selective O
norepinephrine B-CHEMICAL
(noradrenaline) B-CHEMICAL
reuptake O
inhibitor O
that O
is O
not O
classified O
as O
a O
stimulant, O
and O
is O
indicated O
for O
use O
in O
patients O
with O
attention-deficit O
hyperactivity O
disorder O
(ADHD). O
Atomoxetine B-CHEMICAL
is O
effective O
and O
generally O
well O
tolerated. O
It O
is O
significantly O
more O

effective O
than O
placebo O
and O
standard O
current O
therapy O
and O
does O
not O
differ O
significantly O
from O
or O
is O
noninferior O
to O
immediate-release O
methylphenidate; B-CHEMICAL
however, O
it O
is O
significantly O
less O
effective O
than O
the O
extended-release O
methylphenidate B-CHEMICAL
formulation O
OROS(R) O
methylphenidate B-CHEMICAL
(hereafter O
referred O
to O
as O
osmotically O
released O
methylphenidate) B-CHEMICAL
and O
extended-release O
mixed O
amfetamine B-CHEMICAL
salts. O
Atomoxetine B-CHEMICAL
can O
be O
administered O
either O
as O
a O
single O
daily O
dose O
or O
split O
into O
two O
evenly O
divided O
doses, O
has O
a O
negligible O
risk O
of O
abuse O
or O
misuse, O
and O
is O
not O
a O
controlled O
substance O
in O
the O

US. O
Atomoxetine B-CHEMICAL
is O
particularly O
useful O
for O
patients O
at O
risk O
of O
substance O
abuse, O
as O
well O
as O
those O
who O
have O
co-morbid O
anxiety O
or O
tics, O
or O
who O
do O
not O
wish O
to O
take O
a O
controlled O
substance. O
Thus, O
atomoxetine B-CHEMICAL
is O
a O
useful O
option O
in O
the O
treatment O
of O
ADHD O
in O
children O
and O
adolescents. O
The O
mechanism O
of O
action O
of O
atomoxetine B-CHEMICAL
is O
unclear, O
but O
is O
thought O
to O
be O
related O
to O
its O
selective O
inhibition O
of O
presynaptic O
norepinephrine B-CHEMICAL
reuptake O
in O
the O
prefrontal O
cortex. O
Atomoxetine B-CHEMICAL
has O
a O
high O
affinity O
and O
selectivity O
for O
norepinephrine B-CHEMICAL

transporters, I-GENE-Y
but O
little O
or O
no O
affinity O
for O
various O
neurotransmitter B-GENE-N
receptors. I-GENE-N
Atomoxetine B-CHEMICAL
has O
a O
demonstrated O
ability O
to O
selectively O
inhibit O
norepinephrine B-CHEMICAL
uptake O
in O
humans O
and O
animals, O
and O
studies O
have O
shown O
that O
it O
preferentially O
binds O
to O
areas O
of O
known O
high O
distribution O
of O
noradrenergic O
neurons, O
such O
as O
the O
fronto-cortical O
subsystem. O
Atomoxetine B-CHEMICAL
was O
generally O
associated O
with O
statistically, O
but O
not O
clinically, O
significant O
increases O
in O
both O
heart O
rate O
and O
blood O
pressure O
in O
pediatric O
patients O
with O
ADHD. O
While O
there O
was O
an O
initial O
loss O
in O
expected O
height O
and O
weight O
among O

atomoxetine B-CHEMICAL
recipients, O
this O
eventually O
returned O
to O
normal O
in O
the O
longer O
term. O
Data O
suggest O
that O
atomoxetine B-CHEMICAL
is O
unlikely O
to O
have O
any O
abuse O
potential. O
Atomoxetine B-CHEMICAL
appeared O
less O
likely O
than O
methylphenidate B-CHEMICAL
to O
exacerbate O
disordered O
sleep O
in O
pediatric O
patients O
with O
ADHD. O
Atomoxetine B-CHEMICAL
is O
rapidly O
absorbed, O
and O
demonstrates O
dose-proportional O
increases O
in O
plasma O
exposure. O
It O
undergoes O
extensive O
biotransformation, O
which O
is O
affected O
by O
poor O
metabolism O
by O
cytochrome B-GENE-Y
P450 I-GENE-Y
(CYP) I-GENE-Y
2D6 I-GENE-Y
in O
a O
small O
percentage O
of O
the O
population; O
these O
patients O
have O
greater O
exposure O
to O
and O
slower O
elimination O
of O

atomoxetine B-CHEMICAL
than O
extensive O
metabolizers. O
Patients O
with O
hepatic O
insufficiency O
show O
an O
increase O
in O
atomoxetine B-CHEMICAL
exposure. O
CYP2D6 B-GENE-Y
inhibitors, O
such O
as O
paroxetine, B-CHEMICAL
are O
associated O
with O
changes O
in O
atomoxetine B-CHEMICAL
pharmacokinetics O
similar O
to O
those O
observed O
among O
poor O
CYP2D6 B-GENE-Y
metabolizers. O
Once- O
or O
twice-daily O
atomoxetine B-CHEMICAL
was O
effective O
in O
the O
short-term O
treatment O
of O
ADHD O
in O
children O
and O
adolescents, O
as O
observed O
in O
several O
well O
designed O
placebo-controlled O
trials. O
Atomoxetine B-CHEMICAL
also O
demonstrated O
efficacy O
in O
the O
longer O
term O

treatment O
of O
these O
patients. O
A O
single O
morning O
dose O
was O
shown O
to O
be O
effective O
into O
the O
evening, O
and O
discontinuation O
of O
atomoxetine B-CHEMICAL
was O
not O
associated O
with O
symptom O
rebound. O
Atomoxetine B-CHEMICAL
efficacy O
did O
not O
appear O
to O
differ O
between O
children O
and O
adolescents. O
Stimulant-naive O
patients O
also O
responded O
well O
to O
atomoxetine B-CHEMICAL
treatment. O
Atomoxetine B-CHEMICAL
did O
not O
differ O
significantly O
from O
or O
was O
noninferior O
to O
immediate-release O
methylphenidate B-CHEMICAL
in O
children O
and O
adolescents O
with O
ADHD O
with O
regard O
to O
efficacy, O
and O
was O
significantly O
more O
effective O
than O
standard O
current O
therapy O
(any O
combination O
of O
medicines O
[excluding O

atomoxetine] B-CHEMICAL
and/or O
behavioral O
counseling, O
or O
no O
treatment). O
However, O
atomoxetine B-CHEMICAL
was O
significantly O
less O
effective O
than O
osmotically O
released O
methylphenidate B-CHEMICAL
and O
extended-release O
mixed O
amfetamine B-CHEMICAL
salts. O
The O
efficacy O
of O
atomoxetine B-CHEMICAL
did O
not O
appear O
to O
be O
affected O
by O
the O
presence O
of O
co-morbid O
disorders, O
and O
symptoms O
of O
the O
co-morbid O
disorders O
were O
not O
affected O
or O
were O
improved O
by O
atomoxetine B-CHEMICAL
administration. O
Health-related O
quality O
of O
life O
(HR-QOL) O
appeared O
to O
be O
positively O
affected O
by O
atomoxetine B-CHEMICAL
in O
both O
short- O
and O
long-term O
studies; O

atomoxetine B-CHEMICAL
also O
improved O
HR-QOL O
to O
a O
greater O
extent O
than O
standard O
current O
therapy. O
Atomoxetine B-CHEMICAL
was O
generally O
well O
tolerated O
in O
children O
and O
adolescents O
with O
ADHD. O
Common O
adverse O
events O
included O
headache, O
abdominal O
pain, O
decreased O
appetite, O
vomiting, O
somnolence, O
and O
nausea. O
The O
majority O
of O
adverse O
events O
were O
mild O
or O
moderate; O
there O
was O
a O
very O
low O
incidence O
of O
serious O
adverse O
events. O
Few O
patients O
discontinued O
atomoxetine B-CHEMICAL
treatment O
because O
of O
adverse O
events. O
Atomoxetine B-CHEMICAL
discontinuation O
appeared O
to O
be O
well O
tolerated, O
with O
a O
low O
incidence O
of O
discontinuation-emergent O
adverse O
events. O

Atomoxetine B-CHEMICAL
appeared O
better O
tolerated O
among O
extensive O
CYP2D6 B-GENE-Y
metabolizers O
than O
among O
poor O
metabolizers. O
Slight O
differences O
were O
evident O
in O
the O
adverse O
event O
profiles O
of O
atomoxetine B-CHEMICAL
and O
stimulants, O
both O
immediate- O
and O
extended-release. O
Somnolence O
appeared O
more O
common O
among O
atomoxetine B-CHEMICAL
recipients O
and O
insomnia O
appeared O
more O
common O
among O
stimulant O
recipients. O
A O
black-box O
warning O
for O
suicidal O
ideation O
has O
been O
published O
in O
the O
US O
prescribing O
information, O
based O
on O
findings O
from O
a O
meta-analysis O
showing O
that O
atomoxetine B-CHEMICAL
is O
associated O
with O
a O
significantly O
higher O
incidence O

of O
suicidal O
ideation O
than O
placebo. O
Rarely, O
atomoxetine B-CHEMICAL
may O
also O
be O
associated O
with O
serious O
liver O
injury; O
postmarketing O
data O
show O
that O
three O
patients O
have O
had O
liver-related O
adverse O
events O
deemed O
probably O
related O
to O
atomoxetine B-CHEMICAL
treatment. O
Treatment O
algorithms O
involving O
the O
initial O
use O
of O
atomoxetine B-CHEMICAL
appear O
cost O
effective O
versus O
algorithms O
involving O
initial O
methylphenidate B-CHEMICAL
(immediate- O
or O
extended-release), O
dexamfetamine, B-CHEMICAL
tricyclic B-CHEMICAL
antidepressants, O
or O
no O
treatment O
in O
stimulant-naive, O
-failed, O
and O
-contraindicated O
children O
and O
adolescents O
with O
ADHD. O
The O

incremental O
cost O
per O
quality-adjusted O
life-year O
is O
below O
commonly O
accepted O
cost-effectiveness O
thresholds, O
as O
shown O
in O
several O
Markov O
model O
analyses O
conducted O
from O
the O
perspective O
of O
various O
European O
countries, O
with O
a O
time O
horizon O
of O
1 O
year. O
Novel O
inhibitors O
complexed O
with O
glutamate B-GENE-Y
dehydrogenase: I-GENE-Y
allosteric O
regulation O
by O
control O
of O
protein O
dynamics. O
Mammalian B-GENE-N
glutamate B-CHEMICAL
dehydrogenase I-GENE-N
(GDH) B-GENE-N
is O
a O
homohexameric O
enzyme O
that O
catalyzes O
the O
reversible O
oxidative O
deamination O
of O
l-glutamate B-CHEMICAL
to O

2-oxoglutarate B-CHEMICAL
using O
NAD(P)(+) B-CHEMICAL
as O
coenzyme. O
Unlike O
its O
counterparts O
from O
other O
animal O
kingdoms, O
mammalian B-GENE-N
GDH I-GENE-N
is O
regulated O
by O
a O
host O
of O
ligands. O
The O
recently O
discovered O
hyperinsulinism/hyperammonemia O
disorder O
showed O
that O
the O
loss O
of O
allosteric O
inhibition O
of O
GDH B-GENE-Y
by O
GTP B-CHEMICAL
causes O
excessive O
secretion O
of O
insulin. B-GENE-Y
Subsequent O
studies O
demonstrated O
that O
wild-type O
and O
hyperinsulinemia/hyperammonemia O
forms O
of O
GDH B-GENE-Y
are O
inhibited O
by O
the O
green O
tea O
polyphenols, O

epigallocatechin B-CHEMICAL
gallate I-CHEMICAL
and O
epicatechin B-CHEMICAL
gallate. I-CHEMICAL
This O
was O
followed O
by O
high O
throughput O
studies O
that O
identified O
more O
stable O
inhibitors, O
including O
hexachlorophene, B-CHEMICAL
GW5074, B-CHEMICAL
and O
bithionol. B-CHEMICAL
Shown O
here O
are O
the O
structures O
of O
GDH B-GENE-Y
complexed O
with O
these O
three O
compounds. O
Hexachlorophene B-CHEMICAL
forms O
a O
ring O
around O
the O
internal O
cavity O
in O
GDH B-GENE-Y
through O
aromatic O
stacking O
interactions O
between O
the O
drug O
and O
GDH B-GENE-Y
as O
well O
as O
between O
the O
drug O
molecules O
themselves. O
In O
contrast, O
GW5074 B-CHEMICAL
and O
bithionol B-CHEMICAL
both O
bind O
as O
pairs O
of O

stacked O
compounds O
at O
hexameric O
2-fold O
axes O
between O
the O
dimers O
of O
subunits. O
The O
internal O
core O
of O
GDH B-GENE-Y
contracts O
when O
the O
catalytic O
cleft O
closes O
during O
enzymatic O
turnover. O
None O
of O
the O
drugs O
cause O
conformational O
changes O
in O
the O
contact O
residues, O
but O
all O
bind O
to O
key O
interfaces O
involved O
in O
this O
contraction O
process. O
Therefore, O
it O
seems O
likely O
that O
the O
drugs O
inhibit O
enzymatic O
turnover O
by O
inhibiting O
this O
transition. O
Indeed, O
this O
expansion/contraction O
process O
may O
play O
a O
major O
role O
in O
the O
inter-subunit O
communication O
and O
allosteric O
regulation O
observed O
in O
GDH. B-GENE-Y
The O
effect O
of O
a O
peripheral O
block O
on O
inflammation-induced O

prostaglandin B-CHEMICAL
E2 I-CHEMICAL
and O
cyclooxygenase B-GENE-N
expression O
in O
rats. O
BACKGROUND: O
Peripheral O
inflammatory O
pain O
is O
associated O
with O
an O
upregulation O
of O
spinal O
cord O
COX-2 B-GENE-Y
(cyclooxygenase-2), B-GENE-Y
with O
a O
subsequent O
increase O
in O
central O
prostaglandin B-CHEMICAL
E2 I-CHEMICAL
(PGE2) B-CHEMICAL
levels O
associated O
with O
the O
development O
of O
hyperalgesia. O
In O
this O
study, O
we O
evaluated O
the O
effect O
of O
bupivacaine B-CHEMICAL
administered O
via O
a O
nerve O
block O
or O
via O
a O
systemic O
route O
on O
the O
spinal O
expression O
of O
PGE2 B-CHEMICAL
and O

COX B-GENE-N
in O
a O
model O
of O
peripheral O
inflammation O
in O
rats. O
METHODS: O
All O
rats O
randomly O
received O
three O
injections: O
1) O
a O
left O
subcutaneous O
hindpaw O
injection O
(0.2 O
mL O
with O
either O
carrageenan O
2% O
w/v O
or O
saline), O
2) O
a O
left O
sciatic O
block O
(0.2 O
mL O
with O
either O
bupivacaine B-CHEMICAL
0.5% O
or O
saline), O
and O
3) O
a O
systemic O
injection O
(subcutaneous O
interscapular O
with O
0.2 O
mL O
with O
either O
bupivacaine B-CHEMICAL
0.5% O
or O
saline). O
Local O
edema, O

thermal, O
and O
mechanical O
hyperalgesia O
as O
well O
as O
cerebrospinal O
fluid O
PGE2 B-CHEMICAL
concentration O
and O
COX-1 B-GENE-Y
and O
COX-2 B-GENE-Y
expression O
in O
the O
spinal O
cord O
in O
dorsal O
root O
ganglions O
were O
measured. O
RESULTS: O
We O
confirmed O
that O
a O
bupivacaine B-CHEMICAL
block O
attenuates O
hyperalgesia O
and O
local O
inflammation O
in O
a O
model O
of O
inflammatory O
pain. O
This O
effect O
was O
associated O
with O
an O
inhibition O
of O
the O
increase O
in O
COX-2 B-GENE-Y
expression O
induced O
by O
peripheral O
inflammation O
in O
dorsal O
root O
ganglions O
and O
cord. O
The O
subsequent O
production O
of O
PGE2 B-CHEMICAL
in O
cerebrospinal O
fluid O
was O

also O
impaired. O
Systemic O
bupivacaine B-CHEMICAL
did O
not O
modify O
either O
the O
hyperalgesia O
and O
local O
inflammation O
or O
COX B-GENE-N
expression. O
CONCLUSION: O
These O
results O
constitute O
a O
key O
element O
strongly O
suggesting O
that O
local O
anesthetics O
act O
at O
a O
different O
level O
when O
administered O
systematically O
or O
via O
a O
nerve O
block. O
Two O
pharmacologically O
distinct O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
subtypes O
in O
the O
contraction O
of O
rabbit O
aorta: O
each O
subtype O
couples O
with O
a O
different O
Ca2+ B-CHEMICAL
signalling O
mechanism O
and O
plays O
a O
different O
physiological O
role. O
Using O
the O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
subtype-selective O
antagonists O

chlorethylclonidine B-CHEMICAL
(CEC), B-CHEMICAL
WB4101, B-CHEMICAL
and O
5-methyl-urapidil, B-CHEMICAL
we O
have O
examined O
the O
possible O
heterogeneity O
in O
the O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
populations O
in O
rabbit O
aorta. O
The O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
alkylating O
agent O
CEC O
selectively O
inhibited O
the O
phasic O
component O
of O
the O
norepinephrine-induced B-CHEMICAL
contractile O
response, O
with O
little O
effect O
on O
the O
tonic O
component. O
The O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
occupancy-response O
relationship O
defined O
by O
the O

phenoxybenzamine B-CHEMICAL
inactivation O
method O
was O
rectangular O
hyperbolic O
for O
the O
tonic O
response, O
whereas O
that O
for O
the O
phasic O
response O
was O
linear, O
indicating O
the O
different O
degree O
of O
receptor O
reserve O
for O
the O
two O
responses. O
Radioligand O
binding O
studies O
with O
the O
nonselective O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
antagonist O
radioligand O
125I-BE2254 B-CHEMICAL
showed O
that O
73-87% O
of O
the O
binding O
sites O
in O
rabbit O
aorta O
are O
CEC B-CHEMICAL
sensitive O
and O
they O
are O
predominantly O
low O
affinity O
sites O
both O
for O
WB4101 B-CHEMICAL
(pKd O
= O
8.1) O
and O
for O
5-methylurapidil B-CHEMICAL

(pKd O
= O
7.1). O
Moreover, O
alpha B-GENE-N
1-adrenoceptor-mediated I-GENE-N
phosphatidylinositol B-CHEMICAL
(PI) B-CHEMICAL
hydrolysis O
was O
CEC B-CHEMICAL
sensitive, O
and O
fractional O
inactivation O
of O
alpha B-GENE-N
1 I-GENE-N
receptors I-GENE-N
with O
CEC B-CHEMICAL
showed O
equivalent O
increments O
in O
the O
reduction O
of O
PI B-CHEMICAL
hydrolysis O
and O
phasic O
contractile O
response, O
suggesting O
that O
both O
responses O
are O
linearly O
related O
to O
the O
CEC-sensitive B-CHEMICAL
receptor O
sites. O
The O
Schild O
plots O
for O
the O
competitive O
antagonists O
WB4101 B-CHEMICAL
and O
5-methyl-urapidil B-CHEMICAL
against O
alpha B-GENE-Y

1a-adrenoceptor-selective I-GENE-Y
agonist O
methoxamine-induced B-CHEMICAL
contraction O
were O
linear O
and O
had O
slopes O
not O
significantly O
different O
from O
unity, O
with O
a O
pA2 O
of O
9.07 O
+/- O
0.07 O
(n O
= O
5) O
for O
WB4101 B-CHEMICAL
and O
9.09 O
+/- O
0.05 O
(n O
= O
3) O
for O
5-methyl-urapidil. B-CHEMICAL
However, O
the O
Schilod O
plots O
for O
these O
antagonists O
against O
norepinephrine B-CHEMICAL
were O
curvilinear. O
Computer-assisted O
analysis O
of O
these O
curvilinear O
Schild O
plots O
in O
a O
two-receptor O
system O

indicated O
that O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
populations O
responsible O
for O
the O
constrictive O
response O
are O
predominantly O
(approximately O
80-90%) O
low O
affinity O
sites O
for O
the O
two O
antagonists O
(pKd O
approximately O
8.1 O
for O
WB4101 B-CHEMICAL
and O
pKd O
approximately O
7.1 O
for O
5-methyl-urapidil) B-CHEMICAL
and O
a O
small O
population O
(approximately O
10-20%) O
are O
high O
affinity O
sites O
(pKd O
approximately O
9.1 O
for O
both O
WB4101 B-CHEMICAL
and O
5-methyl-urapidil), B-CHEMICAL
which O
was O
in O
good O
agreement O
with O
radioligand O
binding O
studies.(ABSTRACT O

TRUNCATED O
AT O
400 O
WORDS) O
Ambrisentan B-CHEMICAL
for O
the O
treatment O
of O
pulmonary O
arterial O
hypertension. O
Ambrisentan B-CHEMICAL
is O
an O
endothelin B-GENE-N
receptor I-GENE-N
antagonist O
(ERA) O
that O
was O
recently O
approved O
for O
treatment O
of O
pulmonary O
arterial O
hypertension O
(PAH). O
Endothelin B-GENE-N
(ET) B-GENE-N
is O
a O
potent O
vasoconstrictor O
with O
mitogenic, O
hypertrophic O
and O
pro-inflammatory O
properties O
that O
is O
upregulated O
in O
pulmonary O
hypertensive O
diseases. O
The O
biologic O
effects O
of O
ET B-GENE-N
are O
mediated O
by O
2 O
cell O
surface O
receptors O
termed O
ET(A) B-GENE-Y
and O

ET(B). B-GENE-Y
ET(A) B-GENE-Y
mediates O
the O
vasoconstrictor O
effect O
of O
ET B-GENE-N
on O
vascular O
smooth O
muscle, O
whereas O
ET(B) B-GENE-Y
is O
expressed O
primarily O
on O
vascular O
endothelial O
cells O
where O
it O
induces O
nitric B-CHEMICAL
oxide I-CHEMICAL
synthesis O
and O
acts O
to O
clear O
ET B-GENE-N
from O
the O
circulation. O
Ambrisentan B-CHEMICAL
is O
the O
first O
ET(A) B-GENE-Y
selective O
ERA O
approved O
for O
use O
in O
the O
US. O
Recently O
published O
clinical O
trials O
in O
patients O
with O
PAH O
demonstrate O
improvement O
in O
functional O
capacity O
and O
pulmonary O
hemodynamics O
similar O
to O
other O
ET(A) B-GENE-Y
selective O
and O
non-selective O
ERAs. O
Its O
once O
daily O
dosing O
and O
lower O
incidence O
of O
serum O

aminotransferase B-GENE-N
elevation O
offer O
potential O
advantages O
over O
other O
ERAs, O
but O
further O
experience O
with O
this O
agent O
is O
needed O
to O
fully O
understand O
its O
long-term O
efficacy O
and O
safety. O
This O
review O
discusses O
the O
endothelin B-GENE-N
family O
of O
proteins O
and O
receptors O
and O
their O
role O
in O
the O
pathophysiology O
of O
pulmonary O
hypertensive O
diseases. O
It O
also O
examines O
the O
development O
process, O
safety O
profile O
and O
clinical O
trials O
that O
have O
resulted O
in O
ambrisentan B-CHEMICAL
being O
approved O
for O
treatment O
of O
PAH. O
Design, O
synthesis, O
and O
in-vivo O
evaluation O
of O
4,5-diaryloxazole B-CHEMICAL
as O
novel O
nonsteroidal O
anti-inflammatory O
drug. O
A O
series O
of O

4,5-diaryloxazole B-CHEMICAL
analogs O
were O
designed O
and O
the O
interaction O
between O
oxaprozin B-CHEMICAL
and O
cyclooxygenase-2 B-GENE-Y
studied O
by O
the O
docking O
method O
to O
improve O
the O
biological O
activity O
and O
reduce O
the O
gastrointestinal O
side O
effects O
of O
oxaprozin. B-CHEMICAL
Finally, O
3-(4-(4-fluorophenyl)-5-(4-aminosulfonyl-3-fluorophenyl)-oxazole-2-yl) B-CHEMICAL
propanoic I-CHEMICAL
acid I-CHEMICAL
(NC-2142), B-CHEMICAL
the O
best O
candidate, O
was O
selected O
for O

synthesis O
and O
bioassay O
based O
on O
the O
screening O
result. O
NC-2142 B-CHEMICAL
could O
lower O
the O
tumefaction O
rates O
of O
back O
metatarsus O
in O
rats, O
as O
well O
as O
reduce O
the O
writhing O
times O
in O
mice. O
NC-2142 B-CHEMICAL
produced O
fewer O
gastric O
lesions O
than O
oxaprozin. B-CHEMICAL
After O
the O
aminosulfonyl B-CHEMICAL
group O
was O
introduced O
into O
the O
benzene B-CHEMICAL
ring O
of O
oxaprozin, B-CHEMICAL
its O
analgesic O
and O
anti-inflammatory O
activities O
remained O
unchanged, O
and O
it O
reduced O
the O
number O
of O
gastric O
lesions. O
This O
provided O
a O
feasible O
method O
for O
further O
structure O
modification O
and O
optimization O
of O
oxaprozin. B-CHEMICAL
Breast O
cancer O

and O
steroid B-CHEMICAL
metabolizing O
enzymes: O
the O
role O
of O
progestogens. B-CHEMICAL
It O
is O
well O
documented O
that O
breast O
tissue, O
both O
normal O
and O
cancerous, O
contains O
all O
the O
enzymatic O
systems O
necessary O
for O
the O
bioformation O
and O
metabolic O
transformation O
of O
estrogens, B-CHEMICAL
androgens B-CHEMICAL
and O
progesterone. B-CHEMICAL
These O
include O
sulfatases, B-GENE-N
aromatase, B-GENE-Y
hydroxysteroid-dehydrogenases, B-CHEMICAL
sulfotransferases, B-GENE-N
hydroxylases B-GENE-N
and O
glucuronidases. B-GENE-N
The O
control O
of O
these O
enzymes O
plays O
an O
important O
role O
in O
the O
development O
and O
pathogenesis O
of O
hormone-dependent O
breast O

cancer. O
As O
discussed O
in O
this O
review, O
various O
progestogens B-CHEMICAL
including O
dydrogesterone B-CHEMICAL
and O
its O
20alpha-dihydro-derivative, O
medrogestone, B-CHEMICAL
promegestone, B-CHEMICAL
nomegestrol B-CHEMICAL
acetate I-CHEMICAL
and O
norelgestromin B-CHEMICAL
can O
reduce O
intratissular O
levels O
of O
estradiol B-CHEMICAL
in O
breast O
cancer O
by O
blocking O
sulfatase B-GENE-N
and O
17beta-hydroxysteroid-dehydrogenase B-GENE-Y
type I-GENE-Y
1 I-GENE-Y
activities. O
A O
possible O
correlation O
has O
been O
postulated O
between O
breast O
cell O
proliferation O
and O
estrogen B-GENE-Y
sulfotransferase I-GENE-Y
activity. O
Progesterone B-CHEMICAL
is O
largely O
transformed O

in O
the O
breast; O
normal O
breast O
produces O
mainly O
4-ene O
derivatives, O
whereas O
5alpha-derivatives O
are O
most O
common O
in O
breast O
cancer O
tissue. O
It O
has O
been O
suggested O
that O
this O
specific O
conversion O
of O
progesterone B-CHEMICAL
may O
be O
involved O
in O
breast O
carcinogenesis. O
In O
conclusion, O
treatment O
with O
anti-aromatases O
combined O
with O
anti-sulfatase B-GENE-N
or O
17beta-hydroxysteroid-dehydrogenase B-CHEMICAL
type I-GENE-Y
1 I-GENE-Y
could O
provide O
new O
therapeutic O
possibilities O
in O
the O
treatment O
of O
patients O
with O
hormone-dependent O
breast O
cancer. O
Mechanism O
of O
right O
precordial O
ST-segment O
elevation O
in O
structural O
heart O
disease: O
excitation O
failure O
by O

current-to-load O
mismatch. O
BACKGROUND: O
The O
Brugada O
sign O
has O
been O
associated O
with O
mutations O
in O
SCN5A B-GENE-Y
and O
with O
right O
ventricular O
structural O
abnormalities. O
Their O
role O
in O
the O
Brugada O
sign O
and O
the O
associated O
ventricular O
arrhythmias O
is O
unknown. O
OBJECTIVE: O
The O
purpose O
of O
this O
study O
was O
to O
delineate O
the O
role O
of O
structural O
abnormalities O
and O
sodium B-GENE-N
channel I-GENE-N
dysfunction O
in O
the O
Brugada O
sign. O
METHODS: O
Activation O
and O
repolarization O
characteristics O
of O
the O
explanted O
heart O
of O
a O
patient O
with O
a O

loss-of-function O
mutation O
in O
SCN5A B-GENE-Y
(G752R) B-GENE-N
and O
dilated O
cardiomyopathy O
were O
determined O
after O
induction O
of O
right-sided O
ST-segment O
elevation O
by O
ajmaline. B-CHEMICAL
In O
addition, O
right O
ventricular O
structural O
discontinuities O
and O
sodium B-GENE-N
channel I-GENE-N
dysfunction O
were O
simulated O
in O
a O
computer O
model O
encompassing O
the O
heart O
and O
thorax. O
RESULTS: O
In O
the O
explanted O
heart, O
disappearance O
of O
local O
activation O
in O
unipolar O
electrograms O
at O
the O
basal O
right O
ventricular O
epicardium O
was O
followed O
by O
monophasic O
ST-segment O
elevation. O
The O
local O
origin O
of O
this O
phenomenon O

was O
confirmed O
by O
coaxial O
electrograms. O
Neither O
early O
repolarization O
nor O
late O
activation O
correlated O
with O
ST-segment O
elevation. O
At O
sites O
of O
local O
ST-segment O
elevation, O
the O
subepicardium O
was O
interspersed O
with O
adipose O
tissue O
and O
contained O
more O
fibrous O
tissue O
than O
either O
the O
left O
ventricle O
or O
control O
hearts. O
In O
computer O
simulations O
entailing O
right O
ventricular O
structural O
discontinuities, O
reduction O
of O
sodium B-GENE-N
channel I-GENE-N
conductance O
or O
size O
of O
the O
gaps O
between O
introduced O
barriers O
resulted O
in O
subepicardial O
excitation O
failure O
or O
delayed O
activation O
by O
current-to-load O
mismatch O
and O
in O
the O
Brugada O

sign O
on O
the O
ECG. O
CONCLUSION: O
Right O
ventricular O
excitation O
failure O
and O
activation O
delay O
by O
current-to-load O
mismatch O
in O
the O
subepicardium O
can O
cause O
the O
Brugada O
sign. O
Therefore, O
current-to-load O
mismatch O
may O
underlie O
the O
ventricular O
arrhythmias O
in O
patients O
with O
the O
Brugada O
sign. O
Combination O
therapy O
with O
mitiglinide B-CHEMICAL
and O
voglibose B-CHEMICAL
improves O
glycemic O
control O
in O
type O
2 O
diabetic O
patients O
on O
hemodialysis. O
OBJECTIVE: O

Mitiglinide, B-CHEMICAL
a O
rapid- O
and O
short-acting O
insulinotropic O
sulfonylurea B-GENE-N
receptor I-GENE-N
ligand, O
exhibits O
hypoglycemic O
action O
unlike O
other O
sulfonylureas. B-CHEMICAL
The O
efficacy O
of O
the O
combination O
of O
mitiglinide B-CHEMICAL
and O
alpha-glucosidase B-GENE-Y
inhibitors O
for O
diabetic O
patients O
on O
hemodialysis O
(HD) O
has O
not O
been O
prospectively O
evaluated; O
therefore, O
we O
evaluated O
the O
efficacy O
and O
safety O
of O
mitiglinide B-CHEMICAL
in O
these O
patients. O
RESEARCH O
DESIGN O
AND O
METHODS: O
We O
performed O
an O
open-label O
randomized O
study O
with O

36 O
type O
2 O
diabetics O
with O
poor O
glycemic O
control O
on O
HD O
and O
receiving O
daily O
doses O
of O
voglibose B-CHEMICAL
(0.9 O
mg). O
The O
patients O
were O
randomly O
assigned O
to O
two O
groups: O
a O
combination-therapy O
group O
(mitiglinide B-CHEMICAL
group), O
mitiglinide B-CHEMICAL
initial O
dose O
7.5 O
- O
15 O
mg O
titrated O
to O
30 O
mg O
daily O
and O
constant O
daily O
dose O
0.9 O
mg O
of O
voglibose, B-CHEMICAL
and O
a O
monotherapy O
group O
(control O
group), O
constant O
daily O
dose O
0.9 O
mg O
of O
voglibose B-CHEMICAL
alone. O
The O
efficacy O
of O
the O
treatment O
was O
determined O
by O
monitoring O
plasma O
glucose, B-CHEMICAL

hemoglobin B-GENE-Y
A1c I-GENE-Y
(Hb(A1c)), B-GENE-Y
and O
glycated B-GENE-Y
albumin I-GENE-Y
(GA) B-GENE-Y
levels O
and O
using O
homeostasis O
model O
assessment O
of O
insulin B-GENE-Y
resistance O
(HOMA-IR). O
Safety O
and O
tolerance O
were O
determined O
by O
monitoring O
clinical O
and O
laboratory O
parameters. O
RESULTS: O
The O
final O
dose O
of O
mitiglinide B-CHEMICAL
was O
22.9 O
+/- O
8.9 O
(mean O
+/- O
s.d.) O
mg O
(0.41 O
mg/kg) O
daily. O
Mitiglinide B-CHEMICAL
reduced O
fasting O
plasma O
glucose B-CHEMICAL
and O
GA B-GENE-Y
levels O
after O
4 O
weeks O
and O
Hb(A1c) B-GENE-Y
levels O
after O

8 O
weeks. O
Triglyceride B-CHEMICAL
levels O
and O
HOMA-IR O
values O
also O
decreased O
significantly O
after O
mitiglinide B-CHEMICAL
treatment. O
No O
significant O
changes O
in O
blood O
pressure O
levels O
or O
serious O
adverse O
effects O
such O
as O
hypoglycemia O
or O
liver O
impairment O
were O
observed. O
CONCLUSIONS: O
This O
study O
suggests O
a O
combination O
therapy O
of O
mitiglinide B-CHEMICAL
and O
voglibose B-CHEMICAL
may O
have O
potential O
for O
the O
treatment O
of O
diabetics O
on O
HD. O
Due O
to O
the O
small O
sample O
size O
used, O
further O
studies O
should O
be O
performed, O
particularly O
to O
assess O
the O
safety O
of O
mitiglinide B-CHEMICAL
treatment. O
A O
fluorescence O
resonance O
energy O
transfer-based O

M2 B-GENE-Y
muscarinic I-GENE-Y
receptor I-GENE-Y
sensor O
reveals O
rapid O
kinetics O
of O
allosteric O
modulation. O
Allosteric O
modulators O
have O
been O
identified O
for O
several O
G B-GENE-N
protein-coupled I-GENE-N
receptors, I-GENE-N
most O
notably O
muscarinic B-GENE-N
receptors. I-GENE-N
To O
study O
their O
mechanism O
of O
action, O
we O
made O
use O
of O
a O
recently O
developed O
technique O
to O
generate O
fluorescence O
resonance O
energy O
transfer O
(FRET)-based O
sensors O
to O
monitor O
G B-GENE-N
protein-coupled I-GENE-N
receptor I-GENE-N
activation. O
Cyan O
fluorescent O
protein O
was O
fused O
to O
the O
C B-CHEMICAL
terminus O
of O
the O
M(2) B-GENE-Y
muscarinic I-GENE-Y
receptor, I-GENE-Y
and O
a O
specific O
binding O
sequence O
for O
the O
small O
fluorescent O
compound O
fluorescein B-CHEMICAL

arsenical O
hairpin O
binder, O
FlAsH, O
was O
inserted O
into O
the O
third O
intracellular O
loop; O
the O
latter O
site O
was O
labeled O
in O
intact O
cells O
by O
incubation O
with O
FlAsH. O
We O
then O
measured O
FRET O
between O
the O
donor O
cyan O
fluorescent O
protein O
and O
the O
acceptor O
FlAsH O
in O
intact O
cells O
and O
monitored O
its O
changes O
in O
real O
time. O
Agonists O
such O
as O
acetylcholine B-CHEMICAL
and O
carbachol B-CHEMICAL
induced O
rapid O
changes O
in O
FRET, O
indicative O
of O
agonist-induced O
conformational O
changes. O
Removal O
of O
the O
agonists O
or O
addition O
of O
an O
antagonist O
caused O
a O
reversal O
of O
this O
signal O
with O

rate O
constants O
between O
400 O
and O
1100 O
ms. O
The O
allosteric O
ligands O
gallamine B-CHEMICAL
and O
dimethyl-W84 B-CHEMICAL
caused O
no O
changes O
in O
FRET O
when O
given O
alone, O
but O
increased O
FRET O
when O
given O
in O
the O
presence O
of O
an O
agonist, O
compatible O
with O
an O
inactivation O
of O
the O
receptors. O
The O
kinetics O
of O
these O
effects O
were O
very O
rapid, O
with O
rate O
constants O
of O
80-100 O
ms O
and O
approximately O
200 O
ms O
for O
saturating O
concentrations O
of O
gallamine B-CHEMICAL
and O
dimethyl-W84, B-CHEMICAL
respectively. O
Because O
these O
speeds O
are O
significantly O
faster O
than O
the O
responses O
to O
antagonists, O
these O
data O
indicate O
that O

gallamine B-CHEMICAL
and O
dimethyl-W84 B-CHEMICAL
are O
allosteric O
ligands O
and O
actively O
induce O
a O
conformation O
of O
the O
M(2) B-GENE-Y
receptor I-GENE-Y
with O
a O
reduced O
affinity O
for O
its O
agonists. O
A O
molecular O
mechanism O
for O
ibuprofen-mediated B-CHEMICAL
RhoA B-GENE-Y
inhibition O
in O
neurons. O
Ibuprofen B-CHEMICAL
is O
a O
nonsteroidal O
anti-inflammatory O
drug O
widely O
used O
to O
relieve O
pain O
and O
inflammation O
in O
many O
disorders O
via O
inhibition O
of O
cyclooxygenases. B-GENE-N
Recently, O
we O
have O
demonstrated O
that O
ibuprofen B-CHEMICAL
inhibits O
intracellular O
signaling O
of O
RhoA B-GENE-Y
and O
promotes O
significant O
axonal O

growth O
and O
functional O
recovery O
following O
spinal O
cord O
lesions O
in O
rodents. O
In O
addition, O
another O
study O
suggests O
that O
ibuprofen B-CHEMICAL
reduces O
generation O
of O
amyloid-beta42 B-GENE-Y
peptide O
via O
inactivation O
of O
RhoA B-GENE-Y
signaling, O
although O
it O
may O
also O
regulate O
amyloid-beta42 B-GENE-Y
formation O
by O
direct O
inhibition O
of O
the O
gamma-secretase B-GENE-N
complex. I-GENE-N
The O
molecular O
mechanisms O
by O
which O
ibuprofen B-CHEMICAL
inhibits O
the O
RhoA B-GENE-Y
signal O
in O
neurons, O
however, O
remain O
unclear. O
Here, O
we O
report O
that O
the O
transcription O
factor O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
gamma I-GENE-Y
(PPARgamma) B-GENE-Y
is O
essential O
for O
coupling O

ibuprofen B-CHEMICAL
to O
RhoA B-GENE-Y
inhibition O
and O
subsequent O
neurite O
growth O
promotion O
in O
neurons. O
Ibuprofen B-CHEMICAL
activates O
PPARgamma B-GENE-Y
in O
neuron-like O
PC12 O
and O
B104 O
cells. O
Activation O
of O
PPARgamma B-GENE-Y
with O
traditional O
agonists O
mimics O
the O
RhoA-inhibiting B-GENE-Y
properties O
of O
ibuprofen B-CHEMICAL
in O
PC12 O
cells O
and, O
like O
ibuprofen, B-CHEMICAL
promotes O
neurite O
elongation O
in O
primary O
cultured O
neurons O
exposed O
to O
axonal O
growth O
inhibitors. O
Protein O
knockdown O
with O
small O
interfering O
RNA O
specific O
for O
PPARgamma B-GENE-Y
blocks O
RhoA B-GENE-Y

suppression O
of O
PPARgamma B-GENE-Y
agonists O
in O
PC12 O
cells. O
Moreover, O
the O
effect O
of O
ibuprofen B-CHEMICAL
on O
RhoA B-GENE-Y
activity O
and O
neurite O
growth O
in O
neuronal O
cultures O
is O
prevented O
by O
selective O
PPARgamma B-GENE-Y
inhibition. O
These O
findings O
support O
that O
PPARgamma B-GENE-Y
plays O
an O
essential O
role O
in O
mediating O
the O
RhoA-inhibiting B-GENE-Y
effect O
of O
ibuprofen. B-CHEMICAL
Elucidation O
of O
the O
novel O
molecular O
mechanisms O
linking O
ibuprofen B-CHEMICAL
to O
RhoA B-GENE-Y
inhibition O
may O
provide O
additional O
therapeutic O
targets O
to O
the O
disorders O
characterized O
by O
RhoA B-GENE-Y
activation, O
including O
spinal O
cord O
injuries O
and O
Alzheimer's O

disease. O
Comparative O
efficacy O
and O
safety O
of O
the O
novel O
oral O
anticoagulants O
dabigatran, B-CHEMICAL
rivaroxaban B-CHEMICAL
and O
apixaban B-CHEMICAL
in O
preclinical O
and O
clinical O
development. O
Therapeutic O
oral O
anticoagulation O
is O
still O
commonly O
achieved O
by O
administration O
of O
warfarin B-CHEMICAL
or O
other O
vitamin B-CHEMICAL
K I-CHEMICAL
antagonists O
that O
are O
associated O
with O
an O
untoward O
pharmacokinetic O
/ O
pharmacodynamic O
(PK/PD) O
profile O
leading O
to O
a O
high O
incidence O
of O
bleeding O
complications O
or O
therapeutic O
failure. O
Hence, O
there O
is O
an O
unmet O
medical O
need O
of O
novel O
easy-to-use O
oral O
anticoagulants O
with O
improved O
efficacy O
and O

safety. O
Recent O
developments O
include O
the O
identification O
of O
non-peptidic O
small-molecules O
that O
selectively O
inhibit O
certain O
serine B-CHEMICAL
proteases I-GENE-N
within O
the O
coagulation O
cascade. O
Of O
these, O
the O
thrombin B-GENE-Y
inhibitor O
dabigatran B-CHEMICAL
and O
factor B-GENE-Y
Xa I-GENE-Y
inhibitor O
rivaroxaban B-CHEMICAL
have O
recently O
been O
licensed O
for O
thromboprophylaxis O
after O
orthopaedic O
surgery O
mainly O
in O
Europe. O
In O
addition, O
the O
factor B-GENE-Y
Xa I-GENE-Y
inhibitor O
apixaban B-CHEMICAL
is O
in O
late-stage O
clinical O
development. O
Each O
drug O
is O
prescribed O
at O
fixed O
doses O
without O
the O
need O
of O
anticoagulant O
monitoring. O
Phase O
III O
trials O
in O

orthopaedic O
patients O
essentially O
resulted O
in O
non-inferior O
efficacy O
of O
dabigatran B-CHEMICAL
and O
superior O
efficacy O
of O
rivaroxaban B-CHEMICAL
over O
enoxaparin O
without O
any O
marked O
differences O
of O
drug O
safety, O
while O
apixaban B-CHEMICAL
data O
is O
still O
controversial. O
However, O
alterations O
of O
rivaroxaban B-CHEMICAL
and O
apixaban B-CHEMICAL
pharmacokinetics O
upon O
interactions O
with O
inhibitors O
and O
inducers O
of O
CYP3A4 B-GENE-Y
or O
P-glycoprotein B-GENE-N
may O
complicate O
the O
use O
of O
these O
compounds O
in O
daily O
practice, O
whereas O
dabigatran B-CHEMICAL
elimination O
largely O
depends O
on O
renal O
function. O
Hence, O
this O
review O
reports O

PK/PD, O
efficacy O
and O
safety O
data O
of O
dabigatran, B-CHEMICAL
rivaroxaban B-CHEMICAL
and O
apixaban B-CHEMICAL
throughout O
preclinical O
and O
clinical O
development. O
Captopril B-CHEMICAL
directly O
inhibits O
matrix B-GENE-Y
metalloproteinase-2 I-GENE-Y
activity O
in O
continuous O
ambulatory O
peritoneal O
dialysis O
therapy. O
BACKGROUND: O
Matrix B-GENE-Y
metalloproteinase I-GENE-Y
(MMP)-2 I-GENE-Y
plays O
an O
important O
role O
in O
tissue O
remodeling O
related O
to O
inflammation O
during O
continuous O
ambulatory O
peritoneal O
dialysis O
(CAPD) O
therapy. O
But O
its O
inhibitors O
were O
not O
applied O
clinically. O
We O

determined O
whether O
an O
angiotensin-converting B-CHEMICAL
enzyme I-GENE-Y
(ACE) B-GENE-Y
inhibitor, O
captopril, B-CHEMICAL
inhibits O
MMP-2 B-GENE-Y
activity O
in O
peritoneal O
effluents O
from O
patients O
on O
CAPD, O
and O
simulated O
molecular O
models O
of O
the O
MMP-2-captopril B-GENE-Y
complex. O
METHODS: O
The O
inhibitory O
effect O
of O
captopril B-CHEMICAL
on O
MMP-2 B-GENE-Y
activity O
was O
measured O
in O
peritoneal O
effluents O
from O
17 O
patients O
on O
CAPD. O
Molecular O
models O
of O
the O
MMP-2-captopril B-GENE-Y
complex O
were O
simulated O
by O
1000 O
iterations O
of O
random O
docking O
and O
energy O
minimization. O

RESULTS: O
Captopril B-CHEMICAL
directly O
inhibited O
MMP-2 B-GENE-Y
activity O
in O
peritoneal O
effluents O
from O
patients O
on O
CAPD O
(IC50; O
48 O
micromol/l), O
and O
that O
captopril B-CHEMICAL
binding O
to O
the O
MMP-2 B-GENE-Y
active O
site O
could O
be O
formed O
in O
each O
complex O
model O
without O
molecular O
distortion. O
CONCLUSION: O
ACE B-GENE-Y
inhibitors, O
such O
as O
captopril, B-CHEMICAL
may O
be O
applied O
as O
important O
compounds O
for O
MMP-2 B-GENE-Y
inhibition O
in O
inflammation O
caused O
by O
CAPD. O
Phenformin B-CHEMICAL
has O
a O
direct O
inhibitory O
effect O
on O
the O
ATP-sensitive B-GENE-N
potassium I-GENE-N
channel. I-GENE-N
The O

biguanides, B-CHEMICAL
phenformin B-CHEMICAL
and O
metformin, B-CHEMICAL
are O
used O
in O
the O
treatment O
of O
type O
II O
diabetes O
mellitus, O
as O
well O
as O
being O
routinely O
used O
in O
studies O
investigating O
AMPK B-GENE-N
activity. O
We O
used O
the O
patch-clamp O
technique O
and O
rubidium B-CHEMICAL
flux O
assays O
to O
determine O
the O
role O
of O
these O
drugs O
in O
ATP-sensitive B-GENE-N
K+ I-GENE-N
channel I-GENE-N
(K(ATP)) B-GENE-N
regulation O
in O
cell O
lines O
expressing O
the O
cloned O
components O
of O
K(ATP) B-GENE-N
and O
the O
current O
natively O
expressed O
in O
vascular O
smooth O
muscle O
cells O
(VSMCs). O
Phenformin B-CHEMICAL
but O
not O
metformin B-CHEMICAL
inhibits O
a O
number O
of O
variants O
of O

K(ATP) B-GENE-N
including O
the O
cloned O
equivalents O
of O
currents O
present O
in O
vascular O
and O
non-vascular O
smooth O
muscle O
(Kir6.1/SUR2B B-GENE-Y
and O
Kir6.2/SUR2B) B-GENE-Y
and O
pancreatic O
beta-cells O
(Kir6.2/SUR1). B-GENE-Y
However O
it O
does O
not O
inhibit O
the O
current O
potentially O
present O
in O
cardiac O
myocytes O
(Kir6.2/SUR2A). B-GENE-Y
The O
highest O
affinity O
interaction O
is O
seen O
with O
Kir6.1/SUR2B B-GENE-Y
(IC50=0.55 O
mM) O
and O
it O
also O
inhibits O
the O
current O

in O
native O
vascular O
smooth O
muscle O
cells. O
The O
extent O
and O
rate O
of O
inhibition O
are O
similar O
to O
that O
seen O
with O
the O
known O
K(ATP) B-GENE-N
blocker O
PNU B-CHEMICAL
37883A. I-CHEMICAL
Additionally, O
phenformin B-CHEMICAL
inhibited O
the O
current O
elicited O
through O
the O
Kir6.2DeltaC26 B-GENE-Y
(functional O
without O
SUR) B-GENE-Y
channel O
with O
an O
IC50 O
of O
1.78 O
mM. O
Phenformin B-CHEMICAL
reduced O
the O
open O
probability O
of O
Kir6.1/SUR2B B-GENE-Y
channels O
by O
approximately O
90% O
in O
inside-out O
patches. O
These O
findings O
suggest O
that O
phenformin B-CHEMICAL
interacts O
directly O
with O
the O

pore-forming O
Kir6.0 B-GENE-N
subunit O
however O
the O
sulphonylurea B-CHEMICAL
receptor I-GENE-Y
is O
able O
to O
significantly O
modulate O
the O
affinity. O
It O
is O
likely O
to O
block O
from O
the O
intracellular O
side O
of O
the O
channel O
in O
a O
manner O
analogous O
to O
that O
of O
PNU B-CHEMICAL
37883A. I-CHEMICAL
Comparison O
of O
the O
pharmacological O
effects O
of O
paricalcitol B-CHEMICAL
and O
doxercalciferol B-CHEMICAL
on O
the O
factors O
involved O
in O
mineral O
homeostasis. O
Vitamin B-GENE-Y
D I-GENE-Y
receptor I-GENE-Y
agonists O
(VDRAs) O
directly O
suppress O
parathyroid B-GENE-Y
hormone I-GENE-Y
(PTH) B-GENE-Y
mRNA O
expression. O
Different O
VDRAs O
are O
known O
to O
have O

differential O
effects O
on O
serum O
calcium B-CHEMICAL
(Ca), B-CHEMICAL
which O
may O
also O
affect O
serum O
PTH B-GENE-Y
levels O
since O
serum O
Ca B-CHEMICAL
regulates O
PTH B-GENE-Y
secretion O
mediated O
by O
the O
Ca-sensing B-CHEMICAL
receptor I-GENE-Y
(CaSR). B-GENE-Y
In O
this O
study, O
we O
compared O
the O
effects O
of O
paricalcitol B-CHEMICAL
and O
doxercalciferol B-CHEMICAL
on O
regulating O
serum O
Ca B-CHEMICAL
and O
PTH, B-GENE-Y
and O
also O
the O
expression O
of O
PTH, B-GENE-Y
VDR, B-GENE-Y
and O
CaSR B-GENE-Y
mRNA. O
The O
5/6 O
nephrectomized O
(NX) O
Sprague-Dawley O
rats O
on O
a O
normal O
or O
hyperphosphatemia-inducing O
diet O

were O
treated O
with O
vehicle, O
paricalcitol, B-CHEMICAL
or O
doxercalciferol B-CHEMICAL
for O
two O
weeks. O
Both O
drugs O
at O
the O
tested O
doses O
(0.042-0.33 O
mug/kg) O
suppressed O
PTH B-GENE-Y
mRNA O
expression O
and O
serum O
PTH B-GENE-Y
effectively O
in O
the O
5/6 O
NX O
rats, O
but O
paricalcitol B-CHEMICAL
was O
less O
potent O
in O
raising O
serum O
Ca B-CHEMICAL
than O
doxercalciferol. B-CHEMICAL
In O
pig O
parathyroid O
cells, O
paricalcitol B-CHEMICAL
and O
the O
active O
form O
of O
doxercalciferol B-CHEMICAL
induced O
VDR B-GENE-Y
translocation O
from O
the O
cytoplasm O
into O
the O
nucleus, O
suppressed O

PTH B-GENE-Y
mRNA O
expression O
and O
inhibited O
cell O
proliferation O
in O
a O
similar O
manner, O
although O
paricalcitol B-CHEMICAL
induced O
the O
expression O
of O
CaSR B-GENE-Y
mRNA O
more O
effectively. O
The O
multiple O
effects O
of O
VDRAs O
on O
modulating O
serum O
Ca, B-CHEMICAL
parathyroid O
cell O
proliferation, O
and O
the O
expression O
of O
CaSR B-GENE-N
and O
PTH B-GENE-N
mRNA O
reflect O
the O
complex O
involvement O
of O
the O
vitamin B-CHEMICAL
D I-CHEMICAL
axis O
in O
regulating O
the O
mineral O
homeostasis O
system. O
Identification O
of O
a O
primary O
target O
of O
thalidomide B-CHEMICAL
teratogenicity. O
Half O
a O
century O
ago, O
thalidomide B-CHEMICAL
was O
widely O
prescribed O
to O
pregnant O
women O
as O
a O
sedative O
but O
was O
found O
to O

be O
teratogenic, O
causing O
multiple O
birth O
defects. O
Today, O
thalidomide B-CHEMICAL
is O
still O
used O
in O
the O
treatment O
of O
leprosy O
and O
multiple O
myeloma, O
although O
how O
it O
causes O
limb O
malformation O
and O
other O
developmental O
defects O
is O
unknown. O
Here, O
we O
identified O
cereblon B-GENE-N
(CRBN) B-GENE-N
as O
a O
thalidomide-binding B-CHEMICAL
protein. I-GENE-N
CRBN B-GENE-N
forms O
an O
E3 B-GENE-N
ubiquitin I-GENE-N
ligase I-GENE-N
complex I-GENE-N
with O
damaged B-GENE-N
DNA I-GENE-N
binding I-GENE-N
protein I-GENE-N
1 I-GENE-N
(DDB1) B-GENE-N
and O
Cul4A B-GENE-N
that O
is O
important O
for O
limb O
outgrowth O
and O
expression O
of O
the O
fibroblast B-GENE-N
growth I-GENE-N
factor I-GENE-N
Fgf8 B-GENE-N
in O

zebrafish O
and O
chicks. O
Thalidomide B-CHEMICAL
initiates O
its O
teratogenic O
effects O
by O
binding O
to O
CRBN B-GENE-N
and O
inhibiting O
the O
associated O
ubiquitin B-GENE-N
ligase I-GENE-N
activity. O
This O
study O
reveals O
a O
basis O
for O
thalidomide B-CHEMICAL
teratogenicity O
and O
may O
contribute O
to O
the O
development O
of O
new O
thalidomide B-CHEMICAL
derivatives O
without O
teratogenic O
activity. O
A O
dilated O
cardiomyopathy O
troponin B-GENE-Y
C I-GENE-Y
mutation O
lowers O
contractile O
force O
by O
reducing O
strong O
myosin-actin B-GENE-N
binding. O
In O
this O
study O
we O
explore O
the O
mechanisms O
by O
which O
a O
double O
mutation O
(E59D/D75Y) B-GENE-N
in O

cardiac B-GENE-Y
troponin I-GENE-Y
C I-GENE-Y
(CTnC) B-GENE-Y
associated O
with O
dilated O
cardiomyopathy O
reduces O
the O
Ca(2+)-activated B-CHEMICAL
maximal O
tension O
of O
cardiac O
muscle. O
Studying O
the O
single O
mutants O
(i.e. O
E59D B-GENE-N
or O
D75Y) B-GENE-N
indicates O
that O
D75Y, B-GENE-N
but O
not O
E59D, B-GENE-N
causes O
a O
reduction O
in O
the O
calcium O
affinity O
of O
CTnC B-GENE-Y
in O
troponin B-GENE-N
complex, O
regulated B-GENE-N
thin I-GENE-N
filaments I-GENE-N
(RTF), B-GENE-N
and O
the O
Ca(2+) B-CHEMICAL
sensitivity O
of O
contraction O
and O
ATPase B-GENE-N
in O
cardiac O
muscle O
preparations. O
However, O
both O
D75Y B-GENE-N
and O

E59D B-GENE-N
are O
required O
to O
reduce O
the O
actomyosin B-GENE-N
ATPase B-GENE-N
activity O
and O
maximal O
force O
in O
muscle O
fibers, O
indicating O
that O
E59D B-GENE-N
enhances O
the O
effects O
of O
D75Y. B-GENE-N
Part O
of O
the O
reduction O
in O
force/ATPase B-GENE-N
may O
be O
due O
to O
a O
defect O
in O
the O
interactions O
between O
CTnC B-GENE-Y
and O
cardiac B-GENE-Y
troponin I-GENE-Y
T, I-GENE-Y
which O
are O
known O
to O
be O
necessary O
for O
ATPase B-GENE-N
activation. O
An O
additional O
mechanism O
for O
the O
reduction O
in O
force/ATPase B-GENE-N
comes O
from O
measurements O
of O
the O
binding O
stoichiometry O
of O
myosin B-GENE-N
subfragment-1 I-GENE-N
(S-1) B-GENE-N
to O
the O
RTF. B-GENE-N
Using O
wild O
type O

RTFs, B-GENE-N
4.8 O
mol O
S-1 B-GENE-N
was O
bound O
per O
mol O
filament O
(seven O
actins), O
whereas O
with O
E59D/D75Y B-GENE-N
RTFs, B-GENE-N
the O
number O
of O
binding O
sites O
was O
reduced O
by O
approximately O
23% O
to O
3.7. O
Altogether, O
these O
results O
suggest O
that O
the O
reduction O
in O
force O
and O
ATPase B-GENE-N
activation O
is O
possibly O
due O
to O
a O
thin O
filament O
conformation O
that O
promotes O
fewer O
accessible O
S-1-binding B-GENE-N
sites. I-GENE-N
In O
the O
absence O
of O
any O
family O
segregation O
data, O
the O
functional O
results O
presented O
here O
support O
the O
concept O
that O
this O
is O
likely O
a O
dilated O
cardiomyopathy-causing O

mutation. O
Zolmitriptan B-CHEMICAL
and O
human O
aggression: O
interaction O
with O
alcohol. B-CHEMICAL
RATIONALE: O
The O
serotonin B-CHEMICAL
1(B/D) I-GENE-N
(5-HT1(B/D)) B-GENE-N
receptor O
has O
shown O
potential O
as O
a O
target O
for O
decreasing O
aggression. O
The O
5-HT1(B/D) B-GENE-N
agonist O
zolmitriptan's O
ability O
to O
reduce O
aggressive O
behavior O
in O
humans O
and O
its O
interaction O
with O
the O
well-known O
aggression-enhancing O
drug O
alcohol B-CHEMICAL
were O
examined. O
OBJECTIVES: O
Our O
objective O
was O
to O
investigate O
zolmitriptan's O
potential O
to O
modify O
human O
aggression O
in O
a O
laboratory O

paradigm O
across O
a O
range O
of O
alcohol B-CHEMICAL
doses. O
Alcohol B-CHEMICAL
has O
been O
consistently O
associated O
with O
aggression O
and O
violence, O
thus O
we O
hoped O
to O
expand O
current O
understanding O
of O
alcohol's O
role O
in O
aggressive O
behavior O
via O
manipulation O
of O
the O
serotonin B-CHEMICAL
(5-HT) B-CHEMICAL
system. O
METHODS: O
Eleven O
social O
drinkers, O
seven O
male, O
were O
recruited O
to O
participate O
in O
a O
research O
study O
lasting O
3-4 O
weeks. O
Aggression O
was O
measured O
using O
the O
point-subtraction O
aggression O
paradigm O
(PSAP), O
a O
laboratory O
model O
widely O
used O
in O
human O
aggression O
studies. O
Subjects O
were O
administered O
5-mg O
zolmitriptan B-CHEMICAL
and O
placebo O
capsules O
along O
with O
alcohol B-CHEMICAL

doses O
of O
0.0, O
0.4 O
and O
0.8 O
g/kg O
in O
a O
within-subject, O
counterbalanced O
dosing O
design. O
Data O
were O
analyzed O
as O
the O
ratio O
of O
aggressive/monetary-earning O
responses, O
to O
account O
for O
possible O
changes O
in O
overall O
motor O
function O
due O
to O
alcohol. B-CHEMICAL
RESULTS: O
There O
was O
a O
significant O
alcohol B-CHEMICAL
by O
zolmitriptan B-CHEMICAL
interaction O
on O
the O
aggressive/monetary O
response O
ratio. O
Specifically, O
compared O
to O
placebo, O
zolmitriptan B-CHEMICAL
decreased O
the O
aggressive/monetary O
ratio O
at O
the O
0.4- O
and O
0.8-g/kg O
alcohol B-CHEMICAL
doses. O
CONCLUSIONS: O
A O

5-mg O
dose O
of O
zolmitriptan B-CHEMICAL
effectively O
reduced O
alcohol-related B-CHEMICAL
aggression O
in O
an O
acute O
dosing O
protocol, O
demonstrating O
an O
interaction O
of O
5-HT B-CHEMICAL
and O
alcohol B-CHEMICAL
in O
human O
aggressive O
behavior. O
New O
standards O
in O
hypertension O
and O
cardiovascular O
risk O
management: O
focus O
on O
telmisartan. B-CHEMICAL
Blockade O
of O
the O
renin-angiotensin B-GENE-Y
system O
is O
an O
important O
approach O
in O
managing O
high O
blood O
pressure, O
and O
has O
increasingly O
been O
shown O
to O
affect O
cardiovascular O
disease O
processes O
mediated O
by O
angiotensin B-CHEMICAL
II I-CHEMICAL
throughout O
the O
cardiovascular O
and O
renal O
continua. O
Telmisartan B-CHEMICAL
is O
an O
angiotensin B-CHEMICAL
II I-CHEMICAL
receptor I-GENE-N
blocker O

(ARB) O
displaying O
unique O
pharmacologic O
properties, O
including O
a O
longer O
half O
life O
than O
any O
other O
ARB, O
that O
result O
in O
large O
and O
sustained O
reductions O
of O
blood O
pressure. O
In O
patients O
with O
mild-to-moderate O
hypertension, O
telmisartan B-CHEMICAL
has O
proved O
superior O
to O
other O
antihypertensive O
agents O
(valsartan, B-CHEMICAL
losartan, B-CHEMICAL
ramipril, B-CHEMICAL
perindopril, B-CHEMICAL
and O
atenolol) B-CHEMICAL
in O
controlling O
blood O
pressure O
particularly O
towards O
the O
end O
of O
the O
dosing O
interval. O
There O
is O
also O
clinical O
evidence O
that O
telmisartan B-CHEMICAL
reduces O
left O
ventricular O
hypertrophy, O

reduces O
arterial O
stiffness O
and O
the O
recurrence O
of O
atrial O
fibrillation, O
and O
confers O
renoprotection. O
The O
ONgoing O
Telmisartan B-CHEMICAL
Alone O
and O
in O
combination O
with O
Ramipril B-CHEMICAL
Global O
Endpoint O
Trial O
(ONTARGET) O
study O
has O
demonstrated O
that O
telmisartan B-CHEMICAL
has O
similar O
cardiovascular O
protective O
effects O
to O
ramipril B-CHEMICAL
in O
a O
large, O
high-risk O
patient O
population O
but O
was O
better O
tolerated. O
The O
powerful O
and O
sustained O
blood O
pressure O
control O
apparent O
in O
clinical O
trials, O
together O
with O
cardiovascular O
protection O
and O
tolerability O
demonstrated O
in O
ONTARGET O
means O
that O
telmisartan B-CHEMICAL
may O
be O
a O
preferred O

option O
for O
patients O
with O
hypertension. O
Jostling O
for O
position: O
optimizing O
linker O
location O
in O
the O
design O
of O
estrogen B-GENE-N
receptor-targeting I-GENE-N
PROTACs. O
Estrogen B-CHEMICAL
receptor-alpha I-GENE-N
(ER) B-GENE-N
antagonists O
have O
been O
widely O
used O
for O
breast O
cancer O
therapy. O
Despite O
initial O
responsiveness, O
hormone-sensitive O
ER-positive B-GENE-N
cancer O
cells O
eventually O
develop O
resistance O
to O
ER B-GENE-N
antagonists. O
It O
has O
been O
shown O
that O
in O
most O
of O
these O
resistant O
tumor O
cells, O
the O
ER B-GENE-N
is O
expressed O
and O
continues O
to O
regulate O
tumor O
growth. O
Recent O
studies O
indicate O
that O
tamoxifen B-CHEMICAL
initially O
acts O
as O
an O
antagonist, O
but O
later O
functions O
as O
an O
ER B-GENE-N
agonist, O

promoting O
tumor O
growth. O
This O
suggests O
that O
targeted O
ER B-GENE-N
degradation O
may O
provide O
an O
effective O
therapeutic O
approach O
for O
breast O
cancers, O
even O
those O
that O
are O
resistant O
to O
conventional O
therapies. O
With O
this O
in O
mind, O
we O
previously O
demonstrated O
that O
proteolysis O
targeting O
chimeras O
(PROTACs) O
effectively O
induce O
degradation O
of O
the O
ER B-GENE-N
as O
a O
proof-of-concept O
experiment. O
Herein O
we O
further O
refined O
the O
PROTAC O
approach O
to O
target O
the O
ER B-GENE-N
for O
degradation. O
The O
ER-targeting B-GENE-N
PROTACs O
are O
composed O
of O
an O
estradiol B-CHEMICAL
on O
one O
end O
and O
a O
hypoxia-inducing B-GENE-N
factor I-GENE-N
1alpha I-GENE-N

(HIF-1alpha)-derived B-GENE-N
synthetic O
pentapeptide O
on O
the O
other. O
The O
pentapeptide O
is O
recognized O
by O
an O
E3 B-GENE-N
ubiquitin I-GENE-N
ligase I-GENE-N
called O
the O
von B-GENE-N
Hippel I-GENE-N
Lindau I-GENE-N
tumor I-GENE-N
suppressor I-GENE-N
protein I-GENE-N
(pVHL), B-GENE-N
thereby O
recruiting O
the O
ER B-GENE-N
to O
this O
E3 B-GENE-N
ligase I-GENE-N
for O
ubiquitination O
and O
degradation. O
Specifically, O
the O
pentapeptide O
is O
attached O
at O
three O
different O
locations O
on O
estradiol B-CHEMICAL
to O
generate O
three O
different O
PROTAC O
types. O
With O
the O
pentapeptide O
linked O
through O
the O
C7alpha O
position O
of O
estradiol, B-CHEMICAL
the O
resulting O

PROTAC O
shows O
the O
most O
effective O
ER B-GENE-N
degradation O
and O
highest O
affinity O
for O
the O
estrogen B-CHEMICAL
receptor. I-GENE-N
This O
result O
provides O
an O
opportunity O
to O
develop O
a O
novel O
type O
of O
ER B-GENE-N
antagonist O
that O
may O
overcome O
the O
resistance O
of O
breast O
tumors O
to O
conventional O
drugs O
such O
as O
tamoxifen B-CHEMICAL
and O
fulvestrant B-CHEMICAL
(Faslodex). B-CHEMICAL
C677T B-GENE-N
polymorphism O
of O
the O
methylenetetrahydrofolate B-GENE-Y
reductase I-GENE-Y
gene O
does O
not O
affect O
folic B-CHEMICAL
acid, I-CHEMICAL
vitamin B-CHEMICAL
B12, I-CHEMICAL
and O
homocysteine B-CHEMICAL
serum O
levels O
in O
Turkish O
children O
with O
neural O
tube O
defects. O
Association O
between O
neural O
tube O
defects O
(NTDs) O
and O

C677T B-GENE-N
polymorphism O
of O
the O
methylenetetrahydrofolate B-GENE-Y
reductase I-GENE-Y
(MTHFR) B-GENE-Y
gene O
was O
suspected, O
because O
the O
MTHFR B-GENE-Y
gene O
codes O
for O
a O
key O
enzyme O
in O
folate B-CHEMICAL
metabolism. O
Its O
deficiency O
usually O
leads O
to O
significant O
reductions O
in O
plasma O
concentrations O
of O
folate, B-CHEMICAL
vitamin B-CHEMICAL
B(12) I-CHEMICAL
and O
methionine, B-CHEMICAL
whereas O
homocysteine B-CHEMICAL
levels O
are O
increased. O
We O
examined O
folate, B-CHEMICAL
vitamin B-CHEMICAL
B(12) I-CHEMICAL
and O
homocysteine B-CHEMICAL
serum O
concentrations O
and O
polymorphism O
of O
the O
C677T B-GENE-N
MTHFR B-GENE-Y
gene O
in O
Turkish O
children O
with O
neural O

tube O
defects. O
Thirty-three O
children O
with O
NTDs, O
26 O
mothers O
and O
48 O
healthy O
individuals O
were O
studied. O
C677T B-GENE-N
MTHFR B-GENE-Y
polymorphism O
was O
determined O
by O
melting O
curve O
analyses O
(LightCycler). O
The O
levels O
of O
folate, B-CHEMICAL
vitamin B-CHEMICAL
B(12) I-CHEMICAL
and O
homocysteine B-CHEMICAL
serum O
concentrations O
in O
NTDs O
were O
evaluated O
and O
compared, O
along O
with O
information O
concerning O
alleles O
of O
the O
MTHFR B-GENE-Y
gene. O
C677T B-GENE-N
allele O
frequencies O
in O
NTD O
children O
and O
their O
mothers O
were O
similar O
to O
those O
found O
in O
controls. O
Serum O
folate B-CHEMICAL
and O
vitamin B-CHEMICAL
B(12) I-CHEMICAL
concentrations O
were O

significantly O
higher O
in O
NTD O
children O
than O
that O
of O
controls. O
Serum O
homocysteine B-CHEMICAL
concentrations O
were O
not O
significantly O
higher O
in O
NTD O
children O
and O
mothers. O
We O
concluded O
that O
C677T B-GENE-N
MTHFR B-GENE-Y
gene O
polymorphism O
does O
not O
affect O
folic B-CHEMICAL
acid, I-CHEMICAL
vitamin B-CHEMICAL
B(12) I-CHEMICAL
and O
homocysteine B-CHEMICAL
metabolism O
in O
Turkish O
children O
with O
NTDs. O
C677T B-GENE-N
polymorphism O
of O
the O
MTHFR B-GENE-Y
gene O
cannot O
be O
regarded O
as O
a O
major O
risk O
factor O
for O
NTDs O
in O
Turkish O
children. O
The O
selectivity O
of O
beta-adrenoceptor B-GENE-N
agonists O
at O
human B-GENE-N

beta1-, I-GENE-N
beta2- I-GENE-N
and I-GENE-N
beta3-adrenoceptors. I-GENE-N
BACKGROUND O
AND O
PURPOSE: O
There O
are O
two O
important O
properties O
of O
receptor-ligand O
interactions: O
affinity O
(the O
ability O
of O
the O
ligand O
to O
bind O
to O
the O
receptor) O
and O
efficacy O
(the O
ability O
of O
the O
receptor-ligand O
complex O
to O
induce O
a O
response). O
Ligands O
are O
classified O
as O
agonists O
or O
antagonists O
depending O
on O
whether O
or O
not O
they O
have O
efficacy. O
In O
theory, O
it O
is O
possible O
to O
develop O
selective O
agonists O
based O
on O
selective O
affinity, O
selective O
intrinsic O
efficacy O
or O
both. O
This O
study O
examined O
the O
affinity O
and O

intrinsic O
efficacy O
of O
31 O
beta-adrenoceptor B-GENE-N
agonists O
at O
the O
three O
human B-GENE-N
beta-adrenoceptors I-GENE-N
to O
determine O
whether O
the O
current O
agonists O
are O
subtype O
selective O
because O
of O
affinity O
or O
intrinsic O
efficacy. O
EXPERIMENTAL O
APPROACH: O
Stable O
clonal O
CHO-K1 O
cell O
lines, O
transfected O
with O
either O
the O
human B-GENE-N
beta(1), I-GENE-N
beta(2) I-GENE-N
or I-GENE-N
beta(3)-adrenoceptor, I-GENE-N
were O
used, O
and O
whole-cell O
[(3)H]-CGP B-CHEMICAL
12177 I-CHEMICAL
radioligand O
binding O
and O

[(3)H]-cAMP B-CHEMICAL
accumulation O
were O
measured. O
KEY O
RESULTS: O
Several O
agonists O
were O
found O
to O
be O
highly O
subtype O
selective O
because O
of O
selective O
affinity O
(e.g. O
salmeterol B-CHEMICAL
and O
formoterol, B-CHEMICAL
for O
the O
beta(2)-adrenoceptor B-GENE-Y
over O
the O
beta(1) B-GENE-Y
or O
beta(3)), B-GENE-Y
while O
others O
(e.g. O
isoprenaline) B-CHEMICAL
had O
little O
affinity-selectivity. O
However, O
the O
intrinsic O
efficacy O
of O
salmeterol, B-CHEMICAL
formoterol B-CHEMICAL
and O
isoprenaline B-CHEMICAL
was O
similar O
across O
all O
three O
receptor O
subtypes. O

Other O
ligands O
(e.g. O
denopamine B-CHEMICAL
for O
beta(1); B-GENE-Y
clenbuterol, B-CHEMICAL
AZ B-CHEMICAL
40140d, I-CHEMICAL
salbutamol B-CHEMICAL
for O
beta(2)) B-GENE-Y
were O
found O
to O
have O
subtype-selective O
intrinsic O
efficacy. O
Several O
ligands O
appeared O
to O
activate O
two O
agonist O
conformations O
of O
the O
beta(1)- B-GENE-N
and I-GENE-N
beta(3)-adrenoceptors. I-GENE-N
CONCLUSIONS O
AND O
IMPLICATIONS: O
There O
are O
agonists O
with O
subtype O
selectivity O
based O
upon O
both O
selective O
affinity O
and O
selective O
intrinsic O
efficacy. O
Therefore, O
there O
is O
scope O
to O
develop O
better O

selective O
agonists O
based O
upon O
both O
selective O
affinity O
and O
selective O
intrinsic O
efficacy. O
Rasagiline: B-CHEMICAL
a O
novel O
anti-Parkinsonian O
monoamine B-GENE-Y
oxidase-B I-GENE-Y
inhibitor O
with O
neuroprotective O
activity. O
Rasagiline B-CHEMICAL
(N-propargyl-1-(R)-aminoindan) B-CHEMICAL
is O
a O
novel, O
highly O
potent O
irreversible O
monoamine B-GENE-Y
oxidase I-GENE-Y
(MAO)-B I-GENE-Y
inhibitor, O
anti-Parkinsonian O
drug. O
Rasagiline B-CHEMICAL
is O
effective O
as O
monotherapy O
or O
adjunct O
to O
L-Dopa B-CHEMICAL
for O
patients O
with O
early O
and O
late O
Parkinson's O
disease O
(PD). O

Its O
S-isomer, O
TVP1022 B-CHEMICAL
is O
thousand O
times O
less O
potent O
as O
an O
MAO-B B-GENE-Y
inhibitor. O
However, O
both O
compounds O
have O
similar O
molecular O
mechanisms O
of O
neuroprotection O
in O
neuronal O
cell O
cultures O
and O
animal O
neurodegenerative O
models, O
indicating O
that O
the O
neuroprotective O
effect O
of O
rasagiline B-CHEMICAL
does O
not O
depend O
on O
inhibition O
of O
MAO-B, B-GENE-Y
but O
rather O
is O
associated O
with O
the O
N-propargyl B-CHEMICAL
moiety, O
which O
promotes O
mitochondrial O
viability O
and O
stabilizes O
permeability O
transition O
by O
regulating O
Bcl-2 B-GENE-Y
family O
proteins. O
Novel O
findings O
demonstrated O
that O
the O
major O
metabolite O

of O
rasagiline, B-CHEMICAL
1-(R)-aminoindan B-CHEMICAL
has O
antioxidant O
and O
neuroprotective O
capabilities O
and O
thus, O
may O
contribute O
to O
the O
overt O
activity O
of O
its O
parent O
compound, O
rasagiline. B-CHEMICAL
This O
paper O
will O
review O
the O
earlier O
and O
present O
studies O
in O
the O
development O
of O
rasagiline B-CHEMICAL
for O
treatment O
of O
PD O
and O
discuss O
its O
pharmacology O
and O
applicable O
mechanism O
of O
action. O
Resistance O
to O
thyroid O
hormone O
due O
to O
a O
novel O
thyroid B-GENE-N
hormone I-GENE-N
receptor I-GENE-N
mutant O
in O
a O
patient O
with O
hypothyroidism O
secondary O
to O
lingual O
thyroid O
and O
functional O
characterization O
of O
the O
mutant O
receptor. O

BACKGROUND: O
We O
describe O
a O
rare O
case O
of O
congenital O
hypothyroidism O
and O
an O
extremely O
high O
serum O
thyrotropin B-GENE-N
(TSH) B-GENE-N
level O
caused O
by O
a O
combination O
of O
resistance O
to O
thyroid O
hormone O
(RTH) O
and O
a O
lingual O
thyroid. O
As O
the O
RTH O
mutant, O
R316C, B-GENE-N
was O
new, O
the O
optimum O
dose O
of O
levothyroxine B-CHEMICAL
was O
unclear. O
To O
aid O
in O
assessment O
of O
the O
therapy, O
we O
characterized O
the O
mutant O
R316C B-GENE-N
thyroid B-GENE-N
hormone I-GENE-N
receptor I-GENE-N
(TR) B-GENE-N
and O
compared O
it O
with O
a O
common O
mutant, O
R316H, B-GENE-N

using O
in O
vitro O
studies. O
SUMMARY: O
The O
patient O
was O
a O
newborn O
female O
having O
severe O
hypothyroidism O
with O
a O
free O
thyroxine B-CHEMICAL
level O
of O
0.36 O
ng/dL O
and O
a O
serum O
TSH B-GENE-N
level O
of O
177 O
microU/mL. O
A O
scintiscan O
showed O
ectopic O
lingual O
thyroid O
tissue O
without O
a O
normal O
thyroid O
gland. O
Supplementation O
with O
levothyroxine B-CHEMICAL
at O
a O
dose O
of O
>350 O
microg/day O
did O
not O
normalize O
the O
serum O
TSH B-GENE-N
level; O
however, O
the O
patient O
showed O
normal O
growth O
and O
intelligence O
at O
14 O
years O

of O
age. O
Consistent O
with O
the O
results O
of O
a O
computer O
analysis, O
the O
binding O
of O
R316C B-GENE-N
to O
triiodothyronine B-CHEMICAL
(T3) B-CHEMICAL
was O
significantly O
decreased O
to O
38% O
that O
of O
the O
wild O
type. O
Electrophoretic O
mobility O
shift O
assay O
demonstrated O
that O
like O
R316H, B-GENE-N
R316C B-GENE-N
did O
not O
form O
a O
homodimer, O
but O
formed O
a O
heterodimer O
with O
RXR. B-GENE-N
However, O
a O
glutathione-S-transferase B-CHEMICAL
pull-down O
assay O
showed O
reduced O
binding O
of O
R316C B-GENE-N
with O
NCoR B-GENE-Y
in O
the O
absence O
of O
T3 B-CHEMICAL
and O
impaired O
release O

in O
the O
presence O
of O
T3. B-CHEMICAL
In O
addition, O
transient O
transfection O
experiments O
demonstrated O
that O
unlike O
R316H, B-GENE-N
R316C B-GENE-N
had O
severe O
impairment O
of O
transcriptional O
activity O
on O
genes O
both O
positively O
and O
negatively O
regulated O
by O
thyroid O
hormone. O
It O
also O
had O
a O
clear O
dominant O
negative O
effect O
on O
genes O
negatively, O
but O
not O
positively, O
regulated O
by O
thyroid O
hormone, O
including O
the O
TSH-releasing B-GENE-Y
hormone I-GENE-Y
and O
TSHbeta B-GENE-Y
genes. O
CONCLUSION: O
This O
is O
the O
first O
reported O
case O
of O
a O
R316C B-GENE-N
TR B-GENE-N
mutation. O
The O
characteristics O
of O
the O
R316C B-GENE-N
mutant O
differed O
from O
those O
of O
the O

R316H B-GENE-N
mutant. O
Our O
findings O
suggest O
that O
R316C B-GENE-N
causes O
reduced O
association O
with O
and O
impaired O
release O
of O
NCoR, B-GENE-Y
resulting O
in O
RTH O
predominantly O
at O
the O
pituitary O
level, O
and O
that O
slightly O
elevated O
serum O
TSH B-GENE-N
level O
with O
high O
dose O
of O
levothyroxine B-CHEMICAL
might O
be O
optimum O
for O
normal O
growth. O
Identification O
of O
neuronal O
target O
areas O
for O
nerve O
agents O
and O
specification O
of O
receptors O
for O
pharmacological O
treatment. O
In O
order O
to O
shorten O
the O
list O
of O
candidate O
drugs O
with O
anticonvulsant O
potential O
against O
nerve O
agents, O
critical O
subreceptors O
in O
seizure O
controlling O
brain O
regions O
should O
be O
specified. O

Epileptiform O
activity O
does O
not O
spread O
randomly O
throughout O
the O
brain, O
but O
appears O
to O
be O
generated O
and O
propagated O
by O
specific O
anatomical O
routes. O
Nerve O
agents O
evoke O
seizure O
activity O
in O
the O
forebrain O
that O
progresses O
to O
the O
hind O
brain O
resulting O
in O
tonic-clonic O
convulsions. O
In O
some O
recent O
studies, O
it O
was O
shown O
that O
lesion O
of O
the O
area O
tempestas O
(AT), O
medial O
septum O
(MS), O
perirhinal O
cortex O
(PRC), O
or O
posterior O
piriform O
cortex O
(PPC) O
produces O
anticonvulsant O
effects O
(prevention O
of O
convulsions O
or O
delayed O

onset O
of O
convulsions) O
in O
rats O
exposed O
to O
soman, B-CHEMICAL
whereas O
damage O
to O
nucleus O
accumbens, O
nucleus O
basalis O
magnocellularis, O
amygdala, O
hippocampus, O
or O
entorhinal O
cortex O
does O
not O
cause O
anticonvulsant O
impact. O
These O
results O
are O
in O
compliance O
with O
findings O
that O
seizures O
can O
be O
generated O
in O
AT, O
MS, O
PRC, O
and O
PPC O
by O
means O
of O
nerve O
agents, O
chemoconvulsants, O
or O
kindling. O
Results O
from O
microinfusion O
studies O
show O
that O
anticonvulsant O
efficacy O
is O
obtained O
by O
GABA(A) B-CHEMICAL

modulators O
or O
cholinergic O
antagonists O
(M1-M5) B-GENE-Y
in O
AT, O
cholinergic O
antagonists O
(M1-M5) B-GENE-Y
in O
MS, O
combined O
glutamatergic O
(NMDA) B-CHEMICAL
and O
cholinergic O
antagonist O
(M1-M4), B-GENE-Y
AMPA B-CHEMICAL
antagonist, O
or O
modulators O
of O
metabotropic B-GENE-N
glutamate B-CHEMICAL
receptors I-GENE-N
(mGluR5, B-GENE-Y
mGluR2/3) B-GENE-N
in O
PRC, O
and O
cholinergic O
antagonist O
(M1-M5) B-GENE-Y
or O
GABA(A) B-GENE-N
agonist O
in O
PPC. O
Calculation O
of O
impact O
factors O
for O
the O
most O
potent O

drugs O
(percentage O
of O
positive O
effects O
in O
the O
seizure O
controlling O
sites) O
showed O
that O
scopolamine B-CHEMICAL
and O
procyclidine B-CHEMICAL
were O
ranking O
highest O
(75) O
followed O
by O
muscimol B-CHEMICAL
(50), O
NBQX B-CHEMICAL
(33), O
and O
caramiphen B-CHEMICAL
(33). O
Potential O
strategies O
for O
prophylactic O
and O
post-exposure O
treatments O
are O
discussed. O
Selective O
cyclooxygenase-2 B-GENE-Y
(COX-2) B-GENE-Y
inhibitors O
and O
breast O
cancer O
risk. O
BACKGROUND: O
Recent O
epidemiologic O
and O
laboratory O
studies O
have O
suggested O
that O
non-steroidal B-CHEMICAL

anti-inflammatory O
drugs O
(NSAIDs) O
may O
reduce O
the O
risk O
of O
breast O
cancer O
through O
inhibition O
of O
cyclooxygenase-2 B-GENE-Y
(COX-2). B-GENE-Y
METHODS: O
We O
conducted O
a O
case-control O
study O
to O
measure O
the O
association O
between O
selective O
cox-2 B-GENE-Y
inhibitors, O
particularly O
celecoxib, B-CHEMICAL
rofecoxib, B-CHEMICAL
valdecoxib B-CHEMICAL
and O
non-specific O
NSAID O
subgroups, O
and O
breast O
cancer O
risk. O
Between O
2003 O
and O
2006, O
a O
total O
of O
18,368 O
incident O
breast O
cancer O
cases O
were O
identified O
in O
the O
Ingenix/Lab O
Rx O
insurance O
database, O
which O
contains O

clinical O
encounter O
and O
drug O
prescription O
data. O
Four O
controls O
per O
case O
were O
randomly O
selected, O
matched O
on O
age O
and O
time O
in O
database. O
Odds O
ratios O
(OR) O
and O
95% O
confidence O
intervals O
(CI) O
were O
estimated O
using O
conditional O
logistic O
regression. O
RESULTS: O
Breast O
cancer O
risk O
was O
inversely O
associated O
with O
both O
non-specific O
NSAID O
and O
selective O
COX-2 B-GENE-Y
inhibitor O
use. O
Greater O
than O
12 O
months' O
duration O
of O
use O
of O
Celecoxib B-CHEMICAL
at O
a O
standard O
dose O
(200mg/day) O
was O
associated O
with O
a O
16% O
decrease O
in O
breast O
cancer O
risk O
(OR=0.84, O
95% O

CI=0.73, O
0.97). O
We O
observed O
the O
greatest O
risk O
reduction O
in O
association O
with O
>2 O
years O
of O
rofecoxib B-CHEMICAL
exposure O
(OR=0.54, O
95% O
CI=0.37, O
0.80). O
Acetaminophen, B-CHEMICAL
a O
compound O
with O
less O
biological O
plausibility O
for O
chemoprevention, O
showed O
no O
significant O
association O
with O
the O
risk O
of O
developing O
breast O
cancer. O
CONCLUSION: O
Consistent O
with O
animal O
models O
and O
laboratory O
investigations, O
higher O
doses O
of O
selective O
COX-2 B-GENE-Y
inhibitors O
were O
more O
protective O
against O
breast O
cancer O
than O
non-specific O
NSAIDs. O
With O

exposure O
to O
rofecoxib, B-CHEMICAL
a O
selective O
COX-2 B-GENE-Y
inhibitor, O
breast O
cancer O
risk O
reduction O
was O
appreciable O
(46%), O
suggesting O
a O
possible O
role O
for O
selective O
COX-2 B-GENE-Y
inhibitors O
in O
breast O
cancer O
prophylaxis. O
Barrel O
rotation O
in O
rats O
induced O
by O
SMS B-CHEMICAL
201-995: I-CHEMICAL
suppression O
by O
ceruletide. B-CHEMICAL
Intracerebroventricular O
administration O
of O
SMS B-CHEMICAL
201-995 I-CHEMICAL
(5 O
micrograms/rat), O
a O
somatostatin B-GENE-Y
analogue, O
induced O
barrel O
rotation O
in O
rats. O
Pretreatment O
with O
ceruletide B-CHEMICAL
(40 O
micrograms/100 O
g O

b. O
wt., O
IP) O
3 O
days O
or O
7 O
days O
prior O
to O
the O
injection O
of O
SMS B-CHEMICAL
201-995 I-CHEMICAL
significantly O
inhibited O
the O
response O
rate O
of O
barrel O
rotation O
induced O
by O
SMS B-CHEMICAL
201-995, I-CHEMICAL
but O
not O
that O
induced O
by O
arginine-vasopressin B-CHEMICAL
(1 O
microgram/rat, O
ICV). O
The O
suppressive O
effect O
of O
ceruletide B-CHEMICAL
on O
barrel O
rotation O
could O
be O
partially O
countered O
by O
MK-329, B-CHEMICAL
a O
selective O
peripheral O
CCK B-GENE-Y
(CCK-A) B-GENE-Y
receptor I-GENE-Y
antagonist. O
Desulfated O
cerulein O
did O
not O
affect O
the O
barrel O
rotation O
induced O
by O
SMS B-CHEMICAL
201-995. I-CHEMICAL

These O
findings O
suggest O
that O
ceruletide B-CHEMICAL
specifically O
suppresses O
the O
barrel O
rotation O
evoked O
by O
SMS B-CHEMICAL
201-995 I-CHEMICAL
in O
a O
long-lasting O
manner O
possibly O
acting O
through O
CCK-A B-GENE-Y
receptor. I-GENE-Y
Effects O
of O
the O
histamine B-CHEMICAL
H1 I-GENE-Y
antagonist O
chlorcyclizine B-CHEMICAL
on O
rat O
fetal O
palate O
development. O
BACKGROUND: O
The O
effects O
of O
histamine B-CHEMICAL
H1 I-GENE-Y
antagonist O
chlorcyclizine B-CHEMICAL
on O
rat O
palate O
development O
were O
characterized O
following O
in O
utero O
exposure. O
METHODS: O
To O
identify O
the O
optimum O
dose O
for O
inducing O
cleft O
palate, O
pregnant O
rats O
were O
administered O
30, O
60, O

or O
90 O
mg/kg O
chlorcyclizine B-CHEMICAL
on O
Gestation O
Days O
11 O
to O
14. O
Fetal O
palate O
gene O
expression O
was O
also O
assessed O
after O
90 O
mg/kg O
chlorcyclizine B-CHEMICAL
at O
8, O
15 O
and O
30 O
hours O
post-dose O
on O
Gestation O
Day O
14 O
using O
microarray O
and O
qRT-PCR. O
RESULTS: O
Rats O
in O
the O
60- O
and O
90-mg/kg O
groups O
exhibited O
adverse O
clinical O
signs O
and O
body O
weight O
loss. O
Rats O
in O
the O
90-mg/kg O
group O
also O
demonstrated O
increases O
in O
late O
resorptions O
and O
decreases O
in O
fetal O
weight. O
Effects O
in O
the O

low-dose O
group O
were O
limited O
to O
decreases O
in O
body O
weight O
gain. O
Fetal O
assessment O
on O
Gestation O
Day O
21 O
revealed O
that O
findings O
were O
limited O
to O
the O
60- O
and O
90-mg/kg O
groups, O
and O
included O
cleft O
palate O
(80% O
of O
litters O
for O
both O
groups), O
high O
arched O
palate, O
small O
nose, O
micrognathia, O
high O
domed O
head, O
digits O
shortened/absent O
and O
small O
limb. O
The O
fetal O
incidence O
of O
cleft O
palate O
was O
higher O
at O
90 O
mg/kg, O
thus O
this O
dose O
was O
selected O
to O
assess O
palate O
gene O
expression. O
The O
altered O
genes O
associated O
with O

chlorcyclizine-induced B-CHEMICAL
cleft O
palate O
included O
Wnt5a, B-GENE-Y
Bmp2, B-GENE-Y
Bmp4, B-GENE-Y
Fgf10, B-GENE-Y
Fgfr2, B-GENE-Y
Msx1, B-GENE-Y
and O
Insig1 B-GENE-Y
but O
the O
magnitude O
of O
the O
change O
was O
relatively O
small O
(1.5- O
to O
2-fold). O
CONCLUSIONS: O
Expression O
of O
several O
genes O
involved O
in O
palate, O
limb O
and O
digit O
development O
was O
altered O
in O
the O
fetal O
palate O
following O
in O
utero O
exposure O
to O
chlorcyclizine. B-CHEMICAL
The O
subtle O
perturbation O
and O
interplay O
of O
these O
genes O
may O
have O
profound O

effects O
on O
the O
dynamics O
of O
fetal O
palate O
development. O
GABA(A) B-GENE-N
receptors I-GENE-N
as O
molecular O
targets O
of O
general O
anesthetics: O
identification O
of O
binding O
sites O
provides O
clues O
to O
allosteric O
modulation. O
PURPOSE: O
The O
purpose O
of O
this O
review O
is O
to O
summarize O
current O
knowledge O
of O
detailed O
biochemical O
evidence O
for O
the O
role O
of O
gamma-aminobutyric B-CHEMICAL
acid I-CHEMICAL
type I-GENE-N
A I-GENE-N
receptors I-GENE-N
(GABA(A)-Rs) B-GENE-N
in O
the O
mechanisms O
of O
general O
anesthesia. O
PRINCIPAL O
FINDINGS: O
With O
the O
knowledge O
that O
all O
general O
anesthetics O
positively O
modulate O

GABA(A)-R-mediated B-GENE-N
inhibitory O
transmission, O
site-directed O
mutagenesis O
comparing O
sequences O
of O
GABA(A)-R B-GENE-N
subunits O
of O
varying O
sensitivity O
led O
to O
identification O
of O
amino B-CHEMICAL
acid I-CHEMICAL
residues O
in O
the O
transmembrane O
domain O
that O
are O
critical O
for O
the O
drug O
actions O
in O
vitro. O
Using O
a O
photo O
incorporable O
analogue O
of O
the O
general O
anesthetic, O
R(+)etomidate, B-CHEMICAL
we O
identified O
two O
transmembrane O
amino B-CHEMICAL
acids I-CHEMICAL
that O
were O
affinity O
labelled O
in O
purified O
bovine B-GENE-N
brain I-GENE-N
GABA(A)-R. I-GENE-N
Homology O
protein O
structural O
modelling O
positions O
these O
two O
residues, O

alphaM1-11' O
and O
betaM3-4', O
close O
to O
each O
other O
in O
a O
single O
type O
of O
intersubunit B-GENE-N
etomidate I-GENE-N
binding I-GENE-N
pocket I-GENE-N
at O
the O
beta/alpha B-GENE-N
interface. I-GENE-N
This O
position O
would O
be O
appropriate O
for O
modulation O
of O
agonist O
channel O
gating. O
Overall, O
available O
information O
suggests O
that O
these O
two O
etomidate B-CHEMICAL
binding O
residues O
are O
allosterically O
coupled O
to O
sites O
of O
action O
of O
steroids, B-CHEMICAL
barbiturates, B-CHEMICAL
volatile O
agents, O
and O
propofol, B-CHEMICAL
but O
not O
alcohols. B-CHEMICAL
Residue O
alpha/betaM2-15' O
is O
probably O
not O
a O
binding O
site O
but O
allosterically O
coupled O
to O

action O
of O
volatile O
agents, O
alcohols, B-CHEMICAL
and O
intravenous O
agents, O
and O
alpha/betaM1-(-2') O
is O
coupled O
to O
action O
of O
intravenous O
agents. O
CONCLUSIONS: O
Establishment O
of O
a O
coherent O
and O
consistent O
structural O
model O
of O
the O
GABA(A)-R B-GENE-N
lends O
support O
to O
the O
conclusion O
that O
general O
anesthetics O
can O
modulate O
function O
by O
binding O
to O
appropriate O
domains O
on O
the O
protein. O
Genetic O
engineering O
of O
mice O
with O
mutation O
in O
some O
of O
these O
GABA(A)-R B-GENE-N
residues O
are O
insensitive O
to O
general O
anesthetics O
in O
vivo, O
suggesting O
that O
further O
analysis O
of O

these O
domains O
could O
lead O
to O
development O
of O
more O
potent O
and O
specific O
drugs. O
Role O
of O
extracellular O
calcium B-CHEMICAL
and O
calmodulin B-GENE-Y
in O
prolactin B-GENE-Y
secretion O
induced O
by O
hyposmolarity, O
thyrotropin-releasing B-GENE-Y
hormone, I-GENE-Y
and O
high O
K+ B-CHEMICAL
in O
GH4C1 O
cells. O
The O
mechanism O
by O
which O
30% O
medium O
hyposmolarity O
induces O
PRL B-GENE-Y
secretion O
by O
GH4C1 O
cells O
was O
compared O
with O
that O
induced O
by O
100 O
nmol/l O
TRH B-GENE-Y
or O
30 O
mmol/l O
K+. B-CHEMICAL
Removing O
medium O
Ca2+, B-CHEMICAL
blocking O
Ca2+ B-CHEMICAL
channels I-GENE-N
with O
50 O

mumol/l O
verapamil, B-CHEMICAL
or O
inhibiting O
calmodulin B-GENE-Y
activation O
with O
20 O
mumol/l O
trifluoperazine, B-CHEMICAL
10 O
mumol/l O
chlorpromazine B-CHEMICAL
or O
10 O
mumol/l O
pimozide B-CHEMICAL
almost O
completely O
blocked O
hyposmolarity-induced O
secretion. O
The O
smooth O
muscle O
relaxant, O
W-7, B-CHEMICAL
which O
is O
believed O
relatively O
specific O
in O
inhibiting O
the O
Ca2(+)-calmodulin B-CHEMICAL
interaction, O
depressed O
hyposmolarity-induced O
PRL B-GENE-Y
secretion O
in O
a O
dose-dependent O
manner O
(r O
= O
-0.991, O
p O

less O
than O
0.01). O
The O
above O
drugs O
also O
blocked O
or O
decreased O
high O
K(+)-induced B-CHEMICAL
secretion, O
but O
had O
much O
less O
effect O
on O
TRH-induced B-GENE-Y
secretion. O
Secretion O
induced O
by O
TRH, B-GENE-Y
hyposmolarity, O
or O
high O
K+ B-CHEMICAL
was O
optimal O
at O
pH O
7.3-7.65 O
and O
was O
significantly O
depressed O
at O
pH O
6.0 O
or O
8.0, O
indicating O
that O
release O
of O
hormone O
induced O
by O
all O
3 O
stimuli O
is O
due O
to O
an O
active O
cell O
process O
requiring O
a O
physiologic O
extracellular O
pH O
and O
is O
not O
produced O
by O
nonspecific O
cell O
toxicity. O
The O
data O
suggest O

hyposmolarity O
and O
high O
K+ B-CHEMICAL
may O
share O
some O
similarities O
in O
their O
mechanism O
of O
stimulating O
secretion, O
which O
is O
different O
from O
that O
of O
TRH. B-GENE-Y
Use O
of O
(Gyro) O
Gy O
and O
spermine B-GENE-Y
synthase I-GENE-Y
transgenic O
mice O
to O
study O
functions O
of O
spermine. B-CHEMICAL
The O
polyamines B-CHEMICAL
putrescine, B-CHEMICAL
spermidine, B-CHEMICAL
and O
spermine B-CHEMICAL
are O
essential O
for O
mammalian O
cell O
growth, O
-differentiation, O
and O
cell O
death O
and O
have O
important O
physiological O
roles O
in O
all O
tissues. O
Many O
of O
the O
properties O
of O
polyamines B-CHEMICAL
that O
can O
be O
demonstrated O
in O
vitro O
are O
common O
to O
all O
three O
molecules O
with O
differences O
only O
in O

potency. O
Loss O
of O
any O
of O
the O
enzymes O
needed O
to O
make O
either O
putrescine B-CHEMICAL
or O
spermidine B-CHEMICAL
(which O
also O
-prevent O
the O
production O
of O
spermine) B-CHEMICAL
is O
lethal, O
but O
male O
mice O
lacking O
spermine B-GENE-Y
synthase I-GENE-Y
(SpmS) B-GENE-Y
due O
to O
a O
deletion O
of O
part O
of O
the O
X O
chromosome O
are O
viable O
on O
the O
B6C3H O
background. O
These O
mice O
are O
termed O
Gyro O
(Gy) O
due O
to O
their O
circling O
behavior. O
They O
have O
a O
variety O
of O
abnormalities O
including O
deafness, O
neurological O
problems, O
small O
size, O
and O
a O
tendency O
to O
early O
death. O
They O
can O
therefore O
be O
used O
to O
evaluate O
the O
physiological O

function(s) O
uniquely O
provided O
by O
spermine. B-CHEMICAL
They O
also O
provide O
a O
potential O
animal O
model O
for O
Snyder-Robinson O
syndrome O
(SRS), O
a O
rare O
human O
inherited O
disease O
due O
to O
a O
loss O
of O
SpmS B-GENE-Y
activity. O
An O
essential O
control O
in O
experiments O
using O
Gy O
mice O
is O
to O
demonstrate O
that O
the O
abnormal O
phenotypes O
exhibited O
by O
these O
mice O
are O
abolished O
by O
providing O
replacement O
spermine B-CHEMICAL
and O
this O
can O
be O
accomplished O
by O
breeding O
with O
CAG-SMS B-GENE-Y
mice O
that O
express O
SpmS B-GENE-Y
from O
a O
ubiquitous O
promoter. O
Techniques O
for O
identifying, O
characterizing, O
and O
using O
these O
mouse O
strains O
and O
limitations O
of O
this O
approach O
are O
described O
in O
this O
chapter. O

Cabozantinib B-CHEMICAL
(XL184), B-CHEMICAL
a O
novel O
MET B-GENE-Y
and O
VEGFR2 B-GENE-Y
inhibitor, O
simultaneously O
suppresses O
metastasis, O
angiogenesis, O
and O
tumor O
growth. O
The O
signaling O
pathway O
of O
the O
receptor B-GENE-Y
tyrosine I-GENE-Y
kinase I-GENE-Y
MET I-GENE-Y
and O
its O
ligand O
hepatocyte B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(HGF) B-GENE-Y
is O
important O
for O
cell O
growth, O
survival, O
and O
motility O
and O
is O
functionally O
linked O
to O
the O
signaling O
pathway O
of O
VEGF, B-GENE-Y
which O
is O
widely O
recognized O
as O
a O
key O
effector O
in O
angiogenesis O
and O
cancer O
progression. O
Dysregulation O
of O
the O
MET/VEGF B-GENE-Y

axis O
is O
found O
in O
a O
number O
of O
human O
malignancies O
and O
has O
been O
associated O
with O
tumorigenesis. O
Cabozantinib B-CHEMICAL
(XL184) B-CHEMICAL
is O
a O
small-molecule O
kinase B-GENE-N
inhibitor O
with O
potent O
activity O
toward O
MET B-GENE-Y
and O
VEGF B-GENE-Y
receptor I-GENE-Y
2 I-GENE-Y
(VEGFR2), B-GENE-Y
as O
well O
as O
a O
number O
of O
other O
receptor B-GENE-N
tyrosine B-CHEMICAL
kinases I-GENE-N
that O
have O
also O
been O
implicated O
in O
tumor O
pathobiology, O
including O
RET, B-GENE-Y
KIT, B-GENE-Y
AXL, B-GENE-Y
and O
FLT3. B-GENE-Y
Treatment O
with O
cabozantinib B-CHEMICAL
inhibited O
MET B-GENE-Y
and O
VEGFR2 B-GENE-Y
phosphorylation O
in O

vitro O
and O
in O
tumor O
models O
in O
vivo O
and O
led O
to O
significant O
reductions O
in O
cell O
invasion O
in O
vitro. O
In O
mouse O
models, O
cabozantinib B-CHEMICAL
dramatically O
altered O
tumor O
pathology, O
resulting O
in O
decreased O
tumor O
and O
endothelial O
cell O
proliferation O
coupled O
with O
increased O
apoptosis O
and O
dose-dependent O
inhibition O
of O
tumor O
growth O
in O
breast, O
lung, O
and O
glioma O
tumor O
models. O
Importantly, O
treatment O
with O
cabozantinib B-CHEMICAL
did O
not O
increase O
lung O
tumor O
burden O
in O
an O
experimental O
model O
of O
metastasis, O
which O
has O
been O
observed O
with O
inhibitors O
of O
VEGF B-GENE-Y
signaling O
that O
do O
not O
target O
MET. B-GENE-Y
Collectively, O
these O
data O

suggest O
that O
cabozantinib B-CHEMICAL
is O
a O
promising O
agent O
for O
inhibiting O
tumor O
angiogenesis O
and O
metastasis O
in O
cancers O
with O
dysregulated O
MET B-GENE-Y
and O
VEGFR B-GENE-N
signaling. O
Thiocolchicoside B-CHEMICAL
suppresses O
osteoclastogenesis O
induced O
by O
RANKL B-GENE-Y
and O
cancer O
cells O
through O
inhibition O
of O
inflammatory O
pathways: O
a O
new O
use O
for O
an O
old O
drug. O
BACKGROUND O
AND O
PURPOSE: O
Most O
patients O
with O
cancer O
die O
not O
because O
of O
the O
tumour O
in O
the O
primary O
site, O
but O
because O
it O
has O
spread O
to O
other O
sites. O
Common O
tumours, O
such O
as O

breast, O
multiple O
myeloma, O
and O
prostate O
tumours, O
frequently O
metastasize O
to O
the O
bone. O
To O
search O
for O
an O
inhibitor O
of O
cancer-induced O
bone O
loss, O
we O
investigated O
the O
effect O
of O
thiocolchicoside, B-CHEMICAL
a O
semi-synthetic O
colchicoside B-CHEMICAL
derived O
from O
the O
plant O
Gloriosa O
superba O
and O
clinically O
used O
as O
a O
muscle O
relaxant, O
on O
osteoclastogenesis O
induced O
by O
receptor B-GENE-Y
activator I-GENE-Y
of I-GENE-Y
NF-kappaB I-GENE-Y
ligand I-GENE-Y
(RANKL) B-GENE-Y
and O
tumour O
cells. O
EXPERIMENTAL O
APPROACH: O
We O
used O

RAW O
264.7 O
(murine O
macrophage) O
cells, O
a O
well-established O
system O
for O
osteoclastogenesis, O
and O
evaluated O
the O
effect O
of O
thiocolchicoside B-CHEMICAL
on O
RANKL-induced B-GENE-Y
NF-kappaB B-GENE-N
signalling O
and O
osteoclastogenesis O
as O
well O
as O
on O
osteoclastogenesis O
induced O
by O
tumour O
cells. O
KEY O
RESULTS: O
Thiocolchicoside B-CHEMICAL
suppressed O
osteoclastogenesis O
induced O
by O
RANKL, B-GENE-Y
and O
by O
breast O
cancer O
and O
multiple O
myeloma O
cells. O
Inhibition O
of O
the O

NF-kappaB B-GENE-N
pathway O
was O
responsible O
for O
this O
effect O
since O
the O
colchicoside B-CHEMICAL
inhibited O
RANKL-induced B-GENE-Y
NF-kappaB B-GENE-N
activation, O
activation O
of O
IkappaB B-GENE-N
kinase I-GENE-N
(IKK) B-GENE-N
and O
suppressed O
inhibitor O
of O
NF-kappaBalpha B-GENE-Y
(IkappaBalpha) B-GENE-Y
phosphorylation O
and O
degradation, O
an O
inhibitor O
of O
NF-kappaB. B-GENE-N
Furthermore, O
an O
inhibitor O
of O
the O
IkappaBalpha B-GENE-Y
kinase B-GENE-N
gamma O
or O
NF-kappaB B-GENE-N
essential O
modulator, O
the O
regulatory O
component O
of O
the O
IKK B-GENE-N
complex, O
demonstrated O
that O
the O

NF-kappaB B-GENE-N
signalling O
pathway O
is O
mandatory O
for O
osteoclastogenesis O
induced O
by O
RANKL. B-GENE-Y
CONCLUSIONS O
AND O
IMPLICATIONS: O
Together, O
these O
data O
suggest O
that O
thiocolchicoside B-CHEMICAL
significantly O
suppressed O
osteoclastogenesis O
induced O
by O
RANKL B-GENE-Y
and O
tumour O
cells O
via O
the O
NF-kappaB B-GENE-N
signalling O
pathway. O
Thus, O
thiocolchicoside, B-CHEMICAL
a O
drug O
that O
has O
been O
used O
for O
almost O
half O
a O
century O
to O
treat O
muscle O
pain, O
may O
also O
be O
considered O
as O
a O
new O
treatment O
for O
bone O
loss. O
Endothelial B-GENE-Y
nitric B-CHEMICAL
oxide I-CHEMICAL

synthase I-GENE-Y
genotypes O
and O
haplotypes O
modify O
the O
responses O
to O
sildenafil B-CHEMICAL
in O
patients O
with O
erectile O
dysfunction. O
Erectile O
dysfunction O
(ED) O
is O
usually O
treated O
with O
sildenafil. B-CHEMICAL
Although O
genetic O
polymorphisms O
in O
the O
endothelial B-GENE-Y
nitric I-GENE-Y
oxide I-GENE-Y
synthase I-GENE-Y
(eNOS) B-GENE-Y
gene O
may O
impair O
endogenous O
NO B-CHEMICAL
formation, O
there O
is O
little O
information O
about O
how O
eNOS B-GENE-Y
polymorphisms O
and O
haplotypes O
affect O
the O
responses O
to O
sildenafil. B-CHEMICAL
We O
studied O
118 O
patients; O
63 O
patients O
had O
ED O

secondary O
to O
radical O
prostatectomy O
(PED) O
and O
55 O
had O
organic, O
clinical O
ED. O
eNOS B-GENE-Y
genotypes O
for O
three O
eNOS B-GENE-Y
polymorphisms O
(T(-786)C, O
rs2070744; O
a O
variable O
number O
of O
tandem O
repeats O
(VNTR) O
in O
intron O
4; O
and O
Glu298Asp, O
rs1799983) O
were O
determined, O
and O
eNOS B-GENE-Y
haplotypes O
were O
estimated O
using O
PHASE O
2.1. O
The O
clinical O
responses O
to O
sildenafil B-CHEMICAL
were O
evaluated O
and O
the O
patients O
were O
classified O
as O
good O

responders O
(GR) O
or O
poor O
responders O
(PR) O
when O
their O
changes O
in O
five-item O
version O
of O
International O
Index O
for O
Erectile O
Function O
questionnaire O
were O
above O
or O
below O
the O
median O
value. O
The O
TC/CC O
genotypes O
and O
the O
C O
allele O
for O
the O
T(-786)C O
polymorphism O
were O
more O
common O
in O
GR, O
compared O
with O
PR O
patients O
with O
PED. O
However, O
the O
4b4a/4a4a O
genotypes O
and O
the O
4a O
allele O
for O
the O
VNTR O
polymorphism O
in O
intron O
4 O
were O
more O
common O
in O
GR, O
compared O

with O
PR O
patients O
with O
clinical O
ED. O
The O
C-4a-Glu O
haplotype O
was O
more O
common O
in O
GR O
than O
in O
PR O
patients O
with O
PED. O
Conversely, O
the O
T-4b-Asp O
haplotype O
was O
less O
common O
in O
GR O
than O
in O
PR O
patients O
with O
PED. O
No O
other O
significant O
differences O
were O
found. O
Our O
findings O
show O
evidence O
that O
eNOS B-GENE-Y
polymorphisms O
affect O
the O
responses O
of O
PED O
and O
clinical O
ED O
patients O
to O
sildenafil. B-CHEMICAL
Mercury B-CHEMICAL
induces O
the O
expression O
of O
cyclooxygenase-2 B-GENE-Y
and O
inducible B-GENE-Y
nitric B-CHEMICAL
oxide I-CHEMICAL

synthase. I-GENE-Y
Nuclear B-GENE-N
factor-B I-GENE-N
(NF-B) B-GENE-N
is O
a O
transcription O
factor O
that O
mediates O
the O
inducible O
expression O
of O
a O
variety O
of O
genes O
involved O
in O
immune O
and O
inflammatory O
responses. O
NF-B B-GENE-N
activation O
induces O
numerous O
proinflammatory O
gene O
products O
including O
cytokines, B-GENE-N
cyclooxygenase-2 B-GENE-Y
(COX-2), B-GENE-Y
and O
inducible B-GENE-Y
nitric B-CHEMICAL
oxide I-CHEMICAL
synthase I-GENE-Y
(iNOS). B-GENE-Y
The O
divalent O
heavy O
metal O
mercury B-CHEMICAL
has O
been O
used O
for O
thousands O
of O
years. O
Although O
mercury B-CHEMICAL
is O
clearly O
toxic O
to O
most O
mammalian O
organ O
systems, O
especially O
the O
immune O

system, O
exposure O
has O
still O
increased O
in O
some O
areas O
of O
the O
world. O
However, O
the O
underlying O
toxic O
mechanism O
is O
not O
clearly O
identified. O
Here, O
we O
report O
biochemical O
evidence O
that O
mercury B-CHEMICAL
alone O
induces O
NF-B B-GENE-N
activation, O
resulting O
in O
the O
induced O
expression O
of O
COX-2 B-GENE-Y
and O
iNOS. B-GENE-Y
The O
results O
suggest O
that O
mercury B-CHEMICAL
can O
induce O
inflammatory O
diseases O
by O
lowering O
host O
defense. O
Pharmacological O
evidence O
of O
functional O
inhibitory O
metabotrophic B-GENE-N
glutamate I-GENE-N
receptors I-GENE-N
on O
mouse O
arousal-related O
cholinergic O
laterodorsal O
tegmental O
neurons. O
Cholinergic O
neurons O
of O
the O
pontine O
laterodorsal O
tegmentum O

(LDT) O
are O
importantly O
involved O
in O
neurobiological O
mechanisms O
governing O
states O
of O
arousal O
such O
as O
sleep O
and O
wakefulness O
as O
well O
as O
other O
appetitive O
behaviors, O
such O
as O
drug-seeking. O
Accordingly, O
mechanisms O
controlling O
their O
excitability O
are O
important O
to O
elucidate O
if O
we O
are O
to O
understand O
how O
these O
LDT O
neurons O
generate O
arousal O
states. O
Glutamate B-CHEMICAL
mediates O
the O
vast O
majority O
of O
excitatory O
synaptic O
transmission O
in O
the O
vertebrate O
CNS O
and O
while O
presence O
of O
glutamate B-CHEMICAL
input O
in O
the O
LDT O
has O
been O
shown O
and O
ionotropic O
responses O
to O
glutamate B-CHEMICAL
have O
been O
reported O

in O
the O
LDT, O
characterization O
of O
metabotropic O
responses O
is O
lacking. O
Therefore, O
electrophysiological O
responses O
and O
changes O
in O
levels O
of O
intracellular O
Ca(2+) B-CHEMICAL
in O
mouse O
cholinergic O
LDT O
neurons O
following O
application O
of O
specific O
mGluR B-GENE-N
agonists O
and O
antagonists O
were O
examined. O
Unexpectedly, O
both O
the O
mGluR(5)specific B-GENE-Y
agonist, O
CHPG, B-CHEMICAL
and O
the O
group B-GENE-N
II I-GENE-N
mGluR I-GENE-N
(mGlu(2/3)) B-GENE-N
agonist, O
LY379268 B-CHEMICAL
(LY), O
induced O
a O
TTX-insensitive B-CHEMICAL
outward O

current/hyperpolarization. O
Both O
outward O
currents O
were O
significantly O
reduced O
by O
the O
mGluR B-GENE-N
antagonist O
MCPG B-CHEMICAL
and O
the O
CHPG-induced B-CHEMICAL
current O
was O
blocked O
by O
the O
specific O
mGluR(5) B-GENE-Y
antagonist O
MTEP. B-CHEMICAL
Concurrent O
Ca(2+)imaging B-CHEMICAL
revealed O
that O
while O
CHPG B-CHEMICAL
actions O
did O
include O
release O
of O
Ca(2+) B-CHEMICAL
from O
CPA/thapsigargin-sensitive B-CHEMICAL
intracellular O
stores, O
actions O
of O
LY O
did O
not. O
Both O
CHPG- B-CHEMICAL
and O
LY-induced O
outward O
currents O
were O
mediated O
by O
a O
TEA-sensitive B-CHEMICAL
potassium B-CHEMICAL
conductance. O
The O

large-conductance, O
Ca(2+)-dependent B-GENE-N
potassium I-GENE-N
(BK) I-GENE-N
channel I-GENE-N
blocker, O
iberiotoxin, O
attenuated O
CHPG B-CHEMICAL
actions. O
Consistent O
with O
actions O
on O
the O
BK O
conductance, O
CHPG B-CHEMICAL
enhanced O
the O
amplitude O
of O
the O
fast O
component O
of O
the O
after O
hyperpolarizing O
potential, O
concurrent O
with O
a O
reduction O
in O
the O
firing O
rate. O
We O
conclude O
that O
stimulation O
of O
mGluR(5) B-GENE-Y
and O
group O
II O
(mGluR(2/3)) B-GENE-N
elicits O
postsynaptically-mediated O
outward O
currents/hyperpolarizations O
in O
cholinergic O

LDT O
neurons. O
Effects O
of O
glutamatergic O
input O
would O
be, O
thus, O
expected O
not O
only O
to O
be O
excitation O
via O
stimulation O
of O
ionotropic B-GENE-N
glutamate I-GENE-N
receptors I-GENE-N
and O
mGluR(1), B-GENE-Y
but O
also O
inhibition O
via O
actions O
at O
mGluR(5) B-GENE-Y
and O
mGluR(2/3) B-GENE-N
on O
these O
neurons. O
As O
these O
two O
processes O
counteract O
each O
other, O
these O
surprising O
findings O
necessitate O
revision O
of O
predictions O
regarding O
the O
net O
level O
of O
excitation O
generated O
by O
glutamate B-CHEMICAL
input O
to O
cholinergic O
LDT O
cells O
and, O
by O
extension, O
the O
functional O
outcome O
of O
glutamate B-CHEMICAL

transmission O
on O
processes O
which O
these O
neurons O
regulate. O
This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
'Metabotropic B-GENE-N
Glutamate I-GENE-N
Receptors'. I-GENE-N
A O
potent O
Chk1 B-GENE-Y
inhibitor O
is O
selectively O
cytotoxic O
in O
melanomas O
with O
high O
levels O
of O
replicative O
stress. O
There O
are O
few O
effective O
treatments O
for O
metastatic O
melanoma. O
Checkpoint B-GENE-Y
kinase I-GENE-Y
1 I-GENE-Y
(Chk1) B-GENE-Y
inhibitors O
are O
being O
trialled O
for O
their O
efficacy O
in O
enhancing O
conventional O
chemotherapeutic O
agents, O
but O
their O
effectiveness O
as O
single O
agents O
is O
not O
known. O
We O
have O
examined O
the O
effectiveness O
of O
two O
novel O
Chk1 B-GENE-Y
selective O
inhibitors, O

AR323 B-CHEMICAL
and O
AR678, B-CHEMICAL
in O
a O
panel O
of O
melanoma O
cell O
lines O
and O
normal O
cell O
types. O
We O
demonstrate O
that O
these O
drugs O
display O
single-agent O
activity, O
with O
IC50s O
in O
the O
low O
nanomolar O
range. O
The O
drugs O
produce O
cytotoxic O
effects O
in O
cell O
lines O
that O
are O
most O
sensitive O
to O
these O
drugs, O
whereas O
normal O
cells O
are O
only O
sensitive O
to O
these O
drugs O
at O
the O
higher O
concentrations O
where O
they O
have O
cytostatic O
activity. O
The O
cytotoxic O
effect O
is O
the O
consequence O
of O
inhibition O
of O
S-phase O
Chk1, B-GENE-Y
which O
drives O
cells O
prematurely O
from O
late O
S O
phase O
into O
an O
aberrant O

mitosis O
and O
results O
in O
either O
failure O
of O
cytokinesis O
or O
cell O
death O
through O
an O
apoptotic O
mechanism. O
The O
sensitivity O
to O
the O
Chk1 B-GENE-Y
inhibitors O
was O
correlated O
with O
the O
level O
of O
endogenous O
DNA O
damage O
indicating O
replicative O
stress. O
Chk1 B-GENE-Y
inhibitors O
are O
viable O
single-agent O
therapies O
that O
target O
melanoma O
cells O
with O
high O
levels O
of O
endogenous O
DNA O
damage. O
This O
sensitivity O
suggests O
that O
Chk1 B-GENE-Y
is O
a O
critical O
component O
of O
an O
adaptation O
to O
replicative O
stress O
in O
these O
cells. O
It O
also O
suggests O
that O
markers O
of O
DNA O
damage O
may O
be O
useful O
in O
identifying O
the O
melanomas O
and O
potentially O
other O
tumour O
types O
that O
are O

more O
likely O
to O
be O
sensitive O
to O
Chk1 B-GENE-Y
inhibitors O
as O
single O
agents. O
Aspirin B-CHEMICAL
inhibits O
mTOR B-GENE-Y
signaling, O
activates O
AMP-activated B-GENE-N
protein I-GENE-N
kinase, I-GENE-N
and O
induces O
autophagy O
in O
colorectal O
cancer O
cells. O
BACKGROUND O
& O
AIMS: O
Aspirin B-CHEMICAL
reduces O
the O
incidence O
of O
and O
mortality O
from O
colorectal O
cancer O
(CRC) O
by O
unknown O
mechanisms. O
Cancer O
cells O
have O
defects O
in O
signaling O
via O
the O
mechanistic B-GENE-Y
target I-GENE-Y
of I-GENE-Y
rapamycin I-GENE-Y
(mTOR), B-GENE-Y
which O
regulates O
proliferation. O
We O
investigated O
whether O
aspirin B-CHEMICAL
affects O
adenosine B-GENE-N
monophosphate-activated I-GENE-N

protein I-GENE-N
kinase I-GENE-N
(AMPK) B-GENE-N
and O
mTOR B-GENE-Y
signaling O
in O
CRC O
cells. O
METHODS: O
The O
effects O
of O
aspirin B-CHEMICAL
on O
mTOR B-GENE-Y
signaling, O
the O
ribosomal B-GENE-Y
protein I-GENE-Y
S6, I-GENE-Y
S6 B-GENE-Y
kinase I-GENE-Y
1 I-GENE-Y
(S6K1), B-GENE-Y
and O
eukaryotic B-GENE-Y
translation I-GENE-Y
initiation I-GENE-Y
factor I-GENE-Y
4E I-GENE-Y
binding I-GENE-Y
protein I-GENE-Y
1 I-GENE-Y
(4E-BP1) B-GENE-Y
were O
examined O
in O
CRC O
cells O
by O
immunoblotting. O
Phosphorylation O
of O
AMPK B-GENE-N
was O
measured; O
the O
effects O
of O
loss O
of O
AMPKalpha B-GENE-N
on O
the O
aspirin-induced B-CHEMICAL
effects O
of O
mTOR B-GENE-Y
were O
determined O
using O
small O
interfering O
RNA O

(siRNA) O
in O
CRC O
cells O
and O
in O
AMPK(alpha1/alpha2-/-) B-GENE-N
mouse O
embryonic O
fibroblasts. O
LC3 B-GENE-N
and O
ULK1 B-GENE-Y
were O
used O
as O
markers O
of O
autophagy. O
We O
analyzed O
rectal O
mucosa O
samples O
from O
patients O
given O
600 O
mg O
aspirin, B-CHEMICAL
once O
daily O
for O
1 O
week. O
RESULTS: O
Aspirin B-CHEMICAL
reduced O
mTOR B-GENE-Y
signaling O
in O
CRC O
cells O
by O
inhibiting O
the O
mTOR B-GENE-Y
effectors O
S6K1 B-GENE-Y
and O
4E-BP1. B-GENE-Y
Aspirin B-CHEMICAL
changed O
nucleotide O
ratios O
and O
activated O

AMPK B-GENE-N
in O
CRC O
cells. O
mTOR B-CHEMICAL
was O
still O
inhibited O
by O
aspirin B-CHEMICAL
in O
CRC O
cells O
after O
siRNA O
knockdown O
of O
AMPKalpha, B-GENE-N
indicating O
AMPK-dependent B-GENE-N
and O
AMPK-independent B-GENE-N
mechanisms O
of O
aspirin-induced B-CHEMICAL
inhibition O
of O
mTOR. B-CHEMICAL
Aspirin B-CHEMICAL
induced O
autophagy, O
a O
feature O
of O
mTOR B-CHEMICAL
inhibition. O
Aspirin B-CHEMICAL
and O
metformin B-CHEMICAL
(an O
activator O
of O
AMPK) B-GENE-N
increased O
inhibition O
of O
mTOR B-GENE-Y
and O
Akt, B-GENE-N
as O
well O
as O
autophagy O
in O
CRC O
cells. O
Rectal O
mucosal O
samples O

from O
patients O
given O
aspirin B-CHEMICAL
had O
reduced O
phosphorylation O
of O
S6K1 B-GENE-Y
and O
S6. B-GENE-Y
CONCLUSIONS: O
Aspirin B-CHEMICAL
is O
an O
inhibitor O
of O
mTOR B-GENE-Y
and O
an O
activator O
of O
AMPK, B-GENE-N
targeting O
regulators O
of O
intracellular O
energy O
homeostasis O
and O
metabolism. O
These O
could O
contribute O
to O
its O
protective O
effects O
against O
development O
of O
CRC. O
Oncogenic O
K-ras B-GENE-Y
expression O
is O
associated O
with O
derangement O
of O
the O
cAMP/PKA B-CHEMICAL
pathway O
and O
forskolin-reversible B-CHEMICAL
alterations O
of O
mitochondrial O
dynamics O
and O
respiration. O
The O
Warburg O
effect O
in O
cancer O
cells O
has O
been O
proposed O
to O
involve O

several O
mechanisms, O
including O
adaptation O
to O
hypoxia, O
oncogenes O
activation O
or O
loss O
of O
oncosuppressors O
and O
impaired O
mitochondrial O
function. O
In O
previous O
papers, O
it O
has O
been O
shown O
that O
K-ras B-GENE-Y
transformed O
mouse O
cells O
are O
much O
more O
sensitive O
as O
compared O
with O
normal O
cells O
to O
glucose B-CHEMICAL
withdrawal O
(undergoing O
apoptosis) O
and O
present O
a O
high O
glycolytic O
rate O
and O
a O
strong O
reduction O
of O
mitochondrial B-GENE-N
complex I-GENE-N
I. I-GENE-N
Recent O
observations O
suggest O
that O
transformed O
cells O
have O
a O
derangement O
in O
the O
cyclic B-CHEMICAL
adenosine I-CHEMICAL
monophosphate/cAMP-dependent I-CHEMICAL
protein I-GENE-N
kinase I-GENE-N
(cAMP/PKA) B-CHEMICAL
pathway, O
which O
is O
known O

to O
regulate O
several O
mitochondrial O
functions. O
Herein, O
the O
derangement O
of O
the O
cAMP/PKA B-CHEMICAL
pathway O
and O
its O
impact O
on O
transformation-linked O
changes O
of O
mitochondrial O
functions O
is O
investigated. O
Exogenous O
stimulation O
of O
PKA B-GENE-N
activity, O
achieved O
by O
forskolin B-CHEMICAL
treatment, O
protected O
K-ras-transformed B-GENE-Y
cells O
from O
apoptosis O
induced O
by O
glucose B-CHEMICAL
deprivation, O
enhanced O
complex B-GENE-N
I I-GENE-N
activity, O
intracellular O
adenosine B-CHEMICAL
triphosphate I-CHEMICAL
(ATP) B-CHEMICAL
levels, O
mitochondrial O
fusion O
and O
decreased O
intracellular O
reactive O
oxygen B-CHEMICAL
species O
(ROS) O
levels. O
Several O
of O
these O
effects O
were O
almost O
completely O
prevented O
by O
inhibiting O
the O
PKA B-GENE-N
activity. O

Short-time O
treatment O
with O
compounds O
favoring O
mitochondrial O
fusion O
strongly O
decreased O
the O
cellular O
ROS O
levels O
especially O
in O
transformed O
cells. O
These O
findings O
support O
the O
notion O
that O
glucose B-CHEMICAL
shortage-induced O
apoptosis, O
specific O
of O
K-ras-transformed B-GENE-Y
cells, O
is O
associated O
to O
a O
derangement O
of O
PKA B-GENE-N
signaling O
that O
leads O
to O
mitochondrial B-GENE-N
complex I-GENE-N
I I-GENE-N
decrease, O
reduction O
of O
ATP B-CHEMICAL
formation, O
prevalence O
of O
mitochondrial O
fission O
over O
fusion, O
and O
thereby O
opening O
new O
approaches O
for O
development O
of O
anticancer O
drugs. O
Berberine B-CHEMICAL
inhibits O
myofibroblast O
differentiation O
in O
nasal O
polyp-derived O
fibroblasts O
via O
the O
p38 B-GENE-N
pathway. O
The O
purposes O
of O
this O
study O
were O

to O
determine O
whether O
berberine B-CHEMICAL
has O
any O
effect O
on O
phenotype O
changes O
and O
extracellular O
matrix O
(ECM) O
production O
in O
nasal O
polyp-derived O
fibroblasts O
(NPDFs) O
and O
to O
investigate O
the O
underlying O
molecular O
mechanism. O
NPDFs O
were O
pre-treated O
with O
berberine B-CHEMICAL
prior O
to O
induction O
by O
transforming B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(TGF)-1. I-GENE-Y
The O
expression O
of O
-smooth B-GENE-Y
muscle I-GENE-Y
actin I-GENE-Y
(SMA) B-GENE-Y
and O
collagen B-GENE-N
type I-GENE-N
I I-GENE-N
mRNA O
was O
determined O
by O
a O
reverse O
transcription-polymerase O
chain O
reaction, O
and O
the O
expression O
of O
-SMA B-GENE-Y
protein O
and O
collagen B-GENE-N
type I-GENE-N
I I-GENE-N
was O
determined O

by O
western O
blotting O
and/or O
immunofluorescent O
staining. O
The O
total O
soluble O
collagen B-GENE-N
production O
was O
analysed O
by O
the O
SirCol O
collagen O
assay. O
The O
expression O
of O
several O
signaling O
molecules O
of O
the O
TGF-1 B-GENE-Y
pathway O
was O
evaluated O
by O
western O
blot O
analysis. O
In O
TGF-1-induced B-GENE-Y
NPDFs, O
berberine B-CHEMICAL
significantly O
inhibited O
the O
expression O
of O
-SMA B-GENE-Y
and O
collagen B-GENE-N
type I-GENE-N
I I-GENE-N
mRNA O
and O
reduced O
-SMA B-GENE-Y
and O
collagen B-GENE-N
protein O
levels. O
Berberine B-CHEMICAL
only O
suppressed O
the O
expression O
of O
pp38 B-GENE-N
among O
the O
evaluated O
signaling O

molecules. O
SB203580 B-CHEMICAL
(a O
specific O
inhibitor O
of O
p38 B-GENE-N
kinase) B-GENE-N
markedly O
suppressed O
the O
increased O
expression O
of O
collagen B-GENE-N
type I-GENE-N
I I-GENE-N
and O
-SMA B-GENE-Y
in O
TGF-1-induced B-GENE-Y
NPDFs. O
Berberine B-CHEMICAL
exerts O
suppressive O
effects O
on O
phenotype O
changes O
and O
ECM O
production O
in O
NPDFs O
via O
p38 B-GENE-N
signaling O
pathway O
interference. O
The O
findings O
provide O
new O
therapeutic O
options O
for O
ECM O
production O
in O
nasal O
polyps. O
Glaucogenin B-CHEMICAL
E, I-CHEMICAL
a O
new O
C21 B-CHEMICAL
steroid B-CHEMICAL
from O
Cynanchum O
stauntonii. O
Glaucogenin B-CHEMICAL
E I-CHEMICAL

(1), O
a O
new O
C(21) B-CHEMICAL
steroid B-CHEMICAL
sapogenin, O
along O
with O
three O
known O
ones O
(2-4) O
were O
isolated O
from O
the O
rhizomes O
of O
Cynanchum O
stauntonii O
(Decne.) O
Schltr. O
ex O
Levl. O
Their O
structures O
were O
established O
mainly O
by O
the O
spectroscopic O
analysis, O
including O
2D O
NMR. O
All O
the O
isolated O
compounds O
were O
evaluated O
for O
their O
cytotoxicity O
against O
human O
cancer O
cell O
lines O
HeLa, O
Bel-7402, O
SGC-7901 O
and O
BGC-823. O
New O
triterpenoids B-CHEMICAL
from O
the O
stem O

bark O
of O
Hypodaphnis O
zenkeri. O
A O
new O
pentacyclic B-CHEMICAL
triterpenoid I-CHEMICAL
and O
three O
new O
derivatives O
based O
on O
the O
taraxer-14-ene B-CHEMICAL
skeleton O
with O
a O
C-28 O
attached O
a O
carboxylic B-CHEMICAL
acid I-CHEMICAL
group O
have O
been O
isolated O
from O
the O
stem O
bark O
of O
Hypodaphnis O
zenkeri, O
together O
with O
six O
known O
compounds. O
The O
new O
product O
was O
identified O
as O
2,3-dihydroxytaraxer-14-en-28-oic B-CHEMICAL
acid I-CHEMICAL
(1). O
Its O
derivatives, O

2,3-diacetyltaraxer-14-en-28-oic B-CHEMICAL
acid I-CHEMICAL
(2), O
2,3-di-O-carbonyl-2,3-dihydroxytaraxer-14-en-28-oic B-CHEMICAL
acid I-CHEMICAL
(3) O
and O
2,3-dipropionyltaraxer-14-en-28-oic B-CHEMICAL
acid I-CHEMICAL
(4) O
were O
obtained O
by O
semisynthesis. O
The O
known O
compounds O
were O
identified O
as O
3-hydroxytaraxer-14-en-28-oic B-CHEMICAL
acid I-CHEMICAL

or O
aleuritolic B-CHEMICAL
acid I-CHEMICAL
(5) O
(McPhail, O
A.T., O
McPhail, O
D.R., O
Wani, O
M.C., O
Wall, O
M.E. O
& O
A.W., O
Nicholas, O
A.W. O
(1989). O
Identity O
of O
maprounic B-CHEMICAL
acid I-CHEMICAL
with O
aleuritolic B-CHEMICAL
acid. I-CHEMICAL
Revision O
of O
the O
structure O
of O
maprounic B-CHEMICAL
acid: I-CHEMICAL
X-ray O
crystal O
structure O
of O
p-bromobenzyl B-CHEMICAL
acetylmaprounate. I-CHEMICAL
Journal O
Natural O
Products, O
52, O
212), O

3-hydroxytaraxer-14-en-28-oic B-CHEMICAL
acid I-CHEMICAL
or O
isoaleuritolic B-CHEMICAL
acid I-CHEMICAL
(6), O
3-acetyltaraxer-14-en-28-oic B-CHEMICAL
acid I-CHEMICAL
acetate I-CHEMICAL
or O
aleuritolic B-CHEMICAL
acid I-CHEMICAL
acetate I-CHEMICAL
(7) O
(Chaudhuri, O
S.K., O
Fullas, O
F., O
Brown, O
D.M., O
Wani, O
M.C., O
Wall, O
M.E., O
Cai, O
L., O
 O
Kinghorn, O
A.D. O
(1995). O
Isolation O
and O
structural O

elucidation O
of O
pentacyclic O
triterpenoids O
from O
Maprounea O
africana. O
Journal O
of O
Natural O
Products, O
58, O
1-9), O
3-oxo-taraxer-14-ene B-CHEMICAL
or O
taraxerone B-CHEMICAL
(8) O
-sitosterol B-CHEMICAL
(9) O
and O
stigmasterol B-CHEMICAL
(10) O
(Kamboj O
& O
Saluja, O
2011), O
together O
with O
fatty O
acids. O
Their O
structures O
were O
established O
on O
the O
basis O
of O
spectroscopic O
studies O
and O
chemical O
transformations. O
Two O
new O
C-15 O
enolic B-CHEMICAL
acyl I-CHEMICAL
phragmalin-type I-CHEMICAL

limonoids B-CHEMICAL
from O
Chukrasia O
tabularis O
var. O
velutina. O
Two O
new O
C-15 O
enolic B-CHEMICAL
acyl I-CHEMICAL
phragmalin-type I-CHEMICAL
limonoid B-CHEMICAL
orthoesters, I-CHEMICAL
chukvelutilide B-CHEMICAL
G I-CHEMICAL
(1) O
and O
chukrasine B-CHEMICAL
F I-CHEMICAL
(2), O
were O
isolated O
from O
the O
stem O
barks O
of O
Chukrasia O
tabularis O
var. O
velutina. O
Their O
structures O
were O
elucidated O
by O
their O
extensive O
high O
resolution-electrospray O
ionization O
mass O
spectrometry O
(HR-ESI-MS), O
one- O
and O
two-dimensional O
spectroscopic O
analysis, O
including O

heteronuclear O
single O
quantum O
coherence O
(HSQC), O
HMBC O
and O
NOESY O
experiments. O
Cereblon B-GENE-Y
is O
a O
direct O
protein O
target O
for O
immunomodulatory O
and O
antiproliferative O
activities O
of O
lenalidomide B-CHEMICAL
and O
pomalidomide. B-CHEMICAL
Thalidomide B-CHEMICAL
and O
the O
immunomodulatory O
drug, O
lenalidomide, B-CHEMICAL
are O
therapeutically O
active O
in O
hematological O
malignancies. O
The O
ubiquitously O
expressed O
E3 O
ligase O
protein O
cereblon B-GENE-Y
(CRBN) B-GENE-Y
has O
been O
identified O
as O
the O
primary O
teratogenic O

target O
of O
thalidomide. B-CHEMICAL
Our O
studies O
demonstrate O
that O
thalidomide, B-CHEMICAL
lenalidomide B-CHEMICAL
and O
another O
immunomodulatory O
drug, O
pomalidomide, B-CHEMICAL
bound O
endogenous O
CRBN B-GENE-Y
and O
recombinant O
CRBN-DNA B-GENE-Y
damage I-GENE-Y
binding I-GENE-Y
protein-1 I-GENE-Y
(DDB1) B-GENE-Y
complexes. O
CRBN B-GENE-Y
mediated O
antiproliferative O
activities O
of O
lenalidomide B-CHEMICAL
and O
pomalidomide B-CHEMICAL
in O
myeloma O
cells, O
as O
well O
as O
lenalidomide- B-CHEMICAL
and O
pomalidomide-induced B-CHEMICAL
cytokine B-GENE-N
production O
in O
T O
cells. O
Lenalidomide B-CHEMICAL
and O

pomalidomide B-CHEMICAL
inhibited O
autoubiquitination O
of O
CRBN B-GENE-Y
in O
HEK293T O
cells O
expressing O
thalidomide-binding B-CHEMICAL
competent O
wild-type O
CRBN, B-GENE-Y
but O
not O
thalidomide-binding B-CHEMICAL
defective O
CRBN(YW/AA). B-GENE-Y
Overexpression O
of O
CRBN B-GENE-Y
wild-type O
protein, O
but O
not O
CRBN(YW/AA) B-GENE-Y
mutant O
protein, O
in O
KMS12 O
myeloma O
cells, O
amplified O
pomalidomide-mediated B-CHEMICAL
reductions O
in O
c-myc B-GENE-Y
and O
IRF4 B-GENE-Y
expression O
and O
increases O
in O

p21(WAF-1) B-GENE-Y
expression. O
Long-term O
selection O
for O
lenalidomide B-CHEMICAL
resistance O
in O
H929 O
myeloma O
cell O
lines O
was O
accompanied O
by O
a O
reduction O
in O
CRBN, B-GENE-Y
while O
in O
DF15R O
myeloma O
cells O
resistant O
to O
both O
pomalidomide B-CHEMICAL
and O
lenalidomide, B-CHEMICAL
CRBN B-GENE-Y
protein O
was O
undetectable. O
Our O
biophysical, O
biochemical O
and O
gene O
silencing O
studies O
show O
that O
CRBN B-GENE-Y
is O
a O
proximate, O
therapeutically O
important O
molecular O
target O
of O
lenalidomide B-CHEMICAL
and O
pomalidomide. B-CHEMICAL
Evaluation O
of O
food-drug O
interaction O
of O
guava O

leaf O
tea. O
Guava O
leaf O
tea O
(GLT) O
contains O
guava O
leaf O
polyphenol B-CHEMICAL
(Gvpp), O
which O
regulates O
the O
absorption O
of O
dietary O
carbohydrate B-CHEMICAL
from O
the O
intestines. O
Borderline O
diabetics, O
who O
are O
at O
high O
risk O
of O
development O
of O
diabetes, O
take O
GLT O
to O
suppress O
a O
rapid O
increase O
of O
blood O
sugar B-CHEMICAL
level O
after O
meals. O
However, O
patients O
with O
diabetes O
in O
whom O
diabetic O
drugs O
or O
warfarin B-CHEMICAL
as O
a O
blood O
thinner O
are O
prescribed O
also O
take O
GLT O
with O
the O
expectation O
of O
glycemic O
control. O
Therefore, O
we O
studied O
whether O
GLT O
had O
potential O
for O
inhibition O
or O

induction O
of O
cytochrome B-GENE-N
P450 I-GENE-N
(CYP) B-GENE-N
and O
an O
influence O
on O
the O
action O
of O
warfarin. B-CHEMICAL
Extract O
of O
guava O
leaf O
(GvEx) O
consists O
of O
carbohydrate B-CHEMICAL
and O
polyphenols, B-CHEMICAL
which O
are O
Gvpp, O
quercetin, B-CHEMICAL
and O
ellagic B-CHEMICAL
acid. I-CHEMICAL
These O
polyphenols, B-CHEMICAL
but O
not O
GvEx, O
showed O
a O
certain O
level O
of O
inhibition O
of O
human-cDNA-expressed O
CYPs. B-GENE-N
In O
a O
comparison O
of O
GLT O
and O
grapefruit O
juice, O
GLT O
showed O
weaker O
inhibition O
of O
CYP B-GENE-N
activities O
and O
of O

midazolam B-CHEMICAL
1'-hydroxylation O
than O
grapefruit O
juice. O
Furthermore, O
neither O
liver O
weight O
nor O
CYP3A B-GENE-N
expression O
in O
the O
liver O
was O
changed O
in O
rats O
that O
received O
GvEx O
for O
90 O
days O
compared O
with O
the O
control O
group. O
When O
rats O
were O
concomitantly O
treated O
with O
GLT O
and O
warfarin, B-CHEMICAL
the O
prolongation O
of O
clotting O
time O
of O
blood O
by O
warfarin B-CHEMICAL
was O
not O
influenced. O
These O
data O
suggest O
that O
GLT O
is O
unlikely O
to O
interact O
with O
drugs. O
Crizotinib B-CHEMICAL
in O
the O
treatment O
of O
non-small-cell O
lung O
cancer. O
INTRODUCTION: O
Recent O
progress O
in O
identifying O

distinct O
subsets O
of O
lung O
cancer, O
based O
on O
critical O
driver O
mutations, O
has O
led O
to O
increasingly O
focused O
efforts O
in O
the O
development O
of O
selectively O
targeted O
therapies. O
The O
fusion O
oncogene, O
echinoderm B-GENE-Y
microtubule-associated I-GENE-Y
protein-like I-GENE-Y
4 I-GENE-Y
- O
anaplastic B-GENE-Y
lymphoma I-GENE-Y
kinase I-GENE-Y
(EML4-ALK), B-GENE-N
is O
present O
in O
approximately O
5% O
of O
non-small-cell O
lung O
cancer O
(NSCLC) O
tumors. O
Crizotinib B-CHEMICAL
is O
an O
oral O
tyrosine B-CHEMICAL
kinase I-GENE-N
inhibitor O
(TKI), O
which O
silences O
the O
protein O
product O
of O
the O
ALK B-GENE-Y
fusion O
gene O
and O
has O
recently O
been O
approved O
for O
the O

treatment O
of O
NSCLC O
aberrantly O
expressing O
ALK. B-GENE-Y
Emerging O
data O
suggest O
that O
crizotinib B-CHEMICAL
may O
also O
have O
activity O
in O
other O
subsets O
of O
lung O
cancer, O
including O
tumors O
demonstrating O
amplification O
or O
mutation O
of O
the O
MET B-GENE-Y
oncogene, O
or O
translocation O
of O
the O
ROS1 B-GENE-Y
oncogene. O
AREAS O
COVERED: O
This O
paper O
gives O
an O
overview O
of O
the O
molecular O
pathogenesis O
of O
ALK-associated B-GENE-Y
NSCLC. O
It O
also O
reviews O
the O
pharmacokinetic O
and O
pharmacodynamic O
data O
on O
crizotinib B-CHEMICAL
and O
outlines O
the O
preclinical O
and O
clinical O
studies O
leading O
to O

the O
approval O
of O
crizotinib. B-CHEMICAL
In O
addition, O
it O
discusses O
its O
role O
in O
the O
treatment O
of O
NSCLC O
expressing O
ALK. B-GENE-Y
EXPERT O
OPINION: O
Crizotinib B-CHEMICAL
represents O
the O
newest O
example O
of O
a O
focused O
strategy O
for O
drug O
development O
in O
lung O
cancer, O
based O
on O
identification O
and O
targeted O
inhibition O
of O
critical O
tumor-specific O
driver O
mutations. O
Crizotinib B-CHEMICAL
has O
demonstrated O
efficacy O
against O
ALK-rearranged B-GENE-Y
NSCLC, O
and O
has O
potential O
for O
broader O
application O
in O
select O
subsets O
of O
lung O
cancer. O
Central O
adenosinergic O
system O
involvement O
in O
ethanol-induced B-CHEMICAL
motor O
incoordination O
in O
mice. O
To O
clarify O

if O
the O
behavioral O
interaction O
between O
ethanol B-CHEMICAL
and O
adenosine B-GENE-N
reported O
previously O
occur O
centrally O
or O
due O
to O
a O
peripheral O
hemodynamic O
change, O
the O
effect O
of O
i.c.v. O
adenosine B-GENE-N
agonists, O
N6-(R-phenylisopropyl)adenosine B-CHEMICAL
(R-PIA), B-CHEMICAL
N6-(S-phenylisopropyl)adenosine, B-CHEMICAL
5'-(N-cyclopropyl)-carboxamidoadenosine, B-CHEMICAL
antagonists, O
theophylline B-CHEMICAL
and O

8-p-(sulfophenyl)theophylline B-CHEMICAL
as O
well O
as O
enprofylline B-CHEMICAL
on O
ethanol-(i.p.)-induced B-CHEMICAL
motor O
incoordination O
was O
evaluated O
by O
rotorod. O
Adenosine B-GENE-N
agonists O
and O
antagonists O
dose O
dependently O
accentuated O
and O
attenuated, O
respectively, O
ethanol-induced B-CHEMICAL
motor O
incoordination, O
thereby O
suggesting O
a O
central O
mechanism O
of O
adenosine B-GENE-N
modulation O
of O
this O
effect O
of O
ethanol B-CHEMICAL
and O
confirmed O
our O
previous O
reports O
in O
which O
adenosine B-GENE-N
agonists O
and O
antagonists O
were O
given O
i.p. O
Enprofylline, B-CHEMICAL
a O
weak O

adenosine B-GENE-N
antagonist O
but O
potent O
inhibitor O
of O
cyclic B-GENE-N
AMP I-GENE-N
phosphodiesterase, I-GENE-N
did O
not O
alter O
ethanol's O
motor O
incoordination, O
further O
supporting O
involvement O
of O
brain O
adenosine B-GENE-N
receptor I-GENE-N
mechanism(s) O
in O
ethanol-adenosine B-CHEMICAL
interactions. O
Results O
from O
R-PIA O
and O
N6-(S-phenylisopropyl)adenosine B-CHEMICAL
experiments O
showed O
nearly O
a O
40-fold O
greater O
potency O
of O
R-vs. O
S-diastereoisomer, O
suggesting O
predominance O
of O
adenosine B-CHEMICAL
A1 I-GENE-Y
subtype. O
However, O

5'-(N-cyclopropyl)-carboxamidoadenosine B-CHEMICAL
data O
indicate O
complexity O
of O
the O
mechanism(s) O
and O
point O
toward O
an O
additional O
involvement O
of O
a O
yet O
unknown O
subtype O
of O
adenosine B-CHEMICAL
A2. I-GENE-N
No O
effect O
of O
ethanol O
on O
blood O
or O
brain O
levels O
of O
[3H]R-PIA B-CHEMICAL
was O
noted O
and O
sufficient O
amount O
of O
the O
latter O
entered O
the O
brain O
to O
suggest O
adenosine B-CHEMICAL
receptor I-GENE-N
activation O
adequate O
to O
produce O
behavioral O
interaction O
with O
ethanol. B-CHEMICAL
There O
was O
no O
escape O
of O
i.c.v.-administered O
[3H]R-PIA B-CHEMICAL
from O
brain O
to O
the O
peripheral O
circulation O
ruling O
out O
a O
peripheral O
and O

supporting O
a O
central O
mechanism O
of O
ethanol-adenosine B-CHEMICAL
interaction.(ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS) O
TGF- B-GENE-Y
and O
NF-B B-GENE-N
signal O
pathway O
cross-talk O
is O
mediated O
through O
TAK1 B-GENE-Y
and O
SMAD7 B-GENE-Y
in O
a O
subset O
of O
head O
and O
neck O
cancers. O
Transforming B-GENE-Y
growth I-GENE-Y
factor-beta I-GENE-Y
(TGF-) B-GENE-Y
has O
a O
dual O
role O
in O
epithelial O
malignancies, O
including O
head O
and O
neck O
squamous O
cell O
carcinoma O
(HNSCC). O
Attenuation O
of O
canonical O
TGF- B-GENE-Y
signaling O
enhances O
de O

novo O
tumor O
development, O
whereas O
TGF- B-GENE-Y
overexpression O
and O
signaling O
paradoxically O
promotes O
malignant O
progression. O
We O
recently O
observed O
that O
TGF--induced B-GENE-Y
growth O
arrest O
response O
is O
attenuated, O
in O
association O
with O
aberrant O
activation O
of O
nuclear B-GENE-N
factor-B I-GENE-N
(NF-B), B-GENE-N
a O
transcription O
factor, O
which O
promotes O
malignant O
progression O
in O
HNSCC. O
However, O
what O
role O
cross-talk O
between O
components O
of O
the O
TGF- B-GENE-Y
and O
NF-B B-GENE-N
pathways O
plays O
in O
altered O
activation O
of O
these O
pathways O
has O
not O
been O
established. O
Here, O
we O
show O
TGF- B-GENE-Y
receptor I-GENE-Y

II I-GENE-Y
and O
TGF--activated B-GENE-Y
kinase I-GENE-Y
1 I-GENE-Y
(TAK1) B-GENE-Y
are O
predominantly O
expressed O
in O
a O
subset O
of O
HNSCC O
tumors O
with O
nuclear O
activation O
of O
NF-B B-GENE-N
family O
member O
RELA B-GENE-Y
(p65). B-GENE-Y
Further, O
TGF-1 B-GENE-Y
treatment O
induced O
sequential O
phosphorylation O
of O
TAK1, B-GENE-Y
IKK, B-GENE-N
IB B-GENE-Y
and O
RELA B-GENE-Y
in O
human O
HNSCC O
lines. O
TAK1 B-GENE-Y
enhances O
TGF--induced B-GENE-Y
NF-B B-GENE-N
activation, O
as O
TAK1 B-GENE-Y
siRNA O
knockdown O
decreased O

TGF-1-induced B-GENE-Y
phosphorylation O
of O
IKK, B-GENE-N
IB B-GENE-Y
and O
RELA, B-GENE-Y
degradation O
of O
IB, B-GENE-Y
RELA B-GENE-Y
nuclear O
translocation O
and O
DNA O
binding, O
and O
NF-B-induced B-GENE-N
reporter O
and O
target O
gene O
transcription. O
Functionally, O
TAK1 B-GENE-Y
siRNA O
inhibited O
cell O
proliferation, O
migration O
and O
invasion. O
Celastrol, B-CHEMICAL
a O
TAK1 B-GENE-Y
inhibitor O
and O
anti-inflammatory O
compound O
used O
in O
traditional O
Chinese O
medicine, O
also O
decreased O
TGF-1-induced B-GENE-Y
phosphorylation O
of O
TAK1 B-GENE-Y
and O
RELA, B-GENE-Y
and O
suppressed O

basal, O
TGF-1- B-GENE-Y
and O
tumor B-GENE-Y
necrosis I-GENE-Y
factor-alpha I-GENE-Y
(TNF-)-induced B-GENE-Y
NF-B B-GENE-N
reporter O
gene O
activity. O
Celastrol B-CHEMICAL
also O
inhibited O
cell O
proliferation, O
while O
increasing O
sub-G0 O
DNA O
fragmentation O
and O
Annexin B-GENE-Y
V I-GENE-Y
markers O
of O
apoptosis. O
Furthermore, O
TGF- B-GENE-Y
and O
RELA B-GENE-Y
activation O
promoted O
SMAD7 B-GENE-Y
expression. O
In O
turn, O
SMAD7 B-GENE-Y
preferentially O
suppressed O
TGF--induced B-GENE-Y
SMAD B-GENE-N
and O
NF-B B-GENE-N
reporters O
when O
compared O
with O
constitutive O
or O
TNF--induced B-GENE-Y
NF-B B-GENE-N

reporter O
gene O
activation. O
Thus, O
cross-talk O
by O
TGF- B-GENE-Y
via O
TAK1 B-GENE-Y
and O
NF-B B-GENE-N
promotes O
the O
malignant O
phenotype O
of O
HNSCC. O
Moreover, O
NF-B B-GENE-N
may O
contribute O
to O
the O
downstream O
attenuation O
of O
canonical O
TGF- B-GENE-Y
signaling O
through O
increased O
SMAD7 B-GENE-Y
expression. O
Celastrol B-CHEMICAL
highlights O
the O
therapeutic O
potential O
of O
agents O
targeting O
TAK1 B-GENE-Y
as O
a O
key O
node O
in O
this O
pro-oncogenic O
TGF--NF-B B-GENE-Y
signal O
pathway. O
Dendritic O
cell O
migration O
assay: O
a O
potential O
prediction O
model O
for O
identification O
of O
contact O

allergens. O
This O
manuscript O
describes O
methodology O
and O
a O
prediction O
model O
for O
the O
MUTZ-LC O
migration O
assay. O
The O
assay O
represents O
the O
physiological O
change O
in O
Langerhans O
cell O
(LC) O
behavior O
after O
exposure O
to O
a O
sensitizing O
chemical, O
resulting O
in O
LC O
migration O
from O
the O
epidermis O
to O
the O
dermis. O
MUTZ-LC O
are O
derived O
from O
the O
commercially O
available O
MUTZ-3 O
cell O
line. O
Upon O
exposure O
to O
a O
sensitizer O
MUTZ-LC O
migrate O
preferentially O
towards O
CXCL12 B-GENE-Y
whereas O
upon O
exposure O
to O
a O
non-sensitizer O

MUTZ-LC O
migrate O
towards O
CCL5. B-GENE-Y
A O
CXCL12/CCL5 B-GENE-Y
ratio O
>1.10 O
in O
2/3 O
independent O
experiments O
is O
indicative O
of O
a O
sensitizer, O
whereas O
a O
CXCL12/CCL5 B-GENE-Y
ratio O
1.10 O
is O
indicative O
of O
a O
non-sensitizer. O
At O
non O
cytotoxic O
chemical O
concentrations O
9 O
sensitizers O
(2,4-dinitrochlorobenzene, B-CHEMICAL
paraphenylendiamine, B-CHEMICAL
cinnamaldehyde, B-CHEMICAL
isoeugenol, B-CHEMICAL
nickel-sulfate, B-CHEMICAL

tetramethylthiuram B-CHEMICAL
disulfide, I-CHEMICAL
eugenol, B-CHEMICAL
cinnamic-alcohol, B-CHEMICAL
ammonium-hexachloroplatinate) B-CHEMICAL
were O
distinguished O
from O
4 O
non O
sensitizers O
(sodium B-CHEMICAL
lauryl I-CHEMICAL
sulfate, I-CHEMICAL
salicylic B-CHEMICAL
acid, I-CHEMICAL
phenol, B-CHEMICAL
octanoic B-CHEMICAL
acid). I-CHEMICAL
Critical O
points O
in O
assay O
performance O
are O
(i) O
MUTZ-3 O
passage O
number O
after O
thawing O
(p6-p40); O
(ii) O
cell O
viability O
(>80%); O
(iii) O
standard O
curve O
to O
optimize O
correlation O
of O
fluorescence O

with O
cell O
number; O
and O
(iv) O
optimization O
of O
the O
concentration O
of O
rhCXCL12 B-GENE-Y
and O
rhCCL5 B-GENE-Y
in O
transwell. O
The O
protocol O
has O
been O
tested O
in O
three O
European O
laboratories O
and O
results O
suggest O
that O
it O
may O
provide O
working O
conditions O
for O
performing O
the O
DC O
migration O
assay O
which O
is O
aimed O
at O
distinguishing O
sensitizers O
from O
non O
sensitizers. O
The O
atypical O
antidepressant O
mianserin B-CHEMICAL
exhibits O
agonist O
activity O
at O
kappa-opioid B-GENE-Y
receptors. I-GENE-Y
BACKGROUND O
AND O
PURPOSE: O
Antidepressants O
are O
known O
to O
interact O
with O
the O
opioid O
system O
through O
mechanisms O
not O

completely O
understood. O
We O
previously O
reported O
that O
tricyclic B-CHEMICAL
antidepressants O
act O
as O
agonists O
at O
distinct O
opioid B-GENE-N
receptors. I-GENE-N
Here, O
we O
investigated O
the O
effect O
of O
the O
atypical O
antidepressant O
mianserin B-CHEMICAL
at O
cloned O
and O
native O
opioid B-GENE-N
receptors. I-GENE-N
EXPERIMENTAL O
APPROACH: O
Effects O
of O
mianserin B-CHEMICAL
were O
examined O
in O
CHO O
cells O
transfected O
with O
human B-GENE-N
opioid I-GENE-N
receptors, I-GENE-N
C6 O
glioma O
cells O
and O
rat O
brain O
membranes O
by O
the O
use O
of O
radioligand O
binding O
and O
functional O
assays O
including O
the O
stimulation O
of O

[(35)S]GTPgammaS B-CHEMICAL
binding O
and O
MAPK B-GENE-N
phosphorylation. O
KEY O
RESULTS: O
Mianserin B-CHEMICAL
displayed O
12- O
and O
18-fold O
higher O
affinity O
for O
kappa- B-GENE-N
than I-GENE-N
micro- I-GENE-N
and I-GENE-N
delta-opioid I-GENE-N
receptors I-GENE-N
respectively. O
In O
[(35)S]GTPgammaS B-CHEMICAL
assays, O
mianserin B-CHEMICAL
selectively O
activated O
kappa-opioid B-GENE-Y
receptors. I-GENE-Y
The O
agonist O
activity O
was O
antagonized O
by O
the O
selective O
kappa-opioid B-GENE-Y
blocker O
nor-binaltorphimine B-CHEMICAL
(nor-BNI). B-CHEMICAL
The O

mianserin B-CHEMICAL
analogue O
mirtazapine B-CHEMICAL
also O
displayed O
kappa-opioid B-GENE-Y
agonist O
activity. O
Mianserin B-CHEMICAL
and O
mirtazapine B-CHEMICAL
increased O
ERK1/2 B-GENE-N
phosphorylation O
in O
CHO O
cells O
expressing O
kappa-opioid B-GENE-Y
receptors I-GENE-Y
and O
C6 O
cells, O
and O
these O
effects O
were O
antagonized O
by O
nor-BNI. B-CHEMICAL
In O
rat O
striatum O
and O
nucleus O
accumbens, O
mianserin B-CHEMICAL
stimulated O
[35S]GTPgammaS B-CHEMICAL
binding O
in O
a O
nor-BNI-sensitive B-CHEMICAL
manner O
with O
maximal O
effects O
lower O
than O
those O
of O
the O
full O
kappa-opioid B-GENE-Y

agonists O
(-)-U50,488 B-CHEMICAL
and O
dynorphin B-CHEMICAL
A. I-CHEMICAL
When O
combined, O
mianserin B-CHEMICAL
antagonized O
the O
effects O
of O
the O
full O
kappa-opioid B-GENE-Y
receptor I-GENE-Y
agonists O
in O
[(35)S]GTPgammaS B-CHEMICAL
assays O
and O
reduced O
the O
stimulation O
of O
p38 B-GENE-N
MAPK B-GENE-N
and O
ERK1/2 B-GENE-N
phosphorylation O
by O
dynorphin B-GENE-Y
A. I-GENE-Y
CONCLUSIONS O
AND O
IMPLICATIONS: O
In O
different O
cell O
systems, O
mianserin B-CHEMICAL
directly O
activates O
kappa-opioid B-GENE-Y
receptors, I-GENE-Y
displaying O
partial O

agonist O
activity O
at O
brain O
receptors. O
Thus, O
this O
property O
appears O
to O
be O
a O
common O
feature O
of O
different O
classes O
of O
antidepressants. O
Lipid O
biomarkers O
of O
oxidative O
stress O
in O
a O
genetic O
mouse O
model O
of O
Smith-Lemli-Opitz O
syndrome. O
7-Dehydrocholesterol B-CHEMICAL
(7-DHC) B-CHEMICAL
accumulates O
in O
tissues O
and O
fluids O
of O
patients O
with O
Smith-Lemli-Opitz O
syndrome O
(SLOS), O
which O
is O
caused O
by O
mutations O
in O
the O
gene O
encoding O
3-hydroxysterol-(7)-reductase B-GENE-Y
(DHCR7). B-GENE-Y

We O
recently O
reported O
that O
7-DHC B-CHEMICAL
is O
the O
most O
reactive O
lipid O
molecule O
toward O
free O
radical O
oxidation O
(lipid O
peroxidation) O
and O
14 O
oxysterols B-CHEMICAL
have O
been O
identified O
as O
products O
of O
oxidation O
of O
7-DHC B-CHEMICAL
in O
solution. O
As O
the O
high O
oxidizability O
of O
7-DHC B-CHEMICAL
may O
lead O
to O
systemic O
oxidative O
stress O
in O
SLOS O
patients, O
we O
report O
here O
lipid O
biomarkers O
of O
oxidative O
stress O
in O
a O
Dhcr7-KO B-GENE-Y
mouse O
model O
of O
SLOS, O
including O
oxysterols, B-CHEMICAL
isoprostanes B-CHEMICAL
(IsoPs), B-CHEMICAL
and O

neuroprostanes B-CHEMICAL
(NeuroPs) B-CHEMICAL
that O
are O
formed O
from O
the O
oxidation O
of O
7-DHC, B-CHEMICAL
arachidonic B-CHEMICAL
acid I-CHEMICAL
and O
docosahexaenoic B-CHEMICAL
acid, I-CHEMICAL
respectively. O
In O
addition O
to O
a O
previously O
described O
oxysterol, B-CHEMICAL
3,5-dihydroxycholest-7-en-6-one B-CHEMICAL
(DHCEO), B-CHEMICAL
we O
provide O
evidence O
for O
the O
chemical O
structures O
of O
three O
new O
oxysterols B-CHEMICAL
in O
the O
brain O
and/or O
liver O
tissue O
of O
Dhcr7-KO B-GENE-Y
mice, O
two O
of O
which O
were O
quantified. O
We O
find O
that O
levels O

of O
IsoPs B-CHEMICAL
and O
NeuroPs B-CHEMICAL
are O
also O
elevated O
in O
brain O
and/or O
liver O
tissues O
of O
Dhcr7-KO B-GENE-Y
mice O
relative O
to O
matching O
WT O
mice. O
While O
IsoPs B-CHEMICAL
and O
NeuroPs B-CHEMICAL
have O
been O
established O
as O
a O
reliable O
measurement O
of O
lipid O
peroxidation O
and O
oxidative O
stress O
in O
vivo, O
we O
show O
that O
in O
this O
genetic O
SLOS O
mouse O
model, O
7-DHC-derived B-CHEMICAL
oxysterols B-CHEMICAL
are O
present O
at O
much O
higher O
levels O
than O
IsoPs B-CHEMICAL
and O
NeuroPs B-CHEMICAL
and O
thus O
are O
better O
markers O
of O
lipid O
oxidation O
and O
related O
oxidative O
stress. O
Correlation O
of O

high O
urinary O
Smad1 B-GENE-Y
level O
with O
glomerular O
hyperfiltration O
in O
type O
2 O
diabetes O
mellitus. O
The O
aim O
of O
this O
study O
was O
to O
assess O
the O
relationship O
between O
urinary O
Smad1 B-GENE-Y
and O
glomerular O
hyperfiltration O
(GHF) O
in O
type O
2 O
diabetes O
mellitus O
(T2DM), O
and O
to O
explore O
the O
factors O
related O
to O
the O
urinary O
Smad1 B-GENE-Y
in O
T2DM. O
The O
reference O
value O
of O
the O
estimated O
glomerular O
filtration O
rate O
(eGFR) O
was O
determined O
in O
248 O
healthy O
individuals. O
30 O
patients O
with O
GHF, O
58 O
patients O
with O

norm-GFR O
T2DM, O
and O
24 O
healthy O
patients O
who O
served O
as O
controls O
were O
recruited. O
Urinary O
Smad1, B-GENE-Y
fasting O
plasma O
glucose B-CHEMICAL
(FPG), O
fasting O
serum O
C-Peptide B-GENE-Y
(C-P), B-GENE-Y
hemoglobin B-GENE-Y
A1C I-GENE-Y
(HbA1c), B-GENE-Y
cystatin B-GENE-Y
C, I-GENE-Y
and O
other O
chemistry O
laboratory O
parameters O
of O
T2DM O
participants O
and O
controls O
were O
measured. O
Patients O
with O
GHF O
had O
higher O
levels O
of O
urinary O
Smad1 B-GENE-Y
than O
the O
control O
group, O
and O
those O
with O
norm-GFR. O
For O
T2DM O
patients O
with O
body O
mass O
index, O
age, O

and O
gender O
adjustments, O
urinary O
Smad1 B-GENE-Y
was O
positively O
correlated O
with O
FPG, O
HbA1C, B-GENE-Y
and O
eGFR, O
but O
negatively O
correlated O
with O
fasting O
serum O
C-P. B-GENE-N
Multivariate O
linear O
regression O
analysis O
demonstrated O
that O
eGFR, O
HbA1C, B-GENE-Y
and O
fasting O
serum O
C-P B-GENE-Y
were O
independently O
associated O
with O
urinary O
Smad1. B-GENE-Y
High O
levels O
of O
urinary O
Smad1 B-GENE-Y
were O
found O
in O
GHF O
patients O
with O
T2DM, O
which O
may O
be O
another O
potential O
mechanism O
of O
GHF O
in O
relation O
to O
diabetic O
nephropathy. O
Propranolol B-CHEMICAL
restores O

cognitive O
deficits O
and O
improves O
amyloid B-GENE-Y
and O
Tau B-GENE-Y
pathologies O
in O
a O
senescence-accelerated O
mouse O
model. O
Ageing O
is O
associated O
with O
a O
deterioration O
of O
cognitive O
performance O
and O
with O
increased O
risk O
of O
neurodegenerative O
disorders. O
Hypertension O
is O
the O
most-prevalent O
modifiable O
risk O
factor O
for O
cardiovascular O
morbidity O
and O
mortality O
worldwide, O
and O
clinical O
data O
suggest O
that O
hypertension O
is O
a O
risk O
factor O
for O
Alzheimer's O
disease O
(AD). O
In O
the O
present O
study O
we O
tested O
whether O
propranolol, B-CHEMICAL
a O
-receptor B-GENE-N
antagonist O
commonly O
used O
as O
antihypertensive O
drug, O
could O

ameliorate O
the O
cognitive O
impairments O
and O
increases O
in O
AD-related O
markers O
shown O
by O
the O
senescence-accelerated O
mouse O
prone-8 O
(SAMP8). O
Propranolol B-CHEMICAL
administration O
(5 O
mg/kg O
for O
3 O
weeks) O
to O
6-month-old O
SAMP8 O
mice O
attenuated O
cognitive O
memory O
impairments O
shown O
by O
these O
mice O
in O
the O
novel O
object O
recognition O
test. O
In O
the O
hippocampus O
of O
SAMP8 O
mice O
it O
has O
been O
found O
increases O
in O
A(42) B-GENE-Y
levels, O
the O
principal O
constituent O
of O
amyloid B-GENE-Y
plaques O
observed O
in O
AD, O
accompanied O
by O
both O
an O
increased O
expression O
of O
the O
cleaving O

enzyme O
BACE1 B-GENE-Y
and O
a O
decreased O
expression O
of O
the O
degrading O
enzyme O
IDE. B-GENE-Y
All O
these O
effects O
were O
reversed O
by O
propranolol B-CHEMICAL
treatment. O
Tau B-GENE-Y
hyperphosphorylation O
(PHF-1 O
epitope) O
shown O
by O
SAMP8 O
mice O
at O
this O
age O
was O
also O
decreased O
in O
the O
hippocampus O
of O
propranolol-treated B-CHEMICAL
mice, O
an O
effect O
probably O
related O
to O
a O
decrease O
in O
JNK1 B-GENE-Y
expression. O
Interestingly, O
propranolol B-CHEMICAL
also O
phosphorylated O
Akt B-GENE-N
in O
SAMP8 O
mice, O
which O
was O
associated O
with O
an O
increase O
of O
glycogen B-GENE-Y
synthase I-GENE-Y
kinase-3 I-GENE-Y

phosphorylation, O
contributing O
therefore O
to O
the O
reductions O
in O
Tau B-GENE-Y
hyperphosphorylation. O
Synaptic O
pathology O
in O
SAMP8 O
mice, O
as O
shown O
by O
decreases O
in O
synaptophysin B-GENE-Y
and O
BDNF, B-GENE-Y
was O
also O
counteracted O
by O
propranolol B-CHEMICAL
treatment. O
Overall, O
propranolol B-CHEMICAL
might O
be O
beneficial O
in O
age-related O
brain O
dysfunction O
and O
could O
be O
an O
emerging O
candidate O
for O
the O
treatment O
of O
other O
neurodegenerative O
diseases. O
This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
'Cognitive O
Enhancers'. O
Leydig O
cell O
hyperplasia O
and O

Leydig O
cell O
tumour O
in O
postmenopausal O
women: O
report O
of O
two O
cases. O
Leydig O
cell O
hyperplasia O
and O
Leydig O
cell O
tumours O
of O
the O
ovary O
are O
rare. O
We O
present O
two O
cases O
in O
which O
patients O
had O
increased O
blood O
levels O
of O
testosterone B-CHEMICAL
and O
frank O
hirsutism. O
Imaging O
showed O
minimal O
abnormalities. O
After O
adrenal O
disease O
had O
been O
ruled O
out, O
they O
underwent O
a O
bilateral O
oophorectomy. O
One O
case O
showed O
a O
Leydig O
cell O
hyperplasia, O
the O
other O
a O
Leydig O
cell O
tumour. O
An O
androgen B-CHEMICAL
producing O
tumour O
should O
be O
excluded O
in O
every O
woman O

with O
evidence O
of O
hirsutism O
or O
frank O
virilization O
and O
markedly O
elevated O
testosterone B-CHEMICAL
levels. O
Adrenal O
disease O
with O
androgen B-CHEMICAL
hypersecretion O
can O
be O
suspected O
by O
detailed O
clinical, O
laboratory O
and O
radiologic O
imaging. O
Although O
DHEAS B-CHEMICAL
has O
a O
good O
sensitivity O
in O
the O
detection O
of O
adrenal O
origin O
of O
hyperandrogenism O
(and O
hence O
a O
good O
negative O
predictive O
value) O
it O
is O
not O
specific O
(specificity O
ranging O
from O
85 O
to O
98%). O
Imaging O
of O
the O
ovaries O
can O
be O
helpful O
but O
does O
not O
rule O
out O
ovarian O
disease O
if O
normal. O
Indeed, O
diffuse O
stromal O

Leydig O
cell O
hyperplasia O
and O
Leydig O
cell O
tumours O
(usually O
small) O
may O
escape O
imaging O
and O
in O
some O
cases O
diagnosis O
can O
only O
be O
made O
on O
pathology. O
As O
these O
clinical O
entities O
represent O
a O
diagnostic O
and O
therapeutic O
challenge, O
oophorectomy O
should O
be O
considered O
in O
postmenopausal O
women O
with O
hirsutism O
and O
elevated O
testosterone B-CHEMICAL
levels, O
after O
the O
exclusion O
of O
adrenal O
causes. O
The O
procedure O
is O
relatively O
safe O
and O
effective. O
Follow-up O
remains O
indicated. O
Incretin B-GENE-Y
and O
pancreatic O
hormone O
secretion O
in O
Caucasian O
non-diabetic O
carriers O
of O
the O
TCF7L2 B-GENE-Y

rs7903146 O
risk O
T O
allele. O
We O
characterised O
62 O
non-diabetic, O
middle-aged, O
Caucasians O
with O
and O
without O
the O
T O
risk O
allele O
of O
rs7903146 O
in O
transcription B-GENE-Y
factor I-GENE-Y
7-like I-GENE-Y
2 I-GENE-Y
(TCF7L2) B-GENE-Y
with O
regard O
to O
secretion O
of O
insulin, B-GENE-Y
glucagon, B-GENE-Y
glucose-dependent B-CHEMICAL
insulinotropic I-GENE-Y
polypeptide I-GENE-Y
(GIP), B-GENE-Y
glucagon-like B-GENE-Y
peptide-1 I-GENE-Y
(GLP-1) B-GENE-Y
as O
well O
as O
insulin B-GENE-Y
sensitivity O
and O
endogenous O
glucose B-CHEMICAL
production. O
All O
participants O
had O
a O
3-h O
oral O
glucose B-CHEMICAL
tolerance O
test O

(OGTT), O
an O
intravenous O
glucose B-CHEMICAL
tolerance O
test O
and O
a O
euglycaemic, O
hyperinsulinaemic O
clamp. O
After O
adjustment O
for O
age O
and O
sex, O
risk O
T O
allele O
carriers O
had O
higher O
haemoglobin B-GENE-Y
A1c I-GENE-Y
levels O
(p O
= O
0.030), O
reduced O
first-phase O
insulin B-GENE-Y
response O
(p O
= O
0.048), O
higher O
peripheral O
insulin B-GENE-Y
sensitivity O
(p O
= O
0.050) O
and O
lower O
fasting O
GIP B-GENE-Y
concentrations O
(p O
= O
0.003) O
than O
CC O
allele O
carriers. O
The O
latter O
was O
also O
reflected O
by O
lower O
total O
GIP B-GENE-Y
secretion O
during O
the O

OGTT O
(p O
= O
0.018). O
We O
found O
no O
significant O
differences O
in O
endogenous O
glucose B-CHEMICAL
production, O
hepatic O
insulin B-GENE-Y
sensitivity O
or O
fasting O
concentrations O
of O
glucose, B-CHEMICAL
insulin, B-GENE-Y
glucagon B-GENE-Y
and O
GLP-1 B-GENE-Y
between O
the O
groups. O
The O
findings O
suggest O
that O
the O
effect O
of O
TCF7L2 B-GENE-Y
on O
diabetes O
risk O
may O
include O
reduced O
secretion O
of O
GIP. B-GENE-Y
Anti-inflammatory O
trends O
of O
1, B-CHEMICAL
3-diphenyl-2-propen-1-one I-CHEMICAL
derivatives. O
Chalcones B-CHEMICAL
(1, B-CHEMICAL
3-Diphenyl-2-propen-1-one) I-CHEMICAL
are O
constituted O
by O
a O
three O

carbon B-CHEMICAL
, B-CHEMICAL
-unsaturated I-CHEMICAL
carbonyl I-CHEMICAL
system. O
The O
biosynthesis O
of O
flavonoids B-CHEMICAL
and O
isoflavonoids B-CHEMICAL
is O
initiated O
by O
chalcones. B-CHEMICAL
Notable O
pharmacological O
activities O
of O
chalcones B-CHEMICAL
and O
its O
derivatives O
include O
anti-inflammatory, O
antifungal, O
antibacterial, O
antimalarial, O
antituberculosis, O
antitumor, O
antimicrobial O
and O
antiviral O
effects O
respectively. O
Owing O
to O
simplicity O
of O
the O
chemical O
structures O
and O
a O
huge O
variety O
of O
pharmacological O
actions O
exhibited, O
the O
entities O
derived O
from O
chalcones B-CHEMICAL
are O
subjected O
to O
extensive O

consideration. O
This O
review O
article O
is O
an O
effort O
to O
sum O
up O
the O
anti-inflammatory O
activities O
of O
chalcone B-CHEMICAL
derived O
chemical O
entities. O
Effect O
of O
chalcones B-CHEMICAL
on O
lipid O
peroxidation, O
heme B-GENE-Y
oxygenase I-GENE-Y
1(HO-1), I-GENE-Y
cyclooxygenase B-GENE-N
(COX), B-GENE-N
interleukin B-GENE-Y
5 I-GENE-Y
(IL-5), B-GENE-Y
nitric B-CHEMICAL
oxide I-CHEMICAL
(NO) B-CHEMICAL
and O
expression O
of O
cell O
adhesion O
molecules O
(CAM) O
is O
summarized O
stepwise. O
Oxysterol B-CHEMICAL
generation O
and O
liver B-GENE-N
X I-GENE-N
receptor-dependent I-GENE-N
reverse O
cholesterol B-CHEMICAL
transport: O
not O
all O
roads O
lead O
to O
Rome. O
Cell O

cholesterol B-CHEMICAL
metabolism O
is O
a O
tightly O
regulated O
process, O
dependent O
in O
part O
on O
activation O
of O
nuclear B-GENE-N
liver I-GENE-N
X I-GENE-N
receptors I-GENE-N
(LXRs) B-GENE-N
to O
increase O
expression O
of O
genes O
mediating O
removal O
of O
excess O
cholesterol B-CHEMICAL
from O
cells O
in O
the O
reverse O
cholesterol B-CHEMICAL
transport O
pathway. O
LXRs B-GENE-N
are O
thought O
to O
be O
activated O
predominantly O
by O
oxysterols B-CHEMICAL
generated O
enzymatically O
from O
cholesterol B-CHEMICAL
in O
different O
cell O
organelles. O
Defects O
resulting O
in O
slowed O
release O
of O
cholesterol B-CHEMICAL
from O
late O
endosomes O
and O
lysosomes O
or O
reduction O
in O
sterol-27-hydroxylase B-CHEMICAL
activity O
lead O
to O
specific O
blocks O
in O

oxysterol B-CHEMICAL
production O
and O
impaired O
LXR-dependent B-GENE-N
gene O
activation. O
This O
block O
does O
not O
appear O
to O
be O
compensated O
by O
oxysterol B-CHEMICAL
production O
in O
other O
cell O
compartments. O
The O
purpose O
of O
this O
review O
is O
to O
summarize O
current O
knowledge O
about O
oxysterol-dependent B-CHEMICAL
activation O
by O
LXR B-GENE-N
of O
genes O
involved O
in O
reverse O
cholesterol B-CHEMICAL
transport, O
and O
what O
these O
defects O
of O
cell O
cholesterol B-CHEMICAL
homeostasis O
can O
teach O
us O
about O
the O
critical O
pathways O
of O
oxysterol B-CHEMICAL
generation O
for O
expression O
of O
LXR-dependent B-GENE-N
genes. O
Assessment O
of O
developmental O
delay O
in O
the O
zebrafish O
embryo O
teratogenicity O

assay. O
In O
this O
study O
we O
analyzed O
some O
aspects O
of O
the O
assessment O
of O
developmental O
delay O
in O
the O
zebrafish O
embryotoxicity/teratogenicity O
test O
and O
explored O
the O
suitability O
of O
acetylcholinesterase B-GENE-Y
(AChE) B-GENE-Y
activity O
as O
a O
biochemical O
marker O
and O
as O
a O
higher O
throughput O
alternative O
to O
morphological O
endpoints O
such O
as O
head-trunk O
angle, O
tail O
length O
and O
morphological O
score. O
Embryos O
were O
exposed O
from O
4 O
to O
52 O
h O
post-fertilization O
(hpf) O
to O
a O
selection O
of O
known O
embryotoxic/teratogen O
compounds O

(valproic B-CHEMICAL
acid, I-CHEMICAL
retinoic B-CHEMICAL
acid, I-CHEMICAL
caffeine, B-CHEMICAL
sodium B-CHEMICAL
salicylate, I-CHEMICAL
glucose, B-CHEMICAL
hydroxyurea, B-CHEMICAL
methoxyacetic B-CHEMICAL
acid, I-CHEMICAL
boric B-CHEMICAL
acid I-CHEMICAL
and O
paraoxon-methyl) B-CHEMICAL
over O
a O
concentration O
range. O
They O
were O
evaluated O
for O
AChE B-GENE-Y
activity, O
head-trunk O
angle, O
tail O
length O
and O
several O
qualitative O
parameters O
integrated O
in O
a O
morphological O
score. O
In O
general, O
the O
different O
patterns O
of O
the O
concentration-response O
curves O
allowed O
distinguishing O
between O
chemicals O
that O
produced O
growth O
retardation O
(valproic B-CHEMICAL
and I-CHEMICAL
methoxyacetic I-CHEMICAL
acid) I-CHEMICAL
and O
chemicals O
that O
produced O

non-growth-delay O
related O
malformations. O
An O
acceptable O
correlation O
between O
the O
morphological O
score, O
AChE B-GENE-Y
activity O
and O
head-trunk O
angle O
as O
markers O
of O
developmental O
delay O
was O
observed, O
being O
AChE B-GENE-Y
activity O
particularly O
sensitive O
to O
detect O
delay O
in O
the O
absence O
of O
malformations. O
Cresyl B-CHEMICAL
saligenin I-CHEMICAL
phosphate I-CHEMICAL
makes O
multiple O
adducts O
on O
free O
histidine, B-CHEMICAL
but O
does O
not O
form O
an O
adduct O
on O
histidine B-CHEMICAL
438 O
of O
human B-GENE-Y
butyrylcholinesterase. I-GENE-Y
Cresyl B-CHEMICAL
saligenin I-CHEMICAL
phosphate I-CHEMICAL
(CBDP) B-CHEMICAL
is O
a O
suspected O
causative O
agent O
of O
"aerotoxic O

syndrome", O
affecting O
pilots, O
crew O
members O
and O
passengers. O
CBDP B-CHEMICAL
is O
produced O
in O
vivo O
from O
ortho-containing O
isomers O
of O
tricresyl B-CHEMICAL
phosphate I-CHEMICAL
(TCP), B-CHEMICAL
a O
component O
of O
jet O
engine O
lubricants O
and O
hydraulic O
fluids. O
CBDP B-CHEMICAL
irreversibly O
inhibits O
butyrylcholinesterase B-GENE-Y
(BChE) B-GENE-Y
in O
human O
plasma O
by O
forming O
adducts O
on O
the O
active O
site O
serine B-CHEMICAL
(Ser-198). B-CHEMICAL
Inhibited O
BChE B-GENE-Y
undergoes O
aging O
to O
release O
saligenin B-CHEMICAL
and O
o-cresol. B-CHEMICAL
The O
active O
site O
histidine B-CHEMICAL
(His-438) B-CHEMICAL

was O
hypothesized O
to O
abstract O
o-hydroxybenzyl B-CHEMICAL
moiety O
from O
the O
initial O
adduct O
on O
Ser-198. B-CHEMICAL
Our O
goal O
was O
to O
test O
this O
hypothesis. O
Mass O
spectral O
analysis O
of O
CBDP-inhibited B-CHEMICAL
BChE B-GENE-Y
digested O
with O
Glu-C B-CHEMICAL
showed O
an O
o-hydroxybenzyl B-CHEMICAL
adduct O
(+106amu) O
on O
lysine B-CHEMICAL
499, O
a O
residue O
far O
from O
the O
active O
site, O
but O
not O
on O
His-438. B-CHEMICAL
Nevertheless, O
the O
nitrogen B-CHEMICAL
of O
the O
imidazole B-CHEMICAL
ring O
of O
free O
l-histidine B-CHEMICAL
formed O
a O
variety O
of O
adducts O
upon O

reaction O
with O
CBDP, B-CHEMICAL
including O
the O
o-hydroxybenzyl B-CHEMICAL
adduct, O
suggesting O
that O
histidine-CBDP B-CHEMICAL
adducts O
may O
form O
on O
other O
proteins. O
The O
role O
of O
long O
chain O
omega-3 B-CHEMICAL
polyunsaturated I-CHEMICAL
fatty I-CHEMICAL
acids I-CHEMICAL
in O
reducing O
lipid O
peroxidation O
among O
elderly O
patients O
with O
mild O
cognitive O
impairment: O
a O
case-control O
study. O
The O
present O
work O
explores O
the O
effect O
of O
dietary O
omega-3 B-CHEMICAL
polyunsaturated I-CHEMICAL
fatty I-CHEMICAL
acids I-CHEMICAL
(PUFAs) B-CHEMICAL
intake O
on O
lipid O
peroxidation O
among O
mild O
cognitive O
impairment O
(MCI) O
patients. O

The O
plasma O
lipid O
hydroperoxide B-CHEMICAL
(LPO) O
levels O
in O
67 O
MCI O
patients O
were O
compared O
to O
those O
of O
134 O
healthy O
elderly O
controls. O
Omega-3 B-CHEMICAL
PUFA I-CHEMICAL
intake O
was O
assessed O
using O
an O
interviewer-administered O
food O
frequency O
questionnaire. O
Apolipoprotein B-GENE-Y
E I-GENE-Y
genotyping O
was O
performed O
using O
polymerase O
chain O
reaction O
and O
restriction O
enzyme O
digestion. O
The O
association O
between O
various O
confounders O
and O
lipid O
peroxidation O
was O
evaluated O
using O
regression O
analysis. O
The O
influence O
of O
docosahexaenoic B-CHEMICAL
acid I-CHEMICAL
(DHA) B-CHEMICAL
and O
eicosapentaenoic B-CHEMICAL
acid I-CHEMICAL
(EPA) B-CHEMICAL
intake O
on O
LPO O
level O
was O

investigated. O
The O
results O
revealed O
that O
LPO O
levels O
were O
significantly O
higher O
in O
the O
MCI O
group O
than O
in O
the O
control O
group. O
Inverse O
correlations O
were O
found O
between O
DHA B-CHEMICAL
and O
EPA B-CHEMICAL
intake O
and O
LPO O
level O
among O
the O
MCI O
group. O
LPO O
levels O
decreased O
significantly O
with O
increasing O
DHA B-CHEMICAL
and O
EPA B-CHEMICAL
intake. O
In O
summary, O
the O
findings O
revealed O
that O
DHA B-CHEMICAL
and O
EPA B-CHEMICAL
can O
play O
a O
role O
in O
alleviating O
oxidative O
stress O
and O
reducing O
the O
risk O
of O
neurodegenerative O
diseases. O
Vitamin B-CHEMICAL
E I-CHEMICAL
deficiency O
impairs O
the O
somatostatinergic B-GENE-N
receptor-effector I-GENE-N
system O
and O
leads O
to O
phosphotyrosine B-GENE-N

phosphatase I-GENE-N
overactivation O
and O
cell O
death O
in O
the O
rat O
hippocampus. O
Vitamin B-CHEMICAL
E I-CHEMICAL
plays O
an O
essential O
role O
in O
maintaining O
the O
structure O
and O
function O
of O
the O
nervous O
system, O
and O
its O
deficiency, O
commonly O
associated O
with O
fat O
malabsorption O
diseases, O
may O
reduce O
neuronal O
survival. O
We O
previously O
demonstrated O
that O
the O
somatostatinergic O
system, O
implicated O
in O
neuronal O
survival O
control, O
can O
be O
modulated O
by O
-tocopherol B-CHEMICAL
in O
the O
rat O
dentate O
gyrus, O
increasing O
cyclic B-GENE-N
adenosine I-GENE-N
monophosphate I-GENE-N
response I-GENE-N
element I-GENE-N
binding I-GENE-N
protein I-GENE-N
phosphorylation. O
To O
gain O
a O
better O
understanding O

of O
the O
molecular O
actions O
of O
tocopherols B-CHEMICAL
and O
examine O
the O
link O
among O
vitamin B-CHEMICAL
E, I-CHEMICAL
somatostatin B-GENE-Y
and O
neuronal O
survival, O
we O
have O
investigated O
the O
effects O
of O
a O
deficiency O
and O
subsequent O
administration O
of O
tocopherol B-CHEMICAL
on O
the O
somatostatin B-GENE-Y
signaling O
pathway O
and O
neuronal O
survival O
in O
the O
rat O
hippocampus. O
No O
changes O
in O
somatostatin B-GENE-Y
expression O
were O
detected O
in O
vitamin-E-deficient B-CHEMICAL
rats. O
These O
rats, O
however, O
showed O
a O
significant O
increase O
in O
the O
somatostatin B-GENE-N
receptor I-GENE-N
density O
and O
dissociation O
constant, O
which O
correlated O
with O
a O
significant O
increase O
in O
the O
protein O
levels O
of O
somatostatin B-CHEMICAL

receptors. I-GENE-N
Nevertheless, O
vitamin B-CHEMICAL
E I-CHEMICAL
deficiency O
impaired O
the O
ability O
of O
the O
somatostatin B-CHEMICAL
receptors I-GENE-N
to O
couple O
to O
the O
effectors O
adenylyl B-CHEMICAL
cyclase O
and O
phosphotyrosine B-CHEMICAL
phosphatase I-GENE-N
by O
diminishing O
Gi B-GENE-N
protein I-GENE-N
functionality. O
Furthermore, O
vitamin B-CHEMICAL
E I-CHEMICAL
deficiency O
significantly O
increased O
phosphotyrosine B-CHEMICAL
phosphatase I-GENE-N
activity O
and O
PTP B-GENE-Y
expression, O
as O
well O
as O
PKC B-GENE-Y
activation, O
and O
decreased O
extracellular-signal-regulated B-GENE-N
kinase I-GENE-N
phosphorylation. O
All O
these O
changes O
were O
accompanied O
by O
an O
increase O
in O
neuronal O
cell O
death. O
Subsequent O
-tocopherol B-CHEMICAL
administration O
partially O

or O
completely O
reversed O
all O
these O
values O
to O
control O
levels. O
Altogether, O
our O
results O
prove O
the O
importance O
of O
vitamin B-CHEMICAL
E I-CHEMICAL
homeostasis O
in O
the O
somatostatin B-GENE-N
receptor-effector I-GENE-N
system O
and O
suggest O
a O
possible O
mechanism O
by O
which O
this O
vitamin O
may O
regulate O
the O
neuronal O
cell O
survival O
in O
the O
adult O
hippocampus. O
CCAAT/Enhancer-binding B-GENE-Y
protein-homologous I-GENE-Y
protein I-GENE-Y
sensitizes O
to O
SU5416 B-CHEMICAL
by O
modulating O
p21 B-GENE-Y
and O
PI3K/Akt B-GENE-N
signal O
pathway O
in O
FRO O
anaplastic O
thyroid O
carcinoma O
cells. O
SU5416, B-CHEMICAL
vascular O

endothelial O
cell O
growth O
factor O
receptor O
inhibitor, O
suppresses O
hypoxia-induced O
angiogenesis, O
growth, O
proliferation, O
and O
metastasis O
in O
cancer O
cells. O
CCAAT/enhancer-binding B-GENE-Y
protein-homologous I-GENE-Y
protein I-GENE-Y
(CHOP) B-GENE-Y
has O
pivotal O
roles O
in O
regulation O
of O
growth O
and O
survival. O
In O
the O
present O
study, O
we O
evaluated O
the O
effects O
of O
SU5416 B-CHEMICAL
on O
cell O
survival, O
p21, B-GENE-Y
and O
PI3K/Akt B-GENE-N
signal O
pathway O
in O
FRO O
anaplastic O
thyroid O
carcinoma O
(ATC) O
cells. O
Moreover, O
we O
investigated O
the O
roles O
of O
CHOP B-GENE-Y
in O
cell O
survival O
under O
condition O

of O
SU5416 B-CHEMICAL
treatment O
in O
FRO O
ATC O
cells. O
After O
SU5416 B-CHEMICAL
treatment, O
cell O
viability, O
PARP-1, B-GENE-Y
and O
caspase-3 B-GENE-Y
protein O
levels O
were O
not O
changed. O
p53 B-GENE-Y
and O
p27 B-GENE-Y
protein O
levels O
decreased O
while O
p21 B-GENE-Y
protein O
levels O
increased. O
Phospho-Akt B-CHEMICAL
protein O
levels O
were O
not O
altered. O
In O
SU5416-treated B-CHEMICAL
situation, O
cell O
viability O
was O
not O
different O
before O
and O
after O
administration O
of O
either O
p21 B-GENE-Y
siRNA O
or O
LY294002 B-CHEMICAL
whereas O
it O
was O
lessened O
after O
co-administration O
of O
p21 B-GENE-Y
siRNA O
and O
LY294002. B-CHEMICAL

Compared O
to O
SU5416 B-CHEMICAL
treatment O
alone, O
cell O
viability O
was O
reduced O
with O
CHOP B-GENE-Y
plasmid O
but O
it O
was O
unchanged O
with O
CHOP B-GENE-Y
siRNA. O
PARP-1 B-GENE-N
and O
caspase-3 B-GENE-N
protein O
levels O
with O
CHOP B-GENE-Y
plasmid O
were O
elevated O
whereas O
the O
protein O
levels O
with O
CHOP B-GENE-Y
siRNA O
were O
similar. O
While O
CHOP B-GENE-Y
plasmid O
transfection O
diminished O
p21 B-GENE-Y
and O
phospho-Akt B-CHEMICAL
protein O
levels, O
CHOP B-GENE-Y
siRNA O
transfection O
did O
not O
alter O
the O
protein O
levels. O
In O
conclusion, O
these O
results O
suggest O
that O
CHOP B-GENE-Y
may O
sensitize O
FRO O
ATC O
cells O
to O

SU5416 B-CHEMICAL
thereby O
inhibiting O
cell O
survival O
by O
modulating O
p21 B-GENE-Y
and O
PI3K/Akt B-GENE-N
signal O
pathway. O
Furthermore, O
these O
findings O
imply O
that O
CHOP B-GENE-Y
may O
be O
a O
possible O
candidate O
as O
the O
chemosensitizing O
factor O
for O
induction O
of O
cytotoxicity O
in O
ATC O
cells O
exposed O
to O
SU5416. B-CHEMICAL
An O
overview O
of O
transcriptional O
regulation O
in O
response O
to O
toxicological O
insult. O
The O
completion O
of O
the O
human O
genome O
project O
and O
the O
subsequent O
advent O
of O
DNA O
microarray O
and O
high-throughput O
sequencing O
technologies O
have O
led O
to O
a O
renaissance O
in O
molecular O
toxicology. O
Toxicogenomic O

data O
sets, O
from O
both O
in O
vivo O
and O
in O
vitro O
studies, O
are O
growing O
exponentially, O
providing O
a O
wealth O
of O
information O
on O
regulation O
of O
stress O
pathways O
at O
the O
transcriptome O
level. O
Through O
such O
studies, O
we O
are O
now O
beginning O
to O
appreciate O
the O
diversity O
and O
complexity O
of O
biological O
responses O
to O
xenobiotics. O
In O
this O
review, O
we O
aim O
to O
consolidate O
and O
summarise O
the O
major O
toxicologically O
relevant O
transcription O
factor-governed O
molecular O
pathways. O
It O
is O
becoming O
clear O
that O
different O
chemical O
entities O
can O
cause O
oxidative, O
genotoxic O
and O
proteotoxic O
stress, O
which O
induce O
cellular O
responses O
in O
an O
effort O
to O
restore O

homoeostasis. O
Primary O
among O
the O
response O
pathways O
involved O
are O
NFE2L2 B-GENE-Y
(Nrf2), B-GENE-Y
NFE2L1 B-GENE-Y
(Nrf1), B-GENE-Y
p53, B-GENE-Y
heat B-GENE-N
shock I-GENE-N
factor I-GENE-N
and O
the O
unfolded O
protein O
response. O
Additionally, O
more O
specific O
mechanisms O
exist O
where O
xenobiotics O
act O
as O
ligands, O
including O
the O
aryl B-GENE-Y
hydrocarbon I-GENE-Y
receptor, I-GENE-Y
metal-responsive B-GENE-Y
transcription I-GENE-Y
factor-1 I-GENE-Y
and O
the O
nuclear B-GENE-N
receptor I-GENE-N
family O
of O
transcription O
factors. O
Other O
pathways O
including O
the O
immunomodulatory O
transcription O
factors O
NF-B B-GENE-N
and O
STAT B-GENE-N
together O
with O
the O
hypoxia-inducible B-GENE-N

transcription I-GENE-N
factor I-GENE-N
HIF B-GENE-N
are O
also O
implicated O
in O
cellular O
responses O
to O
xenobiotic O
exposure. O
A O
less O
specific O
but O
equally O
important O
aspect O
to O
cellular O
injury O
controlled O
by O
transcriptional O
activity O
is O
loss O
of O
tissue-specific O
gene O
expression, O
resulting O
in O
dedifferentiation O
of O
target O
cells O
and O
compromise O
of O
tissue O
function. O
Here, O
we O
review O
these O
pathways O
and O
the O
genes O
they O
regulate O
in O
order O
to O
provide O
an O
overview O
of O
this O
growing O
field O
of O
molecular O
toxicology. O
Cholinergic O
modulation O
by O
opioid B-GENE-N
receptor I-GENE-N
ligands: O
potential O
application O
to O
Alzheimer's O
disease. O
Morphinans B-CHEMICAL
have O
a O
storied O
history O
in O
medicinal O
chemistry O
as O
pain O
management O
drugs O
but O
have O
received O
attention O
as O

modulators O
of O
cholinergic O
signaling O
for O
the O
treatment O
of O
Alzheimer's O
Disease O
(AD). O
Galantamine B-CHEMICAL
is O
a O
reversible, O
competitive O
acetylcholinesterase B-GENE-Y
(AChE) B-GENE-Y
inhibitor O
and O
allosteric O
potentiating O
ligand O
of O
nicotinic B-GENE-N
acetylcholine B-CHEMICAL
receptors I-GENE-N
(nAChR-APL) B-GENE-N
that O
shares O
many O
common O
structural O
elements O
with O
morphinan-based B-CHEMICAL
opioids. O
The O
structurally O
diverse O
opioids O
codeine B-CHEMICAL
and O
eseroline, B-CHEMICAL
like O
galantamine, B-CHEMICAL
are O
also O
nAChR-APL B-GENE-N
that O
have O
greatly O
diminished O
affinity O
for O

AChE, B-GENE-Y
representing O
potential O
lead O
compounds O
for O
selective O
nAChR-APL B-GENE-N
development. O
In O
accordance O
with O
the O
emerging O
repurposing O
trend O
of O
evaluating O
known O
compounds O
for O
novel O
pharmacological O
activity, O
ongoing O
research O
on O
augmentation O
of O
cholinergic O
signaling O
that O
has O
been O
aided O
by O
the O
use O
of O
opioids O
will O
be O
reviewed. O
Adhesion O
of O
osteoblasts O
to O
a O
vertically O
aligned O
TiO2 B-CHEMICAL
nanotube O
surface. O
The O
adhesion O
of O
cells O
to O
vertically O
aligned O
TiO2 B-CHEMICAL
nanotubes O
is O
reviewed. O
The O
attraction O
between O
a O
negatively O
charged O
nanotube O
surface O
and O
a O
negatively O
charged O
osteoblast O
is O

facilitated O
by O
charged O
protein-mediators O
like O
proteins O
with O
a O
quadrupolar O
internal O
charge O
distribution, O
fibronectin B-GENE-Y
and O
vitronectin. B-GENE-Y
It O
is O
shown O
that O
adhesion O
and O
spreading O
of O
osteoblasts O
on O
vertically O
aligned O
TiO2 B-CHEMICAL
nanotube O
surfaces O
depend O
on O
the O
diameter O
of O
the O
nanotubes. O
Apparently, O
a O
small O
diameter O
nanotube O
surface O
has O
on O
average O
more O
sharp O
convex O
edges O
per O
unit O
area O
than O
a O
large O
one, O
leading O
to O
stronger O
binding O
affinity O
on O
its O
surface. O
Abnormal O
uterine O
bleeding O
and O
dysfunctional O
uterine O
bleeding O
in O
pediatric O
and O
adolescent O
gynecology. O

Abnormal O
uterine O
bleeding O
(AUB), O
which O
is O
defined O
as O
excessively O
heavy, O
prolonged O
and/or O
frequent O
bleeding O
of O
uterine O
origin, O
is O
a O
frequent O
cause O
of O
visits O
to O
the O
Emergency O
Department O
and/or O
health O
care O
provider. O
While O
there O
are O
many O
etiologies O
of O
AUB, O
the O
one O
most O
likely O
among O
otherwise O
healthy O
adolescents O
is O
dysfunctional O
uterine O
bleeding O
(DUB), O
which O
is O
characterizing O
any O
AUB O
when O
all O
possible O
underlying O
pathologic O
causes O
have O
been O
previously O
excluded. O
The O
most O
common O
cause O
of O
DUB O
in O
adolescence O
is O
anovulation, O
which O
is O
very O
frequent O

in O
the O
first O
2-3 O
post-menarchal O
years O
and O
is O
associated O
with O
immaturity O
of O
the O
hypothalamic O
- O
pituitary O
- O
ovarian O
axis. O
Management O
of O
AUB O
is O
based O
on O
the O
underlying O
etiology O
and O
the O
severity O
of O
the O
bleeding O
and O
primary O
goals O
are O
prevention O
of O
complications, O
such O
as O
anemia O
and O
reestablishment O
of O
regular O
cyclical O
bleeding, O
while O
the O
management O
of O
DUB O
can O
in O
part O
be O
directed O
by O
the O
amount O
of O
flow, O
the O
degree O
of O
associated O
anemia, O
as O
well O
as O
patient O
and O
family O
comfort O
with O
different O
treatment O
modalities. O
Treatment O
options O
for O
DUB O
are: O
combined O

oral O
contraceptives O
(COCs), O
progestogens, B-CHEMICAL
non O
steroidal O
anti O
inflammatory O
drugs O
(NSAIDs), O
tranexamic B-CHEMICAL
acid I-CHEMICAL
(anti-fibrinolytic), O
GnRH B-GENE-Y
analogues, O
Danazol B-CHEMICAL
and O
Levonorgestrel B-CHEMICAL
releasing O
intra O
uterine O
system O
(LNG O
IUS). O
Role O
of O
oestrogen B-GENE-Y
receptors I-GENE-Y
on O
the O
modulation O
of O
NADPH-diaphorase-positive B-GENE-N
cell O
number O
in O
supraoptic O
and O
paraventricular O
nuclei O
of O
ovariectomised O
female O
rats. O
Modulation O
of O
the O
nitric B-CHEMICAL

oxide I-CHEMICAL
producing O
system O
(demonstrated O
via O
the O
NADPH-diaphorase B-GENE-N
histochemical O
reaction) O
by O
oestradiol B-CHEMICAL
has O
been O
established O
in O
several O
structures O
of O
the O
rat O
brain. O
The O
present O
study O
aimed O
to O
explore O
the O
possible O
regulation O
of O
NADPH-diaphorase B-CHEMICAL
activity O
by O
oestradiol B-CHEMICAL
in O
neurones O
of O
the O
supraoptic O
(SON) O
and O
paraventricular O
(PVN) O
nuclei O
and O
the O
role O
of O
oestrogen B-CHEMICAL
receptors I-GENE-Y
(ER B-GENE-Y
and O
ER) B-GENE-Y
in O
this O
regulation. O
Adult O
ovariectomised O
rats O
were O
divided O
into O
six O
groups O
and O
injected O
either O
with O
vehicle O
or O
a O
single O

dose O
of O
oestradiol, B-CHEMICAL
a O
selective O
ER B-GENE-Y
agonist-PPT B-CHEMICAL
[4,4',4-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], B-CHEMICAL
a O
selective O
ER B-GENE-Y
agonist-DPN B-CHEMICAL
[2,3-bis(4-hydroxyphenyl)-propionitrile], B-CHEMICAL
a O
selective O
ER B-GENE-Y
antagonist-MPP B-CHEMICAL

[1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole B-CHEMICAL
dihydrochloride] I-CHEMICAL
or O
a O
selective O
ER B-GENE-Y
antagonist-PHTPP B-CHEMICAL
(4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol). B-CHEMICAL
The O
number O
of O

NADPH-diaphorase B-GENE-N
positive O
elements O
in O
the O
SON O
and O
the O
PVN O
was O
modulated O
by O
both O
ERs B-GENE-Y
but, O
depending O
on O
the O
nucleus, O
ER B-GENE-Y
and O
ER B-GENE-Y
ligands O
induced O
different O
effects. O
These O
results O
suggest O
that O
the O
regulation O
of O
nitrergic O
system O
by O
ERs B-GENE-Y
may O
play O
a O
role O
in O
the O
control O
of O
oestrogen-dependent B-CHEMICAL
physiological O
mechanisms O
regulated O
by O
the O
SON O
and O
the O
PVN. O
Human B-GENE-Y
plasma-derived I-GENE-Y
BuChE I-GENE-Y
as O
a O
stoichiometric O
bioscavenger O
for O
treatment O
of O
nerve O
agent O
poisoning. O
Potent O
organophosphorous B-CHEMICAL
(OP) O
agents, O

such O
as O
VX, O
are O
hazardous O
by O
absorption O
through O
the O
skin O
and O
are O
resistant O
to O
conventional O
pharmacological O
antidotal O
treatments. O
The O
residence O
time O
of O
a O
stoichiometric O
bioscavenger, O
human B-GENE-Y
butyrylcholinesterase I-GENE-Y
(huBuChE), B-GENE-Y
in O
the O
plasma O
more O
closely O
matches O
that O
of O
VX O
than O
do O
the O
residence O
times O
of O
conventional O
therapy O
drugs O
(oxime, B-CHEMICAL
anti-muscarinic, O
anticonvulsant). O
Intramuscular O
(i.m.) O
huBuChE B-GENE-Y
afforded O
almost O
complete O
protection O
when O
administered O
prior O
to O
the O
onset O
of O

observable O
cholinergic O
signs O
of O
VX O
poisoning, O
but O
once O
signs O
of O
poisoning O
became O
evident O
the O
efficacy O
of O
i.m. O
huBuChE B-GENE-Y
decreased. O
A O
combination O
of O
nerve O
agent O
therapy O
drugs O
(oxime, B-CHEMICAL
anti-muscarinic, O
anticonvulsant) O
with O
huBuChE B-GENE-Y
(i.m.) O
protected O
100% O
(8/8) O
of O
guinea-pigs O
from O
a O
lethal O
dose O
of O
VX O
(0.74mg/kg) O
to O
48h, O
even O
when O
administered O
on O
signs O
of O
poisoning. O
Survival O
was O
presumed O
to O
be O
due O
to O
immediate O

alleviation O
of O
the O
cholinergic O
crisis O
by O
the O
conventional O
pharmacological O
treatment O
drugs, O
in O
conjunction O
with O
bioscavenger O
that O
prevented O
further O
absorbed O
agent O
reaching O
the O
AChE B-GENE-Y
targets. O
Evidence O
to O
support O
this O
proposed O
mechanism O
of O
action O
was O
obtained O
from O
PKPD O
experiments O
in O
which O
multiple O
blood O
samples O
and O
microdialysate O
samples O
were O
collected O
from O
individual O
conscious O
ambulatory O
animals. O
Plasma O
concentrations O
of O
intramuscularly-administered O
atropine, B-CHEMICAL
diazepam B-CHEMICAL
and O
HI-6 B-CHEMICAL
reached O
a O
peak O
within O
15min O
and O
were O
eliminated O
rapidly O
within O
4h. O
Plasma O
concentrations O
of O
huBuChE B-GENE-Y
administered O

by O
the O
i.m. O
route O
took O
approximately O
24h O
to O
reach O
a O
peak, O
but O
were O
well-maintained O
over O
the O
subsequent O
7days. O
Thus, O
the O
pharmacological O
therapy O
rapidly O
treated O
the O
initial O
signs O
of O
poisoning, O
whilst O
the O
bioscavenger O
provided O
prolonged O
protection O
by O
neutralising O
further O
nerve O
agent O
entering O
the O
bloodstream O
and O
preventing O
it O
from O
reaching O
the O
target O
organs. O
Verrucarin B-CHEMICAL
A I-CHEMICAL
sensitizes O
TRAIL-induced B-GENE-Y
apoptosis O
via O
the O
upregulation O
of O
DR5 B-GENE-Y
in O
an O
eIF2/CHOP-dependent B-GENE-Y
manner. O
Tumor B-GENE-Y
necrosis I-GENE-Y
factor-related I-GENE-Y
apoptosis-inducing I-GENE-Y

ligand I-GENE-Y
(TRAIL) B-GENE-Y
is O
one O
of O
the O
most O
promising O
candidates O
for O
new O
cancer O
therapeutics. O
However, O
resistance O
to O
TRAIL B-GENE-Y
in O
some O
cancers O
remains O
a O
current O
problem O
in O
recent. O
The O
protein-folding O
compartment O
of O
the O
endoplasmic O
reticulum O
(ER) O
is O
particularly O
sensitive O
to O
disturbances, O
which, O
if O
severe, O
may O
trigger O
apoptosis. O
Therefore, O
we O
examined O
whether O
verrucarin B-CHEMICAL
A I-CHEMICAL
(VA) O
sensitize O
TRAIL-induced B-GENE-Y
apoptosis O
in O
cancer O
cells O
by O
induction O
of O
ER O
stress. O
We O
first O
found O
that O
VA O
induces O
a O
major O
molecule O
of O
ER O
stress, O

CCAAT/enhancer B-GENE-Y
binding I-GENE-Y
protein I-GENE-Y
homologous I-GENE-Y
protein I-GENE-Y
(CHOP)-dependent B-GENE-Y
DR5 B-GENE-N
induction O
and O
subsequently O
increases O
TRAIL-induced B-GENE-Y
cleavage O
of O
caspases B-GENE-N
and O
PARP B-GENE-N
in O
TRAIL-resistant B-GENE-Y
Hep3B O
cells. O
Importantly, O
the O
transient O
knockdown O
using O
siRNA O
for O
CHOP B-GENE-Y
abrogated O
VA-induced O
DR5 B-GENE-Y
expression O
and O
attenuated O
TRAIL-induced B-GENE-Y
apoptosis. O
Treatment O
with O
VA O
also O
increased O
the O
levels O
of O
phosphorylation O
of O
eukaryotic B-GENE-Y
translation I-GENE-Y
initiation I-GENE-Y
factor-2 I-GENE-Y
(eIF2), B-GENE-Y
which O
is O
a O
common O
cellular O
response O
of O

ER O
stress. O
Furthermore, O
salubrinal, B-CHEMICAL
a O
specific O
eIF2 B-GENE-Y
phosphorylation-inducing O
agent, O
increased O
CHOP B-GENE-Y
and O
DR5 B-GENE-Y
expression O
in O
the O
presence O
of O
VA. O
In O
contrast, O
transfection O
of O
mutant-eIF2 B-GENE-Y
significantly O
reversed O
VA-induced O
apoptosis O
with O
downregulation O
of O
CHOP-dependent B-GENE-Y
DR5 B-GENE-Y
expression. O
Therefore, O
VA-induced O
eIF2 B-GENE-Y
phosphorylation O
seemed O
to O
be O
important O
for O
CHOP B-GENE-Y
and O
DR5 B-GENE-Y
upregulation O
and O
TRAIL-induced B-GENE-Y
apoptosis. O
In O
addition, O
generation O
of O
reactive O
oxygen B-CHEMICAL
species O
(ROS) O
is O
an O

effector O
molecular O
in O
sensitization O
of O
VA-induced O
ER O
stress. O
We O
concluded O
that O
VA O
triggers O
TRAIL-induced B-GENE-Y
apoptosis O
by O
eIF2/CHOP-dependent B-GENE-Y
DR5 B-GENE-Y
induction O
via O
ROS O
generation. O
Proteolytic O
processing O
of O
osteopontin B-GENE-Y
by O
PHEX B-GENE-Y
and O
accumulation O
of O
osteopontin B-GENE-Y
fragments O
in O
Hyp O
mouse O
bone, O
the O
murine O
model O
of O
X-linked O
hypophosphatemia. O
X-linked O
hypophosphatemia O
(XLH/HYP)-with O
renal O
phosphate B-CHEMICAL
wasting, O
hypophosphatemia, O

osteomalacia, O
and O
tooth O
abscesses-is O
caused O
by O
mutations O
in O
the O
zinc-metallopeptidase B-CHEMICAL
PHEX B-GENE-Y
gene O
(phosphate-regulating B-CHEMICAL
gene O
with O
homologies O
to O
endopeptidase B-GENE-N
on O
the O
X O
chromosome). O
PHEX B-GENE-Y
is O
highly O
expressed O
by O
mineralized O
tissue O
cells. O
Inactivating O
mutations O
in O
PHEX B-GENE-Y
lead O
to O
distal O
renal O
effects O
(implying O
accumulation O
of O
a O
secreted, O
circulating O
phosphaturic O
factor) O
and O
accumulation O
in O
bone O
and O
teeth O
of O
mineralization-inhibiting, O
acidic B-GENE-N
serine- B-CHEMICAL
and I-GENE-N
aspartate-rich B-CHEMICAL
motif I-GENE-N
(ASARM)-containing B-GENE-N

peptides, O
which O
are O
proteolytically O
derived O
from O
the O
mineral-binding O
matrix O
proteins O
of O
the O
SIBLING B-GENE-N
family O
(small, B-GENE-N
integrin-binding I-GENE-N
ligand I-GENE-N
N-linked B-CHEMICAL
glycoproteins). I-GENE-N
Although O
the O
latter O
observation O
suggests O
a O
local, O
direct O
matrix O
effect O
for O
PHEX, B-GENE-Y
its O
physiologically O
relevant O
substrate O
protein(s) O
have O
not O
been O
identified. O
Here, O
we O
investigated O
two O
SIBLING B-GENE-N
proteins O
containing O
the O
ASARM B-GENE-N
motif-osteopontin I-GENE-N
(OPN) B-GENE-Y
and O
bone B-GENE-Y
sialoprotein I-GENE-Y
(BSP)-as B-GENE-Y
potential O
substrates O
for O
PHEX. B-GENE-Y
Using O

cleavage O
assays, O
gel O
electrophoresis, O
and O
mass O
spectrometry, O
we O
report O
that O
OPN B-GENE-Y
is O
a O
full-length O
protein O
substrate O
for O
PHEX. B-GENE-Y
Degradation O
of O
OPN B-GENE-Y
was O
essentially O
complete, O
including O
hydrolysis O
of O
the O
ASARM B-GENE-N
motif, I-GENE-N
resulting O
in O
only O
very O
small O
residual O
fragments. O
Western O
blotting O
of O
Hyp B-GENE-Y
(the O
murine O
homolog O
of O
human B-GENE-Y
XLH) I-GENE-Y
mouse O
bone O
extracts O
having O
no O
PHEX B-GENE-Y
activity O
clearly O
showed O
accumulation O
of O
an O
35 O
kDa O
OPN B-GENE-Y
fragment O
that O
was O
not O
present O
in O
wild-type O
mouse O
bone. O

Immunohistochemistry O
and O
immunogold O
labeling O
(electron O
microscopy) O
for O
OPN B-GENE-Y
in O
Hyp O
bone O
likewise O
showed O
an O
accumulation O
of O
OPN B-GENE-Y
and/or O
its O
fragments O
compared O
with O
normal O
wild-type O
bone. O
Incubation O
of O
Hyp O
mouse O
bone O
extracts O
with O
PHEX B-GENE-Y
resulted O
in O
the O
complete O
degradation O
of O
these O
fragments. O
In O
conclusion, O
these O
results O
identify O
full-length O
OPN B-GENE-Y
and O
its O
fragments O
as O
novel, O
physiologically O
relevant O
substrates O
for O
PHEX, B-GENE-Y
suggesting O
that O
accumulation O
of O
mineralization-inhibiting O
OPN B-GENE-Y
fragments O
may O
contribute O
to O
the O
mineralization O
defect O
seen O
in O
the O

osteomalacic O
bone O
characteristic O
of O
XLH/HYP. O
Targeted O
disruption O
of O
inducible B-GENE-Y
nitric B-CHEMICAL
oxide I-CHEMICAL
synthase I-GENE-Y
protects O
against O
aging, O
S-nitrosation, B-CHEMICAL
and O
insulin B-GENE-N
resistance O
in O
muscle O
of O
male O
mice. O
Accumulating O
evidence O
has O
demonstrated O
that O
S-nitrosation B-CHEMICAL
of O
proteins O
plays O
a O
critical O
role O
in O
several O
human O
diseases. O
Here, O
we O
explored O
the O
role O
of O
inducible B-GENE-Y
nitric B-CHEMICAL
oxide I-CHEMICAL
synthase I-GENE-Y
(iNOS) B-GENE-Y
in O
the O
S-nitrosation B-CHEMICAL
of O
proteins O
involved O
in O
the O
early O
steps O
of O
the O
insulin-signaling B-GENE-N
pathway O
and O
insulin B-GENE-N
resistance O
in O
the O
skeletal O
muscle O
of O
aged O
mice. O
Aging O

increased O
iNOS B-GENE-Y
expression O
and O
S-nitrosation B-CHEMICAL
of O
major O
proteins O
involved O
in O
insulin B-GENE-N
signaling, O
thereby O
reducing O
insulin B-GENE-N
sensitivity O
in O
skeletal O
muscle. O
Conversely, O
aged O
iNOS-null B-GENE-Y
mice O
were O
protected O
from O
S-nitrosation-induced B-CHEMICAL
insulin B-GENE-N
resistance. O
Moreover, O
pharmacological O
treatment O
with O
an O
iNOS B-GENE-Y
inhibitor O
and O
acute O
exercise O
reduced O
iNOS-induced B-GENE-Y
S-nitrosation B-CHEMICAL
and O
increased O
insulin B-GENE-N
sensitivity O
in O
the O
muscle O
of O
aged O
animals. O
These O
findings O
indicate O
that O
the O
insulin B-GENE-N
resistance O
observed O
in O
aged O
mice O
is O
mainly O
mediated O
through O
the O
S-nitrosation B-CHEMICAL
of O
the O
insulin-signaling B-GENE-N
pathway. O
Genetic O
correlate O
of O
cognitive O
training O
response O
in O

schizophrenia. O
Intensive O
computerized O
auditory O
training O
results O
in O
improved O
cognition O
for O
schizophrenia O
patients, O
but O
participants O
show O
variation O
in O
their O
cognitive O
gains O
and O
the O
biological O
factors O
that O
affect O
the O
response O
to O
training O
are O
unknown. O
Single O
nucleotide O
polymorphisms O
(SNPs) O
in O
the O
catechol-O-methyltransferase B-GENE-Y
(COMT) B-GENE-Y
gene O
have O
been O
related O
to O
cognitive O
function. O
Here O
we O
asked O
if O
functional O
variation O
in O
this O
gene O
has O
an O
impact O
on O
the O
response O
of O
schizophrenia O
patients O
to O
cognitive O
training. O
We O
genotyped O
48 O
schizophrenia O
patients O
who O
completed O
50 O
h O
of O
computerized O
cognitive O

training O
and O
analyzed O
the O
association O
between O
DNA O
variants O
in O
the O
COMT B-GENE-Y
gene O
and O
the O
improvement O
in O
global O
cognition. O
Although O
conventional O
analyses O
did O
not O
reveal O
any O
significant O
associations, O
a O
set-based O
analysis O
examining O
the O
aggregate O
effect O
of O
common O
variation O
in O
the O
COMT B-GENE-Y
gene O
(42 O
SNPs) O
suggested O
association O
with O
improvement O
in O
global O
cognition. O
Eight O
SNPs, O
mostly O
located O
in O
the O
3' O
end O
of O
the O
COMT B-GENE-Y
gene, O
were O
nominally O
associated O
with O
improvement O
in O
cognition. O
These O
data O
suggest O
that O
genotype O
influences O
the O
response O
to O
intensive O
cognitive O
training O
in O
schizophrenia, O
and O
may O
indicate O
that O
cognitive O
training O
regimens O
need O
to O
be O
personalized O
to O
the O
underlying O

biosignatures O
of O
each O
individual O
patient. O
This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
'Cognitive O
Enhancers'. O
Microtubule O
network O
is O
required O
for O
insulin-induced B-GENE-Y
signal O
transduction O
and O
actin O
remodeling. O
Both O
microtubule O
and O
actin B-GENE-N
are O
required O
for O
insulin-induced B-GENE-Y
glucose B-CHEMICAL
uptake. O
However, O
the O
roles O
of O
these O
two O
cytoskeletons O
and O
their O
relationship O
in O
insulin B-GENE-Y
action O
still O
remain O
unclear. O
In O
this O
work, O
we O
examined O
the O
morphological O
change O
of O
microtubule/actin B-GENE-N
and O
their O
involvement O
in O
insulin B-GENE-N
signal O
transduction O
using O
rat O
skeletal O
muscle O
cells. O
Insulin B-GENE-N
rapidly O
led O

to O
microtubule O
clustering O
from O
ventral O
to O
dorsal O
surface O
of O
the O
cell. O
Microtubule O
filaments O
were O
rearranged O
to O
create O
space O
where O
new O
actin B-GENE-N
structures O
formed. O
Disruption O
of O
microtubule O
prevented O
insulin-induced B-GENE-N
actin B-GENE-N
remodeling O
and O
distal O
insulin B-GENE-N
signal O
transduction, O
with O
reduction O
in O
surface O
glucose B-CHEMICAL
transporter I-GENE-Y
isoform I-GENE-Y
4 I-GENE-Y
(GLUT4) B-GENE-Y
and O
glucose B-CHEMICAL
uptake. O
Though O
microtubule O
mediated O
actin B-GENE-N
remodeling O
through O
PKC, B-GENE-Y
reorganization O
of O
microtubule O
depended O
on O
tyrosine B-CHEMICAL
phosphorylation O
of O
insulin B-GENE-Y
receptor, I-GENE-Y
the O
mechanism O
is O
different O
from O

insulin-induced B-GENE-N
actin B-GENE-N
remodeling, O
which O
relied O
on O
the O
activity O
of O
PI3-kinase B-GENE-N
and O
PKC. B-GENE-Y
We O
propose O
that O
microtubule O
network O
is O
required O
for O
insulin-induced B-GENE-N
signal O
transduction O
and O
actin B-GENE-N
remodeling O
in O
skeletal O
muscle O
cells. O
The O
influence O
of O
chronic O
fluorosis O
on O
mitochondrial O
dynamics O
morphology O
and O
distribution O
in O
cortical O
neurons O
of O
the O
rat O
brain. O
The O
present O
study O
was O
designed O
to O
evaluate O
the O
effects O
of O
chronic O
fluorosis O
on O
the O
dynamics O
(including O
fusion O
and O
fission O
proteins), O
fragmentation, O
and O
distribution O
of O
mitochondria O
in O
the O
cortical O
neurons O
of O
the O
rat O
brain O
in O
an O

attempt O
to O
elucidate O
molecular O
mechanisms O
underlying O
the O
brain O
damage O
associated O
with O
excess O
accumulation O
of O
fluoride. B-CHEMICAL
Sixty O
Sprague-Dawley O
rats O
were O
divided O
randomly O
into O
three O
groups O
of O
20 O
each, O
that O
is, O
the O
untreated O
control O
group O
(drinking O
water O
naturally O
containing O
<0.5 O
mg O
fluoride/l, B-CHEMICAL
NaF), B-CHEMICAL
the O
low-fluoride B-CHEMICAL
group O
(whose O
drinking O
water O
was O
supplemented O
with O
10 O
mg O
fluoride/l) B-CHEMICAL
and O
the O
high-fluoride B-CHEMICAL
group O
(50 O
mg O
fluoride/l). B-CHEMICAL
After O
6 O
months O
of O
exposure, O
the O
expression O
of O
mitofusin-1 B-GENE-Y

(Mfn1), B-GENE-Y
fission-1 B-GENE-Y
(Fis1), B-GENE-Y
and O
dynamin-related B-GENE-Y
protein-1 I-GENE-Y
(Drp1) B-GENE-Y
at O
both O
the O
protein O
and O
mRNA O
levels O
were O
detected O
by O
Western O
blotting, O
immunohistochemistry, O
and O
real-time O
PCR, O
respectively. O
Moreover, O
mitochondrial O
morphology O
and O
distribution O
in O
neurons O
were O
observed O
by O
transmission O
electron O
or O
fluorescence O
microscopy. O
In O
the O
cortices O
of O
the O
brains O
of O
rats O
with O
chronic O
fluorosis, O
the O
level O
of O
Mfn1 B-GENE-Y
protein O
was O
clearly O
reduced, O
whereas O
the O
levels O
of O
Fis1 B-GENE-Y
and O
Drp1 B-GENE-Y
were O
elevated. O

The O
alternations O
of O
expression O
of O
the O
mRNAs O
encoding O
all O
three O
of O
these O
proteins O
were O
almost O
the O
same O
as O
the O
corresponding O
changes O
at O
the O
protein O
levels. O
The O
mitochondria O
were O
fragmented O
and O
the O
redistributed O
away O
from O
the O
axons O
of O
the O
cortical O
neurons. O
These O
findings O
indicate O
that O
chronic O
fluorosis O
induces O
abnormal O
mitochondrial O
dynamics, O
which O
might O
in O
turn O
result O
in O
a O
high O
level O
of O
oxidative O
stress. O
Quantitative O
analysis O
of O
the O
interaction O
of O
constitutive B-GENE-N
androstane B-CHEMICAL
receptor I-GENE-N
with O
chemicals O
and O
steroid B-GENE-N
receptor I-GENE-N
coactivator I-GENE-N
1 I-GENE-N
using O
surface O
plasmon O
resonance O
biosensor O

systems: O
a O
case O
study O
of O
the O
Baikal O
seal O
(Pusa O
sibirica) O
and O
the O
mouse. O
The O
constitutive B-GENE-Y
androstane B-CHEMICAL
receptor I-GENE-Y
(CAR) B-GENE-Y
not O
only O
displays O
a O
high O
basal O
transcriptional O
activity O
but O
also O
acts O
as O
a O
ligand-dependent O
transcriptional O
factor. O
It O
is O
known O
that O
CAR B-GENE-Y
exhibits O
different O
ligand O
profiles O
across O
species. O
However, O
the O
mechanisms O
underlying O
CAR B-GENE-Y
activation O
by O
chemicals O
and O
the O
species-specific O
responses O
are O
not O
fully O
understood. O
The O
objectives O
of O
this O
study O
are O
to O
establish O
a O
high-throughput O
tool O
to O
screen O
CAR B-GENE-N
ligands O
and O
to O
clarify O
how O
CAR B-GENE-N
proteins O
from O
the O

Baikal O
seal O
(bsCAR) B-GENE-Y
and O
the O
mouse O
(mCAR) B-GENE-Y
interact O
with O
chemicals O
and O
steroid B-CHEMICAL
receptor I-GENE-N
coactivator I-GENE-N
1 I-GENE-N
(SRC1). B-GENE-N
We O
developed O
the O
surface O
plasmon O
resonance O
(SPR) O
system O
to O
assess O
quantitatively O
the O
interaction O
of O
CAR B-GENE-N
with O
potential O
ligands O
and O
SRC1. B-GENE-N
The O
ligand-binding O
domain O
(LBD) O
of O
bsCAR B-GENE-Y
and O
mCAR B-GENE-Y
was O
synthesized O
in O
a O
wheat O
germ O
cell-free O
system. O
The O
purified O
CAR B-GENE-N
LBD I-GENE-N
was O
then O
immobilized O
on O
the O
sensor O
chip O
for O
the O
SPR O

assay, O
and O
the O
kinetics O
of O
direct O
interaction O
of O
CARs B-GENE-N
with O
ligand O
candidates O
was O
measured. O
Androstanol B-CHEMICAL
and O
androstenol, B-CHEMICAL
estrone, B-CHEMICAL
17-estradiol, B-CHEMICAL
TCPOBOP, B-CHEMICAL
and O
CITCO B-CHEMICAL
showed O
compound-specific O
but O
similar O
affinities O
for O
both O
CARs. B-GENE-N
The O
CAR-SRC1 B-GENE-N
interaction O
was O
ligand O
dependent O
but O
exhibited O
a O
different O
ligand O
profile O
between O
the O
seal O
and O
the O
mouse. O
The O
results O
of O
SRC1 B-GENE-N
interaction O
assay O
accounted O
for O
those O
of O
our O
previous O
in O
vitro O
CAR-mediated B-GENE-N
transactivation O
assay. O
In O

silico O
analyses O
also O
supported O
the O
results O
of O
CAR-SRC1 B-GENE-N
interaction; O
there O
is O
little O
structural O
difference O
in O
the O
ligand-binding O
pocket O
of O
bsCAR B-GENE-Y
and O
mCAR, B-GENE-Y
but O
there O
is O
a O
distinct O
discrimination O
in O
the O
helix O
11 O
and O
12 O
of O
these O
receptors, O
suggesting O
that O
the O
interaction O
of O
ligand-bound O
CAR B-GENE-N
and O
SRC1 B-GENE-N
is O
critical O
for O
determining O
species-specific O
and O
ligand-dependent O
transactivation O
over O
the O
basal O
activity. O
The O
SPR O
assays O
demonstrated O
a O
potential O
as O
a O
high-throughput O
screening O
tool O
of O
CAR B-GENE-N
ligands. O
Studies O
on O
the O
antioxidant O
potential O
of O

flavones B-CHEMICAL
of O
Allium O
vineale O
isolated O
from O
its O
water-soluble O
fraction. O
The O
aim O
of O
this O
work O
was O
to O
examine O
the O
chemical O
constituents O
and O
antioxidant O
potential O
of O
water-soluble O
fractions O
from O
the O
commonly O
consumed O
vegetable, O
Allium O
vineale. O
The O
water-soluble O
fraction, O
containing O
phenolic O
compounds, O
was O
extracted O
with O
ethyl B-CHEMICAL
acetate I-CHEMICAL
to O
obtain O
flavonoids B-CHEMICAL
which O
were O
separated O
and O
purified O
by O
repeated O
column O
chromatography O
over O
Sephadex O
LH-20, O
RP O
C18 O
and O
silica B-CHEMICAL
gel. I-CHEMICAL
The O
isolated O
compounds O
were O
identified O
according O
to O
their O
physicochemical O
properties O
and O
spectral O
data O
(UV, O

HPLC-TOF/MS, O
(1)H B-CHEMICAL
NMR, O
(13)C B-CHEMICAL
NMR O
and O
2D O
NMR). O
Three O
flavonoids O
were O
isolated O
and O
identified O
as O
chrysoeriol-7-O-[2-O-E-feruloyl]--d-glucoside B-CHEMICAL
(1), O
chrysoeriol B-CHEMICAL
(2), O
and O
isorhamnetin-3--d-glucoside B-CHEMICAL
(3). O
Antioxidant O
studies O
of O
the O
aqueous O
extract O
and O
three O
isolated O
compounds, O
1, O
2, O
3, O
were O

undertaken O
and O
they O
were O
found O
to O
have O
significant O
antioxidant O
activity. O
Antioxidant O
activities O
were O
evaluated O
for O
total O
antioxidant O
activity O
by O
the O
ferric B-CHEMICAL
thiocyanate I-CHEMICAL
method, O
ferric B-CHEMICAL
ion O
(Fe(3+)) B-CHEMICAL
reducing O
antioxidant O
power O
assay O
(FRAP), O
ferrous B-CHEMICAL
ion O
(Fe(2+)) B-CHEMICAL
metal O
chelating O
activity, O
and O
DPPH B-CHEMICAL
free O
radical-scavenging O
activity. O
The O
water-soluble O
ethyl B-CHEMICAL
acetate I-CHEMICAL
and O
methanol B-CHEMICAL
extraction O
methods O
were O
also O
compared O
using O
HPLC-TOF/MS. O
Amino B-CHEMICAL
acid I-CHEMICAL
composition, O

antinutrients O
and O
allergens O
in O
the O
peanut O
protein O
fraction O
obtained O
by O
an O
aqueous O
enzymatic O
process. O
Enzyme-assisted O
aqueous O
extraction O
(EAE) O
of O
peanut O
kernel O
was O
used O
to O
extract O
oil O
and O
protein. O
The O
aqueous O
fraction O
(AF) O
obtained O
by O
EAE O
had O
a O
better O
essential O
amino B-CHEMICAL
acid I-CHEMICAL
profile O
than O
the O
residues O
obtained O
by O
solvent O
extraction O
(Rs) O
and O
cold O
pressing O
(Rc). O
No O
major O
difference O
in O
the O
trypsin B-GENE-N
inhibitor O
activity O
among O
AF, O
Rs O
and O
Rc O
was O
observed; O
however, O
the O
trypsin B-GENE-N
inhibitor O
activity O
was O
drastically O
reduced O
in O
the O
residue O
obtained O
after O

EAE. O
AF O
was O
subjected O
to O
MALDI-TOF/MS, O
revealing O
it O
to O
be O
rich O
in O
peptides O
(107) O
with O
molecular O
masses O
from O
m/z O
700 O
to O
2369Da. O
AF O
had O
an O
extremely O
low O
phytate B-CHEMICAL
content O
and O
was O
rich O
in O
peptides, O
which O
could O
be O
used O
as O
a O
food O
supplement. O
ESI-MS/MS O
data O
were O
used O
for O
the O
identification O
of O
major O
peanut B-GENE-N
allergens, I-GENE-N
viz., O
Ara B-GENE-N
h1, I-GENE-N
h3, I-GENE-N
h6-8. I-GENE-N
Their O
allergenic O
potential O
needs O
to O
be O
established. O
NMDA B-GENE-N
receptor I-GENE-N
blockade O
impairs O
the O

muscarinic O
conversion O
of O
sub-threshold O
transient O
depression O
into O
long-lasting O
LTD O
in O
the O
hippocampus-prefrontal O
cortex O
pathway O
in O
vivo: O
correlation O
with O
gamma O
oscillations. O
Cholinergic O
fibers O
from O
the O
brainstem O
and O
basal O
forebrain O
innervate O
the O
medial O
prefrontal O
cortex O
(mPFC) O
modulating O
neuronal O
activity O
and O
synaptic O
plasticity O
responses O
to O
hippocampal O
inputs. O
Here, O
we O
investigated O
the O
muscarinic O
and O
glutamatergic O
modulation O
of O
long-term O
depression O
(LTD) O
in O
the O
intact O
projections O
from O

CA1 O
to O
mPFC O
in O
vivo. O
Cortical-evoked O
responses O
were O
recorded O
in O
urethane-anesthetized B-CHEMICAL
rats O
for O
30 O
min O
during O
baseline O
and O
4 O
h O
following O
LTD. O
In O
order O
to O
test O
the O
potentiating O
effects O
of O
pilocarpine B-CHEMICAL
(PILO), B-CHEMICAL
independent O
groups O
of O
rats O
received O
either O
a O
microinjection O
of O
PILO B-CHEMICAL
(40 O
nmol; O
i.c.v.) O
or O
vehicle, O
immediately O
before O
or O
20 O
min O
after O
a O
sub-threshold O
LTD O
protocol O
(600 O
pulses, O
1 O
Hz; O
LFS600). O
Other O
groups O
received O
either O
an O
infusion O
of O

the O
selective O
NMDA B-GENE-N
receptor I-GENE-N
antagonist O
(AP7; B-CHEMICAL
10 O
nmol; O
intra-mPFC) O
or O
vehicle, O
10 O
min O
prior O
to O
PILO B-CHEMICAL
preceding O
LFS600, O
or O
prior O
to O
a O
supra-threshold O
LTD O
protocol O
(900 O
pulses, O
1 O
Hz; O
LFS900). O
Our O
results O
show O
that O
PILO B-CHEMICAL
converts O
a O
transient O
cortical O
depression O
induced O
by O
LFS600 O
into O
a O
robust O
LTD, O
stable O
for O
at O
least O
4 O
h. O
When O
applied O
after O
LFS600, O
PILO B-CHEMICAL
does O
not O
change O
either O
mPFC O
basal O
neurotransmission O
or O
late O

LTD. O
Our O
data O
also O
indicate O
that O
NMDA B-CHEMICAL
receptor I-GENE-N
pre-activation O
is O
essential O
to O
the O
muscarinic O
enhancement O
of O
mPFC O
synaptic O
depression, O
since O
AP7 B-CHEMICAL
microinjection O
into O
the O
mPFC O
blocked O
the O
conversion O
of O
transient O
depression O
into O
long-lasting O
LTD O
produced O
by O
PILO. B-CHEMICAL
In O
addition, O
AP7 B-CHEMICAL
effectively O
blocked O
the O
long-lasting O
LTD O
induced O
by O
LFS900. O
Therefore, O
our O
findings O
suggest O
that O
the O
glutamatergic O
co-activation O
of O
prefrontal O
neurons O
is O
important O
for O
the O
effects O
of O
PILO B-CHEMICAL
on O
mPFC O
synaptic O
depression, O

which O
could O
play O
an O
important O
role O
in O
the O
control O
of O
executive O
and O
emotional O
functions. O
Metabolism O
of O
triethylenetetramine B-CHEMICAL
and O
1,12-diamino-3,6,9-triazadodecane B-CHEMICAL
by O
the O
spermidine/spermine-N(1)-acetyltransferase B-GENE-Y
and O
thialysine B-GENE-N
acetyltransferase. I-GENE-N
Triethylenetetramine B-CHEMICAL
(TETA; B-CHEMICAL
Syprine; B-CHEMICAL
Merck O
Rahway, O
NJ), O
a O
drug O
for O
Wilson's O
disease, O
is O
a O
copper B-CHEMICAL
chelator O
and O
a O

charge-deficient O
analog O
of O
polyamine B-CHEMICAL
spermidine. B-CHEMICAL
We O
recently O
showed O
that O
TETA B-CHEMICAL
is O
metabolized O
in O
vitro O
by O
polyamine B-CHEMICAL
catabolic O
enzyme O
spermidine/spermine-N(1)-acetyltransferase B-GENE-Y
(SSAT1) B-GENE-Y
and O
by O
thialysine B-GENE-Y
acetyltransferase I-GENE-Y
(SSAT2) B-GENE-Y
to O
its O
monoacetylated O
derivative O
(MAT). O
The O
acetylation O
of O
TETA B-CHEMICAL
is O
increased O
in O
SSAT1-overexpressing B-GENE-Y
mice O
compared O
with O
wild-type O
mice. O
However, O
SSAT1-deficient B-GENE-Y
mice O

metabolize O
TETA B-CHEMICAL
at O
the O
same O
rate O
as O
the O
wild-type O
mice, O
indicating O
the O
existence O
of O
another O
N-acetylase B-GENE-N
respons O
2ible O
for O
its O
metabolism O
in O
mice. O
Here, O
we O
show O
that O
siRNA-mediated O
knockdown O
of O
SSAT2 B-GENE-Y
in O
HEPG2 O
cells O
and O
in O
primary O
hepatocytes O
from O
the O
SSAT1-deficient B-GENE-Y
or O
wild-type O
mice O
reduced O
the O
metabolism O
of O
TETA B-CHEMICAL
to O
MAT. O
By O
contrast, O
1,12-diamino-3,6,9-triazadodecane(SpmTrien), B-CHEMICAL
a O
charge-deficient O

spermine B-CHEMICAL
analog, O
was O
an O
extremely O
poor O
substrate O
of O
human B-GENE-Y
recombinant I-GENE-Y
SSAT2 I-GENE-Y
and O
was O
metabolized O
by O
SSAT1 B-GENE-Y
in O
HEPG2 O
cells O
and O
in O
wild-type O
primary O
hepatocytes. O
Thus, O
despite O
the O
similar O
structures O
of O
TETA B-CHEMICAL
and O
SpmTrien, B-CHEMICAL
SSAT2 B-GENE-Y
is O
the O
main O
acetylator O
of O
TETA, B-CHEMICAL
whereas O
SpmTrien B-CHEMICAL
is O
primarily O
acetylated O
by O
SSAT1. B-GENE-Y
In O
vitro O
metabolism O
of O
the O
5-hydroxytryptamine1B B-GENE-Y
receptor O
antagonist O
elzasonan. B-CHEMICAL
The O
metabolism O
of O
elzasonan B-CHEMICAL
has O
been O
examined O
in O

vitro O
using O
hepatic O
microsomes O
from O
human O
and O
recombinant O
heterologously O
expressed O
P450 B-GENE-N
enzymes I-GENE-N
(rCYP). B-GENE-N
Metabolism O
occurs O
primarily O
via O
oxidative O
N-demethylation B-CHEMICAL
to O
form O
M4 O
and O
oxidation O
reactions O
to O
form O
elzasonan B-CHEMICAL
N-oxide I-CHEMICAL
(M5) O
and O
5-hydroxyelzasonan B-CHEMICAL
metabolite O
(M3). O
Additionally, O
elzasonan B-CHEMICAL
was O
shown O
to O
be O
metabolized O
to O
the O
novel O
cyclized O
indole B-CHEMICAL
metabolite O
(M6) O
which O
undergoes O
subsequent O
oxidation O
to O
form O
the O

iminium B-CHEMICAL
ion O
metabolite O
(M3a). O
The O
rCYP B-GENE-N
data O
was O
normalized O
relative O
to O
the O
levels O
of O
each O
CYP B-GENE-N
form O
in O
native O
human O
liver O
microsomes O
to O
better O
assess O
the O
contribution O
of O
each O
rCYP B-GENE-N
in O
the O
metabolism O
of O
elzasonan. B-CHEMICAL
Results O
demonstrated O
the O
involvement O
of O
CYP3A4 B-GENE-Y
in O
the O
pathways O
leading O
to O
M3a, O
M3, O
M5 O
and O
M6 O
and O
CYP2C8 B-GENE-Y
in O
the O
formation O
of O
M4. O
Kinetic O
constants O
for O
the O
formation O
of O
M3 O
were O
determined O
and O
correlation O
and O
inhibition O
studies O
suggested O
that O
CYP3A4 B-GENE-Y
is O
primarily O
responsible O
for O

the O
formation O
of O
M3 O
and O
CYP2C19 B-GENE-Y
plays O
a O
very O
minor O
role O
in O
its O
formation. O
Cytochrome B-GENE-Y
b5 I-GENE-Y
has O
shown O
to O
be O
an O
essential O
component O
in O
P450 B-GENE-Y
3A4 I-GENE-Y
catalyzed O
5-hydroxyelzasonan B-CHEMICAL
formation O
and O
provides O
insights O
on O
the O
disconnect O
between O
human O
liver O
microsomes O
data O
and O
that O
of O
rCYP. B-GENE-N
Furthermore, O
rCYP3A4 B-GENE-Y
containing O
b5 O
are O
useful O
models O
for O
predicting O
the O
rates O
for O
liver O
microsomes O
P450-dependent B-GENE-N
drug O
oxidations O
and O
should O
be O
utilized O
routinely. O
Effective O
phagocytosis O
of O
low O
Her2 B-GENE-Y
tumor O
cell O

lines O
with O
engineered, O
aglycosylated B-GENE-N
IgG I-GENE-N
displaying O
high O
FcRIIa B-GENE-Y
affinity O
and O
selectivity. O
Glycans O
anchored O
to O
residue O
N297 O
of O
the O
antibody O
IgG B-GENE-N
Fc I-GENE-N
domain I-GENE-N
are O
critical O
in O
mediating O
binding O
toward O
FcRs B-GENE-N
to O
direct O
both O
adaptive O
and O
innate O
immune O
responses. O
However, O
using O
a O
full O
length O
bacterial B-GENE-N
IgG I-GENE-N
display O
system, O
we O
have O
isolated O
aglycosylated B-GENE-N
Fc I-GENE-N
domains I-GENE-N
with O
mutations O
that O
confer O
up O
to O
a O
160-fold O
increase O
in O
the O
affinity O
toward O
the O
low O
affinity O
FcRIIa-R131 B-GENE-Y
allele O
as O
well O
as O
high O

selectivity O
against O
binding O
to O
the O
remarkably O
homologous O
human O
inhibitory O
receptor, O
FcRIIb. B-GENE-Y
The O
mutant O
Fc B-GENE-N
domain I-GENE-N
(AglycoT-Fc1004) B-GENE-N
contained O
a O
total O
of O
5 O
amino B-CHEMICAL
acid I-CHEMICAL
substitutions O
that O
conferred O
an O
activating O
to O
inhibitory O
ratio O
of O
25 O
(A/I O
ratio; O
FcyRIIa-R131:FcRIIb). B-GENE-Y
Incorporation O
of O
this O
engineered O
Fc B-GENE-N
into O
trastuzumab, O
an O
anti-Her2 B-GENE-Y
antibody, O
resulted O
in O
a O
75% O
increase O
in O
tumor O
cell O
phagocytosis O
by O

macrophages O
compared O
to O
that O
of O
the O
parental O
glycosylated O
trastuzumab O
with O
both O
medium O
and O
low O
Her2-expressing B-GENE-Y
cancer O
cells. O
A O
mathematical O
model O
has O
been O
developed O
to O
help O
explain O
how O
receptor O
affinity O
and O
the O
A/I O
ratio O
relate O
to O
improved O
antibody O
dependent O
cell-mediated O
phagocytosis. O
Our O
model O
provides O
guidelines O
for O
the O
future O
engineering O
of O
Fc B-GENE-N
domains I-GENE-N
with O
enhanced O
effector O
function. O
Exposure O
to O
valproic B-CHEMICAL
acid I-CHEMICAL
inhibits O
chondrogenesis O
and O
osteogenesis O
in O
mid-organogenesis O
mouse O
limbs. O
In O
utero O
exposure O
to O
valproic B-CHEMICAL
acid I-CHEMICAL

(VPA), B-CHEMICAL
a O
histone B-GENE-N
deacetylase I-GENE-N
(HDAC) B-GENE-N
inhibitor, O
causes O
neural O
tube, O
heart, O
and O
limb O
defects. O
Valpromide B-CHEMICAL
(VPD), B-CHEMICAL
the O
amide B-CHEMICAL
derivative O
of O
VPA, B-CHEMICAL
does O
not O
inhibit O
HDAC B-GENE-N
activity O
and O
is O
a O
weak O
teratogen O
in O
vivo. O
The O
detailed O
mechanism O
of O
action O
of O
VPA B-CHEMICAL
as O
a O
teratogen O
is O
not O
known. O
The O
goal O
of O
this O
study O
was O
to O
test O
the O
hypothesis O
that O
VPA B-CHEMICAL
disrupts O
regulation O
of O
the O
expression O
of O
genes O
that O
are O
critical O
in O
chondrogenesis O
and O
osteogenesis O
during O
limb O
development. O
Murine O
gestation O
day-12 O

embryonic O
forelimbs O
were O
excised O
and O
exposed O
to O
VPA B-CHEMICAL
or O
VPD B-CHEMICAL
in O
a O
limb O
bud O
culture O
system. O
VPA B-CHEMICAL
caused O
a O
significant O
concentration- O
dependent O
increase O
in O
limb O
abnormalities, O
which O
was O
correlated O
with O
its O
HDAC B-GENE-N
inhibitory O
effect. O
The O
signaling O
of O
both O
Sox9 B-GENE-Y
and O
Runx2, B-GENE-Y
key O
regulators O
of O
chondrogenesis, O
was O
downregulated O
by O
VPA. B-CHEMICAL
In O
contrast, O
VPD B-CHEMICAL
had O
little O
effect O
on O
limb O
morphology O
and O
no O
significant O
effect O
on O
HDAC B-GENE-N
activity O
or O
the O
expression O
of O
marker O
genes. O
Thus, O
VPA B-CHEMICAL
exposure O
dysregulated O
the O
expression O
of O
target O
genes O
directly O
involved O
in O

chondrogenesis O
and O
osteogenesis O
in O
the O
developing O
limb. O
Disturbances O
in O
these O
signaling O
pathways O
are O
likely O
to O
be O
a O
consequence O
of O
HDAC B-GENE-N
inhibition O
because O
VPD B-CHEMICAL
did O
not O
affect O
their O
expressions. O
Tumor B-GENE-Y
necrosis I-GENE-Y
factor-alpha I-GENE-Y
potentiates O
the O
cytotoxicity O
of O
amiodarone B-CHEMICAL
in O
Hepa1c1c7 O
cells: O
roles O
of O
caspase B-GENE-N
activation O
and O
oxidative O
stress. O
Amiodarone B-CHEMICAL
(AMD), B-CHEMICAL
a O
class O
III O
antiarrhythmic O
drug, O
causes O
idiosyncratic O
hepatotoxicity O
in O
human O
patients. O
We O
demonstrated O
previously O

that O
tumor B-GENE-Y
necrosis I-GENE-Y
factor-alpha I-GENE-Y
(TNF-) B-GENE-Y
plays O
an O
important O
role O
in O
a O
rat O
model O
of O
AMD-induced B-CHEMICAL
hepatotoxicity O
under O
inflammatory O
stress. O
In O
this O
study, O
we O
developed O
a O
model O
in O
vitro O
to O
study O
the O
roles O
of O
caspase B-GENE-N
activation O
and O
oxidative O
stress O
in O
TNF B-GENE-Y
potentiation O
of O
AMD B-CHEMICAL
cytotoxicity. O
AMD B-CHEMICAL
caused O
cell O
death O
in O
Hepa1c1c7 O
cells, O
and O
TNF B-GENE-Y
cotreatment O
potentiated O
its O
toxicity. O
Activation O
of O
caspases B-GENE-N
9 I-GENE-N
and I-GENE-N
3/7 I-GENE-N
was O
observed O
in O

AMD/TNF-cotreated B-CHEMICAL
cells, O
and O
caspase O
inhibitors O
provided O
minor O
protection O
from O
cytotoxicity. O
Intracellular O
reactive O
oxygen B-CHEMICAL
species O
(ROS) O
generation O
and O
lipid O
peroxidation O
were O
observed O
after O
treatment O
with O
AMD B-CHEMICAL
and O
were O
further O
elevated O
by O
TNF B-GENE-Y
cotreatment. O
Adding O
water-soluble O
antioxidants O
(trolox, B-CHEMICAL
N-acetylcysteine, B-CHEMICAL
glutathione, B-CHEMICAL
or O
ascorbate) B-CHEMICAL
produced O
only O
minor O
attenuation O
of O
AMD/TNF-induced B-CHEMICAL
cytotoxicity O
and O
did O
not O
influence O
the O
effect O
of O
AMD B-CHEMICAL

alone. O
On O
the O
other O
hand, O
-tocopherol B-CHEMICAL
(TOCO), B-CHEMICAL
which O
reduced O
lipid O
peroxidation O
and O
ROS O
generation, O
prevented O
AMD B-CHEMICAL
toxicity O
and O
caused O
pronounced O
reduction O
in O
cytotoxicity O
from O
AMD/TNF B-CHEMICAL
cotreatment. O
-TOCO B-CHEMICAL
plus O
a O
pancaspase B-GENE-N
inhibitor O
completely O
abolished O
AMD/TNF-induced B-CHEMICAL
cytotoxicity. O
In O
summary, O
activation O
of O
caspases B-GENE-N
and O
oxidative O
stress O
were O
observed O
after O
AMD/TNF B-CHEMICAL
cotreatment, O
and O
caspase B-GENE-N
inhibitors O
and O
a O
lipid-soluble O
free-radical O

scavenger O
attenuated O
AMD/TNF-induced B-CHEMICAL
cytotoxicity. O
Amino B-CHEMICAL
acid I-CHEMICAL
residues O
at O
the O
N- O
and O
C-termini O
are O
essential O
for O
the O
folding O
of O
active O
human B-GENE-Y
butyrylcholinesterase I-GENE-Y
polypeptide. O
Human B-GENE-Y
serum I-GENE-Y
butyrylcholinesterase I-GENE-Y
(HuBChE) B-GENE-Y
is O
currently O
the O
most O
suitable O
bioscavenger O
for O
the O
prophylaxis O
of O
highly O
toxic O
organophosphate B-CHEMICAL
(OP) O
nerve O
agents. O
A O
dose O
of O
200mg O
of O
HuBChE B-GENE-Y
is O
envisioned O
as O
a O
prophylactic O
treatment O
that O
can O
protect O
humans O
from O
an O
exposure O
of O
up O

to O
2LD50 O
of O
soman. O
The O
limited O
availability O
and O
administration O
of O
multiple O
doses O
of O
this O
stoichiometric O
bioscavenger O
make O
this O
pretreatment O
difficult. O
Thus, O
the O
goal O
of O
this O
study O
was O
to O
produce O
a O
smaller O
enzymatically O
active O
HuBChE B-GENE-Y
polypeptide O
(HBP) O
that O
could O
bind O
to O
nerve O
agents O
with O
high O
affinity O
thereby O
reducing O
the O
dose O
of O
enzyme. O
Studies O
have O
indicated O
that O
the O
three-dimensional O
structure O
and O
the O
domains O
of O
HuBChE B-GENE-Y
(acyl B-CHEMICAL
pocket, O
lip O
of O
the O
active O
center O
gorge, O
and O
the O
anionic O
substrate-binding O
domain) O
that O
are O
critical O
for O

the O
binding O
of O
substrate O
are O
also O
essential O
for O
the O
selectivity O
and O
binding O
of O
inhibitors O
including O
OPs. O
Therefore, O
we O
designed O
three O
HBPs O
by O
deleting O
some O
N- O
and O
C-terminal O
residues O
of O
HuBChE B-GENE-Y
by O
maintaining O
the O
folds O
of O
the O
active O
site O
core O
that O
includes O
the O
three O
active O
site O
residues O
(S198, O
E325, O
and O
H438). O
HBP-4 B-GENE-N
that O
lacks O
45 O
residues O
from O
C-terminus O
but O
known O
to O
have O
BChE B-GENE-Y
activity O
was O
used O
as O
a O
control. O
The O
cDNAs O
for O
the O
HBPs O
containing O
signal O
sequences O
were O
synthesized, O
cloned O
into O
different O
mammalian O
expression O

vectors, O
and O
recombinant O
polypeptides O
were O
transiently O
expressed O
in O
different O
cell O
lines. O
No O
BChE B-GENE-Y
activity O
was O
detected O
in O
the O
culture O
media O
of O
cells O
transfected O
with O
any O
of O
the O
newly O
designed O
HBPs, O
and O
the O
inactive O
polypeptides O
remained O
inside O
the O
cells. O
Only O
enzymatically O
active O
HBP-4 B-GENE-N
was O
secreted O
into O
the O
culture O
medium. O
These O
results O
suggest O
that O
residues O
at O
the O
N- O
and O
C-termini O
are O
required O
for O
the O
folding O
and/or O
maintenance O
of O
HBP O
into O
an O
active O
stable, O
conformation. O
Claudin-3 B-GENE-Y
and O
claudin-4 B-GENE-Y
regulate O

sensitivity O
to O
cisplatin B-CHEMICAL
by O
controlling O
expression O
of O
the O
copper B-GENE-N
and I-GENE-N
cisplatin I-GENE-N
influx I-GENE-N
transporter I-GENE-N
CTR1. B-GENE-Y
Claudin-3 B-GENE-Y
(CLDN3) B-GENE-Y
and O
claudin-4 B-GENE-Y
(CLDN4) B-GENE-Y
are O
the O
major O
structural O
molecules O
that O
form O
tight O
junctions O
(TJs) O
between O
epithelial O
cells. O
We O
found O
that O
knockdown O
of O
the O
expression O
of O
either O
CLDN3 B-GENE-Y
or O
CLDN4 B-GENE-Y
produced O
marked O
changes O
in O
the O
phenotype O
of O
ovarian O
cancer O
cells, O
including O
an O
increase O
in O
resistance O
to O
cisplatin B-CHEMICAL
(cDDP). O
The O
effect O
of O

CLND3 B-GENE-Y
and O
CLDN4 B-GENE-Y
on O
cDDP O
cytotoxicity, O
cDDP O
cellular O
accumulation, O
and O
DNA O
adduct O
formation O
was O
compared O
in O
the O
CLDN3- B-GENE-Y
and O
CLDN4-expressing B-GENE-Y
parental O
human O
ovarian O
carcinoma O
2008 O
cells O
and O
CLDN3 B-GENE-Y
and O
CLDN4 B-GENE-Y
knockdown O
sublines O
(CLDN3KD B-GENE-Y
and O
CLDN4KD, B-GENE-Y
respectively). O
Knockdown O
of O
CLDN3 B-GENE-Y
or O
CLDN4 B-GENE-Y
rendered O
human O
ovarian O
carcinoma O
2008 O
cells O
resistant O
to O
cDDP O
in O
both O
in O
vitro O
culture O
and O
in O

vivo O
xenograft O
model. O
The O
net O
accumulation O
of O
platinum B-CHEMICAL
(Pt) B-CHEMICAL
and O
the O
Pt-DNA B-CHEMICAL
adduct O
levels O
were O
reduced O
in O
CLDN3KD B-GENE-Y
and O
CLDN4KD B-GENE-Y
cells. O
The O
endogenous O
mRNA O
levels O
of O
copper B-GENE-N
influx I-GENE-N
transporter I-GENE-N
CTR1 B-GENE-Y
were O
found O
to O
be O
significantly O
reduced O
in O
the O
knockdown O
cells, O
and O
exogenous O
expression O
of O
CTR1 B-GENE-Y
restored O
their O
sensitivity O
to O
cDDP. O
Reexpression O
of O
an O
shRNAi-resistant O
CLDN3 B-GENE-Y
or O
CLDN4 B-GENE-Y
up-regulated O
CTR1 B-GENE-Y
levels, O
reversed O
the O
cDDP O
resistance, O
and O

enhanced O
TJ O
formation O
in O
the O
knockdown O
cells. O
Baseline O
copper B-CHEMICAL
(Cu) B-CHEMICAL
level, O
Cu B-CHEMICAL
uptake, O
and O
Cu B-CHEMICAL
cytotoxicity O
were O
also O
reduced O
in O
CLDN3KD B-GENE-Y
and O
CLDN4KD B-GENE-Y
cells. O
Cu-dependent B-CHEMICAL
tyrosinase B-GENE-Y
activity O
was O
also O
markedly O
reduced O
in O
both O
types O
of O
CLDN B-GENE-N
knockdown O
cells O
when O
incubated O
with O
the O
substrate O
l-DOPA. B-CHEMICAL
These O
results O
indicate O
that O
CLDN3 B-GENE-Y
and O
CLDN4 B-GENE-Y
affect O
sensitivity O
of O
the O
ovarian O
cancer O
cells O
to O
the O
cytotoxic O
effect O
of O
cDDP O
by O
regulating O

expression O
of O
the O
Cu B-CHEMICAL
transporter I-GENE-N
CTR1. B-GENE-Y
Regulation O
of O
hepatic O
phase O
II O
metabolism O
in O
pregnant O
mice. O
Phase O
II O
enzymes, O
including O
Ugts, B-GENE-N
Sults, B-GENE-N
and O
Gsts, B-GENE-N
are O
critical O
for O
the O
disposition O
and O
detoxification O
of O
endo- O
and O
xenobiotics. O
In O
this O
study, O
the O
mRNA O
and O
protein O
expression O
of O
major O
phase O
II O
enzymes, O
as O
well O
as O
key O
regulatory O
transcription O
factors, O
were O
quantified O
in O
livers O
of O
time-matched O
pregnant O
and O
virgin O
control O
C57BL/6 O
mice O
on O
gestation O
days O
(GD) O
7, O
11, O
14, O
17, O
and O
postnatal O
days O

(PND) O
1, O
15, O
and O
30. O
Compared O
with O
virgin O
controls, O
the O
mRNA O
expression O
of O
Ugt1a1, B-GENE-N
1a6, I-GENE-N
1a9, I-GENE-N
2a3, I-GENE-N
2b1, I-GENE-N
2b34, I-GENE-N
and I-GENE-N
2b35 I-GENE-N
decreased O
40 O
to O
80% O
in O
pregnant O
dams. O
Protein O
expression O
of O
Ugt1a6 B-GENE-Y
also O
decreased O
and O
corresponded O
with O
reduced O
in O
vitro O
glucuronidation O
of O
bisphenol B-CHEMICAL
A I-CHEMICAL
in O
S9 O
fractions O
from O
livers O
of O
pregnant O
mice. O
Similar O
to O
Ugts B-GENE-N
levels, O
Gsta1 B-GENE-N
and I-GENE-N
a4 I-GENE-N
mRNAs O
were O
reduced O
in O
pregnant O
dams O
in O

mid O
to O
late O
gestation; O
however O
no O
change O
in O
protein O
expression O
was O
observed. O
Conversely, O
Sult1a1, B-GENE-N
2a1/2, I-GENE-N
and I-GENE-N
3a1 I-GENE-N
mRNAs O
increased O
100 O
to O
500% O
at O
various O
time O
points O
in O
pregnant O
and O
lactating O
mice O
and O
corresponded O
with O
enhanced O
in O
vitro O
sulfation O
of O
acetaminophen B-CHEMICAL
in O
liver O
S9 O
fractions. O
Coinciding O
with O
maximal O
decreases O
in O
Ugts B-GENE-N
as O
well O
as O
increases O
in O
Sults, B-GENE-N
the O
expression O
of O
transcription O
factors O
CAR, B-GENE-Y
PPAR, B-GENE-Y
and O
PXR B-GENE-Y
and O
their O
target O
genes O
were O
downregulated, O
whereas O

ER B-GENE-Y
mRNA O
was O
upregulated. O
Collectively, O
these O
data O
demonstrate O
altered O
regulation O
of O
hepatic O
phase O
II O
metabolism O
in O
mice O
during O
pregnancy O
and O
suggest O
that O
CAR, B-GENE-Y
PPAR, B-GENE-Y
PXR, B-GENE-Y
and O
ER B-GENE-Y
signaling O
pathways O
may O
be O
candidate O
signaling O
pathways O
responsible O
for O
these O
changes. O
Dimethylfumarate B-CHEMICAL
attenuates O
renal O
fibrosis O
via O
NF-E2-related B-GENE-Y
factor I-GENE-Y
2-mediated I-GENE-Y
inhibition O
of O
transforming B-GENE-Y
growth I-GENE-Y
factor-beta/Smad I-GENE-Y
signaling. O
TGF-beta B-GENE-Y
plays O
a O
key O
role O
in O
the O
development O
of O
renal O
fibrosis. O
Suppressing O
the O

TGF-beta B-GENE-Y
signaling O
pathway O
is O
a O
possible O
therapeutic O
approach O
for O
preventing O
this O
disease, O
and O
reports O
have O
suggested O
that O
Nrf2 B-GENE-Y
protects O
against O
renal O
fibrosis O
by O
inhibiting O
TGF-beta B-GENE-Y
signaling. O
This O
study O
examines O
whether O
dimethylfumarate B-CHEMICAL
(DMF), B-CHEMICAL
which O
stimulates O
Nrf2, B-GENE-Y
prevents O
renal O
fibrosis O
via O
the O
Nrf2-mediated B-GENE-Y
suppression O
of O
TGF-beta B-GENE-Y
signaling. O
Results O
showed O
that O
DMF B-CHEMICAL
increased O
nuclear O
levels O
of O
Nrf2, B-GENE-Y
and O
both O
DMF B-CHEMICAL
and O
adenovirus-mediated O
overexpression O
of O
Nrf2 B-GENE-Y
(Ad-Nrf2) B-GENE-Y
decreased O

PAI-1, B-GENE-Y
alpha-smooth B-GENE-Y
muscle I-GENE-Y
actin I-GENE-Y
(alpha-SMA), B-GENE-Y
fibronectin B-GENE-Y
and O
type B-GENE-N
1 I-GENE-N
collagen I-GENE-N
expression O
in O
TGF-beta-treated B-GENE-Y
rat O
mesangial O
cells O
(RMCs) O
and O
renal O
fibroblast O
cells O
(NRK-49F). O
Additionally, O
DMF B-CHEMICAL
and O
Ad-Nrf2 B-GENE-Y
repressed O
TGF-beta-stimulated B-GENE-Y
Smad3 B-GENE-Y
activity O
by O
inhibiting O
Smad3 B-GENE-Y
phosphorylation, O
which O
was O
restored O
by O
siRNA-mediated O
knockdown O
of O
Nrf2 B-GENE-Y
expression. O
However, O
downregulation O
of O
the O

antioxidant B-GENE-N
response I-GENE-N
element I-GENE-N
(ARE)-driven B-GENE-N
Nrf2 B-GENE-Y
target O
genes O
such O
as O
NQO1, B-GENE-Y
HO-1 B-GENE-Y
and O
glutathione B-CHEMICAL
S-transferase B-CHEMICAL
(GST) B-GENE-N
did O
not O
reverse O
the O
inhibitory O
effect O
of O
DMF B-CHEMICAL
on O
TGF-beta-induced B-GENE-Y
upregulation O
of O
profibrotic O
genes O
or O
extracellular O
matrix O
proteins, O
suggesting O
an O
ARE-independent B-GENE-N
anti-fibrotic O
activity O
of O
DMF. B-CHEMICAL
Finally, O
DMF B-CHEMICAL
suppressed O
unilateral O
ureteral O
obstruction O
(UUO)-induced O
renal O
fibrosis O
and O
alpha-SMA, B-GENE-Y

fibronectin B-GENE-Y
and O
type B-GENE-N
1 I-GENE-N
collagen I-GENE-N
expression O
in O
the O
obstructed O
kidneys O
from O
UUO O
mice, O
along O
with O
increased O
and O
decreased O
expression O
of O
Nrf2 B-GENE-Y
and O
phospho-Smad3, B-GENE-Y
respectively. O
In O
summary, O
DMF B-CHEMICAL
attenuated O
renal O
fibrosis O
via O
the O
Nrf2-mediated B-GENE-Y
inhibition O
of O
TGF-beta/Smad3 B-GENE-Y
signaling O
in O
an O
ARE-independent B-GENE-N
manner, O
suggesting O
that O
DMF B-CHEMICAL
could O
be O
used O
to O
treat O
renal O
fibrosis. O
The O
effect O
of O
CCL3 B-GENE-Y
and O
CCR1 B-GENE-Y
in O
bone O
remodeling O
induced O
by O
mechanical O
loading O
during O

orthodontic O
tooth O
movement O
in O
mice. O
Bone O
remodeling O
is O
affected O
by O
mechanical O
loading O
and O
inflammatory O
mediators, O
including O
chemokines. B-GENE-N
The O
chemokine B-GENE-Y
(C-C I-GENE-Y
motif) I-GENE-Y
ligand I-GENE-Y
3 I-GENE-Y
(CCL3) B-GENE-Y
is O
involved O
in O
bone O
remodeling O
by O
binding O
to O
C-C B-GENE-N
chemokine I-GENE-N
receptors I-GENE-N
1 I-GENE-N
and I-GENE-N
5 I-GENE-N
(CCR1 B-GENE-Y
and O
CCR5) B-GENE-Y
expressed O
on O
osteoclasts O
and O
osteoblasts. O
Our O
group O
has O
previously O
demonstrated O
that O
CCR5 B-GENE-Y
down-regulates O
mechanical O
loading-induced O
bone O
resorption. O
Thus, O
the O
present O
study O
aimed O
to O
investigate O

the O
role O
of O
CCR1 B-GENE-Y
and O
CCL3 B-GENE-Y
in O
bone O
remodeling O
induced O
by O
mechanical O
loading O
during O
orthodontic O
tooth O
movement O
in O
mice. O
Our O
results O
showed O
that O
bone O
remodeling O
was O
significantly O
decreased O
in O
CCL3(-/-) B-GENE-Y
and O
CCR1(-/-) B-GENE-Y
mice O
and O
in O
animals O
treated O
with O
Met-RANTES B-CHEMICAL
(an O
antagonist O
of O
CCR5 B-GENE-Y
and O
CCR1). B-GENE-Y
mRNA O
levels O
of O
receptor B-GENE-Y
activator I-GENE-Y
of I-GENE-Y
nuclear I-GENE-Y
factor I-GENE-Y
kappa-B I-GENE-Y
(RANK), B-GENE-Y
its O
ligand O
RANKL, B-GENE-Y
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
alpha I-GENE-Y

(TNF-) B-GENE-Y
and O
RANKL/osteoprotegerin B-GENE-Y
(OPG) B-GENE-Y
ratio O
were O
diminished O
in O
the O
periodontium O
of O
CCL3(-/-) B-GENE-Y
mice O
and O
in O
the O
group O
treated O
with O
Met-RANTES. B-CHEMICAL
Met-RANTES B-CHEMICAL
treatment O
also O
reduced O
the O
levels O
of O
cathepsin B-GENE-Y
K I-GENE-Y
and O
metalloproteinase B-GENE-Y
13 I-GENE-Y
(MMP13). B-GENE-Y
The O
expression O
of O
the O
osteoblast O
markers O
runt-related B-GENE-Y
transcription I-GENE-Y
factor I-GENE-Y
2 I-GENE-Y
(RUNX2) B-GENE-Y
and O
periostin B-GENE-Y
was O
decreased, O
while O
osteocalcin B-GENE-Y
(OCN) B-GENE-Y
was O
augmented O
in O

CCL3(-/-) B-GENE-Y
and O
Met-RANTES-treated B-CHEMICAL
mice. O
Altogether, O
these O
findings O
show O
that O
CCR1 B-GENE-Y
is O
pivotal O
for O
bone O
remodeling O
induced O
by O
mechanical O
loading O
during O
orthodontic O
tooth O
movement O
and O
these O
actions O
depend, O
at O
least O
in O
part, O
on O
CCL3. B-GENE-Y
Nano-graphene B-CHEMICAL
in O
biomedicine: O
theranostic O
applications. O
Owing O
to O
their O
unique O
physical O
and O
chemical O
properties, O
graphene B-CHEMICAL
and O
its O
derivatives O
such O
as O
graphene B-CHEMICAL
oxide I-CHEMICAL
(GO), O
reduced B-CHEMICAL
graphene I-CHEMICAL
oxide I-CHEMICAL
(RGO) B-CHEMICAL
and O
GO-nanocomposites O
have O
attracted O
tremendous O
interest O

in O
many O
different O
fields O
including O
biomedicine O
in O
recent O
years. O
With O
every O
atom O
exposed O
on O
its O
surface, O
single-layered O
graphene B-CHEMICAL
shows O
ultra-high O
surface O
area O
available O
for O
efficient O
molecular O
loading O
and O
bioconjugation, O
and O
has O
been O
widely O
explored O
as O
novel O
nano-carriers O
for O
drug O
and O
gene O
delivery. O
Utilizing O
the O
intrinsic O
near-infrared O
(NIR) O
optical O
absorbance, O
in O
vivo O
graphene-based B-CHEMICAL
photothermal O
therapy O
has O
been O
realized, O
achieving O
excellent O
anti-tumor O
therapeutic O
efficacy O
in O
animal O
experiments. O
A O
variety O
of O
inorganic O
nanoparticles O
can O
be O
grown O
on O
the O
surface O
of O
nano-graphene, B-CHEMICAL

obtaining O
functional O
graphene-based B-CHEMICAL
nanocomposites O
with O
interesting O
optical O
and O
magnetic O
properties O
useful O
for O
multi-modal O
imaging O
and O
imaging-guided O
cancer O
therapy. O
Moreover, O
significant O
efforts O
have O
also O
been O
devoted O
to O
study O
the O
behaviors O
and O
toxicology O
of O
functionalized O
nano-graphene B-CHEMICAL
in O
animals. O
It O
has O
been O
uncovered O
that O
both O
surface O
chemistry O
and O
sizes O
play O
key O
roles O
in O
controlling O
the O
biodistribution, O
excretion, O
and O
toxicity O
of O
nano-graphene. B-CHEMICAL
Biocompatibly O
coated O
nano-graphene B-CHEMICAL
with O
ultra-small O
sizes O
can O
be O
cleared O
out O
from O
body O
after O
systemic O
administration, O
without O
rendering O
noticeable O
toxicity O
to O
the O
treated O

mice. O
In O
this O
review O
article, O
we O
will O
summarize O
the O
latest O
progress O
in O
this O
rapidly O
growing O
field, O
and O
discuss O
future O
prospects O
and O
challenges O
of O
using O
graphene-based B-CHEMICAL
materials O
for O
theranostic O
applications. O
Human B-GENE-Y
ether-a-go-go-related I-GENE-Y
gene I-GENE-Y
channel O
blockers O
and O
its O
structural O
analysis O
for O
drug O
design. O
The O
human B-GENE-Y
ether-a-go-go-related B-CHEMICAL
gene I-GENE-Y
(hERG) B-GENE-Y
is O
a O
K+ B-CHEMICAL
channel I-GENE-N
protein O
mainly O
expressed O
in O
the O
heart O
and O
the O
nervous O
systems O
and O
its O
blockade O
by O
non-cardiovascular O
acting O
drugs O
resulted O
in O
tachycardia O
and O
sudden O
death. O
In O
this O
present O
review, O
we O
have O
focused O
the O

physicochemical O
properties O
responsible O
for O
the O
hERG B-GENE-Y
blocking O
activity O
of O
structurally O
different O
compounds. O
The O
reported O
research O
works O
showed O
that O
the O
hydrophobicity O
on O
the O
van O
der O
Waals O
(vdW) O
surface O
of O
the O
molecules O
(aroused O
from O
the O
aromatic O
ring) O
necessary O
for O
the O
hERG B-GENE-Y
blocking O
activity O
along O
with O
topological O
and O
electronic O
properties. O
The O
quinolizidine B-CHEMICAL
alkaloids I-CHEMICAL
(natural O
products) O
such O
as O
oxymatrine, B-CHEMICAL
sophoridine, B-CHEMICAL
sophocarpine B-CHEMICAL
and O
matrine B-CHEMICAL
carry O
the O
common O
molecular O
structure O
of O
O=C=N-C-C-C-N B-CHEMICAL
that O
possessed O
positive O

ionotropic O
effect O
and O
hERG B-GENE-Y
blocking O
activity. O
Acehytisine B-CHEMICAL
hydrochloride I-CHEMICAL
(previously O
named O
Guangfu B-CHEMICAL
base I-CHEMICAL
A) I-CHEMICAL
was O
isolated O
from O
the O
root O
of O
Aconitum O
coreanum O
(Levl.), O
is O
an O
anti-arrhythmic O
drug O
in O
phase O
IV O
clinical O
trial. O
The O
isoquinoline B-CHEMICAL
alkaloid, I-CHEMICAL
neferine B-CHEMICAL
(Nef) B-CHEMICAL
induces O
a O
concentration-dependent O
decrease O
in O
current O
amplitude O
(IC50 O
of O
7.419 O
MM). O
Most O
of O
these O
natural O
product O
compounds O
contain O
non-flexible O
aromatic O
structures O
but O
have O
significant O
activity O
due O
to O
the O
presence O
of O

optimum O
hydrophobicity. O
Recent O
research O
works O
revealed O
that O
Eag B-GENE-Y
and O
hERG B-GENE-Y
channels O
are O
expressed O
by O
a O
variety O
of O
cancer O
cell O
lines O
and O
tissues. O
The O
Eag B-GENE-Y
channel O
showed O
an O
oncogenic O
potential O
while O
hERG B-GENE-Y
channels O
are O
associated O
with O
more O
aggressive O
tumors O
and O
have O
a O
role O
in O
mediating O
invasion. O
This O
review O
concluded O
that O
the O
consideration O
of O
physicochemical O
properties O
necessary O
for O
the O
hERG B-GENE-Y
blocking O
activity O
will O
guide O
to O
develop O
novel O
drugs O
with O
less O
cardiotoxicity. O
Multifunctional O
targets O
of O
dietary O
polyphenols B-CHEMICAL
in O
disease: O
a O
case O
for O
the O
chemokine B-GENE-N
network O
and O
energy O
metabolism. O

Chronic, O
non-acute O
inflammation O
is O
behind O
conditions O
that O
represent O
most O
of O
the O
disease O
burden O
in O
humans O
and O
is O
clearly O
linked O
to O
immune O
and O
metabolic O
mechanisms. O
The O
convergence O
of O
pathways O
involving O
the O
immune O
response, O
oxidative O
stress, O
increased O
circulating O
lipids O
and O
aberrant O
insulin B-GENE-Y
signaling O
results O
in O
CCL2-associated B-GENE-Y
macrophage O
recruitment O
and O
altered O
energy O
metabolism. O
The O
CCL2/CCR2 B-GENE-Y
pathway O
and O
the O
energy O
sensor O
AMP-activated B-GENE-Y
protein I-GENE-Y
kinase I-GENE-Y
(AMPK) B-GENE-Y
are O
attractive O
therapeutic O
targets O
as O
a O
part O
of O
preventive O
management O
of O
disease. O
Several O
effects O
of O
polyphenols B-CHEMICAL
are O
useful O
in O
this O
scenario, O
including O
a O
reduction O
in O

the O
activities O
of O
cytokines B-GENE-N
and O
modulation O
of O
cellular O
metabolism O
through O
histone B-GENE-N
deacetylase I-GENE-N
inhibitors, O
AMPK B-GENE-Y
activators, O
calorie-restriction O
mimetics O
or O
epigenetic O
regulators. O
Research O
is O
currently O
underway O
to O
develop O
orally O
active O
drugs O
with O
these O
effects, O
but O
it O
is O
convenient O
to O
examine O
more O
closely O
what O
we O
are O
eating. O
If O
a O
lack O
of O
relevance O
in O
terms O
of O
toxicity O
and O
substantial O
effectiveness O
are O
confirmed, O
plant-derived O
components O
may O
provide O
useful O
druggable O
components O
and O
dietary O
supplements. O
We O
consider O
therapeutic O
actions O
as O
a O
combination O
of O
synergistic O
and/or O
antagonistic O
interactions O
in O
a O

multi-target O
strategy. O
Hence, O
improvement O
in O
food O
through O
enrichment O
with O
polyphenols B-CHEMICAL
with O
demonstrated O
activity O
may O
represent O
a O
major O
advance O
in O
the O
design O
of O
diets O
with O
both O
industrial O
and O
sanitary O
value. O
Inhibition O
of O
EGF/EGFR B-GENE-Y
activation O
with O
naphtho[1,2-b]furan-4,5-dione B-CHEMICAL
blocks O
migration O
and O
invasion O
of O
MDA-MB-231 O
cells. O
Naphtho[1,2-b]furan-4,5-dione B-CHEMICAL
(NFD), B-CHEMICAL
a O
bioactive O
component O
of O
Avicennia O
marina, O

has O
been O
demonstrated O
to O
display O
anti-cancer O
activity. O
Activation O
of O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(EGFR)-induced B-GENE-Y
signaling O
pathway O
has O
been O
correlated O
with O
cancer O
metastasis O
in O
various O
tumors, O
including O
breast O
carcinoma. O
We O
use O
EGF B-GENE-Y
as O
a O
metastatic O
inducer O
of O
MDA-MB-231 O
cells O
to O
investigate O
the O
effect O
of O
NFD B-CHEMICAL
on O
cell O
migration O
and O
invasion. O
NFD B-CHEMICAL
suppressed O
EGF-mediated B-GENE-Y
protein O
levels O
of O
c-Jun B-GENE-Y
and O
c-Fos, B-GENE-Y
and O
reduced O
MMP-9 B-GENE-Y
expression O
and O
activity, O
concomitantly O
with O
a O
marked O
inhibition O
on O
cell O
migration O
and O
invasion O

without O
obvious O
cellular O
cytotoxicity. O
NFD B-CHEMICAL
abrogated O
EGF-induced B-GENE-Y
phosphorylation O
of O
EGF B-GENE-Y
receptor I-GENE-Y
(EGFR) B-GENE-Y
and O
phosphatidylinositol B-CHEMICAL
3-kinase I-GENE-N
(PI3K)/Akt. B-GENE-N
The O
specific O
PI3K B-GENE-N
inhibitor, O
wortmannin, B-CHEMICAL
blocked O
significantly O
EGF-induced B-GENE-Y
cell O
migration O
and O
invasion. O
Furthermore, O
the O
EGFR B-GENE-Y
inhibitor O
AG1478 B-CHEMICAL
inhibited O
EGF-induced B-GENE-Y
MMP-9 B-GENE-Y
expression, O
cell O
migration O
and O
invasion, O
as O
well O
as O
the O
activation O
of O

PI3K/Akt, B-GENE-N
suggesting O
that O
PI3K/Akt B-GENE-N
activation O
occur O
downstream O
of O
EGFR B-GENE-Y
activation. O
These O
findings O
suggest O
that O
NFD B-CHEMICAL
inhibited O
the O
EGF-induced B-GENE-Y
invasion O
and O
migration O
of O
MDA-MB-231 O
cells O
via O
EGFR-dependent B-GENE-Y
PI3K/Akt B-GENE-N
signaling, O
leading O
to O
the O
down-regulation O
of O
MMP-9 B-GENE-Y
expression. O
These O
results O
provide O
a O
novel O
mechanism O
to O
explain O
the O
role O
of O
NFD B-CHEMICAL
as O
a O
potent O
anti-metastatic O
agent O
in O
MDA-MB-231 O
cells. O
A O
novel O
EPAC-specific B-GENE-Y
inhibitor O
suppresses O
pancreatic O

cancer O
cell O
migration O
and O
invasion. O
Exchange B-GENE-Y
protein I-GENE-Y
directly I-GENE-Y
activated I-GENE-Y
by I-GENE-Y
cAMP I-GENE-Y
(EPAC) B-GENE-Y
and O
cAMP-dependent B-CHEMICAL
protein I-GENE-N
kinase I-GENE-N
(PKA) B-GENE-N
are O
two O
intracellular O
receptors O
that O
mediate O
the O
effects O
of O
the O
prototypic O
second O
messenger O
cAMP. B-CHEMICAL
Identifying O
pharmacological O
probes O
for O
selectively O
modulating O
EPAC B-GENE-Y
activity O
represents O
a O
significant O
unmet O
need O
within O
the O
research O
field. O
Herein, O
we O
report O
the O
identification O
and O
characterization O
of O

3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile B-CHEMICAL
(ESI-09), B-CHEMICAL
a O
novel O
noncyclic O
nucleotide B-CHEMICAL
EPAC B-GENE-Y
antagonist O
that O
is O
capable O
of O
specifically O
blocking O
intracellular O
EPAC-mediated B-GENE-Y
Rap1 B-GENE-Y
activation O
and O
Akt B-GENE-N
phosphorylation, O
as O
well O
as O
EPAC-mediated B-GENE-Y
insulin B-GENE-Y
secretion O
in O
pancreatic O
 O
cells. O
Using O
this O
novel O
EPAC-specific B-GENE-Y
inhibitor, O
we O

have O
probed O
the O
functional O
roles O
of O
overexpression O
of O
EPAC1 B-GENE-Y
in O
pancreatic O
cancer O
cells. O
Our O
studies O
show O
that O
EPAC1 B-GENE-Y
plays O
an O
important O
role O
in O
pancreatic O
cancer O
cell O
migration O
and O
invasion, O
and O
thus O
represents O
a O
potential O
target O
for O
developing O
novel O
therapeutic O
strategies O
for O
pancreatic O
cancer. O
Metformin B-CHEMICAL
directly O
inhibits O
ghrelin B-GENE-Y
secretion O
through O
AMP-activated B-GENE-Y
protein I-GENE-Y
kinase I-GENE-Y
in O
rat O
primary O
gastric O
cells. O
The O
antidiabetic O
drug O
Metformin B-CHEMICAL
causes O
weight O
loss O
in O
both O
diabetic O
and O
non-diabetic O
individuals. O
Metformin B-CHEMICAL
treatment O
is O
also O
associated O
with O
lower O
circulating O
levels O
of O
the O

orexigenic B-GENE-N
hormone I-GENE-N
ghrelin. B-GENE-Y
To O
test O
whether O
Metformin B-CHEMICAL
directly O
affects O
ghrelin B-GENE-Y
cells, O
rat O
primary O
stomach O
cells O
were O
treated O
with O
Metformin B-CHEMICAL
and O
the O
levels O
of O
ghrelin B-GENE-Y
secretion, O
proghrelin B-GENE-Y
gene O
expression O
and O
activation O
of O
adenosine B-CHEMICAL
monophosphate-activated I-CHEMICAL
protein I-GENE-Y
kinase I-GENE-Y
(AMPK) B-GENE-Y
were O
examined. O
Metformin B-CHEMICAL
significantly O
reduced O
ghrelin B-GENE-Y
secretion O
and O
proghrelin B-GENE-Y
mRNA O
production O
and O
both O
these O
effects O
were O
blocked O
by O
co-incubation O
with O
the O
AMPK B-GENE-Y
inhibitor O
compound B-CHEMICAL
C. I-CHEMICAL
Furthermore, O
the O
AMPK B-GENE-Y
activator O

5-amino-1--D-ribofuranosyl-imidazole-4-carboxamide B-CHEMICAL
(AICAR) B-CHEMICAL
significantly O
inhibited O
ghrelin B-GENE-Y
secretion. O
Additionally, O
ghrelin B-GENE-Y
cells O
were O
shown O
to O
express O
AMPK. B-GENE-Y
Finally, O
Metformin B-CHEMICAL
treatment O
caused O
a O
significant O
increase O
in O
the O
level O
of O
phosphorylated B-GENE-Y
(active) I-GENE-Y
AMPK. I-GENE-Y
Our O
results O
show O
that O
Metformin B-CHEMICAL
directly O
inhibits O
stomach O
ghrelin B-GENE-Y
production O
and O
secretion O
through O
AMPK. B-GENE-Y
This O
reduction O
in O
ghrelin O
secretion O
may O
be O
one O
of O
the O
key O
components O
in O

Metformin's B-CHEMICAL
mechanism O
of O
weight O
loss. O
Fungicide O
prochloraz B-CHEMICAL
and O
environmental O
pollutant O
dioxin B-CHEMICAL
induce O
the O
ABCG2 B-GENE-Y
transporter O
in O
bovine O
mammary O
epithelial O
cells O
by O
the O
arylhydrocarbon B-GENE-Y
receptor I-GENE-Y
signaling O
pathway. O
The O
molecular O
mechanisms O
by O
which O
environmental O
pollutants O
including O
2,3,7,8-tetrachlorodibenzo-p-dioxin B-CHEMICAL
(TCDD) B-CHEMICAL
or O
widely O
used O
imidazole B-CHEMICAL
fungicide O
prochloraz B-CHEMICAL
display O
their O
toxic O
effects O
in O
vertebrates O
are O
still O
not O
well O
understood. O
Using O
computer O

analysis, O
we O
recently O
identified O
nuclear O
aryl B-CHEMICAL
hydrocarbon I-CHEMICAL
receptor I-GENE-Y
(AhR) B-GENE-Y
binding O
sites O
termed O
"dioxin B-GENE-N
response I-GENE-N
elements" I-GENE-N
(DREs) B-GENE-N
in O
the O
5'-untranslated O
region O
(5'-UTR) O
of O
efflux B-GENE-N
transporter I-GENE-N
ABCG2 B-GENE-Y
(Accession O
No. O
EU570105) B-GENE-Y
from O
the O
bovine O
mammary O
gland. O
As O
these O
regulatory O
motifs O
mediate O
regulation O
of O
target O
genes O
by O
AhR B-GENE-Y
agonists O
including O
TCDD B-CHEMICAL
and O
prochloraz, B-CHEMICAL
we O
have O
systematically O
investigated O
the O
effect O
of O
both O
contaminants O
on O
functional O
ABCG2 B-GENE-Y
transport O
activity O
in O
primary O

bovine O
mammary O
epithelial O
cells. O
TCDD B-CHEMICAL
or O
prochloraz B-CHEMICAL
doubled O
ABCG2-mediated B-GENE-Y
Hoechst B-CHEMICAL
H33342 I-CHEMICAL
secretion. O
This O
effect O
was O
almost O
completely O
reversed O
by O
specific O
ABCG2 B-GENE-Y
inhibitor O
Ko143. B-CHEMICAL
In O
further O
mechanistic O
studies, O
we O
showed O
that O
this O
induction O
was O
due O
to O
binding O
of O
activated O
AhR B-GENE-Y
to O
DRE B-GENE-N
sequences O
in O
the O
ABCG2 B-GENE-Y
5'-UTR. O
Receptor O
binding O
was O
significantly O
reduced O
by O
specific O
AhR B-GENE-Y
antagonist O
salicyl B-CHEMICAL
amide. I-CHEMICAL
Induction O
of O
AhR B-GENE-Y
by O
TCDD B-CHEMICAL
and O
prochloraz B-CHEMICAL
resulted O
in O
a O
time- O
and O

dose-dependent O
increase O
of O
ABCG2 B-GENE-Y
gene O
expression O
and O
transporter O
protein O
levels. O
As O
ABCG2 B-GENE-Y
represents O
the O
main O
mammary O
transporter O
for O
xenobiotics O
including O
drugs O
and O
toxins, O
exposure O
to O
prevalent O
AhR B-GENE-Y
agonists O
may O
enhance O
transporter-mediated O
secretion O
of O
potential O
harmful O
compounds O
into O
milk. O
Through O
identification O
of O
mammary O
ABCG2 B-GENE-Y
as O
a O
novel O
target O
gene O
of O
pesticide O
prochloraz B-CHEMICAL
and O
dioxin, B-CHEMICAL
our O
results O
may O
therefore O
help O
to O
improve O
the O
protection O
of O
breast-feeding O
infants O
and O
the O
consumer O
of O
dairy O
products. O
Molecular O
analyses O
of O
dinosaur O
osteocytes O
support O
the O
presence O
of O
endogenous O
molecules. O

The O
discovery O
of O
soft, O
transparent O
microstructures O
in O
dinosaur O
bone O
consistent O
in O
morphology O
with O
osteocytes O
was O
controversial. O
We O
hypothesize O
that, O
if O
original, O
these O
microstructures O
will O
have O
molecular O
features O
in O
common O
with O
extant O
osteocytes. O
We O
present O
immunological O
and O
mass O
spectrometry O
evidence O
for O
preservation O
of O
proteins O
comprising O
extant O
osteocytes O
(Actin, B-GENE-N
Tubulin, B-GENE-N
PHEX, B-GENE-N
Histone B-GENE-N
H4) I-GENE-N
in O
osteocytes O
recovered O
from O
two O
non-avian O
dinosaurs. O
Furthermore, O
antibodies O
to O
DNA O
show O
localized O
binding O
to O
these O
microstructures, O
which O
also O
react O
positively O
with O
DNA O
intercalating O
stains O

propidium B-CHEMICAL
iodide I-CHEMICAL
(PI) O
and O
4',6'-diamidino-2-phenylindole B-CHEMICAL
dihydrochloride I-CHEMICAL
(DAPI). B-CHEMICAL
Each O
antibody O
binds O
dinosaur O
cells O
in O
patterns O
similar O
to O
extant O
cells. O
These O
data O
are O
the O
first O
to O
support O
preservation O
of O
multiple O
proteins O
and O
to O
present O
multiple O
lines O
of O
evidence O
for O
material O
consistent O
with O
DNA O
in O
dinosaurs, O
supporting O
the O
hypothesis O
that O
these O
structures O
were O
part O
of O
the O
once O
living O
animals. O
We O
propose O
mechanisms O
for O
preservation O
of O
cells O
and O
component O
molecules, O
and O
discuss O
implications O
for O
dinosaurian O
cellular O
biology. O
Effects O
of O
silver B-CHEMICAL
nanoparticles O
on O
the O
liver O
and O

hepatocytes O
in O
vitro. O
With O
the O
increasing O
use O
and O
incorporation O
of O
nanoparticles O
(NPs) O
into O
consumer O
products, O
screening O
for O
potential O
toxicity O
is O
necessary O
to O
ensure O
customer O
safety. O
NPs O
have O
been O
shown O
to O
translocate O
to O
the O
bloodstream O
following O
inhalation O
and O
ingestion, O
and O
such O
studies O
demonstrate O
that O
the O
liver O
is O
an O
important O
organ O
for O
accumulation. O
Silver B-CHEMICAL
(Ag) B-CHEMICAL
NPs O
are O
highly O
relevant O
for O
human O
exposure O
due O
to O
their O
use O
in O
food O
contact O
materials, O
dietary O
supplements, O
and O
antibacterial O
wound O
treatments. O
Due O
to O
the O
large O
number O
of O
different O
NPs O
already O
used O
in O
various O
products O

and O
being O
developed O
for O
new O
applications, O
it O
is O
essential O
that O
relevant, O
quick, O
and O
cheap O
methods O
of O
in O
vitro O
risk O
assessment O
suitable O
for O
these O
new O
materials O
are O
established. O
Therefore, O
this O
study O
used O
a O
simple O
hepatocytes O
model O
combined O
with O
an O
in O
vivo O
injection O
model O
to O
simulate O
the O
passage O
of O
a O
small O
amount O
of O
NPs O
into O
the O
bloodstream O
following O
exposure, O
e.g., O
via O
ingestion O
or O
inhalation, O
and O
examined O
the O
potential O
of O
Ag B-CHEMICAL
NPs O
of O
20 O
nm O
diameter O
to O
cause O
toxicity, O
inflammation, O
and O
oxidative O
stress O
in O
the O
liver O
following O
in O
vivo O
exposures O
of O
female O

Wistar O
rats O
via O
iv O
injection O
to O
50 O
g O
of O
NPs O
and O
in O
vitro O
exposures O
using O
the O
human O
hepatocyte O
cell O
line O
C3A. O
We O
found O
that O
Ag B-CHEMICAL
NPs O
were O
highly O
cytotoxic O
to O
hepatocytes O
(LC(50) O
lactate B-CHEMICAL
dehydrogenase: I-GENE-N
2.5 O
g/cm(2)) O
and O
affected O
hepatocyte O
homeostasis O
by O
reducing O
albumin B-GENE-Y
release. O
At O
sublethal O
concentrations O
with O
normal O
cell O
or O
tissue O
morphology, O
Ag B-CHEMICAL
NPs O
were O
detected O
in O
cytoplasm O
and O
nuclei O
of O

hepatocytes. O
We O
observed O
similar O
effects O
of O
Ag B-CHEMICAL
NPs O
on O
inflammatory O
mediator O
expression O
in O
vitro O
and O
in O
vivo O
with O
increase O
of O
interleukin-8 B-GENE-Y
(IL-8)/macrophage B-GENE-Y
inflammatory I-GENE-N
protein I-GENE-N
2, I-GENE-N
IL-1RI, B-GENE-Y
and O
tumor B-GENE-Y
necrosis I-GENE-Y
factor- I-GENE-Y
expression O
in O
both O
models O
and O
increased O
IL-8 B-GENE-Y
protein O
release O
in O
vitro. O
This O
article O
presents O
evidence O
of O
the O
potential O
toxicity O
and O
inflammogenic O
potential O
of O
Ag B-CHEMICAL
NPs O
in O
the O
liver O
following O
ingestion. O
In O
addition, O
the O
similarities O
between O
in O
vitro O
and O
in O
vivo O
responses O
are O
striking O
and O
encouraging O

for O
future O
reduction, O
refinement, O
and O
replacement O
of O
animal O
studies O
by O
the O
use O
of O
hepatocyte O
cell O
lines O
in O
particle O
risk O
assessment. O
Extracellular B-GENE-N
loop I-GENE-N
II I-GENE-N
modulates O
GTP B-CHEMICAL
sensitivity O
of O
the O
prostaglandin B-GENE-Y
EP3 I-GENE-Y
receptor. I-GENE-Y
Unlike O
the O
majority O
of O
G B-GENE-N
protein-coupled I-GENE-N
receptors, I-GENE-N
the O
prostaglandin B-CHEMICAL
E(2) I-CHEMICAL
(PGE(2)) I-GENE-Y
E-prostanoid I-GENE-Y
3 I-GENE-Y
(EP3) I-GENE-Y
receptor I-GENE-Y
binds O
agonist O
with O
high O
affinity O
that O
is O
insensitive O
to O
the O
presence O
of O
guanosine B-CHEMICAL
5[prime]-O-(3-thio)triphosphate I-CHEMICAL

(GTPS). B-CHEMICAL
We O
report O
the O
identification O
of O
mutations O
that O
confer O
GTPS B-CHEMICAL
sensitivity O
to O
agonist O
binding. O
Seven O
point O
mutations O
were O
introduced O
into O
the O
conserved O
motif O
in O
the O
second B-GENE-N
extracellular I-GENE-N
loop I-GENE-N
(ECII) B-GENE-N
of O
EP3, B-GENE-Y
resulting O
in O
acquisition O
of O
GTP-sensitive B-CHEMICAL
agonist O
binding. O
One O
receptor O
mutation O
W203A B-GENE-N
was O
studied O
in O
detail. O
Loss O
of O
agonist O
binding O
was O
observed O
on O
intact O
human O
embryonic O
kidney O
293 O
cells O
expressing O
the O
W203A B-GENE-N
receptor, O
conditions O
where O
high O
GTP B-CHEMICAL
levels O
are O
present; O
however, O
high O
affinity O
binding O
[(3)H]PGE(2) B-CHEMICAL
was O
observed O

in O
broken O
cell O
preparations O
washed O
free O
of O
GTP. B-CHEMICAL
The O
[(3)H]PGE(2) B-CHEMICAL
binding O
of O
W203A B-GENE-N
in O
broken O
cell O
membrane O
fractions O
was O
inhibited O
by O
addition O
of O
GTPS B-CHEMICAL
(IC(50) O
21 O
 O
1.8 O
nM). O
Taken O
together, O
these O
results O
suggest O
that O
the O
wild-type O
EP3 B-GENE-Y
receptor O
displays O
unusual O
characteristics O
of O
the O
complex O
coupled O
equilibria O
between O
agonist-receptor O
and O
receptor-G B-GENE-N
protein I-GENE-N
interaction. O
Moreover, O
mutation O
of O
ECII B-GENE-N
can O
alter O
this O
coupled O
equilibrium O
from O
GTP-insensitive B-CHEMICAL
agonist O
binding O
to O
more O
conventional O
GTP-sensitive B-CHEMICAL

binding. O
This O
suggests O
that O
for O
the O
mutant O
receptors, O
ECII B-GENE-N
plays O
a O
critical O
role O
in O
linking O
the O
agonist O
bound O
receptor O
conformation O
to O
the O
G B-GENE-N
protein I-GENE-N
nucleotide B-CHEMICAL
bound O
state. O
Identification O
of O
Dlk1-Dio3 B-GENE-Y
imprinted O
gene O
cluster O
noncoding O
RNAs O
as O
novel O
candidate O
biomarkers O
for O
liver O
tumor O
promotion. O
The O
molecular O
events O
during O
nongenotoxic O
carcinogenesis O
and O
their O
temporal O
order O
are O
poorly O
understood O
but O
thought O
to O
include O
long-lasting O
perturbations O
of O
gene O
expression. O
Here, O
we O
have O
investigated O
the O
temporal O
sequence O
of O
molecular O
and O
pathological O
perturbations O
at O
early O
stages O
of O

phenobarbital B-CHEMICAL
(PB) O
mediated O
liver O
tumor O
promotion O
in O
vivo. O
Molecular O
profiling O
(mRNA, O
microRNA O
[miRNA], O
DNA O
methylation, O
and O
proteins) O
of O
mouse O
liver O
during O
13 O
weeks O
of O
PB O
treatment O
revealed O
progressive O
increases O
in O
hepatic O
expression O
of O
long O
noncoding O
RNAs O
and O
miRNAs O
originating O
from O
the O
Dlk1-Dio3 B-GENE-Y
imprinted O
gene O
cluster, O
a O
locus O
that O
has O
recently O
been O
associated O
with O
stem O
cell O
pluripotency O
in O
mice O
and O
various O
neoplasms O
in O
humans. O
PB O
induction O
of O
the O
Dlk1-Dio3 B-GENE-Y
cluster O

noncoding O
RNA O
(ncRNA) O
Meg3 O
was O
localized O
to O
glutamine B-CHEMICAL
synthetase-positive I-GENE-N
hypertrophic O
perivenous O
hepatocytes, O
suggesting O
a O
role O
for O
-catenin B-GENE-N
signaling O
in O
the O
dysregulation O
of O
Dlk1-Dio3 B-GENE-Y
ncRNAs. O
The O
carcinogenic O
relevance O
of O
Dlk1-Dio3 B-GENE-Y
locus O
ncRNA O
induction O
was O
further O
supported O
by O
in O
vivo O
genetic O
dependence O
on O
constitutive B-GENE-N
androstane I-GENE-N
receptor I-GENE-N
and O
-catenin B-GENE-N
pathways. O
Our O
data O
identify O
Dlk1-Dio3 B-GENE-Y
ncRNAs O

as O
novel O
candidate O
early O
biomarkers O
for O
mouse O
liver O
tumor O
promotion O
and O
provide O
new O
opportunities O
for O
assessing O
the O
carcinogenic O
potential O
of O
novel O
compounds. O
GH B-GENE-Y
improves O
spatial O
memory O
and O
reverses O
certain O
anabolic O
androgenic O
steroid-induced O
effects O
in O
intact O
rats. O
GH B-GENE-Y
has O
previously O
been O
shown O
to O
promote O
cognitive O
functions O
in O
GH-deficient B-GENE-Y
rodents. O
In O
this O
study O
we O
report O
the O
effects O
of O
GH B-GENE-Y
on O
learning O
and O
memory O
in O
intact O
rats O
pretreated O
with O
the O
anabolic O
androgenic O
steroid B-CHEMICAL
nandrolone. B-CHEMICAL
Male O
Wistar O
rats O
received O
nandrolone B-CHEMICAL
decanoate I-CHEMICAL
(15 O

mg/kg) O
or O
peanut O
oil O
every O
third O
day O
for O
3 O
weeks O
and O
were O
subsequently O
treated O
with O
recombinant O
human B-GENE-Y
GH I-GENE-Y
(1.0 O
IU/kg) O
or O
saline O
for O
10 O
consecutive O
days. O
During O
the O
GH/saline B-GENE-Y
treatment O
spatial O
learning O
and O
memory O
were O
tested O
in O
the O
Morris O
water O
maze O
(MWM). O
Also, O
plasma O
levels O
of O
IGF1 B-GENE-Y
were O
assessed O
and O
the O
gene O
expression O
of O
the O
GH B-GENE-Y
receptors I-GENE-Y
(Ghr), B-GENE-Y
Igf1 B-GENE-Y
and O
Igf2, B-GENE-Y
in O
hippocampus O
and O
frontal O
cortex O
was O
analyzed. O
The O
results O
demonstrated O
a O
significant O
positive O
effect O
of O
GH B-GENE-Y
on O
memory O
functions O

and O
increased O
gene O
expression O
of O
Igf1 B-GENE-Y
in O
the O
hippocampus O
was O
found O
in O
the O
animals O
treated O
with O
GH. B-GENE-Y
In O
addition, O
GH B-GENE-Y
was O
demonstrated O
to O
increase O
the O
body O
weight O
gain O
and O
was O
able O
to O
attenuate O
the O
reduced O
body O
weight O
seen O
in O
nandrolone-treated B-CHEMICAL
animals. O
In O
general, O
the O
rats O
treated O
with O
nandrolone B-CHEMICAL
alone O
did O
not O
exhibit O
any O
pronounced O
alteration O
in O
memory O
compared O
with O
controls O
in O
the O
MWM, O
and O
in O
many O
cases O
GH B-GENE-Y
did O
not O
induce O
any O
alteration. O
Regarding O
target O
zone O
crossings, O
considered O
to O
be O
associated O
with O
spatial O
memory, O
the O
difference O
between O
GH- B-GENE-Y
and O
steroid-treated O

animals O
was O
significant O
and O
administration O
of O
GH B-GENE-Y
improved O
this O
parameter O
in O
the O
latter O
group. O
In O
conclusion, O
GH B-GENE-Y
improves O
spatial O
memory O
in O
intact O
rats O
and O
can O
reverse O
certain O
effects O
induced O
by O
anabolic O
androgenic O
steroid. B-CHEMICAL
Phosphoinositide-dependent B-GENE-Y
kinase-1 I-GENE-Y
and O
protein B-GENE-Y
kinase I-GENE-Y
C I-GENE-Y
contribute O
to O
endothelin-1 B-GENE-Y
constriction O
and O
elevated O
blood O
pressure O
in O
intermittent O
hypoxia. O
Obstructive O
sleep O
apnea O
(OSA) O
is O
associated O
with O
cardiovascular O
complications O
including O
hypertension. O
Previous O
findings O
from O
our O
laboratory O
indicate O
that O
exposure O
to O
intermittent O
hypoxia O

(IH), O
to O
mimic O
sleep O
apnea, O
increases O
blood O
pressure O
in O
rats. O
IH O
also O
increases O
endothelin-1 B-GENE-Y
(ET-1) B-GENE-Y
constrictor O
sensitivity O
in O
a O
protein B-GENE-Y
kinase I-GENE-Y
C I-GENE-Y
(PKC) I-GENE-Y
-dependent I-GENE-Y
manner O
in O
mesenteric O
arteries. O
Because O
phosphoinositide-dependent B-GENE-Y
kinase-1 I-GENE-Y
(PDK-1) B-GENE-Y
regulates O
PKC B-GENE-Y
activity, O
we O
hypothesized O
that O
PDK-1 B-GENE-Y
contributes O
to O
the O
augmented O
ET-1 B-GENE-Y
constrictor O
sensitivity O
and O
elevated O
blood O
pressure O
following O
IH. O
Male O
Sprague-Dawley O
rats O
were O
exposed O

to O
either O
sham O
or O
IH O
(cycles O
between O
21% O
O(2)/0% B-CHEMICAL
CO(2) B-CHEMICAL
and O
5% O
O(2)/5% B-CHEMICAL
CO(2)) B-CHEMICAL
conditions O
for O
7 O
h/day O
for O
14 O
or O
21 O
days. O
The O
contribution O
of O
PKC B-GENE-Y
and O
PDK-1 B-GENE-Y
to O
ET-1-mediated B-GENE-Y
vasoconstriction O
was O
assessed O
in O
mesenteric O
arteries O
using O
pharmacological O
inhibitors. O
Constrictor O
sensitivity O
to O
ET-1 B-GENE-Y
was O
enhanced O
in O
arteries O
from O
IH-exposed O
rats. O
Inhibition O
of O
PKC B-GENE-Y
or O
PDK-1 B-GENE-Y
blunted O

ET-1 B-GENE-Y
constriction O
in O
arteries O
from O
IH O
but O
not O
sham O
group O
rats. O
Western O
analysis O
revealed O
similar O
levels O
of O
total O
and O
phosphorylated B-GENE-Y
PDK-1 I-GENE-Y
in O
arteries O
from O
sham O
and O
IH O
group O
rats O
but O
decreased O
protein-protein O
interaction O
between O
PKC B-GENE-Y
and O
PDK-1 B-GENE-Y
in O
arteries O
from O
IH- O
compared O
with O
sham-exposed O
rats. O
Blood O
pressure O
was O
increased O
in O
rats O
exposed O
to O
IH, O
and O
treatment O
with O
the O
PDK-1 B-GENE-Y
inhibitor O
OSU-03012 B-CHEMICAL

[2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide] B-CHEMICAL
(33 O
mg/day) O
lowered O
blood O
pressure O
in O
IH O
but O
not O
sham O
group O
rats. O
Our O
results O
suggest O
that O
exposure O
to O
IH O
unmasks O
a O
role O
for O
PDK-1 B-GENE-Y
in O
regulating O
ET-1 B-GENE-Y
constrictor O
sensitivity O
and O
blood O
pressure O
that O
is O
not O
present O
under O
normal O
conditions. O
These O
novel O
findings O
suggest O
that O
PDK-1 B-GENE-Y
may O

be O
a O
uniquely O
effective O
antihypertensive O
therapy O
for O
OSA O
patients. O
Intercellular B-GENE-Y
adhesion I-GENE-Y
molecule-2 I-GENE-Y
is O
involved O
in O
apical O
ectoplasmic O
specialization O
dynamics O
during O
spermatogenesis O
in O
the O
rat. O
In O
this O
study, O
we O
investigated O
the O
role O
of O
intercellular B-GENE-Y
adhesion I-GENE-Y
molecule-2 I-GENE-Y
(ICAM2) B-GENE-Y
in O
the O
testis. O
ICAM2 B-GENE-Y
is O
a O
cell O
adhesion O
protein O
having O
important O
roles O
in O
cell O
migration, O
especially O
during O
inflammation O
when O
leukocytes O
cross O
the O
endothelium. O
Herein, O
we O
showed O
ICAM2 B-GENE-Y
to O
be O
expressed O
by O
germ O
and O
Sertoli O
cells O
in O
the O
rat O

testis. O
When O
a O
monospecific O
antibody O
was O
used O
for O
immunolocalization O
experiments, O
ICAM2 B-GENE-Y
was O
found O
to O
surround O
the O
heads O
of O
elongating/elongated O
spermatids O
in O
all O
stages O
of O
the O
seminiferous O
epithelial O
cycle. O
To O
determine O
whether O
ICAM2 B-GENE-Y
is O
a O
constituent O
of O
apical O
ectoplasmic O
specialization O
(ES), O
co-immunoprecipitation O
and O
dual O
immunofluorescence O
staining O
were O
performed. O
Interestingly, O
ICAM2 B-GENE-Y
was O
found O
to O
associate O
with O
1-integrin, B-GENE-Y

nectin-3, B-GENE-Y
afadin, B-GENE-Y
Src, B-GENE-Y
proline-rich B-GENE-Y
tyrosine B-CHEMICAL
kinase I-GENE-Y
2, I-GENE-Y
annexin B-GENE-Y
II, I-GENE-Y
and O
actin. B-GENE-N
Following O
CdCl B-CHEMICAL
treatment, O
ICAM2 B-GENE-Y
was O
found O
to O
be O
upregulated O
during O
restructuring O
of O
the O
seminiferous O
epithelium, O
with O
round O
spermatids O
becoming O
increasingly O
immunoreactive O
for O
ICAM2 B-GENE-Y
by O
6-16 O
h. O
Interestingly, O
there O
was O
a O
loss O
in O
the O
binding O
of O
ICAM2 B-GENE-Y
to O
actin B-GENE-N
during O
CdCl-induced B-CHEMICAL
germ O
cell O
loss, O
suggesting O
that O
a O
loss O
of O

ICAM2-actin B-GENE-Y
interactions O
might O
have O
facilitated O
junction O
restructuring. O
Taken O
collectively, O
these O
results O
illustrate O
that O
ICAM2 B-GENE-Y
plays O
an O
important O
role O
in O
apical O
ES O
dynamics O
during O
spermatogenesis. O
The O
catalytic O
competence O
of O
cytochrome B-GENE-N
P450 I-GENE-N
in O
the O
synthesis O
of O
serotonin B-CHEMICAL
from O
5-methoxytryptamine B-CHEMICAL
in O
the O
brain: O
an O
in O
vitro O
study. O
Brain O
serotonin B-CHEMICAL
has O
been O
implicated O
in O
the O
pathophysiology O
of O
a O
wide O
spectrum O
of O
psychiatric O
disorders, O
as O
well O
as O
in O
the O
mechanism O
of O
action O
of O
psychotropic O
drugs. O
The O
aim O
of O
present O
study O
was O
to O

identify O
rat B-GENE-N
cytochrome I-GENE-N
P450 I-GENE-N
(CYP) B-GENE-N
isoforms O
which O
can O
catalyze O
the O
O-demethylation B-CHEMICAL
of O
5-methoxytryptamine B-CHEMICAL
to O
serotonin, B-CHEMICAL
and O
to O
find O
out O
whether O
that O
alternative O
pathway O
of O
serotonin B-CHEMICAL
synthesis O
may O
take O
place O
in O
the O
brain. O
The O
study O
was O
conducted O
on O
cDNA-expressed O
CYPs B-GENE-N
(rat B-GENE-N
CYP1A1/2, I-GENE-N
2A1/2, I-GENE-N
2B1, I-GENE-N
2C6/11/13, I-GENE-N
2D1/2/4/18, I-GENE-N
2E1, I-GENE-N
3A2 I-GENE-N
and O
human B-GENE-Y

CYP2D6), I-GENE-Y
on O
rat O
brain O
and O
liver O
microsomes O
and O
on O
human O
liver O
microsomes O
(the O
wild-type O
CYP2D6 B-GENE-N
or O
the O
allelic O
variant O
2D6*4*4). B-GENE-N
Of O
the O
rat B-GENE-N
CYP I-GENE-N
isoforms O
studied, O
CYP2D B-GENE-N
isoforms O
were O
the O
most O
efficient O
in O
catalyzing O
the O
O-demethylation B-CHEMICAL
of O
5-methoxytryptamine B-CHEMICAL
to O
serotonin, B-CHEMICAL
but O
they O
were O
less O
effective O
than O
the O
human B-GENE-Y
isoform I-GENE-Y
CYP2D6. I-GENE-Y
Microsomes O
from O
different O
brain O
regions O
were O
capable O
of O
metabolizing O

5-methoxytryptamine B-CHEMICAL
to O
serotonin. B-CHEMICAL
The O
reaction O
was O
inhibited O
by O
the O
specific O
CYP2D B-GENE-N
inhibitors O
quinine B-CHEMICAL
and O
fluoxetine. B-CHEMICAL
Human O
liver O
microsomes O
of O
the O
wild-type O
CYP2D6 B-GENE-Y
metabolized O
5-methoxytryptamine B-CHEMICAL
to O
serotonin B-CHEMICAL
more O
effectively O
than O
did O
the O
defective O
CYP2D6*4*4 B-GENE-Y
ones. O
The O
obtained O
results O
indicate O
that O
rat B-GENE-N
brain I-GENE-N
CYP2D I-GENE-N
isoforms O
catalyze O
the O
formation O
of O
serotonin B-CHEMICAL
from O
5-methoxytryptamine, B-CHEMICAL
and O
that O
the O
deficit O
or O

genetic O
defect O
of O
CYP2D B-GENE-N
may O
affect O
serotonin B-CHEMICAL
metabolism O
in O
the O
brain. O
The O
results O
are O
discussed O
in O
the O
context O
of O
their O
possible O
physiological O
and O
pharmacological O
significance O
in O
vivo. O
Estrogen B-CHEMICAL
receptor I-GENE-Y
signaling O
as O
a O
target O
for O
novel O
breast O
cancer O
therapeutics. O
In O
breast O
cancer O
(BC) O
epithelial O
cells, O
the O
mitogenic O
action O
of O
estradiol B-CHEMICAL
is O
transduced O
through O
binding O
to O
two O
receptors, O
ER B-GENE-Y
and O
ER, B-GENE-Y
which O
act O
as O
transcription O
factors. O
Anti-estrogens B-CHEMICAL
(AEs) O
and O
aromatase B-GENE-Y
inhibitors O
(AIs) O
are O
used O
clinically O
to O
arrest O
the O
estrogen-dependent B-CHEMICAL
growth O

of O
BC. O
In O
the O
case O
of O
AE O
or O
AI O
resistance, O
Herceptin O
or O
lapatinib B-CHEMICAL
may O
be O
used O
to O
inhibit O
growth O
factors. O
Estrogen B-CHEMICAL
effects O
are O
mediated O
not O
only O
through O
nuclear O
ERs B-GENE-Y
but O
also O
through O
cytoplasmic/membrane O
ERs B-GENE-Y
and O
G-protein-coupled B-GENE-N
ERs. B-GENE-Y
These O
estrogen-binding B-CHEMICAL
systems O
associate O
with O
various O
proteins O
that O
direct O
cell O
cycle O
signaling, O
proliferation O
and O
survival. O
The O
partners O
of O
nuclear O
ER B-GENE-Y
include O
SRC1-3, B-GENE-N
HDACs B-GENE-N
and O
ER B-GENE-Y
itself O
as O
well O
as O
newly O
identified O
proteins, O
such O
as O
E6-AP, B-GENE-Y
LKB1, B-GENE-Y

PELP1, B-GENE-Y
PAX-2 B-GENE-Y
and O
FOXA1. B-GENE-Y
The O
partners O
of O
extra-nuclear O
ER B-GENE-Y
include O
PI3K B-GENE-N
and O
the O
tyrosine B-CHEMICAL
kinase I-GENE-N
Src. B-GENE-Y
These O
various O
factors O
are O
all O
potential O
targets O
for O
therapeutic O
intervention. O
In O
addition, O
BC O
proliferation O
is O
enhanced O
by O
insulin B-GENE-Y
and O
EGF, B-GENE-Y
which O
stimulate O
signaling O
through O
the O
MAPK B-GENE-N
and O
PI3K/AKT B-GENE-N
pathways O
by O
activation O
of O
the O
IGF-1R B-GENE-Y
and O
EGFR B-GENE-Y
axes, O
respectively. O
These O
pathways O
are O
tightly O
interconnected O
with O
ER-activated B-GENE-Y
signaling, O
and O
membrane O
ER B-GENE-Y
forms O
complexes O
with O
Src B-GENE-Y
and O
PI3K. B-GENE-N

Chemokine-mediated B-GENE-N
signaling O
also O
modulates O
the O
estrogen B-CHEMICAL
response. O
Inhibiting O
these O
pathways O
with O
specific O
inhibitors O
or O
activating O
some O
of O
the O
pathways O
by O
gene O
manipulation O
may O
be O
therapeutically O
valuable O
for O
arresting O
BC O
cell O
cycle O
progression O
and O
for O
inducing O
apoptosis O
to O
antagonize O
hormone-resistance. O
Here, O
we O
review O
some O
newly O
identified O
putatively O
targetable O
ER B-GENE-Y
partners O
and O
highlight O
the O
need O
to O
develop O
tumor-targeting O
drug O
carrier O
systems O
affecting O
both O
the O
tumor O
cells O
and O
the O
tumor O
environment. O
Toosendanin B-CHEMICAL
induces O
apoptosis O
through O
suppression O
of O
JNK B-GENE-N
signaling O
pathway O
in O
HL-60 O
cells. O
Toosendanin B-CHEMICAL

(TSN), B-CHEMICAL
a O
triterpenoid B-CHEMICAL
isolated O
from O
Melia O
toosendan O
Sieb. O
et O
Zucc., O
has O
been O
found O
to O
suppress O
proliferation O
and O
induce O
apoptosis O
in O
a O
variety O
of O
human O
cancer O
cells. O
However, O
the O
mechanism O
how O
TSN B-CHEMICAL
induces O
apoptosis O
remains O
poorly O
understood. O
In O
this O
study, O
we O
examined O
the O
effects O
of O
TSN B-CHEMICAL
on O
the O
growth, O
cell O
cycle O
arrest, O
induction O
of O
apoptosis O
and O
the O
involved O
signaling O
pathway O
in O
human O
promyelocytic O
leukemia O
HL-60 O
cells. O
Proliferation O
of O
HL-60 O
cells O
was O
inhibited O
in O
a O
dose-dependent O
manner O

with O
the O
IC(50 O
(48 O
h)) O
of O
28 O
ng/mL. O
The O
growth O
inhibition O
was O
due O
primarily O
to O
the O
S O
phase O
arrest O
and O
cell O
apoptosis. O
Cell O
apoptosis O
induced O
by O
TSN B-CHEMICAL
was O
confirmed O
by O
Annexin O
V-FITC/propidium B-CHEMICAL
iodide I-CHEMICAL
staining. O
The O
increase O
of O
the O
pro-apoptotic O
protein O
Bax, B-GENE-Y
cleaved O
PARP B-GENE-N
and O
caspase-3, B-GENE-Y
and O
the O
decrease O
of O
anti-apoptotic O
protein O
Bcl-2 B-GENE-Y
were O
observed. O
Western O
blot O
analysis O
indicated O
that O
TSN B-CHEMICAL
inhibits O
the O

CDC42/MEKK1/JNK B-GENE-Y
pathway. O
Taken O
together, O
our O
study O
suggested, O
for O
the O
first O
time, O
that O
the O
pro-apoptotic O
effects O
of O
TSN B-CHEMICAL
on O
HL-60 O
cells O
were O
mediated O
through O
JNK B-GENE-N
signaling O
pathway. O
Novel O
insights O
on O
the O
effect O
of O
nicotine B-CHEMICAL
in O
a O
murine O
colitis O
model. O
Studies O
showed O
that O
nicotine B-CHEMICAL
has O
a O
positive O
influence O
on O
symptoms O
of O
ulcerative O
colitis. O
In O
the O
present O
study, O
we O
explored O
the O
effect O
of O
nicotine B-CHEMICAL
treatment O
using O
different O
routes O
of O
administration O
in O
the O
dextran O
sodium B-CHEMICAL
sulfate I-CHEMICAL
(DSS) O

colitis O
mouse O
model. O
We O
also O
investigated O
the O
effects O
of O
cotinine, B-CHEMICAL
a O
major O
metabolite O
of O
nicotine, B-CHEMICAL
in O
the O
model. O
C57BL6 O
adult O
male O
mice O
were O
given O
DSS O
solution O
freely O
in O
the O
drinking O
water O
for O
seven O
consecutive O
days, O
and O
tap O
water O
was O
given O
thereafter. O
Disease O
severity, O
length O
of O
the O
colon, O
colon O
tissue O
histology, O
and O
inflammatory O
markers, O
including O
colonic B-GENE-Y
myeloperoxidase I-GENE-Y
activity O
and O
colonic B-GENE-Y
tumor I-GENE-Y
necrosis I-GENE-Y
factor- I-GENE-Y
levels, O
were O
evaluated. O
The O
effect O
of O
nicotine B-CHEMICAL
and O
cotinine B-CHEMICAL
treatments O
via O
various O
different O
routes O
of O
administration O
were O
examined O
the O

DSS O
model. O
In O
addition, O
we O
measured O
the O
plasma O
levels O
of O
nicotine B-CHEMICAL
and O
cotinine B-CHEMICAL
in O
our O
treatment O
protocols. O
Administration O
of O
low, O
but O
not O
high, O
doses O
of O
oral O
nicotine B-CHEMICAL
in O
DSS-treated O
mice O
resulted O
in O
a O
significant O
decrease O
in O
disease O
severity, O
histologic O
damage O
scores, O
as O
well O
as O
colonic O
level O
of O
tumor B-GENE-Y
necrosis I-GENE-Y
factor-. I-GENE-Y
However, O
the O
anti-inflammatory O
effect O
of O
nicotine B-CHEMICAL
was O
not O
seen O
after O
chronic O
s.c. O
or O
minipump O
infusion O
of O
the O
drug. O
Differences O
in O
plasma O
levels O
of O
nicotine B-CHEMICAL
and O
cotinine B-CHEMICAL
do O
not O
seem O
to O
account O

for O
this O
lack O
of O
effect. O
Finally, O
oral O
cotinine B-CHEMICAL
alone O
failed O
to O
show O
a O
significant O
effect O
in O
the O
DSS O
model O
of O
colitis. O
These O
results O
highlight O
that O
dose O
and O
route O
of O
administration O
play O
a O
critical O
role O
in O
the O
protective O
effect O
of O
nicotine B-CHEMICAL
in O
the O
DSS O
mouse O
colitis O
model. O
The O
S349T B-GENE-N
mutation O
of O
SQSTM1 B-GENE-Y
links O
Keap1/Nrf2 B-GENE-Y
signalling O
to O
Paget's O
disease O
of O
bone. O
Mutations O
affecting O
the O
Sequestosome B-GENE-Y
1 I-GENE-Y
(SQSTM1) B-GENE-Y
gene O
commonly O
occur O
in O
patients O
with O
the O
skeletal O
disorder O
Paget's O
disease O
of O
bone O

(PDB), O
a O
condition O
characterised O
by O
defective O
osteoclast O
differentiation O
and O
function. O
Whilst O
most O
mutations O
cluster O
within O
the O
ubiquitin-associated B-GENE-N
(UBA) I-GENE-N
domain I-GENE-N
of O
the O
SQSTM1 B-GENE-Y
protein, O
and O
are O
associated O
with O
dysregulated O
NFB B-GENE-N
signalling, O
several O
non-UBA B-GENE-N
domain I-GENE-N
mutations O
have O
also O
been O
identified. O
Keap1 B-GENE-Y
is O
a O
SQSTM1-interacting B-GENE-Y
protein O
that O
regulates O
the O
levels O
and O
activity O
of O
the O
Nrf2 B-GENE-Y
transcription O
factor. O
This O
in O
turn O
controls O
the O
expression O
of O
numerous O
cytoprotective O
genes O
that O
contribute O
to O
the O
cell's O
capacity O
to O
defend O
itself O
against O

chemical O
and O
oxidative O
stress, O
through O
binding O
to O
the O
antioxidant B-GENE-N
response I-GENE-N
element I-GENE-N
(ARE). B-GENE-N
The O
PDB-associated O
S349T B-GENE-N
mutation O
maps O
to O
the O
Keap1-interacting B-GENE-N
region I-GENE-N
(KIR) B-GENE-N
of O
SQSTM1, B-GENE-Y
however O
the O
effects O
of O
PDB O
mutant O
SQSTM1 B-GENE-Y
on O
Keap1 B-GENE-Y
function O
have O
not O
been O
investigated. O
Here O
we O
show O
that O
unlike O
other O
SQSTM1 B-GENE-Y
mutations, O
the O
S349T B-GENE-N
mutation O
results O
in O
neither O
impaired O
ubiquitin-binding B-GENE-N
function O
in O
pull-down O
assays, O
nor O
dysregulated O
NFB B-GENE-N
signalling O
in O

luciferase O
reporter O
assays. O
Keap1 B-GENE-Y
is O
expressed O
in O
differentiating O
osteoclast-like O
cells O
and O
the O
S349T B-GENE-N
mutation O
selectively O
impairs O
the O
SQSTM1-Keap1 B-GENE-Y
interaction O
in O
co-immunoprecipitations, O
which O
molecular O
modelling O
indicates O
results O
from O
effects O
on O
critical O
hydrogen B-CHEMICAL
bonds O
required O
to O
stabilise O
the O
KIR-Keap1 B-GENE-N
complex. O
Further, O
S349T B-GENE-N
mutant O
SQSTM1, B-GENE-Y
but O
not O
other O
PDB-associated O
mutants, O
showed O
reduced O
ability O
to O
activate O
Nrf2 B-GENE-Y
signalling O
as O
assessed O
by O
ARE-luciferase B-GENE-N
reporter O

assays. O
Thus, O
SQSTM1-mediated B-GENE-Y
dysregulation O
of O
the O
Keap1-Nrf2 B-GENE-Y
axis, O
which O
could O
potentially O
lead O
to O
aberrant O
production O
of O
oxidative O
response O
genes, O
may O
contribute O
to O
disease O
aetiology O
in O
a O
subset O
of O
PDB O
patients. O
Orexin-A B-GENE-Y
suppresses O
postischemic O
glucose B-CHEMICAL
intolerance O
and O
neuronal O
damage O
through O
hypothalamic O
brain-derived B-GENE-Y
neurotrophic I-GENE-Y
factor. I-GENE-Y
Orexin-A B-GENE-Y
(a O
glucose-sensing B-CHEMICAL
neuropeptide O
in O
the O
hypothalamus) O
and O
brain-derived B-GENE-Y
neurotrophic I-GENE-Y
factor I-GENE-Y

(BDNF; B-GENE-Y
a O
member O
of O
the O
neurotrophin B-GENE-N
family) O
play O
roles O
in O
many O
physiologic O
functions, O
including O
regulation O
of O
glucose B-CHEMICAL
metabolism. O
We O
previously O
showed O
that O
the O
development O
of O
postischemic O
glucose B-CHEMICAL
intolerance O
is O
one O
of O
the O
triggers O
of O
ischemic O
neuronal O
damage. O
The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
there O
was O
an O
interaction O
between O
orexin-A B-GENE-Y
and O
BDNF B-GENE-Y
functions O
in O
the O
hypothalamus O
after O
cerebral O
ischemic O
stress. O
Male O
ddY O
mice O
were O
subjected O
to O
2 O
hours O
of O
middle O
cerebral O
artery O
occlusion O
(MCAO). O
Neuronal O
damage O
was O

estimated O
by O
histologic O
and O
behavioral O
analyses. O
Expression O
of O
protein O
levels O
was O
analyzed O
by O
Western O
blot. O
Small O
interfering O
RNA O
directed O
BDNF, B-GENE-Y
orexin-A, B-GENE-Y
and O
SB334867 B-CHEMICAL
[N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl B-CHEMICAL
urea; I-CHEMICAL
a O
specific O
orexin-1 B-GENE-Y
receptor I-GENE-Y
antagonist] O
were O
administered O
directly O
into O
the O
hypothalamus. O
The O
level O
of O
hypothalamic O
orexin-A, B-GENE-Y
detected O
by O
immunohistochemistry, O
was O
decreased O
on O

day O
1 O
after O
MCAO. O
Intrahypothalamic O
administration O
of O
orexin-A B-GENE-Y
(1 O
or O
5 O
pmol/mouse) O
significantly O
and O
dose-dependently O
suppressed O
the O
development O
of O
postischemic O
glucose B-CHEMICAL
intolerance O
on O
day O
1 O
and O
development O
of O
neuronal O
damage O
on O
day O
3. O
The O
MCAO-induced O
decrease O
in O
insulin B-GENE-Y
receptor I-GENE-Y
levels O
in O
the O
liver O
and O
skeletal O
muscle O
on O
day O
1 O
was O
recovered O
to O
control O
levels O
by O
orexin-A, B-GENE-Y
and O
this O
effect O
of O
orexin-A B-GENE-Y
was O
reversed O
by O
the O
administration O
of O
SB334867 B-CHEMICAL
as O
well O
as O
by O
hypothalamic O
BDNF B-GENE-Y
knockdown. O
These O
results O
suggest O

that O
suppression O
of O
postischemic O
glucose B-CHEMICAL
intolerance O
by O
orexin-A B-GENE-Y
assists O
in O
the O
prevention O
of O
cerebral O
ischemic O
neuronal O
damage. O
In O
addition, O
hypothalamic O
BDNF B-GENE-Y
may O
play O
an O
important O
role O
in O
this O
effect O
of O
orexin-A. B-GENE-Y
Mesalamine B-CHEMICAL
modulates O
intercellular O
adhesion O
through O
inhibition O
of O
p-21 B-GENE-Y
activated I-GENE-Y
kinase-1. I-GENE-Y
Mesalamine B-CHEMICAL
(5-ASA) B-CHEMICAL
is O
widely O
used O
for O
the O
treatment O
of O
ulcerative O
colitis, O
a O
remitting O
condition O
characterized O
by O
chronic O
inflammation O
of O
the O
colon. O
Knowledge O
about O
the O
molecular O
and O
cellular O
targets O
of O
5-ASA B-CHEMICAL
is O

limited O
and O
a O
clear O
understanding O
of O
its O
activity O
in O
intestinal O
homeostasis O
and O
interference O
with O
neoplastic O
progression O
is O
lacking. O
We O
sought O
to O
identify O
molecular O
pathways O
interfered O
by O
5-ASA, B-CHEMICAL
using O
CRC O
cell O
lines O
with O
different O
genetic O
background. O
Microarray O
was O
performed O
for O
gene O
expression O
profile O
of O
5-ASA-treated B-CHEMICAL
and O
untreated O
cells O
(HCT116 O
and O
HT29). O
Filtering O
and O
analysis O
of O
data O
identified O
three O
oncogenic O
pathways O
interfered O
by O
5-ASA: B-CHEMICAL
MAPK/ERK B-GENE-N
pathway, O
cell O
adhesion O
and O
-catenin/Wnt B-GENE-Y
signaling. O

PAK1 B-GENE-Y
emerged O
as O
a O
consensus O
target O
of O
5-ASA, B-CHEMICAL
orchestrating O
these O
pathways. O
We O
further O
investigated O
the O
effect O
of O
5-ASA B-CHEMICAL
on O
cell O
adhesion. O
5-ASA B-CHEMICAL
increased O
cell O
adhesion O
which O
was O
measured O
by O
cell O
adhesion O
assay O
and O
transcellular-resistance O
measurement. O
Moreover, O
5-ASA B-CHEMICAL
treatment O
restored O
membranous O
expression O
of O
adhesion O
molecules O
E-cadherin B-GENE-Y
and O
-catenin. B-GENE-Y
Role O
of O
PAK1 B-GENE-Y
as O
a O
mediator O
of O
mesalamine O
activity O
was O
validated O
in O
vitro O
and O
in O
vivo. O
Inhibition O
of O
PAK1 B-GENE-Y
by O
RNA O
interference O
also O
increased O
cell O

adhesion. O
PAK1 B-GENE-Y
expression O
was O
elevated O
in O
APC(min) O
polyps O
and O
5-ASA B-CHEMICAL
treatment O
reduced O
its O
expression. O
Our O
data O
demonstrates O
novel O
pharmacological O
mechanism O
of O
mesalamine B-CHEMICAL
in O
modulation O
of O
cell O
adhesion O
and O
role O
of O
PAK1 B-GENE-Y
in O
APC(min) O
polyposis. O
We O
propose O
that O
inhibition O
of O
PAK1 B-GENE-Y
expression O
by O
5-ASA B-CHEMICAL
can O
impede O
with O
neoplastic O
progression O
in O
colorectal O
carcinogenesis. O
The O
mechanism O
of O
PAK1 B-GENE-Y
inhibition O
and O
induction O
of O
membranous O
translocation O
of O
adhesion O
proteins O
by O
5-ASA B-CHEMICAL
might O
be O

independent O
of O
its O
known O
anti-inflammatory O
action. O
Cholestatic O
effect O
of O
epigallocatechin B-CHEMICAL
gallate I-CHEMICAL
in O
rats O
is O
mediated O
via O
decreased O
expression O
of O
Mrp2. B-GENE-Y
Epigallocatechin B-CHEMICAL
gallate I-CHEMICAL
(EGCG) B-CHEMICAL
has O
been O
shown O
to O
be O
protective O
in O
various O
experimental O
models O
of O
liver O
injury, O
although O
opposite O
effects O
have O
also O
been O
reported. O
Since O
its O
effect O
on O
biliary O
physiology O
has O
not O
been O
thoroughly O
investigated, O
the O
present O
study O
evaluated O
effect O
of O
EGCG B-CHEMICAL
on O
bile O
flow O
and O
bile B-CHEMICAL
acid I-CHEMICAL
homeostasis O
in O
rats. O
Compared O
to O
controls, O
EGCG B-CHEMICAL
treatment O
decreased O
bile O
flow O
by O
23%. O
Hepatic O

paracellular O
permeability O
and O
biliary O
bile B-CHEMICAL
acid I-CHEMICAL
excretion O
were O
not O
altered O
by O
EGCG B-CHEMICAL
administration, O
but O
biliary O
glutathione B-CHEMICAL
excretion O
was O
reduced O
by O
70%. O
Accordingly, O
the O
main O
glutathione B-GENE-N
transporter I-GENE-N
on O
the O
hepatocyte O
canalicular O
membrane, O
multidrug B-GENE-Y
resistance-associated I-GENE-Y
protein I-GENE-Y
2 I-GENE-Y
(Mrp2), B-GENE-Y
was O
significantly O
decreased O
at O
the O
protein O
level. O
EGCG B-CHEMICAL
administration O
also O
doubled O
plasma O
bile B-CHEMICAL
acid I-CHEMICAL
levels O
compared O
to O
controls. O
While O
protein O
levels O
of O
the O
main O
hepatic B-GENE-Y
bile I-GENE-Y
acid I-GENE-Y
transporters I-GENE-Y
were O
unchanged, O
the O
rate-limiting O
enzyme O
in O
the O
bile B-CHEMICAL
acid I-CHEMICAL

synthesis, O
Cyp7a1, B-GENE-Y
was O
significantly O
increased O
by O
EGCG. B-CHEMICAL
Enhanced O
bile B-CHEMICAL
acid I-CHEMICAL
synthesis O
in O
these O
animals O
was O
also O
confirmed O
by O
a O
2-fold O
increase O
in O
plasma O
marker O
7-hydroxy-4-cholesten-3-one. B-CHEMICAL
In O
contrast, O
EGCG B-CHEMICAL
markedly O
downregulated O
major O
bile B-CHEMICAL
acid I-CHEMICAL
transporters I-GENE-N
(Asbt B-GENE-Y
and O
Ost) B-GENE-Y
and O
regulatory O
molecules O
(Shp B-GENE-Y
and O
Fgf15) B-GENE-Y
in O
the O
ileum. O
When O
EGCG B-CHEMICAL
was O
coadministered O
with O
ethinylestradiol, B-CHEMICAL
a O
potent O
cholestatic O
agent, O
it O
did O
not O
show O

any O
additional O
effect O
on O
the O
induced O
cholestasis. O
This O
study O
shows O
ability O
of O
EGCG B-CHEMICAL
to O
raise O
plasma O
bile B-CHEMICAL
acid I-CHEMICAL
concentrations, O
mainly O
through O
Cyp7a1 B-GENE-Y
upregulation, O
and O
to O
decrease O
bile O
production O
through O
reduction O
in O
Mrp2-mediated B-GENE-Y
bile B-CHEMICAL
acid-independent I-CHEMICAL
bile O
flow. O
In O
conclusion, O
our O
data O
demonstrate O
that O
under O
certain O
conditions O
EGCG B-CHEMICAL
may O
induce O
cholestasis. O
Effects-based O
marine O
ecological O
risk O
assessment O
at O
a O
polychlorinated B-CHEMICAL
biphenyl-contaminated I-CHEMICAL
site O
in O
Saglek, O
Labrador, O
Canada. O
Although O
the O
presence O
and O
distribution O
of O
polychlorinated B-CHEMICAL

biphenyls I-CHEMICAL
(PCBs) B-CHEMICAL
in O
Arctic O
marine O
environments O
has O
been O
well O
documented, O
the O
implications O
for O
the O
health O
of O
biota O
are O
poorly O
understood. O
In O
the O
present O
study, O
multiple O
lines O
of O
evidence, O
including O
site-specific O
effects O
data, O
were O
used O
to O
assess O
PCB-related B-CHEMICAL
risks O
to O
marine O
biota O
at O
a O
contaminated O
military O
site O
in O
Saglek O
Bay, O
Labrador, O
Canada, O
from O
1997 O
to O
1999. O
Risks O
were O
evaluated O
for O
three O
components O
of O
the O
ecosystem: O
benthic O
invertebrates, O
a O
bottom-feeding O
fish O
(shorthorn O
sculpin, O
Myoxocephalus O
scorpius), O
and O
a O
diving O

seabird O
(black O
guillemot, O
Cepphus O
grylle). O
Average O
sediment O
PCB B-CHEMICAL
concentrations O
exceeded O
the O
Canadian O
interim O
sediment O
quality O
guideline O
level O
by O
41-fold. O
However, O
sediment O
toxicity O
testing O
and O
a O
benthic O
community O
survey O
showed O
no O
evidence O
of O
adverse O
effects. O
In O
contrast, O
shorthorn O
sculpin O
and O
black O
guillemot O
PCB B-CHEMICAL
exposures O
(measured O
as O
sum O
of O
55 O
congeners) O
were O
elevated O
enough O
to O
pose O
risks O
to O
survival O
or O
reproduction. O
Based O
on O
the O
collective O
evidence, O
the O
authors O
estimated O
that O
risks O
were O
posed O
by O
sediment O
PCB B-CHEMICAL
concentrations O
greater O
than O
77 O
ng/g O
dry O
weight O
for O
black O
guillemots O

and O
750 O
ng/g O
dry O
weight O
for O
shorthorn O
sculpins. O
The O
present O
study, O
along O
with O
two O
parallel O
studies, O
provided O
information O
to O
support O
the O
management O
decisions O
concerning O
potential O
remedial O
action O
on O
the O
contaminated O
sediments. O
This O
ecological O
risk O
assessment O
describes O
the O
steps O
and O
rationale O
taken O
to O
evaluate O
the O
risk O
posed O
by O
an O
area O
of O
PCB-contaminated B-CHEMICAL
marine O
sediments O
in O
an O
otherwise O
relatively O
pristine O
northern O
coastal O
environment. O
Ablation O
of O
Egr2-positive B-GENE-Y
cells O
in O
male O
mouse O
anterior O
pituitary O
leads O
to O
atypical O
isolated O
GH O
deficiency. O
In O
this O
study, O
we O
have O
investigated O
the O
expression O
and O
function O
of O
the O
transcription O
factor O
early B-GENE-Y
growth I-GENE-Y

response I-GENE-Y
factor I-GENE-Y
2 I-GENE-Y
(Egr2)/Krox20 B-GENE-Y
in O
the O
developing O
anterior O
pituitary. O
Egr2 B-GENE-Y
is O
initially O
expressed O
in O
all O
differentiating O
hormonal O
cells O
types, O
but O
its O
expression O
is O
mostly O
restricted O
to O
the O
somatotroph O
lineage O
after O
birth. O
Egr2 B-GENE-Y
knockout O
results O
in O
anterior O
pituitary O
hypoplasia. O
However, O
the O
analysis O
of O
a O
conditional O
mutant O
demonstrates O
that O
this O
phenotype O
does O
not O
originate O
from O
a O
lack O
of O
Egr2 B-GENE-Y
expression O
in O
the O
pituitary. O
Using O
an O
Egr2 B-GENE-Y
allele O
driving O
a O
Cre-activable O
toxin O
gene, O
we O
performed O
a O

genetic O
ablation O
of O
Egr2-positive B-GENE-Y
cells O
in O
the O
pituitary. O
During O
the O
postnatal O
period, O
this O
ablation O
leads O
to O
specific O
and O
progressive O
depletion O
of O
the O
somatotroph O
population, O
creating O
a O
novel O
model O
of O
early-onset O
isolated O
GH O
deficiency O
(GHD). O
Mutant O
animals O
were O
subjected O
to O
a O
complete O
metabolic O
analysis, O
revealing O
atypical O
and O
expected O
features. O
Consistent O
with O
an O
adult-onset O
isolated O
GHD O
model, O
mutant O
animals O
are O
hypoglycemic O
and O
display O
increased O
insulin B-GENE-N
sensitivity O
and O
glucose B-CHEMICAL
clearance. O
This O
latter O
phenotype O
is O
in O
contrast O
to O
the O
glucose B-CHEMICAL

intolerance O
observed O
in O
another O
early-onset O
GHD O
model. O
Surprisingly, O
increased O
insulin O
sensitivity O
is O
not O
accompanied O
by O
a O
modified O
balance O
between O
fat O
and O
lean O
tissues, O
but O
by O
reduced O
metabolic O
adaptability O
between O
glucose B-CHEMICAL
and O
lipid O
oxidation O
conditions. O
This O
suggests O
that O
the O
relationship O
between O
these O
metabolic O
features O
and O
insulin O
sensitivity O
should O
be O
reconsidered. O
In O
conclusion, O
our O
mutant O
may O
be O
a O
valuable O
genetic O
model O
with O
which O
to O
study O
the O
effects O
of O
long-term O
GH O
deficiency, O
in O
conditions O
of O
normal O
pancreatic O
function O
and O
unaffected O
balance O
between O
fat O
and O
glucose B-CHEMICAL
metabolism. O
The O
scintigraphic O
evaluation O
and O
genetic O
correlation O
of O
joint O
involvements O
in O

pediatric O
patients O
with O
familial O
Mediterranean O
fever. O
Purpose: O
We O
aimed O
to O
evaluate O
the O
articular O
involvements O
in O
pediatric O
patients O
with O
familial O
Mediterranean O
fever O
(FMF) O
with O
joint O
symptoms O
by O
bone O
scintigraphy O
and O
to O
correlate O
the O
involved O
joints O
with O
the O
gene O
mutations. O
Materials O
and O
methods: O
A O
total O
of O
41 O
newly O
diagnosed O
patients O
in O
pediatric O
age O
group O
(28 O
girls O
and O
13 O
boys; O
mean O
age O
9.14 O
 O
2.91 O
years) O
with O
joint O
involvement O
symptoms O
were O
included O
in O
this O
study. O
Scintigraphic O
images O
were O
obtained O
at O
5th O
min O
(blood O
pool O
or O
early O
phase) O
and O
starting O
at O
3 O
h O

(late O
phase) O
after O
(after O
tracer O
injection) O
intravenous O
administration O
of O
technetium-99m B-CHEMICAL
(99mTc)-methylendiphosphonate B-CHEMICAL
(MDP). B-CHEMICAL
Genomic O
DNA O
was O
isolated O
from O
leukocytes O
using O
standard O
salting O
out O
procedure. O
The O
sequencing O
data O
were O
analyzed. O
Results: O
Of O
the O
41 O
patients, O
arthritis O
was O
found O
in O
21 O
(51.2%) O
patients. O
Of O
the O
21 O
patients, O
there O
was O
single O
joint O
involvement O
in O
15 O
(71.4%) O
patients O
and O
multiple O
joint O
involvement O
in O
six O
(28.6%) O
patients. O
The O
mean O
age O
of O
patients O

with O
joint O
involvement O
(8 O
 O
2.3 O
years) O
were O
considerably O
lower O
than O
the O
patients O
without O
joint O
involvement O
(10.35 O
 O
3.04 O
years), O
and O
this O
was O
statistically O
significant O
(p O
= O
0.008). O
The O
most O
commonly O
involved O
joints O
were O
ankles O
and O
knees. O
Multiple O
joint O
involvements O
were O
most O
frequently O
observed O
in O
the O
M694V B-GENE-N
and O
M694I B-GENE-N
gene O
mutations O
(16.7%). O
Conclusions: O
We O
use O
and O
recommend O
the O
bone O
scintigraphy O
in O
patients O
with O
FMF O
to O
determine O
the O
presence O
and O
distribution O
of O
arthritis, O
since O
bone O
scintigraphy O
is O
inexpensive, O

noninvasive, O
easy-to-use, O
and O
also O
is O
more O
sensitive O
in O
the O
diagnosis O
and O
distribution O
of O
arthritis O
than O
conventional O
radiological O
methods O
and O
clinical O
examination. O
Serotonin B-CHEMICAL
receptors I-GENE-N
of O
type O
6 O
(5-HT6): B-GENE-Y
from O
neuroscience O
to O
clinical O
pharmacology. O
The O
serotonin B-GENE-N
(5-HT) I-GENE-N
receptors I-GENE-N
of O
type O
6 O
(5-HT6) B-GENE-Y
are O
quite O
different O
from O
all O
other O
5-HT B-CHEMICAL
receptors, I-GENE-N
as O
they O
include O
a O
short O
third O
cytoplasmatic O
loop O
and O
a O
long O
C-terminal B-CHEMICAL
tail, O
and O
one O
intron O
located O
in O
the O
middle O
of O
the O
third O

cytoplasmatic O
loop. O
A O
lot O
of O
controversies O
still O
exist O
regarding O
their O
binding O
affinity, O
effects O
of O
5-HT6 B-GENE-Y
ligands O
on O
brain O
catecholamines, B-CHEMICAL
behavioral O
syndromes O
regulated O
by O
them, O
and O
brain O
distribution. O
In O
spite O
of O
the O
lack O
of O
information O
on O
metabolic O
pattern O
of O
the O
various O
compounds, O
some O
of O
5-HT6 B-GENE-Y
receptor O
ligands O
entered O
the O
clinical O
development O
as O
potential O
anti-dementia, O
antipsychotic, O
antidepressant O
and O
anti-obese O
drugs. O
The O
present O
paper O
is O
a O
comprehensive O
review O
on O
the O
state O
of O
art O
of O
the O
5-HT6 B-GENE-Y
receptors, O

while O
highlighting O
the O
potential O
clinical O
applications O
of O
5-HT6 B-GENE-Y
receptor O
agonists/antagonists. O
Expression O
of O
cAMP-responsive B-CHEMICAL
element I-GENE-N
binding I-GENE-N
proteins I-GENE-N
(CREBs) B-GENE-N
in O
fast- O
and O
slow-twitch O
muscles: O
A O
signaling O
pathway O
to O
account O
for O
the O
synaptic O
expression O
of O
collagen-tailed B-GENE-Y
subunit I-GENE-Y
(ColQ) B-GENE-Y
of O
acetylcholinesterase B-GENE-Y
at O
the O
rat O
neuromuscular O
junction. O
The O
gene O
encoding O
the O
collagen-tailed B-GENE-Y
subunit I-GENE-Y
(ColQ) B-GENE-Y
of O
acetylcholinesterase B-GENE-Y
(AChE) B-GENE-Y
contains O
two O
distinct O
promoters O
that O
drive O
the O
production O
of O
two O

ColQ B-GENE-Y
mRNAs, O
ColQ-1 B-GENE-Y
and O
ColQ-1a, B-GENE-Y
in O
slow- O
and O
fast-twitch O
muscles, O
respectively. O
ColQ-1a B-GENE-Y
is O
expressed O
at O
the O
neuromuscular O
junction O
(NMJ) O
in O
fast-twitch O
muscle, O
and O
this O
expression O
depends O
on O
trophic O
factors O
supplied O
by O
motor O
neurons O
signaling O
via O
a O
cAMP-dependent B-CHEMICAL
pathway O
in O
muscle. O
To O
further O
elucidate O
the O
molecular O
basis O
of O
ColQ-1a's B-GENE-Y
synaptic O
expression, O
here O
we O
investigated O
the O
expression O
and O
localization O
of O
cAMP-responsive B-CHEMICAL
element I-GENE-N
binding I-GENE-N
protein I-GENE-N
(CREB) B-GENE-N
at O

the O
synaptic O
and O
extra-synaptic O
regions O
of O
fast- O
and O
slow-twitch O
muscles O
from O
adult O
rats. O
The O
total O
amount O
of O
active, O
phosphorylated B-GENE-N
CREB I-GENE-N
(P-CREB) B-GENE-N
present O
in O
slow-twitch O
soleus O
muscle O
was O
higher O
than O
that O
in O
fast-twitch O
tibialis O
muscle, O
but O
P-CREB B-GENE-N
was O
predominantly O
expressed O
in O
the O
fast-twitch O
muscle O
at O
NMJs. O
In O
contrast, O
P-CREB B-GENE-N
was O
detected O
in O
both O
synaptic O
and O
extra-synaptic O
regions O
of O
slow-twitch O
muscle. O
These O
results O
reveal, O
for O
the O
first O
time, O
the O
differential O
distribution O

of O
P-CREB B-GENE-N
in O
fast- O
and O
slow-twitch O
muscles, O
which O
might O
support O
the O
crucial O
role O
of O
cAMP-dependent B-CHEMICAL
signaling O
in O
controlling O
the O
synapse-specific O
expression O
of O
ColQ-1a B-GENE-Y
in O
fast-twitch O
muscles. O
Analysis O
of O
mammalian B-GENE-Y
alcohol B-CHEMICAL
dehydrogenase I-GENE-Y
5 I-GENE-Y
(ADH5): B-GENE-Y
characterisation O
of O
rat B-GENE-Y
ADH5 I-GENE-Y
with O
comparisons O
to O
the O
corresponding O
human O
variant. O
Alcohol B-GENE-Y
dehydrogenase I-GENE-Y
5 I-GENE-Y
(ADH5) B-GENE-Y
is O
a O
member O
of O
the O
mammalian B-GENE-N
alcohol B-CHEMICAL
dehydrogenase I-GENE-N
family O
of O
yet O
undefined O
functions. O
ADH5 B-GENE-Y
was O
first O
identified O
at O
the O

DNA O
level O
in O
human O
and O
deer O
mouse. O
A O
rat B-GENE-N
alcohol B-CHEMICAL
dehydrogenase I-GENE-N
structure O
of O
similar O
type O
has O
been O
isolated O
at O
the O
cDNA O
level O
using O
human B-GENE-Y
ADH5 I-GENE-Y
as O
a O
screening O
probe, O
where O
the O
rat O
cDNA O
structure O
displayed O
several O
atypical O
properties. O
mRNA O
for O
rat B-GENE-Y
ADH5 I-GENE-Y
was O
found O
in O
multiple O
tissues, O
especially O
in O
the O
kidney. O
In O
vitro O
translation O
experiments O
indicated O
that O
rat B-GENE-Y
ADH5 I-GENE-Y
is O
expressed O
as O
efficiently O
as O
ADH1 B-GENE-Y
and O
furthermore, O
rat B-GENE-Y
ADH5 I-GENE-Y
was O
readily O
expressed O
in O
COS O
cells O
fused O
to O
Green O
Fluorescent O
Protein. O
However, O
no O
soluble O
ADH5 B-GENE-Y
protein O
could O
be O

heterologously O
expressed O
in O
Escherichia O
coli O
cells O
with O
expression O
systems O
successfully O
used O
for O
other O
mammalian B-GENE-N
ADHs, I-GENE-N
including O
fused O
to O
glutathione-S-transferase. B-CHEMICAL
Molecular O
modelling O
of O
the O
enzyme O
indicated O
that O
the O
protein O
does O
not O
fold O
in O
a O
productive O
way, O
which O
can O
be O
the O
explanation O
why O
no O
stable O
and O
active O
ADH5 B-GENE-Y
has O
been O
isolated. O
These O
results O
indicate O
that O
ADH5, B-GENE-Y
while O
readily O
expressed O
at O
the O
mRNA O
level, O
does O
not O
behave O
similarly O
to O
other O
mammalian B-GENE-N
ADHs I-GENE-N
investigated. O
The O
results, O
in O
vitro O
and O
in O
silico, O
suggest O
an O
unstable O
ADH5 B-GENE-Y
structure, O

which O
can O
explain O
for O
why O
no O
active O
and O
stable O
protein O
can O
be O
isolated. O
Further O
possibilities O
are O
conceivable: O
the O
ADH5 B-GENE-Y
protein O
may O
have O
to O
interact O
with O
a O
stabiliser, O
or O
the O
gene O
is O
actually O
a O
pseudogene. O
Combining O
quantum O
mechanical O
ligand O
conformation O
analysis O
and O
protein O
modeling O
to O
elucidate O
GPCR-ligand B-GENE-N
binding O
modes. O
SAR O
beyond O
protein-ligand O
interactions: O
By O
combining O
structure-affinity O
relationships, O
protein-ligand O
modeling O
studies, O
and O
quantum O
mechanical O
calculations, O
we O
show O
that O
ligand O
conformational O
energies O
and O
basicity O
play O
critical O
roles O
in O
ligand O
binding O
to O
the O

histamine B-GENE-Y
H4 I-GENE-Y
receptor, I-GENE-Y
a O
GPCR B-GENE-N
that O
plays O
a O
key O
role O
in O
inflammation. O
Catalpol B-CHEMICAL
inhibits O
LPS O
plus O
IFN--induced B-GENE-Y
inflammatory O
response O
in O
astrocytes O
primary O
cultures. O
A O
large O
body O
of O
evidence O
suggests O
that O
the O
inflammatory O
reaction O
plays O
an O
important O
role O
in O
the O
pathogenesis O
of O
neurodegenerative O
diseases. O
Our O
previous O
studies O
described O
the O
neuroprotective O
effects O
of O
catalpol B-CHEMICAL
in O
lipopolysaccharide O
(LPS)-induced O
inflammatory O
models, O
in O
which O
catalpol B-CHEMICAL
was O
shown O
to O
prevent O
mesencephalic O
neuron O
death O
and O
ameliorate O
cognitive O
ability O

animals. O
To O
further O
investigate O
the O
protective O
effect O
and O
underlying O
mechanism O
of O
catalpol, B-CHEMICAL
astrocytes O
were O
pretreated O
with O
low O
(0.1mM) O
and O
high O
dose O
(0.5mM) O
catalpol B-CHEMICAL
for O
1h O
prior O
to O
LPS O
plus O
interferon- B-GENE-Y
stimulation. O
Biochemical O
analyses O
showed O
that O
NO B-CHEMICAL
and O
ROS O
production O
and O
iNOS B-GENE-Y
activity O
were O
significantly O
reduced O
by O
catalpol. B-CHEMICAL
Data O
at O
transcriptional O
level O
also O
demonstrated O
that O
catalpol B-CHEMICAL
potently O
attenuated O
gene O
expressions O
involved O
in O
inflammation, O
such O
as O
iNOS, B-GENE-Y
COX-2 B-GENE-Y
and O
TLR4. B-GENE-Y
In O
addition, O
our O

exploration O
further O
revealed O
that O
the O
suppressive O
action O
of O
catalpol B-CHEMICAL
on O
inflammation O
was O
mediated O
via O
inhibiting O
nuclear B-GENE-N
factor-B I-GENE-N
(NF-B) B-GENE-N
activation. O
Collectively, O
these O
results O
suggest O
that O
catalpol B-CHEMICAL
can O
exert O
inhibitory O
effects O
on O
the O
inflammatory O
reaction O
in O
astrocytes O
and O
that O
inactivation O
of O
NF-B B-GENE-N
could O
be O
the O
major O
determinant O
for O
its O
anti-inflammatory O
mechanism. O
Therefore, O
catalpol B-CHEMICAL
may O
potentially O
be O
a O
highly O
effective O
therapeutic O
agent O
in O
treating O
neurodegenerative O
diseases O
associated O
with O
inflammation. O
Cardiolipin-dependent B-CHEMICAL
reconstitution O
of O
respiratory O
supercomplexes O

from O
purified O
Saccharomyces O
cerevisiae O
complexes O
III O
and O
IV. O
Here, O
we O
report O
for O
the O
first O
time O
in O
vitro O
reconstitution O
of O
the O
respiratory O
supercomplexes O
from O
individual O
complexes O
III O
and O
IV. O
Complexes O
III O
and O
IV O
were O
purified O
from O
Saccharomyces O
cerevisiae O
mitochondria. O
Complex O
III O
contained O
eight O
molecules O
of O
cardiolipin, B-CHEMICAL
and O
complex O
IV O
contained O
two O
molecules O
of O
cardiolipin, B-CHEMICAL
as O
determined O
by O
electrospray O
ionization-mass O
spectrometry. O
Complex O
IV O
also O
contained O
Rcf1p. B-GENE-Y
No O
supercomplexes O
were O
formed O
upon O

mixing O
of O
the O
purified O
complexes, O
and O
low O
amounts O
of O
the O
supercomplex O
trimer O
III(2)IV(1) O
were O
formed O
after O
reconstitution O
into O
proteoliposomes O
containing O
only O
phosphatidylcholine B-CHEMICAL
and O
phosphatidylethanolamine. B-CHEMICAL
Further O
addition O
of O
cardiolipin O
to O
the O
proteoliposome O
reconstitution O
mixture O
resulted O
in O
distinct O
formation O
of O
both O
the O
III(2)IV(1) O
supercomplex O
trimer O
and O
III(2)IV(2) O
supercomplex O
tetramer. O
No O
other O
anionic O
phospholipid O
was O

as O
effective O
as O
cardiolipin B-CHEMICAL
in O
supporting O
tetramer O
formation. O
Phospholipase B-GENE-N
treatment O
of O
complex O
IV O
prevented O
trimer O
formation O
in O
the O
absence O
of O
cardiolipin. B-CHEMICAL
Both O
trimer O
and O
tetramer O
formations O
were O
restored O
by O
cardiolipin. B-CHEMICAL
Analysis O
of O
the O
reconstituted O
tetramer O
by O
single O
particle O
electron O
microscopy O
confirmed O
native O
organization O
of O
individual O
complexes O
within O
the O
supercomplex. O
In O
conclusion, O
although O
some O
trimer O
formation O
occurred O
dependent O
only O
on O
tightly O
bound O
cardiolipin, B-CHEMICAL
tetramer O
formation O
required O
additional O
cardiolipin. B-CHEMICAL
This O
is O
consistent O
with O
the O
high O
cardiolipin B-CHEMICAL
content O
in O
the O
native O

tetramer. O
The O
dependence O
on O
cardiolipin B-CHEMICAL
for O
supercomplex O
formation O
suggests O
that O
changes O
in O
cardiolipin B-CHEMICAL
levels O
resulting O
from O
changes O
in O
physiological O
conditions O
may O
control O
the O
equilibrium O
between O
individual O
respiratory O
complexes O
and O
supercomplexes O
in O
vivo. O
Protein B-GENE-Y
tyrosine B-CHEMICAL
phosphatase I-GENE-Y
1B I-GENE-Y
inhibitory O
effect O
by O
dammarane-type B-CHEMICAL
triterpenes B-CHEMICAL
from O
hydrolyzate O
of O
total O
Gynostemma O
pentaphyllum O
saponins. B-CHEMICAL
Protein B-GENE-Y
tyrosine I-GENE-Y
phosphatase I-GENE-Y
1B I-GENE-Y
(PTP1B) B-GENE-Y
is O
an O
important O
factor O
in O
non-insulin-dependent B-GENE-Y
diabetes O

mellitus O
(type-2 O
diabetes), O
and O
a O
promising O
target O
for O
treatment O
of O
diabetes O
and O
obesity. O
Therefore, O
the O
aim O
of O
this O
study O
is O
to O
investigate O
the O
inhibitory O
activities O
of O
constituents O
(three O
new O
together O
with O
twelve O
known O
triterpenes B-CHEMICAL
compounds) O
isolated O
from O
the O
hydrolyzate O
of O
total O
saponins B-CHEMICAL
from O
Gynostemma O
pentaphyllum. O
Their O
structures O
were O
accomplished O
mainly O
base O
on O
the O
spectroscopic O
methods, O
and O
then O
were O
further O
confirmed O
by O
X-ray O
crystal O
diffraction. O
All O
the O
compounds O
were O
evaluated O
for O
inhibitory O
activity O
against O
PTP1B. B-GENE-Y
Current O
data O
suggested O
that O
the O
compounds O

1, O
3, O
12, O
13 O
and O
14 O
were O
considered O
to O
be O
potential O
as O
antidiabetic O
agents, O
in O
which O
they O
could O
significantly O
inhibit O
the O
PTP1B B-GENE-Y
enzyme O
activity O
in O
a O
dose-dependent O
manner. O
Disrupted O
cytoskeletal O
homeostasis, O
astrogliosis O
and O
apoptotic O
cell O
death O
in O
the O
cerebellum O
of O
preweaning O
rats O
injected O
with O
diphenyl B-CHEMICAL
ditelluride. I-CHEMICAL
In O
the O
present O
report O
15 O
day-old O
rats O
were O
injected O
with O
0.3mol O
of O
diphenyl B-CHEMICAL
ditelluride I-CHEMICAL
(PhTe)(2)/kg B-CHEMICAL
body O
weight O

and O
parameters O
of O
neurodegeneration O
were O
analyzed O
in O
slices O
from O
cerebellum O
3 O
and O
6 O
days O
afterwards. O
The O
earlier O
responses, O
at O
day O
3 O
after O
injection, O
included O
hyperphosphorylation O
of O
intermediate O
filament O
(IF) O
proteins O
from O
astrocyte O
(glial B-GENE-Y
fibrillary I-GENE-Y
acidic I-GENE-Y
protein I-GENE-Y
- O
GFAP B-GENE-Y
- O
and O
vimentin) B-GENE-Y
and O
neuron O
(low-, B-GENE-N
medium- I-GENE-N
and I-GENE-N
high I-GENE-N
molecular I-GENE-N
weight I-GENE-N
neurofilament I-GENE-N
subunits: I-GENE-N
NF-L, B-GENE-Y
NF-M B-GENE-Y
and O
NF-H); B-GENE-Y
increased O
mitogen-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
(MAPK) B-GENE-N

(Erk B-GENE-N
and O
p38MAPK) B-GENE-N
and O
cAMP-dependent B-CHEMICAL
protein I-GENE-N
kinase I-GENE-N
(PKA) B-GENE-N
activities. O
Also, O
reactive O
astrogliosis O
takes O
part O
of O
the O
early O
responses O
to O
the O
insult O
with O
(PhTe)(2), B-CHEMICAL
evidenced O
by O
upregulated O
GFAP B-GENE-Y
in O
Western O
blot, O
PCR O
and O
immunofluorescence O
analysis. O
Six O
days O
after O
(PhTe)(2) B-CHEMICAL
injection O
we O
found O
persistent O
astrogliosis, O
increased O
propidium B-CHEMICAL
iodide I-CHEMICAL
(PI) O
positive O
cells O
in O
NeuN B-GENE-Y
positive O
population O
evidenced O
by O
flow O
cytometry O
and O
reduced O

immunofluorescence O
for O
NeuN, B-GENE-Y
suggesting O
that O
the O
in O
vivo O
exposure O
to O
(PhTe)(2) B-CHEMICAL
progressed O
to O
neuronal O
death. O
Moreover, O
activated O
caspase B-GENE-Y
3 I-GENE-Y
suggested O
apoptotic O
neuronal O
death. O
Neurodegeneration O
was O
related O
with O
decreased O
[(3)H]glutamate B-CHEMICAL
uptake O
and O
decreased O
Akt B-GENE-N
immunoreactivity, O
however O
phospho-GSK-3- B-GENE-Y
(Ser9) B-CHEMICAL
was O
not O
altered O
in O
(PhTe)(2) B-CHEMICAL
injected O
rat. O
Therefore, O
the O
present O
results O
show O
that O
the O
earlier O

cerebellar O
responses O
to O
(PhTe)(2) B-CHEMICAL
include O
disruption O
of O
cytoskeletal O
homeostasis O
that O
could O
be O
related O
with O
MAPK B-GENE-N
and O
PKA B-GENE-N
activation O
and O
reactive O
astrogliosis. O
Akt B-GENE-N
inhibition O
observed O
at O
this O
time O
could O
also O
play O
a O
role O
in O
the O
neuronal O
death O
evidenced O
afterwards. O
The O
later O
events O
of O
the O
neurodegenerative O
process O
are O
characterized O
by O
persistent O
astrogliosis O
and O
activation O
of O
apoptotic O
neuronal O
death O
through O
caspase B-GENE-Y
3 I-GENE-Y
mediated O
mechanisms, O
which O
could O
be O
related O
with O
glutamate B-CHEMICAL
excitotoxicity. O
The O
progression O
of O
these O
responses O
are O

therefore O
likely O
to O
be O
critical O
for O
the O
outcome O
of O
the O
neurodegeneration O
provoked O
by O
(PhTe)(2) B-CHEMICAL
in O
rat O
cerebellum. O
The O
presence O
of O
D-fagomine B-CHEMICAL
in O
the O
human O
diet O
from O
buckwheat-based O
foodstuffs. O
Buckwheat O
(Fagopyrum O
esculentum O
Moench) O
groats O
contain O
the O
iminosugar O
D-fagomine B-CHEMICAL
as O
a O
minor O
component O
that O
might O
contribute O
to O
the O
alleged O
health O
benefits O
of O
this O
pseudo-cereal. O
This O
study O
presents O
analysis O
of O
D-fagomine B-CHEMICAL
in O
buckwheat-based O
foodstuffs O
by O
liquid O
chromatography O

coupled O
to O
mass O
spectrometry O
and O
an O
estimation O
of O
its O
presence O
in O
the O
human O
diet O
based O
on O
a O
published O
population-based O
cross-sectional O
nutrition O
survey. O
D-fagomine B-CHEMICAL
is O
present O
in O
common O
buckwheat-based O
foodstuffs O
in O
amounts O
ranging O
from O
1 O
to O
25 O
mg/kg O
or O
mg/L, O
it O
is O
stable O
during O
boiling, O
baking, O
frying O
and O
fermentation, O
and O
it O
is O
biosynthesised O
upon O
sprouting. O
The O
estimated O
total O
intake O
of O
D-fagomine B-CHEMICAL
resulting O
from O
a O
diet O
that O
includes O
such O
foodstuffs O
would O
be O
between O
3 O
and O
17 O
mg O
per O
day O
(mean O
for O

both O
genders; O
range O
from O
P5 O
to O
P95). O
A O
diet O
rich O
in O
buckwheat O
products O
would O
provide O
a O
daily O
amount O
of O
D-fagomine B-CHEMICAL
that O
may O
in O
part O
explain O
the O
beneficial O
properties O
traditionally O
attributed O
to O
buckwheat O
consumption. O
Profluorogenic O
reductase O
substrate O
for O
rapid, O
selective, O
and O
sensitive O
visualization O
and O
detection O
of O
human O
cancer O
cells O
that O
overexpress O
NQO1. B-GENE-Y
Achieving O
the O
vision O
of O
identifying O
and O
quantifying O
cancer-related O
events O
and O
targets O
for O
future O
personalized O
oncology O
is O
predicated O
on O
the O
existence O
of O
synthetically O
accessible O
and O
economically O
viable O
probe O
molecules O
fully O
able O
to O
report O

the O
presence O
of O
these O
events O
and O
targets O
in O
a O
rapid O
and O
highly O
selective O
and O
sensitive O
fashion. O
Delineated O
here O
are O
the O
design O
and O
evaluation O
of O
a O
newly O
synthesized O
turn-on O
probe O
whose O
intense O
fluorescent O
reporter O
signature O
is O
revealed O
only O
through O
probe O
activation O
by O
a O
specific O
intracellular O
enzyme O
present O
in O
tumor O
cells O
of O
multiple O
origins. O
Quenching O
of O
molecular O
probe O
fluorescence O
is O
achieved O
through O
unique O
photoinduced O
electron O
transfer O
between O
the O
naphthalimide B-CHEMICAL
dye O
reporter O
and O
a O
covalently O
attached, O
quinone-based B-CHEMICAL
enzyme O
substrate. O
Fluorescence O
of O
the O
reporter O
dye O
is O
turned O
on O
by O
rapid O
removal O
of O
the O
quinone B-CHEMICAL
quencher, O

an O
event O
that O
immediately O
occurs O
only O
after O
highly O
selective, O
two-electron O
reduction O
of O
the O
sterically O
and O
conformationally O
restricted O
quinone B-CHEMICAL
substrate O
by O
the O
cancer-associated O
human B-GENE-Y
NAD(P)H:quinone I-GENE-Y
oxidoreductase I-GENE-Y
isozyme I-GENE-Y
1 I-GENE-Y
(hNQO1). B-GENE-Y
Successes O
of O
the O
approach O
include O
rapid O
differentiation O
of O
NQO1-expressing B-GENE-Y
and O
-nonexpressing O
cancer O
cell O
lines O
via O
the O
unaided O
eye, O
flow O
cytometry, O
fluorescence O
imaging, O
and O
two-photon O
microscopy. O
The O
potential O
for O
use O
of O
the O
turn-on O
probe O
in O
longer-term O

cellular O
studies O
is O
indicated O
by O
its O
lack O
of O
influence O
on O
cell O
viability O
and O
its O
in O
vitro O
stability. O
Synthesis, O
biological O
evaluation, O
and O
molecular O
modeling O
of O
glycyrrhizin B-CHEMICAL
derivatives O
as O
potent O
high-mobility B-GENE-Y
group I-GENE-Y
box-1 I-GENE-Y
inhibitors O
with O
anti-heart-failure O
activity O
in O
vivo. O
Novel O
glycyrrhizin B-CHEMICAL
(GL) O
derivatives O
were O
designed O
and O
synthesized O
by O
introducing O
various O
amine B-CHEMICAL
or O
amino B-CHEMICAL
acid I-CHEMICAL
residues O
into O
the O
carbohydrate B-CHEMICAL
chain O
and O
at O
C-30. O
Their O
inhibitory O
effects O
on O
high-mobility B-GENE-Y
group I-GENE-Y
box I-GENE-Y
1 I-GENE-Y
(HMGB1) B-GENE-Y
were O
evaluated O
using O
a O
cell-based O

lipopolysaccharide O
(LPS) O
induced O
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
 I-GENE-Y
(TNF-) B-GENE-Y
release O
study. O
Compounds O
10, O
12, O
18-20, O
23, O
and O
24, O
which O
had O
substituents O
introduced O
at O
C-30, O
demonstrated O
moderate O
HMGB1 B-GENE-Y
inhibition O
with O
ED O
values O
ranging O
from O
337 O
to O
141 O
M, O
which O
are O
values O
comparable O
to O
that O
of O
the O
leading O
GL O
compound O
(1) O
(ED O
= O
70 O
M). O
Compounds O
23 O
and O
24 O
emerged O
as O
novel O
and O
interesting O
HMGB1 B-GENE-Y
inhibitors. O
These O
compounds O
were O
able O
to O

extend O
the O
survival O
of O
mice O
with O
chronic O
heart O
failure O
(CHF) O
and O
acute O
heart O
failure O
(AHF), O
respectively. O
In O
addition, O
molecular O
modeling O
studies O
were O
performed O
to O
support O
the O
biological O
data. O
Further O
exploration O
of O
M O
allosteric O
agonists: O
subtle O
structural O
changes O
abolish O
M O
allosteric O
agonism O
and O
result O
in O
pan-mAChR B-GENE-N
orthosteric O
antagonism. O
This O
letter O
describes O
the O
further O
exploration O
of O
two O
series O
of O
M(1) O
allosteric O
agonists, O
TBPB B-CHEMICAL
and O
VU0357017, B-CHEMICAL
previously O
reported O
from O
our O
lab. O
Within O
the O
TPBP B-CHEMICAL

scaffold, O
either O
electronic O
or O
steric O
perturbations O
to O
the O
central O
piperidine B-CHEMICAL
ring O
led O
to O
a O
loss O
of O
selective O
M(1) O
allosteric O
agonism O
and O
afforded O
pan-mAChR B-GENE-N
antagonism, O
which O
was O
demonstrated O
to O
be O
mediated O
via O
the O
orthosteric O
site. O
Additional O
SAR O
around O
a O
related O
M(1) O
allosteric O
agonist O
family O
(VU0357017) B-CHEMICAL
identified O
similar, O
subtle O
'molecular O
switches' O
that O
modulated O
modes O
of O
pharmacology O
from O
allosteric O
agonism O
to O
pan-mAChR B-GENE-N
orthosteric O

antagonism. O
Therefore, O
all O
of O
these O
ligands O
are O
best O
classified O
as O
bi-topic O
ligands O
that O
possess O
high O
affinity O
binding O
at O
an O
allosteric O
site O
to O
engender O
selective O
M(1) O
activation, O
but O
all O
bind, O
at O
higher O
concentrations, O
to O
the O
orthosteric O
ACh O
site, O
leading O
to O
non-selective O
orthosteric O
site O
binding O
and O
mAChR B-GENE-N
antagonism. O
Effects O
of O
single O
or O
repeated O
silymarin O
administration O
on O
pharmacokinetics O
of O
risperidone B-CHEMICAL
and O
its O
major O
metabolite, O
9-hydroxyrisperidone B-CHEMICAL
in O
rats. O
1. O

The O
interactions O
between O
herbal O
dietary O
supplements O
and O
therapeutic O
drugs O
have O
emerged O
as O
an O
important O
issue O
and O
P-glycoprotein B-GENE-Y
(P-gp) B-GENE-Y
has O
been O
reported O
as O
one O
of O
the O
significant O
factors O
of O
these O
interactions. O
2. O
The O
objective O
of O
this O
article O
is O
to O
examine O
the O
effects O
of O
single O
and O
repeated O
administrations O
of O
silymarin O
on O
pharmacokinetics O
of O
a O
P-gp B-GENE-Y
substrate, O
risperidone, B-CHEMICAL
and O
its O
major O
metabolite, O
9-hydroxyrisperidone, B-CHEMICAL
in O
rats. O
3. O
To O
determine O
the O
plasma O
levels O
of O
risperidone B-CHEMICAL
and O

9-hydroxyrisperidone B-CHEMICAL
in O
rats, O
a O
HPLC O
method O
was O
developed O
using O
a O
liquid-liquid O
acid O
back O
extraction. O
When O
risperidone B-CHEMICAL
(6 O
mg/kg) O
was O
co-administered O
with O
silymarin O
(40 O
mg/kg) O
to O
rats O
orally, O
the O
C(max) O
of O
9-hydroxyrisperidone B-CHEMICAL
was O
significantly O
increased O
to1.3-fold O
(p O
< O
0.05), O
while O
the O
other O
pharmacokinetic O
parameters O
did O
not O
show O
any O
significant O
differences. O
Expanding O
the O
experiment O
where O
rats O
were O
repeatedly O
administered O
with O
silymarin O
for O
5 O

days O
prior O
to O
giving O
risperidone, B-CHEMICAL
the O
C(max) O
of O
risperidone B-CHEMICAL
and O
9-hydroxyrisperidone B-CHEMICAL
were O
significantly O
increased O
to O
2.4-fold O
(p O
< O
0.001) O
and O
1.7-fold O
(p O
< O
0.001), O
respectively, O
and O
the O
AUC(0-t), O
as O
well O
to O
1.7-fold O
(p O
< O
0.05) O
and O
2.1-fold O
(p O
< O
0.01), O
respectively. O
4. O
The O
repeated O
exposures O
of O
silymarin, O
compared O
to O
single O
administration O
of O

silymarin, O
increased O
oral O
bioavailability O
and O
affected O
the O
pharmacokinetics O
of O
risperidone B-CHEMICAL
and O
9-hydroxyrisperidone, B-CHEMICAL
by O
inhibiting O
P-gp. B-GENE-Y
Design, O
synthesis O
and O
structure-activity O
relationship O
of O
new O
arginine B-GENE-Y
vasopressin I-GENE-Y
analogues O
containing O
proline B-CHEMICAL
derivatives O
in O
position O
2. O
In O
this O
study, O
we O
present O
the O
synthesis O
and O
pharmacological O
properties O
of O
new O
analogues O
of O
arginine B-GENE-Y
vasopressin I-GENE-Y
modified O
in O
the O
N-terminal B-CHEMICAL
part O
of O
the O
molecule O
with O
proline B-CHEMICAL
derivatives: O

indoline-2-carboxylic B-CHEMICAL
acid I-CHEMICAL
(Ica) B-CHEMICAL
and O
(2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic B-CHEMICAL
acid. I-CHEMICAL
All O
the O
peptides O
were O
tested O
for O
pressor, O
antidiuretic O
and O
in O
vitro O
uterotonic O
activities. O
We O
also O
determined O
their O
binding O
affinity O
to O
the O
human B-GENE-Y
oxytocin B-CHEMICAL
receptor. I-GENE-Y
The O
Ica(2) B-CHEMICAL
substitution O
resulted O
in O
two O
moderately O
potent O
and O
selective O
antioxytocic O
agents: O
[Mpa(1), B-CHEMICAL

Ica(2), I-CHEMICAL
D-Arg(8)]VP I-CHEMICAL
and O
[Mpa(1),Ica(2),Val(4),D-Arg(8)]VP B-CHEMICAL
(pA(2) O
= O
7.09 O
and O
7.50, O
respectively). O
On O
the O
other O
hand, O
peptides O
modified O
with O
(2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic B-CHEMICAL
acid, I-CHEMICAL
apart O
from O
their O
moderate O
antioxytocic O
activity, O
turned O
out O
to O
be O
weak O
antagonists O

of O
the O
pressor O
response O
to O
arginine B-GENE-Y
vasopressin. I-GENE-Y
The O
results O
of O
this O
study O
provide O
useful O
information O
about O
the O
structure-activity O
relationship O
of O
arginine B-GENE-Y
vasopressin I-GENE-Y
analogues O
and O
can O
help O
to O
design O
compounds O
with O
desired O
biological O
properties. O
Liver B-GENE-N
X I-GENE-N
Receptors I-GENE-N
and O
female O
reproduction: O
when O
cholesterol B-CHEMICAL
meets O
fertility! O
The O
role O
of O
cholesterol B-CHEMICAL
in O
female O
reproductive O
physiology O
has O
been O
suspected O
for O
a O
long O
time, O
while O
the O
molecular O
bases O
were O
unknown. O
Cholesterol B-CHEMICAL
is O
the O
precursor O
of O
ovarian O
steroid B-CHEMICAL
biosynthesis O
and O
is O
also O
essential O
for O
fertility. O
In O
the O

uterus, O
cholesterol B-CHEMICAL
is O
essential O
to O
achieve O
correct O
contractions O
at O
term, O
but O
an O
excessive O
uterine O
cholesterol B-CHEMICAL
concentration O
has O
been O
associated O
with O
contractility O
defects. O
Liver B-GENE-Y
X I-GENE-Y
Receptor I-GENE-Y
(LXR) I-GENE-Y
 I-GENE-Y
and O
LXR B-GENE-Y
 I-GENE-Y
are O
nuclear O
receptors O
activated O
by O
oxysterols, B-CHEMICAL
oxidized O
derivatives O
of O
cholesterol. B-CHEMICAL
Since O
their O
discovery, O
the O
role O
of O
LXR B-GENE-N
in O
the O
control O
of O
cholesterol B-CHEMICAL
homeostasis O
has O
been O
widely O
described. O
Beyond O
their O
cholesterol-lowering B-CHEMICAL
role, O
more O
recent O
data O
have O
linked O
these O
nuclear O
receptors O
to O
various O
physiological O
processes. O
In O
particular, O
they O

control O
ovarian O
endocrine O
and O
exocrine O
functions, O
as O
well O
as O
uterine O
contractility. O
Their O
contribution O
to O
female O
reproductive O
cancers O
will O
also O
be O
discussed. O
This O
review O
will O
try O
to O
enlighten O
on O
the O
LXR B-GENE-N
as O
a O
molecular O
link O
between O
dietary O
cholesterol B-CHEMICAL
and O
reproductive O
diseases O
in O
women. O
In O
the O
future, O
a O
better O
comprehension O
of O
the O
various O
physiological O
processes O
regulated O
by O
the O
LXR B-GENE-N
will O
help O
to O
develop O
new O
ligands O
to O
prevent O
or O
to O
cure O
these O
pathologies O
in O
women. O
-catenin B-GENE-Y
regulates O
GnRH-induced B-GENE-Y
FSH B-GENE-Y
gene O
expression. O
The O
regulation O
of O

gonadotropin B-GENE-N
synthesis O
by O
GnRH B-CHEMICAL
plays O
an O
essential O
role O
in O
the O
neuroendocrine O
control O
of O
reproduction. O
The O
known O
signaling O
mechanisms O
involved O
in O
gonadotropin B-GENE-N
synthesis O
have O
been O
expanding. O
For O
example, O
involvement O
of O
-catenin B-GENE-Y
in O
LH O
induction O
by O
GnRH B-CHEMICAL
has O
been O
discovered. O
We O
examined O
the O
role O
of O
-catenin B-GENE-Y
in O
FSH B-GENE-Y
gene O
expression O
in O
LT2 O
gonadotrope O
cells. O
GnRH B-CHEMICAL
caused O
a O
sustained O
increase O
in O
nuclear O
-catenin B-GENE-Y
levels, O
which O
was O
significantly O
reduced O
by O
c-Jun B-GENE-N
N-terminal B-CHEMICAL
kinase I-GENE-N
(JNK) B-GENE-N

inhibition. O
Small O
interfering O
RNA-mediated O
knockdown O
of O
-catenin B-GENE-Y
mRNA O
demonstrated O
that O
induction O
of O
FSH B-GENE-Y
mRNA O
by O
GnRH B-CHEMICAL
depended O
on O
-catenin B-GENE-Y
and O
that O
regulation O
of O
FSH B-GENE-Y
by O
-catenin B-GENE-Y
occurred O
independently O
of O
the O
JNK-c-jun B-GENE-N
pathway. O
-Catenin B-GENE-Y
depletion O
had O
no O
impact O
on O
FSH B-GENE-Y
mRNA O
stability. O
In O
LT2 O
cells O
transfected O
with O
FSH B-GENE-N
promoter I-GENE-N
luciferase O
fusion O
constructs, O
GnRH B-CHEMICAL
responsiveness O
was O
conferred O
by O
the O
proximal O
promoter O

(-944/-1) O
and O
was O
markedly O
decreased O
by O
-catenin B-GENE-Y
knockdown. O
However, O
none O
of O
the O
T-cell B-GENE-N
factor/lymphoid I-GENE-N
enhancer I-GENE-N
factor I-GENE-N
binding I-GENE-N
sites I-GENE-N
in O
that O
region O
were O
required O
for O
promoter O
activation O
by O
GnRH. B-CHEMICAL
Chromatin O
immunoprecipitation O
further O
corroborated O
the O
absence O
of O
direct O
interaction O
between O
-catenin B-GENE-Y
and O
the O
1.8-kb O
FSH B-GENE-N
promoter. I-GENE-N
To O
elucidate O
the O
mechanism O
for O
the O
-catenin B-GENE-Y
effect, O
we O
analyzed O
approximately O
1 O
billion O
reads O
of O
next-generation O
RNA O
sequencing O

-catenin B-GENE-Y
knockdown O
assays O
and O
selected O
the O
nuclear O
cofactor O
breast B-GENE-Y
cancer I-GENE-Y
metastasis-suppressor I-GENE-Y
1-like I-GENE-Y
(Brms1L) B-GENE-Y
as O
one O
candidate O
for O
further O
study. O
Subsequent O
experiments O
confirmed O
that O
Brms1L B-GENE-Y
mRNA O
expression O
was O
decreased O
by O
-catenin B-GENE-Y
knockdown O
as O
well O
as O
by O
JNK B-GENE-N
inhibition. O
Furthermore, O
knockdown O
of O
Brms1L B-GENE-Y
significantly O
attenuated O
GnRH-induced B-CHEMICAL
FSH B-GENE-Y
expression. O
Thus, O
our O
findings O
indicate O
that O
the O
expression O
of O
Brms1L B-GENE-Y
depends O
on O
-catenin B-GENE-Y
activity O
and O
contributes O
to O
FSH B-GENE-Y
induction O
by O

GnRH. B-CHEMICAL
Doxorubicin B-CHEMICAL
decreases O
paraquat B-CHEMICAL
accumulation O
and O
toxicity O
in O
Caco-2 O
cells. O
P-glycoprotein B-GENE-N
(P-gp) B-GENE-N
is O
an O
efflux B-GENE-N
pump I-GENE-N
belonging O
to O
the O
ATP-binding B-GENE-N
cassette I-GENE-N
transporter I-GENE-N
superfamily O
expressed O
in O
several O
organs. O
Considering O
its O
potential O
protective O
effects, O
the O
induction O
of O
de O
novo O
synthesis O
of O
P-gp B-GENE-N
could O
be O
used O
therapeutically O
in O
the O
treatment O
of O
intoxications O
by O
its O
substrates. O
The O
herbicide O
paraquat B-CHEMICAL
(PQ) O
is O
a O
P-gp B-GENE-N
substrate O
responsible O
for O
thousands O
of O
fatal O
intoxications O
worldwide O
that O
still O
lacks O
an O

effective O
antidote. O
The O
aim O
of O
the O
present O
work O
was O
to O
evaluate O
the O
effectiveness O
of O
such O
an O
antidote O
by O
testing O
whether O
doxorubicin B-CHEMICAL
(DOX), B-CHEMICAL
a O
known O
P-gp B-GENE-N
inducer, O
could O
efficiently O
protect O
Caco-2 O
cells O
against O
PQ O
cytotoxicity, O
6 O
h O
after O
the O
incubation O
with O
the O
herbicide, O
reflecting O
a O
real-life O
intoxication O
scenario. O
Cytotoxicity O
was O
evaluated O
by O
the O
MTT B-CHEMICAL
assay O
and O
PQ O
intracellular O
concentrations O
were O
measured O
by O
gas O
chromatography-ion O
trap-mass O
spectrometry O
(GC-IT-MS). O

Also, O
the O
DOX B-CHEMICAL
modulatory O
effect O
on O
choline B-CHEMICAL
uptake O
transport O
system O
was O
assessed O
by O
measuring O
the O
uptake O
of O
[H]-choline. B-CHEMICAL
The O
results O
show O
that O
DOX B-CHEMICAL
exerts O
protective O
effects O
against O
PQ O
cytotoxicity, O
preventing O
the O
intracellular O
accumulation O
of O
the O
herbicide. O
These O
protective O
effects O
were O
not O
completely O
prevented O
by O
the O
incubation O
with O
the O
UIC2 O
antibody, O
a O
specific O
P-gp B-GENE-N
inhibitor, O
suggesting O
the O
involvement O
of O
alternative O
protection O
mechanisms. O
In O
fact, O
DOX B-CHEMICAL
also O
efficiently O
inhibited O
the O
choline B-CHEMICAL
transport O
system O
that O
influences O
PQ O
cellular O
uptake. O
In O

conclusion, O
in O
this O
cellular O
model, O
DOX B-CHEMICAL
effectively O
protects O
against O
PQ O
toxicity O
by O
inducing O
P-gp B-GENE-N
and O
through O
the O
interaction O
with O
the O
choline B-CHEMICAL
transporter, I-GENE-N
suggesting O
that O
compounds O
presenting O
this O
double O
feature O
of O
promoting O
the O
efflux O
and O
limiting O
the O
uptake O
of O
PQ O
could O
be O
used O
as O
effective O
antidotes O
to O
treat O
intoxications. O
Sirtuins B-GENE-N
as O
emerging O
anti-parasitic O
targets. O
Silent B-GENE-Y
information I-GENE-Y
regulator I-GENE-Y
2 I-GENE-Y
(Sir2) B-GENE-Y
enzymes O
or O
sirtuins B-GENE-N
are O
a O
family O
of O
NAD(+)-dependent B-CHEMICAL
protein I-GENE-N
N()-acetyl-lysine B-CHEMICAL
(AcK) I-GENE-N

deacetylases. I-GENE-N
Sirtuins B-GENE-N
are O
also O
evolutionarily O
conserved O
proteins O
that O
are O
present O
in O
all O
kingdoms O
of O
life O
ranging O
from O
bacteria O
to O
humans. O
Interestingly, O
it O
was O
recently O
found O
that O
the O
sirtuins B-GENE-N
found O
in O
various O
human O
parasites O
(especially O
the O
Plasmodium, O
Trypanosoma, O
and O
Leishmania O
species) O
were O
pro-survival O
for O
the O
parasites O
under O
various O
conditions. O
Therefore, O
these O
parasitic B-GENE-N
sirtuins I-GENE-N
have O
emerged O
as O
novel O
anti-parasitic O
therapeutic O
targets. O
This O
article O
reviews O
the O
currently O
available O
structural, O
biochemical, O
pharmacological, O
and O
medicinal O
chemistry O
studies O
on O
these O
enzymes, O
and O
discusses O
the O
perspectives O

of O
selectively O
targeting O
the O
parasitic B-GENE-N
sirtuins I-GENE-N
as O
a O
novel O
therapeutic O
strategy O
for O
the O
human O
parasitic O
diseases. O
The O
selective O
SYK B-GENE-Y
inhibitor O
P505-15 B-CHEMICAL
(PRT062607) B-CHEMICAL
inhibits O
B O
cell O
signaling O
and O
function O
in O
vitro O
and O
in O
vivo O
and O
augments O
the O
activity O
of O
fludarabine B-CHEMICAL
in O
chronic O
lymphocytic O
leukemia. O
B-cell B-GENE-N
receptor I-GENE-N
(BCR) B-GENE-N
associated O
kinases B-GENE-N
including O
spleen B-GENE-Y
tyrosine B-CHEMICAL
kinase I-GENE-Y
(SYK) B-GENE-Y
contribute O
to O
the O
pathogenesis O
of O
B-cell O
malignancies. O
SYK B-GENE-Y
is O
persistently O

phosphorylated O
in O
a O
subset O
of O
non-Hodgkin O
lymphoma O
(NHL) O
and O
chronic O
lymphocytic O
leukemia O
(CLL), O
and O
SYK B-GENE-Y
inhibition O
results O
in O
abrogation O
of O
downstream O
kinase B-GENE-N
activity O
and O
apoptosis. O
P505-15 B-CHEMICAL
(also O
known O
as O
PRT062607) B-CHEMICAL
is O
a O
novel, O
highly O
selective, O
and O
orally O
bioavailable O
small O
molecule O
SYK B-GENE-Y
inhibitor O
(SYK B-GENE-Y
IC(50) O
= O
1 O
nM) O
with O
anti-SYK B-GENE-Y
activity O
that O
is O
at O
least O
80-fold O
greater O
than O
its O
affinity O
for O
other O

kinases. B-GENE-N
We O
evaluated O
the O
preclinical O
characteristics O
of O
P505-15 B-CHEMICAL
in O
models O
of O
NHL O
and O
CLL. O
P505-15 B-CHEMICAL
successfully O
inhibited O
SYK-mediated B-GENE-Y
B-cell B-GENE-N
receptor I-GENE-N
signaling O
and O
decreased O
cell O
viability O
in O
NHL O
and O
CLL. O
Oral O
dosing O
in O
mice O
prevented O
BCR-mediated B-GENE-N
splenomegaly O
and O
significantly O
inhibited O
NHL O
tumor O
growth O
in O
a O
xenograft O
model. O
In O
addition, O
combination O
treatment O
of O
primary O
CLL O
cells O
with O
P505-15 B-CHEMICAL
plus O
fludarabine B-CHEMICAL
produced O
synergistic O
enhancement O
of O
activity O
at O
nanomolar O
concentrations. O
Our O
findings O

support O
the O
ongoing O
development O
of O
P505-15 B-CHEMICAL
as O
a O
therapeutic O
agent O
for O
B-cell O
malignancies. O
A O
dose O
finding O
study O
in O
healthy O
volunteers O
has O
been O
completed. O
The O
fidelity O
of O
transcription: O
RPB1 B-GENE-Y
(RPO21) B-GENE-Y
mutations O
that O
increase O
transcriptional O
slippage O
in O
S. O
cerevisiae. O
The O
fidelity O
of O
RNA O
synthesis O
depends O
on O
both O
accurate O
template-mediated O
nucleotide B-CHEMICAL
selection O
and O
proper O
maintenance O
of O
register O
between O
template O
and O
RNA. O
Loss O
of O
register, O
or O
transcriptional O
slippage, O
is O
particularly O
likely O
on O
homopolymeric O
runs O
in O
the O
template. O
Transcriptional O
slippage O
can O
alter O
the O
coding O
capacity O

of O
mRNAs O
and O
is O
used O
as O
a O
regulatory O
mechanism. O
Here O
we O
describe O
mutations O
in O
the O
largest O
subunit O
of O
Saccharomyces B-GENE-N
cerevisiae I-GENE-N
RNA I-GENE-N
polymerase I-GENE-N
II I-GENE-N
that O
substantially O
increase O
the O
level O
of O
transcriptional O
slippage. O
Alleles O
of O
RPB1 B-GENE-Y
(RPO21) B-GENE-Y
with O
elevated O
slippage O
rates O
were O
identified O
among O
6-azauracil-sensitive B-CHEMICAL
mutants O
and O
were O
also O
isolated O
using O
a O
slippage-dependent O
reporter O
gene. O
Biochemical O
characterization O
of O
polymerase B-GENE-N
II I-GENE-N
isolated O
from O
these O
mutants O
confirms O
elevated O
levels O
of O
transcriptional O
slippage. O
Effect O
of O
nuclear O
vibrations, O
temperature, O
co-adsorbed O

water, O
and O
dye O
orientation O
on O
light O
absorption, O
charge O
injection O
and O
recombination O
conditions O
in O
organic O
dyes O
on O
TiO2. B-CHEMICAL
We O
study O
the O
effect O
of O
nuclear O
motions O
at O
different O
temperatures, O
including O
the O
effect O
of O
a O
dye O
molecule's O
orientation O
with O
respect O
to O
the O
oxide B-CHEMICAL
surface, O
on O
factors O
determining O
the O
performance O
of O
dye O
sensitized O
solar O
cells: O
light O
absorption, O
electron O
injection, O
and O
back-donation. O
We O
perform O
ab O
initio O
molecular O
dynamics O
simulations O
of O
aminophenyl B-CHEMICAL
acid I-CHEMICAL
dyes O
NK1 B-CHEMICAL
and O
NK7, B-CHEMICAL
differing O
by O
the O
electron O
donating O
group, O
in O
a O
vacuum O
and O
adsorbed O
in O
mono- O
and O

bi-dentate O
modes O
on O
a O
dry O
and O
a O
water-covered O
anatase B-CHEMICAL
(101) I-CHEMICAL
surface O
of O
TiO(2), B-CHEMICAL
at O
300 O
and O
350 O
K. O
Nuclear O
vibrations O
and O
an O
increase O
of O
temperature O
cause O
a O
red O
shift O
in O
the O
absorption O
spectra O
of O
free O
dyes. O
This O
effect O
is O
preserved O
in O
dyes O
on O
dry O
TiO(2) B-CHEMICAL
but O
largely O
disappears O
in O
the O
presence O
of O
water. O
Averaged O
over O
nuclear O
vibrations, O
the O
driving O
force O
to O
injection, O
G, O
differs O
from O
the O
static O
estimate. O
It O
depends O
on O
the O
adsorption O
mode O
and O
the O
presence O
of O
H(2)O B-CHEMICAL
but O
is O
almost O
the O
same O
for O

300 O
and O
350 O
K. O
Recombination O
to O
the O
dye O
cation O
is O
expected O
to O
be O
much O
enhanced O
by O
the O
approach O
of O
the O
dye O
oxidation O
equivalent O
hole O
to O
the O
surface O
during O
dye O
wagging O
around O
TiO(2). B-CHEMICAL
This O
effect O
is O
somewhat O
mitigated O
by O
the O
co-adsorbed O
water. O
The O
dynamics O
of O
G(t) O
are O
explained O
by O
uncorrelated O
evolution O
of O
the O
energies O
of O
the O
dye O
excited O
state O
and O
the O
conduction O
band O
minimum O
of O
the O
oxide B-CHEMICAL
due O
to O
their O
respective O
vibrations, O
and O
are O
almost O
independent O
of O
dye O
orientation. O
It O
may O
therefore O
be O
possible O
to O
independently O
control O
the O
conditions O
of O
recombination O
and O
of O
injection. O

Proteomic O
and O
metabolomic O
responses O
to O
connexin43 B-GENE-Y
silencing O
in O
primary O
hepatocyte O
cultures. O
Freshly O
established O
cultures O
of O
primary O
hepatocytes O
progressively O
adopt O
a O
foetal-like O
phenotype O
and O
display O
increased O
production O
of O
connexin43. B-GENE-Y
The O
latter O
is O
a O
multifaceted O
cellular O
entity O
with O
variable O
subcellular O
locations, O
including O
the O
mitochondrial O
compartment. O
Cx43 B-GENE-Y
forms O
hemichannels B-GENE-N
and O
gap O
junctions O
that O
are O
involved O
in O
a O
plethora O
of O
physiological O
and O
pathological O
processes, O
such O
as O
apoptosis. O
The O
present O
study O
was O
conducted O
with O
the O
goal O
of O
shedding O
more O
light O
onto O
the O

role O
of O
connexin43 B-GENE-Y
in O
primary O
hepatocyte O
cultures. O
Connexin43 B-GENE-Y
expression O
was O
suppressed O
by O
means O
of O
RNA O
interference O
technology, O
and O
the O
overall O
outcome O
of O
this O
treatment O
on O
the O
hepatocellular O
proteome O
and O
metabolome O
was O
investigated O
using O
tandem O
mass O
tag-based O
differential O
protein O
profiling O
and O
(1)H B-CHEMICAL
NMR O
spectroscopy, O
respectively. O
Global O
protein O
profiling O
revealed O
a O
number O
of O
targets O
of O
the O
connexin43 B-GENE-Y
knock-down O
procedure, O
including O
mitochondrial O
proteins O
(heat B-GENE-Y
shock I-GENE-Y
protein I-GENE-Y
60, I-GENE-Y
glucose-regulated B-CHEMICAL
protein I-GENE-Y
75, I-GENE-Y
thiosulphate B-CHEMICAL
sulphurtransferase I-GENE-Y
and O

adenosine B-GENE-N
triphosphate I-GENE-N
synthase) I-GENE-N
and O
detoxifying O
enzymes O
(glutathione B-GENE-Y
S-transferase I-GENE-Y
 I-GENE-Y
2 I-GENE-Y
and O
cytochrome B-GENE-N
P450 I-GENE-N
2C70). I-GENE-N
At O
the O
metabolomic O
level, O
connexin43 B-GENE-Y
silencing O
caused O
no O
overt O
changes, O
though O
there O
was O
some O
evidence O
for O
a O
subtle O
increase O
in O
intracellular O
glycine B-CHEMICAL
quantities. O
Collectively, O
these O
data O
could O
further O
substantiate O
the O
established O
existence O
of O
a O
mitochondrial O
connexin B-GENE-N
pool O
and O
could O
be O
reconciled O
with O
the O
previously O
reported O
involvement O
of O
connexin43 B-GENE-N
signalling O
in O
spontaneously O
occurring O
apoptosis O
in O
primary O

hepatocyte O
cultures. O
Aryl B-GENE-Y
hydrocarbon I-GENE-Y
receptor I-GENE-Y
is O
a O
target O
of O
17-Allylamino-17-demethoxygeldanamycin B-CHEMICAL
and O
enhances O
its O
anticancer O
activity O
in O
lung O
adenocarcinoma O
cells. O
We O
have O
demonstrated O
that O
aryl B-GENE-Y
hydrocarbon I-GENE-Y
receptor I-GENE-Y
(AhR) B-GENE-Y
is O
overexpressed O
in O
lung O
adenocarcinoma O
(AD). O
AhR B-GENE-Y
is O
usually O
associated O
with O
heat B-GENE-N
shock I-GENE-N
protein I-GENE-N
90 I-GENE-N
(Hsp90) B-GENE-N
in O
the O
cytoplasm. O
17-Allylamino-17-demethoxygeldanamycin B-CHEMICAL

(17-AAG), B-CHEMICAL
an O
Hsp90 B-GENE-N
inhibitor, O
is O
currently O
under O
evaluation O
for O
its O
anticancer O
activity O
in O
clinical O
trials. O
Here O
we O
investigated O
whether O
AhR B-GENE-Y
plays O
a O
role O
in O
17-AAG-mediated B-CHEMICAL
anticancer O
activity O
by O
functioning O
as O
a O
downstream O
target O
or O
by O
modulating O
its O
anticancer O
efficacy. O
AhR B-GENE-Y
expression O
in O
lung O
AD O
cells O
was O
modulated O
by O
siRNA O
interference O
or O
overexpression. O
Tumor O
growth O
was O
determined O
with O
colony O
formation O
in O
vitro O
or O
in O
vivo. O
Anticancer O
activity O
of O
17-AAG B-CHEMICAL
was O
determined O
by O
measuring O
cell O
viability, O
cell O
cycle O
distribution, O
and O
expression O
of O

cell O
cycle O
regulators. O
Proteins O
and O
mRNA O
levels O
were O
examined O
by O
immunoblotting O
and O
the O
real-time O
reverse O
transcription-polymerase O
chain O
reaction, O
respectively. O
In O
this O
study, O
AhR B-GENE-Y
overexpression O
positively O
modulated O
growth O
of O
lung O
AD O
cells, O
at O
least O
partially, O
via O
RelA-dependent B-GENE-Y
mechanisms. O
Although O
treatment O
with O
17-AAG B-CHEMICAL
reduced O
AhR B-GENE-Y
levels O
and O
AhR-regulated B-GENE-Y
gene O
expression O
in O
lung O
AD O
cells, O
AhR B-GENE-Y
expression O
increased O
anticancer O
activity O
of O
17-AAG. B-CHEMICAL
In O
addition, O
17-AAG B-CHEMICAL
treatment O
reduced O
cell O
viability, O
CDK2, B-GENE-Y
CDK4, B-GENE-Y

cyclin B-GENE-N
E, I-GENE-N
cyclin B-GENE-Y
D1, I-GENE-Y
and O
phosphorylated B-GENE-Y
Rb I-GENE-Y
levels O
in O
AhR-expressing B-GENE-Y
lung O
AD O
cells. O
NAD(P)H:quinone B-CHEMICAL
oxidoreductase I-GENE-Y
(NQO1), B-GENE-Y
which O
is O
regulated O
by O
AhR, B-GENE-Y
was O
shown O
to O
increase O
anticancer O
activity O
of O
17-AAG B-CHEMICAL
in O
cells. O
Knockdown O
of O
NQO1 B-GENE-Y
expression O
attenuated O
the O
reduction O
of O
cell O
cycle O
regulators O
by O
17-AAG B-CHEMICAL
treatment O
in O
AhR B-GENE-Y
overexpressed O
cells. O
We O
demonstrated O
that O
AhR B-GENE-Y
protein O
not O
only O
functions O
as O
a O
downstream O
target O
of O

17-AAG, B-CHEMICAL
but O
also O
enhances O
anticancer O
activity O
of O
17-AAG B-CHEMICAL
in O
lung O
AD O
cells. O
Pharmacogenomics O
of O
gemcitabine B-CHEMICAL
metabolism: O
functional O
analysis O
of O
genetic O
variants O
in O
cytidine B-GENE-Y
deaminase I-GENE-Y
and O
deoxycytidine B-GENE-Y
kinase. I-GENE-Y
Gemcitabine B-CHEMICAL
(dFdC, B-CHEMICAL
2',2'-difluorodeoxycytidine) B-CHEMICAL
is O
metabolized O
by O
cytidine B-GENE-Y
deaminase I-GENE-Y
(CDA) B-GENE-Y
and O
deoxycytidine B-GENE-Y
kinase I-GENE-Y
(DCK), B-GENE-Y
but O
the O
contribution O
of O
genetic O
variation O
in O
these O

enzymes O
to O
the O
variability O
in O
systemic O
exposure O
and O
response O
observed O
in O
cancer O
patients O
is O
unclear. O
Wild-type O
enzymes O
and O
variants O
of O
CDA B-GENE-Y
(Lys27Gln B-GENE-N
and O
Ala70Thr) B-GENE-N
and O
DCK B-GENE-Y
(Ile24Val, B-GENE-N
Ala119Gly, B-GENE-N
and O
Pro122Ser) B-GENE-N
were O
expressed O
in O
and O
purified O
from O
Escherichia O
coli, O
and O
enzyme O
kinetic O
parameters O
were O
estimated O
for O
cytarabine B-CHEMICAL
(Ara-C), B-CHEMICAL
dFdC, B-CHEMICAL
and O
its O
metabolite O
2',2'-difluorodeoxyuridine B-CHEMICAL
(dFdU) B-CHEMICAL
as O

substrates. O
All O
three O
CDA B-GENE-Y
proteins O
showed O
similar O
K(m) O
and O
V(max) O
for O
Ara-C B-CHEMICAL
and O
dFdC B-CHEMICAL
deamination, O
except O
for O
CDA70Thr, B-GENE-Y
which O
had O
a O
2.5-fold O
lower O
K(m) O
and O
6-fold O
lower O
V(max) O
for O
Ara-C B-CHEMICAL
deamination. O
All O
four O
DCK B-GENE-Y
proteins O
yielded O
comparable O
metabolic O
activity O
for O
Ara-C B-CHEMICAL
and O
dFdC B-CHEMICAL
monophosphorylation, O
except O
for O
DCK24Val, B-GENE-Y
which O
demonstrated O
an O
approximately O
2-fold O
increase O
(P O
< O
0.05) O
in O
the O
intrinsic O
clearance O
of O

dFdC B-CHEMICAL
monophosphorylation O
due O
to O
a O
40% O
decrease O
in O
K(m) O
(P O
< O
0.05). O
DCK B-GENE-Y
did O
not O
significantly O
contribute O
to O
dFdU B-CHEMICAL
monophosphorylation. O
In O
conclusion, O
the O
Lys27Gln B-GENE-N
substitution O
does O
not O
significantly O
modulate O
CDA B-GENE-Y
activity O
toward O
dFdC, B-CHEMICAL
and O
therefore O
would O
not O
contribute O
to O
interindividual O
variability O
in O
response O
to O
gemcitabine. B-CHEMICAL
The O
higher O
in O
vitro O
catalytic O
efficiency O
of O
DCK24Val B-GENE-Y
toward O
dFdC B-CHEMICAL
monophosphorylation O
may O
be O
relevant O
to O

dFdC B-CHEMICAL
clinical O
response. O
The O
substrate-dependent O
alterations O
in O
activities O
of O
CDA70Thr B-GENE-Y
and O
DCK24Val B-GENE-Y
in O
vitro O
were O
observed O
for O
the O
first O
time, O
and O
demonstrate O
that O
the O
in O
vivo O
consequences O
of O
these O
genetic O
variations O
should O
not O
be O
extrapolated O
from O
one O
substrate O
of O
these O
enzymes O
to O
another. O
Discovery O
of O
4-phenyl-2-phenylaminopyridine B-CHEMICAL
based O
TNIK B-GENE-Y
inhibitors. O
A O
series O
of O
compounds O
based O
on O
a O
4-phenyl-2-phenylaminopyridine B-CHEMICAL
scaffold O
that O
are O
potent O
and O
selective O
inhibitors O
of O

Traf2- B-GENE-Y
and I-GENE-Y
Nck-interacting I-GENE-Y
kinase I-GENE-Y
(TNIK) B-GENE-Y
activity O
are O
described. O
These O
compounds O
were O
used O
as O
tools O
to O
test O
the O
importance O
of O
TNIK B-GENE-Y
kinase B-GENE-N
activity O
in O
signaling O
and O
proliferation O
in O
Wnt-activated B-GENE-N
colorectal O
cancer O
cells. O
The O
results O
indicate O
that O
pharmacological O
inhibition O
of O
TNIK B-GENE-Y
kinase B-GENE-N
activity O
has O
minimal O
effects O
on O
either O
Wnt/TCF4/-catenin-driven B-GENE-N
transcription O
or O
viability. O
The O
findings O
suggest O
that O
the O
kinase B-GENE-N
activity O
of O
TNIK B-GENE-Y
may O
be O
less O
important O
to O
Wnt B-GENE-N
signaling O
than O
other O
aspects O
of O
TNIK B-GENE-Y
function, O
such O
as O
its O
putative O
role O
in O

stabilizing O
the O
TCF4/-catenin B-GENE-Y
transcriptional O
complex. O
Hybrid O
carbon B-CHEMICAL
nanotube O
networks O
as O
efficient O
hole O
extraction O
layers O
for O
organic O
photovoltaics. O
Transparent, O
highly O
percolated O
networks O
of O
regioregular O
poly(3-hexylthiophene) B-CHEMICAL
(rr-P3HT)-wrapped B-CHEMICAL
semiconducting O
single-walled O
carbon B-CHEMICAL
nanotubes O
(s-SWNTs) O
are O
deposited, O
and O
the O
charge O
transfer O
processes O
of O
these O
nanohybrids O
are O
studied O
using O
spectroscopic O
and O
electrical O
measurements. O
The O
data O
disclose O
hole O
doping O

of O
s-SWNTs O
by O
the O
polymer, O
challenging O
the O
prevalent O
electron-doping O
hypothesis. O
Through O
controlled O
fabrication, O
high- O
to O
low-density O
nanohybrid O
networks O
are O
achieved, O
with O
low-density O
hybrid O
carbon B-CHEMICAL
nanotube O
networks O
tested O
as O
hole O
transport O
layers O
(HTLs) O
for O
bulk O
heterojunction O
(BHJ) O
organic O
photovoltaics O
(OPV). O
OPVs O
incorporating O
these O
rr-P3HT/s-SWNT B-CHEMICAL
networks O
as O
the O
HTL O
demonstrate O
the O
best O
large O
area O
(70 O
mm(2)) O
carbon B-CHEMICAL
nanotube O
incorporated O
organic O
solar O
cells O
to O
date O

with O
a O
power O
conversion O
efficiency O
of O
7.6%. O
This O
signifies O
the O
strong O
capability O
of O
nanohybrids O
as O
an O
efficient O
hole O
extraction O
layer, O
and O
we O
believe O
that O
dense O
nanohybrid O
networks O
have O
the O
potential O
to O
replace O
expensive O
and O
material O
scarce O
inorganic O
transparent O
electrodes O
in O
large O
area O
electronics O
toward O
the O
realization O
of O
low-cost O
flexible O
electronics. O
Chemical O
assessment O
and O
antioxidant O
capacity O
of O
pepper O
(Capsicum O
annuum O
L.) O
seeds. O
Capsicum O
annuum O
L. O
is O
reported O
to O
be O
the O
most O
widely O
cultivated O
species. O
Recently, O
waste O
of O
vegetable O
processing, O
like O
seeds, O
has O
been O
the O
subject O
of O

many O
studies O
as O
an O
attempt O
to O
find O
new, O
alternative O
and O
cheap O
resources O
of O
bioactive O
compounds O
with O
application O
in O
several O
industries. O
Despite O
their O
chemical, O
biological O
and O
ecological O
importance, O
C. O
annuum O
seeds O
are O
still O
poorly O
studied. O
To O
improve O
the O
knowledge O
on O
the O
metabolic O
profile O
of O
this O
matrix, O
a O
targeted O
metabolite O
analysis O
was O
performed O
in O
"sweet O
Italian" O
and O
"Reus O
long O
pairal" O
pepper O
seeds. O
Sterols, B-CHEMICAL
triterpenes, B-CHEMICAL
organic O
acids, O
fatty B-CHEMICAL
acids I-CHEMICAL
and O
volatile O
compounds O
were O
determined O
by O
different O
chromatographic O
methods. O
The O
antioxidant O
activity O
was O
assessed O
against O
DPPH(), B-CHEMICAL
superoxide B-CHEMICAL
and O

nitric B-CHEMICAL
oxide I-CHEMICAL
radicals. O
A O
concentration-dependent O
activity O
was O
noticed O
against O
all O
radicals. O
Acetylcholinesterase B-GENE-Y
inhibitory O
capacity O
was O
also O
evaluated, O
but O
no O
effect O
was O
found. O
Data O
provide O
evidence O
of O
great O
similarities O
between O
"sweet O
Italian" O
and O
"Reus O
long O
pairal" O
pepper O
seeds. O
The O
present O
study O
indicates O
that O
C. O
annuum O
seeds O
are O
a O
potential O
source O
of O
valuable O
bioactive O
compounds O
that O
could O
be O
used O
in O
food O
industry. O
Boron-based B-CHEMICAL
inhibitors O
of O
acyl B-CHEMICAL
protein I-GENE-N
thioesterases I-GENE-N
1 I-GENE-N
and I-GENE-N
2. I-GENE-N
Ras B-GENE-N
proteins O
are O
of O
importance O
in O
cell O
proliferation, O
and O
hence O
their O
mutated O
forms O
play O

causative O
roles O
in O
many O
kinds O
of O
cancer O
in O
different O
tissues. O
Inhibition O
of O
the O
Ras-depalmitoylating B-GENE-N
enzyme O
acyl B-GENE-N
protein I-GENE-N
thioesterases I-GENE-N
APT1 I-GENE-N
and I-GENE-N
-2 I-GENE-N
is O
a O
new O
approach O
to O
modulating O
the O
Ras B-GENE-N
cycle. O
Here O
we O
present O
boronic B-CHEMICAL
and O
borinic B-CHEMICAL
acid I-CHEMICAL
derivatives O
as O
a O
new O
class O
of O
potent O
and O
nontoxic O
APT B-GENE-N
inhibitors. O
These O
compounds O
were O
detected O
by O
extensive O
library O
screening O
using O
chemical O
arrays O
and O
turned O
out O
to O
inhibit O
human B-GENE-N
APT1 I-GENE-N
and I-GENE-N
-2 I-GENE-N
in O
a O
competitive O
mode. O
Furthermore, O
one O
of O
the O
molecules O
was O
demonstrated O
to O
inhibit O

Erk1/2 B-GENE-N
phosphorylation O
significantly. O
Three-Dimensional O
CdS-Titanate B-CHEMICAL
Composite O
Nanomaterials O
for O
Enhanced O
Visible-Light-Driven O
Hydrogen B-CHEMICAL
Evolution. O
3D O
Hierarchical O
echinus-like O
titanate B-CHEMICAL
spheres O
(HETSs), O
serving O
as O
the O
supporting O
material O
for O
CdS B-CHEMICAL
nanoparticles, O
are O
synthesized O
via O
a O
fast O
one-step O
hydrothermal O
method. O
The O
obtained O
3D O
CdS-HETS B-CHEMICAL
composite O
materials O
show O
enhanced O
H2 B-CHEMICAL
generation O
under O
visible O
light O
irradiation. O

UPLC-Q-TOF/HSMS/MS(E)-based O
metabonomics O
for O
adenine-induced B-CHEMICAL
changes O
in O
metabolic O
profiles O
of O
rat O
faeces O
and O
intervention O
effects O
of O
ergosta-4,6,8(14),22-tetraen-3-one. B-CHEMICAL
Ergosta-4,6,8(14),22-tetraen-3-one B-CHEMICAL
(ergone), B-CHEMICAL
isolated O
from O
the O
medicinal O
fungus O
Polyporus O
umbellatus, O
has O
been O
proven O
to O
prevent O
the O
progression O
of O
renal O
injury O
and O
the O
subsequent O
renal O
fibrosis. O
Ultra O

performance O
liquid O
chromatography O
coupled O
with O
quadrupole O
time-of-flight O
high-sensitivity O
mass O
spectrometry O
and O
a O
novel O
mass O
spectrometry(Elevated O
Energy) O
(MS(E)) O
data O
collection O
technique O
was O
employed O
to O
investigate O
metabonomic O
characters O
of O
chronic O
renal O
failure O
(CRF) O
induced O
adenine B-CHEMICAL
and O
the O
protective O
effects O
of O
ergosta-4,6,8(14),22-tetraen-3-one B-CHEMICAL
(ergone). B-CHEMICAL
Coupled O
with O
blood O
biochemistry O
and O
kidney O
histopathology O
results, O
the O
significant O
difference O
in O
metabolic O
profiling O
between O

adenine-induced B-CHEMICAL
CRF O
group O
and O
ergone-treated B-CHEMICAL
CRF O
group O
by O
using O
pattern O
recognition O
analysis O
indicated O
that O
changes O
in O
global O
faecal O
metabolites O
were O
occurred. O
Seven O
endogenous O
metabolites O
were O
identified O
by O
using O
metabonomic O
method O
combined O
with O
multivariate O
data O
analysis, O
the O
accurate O
mass, O
isotopic O
pattern, O
MS(E) O
fragments O
information O
and O
MassLynx O
i-FIT O
algorithm. O
These O
biochemical O
changes O
in O
faecal O
metabolites O
are O
related O
to O
the O
perturbations O
of O
bile B-CHEMICAL
acid I-CHEMICAL
metabolism O
and O
phospholipid O
metabolism, O
which O
may O
be O
helpful O
to O
further O
understand O
the O

CRF O
and O
therapeutic O
mechanisms O
of O
ergone. B-CHEMICAL
This O
research O
proved O
that O
MS(E) O
can O
simultaneous O
acquire O
precursor O
ion O
information O
and O
fragment O
ion O
data O
at O
high O
and O
low O
collision O
energy O
in O
one O
analytical O
run, O
which O
facilitated O
the O
fast O
structural O
characterization O
of O
metabolites. O
Selective O
separation O
of O
similarly O
sized O
proteins O
with O
tunable O
nanoporous O
block O
copolymer O
membranes. O
An O
integral O
asymmetric O
membrane O
was O
fabricated O
in O
a O
fast O
and O
one-step O
process O
by O
combining O
the O
self-assembly O
of O
an O
amphiphilic O
block O
copolymer O
(PS-b-P4VP) B-CHEMICAL
with O
nonsolvent-induced O
phase O
separation. O
The O
structure O
was O
found O

to O
be O
composed O
of O
a O
thin O
layer O
of O
densely O
packed O
highly O
ordered O
cylindrical O
channels O
with O
uniform O
pore O
sizes O
perpendicular O
to O
the O
surface O
on O
top O
of O
a O
nonordered O
sponge-like O
layer. O
The O
as-assembled O
membrane O
obtained O
a O
water O
flux O
of O
more O
than O
3200 O
L O
m(-2) O
h(-1) O
bar(-1), O
which O
was O
at O
least O
an O
order O
of O
magnitude O
higher O
than O
the O
water O
fluxes O
of O
commercially O
available O
membranes O
with O
comparable O
pore O
sizes, O
making O
this O
membrane O
particularly O
well O
suited O
to O
size-selective O
and O
charge-based O
separation O
of O
biomolecules. O
To O
test O
the O
performance O
of O
the O
membrane, O
we O
conducted O
diffusion O

experiments O
at O
the O
physiological O
pH O
of O
7.4 O
using O
bovine B-GENE-Y
serum I-GENE-Y
albumin I-GENE-Y
(BSA) B-GENE-Y
and O
globulin-, B-GENE-N
two O
proteins O
with O
different O
diameters O
but O
too O
close O
in O
size O
(2-fold O
difference O
in O
molecular O
mass) O
to O
be O
efficiently O
separated O
via O
conventional O
dialysis O
membrane O
processes. O
The O
diffusion O
rate O
differed O
by O
a O
factor O
of O
87, O
the O
highest O
value O
reported O
to O
date. O
We O
also O
analyzed O
charge-based O
diffusive O
transport O
and O
separation O
of O
two O
proteins O
of O
similar O
molecular O
weight O
(BSA B-GENE-Y
and O
bovine B-GENE-N
hemoglobin I-GENE-N
(BHb)) B-GENE-N
through O
the O
membrane O
as O
a O
function O
of O
external O
pH. O
The O
membrane O
achieved O

a O
selectivity O
of O
about O
10 O
at O
pH O
4.7, O
the O
isoelectric O
point O
(pI) O
of O
BSA. B-GENE-Y
We O
then O
positively O
charged O
the O
membrane O
to O
improve O
the O
separation O
selectivity. O
With O
the O
modified O
membrane O
BSA B-GENE-Y
was O
completely O
blocked O
when O
the O
pH O
was O
7.0, O
the O
pI O
of O
BHb, B-GENE-N
while O
BHb B-GENE-N
was O
completely O
blocked O
at O
pH O
4.7. O
Our O
results O
demonstrate O
the O
potential O
of O
our O
asymmetric O
membrane O
to O
efficiently O
separate O
biological O
substances/pharmaceuticals O
in O
bioscience, O
biotechnology, O
and O
biomedicine O
applications. O
Phytoestrogen O
genistein B-CHEMICAL
protects O
against O
endothelial O
barrier O

dysfunction O
in O
vascular O
endothelial O
cells O
through O
PKA-mediated B-GENE-N
suppression O
of O
RhoA B-GENE-Y
signaling. O
The O
soy-derived O
phytoestrogen O
genistein B-CHEMICAL
has O
received O
attention O
for O
its O
potential O
to O
improve O
vascular O
function, O
but O
its O
mechanism O
remains O
unclear. O
Here, O
we O
report O
that O
genistein B-CHEMICAL
at O
physiologically O
relevant O
concentrations O
(0.1-10 O
M) O
significantly O
inhibited O
thrombin-induced B-GENE-Y
increase O
in O
endothelial O
monolayer O
permeability. O
Genistein B-CHEMICAL
also O
reduced O
the O
formation O
of O
stress O
fibers O
by O
thrombin B-GENE-Y
and O
suppressed O
thrombin-induced B-GENE-Y
phosphorylation O
of O
myosin B-GENE-N

light I-GENE-N
chain I-GENE-N
(MLC) B-GENE-N
on O
Ser(19)/Thr(18) B-CHEMICAL
in O
endothelial O
cells O
(ECs). O
Genistein B-CHEMICAL
had O
no O
effect O
on O
resting O
intracellular O
[Ca(2+)] B-CHEMICAL
or O
thrombin-induced B-GENE-Y
increase O
in O
Ca(2+) B-CHEMICAL
mobilization. O
Addition O
of O
the O
inhibitors O
of O
endothelial B-GENE-Y
nitric I-GENE-Y
oxide I-GENE-Y
synthase I-GENE-Y
or O
estrogen B-GENE-Y
receptor I-GENE-Y
did O
not O
alter O
the O
protective O
effect O
of O
genistein. B-CHEMICAL
RhoA B-GENE-Y
is O
a O
small O
GTPase B-GENE-N
that O
plays O
an O
important O
role O
in O
actin-myosin B-GENE-N
contraction O
and O
endothelial O
barrier O

dysfunction. O
RhoA B-GENE-Y
inhibitor O
blocked O
the O
protective O
effect O
of O
genistein B-CHEMICAL
on O
endothelial O
permeability O
and O
also O
ablated O
thrombin-induced B-GENE-Y
MLC-phosphorylation B-GENE-N
in O
ECs. O
Inhibition O
of O
PKA B-GENE-N
significantly O
attenuated O
the O
effect O
of O
genistein B-CHEMICAL
on O
thrombin-induced B-GENE-Y
EC O
permeability, O
MLC B-GENE-N
phosphorylation, O
and O
RhoA B-GENE-Y
membrane O
translocation O
in O
ECs. O
Furthermore, O
thrombin B-GENE-Y
diminished O
cAMP B-CHEMICAL
production O
in O
ECs, O
which O
were O
prevented O
by O
treatment O
with O
genistein. B-CHEMICAL
These O
findings O
demonstrated O
that O
genistein B-CHEMICAL
improves O

thrombin-induced B-GENE-Y
endothelial O
barrier O
dysfunction O
in O
ECs O
through O
PKA-mediated B-GENE-N
suppression O
of O
RhoA B-GENE-Y
signaling. O
Metabolic O
effects O
of O
honey O
in O
type O
1 O
diabetes O
mellitus: O
a O
randomized O
crossover O
pilot O
study. O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
metabolic O
effects O
of O
12-week O
honey O
consumption O
on O
patients O
suffering O
from O
type O
1 O
diabetes O
mellitus O
(DM). O
This O
was O
a O
randomized O
crossover O
clinical O
trial O
done O
in O
the O
National O
Institute O
for O
Diabetes O
and O
Endocrinology, O
Cairo, O
Egypt. O
Twenty O
patients O
of O
both O
sexes O
aged O
4-18 O
years O
with O
type O
1 O
DM O
and O

HbA1C<10% B-GENE-Y
participated O
in O
the O
study. O
They O
were O
randomized O
into O
two O
equal O
groups O
(intervention O
to O
control O
and O
control O
to O
intervention). O
The O
dietary O
intervention O
was O
12-week O
honey O
consumption O
in O
a O
dose O
of O
0.5 O
mL/kg O
body O
weight O
per O
day. O
The O
main O
outcome O
measures O
were O
serum O
glucose, B-CHEMICAL
lipids, O
and O
C-peptide, B-GENE-Y
and O
anthropometric O
measurements. O
None O
of O
participants O
were O
lost O
in O
follow-up. O
The O
intervention O
resulted O
in O
significant O
decreases O
in O
subscapular O
skin O
fold O
thickness O
(SSFT; O
P=.002), O
fasting O
serum O
glucose B-CHEMICAL
(FSG; O

P=.001), O
total O
cholesterol B-CHEMICAL
(P=.0001), O
serum O
triglycerides B-CHEMICAL
(TG; O
P=.0001), O
and O
low-density B-GENE-N
lipoprotein I-GENE-N
(P=.0009), O
and O
significant O
increases O
in O
fasting B-GENE-Y
C-peptide I-GENE-Y
(FCP; B-GENE-Y
P=.0004) O
and O
2-h O
postprandial B-GENE-Y
C-peptide I-GENE-Y
(PCP; B-GENE-Y
P=.002). O
As O
possible O
long-term O
effects O
of O
honey O
after O
its O
withdrawal, O
statistically O
significant O
reductions O
in O
midarm O
circumference O

(P=.000), O
triceps O
skin O
fold O
thickness O
(P=.006), O
SSFT O
(P=.003), O
FSG O
(P=.005), O
2-h O
postprandial O
serum O
glucose B-CHEMICAL
(P=.000), O
TG O
(P=.003), O
and O
HbA1C B-GENE-Y
(P=.043), O
and O
significant O
increases O
in O
FCP B-GENE-Y
(P=.002) O
and O
PCP B-GENE-Y
(P=.003) O
were O
observed. O
This O
small O
clinical O
trial O
suggests O
that O
long-term O
consumption O
of O
honey O
might O
have O
positive O
effects O
on O
the O

metabolic O
derangements O
of O
type O
1 O
DM. O
Evaluation O
of O
drug O
interactions O
of O
GSK1292263 B-CHEMICAL
(a O
GPR119 B-GENE-Y
agonist) O
with O
statins: O
from O
in O
vitro O
data O
to O
clinical O
study O
design. O
1. O
This O
work O
investigated O
the O
drug O
interaction O
potential O
of O
GSK1292263, B-CHEMICAL
a O
novel O
GPR119 B-GENE-Y
agonist, O
with O
the O
HMG-coA B-GENE-Y
reductase I-GENE-Y
inhibitors O
simvastatin B-CHEMICAL
and O
rosuvastatin. B-CHEMICAL
2. O
In O
vitro O
experiments O
assessed O
the O
inhibition O
of O
transporters B-GENE-N
and O
CYP B-GENE-N
enzymes O
by O

GSK1292263, B-CHEMICAL
and O
a O
clinical O
drug O
interaction O
study O
investigated O
the O
effect O
of O
GSK1292263 B-CHEMICAL
(300 O
mg O
BID) O
on O
the O
pharmacokinetic O
profile O
of O
simvastatin B-CHEMICAL
(40 O
mg O
single O
dose) O
and O
rosuvastatin B-CHEMICAL
(10 O
mg O
single O
dose). O
3. O
In O
vitro, O
GSK1292263 B-CHEMICAL
demonstrated O
little/weak O
inhibition O
(IC50 O
values O
>30 O
M) O
towards O
CYPs B-GENE-N
(CYP1A2, B-GENE-Y
2C9, B-GENE-Y
2C19, B-GENE-Y
2D6, B-GENE-Y
3A4), B-GENE-Y

Pgp, B-GENE-N
OATP1B3, B-GENE-Y
or O
OCT2. B-GENE-Y
However, O
GSK1292263 B-CHEMICAL
inhibited O
BCRP B-GENE-Y
and O
OATP1B1, B-GENE-Y
which O
are O
transporters O
involved O
in O
statin O
disposition. O
4. O
In O
the O
clinical O
study, O
small O
increases O
in O
the O
AUC(0-inf) O
of O
simvastatin B-CHEMICAL
[mean O
ratio O
(90% O
CI) O
of O
1.34 O
(1.22, O
1.48)] O
and O
rosuvastatin B-CHEMICAL
[mean O
ratio O
(90% O
CI) O
of O
1.39 O
(1.30, O

1.49)] O
were O
observed O
when O
co-administered O
with O
GSK1292263, B-CHEMICAL
which O
is O
consistent O
with O
an O
inhibitory O
effect O
on O
intestinal O
BCRP B-GENE-Y
and O
CYP3A4. B-GENE-Y
In O
contrast, O
GSK1292263 B-CHEMICAL
did O
not O
inhibit O
OATP1B1 B-GENE-Y
based O
on O
the O
lack O
of O
changes O
in O
simvastatin B-CHEMICAL
acid O
exposure O
[mean O
AUC(0-inf) O
ratio O
(90% O
CI) O
of O
1.05 O
(0.91, O
1.21)]. O
5. O
GSK1292263 B-CHEMICAL
has O
a O
weak O
drug O
interaction O
with O

simvastatin B-CHEMICAL
and O
rosuvastain. B-CHEMICAL
This O
study O
provides O
a O
mechanistic O
understanding O
of O
the O
in O
vivo O
inhibition O
of O
transporters B-GENE-N
and O
enzymes O
by O
GSK1292263. B-CHEMICAL
Antioxidants O
and O
mucolytics O
in O
COPD O
management: O
when O
(if O
ever) O
and O
in O
whom? O
Chronic O
obstructive O
pulmonary O
disease O
(COPD) O
is O
a O
major O
cause O
of O
morbidity O
and O
mortality O
worldwide. O
Oxidative O
stress O
is O
an O
important O
mechanism O
in O
the O
pathogenesis O
of O
this O
disease. O
The O
oxidant/ O
antioxidant O
imbalance O
occurring O
in O
smokers O
and O
patients O

with O
COPD O
is O
well O
established. O
Thus, O
therapeutic O
strategies O
targeting O
oxidative O
stress O
with O
pharmacological O
antioxidant O
agents O
or O
boosting O
the O
endogenous O
levels O
of O
antioxidants O
is O
likely O
to O
be O
beneficial O
as O
an O
adjunctive O
tool O
in O
the O
treatment O
of O
COPD O
patients. O
Thiol B-CHEMICAL
compounts O
such O
as O
N-acetyl-L-cysteine B-CHEMICAL
(NAC), B-CHEMICAL
carbocysteine, B-CHEMICAL
erdosteine, B-CHEMICAL
and O
fudosteine B-CHEMICAL
have O
been O
extensively O
studied. O
Although O
some O
results O
remain O
controversial, O
NAC B-CHEMICAL
and O
carbocysteine B-CHEMICAL
seem O
to O
have O
beneficial O
effect O
in O
patients O

not O
receiving O
inhaled O
corticosteroids B-CHEMICAL
who O
suffer O
from O
frequent O
exacerbations. O
In O
addition, O
other O
antioxidants O
like O
superoxide B-GENE-N
dismutase I-GENE-N
(SOD) B-GENE-N
mimetics O
and O
nuclear B-GENE-Y
factor-erythroid I-GENE-Y
2 I-GENE-Y
related I-GENE-Y
factor I-GENE-Y
2 I-GENE-Y
(Nrf2) B-GENE-Y
are O
shown O
to O
decrease O
markers O
of O
oxidative O
stress O
in O
patients O
with O
emphysema, O
while O
others O
like O
glutathione B-CHEMICAL
peroxidase I-GENE-N
(GPx) B-GENE-N
mimetics O
and O
NO B-CHEMICAL
synthase I-GENE-N
(iNOS) B-GENE-Y
can O
prevent O
both O
inflammation O
and O
oxidative O
stress O
in O
clinical O
trials O
in O
vivo O
(or O
in O
mouse O
models). O

In O
this O
article O
we O
review O
the O
effectiveness O
of O
various O
antioxidant O
factors O
in O
COPD O
and O
their O
potential O
beneficial O
effect O
in O
the O
treatment O
of O
the O
disease. O
Steroid B-CHEMICAL
toxicity O
and O
detoxification O
in O
ascomycetous O
fungi. O
In O
the O
last O
couple O
of O
decades O
fungal O
infections O
have O
become O
a O
significant O
clinical O
problem. O
A O
major O
interest O
into O
fungal O
steroid B-CHEMICAL
action O
has O
been O
provoked O
since O
research O
has O
proven O
that O
steroid B-CHEMICAL
hormones O
are O
toxic O
to O
fungi O
and O
affect O
the O
host/fungus O
relationship. O
Steroid B-CHEMICAL
hormones O
were O
found O
to O
differ O
in O
their O
antifungal O
activity O
in O
ascomycetous O
fungi O
Hortaea O

werneckii, O
Saccharomyces O
cerevisiae O
and O
Aspergillus O
oryzae. O
Dehydroepiandrosterone O
was O
shown O
to O
be O
the O
strongest O
inhibitor O
of O
growth O
in O
all O
three O
varieties O
of O
fungi O
followed O
by O
androstenedione B-CHEMICAL
and O
testosterone. B-CHEMICAL
For O
their O
protection, O
fungi O
use O
several O
mechanisms O
to O
lower O
the O
toxic O
effects O
of O
steroids. B-CHEMICAL
The O
efficiency O
of O
biotransformation O
in O
detoxification O
depended O
on O
the O
microorganism O
and O
steroid B-CHEMICAL
substrate O
used. O
Biotransformation O
was O
a O
relatively O
slow O
process O
as O
it O
also O
depended O
on O
the O
growth O
phase O
of O
the O
fungus. O
In O
addition O
to O

biotransformation, O
steroid B-CHEMICAL
extrusion O
out O
of O
the O
cells O
contributed O
to O
the O
lowering O
of O
the O
active O
intracellular O
steroid B-CHEMICAL
concentration. O
Plasma O
membrane O
Pdr5 B-GENE-N
transporter O
was O
found O
to O
be O
the O
most O
effective, O
followed O
by O
Snq2 B-GENE-N
transporter O
and O
vacuolar O
transporters O
Ybt1 B-GENE-N
and O
Ycf1. B-GENE-N
Proteins O
Aus1 B-GENE-N
and O
Dan1 B-GENE-N
were O
not O
found O
to O
be O
involved O
in O
steroid B-CHEMICAL
import. O
The O
research O
of O
possible O
targets O
of O
steroid B-CHEMICAL
hormone O
action O
in O
fungi O
suggests O
that O
steroid B-CHEMICAL
hormones O
inhibit O
ergosterol B-CHEMICAL
biosynthesis O
in O
S. O

cerevisiae O
and O
H. O
werneckii. O
Results O
of O
this O
inhibition O
caused O
changes O
in O
the O
sterol B-CHEMICAL
content O
of O
the O
cellular O
membrane. O
The O
presence O
of O
steroid B-CHEMICAL
hormones O
most O
probably O
causes O
the O
degradation O
of O
the O
Tat2 B-GENE-N
permease O
and O
impairment O
of O
tryptophan B-CHEMICAL
import. O
Cell-cycle O
and O
DNA O
damage O
regulation O
of O
the O
DNA B-GENE-Y
mismatch I-GENE-Y
repair I-GENE-Y
protein I-GENE-Y
Msh2 I-GENE-Y
occurs O
at O
the O
transcriptional O
and O
post-transcriptional O
level. O
DNA O
mismatch O
repair O
during O
replication O
is O
a O
conserved O
process O
essential O
for O
maintaining O
genomic O
stability. O
Mismatch O
repair O
is O
also O
implicated O
in O
cell-cycle O
arrest O
and O
apoptosis O

after O
DNA O
damage. O
Because O
yeast O
and O
human O
mismatch O
repair O
systems O
are O
well O
conserved, O
we O
have O
employed O
the O
budding O
yeast O
Saccharomyces O
cerevisiae O
to O
understand O
the O
regulation O
and O
function O
of O
the O
mismatch O
repair O
gene O
MSH2. B-GENE-Y
Using O
a O
luciferase-based O
transcriptional O
reporter, O
we O
defined O
a O
218-bp O
region O
upstream O
of O
MSH2 B-GENE-Y
that O
contains O
cell-cycle B-GENE-N
and I-GENE-N
DNA I-GENE-N
damage I-GENE-N
responsive I-GENE-N
elements. I-GENE-N
The O
5' O
end O
of O
the O
MSH2 B-GENE-Y
transcript O
was O
mapped O
by O
primer O
extension O
and O
was O
found O
to O
encode O
a O
small O
upstream B-GENE-N
open I-GENE-N
reading I-GENE-N
frame I-GENE-N
(uORF). B-GENE-N

Mutagenesis O
of O
the O
uORF B-GENE-N
start I-GENE-N
codon I-GENE-N
or O
of O
the O
uORF B-GENE-N
stop I-GENE-N
codon, I-GENE-N
which O
creates O
a O
continuous O
reading O
frame O
with O
MSH2, B-GENE-Y
increased O
Msh2 B-GENE-Y
steady-state O
protein O
levels O
2-fold. O
Furthermore, O
we O
found O
that O
the O
cell-cycle O
transcription O
factors O
Swi6, B-GENE-Y
Swi4, B-GENE-Y
and O
Mbp1-along B-GENE-Y
with O
SCB/MCB B-GENE-N
cell-cycle I-GENE-N
binding I-GENE-N
sites I-GENE-N
upstream O
of O
MSH2-are B-GENE-Y
all O
required O
for O
full O
basal O
expression O
of O
MSH2. B-GENE-Y
Mutagenesis O
of O
the O
cell-cycle B-GENE-N
boxes I-GENE-N
resulted O
in O
a O
minor O
reduction O
in O
basal O
Msh2 B-GENE-Y
levels O
and O
a O

3-fold O
defect O
in O
mismatch O
repair. O
Disruption O
of O
the O
cell-cycle B-GENE-N
boxes I-GENE-N
also O
affected O
growth O
in O
a O
DNA B-GENE-N
polymerase-defective I-GENE-N
strain O
background O
where O
mismatch O
repair O
is O
essential, O
particularly O
in O
the O
presence O
of O
the O
DNA O
damaging O
agent O
methyl B-CHEMICAL
methane I-CHEMICAL
sulfonate I-CHEMICAL
(MMS). B-CHEMICAL
Promoter O
replacements O
conferring O
constitutive O
expression O
of O
MSH2 B-GENE-Y
revealed O
that O
the O
transcriptional O
induction O
in O
response O
to O
MMS B-CHEMICAL
is O
required O
to O
maintain O
induced O
levels O
of O
Msh2. B-GENE-Y
Turnover O
experiments O
confirmed O
an O
elevated O
rate O
of O
degradation O
in O
the O
presence O
of O
MMS. B-CHEMICAL
Taken O
together, O
the O
data O
show O
that O

the O
DNA O
damage O
regulation O
of O
Msh2 B-GENE-Y
occurs O
at O
the O
transcriptional O
and O
post-transcriptional O
levels. O
The O
transcriptional O
and O
translational O
control O
elements O
identified O
are O
conserved O
in O
mammalian O
cells, O
underscoring O
the O
use O
of O
yeast O
as O
a O
model O
system O
to O
examine O
the O
regulation O
of O
MSH2. B-GENE-Y
Inhibition O
of O
Th1/Th17 O
responses O
via O
suppression O
of O
STAT1 B-GENE-Y
and O
STAT3 B-GENE-Y
activation O
contributes O
to O
the O
amelioration O
of O
murine O
experimental O
colitis O
by O
a O
natural O
flavonoid B-CHEMICAL
glucoside O
icariin. B-CHEMICAL
Inflammatory O
bowel O
disease O
(IBD) O
is O
a O
chronic O
inflammatory O

disorder O
in O
the O
intestine O
which O
involves O
overproduction O
of O
pro-inflammatory O
cytokines B-GENE-N
and O
excessive O
functions O
of O
inflammatory O
cells. O
However, O
current O
treatments O
for O
IBD O
may O
have O
potential O
adverse O
effects O
including O
steroid B-CHEMICAL
dependence, O
infections O
and O
lymphoma. O
Therefore O
new O
therapies O
or O
drug O
candidates O
for O
the O
treatment O
of O
IBD O
are O
desperately O
needed. O
In O
the O
present O
study O
we O
found O
that O
icariin, B-CHEMICAL
a O
major O
bioactive O
compound O
from O
plants O
in O
Epimedium O
family, O
exerted O
protective O
effect O
on O
intestinal O
inflammation O
in O
mice O
induced O
by O
dextran O
sulfate B-CHEMICAL
sodium. B-CHEMICAL
Oral O
administration O
of O

icariin B-CHEMICAL
significantly O
attenuated O
the O
disease O
progression O
and O
alleviated O
the O
pathological O
changes O
of O
colitis. O
It O
also O
inhibited O
the O
production O
of O
pro-inflammatory O
cytokines B-GENE-N
and O
expression O
of O
p-p65, B-GENE-Y
p-STAT1 B-GENE-Y
and O
p-STAT3 B-GENE-Y
in O
colon O
tissues. O
Further O
study O
showed O
that O
icariin B-CHEMICAL
dose-dependently O
inhibited O
the O
proliferation O
and O
activation O
of O
T O
lymphocytes, O
and O
suppressed O
pro-inflammatory O
cytokine B-GENE-N
levels O
of O
activated O
T O
cells. O
Moreover, O
icariin B-CHEMICAL
treatment O
inhibited O
the O
phosphorylations O
of O
STAT1 B-GENE-Y
and O

STAT3 B-GENE-Y
in O
CD4(+) O
T O
cells, O
which O
were O
the O
crucial O
transcription O
factors O
for O
Th1 O
and O
Th17 O
respectively. O
Taken O
together, O
these O
results O
indicate O
that O
icariin B-CHEMICAL
is O
a O
potential O
therapeutic O
agent O
for O
IBD. O
Stimulatory O
effect O
of O
insulin B-GENE-Y
on O
theca-interstitial O
cell O
proliferation O
and O
cell O
cycle O
regulatory O
proteins O
through O
MTORC1 B-GENE-N
dependent O
pathway. O
The O
present O
study O
examined O
the O
effect O
of O
insulin-mediated B-GENE-Y
activation O
of O
the O
mammalian B-GENE-N
target I-GENE-N
of I-GENE-N
rapamycin B-CHEMICAL
complex I-GENE-N
1 I-GENE-N
(MTORC1) B-GENE-N
signaling O
network O
on O
the O
proliferation O
of O
primary O
culture O
of O
theca-interstitial O

(T-I) O
cells. O
Our O
results O
show O
that O
insulin O
treatment O
increased O
proliferation O
of O
the O
T-I O
cells O
through O
the O
MTORC1-dependent B-GENE-N
signaling O
pathway O
by O
increasing O
cell O
cycle O
regulatory O
proteins. O
Inhibition O
of O
ERK1/2 B-GENE-N
signaling O
caused O
partial O
reduction O
of O
insulin-induced B-GENE-Y
phosphorylation O
of O
RPS6KB1 B-GENE-Y
and O
RPS6 B-GENE-Y
whereas O
inhibition O
of O
PI3-kinase B-GENE-N
signaling O
completely O
blocked O
the O
insulin B-GENE-Y
response. O
Pharmacological O
inhibition O
of O
MTORC1 B-GENE-N
with O
rapamycin B-CHEMICAL
abrogated O
the O
insulin-induced B-GENE-Y
phosphorylation O
of O
EIF4EBP1, B-GENE-Y

RPS6KB1 B-GENE-Y
and O
its O
downstream O
effector, O
RPS6. B-GENE-Y
These O
results O
were O
further O
confirmed O
by O
demonstrating O
that O
knockdown O
of O
Mtor B-GENE-Y
using O
siRNA O
reduced O
the O
insulin-stimulated B-GENE-Y
MTORC1 B-GENE-N
signaling. O
Furthermore, O
insulin-stimulated B-GENE-Y
T-I O
cell O
proliferation O
and O
the O
expression O
of O
cell B-GENE-N
cycle I-GENE-N
regulatory I-GENE-N
proteins I-GENE-N
CDK4, B-GENE-Y
CCND3 B-GENE-Y
and O
PCNA B-GENE-Y
were O
also O
blocked O
by O
rapamycin. B-CHEMICAL
Taken O
together, O
the O
present O
studies O
show O
that O
insulin O
stimulates O
cell O
proliferation O
and O
cell O
cycle O
regulatory O
proteins O
in O
T-I O
cells O
via O
activation O
of O
the O
MTORC1 B-GENE-N
signaling O
pathway. O
The O
conserved O
PHD1-PHD2 B-GENE-N

domain I-GENE-N
of O
ZFP-1/AF10 B-GENE-Y
is O
a O
discrete O
functional O
module O
essential O
for O
viability O
in O
Caenorhabditis O
elegans. O
Plant B-GENE-N
homeodomain I-GENE-N
(PHD)-type I-GENE-N
zinc I-GENE-N
fingers I-GENE-N
play O
an O
important O
role O
in O
recognizing O
chromatin O
modifications O
and O
recruiting O
regulatory O
proteins O
to O
specific O
genes. O
A O
specific O
module O
containing O
a O
conventional O
PHD B-GENE-N
finger I-GENE-N
followed O
by O
an O
extended O
PHD B-GENE-N
finger I-GENE-N
exists O
in O
the O
mammalian O
AF10 B-GENE-N
protein, O
among O
a O
few O
others. O
AF10 B-GENE-Y
has O
mostly O
been O
studied O
in O
the O
context O
of O
the O
leukemic O
MLL-AF10 B-GENE-Y
fusion O
protein, O
which O
lacks O
the O
N-terminal B-CHEMICAL
PHD I-GENE-N
fingers I-GENE-N

of O
AF10. B-GENE-Y
Although O
this O
domain O
of O
AF10 B-GENE-Y
is O
the O
most O
conserved O
region O
of O
the O
protein, O
its O
biological O
significance O
has O
not O
been O
elucidated. O
In O
this O
study, O
we O
used O
genetic O
and O
biochemical O
approaches O
to O
examine O
the O
PHD1-PHD2 B-GENE-N
region O
of O
the O
Caenorhabditis O
elegans O
ortholog O
of O
AF10, B-GENE-Y
zinc B-CHEMICAL
finger I-GENE-Y
protein I-GENE-Y
1 I-GENE-Y
(ZFP-1). B-GENE-Y
We O
demonstrate O
that O
the O
PHD1-PHD2 B-GENE-N
region O
is O
essential O
for O
viability O
and O
that O
the O
first O
PHD B-GENE-N
finger I-GENE-N
contributes O
to O
the O
preferred O
binding O
of O
PHD1-PHD2 B-GENE-N
to O
lysine B-CHEMICAL

4-methylated O
histone O
H3 O
tails. O
Moreover, O
we O
show O
that O
ZFP-1 B-GENE-Y
localization O
peaks O
overlap O
with O
H3K4 O
methylation-enriched O
promoters O
of O
actively O
expressed O
genes O
genomewide O
and O
that O
H3K4 O
methylation O
is O
important O
for O
ZFP-1 B-GENE-Y
localization O
to O
promoters O
in O
the O
embryo. O
We O
predict O
that O
the O
essential O
biological O
role O
of O
the O
PHD1-PHD2 B-GENE-N
module O
of O
ZFP-1/AF10 B-GENE-Y
is O
connected O
to O
the O
regulation O
of O
actively O
expressed O
genes O
during O
early O
development. O
Novel O
limonene B-CHEMICAL
and O
citral B-CHEMICAL
based O

2,5-disubstituted-1,3,4-oxadiazoles: B-CHEMICAL
a O
natural O
product O
coupled O
approach O
to O
semicarbazones B-CHEMICAL
for O
antiepileptic O
activity. O
Two O
novel O
series O
of O

N(4)-(5-(2/3/4-substituted-phenyl)-1,3,4-oxadiazol-2-yl)-N(1)-(2-methyl-5-(prop-1-en-2-yl)cyclohex-2-enylidene)semicarbazide B-CHEMICAL
and O

N(4)-(5-(2/3/4-substituted-phenyl)-1,3,4-oxadiazol-2-yl)-N(1)-(3,7-dimethylocta-3,6-dienylidene)-semicarbazide B-CHEMICAL
were O
synthesized O
to O
meet O
structural O
prerequisite O
indispensable O
for O
anticonvulsant O
activity. O
The O
anticonvulsant O
activities O
of O
the O
compounds O
were O
investigated O
using O
maximal O
electroshock O
seizure O
(MES), O
subcutaneous O
pentylenetrtrazole B-CHEMICAL

(scPTZ) O
and O
subcutaneous O
strychnine B-CHEMICAL
(scSTY) O
models. O
The O
rotorod O
test O
was O
conducted O
to O
evaluate O
neurotoxicity. O
Some O
of O
the O
selected O
active O
compounds O
were O
subjected O
to O
GABA B-CHEMICAL
assay O
to O
confirm O
their O
mode O
of O
action. O
The O
outcome O
of O
the O
present O
investigations O
proved O
that O
the O
four O
binding O
sites O
pharmacophore O
model O
is O
vital O
for O
anticonvulsant O
activity. O
The O
efforts O
were O
also O
made O
to O
establish O
structure-activity O
relationships O
among O
test O
compounds. O
Synthesis O
and O
evaluation O
of O
8-oxoadenine B-CHEMICAL
derivatives O
as O
potent O
Toll-like B-GENE-Y
receptor I-GENE-Y
7 I-GENE-Y
agonists O

with O
high O
water O
solubility. O
We O
report O
the O
discovery O
of O
novel O
series O
of O
highly O
potent O
TLR7 B-GENE-Y
agonists O
based O
on O
8-oxoadenines, B-CHEMICAL
1 O
and O
2 O
by O
introducing O
and O
optimizing O
various O
tertiary B-CHEMICAL
amines I-CHEMICAL
onto O
the O
N(9)-position B-CHEMICAL
of O
the O
adenine B-CHEMICAL
moiety. O
The O
introduction O
of O
the O
amino B-CHEMICAL
group O
resulted O
in O
not O
only O
improved O
water O
solubility O
but O
also O
enhanced O
TLR7 B-GENE-Y
agonistic O
activity. O
In O
particular O
compound O
20 O
(DSR-6434) B-CHEMICAL
indicated O
an O
optimal O
balance O
between O
the O
agonistic O
potency O
and O
high O
water O
solubility. O
It O
also O
demonstrated O
a O
strong O
antitumor O

effect O
in O
vivo O
by O
intravenous O
administration O
in O
a O
tumor O
bearing O
mice O
model. O
Discovery O
of O
liver-targeted O
inhibitors O
of O
stearoyl-CoA B-GENE-Y
desaturase I-GENE-Y
(SCD1). B-GENE-Y
Inhibitors O
based O
on O
a O
benzo-fused B-CHEMICAL
spirocyclic I-CHEMICAL
oxazepine I-CHEMICAL
scaffold O
were O
discovered O
for O
stearoyl-coenzyme B-GENE-Y
A I-GENE-Y
(CoA) I-GENE-Y
desaturase I-GENE-Y
1 I-GENE-Y
(SCD1) B-GENE-Y
and O
subsequently O
optimized O
to O
potent O
compounds O
with O
favorable O
pharmacokinetic O
profiles O
and O
in O
vivo O
efficacy O
in O
reducing O
the O
desaturation O
index O
in O
a O
mouse O

model. O
Initial O
optimization O
revealed O
potency O
preferences O
for O
the O
oxazepine B-CHEMICAL
core O
and O
benzylic B-CHEMICAL
positions, O
while O
substituents O
on O
the O
piperidine B-CHEMICAL
portions O
were O
more O
tolerant O
and O
allowed O
for O
tuning O
of O
potency O
and O
PK O
properties. O
After O
preparation O
and O
testing O
of O
a O
range O
of O
functional O
groups O
on O
the O
piperidine B-CHEMICAL
nitrogen, B-CHEMICAL
three O
classes O
of O
analogs O
were O
identified O
with O
single O
digit O
nanomolar O
potency: O
glycine B-CHEMICAL
amides, I-CHEMICAL
heterocycle-linked O
amides, B-CHEMICAL
and O
thiazoles. B-CHEMICAL
Responding O
to O
concerns O
about O
target O
localization O
and O
potential O
mechanism-based O
side O
effects, O
an O
initial O
effort O
was O
also O
made O

to O
improve O
liver O
concentration O
in O
an O
available O
rat O
PK O
model. O
An O
advanced O
compound O
17m O
with O
a O
5-carboxy-2-thiazole B-CHEMICAL
substructure O
appended O
to O
the O
spirocyclic B-CHEMICAL
piperidine I-CHEMICAL
scaffold O
was O
developed O
which O
satisfied O
the O
in O
vitro O
and O
in O
vivo O
requirements O
for O
more O
detailed O
studies. O
N-acetylgalactosamine B-CHEMICAL
functionalized O
mixed O
micellar O
nanoparticles O
for O
targeted O
delivery O
of O
siRNA O
to O
liver. O
Due O
to O
its O
efficient O
and O
specific O
gene O
silencing O
ability, O
RNA O
interference O
has O
shown O
great O
potential O
in O
the O
treatment O
of O
liver O
diseases. O
However, O
achieving O
in O

vivo O
delivery O
of O
siRNA O
to O
critical O
liver O
cells O
remains O
the O
biggest O
obstacle O
for O
this O
technique O
to O
be O
a O
real O
clinic O
therapeutic O
modality. O
Here, O
we O
describe O
a O
promising O
liver O
targeting O
siRNA O
delivery O
system O
based O
on O
N-acetylgalactosamine B-CHEMICAL
functionalized O
mixed O
micellar O
nanoparticles O
(Gal-MNP), O
which O
can O
efficiently O
deliver O
siRNA O
to O
hepatocytes O
and O
silence O
the O
target O
gene O
expression O
after O
systemic O
administration. O
The O
Gal-MNP O
were O
assembled O
in O
aqueous O
solution O
from O
mixed O
N-acetylgalactosamine B-CHEMICAL
functionalized O
poly(ethylene B-CHEMICAL

glycol)-b-poly(-caprolactone) I-CHEMICAL
and O
cationic O
poly(-caprolactone)-b-poly(2-aminoethyl B-CHEMICAL
ethylene I-CHEMICAL
phosphate) I-CHEMICAL
(PCL-b-PPEEA); B-CHEMICAL
the O
properties O
of O
nanoparticles, O
including O
particle O
size, O
zeta O
potential O
and O
the O
density O
of O
poly(ethylene B-CHEMICAL
glycol) I-CHEMICAL
could O
be O
easily O
regulated. O
The O
hepatocyte-targeting O
effect O
of O
Gal-MNP O
was O
demonstrated O
by O
significant O
enriching O
of O
fluorescent O
siRNA O
in O
primary O

hepatocytes O
in O
vitro O
and O
in O
vivo. O
Successful O
down-regulation O
of O
liver-specific O
apolipoprotein B-GENE-Y
B I-GENE-Y
(apoB) B-GENE-Y
expression O
was O
achieved O
in O
mouse O
liver, O
at O
both O
the O
transcriptional O
and O
protein O
level, O
following O
intravenous O
injection O
of O
Gal-MNP/siapoB B-GENE-Y
to O
BALB/c O
mice. O
Systemic O
delivery O
of O
Gal-MNP/siRNA O
did O
not O
induce O
the O
innate O
immune O
response O
or O
positive O
hepatotoxicity. O
The O
results O
of O
this O
study O
suggested O
therapeutic O
potential O
for O
the O
Gal-MNP/siRNA O
system O
in O
liver O

disease. O
Effects O
of O
Yerba O
Mate O
tea O
(Ilex O
paraguariensis) O
on O
vascular O
endothelial O
function O
and O
liver O
lipoprotein B-GENE-N
receptor I-GENE-N
gene O
expression O
in O
hyperlipidemic O
rats. O
Yerba O
Mate O
tea O
(Mate), O
an O
infusion O
made O
from O
the O
leaves O
of O
the O
tree O
Ilex O
paraguariensis, O
is O
a O
widely O
consumed O
beverage O
in O
South O
America. O
This O
study O
was O
performed O
to O
investigate O
the O
effect O
of O
Mate O
tea O
on O
vascular O
endothelial O
dysfunction O
and O
liver O
lipoprotein B-GENE-N
receptor I-GENE-N
gene O
expression O
in O
hyperlipidemic O
rats, O
with O
the O
aim O
of O
gaining O
insight O
into O
its O
known O

lipid-lowering O
protective O
mechanisms. O
Sixty O
male O
Sprague-Dawley O
rats O
were O
randomly O
divided O
into O
five O
groups: O
a O
normal O
control O
group O
(NC), O
a O
high-fat O
diet O
group O
(HC), O
and O
three O
Mate O
tea-treated O
groups. O
In O
the O
NC O
group, O
rats O
were O
fed O
with O
standard O
diet O
while O
in O
the O
other O
groups O
the O
rats O
were O
fed O
a O
high-fat O
diet O
for O
8weeks. O
In O
the O
Mate O
tea-treated O
groups, O
the O
rats O
were O
fed O
a O
high-fat O
diet O
supplemented O
with O
low, O
moderate O
or O
high O
concentrations O
of O
aqueous O
Mate O
tea O
extract O
for O
the O
final O
4weeks. O
Compared O
to O
the O
HC O

group, O
aqueous O
Mate O
tea O
extract O
significantly O
reduced O
endothelin B-GENE-N
(ET) B-GENE-N
and O
thromboxane B-CHEMICAL
B(2) I-CHEMICAL
(TXB(2)) B-CHEMICAL
levels O
and O
increased O
nitric B-CHEMICAL
oxide I-CHEMICAL
(NO) B-CHEMICAL
and O
6-keto B-CHEMICAL
prostaglandin I-CHEMICAL
F(1) I-CHEMICAL
(6-keto-PGF(1)) B-CHEMICAL
levels O
in O
the O
blood, O
reduced O
the O
pathological O
damage O
of O
vascular O
endothelial O
cells, O
decreased O
intercellular B-GENE-Y
adhesion I-GENE-Y
molecule-1 I-GENE-Y
(ICAM-1) B-GENE-Y
protein O
expression O
in O
the O
thoracic O
aorta, O
and O
upregulated O
mRNA O
expression O
of O

hepatic O
low B-GENE-Y
density I-GENE-Y
lipoprotein I-GENE-Y
receptor I-GENE-Y
(LDLR) B-GENE-Y
and O
scavenger B-GENE-Y
receptor I-GENE-Y
B1 I-GENE-Y
(SR-B1). B-GENE-Y
These O
findings O
indicate O
that O
Mate O
tea O
administration O
might O
have O
a O
regulatory O
effect O
on O
blood O
fat O
and O
endothelial O
function O
in O
hyperlipidemia O
rats. O
The O
mechanism O
may O
involve O
protecting O
vascular O
endothelial O
cell O
function O
and O
upregulating O
the O
expression O
of O
LDLR B-GENE-Y
and O
SR-B1 B-GENE-Y
genes, O
thereby O
inhibiting O
the O
occurrence O
of O
atherosclerosis. O
Development O
of O
hypoxia-inducible B-GENE-Y
factor I-GENE-Y
(HIF)-1 I-GENE-Y
inhibitors: O
effect O
of O

ortho-carborane B-CHEMICAL
substituents O
on O
HIF B-GENE-N
transcriptional O
activity O
under O
hypoxia. O
A O
series O
of O
substituted O
ortho-carboranylphenoxyacetanilides B-CHEMICAL
were O
synthesized O
and O
evaluated O
for O
their O
ability O
to O
inhibit O
hypoxia-induced O
HIF-1 B-GENE-N
transcriptional O
activity O
using O
a O
cell-based O
reporter O
assay O
in O
HeLa O
cells O
expressing O
the O
HRE-dependent B-GENE-N
firefly O
luciferase O
reporter O
construct O
(HRE-Luc) B-GENE-N
and O
constitutively O
expressing O
CMV-driven O
Renilla O
luciferase O
reporter, O
and O
their O
ability O
to O
inhibit O
cell O

growth O
(GI(50)) O
using O
the O
MTT B-CHEMICAL
assay. O
Among O
the O
compounds O
synthesized, O
1g O
and O
1l O
showed O
significant O
inhibition O
of O
hypoxia-induced O
HIF-1 B-GENE-N
transcriptional O
activity O
(IC(50): O
1.9 O
 O
0.4 O
and O
1.4 O
 O
0.2 O
M, O
respectively). O
Both O
compounds O
suppressed O
HIF-1 B-GENE-Y
accumulation O
in O
a O
concentration-dependent O
manner. O
The O
porcine B-GENE-N
heart I-GENE-N
malate B-CHEMICAL
dehydrogenase I-GENE-N
(MDH) B-GENE-N
refolding O
assay O
revealed O
that O
compound O
1l O
inhibited O
human B-GENE-Y
Hsp60 I-GENE-Y
chaperone O
activity O

(IC(50): O
6.80 O
 O
0.25 O
M) O
and O
this O
inhibition O
activity O
was O
higher O
than O
that O
of O
ETB B-CHEMICAL
(IC(50): O
10.9 O
 O
0.63 O
M). O
Apocynin B-CHEMICAL
and O
raisanberine B-CHEMICAL
alleviate O
intermittent O
hypoxia O
induced O
abnormal O
StAR B-GENE-Y
and O
3-HSD B-GENE-N
and O
low O
testosterone B-CHEMICAL
by O
suppressing O
endoplasmic O
reticulum O
stress O
and O
activated O
p66Shc B-GENE-Y
in O
rat O
testes. O
We O
hypothesized O
that O
hypoxia O
induced O
testicular O
damage O
is O
mediated O
by O
an O
activated O
NADPH B-CHEMICAL

oxidase I-GENE-N
(NOX), B-GENE-N
therefore, O
APO B-CHEMICAL
(apocynin) B-CHEMICAL
an O
inhibitor O
of O
NOX B-GENE-N
and O
raisanberine B-CHEMICAL
(RS), O
a O
calcium B-CHEMICAL
influx O
inhibitor O
were O
tested O
if O
they O
could O
attenuate O
hypoxic O
toxicity O
to O
the O
testis. O
Male O
Sprague-Dawley O
rats O
were O
exposed O
to O
hypoxia O
(100.5% O
O2) O
for O
17d O
and O
intervened O
with O
APO B-CHEMICAL
and O
RS O
in O
the O
last O
6d. O
Histological O
changes O
and O
expression O
of O
pro-inflammation O
factors O
were O
evaluated O
in O
vivo. O
Biomarkers O
in O
isolated O
Leydig O
cells O

incubated O
with O
H2O2 B-CHEMICAL
were O
also O
assayed O
in O
vitro. O
Hypoxic O
rats O
displayed O
lower O
serum O
testosterone B-CHEMICAL
and O
higher O
LH B-GENE-N
and O
FSH. B-GENE-N
Upregulation O
of O
p22/p47(phox), B-GENE-N
NOX2, B-GENE-Y
MMP9, B-GENE-Y
PERK B-GENE-Y
and O
p66Shc B-GENE-Y
was O
associated O
with O
downregulation O
of O
StAR, B-GENE-Y
3-HSD B-GENE-N
and O
Cx43 B-GENE-Y
in O
the O
hypoxia O
testis, O
revealed O
by O
Western O
blot O
and O
immunohistochemical O
assay, O
respectively. O
APO B-CHEMICAL
and O
RS O
at O
least O
partially O

normalize O
hypoxia O
caused O
male O
hypogonadism O
by O
suppressing O
ER O
stress, O
and O
p66Shc B-GENE-Y
in O
testes. O
Coming O
full O
circle: O
contributions O
of O
central O
and O
peripheral O
oxytocin B-CHEMICAL
actions O
to O
energy O
balance. O
The O
neuropeptide O
oxytocin B-GENE-Y
has O
emerged O
as O
an O
important O
anorexigen B-CHEMICAL
in O
the O
regulation O
of O
energy O
balance. O
Its O
effects O
on O
food O
intake O
have O
largely O
been O
attributed O
to O
limiting O
meal O
size O
through O
interactions O
in O
key O
regulatory O
brain O
regions O
such O
as O
the O
hypothalamus O
and O
hindbrain. O
Pharmacologic O
and O
pair-feeding O
studies O
indicate O
that O
its O
ability O
to O
reduce O
body O
mass O

extends O
beyond O
that O
of O
food O
intake, O
affecting O
multiple O
factors O
that O
determine O
energy O
balance O
such O
as O
energy O
expenditure, O
lipolysis, O
and O
glucose B-CHEMICAL
regulation. O
Systemic O
administration O
of O
oxytocin B-GENE-Y
recapitulates O
many O
of O
its O
effects O
when O
administered O
centrally, O
raising O
the O
questions O
of O
whether O
and O
to O
what O
extent O
circulating O
oxytocin B-CHEMICAL
contributes O
to O
energy O
regulation. O
Its O
therapeutic O
potential O
to O
treat O
metabolic O
conditions O
remains O
to O
be O
determined, O
but O
data O
from O
diet-induced O
and O
genetically O
obese O
rodent O
models O
as O
well O
as O
application O
of O
oxytocin B-CHEMICAL
in O
humans O
in O
other O
areas O
of O
research O
have O
revealed O
promising O
results O
thus O
far. O
Arsenic B-CHEMICAL
suppresses O
cell O
survival O
via O

Pirh2-mediated B-GENE-Y
proteasomal O
degradation O
of O
Np63 B-GENE-Y
protein. O
Transcription B-GENE-Y
factor I-GENE-Y
p63, I-GENE-Y
a O
member O
of O
the O
p53 B-GENE-Y
family, O
shares O
a O
high O
degree O
of O
sequence O
similarity O
with O
p53. B-GENE-Y
Because O
of O
transcription O
from O
two O
distinct O
promoters, O
the O
p63 B-GENE-N
gene O
encodes O
two O
isoforms, O
TAp63 B-GENE-Y
and O
Np63. B-GENE-Y
Although O
TAp63 B-GENE-Y
acts O
as O
a O
tumor O
suppressor, O
Np63 B-GENE-Y
functions O
as O
an O
oncogene O
and O
is O
often O
overexpressed O
in O
squamous O
cell O
carcinomas. O
Thus, O
therapeutic O
agents O
targeting O

Np63 B-GENE-Y
might O
be O
used O
to O
manage O
tumors O
that O
overexpress O
Np63. B-GENE-Y
Here O
we O
found O
that O
arsenic B-CHEMICAL
trioxide, I-CHEMICAL
a O
frontline O
agent O
for O
acute O
promyelocytic O
leukemia, O
inhibits O
Np63 B-GENE-Y
but O
not O
TAp63 B-GENE-Y
expression O
in O
time- O
and O
dose-dependent O
manners. O
In O
addition, O
we O
found O
that O
arsenic B-CHEMICAL
trioxide I-CHEMICAL
decreases O
the O
stability O
of O
Np63 B-GENE-Y
protein O
via O
a O
proteasome-dependent B-GENE-N
pathway O
but O
has O
little O
effect O
on O
the O
level O
of O
Np63 B-GENE-Y
transcript. O
Furthermore, O
we O
found O
that O

arsenic B-CHEMICAL
trioxide I-CHEMICAL
activates O
the O
Pirh2 B-GENE-N
promoter I-GENE-N
and O
consequently O
induces O
Pirh2 B-GENE-Y
expression. O
Consistent O
with O
this, O
we O
found O
that O
knockdown O
of O
Pirh2 B-GENE-Y
inhibits, O
whereas O
ectopic O
expression O
of O
Pirh2 B-GENE-Y
enhances, O
arsenic-induced B-CHEMICAL
degradation O
of O
Np63 B-GENE-Y
protein. O
Importantly, O
we O
found O
that O
knockdown O
of O
Np63 B-GENE-Y
sensitizes, O
whereas O
ectopic O
expression O
of O
Np63 B-GENE-Y
inhibits, O
growth O
suppression O
induced O
by O
arsenic. B-CHEMICAL
Together, O
these O
data O
suggest O
that O
arsenic B-CHEMICAL

degrades O
Np63 B-GENE-Y
protein O
at O
least O
in O
part O
via O
Pirh2-dependent B-GENE-Y
proteolysis O
and O
that O
inhibition O
of O
Np63 B-GENE-Y
expression O
facilitates O
tumor O
cells O
to O
arsenic-induced B-CHEMICAL
death. O
Jaceosidin, B-CHEMICAL
isolated O
from O
dietary O
mugwort O
(Artemisia O
princeps), O
induces O
G2/M O
cell O
cycle O
arrest O
by O
inactivating O
cdc25C-cdc2 B-GENE-Y
via O
ATM-Chk1/2 B-GENE-Y
activation. O
Jaceosidin, B-CHEMICAL
a O
flavonoid B-CHEMICAL
derived O
from O
Artemisia O
princeps O
(Japanese O
mugwort), O
has O
been O
shown O

to O
inhibit O
the O
growth O
of O
several O
human O
cancer O
cells, O
However, O
the O
exact O
mechanism O
for O
the O
cytotoxic O
effect O
of O
jaceosidin B-CHEMICAL
is O
not O
completely O
understood. O
In O
this O
study, O
we O
investigated O
the O
molecular O
mechanism O
involved O
in O
the O
antiproliferative O
effect O
of O
jaceosidin B-CHEMICAL
in O
human O
endometrial O
cancer O
cells. O
We O
demonstrated O
that O
jaceosidin B-CHEMICAL
is O
a O
more O
potent O
inhibitor O
of O
cell O
growth O
than O
cisplatin B-CHEMICAL
in O
human O
endometrial O
cancer O
cells. O
In O
contrast, O
jaceosidin-induced B-CHEMICAL
cytotoxicity O
in O
normal O
endometrial O
cells O
was O
lower O
than O
that O
observed O

for O
cisplatin. B-CHEMICAL
Jaceosidin B-CHEMICAL
induced O
G2/M O
phase O
cell O
cycle O
arrest O
and O
modulated O
the O
levels O
of O
cyclin B-GENE-Y
B I-GENE-Y
and O
p-Cdc2 B-GENE-Y
in O
Hec1A O
cells. O
Knockdown O
of O
p21 B-GENE-Y
using O
specific O
siRNAs O
partially O
abrogated O
jaceosidin-induced B-CHEMICAL
cell O
growth O
inhibition. O
Additional O
mechanistic O
studies O
revealed O
that O
jaceosidin B-CHEMICAL
treatment O
resulted O
in O
an O
increase O
in O
phosphorylation O
of O
Cdc25C B-GENE-Y
and O
ATM-Chk1/2. B-GENE-Y
Ku55933, O
an O
ATM B-GENE-Y
inhibitor, O
reversed O

jaceosidin-induced B-CHEMICAL
cell O
growth O
inhibition, O
in O
part. O
Moreover, O
jaceosidin B-CHEMICAL
treatment O
resulted O
in O
phosphorylation O
of O
ERK, B-GENE-N
and O
pretreatment O
with O
the O
ERK B-GENE-N
inhibitor, O
PD98059, B-CHEMICAL
attenuated O
cell O
growth O
inhibition O
by O
jaceosidin. B-CHEMICAL
These O
data O
suggest O
that O
jaceosidin, B-CHEMICAL
isolated O
from O
Japanese O
mugwort, O
modulates O
the O
ERK/ATM/Chk1/2 B-GENE-N
pathway, O
leading O
to O
inactivation O
of O
the O
Cdc2-cyclin B-GENE-Y
B1 I-GENE-Y
complex, O
followed O
by O
G2/M O
cell O

cycle O
arrest O
in O
endometrial O
cancer O
cells. O
EphA5-EphrinA5 B-GENE-Y
interactions O
within O
the O
ventromedial O
hypothalamus O
influence O
counterregulatory O
hormone O
release O
and O
local O
glutamine/glutamate B-CHEMICAL
balance O
during O
hypoglycemia. O
Activation O
of O
-cell O
EphA5 B-GENE-Y
receptors I-GENE-Y
by O
its O
ligand O
ephrinA5 B-GENE-Y
from O
adjacent O
-cells O
has O
been O
reported O
to O
decrease O
insulin O
secretion O
during O
hypoglycemia. O
Given O
the O
similarities O
between O
islet O
and O
ventromedial O
hypothalamus O
(VMH) O
glucose B-CHEMICAL
sensing, O
we O
tested O
the O

hypothesis O
that O
the O
EphA5/ephrinA5 B-GENE-Y
system O
might O
function O
within O
the O
VMH O
during O
hypoglycemia O
to O
stimulate O
counterregulatory O
hormone O
release O
as O
well. O
Counterregulatory O
responses O
and O
glutamine/glutamate B-CHEMICAL
concentrations O
in O
the O
VMH O
were O
assessed O
during O
a O
hyperinsulinemic-hypoglycemic O
glucose B-CHEMICAL
clamp O
study O
in O
chronically O
catheterized O
awake O
male O
Sprague-Dawley O
rats O
that O
received O
an O
acute O
VMH O
microinjection O
of O
ephrinA5-Fc, B-GENE-Y
chronic O
VMH O
knockdown, O
or O

overexpression O
of O
ephrinA5 B-GENE-Y
using O
an O
adenoassociated O
viral O
construct. O
Local O
stimulation O
of O
VMH O
EphA5 B-GENE-Y
receptors I-GENE-Y
by O
ephrinA5-Fc B-GENE-Y
or O
ephrinA5 B-GENE-Y
overexpression O
increased, O
whereas O
knockdown O
of O
VMH O
ephrinA5 B-GENE-Y
reduced O
counterregulatory O
responses O
during O
hypoglycemia. O
Overexpression O
of O
VMH O
ephrinA5 B-GENE-Y
transiently O
increased O
local O
glutamate B-CHEMICAL
concentrations, O
whereas O
ephrinA5 B-GENE-Y
knockdown O
produced O
profound O
suppression O
of O
VMH O
interstitial O
fluid O
glutamine B-CHEMICAL

concentrations O
in O
the O
basal O
state O
and O
during O
hypoglycemia. O
Changes O
in O
ephrinA5/EphA5 B-GENE-Y
interactions O
within O
the O
VMH, O
a O
key O
brain O
glucose-sensing B-CHEMICAL
region, O
act O
in O
concert O
with O
islets O
to O
restore O
glucose B-CHEMICAL
homeostasis O
during O
acute O
hypoglycemia, O
and O
its O
effect O
on O
counterregulation O
may O
be O
mediated O
by O
changes O
in O
glutamate/glutamine B-CHEMICAL
cycling. O
Electrical O
Stimuli O
Release O
ATP B-CHEMICAL
to O
Increase O
GLUT4 B-GENE-Y
Translocation O
and O
Glucose B-CHEMICAL
Uptake O
via O
PI3K-Akt-AS160 B-GENE-Y
in O
Skeletal O

Muscle O
Cells. O
Skeletal O
muscle O
glucose B-CHEMICAL
uptake O
in O
response O
to O
exercise O
is O
preserved O
in O
insulin-resistant B-GENE-Y
conditions, O
but O
the O
signals O
involved O
are O
debated. O
ATP B-CHEMICAL
is O
released O
from O
skeletal O
muscle O
by O
contractile O
activity O
and O
can O
autocrinely O
signal O
through O
purinergic B-GENE-N
receptors, I-GENE-N
and O
we O
hypothesized O
it O
may O
influence O
glucose B-CHEMICAL
uptake. O
Electrical O
stimulation, O
ATP, B-CHEMICAL
and O
insulin B-GENE-Y
each O
increased O
fluorescent O
2-NBD-Glucose B-CHEMICAL
(2-NBDG) B-CHEMICAL
uptake O
in O
primary O
myotubes, O
but O
only O
electrical O
stimulation O
and O
ATP-dependent B-CHEMICAL
2-NBDG B-CHEMICAL
uptake O
were O

inhibited O
by O
adenosine-phosphate B-GENE-N
phosphatase I-GENE-N
and O
by O
purinergic B-GENE-N
receptor I-GENE-N
blockade O
(suramin). B-CHEMICAL
Electrical O
stimulation O
transiently O
elevated O
extracellular O
ATP B-CHEMICAL
and O
caused O
Akt B-GENE-N
phosphorylation O
that O
was O
additive O
to O
insulin B-GENE-Y
and O
inhibited O
by O
suramin. B-CHEMICAL
Exogenous O
ATP B-CHEMICAL
transiently O
activated O
Akt B-GENE-N
and, O
inhibiting O
phosphatidylinositol B-GENE-N
3-kinase I-GENE-N
(PI3K) B-GENE-N
or O
Akt B-GENE-N
as O
well O
as O
dominant-negative O
Akt B-GENE-N
mutant, O
reduced O
ATP-dependent B-CHEMICAL
2-NBDG B-CHEMICAL
uptake O
and O
Akt B-GENE-N

phosphorylation. O
ATP-dependent B-CHEMICAL
2-NBDG B-CHEMICAL
uptake O
was O
also O
inhibited O
by O
the O
G B-GENE-N
protein I-GENE-N
 I-GENE-N
subunit-interacting O
peptide O
ark-ct O
and O
by O
the O
phosphatidylinositol B-GENE-Y
3-kinase- I-GENE-Y
(PI3K) B-GENE-Y
inhibitor O
AS605240. B-CHEMICAL
ATP B-CHEMICAL
caused O
translocation O
of O
GLUT4myc-eGFP B-GENE-Y
to O
the O
cell O
surface, O
mechanistically O
mediated O
by O
increased O
exocytosis O
involving O
AS160/Rab8A B-GENE-Y
reduced O
by O
dominant-negative O
Akt B-GENE-N
or O
PI3K B-GENE-Y
kinase-dead B-GENE-N

mutants, O
and O
potentiated O
by O
myristoylated B-GENE-Y
PI3K. I-GENE-Y
ATP B-CHEMICAL
stimulated O
2-NBDG B-CHEMICAL
uptake O
in O
normal O
and O
insulin-resistant B-GENE-Y
adult O
muscle O
fibers, O
resembling O
the O
reported O
effect O
of O
exercise. O
Hence, O
the O
ATP-induced B-CHEMICAL
pathway O
may O
be O
tapped O
to O
bypass O
insulin B-GENE-Y
resistance. O
The O
COP9 B-GENE-N
signalosome I-GENE-N
interacts O
with O
and O
regulates O
interferon B-GENE-Y
regulatory I-GENE-Y
factor I-GENE-Y
5 I-GENE-Y
protein I-GENE-Y
stability. O
The O
transcription O
factor O
interferon B-GENE-Y
regulatory I-GENE-Y
factor I-GENE-Y
5 I-GENE-Y
(IRF5) B-GENE-Y
exerts O
crucial O
functions O
in O
the O
regulation O
of O
host O
immunity O
against O
extracellular O
pathogens, O
DNA O
damage-induced O
apoptosis, O
death B-GENE-N
receptor I-GENE-N

signaling, O
and O
macrophage O
polarization. O
Tight O
regulation O
of O
IRF5 B-GENE-Y
is O
thus O
warranted O
for O
an O
efficient O
response O
toward O
extracellular O
stressors O
and O
for O
limiting O
autoimmune O
and O
inflammatory O
responses. O
Here O
we O
report O
that O
the O
COP9 B-GENE-N
signalosome I-GENE-N
(CSN), B-GENE-N
a O
general O
modulator O
of O
diverse O
cellular O
and O
developmental O
processes, O
associates O
constitutively O
with O
IRF5 B-GENE-Y
and O
promotes O
its O
protein O
stability. O
The O
constitutive O
CSN/IRF5 B-GENE-N
interaction O
was O
identified O
using O
proteomics O
and O
confirmed O
by O
endogenous O
immunoprecipitations. O
The O

CSN/IRF5 B-GENE-N
interaction O
occurred O
on O
the O
carboxyl B-CHEMICAL
and O
amino B-CHEMICAL
termini O
of O
IRF5; B-GENE-Y
a O
single O
internal O
deletion O
from O
amino B-CHEMICAL
acids I-CHEMICAL
455 O
to O
466 O
(455-466) O
was O
found O
to O
significantly O
reduce O
IRF5 B-GENE-Y
protein O
stability. O
CSN B-GENE-Y
subunit I-GENE-Y
3 I-GENE-Y
(CSN3) B-GENE-Y
was O
identified O
as O
a O
direct O
interacting O
partner O
of O
IRF5, B-GENE-Y
and O
knockdown O
of O
this O
subunit O
with O
small O
interfering O
RNAs O
resulted O
in O
enhanced O
degradation. O
Degradation O
was O
further O
augmented O
by O
knockdown O
of O
CSN1 B-GENE-Y
and O
CSN3 B-GENE-Y
together. O
The O
ubiquitin B-GENE-N
E1 I-GENE-N
inhibitor O

UBEI-41 O
or O
the O
proteasome B-GENE-N
inhibitor O
MG132 O
prevented O
IRF5 B-GENE-Y
degradation, O
supporting O
the O
idea O
that O
its O
stability O
is O
regulated O
by O
the O
ubiquitin-proteasome B-GENE-N
system. O
Importantly, O
activation O
of O
IRF5 B-GENE-Y
by O
the O
death B-GENE-N
receptor I-GENE-N
ligand O
tumor B-GENE-Y
necrosis I-GENE-Y
factor-related I-GENE-Y
apoptosis-inducing I-GENE-Y
ligand I-GENE-Y
(TRAIL) B-GENE-Y
resulted O
in O
enhanced O
degradation O
via O
loss O
of O
the O
CSN/IRF5 B-GENE-N
interaction. O
This O
study O
defines O
CSN B-GENE-N
to O
be O
a O
new O
interacting O
partner O
of O
IRF5 B-GENE-Y
that O
controls O
its O
stability. O
Structure-based O
design, O
synthesis O
and O
evaluation O

of O
novel O
anthra[1,2-d]imidazole-6,11-dione B-CHEMICAL
derivatives O
as O
telomerase B-GENE-Y
inhibitors O
and O
potential O
for O
cancer O
polypharmacology. O
A O
series O
of O
anthra[1,2-d]imidazole-6,11-dione B-CHEMICAL
derivatives O
were O
synthesized O
and O
evaluated O
for O
telomerase B-GENE-Y
inhibition, O
hTERT B-GENE-Y
expression O
and O
suppression O
of O
cancer O
cell O
growth O
in O
vitro. O
All O
of O
the O
compounds O
tested, O
except O
for O
compounds O
4, O
7, O
16, O
24, O
27 O
and O
28 O
were O
selected O
by O
the O
NCI O
screening O
system. O
Among O
them, O
compounds O
16, O

39, O
and O
40 O
repressed O
hTERT B-GENE-Y
expression O
without O
greatly O
affecting O
cell O
growth, O
suggesting O
for O
the O
selectivity O
toward O
hTERT B-GENE-Y
expression. O
Taken O
together, O
our O
findings O
indicated O
that O
the O
analysis O
of O
cytotoxicity O
and O
telomerase B-GENE-Y
inhibition O
might O
provide O
information O
applicable O
for O
further O
developing O
potential O
telomerase B-GENE-Y
and O
polypharmacological O
targeting O
strategy. O
Zinc B-CHEMICAL
sulphate I-CHEMICAL
and O
vitamin B-CHEMICAL
E I-CHEMICAL
alleviate O
reproductive O
toxicity O
caused O
by O
aluminium B-CHEMICAL
sulphate I-CHEMICAL
in O
male O
albino O
rats. O
This O
study O
was O
designed O
to O
investigate O
the O
reproductive O
toxicity O
of O
aluminium B-CHEMICAL
sulphate I-CHEMICAL
and O
the O
therapeutic O
effects O
of O
administration O
of O
zinc B-CHEMICAL
sulphate I-CHEMICAL
and O
vitamin B-CHEMICAL
E I-CHEMICAL
individually O
or O
in O

combination O
against O
the O
toxic O
effect O
caused O
by O
aluminium B-CHEMICAL
(Al) B-CHEMICAL
in O
male O
albino O
rats. O
The O
animals O
were O
divided O
into O
five O
groups: O
group O
1 O
received O
distilled O
water O
and O
served O
as O
control; O
group O
2 O
received O
only O
aluminium B-CHEMICAL
sulphate I-CHEMICAL
(50 O
mg/kg O
body O
weight O
(b.w.)); O
group O
3 O
received O
aluminium B-CHEMICAL
sulphate I-CHEMICAL
(50 O
mg/kg O
b.w.) O
plus O
zinc B-CHEMICAL
sulphate I-CHEMICAL
(50 O
mg/kg O
b.w.); O
group O
4 O
received O
aluminium B-CHEMICAL
sulphate I-CHEMICAL
(50 O
mg/kg O
b.w.) O
and O
vitamin B-CHEMICAL
E I-CHEMICAL
(15 O
mg/kg O
b.w.); O
group O

5 O
received O
aluminium B-CHEMICAL
sulphate I-CHEMICAL
plus O
a O
combination O
of O
zinc B-CHEMICAL
sulphate I-CHEMICAL
and O
vitamin B-CHEMICAL
E I-CHEMICAL
in O
similar O
doses O
as O
above. O
Doses O
were O
administered O
orally O
once O
daily O
for O
45 O
consecutive O
days. O
The O
results O
revealed O
that O
aluminium B-CHEMICAL
sulphate I-CHEMICAL
induced O
significant O
decrease O
in O
body O
weight O
gain O
and O
testis O
weight O
and O
significant O
increase O
in O
Al B-CHEMICAL
level O
in O
both O
serum O
and O
testes O
of O
male O
rats. O
Biochemical O
analysis O
showed O
significant O
decrease O
in O
serum O
total O
protein O
and O
phospholipids O
levels, O
while O
serum O
total O
lipid O
was O
significantly O
elevated O
post O
Al B-CHEMICAL
treatment. O
In O
addition, O
significant O
decrease O
in O
total O
protein, O
phospholipids O
and O
cholesterol B-CHEMICAL
levels O
in O
the O

testes O
of O
Al-treated B-CHEMICAL
rats O
was O
recorded. O
The O
data O
also O
showed O
significant O
decrease O
in O
the O
levels O
of O
serum O
testosterone, B-CHEMICAL
leutinizing B-GENE-N
hormone I-GENE-N
and O
follicle B-GENE-N
stimulating I-GENE-N
hormone I-GENE-N
and O
significant O
increase O
in O
the O
level O
of O
serum O
prolactin B-GENE-Y
in O
Al-intoxicated B-CHEMICAL
rats. O
Moreover, O
histological O
examination O
showed O
that O
aluminium B-CHEMICAL
sulphate I-CHEMICAL
caused O
apparent O
alterations O
in O
the O
testicular O
structure O
of O
the O
treated O
animals. O
Treatment O
with O
zinc B-CHEMICAL
sulphate I-CHEMICAL
and O
vitamin B-CHEMICAL
E I-CHEMICAL
individually O
or O
in O
combination O
ameliorated O
the O
harmful O
effects O
of O
Al, B-CHEMICAL
which O
was O
proved O
histopathologically O
by O
the O
noticeable O
improvement O
in O
the O
testicular O
tissues. O
We O
can O
conclude O

that O
the O
tested O
dose O
of O
aluminium B-CHEMICAL
sulphate I-CHEMICAL
induced O
toxic O
effect O
on O
the O
reproductive O
system O
of O
male O
albino O
rats O
and O
the O
treatment O
with O
zinc B-CHEMICAL
sulphate I-CHEMICAL
and/or O
vitamin B-CHEMICAL
E I-CHEMICAL
alleviated O
these O
toxic O
effects. O
In O
some O
cases, O
vitamin B-CHEMICAL
E I-CHEMICAL
exerted O
a O
more O
potent O
effect, O
while O
in O
other O
cases, O
the O
more O
potent O
effect O
is O
related O
to O
zinc B-CHEMICAL
sulphate I-CHEMICAL
and O
the O
combination O
of O
both O
at O
most O
of O
the O
recorded O
data. O
Trichostatin B-CHEMICAL
A I-CHEMICAL
inhibits O
transforming B-GENE-Y
growth I-GENE-Y
factor--induced I-GENE-Y
reactive O
oxygen B-CHEMICAL
species O
accumulation O
and O
myofibroblast O
differentiation O
via O
enhanced O
NF-E2-related B-GENE-Y
factor I-GENE-Y
2-antioxidant I-GENE-Y
response I-GENE-N
element I-GENE-N

signaling. O
Trichostatin B-CHEMICAL
A I-CHEMICAL
(TSA) B-CHEMICAL
has O
been O
shown O
to O
prevent O
fibrosis O
in O
vitro O
and O
in O
vivo. O
The O
present O
study O
aimed O
at O
investigating O
the O
role O
of O
reactive O
oxygen B-CHEMICAL
species O
(ROS) O
scavenging O
by O
TSA B-CHEMICAL
on O
transforming B-GENE-Y
growth I-GENE-Y
factor- I-GENE-Y
(TGF-)-induced B-GENE-Y
myofibroblast O
differentiation O
of O
corneal O
fibroblasts O
in O
vitro. O
Human O
immortalized O
corneal O
fibroblasts O
were O
treated O
with O
TGF- B-GENE-Y
in O
the O
presence O
of O
TSA, B-CHEMICAL
the O
NAD(P)H B-GENE-N
oxidase I-GENE-N
inhibitor O

diphenyleneiodonium B-CHEMICAL
(DPI), B-CHEMICAL
the O
antioxidant O
N-acetyl-cysteine B-CHEMICAL
(NAC), B-CHEMICAL
the O
NF-E2-related B-GENE-Y
factor I-GENE-Y
2-antioxidant I-GENE-Y
response I-GENE-N
element I-GENE-N
(Nrf2-ARE) B-GENE-Y
activator O
sulforaphane, B-CHEMICAL
or O
small O
interfering O
RNA. O
Myofibroblast O
differentiation O
was O
assessed O
by O
-smooth B-GENE-Y
muscle I-GENE-Y
actin I-GENE-Y
(-SMA) B-GENE-Y
expression, O
F-actin B-GENE-N
bundle O
formation, O
and O
collagen B-GENE-N
gel O
contraction. O
ROS, O
H(2)O(2), B-CHEMICAL
intracellular O

glutathione B-CHEMICAL
(GSH) B-CHEMICAL
level, O
cellular O
total O
antioxidant O
capacity, O
and O
the O
activation O
of O
Nrf2-ARE B-GENE-Y
signaling O
were O
determined O
with O
various O
assays. O
Treatment O
with O
TSA B-CHEMICAL
and O
the O
Nrf2-ARE B-GENE-Y
activator O
resulted O
in O
increased O
inhibition O
of O
the O
TGF--induced B-GENE-Y
myofibroblast O
differentiation O
as O
compared O
with O
treatment O
with O
DPI B-CHEMICAL
or O
NAC. B-CHEMICAL
Furthermore, O
TSA B-CHEMICAL
also O
decreased O
cellular O
ROS O
and O
H(2)O(2) B-CHEMICAL
accumulation O
induced O
by O
TGF-, B-GENE-Y
whereas O
it O
elevated O
intracellular O
GSH B-CHEMICAL
level O
and O
cellular O
total O

antioxidant O
capacity. O
In O
addition, O
TSA B-CHEMICAL
induced O
Nrf2 B-GENE-Y
nuclear O
translocation O
and O
up-regulated O
the O
expression O
of O
Nrf2-ARE B-GENE-Y
downstream O
antioxidant O
genes, O
whereas O
Nrf2 B-GENE-Y
knockdown O
by O
RNA O
interference O
blocked O
the O
inhibition O
of O
TSA B-CHEMICAL
on O
myofibroblast O
differentiation. O
In O
conclusion, O
this O
study O
provides O
the O
first O
evidence O
implicating O
that O
TSA B-CHEMICAL
inhibits O
TGF--induced B-GENE-Y
ROS O
accumulation O
and O
myofibroblast O
differentiation O
via O
enhanced O
Nrf2-ARE B-GENE-Y
signaling. O
Cannabinoid B-CHEMICAL
discrimination O
and O
antagonism O
by O
CB(1) B-GENE-N
neutral O
and O
inverse O
agonist O

antagonists. O
Cannabinoid B-CHEMICAL
receptor I-GENE-N
1 I-GENE-N
(CB(1)) B-GENE-N
inverse O
agonists O
(e.g., O
rimonabant) B-CHEMICAL
have O
been O
reported O
to O
produce O
adverse O
effects O
including O
nausea, O
emesis, O
and O
anhedonia O
that O
limit O
their O
clinical O
applications. O
Recent O
laboratory O
studies O
suggest O
that O
the O
effects O
of O
CB(1) B-GENE-N
neutral O
antagonists O
differ O
from O
those O
of O
such O
inverse O
agonists, O
raising O
the O
possibility O
of O
improved O
clinical O
utility. O
However, O
little O
is O
known O
regarding O
the O
antagonist O
properties O
of O
neutral O
antagonists. O
In O
the O
present O
studies, O
the O
CB(1) B-GENE-N
inverse O
agonist O
SR141716A B-CHEMICAL
(rimonabant) B-CHEMICAL
and O
the O

CB(1) B-GENE-N
neutral O
antagonist O
AM4113 B-CHEMICAL
were O
compared O
for O
their O
ability O
to O
modify O
CB(1) B-GENE-N
receptor-mediated I-GENE-N
discriminative O
stimulus O
effects O
in O
nonhuman O
primates O
trained O
to O
discriminate O
the O
novel O
CB(1) B-GENE-N
full O
agonist O
AM4054. B-CHEMICAL
Results O
indicate O
that O
AM4054 B-CHEMICAL
serves O
as O
an O
effective O
CB(1) B-GENE-N
discriminative O
stimulus, O
with O
an O
onset O
and O
time O
course O
of O
action O
comparable O
with O
that O
of O
the O
CB(1) B-GENE-N
agonist O
(9)-tetrahydrocannabinol, B-CHEMICAL
and O
that O
the O
inverse O
agonist O
rimonabant B-CHEMICAL
and O
the O
neutral O
antagonist O
AM4113 B-CHEMICAL
produce O

dose-related O
rightward O
shifts O
in O
the O
AM4054 B-CHEMICAL
dose-effect O
curve, O
indicating O
that O
both O
drugs O
surmountably O
antagonize O
the O
discriminative O
stimulus O
effects O
of O
AM4054. B-CHEMICAL
Schild O
analyses O
further O
show O
that O
rimonabant B-CHEMICAL
and O
AM4113 B-CHEMICAL
produce O
highly O
similar O
antagonist O
effects, O
as O
evident O
in O
comparable O
pA(2) O
values O
(6.9). O
Taken O
together O
with O
previous O
studies, O
the O
present O
data O
suggest O
that O
the O
improved O
safety O
profile O
suggested O
for O
CB(1) B-GENE-N
neutral O
antagonists O
over O
inverse O
agonists O
is O
not O
accompanied O
by O
a O
loss O
of O
antagonist O
action O
at O
CB(1) B-GENE-N
receptors. I-GENE-N
Marked O
decline O

in O
beta O
cell O
function O
during O
pregnancy O
leads O
to O
the O
development O
of O
glucose B-CHEMICAL
intolerance O
in O
Japanese O
women. O
The O
aim O
of O
this O
study O
is O
to O
investigate O
glucose B-CHEMICAL
metabolism O
longitudinally O
during O
pregnancy O
to O
explore O
mechanisms O
underlying O
gestational O
diabetes O
mellitus O
(GDM). O
We O
reviewed O
a O
total O
of O
62 O
pregnant O
Japanese O
women O
who O
underwent O
a O
75g O
oral O
glucose B-CHEMICAL
tolerance O
test O
(OGTT) O
twice O
during O
pregnancy O
(median: O
early, O
13; O
late, O
28 O
weeks' O
gestation) O
because O
of O
positive O
GDM O
screening. O
All O
showed O
normal O
OGTT O
results O
in O
early O
pregnancy. O
Based O
on O
late O
OGTT, O
15 O
had O
GDM O
(late-onset O

GDM) O
and O
47 O
normal O
glucose B-CHEMICAL
tolerance O
(NGT). O
In O
early O
pregnancy, O
there O
were O
no O
significant O
differences O
in O
insulin B-GENE-Y
sensitivity O
(insulin B-GENE-Y
sensitivity O
index O
derived O
from O
OGTT O
[ISOGTT] O
and O
homeostasis O
model O
assessment O
for O
insulin B-GENE-Y
resistance O
[HOMA-IR]) O
and O
insulin B-GENE-Y
secretion O
(a O
ratio O
of O
the O
total O
area-under-the-insulin-curve B-GENE-Y
to O
the O
total O
area-under-the-glucose-curve B-CHEMICAL
[AUCins/glu] O
and O
insulinogenic O
index O
[IGI]) O
between O
the O
NGT O
and O
late-onset O
GDM O
groups. O
In O
each O
group, O
insulin B-GENE-Y
sensitivity O
significantly O

decreased O
from O
early O
to O
late O
pregnancy, O
most O
in O
the O
late-onset O
GDM O
group O
(each O
p O
< O
0.05). O
The O
insulin B-GENE-Y
secretion O
showed O
no O
significant O
changes O
with O
advancing O
pregnancy O
in O
both O
of O
the O
groups, O
although O
late-onset O
GDM O
showed O
significantly O
lower O
IGI O
compared O
with O
NGT O
in O
late O
OGTT O
(p O
< O
0.05). O
When O
assessed O
beta O
cell O
function O
by O
OGTT-derived O
disposition O
index O
(i.e. O
Insulin B-GENE-Y
Secretion-Sensitivity O
Index-2 O
and O
IGI/fasting O
insulin), B-GENE-Y
the O
indices O
significantly O
decreased O
from O
early O
to O
late O
pregnancy O
in O
the O
both O
groups O

(each O
p O
< O
0.05). O
Women O
with O
late-onset O
GDM O
showed O
significantly O
lower O
indices O
compared O
with O
NGT O
(each O
p O
< O
0.05). O
The O
failure O
of O
beta O
cell O
to O
compensate O
for O
decreased O
insulin B-GENE-Y
sensitivity O
could O
contribute O
to O
the O
development O
of O
the O
late-onset O
GDM. O
New O
oral O
anticoagulants: O
comparative O
pharmacology O
with O
vitamin B-CHEMICAL
K I-CHEMICAL
antagonists. O
New O
oral O
anticoagulants O
(OACs) O
that O
directly O
inhibit O
Factor B-GENE-Y
Xa I-GENE-Y
(FXa) B-GENE-Y
or O
thrombin B-GENE-Y
have O
been O
developed O
for O
the O
long-term O
prevention O
of O
thromboembolic O
disorders. O
These O
novel O
agents O
provide O
numerous O
benefits O

over O
older O
vitamin B-CHEMICAL
K I-CHEMICAL
antagonists O
(VKAs) O
due O
to O
major O
pharmacological O
differences. O
VKAs O
are O
economical O
and O
very O
well O
characterized, O
but O
have O
important O
limitations O
that O
can O
outweigh O
these O
advantages, O
such O
as O
slow O
onset O
of O
action, O
narrow O
therapeutic O
window O
and O
unpredictable O
anticoagulant O
effect. O
VKA-associated O
dietary O
precautions, O
monitoring O
and O
dosing O
adjustments O
to O
maintain O
international O
normalized O
ratio O
(INR) O
within O
therapeutic O
range, O
and O
bridging O
therapy, O
are O
inconvenient O
for O
patients, O
expensive, O
and O
may O
result O
in O
inappropriate O
use O
of O
VKA O
therapy. O
This O
may O
lead O
to O
increased O
bleeding O
risk O
or O
reduced O

anticoagulation O
and O
increased O
risk O
of O
thrombotic O
events. O
The O
new O
OACs O
have O
rapid O
onset O
of O
action, O
low O
potential O
for O
food O
and O
drug O
interactions, O
and O
predictable O
anticoagulant O
effect O
that O
removes O
the O
need O
for O
routine O
monitoring. O
FXa B-GENE-Y
inhibitors, O
e.g. O
rivaroxaban B-CHEMICAL
and O
apixaban, B-CHEMICAL
are O
potent, O
oral O
direct O
inhibitors O
of O
prothrombinase-bound, B-GENE-N
clot-associated O
or O
free O
FXa. B-GENE-Y
Both O
agents O
have O
a O
rapid O
onset O
of O
action, O
a O
wide O
therapeutic O
window, O
little O
or O
no O
interaction O
with O
food O
and O
other O
drugs, O
minimal O
inter-patient O
variability, O
and O
display O

similar O
pharmacokinetics O
in O
different O
patient O
populations. O
Since O
both O
are O
substrates, O
co-administration O
of O
rivaroxaban B-CHEMICAL
and O
apixaban B-CHEMICAL
with O
strong O
cytochrome B-GENE-Y
P450 I-GENE-Y
(CYP) I-GENE-Y
3A4 I-GENE-Y
and O
permeability B-GENE-Y
glycoprotein I-GENE-Y
(P-gp) B-GENE-Y
inhibitors O
and O
inducers O
can O
result O
in O
substantial O
changes O
in O
plasma O
concentrations O
due O
to O
altered O
clearance O
rates; O
consequently, O
their O
concomitant O
use O
is O
contraindicated O
and O
caution O
is O
required O
when O
used O
concomitantly O
with O
strong O
CYP3A4 B-GENE-Y
and O
P-gp B-GENE-Y
inducers. O
Although O
parenteral O
oral O
direct O

thrombin B-GENE-Y
inhibitors O
(DTIs), O
such O
as O
argatroban B-CHEMICAL
and O
bivalirudin, O
have O
been O
on O
the O
market O
for O
years, O
DTIs O
such O
as O
dabigatran B-CHEMICAL
are O
novel O
synthetic O
thrombin B-GENE-Y
antagonists. O
Dabigatran B-CHEMICAL
etexilate I-CHEMICAL
is O
a O
low-molecular-weight O
non-active O
pro-drug O
that O
is O
administered O
orally O
and O
converted O
rapidly O
to O
its O
active O
form, O
dabigatran--a B-CHEMICAL
potent, O
competitive O
and O
reversible O
DTI. O
Dabigatran B-CHEMICAL
has O
an O
advantage O
over O
the O
indirect O
thrombin B-GENE-Y
inhibitors, O
unfractionated O
heparin O
and O

low-molecular-weight O
heparin, O
in O
that O
it O
inhibits O
free O
and O
fibrin-bound B-GENE-N
thrombin. B-GENE-Y
The O
reversible O
binding O
of O
dabigatran B-CHEMICAL
may O
provide O
safer O
and O
more O
predictable O
anticoagulant O
treatment O
than O
seen O
with O
irreversible, O
non-covalent O
thrombin B-GENE-Y
inhibitors, O
e.g. O
hirudin. O
Dabigatran B-CHEMICAL
shows O
a O
very O
low O
potential O
for O
drug-drug O
interactions. O
However, O
co-administration O
of O
dabigatran B-CHEMICAL
etexilate I-CHEMICAL
with O
other O
anticoagulants O
and O
antiplatelet O
agents O
can O
increase O
the O
bleeding O
risk. O
Although O
the O
new O
agents O
are O

pharmacologically O
better O
than O
VKAs--particularly O
in O
terms O
of O
fixed O
dosing, O
rapid O
onset O
of O
action, O
no O
INR O
monitoring O
and O
lower O
risk O
of O
drug O
interactions--there O
are O
some O
differences O
between O
them: O
the O
bioavailability O
of O
dabigatran B-CHEMICAL
is O
lower O
than O
rivaroxaban B-CHEMICAL
and O
apixaban, B-CHEMICAL
and O
so O
the O
dabigatran B-CHEMICAL
dosage O
required O
is O
higher; O
lower O
protein O
binding O
of O
dabigatran B-CHEMICAL
reduces O
the O
variability O
related O
to O
albuminaemia. O
The O
risk O
of O
metabolic O
drug-drug O
interactions O
also O
appears O
to O
differ O
between O
OACs: O
VKAs O
> O
rivaroxaban B-CHEMICAL
> O

apixaban B-CHEMICAL
> O
dabigatran. B-CHEMICAL
The O
convenience O
of O
the O
new O
OACs O
has O
translated O
into O
improvements O
in O
efficacy O
and O
safety O
as O
shown O
in O
phase O
III O
randomized O
trials. O
The O
new O
anticoagulants O
so O
far O
offer O
the O
greatest O
promise O
and O
opportunity O
for O
the O
replacement O
of O
VKAs. O
Effects O
of O
smoking O
on O
the O
oxidant/antioxidant O
balance O
and O
the O
blood O
lipids O
in O
pesticide O
sprayers. O
The O
present O
study O
was O
conducted O
on O
80 O
pesticide O
male O
sprayers O
(42 O
nonsmokers O
and O
38 O
smokers). O
Our O
aim O
was O
to O
estimate O
the O
smoking O
effects O
on O
blood O
lipids O
and O

oxidant/antioxidant O
status O
in O
pesticide O
sprayers. O
Results O
revealed O
that O
cholesterol, B-CHEMICAL
low-density B-GENE-N
lipoprotein I-GENE-N
(LDL) B-GENE-N
and O
glutathion B-CHEMICAL
peroxidase I-GENE-N
(GPx) B-GENE-N
enzyme O
were O
significantly O
higher O
in O
the O
38 O
smoker O
sprayers O
than O
in O
the O
42 O
nonsmoker O
sprayers. O
Cholesterol B-CHEMICAL
and O
LDL B-GENE-N
were O
correlated O
with O
smoking O
index O
and O
high-density B-GENE-N
lipoprotein I-GENE-N
(HDL), B-GENE-N
superoxide B-CHEMICAL
dismutase I-GENE-N
(SOD) B-GENE-N
enzyme O
and O
zinc B-CHEMICAL
(Zn) B-CHEMICAL
were O
inversely O
correlated O
with O
duration O
of O
pesticides' O
exposure. O

In O
nonsmokers, O
LDL B-GENE-N
and O
cholesterol B-CHEMICAL
were O
negatively O
correlated O
with O
SOD B-GENE-N
and O
correlated O
with O
malondialdehyde B-CHEMICAL
(MDA), B-CHEMICAL
and O
cholesterol B-CHEMICAL
was O
negatively O
correlated O
with O
Zn. B-CHEMICAL
HDL B-GENE-N
was O
negatively O
correlated O
with O
MDA B-CHEMICAL
in O
all O
the O
sprayers, O
but O
was O
correlated O
with O
GPx B-GENE-N
in O
smokers O
and O
with O
Zn B-CHEMICAL
in O
nonsmokers. O
In O
smokers, O
LDL B-GENE-N
was O
negatively O
correlated O
with O
GPx, B-GENE-N
HDL B-GENE-N
was O
negatively O
correlated O
with O
MDA B-CHEMICAL
and O
triglycerides B-CHEMICAL
and O
very-low-density B-GENE-N
lipoprotein I-GENE-N
were O
negatively O
correlated O
with O
Zn. B-CHEMICAL
MDA B-CHEMICAL
was O
negatively O

correlated O
with O
SOD, B-GENE-N
GPx B-GENE-N
and O
Zn. B-CHEMICAL
Smoking O
and O
pesticide O
exposure O
could O
be O
responsible O
for O
hyperlipidemia O
and O
oxidative O
stress. O
Therefore, O
improvement O
in O
the O
antioxidant O
status O
is O
mandatory O
for O
pesticide O
sprayers O
especially O
the O
ones O
who O
smoke. O
Fluorescence O
lifetime O
analysis O
and O
effect O
of O
magnesium B-CHEMICAL
ions O
on O
binding O
of O
NADH B-CHEMICAL
to O
human B-GENE-Y
aldehyde I-GENE-Y
dehydrogenase I-GENE-Y
1. I-GENE-Y
Aldehyde B-GENE-Y
dehydrogenase I-GENE-Y
1 I-GENE-Y
(ALDH1A1) B-GENE-Y
catalyzes O
the O
oxidation O
of O
toxic O
aldehydes B-CHEMICAL
to O
carboxylic B-CHEMICAL
acids. I-CHEMICAL

Physiologic O
levels O
of O
Mg(2+) B-CHEMICAL
ions O
decrease O
ALDH1 B-GENE-Y
activity O
in O
part O
by O
increasing O
NADH B-CHEMICAL
binding O
affinity O
to O
the O
enzyme. O
By O
using O
time-resolved O
fluorescence O
spectroscopy, O
we O
have O
resolved O
the O
fluorescent O
lifetimes O
() O
of O
free O
NADH B-CHEMICAL
in O
solution O
(=0.4 O
ns) O
and O
two O
enzyme-bound O
NADH B-CHEMICAL
states O
(=2.0 O
ns O
and O
=7.7 O
ns). O
We O
used O
this O
technique O
to O
investigate O
the O
effects O
of O
Mg(2+) B-CHEMICAL
ions O
on O
the O
ALDH1A1-NADH B-GENE-Y
binding O

characteristics O
and O
enzyme O
catalysis. O
From O
the O
resolved O
free O
and O
bound O
NADH B-CHEMICAL
fluorescence O
signatures, O
the O
KD O
values O
for O
both O
NADH B-CHEMICAL
conformations O
in O
ALDH1A1 B-GENE-Y
ranged O
from O
about O
24 O
M O
to O
1 O
M O
for O
Mg(2+) B-CHEMICAL
ion O
concentrations O
of O
0-6000 O
M, O
respectively. O
The O
rate O
constants O
for O
dissociation O
of O
the O
enzyme-NADH B-CHEMICAL
complex O
ranged O
from O
0.03 O
s(-1) O
(6000 O
M O
Mg(2+)) B-CHEMICAL
to O
0.30s(-1) O
(0 O
M O
Mg(2+)) B-CHEMICAL
as O

determined O
by O
addition O
of O
excess O
NAD(+) B-CHEMICAL
to O
prevent O
re-association O
of O
NADH B-CHEMICAL
and O
resolving O
the O
real-time O
NADH B-CHEMICAL
fluorescence O
signal. O
During O
the O
initial O
reaction O
of O
enzyme O
with O
NAD(+) B-CHEMICAL
and O
butyraldehyde, B-CHEMICAL
there O
was O
an O
immediate O
rise O
in O
the O
NADH B-CHEMICAL
fluorescence, O
due O
to O
the O
formation O
of O
bound O
NADH B-CHEMICAL
complexes, O
with O
a O
constant O
steady-state O
rate O
of O
production O
of O
free O
NADH. B-CHEMICAL
As O
the O
Mg(2+) B-CHEMICAL
ion O
concentration O
was O
increased, O
there O
was O
a O
consistent O
decrease O
of O
the O
enzyme O
catalytic O
turnover O
from O
0.31 O

s(-1) O
(0 O
M O
Mg(2+)) B-CHEMICAL
to O
0.050 O
s(-1) O
(6000 O
M O
Mg(2+)) B-CHEMICAL
and O
a O
distinct O
shift O
in O
steady-state O
conformational O
population O
from O
one O
that O
favors O
the O
ALDH1-NADH B-GENE-Y
complex O
with O
the O
shorter O
fluorescence O
lifetime O
(33% O
excess) O
in O
the O
absence O
of O
magnesium B-CHEMICAL
ion O
to O
one O
that O
favors O
the O
ALDH1-NADH B-GENE-Y
complex O
with O
the O
longer O
fluorescence O
lifetime O
(13% O
excess) O
at O
6000 O
M O
Mg(2+). B-CHEMICAL
This O
shift O
in O
conformational O
population O
at O
higher O

Mg(2+) B-CHEMICAL
ion O
concentrations O
and O
to O
lower O
enzyme O
activity O
may O
be O
due O
to O
longer O
residence O
time O
of O
the O
NADH B-CHEMICAL
in O
the O
ALDH1 B-GENE-Y
pocket. O
The O
results O
from O
monitoring O
enzyme O
catalysis O
in O
the O
absence O
of O
magnesium B-CHEMICAL
suggests O
that O
the O
ALDH1-NADH B-GENE-Y
complex O
with O
the O
shorter O
fluorescence O
lifetime O
is O
the O
form O
initially O
produced, O
and O
the O
complex O
with O
the O
longer O
fluorescence O
lifetime O
is O
produced O
through O
isomerization. O
Acrolein B-CHEMICAL
induces O
Alzheimer's O
disease-like O
pathologies O
in O
vitro O
and O
in O
vivo. O
The O
pathologic O
mechanisms O
of O
Alzheimer's O
disease O
(AD) O
have O
not O
been O

fully O
uncovered. O
Acrolein, B-CHEMICAL
a O
ubiquitous O
dietary O
pollutant O
and O
by-product O
of O
oxidative O
stress, O
can O
induce O
cytotoxicity O
in O
neurons, O
which O
might O
play O
an O
important O
role O
in O
the O
etiology O
of O
AD. O
Here, O
we O
examined O
the O
effects O
of O
Acrolein B-CHEMICAL
on O
the O
AD O
pathologies O
in O
vitro O
and O
in O
vivo. O
We O
found O
Acrolein B-CHEMICAL
induced O
HT22 O
cells O
death O
in O
concentration- O
and O
time-dependent O
manners. O
Interestingly, O
Acrolein B-CHEMICAL
increased O
proteins' O
levels O
of O
amyloid B-GENE-Y
precursor I-GENE-Y
protein I-GENE-Y
(APP), B-GENE-Y
-secretase B-GENE-N

(BACE-1) B-GENE-Y
and O
the O
amyloid B-GENE-Y
-peptide I-GENE-Y
transporter I-GENE-Y
receptor B-GENE-Y
for I-GENE-Y
advanced I-GENE-Y
glycation I-GENE-Y
end I-GENE-Y
products, I-GENE-Y
and O
decreased O
A-disintegrin B-GENE-Y
and I-GENE-Y
metalloprotease I-GENE-Y
(ADAM) I-GENE-Y
10 I-GENE-Y
levels. O
In O
vivo, O
chronic O
oral O
exposure O
to O
Acrolein B-CHEMICAL
(2.5 O
mg/kg/day O
by O
intragastric O
gavage O
for O
8 O
weeks) O
induced O
mild O
cognitive O
declination O
and O
pyknosis/atrophy O
of O
hippocampal O
neurons. O
The O
activity O
of O
superoxide B-CHEMICAL
dismutase I-GENE-N
was O
down-regulated O
while O
the O
level O
of O
malondialdehyde B-CHEMICAL
was O

up-regulated O
in O
rat O
brain. O
Moreover, O
Acrolein B-CHEMICAL
resulted O
in O
activation O
of O
astrocytes, O
up-regulation O
of O
BACE-1 B-GENE-Y
in O
cortex O
and O
down-regulation O
of O
ADAM-10 B-GENE-Y
in O
hippocampus O
and O
cortex. O
Taken O
together, O
our O
findings O
suggest O
that O
exposure O
to O
Acrolein B-CHEMICAL
induces O
AD-like O
pathology O
in O
vitro O
and O
in O
vivo. O
Scavenging O
Acrolein B-CHEMICAL
might O
be O
beneficial O
for O
the O
therapy O
of O
AD. O
Membrane-initiated O
estradiol B-CHEMICAL
signaling O
in O
immortalized O
hypothalamic O
N-38 O
neurons. O
Regulation O
of O
sexual O
reproduction O
by O
estradiol B-CHEMICAL
involves O

the O
activation O
of O
estrogen B-CHEMICAL
receptors I-GENE-Y
(ERs) B-GENE-Y
in O
the O
hypothalamus. O
Of O
the O
two O
classical O
ERs B-GENE-Y
involved O
in O
reproduction, O
ER B-GENE-Y
appears O
to O
be O
the O
critical O
isoform. O
The O
role O
of O
ER B-GENE-Y
in O
reproduction O
has O
been O
found O
to O
involve O
a O
nuclear O
ER B-GENE-Y
that O
induces O
a O
genomic O
mechanism O
of O
action. O
More O
recently, O
a O
plasma O
membrane O
ER B-GENE-Y
has O
been O
shown O
to O
trigger O
signaling O
pathways O
involved O
in O
reproduction. O
Mechanisms O
underlying O
membrane-initiated O
estradiol O
signaling O
are O
emerging, O
including O
evidence O
that O
activation O
of O
plasma O
membrane O
ER B-GENE-Y
involves O
receptor O
trafficking. O
The O
present O
study O
examined O
the O
insertion O
of O
ER B-GENE-Y
into O
the O
plasma O
membrane O
of O

N-38 O
neurons, O
an O
immortalized O
murine O
hypothalamic O
cell O
line. O
We O
identified, O
using O
western O
blotting O
and O
PCR O
that O
N-38 O
neurons O
express O
full-length O
66kDa O
ER B-GENE-Y
and O
a O
52kDa O
ER B-GENE-Y
spliced O
variant O
missing O
the O
fourth O
exon O
- O
ER4. B-GENE-Y
Using O
surface O
biotinylation, O
we O
observed O
that O
treatment O
of O
N-38 O
neurons O
with O
estradiol B-CHEMICAL
or O
with O
a O
membrane O
impermeant O
estradiol B-CHEMICAL
elevated O
plasma O
membrane O
ER B-GENE-Y
protein O
levels, O
indicating O
that O
membrane O
signaling O
increased O
receptor O
insertion O
into O
the O
cell O
membrane. O
Insertion O
of O
ER B-GENE-Y

was O
blocked O
by O
the O
ER B-GENE-Y
antagonist O
ICI B-CHEMICAL
182,780 I-CHEMICAL
or O
with O
the O
protein B-GENE-N
kinase I-GENE-N
C I-GENE-N
(PKC) B-GENE-N
pathway O
inhibitor O
bisindolylmaleimide B-CHEMICAL
(BIS). B-CHEMICAL
Downstream O
membrane-initiated O
signaling O
was O
confirmed O
by O
estradiol B-CHEMICAL
activation O
of O
PKC-theta B-GENE-Y
(PKC) B-GENE-Y
and O
the O
release O
of O
intracellular O
calcium. O
These O
results O
indicate O
that O
membrane O
ER B-GENE-Y
levels O
in O
N-38 O
neurons O
are O
dynamically O
autoregulated O
by O
estradiol. B-CHEMICAL
Neuroprotective O
and O
anti-inflammatory O
properties O
of O
a O
coffee O
component O
in O
the O
MPTP B-CHEMICAL
model O
of O
Parkinson's O
disease. O
Consumption O

of O
coffee O
is O
associated O
with O
reduced O
risk O
of O
Parkinson's O
disease O
(PD), O
an O
effect O
that O
has O
largely O
been O
attributed O
to O
caffeine. O
However, O
coffee O
contains O
numerous O
components O
that O
may O
also O
be O
neuroprotective. O
One O
of O
these O
compounds O
is O
eicosanoyl-5-hydroxytryptamide B-CHEMICAL
(EHT), B-CHEMICAL
which O
ameliorates O
the O
phenotype O
of O
-synuclein B-GENE-Y
transgenic O
mice O
associated O
with O
decreased O
protein O
aggregation O
and O
phosphorylation, O
improved O
neuronal O
integrity O
and O
reduced O
neuroinflammation. O
Here, O
we O
sought O
to O
investigate O
if O
EHT B-CHEMICAL
has O

an O
effect O
in O
the O
MPTP B-CHEMICAL
model O
of O
PD. O
Mice O
fed O
a O
diet O
containing O
EHT B-CHEMICAL
for O
four O
weeks O
exhibited O
dose-dependent O
preservation O
of O
nigral O
dopaminergic O
neurons O
following O
MPTP B-CHEMICAL
challenge O
compared O
to O
animals O
given O
control O
feed. O
Reductions O
in O
striatal O
dopamine B-CHEMICAL
and O
tyrosine B-GENE-Y
hydroxylase I-GENE-Y
content O
were O
also O
less O
pronounced O
with O
EHT B-CHEMICAL
treatment. O
The O
neuroinflammatory O
response O
to O
MPTP B-CHEMICAL
was O
markedly O
attenuated, O
and O
indices O
of O
oxidative O
stress O
and O
JNK B-GENE-N
activation O
were O
significantly O
prevented O
with O
EHT. B-CHEMICAL
In O
cultured O
primary O
microglia O
and O

astrocytes, O
EHT B-CHEMICAL
had O
a O
direct O
anti-inflammatory O
effect O
demonstrated O
by O
repression O
of O
lipopolysaccharide-induced O
NFB B-GENE-N
activation, O
iNOS B-GENE-Y
induction, O
and O
nitric B-CHEMICAL
oxide I-CHEMICAL
production. O
EHT B-CHEMICAL
also O
exhibited O
a O
robust O
anti-oxidant O
activity O
in O
vitro. O
Additionally, O
in O
SH-SY5Y O
cells, O
MPP(+)-induced B-CHEMICAL
demethylation O
of O
phosphoprotein B-GENE-N
phosphatase I-GENE-N
2A I-GENE-N
(PP2A), B-GENE-N
the O
master O
regulator O
of O
the O
cellular O
phosphoregulatory O
network, O
and O
cytotoxicity O
were O

ameliorated O
by O
EHT. B-CHEMICAL
These O
findings O
indicate O
that O
the O
neuroprotective O
effect O
of O
EHT B-CHEMICAL
against O
MPTP B-CHEMICAL
is O
through O
several O
mechanisms O
including O
its O
anti-inflammatory O
and O
antioxidant O
activities O
as O
well O
as O
its O
ability O
to O
modulate O
the O
methylation O
and O
hence O
activity O
of O
PP2A. B-GENE-N
Our O
data, O
therefore, O
reveal O
a O
strong O
beneficial O
effect O
of O
a O
novel O
component O
of O
coffee O
in O
multiple O
endpoints O
relevant O
to O
PD. O
Hydrogen B-CHEMICAL
sulfide, I-CHEMICAL
the O
next O
potent O
preventive O
and O
therapeutic O
agent O
in O
aging O
and O
age-associated O
diseases. O
Hydrogen B-CHEMICAL
sulfide I-CHEMICAL
(H(2)S) B-CHEMICAL
is O
the O
third O

endogenous O
signaling O
gasotransmitter, O
following O
nitric B-CHEMICAL
oxide I-CHEMICAL
and O
carbon B-CHEMICAL
monoxide. I-CHEMICAL
It O
is O
physiologically O
generated O
by O
cystathionine--lyase, B-CHEMICAL
cystathionine--synthase, B-CHEMICAL
and O
3-mercaptopyruvate B-CHEMICAL
sulfurtransferase. I-GENE-Y
H(2)S B-CHEMICAL
has O
been O
gaining O
increasing O
attention O
as O
an O
important O
endogenous O
signaling O
molecule O
because O
of O
its O
significant O
effects O
on O
the O
cardiovascular O
and O
nervous O
systems. O
Substantial O
evidence O
shows O
that O
H(2)S B-CHEMICAL
is O
involved O
in O
aging O
by O
inhibiting O
free-radical O
reactions, O
activating O

SIRT1, B-GENE-Y
and O
probably O
interacting O
with O
the O
age-related O
gene O
Klotho. B-GENE-Y
Moreover, O
H(2)S B-CHEMICAL
has O
been O
shown O
to O
have O
therapeutic O
potential O
in O
age-associated O
diseases. O
This O
article O
provides O
an O
overview O
of O
the O
physiological O
functions O
and O
effects O
of O
H(2)S B-CHEMICAL
in O
aging O
and O
age-associated O
diseases, O
and O
proposes O
the O
potential O
health O
and O
therapeutic O
benefits O
of O
H(2)S. B-CHEMICAL
Induction O
of O
HO-1 B-GENE-Y
through O
p38 B-GENE-N
MAPK/Nrf2 B-GENE-N
signaling O
pathway O
by O
ethanol B-CHEMICAL
extract O
of O
Inula O
helenium O
L. O
reduces O
inflammation O
in O
LPS-activated O
RAW O
264.7 O
cells O
and O
CLP-induced O

septic O
mice. O
High B-GENE-Y
mobility I-GENE-Y
group I-GENE-Y
box I-GENE-Y
1 I-GENE-Y
(HMGB1) B-GENE-Y
plays O
a O
crucial O
mediator O
in O
the O
pathogenesis O
of O
many O
inflammatory O
diseases. O
We O
recently O
proposed O
that O
heme B-CHEMICAL
oxygenase-1 I-GENE-Y
(HO-1) B-GENE-Y
negatively O
regulates O
HMGB1 B-GENE-Y
in O
inflammatory O
conditions. O
We O
investigated O
whether O
ethanol B-CHEMICAL
extract O
of O
Inula O
helenium O
L. O
(EIH) O
activates O
p38 B-GENE-N
MAPK/Nrf2/HO-1 B-GENE-N
pathways O
in O
RAW264.7 O
cells O
and O
reduces O
inflammation O
in O
CLP-induced O
septic O
mice. O
EIH O
induced O
expression O
of O
HO-1 B-GENE-Y
protein O
in O
a O
time- O
and O

concentration-dependent O
manner. O
EIH O
significantly O
diminished O
HO-1 B-GENE-Y
expression O
in O
siNrf2 B-GENE-Y
RNA-transfected O
cells. O
As O
expected, O
the O
inhibited O
expression O
of O
iNOS/NO, B-GENE-Y
COX-2/PGE2, B-GENE-Y
HMGB1 B-GENE-Y
release O
by O
EIH O
in O
LPS-activated O
RAW264.7 O
cells O
was O
significantly O
reversed O
by O
siHO-1RNA B-GENE-Y
transfection. O
Furthermore, O
EIH O
not O
only O
inhibited O
NF-B B-GENE-N
luciferase O
activity, O
phosphorylation O
of O
IB B-GENE-Y
in O
LPS-activated O
cells O
but O
also O
significantly O
suppressed O
expression O

of O
adhesion O
molecules O
(ICAM-1 B-GENE-Y
and O
VCAM-1) B-GENE-Y
in O
TNF- B-GENE-Y
activated O
human O
umbilical O
vein O
endothelial O
cells. O
The O
induction O
of O
HO-1 B-GENE-Y
by O
EIH O
was O
inhibited O
by O
SB203580 B-CHEMICAL
but O
not O
by O
SP600125, B-CHEMICAL
PD98059, B-CHEMICAL
nor O
LY294002. B-CHEMICAL
Most O
importantly, O
administration O
of O
EIH O
significantly O
reduced O
not O
only O
increase O
in O
blood O
HMGB1, B-GENE-Y
ALT, B-GENE-N
AST, B-GENE-N
BUN, O
creatinine B-CHEMICAL
levels O
but O
also O
decrease O
macrophage O
infiltrate O
in O
the O
liver O
of O
septic O

mice, O
which O
were O
reversed O
by O
ZnPPIX, O
a O
HO-1 B-GENE-Y
inhibitor. O
We O
concluded O
that O
EIH O
has O
anti-inflammatory O
effect O
via O
the O
induction O
of O
p38 B-GENE-N
MAPK-dependent B-GENE-N
HO-1 B-GENE-Y
signaling O
pathway. O
Protease-activated B-GENE-Y
receptor I-GENE-Y
(PAR) I-GENE-Y
1 I-GENE-Y
and O
PAR4 B-GENE-Y
differentially O
regulate O
factor B-GENE-Y
V I-GENE-Y
expression O
from O
human O
platelets. O
With O
the O
recent O
interest O
of O
protease-activated B-GENE-Y
receptors I-GENE-Y
(PAR) I-GENE-Y
1 I-GENE-Y
and O
PAR4 B-GENE-Y
as O
possible O
targets O
for O
the O
treatment O
of O
thrombotic O
disorders, O
we O
compared O
the O
efficacy O
of O
protease-activated B-GENE-Y
receptor I-GENE-Y
(PAR)1 I-GENE-Y
and O
PAR4 B-GENE-Y

in O
the O
generation O
of O
procoagulant O
phenotypes O
on O
platelet O
membranes. O
PAR4-activating B-GENE-Y
peptide O
(AP)-stimulated O
platelets O
promoted O
thrombin B-GENE-Y
generation O
in O
plasma O
up O
to O
5 O
minutes O
earlier O
than O
PAR1-AP-stimulated B-GENE-Y
platelets. O
PAR4-AP-mediated B-GENE-Y
factor B-GENE-Y
V I-GENE-Y
(FV) B-GENE-Y
association O
with O
the O
platelet O
surface O
was O
1.6-fold O
greater O
than O
for O
PAR1-AP. B-GENE-Y
Moreover, O
PAR4 B-GENE-Y
stimulation O
resulted O
in O
a O
3-fold O
greater O
release O
of O
microparticles, O
compared O
with O
PAR1 B-GENE-Y
stimulation. O
More O
robust O
FV B-GENE-Y
secretion O
and O

microparticle O
generation O
with O
PAR4-AP B-GENE-Y
was O
attributable O
to O
stronger O
and O
more O
sustained O
phosphorylation O
of O
myosin O
light O
chain O
at O
serine B-CHEMICAL
19 O
and O
threonine B-CHEMICAL
18. O
Inhibition O
of O
Rho-kinase B-GENE-N
reduced O
PAR4-AP-mediated B-GENE-Y
FV B-GENE-Y
secretion O
and O
microparticle O
generation O
to O
PAR1-AP-mediated B-GENE-Y
levels. O
Thrombin B-GENE-Y
generation O
assays O
measuring O
prothrombinase B-GENE-N
complex O
activity O
demonstrated O
1.5-fold O
higher O
peak O
thrombin B-GENE-Y
levels O
on O
PAR4-AP-stimulated B-GENE-Y
platelets, O
compared O
with O

PAR1-AP-stimulated B-GENE-Y
platelets. O
Rho-kinase B-GENE-N
inhibition O
reduced O
PAR4-AP-mediated B-GENE-Y
peak O
thrombin O
generation O
by O
25% O
but O
had O
no O
significant O
effect O
on O
PAR1-AP-mediated B-GENE-Y
thrombin B-GENE-Y
generation. O
In O
conclusion, O
stimulation O
of O
PAR4 B-GENE-Y
on O
platelets O
leads O
to O
faster O
and O
more O
robust O
thrombin O
generation, O
compared O
with O
PAR1 B-GENE-Y
stimulation. O
The O
greater O
procoagulant O
potential O
is O
related O
to O
more O
efficient O
FV B-GENE-Y
release O
from O
intracellular O
stores O
and O
microparticle O
production O
driven O
by O
stronger O
and O
more O
sustained O
myosin O
light O
chain O
phosphorylation. O
These O
data O
have O

implications O
about O
the O
role O
of O
PAR4 B-GENE-Y
during O
hemostasis O
and O
are O
clinically O
relevant O
in O
light O
of O
recent O
efforts O
to O
develop O
PAR B-GENE-N
antagonists O
to O
treat O
thrombotic O
disorders. O
Diels-Alder O
mediated O
controlled O
release O
from O
a O
poly(ethylene B-CHEMICAL
glycol) I-CHEMICAL
based O
hydrogel. O
A O
synthetic O
amino B-CHEMICAL
acid I-CHEMICAL
bearing O
a O
furan B-CHEMICAL
functionality O
was O
developed O
and O
incorporated O
into O
peptide O
sequences O
using O
solid O
phase O
synthesis. O
Peptides O
expressing O
the O
furan B-CHEMICAL
moiety O
were O
attached O
to O
poly(ethylene B-CHEMICAL
glycol) I-CHEMICAL
(PEG) B-CHEMICAL
hydrogels O
through O
a O
thermally O
reversible O
covalent O
bond O
formed O

by O
a O
Diels-Alder O
reaction. O
Reactions O
of O
thiol B-CHEMICAL
and O
maleimide B-CHEMICAL
PEG I-CHEMICAL
macromers O
in O
an O
off-stoichiometric O
Michael O
addition O
were O
performed, O
such O
that O
the O
maleimide B-CHEMICAL
moiety O
was O
in O
excess, O
to O
create O
hydrogel O
networks O
with O
pendant O
Diels-Alder O
compatible O
tethering O
sites, O
that O
is, O
the O
maleimide. B-CHEMICAL
By O
making O
use O
of O
the O
Diels-Alder O
reaction, O
it O
was O
possible O
to O
control O
the O
release O
rate O
of O
reversibly O
bound O
moieties O
from O
the O
hydrogel O
by O
changing O
the O
temperature; O
higher O
temperatures O
favor O
a O
faster O

retro-Diels-Alder O
reaction O
and, O
therefore, O
a O
faster O
release O
from O
the O
polymer O
network. O
This O
concept O
was O
demonstrated O
by O
incorporating O
a O
fluorescently O
labeled O
furan-RGDS B-CHEMICAL
sequence O
into O
a O
hydrogel O
possessing O
excess O
maleimide B-CHEMICAL
functionalities O
and O
monitoring O
the O
subsequent O
liberation O
of O
RGDS O
at O
various O
temperatures, O
illustrating O
a O
Diels-Alder O
mediated O
release O
mechanism. O
The O
release O
profile O
was O
quantified O
at O
temperatures O
ranging O
from O
physiological O
(37 O
C) O
to O
80 O
C. O
By O
changing O
the O
temperature, O
varying O
extents O
of O
release O
were O
attained O
over O
the O
time O
course O
of O
several O
days, O
ranging O
from O
40% O
release O
for O
lower O
temperatures O
to O
complete O

release O
for O
the O
highest O
temperature O
considered. O
Further O
confirmation O
of O
a O
reaction-diffusion O
controlled O
release O
mechanism O
was O
obtained O
through O
comparison O
of O
experimental O
release O
data O
to O
a O
reaction-diffusion O
model O
of O
the O
release. O
In O
addition O
to O
thermal O
modulation, O
tuning O
of O
the O
release O
rate O
was O
accomplished O
by O
altering O
the O
number O
of O
possible O
Diels-Alder O
tethering O
sites O
present O
in O
the O
hydrogel. O
Increasing O
the O
amount O
of O
free O
maleimide B-CHEMICAL
and, O
therefore, O
the O
number O
of O
potential O
Diels-Alder O
reaction O
sites, O
effectively O
slowed O
the O
release O
of O
peptide O
from O
the O
polymer. O
For O
instance, O
doubling O
the O
amount O
of O
maleimide B-CHEMICAL
sites O
present O
in O
the O
hydrogel O

system O
decreased O
the O
amount O
of O
peptide O
released O
from O
approximately O
60% O
to O
about O
40% O
in O
the O
same O
span O
of O
time. O
Trimethylamine-N-oxide, B-CHEMICAL
a O
metabolite O
associated O
with O
atherosclerosis, O
exhibits O
complex O
genetic O
and O
dietary O
regulation. O
Circulating O
trimethylamine-N-oxide B-CHEMICAL
(TMAO) B-CHEMICAL
levels O
are O
strongly O
associated O
with O
atherosclerosis. O
We O
now O
examine O
genetic, O
dietary, O
and O
hormonal O
factors O
regulating O
TMAO B-CHEMICAL
levels. O
We O
demonstrate O
that O
two O
flavin B-CHEMICAL
mono-oxygenase I-GENE-N
family O
members, O
FMO1 B-GENE-Y
and O
FMO3, B-GENE-Y
oxidize O

trimethylamine B-CHEMICAL
(TMA), B-CHEMICAL
derived O
from O
gut O
flora O
metabolism O
of O
choline, B-CHEMICAL
to O
TMAO. B-CHEMICAL
Further, O
we O
show O
that O
FMO3 B-GENE-Y
exhibits O
10-fold O
higher O
specific O
activity O
than O
FMO1. B-GENE-Y
FMO3 B-GENE-Y
overexpression O
in O
mice O
significantly O
increases O
plasma O
TMAO B-CHEMICAL
levels O
while O
silencing O
FMO3 B-GENE-Y
decreases O
TMAO B-CHEMICAL
levels. O
In O
both O
humans O
and O
mice, O
hepatic O
FMO3 B-GENE-Y
expression O
is O
reduced O
in O
males O
compared O
to O
females. O
In O
mice, O
this O
reduction O
in O
FMO3 B-GENE-Y
expression O
is O
due O
primarily O
to O
downregulation O
by O
androgens. B-CHEMICAL
FMO3 B-GENE-Y
expression O
is O
induced O
by O
dietary O

bile B-CHEMICAL
acids I-CHEMICAL
by O
a O
mechanism O
that O
involves O
the O
farnesoid B-GENE-Y
X I-GENE-Y
receptor I-GENE-Y
(FXR), B-GENE-Y
a O
bile B-CHEMICAL
acid-activated I-CHEMICAL
nuclear O
receptor. O
Analysis O
of O
natural O
genetic O
variation O
among O
inbred O
strains O
of O
mice O
indicates O
that O
FMO3 B-GENE-Y
and O
TMAO B-CHEMICAL
are O
significantly O
correlated, O
and O
TMAO B-CHEMICAL
levels O
explain O
11% O
of O
the O
variation O
in O
atherosclerosis. O
Tricycloalternarenes B-CHEMICAL
F-H: I-CHEMICAL
three O
new O
mixed O
terpenoids B-CHEMICAL
produced O
by O
an O
endolichenic O
fungus O
Ulocladium O
sp. O
using O
OSMAC O
method. O
Three O
new O
mixed O
terpenoids, B-CHEMICAL

tricycloalternarenes B-CHEMICAL
(TCAs) B-CHEMICAL
F-H O
(1-3), O
together O
with O
ten O
known O
tricycloalternarenes B-CHEMICAL
(4-13), O
were O
isolated O
from O
the O
Czapek's O
culture O
of O
an O
endophytic O
fungus O
Ulocladium O
sp. O
Their O
structures O
were O
identified O
by O
extensive O
spectroscopic O
experiments O
(NMR O
and O
MS) O
and O
comparison O
with O
literature O
data. O
TCA B-CHEMICAL
1b O
(5) O
showed O
weak O
activity O
against O
the O
Bacille O
Calmette-Guerin O
strain O
with O
the O
MIC O
of O
125g/mL. O

TCA B-CHEMICAL
9b O
(10) O
exhibited O
strong O
cytotoxic O
activity O
against O
Hela O
cell O
line O
with O
IC50 O
of O
8.58M. O
What O
are O
the O
physiological O
estrogens? B-CHEMICAL
Estradiol B-CHEMICAL
(E2) O
is O
the O
principal O
physiological O
estrogen O
in O
mammals. O
E2 O
and O
its O
active O
metabolites, O
estrone B-CHEMICAL
and O
estriol B-CHEMICAL
have O
a O
characteristic O
phenolic O
A O
ring, O
unlike O
progesterone, B-CHEMICAL
testosterone, B-CHEMICAL
cortisol B-CHEMICAL
and O
aldosterone, B-CHEMICAL
which O
have O
an O
A O
ring O
containing O
a O
C3-ketone, B-CHEMICAL
a O
(4) O
bond O
and O
a O
C19 O
methyl B-CHEMICAL

group. O
Crystal O
structures O
of O
E2 O
in O
the O
estrogen B-CHEMICAL
receptor I-GENE-Y
(ER) B-GENE-Y
confirm O
the O
importance O
of O
the O
A O
ring O
in O
stabilizing O
E2 O
in O
the O
ER. B-GENE-Y
However, O
other O
steroids, B-CHEMICAL
including O
(5)-androstenediol, B-CHEMICAL
5-androstanediol B-CHEMICAL
and O
27-hydroxycholesterol, B-CHEMICAL
which O
have O
a O
saturated O
A O
ring O
containing O
a O
3-hydroxyl B-CHEMICAL
and O
a O
C19 O
methyl B-CHEMICAL
group, O
also O
mediate O
physiological O
responses O
through O
binding O
to O
estrogen B-GENE-Y
receptor- I-GENE-Y
(ER) B-GENE-Y
and O
ER. B-GENE-Y
Moreover, O
selective O
estrogen B-CHEMICAL
response O
modulators O

(SERMs) O
with O
diverse O
structures O
also O
regulate O
transcription O
of O
ER B-GENE-Y
and O
ER. B-GENE-Y
Our O
understanding O
of O
the O
physiological O
responses O
mediated O
by O
these O
"alternative" O
estrogens B-CHEMICAL
is O
in O
its O
infancy. O
Further O
studies O
of O
the O
role O
of O
these O
steroids B-CHEMICAL
and O
SERMs O
in O
regulating O
responses O
mediated O
by O
ER B-GENE-Y
and O
ER B-GENE-Y
a O
variety O
of O
tissues, O
during O
different O
stages O
of O
development, O
are O
likely O
to O
uncover O
additional O
estrogenic O
activities. O
Synthesis O
of O
quinoline B-CHEMICAL
derivatives: O
discovery O
of O
a O
potent O
and O
selective O
phosphodiesterase B-GENE-Y
5 I-GENE-Y
inhibitor O
for O
the O
treatment O
of O
Alzheimer's O
disease. O
Phosphodiesterase B-GENE-Y
type I-GENE-Y
5 I-GENE-Y

(PDE5) B-GENE-Y
mediates O
the O
degradation O
of O
cGMP B-CHEMICAL
in O
a O
variety O
of O
tissues O
including O
brain. O
Recent O
studies O
have O
demonstrated O
the O
importance O
of O
the O
nitric B-CHEMICAL
oxide/cGMP/cAMP-responsive I-CHEMICAL
element-binding I-GENE-N
protein I-GENE-N
(CREB) B-GENE-N
pathway O
to O
the O
process O
of O
learning O
and O
memory. O
Thus, O
PDE5 B-GENE-Y
inhibitors O
(PDE5Is) O
are O
thought O
to O
be O
promising O
new O
therapeutic O
agents O
for O
the O
treatment O
of O
Alzheimer's O
disease O
(AD), O
a O
neurodegenerative O
disorder O
characterized O
by O
memory O
loss. O
To O
explore O
this O
possibility, O
a O
series O
of O
quinoline B-CHEMICAL
derivatives O
were O
synthesized O
and O

evaluated. O
We O
found O
that O
compound O
7a O
selectively O
inhibits O
PDE5 B-GENE-Y
with O
an O
IC(50) O
of O
0.27 O
nM O
and O
readily O
crosses O
the O
blood O
brain O
barrier. O
In O
an O
in O
vivo O
mouse O
model O
of O
AD, O
compound O
7a O
rescues O
synaptic O
and O
memory O
defects. O
Quinoline-based, B-CHEMICAL
CNS-permeant O
PDE5Is O
have O
potential O
for O
AD O
therapeutic O
development. O
Fragment-based O
design, O
synthesis, O
and O
biological O
evaluation O
of O
N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide B-CHEMICAL

derivatives O
as O
novel O
Mcl-1 B-GENE-N
inhibitors. O
We O
have O
previously O
reported O
a O
nanomolar O
inhibitor O
of O
antiapoptotic O
Mcl-1 B-GENE-Y
protein, O
3-thiomorpholin-8-oxo-8H-acenaphtho B-CHEMICAL
[1,2-b] I-CHEMICAL
pyrrole-9-carbonitrile I-CHEMICAL
(S1). O
S1 O
plays O
its O
function O
by O
binding O
to O
the O
BH3 O
groove O
of O
Mcl-1. B-GENE-Y
Basing O
on O
this O
spacial O
structural O
characteristic, O
we O
developed O
a O
novel O
class O
of O
Mcl-1 B-GENE-Y
inhibitor O
using O
fragment-based O
drug O
discovery O

approach. O
By O
dissecting O
S1, O
we O
identified O
the O
compound O
4 O
with O
a O
2-hydroxypyridine B-CHEMICAL
core O
as O
the O
starting O
fragment. O
In O
the O
following O
molecular O
growth, O
we O
used O
the O
ligand O
efficiency O
evaluation O
and O
fit O
quality O
score O
to O
assess O
the O
fragments. O
A O
novel O
potent O
compound, O
N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl B-CHEMICAL
nicotinamide I-CHEMICAL
(12c), O
which O
binds O
Mcl-1 B-GENE-Y
with O
an O
IC(50) O
value O
of O
54 O
nM O
was O
obtained. O
Compound O
12c O
demonstrated O
a O
better O

aqueous O
solubility O
than O
S1. O
Transaldolase B-GENE-Y
deficiency: O
report O
of O
12 O
new O
cases O
and O
further O
delineation O
of O
the O
phenotype. O
PURPOSE: O
Transaldolase B-GENE-Y
deficiency O
is O
a O
recently O
described O
inborn O
error O
of O
pentose B-CHEMICAL
phosphate I-CHEMICAL
pathway. O
We O
conducted O
this O
study O
to O
further O
delineate O
the O
associated O
phenotype. O
METHODS O
AND O
RESULTS: O
We O
report O
on O
12 O
new O
cases O
representing O
six O
families O
with O
this O
metabolic O
defect O
that O
were O
observed O
over O
an O
8 O
year O
span. O
None O
of O
these O
cases O
received O
the O
correct O
diagnosis O
initially O
because O
of O
significant O
overlap O
in O
the O
presenting O
symptoms O
(growth O
retardation, O

dysmorphic O
features, O
cutis O
laxa, O
congenital O
heart O
disease, O
hepatosplenomegaly, O
pancytopenia, O
and O
bleeding O
tendency) O
with O
a O
wide O
range O
of O
genetic O
disorders. O
However, O
the O
consanguineous O
nature O
of O
these O
families O
allowed O
us O
to O
pursue O
autozygome O
analysis, O
which O
highlighted O
TALDO B-GENE-Y
as O
the O
likely O
candidate O
gene O
and O
sequencing O
confirmed O
segregation O
of O
a O
novel O
homozygous O
mutation O
with O
the O
disease O
in O
all O
the O
studied O
families. O
Biochemical O
analysis O
was O
also O
consistent O
with O
transaldolase B-GENE-Y
deficiency. O
CONCLUSION: O
This O
study O
expands O
the O
clinical O
definition O
of O
transaldolase B-GENE-Y

deficiency, O
and O
adds O
to O
its O
allelic O
heterogeneity. O
In O
addition, O
we O
emphasize O
the O
diagnostic O
challenge O
posed O
by O
this O
rare O
and O
pleiotropic O
metabolic O
disorder. O
Cellular O
signaling O
crosstalk O
between O
multiple O
receptors O
for O
investigation O
of O
pathophysiology O
in O
multifactorial O
diseases--what O
is O
clinically-relevant O
crosstalk? O
Recently, O
genomics O
and O
proteomics O
have O
been O
utilized O
as O
advanced O
tools O
for O
investigation O
of O
cellular O
signaling O
pathways O
and O
molecular O
interactions, O
and O
elucidated O
promiscuous O
networks O
composed O
of O
numerous O
interactions O
among O
pathways. O
However, O
some O
of O
these O
interactions O
are O
considered O
to O
be O
simply O
contributing O
to O
background O

'noise' O
and O
others O
are O
as O
'crosstalk' O
biologically-relevant O
to O
cellular O
physiology, O
leading O
to O
synergy O
effects O
more O
than O
additive O
responses O
in O
an O
entire O
organism. O
Effort O
is O
now O
required O
to O
determine O
which O
interactions O
truly O
contribute O
to O
final O
physiological O
output. O
A O
receptor O
is O
the O
prime O
example O
of O
connectors O
among O
the O
networks. O
It O
functions, O
not O
simply O
as O
a O
signaling O
gateway, O
but O
also O
as O
an O
active O
trader O
by O
forming O
inter-receptor O
dimers. O
Furthermore, O
various O
receptors O
can O
modulate O
the O
function O
of O
the O
other O
receptors O
by O
input O
to O
common O
intracellular O
signaling O
pathways, O
establishing O
functional O
crosstalk O
among O
networks. O
Our O
findings O
by O
combined O

analyses O
of O
gene O
polymorphisms O
of O
two O
separate O
genes O
present O
evidences O
that O
such O
is O
the O
case O
with O
human O
body O
in O
a O
clinical O
setting: O
1) O
an O
integrated O
effect O
of O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(EGFR) B-GENE-Y
and O
protease B-GENE-Y
activated I-GENE-Y
receptor-1 I-GENE-Y
(PAR-1) B-GENE-Y
on O
susceptibility O
to O
airway O
hyperresponsiveness O
(AHR), O
and O
2) O
a O
crosstalk O
effect O
between O
muscarinic B-GENE-N
acetylcholine I-GENE-N
receptor I-GENE-N
(mAChRs) B-GENE-N
and O
(2) B-GENE-Y
adrenoceptor I-GENE-Y

((2)AR) B-GENE-Y
on O
bronchodilatory O
response O
to O
anticholinergic O
agents O
in O
patients O
with O
COPD. O
These O
results O
indicate O
that O
these O
interactions O
are O
unlikely O
to O
be O
'noise' O
but O
functionally-relevant O
'crosstalk' O
in O
a O
human O
body. O
This O
review O
attempts O
to O
highlight O
the O
clinically-relevant O
'crosstalk' O
paradigm O
in O
a O
human O
body O
which O
provides O
us O
a O
novel O
insight O
necessary O
to O
investigate O
pathophysiology O
in O
common O
multifactorial O
diseases O
and O
to O
develop O
new O
drugs. O
Peginesatide B-CHEMICAL
clearance, O
distribution, O
metabolism, O
and O
excretion O
in O
monkeys O
following O
intravenous O
administration. O

Peginesatide, B-CHEMICAL
a O
polyethylene B-CHEMICAL
glycol I-CHEMICAL
(PEG)ylated B-CHEMICAL
peptide-based O
erythropoiesis-stimulating O
agent, O
stimulates O
the O
erythropoietin B-GENE-N
receptor I-GENE-N
dimer O
that O
governs O
erythropoiesis. O
Studies O
were O
designed O
to O
determine O
the O
erythropoietic O
response, O
pharmacokinetics O
(PK), O
tissue O
distribution, O
metabolism, O
and O
excretion O
of O
peginesatide B-CHEMICAL
in O
nonhuman O
primates O
following O
a O
single O
i.v. O
dose. O
The O
PK O
profile O
of O
peginesatide B-CHEMICAL

(0.1-5 O
mg/kg) O
is O
characterized O
by O
low, O
dose-dependent O
plasma O
clearance; O
small O
volume O
of O
distribution; O
and O
long O
half-life. O
The O
peginesatide B-CHEMICAL
PK O
profile O
following O
a O
single O
i.v. O
dose O
is O
consistent O
with O
the O
sustained O
erythropoiesis. O
Biodistribution O
quantitative O
whole-body O
autoradiography O
demonstrated O
high O
peginesatide B-CHEMICAL
levels O
in O
bone O
marrow O
(i.e., O
primary O
hematopoietic O
site) O
as O
well O
as O
other O
known O
hematopoietic O
sites O
persisting O
through O
at O
least O
3 O
weeks O
at O
2.1 O
mg/kg. O

Microautoradiography O
analysis O
at O
48 O
hours O
postdose O
revealed O
uniform O
and O
high O
distribution O
of O
radioactivity O
in O
the O
bone O
marrow O
and O
splenic O
red O
pulp O
with O
less O
extensive O
distribution O
in O
the O
renal O
cortex O
(glomeruli, O
associated O
ducts, O
interstitial O
cells). O
Radioactivity O
in O
the O
kidney O
was O
most O
prominent O
in O
the O
outer O
medullary O
and O
papillary O
interstitium. O
At O
2 O
weeks O
after O
dosing, O
cumulative O
radioactivity O
recovery O
in O
the O
urine O
and O
feces O
was O
60 O
and O
7% O
of O
the O
administered O
dose, O
respectively, O
with O
most O
of O
the O
radioactivity O
associated O
with O
the O
parent O

molecule. O
In O
conclusion, O
the O
PK O
characteristics O
are O
consistent O
with O
a O
PEGylated O
peptide O
of O
a O
45-kDa O
molecular O
mass, O
specifically O
low O
volume O
of O
distribution O
and O
long O
half-life. O
Drug O
was O
localized O
principally O
to O
hematopoietic O
sites, O
and O
nonspecific O
tissue O
retention O
was O
not O
observed. O
The O
nonhuman O
primate O
data O
indicate O
that O
peginesatide B-CHEMICAL
is O
metabolically O
stable O
and O
primarily O
excreted O
in O
the O
urine. O
Comparison O
of O
orientation O
and O
rotational O
motion O
of O
skeletal O
muscle O
cross-bridges O
containing O
phosphorylated B-GENE-Y
and I-GENE-Y
dephosphorylated I-GENE-Y
myosin I-GENE-Y
regulatory I-GENE-Y
light I-GENE-Y
chain. I-GENE-Y

Calcium B-CHEMICAL
binding O
to O
thin O
filaments O
is O
a O
major O
element O
controlling O
active O
force O
generation O
in O
striated O
muscles. O
Recent O
evidence O
suggests O
that O
processes O
other O
than O
Ca(2+) B-CHEMICAL
binding, O
such O
as O
phosphorylation O
of O
myosin B-GENE-Y
regulatory I-GENE-Y
light I-GENE-Y
chain I-GENE-Y
(RLC) B-GENE-Y
also O
controls O
contraction O
of O
vertebrate O
striated O
muscle O
(Cooke, O
R. O
(2011) O
Biophys. O
Rev. O
3, O
33-45). O
Electron O
paramagnetic O
resonance O
(EPR) O
studies O
using O
nucleotide B-CHEMICAL
analog O
spin O
label O
probes O
showed O
that O
dephosphorylated B-GENE-N
myosin I-GENE-N
heads O
are O
highly O

ordered O
in O
the O
relaxed O
fibers O
and O
have O
very O
low O
ATPase B-GENE-N
activity. O
This O
ordered O
structure O
of O
myosin B-GENE-N
cross-bridges O
disappears O
with O
the O
phosphorylation O
of O
RLC O
(Stewart, O
M. O
(2010) O
Proc. O
Natl. O
Acad. O
Sci. O
U.S.A. O
107, O
430-435). O
The O
slower O
ATPase B-GENE-N
activity O
in O
the O
dephosporylated O
moiety O
has O
been O
defined O
as O
a O
new O
super-relaxed O
state O
(SRX). O
It O
can O
be O
observed O
in O
both O
skeletal O
and O
cardiac O
muscle O
fibers O
(Hooijman, O
P., O
Stewart, O
M. O
A., O

and O
Cooke, O
R. O
(2011) O
Biophys. O
J. O
100, O
1969-1976). O
Given O
the O
importance O
of O
the O
finding O
that O
suggests O
a O
novel O
pathway O
of O
regulation O
of O
skeletal O
muscle, O
we O
aim O
to O
examine O
the O
effects O
of O
phosphorylation O
on O
cross-bridge O
orientation O
and O
rotational O
motion. O
We O
find O
that: O
(i) O
relaxed O
cross-bridges, O
but O
not O
active O
ones, O
are O
statistically O
better O
ordered O
in O
muscle O
where O
the O
RLC B-GENE-Y
is O
dephosporylated O
compared O
with O
phosphorylated B-GENE-Y
RLC; I-GENE-Y
(ii) O
relaxed O
phosphorylated O
and O
dephosphorylated O
cross-bridges O
rotate O

equally O
slowly; O
and O
(iii) O
active O
phosphorylated O
cross-bridges O
rotate O
considerably O
faster O
than O
dephosphorylated O
ones O
during O
isometric O
contraction O
but O
the O
duty O
cycle O
remained O
the O
same, O
suggesting O
that O
both O
phosphorylated O
and O
dephosphorylated O
muscles O
develop O
the O
same O
isometric O
tension O
at O
full O
Ca(2+) B-CHEMICAL
saturation. O
A O
simple O
theory O
was O
developed O
to O
account O
for O
this O
fact. O
LPA1-induced B-GENE-Y
cytoskeleton O
reorganization O
drives O
fibrosis O
through O
CTGF-dependent B-GENE-Y
fibroblast O
proliferation. O
There O
has O
been O
much O
recent O
interest O
in O
lysophosphatidic B-CHEMICAL
acid I-CHEMICAL

(LPA) B-CHEMICAL
signaling O
through O
one O
of O
its O
receptors, O
LPA1, B-GENE-Y
in O
fibrotic O
diseases, O
but O
the O
mechanisms O
by O
which O
LPA-LPA1 B-CHEMICAL
signaling O
promotes O
pathological O
fibrosis O
remain O
to O
be O
fully O
elucidated. O
Using O
a O
mouse O
peritoneal O
fibrosis O
model, O
we O
demonstrate O
central O
roles O
for O
LPA B-CHEMICAL
and O
LPA1 B-GENE-Y
in O
fibroblast O
proliferation. O
Genetic O
deletion O
or O
pharmacological O
antagonism O
of O
LPA1 B-GENE-Y
protected O
mice O
from O
peritoneal O
fibrosis, O
blunting O
the O
increases O
in O
peritoneal O
collagen B-GENE-N
by O
65.4 O
and O
52.9%, O

respectively, O
compared O
to O
control O
animals O
and O
demonstrated O
that O
peritoneal O
fibroblast O
proliferation O
was O
highly O
LPA1 B-GENE-Y
dependent. O
Activation O
of O
LPA1 B-GENE-Y
on O
mesothelial O
cells O
induced O
these O
cells O
to O
express O
connective B-GENE-Y
tissue I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(CTGF), B-GENE-Y
driving O
fibroblast O
proliferation O
in O
a O
paracrine O
fashion. O
Activation O
of O
mesothelial O
cell O
LPA1 B-GENE-Y
induced O
CTGF B-GENE-Y
expression O
by O
inducing O
cytoskeleton O
reorganization O
in O
these O
cells, O
causing O
nuclear O
translocation O
of O
myocardin-related B-GENE-Y
transcription I-GENE-Y
factor I-GENE-Y
(MRTF)-A I-GENE-Y
and O
MRTF-B. B-GENE-Y
Pharmacological O
inhibition O
of O

MRTF-induced B-GENE-N
transcription O
also O
diminished O
CTGF B-GENE-Y
expression O
and O
fibrosis O
in O
the O
peritoneal O
fibrosis O
model, O
mitigating O
the O
increase O
in O
peritoneal O
collagen B-GENE-N
content O
by O
57.9% O
compared O
to O
controls. O
LPA1-induced B-GENE-Y
cytoskeleton O
reorganization O
therefore O
makes O
a O
previously O
unrecognized O
but O
critically O
important O
contribution O
to O
the O
profibrotic O
activities O
of O
LPA B-CHEMICAL
by O
driving O
MRTF-dependent B-GENE-N
CTGF B-GENE-Y
expression, O
which, O
in O
turn, O
drives O
fibroblast O
proliferation.-Sakai, O
N., O
Chun, O
J., O
Duffield, O
J. O
S., O

Wada, O
T., O
Luster, O
A. O
D., O
Tager, O
A. O
M. O
LPA1-induced B-GENE-Y
cytoskeleton O
reorganization O
drives O
fibrosis O
through O
CTGF-dependent B-GENE-Y
fibroblast O
proliferation. O
Cooperative O
effects O
for O
CYP2E1 B-GENE-Y
differ O
between O
styrene B-CHEMICAL
and O
its O
metabolites. O
Abstract O
1. O
Cooperative O
interactions O
are O
frequently O
observed O
in O
the O
metabolism O
of O
drugs O
and O
pollutants O
by O
cytochrome B-GENE-N
P450s; I-GENE-N
nevertheless, O
the O
molecular O
determinants O
for O
cooperativity O
remain O
elusive. O
Previously, O
we O
demonstrated O
that O
steady-state O
styrene O
metabolism O
by O

CYP2E1 B-GENE-Y
exhibits O
positive O
cooperativity. O
2. O
We O
hypothesized O
that O
styrene B-CHEMICAL
metabolites O
have O
lower O
affinity O
than O
styrene B-CHEMICAL
toward O
CYP2E1 B-GENE-Y
and O
limited O
ability O
to O
induce O
cooperative O
effects O
during O
metabolism. O
To O
test O
the O
hypothesis, O
we O
determined O
the O
potency O
and O
mechanism O
of O
inhibition O
for O
styrene B-CHEMICAL
and O
its O
metabolites O
toward O
oxidation O
of O
4-nitrophenol B-CHEMICAL
using O
CYP2E1 B-GENE-Y
Supersomes O
and O
human O
liver O
microsomes. O
3. O
Styrene B-CHEMICAL
inhibited O
the O
reaction O
through O
a O
mixed O
cooperative O
mechanism O
with O
high O
affinity O
for O
the O
catalytic O
site O
(67 O

M) O
and O
lower O
affinity O
for O
the O
cooperative O
site O
(1100 O
M), O
while O
increasing O
substrate O
turnover O
at O
high O
concentrations. O
Styrene B-CHEMICAL
oxide I-CHEMICAL
and O
4-vinylphenol B-CHEMICAL
possessed O
similar O
affinity O
for O
CYP2E1. B-GENE-Y
Styrene B-CHEMICAL
oxide I-CHEMICAL
behaved O
cooperatively O
like O
styrene, B-CHEMICAL
but O
4-vinylphenol B-CHEMICAL
decreased O
turnover O
at O
high O
concentrations. O
Styrene B-CHEMICAL
glycol I-CHEMICAL
was O
a O
very O
poor O
competitive O
inhibitor. O
Among O
all O
compounds, O
there O
was O
a O
positive O
correlation O
with O
binding O
and O
hydrophobicity. O
4. O
Taken O
together, O
these O
findings O
for O
CYP2E1 B-GENE-Y
further O
validate O
contributions O
of O
cooperative O
mechanisms O
to O
metabolic O

processes, O
demonstrate O
the O
role O
of O
molecular O
structure O
on O
those O
mechanisms O
and O
underscore O
the O
potential O
for O
heterotropic O
cooperative O
effects O
between O
different O
compounds. O
Nonalcoholic O
fatty O
liver O
disease: O
current O
issues O
and O
novel O
treatment O
approaches. O
Nonalcoholic O
fatty O
liver O
disease O
(NAFLD) O
is O
considered O
the O
most O
common O
liver O
disorder O
in O
the O
Western O
world. O
It O
is O
commonly O
associated O
with O
insulin B-GENE-Y
resistance, O
obesity, O
dyslipidaemia, O
type O
2 O
diabetes O
mellitus O
(T2DM) O
and O
cardiovascular O
disease. O
Nonalcoholic O
steatohepatitis O
(NASH) O
is O
characterized O
by O
steatosis O
with O

necroinflammation O
and O
eventual O
fibrosis, O
which O
can O
lead O
to O
end-stage O
liver O
disease O
and O
hepatocellular O
carcinoma. O
Its O
pathogenesis O
is O
complex, O
and O
involves O
a O
state O
of O
'lipotoxicity' O
in O
which O
insulin B-GENE-Y
resistance, O
with O
increased O
free B-CHEMICAL
fatty I-CHEMICAL
acid I-CHEMICAL
release O
from O
adipose O
tissue O
to O
the O
liver, O
play O
a O
key O
role O
in O
the O
onset O
of O
a O
'lipotoxic O
liver O
disease' O
and O
its O
progression O
to O
NASH. O
The O
diagnosis O
of O
NASH O
is O
challenging, O
as O
most O
affected O
patients O
are O
symptom O
free O
and O
the O
role O
of O
routine O
screening O
is O
not O
clearly O
established. O
A O
complete O
medical O
history O

is O
important O
to O
rule O
out O
other O
causes O
of O
fatty O
liver O
disease O
(alcohol B-CHEMICAL
abuse, O
medications, O
other). O
Plasma B-GENE-N
aminotransferase I-GENE-N
levels O
and O
liver O
ultrasound O
are O
helpful O
in O
the O
diagnosis O
of O
NAFLD/NASH, O
but O
a O
liver O
biopsy O
is O
often O
required O
for O
a O
definitive O
diagnosis. O
However, O
there O
is O
an O
active O
search O
for O
plasma O
biomarkers O
and O
imaging O
techniques O
that O
may O
non-invasively O
aid O
in O
the O
diagnosis. O
The O
treatment O
of O
NASH O
requires O
a O
multifaceted O
approach. O
The O
goal O
is O
to O
reverse O
obesity-associated O
lipotoxicity O
and O
insulin B-GENE-Y
resistance O
via O
lifestyle O
intervention. O
Although O
there O
is O
no O
pharmacological O
agent O

approved O
for O
the O
treatment O
of O
NAFLD, O
vitamin B-CHEMICAL
E I-CHEMICAL
(in O
patients O
without O
T2DM) O
and O
the O
thiazolidinedione O
pioglitazone B-CHEMICAL
(in O
patients O
with O
and O
without O
T2DM) O
have O
shown O
the O
most O
consistent O
results O
in O
randomized O
controlled O
trials. O
This O
review O
concentrates O
on O
our O
current O
understanding O
of O
the O
disease, O
with O
a O
focus O
on O
the O
existing O
therapeutic O
approaches O
and O
potential O
future O
pharmacological O
developments O
for O
NAFLD O
and O
NASH. O
Nuclear B-GENE-N
receptors I-GENE-N
in O
bile B-CHEMICAL
acid I-CHEMICAL
metabolism. O
Bile B-CHEMICAL
acids I-CHEMICAL
are O
signaling O
molecules O
that O
activate O
nuclear B-GENE-N
receptors, I-GENE-N
such O
as O
farnesoid B-GENE-Y
X I-GENE-Y
receptor, I-GENE-Y
pregnane B-CHEMICAL
X I-GENE-Y
receptor, I-GENE-Y

constitutive B-GENE-Y
androstane B-CHEMICAL
receptor, I-GENE-Y
and O
vitamin B-CHEMICAL
D I-CHEMICAL
receptor, I-GENE-Y
and O
play O
a O
critical O
role O
in O
the O
regulation O
of O
lipid, O
glucose, B-CHEMICAL
energy, O
and O
drug O
metabolism. O
These O
xenobiotic/endobiotic-sensing B-GENE-N
nuclear I-GENE-N
receptors I-GENE-N
regulate O
phase O
I O
oxidation, O
phase O
II O
conjugation, O
and O
phase O
III O
transport O
in O
bile B-CHEMICAL
acid I-CHEMICAL
and O
drug O
metabolism O
in O
the O
digestive O
system. O
Integration O
of O
bile B-CHEMICAL
acid I-CHEMICAL
metabolism O
with O
drug O
metabolism O
controls O
absorption, O
transport, O
and O
metabolism O
of O
nutrients O
and O
drugs O
to O
maintain O
metabolic O
homeostasis O
and O
also O
protects O
against O
liver O
injury, O
inflammation, O
and O
related O
metabolic O
diseases, O
such O
as O
nonalcoholic O
fatty O
liver O

disease, O
diabetes, O
and O
obesity. O
Bile-acid-based B-CHEMICAL
drugs O
targeting O
nuclear O
receptors O
are O
in O
clinical O
trials O
for O
treating O
cholestatic O
liver O
diseases O
and O
fatty O
liver O
disease. O
Green O
tea O
catechin B-CHEMICAL
leads O
to O
global O
improvement O
among O
Alzheimer's O
disease-related O
phenotypes O
in O
NSE/hAPP-C105 B-GENE-Y
Tg O
mice. O
Amyloid B-GENE-Y
 I-GENE-Y
() B-GENE-Y
has O
been O
reported O
to O
be O
responsible O
for O
the O
functional O
and O
structural O
abnormalities O
of O
Alzheimer's O
disease O
(AD) O
through O
the O
induction O
of O
oxidative O
stress. O
The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
or O
not O
treatment O
of O
transgenic O

(Tg) O
mice O
with O
green O
tea O
catechin B-CHEMICAL
(GTC), O
a O
radical O
scavenger, O
improves O
AD O
phenotypes. O
To O
test O
this, O
7-month-old O
Tg O
mice O
were O
treated O
with O
a O
low O
(1 O
mg) O
or O
high O
(10 O
mg) O
dose O
of O
GTC O
for O
6 O
months. O
Surprisingly, O
GTC-treated O
Tg O
mice O
exhibited O
significant O
decreases O
in O
behavioral O
impairment, O
A-42 B-GENE-Y
production, O
APP-C99/89 B-GENE-Y
expression, O
-secretase B-GENE-Y
component O
and O
Wnt B-GENE-N
protein O
levels, O
-secretase B-GENE-Y
activity O
and O
MAPK B-GENE-N
activation. O
In O

contrast, O
the O
levels O
of O
APP-C83 B-GENE-Y
protein O
and O
enzyme O
activities O
(-secretase, B-GENE-Y
neprilysin B-GENE-Y
and O
Pin1) B-GENE-Y
were O
elevated O
in O
the O
GTC-treated O
groups. O
Moreover, O
GTC-treated O
groups O
showed O
lower O
levels O
of O
total O
cholesterol B-CHEMICAL
and O
low-density B-GENE-N
lipoprotein I-GENE-N
cholesterol, B-CHEMICAL
whereas O
the O
level O
of O
high-density B-GENE-N
lipoprotein I-GENE-N
cholesterol B-CHEMICAL
increased. O
These O
results O
provide O
the O
first O
experimental O
evidence O
that O
GTC O
improves O
AD O
phenotypes, O
thereby O
suggesting O
that O
GTC O
can O
be O
used O
in O
the O
prevention O
of O
AD O
or O
treatment O
of O
AD O
patients. O
RIF1 B-GENE-Y

is O
essential O
for O
53BP1-dependent B-GENE-Y
nonhomologous O
end O
joining O
and O
suppression O
of O
DNA O
double-strand O
break O
resection. O
The O
appropriate O
execution O
of O
DNA O
double-strand O
break O
(DSB) O
repair O
is O
critical O
for O
genome O
stability O
and O
tumor O
avoidance. O
53BP1 B-GENE-Y
and O
BRCA1 B-GENE-Y
directly O
influence O
DSB O
repair O
pathway O
choice O
by O
regulating O
5' O
end O
resection, O
but O
how O
this O
is O
achieved O
remains O
uncertain. O
Here O
we O
report O
that O
Rif1(-/-) B-GENE-Y
mice O
are O
severely O
compromised O
for O
53BP1-dependent B-GENE-Y
class O
switch O
recombination O
(CSR) O
and O
fusion O
of O
dysfunctional O
telomeres. O

The O
inappropriate O
accumulation O
of O
RIF1 B-GENE-Y
at O
DSBs O
in O
S O
phase O
is O
antagonized O
by O
BRCA1, B-GENE-Y
and O
deletion O
of O
Rif1 B-GENE-Y
suppresses O
toxic O
nonhomologous O
end O
joining O
(NHEJ) O
induced O
by O
PARP B-GENE-N
inhibition O
in O
Brca1-deficient B-GENE-Y
cells. O
Mechanistically, O
RIF1 B-GENE-Y
is O
recruited O
to O
DSBs O
via O
the O
N-terminal B-CHEMICAL
phospho-SQ/TQ B-CHEMICAL
domain I-GENE-N
of O
53BP1, B-GENE-Y
and O
DSBs O
generated O
by O
ionizing O
radiation O
or O
during O
CSR O
are O
hyperresected O
in O
the O
absence O
of O
RIF1. B-GENE-Y
Thus, O

RIF1 B-GENE-Y
and O
53BP1 B-GENE-Y
cooperate O
to O
block O
DSB O
resection O
to O
promote O
NHEJ O
in O
G1, O
which O
is O
antagonized O
by O
BRCA1 B-GENE-Y
in O
S O
phase O
to O
ensure O
a O
switch O
of O
DSB O
repair O
mode O
to O
homologous O
recombination. O
RANKL B-GENE-Y
targeted O
peptides O
inhibit O
osteoclastogenesis O
and O
attenuate O
adjuvant O
induced O
arthritis O
by O
inhibiting O
NF-B B-GENE-N
activation O
and O
down O
regulating O
inflammatory O
cytokines. B-GENE-N
Peptides O
designed O
from O
osteoprotegerin O
(OPG) O
have O
previously O
been O
shown O
to O
inhibit O
receptor B-GENE-Y

activator I-GENE-Y
of I-GENE-Y
NF-B I-GENE-Y
ligand I-GENE-Y
(RANKL) B-GENE-Y
and O
prevent O
bone O
loss O
without O
significantly O
inhibiting O
inflammation. O
The O
objective O
of O
this O
study O
was O
to O
develop O
a O
novel O
peptide O
with O
dual O
inhibitory O
activity O
against O
bone O
loss O
and O
inflammation O
using O
site-directed O
mutagenesis. O
Out O
of O
the O
three O
putative O
sites O
(i.e., O
Tyr70-Asp78, B-CHEMICAL
Tyr82-Glu96, B-CHEMICAL
and O
Leu113-Arg122) B-CHEMICAL
available O
on O
OPG O
for O
RANKL B-GENE-Y
binding, O
Leu113-Arg122 B-CHEMICAL
was O
used O
as O

a O
template O
for O
peptide O
synthesis. O
Peptide O
mutants O
of O
the O
template O
sequence O
(112YLEIEFCLKHR122) O
were O
synthesized O
and O
initially O
screened O
for O
their O
inhibitory O
effect O
on O
RANK-RANKL B-GENE-Y
binding O
by O
competitive O
ELISA. O
The O
most O
active O
peptide O
was O
further O
evaluated O
in O
vitro O
for O
RANKL B-GENE-Y
induced O
osteoclastogenesis O
in O
mouse O
macrophage O
cells, O
and O
in O
vivo O
for O
Freund's O
complete O
adjuvant O
induced O
arthritis O
(AIA) O
in O
Lewis O
rats. O
The O
efficacy O
of O
the O
candidate O
peptide O
was O
compared O
with O
that O
of O
the O
standard O

drug O
celecoxib. B-CHEMICAL
The O
peptide O
YR-11 B-CHEMICAL
(YLEIEFSLKHR), O
obtained O
by O
direct O
substitution O
of O
cysteine B-CHEMICAL
with O
a O
serine B-CHEMICAL
residue O
in O
the O
template O
sequence, O
significantly O
(p<0.05) O
inhibited O
RANK-RANKL B-GENE-Y
binding, O
and O
RANKL B-GENE-Y
induced O
TRAP B-GENE-Y
activity O
and O
formation O
of O
multinucleated O
osteoclasts O
without O
any O
cytotoxicity. O
Administration O
of O
YR-11 B-CHEMICAL
peptide O
at O
the O
dose O
of O
30mg/kg O
(i.p.) O
ameliorated O
both O
bone O
loss O
and O

inflammation O
in O
AIA O
rats. O
To O
elucidate O
the O
mechanism O
for O
inhibition O
of O
inflammation O
in O
arthritic O
rats, O
serum O
and O
tissue O
cytokines B-GENE-N
(TNF-, B-GENE-Y
IL-1, B-GENE-Y
and O
IL-6) B-GENE-Y
were O
analyzed O
by O
ELISA O
and O
RT-PCR O
methods. O
Results O
confirmed O
that O
YR-11 B-CHEMICAL
peptide O
inhibited O
pro-inflammatory O
cytokines B-GENE-N
in O
the O
sera O
and O
hind O
paw O
tissues O
of O
AIA O
rats O
through O
its O
suppressive O
effect O
on O
RANKL B-GENE-Y
induced O
nuclear O
translocation O
of O
NF-B. B-GENE-N
The O
results O
obtained O
in O
this O
study O
substantiate O
the O
therapeutic O

benefit O
of O
this O
novel O
peptide O
in O
the O
prevention O
of O
bone O
loss O
and O
inflammation O
in O
rheumatoid O
arthritis O
with O
reduced O
side O
effects. O
Activation O
of O
Rac1 B-GENE-Y
GTPase B-GENE-N
by O
nanoparticulate O
structures O
in O
human O
macrophages. O
Inflammatory O
activation O
of O
alveolar O
macrophages O
by O
ambient O
particles O
can O
be O
facilitated O
via O
Toll-like B-GENE-N
receptors I-GENE-N
(TLR). B-GENE-N
The O
action O
of O
TLR B-GENE-N
agonists O
and O
antagonists O
has O
been O
reported O
to O
depend O
on O
the O
formation O
of O
nanoparticulate O
structures. O
Aim O
of O
the O
present O
study O
was O
to O
identify O
the O
signaling O
pathways O
induced O
by O

nanoparticulate O
structures O
in O
human O
macrophages, O
which O
might O
be O
critical O
for O
inflammatory O
cell O
activation. O
METHODS: O
Studies O
were O
performed O
in O
primary O
human O
alveolar O
macrophages O
or O
in O
differentiated O
THP-1 O
macrophages. O
Silica B-CHEMICAL
nanoparticles O
were O
prepared O
by O
Stber O
synthesis O
and O
characterized O
by O
dynamic O
light O
scattering O
and O
scanning O
electron O
microscopy. O
Mycobacterial O
DNA O
was O
isolated O
from O
Mycobacterium O
bovis O
BCG, O
and O
nanoparticle O
formation O
was O
assessed O
by O
atomic O
force O
microscopy O
and O
dynamic O
light O
scattering. O
Actin B-GENE-N
polymerization O
was O
measured O
by O

phalloidin-TRITC B-CHEMICAL
staining, O
and O
cell O
activation O
was O
determined O
by O
reverse O
transcription O
quantitative O
PCR O
analysis, O
L929 O
cytotoxicity O
assay O
(cytokine B-GENE-N
induction), O
and O
pull-down O
assays O
(Rho B-GENE-N
GTPases). B-GENE-N
RESULTS: O
In O
contrast O
to O
immune O
stimulatory O
sequence O
ISS O
1018, O
BCG O
DNA O
spontaneously O
formed O
nanoparticulate O
structures O
and O
induced O
actin B-GENE-N
polymerization O
as O
did O
synthetic O
silica B-CHEMICAL
nanoparticles. O
Co-incubation O
with O
silica B-CHEMICAL
nanoparticles O
amplified O
the O

responsiveness O
of O
macrophages O
toward O
the O
TLR9 B-GENE-Y
ligand O
ISS O
1018. O
The O
activation O
of O
Rac1 B-GENE-Y
was O
induced O
by O
silica B-CHEMICAL
nanoparticles O
as O
well O
as O
BCG O
DNA O
and O
is O
suggested O
as O
the O
critical O
signaling O
event O
inducing O
both O
cytoskeleton O
changes O
as O
well O
as O
inflammatory O
cell O
activation. O
CONCLUSION: O
Nanoparticles O
can O
induce O
signaling O
pathways, O
which O
amplify O
an O
inflammatory O
response O
in O
macrophages. O
Enhancing O
macrocyclic O
diterpenes B-CHEMICAL
as O
multidrug-resistance O
reversers: O
structure-activity O
studies O
on O

jolkinol B-CHEMICAL
D I-CHEMICAL
derivatives. O
The O
phytochemical O
study O
of O
Euphorbia O
piscatoria O
yielded O
jolkinol B-CHEMICAL
D I-CHEMICAL
(1) O
in O
a O
large O
amount, O
whose O
derivatization O
gave O
rise O
to O
12 O
ester B-CHEMICAL
derivatives O
(2-13) O
and O
hydrolysis O
to O
compound O
14. O
The O
in O
vitro O
modulation O
of O
P-gp B-GENE-N
of O
compounds O
1-14 O
was O
evaluated O
through O
a O
combination O
of O
transport O
and O
chemosensitivity O
assays, O
using O
the O
L5178 O
mouse O
T O
lymphoma O
cell O
line O
transfected O
with O
the O
human B-GENE-Y
MDR1 I-GENE-Y
gene. O
Apart O
from O
jolkinol B-CHEMICAL

D, I-CHEMICAL
all O
derivatives O
(2-14) O
showed O
potential O
as O
MDR O
reversal O
agents. O
In O
this O
small O
library O
of O
novel O
bioactive O
macrocyclic O
lathyrane B-CHEMICAL
diterpene I-CHEMICAL
derivatives, O
designed O
to O
evaluate O
structure-activity O
relationships O
essential O
in O
overcoming O
multidrug O
resistance O
(MDR), O
some O
correlations O
between O
MDR O
reversal O
and O
molecular O
weight, O
accessible O
solvent O
areas, O
and O
octanol/water B-CHEMICAL
partition O
coefficient O
were O
identified O
that O
can O
contribute O
to O
the O
development O
of O
new O
selective O
P-gp B-GENE-N
reversal O
agents. O
Osteoblasts O
survive O
the O
arsenic B-CHEMICAL
trioxide I-CHEMICAL
treatment O
by O
activation O
of O
ATM-mediated B-GENE-Y
pathway. O

Arsenic B-CHEMICAL
trioxide I-CHEMICAL
(ATO) B-CHEMICAL
is O
widely O
used O
in O
tumor O
treatment, O
but O
excessive O
arsenic B-CHEMICAL
exposure O
can O
have O
adverse O
effects. O
We O
recently O
found O
that, O
in O
primary O
osteoblasts, O
ATO B-CHEMICAL
produces O
oxidative O
stress O
and O
causes O
DNA O
tailing, O
but O
does O
not O
induce O
apoptosis. O
We O
further O
examined O
the O
signaling O
pathway O
by O
which O
osteoblasts O
survive O
ATO B-CHEMICAL
treatment, O
and O
found O
that O
they O
were O
arrested O
at O
G2/M O
phase O
of O
the O
cell O
cycle O
at O
30h O
and O
overrode O
the O
G2/M O
boundary O
at O
48h. O
After O
treatment O
for O
30h, O
there O
was O
increased O

Cdc2 B-GENE-Y
phosphorylation O
and O
expression O
of O
Wee1, B-GENE-Y
a O
Cdc2 B-GENE-Y
kinase, B-GENE-N
and O
expression O
of O
the O
cell O
cycle O
inhibitor, O
p21(waf1/cip1), B-GENE-Y
which O
interacts O
with O
Cdc2. B-GENE-Y
Furthermore, O
levels O
of O
the O
phosphatase B-GENE-Y
Cdc25C, I-GENE-Y
which O
activates O
Cdc2, B-GENE-Y
were O
decreased, O
while O
the O
ratio O
of O
its O
phosphorylated/inactivated O
form O
to O
the O
total O
amount O
was O
increased. O
Moreover, O
phosphorylation/activation O
of O
the O
checkpoint O
kinases O
Chk1, B-GENE-Y
Chk2 B-GENE-Y
and O
p53 B-GENE-Y
levels O
were O

increased, O
as O
were O
levels O
of O
activated O
ATM B-GENE-Y
and O
-H2AX. B-GENE-Y
The O
cell O
viability O
was O
decreased O
as O
an O
ATM B-GENE-Y
inhibitor O
was O
added. O
Additionally, O
these O
effects O
of O
ATO B-CHEMICAL
on O
-H2AX, B-GENE-Y
Chk1, B-GENE-Y
Chk2, B-GENE-Y
p53, B-GENE-Y
and O
p21(waf1/cip1) B-GENE-Y
were O
reduced O
by O
an O
ATM B-GENE-Y
inhibitor. O
These O
findings O
suggest O
that O
G2/M O
phase O
arrest O
of O
osteoblasts O
is O
mediated O
by O
Chk1/Chk2 B-GENE-Y
activation O
via O
an O
ATM-dependent B-GENE-Y
pathway O
by O
which O
osteoblasts O
survive. O
Structure O
prediction O
of O
binary O

pernitride B-CHEMICAL
MN2 B-CHEMICAL
compounds O
(M=Ca, B-CHEMICAL
Sr, B-CHEMICAL
Ba, B-CHEMICAL
La, B-CHEMICAL
and O
Ti). B-CHEMICAL
Metal-pernitride B-CHEMICAL
compounds O
belong O
to O
a O
class O
of O
chemical O
systems O
in O
which O
both O
the O
complex O
ions O
and O
the O
non-bonding O
electrons O
may O
play O
roles O
in O
the O
formation O
of O
their O
modified O
crystalline O
structures. O
To O
investigate O
this O
issue, O
the O
energy O
landscapes O
of O
pernitrides B-CHEMICAL
of O
metals O
with O
different O
maximum O
valence O
(M=Ca, B-CHEMICAL
Sr, B-CHEMICAL
Ba, B-CHEMICAL
La, B-CHEMICAL
and O
Ti) B-CHEMICAL
were O
globally O
explored O
on O
the O
ab O
initio O
level O
at O
standard O
and O
high O
pressures, O
thereby O
yielding O
possible O
(meta)stable O
modifications O

in O
these O
systems O
together O
with O
information O
on O
how O
the O
landscape O
changed O
as O
function O
of O
the O
valence O
of O
the O
metal O
cation. O
For O
all O
of O
the O
systems O
in O
which O
no O
compounds O
had O
been O
synthesized O
so O
far, O
we O
predicted O
the O
existence O
of O
kinetically O
stable O
modifications O
that O
should, O
in O
principle, O
be O
experimentally O
accessible. O
In O
particular, O
TiN2 B-CHEMICAL
should O
crystallize O
in O
a O
new O
structure O
type, O
TiN2-I. B-CHEMICAL
25-Hydroxyvitamin B-CHEMICAL
D I-CHEMICAL
in O
Obese O
Youth O
Across O
the O
Spectrum O
of O
Glucose B-CHEMICAL
Tolerance O
From O
Normal O
to O
Prediabetes O
to O
Type O
2 O
Diabetes. O

OBJECTIVETo O
1) O
determine O
if O
plasma O
25-hydroxyvitamin B-CHEMICAL
D I-CHEMICAL
(25[OH]D) B-CHEMICAL
concentrations O
differ O
among O
obese O
youth O
with O
normal O
glucose B-CHEMICAL
tolerance O
(NGT) O
versus O
prediabetes O
versus O
type O
2 O
diabetes, O
and O
2) O
assess O
the O
relationships O
between O
25(OH)D B-CHEMICAL
and O
in O
vivo O
insulin B-GENE-Y
sensitivity O
and O
-cell O
function O
in O
this O
cohort.RESEARCH O
DESIGN O
AND O
METHODSPlasma O
25(OH)D B-CHEMICAL
concentrations O
were O
examined O
in O
banked O
specimens O
in O
9- O
to O
20-year-old O
obese O
youth O

(n O
= O
175; O
male O
42.3%, O
black O
46.3%) O
(NGT, O
n O
= O
105; O
impaired O
glucose B-CHEMICAL
tolerance O
[IGT], O
n O
= O
43; O
type O
2 O
diabetes, O
n O
= O
27) O
who O
had O
in O
vivo O
insulin B-GENE-Y
sensitivity O
and O
secretion O
measured O
by O
hyperinsulinemic-euglycemic O
and O
hyperglycemic O
clamp O
techniques O
and O
had O
an O
assessment O
of O
total O
body O
composition O
and O
abdominal O
adiposity.RESULTSThe O
mean O
age O
and O
BMI O
of O
the O
subjects O
were O
14.3 O
 O
2.1 O
years O
and O
35.7 O
 O
5.6 O

kg/m(2), O
respectively. O
BMI, O
plasma O
25(OH)D, B-CHEMICAL
and O
the O
proportion O
of O
vitamin B-CHEMICAL
D-deficient I-CHEMICAL
and O
-insufficient O
children O
did O
not O
differ O
across O
the O
three O
groups. O
Furthermore, O
there O
was O
no O
association O
between O
25(OH)D B-CHEMICAL
and O
in O
vivo O
insulin B-GENE-Y
sensitivity O
or O
-cell O
function O
relative O
to O
insulin B-GENE-Y
sensitivity O
(disposition O
index) O
in O
all O
groups O
combined O
or O
in O
each O
group O
separately.CONCLUSIONSOur O
data O
in O
obese O
youth O
show O
1) O
no O
differences O
in O
plasma O
25(OH)D B-CHEMICAL
concentrations O
across O
the O
glucose B-CHEMICAL
tolerance O
groups, O
and O
2) O
no O
relationship O
between O
25(OH)D B-CHEMICAL
and O
in O

vivo O
insulin B-GENE-Y
sensitivity O
and O
-cell O
function O
relative O
to O
insulin B-GENE-Y
sensitivity O
in O
any O
of O
the O
groups. O
It O
remains O
uncertain O
if O
enhancement O
of O
the O
vitamin B-CHEMICAL
D I-CHEMICAL
status O
could O
improve O
pathophysiological O
mechanisms O
of O
prediabetes O
and O
type O
2 O
diabetes O
in O
obese O
youth. O
Binary O
diffusion O
coefficients O
for O
mixtures O
of O
ionic O
liquids O
[EMIM][N(CN)2], B-CHEMICAL
[EMIM][NTf2], B-CHEMICAL
and O
[HMIM][NTf2] B-CHEMICAL
with O
acetone B-CHEMICAL
and O
ethanol B-CHEMICAL
by O
dynamic O
light O
scattering O
(DLS). O
Mutual O
diffusivities O
for O
binary O
mixtures O
of O
the O

ionic O
liquids O
(ILs) O
[EMIM][N(CN)2] B-CHEMICAL
(1-ethyl-3-methylimidazolium B-CHEMICAL
dicyanimide), I-CHEMICAL
[EMIM][NTf2] B-CHEMICAL
(1-ethyl-3-methylimidazolium B-CHEMICAL
bis(trifluoromethylsulfonyl)imide), I-CHEMICAL
and O
[HMIM][NTf2] B-CHEMICAL
(1-hexyl-3-methylimidazolium B-CHEMICAL

bis(trifluoromethylsulfonyl)imide) I-CHEMICAL
with O
acetone B-CHEMICAL
and O
ethanol B-CHEMICAL
were O
studied O
in O
dependence O
on O
composition O
in O
the O
temperature O
range O
from O
283.15 O
to O
323.15 O
K, O
applying O
dynamic O
light O
scattering O
(DLS). O
The O
influence O
of O
experimental O
parameters O
on O
the O
achievable O
uncertainties O
was O
analyzed O
to O
ensure O
the O
acquisition O
of O
accurate O
data O
in O
adequate O
measurement O
times. O
For O
all O
probed O
systems, O
increasing O
binary O
diffusion O
coefficients O
were O
found O
for O
increasing O
temperatures. O
The O
systematic O
variation O
of O
anion O
and O
cation O
of O
the O
investigated O
ILs O
as O
well O
as O
a O
comparison O
with O
the O
literature O
data O
demonstrates O
the O
considerable O
influence O
of O
different O

ions O
on O
the O
resulting O
binary O
diffusion O
coefficients. O
Mutual O
diffusivities O
were O
found O
to O
be O
lower O
for O
the O
mixtures O
with O
ethanol B-CHEMICAL
than O
for O
those O
with O
acetone, B-CHEMICAL
which O
could O
be O
related O
to O
the O
formation O
of O
hydrogen B-CHEMICAL
bonds O
between O
ethanol B-CHEMICAL
and O
the O
ions. O
Most O
of O
the O
investigated O
IL O
solvent O
mixtures O
show O
increasing O
binary O
diffusion O
coefficients O
with O
increasing O
solvent O
concentration. O
For O
the O
mixtures O
of O
[EMIM][NTf2] B-CHEMICAL
with O
ethanol, B-CHEMICAL
however, O
a O
minimum O
of O
the O
mutual O
diffusivities O
was O
found O
in O
the O
ethanol B-CHEMICAL
mole O
fraction O
range O
from O
0.7 O
to O
0.8, O
which O
may O
hint O
at O
the O
vicinity O
of O
a O
critical O
demixing O

point. O
The O
viscosity O
of O
the O
pure O
ILs O
turned O
out O
to O
be O
no O
reliable O
indicator O
for O
the O
mutual O
diffusivity O
in O
mixtures O
with O
the O
same O
solvent. O
Quercetin-loaded B-CHEMICAL
microcapsules O
ameliorate O
experimental O
colitis O
in O
mice O
by O
anti-inflammatory O
and O
antioxidant O
mechanisms. O
Quercetin B-CHEMICAL
(1) O
is O
an O
anti-inflammatory O
and O
antioxidant O
flavonoid. B-CHEMICAL
However, O
the O
oral O
administration O
of O
1 O
did O
not O
lead O
to O
beneficial O
effects O
in O
experimental O
animal O
colitis O
models, O
which O
involve O
cytokines B-GENE-N
and O
oxidative O
stress. O
A O
possible O
explanation O
is O
that O
the O

absorption O
profile O
of O
1 O
prevents O
its O
activity. O
Therefore, O
it O
was O
reasoned O
that O
the O
controlled O
release O
of O
1 O
would O
improve O
its O
therapeutic O
effect. O
Thus, O
the O
therapeutic O
effect O
and O
mechanisms O
of O
1-loaded O
microcapsules O
in O
acetic B-CHEMICAL
acid-induced I-CHEMICAL
colitis O
in O
mice O
were O
evaluated. O
Microcapsules O
were O
prepared O
using O
pectin/casein B-GENE-N
polymer O
and O
1. O
The O
oral O
administration O
of O
1-loaded O
microcapsules O
decreased O
neutrophil O
recruitment, O
attenuated O
histological O
alterations, O
and O
reduced O
macroscopical O
damage, O
edema, O
and O
IL-1 B-GENE-Y
and O
IL-33 B-GENE-Y
production O
in O
the O
colon O
samples. O

Microcapsules O
loaded O
with O
1 O
also O
prevented O
the O
reduction O
of O
anti-inflammatory O
cytokine B-GENE-N
IL-10 B-GENE-Y
and O
the O
antioxidant O
capacity O
of O
the O
colon. O
These O
preclinical O
data O
indicate O
that O
pectin/casein B-GENE-N
polymer O
microcapsules O
loaded O
with O
1 O
improved O
the O
anti-inflammatory O
and O
antioxidant O
effects O
of O
1 O
compared O
to O
the O
nonencapsulated O
drug. O
Therefore, O
quercetin B-CHEMICAL
seems O
to O
be O
a O
promising O
active O
molecule O
in O
inflammatory O
bowel O
disease O
if O
provided O
with O
adequate O
controlled O
release. O
Dietary O
relevant O
mixtures O
of O
phytoestrogens O
inhibit O
adipocyte O
differentiation O
in O

vitro. O
Phytoestrogens O
(PEs) O
are O
naturally O
occurring O
plant O
components, O
with O
the O
ability O
to O
induce O
biological O
responses O
in O
vertebrates O
by O
mimicking O
or O
modulating O
the O
action O
of O
endogenous O
hormones. O
Single O
isoflavones B-CHEMICAL
have O
been O
shown O
to O
affect O
adipocyte O
differentiation, O
but O
knowledge O
on O
the O
effect O
of O
dietary O
relevant O
mixtures O
of O
PEs, O
including O
for O
instance O
lignans, O
is O
lacking. O
In O
the O
current O
study O
dietary O
relevant O
mixtures O
of O
isoflavones B-CHEMICAL
and O
their O
metabolites, O
lignans B-CHEMICAL
and O
their O
metabolites, O
coumestrol, B-CHEMICAL
and O
a O
mixture O
containing O
all O

of O
them, O
were O
examined O
for O
effects O
on O
adipogenesis O
in O
3T3-L1 O
adipocytes, O
as O
well O
as O
tested O
for O
their O
PPAR B-GENE-Y
activating O
abilities. O
The O
results O
showed O
that O
mixtures O
of O
isoflavonoid B-CHEMICAL
parent O
compounds O
and O
metabolites, O
respectively, O
a O
mixture O
of O
lignan B-CHEMICAL
metabolites, O
as O
well O
as O
coumestrol B-CHEMICAL
concentration-dependently O
inhibited O
adipocyte O
differentiation. O
Furthermore, O
a O
mixture O
of O
isoflavonoid B-CHEMICAL
parent O
compounds, O
and O
a O
mixture O
of O
isoflavonoid B-CHEMICAL
metabolites O
were O
found O
to O
have O
PPAR B-GENE-Y
activating O
abilities. O
These O
results O
suggest O

that O
PEs O
can O
affect O
pathways O
known O
to O
play O
a O
role O
in O
obesity O
development, O
and O
indicate O
that O
the O
inhibitory O
effect O
on O
adipocyte O
differentiation O
does O
not O
appear O
to O
be O
strictly O
associated O
with O
PPAR B-GENE-Y
activation/inhibition. O
The O
current O
study O
support O
the O
hypothesis O
that O
compounds O
with O
endocrine O
activity O
can O
affect O
pathways O
playing O
a O
role O
in O
the O
development O
obesity O
and O
obesity O
related O
diseases. O
Anti-inflammatory O
activity O
of O
patchouli B-CHEMICAL
alcohol I-CHEMICAL
in O
RAW264.7 O
and O
HT-29 O
cells. O
Patchouli B-CHEMICAL
alcohol I-CHEMICAL
(PA) O
is O
a O
chemical O
compound O
extracted O
from O
patchouli O
which O
belongs O
to O
the O
genus O
Pogostemon, O
herb O
of O

mint O
family. O
Recently, O
it O
has O
been O
reported O
that O
PA O
inhibits O
the O
production O
of O
inflammatory O
mediators. O
However, O
the O
biological O
mechanisms O
of O
PA O
for O
anti-inflammatory O
activities O
have O
not O
been O
studied. O
In O
this O
study, O
we O
investigated O
whether O
PA O
decreases O
the O
production O
of O
inflammatory O
mediators O
through O
downregulation O
of O
the O
NF-B B-GENE-N
and O
ERK B-GENE-N
pathway. O
Our O
data O
indicated O
that O
PA O
inhibits O
the O
over-expression O
of O
iNOS B-GENE-N
and O
IL-6 B-GENE-N
in O
protein O
and O
mRNA O
levels O
in O
LPS-stimulated O
RAW264.7 O
and O
TNF- B-GENE-Y
stimulated O
HT-29 O
cells. O
PA O
inhibited O

IB- B-GENE-N
degradation O
and O
p65 B-GENE-N
nuclear O
translocation, O
and O
subsequently O
suppressed O
transcriptional O
activity O
of O
NF-B B-GENE-N
in O
LPS-stimulated O
RAW264.7 O
and O
TNF--stimulated B-GENE-Y
HT-29 O
cells. O
In O
addition, O
PA O
inhibited O
LPS- O
or O
TNF--stimulated B-GENE-Y
ERK1/2 B-GENE-N
activation O
by O
decreasing O
phosphorylation O
of O
ERK1/2. B-GENE-N
These O
findings O
suggest O
that O
PA O
shows O
anti-inflammatory O
activities O
through O
suppressing O
ERK-mediated B-GENE-N
NF-B B-GENE-N
pathway O
in O
mouse O
macrophage O
and O
human O
colorectal O
cancer O
cells. O
Evaluation O

of O
suppressive O
and O
pro-resolving O
effects O
of O
EPA B-CHEMICAL
and O
DHA B-CHEMICAL
in O
human O
primary O
monocytes O
and O
T-helper O
cells. O
Despite O
their O
beneficial O
anti-inflammatory O
properties, O
eicosapentaenoic B-CHEMICAL
acid I-CHEMICAL
(EPA) B-CHEMICAL
and O
docosahexaenoic B-CHEMICAL
acid I-CHEMICAL
(DHA) B-CHEMICAL
may O
increase O
the O
infection O
risk O
at O
high O
doses, O
likely O
by O
generating O
an O
immune-depressed O
state. O
To O
assess O
the O
contribution O
of O
different O
immune O
cell O
populations O
to O
the O
immunomodulatory O
fatty B-CHEMICAL
acid I-CHEMICAL
effect, O
we O
comparatively O
investigated O
several O
aspects O
of O
inflammation O
in O
human O
T-helper O
(Th) O
cells O
and O
monocytes. O
Both O
fatty B-CHEMICAL
acids, I-CHEMICAL
but O

DHA B-CHEMICAL
to O
a O
lesser O
extent O
compared O
with O
EPA, B-CHEMICAL
selectively O
and O
dose-dependently O
reduced O
the O
percentage O
of O
cytokine-expressing B-GENE-N
Th O
cells O
in O
a O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
(PPAR)-dependent I-GENE-Y
fashion, O
whereas O
the O
expression O
of O
the O
cell O
surface O
marker O
CD69 B-GENE-Y
was O
unaltered O
on O
activated O
T O
cells. O
In O
monocytes, O
both O
EPA B-CHEMICAL
and O
DHA B-CHEMICAL
increased O
interleukin B-GENE-Y
(IL)-10 I-GENE-Y
without O
affecting O
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
(TNF)- I-GENE-Y
and O
IL-6. B-GENE-Y
Cellular O
incorporation O
of O
EPA B-CHEMICAL
and O
DHA B-CHEMICAL
occurred O
mainly O
at O
the O
expense O
of O
arachidonic B-CHEMICAL

acid. I-CHEMICAL
Concomitantly, O
thromboxane B-CHEMICAL
B I-CHEMICAL
(TXB)2 B-CHEMICAL
and O
leukotriene B-CHEMICAL
B I-CHEMICAL
(LTB)4 B-CHEMICAL
in O
supernatants O
decreased, O
while O
levels O
of O
TXB3 B-CHEMICAL
and O
LTB5 B-CHEMICAL
increased. O
This O
increase O
was O
independent O
of O
activation O
and O
in O
accordance O
with O
cyclooxygenase B-GENE-N
expression O
patterns O
in O
monocytes. O
Moreover, O
EPA B-CHEMICAL
and O
DHA B-CHEMICAL
gave O
rise O
to O
a O
variety O
of O
mono- B-CHEMICAL
and I-CHEMICAL
trihydroxy I-CHEMICAL
derivatives O
of O
highly O
anti-inflammatory O
potential, O
such O
as O
resolvins B-CHEMICAL
and O
their O
precursors. O
Our O
results O
suggest O
that O
EPA B-CHEMICAL
and O
DHA B-CHEMICAL
do O
not O
generally O
affect O

immune O
cell O
functions O
in O
an O
inhibitory O
manner O
but O
rather O
promote O
pro-resolving O
responses. O
Cell O
penetrating O
peptide O
tethered O
bi-ligand O
liposomes O
for O
delivery O
to O
brain O
in O
vivo: O
Biodistribution O
and O
transfection. O
Targeted O
nano-particulate O
systems O
hold O
extraordinary O
potential O
for O
delivery O
of O
therapeutics O
across O
blood O
brain O
barrier O
(BBB). O
In O
this O
work, O
we O
investigated O
the O
potential O
of O
novel O
bi-ligand O
(transferrin-poly-l-arginine) B-CHEMICAL
liposomal O
vector O
for O
delivery O
of O
desired O
gene O
to O
brain, O
in O
vivo. O
The O
in O
vivo O
evaluation O
of O

the O
delivery O
vectors O
is O
essential O
for O
clinical O
translation. O
We O
followed O
an O
innovative O
approach O
of O
combining O
transferrin O
receptor O
targeting O
with O
enhanced O
cell O
penetration O
to O
design O
liposomal O
vectors O
for O
improving O
the O
transport O
of O
molecules O
into O
brain. O
The O
biodistribution O
profile O
of O
1, B-CHEMICAL
1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine I-CHEMICAL
iodide(DiR)-labeled I-CHEMICAL
liposomes O
was O
evaluated O
in O
adult O
rats O
after O
single O
intravenous O
injection O
at O
dose O
of O
15.2moles O
of O
phospholipids/kg O
body O
weight. O
We O
demonstrated O
that O

bi-ligand O
liposomes O
accumulated O
in O
rat O
brain O
at O
significantly O
(p<0.05) O
higher O
concentrations O
as O
compared O
to O
the O
single-ligand O
(transferrin) B-GENE-Y
or O
plain O
liposomes. O
In O
addition, O
the O
bi-ligand O
liposomes O
resulted O
in O
increased O
expression O
of O
-galactosidase(-gal) B-GENE-Y
plasmid O
in O
rat O
brain O
tissue O
in O
comparison O
to O
the O
single-ligand O
liposomes. O
Histological O
examination O
of O
the O
transfected O
tissues O
did O
not O
show O
any O
signs O
of O
tissue O
necrosis O
or O
inflammation. O
Hemolysis O
assay O
further O
authenticated O
the O

biocompatibility O
of O
bi-ligand O
liposomes O
in O
blood O
up O
to O
600 O
nmoles O
of O
phospholipids/1.410(7) O
erythrocytes. O
The O
findings O
of O
this O
study O
provide O
important O
and O
detailed O
information O
regarding O
the O
distribution O
of O
bi-ligand O
liposomes O
in O
vivo O
and O
accentuate O
their O
ability O
to O
demonstrate O
improved O
brain O
penetration O
and O
transfection O
potential O
over O
single-ligand O
liposomes. O
Encapsulation O
of O
Nod1 B-GENE-Y
and O
Nod2 B-GENE-Y
receptor O
ligands O
into O
poly(lactic B-CHEMICAL
acid) I-CHEMICAL
nanoparticles O
potentiates O
their O

immune O
properties. O
Most O
successful O
vaccines O
are O
able O
to O
induce O
persistent O
antibody O
responses O
that O
can O
last O
a O
lifetime. O
Emerging O
evidences O
indicate O
that O
activation O
of O
immune O
cells O
through O
pattern B-GENE-N
recognition I-GENE-N
receptors I-GENE-N
(PRRs) B-GENE-N
such O
as O
Toll-like B-GENE-N
receptors I-GENE-N
(TLRs) B-GENE-N
or O
Nod-like B-GENE-N
receptors I-GENE-N
(NLRs) B-GENE-N
may O
be O
critical O
mechanisms. O
Among O
PRRs, B-GENE-N
the O
use O
of O
TLR B-GENE-N
ligands O
as O
adjuvants O
is O
already O
largely O
described O
whereas O
the O
use O
of O
NLRs B-GENE-N
ligands O
remains O
largely O
unexplored. O
As O
activation O
of O
intracytoplasmic O
NLRs B-GENE-N
is O
able O
to O
induce O

proinflammatory O
molecules, O
the O
added O
value O
of O
encapsulation O
of O
Nod1 B-GENE-Y
and O
Nod2 B-GENE-Y
receptor O
ligands O
into O
Poly(Lactic B-CHEMICAL
Acid) I-CHEMICAL
(PLA) B-CHEMICAL
biodegradable O
nanocarriers O
to O
modulate O
their O
immune O
properties O
on O
human O
dendritic O
cells O
(DCs) O
maturation O
has O
been O
evaluated. O
Their O
ability O
to O
induce O
systemic O
immune O
responses O
in O
mice O
was O
also O
measured O
and O
compared O
to O
free O
ligands O
and O
the O
Alum O
adjuvant. O
Nod B-GENE-N
ligands O
encapsulated O
into O
PLA B-CHEMICAL
NPs O
were O
efficiently O
taken O
up O
by O
DCs O
and O
subsequently O
induced O
a O
strong O

up-regulation O
of O
maturation O
markers O
and O
the O
enhancement O
of O
proinflammatory O
cytokine B-GENE-N
secretion O
by O
DCs. O
Furthermore, O
co-injection O
of O
encapsulated O
Nod-ligands B-GENE-N
with O
PLA B-CHEMICAL
particles O
carrying O
Gag B-GENE-N
p24 I-GENE-N
HIV-1 O
antigen O
allowed O
a O
100 O
fold O
increase O
in O
antibody O
responses O
in O
comparison O
to O
Alum. O
These O
results O
suggest O
that O
encapsulation O
of O
Nod B-GENE-N
ligands O
into O
PLA-NPs B-CHEMICAL
could O
be O
an O
effective O
way O
to O
improve O
vaccine O
efficiency. O
In O
vitro O
permeability O
analysis, O
pharmacokinetic O
and O
brain O
distribution O
study O
in O
mice O
of O

imperatorin, B-CHEMICAL
isoimperatorin B-CHEMICAL
and O
cnidilin B-CHEMICAL
in O
Radix O
Angelicae O
Dahuricae. O
Coumarins B-CHEMICAL
are O
important O
constituents O
of O
Radix O
Angelicae O
Dahuricae, O
a O
well-known O
traditional O
Chinese O
medicine O
possess O
several O
known O
bioactivities O
with O
potentials O
in O
the O
treatment O
of O
central O
nervous O
system O
diseases. O
By O
using O
an O
HPLC-MS/MS O
method, O
we O
analyzed O
the O
in O
vivo O
plasma O
and O
brain O
pharmacokinetics O
of O
three O
ingredients O
of O
coumarins, B-CHEMICAL
including O
imperatorin, B-CHEMICAL
isoimperatorin B-CHEMICAL
and O
cnidilin B-CHEMICAL
in O
mice O
after O
oral O
administration O

of O
Dahuricae O
extract O
at O
doses O
of O
800mg/kg. O
The O
biosamples O
were O
prepared O
using O
acetonitrile B-CHEMICAL
precipitation O
and O
the O
separation O
was O
achieved O
on O
an O
XDB-C18 O
column O
by O
gradient O
elution. O
The O
BBB O
permeability O
and O
P-gp-mediated B-GENE-N
efflux O
were O
further O
examined O
in O
Madin O
Canine O
kidney O
cells O
transfected O
with O
full O
length O
cDNA O
for O
human B-GENE-Y
multidrug I-GENE-Y
resistance I-GENE-Y
gene1 I-GENE-Y
(MDCKII-MDR1). B-GENE-Y
Our O
results O
demonstrate O
that O
the O
method O
has O
excellent O
and O
satisfactory O
selectivity, O
sensitivity, O
linearity, O
precision, O
and O
accuracy O
for O
simultaneous O
determination O

of O
imperatorin, B-CHEMICAL
isoimperatorin B-CHEMICAL
and O
cnidilin. B-CHEMICAL
The O
pharmacokinetics O
parameters O
were O
determined O
by O
using O
noncompartmental O
analyses, O
including O
the O
AUC(0-t) O
in O
plasma O
(1695.22, O
1326.45 O
and O
636.98mg*h/L), O
the O
AUC(0-t) O
in O
brain O
(1812.35, O
2125.17 O
and O
1145.83ng*h/g) O
as O
well O
as O
the O
T1/2 O
in O
plasma O
(0.66, O
0.82, O
0.97h) O
and O
brain O

(0.96, O
1.1, O
0.99h) O
for O
imperatorin, B-CHEMICAL
isoimperatorin B-CHEMICAL
and O
cnidilin, B-CHEMICAL
respectively, O
suggesting O
that O
the O
three O
coumarins B-CHEMICAL
could O
easily O
pass O
through O
the O
BBB O
in O
vivo. O
In O
the O
in O
vitro O
model O
we O
observed O
high O
permeability O
of O
imperatorin B-CHEMICAL
and O
isoimperatorin B-CHEMICAL
with O
the O
P-gp-mediated B-GENE-N
efflux O
ratios O
of O
0.53 O
and O
0.06, O
as O
well O
as O
medium O
permeability O
of O
cnidilin B-CHEMICAL
with O
0.82. O
All O
data O
suggest O
that O
these O
three O
coumarins B-CHEMICAL
have O
high O

BBB O
permeability O
and O
have O
pharmacokinetic O
potentials O
for O
the O
treatment O
of O
central O
nervous O
system O
diseases. O
Involvement O
of O
Src B-GENE-Y
and O
the O
actin B-GENE-N
cytoskeleton O
in O
the O
antitumorigenic O
action O
of O
adenosine B-CHEMICAL
dialdehyde. I-CHEMICAL
Transmethylation O
is O
an O
important O
reaction O
that O
transfers O
a O
methyl B-CHEMICAL
group O
in O
S-adenosylmethionine B-CHEMICAL
(SAM) B-CHEMICAL
to O
substrates O
such O
as O
DNA, O
RNA, O
and O
proteins. O
It O
is O
known O
that O
transmethylation O
plays O
critical O
roles O
in O
various O
cellular O
responses. O
In O
this O
study, O
we O
examined O
the O
effects O
of O
transmethylation O
on O

tumorigenic O
responses O
and O
its O
regulatory O
mechanism O
using O
an O
upregulation O
strategy O
of O
adenosylhomocysteine B-CHEMICAL
(SAH) B-CHEMICAL
acting O
as O
a O
negative O
feedback O
inhibitor. O
Treatment O
with O
adenosine B-CHEMICAL
dialdehyde I-CHEMICAL
(AdOx), B-CHEMICAL
an O
inhibitor O
of O
transmethylation-suppressive O
adenosylhomocysteine B-GENE-Y
(SAH) I-GENE-Y
hydrolase I-GENE-Y
(SAHH), B-GENE-Y
enhanced O
the O
level O
of O
SAH B-CHEMICAL
and O
effectively O
blocked O
the O
proliferation, O
migration, O
and O
invasion O
of O
cancer O
cells; O
the O
treatment O
also O
induced O
the O
differentiation O
of O
C6 O
glioma O
cells O
and O
suppressed O
the O
neovascular O
genesis O
of O

eggs O
in O
a O
dose-dependent O
manner. O
Through O
immunoblotting O
analysis, O
it O
was O
found O
that O
AdOx B-CHEMICAL
was O
capable O
of O
indirectly O
diminishing O
the O
phosphorylation O
of O
oncogenic O
Src B-GENE-Y
and O
its O
kinase B-GENE-N
activity. O
Interestingly, O
AdOx B-CHEMICAL
disrupted O
actin B-GENE-N
cytoskeleton O
structures, O
leading O
to O
morphological O
changes, O
and O
suppressed O
the O
formation O
of O
a O
signaling O
complex O
composed O
of O
Src B-GENE-Y
and O
p85/PI3K, B-GENE-N
which O
is O
linked O
to O
various O
tumorigenic O
responses. O
In O
agreement O
with O
these O
data, O
the O
exogenous O
treatment O
of O
SAH B-CHEMICAL
or O
inhibition O
of O
SAHH B-GENE-Y
by O
specific O

siRNA O
or O
another O
type O
of O
inhibitor, O
3-deazaadenosine B-CHEMICAL
(DAZA), B-CHEMICAL
similarly O
resulted O
in O
antitumorigenic O
responses, O
suppressive O
activity O
on O
Src, B-GENE-Y
the O
alteration O
of O
actin B-GENE-N
cytoskeleton, O
and O
a O
change O
of O
the O
colocalization O
pattern O
between O
actin B-GENE-N
and O
Src. B-GENE-Y
Taken O
together, O
these O
results O
suggest O
that O
SAH/SAHH-mediated B-CHEMICAL
transmethylation O
could O
be O
linked O
to O
the O
tumorigenic O
processes O
through O
cross-regulation O
between O
the O
actin B-GENE-N
cytoskeleton O
and O
Src B-GENE-Y
kinase B-GENE-N
activity. O
Synthesis O
of O
derivatives O
of O
methyl B-CHEMICAL

rosmarinate I-CHEMICAL
and O
their O
inhibitory O
activities O
against O
matrix B-GENE-Y
metalloproteinase-1 I-GENE-Y
(MMP-1). B-GENE-Y
A O
series O
of O
MMP-1 B-GENE-Y
inhibitors O
have O
been O
identified O
based O
upon O
a O
methyl B-CHEMICAL
rosmarinate I-CHEMICAL
scaffold O
using O
structure-based O
drug O
design O
methods. O
The O
best O
compound O
in O
the O
series O
showed O
an O
IC50 O
value O
of O
0.4 O
M. O
A O
docking O
study O
was O
conducted O
for O
compound O
(S)-10n O
in O
order O
to O
investigate O
its O
binding O
interactions O
with O
MMP-1. B-GENE-Y
The O
structure-activity O
relationships O
(SAR) O
were O
also O
briefly O
discussed. O
Useful O
SAR O
was O
established O
which O
provides O

important O
guidelines O
for O
the O
design O
of O
future O
generations O
of O
potent O
inhibitors O
against O
MMP-1. B-GENE-Y
Synthesis O
and O
biological O
evaluation O
of O
some O
novel O
resveratrol B-CHEMICAL
amide I-CHEMICAL
derivatives O
as O
potential O
anti-tumor O
agents. O
Three O
series O
of O
novel O
resveratrol B-CHEMICAL
amide I-CHEMICAL
derivatives O
(1a-q, O
2a-h, O
3a-l) O
were O
synthesized O
and O
evaluated O
for O
their O
biological O
activities. O
All O
compounds O
were O
characterized O
by O
(1)H B-CHEMICAL
NMR, O
(13)C B-CHEMICAL
NMR, O
MS O
and O
elemental O
analysis. O
Furthermore, O
compound O
3e O
was O
also O
characterized O
by O
X-ray O
crystallography. O
All O
the O
compounds O
were O
evaluated O
for O
their O

anti-tumor O
activity O
against O
MCF-7, O
A549 O
and O
B16-F10 O
tumor O
cell O
lines O
as O
well O
as O
cyclooxygenase-2 B-GENE-Y
(COX-2)-derived B-GENE-Y
prostaglandin B-CHEMICAL
E2 I-CHEMICAL
(PGE2) B-CHEMICAL
inhibitory O
activity O
of O
murine O
macrophage O
RAW O
264.7 O
cell O
line. O
Among O
them, O
compounds O
1c, O
1g O
and O
3e O
displayed O
the O
most O
potent O
COX-2 B-GENE-Y
inhibitory O
activity O
with O
the O
IC50 O
values O
of O
1.02, O
1.27 O
and O
1.98 O
M, O
respectively. O
Molecular O
docking O
studies O
were O
performed O

to O
position O
compounds O
1c O
and O
3e O
into O
the O
active O
site O
of O
COX-2 B-GENE-Y
to O
determine O
the O
probable O
binding O
modes. O
Cystathionase B-GENE-Y
mediates O
senescence O
evasion O
in O
melanocytes O
and O
melanoma O
cells. O
The O
development O
of O
malignant O
melanoma O
is O
a O
highly O
complex O
process, O
which O
is O
still O
poorly O
understood. O
A O
majority O
of O
human O
melanomas O
are O
found O
to O
express O
a O
few O
oncogenic O
proteins, O
such O
as O
mutant O
RAS B-GENE-N
and O
BRAF B-GENE-Y
variants. O
However, O
these O
oncogenes O
are O
also O
found O
in O
nevi, O
and O
it O
is O
now O
a O
well-accepted O
fact O
that O
their O
expression O
alone O
leads O
to O

senescence. O
This O
renders O
the O
understanding O
of O
senescence O
escape O
mechanisms O
an O
important O
point O
to O
understand O
tumor O
development. O
Here, O
we O
approached O
the O
question O
of O
senescence O
evasion O
by O
expressing O
the O
transcription O
factor O
v-myc B-GENE-Y
myelocytomatosis I-GENE-Y
viral I-GENE-Y
oncogene I-GENE-Y
homolog I-GENE-Y
(c-MYC), B-GENE-Y
which O
is O
known O
to O
act O
synergistically O
with O
many O
oncogenes, O
in O
melanocytes. O
We O
observed O
that O
MYC B-GENE-Y
drives O
the O
evasion O
of O
reactive-oxygen B-CHEMICAL
stress-induced O
melanocyte O
senescence, O
caused O
by O
activated O
receptor B-GENE-N
tyrosine B-CHEMICAL
kinase I-GENE-N
signaling. O

Conversely, O
MIZ1, B-GENE-Y
the O
growth O
suppressing O
interaction O
partner O
of O
MYC, B-GENE-Y
is O
involved O
in O
mediating O
melanocyte O
senescence. O
Both, O
MYC B-GENE-Y
overexpression O
and O
Miz1 B-GENE-Y
knockdown O
led O
to O
a O
strong O
reduction O
of O
endogenous O
reactive-oxygen B-CHEMICAL
species O
(ROS), O
DNA O
damage O
and O
senescence. O
We O
identified O
the O
cystathionase B-GENE-Y
(CTH) B-GENE-Y
gene O
product O
as O
mediator O
of O
the O
ROS-related O
MYC B-GENE-Y
and O
MIZ1 B-GENE-Y
effects. O
Blocking O
CTH B-GENE-Y
enzymatic O
activity O
in O
MYC-overexpressing B-GENE-Y
and O
Miz1 B-GENE-Y
knockdown O
cells O

increased O
intracellular O
stress O
and O
senescence. O
Importantly, O
pharmacological O
inhibition O
of O
CTH B-GENE-Y
in O
human O
melanoma O
cells O
also O
reconstituted O
senescence O
in O
the O
majority O
of O
cell O
lines, O
and O
CTH B-GENE-Y
knockdown O
reduced O
tumorigenic O
effects O
such O
as O
proliferation, O
H(2)O(2) B-CHEMICAL
resistance O
and O
soft O
agar O
growth. O
Thus, O
we O
identified O
CTH B-GENE-Y
as O
new O
MYC B-GENE-Y
target O
gene O
with O
an O
important O
function O
in O
senescence O
evasion.Oncogene O
advance O
online O
publication, O
28 O
January O
2013; O
doi:10.1038/onc.2012.641. O
Investigational O

anti-hyperglycemic O
agents: O
the O
future O
of O
type O
2 O
diabetes O
therapy? O
As O
the O
pandemic O
of O
type O
2 O
diabetes O
spreads O
globally, O
clinicians O
face O
many O
challenges O
in O
treating O
an O
increasingly O
diverse O
patient O
population O
varying O
in O
age, O
comorbidities, O
and O
socioeconomic O
status. O
Current O
therapies O
for O
type O
2 O
diabetes O
are O
often O
unable O
to O
alter O
the O
natural O
course O
of O
the O
disease O
and O
provide O
durable O
glycemic O
control, O
and O
side O
effects O
in O
the O
context O
of O
individual O
patient O
characteristics O
often O
limit O
treatment O
choices. O
This O
often O
results O
in O
the O
progression O
to O
insulin B-GENE-Y
use O
and O
complex O
regimens O
that O
are O
difficult O
to O
maintain. O
Therefore, O
a O
number O
of O
agents O
are O
being O

developed O
to O
better O
address O
the O
pathogenesis O
of O
type O
2 O
diabetes O
and O
to O
overcome O
limitations O
of O
current O
therapies. O
The O
hope O
is O
to O
provide O
more O
options O
for O
glucose B-CHEMICAL
lowering O
and O
complication O
reduction O
with O
less O
risk O
for O
hypoglycemia O
and O
other O
adverse O
effects. O
These O
agents O
include O
newer O
incretin-based B-GENE-N
therapies O
and O
PPAR B-GENE-N
agonists, O
as O
well O
as O
new O
therapeutic O
classes O
such O
as O
sodium-coupled B-CHEMICAL
glucose B-CHEMICAL
cotransporter I-GENE-Y
2 I-GENE-Y
inhibitors, O
free B-GENE-N
fatty I-GENE-N
acid I-GENE-N
receptor I-GENE-N
agonists, O
11--hydroxysteroid B-GENE-Y
dehydrogenase I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
inhibitors, O
glucokinase B-GENE-Y

activators, O
and O
several O
others O
that O
may O
enter O
clinical O
use O
over O
the O
next O
decade. O
Herein O
we O
review O
these O
agents O
that O
are O
advancing O
through O
clinical O
trials O
and O
describe O
the O
rationale O
behind O
their O
use, O
mechanisms O
of O
action, O
and O
potential O
for O
glucose B-CHEMICAL
lowering, O
as O
well O
as O
what O
is O
known O
of O
their O
limitations. O
3-Methylglutaconic B-CHEMICAL
aciduria-lessons O
from O
50 O
genes O
and O
977 O
patients. O
Elevated O
urinary O
excretion O
of O
3-methylglutaconic B-CHEMICAL
acid I-CHEMICAL
is O
considered O
rare O
in O
patients O
suspected O
of O
a O
metabolic O
disorder. O
In O
3-methylglutaconyl-CoA B-CHEMICAL
hydratase I-GENE-Y
deficiency O

(mutations O
in O
AUH), B-GENE-Y
it O
derives O
from O
leucine B-CHEMICAL
degradation. O
In O
all O
other O
disorders O
with O
3-methylglutaconic B-CHEMICAL
aciduria O
the O
origin O
is O
unknown, O
yet O
mitochondrial O
dysfunction O
is O
thought O
to O
be O
the O
common O
denominator. O
We O
investigate O
the O
biochemical, O
clinical O
and O
genetic O
data O
of O
388 O
patients O
referred O
to O
our O
centre O
under O
suspicion O
of O
a O
metabolic O
disorder O
showing O
3-methylglutaconic B-CHEMICAL
aciduria O
in O
routine O
metabolic O
screening. O
Furthermore, O
we O
investigate O
591 O
patients O
with O
50 O
different, O
genetically O
proven, O
mitochondrial O
disorders O
for O
the O
presence O
of O
3-methylglutaconic B-CHEMICAL
aciduria. O
Three O
percent O
of O
all O

urine O
samples O
of O
the O
patients O
referred O
showed O
3-methylglutaconic B-CHEMICAL
aciduria, O
often O
in O
correlation O
with O
disorders O
not O
reported O
earlier O
in O
association O
with O
3-methylglutaconic B-CHEMICAL
aciduria O
(e.g. O
organic O
acidurias, O
urea B-CHEMICAL
cycle O
disorders, O
haematological O
and O
neuromuscular O
disorders). O
In O
the O
patient O
cohort O
with O
genetically O
proven O
mitochondrial O
disorders O
11 O
% O
presented O
3-methylglutaconic B-CHEMICAL
aciduria. O
It O
was O
more O
frequently O
seen O
in O
ATPase B-GENE-N
related O
disorders, O
with O
mitochondrial O
DNA O
depletion O
or O
deletion, O
but O
not O
in O
patients O
with O
single O
respiratory B-GENE-N
chain I-GENE-N
complex I-GENE-N
deficiencies. O

Besides, O
it O
was O
a O
consistent O
feature O
of O
patients O
with O
mutations O
in O
TAZ, B-GENE-Y
SERAC1, B-GENE-Y
OPA3, B-GENE-Y
DNAJC19 B-GENE-Y
and O
TMEM70 B-GENE-Y
accounting O
for O
mitochondrial O
membrane O
related O
pathology. O
3-methylglutaconic B-CHEMICAL
aciduria O
is O
found O
quite O
frequently O
in O
patients O
suspected O
of O
a O
metabolic O
disorder, O
and O
mitochondrial O
dysfunction O
is O
indeed O
a O
common O
denominator. O
It O
is O
only O
a O
discriminative O
feature O
of O
patients O
with O
mutations O
in O
AUH, B-GENE-Y
TAZ, B-GENE-Y
SERAC1, B-GENE-Y
OPA3, B-GENE-Y
DNAJC19 B-GENE-Y
TMEM70. B-GENE-Y
These O
conditions O
should O
therefore O
be O
referred O
to O
as O

inborn O
errors O
of O
metabolism O
with O
3-methylglutaconic B-CHEMICAL
aciduria O
as O
discriminative O
feature. O
Bioactives O
and O
nutraceutical O
phytochemicals O
naturally O
occurring O
in O
virgin O
olive O
oil. O
The O
case O
study O
of O
the O
Nocellara O
del O
Belice O
Italian O
olive O
cultivar. O
This O
work O
reports O
on O
the O
composition O
and O
bionutritional O
value O
of O
organic O
virgin O
olive O
oil O
from O
the O
Nocellara O
del O
Belice O
variety, O
one O
cultivated O
in O
the O
olive O
areas O
of O
the O
Sicily O
region, O
Italy. O
Destoned O
oils O
obtained O
by O
processing O
olives O
with O
a O
destoning-based O
procedure O
were O
compared O
with O
conventional O
oils. O
This O
innovative O

technique, O
consisting O
in O
removing O
the O
stone O
from O
fruits O
prior O
to O
processing, O
strongly O
enhanced O
the O
already O
high-quality O
level O
of O
the O
conventional O
product. O
An O
in-depth O
analytical O
investigation O
from O
2008 O
to O
2010 O
showed O
how O
this O
innovative O
olive O
extraction O
process O
led O
to O
an O
excellent O
peculiar O
final O
product, O
mainly O
attributable O
to O
the O
improved O
biophenol O
and O
volatile O
composition, O
as O
well O
as O
higher O
concentrations O
of O
the O
lipophilic O
and O
vitamin O
antioxidants O
(tocopherols B-CHEMICAL
and O
tocotrienols). B-CHEMICAL
It O
had O
higher O
levels O
of O
oleocanthal B-CHEMICAL
(p-HPEA-EDA), B-CHEMICAL
a O
nutraceutical O
compound O
exerting O
actions O
against O

COX1 B-GENE-Y
and O
COX2 B-GENE-Y
(cycloxygenases). B-GENE-N
Its O
head-space O
aroma O
displayed O
new O
volatile O
phytomolecules O
and O
also O
had O
higher O
levels O
of O
green O
volatiles O
from O
the O
lipoxygenase B-GENE-N
(LOX)-pathway B-GENE-N
(one O
having O
as O
precursors O
the O
polyunsaturated B-CHEMICAL
fatty I-CHEMICAL
acids I-CHEMICAL
containing O
a O
cis-cis-1,4-pentadiene B-CHEMICAL
system). O
Among O
the O
other O
bioactives, O
we O
highlight O
its O
significant O
levels O
of O
trans--carotene B-CHEMICAL
and O
xanthophylls B-CHEMICAL
(lutein, B-CHEMICAL
violaxanthin, B-CHEMICAL

neoxanthin B-CHEMICAL
and O
other O
carotenoids). O
Its O
enhanced O
nutritional O
value O
was O
also O
attributable O
to O
the O
increased O
intensity O
of O
valuable O
tasting O
notes. O
Synthesis, O
DNA O
binding O
and O
antitumor O
evaluation O
of O
styelsamine B-CHEMICAL
and O
cystodytin B-CHEMICAL
analogues. O
A O
series O
of O
N-14 O
sidechain O
substituted O
analogues O
of O
styelsamine B-CHEMICAL
(pyrido[4,3,2-mn]acridine) B-CHEMICAL
and O
cystodytin B-CHEMICAL
(pyrido[4,3,2-mn]acridin-4-one) B-CHEMICAL
alkaloids O
have O

been O
prepared O
and O
evaluated O
for O
their O
DNA O
binding O
affinity O
and O
antiproliferative O
activity O
towards O
a O
panel O
of O
human O
tumor O
cell O
lines. O
Overall O
it O
was O
found O
that O
styelsamine B-CHEMICAL
analogues O
were O
stronger O
DNA O
binders, O
with O
the O
natural O
products O
styelsamines B-CHEMICAL
B I-CHEMICAL
and I-CHEMICAL
D I-CHEMICAL
having O
particularly O
high O
affinity O
(K(app) O
5.33 O
 O
10(6) O
and O
3.64 O
 O
10(6) O
M(-1), O
respectively). O
In O
comparison, O
the O
cystodytin B-CHEMICAL
iminoquinone I-CHEMICAL
alkaloids I-CHEMICAL
showed O
lower O
affinity O
for O
DNA, O
but O
were O
typically O
just O
as O
active O
as O
styelsamine B-CHEMICAL
analogues O
at O

inhibiting O
proliferation O
of O
tumor O
cells O
in O
vitro. O
Sub-panel O
selectivity O
towards O
non-small O
cell O
lung, O
melanoma O
and O
renal O
cancer O
cell O
lines O
were O
observed O
for O
a O
number O
of O
the O
analogues. O
Correlation O
was O
observed O
between O
whole O
cell O
activity O
and O
clogP, O
with O
the O
most O
potent O
antiproliferative O
activity O
being O
observed O
for O
3-phenylpropanamide B-CHEMICAL
analogues O
37 O
and O
41 O
(NCI O
panel O
average O
GI(50) O
0.4 O
M O
and O
0.32 O
M, O
respectively) O
with O
clogP O
~4.0-4.5. O
Intercalation O
pathway O

in O
many-particle O
LiFePO4 B-CHEMICAL
electrode O
revealed O
by O
nanoscale O
state-of-charge O
mapping. O
The O
intercalation O
pathway O
of O
lithium B-CHEMICAL
iron I-CHEMICAL
phosphate I-CHEMICAL
(LFP) B-CHEMICAL
in O
the O
positive O
electrode O
of O
a O
lithium-ion B-CHEMICAL
battery O
was O
probed O
at O
the O
40 O
nm O
length O
scale O
using O
oxidation-state-sensitive O
X-ray O
microscopy. O
Combined O
with O
morphological O
observations O
of O
the O
same O
exact O
locations O
using O
transmission O
electron O
microscopy, O
we O
quantified O
the O
local O
state-of-charge O
of O
approximately O
450 O
individual O
LFP B-CHEMICAL
particles O
over O
nearly O
the O
entire O
thickness O
of O
the O
porous O
electrode. O
With O
the O
electrode O
charged O
to O

50% O
state-of-charge O
in O
0.5 O
h, O
we O
observed O
that O
the O
overwhelming O
majority O
of O
particles O
were O
either O
almost O
completely O
delithiated O
or O
lithiated. O
Specifically, O
only O
2% O
of O
individual O
particles O
were O
at O
an O
intermediate O
state-of-charge. O
From O
this O
small O
fraction O
of O
particles O
that O
were O
actively O
undergoing O
delithiation, O
we O
conclude O
that O
the O
time O
needed O
to O
charge O
a O
particle O
is O
1/50 O
the O
time O
needed O
to O
charge O
the O
entire O
particle O
ensemble. O
Surprisingly, O
we O
observed O
a O
very O
weak O
correlation O
between O
the O
sequence O
of O
delithiation O
and O
the O
particle O
size, O
contrary O
to O
the O
common O
expectation O
that O
smaller O
particles O
delithiate O
before O
larger O

ones. O
Our O
quantitative O
results O
unambiguously O
confirm O
the O
mosaic O
(particle-by-particle) O
pathway O
of O
intercalation O
and O
suggest O
that O
the O
rate-limiting O
process O
of O
charging O
is O
initiating O
the O
phase O
transformation O
by, O
for O
example, O
a O
nucleation-like O
event. O
Therefore, O
strategies O
for O
further O
enhancing O
the O
performance O
of O
LFP B-CHEMICAL
electrodes O
should O
not O
focus O
on O
increasing O
the O
phase-boundary O
velocity O
but O
on O
the O
rate O
of O
phase-transformation O
initiation. O
Silica B-CHEMICAL
precipitation O
by O
synthetic O
minicollagens. O
Oligomeric O
Pro-Hyp-Gly- B-CHEMICAL
(POG-) O
peptides, O
wherein O
the O

collagenous B-GENE-N
triple I-GENE-N
helix I-GENE-N
is O
supported O
by O
C-terminal B-CHEMICAL
capping, O
exhibit O
silica B-CHEMICAL
precipitation O
properties O
(O, O
Hyp B-CHEMICAL
= O
(2S,4R)hydroxyproline). B-CHEMICAL
As O
quantified O
by O
a O
molybdate O
assay, O
the O
length O
of O
the O
covalently O
tethered O
triple B-GENE-N
helix I-GENE-N
(number O
of O
POG O
units) O
determines O
the O
amount O
of O
amorphous O
silica B-CHEMICAL
obtained O
from O
silicic B-CHEMICAL
acid I-CHEMICAL
solution. O
Although O
lacking O
charged O
side O
chains, O
the O
synthetic O
collagens B-GENE-N
precipitate O
large O
quantities O
of O
silicic B-CHEMICAL
acid I-CHEMICAL
resulting O
in O
micrometer-sized O
spheres O
of O
varying O

surface O
morphologies O
as O
analyzed O
by O
scanning O
electron O
microscopy. O
Similar O
precipitation O
efficiencies O
on O
a O
fast O
time O
scale O
of O
less O
than O
10 O
min O
were O
previously O
described O
only O
for O
biogenic O
diatom O
proteins O
and O
sponge B-GENE-N
collagen, I-GENE-N
respectively, O
which O
have O
a O
considerably O
higher O
structural O
complexity O
and O
limited O
accessibility. O
The O
minicollagens O
described O
here O
provide O
an O
unexpected O
alternative O
to O
the O
widely O
used O
precipitation O
conditions, O
which O
generally O
depend O
on O
(poly-)amines B-CHEMICAL
in O
phosphate B-CHEMICAL
buffer. O
Collagen B-GENE-N
can O
form O
intimate O
connections O
with O
inorganic O
matter. O
Hence, O
silica-enclosed B-CHEMICAL
collagens B-GENE-N
have O
promising O
perspectives O
as O
composite O
materials. O

Pharmacodynamic O
characteristics O
of O
lixisenatide O
once O
daily O
versus O
liraglutide O
once O
daily O
in O
patients O
with O
type O
2 O
diabetes O
insufficiently O
controlled O
on O
metformin. B-CHEMICAL
AIM: O
Assess O
the O
pharmacodynamics O
of O
lixisenatide O
once O
daily O
(QD) O
versus O
liraglutide O
QD O
in O
type O
2 O
diabetes O
insufficiently O
controlled O
on O
metformin. B-CHEMICAL
METHODS: O
In O
this O
28-day, O
randomized, O
open-label, O
parallel-group, O
multicentre O
study O
(NCT01175473), O
patients O
(mean O
HbA1c B-GENE-Y

7.3%) O
received O
subcutaneous O
lixisenatide O
QD O
(10 O
g O
weeks O
1-2, O
then O
20 O
g; O
n O
= O
77) O
or O
liraglutide O
QD O
(0.6 O
mg O
week O
1, O
1.2 O
mg O
week O
2, O
then O
1.8 O
mg; O
n O
= O
71) O
30 O
min O
before O
breakfast. O
Primary O
endpoint O
was O
change O
in O
postprandial O
plasma O
glucose B-CHEMICAL
(PPG) O
exposure O
from O
baseline O
to O
day O
28 O
during O
a O
breakfast O
test O
meal. O
RESULTS: O
Lixisenatide O
reduced O
PPG O
significantly O
more O
than O
liraglutide O
[mean O
change O

in O
AUC(0) O
(:30-4:30h) O
: O
-12.6 O
vs. O
-4.0 O
h/mmol/l, O
respectively; O
p O
< O
0.0001 O
(0:30 O
h O
= O
start O
of O
meal)]. O
Change O
in O
maximum O
PPG O
excursion O
was O
-3.9 O
mmol/l O
vs. O
-1.4 O
mmol/l, O
respectively O
(p O
< O
0.0001). O
More O
lixisenatide-treated O
patients O
achieved O
2-h O
PPG O
<7.8 O
mmol/l O
(69% O
vs. O
29%). O
Changes O
in O
fasting O

plasma O
glucose O
were O
greater O
with O
liraglutide O
(-0.3 O
vs. O
-1.3 O
mmol/l, O
p O
< O
0.0001). O
Lixisenatide O
provided O
greater O
decreases O
in O
postprandial O
glucagon B-GENE-Y
(p O
< O
0.05), O
insulin B-GENE-Y
(p O
< O
0.0001) O
and O
C-peptide B-GENE-Y
(p O
< O
0.0001). O
Mean O
HbA1c B-GENE-N
decreased O
in O
both O
treatment O
groups O
(from O
7.2% O
to O
6.9% O
with O
lixisenatide O
vs. O
7.4% O
to O
6.9% O
with O

liraglutide) O
as O
did O
body O
weight O
(-1.6 O
kg O
vs. O
-2.4 O
kg, O
respectively). O
Overall O
incidence O
of O
adverse O
events O
was O
lower O
with O
lixisenatide O
(55%) O
versus O
liraglutide O
(65%), O
with O
no O
serious O
events O
or O
hypoglycaemia O
reported. O
CONCLUSIONS: O
Once O
daily O
prebreakfast O
lixisenatide O
provided O
a O
significantly O
greater O
reduction O
in O
PPG O
(AUC) O
during O
a O
morning O
test O
meal O
versus O
prebreakfast O
liraglutide. O
Lixisenatide O
provided O
significant O
decreases O
in O
postprandial O

insulin, B-GENE-Y
C-peptide B-GENE-Y
(vs. O
an O
increase O
with O
liraglutide) O
and O
glucagon, B-GENE-Y
and O
better O
gastrointestinal O
tolerability O
than O
liraglutide. O
The O
contrasting O
activity O
of O
iodido B-CHEMICAL
versus O
chlorido B-CHEMICAL
ruthenium I-CHEMICAL
and O
osmium B-CHEMICAL
arene I-CHEMICAL
azo- I-CHEMICAL
and I-CHEMICAL
imino-pyridine I-CHEMICAL
anticancer O
complexes: O
control O
of O
cell O
selectivity, O
cross-resistance, O
p53 B-GENE-Y
dependence, O
and O
apoptosis O
pathway. O
Organometallic O
half-sandwich O
complexes O

[M(p-cymene)(azo/imino-pyridine)X](+) B-CHEMICAL
where O
M B-CHEMICAL
= I-CHEMICAL
Ru(II) I-CHEMICAL
or I-CHEMICAL
Os(II) I-CHEMICAL
and O
X B-CHEMICAL
 I-CHEMICAL
Cl B-CHEMICAL
or I-CHEMICAL
I, B-CHEMICAL
exhibit O
potent O
antiproliferative O
activity O
toward O
a O
range O
of O
cancer O
cells. O
Not O
only O
are O
the O
iodido B-CHEMICAL
complexes O
more O
potent O
than O
the O
chlorido B-CHEMICAL
analogues, O
but O
they O
are O
not O
cross-resistant O
with O
the O
clinical O
platinum B-CHEMICAL
drugs O
cisplatin B-CHEMICAL
and O
oxaliplatin. B-CHEMICAL
They O
are O
also O
more O
selective O
for O
cancer O
cells O
versus O
normal O
cells O
(fibroblasts) O
and O
show O
high O
accumulation O

in O
cell O
membranes. O
They O
arrest O
cell O
growth O
in O
G1 O
phase O
in O
contrast O
to O
cisplatin B-CHEMICAL
(S O
phase) O
with O
a O
high O
incidence O
of O
late-stage O
apoptosis. O
The O
iodido B-CHEMICAL
complexes O
retain O
potency O
in O
p53 B-GENE-Y
mutant O
colon O
cells. O
All O
complexes O
activate O
caspase B-GENE-Y
3. I-GENE-Y
In O
general, O
antiproliferative O
activity O
is O
greatly O
enhanced O
by O
low O
levels O
of O
the O
glutathione B-GENE-Y
synthase I-GENE-Y
inhibitor O
l-buthionine B-CHEMICAL
sulfoxime. I-CHEMICAL
The O
work O
illustrates O
how O
subtle O
changes O
to O
the O
design O
of O
low-spin O
d(6) O
metal O
complexes O
can O
lead O
to O
major O
changes O
in O
cellular O
metabolism O
and O

to O
potent O
complexes O
with O
novel O
mechanisms O
of O
anticancer O
activity. O
Zinc-dependent B-CHEMICAL
lysosomal O
enlargement O
in O
TRPML1-deficient B-GENE-Y
cells O
involves O
MTF-1 B-GENE-Y
transcription O
factor O
and O
ZnT4 B-GENE-Y
(Slc30a4) B-GENE-Y
transporter. O
Zinc B-CHEMICAL
is O
critical O
for O
a O
multitude O
of O
cellular O
processes, O
including O
gene O
expression, O
secretion O
and O
enzymatic O
activities. O
Cellular O
zinc B-CHEMICAL
is O
controlled O
by O
zinc-chelating B-CHEMICAL
proteins I-GENE-N
and O
by O
zinc B-CHEMICAL
transporters. I-GENE-N
The O
recent O
identification O
of O
zinc B-CHEMICAL
permeability O
of O
the O
lysosomal O
ion B-GENE-N
channel I-GENE-N
TRPML1 B-GENE-Y
(transient B-GENE-Y
receptor I-GENE-Y
potential I-GENE-Y

mucolipin I-GENE-Y
1), I-GENE-Y
and O
the O
evidence O
of O
abnormal O
zinc B-CHEMICAL
levels O
in O
cells O
deficient O
in O
TRPML1, B-GENE-Y
suggested O
a O
role O
for O
TRPML1 B-GENE-Y
in O
zinc B-CHEMICAL
transport. O
In O
the O
present O
study O
we O
provide O
new O
evidence O
for O
such O
a O
role O
and O
identify O
additional O
cellular O
components O
responsible O
for O
it. O
In O
agreement O
with O
the O
previously O
published O
data, O
an O
acute O
siRNA O
(small O
interfering O
RNA)-driven O
TRPML1 B-GENE-Y
KD O
(knockdown) O
leads O
to O
the O
build-up O
of O
large O
cytoplasmic O
vesicles O
positive O
for O
LysoTracker O
and O
zinc B-CHEMICAL
staining, O
when O
cells O
are O
exposed O
to O
high O
concentrations O
of O
zinc. B-CHEMICAL
We O
now O
show O
that O

lysosomal O
enlargement O
and O
zinc B-CHEMICAL
build-up O
in O
TRPML1-KD B-GENE-Y
cells O
exposed O
to O
zinc B-CHEMICAL
are O
ameliorated O
by O
KD O
of O
the O
zinc-sensitive B-GENE-N
transcription I-GENE-N
factor I-GENE-N
MTF-1 B-GENE-Y
(metal-regulatory-element-binding B-GENE-Y
transcription I-GENE-Y
factor-1) I-GENE-Y
or O
the O
zinc B-CHEMICAL
transporter I-GENE-Y
ZnT4. I-GENE-Y
TRPML1 B-GENE-Y
KD O
is O
associated O
with O
a O
build-up O
of O
cytoplasmic O
zinc B-CHEMICAL
and O
with O
enhanced O
transcriptional O
response O
of O
mRNA O
for O
MT2a B-GENE-Y
(metallothionein B-GENE-Y
2a). I-GENE-Y
TRPML1 B-GENE-Y
KD O
did O
not O
suppress O
lysosomal O
secretion, O

but O
it O
did O
delay O
zinc B-CHEMICAL
leak O
from O
the O
lysosomes O
into O
the O
cytoplasm. O
These O
results O
underscore O
a O
role O
for O
TRPML1 B-GENE-Y
in O
zinc B-CHEMICAL
metabolism. O
Furthermore, O
they O
suggest O
that O
TRPML1 B-GENE-Y
works O
in O
concert O
with O
ZnT4 B-GENE-Y
to O
regulate O
zinc B-CHEMICAL
translocation O
between O
the O
cytoplasm O
and O
lysosomes. O
Evaluation O
of O
in O
vivo O
anti-hyperglycemic O
and O
antioxidant O
potentials O
of O
-santalol B-CHEMICAL
and O
sandalwood O
oil. O
Sandalwood O
finds O
numerous O
mentions O
across O
diverse O
traditional O
medicinal O
systems O
in O
use O
worldwide. O
The O
objective O
of O
this O
study O
was O
to O
evaluate O
the O

in O
vivo O
anti-hyperglycemic O
and O
antioxidant O
potential O
of O
sandalwood O
oil O
and O
its O
major O
constituent O
-santalol. B-CHEMICAL
The O
in O
vivo O
anti-hyperglycemic O
experiment O
was O
conducted O
in O
alloxan-induced B-CHEMICAL
diabetic O
male O
Swiss O
albino O
mice O
models. O
The O
in O
vivo O
antioxidant O
experiment O
was O
performed O
in O
d-galactose B-CHEMICAL
mediated O
oxidative O
stress O
induced O
male O
Swiss O
albino O
mice O
models. O
Intraperitoneal O
administration O
of O
-santalol B-CHEMICAL
(100mg/kg O
BW) O
and O
sandalwood O
oil O
(1g/kg O

BW) O
for O
an O
week O
modulated O
parameters O
such O
as O
body O
weight, O
blood O
glucose, B-CHEMICAL
serum O
bilirubin, B-CHEMICAL
liver O
glycogen, O
and O
lipid O
peroxides B-CHEMICAL
contents O
to O
normoglycemic O
levels O
in O
the O
alloxan-induced B-CHEMICAL
diabetic O
mice. O
Similarly, O
intraperitoneal O
administration O
of O
-santalol B-CHEMICAL
(100mg/kg O
BW) O
and O
sandalwood O
oil O
(1g/kg O
BW) O
for O
two O
weeks O
modulated O
parameters O
such O
as O
serum O
aminotransferases, B-GENE-N
alkaline B-GENE-N
phosphatase, I-GENE-N
bilirubin, B-CHEMICAL
superoxide B-GENE-N

dismutase, I-GENE-N
catalase, B-GENE-Y
free O
sulfhydryl, B-CHEMICAL
protein O
carbonyl, B-CHEMICAL
nitric B-CHEMICAL
oxide, I-CHEMICAL
liver O
lipid O
peroxide B-CHEMICAL
contents, O
and O
antioxidant O
capacity O
in O
d-galactose B-CHEMICAL
mediated O
oxidative O
stress O
induced O
mice. O
Besides, O
it O
was O
observed O
that O
the O
beneficial O
effects O
of O
-santalol B-CHEMICAL
were O
well O
complimented, O
differentially O
by O
other O
constituents O
present O
in O
sandalwood O
oil, O
thus O
indicating O
synergism O
in O
biological O
activity O
of O
this O
traditionally O
used O
bioresource. O
Serum B-GENE-N
amyloid I-GENE-N
A I-GENE-N
upsurge O
precedes O
standard O
biomarkers O
of O
hepatotoxicity O
in O

ritodrine-injected B-CHEMICAL
mice. O
The O
tocolytic O
agent O
ritodrine B-CHEMICAL
acts O
on O
the O
2-adrenoceptor B-GENE-Y
and O
is O
an O
effective O
treatment O
option O
for O
preterm O
labor. O
However, O
several O
adverse O
effects O
of O
ritodrine B-CHEMICAL
therapy, O
including O
liver O
damage, O
have O
been O
noted. O
To O
elucidate O
the O
underlying O
mechanisms O
of O
ritodrine-induced B-CHEMICAL
adverse O
effects, O
development O
of O
sensitive O
biomarkers O
of O
these O
adverse O
events O
is O
necessary. O
Here, O
we O
report O
the O
development O
and O
analysis O
of O
an O
animal O
model O
of O
ritodrine-induced B-CHEMICAL
liver O
damage. O
Female O
mice O
received O
daily O
ritodrine B-CHEMICAL
injections O
for O
2 O

weeks; O
liver O
samples O
were O
then O
collected O
and O
subjected O
to O
DNA O
microarray O
analysis. O
Ritodrine B-CHEMICAL
significantly O
altered O
the O
expression O
of O
genes O
related O
to O
steroid B-CHEMICAL
and O
lipid O
metabolism, O
as O
well O
as O
the O
metabolism O
of O
ritodrine B-CHEMICAL
itself. O
Importantly, O
expression O
of O
the O
acute-phase O
reactant O
serum B-GENE-N
amyloid I-GENE-N
A I-GENE-N
(SAA) B-GENE-N
significantly O
increased O
after O
ritodrine B-CHEMICAL
injection, O
with O
values O
indicating O
the O
largest O
fold-change. O
This O
large O
increase O
in O
blood O
SAA B-GENE-N
levels O
serves O
as O
a O
more O
sensitive O
biomarker O
than O
conventional O
liver O
enzymes, O
such O
as O
aspartate B-GENE-Y
aminotransferase I-GENE-Y
and O
alanine B-CHEMICAL

aminotransferase. I-GENE-N
The O
increase O
in O
SAA B-GENE-N
expression O
is O
specific O
to O
ritodrine-induced B-CHEMICAL
liver O
damage, O
because O
SAA B-GENE-N
expression O
was O
not O
induced O
by O
other O
hepatotoxic O
drugs O
such O
as O
acetaminophen, B-CHEMICAL
valproic B-CHEMICAL
acid, I-CHEMICAL
or O
metformin. B-CHEMICAL
Our O
in O
vitro O
studies O
showed O
that O
cyclic B-CHEMICAL
adenosine I-CHEMICAL
3',5'-monophosphate I-CHEMICAL
(cAMP) B-CHEMICAL
accumulation O
was O
not O
a O
primary O
cause O
of O
the O
ritodrine-induced B-CHEMICAL
SAA B-GENE-N
increase. O
Instead, O
SAA B-GENE-N
expression O
was O
enhanced O
by O
indirect O
phosphorylation O
of O
the O
signal B-GENE-Y

transducer I-GENE-Y
and I-GENE-Y
activator I-GENE-Y
of I-GENE-Y
transcription-3 I-GENE-Y
(STAT3) B-GENE-Y
mediated O
by O
interleukin-6. B-GENE-Y
Therefore, O
our O
study O
provides O
a O
method O
for O
sensitive O
and O
early O
detection O
of O
hepatic O
injury, O
and O
may O
thus O
help O
preclude O
serious O
liver O
damage O
due O
to O
ritodrine B-CHEMICAL
use O
in O
preterm O
labor. O
Ceftazidime-avibactam: B-CHEMICAL
a O
novel O
cephalosporin/-lactamase B-CHEMICAL
inhibitor O
combination. O
Avibactam B-CHEMICAL
(formerly O
NXL104, B-CHEMICAL
AVE1330A) B-CHEMICAL
is O
a O
synthetic O
non--lactam, B-CHEMICAL

-lactamase B-GENE-N
inhibitor O
that O
inhibits O
the O
activities O
of O
Ambler B-GENE-N
class I-GENE-N
A I-GENE-N
and I-GENE-N
C I-GENE-N
-lactamases I-GENE-N
and O
some O
Ambler B-GENE-N
class I-GENE-N
D I-GENE-N
enzymes. O
This O
review O
summarizes O
the O
existing O
data O
published O
for O
ceftazidime-avibactam, B-CHEMICAL
including O
relevant O
chemistry, O
mechanisms O
of O
action O
and O
resistance, O
microbiology, O
pharmacokinetics, O
pharmacodynamics, O
and O
efficacy O
and O
safety O
data O
from O
animal O
and O
human O
trials. O
Although O
not O
a O
-lactam, B-CHEMICAL
the O
chemical O
structure O
of O
avibactam B-CHEMICAL
closely O
resembles O
portions O
of O
the O
cephem B-CHEMICAL
bicyclic O
ring O

system, O
and O
avibactam B-CHEMICAL
has O
been O
shown O
to O
bond O
covalently O
to O
-lactamases. B-GENE-N
Very O
little O
is O
known O
about O
the O
potential O
for O
avibactam B-CHEMICAL
to O
select O
for O
resistance. O
The O
addition O
of O
avibactam B-CHEMICAL
greatly O
(4-1024-fold O
minimum O
inhibitory O
concentration O
[MIC] O
reduction) O
improves O
the O
activity O
of O
ceftazidime B-CHEMICAL
versus O
most O
species O
of O
Enterobacteriaceae O
depending O
on O
the O
presence O
or O
absence O
of O
-lactamase B-GENE-N
enzyme(s). O
Against O
Pseudomonas O
aeruginosa, O
the O
addition O
of O

avibactam B-CHEMICAL
also O
improves O
the O
activity O
of O
ceftazidime B-CHEMICAL
(~fourfold O
MIC O
reduction). O
Limited O
data O
suggest O
that O
the O
addition O
of O
avibactam B-CHEMICAL
does O
not O
improve O
the O
activity O
of O
ceftazidime B-CHEMICAL
versus O
Acinetobacter O
species O
or O
most O
anaerobic O
bacteria O
(exceptions: O
Bacteroides O
fragilis, O
Clostridium O
perfringens, O
Prevotella O
spp. O
and O
Porphyromonas O
spp.). O
The O
pharmacokinetics O
of O
avibactam B-CHEMICAL
follow O
a O
two-compartment O
model O
and O
do O
not O
appear O

to O
be O
altered O
by O
the O
co-administration O
of O
ceftazidime. B-CHEMICAL
The O
maximum O
plasma O
drug O
concentration O
(C(max)) O
and O
area O
under O
the O
plasma O
concentration-time O
curve O
(AUC) O
of O
avibactam B-CHEMICAL
increase O
linearly O
with O
doses O
ranging O
from O
50 O
mg O
to O
2,000 O
mg. O
The O
mean O
volume O
of O
distribution O
and O
half-life O
of O
22 O
L O
(~0.3 O
L/kg) O
and O
~2 O
hours, O
respectively, O
are O
similar O
to O
ceftazidime. B-CHEMICAL
Like O
ceftazidime, B-CHEMICAL
avibactam B-CHEMICAL
is O
primarily O
renally O
excreted, O
and O
clearance O

correlates O
with O
creatinine B-CHEMICAL
clearance. O
Pharmacodynamic O
data O
suggest O
that O
ceftazidime-avibactam B-CHEMICAL
is O
rapidly O
bactericidal O
versus O
-lactamase-producing B-GENE-N
Gram-negative O
bacilli O
that O
are O
not O
inhibited O
by O
ceftazidime B-CHEMICAL
alone.Clinical O
trials O
to O
date O
have O
reported O
that O
ceftazidime-avibactam B-CHEMICAL
is O
as O
effective O
as O
standard O
carbapenem B-CHEMICAL
therapy O
in O
complicated O
intra-abdominal O
infection O
and O
complicated O
urinary O
tract O
infection, O
including O
infection O
caused O
by O
cephalosporin-resistant B-CHEMICAL
Gram-negative O

isolates. O
The O
safety O
and O
tolerability O
of O
ceftazidime-avibactam B-CHEMICAL
has O
been O
reported O
in O
three O
phase O
I O
pharmacokinetic O
studies O
and O
two O
phase O
II O
clinical O
studies. O
Ceftazidime-avibactam B-CHEMICAL
appears O
to O
be O
well O
tolerated O
in O
healthy O
subjects O
and O
hospitalized O
patients, O
with O
few O
serious O
drug-related O
treatment-emergent O
adverse O
events O
reported O
to O
date.In O
conclusion, O
avibactam B-CHEMICAL
serves O
to O
broaden O
the O
spectrum O
of O
ceftazidime B-CHEMICAL
versus O
-lactamase-producing B-GENE-N
Gram-negative O
bacilli. O
The O
exact O
roles O

for O
ceftazidime-avibactam B-CHEMICAL
will O
be O
defined O
by O
efficacy O
and O
safety O
data O
from O
further O
clinical O
trials. O
Potential O
future O
roles O
for O
ceftazidime-avibactam B-CHEMICAL
include O
the O
treatment O
of O
suspected O
or O
documented O
infections O
caused O
by O
resistant O
Gram-negative-bacilli O
producing O
extended-spectrum B-GENE-N
-lactamase I-GENE-N
(ESBL), B-GENE-N
Klebsiella B-GENE-N
pneumoniae I-GENE-N
carbapenemases I-GENE-N
(KPCs) B-GENE-N
and/or O
AmpC B-GENE-N
-lactamases. I-GENE-N
In O
addition, O
ceftazidime-avibactam B-CHEMICAL
may O
be O

used O
in O
combination O
(with O
metronidazole) B-CHEMICAL
for O
suspected O
polymicrobial O
infections. O
Finally, O
the O
increased O
activity O
of O
ceftazidime-avibactam B-CHEMICAL
versus O
P. O
aeruginosa O
may O
be O
of O
clinical O
benefit O
in O
patients O
with O
suspected O
or O
documented O
P. O
aeruginosa O
infections. O
Increased O
human O
dermal O
microvascular O
endothelial O
cell O
survival O
induced O
by O
cysteamine. B-CHEMICAL
BACKGROUND: O
Cystinosis O
is O
an O
autosomal O
recessive O
disease O
caused O
by O
intralysosomal O
cystine O
accumulation, O
treated O
with O

cysteamine. B-CHEMICAL
Recently, O
new O
adverse O
effects O
of O
cysteamine B-CHEMICAL
were O
reported. O
Skin O
biopsies O
showed O
microvascular O
proliferation O
(angioendotheliomatosis). O
To O
examine O
the O
mechanism O
of O
angioendotheliomatosis O
associated O
with O
cysteamine B-CHEMICAL
toxicity, O
we O
examined O
the O
effect O
of O
cysteamine B-CHEMICAL
on O
human O
dermal O
microvascular O
endothelial O
cells O
(HDMVEC). O
METHODS: O
After O
cysteamine B-CHEMICAL
exposure O
(range O
0-3.0 O
mM) O
during O
24 O
h, O
cell O
viability O
was O
measured O
using O
water O
soluble O
tetrazolium B-CHEMICAL
salt-1 I-CHEMICAL

(WST-1) O
in O
both O
control O
HDMVEC O
and O
fibroblasts. O
Cell O
proliferation O
and O
apoptosis O
rate O
were O
measured O
in O
HDMVEC O
by O
bromodeoxyuridine B-CHEMICAL
(BrdU) B-CHEMICAL
incorporation O
and O
caspase B-GENE-Y
3 I-GENE-Y
and O
caspase B-GENE-Y
7 I-GENE-Y
activity, O
respectively. O
Intracellular O
glutathione B-CHEMICAL
(GSH) B-CHEMICAL
was O
measured O
in O
HDMVEC O
after O
cysteamine B-CHEMICAL
exposure O
of O
0, O
0.1 O
or O
1.0 O
mM. O
Medium O
and O
cysteamine B-CHEMICAL
were O
refreshed O
every O
6 O
h O
to O
mimic O
the O
in O
vivo O
situation. O
Next, O
cell O
viability O

in O
HDMVEC O
was O
measured O
after O
24 O
h O
of O
GSH B-CHEMICAL
exposure O
(range O
0-10.0 O
mM). O
RESULTS: O
HDMVEC O
viability O
and O
proliferation O
increased O
after O
cysteamine B-CHEMICAL
exposure O
0.03-3.0 O
mM O
(p O
< O
0.01) O
and O
0.03-1.0 O
mM O
(p O
= O
0.01) O
respectively; O
cell O
viability O
in O
fibroblasts O
was O
not O
affected O
by O
incubation O
with O
cysteamine. B-CHEMICAL
Apoptosis O
remained O
unaffected O
by O
incubation O
with O
0-1.0 O
mM O

cysteamine, B-CHEMICAL
3.0 O
mM O
caused O
increased O
apoptosis. O
Intracellular O
GSH B-CHEMICAL
was O
significantly O
increased O
after O
incubation O
with O
cysteamine B-CHEMICAL
0.1 O
mM O
(p O
= O
0.02) O
and O
1.0 O
mM O
(p O
< O
0.01). O
HDMVEC O
viability O
increased O
after O
exposure O
to O
GSH B-CHEMICAL
1.0-5.0 O
mM O
(p O
< O
0.01). O
CONCLUSION: O
Cysteamine B-CHEMICAL
concentrations, O
similar O
to O
those O
described O
in O
plasma O
of O
cystinosis O
patients, O
stimulate O
HDMVEC O
viability O
and O
proliferation O
and O
increase O

intracellular O
GSH B-CHEMICAL
content. O
We O
postulate O
that O
this O
mechanism O
might O
underlie O
angioendotheliomatosis O
induced O
by O
cysteamine. B-CHEMICAL
Novel O
locus O
including O
FGF21 B-GENE-Y
is O
associated O
with O
dietary O
macronutrient O
intake. O
Dietary O
intake O
of O
macronutrients O
(carbohydrate, B-CHEMICAL
protein, O
and O
fat) O
has O
been O
associated O
with O
risk O
of O
chronic O
conditions O
such O
as O
obesity O
and O
diabetes. O
Family O
studies O
have O
reported O
a O
moderate O
contribution O
of O
genetics O
to O
variation O
in O
macronutrient O
intake. O
In O
a O
genome-wide O
meta-analysis O
of O
a O
population-based O
discovery O
cohort O
(n O
= O
33 O

533), O
rs838133 O
in O
FGF21 B-GENE-Y
(19q13.33), O
rs197273 O
near O
TRAF B-GENE-Y
family I-GENE-Y
member-associated I-GENE-Y
NF-kappa-B I-GENE-Y
activator I-GENE-Y
(TANK) B-GENE-Y
(2p24.2), O
and O
rs10163409 O
in O
FTO B-GENE-Y
(16q12.2) O
were O
among O
the O
top O
associations O
(P O
< O
10(-5)) O
for O
percentage O
of O
total O
caloric O
intake O
from O
protein O
and O
carbohydrate. B-CHEMICAL
rs838133 O
was O
replicated O
in O
silico O
in O
an O
independent O
sample O

from O
the O
Cohorts O
for O
Heart O
and O
Aging O
Research O
in O
Genomic O
Epidemiology O
Consortium O
(CHARGE) O
Nutrition O
Working O
Group O
(n O
= O
38 O
360) O
and O
attained O
genome-wide O
significance O
in O
combined O
analysis O
(Pjoint O
= O
7.9 O
 O
10(-9)). O
A O
cytokine B-GENE-N
involved O
in O
cellular O
metabolism, O
FGF21 B-GENE-Y
is O
a O
potential O
susceptibility O
gene O
for O
obesity O
and O
type O
2 O
diabetes. O
Our O
results O
highlight O
the O
potential O
of O
genetic O
variation O
for O
determining O
dietary O
macronutrient O
intake. O
Investigation O
of O
astatine(III) B-CHEMICAL
hydrolyzed O
species: O
experiments O
and O

relativistic O
calculations. O
This O
work O
aims O
to O
resolve O
some O
controversies O
about O
astatine(III) B-CHEMICAL
hydroxide I-CHEMICAL
species O
present O
in O
oxidant O
aqueous O
solution. O
AtO(+) B-CHEMICAL
is O
the O
dominant O
species O
existing O
under O
oxidizing O
and O
acidic O
pH O
conditions. O
This O
is O
consistent O
with O
high-performance O
ion-exchange O
chromatography O
data O
showing O
the O
existence O
of O
one O
species O
holding O
one O
positive O
charge. O
A O
change O
in O
speciation O
occurs O
as O
the O
pH O
changes O
from O
1 O
to O
4, O
while O
remaining O
under O
oxidizing O
conditions. O
Dynamic O
experiments O
with O
ion-exchange O
resins O
evidence O
the O
existence O
of O
a O
neutral O
species O
witnessed O

by O
its O
elution O
in O
the O
void O
volume. O
Batch-experiments O
using O
a O
competition O
method O
show O
the O
exchange O
of O
one O
proton O
indicating O
the O
formation O
of O
the O
AtO(OH) B-CHEMICAL
species. O
The O
hydrolysis O
thermodynamic O
constant, O
extrapolated O
to O
zero O
ionic O
strength, O
was O
determined O
to O
be O
10(-1.9). O
This O
value O
is O
supported O
by O
two-component O
relativistic O
quantum O
calculations O
and O
therefore O
allows O
disclosing O
unambiguously O
the O
structure O
of O
the O
formed O
species. O
Trim24-repressed B-GENE-Y
VL30 B-GENE-N
retrotransposons I-GENE-N
regulate O
gene O
expression O
by O
producing O
noncoding O
RNA. O

Trim24 B-GENE-Y
(Tif1) B-GENE-Y
and O
Trim33 B-GENE-Y
(Tif1) B-GENE-Y
interact O
to O
form O
a O
co-repressor O
complex O
that O
suppresses O
murine O
hepatocellular O
carcinoma. O
Here O
we O
show O
that O
Trim24 B-GENE-Y
and O
Trim33 B-GENE-Y
cooperatively O
repress O
retinoic B-GENE-N
acid I-GENE-N
receptor-dependent I-GENE-N
activity O
of O
VL30-class B-GENE-N
endogenous O
retroviruses O
(ERVs) O
in O
liver. O
In O
Trim24-knockout B-GENE-Y
hepatocytes, O
VL30 B-GENE-N
derepression O
leads O
to O
accumulation O
of O
reverse-transcribed O
VL30 B-GENE-N
cDNA O
in O
the O
cytoplasm O
that O

correlates O
with O
activation O
of O
the O
viral-defense O
interferon B-GENE-N
responses O
mimicking O
the O
preneoplastic O
inflammatory O
state O
seen O
in O
human O
liver O
following O
exogenous O
viral O
infection. O
Furthermore, O
upon O
derepression, O
VL30 B-GENE-N
long I-GENE-N
terminal I-GENE-N
repeats I-GENE-N
(LTRs) B-GENE-N
act O
as O
promoter B-GENE-N
and I-GENE-N
enhancer I-GENE-N
elements I-GENE-N
deregulating O
expression O
of O
neighboring O
genes O
and O
generating O
enhancer O
RNAs O
that O
are O
required O
for O
LTR B-GENE-N
enhancer I-GENE-N
activity O
in O
hepatocytes O
in O
vivo. O
These O
data O
reinforce O
the O
role O
of O
the O
TRIM B-GENE-N
family O
of O
proteins O
in O
retroviral O
restriction O
and O
antiviral O
defense O
and O
provide O
an O
example O
of O
an O
ERV-derived O

oncogenic O
regulatory O
network. O
Apelin B-GENE-Y
inhibits O
diet-induced O
obesity O
by O
enhancing O
lymphatic O
and O
blood O
vessel O
integrity. O
Angiogenesis O
is O
tightly O
associated O
with O
the O
outgrowth O
of O
adipose O
tissue, O
leading O
to O
obesity, O
which O
is O
a O
risk O
factor O
for O
type O
2 O
diabetes O
and O
hypertension, O
mainly O
because O
expanding O
adipose O
tissue O
requires O
an O
increased O
nutrient O
supply O
from O
blood O
vessels. O
Therefore, O
induction O
of O
vessel O
abnormality O
by O
adipokines B-GENE-N
has O
been O
well O
studied, O
whereas O
how O
altered O
vascular O
function O
promotes O
obesity O
is O
relatively O
unexplored. O
Also, O
surviving O
Prox1 B-GENE-Y
heterozygous O
mice O

showed O
abnormal O
lymphatic O
patterning O
and O
adult-onset O
obesity, O
indicating O
that O
accumulation O
of O
adipocytes O
could O
be O
closely O
linked O
with O
lymphatic O
function. O
Here O
we O
propose O
a O
new O
anti-obesity O
strategy O
based O
on O
enhancement O
of O
lymphatic O
and O
blood O
vessel O
integrity O
with O
apelin. B-GENE-Y
Apelin-knockout B-GENE-Y
mice O
given O
a O
high-fat O
diet O
showed O
an O
obese O
phenotype O
associated O
with O
abnormal O
lymphatic O
and O
blood O
vessel O
enlargement. O
Fatty B-CHEMICAL
acids I-CHEMICAL
present O
in O
the O
high-fat O
diet O
induced O
hyperpermeability O
of O
endothelial O
cells, O
causing O
adipocyte O
differentiation, O
whereas O
apelin O
promoted O

vascular O
stabilization. O
Moreover, O
treatment O
of O
high-fat-diet-fed O
apelin-knockout B-GENE-Y
mice O
with O
a O
selective O
cyclooxygenase-2 B-GENE-Y
inhibitor, O
celecoxib, B-CHEMICAL
improved O
vascular O
function, O
and O
also O
attenuated O
obesity. O
Finally, O
apelin B-GENE-Y
transgenic O
mice O
showed O
decreased O
subcutaneous O
adipose O
tissue O
owing O
to O
inhibition O
of O
high-fat-diet-induced O
hyperpermeability O
of O
vessels. O
These O
results O
indicate O
that O
apelin O
inhibits O
high-fat-diet-induced O
obesity O
by O
enhancing O
vessel O
integrity. O
Apelin B-GENE-Y
could O
serve O
as O
a O
therapeutic O
target O
for O
treating O

obesity O
and O
related O
diseases. O
Activation O
of O
the O
anti-cancer O
agent O
upamostat B-CHEMICAL
by O
the O
mARC B-GENE-N
enzyme O
system. O
Abstract O
1. O
Upamostat B-CHEMICAL
(Mesupron) B-CHEMICAL
is O
a O
new O
small O
molecule O
serine B-GENE-N
protease I-GENE-N
inhibitor. O
The O
drug O
candidate O
was O
developed O
to O
inhibit O
the O
urokinase-type B-GENE-Y
plasminogen I-GENE-Y
activator I-GENE-Y
(uPA) B-GENE-Y
system, O
which O
plays O
a O
major O
role O
in O
tumor O
invasion O
and O
metastasis. O
Upamostat B-CHEMICAL
is O
currently O
in O
clinical O
development O
as O
an O
anti-metastatic O
and O
non-cytotoxic O
agent O
against O
pancreatic O
and O
breast O

cancer. O
2. O
Upamostat B-CHEMICAL
is O
the O
orally O
available O
amidoxime- B-CHEMICAL
(i.e. O
hydroxyamidine-) B-CHEMICAL
prodrug O
of O
the O
pharmacologically O
active O
form, O
WX-UK1. B-CHEMICAL
In O
this O
study, O
the O
reductive O
enzymatic O
activation O
of O
upamostat B-CHEMICAL
to O
its O
corresponding O
amidine O
WX-UK1 B-CHEMICAL
was O
analyzed. O
3. O
The O
recently O
discovered O
molybdenum B-CHEMICAL
enzyme O
"mitochondrial B-GENE-N
Amidoxime I-GENE-N
Reducing I-GENE-N
Component" I-GENE-N
(mARC) B-GENE-N
catalyses O
together O
with O
its O
electron B-GENE-N
transport I-GENE-N
proteins I-GENE-N
cytochrome B-GENE-Y
b(5) I-GENE-Y
and O

NADH B-GENE-N
cytochrome I-GENE-N
b(5) I-GENE-N
reductase I-GENE-N
the O
reduction O
of O
N-hydroxylated B-CHEMICAL
prodrugs. O
In O
vitro O
biotransformation O
assays O
with O
porcine O
subcellular O
fractions O
and O
the O
reconstituted O
human O
enzymes O
demonstrate O
an O
mARC-dependent B-GENE-N
N-reduction B-CHEMICAL
of O
upamostat. B-CHEMICAL
Differential O
autophagic O
cell O
death O
under O
stress O
with O
ectopic O
cytoplasmic O
and O
mitochondrial-specific O
PPP2R2B B-GENE-Y
in O
human O
neuroblastoma O
cells. O
Protein B-GENE-N
phosphatase I-GENE-N
2A I-GENE-N
is O
one O
of O
four O
major O
classes O
of O

serine/threonine B-CHEMICAL
phosphatases. I-GENE-N
Overexpression O
of O
brain-specific O
regulatory O
subunit O
PPP2R2 B-GENE-N
in O
neuron O
cells O
is O
implicated O
in O
pathogenesis. O
The O
alternative O
splicing O
of O
PPP2R2B B-GENE-Y
encodes O
two O
isoforms. O
They O
are O
subunit O
of O
cytoplasmic O
specific O
B1 B-GENE-Y
and O
mitochondria-targeted O
B2. B-GENE-Y
The O
two O
constructs O
were O
transfected O
into O
human O
neuroblastoma O
cells, O
SK-N-SH, O
respectively, O
and O
the O
stable O
clones O
overexpressing O
either O
B1 B-GENE-Y
or O
B2 B-GENE-Y
established. O
We O
have O
reported O

that O
B2 B-GENE-Y
clones O
are O
sensitive O
to O
reactive O
oxygen B-CHEMICAL
species O
(ROS) O
treatment O
by O
inducing O
autophagic O
cell O
death. O
To O
study O
more O
on O
the O
onset O
of O
neuropathogenesis O
under O
strain, O
both O
clones O
were O
exposed O
to O
different O
environmental O
stress, O
e.g. O
starvation O
and O
endoplasmic O
reticulum O
(ER) O
stress. O
To O
learn O
how O
PPP2R2B B-GENE-N
overexpression O
responds O
to O
starvation, O
cells O
were O
incubated O
in O
Hank's O
buffered O
salt O
solution O
of O
deprived O
nutrient. O
Cell O
death O
was O
induced O
in O
B1 B-GENE-Y
clones O
after O
6 O
h O
starvation, O
but O
not O
in O
B2 B-GENE-Y

clones. O
The O
pharmacological O
inhibitor, O
Bafilomycin B-CHEMICAL
A1, I-CHEMICAL
rescued O
the O
cell O
death O
while O
suppressing O
autophagy. O
On O
the O
other O
hand, O
to O
assess O
how O
cells O
respond O
to O
ER O
stress, O
the O
cells O
were O
treated O
with O
0.1 O
M O
of O
N-glycosylation B-CHEMICAL
inhibitor, O
tunicamycin B-CHEMICAL
(TM). O
In O
contrast O
with O
B1, B-GENE-Y
the O
apoptotic O
cell O
death O
appeared O
in O
B2 B-GENE-Y
after O
48 O
h O
treatment. O
The O
formation O
of O
autophagolysosome O
was O
detected O
in O
B2 B-GENE-N
following O
12 O
h O
treatment O
with O
TM O
as O
evidenced O
by O
lysotracker O
and O

GFP-LC3 O
staining O
for O
fluorescence O
microscopy O
analysis. O
The O
autophagy O
inhibitor, O
3-methyladenine, B-CHEMICAL
salvaged O
the O
final O
apoptosis. O
The O
stable O
cell O
lines O
with O
ectopically O
transfected O
PPP2R2B B-GENE-Y
genes O
encoding O
isoforms O
of O
brain-specific O
regulatory O
subunit O
exhibit O
distinct O
apoptosis O
under O
different O
stressors. O
The O
induced O
autophagic O
apoptotic O
cell O
death O
is O
related O
to O
mitochondrial O
membrane O
potential O
drop O
and O
ROS O
generation. O
Disturbance O
of O
autophagy O
alleviates O
the O
induced O
cell O
death. O
The O
results O
promised O
a O
good O
model O
for O
understanding O
the O
onset O
in O

pathogenesis O
under O
stress O
in O
neuron O
cells O
with O
aberrant O
PPP2R2B B-GENE-Y
expression. O
Population O
pharmacokinetics O
of O
atorvastatin B-CHEMICAL
and O
its O
active O
metabolites O
in O
children O
and O
adolescents O
with O
heterozygous O
familial O
hypercholesterolemia: O
selective O
use O
of O
informative O
prior O
distributions O
from O
adults. O
The O
population O
pharmacokinetics O
(PPK) O
of O
atorvastatin B-CHEMICAL
and O
its O
principal O
active O
metabolite, O
o-hydroxyatorvastatin, B-CHEMICAL
were O
described O
in O
6-17 O
years O
old O
pediatric O
hypercholesterolemia O
patients O

with O
a O
2-compartment O
model O
for O
both O
parent O
and O
metabolite. O
Informative O
prior O
distributions O
on O
selected O
parameters, O
based O
on O
adult O
data, O
were O
required O
to O
stabilize O
the O
model O
and O
were O
implemented O
using O
a O
Bayesian O
penalty O
term O
on O
the O
likelihood O
function O
in O
the O
nonlinear O
mixed O
effects O
model O
(NONMEM O
VI O
with O
PRIOR). O
Concentrations O
below O
the O
limit O
of O
quantitation O
were O
treated O
as O
censored O
data O
using O
a O
conditional O
likelihood O
function. O
Atorvastatin B-CHEMICAL
apparent O
oral O
clearance O
(CL/F) O
was O
described O
as O
a O
function O
of O
body O
weight O
using O
an O
allometric O
equation. O
Based O
on O
the O
final O
model, O
the O

typical O
CL/F O
estimates O
for O
a O
Tanner O
Stage O
1 O
patient O
(35 O
kg O
weight) O
and O
Tanner O
Stage O
2 O
(50 O
kg O
weight), O
would O
be O
553 O
and O
543 O
L/hour, O
respectively. O
When O
scaled O
allometrically, O
CL/F O
was O
similar O
to O
values O
reported O
for O
adults. O
Variability O
in O
atorvastatin B-CHEMICAL
PK O
was O
primarily O
affected O
by O
weight. O
A O
high-confidence O
interaction O
map O
identifies O
SIRT1 B-GENE-Y
as O
a O
mediator O
of O
acetylation O
of O
USP22 B-GENE-Y
and O
the O
SAGA B-GENE-N
coactivator O
complex. O
Although O
many O
functions O
and O
targets O
have O
been O
attributed O
to O
the O
histone B-GENE-N
and O
protein B-GENE-N

deacetylase I-GENE-N
SIRT1, B-GENE-Y
a O
comprehensive O
analysis O
of O
SIRT1 B-GENE-Y
binding O
proteins O
yielding O
a O
high-confidence O
interaction O
map O
has O
not O
been O
established. O
Using O
a O
comparative O
statistical O
analysis O
of O
binding O
partners, O
we O
have O
assembled O
a O
high-confidence O
SIRT1 B-GENE-Y
interactome. O
Employing O
this O
method, O
we O
identified O
the O
deubiquitinating O
enzyme O
ubiquitin-specific B-GENE-Y
protease I-GENE-Y
22 I-GENE-Y
(USP22), B-GENE-Y
a O
component O
of O
the O
deubiquitinating O
module O
(DUBm) O
of O
the O
SAGA B-GENE-N
transcriptional O
coactivating O
complex, O
as O
a O
SIRT1-interacting B-GENE-Y
partner. O
We O
found O
that O

this O
interaction O
is O
highly O
specific, O
requires O
the O
ZnF-UBP B-CHEMICAL
domain I-GENE-N
of O
USP22, B-GENE-Y
and O
is O
disrupted O
by O
the O
inactivating O
H363Y B-GENE-N
mutation O
within O
SIRT1. B-GENE-Y
Moreover, O
we O
show O
that O
USP22 B-GENE-Y
is O
acetylated O
on O
multiple O
lysine B-CHEMICAL
residues O
and O
that O
alteration O
of O
a O
single O
lysine B-CHEMICAL
(K129) O
within O
the O
ZnF-UBP B-CHEMICAL
domain I-GENE-N
is O
sufficient O
to O
alter O
interaction O
of O
the O
DUBm B-GENE-N
with O
the O
core O
SAGA B-GENE-N
complex. O
Furthermore, O
USP22-mediated B-GENE-Y
recruitment O
of O
SIRT1 B-GENE-Y
activity O
promotes O
the O
deacetylation O
of O
individual O
SAGA B-GENE-N
complex O

components. O
Our O
results O
indicate O
an O
important O
role O
of O
SIRT1-mediated B-GENE-Y
deacetylation O
in O
regulating O
the O
formation O
of O
DUBm B-GENE-N
subcomplexes O
within O
the O
larger O
SAGA B-GENE-N
complex. O
Characterization O
of O
cytosolic B-GENE-Y
glutathione I-GENE-Y
peroxidase I-GENE-Y
and O
phospholipid-hydroperoxide B-GENE-N
glutathione I-GENE-N
peroxidase I-GENE-N
genes O
in O
rainbow O
trout O
(Oncorhynchus O
mykiss) O
and O
their O
modulation O
by O
in O
vitro O
selenium B-CHEMICAL
exposure. O
Selenium B-CHEMICAL
(Se) B-CHEMICAL
is O
an O
oligonutrient O
with O
both O
essential O
biological O
functions O
and O
recognized O
harmful O
effects. O
As O

the O
selenocysteine B-CHEMICAL
(SeCys) B-CHEMICAL
amino B-CHEMICAL
acid, I-CHEMICAL
selenium B-CHEMICAL
is O
integrated O
in O
several O
Se-containing B-CHEMICAL
proteins O
(selenoproteins), O
many O
of O
which O
are O
fundamental O
for O
cell O
homeostasis. O
Nevertheless, O
selenium O
may O
exert O
toxic O
effects O
at O
levels O
marginally O
above O
those O
required, O
mainly O
through O
the O
generation O
of O
reactive O
oxygen B-CHEMICAL
species O
(ROS). O
The O
selenium B-CHEMICAL
chemical O
speciation O
can O
strongly O
affect O
the O
bioavailability O
of O
this O
metal O
and O
its O
impact O
on O
metabolism, O
dictating O
the O
levels O
that O
can O
be O
beneficial O
or O
detrimental O
towards O
an O
organism. O
Glutathione B-GENE-N
peroxidase I-GENE-N

(GPxs) B-GENE-N
is O
the O
largest O
and O
the O
most O
studied O
selenoprotein B-GENE-N
family. O
Cytosolic B-GENE-Y
glutathione I-GENE-Y
peroxidase I-GENE-Y
(cGPx, B-GENE-Y
GPx1) B-GENE-Y
and O
phospholipid B-GENE-N
hydroperoxide I-GENE-N
glutathione I-GENE-N
peroxidase I-GENE-N
(PHGPx, B-GENE-N
GPx4) B-GENE-N
are O
widely O
distributed O
throughout O
tissues, O
and O
play O
a O
pivotal O
role O
in O
regulating O
the O
oxidative O
status O
in O
the O
cell. O
In O
this O
study O
we O
have O
cloned O
GPx1 B-GENE-Y
and O
GPx4 B-GENE-N
genes O
in O
rainbow O
trout O
(Oncorhynchus O
mykiss). O
The O
constitutive O
mRNA O

expression O
of O
these O
GPx B-GENE-N
genes O
was O
examined O
in O
18 O
trout O
tissues O
and O
their O
responsiveness O
to O
Se O
availability O
was O
analysed O
using O
a O
rainbow O
trout O
liver O
cell O
line O
(RTL). O
An O
inorganic O
(sodium B-CHEMICAL
selenite, I-CHEMICAL
Na2SeO3) B-CHEMICAL
and O
organic O
(selenocysteine, B-CHEMICAL
Cys-Se-Se-Cys) B-CHEMICAL
selenocompound O
have O
been O
used O
as O
Se B-CHEMICAL
sources. O
GPx1 B-GENE-Y
activity O
was O
also O
tested O
to O
verify O
the O
impact O
of O
transcript O
changes O
on O
the O
enzymatic O
function O
of O
these O
molecules. O
To O
understand O
if O
the O
results O
obtained O
from O
the O
transcript O
expression O
analysis O

were O
due O
to O
Se B-CHEMICAL
bioavailability O
or O
generation O
of O
ROS, O
the O
cytoxicity O
of O
the O
two O
selenocompounds O
was O
tested O
by O
measuring O
the O
impact O
of O
Se B-CHEMICAL
on O
cell O
membrane O
integrity. O
Lastly, O
Se B-CHEMICAL
availability O
was O
quantified O
by O
mass O
spectrophotometry O
to O
determine O
the O
amount O
of O
Se B-CHEMICAL
in O
the O
cell O
culture O
media, O
the O
Se B-CHEMICAL
background O
due O
to O
the O
foetal O
calf O
serum O
supplement O
and O
the O
contribution O
from O
the O
two O
selenocompounds O
used O
in O
the O
treatments. O
Three O
isoforms O
of O
genes O
for O
both O
GPx1 B-GENE-Y
(GPx1a, B-GENE-N
1b1 I-GENE-N
and I-GENE-N
1b2) I-GENE-N
and O

GPx4 B-GENE-N
(GPx4a1, B-GENE-N
a2 I-GENE-N
and I-GENE-N
b) I-GENE-N
have O
been O
identified. O
The O
discovery O
of O
a O
third O
gene O
encoding O
for O
GPx1 B-GENE-Y
and O
GPx4 B-GENE-N
hints O
that O
salmonids O
may O
have O
the O
biggest O
selenoproteome O
amongst O
all O
vertebrates. O
Transcripts O
of O
GPx4 B-GENE-N
genes O
were O
more O
highly O
expressed O
in O
most O
tissues O
examined O
in O
vivo O
(except O
blood, O
head O
kidney O
and O
spleen), O
whereas O
those O
of O
the O
GPx1 B-GENE-Y
genes O
were O
more O
responsive O
to O
selenium B-CHEMICAL
exposure O
in O
vitro, O
especially O
to O
the O
organic O
form. O
Interestingly, O
GPx1a B-GENE-Y
was O
the O
most O
sensitive O
to O

selenium B-CHEMICAL
availability O
in O
non O
stressful O
conditions, O
whereas O
GPx1b1 B-GENE-Y
and O
GPx1b2 B-GENE-Y
were O
highly O
induced O
by O
exposure O
to O
selenium B-CHEMICAL
levels O
that O
had O
some O
toxic O
effects O
on O
the O
cells. O
Although O
the O
different O
concentrations O
tested O
of O
the O
two O
selenocompounds O
modulate O
GPx1 B-GENE-Y
transcript O
expression O
to O
various O
degrees, O
no O
significant O
change O
of O
GPx1 B-GENE-Y
enzymatic O
activity O
was O
detectable. O
Our O
results O
lead O
us O
to O
conclude O
that O
trout O
GPx1 B-GENE-Y
transcripts O
expression O
level O
may O
represent O
a O
sensitive O
biomarker O
for O
selenium B-CHEMICAL
intake, O
helping O
to O
evaluate O
if O
selenium B-CHEMICAL
concentration O
and O
chemical O
speciation O
impact O
on O

cell O
homeostasis. O
Manganese-exposed B-CHEMICAL
developing O
rats O
display O
motor O
deficits O
and O
striatal O
oxidative O
stress O
that O
are O
reversed O
by O
Trolox. B-CHEMICAL
While O
manganese B-CHEMICAL
(Mn) B-CHEMICAL
is O
essential O
for O
proper O
central O
nervous O
system O
(CNS) O
development, O
excessive O
Mn B-CHEMICAL
exposure O
may O
lead O
to O
neurotoxicity. O
Mn B-CHEMICAL
preferentially O
accumulates O
in O
the O
basal O
ganglia, O
and O
in O
adults O
it O
may O
cause O
Parkinson's O
disease-like O
disorder. O
Compared O
to O
adults, O
younger O
individuals O
accumulate O
greater O
Mn B-CHEMICAL
levels O
in O
the O
CNS O
and O
are O
more O
vulnerable O
to O
its O
toxicity. O
Moreover, O
the O
mechanisms O

mediating O
developmental O
Mn-induced B-CHEMICAL
neurotoxicity O
are O
not O
completely O
understood. O
The O
present O
study O
investigated O
the O
developmental O
neurotoxicity O
elicited O
by O
Mn B-CHEMICAL
exposure O
(5, O
10 O
and O
20 O
mg/kg; O
i.p.) O
from O
postnatal O
day O
8 O
to O
PN27 O
in O
rats. O
Neurochemical O
analyses O
were O
carried O
out O
on O
PN29, O
with O
a O
particular O
focus O
on O
striatal O
alterations O
in O
intracellular O
signaling O
pathways O
(MAPKs, B-GENE-N
Akt B-GENE-N
and O
DARPP-32), B-GENE-Y
oxidative O
stress O
generation O
and O
cell O
death. O
Motor O
alterations O
were O
evaluated O
later O
in O
life O

at O
3, O
4 O
or O
5 O
weeks O
of O
age. O
Mn B-CHEMICAL
exposure O
(20 O
mg/kg) O
increased O
p38(MAPK) B-GENE-N
and O
Akt B-GENE-N
phosphorylation, O
but O
decreased O
DARPP-32-Thr-34 B-GENE-Y
phosphorylation. O
Mn B-CHEMICAL
(10 O
and O
20 O
mg/kg) O
increased O
caspase B-GENE-N
activity O
and O
F(2)-isoprostane B-CHEMICAL
production O
(a O
biological O
marker O
of O
lipid O
peroxidation). O
Paralleling O
the O
changes O
in O
striatal O
biochemical O
parameters, O
Mn B-CHEMICAL
(20 O
mg/kg) O
also O
caused O
motor O
impairment, O
evidenced O
by O
increased O

falling O
latency O
in O
the O
rotarod O
test, O
decreased O
distance O
traveled O
and O
motor O
speed O
in O
the O
open-field O
test. O
Notably, O
the O
antioxidant O
Trolox B-CHEMICAL
reversed O
the O
Mn B-CHEMICAL
(20 O
mg/kg)-dependent O
augmentation O
in O
p38(MAPK) B-GENE-N
phosphorylation O
and O
reduced O
the O
Mn B-CHEMICAL
(20 O
mg/kg)-induced O
caspase B-GENE-N
activity O
and O
F(2)-isoprostane B-CHEMICAL
production. O
Trolox B-CHEMICAL
also O
reversed O
the O
Mn-induced B-CHEMICAL
motor O
coordination O
deficits. O
These O
findings O
are O
the O
first O
to O
show O
that O
long-term O
exposure O
to O
Mn B-CHEMICAL
during O
a O
critical O
period O
of O

neurodevelopment O
causes O
motor O
coordination O
dysfunction O
with O
parallel O
increment O
in O
oxidative O
stress O
markers, O
p38(MAPK) B-GENE-N
phosphorylation O
and O
caspase B-GENE-N
activity O
in O
the O
striatum. O
Moreover, O
we O
establish O
Trolox B-CHEMICAL
as O
a O
potential O
neuroprotective O
agent O
given O
its O
efficacy O
in O
reversing O
the O
Mn-induced B-CHEMICAL
neurodevelopmental O
effects. O
Nocapyrones B-CHEMICAL
H-J, I-CHEMICAL
3,6-Disubstituted B-CHEMICAL
-Pyrones I-CHEMICAL
from O
the O
Marine O
Actinomycete O
Nocardiopsis O
sp. O
KMF-001. O

Three O
new O
3,6-disubstituted B-CHEMICAL
-pyrones, I-CHEMICAL
nocapyrones B-CHEMICAL
H-J I-CHEMICAL
(1-3), O
were O
isolated O
from O
the O
marine O
actinomycete O
Nocardiopsis O
sp. O
KMF-001. O
Their O
structures O
were O
assigned O
to O
be O
3-alkylated B-CHEMICAL
6-(1-methyl-1-propenyl)-2H-pyran-2-ones I-CHEMICAL
on O
the O
basis O
of O
UV, O
MS, O
NMR, O
and O
high O
resolution O
(HR)-FAB-MS O
analyses. O
Nocapyrone B-CHEMICAL
H I-CHEMICAL
(1) O
reduced O
the O

pro-inflammatory O
factor O
such O
as O
nitric B-CHEMICAL
oxide I-CHEMICAL
(NO), B-CHEMICAL
prostaglandin B-CHEMICAL
E2 I-CHEMICAL
(PGE2) B-CHEMICAL
and O
interleukin-1 B-GENE-Y
(IL-1). B-GENE-Y
Moreover, O
nocapyrone B-CHEMICAL
H I-CHEMICAL
showed O
5.82% O
stronger O
inhibitory O
effect O
on O
NO B-CHEMICAL
production O
than O
chrysin O
at O
a O
concentration O
of O
10 O
m O
in O
lipopolysaccharide O
(LPS)-stimulated O
BV-2 O
microglial O
cells. O
Investigating O
the O
enteroenteric O
recirculation O
of O
apixaban, B-CHEMICAL
a O
factor B-GENE-N
Xa I-GENE-N
inhibitor: O
administration O
of O
activated O
charcoal O
to O
bile O

duct-cannulated O
rats O
and O
dogs O
receiving O
an O
intravenous O
dose O
and O
use O
of O
drug O
transporter O
knockout O
rats. O
The O
study O
described O
here O
investigated O
the O
impact O
of O
intestinal O
excretion O
(IE; O
excretion O
of O
drug O
directly O
from O
circulation O
to O
intestinal O
lumen), O
enteroenteric O
recirculation O
(EER), O
and O
renal O
tubule O
recirculation O
(RTR) O
on O
apixaban B-CHEMICAL
pharmacokinetics O
and O
disposition. O
The O
experimental O
approaches O
involve O
integrating O
apixaban B-CHEMICAL
elimination O
pathways O
with O
pharmacokinetic O
profiles O
obtained O
from O
bile O

duct-cannulated O
(BDC) O
rats O
and O
dogs O
receiving O
i.v. O
doses O
together O
with O
oral O
administration O
of O
activated O
charcoal B-CHEMICAL
(AC). O
Additionally, O
the O
role O
of O
P-gp B-GENE-Y
(P-glycoprotein; B-GENE-Y
abcb1) B-GENE-Y
and O
BCRP B-GENE-Y
(breast B-GENE-Y
cancer I-GENE-Y
resistance I-GENE-Y
protein; I-GENE-Y
abcg2) B-GENE-Y
in O
apixaban B-CHEMICAL
disposition O
was O
evaluated O
in O
experiments O
using O
transporter O
inhibitors O
and O
transporter O
knockout O
(KO) O
rats. O
Approximately O
20-50% O
of O
an O
apixaban B-CHEMICAL
i.v. O
dose O
was O
found O
in O
feces O
of O
BDC O
rats O
and O
dogs, O
suggesting O
IE O

leading O
to O
fecal O
elimination O
and O
intestinal O
clearance O
(IC). O
The O
fecal O
elimination, O
IC, O
and O
systemic O
clearance O
of O
apixaban B-CHEMICAL
were O
increased O
upon O
AC O
administration O
in O
both O
BDC O
rats O
and O
dogs O
and O
were O
decreased O
in O
BDC O
rats O
dosed O
with O
GF-120918, B-CHEMICAL
a O
dual O
BCRP B-GENE-Y
and O
P-gp B-GENE-N
inhibitor). O
BCRP B-GENE-Y
appeared O
to O
play O
a O
more O
important O
role O
for O
absorption O
and O
intestinal O
and O
renal O
elimination O
of O
apixaban B-CHEMICAL
than O
P-gp B-GENE-N
in O
transporter-KO O
rats O
after O
oral O
and O
i.v. O
dosing, O
which O
led O
to O
a O
higher O
level O

of O
active O
renal O
excretion O
in O
rat O
than O
other O
species. O
These O
data O
demonstrate O
that O
apixaban B-CHEMICAL
undergoes O
IE, O
EER, O
and O
RTR O
that O
are O
facilitated O
by O
efflux O
transporters. O
Intestinal O
reabsorption O
of O
apixaban B-CHEMICAL
could O
be O
interrupted O
by O
AC O
even O
at O
3 O
hours O
post-drug O
dose O
in O
dogs O
(late O
charcoal B-CHEMICAL
effect). O
This O
study O
demonstrates O
that O
the O
intestine O
is O
an O
organ O
for O
direct O
clearance O
and O
redistribution O
of O
apixaban. B-CHEMICAL
The O
IE, O
EER, O
and O
RTR O
contribute O
to O
overall O
pharmacokinetic O
profiles O
of O

apixaban. B-CHEMICAL
IE O
as O
a O
clearance O
pathway, O
balanced O
with O
metabolism O
and O
renal O
excretion, O
helps O
decrease O
the O
impacts O
of O
intrinsic O
(renal O
or O
hepatic O
impairment) O
and O
extrinsic O
(drug-drug O
interactions) O
factors O
on O
apixaban B-CHEMICAL
disposition. O
Cloning, O
Characterization, O
and O
Sulfonamide B-CHEMICAL
and O
Thiol B-CHEMICAL
Inhibition O
Studies O
of O
an O
-Carbonic B-GENE-Y
Anhydrase I-GENE-Y
from O
Trypanosoma O
cruzi, O
the O
Causative O
Agent O
of O
Chagas O
Disease. O
An O
-carbonic B-GENE-Y
anhydrase I-GENE-Y
(CA, B-GENE-Y
EC B-GENE-Y

4.2.1.1) I-GENE-Y
has O
been O
identified, O
cloned, O
and O
characterized O
from O
the O
unicellular O
protozoan O
Trypanosoma O
cruzi, O
the O
causative O
agent O
of O
Chagas O
disease. O
The O
enzyme O
(TcCA) B-GENE-Y
has O
a O
very O
high O
catalytic O
activity O
for O
the O
CO(2) B-CHEMICAL
hydration O
reaction, O
being O
similar O
kinetically O
to O
the O
human O
(h) O
isoform O
hCA B-GENE-Y
II, I-GENE-Y
although O
it O
is O
devoid O
of O
the O
His64 B-CHEMICAL
proton O
shuttle. O
A O
large O
number O
of O
aromatic/heterocyclic B-CHEMICAL
sulfonamides I-CHEMICAL
and O
some O

5-mercapto-1,3,4-thiadiazoles B-CHEMICAL
were O
investigated O
as O
TcCA B-GENE-Y
inhibitors. O
The O
aromatic B-CHEMICAL
sulfonamides I-CHEMICAL
were O
weak O
inhibitors O
(K(I) O
values O
of O
192 O
nM O
to O
84 O
M), O
whereas O
some O
heterocyclic O
compounds O
inhibited O
the O
enzyme O
with O
K(I) O
values O
in O
the O
range O
61.6-93.6 O
nM. O
The O
thiols B-CHEMICAL
were O
the O
most O
potent O
in O
vitro O
inhibitors O
(K(I) O
values O
of O
21.1-79.0 O
nM), O
and O
some O
of O
them O
also O

inhibited O
the O
epimastigotes O
growth O
of O
two O
T. O
cruzi O
strains O
in O
vivo. O
The O
increased O
number O
of O
Leydig O
cells O
by O
di(2-ethylhexyl) B-CHEMICAL
phthalate I-CHEMICAL
comes O
from O
the O
differentiation O
of O
stem O
cells O
into O
Leydig O
cell O
lineage O
in O
the O
adult O
rat O
testis. O
The O
objective O
of O
the O
present O
study O
is O
to O
determine O
whether O
di(2-ethylhexyl) B-CHEMICAL
phthalate I-CHEMICAL
(DEHP) B-CHEMICAL
exposure O
at O
adulthood O
increases O
rat O
Leydig O
cell O
number O
and O
to O
investigate O
the O
possible O
mechanism. O
90-day-old O
Long-Evans O
rats O
were O
randomly O
divided O
into O
3 O

groups, O
and O
were O
gavaged O
with O
the O
corn O
oil O
(control) O
or O
10 O
or O
750mg/kg O
DEHP B-CHEMICAL
daily O
for O
7 O
days, O
and O
then O
received O
an O
intraperitoneal O
injection O
of O
75mg/kg O
ethane B-CHEMICAL
dimethanesulfonate I-CHEMICAL
(EDS) B-CHEMICAL
to O
eliminate O
Leydig O
cells. O
Serum O
testosterone B-CHEMICAL
concentrations O
were O
assessed O
by O
RIA, O
and O
the O
mRNA O
levels O
of O
Leydig O
cell O
genes O
were O
measured O
by O
qPCR. O
EDS B-CHEMICAL
eliminated O
all O
Leydig O
cells O
in O
the O
control O
testis O
on O
day O
4 O
post-EDS, B-CHEMICAL
as O
judged O
by O
undetectable O
serum O
testosterone B-CHEMICAL
level O

and O
no O
3-hydroxysteroid B-GENE-N
dehydrogenase I-GENE-N
positive O
(3-HSD(pos)) B-GENE-N
cells O
in O
the O
interstitium. O
However, O
in O
DEHP-treated B-CHEMICAL
groups, O
there O
were O
detectable O
serum O
testosterone B-CHEMICAL
concentrations O
and O
some O
oval-shaped O
3-HSD(pos) B-GENE-N
cells O
in O
the O
interstitium. O
These O
3-HSD(pos) B-GENE-N
cells O
were O
not O
stained O
by O
the O
antibody O
against O
11-hydroxysteroid B-GENE-Y
dehydrogenase I-GENE-Y
1 I-GENE-Y
(11-HSD1), B-GENE-Y
a O
marker O
for O
Leydig O
cells O
at O
a O
more O

advanced O
stage. O
The O
disappearance O
of O
mRNAs O
of O
Leydig O
cell O
biomarkers O
including O
Lhcgr, O
Cyp11a1, O
Cyp17a1, O
Insl3 O
and O
Hsd11b1 O
in O
the O
control O
testis O
was O
observed O
on O
day O
4 O
post-EDS. B-CHEMICAL
However, O
there O
were O
detectable O
concentrations O
of O
Lhcgr, B-GENE-Y
Cyp11a1 B-GENE-Y
and O
Cyp17a1 B-GENE-Y
mRNAs O
but O
undetectable O
concentrations O
of O
Insl3, B-GENE-Y
Hsd17b3 B-GENE-Y
and O
Hsd11b1 B-GENE-Y
in O
the O
DEHP-treated B-CHEMICAL
testes, O
indicating O
that O

these O
3-HSD(pos) B-GENE-N
cells O
were O
newly O
formed O
progenitor O
Leydig O
cells. O
The O
mRNA O
level O
for O
nestin B-GENE-Y
(Nes, B-GENE-Y
biomarker O
for O
stem O
Leydig O
cells) O
was O
significantly O
increased O
in O
the O
control O
testis O
on O
day O
4 O
post-EDS, B-CHEMICAL
but O
not O
in O
the O
DEHP B-CHEMICAL
treated O
testes, O
suggesting O
that O
these O
nestin B-GENE-Y
positive O
stem O
cells O
were O
differentiated O
into O
progenitor O
Leydig O
cells O
in O
the O
DEHP-treated B-CHEMICAL
testes. O
The O
present O
study O
suggests O
that O
DEHP B-CHEMICAL
increases O
the O
differentiation O
of O
stem O
cells O
into O
progenitor O
Leydig O
cells. O
GnRH B-GENE-N
pulse O
frequency-dependent O

stimulation O
of O
FSH B-GENE-Y
transcription O
is O
mediated O
via O
activation O
of O
PKA B-GENE-N
and O
CREB. B-GENE-N
Expression O
of O
pituitary O
FSH B-GENE-N
and O
LH, B-GENE-N
under O
the O
control O
of O
pulsatile O
GnRH, B-GENE-N
is O
essential O
for O
fertility. O
cAMP B-CHEMICAL
response I-GENE-N
element-binding I-GENE-N
protein I-GENE-N
(CREB) B-GENE-N
has O
been O
implicated O
in O
the O
regulation O
of O
FSH B-GENE-Y
gene O
expression, O
but O
the O
molecular O
mechanisms O
by O
which O
pulsatile O
GnRH B-CHEMICAL
regulates O
CREB B-GENE-N
activation O
remain O
poorly O
understood. O
We O
hypothesized O
that O
CREB B-GENE-N
is O
activated O
by O
a O
distinct O
signaling O
pathway O
in O
response O
to O
pulsatile O

GnRH B-CHEMICAL
in O
a O
frequency-dependent O
manner O
to O
dictate O
the O
FSH B-GENE-Y
transcriptional O
response. O
GnRH B-CHEMICAL
stimulation O
of O
CREB B-GENE-N
phosphorylation O
(pCREB) B-GENE-N
in O
the O
gonadotrope-derived O
LT2 O
cell O
line O
was O
attenuated O
by O
a O
protein B-GENE-N
kinase I-GENE-N
A I-GENE-N
(PKA) B-GENE-N
inhibitor, O
H89. B-CHEMICAL
A O
dominant B-GENE-N
negative I-GENE-N
PKA I-GENE-N
(DNPKA) B-GENE-N
reduced O
GnRH-stimulated B-GENE-N
pCREB B-GENE-N
and O
markedly O
decreased O
GnRH B-GENE-N
stimulation O
of O
FSH B-GENE-Y
mRNA O
and O
FSHLUC B-GENE-Y
activity, O
but O
had O
little O

effect O
on O
LHLUC B-GENE-Y
activity, O
indicating O
relative O
specificity O
of O
this O
pathway. O
In O
perifusion O
studies, O
FSH B-GENE-Y
mRNA O
levels O
and O
FSHLUC B-GENE-Y
activities O
were O
increased O
by O
pulsatile O
GnRH, B-GENE-N
with O
significantly O
greater O
increases O
at O
low O
compared O
with O
high O
pulse O
frequencies. O
DNPKA B-GENE-N
markedly O
reduced O
these O
GnRH-stimulated B-CHEMICAL
FSH B-GENE-Y
responses O
at O
both O
low O
and O
high O
pulse O
frequencies. O
Correlating O
with O
FSH B-GENE-Y
activation, O
both O
PKA B-GENE-N
activity O
and O
levels O
of O
pCREB B-GENE-N
were O
increased O
to O
a O
greater O
extent O
by O
low O
compared O
with O
high O
GnRH B-CHEMICAL
pulse O

frequencies, O
and O
the O
induction O
of O
pCREB B-GENE-N
was O
also O
attenuated O
by O
overexpression O
of O
DNPKA B-GENE-N
at O
both O
low O
and O
high O
pulse O
frequencies. O
Taken O
together, O
these O
data O
indicate O
that O
a O
PKA-mediated B-GENE-N
signaling O
pathway O
mediates O
GnRH B-CHEMICAL
activation O
of O
CREB B-GENE-N
at O
low-pulse O
frequencies, O
playing O
a O
significant O
role O
in O
the O
decoding O
of O
the O
hypothalamic O
GnRH B-CHEMICAL
signal O
to O
result O
in O
frequency-dependent O
FSH B-GENE-Y
activation. O
Sophocarpine B-CHEMICAL
alleviates O
hepatocyte O
steatosis O
through O
activating O
AMPK B-GENE-Y
signaling O
pathway. O

Sophocarpine, B-CHEMICAL
an O
effective O
compound O
derived O
from O
foxtail-like O
sophora O
herb O
and O
seed, O
has O
been O
reported O
that O
it O
can O
alleviate O
non-alcoholic O
steatohepatitis O
(NASH) O
in O
rats O
and O
affect O
adipocytokine B-GENE-N
synthesis. O
Meanwhile, O
adipocytokines B-GENE-N
could O
adjust O
hepatic O
lipid O
metabolism O
through O
AMPK B-GENE-Y
signaling O
pathway. O
In O
the O
work O
presented O
here, O
primary O
hepatocytes O
were O
isolated O
from O
specific O
pathogen-free O
male O
SD O
rats O
and O
incubated O
with O
200 O
mol/L O
oleic B-CHEMICAL
acid I-CHEMICAL
for O
24h O
to O
induce O
steatotic O

model, O
then O
treated O
with O
sophocarpine B-CHEMICAL
for O
72 O
h. O
Oil O
red O
staining O
was O
performed O
to O
evaluate O
steatosis, O
total O
RNA O
and O
protein O
of O
primary O
hepatocytes O
were O
extracted O
for O
real-time O
RT-PCR O
and O
western O
blot O
analysis. O
A O
cluster O
of O
aberrances O
were O
observed O
in O
the O
model O
group, O
including O
hepatocyte O
steatosis, O
increased O
leptin B-GENE-Y
and O
decreased O
adiponectin B-GENE-Y
mRNA O
expressions. O
While O
sophocarpine B-CHEMICAL
treatment O
resulted O
in: O
significant O
improvement O
of O
steatosis O
(>50% O
decrease), O
decrease O
of O
leptin B-GENE-Y
expression O

(<0.57-fold) O
and O
increase O
of O
adiponectin B-GENE-Y
expression O
(>1.48-fold). O
Moreover, O
compared O
with O
the O
model O
group, O
sophocarpine B-CHEMICAL
could O
significantly O
increase O
P-AMPK B-GENE-N
(>5.82-fold), O
AMPK B-GENE-N
(>1.29-fold) O
and O
ACC B-GENE-N
(>3.27-fold) O
protein O
expressions, O
and O
reduce O
P-ACC B-GENE-N
(<0.30-fold) O
and O
HNF-4 B-GENE-Y
(<0.20-fold) O
protein O
expression. O
The O
mRNA O
expression O
of O
Srebp-1c B-GENE-Y
was O

downregulated O
significantly O
simultaneously O
(<0.68-fold). O
We O
concluded O
that O
sophocarpine B-CHEMICAL
could O
alleviate O
hepatocyte O
steatosis O
and O
the O
potential O
mechanism O
might O
be O
the O
activated O
signaling O
pathway O
of O
AMPK. B-GENE-Y
Elevation O
of O
4-hydroxynonenal B-CHEMICAL
and O
malondialdehyde B-CHEMICAL
modified O
protein O
levels O
in O
cerebral O
cortex O
with O
cognitive O
dysfunction O
in O
rats O
exposed O
to O
1-bromopropane. B-CHEMICAL
1-Bromopropane B-CHEMICAL
(1-BP), B-CHEMICAL
an O
alternative O
to O
ozone-depleting B-CHEMICAL
solvents O
(ODS), O
exhibits O
central O
nervous O
system O

(CNS) O
toxicity O
in O
animals O
and O
humans. O
This O
study O
was O
designed O
to O
relate O
CNS O
damage O
by O
Morris O
water O
maze O
(MWM) O
test O
and O
oxidative O
stress O
to O
1-BP B-CHEMICAL
exposure O
in O
the O
rat. O
Male O
Wistar O
rats O
were O
randomly O
divided O
into O
4 O
groups O
(n=10), O
and O
treated O
with O
0, O
200, O
400 O
and O
800mg/kgbw O
1-BP B-CHEMICAL
for O
consecutive O
12 O
days, O
respectively. O
From O
day O
8 O
to O
day O
12 O
of O
the O
experiment, O
MWM O
test O
was O
employed O
to O
assess O
the O
cognitive O
function O
of O
rats. O
The O
cerebral O
cortex O
of O
rats O
was O
obtained O
immediately O
following O
the O
24h O
after O
MWM O
test O

conclusion. O
Glutathione B-CHEMICAL
(GSH), B-CHEMICAL
oxidized B-CHEMICAL
glutathione I-CHEMICAL
(GSSG) B-CHEMICAL
and O
total O
thiol B-CHEMICAL
(total-SH) B-CHEMICAL
content, O
GSH B-GENE-Y
reductase I-GENE-Y
(GR) B-GENE-Y
and O
GSH B-GENE-N
peroxidase I-GENE-N
(GSH-Px) B-GENE-N
activities, O
malondialdehyde B-CHEMICAL
(MDA) B-CHEMICAL
level, O
as O
well O
as O
4-hydroxynonenal B-CHEMICAL
(4-HNE) B-CHEMICAL
and O
MDA B-CHEMICAL
modified O
proteins O
in O
homogenates O
of O
cerebral O
cortex O
were O
measured. O
The O
obtained O
results O
showed O
that O
1-BP B-CHEMICAL
led O
to O
cognitive O
dysfunction O
of O
rats, O
which O

was O
evidenced O
by O
delayed O
escape O
latency O
time O
and O
swimming O
distances O
in O
MWM O
performance. O
GSH B-CHEMICAL
and O
total-SH B-CHEMICAL
content, O
GSH/GSSG B-CHEMICAL
ratio, O
GR B-GENE-Y
activity O
significantly O
decreased O
in O
cerebral O
cortex O
of O
rats, O
coupling O
with O
the O
increase O
of O
MDA B-CHEMICAL
level. O
4-HNE B-CHEMICAL
and O
MDA B-CHEMICAL
modified O
protein O
levels O
obviously O
elevated O
after O
1-BP B-CHEMICAL
exposure. O
GSH-Px B-GENE-N
activities O
in O
cerebral O
cortex O
of O
rats O
also O
increased. O
These O
data O
suggested O
that O
1-BP B-CHEMICAL
resulted O
in O
enhanced O
lipid O
peroxidation O
of O
brain, O
which O
might O
play O
an O
important O
role O
in O
CNS O
damage O
induced O
by O
1-BP. B-CHEMICAL
Site O
dependent O

intestinal O
absorption O
of O
darunavir B-CHEMICAL
and O
its O
interaction O
with O
ketoconazole. B-CHEMICAL
The O
expression O
of O
P-gp B-GENE-N
increases O
from O
proximal O
to O
distal O
parts O
of O
the O
small O
intestine, O
whereas O
for O
P450 B-GENE-N
enzymes I-GENE-N
the O
expression O
is O
reported O
to O
be O
highest O
in O
duodenum O
and O
jejunum, O
decreasing O
to O
more O
distal O
sites. O
To O
evaluate O
to O
what O
extent O
the O
regional O
differences O
in O
expression O
of O
P-gp B-GENE-N
and O
P450 B-GENE-N
enzymes I-GENE-N
affect O
the O
absorption O
of O
a O
dual O
substrate, O
we O
investigated O
the O
transport O
of O
darunavir B-CHEMICAL
across O
different O
small O
intestinal O
segments O
(duodenum, O
proximal O
jejunum O

and O
ileum). O
Moreover, O
the O
effect O
of O
ketoconazole B-CHEMICAL
on O
the O
intestinal O
absorption O
of O
darunavir B-CHEMICAL
was O
explored, O
since O
these O
drugs O
are O
commonly O
co-administered. O
Performing O
the O
rat O
in O
situ O
intestinal O
perfusion O
technique O
with O
mesenteric O
blood O
sampling, O
we O
found O
no O
significant O
differences O
in O
the O
transport O
of O
darunavir B-CHEMICAL
at O
the O
different O
intestinal O
segments. O
The O
involvement O
of O
P-gp B-GENE-N
in O
the O
absorption O
of O
darunavir B-CHEMICAL
was O
clearly O
shown O
by O
coperfusion O
of O
darunavir B-CHEMICAL
with O
the O
P-gp B-GENE-N
inhibitor O
zosuquidar. B-CHEMICAL
In O
presence O
of O

zosuquidar, B-CHEMICAL
a O
2.2-, O
4.2- O
and O
5.7-fold O
increase O
in O
Papp O
values O
were O
measured O
for O
duodenum, O
proximal O
jejunum O
and O
ileum, O
respectively. O
Involvement O
of O
P450 B-GENE-N
mediated O
metabolism O
in O
the O
absorption O
of O
darunavir B-CHEMICAL
could O
not O
be O
demonstrated O
in O
this O
rat O
model. O
Upon O
studying O
the O
drug-drug O
interaction O
of O
darunavir B-CHEMICAL
with O
ketoconazole, B-CHEMICAL
data O
were O
indicative O
for O
an O
inhibitory O
effect O
of O
ketoconazole B-CHEMICAL
on O
P-gp B-GENE-N
as O
the O
main O
mechanism O
for O
the O
increased O
transport O
of O
darunavir B-CHEMICAL
across O

the O
small O
intestine. O
Protective O
effect O
of O
Codium O
fragile O
against O
UVB-induced O
pro-inflammatory O
and O
oxidative O
damages O
in O
HaCaT O
cells O
and O
BALB/c O
mice. O
Acute O
exposure O
to O
ultraviolet O
(UV) O
radiation O
causes O
pro-inflammatory O
responses O
via O
diverse O
mechanisms O
including O
oxidative O
stress. O
Codium O
fragile O
is O
a O
green O
alga O
of O
Codiales O
family O
and O
has O
been O
reported O
to O
exhibit O
anti-edema, O
anti-allergic, O
anti-protozoal O
and O
anti-mycobacterial O
activities. O
In O
this O
study, O
we O
have O
investigated O
a O
novel O
anti-inflammatory O
potential O

of O
C. O
fragile O
using O
in O
vitro O
cell O
culture O
as O
well O
as O
in O
vivo O
animal O
models. O
In O
HaCaT O
cells, O
buthanol B-CHEMICAL
and O
ethylacetate B-CHEMICAL
fractions O
of O
80% O
methanol B-CHEMICAL
C. O
fragile O
extract O
(CFB O
or O
CFE) O
and O
a O
single O
compound, O
clerosterol B-CHEMICAL
(CLS) B-CHEMICAL
isolated O
from O
CFE O
attenuated O
UVB O
(60mJ/cm(2))-induced O
cytotoxicity O
and O
reduced O
expression O
of O
pro-inflammatory O
proteins O
including O
cyclooxygenase-2 B-GENE-Y
(COX-2), B-GENE-Y
inducible B-GENE-Y
nitric B-CHEMICAL
oxide I-CHEMICAL

synthase I-GENE-Y
(iNOS), B-GENE-Y
and O
tumor B-GENE-Y
necrosis I-GENE-Y
factor- I-GENE-Y
(TNF- B-GENE-Y
). I-GENE-Y
Moreover, O
CFB, O
CFE O
and O
CLS B-CHEMICAL
effectively O
suppressed O
UVB-induced O
production O
of O
pro-inflammatory O
mediators O
such O
as O
prostaglandin B-CHEMICAL
E2 I-CHEMICAL
(PGE2) B-CHEMICAL
and O
nitric B-CHEMICAL
oxide I-CHEMICAL
(NO). B-CHEMICAL
In O
another O
experiment, O
topical O
application O
of O
CFB, O
CFE O
or O
CLS B-CHEMICAL
prior O
to O
UVB O
irradiation O
(200mJ/cm(2)) O
on O
BALB/c O
mice, O
inhibited O
the O
UVB-elevated O
protein O
levels O
of O
COX-2, B-GENE-Y

iNOS, B-GENE-Y
and O
TNF-. B-GENE-Y
Furthermore, O
CFB, O
CFE O
and O
CLS B-CHEMICAL
suppressed O
oxidative O
damages O
caused O
by O
UVB O
irradiation O
for O
example O
lipid O
peroxidation O
and/or O
protein O
carbonylation, O
which O
seemed O
to O
be O
mediated O
by O
up-regulation O
of O
antioxidant O
defense O
enzymes. O
These O
results O
suggest O
that O
C. O
fragile O
could O
be O
an O
effective O
therapeutic O
agent O
providing O
protection O
against O
UVB-induced O
inflammatory O
and O
oxidative O
skin O
damages. O
Strong O
effects O
of O
cluster O
size O
and O
air O
exposure O
on O
oxygen B-CHEMICAL
reduction O
and O
carbon B-CHEMICAL
oxidation O
electrocatalysis O
by O
size-selected O
Pt(n) B-CHEMICAL
(n O
 O

11) O
on O
glassy B-CHEMICAL
carbon I-CHEMICAL
electrodes. O
Model O
Pt(n)/glassy B-CHEMICAL
carbon I-CHEMICAL
electrodes O
(Pt(n)/GCE) B-CHEMICAL
were O
prepared O
by O
deposition O
of O
mass-selected O
Pt(n)(+) B-CHEMICAL
(n O
 O
11) O
on O
GCE O
substrates O
in O
ultrahigh O
vacuum. O
Electrocatalysis O
under O
conditions O
appropriate O
for O
the O
oxygen B-CHEMICAL
reduction O
reaction O
(ORR) O
was O
studied, O
for O
samples O
both O
in O
situ O
with O
no O
exposure O
to O
laboratory O
air O
and O
with O
air O
exposure O
prior O
to O
electrochemical O
measurements. O
Of O
the O
small O
clusters, O
only O
a O
few O
cluster O
sizes O
show O
the O
expected O
ORR O
activity, O
and O
in O
those O

cases, O
the O
activity O
per O
Pt B-CHEMICAL
atom O
is O
similar O
to O
that O
seen O
under O
identical O
conditions O
with O
a O
conventionally O
prepared O
electrode O
with O
Pt B-CHEMICAL
nanoparticles O
grown O
on O
a O
GCE. O
For O
other O
small O
Pt(n) B-CHEMICAL
on O
GCE, O
any O
ORR O
signal O
is O
overwhelmed O
by O
large O
oxidative O
currents O
attributed O
to O
catalysis O
of O
carbon B-CHEMICAL
oxidation O
by O
water. O
If O
the O
samples O
are O
exposed O
to O
air O
prior O
to O
electrochemistry, O
both O
ORR O
and O
carbon B-CHEMICAL
oxidation O
signals O
are O
absent, O
and O
instead O
only O
small O
capacitive O
currents O
or O
currents O
attributed O
to O
redox O
chemistry O
of O
adventitious O
organic O
adsorbates O
are O
observed, O
indicating O
that O
air O
exposure O

results O
in O
passivation O
of O
the O
small O
Pt B-CHEMICAL
clusters. O
Inhibition O
of O
ghrelin B-GENE-Y
O-acyltransferase B-CHEMICAL
attenuates O
food O
deprivation-induced O
increases O
in O
ingestive O
behavior. O
Ghrelin B-GENE-Y
is O
an O
orexigenic B-GENE-N
hormone I-GENE-N
produced O
by O
the O
stomach O
in O
direct O
proportion O
to O
the O
time O
since O
the O
last O
meal O
and O
has O
therefore O
been O
called O
a O
'hunger O
signal'. O
The O
octanoylation O
of O
ghrelin B-GENE-Y
is O
critical O
for O
its O
orexigenic O
functions O
and O
is O
dependent O
upon O
ghrelin B-GENE-Y
O-acyltransferase I-GENE-Y
(GOAT) B-GENE-Y
catalyzation. O
The O
GOAT B-GENE-Y
inhibitor, O

GO-CoA-Tat, O
decreases O
the O
circulating O
concentrations O
of O
octanoylated B-GENE-Y
ghrelin I-GENE-Y
and O
attenuates O
weight O
gain O
on O
a O
high O
fat O
diet O
in O
mice. O
Unlike O
rats O
and O
mice, O
Siberian O
hamsters O
and O
humans O
do O
not O
increase O
food O
intake O
after O
food O
deprivation, O
but O
increase O
food O
hoarding O
after O
food O
deprivation. O
In O
Siberian O
hamsters, O
exogenous O
ghrelin B-GENE-Y
increases O
ingestive O
behaviors O
similarly O
to O
48-56h O
food O
deprivation. O
Therefore, O
we O
tested O
the O
necessity O
of O
increased O
ghrelin B-GENE-Y
in O
food-deprived O
Siberian O
hamsters O
to O
stimulate O
ingestive O
behaviors. O
To O

do O
so O
we O
used O
our O
simulated O
natural O
housing O
system O
that O
allows O
hamsters O
to O
forage O
for O
and O
hoard O
food. O
Animals O
were O
given O
an O
injection O
of O
GO-CoA-Tat O
(i.p., O
11mol/kg) O
every O
6h O
because O
that O
is O
the O
duration O
of O
its O
effective O
inhibition O
of O
octanoylated B-GENE-N
ghrelin I-GENE-N
concentrations O
during O
a O
48h O
food O
deprivation. O
We O
found O
that O
GO-CoA-Tat O
attenuated O
food O
foraging O
(0-1h), O
food O
intake O
(0-1 O
and O
2-4h), O
and O
food O
hoarding O

(0-1h O
and O
2 O
and O
3days) O
post-refeeding O
compared O
with O
saline O
treated O
animals. O
This O
suggests O
that O
increased O
octanoylated B-GENE-N
ghrelin I-GENE-N
concentrations O
play O
a O
role O
in O
the O
food O
deprivation-induced O
increases O
in O
ingestive O
behavior. O
Therefore, O
ghrelin B-GENE-Y
is O
a O
critical O
aspect O
of O
the O
multi-faceted O
mechanisms O
that O
stimulate O
ingestive O
behaviors, O
and O
might O
be O
a O
critical O
point O
for O
a O
successful O
clinical O
intervention O
scheme O
in O
humans. O
The O
accumulation O
of O
metal O
(Co, B-CHEMICAL
Cr, B-CHEMICAL
Cu, B-CHEMICAL
Mn B-CHEMICAL
and O
Zn) B-CHEMICAL
in O
freshwater O
Ulva O
(Chlorophyta) O
and O
its O

habitat. O
The O
possibility O
of O
using O
freshwater O
Ulva O
(Chlorophyta) O
as O
a O
bioaccumulator O
of O
metals O
(Co, B-CHEMICAL
Cr, B-CHEMICAL
Cu, B-CHEMICAL
Mn B-CHEMICAL
and O
Zn) B-CHEMICAL
in O
lake O
and O
river O
water O
was O
examined O
weekly O
in O
the O
summer O
of O
2010 O
in O
three O
types O
of O
samples: O
the O
water, O
the O
sediment O
and O
the O
thalli O
of O
Ulva. O
Samples O
of O
freshwater O
Ulva O
were O
collected O
from O
two O
aqueous O
ecosystems O
lie O
250 O
km O
away O
from O
the O
basin O
of O
the O
Baltic O
Sea O
and O
53 O
km O
from O
each O
other. O
A O
flow O
lake O
located O
in O
the O
centre O
of O
the O
big O
city O
was O
the O
first O
water O
reservoir O
(ten O

sites) O
and O
second, O
the O
suburban O
river O
(six O
sites). O
The O
mean O
metal O
concentrations O
in O
the O
Ulva O
tissue O
from O
the O
river O
and O
the O
lake O
decreased O
in O
the O
following O
order: O
Mn B-CHEMICAL
> O
Zn B-CHEMICAL
> O
Cr B-CHEMICAL
> O
Cu B-CHEMICAL
> O
Co B-CHEMICAL
and O
Mn B-CHEMICAL
> O
Cr B-CHEMICAL
> O
Zn B-CHEMICAL
> O
Cu B-CHEMICAL
> O
Co, B-CHEMICAL
respectively. O
Moreover, O
a O
negative O
and O
statistically O
significant O
correlation O
between O
Mn B-CHEMICAL
concentrations O
in O
the O
Ulva O
thalli O
and O
the O
river O
water O
was O
observed. O
Additionally, O
numerous O
correlations O
were O
noted O
between O
the O
different O
concentrations O
of O
metals O
within O
the O
Ulva O
thalli, O
in O
the O
water O
and O
in O
the O
sediment. O
The O
great O
concentrations O

of O
Mn B-CHEMICAL
and O
Zn B-CHEMICAL
and O
the O
smallest O
of O
Co B-CHEMICAL
were O
found O
in O
thalli O
of O
Ulva, O
irrespective O
of O
the O
type O
of O
the O
ecosystem O
from O
which O
samples O
of O
algal O
thalli O
originated. O
Freshwater O
Ulva O
populations O
examined O
in O
this O
study O
were O
clearly O
characterized O
a O
dozen O
or O
so O
times O
by O
the O
higher O
Mn B-CHEMICAL
and O
Cr B-CHEMICAL
accumulation O
than O
taxa O
from O
that O
genera O
coming O
from O
sea O
ecosystems. O
The O
calculated O
bioconcentration O
factor O
confirm O
the O
high O
potential O
for O
freshwater O
Ulva O
to O
be O
a O
bioaccumulator O
of O
trace O
metals O
in O
freshwater O
ecosystems. O
Exploring O
the O
Interplay O
Between O
Ligand O
Derivatisation O
and O
Cation O

Type O
in O
the O
Assembly O
of O
Hybrid O
Polyoxometalate B-CHEMICAL
Mn-Andersons. B-CHEMICAL
Herein O
a O
library O
of O
hybrid O
Mn-Anderson B-CHEMICAL
polyoxometalates B-CHEMICAL
anions O
are O
presented: O
1, O
[(MnMo(6) B-CHEMICAL
O(18) I-CHEMICAL
)((OCH(2) I-CHEMICAL
)(3) I-CHEMICAL
-C-(CH(2) I-CHEMICAL
)(7) I-CHEMICAL
CHCH(2) I-CHEMICAL
)(2) I-CHEMICAL
](3-) I-CHEMICAL
; O
compound O
2, O
[(MnMo(6) B-CHEMICAL
O(18) I-CHEMICAL
)((OCH(2) I-CHEMICAL
)(3) I-CHEMICAL

C-NHCH(2) I-CHEMICAL
C(16) I-CHEMICAL
H(9) I-CHEMICAL
)(2) I-CHEMICAL
](3-) I-CHEMICAL
; O
compound O
3, O
[(MnMo(6) B-CHEMICAL
O(18) I-CHEMICAL
)((OCH(2) I-CHEMICAL
)(3) I-CHEMICAL
C-(CH(2) I-CHEMICAL
)(7) I-CHEMICAL
CHCH(2) I-CHEMICAL
)(1) I-CHEMICAL
((OCH(2) I-CHEMICAL
)(3) I-CHEMICAL
C-NHCH(2) I-CHEMICAL
C(16) I-CHEMICAL
H(9) I-CHEMICAL
)(1) I-CHEMICAL
](3-) I-CHEMICAL
; O
compound O
4, O
[(MnMo(6) B-CHEMICAL
O(18) I-CHEMICAL

)((OCH(2) I-CHEMICAL
)(3) I-CHEMICAL
C-NHC(O)CH(2) I-CHEMICAL
CHCH(2) I-CHEMICAL
)(2) I-CHEMICAL
](3-) I-CHEMICAL
and O
compounds O
5-9, O
[(MnMo(6) B-CHEMICAL
O(18) I-CHEMICAL
)((OCH(2) I-CHEMICAL
)(3) I-CHEMICAL
C-NHC(O)(CH(2) I-CHEMICAL
)(x) I-CHEMICAL
CH(3) I-CHEMICAL
)(2) I-CHEMICAL
]), I-CHEMICAL
where O
x O
= O
4, O
10, O
12, O
14, O
and O
18 O
respectively. O
The O
compounds O
resulting O
from O
the O
cation O
exchange O
of O
the O
anions O
1-9 O
to O

give O
TBA B-CHEMICAL
(a) O
and O
DMDOA B-CHEMICAL
(b) O
salts, O
and O
additionally O
for O
compounds O
1, O
2 O
and O
3, O
tetraphenylphosphonium B-CHEMICAL
(PPh(4) B-CHEMICAL
) O
(c) O
salts, O
are O
explored O
at O
the O
air/water O
interface O
using O
scanning O
force O
microscopy, O
showing O
a O
range O
of O
architectures O
including O
hexagonal O
structures, O
nanofibers O
and O
other O
supramolecular O
forms. O
Additionally O
the O
solid-state O
structures O
for O
compounds O
1c, O
2c, O
4a, O
6a, O
9a, O
are O
presented O
for O
the O
first O
time O
and O
these O
investigations O
demonstrate O
the O
delicate O
interplay O
between O
the O
structure O

of O
the O
covalently O
derivatised O
hybrid O
organo-clusters O
as O
well O
as O
the O
ion-exchange O
cation O
types. O
Interaction O
of O
silymarin O
flavonolignans B-CHEMICAL
with O
organic B-GENE-N
anion-transporting I-GENE-N
polypeptides. I-GENE-N
Organic B-GENE-N
anion-transporting I-GENE-N
polypeptides I-GENE-N
(OATPs) B-GENE-N
are O
multispecific B-GENE-N
transporters I-GENE-N
mediating O
the O
uptake O
of O
endogenous O
compounds O
and O
xenobiotics O
in O
tissues O
that O
are O
important O
for O
drug O
absorption O
and O
elimination, O
including O
the O
intestine O
and O
liver. O
Silymarin O
is O
a O
popular O
herbal O
supplement O
often O
used O
by O
patients O
with O
chronic O
liver O
disease; O
higher O
oral O
doses O

than O
those O
customarily O
used O
(140 O
mg O
three O
times/day) O
are O
being O
evaluated O
clinically. O
The O
present O
study O
examined O
the O
effect O
of O
silymarin O
flavonolignans B-CHEMICAL
on O
OATP1B1-, B-GENE-Y
OATP1B3-, B-GENE-Y
and O
OATP2B1-mediated B-GENE-Y
transport O
in O
cell O
lines O
stably O
expressing O
these O
transporters O
and O
in O
human O
hepatocytes. O
In O
overexpressing O
cell O
lines, O
OATP1B1- B-GENE-Y
and O
OATP1B3-mediated B-GENE-Y
estradiol-17-glucuronide B-CHEMICAL
uptake O
and O

OATP2B1-mediated B-GENE-Y
estrone-3-sulfate B-CHEMICAL
uptake O
were O
inhibited O
by O
most O
of O
the O
silymarin O
flavonolignans B-CHEMICAL
investigated. O
OATP1B1-, B-GENE-Y
OATP1B3-, B-GENE-Y
and O
OATP2B1-mediated B-GENE-Y
substrate O
transport O
was O
inhibited O
efficiently O
by O
silymarin O
(IC50 O
values O
of O
1.3, O
2.2 O
and O
0.3 O
M, O
respectively), O
silybin B-CHEMICAL
A I-CHEMICAL
(IC50 O
values O
of O
9.7, O
2.7 O
and O
4.5 O
M, O
respectively), O

silybin B-CHEMICAL
B I-CHEMICAL
(IC50 O
values O
of O
8.5, O
5.0 O
and O
0.8 O
M, O
respectively), O
and O
silychristin B-CHEMICAL
(IC50 O
values O
of O
9.0, O
36.4, O
and O
3.6 O
M, O
respectively). O
Furthermore, O
silymarin, O
silybin B-CHEMICAL
A, I-CHEMICAL
and O
silybin B-CHEMICAL
B I-CHEMICAL
(100 O
M) O
significantly O
inhibited O
OATP-mediated B-GENE-N
estradiol-17-glucuronide B-CHEMICAL
and O
rosuvastatin B-CHEMICAL
uptake O
into O
human O
hepatocytes. O
Calculation O
of O
the O
maximal O
unbound O

portal O
vein O
concentrations/IC50 O
values O
indicated O
a O
low O
risk O
for O
silymarin-drug O
interactions O
in O
hepatic O
uptake O
with O
a O
customary O
silymarin O
dose. O
The O
extent O
of O
silymarin-drug O
interactions O
depends O
on O
OATP B-GENE-N
isoform O
specificity O
and O
concentrations O
of O
flavonolignans B-CHEMICAL
at O
the O
site O
of O
drug O
transport. O
Higher O
than O
customary O
doses O
of O
silymarin, O
or O
formulations O
with O
improved O
bioavailability, O
may O
increase O
the O
risk O
of O
flavonolignan B-CHEMICAL
interactions O
with O
OATP B-GENE-N
substrates O
in O
patients. O
Oxidation O
of O
tertiary B-CHEMICAL
amine-derivatized I-CHEMICAL
surfaces O
to O
control O
protein O

adhesion. O
Selective O
oxidation O
of O
-tertiary B-CHEMICAL
amine I-CHEMICAL
self-assembled O
thiol B-CHEMICAL
monolayers O
to O
tertiary B-CHEMICAL
amine I-CHEMICAL
N-oxides I-CHEMICAL
is O
shown O
to O
transform O
the O
adhesion O
of O
model O
proteins O
lysozyme B-GENE-Y
and O
fibrinogen B-GENE-N
upon O
them. O
Efficient O
preparation O
of O
both O
secondary B-CHEMICAL
and I-CHEMICAL
tertiary I-CHEMICAL
linker I-CHEMICAL
amides I-CHEMICAL
as O
judged O
by O
X-ray O
photoelectron O
spectroscopy O
(XPS) O
and O
water O
droplet O
contact O
angle O
was O
achieved O
with O
an O
improved O
amide B-CHEMICAL
bond O
formation O
on O
gold O
quartz B-CHEMICAL
crystal O
microbalance O
(QCM) O
sensors O
using O

2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl B-CHEMICAL
hexafluorophosphate I-CHEMICAL
methanaminium I-CHEMICAL
uronium I-CHEMICAL
(HATU). B-CHEMICAL
Oxidation O
with O
hydrogen B-CHEMICAL
peroxide I-CHEMICAL
was O
similarly O
assessed, O
and O
adhesion O
of O
lysozyme B-GENE-Y
and O
fibrinogen B-GENE-N
from O
phosphate B-CHEMICAL
buffered O
saline O
was O
then O
assayed O
by O
QCM O
and O
imaged O
by O
AFM. O
Tertiary B-CHEMICAL
amine-functionalized I-CHEMICAL
sensors O
adsorbed O
multilayers O
of O
aggregated O
lysozyme, B-GENE-Y
whereas O
tertiary B-CHEMICAL

amine I-CHEMICAL
N-oxides I-CHEMICAL
and O
triethylene B-CHEMICAL
glycol-terminated I-CHEMICAL
monolayers O
are O
consistent O
with O
small O
protein O
aggregates. O
The O
surface O
containing O
a O
dimethylamine B-CHEMICAL
N-oxide I-CHEMICAL
headgroup O
and O
ethyl B-CHEMICAL
secondary I-CHEMICAL
amide I-CHEMICAL
linker O
showed O
the O
largest O
difference O
in O
adsorption O
of O
both O
proteins. O
Oxidation O
of O
tertiary B-CHEMICAL
amine I-CHEMICAL
decorated O
surfaces O
therefore O
holds O
the O
potential O
for O
selective O
deposition O
of O
proteins O
and O
cells O
through O
masking O
and O
other O
patterning O
techniques. O
Stabilisation O
of O
amorphous O
drugs O
under O
high O
humidity O
using O
pharmaceutical O
thin O
films. O
In O
this O
study, O
the O
stabilization O
effects O
of O
three O
polymers O
on O
four O
model O
drugs O

(felodipine, B-CHEMICAL
fenofibrate, B-CHEMICAL
carbamazepine, B-CHEMICAL
and O
celecoxib) B-CHEMICAL
under O
saturated O
humidity O
were O
investigated. O
Three O
different O
types O
of O
thin O
films O
(solid O
dispersions, O
drug O
films O
with O
a O
polymer O
film O
coating O
and O
drug O
films O
laid O
on O
top O
of O
polymer O
coated O
surfaces) O
were O
prepared O
and O
compared O
with O
films O
containing O
the O
drug O
alone. O
ATR-FTIR O
spectroscopy, O
polarised O
light O
microscopy O
(PLM), O
scanning O
electron O
microscopy O
(SEM) O
and O
nano-thermal O
analysis O
(nano-TA) O
were O
performed O
on O
the O
model O
systems O
after O
storage O
under O
saturated O

humidity. O
The O
recrystallisation O
tendency O
of O
the O
drug O
in O
the O
drug O
containing O
thin O
films O
was O
found O
to O
be O
strongly O
related O
to O
the O
intrinsic O
crystallization O
tendency O
of O
the O
drug O
film O
alone O
and O
the O
strength O
of O
drug-polymer O
interactions. O
Additionally, O
under O
high O
humidity, O
the O
glass O
transition O
temperature O
of O
the O
polymer O
is O
no O
longer O
an O
indicator O
of O
its O
drug O
stabilization O
capability. O
Instead, O
it O
is O
the O
hygroscobicity O
of O
the O
polymer O
that O
appears O
to O
be O
the O
most O
important O
parameter. O
Amongst O
the O
polymers O
tested O
in O
this O
study, O
EUDRAGIT B-CHEMICAL
E I-CHEMICAL
PO I-CHEMICAL
was O
found O
to O
have O
the O
greatest O
inhibitory O
effect O
on O
crystallization, O
whilst O

PVP B-CHEMICAL
K30 I-CHEMICAL
was O
found O
to O
have O
the O
least O
protective O
effect; O
presumably O
because O
of O
its O
hygroscopic O
nature. O
Neuroprotective O
effects O
of O
mercaptoethylleonurine B-CHEMICAL
and O
mercaptoethylguanidine B-CHEMICAL
analogs O
on O
hydrogen B-CHEMICAL
peroxide-induced I-CHEMICAL
apoptosis O
in O
human O
neuronal O
SH-SY5Y O
cells. O
A O
series O
of O
mercaptoethylleonurine B-CHEMICAL
and O
mercaptoethylguanidine B-CHEMICAL
derivatives O
were O
designed O
and O
synthesized. O
Their O
neuroprotective O
effects O
toward O
H2O2-induced B-CHEMICAL
apoptosis O
were O
investigated O
in O
human O

SH-SY5Y O
cells. O
The O
results O
from O
these O
studies O
identified O
several O
potent O
compounds, O
with O
compound O
8k O
emerging O
as O
the O
most O
effective. O
Further O
investigation O
demonstrated O
that O
8k O
reduced O
H2O2-induced B-CHEMICAL
activation O
of O
mitochondrial O
apoptosis O
by O
inhibiting O
the O
expression O
of O
Bax B-GENE-N
and O
elevating O
the O
expression O
of O
Bcl-2. B-GENE-N
Moreover, O
the O
molecular O
mechanism O
underlying O
the O
observed O
neuroprotective O
effects O
of O
8k O
was O
exerted O
via O
the O
Akt B-GENE-N
and O
JNK B-GENE-N
pathways. O
Compound O
8k O
can O
be O
a O
lead O
compound O
for O
further O
discovery O
of O
neuroprotective O
medicine. O
Effects O
of O
induced O

hyperinsulinaemia O
with O
and O
without O
hyperglycaemia O
on O
measures O
of O
cardiac O
vagal O
control. O
AIMS/HYPOTHESIS: O
We O
examined O
the O
effects O
of O
serum B-GENE-Y
insulin I-GENE-Y
levels O
on O
vagal O
control O
over O
the O
heart O
and O
tested O
the O
hypothesis O
that O
higher O
fasting O
insulin B-GENE-Y
levels O
are O
associated O
with O
lower O
vagal O
control. O
We O
also O
examined O
whether O
experimentally O
induced O
increases O
in O
insulin B-GENE-Y
by O
beta O
cell O
secretagogues, O
including O
glucagon-like B-GENE-Y
peptide-1 I-GENE-Y
(GLP-1), B-GENE-Y
will O
decrease O
vagal O
control. O
METHODS: O
Respiration O
and O
ECGs O
were O
recorded O
for O
130 O
healthy O

participants O
undergoing O
clamps. O
Three O
variables O
of O
cardiac O
vagal O
effects O
(the O
root O
mean O
square O
of O
successive O
differences O
[rMSSD] O
in O
the O
interbeat O
interval O
of O
the O
heart O
rate O
[IBI], O
heart-rate O
variability O
[HRV] O
caused O
by O
peak-valley O
respiratory O
sinus O
arrhythmia O
[pvRSA], O
and O
high-frequency O
power O
[HF]) O
and O
heart O
rate O
(HR) O
were O
obtained O
at O
seven O
time O
points O
during O
the O
clamps, O
characterised O
by O
increasing O
levels O
of O
insulin B-GENE-Y
(achieved O
by O
administering O
insulin B-GENE-Y
plus O
glucose, B-CHEMICAL
glucose B-CHEMICAL
only, O
glucose B-CHEMICAL
and O
GLP-1, B-GENE-Y
and O

glucose B-CHEMICAL
and O
GLP-1 B-GENE-Y
combined O
with O
arginine). B-CHEMICAL
RESULTS: O
Serum B-GENE-Y
insulin I-GENE-Y
level O
was O
positively O
associated O
with O
HR O
at O
all O
time O
points O
during O
the O
clamps O
except O
the O
first-phase O
hyperglycaemic O
clamp. O
Insulin B-GENE-Y
levels O
were O
negatively O
correlated O
with O
variables O
of O
vagal O
control, O
reaching O
significance O
for O
rMSSD O
and O
log(10)HF, O
but O
not O
for O
pvRSA, O
during O
the O
last O
four O
phases O
of O
the O
hyperglycaemic O
clamp O
(hyperglycaemic O
second O
phase, O
GLP-1 B-GENE-Y
first O
and O
second O
phases, O
and O

arginine). B-CHEMICAL
These O
associations O
disappeared O
when O
adjusted O
for O
age, O
BMI O
and O
insulin B-GENE-Y
sensitivity. O
Administration O
of O
the O
beta O
cell O
secretagogues O
GLP-1 B-GENE-Y
and O
arginine B-CHEMICAL
led O
to O
a O
significant O
increase O
in O
HR, O
but O
this O
was O
not O
paired O
with O
a O
significant O
reduction O
in O
HRV O
measures. O
CONCLUSION/INTERPRETATION: O
Experimentally O
induced O
hyperinsulinaemia O
is O
not O
correlated O
with O
cardiac O
vagal O
control O
or O
HR O
when O
adjusting O
for O
age, O
BMI O
and O
insulin B-GENE-Y
sensitivity O
index. O
Our O
findings O
suggest O
that O
exposure O
to O
a O
GLP-1 B-GENE-Y
during O
hyperglycaemia O
leads O

to O
a O
small O
acute O
increase O
in O
HR O
but O
not O
to O
an O
acute O
decrease O
in O
cardiac O
vagal O
control. O
The O
propeptides O
of O
VEGF-D B-GENE-Y
determine O
heparin O
binding, O
receptor O
heterodimerization, O
and O
effects O
on O
tumor O
biology. O
VEGF-D B-GENE-Y
is O
an O
angiogenic O
and O
lymphangiogenic O
glycoprotein O
that O
can O
be O
proteolytically O
processed O
generating O
various O
forms O
differing O
in O
subunit O
composition O
due O
to O
the O
presence O
or O
absence O
of O
N- B-CHEMICAL
and O
C-terminal B-CHEMICAL
propeptides. O
These O
propeptides O
flank O
the O
central O
VEGF B-GENE-N
homology I-GENE-N
domain, I-GENE-N
that O
contains O
the O
binding O
sites O
for O

VEGF B-GENE-N
receptors I-GENE-N
(VEGFRs), B-GENE-N
but O
their O
biological O
functions O
were O
unclear. O
Characterization O
of O
propeptide O
function O
will O
be O
important O
to O
clarify O
which O
forms O
of O
VEGF-D B-GENE-Y
are O
biologically O
active O
and O
therefore O
clinically O
relevant. O
Here O
we O
use O
VEGF-D B-GENE-Y
mutants O
deficient O
in O
either O
propeptide, O
and O
in O
the O
capacity O
to O
process O
the O
remaining O
propeptide, O
to O
monitor O
the O
functions O
of O
these O
domains. O
We O
report O
for O
the O
first O
time O
that O
VEGF-D B-GENE-Y
binds O
heparin, O
and O
that O
the O
C-terminal B-CHEMICAL
propeptide O
significantly O
enhances O
this O
interaction O
(removal O
of O
this O
propeptide O
from O
full-length O

VEGF-D B-GENE-Y
completely O
prevents O
heparin O
binding). O
We O
also O
show O
that O
removal O
of O
either O
the O
N- B-CHEMICAL
or O
C-terminal B-CHEMICAL
propeptide O
is O
required O
for O
VEGF-D B-GENE-Y
to O
drive O
formation O
of O
VEGFR-2/VEGFR-3 B-GENE-Y
heterodimers O
which O
have O
recently O
been O
shown O
to O
positively O
regulate O
angiogenic O
sprouting. O
The O
mature O
form O
of O
VEGF-D, B-GENE-Y
lacking O
both O
propeptides, O
can O
also O
promote O
formation O
of O
these O
receptor O
heterodimers. O
In O
a O
mouse O
tumor O
model, O
removal O
of O
only O
the O
C-terminal B-CHEMICAL
propeptide O
from O
full-length O
VEGF-D B-GENE-Y

was O
sufficient O
to O
enhance O
angiogenesis O
and O
tumor O
growth. O
In O
contrast, O
removal O
of O
both O
propeptides O
is O
required O
for O
high O
rates O
of O
lymph O
node O
metastasis. O
The O
findings O
reported O
here O
show O
that O
the O
propeptides O
profoundly O
influence O
molecular O
interactions O
of O
VEGF-D B-GENE-Y
with O
VEGF B-GENE-N
receptors, I-GENE-N
co-receptors, O
and O
heparin, O
and O
its O
effects O
on O
tumor O
biology. O
Switchable O
Elastin-Like B-GENE-N
Polypeptides I-GENE-N
that O
Respond O
to O
Chemical O
Inducers O
of O
Dimerization. O
Elastin-like B-GENE-N
polypeptides I-GENE-N
(ELPs) B-GENE-N
are O
protein O
polymers O
that O
reversibly O

phase O
separate O
in O
response O
to O
increased O
temperature, O
pressure, O
concentration, O
ionic O
strength, O
and O
molecular O
weight. O
If O
it O
were O
possible O
to O
engineer O
their O
phase O
separation O
to O
respond O
to O
specific O
molecular O
substrates, O
ELP B-GENE-N
fusion O
proteins O
might O
be O
engineered O
as O
biosensors, O
smart O
biomaterials, O
diagnostic O
imaging O
agents, O
and O
targeted O
therapies. O
What O
has O
been O
lacking O
is O
a O
strategy O
to O
design O
ELPs B-GENE-N
to O
respond O
to O
specific O
substrates. O
To O
address O
this O
deficiency, O
we O
report O
that O
ELP B-GENE-N
fusion O
proteins O
phase O
separate O
in O
response O
to O
chemical O
inducers O
of O
dimerization O
(CID). O
The O
rationale O
is O
that O
ELP B-GENE-N
phase O
separation O
depends O
on O
molecular O
weight, O

concentration, O
and O
local O
hydrophobicity; O
therefore, O
processes O
that O
affect O
these O
properties, O
including O
noncovalent O
dimerization, O
can O
be O
tuned O
to O
produce O
isothermal O
phase O
separation. O
To O
test O
this O
hypothesis, O
constructs O
were O
evaluated O
consisting O
of O
an O
immunophilin: B-GENE-N
human B-GENE-Y
FK-506 B-CHEMICAL
binding I-GENE-Y
protein I-GENE-Y
12 I-GENE-Y
(FKBP) B-GENE-Y
attached O
to O
an O
ELP. B-GENE-N
Under O
stoichiometric O
binding O
of O
a O
CID, O
the O
fusion O
protein O
homodimerizes O
and O
triggers O
phase O
separation. O
This O
dimerization O
is O
reversible O
upon O
saturation O
with O
excess O
CID O
or O
competitive O
binding O
of O
a O
small O
lipophilic O
macrolide O

to O
FKBP. O
By O
modulating O
the O
ELP B-GENE-N
molecular O
weight, O
phase O
separation O
was O
tuned O
for O
isothermal O
response O
to O
CID O
at O
physiological O
ionic O
strength O
and O
temperature O
(37 O
C). O
To O
interpret O
the O
relationship O
between O
transition O
temperature O
and O
equilibrium O
binding O
constants, O
an O
empirical O
mathematical O
model O
was O
employed. O
To O
the O
best O
of O
our O
knowledge, O
this O
report O
is O
the O
first O
demonstration O
of O
reversible O
ELP B-GENE-N
switching O
in O
response O
to O
controlled O
dimerization. O
Due O
to O
its O
simplicity, O
this O
strategy O
may O
be O
useful O
to O
design O
ELP B-GENE-N
fusion O
proteins O
that O
respond O
to O
specific O
dimeric O
biological O
entities. O
Protective O
role O
of O
L-carnitine B-CHEMICAL
and O
vitamin B-CHEMICAL
E I-CHEMICAL
on O

the O
testis O
of O
atherosclerotic O
rats. O
Atherosclerosis O
is O
a O
condition O
caused O
by O
lipid O
build-up O
and O
inflammation O
in O
the O
arteries, O
so O
hyperlipidemia O
is O
the O
major O
reason O
for O
atherosclerosis. O
Testis O
was O
found O
to O
be O
negatively O
affected O
by O
hyperlipidemia O
which O
leads O
to O
its O
impaired O
functions. O
Vitamin B-CHEMICAL
E I-CHEMICAL
and O
<sc>l</sc>-carnitine B-CHEMICAL
have O
well-known O
lipid-lowering O
and O
antioxidative O
activities. O
Triton B-CHEMICAL
WR I-CHEMICAL
1339 I-CHEMICAL
is O
a O
non-ionic O
detergent, O
which O
induces O
severe O

hyperlipidemia O
by O
inhibition O
of O
lipoprotein O
lipase. O
The O
present O
study O
evaluates O
the O
protective O
role O
of O
vitamin B-CHEMICAL
E I-CHEMICAL
and O
<sc>l</sc>-carnitine B-CHEMICAL
on O
the O
testis O
in O
atherosclerosis O
and O
detects O
the O
most O
effective O
choice O
for O
protection O
against O
atherosclerosis; O
vitamin B-CHEMICAL
E, I-CHEMICAL
<sc>l</sc>-carnitine B-CHEMICAL
or O
a O
combination O
of O
both. O
A O
total O
of O
80 O
albino O
male O
rats O
were O
divided O
into O
eight O
groups O
(10 O
rats O
for O
each O
group): O
control O
(G(1)), O
triton B-CHEMICAL

(G(2)), O
<sc>l</sc>-carnitine B-CHEMICAL
(G(3)), O
triton B-CHEMICAL
+ O
<sc>l</sc>-carnitine B-CHEMICAL
(G(4)), O
vitamin B-CHEMICAL
E I-CHEMICAL
(G(5)), O
triton B-CHEMICAL
+ O
vitamin B-CHEMICAL
E I-CHEMICAL
(G(6)), O
<sc>l</sc>-carnitine B-CHEMICAL
+ O
vitamin B-CHEMICAL
E I-CHEMICAL
(G(7)) O
and O
triton B-CHEMICAL
+ O
<sc>l</sc>-carnitine B-CHEMICAL
+ O
vitamin B-CHEMICAL
E I-CHEMICAL

(G(8)). O
Data O
showed O
a O
significant O
increase O
in O
the O
levels O
of O
total O
cholesterol B-CHEMICAL
(TC), O
triglycerides B-CHEMICAL
(TGs), O
low-density O
lipoprotein O
cholesterol B-CHEMICAL
(LDL-C), O
17 B-CHEMICAL
beta I-CHEMICAL
hydroxysteroid I-CHEMICAL
dehydrogenase O
(17 O
 O
HSD), O
testicular O
catalase O
and O
malondialdehyde B-CHEMICAL
(MDA) B-CHEMICAL
in O
G(2) O
when O
compared O
with O
G(1), O
whereas O
high-density O
lipoprotein O
cholesterol B-CHEMICAL
(HDL-C), O
serum O

testosterone, B-CHEMICAL
testicular O
17 O
ketosteroid B-CHEMICAL
reductase O
(17 O
KSR), O
total O
thiol B-CHEMICAL
and O
glutathione-S-transferase B-CHEMICAL
(GST) O
data O
showed O
a O
significant O
decrease O
in O
G(2) O
when O
compared O
with O
G(1). O
Treatment O
with O
<sc>l</sc>-carnitine B-CHEMICAL
or/and O
vitamin B-CHEMICAL
E I-CHEMICAL
helps O
in O
improving O
the O
adverse O
effect O
of O
triton; B-CHEMICAL
also O
the O
histological O
changes O
confirm O
this O
finding. O
So O
the O
present O
study O
recommends O
all O
people O
to O
include O
<sc>l</sc>-carnitine B-CHEMICAL
and O
vitamin B-CHEMICAL
E I-CHEMICAL
in O
their O
diet O

to O
be O
protected O
against O
atherosclerosis. O
The O
CRF(1) B-GENE-Y
receptor I-GENE-Y
antagonist O
SSR125543 B-CHEMICAL
prevents O
stress-induced O
cognitive O
deficit O
associated O
with O
hippocampal O
dysfunction: O
Comparison O
with O
paroxetine B-CHEMICAL
and O
D-cycloserine. B-CHEMICAL
RATIONALE: O
The O
selective O
CRF(1) B-GENE-Y
(corticotropin I-GENE-Y
releasing I-GENE-Y
factor I-GENE-Y
type I-GENE-Y
1) I-GENE-Y
receptor I-GENE-Y
antagonist O
SSR125543 B-CHEMICAL
has O
been O
previously O
shown O
to O
attenuate O
the O
long-term O
cognitive O
deficit O
produced O
by O
traumatic O
stress O
exposure. O
Memory O
disturbances O
described O
in O
post-traumatic O
stress O
disorder O
(PTSD) O
patients O
are O
believed O
to O
be O
associated O

with O
changes O
in O
neuronal O
activity, O
in O
particular O
at O
the O
level O
of O
the O
hippocampus. O
OBJECTIVES: O
The O
present O
study O
aims O
at O
investigating O
whether O
the O
effects O
of O
SSR125543 B-CHEMICAL
(10 O
mg/kg/day O
for O
2 O
weeks) O
on O
cognitive O
impairment O
induced O
by O
traumatic O
stress O
exposure O
are O
associated O
with O
changes O
in O
hippocampal O
excitability. O
Effects O
of O
SSR125543 B-CHEMICAL
were O
compared O
to O
those O
of O
the O
5-HT B-CHEMICAL
reuptake O
inhibitor, O
paroxetine B-CHEMICAL
(10 O
mg/kg/day), O
and O
the O
partial O
N-methyl-D-aspartate B-CHEMICAL

(NMDA) I-GENE-N
receptor I-GENE-N
agonist, O
D-cycloserine B-CHEMICAL
(10 O
mg/kg/day), O
two O
compounds O
which O
have O
demonstrated O
clinical O
efficacy O
against O
PTSD. O
METHODS: O
Mice O
received O
two O
unavoidable O
electric O
foot-shocks. O
Then, O
1 O
or O
16 O
days O
after O
stress, O
they O
were O
tested O
for O
their O
memory O
performance O
using O
the O
object O
recognition O
test. O
Neuronal O
excitability O
was O
recorded O
during O
the O
third O
week O
post-stress O
in O
the O
CA1 O
area O
of O
the O
hippocampus. O
Drugs O
were O
administered O
from O
day O
1 O
post-stress O
to O
the O
day O
preceding O
the O
electrophysiological O
study. O

RESULTS: O
Application O
of O
electric O
shocks O
produced O
cognitive O
impairment O
16, O
but O
not O
1 O
day O
after O
stress, O
an O
effect O
which O
was O
associated O
with O
a O
decrease O
in O
hippocampal O
neuronal O
excitability. O
Both O
stress-induced O
effects O
were O
prevented O
by O
repeated O
administration O
of O
SSR125543, B-CHEMICAL
paroxetine B-CHEMICAL
and O
D-cycloserine. B-CHEMICAL
CONCLUSIONS: O
These O
findings O
confirm O
that O
the O
CRF(1) B-GENE-Y
receptor I-GENE-Y
antagonist O
SSR125543 B-CHEMICAL
is O
able O
to O
attenuate O
the O
behavioral O
effects O
of O
traumatic O
stress O
exposure O
and O
indicate O
that O
these O
effects O
are O
associated O
with O
a O
normalization O
of O

hippocampal O
neuronal O
excitability O
impaired O
by O
stress. O
Synthesis O
and O
structure-activity O
relationships O
of O
indazole B-CHEMICAL
arylsulfonamides I-CHEMICAL
as O
allosteric O
CC-chemokine B-GENE-Y
receptor I-GENE-Y
4 I-GENE-Y
(CCR4) B-GENE-Y
antagonists. O
A O
series O
of O
indazole B-CHEMICAL
arylsulfonamides I-CHEMICAL
were O
synthesized O
and O
examined O
as O
human B-GENE-Y
CCR4 I-GENE-Y
antagonists. O
Methoxy- B-CHEMICAL
or O
hydroxyl-containing B-CHEMICAL
groups O
were O
the O
more O
potent O
indazole B-CHEMICAL
C4 O
substituents. O
Only O
small O
groups O
were O
tolerated O
at O
C5, O
C6, O
or O
C7, O
with O
the O

C6 O
analogues O
being O
preferred. O
The O
most O
potent O
N3-substituent O
was O
5-chlorothiophene-2-sulfonamide. B-CHEMICAL
N1 O
meta-substituted O
benzyl B-CHEMICAL
groups O
possessing O
an O
-amino-3-[(methylamino)acyl]-group B-CHEMICAL
were O
the O
most O
potent O
N1-substituents. O
Strongly O
basic O
amino B-CHEMICAL
groups O
had O
low O
oral O
absorption O
in O
vivo. O
Less O
basic O
analogues, O
such O
as O
morpholines, B-CHEMICAL
had O
good O
oral O
absorption; O
however, O
they O
also O
had O
high O
clearance. O
The O
most O
potent O
compound O
with O
high O
absorption O
in O

two O
species O
was O
analogue O
6 O
(GSK2239633A), B-CHEMICAL
which O
was O
selected O
for O
further O
development. O
Aryl B-CHEMICAL
sulfonamide I-CHEMICAL
antagonists O
bind O
to O
CCR4 B-GENE-Y
at O
an O
intracellular O
allosteric O
site O
denoted O
site O
II. O
X-ray O
diffraction O
studies O
on O
two O
indazole B-CHEMICAL
sulfonamide I-CHEMICAL
fragments O
suggested O
the O
presence O
of O
an O
important O
intramolecular O
interaction O
in O
the O
active O
conformation. O
Comparative O
analysis O
of O
nutritional O
compositions O
of O
transgenic O
high O
iron B-CHEMICAL
rice O
with O
its O
non-transgenic O
counterpart. O
Iron B-CHEMICAL
is O
an O
essential O
micronutrient O
for O
human O
nutrition O
and O
polished O
rice O
contains O
very O
low O
amount O
of O

iron. B-CHEMICAL
Rice O
with O
high O
iron B-CHEMICAL
content O
in O
seed O
endosperm O
has O
been O
developed O
by O
insertion O
of O
soybean B-GENE-N
ferritin I-GENE-N
gene O
under O
the O
control O
of O
the O
endosperm O
specific O
glutelin B-GENE-N
promoter I-GENE-N
into O
the O
genome O
of O
indica O
rice O
line O
IR68144. O
The O
nutritional O
composition O
of O
the O
brown O
and O
milled O
rice O
grain O
has O
been O
compared O
with O
that O
of O
the O
non-transgenic O
rice O
of O
the O
same O
variety. O
In O
this O
study, O
the O
nutritional O
components, O
as O
well O
as O
the O
anti-nutrient O
levels, O
were O
measured. O
Our O
studies O
established O
that O
apart O
from O
the O
increased O
level O
of O
iron B-CHEMICAL
and O
zinc B-CHEMICAL
in O
transgenic O

seeds, O
the O
nutritional O
quality O
of O
both O
the O
brown O
and O
milled O
rice O
grains O
from O
the O
transgenic O
line O
was O
substantially O
equivalent O
to O
that O
of O
the O
non-transgenic O
rice O
plants. O
The O
result O
clearly O
shows O
that O
the O
measured O
amounts O
of O
the O
nutritional O
components O
are O
well O
within O
the O
range O
of O
values O
reported O
for O
other O
commercial O
lines. O
Repeated O
Low O
Dose O
Administration O
of O
the O
Monoacylglycerol B-GENE-Y
Lipase I-GENE-Y
Inhibitor O
JZL184 B-CHEMICAL
Retains O
CB1 B-GENE-Y
Receptor O
Mediated O
Antinociceptive O
and O
Gastroprotective O
Effects. O
The O
monoacylglycerol B-GENE-Y
lipase I-GENE-Y
(MAGL) B-GENE-Y
inhibitor O

JZL184 B-CHEMICAL
produces O
antinociceptive O
and O
anti-inflammatory O
effects. O
However, O
repeated O
administration O
of O
high O
dose O
JZL184 B-CHEMICAL
(40 O
mg/kg) O
causes O
dependence, O
antinociceptive O
tolerance, O
cross-tolerance O
to O
the O
pharmacological O
effects O
of O
cannabinoid B-GENE-N
receptor I-GENE-N
agonists, O
and O
CB(1) B-GENE-Y
receptor O
downregulation O
and O
desensitization. O
This O
functional O
CB(1) B-GENE-Y
receptor O
tolerance O
poses O
a O
hurdle O
in O
the O
development O
of O
MAGL B-GENE-Y
inhibitors O
for O
therapeutic O
use. O
Consequently, O
the O
present O
study O
tested O
whether O
repeated O
administration O
of O
low O
dose O
JZL184 B-CHEMICAL
maintains O
its O

antinociceptive O
actions O
in O
the O
chronic O
constrictive O
injury O
(CCI) O
of O
the O
sciatic O
nerve O
neuropathic O
pain O
model O
and O
protective O
effects O
in O
a O
model O
of O
NSAlD-induced O
gastric O
hemorrhages. O
Mice O
given O
daily O
injections O
of O
high O
dose O
JZL184 B-CHEMICAL
(16 O
mg/kg) O
for O
six O
days O
displayed O
decreased O
CB(1) B-GENE-Y
receptor O
density O
and O
function O
in O
brain, O
as O
assessed O
in O
[(3)H]SR141716A B-CHEMICAL
binding O
and O
CP55,940-stimulated B-CHEMICAL
[(35)S]GTPS B-CHEMICAL
binding O
assays, O
respectively. O
In O

contrast, O
normal O
CB(1) B-GENE-Y
receptor O
expression O
and O
function O
were O
maintained O
following O
repeated O
administration O
of O
low O
dose O
JZL184 B-CHEMICAL
(8 O
mg/kg). O
Likewise, O
the O
antinociceptive O
and O
gastroprotective O
effects O
of O
high O
dose O
JZL184 B-CHEMICAL
underwent O
tolerance O
following O
repeated O
administration, O
but O
these O
effects O
were O
maintained O
following O
repeated O
low O
dose O
JZL184 B-CHEMICAL
treatment. O
Consistent O
with O
these O
observations, O
repeated O
high O
dose O
JZL184, B-CHEMICAL
but O
not O
repeated O
low O
dose O
JZL184, B-CHEMICAL
elicited O
cross-tolerance O
to O
the O
common O
pharmacological O
effects O
of O

(9)-tetrahydrocannabinol B-CHEMICAL
(THC). B-CHEMICAL
This O
same O
pattern O
of O
effects O
was O
found O
in O
a O
rimonabant-precipitated B-CHEMICAL
withdrawal O
model O
of O
cannabinoid O
dependence. O
Taken O
together, O
these O
results O
indicate O
that O
prolonged, O
partial O
MAGL B-GENE-Y
inhibition O
maintains O
potentially O
beneficial O
antinociceptive O
and O
anti-inflammatory O
effects, O
without O
producing O
functional O
CB(1) B-GENE-Y
receptor O
tachyphylaxsis/tolerance O
or O
cannabinoid O
dependence. O
Differential O
gene O
expression O
in O
ER-positive B-GENE-Y
and O
ER-negative B-GENE-Y
breast O
cancer O
cells O
upon O
leptin B-GENE-Y
stimulation. O
In O
postmenopausal O

women, O
adipositas O
represents O
a O
serious O
risk O
factor O
for O
cancer O
development O
and O
progression. O
White O
adipose O
tissue O
secretes O
the O
16 O
kDa O
hormone O
leptin B-GENE-Y
which O
plays O
a O
key O
role O
in O
the O
regulation O
of O
appetite O
and O
metabolism. O
An O
increasing O
number O
of O
reports O
indicate O
that O
leptin B-GENE-Y
also O
interferes O
with O
signal O
transduction O
pathways O
implicated O
in O
the O
development O
of O
breast O
cancer. O
In O
our O
previous O
study, O
we O
identified O
the O
estrogen B-CHEMICAL
receptor I-GENE-Y
alpha I-GENE-Y
(ER) B-GENE-Y
as O
a O
relevant O
enhancer O
of O
leptin-induced B-GENE-Y
signal O
transduction O
leading O
to O
transactivation O
of O
signal B-GENE-Y
transducer I-GENE-Y
and I-GENE-Y
activator I-GENE-Y
of I-GENE-Y
transcription I-GENE-Y
3 I-GENE-Y
(Stat3). B-GENE-Y
The O

purpose O
of O
this O
study O
is O
the O
investigation O
of O
specific O
target O
gene O
expression O
in O
response O
to O
leptin-mediated B-GENE-Y
Stat3 B-GENE-N
signaling. O
We O
performed O
a O
comprehensive O
microarray O
analysis O
of O
ER-positive B-GENE-Y
and O
ER-negative B-GENE-Y
MDA-MB-231 O
cells O
upon O
leptin B-GENE-Y
treatment O
and O
identified O
49 O
genes O
which O
showed O
a O
significant O
ER-dependent B-GENE-Y
regulation O
in O
leptin-treated B-GENE-Y
MDA-MB-231 O
cells. O
There O
was O
no O
intersection O
with O
genes O
which O
were O
merely O
up- O
or O
downregulated O
by O
ER B-GENE-Y
expression O
and O
only O
9 O
and O
11 O
genes O
overlapping O
targets O
which O
were O
regulated O
by O
leptin B-GENE-Y
stimulation O
either O
in O
ER-expressing B-GENE-Y
or O

ER-negative B-GENE-Y
MDA-MB-231 O
cells, O
respectively. O
To O
demonstrate O
the O
specificity, O
expression O
of O
three O
target O
genes O
was O
validated O
by O
quantitative O
real-time O
PCR. O
In O
conclusion, O
these O
data O
imply O
that O
leptin B-GENE-Y
can O
induce O
a O
different O
set O
of O
target O
genes O
dependent O
on O
ER B-GENE-Y
expression, O
which O
might O
contribute O
to O
the O
development O
and O
progression O
of O
cancer O
diseases. O
Design O
and O
synthesis O
of O
bicyclic B-CHEMICAL
pyrazinone I-CHEMICAL
and I-CHEMICAL
pyrimidinone I-CHEMICAL
amides I-CHEMICAL
as O
potent O
TF-FVIIa B-GENE-Y
inhibitors. O
Bicyclic B-CHEMICAL
pyrazinone I-CHEMICAL
and I-CHEMICAL
pyrimidinone I-CHEMICAL
amides I-CHEMICAL
were O
designed O
and O
synthesized O
as O

potent O
TF-FVIIa B-GENE-Y
inhibitors. O
SAR O
demonstrated O
that O
the O
S2 O
and O
S3 O
pockets O
of O
FVIIa B-GENE-Y
prefer O
to O
bind O
small, O
lipophilic O
groups. O
An O
X-ray O
crystal O
structure O
of O
optimized O
compound O
9b O
bound O
in O
the O
active O
site O
of O
FVIIa B-GENE-Y
showed O
that O
the O
bicyclic O
scaffold O
provides O
5 O
hydrogen B-CHEMICAL
bonding O
interactions O
in O
addition O
to O
projecting O
groups O
for O
interactions O
within O
the O
S1, O
S2 O
and O
S3 O
pockets. O
Compound O
9b O
showed O
excellent O
FVIIa B-GENE-Y
potency, O
good O
selectivity O
against O
FIXa, B-GENE-N
Xa, I-GENE-N
XIa I-GENE-N
and O

chymotrypsin, B-GENE-N
and O
good O
clotting O
activity. O
A O
multivalent O
peptide O
as O
an O
activator O
of O
hypoxia B-GENE-Y
inducible I-GENE-Y
factor-1. I-GENE-Y
Hypoxia B-GENE-N
inducible I-GENE-N
factor-1 I-GENE-N
(HIF-1) B-GENE-N
is O
a O
transcription O
factor O
found O
in O
mammalian O
cells O
under O
hypoxia. O
While O
HIF-1 B-GENE-Y
in O
hypoxia O
translocates O
to O
the O
nucleus O
where O
it O
transcribes O
the O
target O
genes O
including O
vascular B-GENE-Y
endothelial I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(VEGF) B-GENE-Y
mRNA, O
HIF-1 B-GENE-Y
is O
degraded O
under O
normoxia, O
which O

involves O
its O
proline B-CHEMICAL
hydroxylation O
and O
subsequent O
binding O
to O
the O
von B-GENE-Y
Hippel-Lindau I-GENE-Y
protein-Elongin I-GENE-Y
B-Elogin I-GENE-Y
C I-GENE-Y
(VBC) B-GENE-N
complex. O
Previously, O
peptide O
inhibitors O
against O
this O
interaction O
between O
hydroxylated O
HIF-1 B-GENE-Y
and O
VBC B-GENE-N
have O
been O
developed O
to O
stabilize O
the O
transcriptional O
activity O
of O
HIF-1 B-GENE-Y
by O
preventing O
the O
degradation O
of O
the O
protein O
even O
under O
normoxia. O
Despite O
the O
specific O
inhibition O
by O
these O
peptides, O
their O
poor O
inhibition O
potency O
needs O
to O
be O
improved O
for O
further O
clinical O
application. O
In O
this O
work, O
we O
have O
designed O
and O
prepared O
a O

streptavidin-based O
multivalent O
peptide O
inhibitor O
against O
the O
HIF-1-VBC B-GENE-Y
complexation. O
We O
have O
evaluated O
the O
potency O
of O
the O
multivalent O
peptide O
in O
terms O
of O
stabilization O
of O
HIF-1 B-GENE-Y
and O
the O
downstream O
effect. O
As O
the O
result, O
we O
have O
found O
that O
the O
inhibitor O
showed O
about O
13-fold O
lowered O
IC50 O
value O
compared O
with O
that O
of O
the O
corresponding O
monovalent O
peptide, O
thereby O
activating O
HIF-1 B-GENE-Y
and O
leading O
to O
up-regulation O
of O
VEGF B-GENE-Y
protein O
at O
the O
cellular O
level. O
Glucagon-induced B-GENE-Y
acetylation O
of O
Foxa2 B-GENE-Y
regulates O

hepatic O
lipid O
metabolism. O
Circulating O
levels O
of O
insulin B-GENE-Y
and O
glucagon B-GENE-Y
reflect O
the O
nutritional O
state O
of O
animals O
and O
elicit O
regulatory O
responses O
in O
the O
liver O
that O
maintain O
glucose B-CHEMICAL
and O
lipid O
homeostasis. O
The O
transcription O
factor O
Foxa2 B-GENE-Y
activates O
lipid O
metabolism O
and O
ketogenesis O
during O
fasting O
and O
is O
inhibited O
via O
insulin-PI3K-Akt B-GENE-Y
signaling-mediated O
phosphorylation O
at O
Thr156 O
and O
nuclear O
exclusion. O
Here O
we O
show O
that, O
in O
addition, O
Foxa2 B-GENE-Y
is O
acetylated O
at O
the O
conserved O
residue O
Lys259 O
following O
inhibition O
of O
histone B-GENE-N

deacetylases I-GENE-N
(HDACs) I-GENE-N
class I-GENE-N
I-III I-GENE-N
and O
the O
cofactors O
p300 B-GENE-Y
and O
SirT1 B-GENE-Y
are O
involved O
in O
Foxa2 B-GENE-Y
acetylation O
and O
deacetylation, O
respectively. O
Physiologically, O
fasting O
states O
and O
glucagon B-GENE-Y
stimulation O
are O
sufficient O
to O
induce O
Foxa2 B-GENE-Y
acetylation. O
Introduction O
of O
the O
acetylation-mimicking O
(K259Q) B-GENE-N
or O
-deficient O
(K259R) B-GENE-N
mutations O
promotes O
or O
inhibits O
Foxa2 B-GENE-Y
activity, O
respectively, O
and O
adenoviral O
expression O
of O
Foxa2-K259Q B-GENE-Y
augments O
expression O

of O
genes O
involved O
in O
fatty B-CHEMICAL
acid I-CHEMICAL
oxidation O
and O
ketogenesis. O
Our O
study O
reveals O
a O
molecular O
mechanism O
by O
which O
glucagon B-GENE-Y
signaling O
activates O
a O
fasting O
response O
through O
acetylation O
of O
Foxa2. B-GENE-Y
Antitumor O
and O
immunomodulatory O
activity O
of O
a O
water-soluble O
low O
molecular O
weight O
polysaccharide O
from O
Schisandra O
chinensis O
(Turcz.) O
Baill. O
A O
water-soluble O
low O
molecular O
weight O
polysaccharide O
(SCPP11) O
was O
extracted O
and O
purified O
using O
DEAE-cellulose O
and O
Sephadex O
G-100 O
column O
from O
Schisandra O
chinensis O

(Turcz.) O
Baill. O
Its O
in O
vivo O
and O
in O
vitro O
antitumor O
and O
immunomodulatory O
activity O
were O
investigated. O
The O
results O
showed O
that O
SCPP11 O
with O
a O
molecular O
weight O
of O
3.410(3)Da O
exhibited O
indirect O
cyctotoxic O
activity O
against O
tumor O
cells O
in O
vitro, O
but O
could O
significantly O
inhibit O
the O
growth O
of O
Heps O
cells O
in O
vivo O
at O
dose O
of O
50mg/kg, O
and O
its O
inhibition O
rate O
is O
higher O
than O
that O
in O
the O
positive O
group. O
Moreover, O
SCPP11 O
could O
ameliorate O
the O
hematological O
and O
biochemical O
parameters O

to O
almost O
normal O
and O
no O
significant O
changes O
in O
organ O
weight, O
and O
could O
increase O
the O
body O
weight. O
In O
addition, O
SCPP11 O
(at O
50mg/kg) O
could O
also O
increased O
in O
thymus O
indexes O
as O
well O
as O
IL-2 B-GENE-Y
and O
TNF- B-GENE-Y
levels O
in O
serum O
in O
vivo O
and O
significantly O
enhance O
the O
phagocytosis O
activity O
and O
the O
productions O
of O
NO B-CHEMICAL
of O
RAW264.7 O
in O
vitro. O
The O
results O
indicated O
that O
antitumor O
properties O
of O
SCPP11 O
might O
be O
achieved O
by O
improving O
immune O
response. O
It O
could O
be O
explored O
as O
a O
potential O
adjuvant O
against O
cancer O
used O
in O
the O
health O
food O
and O
pharmaceutical O
therapy. O

Fragment-based O
drug O
design O
and O
identification O
of O
HJC0123, B-CHEMICAL
a O
novel O
orally O
bioavailable O
STAT3 B-GENE-Y
inhibitor O
for O
cancer O
therapy. O
Fragment-based O
drug O
design O
(FBDD) O
is O
a O
promising O
approach O
for O
the O
generation O
of O
lead O
molecules O
with O
enhanced O
activity O
and O
especially O
drug-like O
properties O
against O
therapeutic O
targets. O
Herein, O
we O
report O
the O
fragment-based O
drug O
design, O
systematic O
chemical O
synthesis O
and O
pharmacological O
evaluation O
of O
novel O
scaffolds O
as O
potent O
anticancer O
agents O
by O
utilizing O
six O
privileged O
fragments O
from O
known O
STAT3 B-GENE-Y
inhibitors. O
Several O
new O
molecules O
such O
as O
compounds O
5, O
12, O
and O

19 O
that O
may O
act O
as O
advanced O
chemical O
leads O
have O
been O
identified. O
The O
most O
potent O
compound O
5 O
(HJC0123) B-CHEMICAL
has O
demonstrated O
to O
inhibit O
STAT3 B-GENE-N
promoter I-GENE-N
activity, O
downregulate O
phosphorylation O
of O
STAT3, B-GENE-Y
increase O
the O
expression O
of O
cleaved O
caspase-3, B-GENE-Y
inhibit O
cell O
cycle O
progression O
and O
promote O
apoptosis O
in O
breast O
and O
pancreatic O
cancer O
cells O
with O
low O
micromolar O
to O
nanomolar O
IC50 O
values. O
Furthermore, O
compound O
5 O
significantly O
suppressed O
estrogen B-GENE-Y
receptor I-GENE-Y
(ER)-negative B-GENE-Y
breast O
cancer O
MDA-MB-231 O
xenograft O
tumor O
growth O
in O
vivo O

(p.o.), O
indicating O
its O
great O
potential O
as O
an O
efficacious O
and O
orally O
bioavailable O
drug O
candidate O
for O
human O
cancer O
therapy. O
Transcription O
forms O
and O
remodels O
supercoiling B-GENE-N
domains I-GENE-N
unfolding O
large-scale O
chromatin O
structures. O
DNA O
supercoiling O
is O
an O
inherent O
consequence O
of O
twisting O
DNA O
and O
is O
critical O
for O
regulating O
gene O
expression O
and O
DNA O
replication. O
However, O
DNA O
supercoiling O
at O
a O
genomic O
scale O
in O
human O
cells O
is O
uncharacterized. O
To O
map O
supercoiling, O
we O
used O
biotinylated B-CHEMICAL
trimethylpsoralen I-CHEMICAL
as O
a O
DNA O
structure O
probe O
to O
show O
that O
the O
human O

genome O
is O
organized O
into O
supercoiling B-GENE-N
domains. I-GENE-N
Domains O
are O
formed O
and O
remodeled O
by O
RNA B-GENE-N
polymerase I-GENE-N
and O
topoisomerase B-GENE-N
activities O
and O
are O
flanked O
by O
GC-AT O
boundaries O
and O
CTCF B-GENE-Y
insulator O
protein-binding O
sites. O
Underwound B-GENE-N
domains I-GENE-N
are O
transcriptionally O
active O
and O
enriched O
in O
topoisomerase B-GENE-Y
I, I-GENE-Y
'open' O
chromatin O
fibers O
and O
DNase B-GENE-Y
I I-GENE-Y
sites, O
but O
they O
are O
depleted O
of O
topoisomerase B-GENE-Y
II. I-GENE-Y
Furthermore, O
DNA O
supercoiling O
affects O
additional O
levels O
of O
chromatin O
compaction O
as O
underwound B-GENE-N
domains I-GENE-N
are O
cytologically O
decondensed, O
topologically O

constrained O
and O
decompacted O
by O
transcription O
of O
short O
RNAs. O
We O
suggest O
that O
supercoiling O
domains O
create O
a O
topological O
environment O
that O
facilitates O
gene O
activation, O
providing O
an O
evolutionary O
purpose O
for O
clustering O
genes O
along O
chromosomes. O
Four O
new O
eudesmane-type B-CHEMICAL
sesquiterpenoid B-CHEMICAL
lactones I-CHEMICAL
from O
atractylenolide B-CHEMICAL
II I-CHEMICAL
by O
biotransformation O
of O
rat O
hepatic O
microsomes. O
The O
biotransformation O
of O
atractylenolide B-CHEMICAL
II, I-CHEMICAL
a O
major O
bioactive O
principle O
of O
the O
rhizomes O
of O
Atractylodes O
macrocephala O
Koidz., O
was O

investigated O
in O
vitro O
by O
incubation O
with O
rat O
hepatic O
microsomes O
pretreated O
with O
sodium B-CHEMICAL
phenobarbital. I-CHEMICAL
The O
biotransformation O
products O
were O
extracted O
and O
purified O
by O
chromatographic O
methods. O
Seven O
biotransformation O
products O
(BP1-BP7) O
were O
obtained O
and O
their O
structures O
were O
elucidated O
by O
NMR O
and O
MS O
data O
analyses O
and O
by O
comparison O
with O
the O
previously O
reported O
values, O
including O
four O
new O
compounds, O
namely O
4(R),15-epoxy-atractylenolide B-CHEMICAL
II I-CHEMICAL
(BP1), O

4(R),15-epoxy-13-hydroxyatractylenolide B-CHEMICAL
II I-CHEMICAL
(BP5), O
4(R),15-epoxy-1-hydroxyatractylenolide B-CHEMICAL
II I-CHEMICAL
(BP6), O
and O
4(R),15-dihydroxyatractylenolide B-CHEMICAL
II I-CHEMICAL
(BP7). O
The O
biotransformation O
pathway O
of O
atractylenolide B-CHEMICAL
II I-CHEMICAL
by O
hepatic O
microsomes O
was O
deducted O
based O
on O
the O
structure O
resolution O
of O
the O
products. O
The O
effects O
of O
the O
phosphodiesterase B-GENE-Y
type I-GENE-Y
5 I-GENE-Y
inhibitor O

vardenafil B-CHEMICAL
on O
cognitive O
performance O
in O
healthy O
adults: O
a O
behavioral- O
electroencephalography O
study. O
Phosphodiesterase B-GENE-Y
type I-GENE-Y
5 I-GENE-Y
inhibitors O
(PDE5-Is) B-GENE-Y
improve O
cognitive O
performance O
of O
rodents, O
but O
the O
few O
human O
studies O
investigating O
their O
effects O
did O
not O
systematically O
investigate O
cognitive O
effects O
and O
the O
results O
have O
been O
quite O
contradictory. O
Therefore, O
we O
examined O
whether O
the O
PDE5-I B-GENE-Y
vardenafil B-CHEMICAL
improves O
memory O
and O
executive O
functioning O
and O
affect O
electroencephalography O
(EEG) O
in O
healthy O
young O
adults. O
Participants O
were O
selected O
out O
of O
a O
group O
of O
volunteers, O
based O
on O
their O
performance O
on O
a O
memory O

screening O
and O
they O
were O
orally O
treated O
with O
vardenafil B-CHEMICAL
(10-20 O
mg O
or O
placebo). O
Memory O
and O
executive O
functioning O
were O
tested O
while O
EEG O
activity O
was O
recorded. O
Additionally, O
a O
simple O
reaction O
time O
task O
and O
questionnaires O
addressing O
various O
complaints O
were O
presented. O
No O
prominent O
effects O
of O
vardenafil B-CHEMICAL
on O
cognition O
were O
found: O
participants O
only O
made O
more O
mistakes O
on O
a O
reaction O
time O
task O
after O
20 O
mg O
vardenafil. B-CHEMICAL
During O
encoding O
of O
words, O
the O
P300 O
was O
generally O
smaller O
after O
vardenafil B-CHEMICAL
treatment. O
Furthermore, O
the O
N400 O
was O
larger O
after O
vardenafil B-CHEMICAL
10 O
mg O
than O
placebo O
treatment O
in O
a O
spatial O
memory O

task O
at O
Fz. O
Finally, O
headache O
and O
feeling O
weak O
were O
reported O
more O
after O
vardenafil B-CHEMICAL
treatment. O
Vardenafil B-CHEMICAL
did O
not O
affect O
cognitive O
performance O
of O
healthy O
adults O
and O
showed O
only O
some O
incidental O
effects O
on O
ERPs. O
These O
findings O
in O
humans O
do O
not O
corroborate O
the O
cognition-enhancing O
effects O
of O
PDE5-Is B-GENE-Y
in O
healthy O
animals. O
Atorvastatin B-CHEMICAL
withdrawal O
elicits O
oxidative/nitrosative O
damage O
in O
the O
rat O
cerebral O
cortex. O
Statins O
are O
inhibitors O
of O
the O
enzyme O
3-hydroxy-3-methylglutaryl B-GENE-Y
coenzyme I-GENE-Y
A I-GENE-Y

reductase, I-GENE-Y
the O
rate-limiting O
step O
in O
cholesterol B-CHEMICAL
biosynthesis. O
Statins O
effectively O
prevent O
and O
reduce O
the O
risk O
of O
coronary O
artery O
disease O
through O
lowering O
serum O
cholesterol, B-CHEMICAL
and O
also O
exert O
anti-thrombotic, O
anti-inflammatory O
and O
antioxidant O
effects O
independently O
of O
changes O
in O
cholesterol B-CHEMICAL
levels. O
On O
the O
other O
hand, O
clinical O
and O
experimental O
evidence O
suggests O
that O
abrupt O
cessation O
of O
statin O
treatment O
(i.e. O
statin O
withdrawal) O
is O
associated O
with O
a O
deleterious O
rebound O
phenomenon. O
In O
fact, O
statin O
withdrawal O
increases O
the O
risk O
of O

thrombotic O
vascular O
events, O
causes O
impairment O
of O
endothelium-dependent O
relaxation O
and O
facilitates O
experimental O
seizures. O
However, O
evidence O
for O
statin O
withdrawal-induced O
detrimental O
effects O
to O
the O
brain O
parenchyma O
is O
still O
lacking. O
In O
the O
present O
study O
adult O
male O
Wistar O
rats O
were O
treated O
with O
atorvastatin B-CHEMICAL
for O
seven O
days O
(10mg/kg/day) O
and O
neurochemical O
assays O
were O
performed O
in O
the O
cerebral O
cortex O
30min O
(atorvastatin B-CHEMICAL
treatment) O
or O
24h O
(atorvastatin B-CHEMICAL
withdrawal) O
after O
the O
last O
atorvastatin B-CHEMICAL
administration. O
We O
found O

that O
atorvastatin B-CHEMICAL
withdrawal O
decreased O
levels O
of O
nitric B-CHEMICAL
oxide I-CHEMICAL
and O
mitochondrial B-GENE-Y
superoxide B-CHEMICAL
dismutase I-GENE-Y
activity, O
whereas O
increased O
NADPH B-CHEMICAL
oxidase I-GENE-N
activity O
and O
immunoreactivity O
for O
the O
protein O
nitration O
marker O
3-nitrotyrosine B-CHEMICAL
in O
the O
cerebral O
cortex. O
Catalase, B-GENE-Y
glutathione-S-transferase B-GENE-N
and O
xanthine B-GENE-Y
oxidase I-GENE-Y
activities O
were O
not O
altered O
by O
atorvastatin B-CHEMICAL
treatment O
or O
withdrawal, O
as O
well O
as O
protein O
carbonyl B-CHEMICAL
and O
4-hydroxy-2-nonenal B-CHEMICAL
immunoreactivity. O
Immunoprecipitation O

of O
mitochondrial B-GENE-Y
SOD I-GENE-Y
followed O
by O
analysis O
of O
3-nitrotyrosine B-CHEMICAL
revealed O
increased O
levels O
of O
nitrated O
mitochondrial B-GENE-Y
SOD, I-GENE-Y
suggesting O
the O
mechanism O
underlying O
the O
atorvastatin B-CHEMICAL
withdrawal-induced O
decrease O
in O
enzyme O
activity. O
Altogether, O
our O
results O
indicate O
the O
atorvastatin B-CHEMICAL
withdrawal O
elicits O
oxidative/nitrosative O
damage O
in O
the O
rat O
cerebral O
cortex, O
and O
that O
changes O
in O
NADPH B-GENE-N
oxidase I-GENE-N
activity O
and O
mitochondrial B-GENE-Y
superoxide I-GENE-Y
dismutase I-GENE-Y
activities O
may O
underlie O
such O
harmful O
effects. O
Hyperthyroidism O
causes O
cardiac O
dysfunction O
by O
mitochondrial O
impairment O
and O
energy O

depletion. O
This O
study O
elucidates O
the O
role O
of O
metabolic O
remodeling O
in O
cardiac O
dysfunction O
induced O
by O
hyperthyroidism. O
Cardiac O
hypertrophy, O
structural O
remodeling, O
and O
expression O
of O
the O
genes O
associated O
with O
fatty B-CHEMICAL
acid I-CHEMICAL
metabolism O
were O
examined O
in O
rats O
treated O
with O
triiodothyronine B-CHEMICAL
(T3) O
alone O
(8 O
g/100 O
g O
body O
weight O
(BW), O
i.p.) O
for O
15 O
days O
or O
along O
with O
a O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
alpha I-GENE-Y
agonist O
bezafibrate B-CHEMICAL
(Bzf; B-CHEMICAL
30 O
g/100 O

g O
BW, O
oral) O
and O
were O
found O
to O
improve O
in O
the O
Bzf B-CHEMICAL
co-treated O
condition. O
Ultrastructure O
of O
mitochondria O
was O
damaged O
in O
T3-treated O
rat O
heart, O
which O
was O
prevented O
by O
Bzf B-CHEMICAL
co-administration. O
Hyperthyroidism-induced O
oxidative O
stress, O
reduction O
in O
cytochrome B-GENE-N
c I-GENE-N
oxidase I-GENE-N
activity, O
and O
myocardial O
ATP B-CHEMICAL
concentration O
were O
also O
significantly O
checked O
by O
Bzf. B-CHEMICAL
Heart O
function O
studied O
at O
different O
time O
points O
during O
the O
course O
of O
T3 O
treatment O
shows O
an O
initial O
improvement O
and O
then O
a O
gradual O
but O
progressive O
decline O
with O
time, O
which O
is O
prevented O
by O
Bzf B-CHEMICAL

co-treatment. O
In O
summary, O
the O
results O
demonstrate O
that O
hyperthyroidism O
inflicts O
structural O
and O
functional O
damage O
to O
mitochondria, O
leading O
to O
energy O
depletion O
and O
cardiac O
dysfunction. O
Endothelial O
cell O
response O
to O
(co)polymer O
nanoparticles O
depending O
on O
the O
inflammatory O
environment O
and O
comonomer O
ratio. O
Endothelial O
cells O
lining O
the O
lumen O
of O
blood O
vessels O
serve O
as O
a O
physiological O
barrier O
controlling O
nanoparticle O
movement O
from O
the O
vasculature O
into O
the O
tissue. O
For O
exploring O
the O
effect O
of O
polymer O
hydrophilicity O
on O
nanoparticle O
interactions O
with O
human O
umbilical O

vein O
endothelial O
cells O
(HUVECs) O
in O
vitro, O
a O
series O
of O
monomodal O
poly[acrylonitrile-co-(N-vinylpyrrolidone)] B-CHEMICAL
model O
nanoparticles O
with O
increasing O
hydrophilicity O
as O
related O
to O
their O
increasing O
content O
(0-30mol.%) O
of O
N-vinylpyrrolidone B-CHEMICAL
(NVP) B-CHEMICAL
were O
synthesized O
by O
miniemulsion O
polymerization. O
Nanoparticles O
with O
a O
low O
NVP B-CHEMICAL
content O
were O
rapidly O
endocytized O
into O
all O
cells O
independent O
from O
the O
particle O
dose O
with O
toxic O
effects O
only O
observed O
at O
high O
particle O

concentrations, O
while O
only O
10-30% O
of O
the O
cells O
incorporated O
particles O
with O
20mol.% O
NVP. B-CHEMICAL
Since O
pathologies O
are O
often O
related O
to O
inflammation, O
an O
inflammatory O
HUVEC O
culture O
condition O
with O
IL-1 B-GENE-Y
stimulation O
has O
been O
introduced O
and O
suggested O
to O
be O
widely O
applied O
for O
studying O
nanocarriers, O
since O
cellular O
uptake O
in O
this O
assay O
was O
clearly O
increased O
for O
NVP B-CHEMICAL
contents O
20mol.%. O
Importantly, O
the O
secretion O
of O
functional O
biological O
mediators O
by O
HUVEC O
was O
not O
relevantly O
influenced O
by O
the O
nanoparticles O
for O
both O
homeostatic O
and O
inflammatory O
conditions. O
These O
findings O
may O
motivate O
concepts O
for O

nanocarriers O
specifically O
targeted O
to O
pathologic O
regions. O
Additionally, O
rapidly O
endocytized O
RhodaminB B-CHEMICAL
loaded O
particles O
with O
low O
NVP B-CHEMICAL
content O
may O
be O
explored O
for O
cell O
labeling O
and O
tracking. O
Molecular O
mechanism O
regulating O
24-hour O
rhythm O
of O
dopamine B-CHEMICAL
d3 I-GENE-Y
receptor I-GENE-Y
expression O
in O
mouse O
ventral O
striatum. O
The O
dopamine B-CHEMICAL
D3 I-GENE-Y
receptor I-GENE-Y
(DRD3) B-GENE-Y
in O
the O
ventral O
striatum O
is O
thought O
to O
influence O
motivation O
and O
motor O
functions. O
Although O
the O
expression O
of O
DRD3 B-GENE-Y
in O
the O
ventral O
striatum O
has O
been O
shown O
to O
exhibit O
24-hour O
variations, O
the O
mechanisms O
underlying O
the O
variation O
remain O
obscure. O

Here, O
we O
demonstrated O
that O
molecular O
components O
of O
the O
circadian O
clock O
act O
as O
regulators O
that O
control O
the O
24-hour O
variation O
in O
the O
expression O
of O
DRD3. B-GENE-Y
The O
transcription O
of O
DRD3 B-GENE-Y
was O
enhanced O
by O
the O
retinoic B-CHEMICAL
acid-related I-CHEMICAL
orphan I-GENE-Y
receptor I-GENE-Y
 I-GENE-Y
(ROR), B-GENE-Y
and O
its O
activation O
was O
inhibited O
by O
the O
orphan B-GENE-N
receptor I-GENE-N
REV-ERB, B-GENE-Y
an O
endogenous O
antagonist O
of O
ROR. B-GENE-Y
The O
serum O
or O
dexamethasone-induced B-CHEMICAL
oscillation O
in O
the O
expression O
of O
DRD3 B-GENE-Y
in O
cells O
was O
abrogated O
by O
the O
downregulation O
or O
overexpression O
of O

REV-ERB, B-GENE-Y
suggesting O
that O
REV-ERB B-GENE-Y
functions O
as O
a O
regulator O
of O
DRD3 B-GENE-Y
oscillations O
in O
the O
cellular O
autonomous O
clock. O
Chromatin O
immunoprecipitation O
assays O
of O
the O
DRD3 B-GENE-N
promoter I-GENE-N
indicated O
that O
the O
binding O
of O
the O
REV-ERB B-GENE-Y
protein O
to O
the O
DRD3 B-GENE-N
promoter I-GENE-N
increased O
in O
the O
early O
dark O
phase. O
DRD3 B-GENE-Y
protein O
expression O
varied O
with O
higher O
levels O
during O
the O
dark O
phase. O
Moreover, O
the O
effects O
of O
the O
DRD3 B-GENE-Y
agonist O
7-hydroxy-N,N-dipropyl-2-aminotetralin B-CHEMICAL

(7-OH-DPAT)-induced B-CHEMICAL
locomotor O
hypoactivity O
were O
significantly O
increased O
when O
DRD3 B-GENE-Y
proteins O
were O
abundant. O
These O
results O
suggest O
that O
ROR B-GENE-Y
and O
REV-ERB B-GENE-Y
consist O
of O
a O
reciprocating O
mechanism O
wherein O
ROR B-GENE-Y
upregulates O
the O
expression O
of O
DRD3, B-GENE-Y
whereas O
REV-ERB B-GENE-Y
periodically O
suppresses O
the O
expression O
at O
the O
time O
of O
day O
when O
REV-ERB B-GENE-Y
is O
abundant. O
Our O
present O
findings O
revealed O
that O
a O
molecular O
link O
between O
the O
circadian O
clock O
and O
the O
function O
of O
DRD3 B-GENE-Y
in O
the O
ventral O
striatum O

acts O
as O
a O
modulator O
of O
the O
pharmacological O
actions O
of O
DRD3 B-GENE-Y
agonists/antagonists. O
Studies O
on O
an O
(S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic B-CHEMICAL
acid I-CHEMICAL
(AMPA) B-GENE-N
receptor I-GENE-N
antagonist O
IKM-159: B-CHEMICAL
asymmetric O
synthesis, O
neuroactivity, O
and O
structural O
characterization. O
IKM-159 B-CHEMICAL
was O
developed O
and O
identified O
as O
a O
member O
of O
a O
new O
class O
of O
heterotricyclic O
glutamate B-CHEMICAL
analogues O
that O
act O
as O
AMPA B-CHEMICAL
receptor-selective I-GENE-N
antagonists. O

However, O
it O
was O
not O
known O
which O
enantiomer O
of O
IKM-159 B-CHEMICAL
was O
responsible O
for O
its O
pharmacological O
activities. O
Here, O
we O
report O
in O
vivo O
and O
in O
vitro O
neuronal O
activities O
of O
both O
enantiomers O
of O
IKM-159 B-CHEMICAL
prepared O
by O
enantioselective O
asymmetric O
synthesis. O
By O
employment O
of O
(R)-2-amino-2-(4-methoxyphenyl)ethanol B-CHEMICAL
as O
a O
chiral O
auxiliary, O
(2R)-IKM-159 B-CHEMICAL
and O
the O
(2S)-counterpart O
were O
successfully O
synthesized O
in O
0.70% O
and O

1.5% O
yields, O
respectively, O
over O
a O
total O
of O
18 O
steps. O
Both O
behavioral O
and O
electrophysiological O
assays O
showed O
that O
the O
biological O
activity O
observed O
for O
the O
racemic O
mixture O
was O
reproduced O
only O
with O
(2R)-IKM-159, B-CHEMICAL
whereas O
the O
(2S)-counterpart O
was O
inactive O
in O
both O
assays. O
Racemic B-CHEMICAL
IKM-159 I-CHEMICAL
was O
crystallized O
with O
the O
ligand-binding O
domain O
of O
GluA2, B-GENE-Y
and O
the O
structure O
revealed O
a O
complex O
containing O
(2R)-IKM-159 B-CHEMICAL
at O
the O
glutamate O
binding O
site. O
(2R)-IKM-159 B-CHEMICAL

locks O
the O
GluA2 B-GENE-Y
in O
an O
open O
form, O
consistent O
with O
a O
pharmacological O
action O
as O
competitive O
antagonist O
of O
AMPA B-GENE-N
receptors. I-GENE-N
Binding O
of O
Diverse O
Environmental O
Chemicals O
with O
Human B-GENE-N
Cytochromes I-GENE-N
P450 I-GENE-N
2A13, I-GENE-N
2A6, I-GENE-N
and I-GENE-N
1B1 I-GENE-N
and O
Enzyme O
Inhibition. O
A O
total O
of O
68 O
chemicals O
including O
derivatives O
of O
naphthalene, B-CHEMICAL
phenanthrene, B-CHEMICAL
fluoranthene, B-CHEMICAL
pyrene, B-CHEMICAL
biphenyl, B-CHEMICAL
and O
flavone B-CHEMICAL
were O
examined O
for O
their O
abilities O
to O
interact O
with O
human B-GENE-N
P450s I-GENE-N
2A13 I-GENE-N
and I-GENE-N
2A6. I-GENE-N
Fifty-one O
of O
these O

68 O
chemicals O
induced O
stronger O
Type O
I O
binding O
spectra O
(iron B-CHEMICAL
low- O
to O
high-spin O
state O
shift) O
with O
P450 B-GENE-Y
2A13 I-GENE-Y
than O
those O
seen O
with O
P450 B-GENE-N
2A6, I-GENE-N
i.e., O
the O
spectral O
binding O
intensities O
(Amax/Ks O
ratio) O
determined O
with O
these O
chemicals O
were O
always O
higher O
for O
P450 B-GENE-Y
2A13. I-GENE-Y
In O
addition, O
benzo[c]phenanthrene, B-CHEMICAL
fluoranthene, B-CHEMICAL
2,3-dihydroxy-2,3-dihydrofluoranthene, B-CHEMICAL
pyrene, B-CHEMICAL

1-hydroxypyrene, B-CHEMICAL
1-nitropyrene, B-CHEMICAL
1-acetylpyrene, B-CHEMICAL
2-acetylpyrene, B-CHEMICAL
2,5,2',5'-tetrachlorobiphenyl, B-CHEMICAL
7-hydroxyflavone, B-CHEMICAL
chrysin, B-CHEMICAL
and O
galangin B-CHEMICAL
were O
found O
to O
induce O
a O
Type O
I O
spectral O
change O
only O
with O
P450 B-GENE-Y
2A13. I-GENE-Y
Coumarin B-CHEMICAL
7-hydroxylation, O
catalyzed O
by O
P450 B-GENE-Y
2A13, I-GENE-Y
was O
strongly O
inhibited O
by O

2'-methoxy-5,7-dihydroxyflavone, B-CHEMICAL
2-ethynylnaphthalene, B-CHEMICAL
2'-methoxyflavone, B-CHEMICAL
2-naphththalene B-CHEMICAL
propargyl I-CHEMICAL
ether, I-CHEMICAL
acenaphthene, B-CHEMICAL
acenaphthylene, B-CHEMICAL
naphthalene, B-CHEMICAL
1-acetylpyrene, B-CHEMICAL
flavanone, B-CHEMICAL
chrysin, B-CHEMICAL
3-ethynylphenanthrene, B-CHEMICAL
flavone, B-CHEMICAL
and O
7-hydroxyflavone; B-CHEMICAL
these O
chemicals O
induced O
Type O
I O
spectral O
changes O
with O
low O
Ks O
values. O
On O

the O
basis O
of O
the O
intensities O
of O
the O
spectral O
changes O
and O
inhibition O
of O
P450 B-GENE-Y
2A13, I-GENE-Y
we O
classified O
the O
68 O
chemicals O
into O
eight O
groups O
based O
on O
the O
order O
of O
affinities O
for O
these O
chemicals O
and O
inhibition O
of O
P450 B-GENE-Y
2A13. I-GENE-Y
The O
metabolism O
of O
chemicals O
by O
P450 B-GENE-Y
2A13 I-GENE-Y
during O
the O
assays O
explained O
why O
some O
of O
the O
chemicals O
that O
bound O
well O
were O
poor O
inhibitors O
of O
P450 B-GENE-Y
2A13. I-GENE-Y
Finally, O
we O
compared O
the O
68 O
chemicals O
for O
their O
abilities O
to O
induce O
Type O
I O
spectral O
changes O
of O
P450 B-GENE-Y
2A13 I-GENE-Y
with O
the O
Reverse O
Type O
I O
binding O
spectra O
observed O
with O
P450 B-GENE-Y

1B1: I-GENE-Y
45 O
chemicals O
interacted O
with O
both O
P450s B-GENE-N
2A13 I-GENE-N
and I-GENE-N
1B1, I-GENE-N
indicating O
that O
the O
two O
enzymes O
have O
some O
similarty O
of O
structural O
features O
regarding O
these O
chemicals. O
Molecular O
docking O
analyses O
suggest O
similarities O
at O
the O
active O
sites O
of O
these O
P450 B-GENE-N
enzymes. I-GENE-N
These O
results O
indicate O
that O
P450 B-GENE-Y
2A13, I-GENE-Y
as O
well O
as O
Family O
1 O
P450 B-GENE-N
enzymes, I-GENE-N
is O
able O
to O
catalyze O
many O
detoxication O
and O
activation O
reactions O
with O
chemicals O
of O
environmental O
interest. O
Discovery O
of O
a O
Novel O
Selective O
PPAR B-GENE-Y
Ligand O
with O
Partial O
Agonist O
Binding O
Properties O
by O
Integrated O
in O
Silico/in O
Vitro O

Work O
Flow. O
Full O
agonists O
to O
the O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
(PPAR), I-GENE-Y
such O
as O
Rosiglitazone, B-CHEMICAL
have O
been O
associated O
with O
a O
series O
of O
undesired O
side O
effects, O
such O
as O
weight O
gain, O
fluid O
retention, O
cardiac O
hypertrophy, O
and O
hepatotoxicity. O
Nevertheless, O
PPAR B-GENE-Y
is O
involved O
in O
the O
expression O
of O
genes O
that O
control O
glucose B-CHEMICAL
and O
lipid O
metabolism O
and O
is O
an O
important O
target O
for O
drugs O
against O
type O
2 O
diabetes, O
dyslipidemia, O
atherosclerosis, O
and O
cardiovascular O
disease. O
In O
an O
effort O
to O
identify O
novel O
PPAR B-GENE-Y

ligands O
with O
an O
improved O
pharmacological O
profile, O
emphasis O
has O
shifted O
to O
selective O
ligands O
with O
partial O
agonist O
binding O
properties. O
Toward O
this O
end O
we O
applied O
an O
integrated O
in O
silico/in O
vitro O
workflow, O
based O
on O
pharmacophore- O
and O
structure-based O
virtual O
screening O
of O
the O
ZINC O
library, O
coupled O
with O
competitive O
binding O
and O
transactivation O
assays, O
and O
adipocyte O
differentiation O
and O
gene O
expression O
studies. O
Hit O
compound O
9 O
was O
identified O
as O
the O
most O
potent O
ligand O
(IC50 O
= O
0.3 O
M) O
and O
a O
relatively O
poor O
inducer O
of O
adipocyte O
differentiation. O

The O
binding O
mode O
of O
compound O
9 O
was O
confirmed O
by O
molecular O
dynamics O
simulation, O
and O
the O
calculated O
free O
energy O
of O
binding O
was O
-8.4 O
kcal/mol. O
A O
novel O
functional O
group, O
the O
carbonitrile B-CHEMICAL
group, O
was O
identified O
to O
be O
a O
key O
substituent O
in O
the O
ligand-protein O
interactions. O
Further O
studies O
on O
the O
transcriptional O
regulation O
properties O
of O
compound O
9 O
revealed O
a O
gene O
regulatory O
profile O
that O
was O
to O
a O
large O
extent O
unique, O
however O
functionally O
closer O
to O
that O
of O
a O
partial O
agonist. O
Structural O
Characterization O
of O
an O
LPA1 B-GENE-Y
Second B-GENE-N
Extracellular I-GENE-N
Loop I-GENE-N
Mimetic O
with O
a O
Self-Assembling O

Coiled-Coil B-GENE-N
Folding O
Constraint. O
G B-GENE-N
protein-coupled I-GENE-N
receptor I-GENE-N
(GPCR) B-GENE-N
structures O
are O
of O
interest O
as O
a O
means O
to O
understand O
biological O
signal O
transduction O
and O
as O
tools O
for O
therapeutic O
discovery. O
The O
growing O
number O
of O
GPCR B-GENE-N
crystal O
structures O
demonstrates O
that O
the O
extracellular B-GENE-N
loops I-GENE-N
(EL) B-GENE-N
connecting O
the O
membrane-spanning B-GENE-N
helices I-GENE-N
show O
tremendous O
structural O
variability O
relative O
to O
the O
more O
structurally-conserved O
seven O
transmembrane O
-helical B-GENE-N
domains. I-GENE-N
The O
EL B-GENE-N
of O
the O
LPA(1) B-CHEMICAL
receptor O
have O
not O
yet O
been O
conclusively O
resolved, O
and O
bear O
limited O
sequence O
identity O
to O
known O
structures. O
This O
study O
involved O
development O
of O

a O
peptide O
to O
characterize O
the O
intrinsic O
structure O
of O
the O
LPA(1) B-CHEMICAL
GPCR B-GENE-N
second O
EL. B-GENE-N
The O
loop O
was O
embedded O
between O
two O
helices O
that O
assemble O
into O
a O
coiled-coil, B-GENE-N
which O
served O
as O
a O
receptor-mimetic O
folding O
constraint O
(LPA(1)-CC-EL2 B-CHEMICAL
peptide). O
The O
ensemble O
of O
structures O
from O
multi-dimensional O
NMR O
experiments O
demonstrated O
that O
a O
robust O
coiled-coil B-GENE-N
formed O
without O
noticeable O
deformation O
due O
to O
the O
EL2 B-GENE-N
sequence. O
In O
contrast, O
the O
EL2 B-GENE-N
sequence O
showed O
well-defined O
structure O
only O
near O
its O
C-terminal B-CHEMICAL
residues. O
The O
NMR O

ensemble O
was O
combined O
with O
a O
computational O
model O
of O
the O
LPA(1) B-GENE-Y
receptor O
that O
had O
previously O
been O
validated. O
The O
resulting O
hybrid O
models O
were O
evaluated O
using O
docking. O
Nine O
different O
hybrid O
models O
interacted O
with O
LPA B-CHEMICAL
18:1 O
as O
expected, O
based O
on O
prior O
mutagenesis O
studies, O
and O
one O
was O
additionally O
consistent O
with O
antagonist O
affinity O
trends. O
The O
(R)-omeprazole B-CHEMICAL
hydroxylation O
index O
reflects O
CYP2C19 B-GENE-Y
activity O
in O
healthy O
Japanese O
volunteers. O
PURPOSE: O
Omeprazole B-CHEMICAL
has O
(R)- O
and O
(S)-enantiomers, O
which O
exhibit O
different O
pharmacokinetics O

(PK) O
among O
patients O
with O
cytochrome B-GENE-Y
P450 I-GENE-Y
(CYP) I-GENE-Y
2C19 I-GENE-Y
genotype O
groups. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
the O
1-point, O
4-h O
postdose O
(R)-omeprazole B-CHEMICAL
hydroxylation O
index O
(HI) O
of O
racemic B-CHEMICAL
omeprazole I-CHEMICAL
reflects O
the O
three O
CYP2C19 B-GENE-Y
genotype O
groups O
in O
Japanese O
individuals. O
METHODS: O
Ninety O
healthy O
Japanese O
individuals O
were O
enrolled O
and O
classified O
into O
the O
three O
different O
CYP2C19 B-GENE-Y
genotype O
groups: O
homozygous O
extensive O
metabolizers O

(hmEMs; O
n O
= O
34), O
heterozygous O
EMs O
(htEMs; O
n O
= O
44), O
and O
poor O
metabolizers O
(PMs; O
n O
= O
12). O
Blood O
samples O
were O
drawn O
4 O
h O
after O
the O
intake O
of O
an O
oral O
dose O
of O
omeprazole B-CHEMICAL
40 O
mg, O
and O
plasma O
levels O
of O
omeprazole B-CHEMICAL
and O
its O
metabolites O
were O
analyzed O
by O
high-performance O
liquid O
chromatography O
(HPLC) O
using O
a O
chiral O
column. O
RESULTS: O
Mean O
plasma O
concentrations O
of O
(R)- B-CHEMICAL
and I-CHEMICAL
(S)-omeprazole I-CHEMICAL
in O

PMs O
were O
significantly O
higher O
than O
those O
in O
hmEMs O
and O
htEMs, O
and O
similar O
results O
were O
obtained O
in O
the O
case O
of O
omeprazole B-CHEMICAL
sulfone. I-CHEMICAL
Additionally, O
there O
was O
a O
significant O
difference O
in O
plasma O
concentrations O
of O
(R)-5-hydroxyomeprazole B-CHEMICAL
among O
CYP2C19 B-GENE-Y
genotype O
groups, O
whereas O
no O
significant O
differences O
were O
observed O
in O
that O
of O
(S)-5-hydroxyomeprazole. B-CHEMICAL
Similarly, O
(R)-omeprazole B-CHEMICAL
HI O
in O
hmEMs, O
htEMs, O
and O
PMs O
were O
5.6, O

3.1, O
and O
0.3, O
respectively, O
which O
were O
significantly O
different, O
but O
no O
significant O
difference O
was O
present O
in O
the O
(S)-omeprazole B-CHEMICAL
HI. O
CONCLUSION: O
Our O
findings O
demonstrate O
that O
(R)-omeprazole B-CHEMICAL
HI O
correlated O
better O
with O
CYP2C19 B-GENE-Y
genotype O
groups O
than O
racemic-omeprazole B-CHEMICAL
HI, O
and O
these O
results O
may O
be O
useful O
for O
classification O
among O
patients O
in O
CYP2C19 B-GENE-Y
genotype O
groups O
prior O
to O
omeprazole O
treatment. O
Induction O
of O
xenobiotic B-GENE-N
receptors, I-GENE-N
transporters, O
and O
drug O
metabolizing O

enzymes O
by O
oxycodone. B-CHEMICAL
Perturbations O
of O
the O
expression O
of O
transporters O
and O
drug-metabolizing O
enzymes O
(DMEs) O
by O
opioids O
can O
be O
the O
locus O
of O
deleterious O
drug-drug O
interactions O
(DDIs). O
Many O
transporters O
and O
DMEs O
are O
regulated O
by O
xenobiotic B-GENE-N
receptors I-GENE-N
[XRs; B-GENE-N
e.g., O
pregnane B-GENE-Y
X I-GENE-Y
receptor I-GENE-Y
(PXR), B-GENE-Y
constitutive B-GENE-Y
androstane B-CHEMICAL
receptor I-GENE-Y
(CAR), B-GENE-Y
and O
Aryl B-CHEMICAL
hydrocarbon I-CHEMICAL
receptor I-GENE-Y
(AhR)]; B-GENE-Y
however, O
there O
is O
a O
paucity O
of O
information O

regarding O
the O
influence O
of O
opioids O
on O
XRs. B-GENE-N
The O
objective O
of O
this O
study O
was O
to O
determine O
the O
influence O
of O
oxycodone B-CHEMICAL
administration O
(15 O
mg/kg O
intraperitoneally O
twice O
daily O
for O
8 O
days) O
on O
liver O
expression O
of O
XRs, B-GENE-N
transporters, O
and O
DMEs O
in O
rats. O
Microarray, O
quantitative O
real-time O
polymerase O
chain O
reaction O
and O
immunoblotting O
analyses O
were O
used O
to O
identify O
significantly O
regulated O
genes. O
Three O
XRs B-GENE-N
(e.g., O
PXR, B-GENE-Y
CAR, B-GENE-Y
and O
AhR), B-GENE-Y
27 O
transporters O
(e.g., O
ABCB1 B-GENE-Y
and O

SLC22A8), B-GENE-Y
and O
19 O
DMEs O
(e.g., O
CYP2B2 B-GENE-Y
and O
CYP3A1) B-GENE-Y
were O
regulated O
(P O
< O
0.05) O
with O
fold O
changes O
ranging O
from O
-46.3 O
to O
17.1. O
Using O
MetaCore O
(computational O
platform), O
we O
identified O
a O
unique O
gene-network O
of O
transporters O
and O
DMEs O
assembled O
around O
PXR, B-GENE-Y
CAR, B-GENE-Y
and O
AhR. B-GENE-Y
Therefore, O
a O
series O
of O
transactivation/translocation O
assays O
were O
conducted O
to O
determine O
whether O
the O
observed O
changes O
of O
transporters/DMEs O
are O
mediated O
by O
direct O
activation O
of O

PXR, B-GENE-Y
CAR, B-GENE-Y
or O
AhR B-GENE-Y
by O
oxycodone B-CHEMICAL
or O
its O
major O
metabolites O
(noroxycodone B-CHEMICAL
and O
oxymorphone). B-CHEMICAL
Neither O
oxycodone B-CHEMICAL
nor O
its O
metabolites O
activated O
PXR, B-GENE-Y
CAR, B-GENE-Y
or O
AhR. B-GENE-Y
Taken O
together, O
these O
findings O
identify O
a O
signature O
hepatic O
gene-network O
associated O
with O
repeated O
oxycodone B-CHEMICAL
administration O
in O
rats O
and O
demonstrate O
that O
oxycodone B-CHEMICAL
alters O
the O
expression O
of O
many O
transporters O
and O
DMEs O
(without O
direct O
activation O
of O
PXR, B-GENE-Y
CAR, B-GENE-Y
and O
AhR), B-GENE-Y
which O
could O
lead O
to O

undesirable O
DDIs O
after O
coadministration O
of O
substrates O
of O
these O
transporters/DMEs O
with O
oxycodone. B-CHEMICAL
Strain-dependent O
dysregulation O
of O
one-carbon B-CHEMICAL
metabolism O
in O
male O
mice O
is O
associated O
with O
choline- B-CHEMICAL
and O
folate-deficient B-CHEMICAL
diet-induced O
liver O
injury. O
Dysregulation O
of O
one-carbon B-CHEMICAL
metabolism-related O
metabolic O
processes O
is O
a O
major O
contributor O
to O
the O
pathogenesis O
of O
nonalcoholic O
fatty O
liver O
disease O
(NAFLD). O
It O
is O
well O
established O
that O
genetic O
and O
gender-specific O
variations O
in O
one-carbon B-CHEMICAL
metabolism O
contribute O
to O
the O
vulnerability O
to O

NAFLD O
in O
humans. O
To O
examine O
the O
role O
of O
one-carbon B-CHEMICAL
metabolism O
dysregulation O
in O
the O
pathogenesis O
and O
individual O
susceptibility O
to O
NAFLD, O
we O
used O
a O
"population-based" O
mouse O
model O
where O
male O
mice O
from O
7 O
inbred O
were O
fed O
a O
choline- B-CHEMICAL
and O
folate-deficient B-CHEMICAL
(CFD) O
diet O
for O
12 O
wk. O
Strain-dependent O
down-regulation O
of O
several O
key O
one-carbon B-CHEMICAL
metabolism O
genes, O
including O
methionine B-GENE-Y
adenosyltransferase I-GENE-Y
1 I-GENE-Y
(Mat1a), B-GENE-Y
cystathionine--synthase B-GENE-Y

(Cbs), B-GENE-Y
methylenetetrahydrofolate B-GENE-Y
reductase I-GENE-Y
(Mthfr), B-GENE-Y
adenosyl-homocysteinase B-GENE-Y
(Ahcy), B-GENE-Y
and O
methylenetetrahydrofolate B-GENE-Y
dehydrogenase I-GENE-Y
1 I-GENE-Y
(Mthfd1), B-GENE-Y
was O
observed. O
These O
changes O
were O
strongly O
associated O
with O
interstrain O
variability O
in O
liver O
injury O
(steatosis, O
necrosis, O
inflammation, O
and O
activation O
of O
fibrogenesis) O
and O
hyperhomocysteinemia. O
Mechanistically, O
the O
decreased O
expression O
of O
Mat1a, B-GENE-Y
Ahcy, B-GENE-Y
and O

Mthfd1 B-GENE-Y
was O
linked O
to O
a O
reduced O
level O
and O
promoter O
binding O
of O
transcription O
factor O
CCAAT/enhancer B-GENE-Y
binding I-GENE-Y
protein I-GENE-Y
 I-GENE-Y
(CEBP), B-GENE-Y
which O
directly O
regulates O
their O
transcription. O
The O
strain O
specificity O
of O
diet-induced O
dysregulation O
of O
one-carbon B-CHEMICAL
metabolism O
suggests O
that O
interstrain O
variation O
in O
the O
regulation O
of O
one-carbon B-CHEMICAL
metabolism O
may O
contribute O
to O
the O
differential O
vulnerability O
to O
NFLD O
and O
that O
correcting O
the O
imbalance O
may O
be O
considered O
as O
preventive O
and O
treatment O
strategies O
for O
NAFLD.-Pogribny, O
I. O
P., O
Kutanzi, O
K., O
Melnyk, O

S., O
de O
Conti, O
A., O
Tryndyak, O
V., O
Montgomery, O
B., O
Pogribna, O
M., O
Muskhelishvili, O
L., O
Latendresse, O
J. O
R., O
James, O
S. O
J., O
Beland, O
F. O
A., O
Rusyn, O
I. O
Strain-dependent O
dysregulation O
of O
one-carbon B-CHEMICAL
metabolism O
in O
male O
mice O
is O
associated O
with O
choline- B-CHEMICAL
and O
folate-deficient B-CHEMICAL
diet-induced O
liver O
injury. O
Vitamin B-CHEMICAL
A I-CHEMICAL
and O
retinoid B-CHEMICAL
signaling: O
genomic O
and O
non-genomic O

effects. O
Vitamin B-CHEMICAL
A I-CHEMICAL
or O
retinol B-CHEMICAL
is O
arguably O
the O
most O
multifunctional O
vitamin B-CHEMICAL
in O
the O
human O
body O
as O
it O
is O
essential O
from O
embryogenesis O
to O
adulthood. O
The O
pleiotropic O
effects O
of O
vitamin B-CHEMICAL
A I-CHEMICAL
are O
exerted O
mainly O
by O
one O
active O
metabolite, O
all-trans B-CHEMICAL
retinoic I-CHEMICAL
acid I-CHEMICAL
(atRA), B-CHEMICAL
which O
regulates O
the O
expression O
of O
a O
battery O
of O
target O
genes O
through O
several O
families O
of O
nuclear B-GENE-N
receptors I-GENE-N
(RARs, B-GENE-N
RXRs B-GENE-N
and O
PPAR/), B-GENE-N
polymorphic B-GENE-N
retinoic B-CHEMICAL
acid I-CHEMICAL
(RA) I-GENE-N
response I-GENE-N
elements I-GENE-N
and O
multiple O
coregulators. O
It O
also O
involves O
extra O
nuclear O
and O

non-transcriptional O
effects O
such O
as O
the O
activation O
of O
kinase B-GENE-N
cascades, O
which O
are O
integrated O
in O
the O
nucleus O
via O
the O
phosphorylation O
of O
several O
actors O
of O
RA O
signaling. O
However, O
vitamin B-CHEMICAL
A I-CHEMICAL
itself O
proved O
recently O
to O
be O
active O
and O
RARs B-GENE-N
to O
be O
present O
in O
the O
cytosol O
to O
regulate O
translation O
and O
cell O
plasticity. O
All O
these O
new O
concepts O
expand O
the O
scope O
of O
the O
biologic O
functions O
of O
vitamin B-CHEMICAL
A I-CHEMICAL
and O
RA. O
Phase O
stability O
and O
elastic O
properties O
of O
chromium B-CHEMICAL
borides I-CHEMICAL
with O
various O
stoichiometries. O
Phase O
stability O
is O
important O
to O
the O
application O
of O
materials. O
By O
first-principles O
calculations, O
we O
establish O
the O
phase O
stability O

of O
chromium B-CHEMICAL
borides I-CHEMICAL
with O
various O
stoichiometries. O
Moreover, O
the O
phases O
of O
CrB3 B-CHEMICAL
and O
CrB4 B-CHEMICAL
have O
been O
predicted O
by O
using O
a O
newly O
developed O
particle O
swarm O
optimization O
(PSO) O
algorithm. O
Formation O
enthalpy-pressure O
diagrams O
reveal O
that O
the O
MoB-type B-CHEMICAL
structure O
is O
more O
energetically O
favorable O
than O
the O
TiI-type B-CHEMICAL
structure O
for O
CrB. B-CHEMICAL
For O
CrB2 B-CHEMICAL
, O
the O
WB2 B-CHEMICAL
-type O
structure O
is O
preferred O
at O
zero O
pressure. O
The O
predicted O
new O
phase O
of O
CrB3 B-CHEMICAL
belongs O
to O
the O
hexagonal O
P-6m2 O
space O
group O
and O
it O
transforms O
into O

an O
orthorhombic O
phase O
as O
the O
pressure O
exceeds O
93 O
GPa. O
The O
predicted O
CrB4 B-CHEMICAL
(space O
group: O
Pnnm) O
phase O
is O
more O
energetically O
favorable O
than O
the O
previously O
proposed O
Immm O
structure. O
The O
mechanical O
and O
thermodynamic O
stabilities O
of O
predicted O
CrB3 B-CHEMICAL
and O
CrB4 B-CHEMICAL
are O
verified O
by O
the O
calculated O
elastic O
constants O
and O
formation O
enthalpies. O
The O
full O
phonon O
dispersion O
calculations O
confirm O
the O
dynamic O
stability O
of O
WB2 B-CHEMICAL
-type O
CrB2 B-CHEMICAL
and O
predicted O
CrB3 B-CHEMICAL
. O
The O
large O
shear O
moduli, O
large O
Young's O
moduli, O
low O

Poisson O
ratios, O
and O
low O
bulk O
and O
shear O
modulus O
ratios O
of O
CrB4 B-CHEMICAL
PSC O
and O
CrB4 B-CHEMICAL
PSD O
indicate O
that O
they O
are O
potential O
hard O
materials. O
Analyses O
of O
Debye O
temperature, O
electronic O
localization O
function, O
and O
electronic O
structure O
provide O
further O
understanding O
of O
the O
chemical O
and O
physical O
properties O
of O
these O
borides. O
Effect O
of O
miR-21 B-GENE-Y
on O
Renal O
Fibrosis O
by O
Regulating O
MMP-9 B-GENE-Y
and O
TIMP1 B-GENE-Y
in O
kk-ay O
Diabetic O
Nephropathy O
Mice. O
MicroRNAs O
(miRs) O
play O
important O
roles O
in O
initiation O
and O
progression O
of O
many O

pathologic O
processes. O
However, O
the O
roles O
of O
miRs O
in O
diabetic O
nephropathy O
remain O
unclear. O
This O
study O
was O
to O
determine O
whether O
miR-21 B-GENE-Y
was O
involved O
in O
diabetic O
nephropathy O
and O
to O
explore O
the O
relationship O
between O
miR-21 B-GENE-Y
and O
MMP9/TIMP1 B-GENE-Y
expression O
in O
diabetic O
nephropathy. O
In O
situ O
hybridization O
studies O
showed O
that O
miR-21 B-GENE-Y
was O
primarily O
localized O
and O
distributed O
in O
cortical O
glomerular O
and O
renal O
tubular O
cells O
in O
diabetic O
kk-ay O
kidney. O
Real-time O
quantitative O
RT-PCR O
demonstrated O
that O

the O
expression O
of O
miR-21 B-GENE-Y
was O
significantly O
increased O
in O
kk-ay O
mice, O
compared O
with O
control O
C57BL O
mice. O
Interestingly, O
miR-21 B-GENE-Y
expression O
positively O
correlated O
with O
urine O
albumin B-GENE-Y
creatine B-CHEMICAL
ratio O
(ACR), O
TIMP1, B-GENE-Y
collagen B-GENE-N
IV I-GENE-N
(ColIV), B-GENE-N
and O
fibronectin B-GENE-Y
(FN); B-GENE-Y
while O
negatively O
correlated O
with O
creatine B-CHEMICAL
clearance O
ratio O
(Ccr) O
and O
MMP-9 B-GENE-Y
protein. O
Importantly, O
antagomir-21 O
not O
only O
ameliorated O
Ccr O
and O
ACR O
but O
also O
decreased O
TIMP1, B-GENE-Y

ColIV, B-GENE-N
and O
FN B-GENE-Y
proteins. O
In O
conclusion, O
our O
data O
demonstrate O
that O
miR-21 B-GENE-Y
contributes O
to O
renal O
fibrosis O
by O
mediating O
MMP9/TIMP1 B-GENE-Y
and O
that O
inhibition O
of O
miR-21 B-GENE-Y
may O
be O
a O
novel O
target O
for O
diabetic O
nephropathy. O
Modification O
of O
the O
Catalytic O
Function O
of O
Human B-GENE-Y
Hydroxysteroid I-GENE-Y
Sulfotransferase I-GENE-Y
hSULT2A1 I-GENE-Y
by O
Formation O
of O
Disulfide B-CHEMICAL
Bonds. O
The O
human B-GENE-Y
cytosolic I-GENE-Y
sulfotransferase I-GENE-Y
hSULT2A1 I-GENE-Y
catalyzes O
the O
sulfation O
of O

a O
broad O
range O
of O
xenobiotics, O
as O
well O
as O
endogenous O
hydroxysteroids B-CHEMICAL
and O
bile B-CHEMICAL
acids. I-CHEMICAL
Reversible O
modulation O
of O
the O
catalytic O
activity O
of O
this O
enzyme O
could O
play O
important O
roles O
in O
its O
physiologic O
functions. O
Whereas O
other O
mammalian B-GENE-N
sulfotransferases I-GENE-N
are O
known O
to O
be O
reversibly O
altered O
by O
changes O
in O
their O
redox O
environment, O
this O
has O
not O
been O
previously O
shown O
for O
hSULT2A1. B-GENE-Y
We O
have O
examined O
the O
hypothesis O
that O
the O
formation O
of O
disulfide B-CHEMICAL
bonds O
in O
hSULT2A1 B-GENE-Y
can O
reversibly O
regulate O
the O
catalytic O
function O
of O
the O

enzyme. O
Three O
thiol B-CHEMICAL
oxidants O
were O
used O
as O
model O
compounds O
to O
investigate O
their O
effects O
on O
homogeneous O
preparations O
of O
hSULT2A1: B-GENE-Y
glutathione B-CHEMICAL
disulfide, I-CHEMICAL
5,5'-dithiobis(2-nitrobenzoic B-CHEMICAL
acid), I-CHEMICAL
and O
1,1'-azobis(N,N-dimethylformamide) B-CHEMICAL
(diamide). B-CHEMICAL
Examination O
of O
the O
effects O
of O
disulfide B-CHEMICAL
bond O
formation O
with O
these O
agents O
indicated O
that O
the O
activity O
of O
the O
enzyme O
is O
reversibly O
altered. O
Studies O
on O
the O
kinetics O
of O
the O

hSULT2A1-catalyzed B-GENE-Y
sulfation O
of O
dehydroepiandrosterone B-CHEMICAL
(DHEA) B-CHEMICAL
showed O
the O
effects O
of O
disulfide B-CHEMICAL
bond O
formation O
on O
the O
substrate O
inhibition O
characteristics O
of O
the O
enzyme. O
The O
effects O
of O
these O
agents O
on O
the O
binding O
of O
substrates O
and O
products, O
liquid O
chromatography-mass O
spectrometry O
identification O
of O
the O
disulfides B-CHEMICAL
formed, O
and O
structural O
modeling O
of O
the O
modified O
enzyme O
were O
examined. O
Our O
results O
indicate O
that O
conformational O
changes O
at O
cysteines B-CHEMICAL
near O
the O
nucleotide B-CHEMICAL
binding O
site O
affect O
the O
binding O
of O
both O
the O
nucleotide B-CHEMICAL
and O
DHEA B-CHEMICAL
to O
the O
enzyme, O

with O
the O
specific O
effects O
dependent O
on O
the O
structure O
of O
the O
resulting O
disulfide. B-CHEMICAL
Thus, O
the O
formation O
of O
disulfide B-CHEMICAL
bonds O
in O
hSULT2A1 B-GENE-Y
is O
a O
potentially O
important O
reversible O
mechanism O
for O
alterations O
in O
the O
rates O
of O
sulfation O
of O
both O
endogenous O
and O
xenobiotic O
substrates. O
Synthesis O
of O
novel O
estrogen B-CHEMICAL
receptor I-GENE-Y
antagonists O
using O
metal-catalyzed O
coupling O
reactions O
and O
characterization O
of O
their O
biological O
activity. O
Estrogen B-GENE-Y
receptor I-GENE-Y
(ER) B-GENE-N
antagonists O
are O
valuable O
in O
the O
treatment O
of O
ER-positive B-GENE-Y
human O
breast O
cancer. O
In O
this O
study, O
we O
designed O
and O
synthesized O
nine O
new O
derivatives O
of O
17-estradiol B-CHEMICAL

(E2) O
with O
a O
bulky O
side O
chain O
attached O
to O
its O
C-7 O
position, O
and O
determined O
their O
ER B-GENE-Y
antagonistic O
activity O
using O
in O
vitro O
bioassays. O
Four O
of O
the O
derivatives O
showed O
a O
strong O
inhibition O
of O
ER B-GENE-Y
transactivation O
activity O
in O
a O
luciferase O
reporter O
assay O
and O
blocked O
ER B-GENE-Y
interactions O
with O
coactivators. O
Similarly, O
these O
derivatives O
also O
strongly O
inhibited O
the O
growth O
of O
the O
ER-positive B-GENE-Y
human O
breast O
cancer O
cells. O
Computational O
docking O
analysis O
was O
conducted O
to O
model O
the O
interaction O
of O
these O
antagonists O
with O
the O
human B-GENE-Y
ER I-GENE-Y
and O
showed O
that O
they O
could O
tightly O
bind O
to O
the O
ER B-GENE-N

in O
a O
manner O
similar O
to O
that O
of O
ICI-182,780, B-CHEMICAL
a O
pure O
ER B-GENE-Y
antagonist. O
These O
results O
provide O
an O
example O
that O
attachment O
of O
a O
bulky O
side O
chain O
to O
the O
C-7 O
position O
of O
E2 O
can O
produce O
ER B-GENE-Y
antagonists O
with O
ER B-GENE-Y
affinity O
comparable O
to O
that O
of O
ICI-182,780. B-CHEMICAL
Discovery O
of O
7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole B-CHEMICAL

(TASP0382088): B-CHEMICAL
a O
potent O
and O
selective O
transforming B-GENE-Y
growth I-GENE-Y
factor- I-GENE-Y
type I-GENE-Y
I I-GENE-Y
receptor I-GENE-Y
inhibitor O
as O
a O
topical O
drug O
for O
alopecia. O
7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole B-CHEMICAL
11 O
(TASP0382088) B-CHEMICAL
was O
synthesized O
and O
evaluated O
as O
transforming B-GENE-Y
growth I-GENE-Y
factor- I-GENE-Y
(TGF-) I-GENE-Y
type I-GENE-Y
I I-GENE-Y
receptor I-GENE-Y
(also O
known O
as O

activin B-GENE-Y
receptor-like I-GENE-Y
kinase I-GENE-Y
5 I-GENE-Y
or O
ALK5) B-GENE-Y
inhibitor. O
Compound O
11, O
a O
potent O
and O
selective O
ALK5 B-GENE-Y
inhibitor, O
exhibited O
good O
enzyme O
inhibitory O
activity O
(IC50=4.8 O
nM) O
as O
well O
as O
inhibitory O
activity O
against O
TGF--induced B-GENE-Y
Smad2/3 B-GENE-N
phosphorylation I-GENE-N
at O
a O
cellular O
level O
(IC50=17 O
nM). O
The O
introduction O
of O
a O
methoxy B-CHEMICAL
group O
to O
the O
benzothiazole B-CHEMICAL
ring O
in O
1 O
and O
the O
break O
up O
of O
the O
planarity O
between O
the O
imidazole B-CHEMICAL
ring O
and O
the O
thiazole B-CHEMICAL
ring O
improved O
the O

solubility O
in O
the O
lotion O
base O
of O
11. O
Furthermore, O
the O
topical O
application O
of O
3% O
11 O
lotion O
significantly O
inhibited O
Smad2 B-GENE-Y
phosphorylation I-GENE-Y
in O
mouse O
skin O
at O
8 O
h O
after O
application O
(71% O
inhibition, O
compared O
with O
vehicle-treated O
animals). O
ARF O
represses O
androgen B-CHEMICAL
receptor I-GENE-Y
transactivation O
in O
prostate O
cancer. O
Androgen B-CHEMICAL
receptor I-GENE-Y
(AR) B-GENE-Y
signaling O
is O
essential O
for O
prostate O
cancer O
(PCa) O
development O
in O
humans. O
The O
initiation O
of O
prostate O
malignancy O
and O
progression O
to O
a O
castration-resistant O
stage O
are O
largely O
contributed O
by O
the O
modulation O
of O
AR B-GENE-Y
activity O
through O
its O

coregulatory O
proteins. O
We O
and O
others O
previously O
reported O
that O
p14 B-GENE-Y
alternative I-GENE-Y
reading I-GENE-Y
frame I-GENE-Y
(ARF) B-GENE-Y
expression O
is O
positively O
correlated O
with O
the O
disease O
progression O
and O
severity O
of O
PCa. O
Here, O
we O
provide O
evidence O
that O
p14ARF B-GENE-Y
physically O
interacts O
with O
AR B-GENE-Y
and O
functions O
as O
an O
AR B-GENE-Y
corespressor O
in O
both O
an O
androgen-dependent B-CHEMICAL
and O
androgen-independent B-CHEMICAL
manner. O
Endogenous O
ARF B-GENE-Y
(p14ARF B-GENE-Y
in O
human O
and O
p19ARF B-GENE-Y
in O
mouse) O
and O
AR B-GENE-Y
colocalize O
in O
both O
human O
PCa O
cells O
in O
vitro O
and O
PCa O
tissues O
of O
mouse O
and O
human O
in O
vivo. O
Overexpression O
of O

p14ARF B-GENE-Y
in O
PCa O
cells O
significantly O
attenuates O
the O
activities O
of O
androgen B-CHEMICAL
response I-GENE-N
region I-GENE-N
(ARR2)-probasin B-GENE-N
and I-GENE-N
prostate-specific I-GENE-N
antigen I-GENE-N
(PSA) I-GENE-N
promoters. I-GENE-N
The O
forced O
expression O
of O
p14ARF B-GENE-Y
in O
cells O
resulted O
in O
a O
suppression O
of O
PSA B-GENE-Y
and O
NK B-GENE-Y
transcription I-GENE-Y
factor I-GENE-Y
locus I-GENE-Y
1 I-GENE-Y
(NKX3.1) B-GENE-Y
expression. O
Conversely, O
knockdown O
of O
endogenous O
p14ARF B-GENE-Y
in O
human O
PCa O
cells O
with O
short O
hairpin O
RNA O
enhanced O
AR B-GENE-Y
transactivation O
activities O
in O
a O
dose-dependent O
and O
p53-independent B-GENE-Y
manner. O
Furthermore, O
we O
demonstrated O
that O

p14ARF B-GENE-Y
binds O
to O
both O
the O
N-terminal B-CHEMICAL
domain O
and O
the O
ligand-binding O
domain O
of O
AR, B-GENE-Y
and O
the O
human B-GENE-N
double I-GENE-N
minute I-GENE-N
2 I-GENE-N
(HDM2)-binding I-GENE-N
motif I-GENE-N
of O
p14ARF B-GENE-Y
is O
required O
for O
the O
interaction O
of O
p14ARF B-GENE-Y
and O
AR B-GENE-Y
proteins. O
p14ARF B-GENE-Y
perturbs O
the O
androgen-induced B-CHEMICAL
interaction O
between O
the O
N B-CHEMICAL
terminus O
and O
C B-CHEMICAL
terminus O
of O
AR. B-GENE-Y
Most O
importantly, O
we O
observed O
that O
the O
expression O
of O
PSA B-GENE-Y
is O
reversely O
correlated O
with O
p14ARF B-GENE-Y
in O
human O
prostate O
tissues. O
Taken O
together, O
our O
results O
reveal O
a O
novel O
function O
of O
ARF B-GENE-Y
in O
modulation O
of O
AR B-GENE-Y

transactivation O
in O
PCa. O
Role O
of O
oxidative O
stress O
in O
chemical O
allergens O
induced O
skin O
cells O
activation. O
Allergic O
contact O
dermatitis O
(ACD) O
is O
an O
important O
occupational O
and O
environmental O
disease O
caused O
by O
topical O
exposure O
to O
chemical O
allergens. O
It O
describes O
the O
adverse O
effects O
that O
may O
results O
when O
exposure O
to O
a O
chemical O
elicits O
a O
T O
cell-mediated O
inflammatory O
skin O
disease. O
The O
ability O
of O
contact O
sensitizers O
to O
induce O
the O
oxidative O
stress O
pathway O
in O
keratinocytes O
and O
dendritic O
cells O
has O
been O
confirmed O
by O
several O
authors. O
Reactive O
oxygen B-CHEMICAL
species O
(ROS) O
can O
serve O
as O
essential O
second O

messengers O
mediating O
cellular O
responses O
resulting O
in O
immune O
cells O
activation. O
Oxidative O
stress O
may O
be O
the O
starter O
point, O
as O
it O
leads O
to O
the O
activation O
of O
transcription O
factors O
and O
signaling O
pathways, O
including O
NF-kB B-GENE-N
and O
p38 B-GENE-N
MAPK, B-GENE-N
which O
leads O
to O
the O
release O
of O
cytokines B-GENE-N
and O
chemokines. B-GENE-N
ROS O
are O
also O
involved O
in O
the O
activation O
of O
the O
NLRP3/NALP3 B-GENE-Y
inflammasome, O
which O
is O
required O
to O
direct O
the O
proteolytic O
maturation O
of O
inflammatory O
cytokines B-GENE-N
such O
as O
IL-1 B-GENE-Y
and O
IL-18, B-GENE-Y
which O
are O
all O
integral O
to O
the O
process O
of O

dendritic O
cells O
mobilization, O
migration O
and O
functional O
maturation. O
Moreover, O
emerging O
evidence O
correlates O
ROS O
to O
changes O
in O
the O
constitution O
of O
the O
extracellular O
microenvironment O
found O
to O
facilitate O
ACD. O
The O
purpose O
of O
this O
review O
is O
to O
provide O
both O
conceptual O
and O
technical O
frameworks O
on O
the O
role O
of O
oxidative O
stress O
in O
chemical O
allergy. O
Relative O
expression O
of O
cholesterol B-CHEMICAL
transport-related I-GENE-N
proteins I-GENE-N
and O
inflammation O
markers O
through O
the O
induction O
of O
7-ketosterol-mediated B-CHEMICAL
stress O
in O
Caco-2 O
cells. O
Human O
diets O
contain O
sterol B-CHEMICAL
oxidation O
products O
that O
can O
induce O
cytotoxic O
effects, O
mainly O

caused O
by O
cholesterol B-CHEMICAL
oxides. I-CHEMICAL
However, O
phytosterol B-CHEMICAL
oxides I-CHEMICAL
effects O
have O
been O
less O
extensively O
investigated. O
This O
study O
evaluates O
the O
production O
of O
inflammatory O
biomarkers O
(IL-1, B-GENE-Y
IL-8, B-GENE-Y
IL-10, B-GENE-Y
TNF) B-GENE-Y
and O
the O
influence O
of O
gene O
expression O
transporters O
and O
enzymes O
related O
to O
cholesterol B-CHEMICAL
absorption O
and O
metabolism O
(NPC1L1, B-GENE-Y
ABCG5/8, B-GENE-N
HMGCoA, B-GENE-Y
ACAT) B-GENE-Y
produced O
by O
7-ketosterols B-CHEMICAL
(stigmasterol/cholesterol) B-CHEMICAL
in O
Caco-2 O
cells. O
These O
effects O
were O
linked O
to O

intracellular O
signaling O
pathways O
by O
using O
several O
inhibitors. O
Results O
showed O
7-ketostigmasterol B-CHEMICAL
to O
have O
a O
greater O
proinflammatory O
potential O
than O
7-ketocholesterol. B-CHEMICAL
In O
non-pre-treated O
cells, O
only O
efflux B-GENE-N
transporters I-GENE-N
were O
down-regulated O
by O
7-ketosterols, B-CHEMICAL
showing O
a O
greater O
influence O
upon O
ABCG5 B-GENE-Y
expression. O
Cell-pre-incubation O
with O
bradykinin B-GENE-Y
induced O
changes O
in O
ABCG B-GENE-N
expression O
levels O
after O
7-ketostigmasterol-incubation; B-CHEMICAL
however, O
the O
energetic O
metabolism O
inhibition O
reduced O
NPC1L1 B-GENE-Y
expression O
only O

in O
7-ketocholesterol-incubated B-CHEMICAL
cells. O
In O
non-pre-treated O
cells, O
HMG-CoA B-CHEMICAL
was O
up-regulated O
by O
both O
7-ketosterols. B-CHEMICAL
However, O
exposure O
to O
inhibitors O
down-regulated O
the O
expression O
levels, O
mainly O
in O
7-ketocholesterol-incubated B-CHEMICAL
cells. O
While O
ACAT B-GENE-Y
expression O
values O
in O
non-pre-treated O
cells O
were O
unchanged, O
exposure O
to O
inhibitors O
caused O
down-regulation O
of O
mRNA O
levels. O
These O
results O
suggest O
that O
internalization O
and O
excretion O
of O
7-ketostigmasterol B-CHEMICAL
is O
probably O
influenced O
by O

[Ca]i, B-CHEMICAL
which O
also O
could O
mediate O
HMGCoA B-CHEMICAL
activity O
in O
POPs O
metabolism. O
However, O
energetic O
metabolism O
and O
reducing O
equivalents O
exert O
different O
influences O
upon O
the O
7-ketosterol B-CHEMICAL
internalization. O
Caffeic B-CHEMICAL
acid I-CHEMICAL
treatment O
alters O
the O
extracellular O
adenine B-CHEMICAL
nucleotide I-CHEMICAL
hydrolysis O
in O
platelets O
and O
lymphocytes O
of O
adult O
rats. O
This O
study O
evaluated O
the O
effects O
of O
caffeic B-CHEMICAL
acid I-CHEMICAL
on O
ectonucleotidase O
activities O
such O
as O
NTPDase B-GENE-N
(nucleoside B-GENE-N
triphosphate I-GENE-N
diphosphohydrolase), I-GENE-N
Ecto-NPP B-GENE-N

(nucleotide I-GENE-N
pyrophosphatase/phosphodiesterase), I-GENE-N
5'-nucleotidase B-GENE-Y
and O
adenosine B-CHEMICAL
deaminase I-GENE-Y
(ADA) B-GENE-Y
in O
platelets O
and O
lymphocytes O
of O
rats, O
as O
well O
as O
in O
the O
profile O
of O
platelet O
aggregation. O
Animals O
were O
divided O
into O
five O
groups: O
I O
(control); O
II O
(oil); O
III O
(caffeic B-CHEMICAL
acid I-CHEMICAL
10mg/kg); O
IV O
(caffeic B-CHEMICAL
acid I-CHEMICAL
50mg/kg); O
and O
V O
(caffeic B-CHEMICAL
acid I-CHEMICAL
100mg/kg). O
Animals O
were O
treated O
with O

caffeic B-CHEMICAL
acid I-CHEMICAL
diluted O
in O
oil O
for O
30days. O
In O
platelets, O
caffeic B-CHEMICAL
acid I-CHEMICAL
decreased O
the O
ATP B-CHEMICAL
hydrolysis O
and O
increased O
ADP B-CHEMICAL
hydrolysis O
in O
groups O
III, O
IV O
and O
V O
when O
compared O
to O
control O
(P<0.05). O
The O
5'-nucleotidase O
activity O
was O
decreased, O
while O
E-NPP B-GENE-N
and O
ADA B-GENE-Y
activities O
were O
increased O
in O
platelets O
of O
rats O
of O
groups O
III, O
IV O
and O
V O
(P<0.05). O
Caffeic B-CHEMICAL
acid I-CHEMICAL
reduced O
significantly O
the O
platelet O
aggregation O
in O
the O
animals O
of O
groups O
III, O
IV O
and O
V O
in O
relation O
to O
group O

I O
(P<0.05). O
In O
lymphocytes, O
the O
NTPDase B-GENE-N
and O
ADA B-GENE-Y
activities O
were O
increased O
in O
all O
groups O
treated O
with O
caffeic B-CHEMICAL
acid I-CHEMICAL
when O
compared O
to O
control O
(P<0.05). O
These O
findings O
demonstrated O
that O
the O
enzymes O
were O
altered O
in O
tissues O
by O
caffeic B-CHEMICAL
acid I-CHEMICAL
and O
this O
compound O
decreased O
the O
platelet O
aggregation O
suggesting O
that O
caffeic B-CHEMICAL
acid I-CHEMICAL
should O
be O
considered O
a O
potentially O
therapeutic O
agent O
in O
disorders O
related O
to O
the O
purinergic O
system. O
Mutant O
B-RAF-Mcl-1 B-GENE-Y
survival O
signaling O
depends O
on O
the O
STAT3 B-GENE-Y
transcription O
factor. O
Approximately O
50% O
of O
melanomas O
depend O

on O
mutant O
B-RAF B-GENE-Y
for O
proliferation, O
metastasis O
and O
survival. O
The O
inhibition O
of O
oncogenic O
B-RAF B-GENE-Y
with O
highly O
targeted O
compounds O
has O
produced O
remarkable O
albeit O
short-lived O
clinical O
responses O
in O
B-RAF B-GENE-Y
mutant O
melanoma O
patients. O
Reactivation O
of O
signaling O
downstream O
of O
B-RAF B-GENE-Y
is O
frequently O
associated O
with O
acquired O
resistance O
to O
B-RAF B-GENE-Y
inhibitors, O
and O
the O
identification O
of O
B-RAF B-GENE-Y
targets O
may O
provide O
new O
strategies O
for O
managing O
melanoma. O
Oncogenic O
B-RAF(V600E) B-GENE-Y
is O
known O
to O
promote O
the O
stabilizing O
phosphorylation O
of O
the O
anti-apoptotic O
protein O

Mcl-1, B-GENE-Y
implicated O
in O
melanoma O
survival O
and O
chemoresistance. O
We O
now O
show O
that O
B-RAF(V600E) B-GENE-Y
signaling O
also O
induces O
the O
transcription O
of O
Mcl-1 B-GENE-Y
in O
melanocytes O
and O
melanoma. O
We O
demonstrate O
that O
activation O
of O
STAT3 B-GENE-Y
serine-727 B-CHEMICAL
and O
tyrosine-705 B-CHEMICAL
phosphorylations O
is O
promoted O
by O
B-RAF(V600E) B-GENE-Y
activity O
and O
that O
the O
Mcl-1 B-GENE-N
promoter I-GENE-N
is O
dependent O
on O
a O
STAT B-GENE-N
consensus-site O
for O
B-RAF-mediated B-GENE-Y
activation. O
Consequently, O
suppression O
of O
STAT3 B-GENE-Y

activity O
disrupted O
B-RAF(V600E)-mediated B-GENE-Y
induction O
of O
Mcl-1 B-GENE-Y
and O
reduced O
melanoma O
cell O
survival. O
We O
propose O
that O
STAT3 B-GENE-Y
has O
a O
central O
role O
in O
the O
survival O
and O
contributes O
to O
chemoresistance O
of O
B-RAF(V600E) B-GENE-Y
melanoma.Oncogene O
advance O
online O
publication, O
4 O
March O
2013; O
doi:10.1038/onc.2013.45. O
Aldehyde B-GENE-N
oxidase I-GENE-N
importance O
in O
vivo O
in O
xenobiotic O
metabolism: O
imidacloprid B-CHEMICAL
nitroreduction O
in O
mice. O
Aldehyde B-GENE-N
oxidase I-GENE-N

(AOX) B-GENE-N
metabolizes O
many O
xenobiotics O
in O
vitro, O
but O
its O
importance O
in O
vivo O
is O
usually O
unknown O
relative O
to O
cytochrome B-GENE-N
P450s I-GENE-N
(CYPs) B-GENE-N
and O
other O
detoxification O
systems. O
Currently, O
the O
most O
important O
insecticides O
are O
neonicotinoids, B-CHEMICAL
which O
are O
metabolized O
in O
vitro O
by O
AOX B-GENE-N
on O
reduction O
of O
the O
nitroimino B-CHEMICAL
group O
and O
by O
CYPs B-GENE-N
via O
oxidation O
reactions. O
The O
goal O
of O
this O
study O
was O
to O
establish O
the O
relative O
importance O
of O
AOX B-GENE-N
and O
CYPs B-GENE-N
in O
vivo O
using O
the O
mouse O
model. O
The O
procedure O
was O
to O
reduce O
liver O
AOX B-GENE-N
activity O
by O

providing O
tungsten B-CHEMICAL
or O
hydralazine B-CHEMICAL
in O
the O
drinking O
water O
or O
to O
use O
the O
AOX-deficient B-GENE-N
DBA/2 O
mouse O
strain. O
None O
of O
these O
approaches O
reduced O
CYP B-GENE-N
activity O
measured O
in O
vitro O
with O
an O
isozyme O
nonspecific O
substrate. O
Liver O
AOX B-GENE-N
activity O
was O
reduced O
by O
45% O
with O
tungsten B-CHEMICAL
and O
61% O
with O
hydralazine B-CHEMICAL
and O
81% O
in O
AOX-deficient B-GENE-N
mice O
relative O
to O
controls. O
When O
mice O
were O
treated O
ip O
with O
the O
major O
neonicotinoid O
imidacloprid B-CHEMICAL
(IMI), B-CHEMICAL
metabolism O
by O
CYP B-GENE-N
oxidation O
reactions O
was O
not O
appreciably O

affected, O
whereas O
the O
AOX-generated B-GENE-N
nitrosoguanidine B-CHEMICAL
metabolite O
was O
decreased O
by O
30% O
with O
tungsten B-CHEMICAL
and O
56% O
with O
hydralazine B-CHEMICAL
and O
86% O
in O
the O
AOX-deficient B-GENE-N
mice. O
The O
other O
IMI B-CHEMICAL
nitroreduction O
metabolite, O
desnitro-IMI, B-CHEMICAL
was O
decreased O
by O
55%, O
65%, O
and O
81% O
with O
tungsten, B-CHEMICAL
hydralazine, B-CHEMICAL
and O
in O
the O
AOX-deficient B-GENE-N
mice, O
respectively. O
Thus, O
decreasing O
liver O
AOX B-GENE-N
activity O
by O
three O
quite O
different O
procedures O
gave O
a O
corresponding O
decrease O
for O
in O
vivo O
reductive O
metabolites O

in O
the O
liver O
of O
IMI-treated B-CHEMICAL
mice. O
Possible O
AOX B-GENE-N
involvement O
in O
IMI B-CHEMICAL
metabolism O
in O
insects O
was O
evaluated O
using O
AOX-expressing B-GENE-N
and O
AOX-deficient B-GENE-N
Drosophila, O
but O
no O
differences O
were O
found O
in O
IMI B-CHEMICAL
nitroreduction O
or O
sensitivity O
between O
the O
two O
strains. O
This O
is O
the O
first O
study O
to O
establish O
the O
in O
vivo O
relevance O
of O
AOX B-GENE-N
in O
neonicotinoid B-CHEMICAL
metabolism O
in O
mammals O
and O
one O
of O
the O
first O
for O
xenobiotics O
in O
general. O
Non-front-fanged O
colubroid O
snakes: O
A O
current O
evidence-based O
analysis O
of O
medical O
significance. O
Non-front-fanged O
colubroid O
snakes O

(NFFC; O
formerly O
and O
artificially O
taxonomically O
assembled O
as O
"colubrids") O
comprise O
about O
70% O
of O
extant O
snake O
species O
and O
include O
several O
taxa O
now O
known O
to O
cause O
lethal O
or O
life O
threatening O
envenoming O
in O
humans. O
Although O
the O
medical O
risks O
of O
bites O
by O
only O
a O
handful O
of O
species O
have O
been O
documented, O
a O
growing O
number O
of O
NFFC O
are O
implicated O
in O
medically O
significant O
bites. O
The O
majority O
of O
these O
snakes O
have O
oral O
products O
(Duvernoy's O
secretions, O
or O
venoms) O
with O
unknown O
biomedical O
properties O
and O
their O
potential O
for O
causing O
harm O
in O
humans O
is O
unknown. O
Increasingly, O
multiple O
NFFC O

species O
are O
entering O
the O
commercial O
snake O
trade O
posing O
an O
uncertain O
risk. O
Published O
case O
reports O
describing O
NFFC O
bites O
were O
assessed O
for O
evidence-based O
value, O
clinical O
detail O
and O
verified O
species O
identification. O
These O
data O
were O
subjected O
to O
meta-analysis O
and O
a O
hazard O
index O
was O
generated O
for O
select O
taxa. O
Cases O
on O
which O
we O
consulted O
or O
personally O
treated O
were O
included O
and O
subjected O
to O
the O
same O
assessment O
criteria. O
Cases O
involving O
approximately O
120 O
species O
met O
the O
selection O
criteria, O
and O
a O
small O
subset O
designated O
Hazard O
Level O
1 O
(most O
hazardous), O
contained O
5 O
species O
with O
lethal O
potential. O
Recommended O
management O
of O
these O
cases O
included O
antivenom O
for O
3 O
species, O
Dispholidus O

typus, O
Rhabdophis O
tiginis, O
Rhabdophis O
subminiatus, O
whereas O
others O
in O
this O
subset O
without O
commercially O
available O
antivenoms O
(Thelotornis O
spp.) O
were O
treated O
with O
plasma/erythrocyte O
replacement O
therapy O
and O
supportive O
care. O
Heparin, O
antifibrinolytics O
and/or O
plasmapheresis/exchange O
transfusion O
have O
been O
used O
in O
the O
management O
of O
some O
Hazard O
Level O
1 O
envenomings, O
but O
evidence-based O
analysis O
positively O
contraindicates O
the O
use O
of O
any O
of O
these O
interventions. O
Hazard O
Level O
2/3 O
species O
were O
involved O
in O
cases O

containing O
mixed O
quality O
data O
that O
implicated O
these O
taxa O
(e.g. O
Boiga O
irregularis, O
Philodryas O
olfersii, O
Malpolon O
monspessulanus) O
with O
bites O
that O
caused O
rare O
systemic O
effects. O
Recommended O
management O
may O
include O
use O
of O
acetylcholinesterase B-GENE-Y
inhibitors O
(e.g. O
neostigmine) B-CHEMICAL
and O
wound O
care O
on O
a O
case-by-case O
basis. O
Hazard O
level O
3 O
species O
comprised O
a O
larger O
group O
capable O
of O
producing O
significant O
local O
effects O
only, O
often O
associated O
with O
a O
protracted O
bite O
(eg O
Heterodon O
nasicus, O
Borikenophis O

(Alsophis) O
portoricensis, O
Platyceps O
(Coluber) O
rhodorachis). O
Management O
is O
restricted O
to O
wound O
care. O
Bites O
by O
Hazard O
level O
4 O
species O
comprised O
the O
majority O
of O
surveyed O
taxa O
and O
these O
showed O
only O
minor O
effects O
of O
no O
clinical O
importance. O
This O
study O
has O
produced O
a O
comprehensive O
evidence-based O
listing O
of O
NFFC O
snakes O
tabulated O
against O
medical O
significance O
of O
bites, O
together O
with O
best-practice O
management O
recommendations. O
This O
analysis O
assumes O
increasing O
importance, O
as O
there O
is O
growing O
exposure O
to O
lesser-known O
NFFC O
snakes, O
particularly O
in O
captive O
collections O
that O
may O
uncover O
further O
species O
of O
significance O
in O
the O
future. O

Careful O
and O
accurate O
documentation O
of O
bites O
by O
verified O
species O
of O
NFFC O
snakes O
is O
required O
to O
increase O
the O
evidence O
base O
and O
establish O
the O
best O
medical O
management O
approach O
for O
each O
species. O
Cell O
cycle O
arrest, O
extracellular O
matrix O
changes O
and O
intrinsic O
apoptosis O
in O
human O
melanoma O
cells O
are O
induced O
by O
Boron B-CHEMICAL
Neutron O
Capture O
Therapy. O
Boron B-CHEMICAL
Neutron O
Capture O
Therapy O
(BNCT) O
involves O
the O
selective O
accumulation O
of O
boron O
carriers O
in O
tumor O
tissue O
followed O
by O
irradiation O
with O
a O
thermal O
or O
epithermal O
neutron O
beam. O
This O
therapy O
is O
therefore O
a O
cellular O
irradiation O
suited O
to O
treat O
tumors O
that O
have O
infiltrated O
into O
healthy O

tissues. O
BNCT O
has O
been O
used O
clinically O
to O
treat O
patients O
with O
cutaneous O
melanomas O
which O
have O
a O
high O
mortality. O
Human O
normal O
melanocytes O
and O
melanoma O
cells O
were O
treated O
with O
BNCT O
at O
different O
boronophenylalanine B-CHEMICAL
concentrations O
for O
signaling O
pathways O
analysis. O
BNCT O
induced O
few O
morphological O
alterations O
in O
normal O
melanocytes, O
with O
a O
negligible O
increase O
in O
free O
radical O
production. O
Melanoma O
cells O
treated O
with O
BNCT O
showed O
significant O
extracellular O
matrix O
(ECM) O
changes O
and O
a O
significant O
cyclin B-GENE-Y
D1 I-GENE-Y
decrease, O
suggesting O
cell O
death O
by O
necrosis O
and O
apoptosis O
and O

cell O
cycle O
arrest, O
respectively. O
BNCT O
also O
induced O
a O
significant O
increase O
in O
cleaved O
caspase-3 B-GENE-Y
and O
a O
decrease O
in O
the O
mitochondrial O
electrical O
potential O
with O
selectivity O
for O
melanoma O
cells. O
Normal O
melanocytes O
had O
no O
significant O
differences O
due O
to O
BNCT O
treatment, O
confirming O
the O
data O
from O
the O
literature O
regarding O
the O
selectivity O
of O
BNCT. O
The O
results O
from O
this O
study O
suggest O
that O
some O
signaling O
pathways O
are O
involved O
in O
human O
melanoma O
treatment O
by O
BNCT, O
such O
as O
cell O
cycle O
arrest, O
ECM O
changes O
and O
intrinsic O
apoptosis. O
Anti-adipogenic O
diarylheptanoids B-CHEMICAL
from O
Alnus O
hirsuta O

f. O
sibirica O
on O
3T3-L1 O
cells. O
A O
new O
diarylheptanoid, B-CHEMICAL
(5S)-hydroxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)-hepta-1E-en-3-one B-CHEMICAL
(1), O
was O
isolated O
along O
with O
seventeen O
known O
diarylheptanoids B-CHEMICAL
(2-18) O
from O
the O
methanol B-CHEMICAL
extract O
of O
Alnus O
hirsuta O
f. O
sibirica O
leaves O
using O
bioactivity-guided O
fractionation. O
Among O
the O
isolated O
compounds, O

compounds O
1 O
and O
2 O
and O
4-12 O
reduced O
lipid O
accumulation O
dose-dependently O
in O
3T3-L1 O
preadipocytes. O
Of O
the O
compounds O
active O
in O
the O
present O
assay O
system, O
the O
most O
potent O
compound O
7, O
platyphyllonol-5-O--d-xylopyranoside, B-CHEMICAL
significantly O
suppressed O
the O
induction O
of O
peroxisome B-GENE-Y
proliferator I-GENE-Y
activated I-GENE-Y
receptor I-GENE-Y
 I-GENE-Y
(PPAR B-GENE-Y
and O
CCAAT/enhancer B-GENE-Y
binding I-GENE-Y
protein I-GENE-Y
 I-GENE-Y
(C/EBP) B-GENE-Y
protein O
expression, O
and O
inhibited O
adipocyte O
differentiation O
induced O
by O
troglitazone, B-CHEMICAL
a O

PPAR B-GENE-Y
agonist. O
It O
was O
demonstrated O
that O
compound O
7 O
has O
anti-adipogenic O
activity O
mediated O
by O
the O
regulation O
of O
PPAR B-GENE-Y
dependent O
pathways. O
Benzenesulfonamides: B-CHEMICAL
a O
unique O
class O
of O
chemokine B-GENE-Y
receptor I-GENE-Y
type I-GENE-Y
4 I-GENE-Y
inhibitors. O
The O
interaction O
of O
CXCR4 B-GENE-Y
with O
CXCL12 B-GENE-Y
(SDF-1) B-GENE-Y
plays O
a O
critical O
role O
in O
cancer O
metastasis O
by O
facilitating O
the O
homing O
of O
tumor O
cells O
to O
metastatic O
sites. O
Based O
on O
our O
previously O
published O
work O
on O
CXCR4 B-GENE-Y
antagonists, O
we O
have O
synthesized O
a O
series O
of O
aryl B-CHEMICAL
sulfonamides I-CHEMICAL
that O
inhibit O
the O

CXCR4/CXCL12 B-GENE-Y
interaction. O
Analogue O
bioactivities O
were O
assessed O
with O
binding O
affinity O
and O
Matrigel O
invasion O
assays. O
Computer O
modeling O
was O
employed O
to O
evaluate O
a O
selection O
of O
the O
new O
analogues O
docked O
into O
the O
CXCR4 B-GENE-Y
X-ray O
structure O
and O
to O
rationalize O
discrepancies O
between O
the O
affinity O
and O
Matrigel O
in O
vitro O
assays. O
A O
lead O
compound O
displays O
nanomolar O
potency O
in O
the O
binding O
affinity O
assay O
(IC(50)=8.0 O
nM) O
and O
the O
Matrigel O
invasion O
assay O
(100 O
% O
blockade O
of O
invasion O
at O
10 O
nM). O

These O
data O
demonstrate O
that O
benzenesulfonamides B-CHEMICAL
are O
a O
unique O
class O
of O
CXCR4 B-GENE-Y
inhibitors O
with O
high O
potency. O
Oncolytic O
activity O
and O
mechanism O
of O
action O
of O
a O
novel O
L-cysteine B-CHEMICAL
derivative, O
L-cysteine, B-CHEMICAL
ethyl I-CHEMICAL
ester, I-CHEMICAL
S-(N-methylcarbamate) I-CHEMICAL
monohydrochloride. I-CHEMICAL
A O
study O
on O
the O
oncolytic O
activity O
of O
the O
L-cysteine B-CHEMICAL
derivative O
L-cysteine, B-CHEMICAL
ethyl I-CHEMICAL
ester, I-CHEMICAL
S-(N-methylcarbamate) I-CHEMICAL
monohydrochloride I-CHEMICAL

(NSC B-CHEMICAL
303861), I-CHEMICAL
revealed O
that O
the O
drug O
caused O
complete O
regression O
of O
the O
MX-1 O
human O
mammary O
tumor O
xenograft. O
The O
compound O
also O
exhibited O
moderate O
antitumor O
activity O
against O
murine O
leukemia O
P388 O
(T/C O
value O
of O
169% O
at O
a O
daily O
dose O
of O
400 O
mg/kg) O
and O
against O
M5076 O
sarcoma O
(T/C O
value O
of O
135% O
at O
a O
daily O
dose O
of O
600 O
mg/kg). O
The O
drug O
was O
inactive O
against O
B16 O
melanoma, O
Lewis O
lung, O
colon O
38 O
and O
CD8F1 O
mammary O

carcinomas. O
The O
compound O
exhibited O
significant O
cytotoxicity O
against O
hepatoma O
3924A O
cells O
in O
culture O
(LC50 O
= O
6 O
microM). O
Studies O
on O
the O
mechanism O
of O
action O
revealed O
that O
the O
cytotoxicity O
of O
the O
drug O
could O
be O
partially O
abrogated O
by O
protecting O
hepatoma O
3924A O
cells O
in O
culture O
with O
L-glutamine. B-CHEMICAL
At O
6 O
h O
after O
injection O
of O
the O
compound O
(400 O
mg/kg) O
into O
rats O
bearing O
hepatoma O
3924A, O
the O
pools O
of O
L-glutamine B-CHEMICAL
and O
L-glutamate B-CHEMICAL
in O
the O
tumor O
decreased O
to O
33% O
and O

71%, O
respectively, O
of O
control O
levels; O
the O
drug O
selectively O
inhibited O
the O
activities O
of O
L-glutamine-requiring B-CHEMICAL
enzymes O
of O
purine B-CHEMICAL
nucleotide I-CHEMICAL
biosynthesis, O
amidophosphoribosyltransferase, B-GENE-Y
FGAM B-CHEMICAL
synthase, I-GENE-Y
and O
GMP B-CHEMICAL
synthase, I-GENE-Y
to O
21%, O
1%, O
and O
69%, O
respectively, O
without O
significantly O
altering O
the O
activities O
of O
pyrimidine B-CHEMICAL
biosynthetic O
enzymes, O
carbamoylphosphate B-CHEMICAL
synthase I-GENE-Y
II I-GENE-Y
and O
CTP B-CHEMICAL
synthase. I-GENE-Y
Measurement O
of O
the O
nucleotide B-CHEMICAL
concentrations O
further O

corroborated O
the O
actions O
of O
the O
drug O
on O
the O
purine B-CHEMICAL
nucleotide I-CHEMICAL
biosynthetic O
enzyme O
activities. O
Drug O
injection O
(400 O
mg/kg) O
in O
the O
hepatoma O
3924A-bearing O
rats O
reduced O
the O
concentrations O
of O
IMP B-CHEMICAL
in O
the O
tumor O
to O
52%, O
those O
of O
total O
adenylates B-CHEMICAL
to O
52%, O
those O
of O
total O
guanylates B-CHEMICAL
to O
57%, O
and O
those O
of O
NAD B-CHEMICAL
to O
73%, O
without O
significantly O
perturbing O
the O
pyrimidine B-CHEMICAL
nucleotide I-CHEMICAL
pools. O
Studies O
on O
the O
mechanism O
of O
action O
of O
the O
L-cysteine B-CHEMICAL
derivative O
suggested O
that O
the O
compound O
behaved O

as O
an O
L-glutamine B-CHEMICAL
antagonist, O
selectively O
acting O
on O
the O
enzymes O
of O
purine B-CHEMICAL
nucleotide I-CHEMICAL
biosynthesis. O
Measurement O
of O
Transport O
Activities O
of O
3-Hydroxy-(5)-bile B-CHEMICAL
Acids I-CHEMICAL
in O
Bile B-GENE-Y
Salt I-GENE-Y
Export I-GENE-Y
Pump I-GENE-Y
and O
Multidrug B-GENE-N
Resistance-Associated I-GENE-N
Proteins I-GENE-N
Using O
LC-MS/MS. O
A O
method O
has O
been O
developed O
for O
the O
measurement O
of O
transport O
activities O
in O
membrane O
vesicles O
obtained O
from O
Sf9 O
cells O
for O
3-hydroxy-(5)-bile B-CHEMICAL
acids I-CHEMICAL
by O
high-performance O
liquid O

chromatography-electrospray O
ionization-tandem O
mass O
spectrometry. O
Calibration O
curves O
for O
the O
bile B-CHEMICAL
acids I-CHEMICAL
were O
linear O
over O
the O
range O
of O
10 O
to O
2000 O
pmol/mL, O
and O
the O
detection O
limit O
was O
less O
than O
1 O
pmol/mL O
for O
3-hydroxy-(5)-bile B-CHEMICAL
acids I-CHEMICAL
using O
selected O
reaction O
monitoring O
analysis. O
The O
analytical O
method O
was O
applied O
to O
measurements O
of O
transport O
activities O
in O
membrane O
vesicles O
obtained O
from O
human B-GENE-N
multidrug I-GENE-N
resistance-associated I-GENE-N
protein I-GENE-N
2-, I-GENE-N
3-, I-GENE-N
and O
human B-GENE-Y
bile B-CHEMICAL
salt I-CHEMICAL
export I-GENE-Y
pump-expressing I-GENE-Y
Sf9 O
cells O
for O
conjugated O

3-hydroxy-(5)-bile B-CHEMICAL
acids. I-CHEMICAL
The O
present O
study O
demonstrated O
that O
human B-GENE-Y
multidrug I-GENE-Y
resistance-associated I-GENE-Y
protein I-GENE-Y
3 I-GENE-Y
vesicles O
accepted O
conjugated O
3-hydroxy-(5)-bile B-CHEMICAL
acids I-CHEMICAL
along O
with O
common O
bile B-CHEMICAL
acids I-CHEMICAL
such O
as O
glycocholic B-CHEMICAL
acid I-CHEMICAL
and O
taurolithocholic B-CHEMICAL
acid I-CHEMICAL
3-sulfate. I-CHEMICAL
An O
Intracellular O
Domain O
Fragment O
of O
the O
p75 B-GENE-Y
Neurotrophin I-GENE-Y
Receptor I-GENE-Y
(p75NTR) B-GENE-Y
Enhances O
Tropomyosin B-GENE-Y
Receptor I-GENE-Y
Kinase I-GENE-Y
A I-GENE-Y
(TrkA) B-GENE-Y
Receptor O

Function. O
Facilitation O
of O
nerve B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(NGF) B-GENE-Y
signaling O
by O
the O
p75 B-GENE-Y
neurotrophin I-GENE-Y
receptor I-GENE-Y
(p75(NTR)) B-GENE-Y
is O
critical O
for O
neuronal O
survival O
and O
differentiation. O
However, O
the O
interaction O
between O
p75(NTR) B-GENE-Y
and O
TrkA B-GENE-Y
receptors O
required O
for O
this O
activity O
is O
not O
understood. O
Here, O
we O
report O
that O
a O
specific O
29-amino B-CHEMICAL
acid I-CHEMICAL
peptide O
derived O
from O
the O
intracellular O
domain O
fragment O
of O
p75(NTR) B-GENE-Y
interacts O
with O
and O
potentiates O
binding O
of O
NGF B-GENE-Y
to O
TrkA-expressing B-GENE-Y
cells, O
leading O
to O
increased O
neurite O
outgrowth O

in O
sympathetic O
neurons O
as O
a O
result O
of O
enhanced O
Erk1/2 B-GENE-N
and O
Akt B-GENE-N
signaling. O
An O
endogenous O
intracellular O
domain O
fragment O
of O
p75(NTR) B-GENE-Y
(p75(ICD)) B-GENE-N
containing O
these O
29 O
amino B-CHEMICAL
acids I-CHEMICAL
is O
produced O
by O
regulated O
proteolysis O
of O
the O
full-length O
receptor. O
We O
demonstrate O
that O
generation O
of O
this O
fragment O
is O
a O
requirement O
for O
p75(NTR) B-GENE-Y
to O
facilitate O
TrkA B-GENE-Y
signaling O
in O
neurons O
and O
propose O
that O
the O
juxtamembrane O
region O
of O
p75(ICD) B-GENE-N
acts O
to O
cause O
a O
conformational O
change O
within O
the O
extracellular O
domain O
of O
TrkA. B-GENE-Y
This O
finding O
provides O
new O

insight O
into O
the O
mechanism O
by O
which O
p75(NTR) B-GENE-Y
and O
TrkA B-GENE-Y
interact O
to O
enhance O
neurotrophic O
signaling. O
Synthesis O
and O
evaluation O
of O
3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines B-CHEMICAL
as O
Bcl-2 B-GENE-Y
inhibitory O
anticancer O
agents. O
A O
series O
of O
substituted O

3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines B-CHEMICAL
has O
been O
synthesised O
and O
tested O
in O
vitro O
as O
potential O
pro-apoptotic O
Bcl-2-inhibitory B-GENE-Y
anticancer O
agents. O
Synthesis O
of O
the O
target O
compounds O
was O
readily O
accomplished O
in O
good O
yields O
through O
a O
cyclisation O
reaction O
between O
indole-3-carboxylic B-CHEMICAL
acid I-CHEMICAL
hydrazide I-CHEMICAL
and O
carbon B-CHEMICAL
disulfide I-CHEMICAL
under O
basic O
conditions, O
followed O
by O

S-benzylation. B-CHEMICAL
Active O
compounds, O
such O
as O
the O
nitrobenzyl B-CHEMICAL
analogue O
6c, O
were O
found O
to O
exhibit O
sub-micromolar O
IC50 O
values O
in O
Bcl-2 B-GENE-Y
expressing O
human O
cancer O
cell O
lines. O
Molecular O
modelling O
and O
ELISA O
studies O
further O
implicated O
anti-apoptotic O
Bcl-2 B-GENE-Y
as O
a O
candidate O
molecular O
target O
underpinning O
anticancer O
activity. O
Effect O
of O
nicotine B-CHEMICAL
pretreatment O
on O
arsenic-induced B-CHEMICAL
oxidative O
stress O
in O
male O
Wistar O
rats. O
Humans O
are O
commonly O
exposed O
to O
nicotine, B-CHEMICAL
one O
of O
the O
most O
important O
lifestyle O
chemicals. O
The O
occurrence O

of O
high O
levels O
of O
arsenic B-CHEMICAL
in O
the O
groundwater O
of O
the O
southeast O
region O
of O
Asia O
has O
received O
much O
attention O
in O
the O
past O
decade O
and O
has O
become O
a O
global O
health O
concern. O
Predominant O
occurrence O
of O
both O
these O
chemicals O
and O
ease O
of O
their O
human O
exposure O
led O
us O
to O
investigate O
the O
effect O
of O
nicotine, B-CHEMICAL
a O
major O
tobacco O
alkaloid, O
on O
arsenic B-CHEMICAL
toxicity. O
Adult O
male O
rats O
were O
pre-exposed O
to O
two O
different O
doses O
of O
nicotine B-CHEMICAL
(0.75 O
and O
3 O
mg/kg, O
intraperitoneally) O
for O
7 O
days O
followed O
by O
30 O
days O
of O
arsenic B-CHEMICAL
exposure O
(50 O
ppm O
sodium B-CHEMICAL
arsenite I-CHEMICAL
in O
drinking O

water). O
Nicotine B-CHEMICAL
pre-exposure O
resulted O
in O
an O
increased O
brain O
arsenic B-CHEMICAL
accumulation O
and O
a O
decreased O
liver O
arsenic B-CHEMICAL
concentration. O
Arsenic B-CHEMICAL
also O
caused O
a O
significant O
oxidative O
stress O
in O
the O
blood, O
brain O
and O
liver O
of O
the O
exposed O
rats. O
Glutathione-S-transferase, B-GENE-N
a O
phase O
II O
enzyme, O
was O
inhibited O
by O
both O
arsenic B-CHEMICAL
and O
nicotine B-CHEMICAL
but O
no O
such O
inhibition O
was O
noted O
in O
arsenic-treated B-CHEMICAL
animals O
pre-exposed O
to O
nicotine. B-CHEMICAL
Upon O
nicotine B-CHEMICAL
pre-exposure, O
brain O
acetylcholinesterase B-GENE-Y
increased, O
while O
monoamine B-GENE-N
oxidase I-GENE-N

(MAO) B-GENE-N
decreased. O
The O
toxic O
effects O
of O
MAO B-GENE-N
significantly O
attenuated O
with O
nicotine B-CHEMICAL
pre-exposure. O
The O
present O
study O
suggests O
that O
nicotine B-CHEMICAL
may O
not O
be O
the O
major O
contributing O
factor O
for O
the O
previously O
reported O
synergistic O
toxic O
interaction O
between O
tobacco O
and O
arsenic. B-CHEMICAL
Nicotine B-CHEMICAL
pre-exposure O
in O
arsenic-exposed B-CHEMICAL
animals O
revealed O
interesting O
toxicokinetics O
and O
oxidative O
stress O
modulating O
interactions O
in O
the O
brain O
and O
liver O
of O
rats, O
which O
requires O
further O
exploration. O
Developing O
Predictive O
Approaches O
to O
Characterize O
Adaptive O
Responses O
of O
the O
Reproductive O
Endocrine O
Axis O
to O

Aromatase B-GENE-Y
Inhibition: O
II. O
Computational O
Modeling. O
Endocrine-disrupting O
chemicals O
can O
affect O
reproduction O
and O
development O
in O
humans O
and O
wildlife. O
We O
developed O
a O
computational O
model O
of O
the O
hypothalamic-pituitary-gonadal O
(HPG) O
axis O
in O
female O
fathead O
minnows O
to O
predict O
dose-response O
and O
time-course O
(DRTC) O
behaviors O
for O
endocrine O
effects O
of O
the O
aromatase B-GENE-Y
inhibitor, O
fadrozole B-CHEMICAL
(FAD). B-CHEMICAL
The O
model O
describes O
adaptive O
responses O
to O
endocrine O
stress O
involving O
regulated O
secretion O
of O
a O
generic O
gonadotropin B-GENE-N

(LH/FSH) B-GENE-N
from O
the O
hypothalamic-pituitary O
complex. O
For O
model O
development, O
we O
used O
plasma O
17-estradiol B-CHEMICAL
(E2) O
concentrations O
and O
ovarian O
cytochrome B-GENE-Y
P450 I-GENE-Y
(CYP) I-GENE-Y
19A I-GENE-Y
aromatase I-GENE-Y
mRNA O
data O
from O
two O
time-course O
experiments, O
each O
of O
which O
included O
both O
an O
exposure O
and O
a O
depuration O
phase, O
and O
plasma O
E2 O
data O
from O
a O
third O
4-day O
study. O
Model O
parameters O
were O
estimated O
using O
E2 O
concentrations O
for O
0, O
0.5, O
and O
3 O
g/l O
FAD B-CHEMICAL
exposure O
concentrations, O
and O
good O
fits O
to O

these O
data O
were O
obtained. O
The O
model O
accurately O
predicted O
CYP19A B-GENE-Y
mRNA O
fold O
changes O
for O
controls O
and O
three O
FAD B-CHEMICAL
doses O
(0, O
0.5, O
and O
3 O
g/l) O
and O
plasma O
E2 O
dose O
response O
from O
the O
4-day O
study. O
Comparing O
the O
model-predicted O
DRTC O
with O
experimental O
data O
provided O
insight O
into O
how O
the O
feedback O
control O
mechanisms O
in O
the O
HPG O
axis O
mediate O
these O
changes: O
specifically, O
adaptive O
changes O
in O
plasma O
E2 O
levels O
occurring O
during O
exposure O
and O
"overshoot" O
occurring O
postexposure. O
This O
study O
demonstrates O
the O
value O
of O
mechanistic O
modeling O
to O
examine O
and O
predict O
dynamic O
behaviors O
in O
perturbed O
systems. O

As O
this O
work O
progresses, O
we O
will O
obtain O
a O
refined O
understanding O
of O
how O
adaptive O
responses O
within O
the O
vertebrate O
HPG O
axis O
affect O
DRTC O
behaviors O
for O
aromatase B-GENE-Y
inhibitors O
and O
other O
types O
of O
endocrine-active O
chemicals O
and O
apply O
that O
knowledge O
in O
support O
of O
risk O
assessments. O
Benzoquinone B-CHEMICAL
Reveals O
a O
Cysteine-Dependent B-CHEMICAL
Desensitization O
Mechanism O
of O
TRPA1. B-GENE-Y
The O
transient B-GENE-Y
receptor I-GENE-Y
potential I-GENE-Y
ankyrin I-GENE-Y
1 I-GENE-Y
(TRPA1) B-GENE-Y
nonselective O
cation B-GENE-N
channel I-GENE-N
has O
a O
conserved O
function O
as O
a O
noxious O
chemical O
sensor O
throughout O
much O
of O
Metazoa. O
Electrophilic O

chemicals O
activate O
both O
insect O
and O
vertebrate O
TRPA1 B-GENE-Y
via O
covalent O
modification O
of O
cysteine B-CHEMICAL
residues O
in O
the O
amino-terminal B-CHEMICAL
region. O
Although O
naturally O
occurring O
electrophilic O
plant O
compounds, O
such O
as O
mustard O
oil O
and O
cinnamaldehyde, B-CHEMICAL
are O
TRPA1 B-GENE-Y
agonists, O
it O
is O
unknown O
whether O
arthropod-produced O
electrophiles O
activate O
mammalian B-GENE-Y
TRPA1. I-GENE-Y
We O
characterized O
the O
effects O
of O
the O
electrophilic O
arthropod O
defensive O
compound O
para-benzoquinone B-CHEMICAL
(pBQN) B-CHEMICAL
on O
the O
human B-GENE-Y
TRPA1 I-GENE-Y
channel. O
We O
used O
whole-cell O
recordings O
of O

human O
embryonic O
kidney O
cells O
heterologously O
expressing O
either O
wild-type O
TRPA1 B-GENE-Y
or O
TRPA1 B-GENE-Y
with O
three O
serine-substituted B-CHEMICAL
cysteines B-CHEMICAL
crucial O
for O
electrophile O
activation O
(C621S, B-GENE-N
C641S, B-GENE-N
C665S). B-GENE-N
We O
found O
that O
pBQN B-CHEMICAL
activates O
TRPA1 B-GENE-Y
starting O
at O
10 O
nM O
and O
peaking O
at O
300 O
nM; O
higher O
concentrations O
caused O
rapid O
activation O
followed O
by O
a O
fast O
decline. O
Activation O
by O
pBQN B-CHEMICAL
required O
reactivity O
with O
cysteine B-CHEMICAL
residues, O
but O
ones O
that O
are O
distinct O
from O
those O
previously O
reported O
to O
be O
the O
key O
targets O
of O

electrophiles. O
The O
current O
reduction O
we O
found O
at O
higher O
pBQN B-CHEMICAL
concentrations O
was O
a O
cysteine-dependent O
desensitization O
of O
TRPA1, B-GENE-Y
and O
did O
not O
require O
prior O
activation. O
The O
cysteines B-CHEMICAL
required O
for O
desensitization O
are O
not O
accessible O
to O
all O
electrophiles O
as O
iodoacetamide B-CHEMICAL
and O
internally O
applied O
2-(trimethylammonium)ethyl B-CHEMICAL
methanesulfonate I-CHEMICAL
failed O
to O
cause O
desensitization O
(despite O
large O
activation). O
Interestingly, O
following O
pBQN B-CHEMICAL
desensitization, O
wild-type O
TRPA1 B-GENE-Y
had O
dramatically O
reduced O
response O
to O
the O

nonelectrophile O
agonist O
carvacrol, B-CHEMICAL
whereas O
the O
triple O
cysteine B-CHEMICAL
mutant O
TRPA1 B-GENE-Y
retained O
its O
full O
response. O
Our O
results O
suggest O
that O
modification O
of O
multiple O
cysteine B-CHEMICAL
residues O
by O
electrophilic O
compounds O
can O
generate O
both O
activation O
and O
desensitization O
of O
the O
TRPA1 B-GENE-Y
channel. O
A O
study O
of O
parabens B-CHEMICAL
and O
bisphenol B-CHEMICAL
A I-CHEMICAL
in O
surface O
water O
and O
fish O
brain O
tissue O
from O
the O
Greater O
Pittsburgh O
Area. O
Pollution O
from O
xenoestrogens B-CHEMICAL
has O
been O
discovered O
in O
the O
aquatic O
environment O
of O
the O
Greater O
Pittsburgh O
Area O
and O
is O
suspected O
to O
be O
caused O
by O
the O
failing O
sewer O
system. O
Personal O
care O
products O
and O

plasticizers O
have O
the O
potential O
to O
enter O
the O
water O
supply O
though O
treated O
and O
untreated O
sewage. O
Many O
of O
these O
compounds O
are O
suspected O
xenoestrogens. B-CHEMICAL
Paraben B-CHEMICAL
detection O
in O
surface O
waters O
was O
as O
follows: O
methyl B-CHEMICAL
paraben I-CHEMICAL
ranged O
between O
2.2 O
to O
17.3 O
ppt; O
ethyl B-CHEMICAL
paraben I-CHEMICAL
was O
not O
detectable; O
propyl B-CHEMICAL
paraben I-CHEMICAL
was O
detected O
at O
9.2 O
and O
12.0 O
ppt; O
butyl B-CHEMICAL
paraben I-CHEMICAL
was O
detected O
at O
0.2 O
ppt. O
BPA B-CHEMICAL
was O
detected O
between O
0.6 O
and O
15.4 O
ppt. O
Estrogenic O
potential O
of O
extracts O
from O
fish O
brain O
tissue O
was O
tested O
via O

Bromodeoxyuridine B-CHEMICAL
MCF-7 O
analysis O
and O
paired O
with O
HPLC-MS O
to O
investigate O
the O
presence O
of O
xenoestrogens. B-CHEMICAL
All O
samples O
were O
non-detectable O
for O
parabens. O
BPA B-CHEMICAL
was O
detected O
in O
44 O
of O
the O
58 O
samples, O
with O
a O
range O
from O
non-detectable O
to O
120 O
pg/g. O
BCFs O
were O
calculated. O
Results O
were O
statistically O
significant O
for O
location O
of O
capture O
(p O
< O
0.05) O
and O
correlation O
existed O
between O
estrogenicity O
and O
BPA. B-CHEMICAL
Synthesis O
and O
in-silico O
studies O
of O
some O
diaryltriazole B-CHEMICAL
derivatives O
as O
potential O

cyclooxygenase B-GENE-N
inhibitors. O
The O
synthesis O
of O
several O
4-phenyl-5-pyridin-4-yl-2,3-dihydro-3H-1,2,4-triazole-3-thiones B-CHEMICAL
possessing O
N-2 O
Mannich B-CHEMICAL
bases I-CHEMICAL
or O
S-alkyl B-CHEMICAL
substituents, O
is O
reported. O
Several O
of O
them O
exhibited O
a O
low O
nanomolar O
COX B-GENE-N
enzyme O
inhibition O
activity. O
Most O
of O
the O
compounds O
showed O
inhibition O
of O
edema O
was O
similar O
to O
that O
evoked O
by O
celocoxib B-CHEMICAL
in O
animal O
model. O

Molecular O
docking O
studies O
of O
the O
compounds O
into O
the O
binding O
sites O
of O
COX-1 B-GENE-Y
and O
COX-2 B-GENE-Y
allowed O
us O
to O
shed O
light O
on O
the O
binding O
mode O
of O
these O
novel O
COX B-GENE-N
inhibitors. O
Multilevel O
regulation O
of O
2-cys B-GENE-N
peroxiredoxin I-GENE-N
reaction O
cycle O
by O
s-nitrosylation. O
S-Nitrosothiols B-CHEMICAL
(SNOs), B-CHEMICAL
formed O
by O
nitric B-CHEMICAL
oxide I-CHEMICAL
(NO)-mediated B-CHEMICAL
S-nitrosylation, B-CHEMICAL
and O
hydrogen B-CHEMICAL
peroxide I-CHEMICAL
(H2O2), B-CHEMICAL
a O
prominent O
reactive O
oxygen B-CHEMICAL
species, O
are O
implicated O
in O
diverse O
physiological O
and O
pathological O
processes. O
Recent O
research O
has O
shown O
that O
the O
cellular O

action O
and O
metabolism O
of O
SNOs B-CHEMICAL
and O
H2O2 B-CHEMICAL
involve O
overlapping, O
thiol-based B-CHEMICAL
mechanisms, O
but O
how O
these O
reactive O
species O
may O
affect O
each O
other's O
fate O
and O
function O
is O
not O
well O
understood. O
In O
this O
study O
we O
investigated O
how O
NO/SNO B-CHEMICAL
may O
affect O
the O
redox O
cycle O
of O
mammalian B-GENE-Y
peroxiredoxin-1 I-GENE-Y
(Prx1), B-GENE-Y
a O
representative O
of O
the O
2-Cys B-GENE-N
Prxs, I-GENE-N
a O
group O
of O
thioredoxin B-GENE-Y
(Trx)-dependent B-GENE-Y
peroxidases. B-GENE-N
We O
found O
that, O
both O
in O
a O
cell-free O
system O
and O
in O
cells, O

NO/SNO B-CHEMICAL
donors O
such O
as O
S-nitrosocysteine B-CHEMICAL
and O
S-nitrosoglutathione B-CHEMICAL
readily O
induced O
the O
S-nitrosylation B-CHEMICAL
of O
Prx1, B-GENE-Y
causing O
structural O
and O
functional O
alterations. O
In O
particular, O
nitrosylation O
promoted O
disulfide B-CHEMICAL
formation O
involving O
the O
pair O
of O
catalytic O
cysteines B-CHEMICAL
(Cys-52 B-CHEMICAL
and O
Cys-173) B-CHEMICAL
and O
disrupted O
the O
oligomeric O
structure O
of O
Prx1, B-GENE-Y
leading O
to O
loss O
of O
peroxidase B-GENE-N
activity. O
A O
highly O
potent O
inhibition O
of O
the O
peroxidase B-GENE-N
catalytic O
reaction O
by O
NO/SNO B-CHEMICAL

was O
seen O
in O
assays O
employing O
the O
coupled O
Prx-Trx B-GENE-N
system. O
In O
this O
setting, O
S-nitrosocysteine B-CHEMICAL
(10 O
m) O
effectively O
blocked O
the O
Trx-mediated B-GENE-Y
regeneration O
of O
oxidized B-GENE-Y
Prx1. I-GENE-Y
This O
effect O
appeared O
to O
be O
due O
to O
both O
competition O
between O
S-nitrosocysteine B-CHEMICAL
and O
Prx1 B-GENE-Y
for O
the O
Trx B-GENE-Y
system O
and O
direct O
modulation O
by O
S-nitrosocysteine B-CHEMICAL
of O
Trx B-GENE-N
reductase I-GENE-N
activity. O
Our O
findings O
that O
NO/SNO B-CHEMICAL
target O
both O
Prx B-GENE-N
and O
Trx B-GENE-N
reductase I-GENE-N
may O
have O

implications O
for O
understanding O
the O
impact O
of O
nitrosylation O
on O
cellular O
redox O
homeostasis. O
A O
Novel O
CUG(exp)MBNL1 B-GENE-Y
Inhibitor O
with O
Therapeutic O
Potential O
for O
Myotonic O
Dystrophy O
Type O
1. O
Myotonic O
dystrophy O
type O
1 O
(DM1) O
is O
caused O
by O
an O
expanded O
CUG O
repeat O
(CUG(exp)) O
that O
sequesters O
muscleblind-like B-GENE-N
1 I-GENE-N
protein I-GENE-N
(MBNL1), B-GENE-Y
a O
protein O
that O
regulates O
alternative O
splicing. O
CUG(exp) O
RNA O
is O
a O
validated O
drug O
target O

for O
this O
currently O
untreatable O
disease. O
Herein, O
we O
develop O
a O
bioactive O
small O
molecule O
(1) O
that O
targets O
CUG(exp) O
RNA O
and O
is O
able O
to O
inhibit O
the O
CUG(exp)MBNL1 B-GENE-Y
interaction O
in O
cells O
that O
model O
DM1. O
The O
core O
of O
this O
small O
molecule O
is O
based O
on O
ligand O
2, O
which O
was O
previously O
reported O
to O
be O
active O
in O
an O
in O
vitro O
assay. O
A O
polyamine-derivative B-CHEMICAL
side O
chain O
was O
conjugated O
to O
this O
core O
to O
make O
it O
aqueous-soluble O
and O
cell-penetrable. O
In O
a O
DM1 O
cell O
model O

this O
conjugate O
was O
found O
to O
disperse O
CUG(exp) O
ribonuclear O
foci, O
release O
MBNL1, B-GENE-Y
and O
partially O
reverse O
the O
mis-splicing O
of O
the O
insulin B-GENE-Y
receptor I-GENE-Y
pre-mRNA. O
Direct O
evidence O
for O
ribonuclear O
foci O
dispersion O
by O
this O
ligand O
was O
obtained O
in O
a O
live O
DM1 O
cell O
model O
using O
time-lapse O
confocal O
microscopy. O
The O
induction O
of O
mitochondria-mediated O
apoptosis O
in O
cancer O
cells O
by O
ruthenium(ii) B-CHEMICAL
asymmetric O
complexes. O
Four O

ruthenium(ii) B-CHEMICAL
asymmetric O
complexes, O
[Ru(bpy)2(PAIDH)](2+) B-CHEMICAL
(bpy B-CHEMICAL
= O
2,2'-bipyridine, B-CHEMICAL
PAIDH B-CHEMICAL
= O
2-pyridyl-1H-anthra[1,2-d]imidazole-6,11-dione, B-CHEMICAL
), O
[Ru(phen)2(PAIDH)](2+) B-CHEMICAL
(phen B-CHEMICAL
= O
1,10-phenanthroline, B-CHEMICAL
), O

[Ru(dmp)2(PAIDH)](2+) B-CHEMICAL
(dmp B-CHEMICAL
= O
4,7-dimethyl-1,10-phenanthroline, B-CHEMICAL
) O
and O
[Ru(dip)2(PAIDH)](2+) B-CHEMICAL
(dip B-CHEMICAL
= O
4,7-diphenyl-1,10-phenanthroline, B-CHEMICAL
), O
have O
been O
synthesized O
and O
characterized. O
These O
complexes O
displayed O
potent O
anti-proliferation O
activity O
against O
various O
cancer O
cell O
lines O
and O
had O
high O
selectivity O
between O
tumor O
cells O
and O
normal O
cells. O
HeLa O
cells O
exhibited O
the O
highest O
sensitivity O
to O
complex O
, O

accounting O
for O
the O
greatest O
cellular O
uptake. O
Complex O
was O
shown O
to O
accumulate O
preferentially O
in O
the O
mitochondria O
of O
HeLa O
cells O
and O
induced O
apoptosis O
via O
the O
mitochondrial O
pathway, O
which O
involved O
ROS O
generation, O
mitochondrial O
membrane O
potential O
depolarisation, O
and O
Bcl-2 B-GENE-Y
and O
caspase B-GENE-N
family O
members O
activation. O
These O
results O
demonstrated O
that O
complex O
induced O
cancer O
cell O
apoptosis O
by O
acting O
on O
mitochondrial O
pathways. O
Platycodi O
Radix O
attenuates O
dimethylnitrosamine-induced B-CHEMICAL
liver O
fibrosis O
in O
rats O
by O
inducing O
Nrf2-mediated B-GENE-Y
antioxidant O
enzymes. O

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
anti-fibrotic O
effects O
of O
the O
aqueous O
extract O
of O
the O
Platycodi O
Radix O
root O
(Changkil: O
CK) O
on O
dimethylnitrosamine B-CHEMICAL
(DMN)-induced B-CHEMICAL
liver O
fibrosis O
in O
rats. O
DMN B-CHEMICAL
treatment O
for O
4weeks O
led O
to O
marked O
liver O
fibrosis O
as O
assessed O
by O
serum O
biochemistry, O
histopathological O
examination, O
and O
hepatic O
lipid O
peroxidation O
and O
collagen B-GENE-N
content. O
CK O
significantly O
inhibited O
DMN-induced B-CHEMICAL
increases O
in O
serum O
alanine B-GENE-N

aminotransferase I-GENE-N
(ALT) B-GENE-N
and O
aspartate B-GENE-N
aminotransferase I-GENE-N
(AST) B-GENE-N
activities, O
fibrosis O
score, O
and O
hepatic O
malondialdehyde B-CHEMICAL
and O
collagen B-GENE-N
content. O
CK O
also O
inhibited O
DMN-induced B-CHEMICAL
reductions O
in O
rat O
body O
and O
liver O
weights. O
Reverse O
transcription O
polymerase O
chain O
reaction O
(RT-PCR) O
and O
western O
blot O
analyses O
revealed O
that O
CK O
inhibited O
DMN-induced B-CHEMICAL
increases O
in O
matrix B-GENE-Y
metalloproteinase-13 I-GENE-Y
(MMP-13), B-GENE-Y
tissue B-GENE-Y
inhibitor I-GENE-Y
of I-GENE-Y
metalloproteinase-1 I-GENE-Y

(TIMP-1), B-GENE-Y
and O
tumor B-GENE-Y
necrosis I-GENE-Y
factor- I-GENE-Y
(TNF-) B-GENE-Y
mRNA, O
and O
collagen B-GENE-N
type I-GENE-N
I I-GENE-N
and O
-smooth B-GENE-Y
muscle I-GENE-Y
actin I-GENE-Y
protein. O
DMN-induced B-CHEMICAL
cyclooxygenase-2 B-GENE-Y
(COX-2) B-GENE-Y
expression O
and O
nuclear B-GENE-N
factor-kappa I-GENE-N
B I-GENE-N
(NF-B) B-GENE-N
activation O
was O
reduced O
by O
CK O
treatment. O
Furthermore, O
CK O
induced O
activation O
of O
nuclear B-GENE-Y
erythroid I-GENE-Y
2-related I-GENE-Y
factor I-GENE-Y
2 I-GENE-Y
(Nrf2)-mediated B-GENE-Y
antioxidant O
enzymes O
such O
as O
-glutamylcysteine B-GENE-Y

synthetase I-GENE-Y
(-GCS), B-GENE-Y
heme B-CHEMICAL
oxygenase-1 I-GENE-Y
(HO-1), B-GENE-Y
NAD(P)H B-CHEMICAL
quinone B-CHEMICAL
oxidoreductase I-GENE-Y
1 I-GENE-Y
(NQO1), B-GENE-Y
and O
glutathione-S-transferase B-CHEMICAL
(GST) B-GENE-N
in O
HepG2 O
cells. O
These O
results O
demonstrated O
that O
CK O
attenuates O
DMN-induced B-CHEMICAL
liver O
fibrosis O
through O
the O
activation O
of O
Nrf2-mediated B-GENE-Y
antioxidant O
enzymes. O
Cadmium B-CHEMICAL
telluride I-CHEMICAL
quantum O
dots O
cause O
oxidative O
stress O
leading O
to O
extrinsic O
and O
intrinsic O

apoptosis O
in O
hepatocellular O
carcinoma O
HepG2 O
cells. O
The O
mechanisms O
of O
toxicity O
related O
to O
human O
hepatocellular O
carcinoma O
HepG2 O
cell O
exposures O
to O
cadmium B-CHEMICAL
telluride I-CHEMICAL
quantum O
dots O
(CdTe-QDs) B-CHEMICAL
were O
investigated. O
CdTe-QDs B-CHEMICAL
caused O
cytotoxicity O
in O
HepG2 O
cells O
in O
a O
dose- O
and O
time-dependent O
manner. O
Treated O
cells O
showed O
an O
increase O
in O
reactive O
oxygen B-CHEMICAL
species O
(ROS). O
Altered O
antioxidant O
levels O
were O
demonstrated O
by O
depletion O
of O
reduced B-CHEMICAL
glutathione I-CHEMICAL

(GSH), B-CHEMICAL
a O
decreased O
ratio O
of O
reduced O
glutathione B-CHEMICAL
to O
oxidized B-CHEMICAL
glutathione I-CHEMICAL
(GSH/GSSG) B-CHEMICAL
and O
an O
increased O
NF-E2-related B-GENE-Y
Factor I-GENE-Y
2 I-GENE-Y
(Nrf2) B-GENE-Y
activation. O
Enzyme O
assays O
showed O
that O
superoxide B-GENE-N
dismutase I-GENE-N
(SOD) B-GENE-N
activity O
was O
elevated O
whereas O
catalase B-GENE-Y
(CAT) B-GENE-Y
and O
glutathione-S-transferase B-GENE-N
(GST) B-GENE-N
activities O
were O
depressed. O
Further O
analyses O
revealed O
that O
CdTe-QD B-CHEMICAL
exposure O
resulted O
in O
apoptosis, O
indicated O
by O
changes O
in O
levels O
of O
caspase-3 B-GENE-Y

activity, O
poly B-GENE-N
ADP-ribose I-GENE-N
polymerase I-GENE-N
(PARP) B-GENE-N
cleavage O
and O
phosphatidylserine B-CHEMICAL
externalization. O
Extrinsic O
apoptotic O
pathway O
markers O
such O
as O
Fas B-GENE-Y
levels O
and O
caspase-8 B-GENE-Y
activity O
increased O
as O
a O
result O
of O
CdTe-QD B-CHEMICAL
exposure. O
Involvement O
of O
the O
intrinsic/mitochondrial O
apoptotic O
pathway O
was O
indicated O
by O
decreased O
levels O
of O
B-cell B-GENE-Y
lymphoma I-GENE-Y
2 I-GENE-Y
(Bcl2) B-GENE-Y
protein O
and O
mitochondrial O
cytochrome B-GENE-Y
c, I-GENE-Y
and O
by O
increased O
levels O
of O
mitochondrial O
Bcl-2-associated B-GENE-Y
X I-GENE-Y
protein I-GENE-Y

(Bax) B-GENE-Y
and O
cytosolic O
cytochrome B-GENE-Y
c. I-GENE-Y
Further, O
mitogen-activated B-GENE-N
protein I-GENE-N
kinases I-GENE-N
(MAPKs) B-GENE-N
such O
as O
c-Jun B-GENE-N
N-terminal I-GENE-N
kinases I-GENE-N
(JNK), B-GENE-N
extracellular B-GENE-N
signal-regulated I-GENE-N
kinases I-GENE-N
(Erk1/2), B-GENE-N
and O
p38 B-GENE-N
were O
all O
activated. O
Our O
findings O
reveal O
that O
CdTe-QDs B-CHEMICAL
cause O
oxidative O
stress, O
interfere O
with O
antioxidant O
defenses O
and O
activate O
protein O
kinases, B-GENE-N
leading O
to O
apoptosis O
via O
both O
extrinsic O
and O
intrinsic O
pathways. O
Since O
the O
effects O
of O
CdTe-QDs B-CHEMICAL
on O

selected O
biomarkers O
were O
similar O
or O
greater O
compared O
to O
those O
of O
CdCl2 B-CHEMICAL
at O
equivalent O
concentrations O
of O
cadmium, B-CHEMICAL
the O
study O
suggests O
that O
the O
toxicity O
of O
CdTe-QDs B-CHEMICAL
arises O
from O
a O
combination O
of O
the O
effects O
of O
cadmium O
and O
ROS O
generated O
from O
the O
NPs. O
Reinforcement O
enhancing O
effects O
of O
nicotine B-CHEMICAL
via O
smoking. O
RATIONALE: O
In O
animals, O
nicotine B-CHEMICAL
enhances O
reinforcement O
from O
stimuli O
unrelated O
to O
nicotine B-CHEMICAL
intake. O
Human O
research O
is O
suggestive O
but O
has O
not O
clearly O
shown O
a O
similar O
influence O
of O
nicotine. B-CHEMICAL
OBJECTIVES: O
We O
assessed O
acute O

effects O
of O
nicotine B-CHEMICAL
via O
smoking O
on O
enhancement O
of O
positive O
(money, O
music) O
or O
negative O
(termination O
of O
noise) O
reinforcers, O
or O
no O
"reward" O
(control). O
These O
different O
rewards O
determined O
the O
generalizability O
of O
nicotine B-CHEMICAL
effects. O
MATERIALS O
AND O
METHODS: O
Dependent O
(n O
= O
25) O
and O
nondependent O
(n O
= O
27) O
smokers O
participated O
in O
three O
sessions, O
each O
after O
overnight O
abstinence. O
Using O
a O
within-subjects O
design, O
sessions O
involved O
no O
smoking O
or O
smoking O
denicotinized O
(0.05 O
mg) O
or O
nicotine B-CHEMICAL
(0.6 O

mg) O
Quest(R) O
brand O
cigarettes. O
For O
comparison, O
a O
fourth O
session O
involved O
no O
abstinence O
prior O
to O
smoking O
one's O
own O
brand O
to O
gauge O
responses O
under O
typical O
nicotine B-CHEMICAL
satiation. O
Reinforcement O
was O
assessed O
by O
responses O
on O
a O
simple O
operant O
computer O
task O
for O
the O
rewards, O
each O
available O
singly O
on O
a O
progressive O
ratio O
schedule O
during O
separate O
trials. O
RESULTS: O
The O
reinforcing O
effect O
of O
music, O
but O
not O
other O
rewards, O
was O
greater O
due O
to O
the O
nicotine B-CHEMICAL
cigarette, O
compared O
to O
the O
denicotinized O
cigarette O
or O
no O
smoking. O
Reinforcement O
enhancing O
effects O
of O
nicotine B-CHEMICAL
did O
not O
differ O

between O
dependent O
and O
nondependent O
groups, O
indicating O
no O
influence O
of O
withdrawal O
relief. O
Responding O
due O
to O
acute O
nicotine B-CHEMICAL
after O
abstinence O
was O
very O
similar O
to O
responding O
to O
one's O
own O
brand O
after O
no O
abstinence. O
CONCLUSIONS: O
Acute O
nicotine B-CHEMICAL
intake O
per O
se O
from O
smoking O
after O
abstinence O
enhances O
the O
reinforcing O
value O
of O
rewards O
unassociated O
with O
smoking, O
perhaps O
in O
a O
manner O
comparable O
to O
ad O
lib O
smoking O
after O
no O
abstinence. O
Nicotine's B-CHEMICAL
reinforcement O
enhancing O
effects O
may O
be O
specific O
to O
certain O
rewards, O
perhaps O
those O
sensory O
in O
nature. O

Anti-apoptotic O
cardioprotective O
effects O
of O
SHP-1 B-GENE-Y
gene O
silencing O
against O
ischemia-reperfusion O
injury: O
Use O
of O
deoxycholic B-CHEMICAL
acid-modified I-CHEMICAL
low O
molecular O
weight O
polyethyleneimine B-CHEMICAL
as O
a O
cardiac O
siRNA-carrier. O
The O
cardiomyocyte O
apoptosis O
plays O
a O
critical O
role O
in O
the O
development O
of O
myocardial O
injury O
after O
ischemia O
and O
reperfusion. O
Thus, O
alteration O
of O
the O
major O
apoptosis-regulatory O
factors O
during O
myocardial O
ischemia-reperfusion O
is O
expected O
to O
have O
favorable O
cardioprotective O
effects. O

Herein, O
we O
report O
ischemic-reperfused O
myocardial O
infarction O
(MI) O
repair O
with O
siRNA O
against O
Src B-GENE-Y
homology I-GENE-Y
region I-GENE-Y
2 I-GENE-Y
domain-containing I-GENE-Y
tyrosine B-CHEMICAL
phosphatase-1 I-GENE-Y
(SHP-1), B-GENE-Y
which O
is O
known O
as O
a O
key O
factor O
involved O
in O
regulating O
the O
progress O
of O
apoptosis O
in O
many O
cell O
types. O
A O
low O
molecular O
weight O
polyethyleneimine B-CHEMICAL
modified O
with O
deoxycholic B-CHEMICAL
acid I-CHEMICAL
(PEI1.8-DA)-based O
delivery O
strategy O
was O
suggested O
for O
the O
cardiac O
application O
of O
SHP-1 B-GENE-Y
siRNA O
to O
overcome O
the O
poor O
gene O
delivery O
efficiency O

to O
myocardium O
due O
to O
the O
highly O
charged O
structures O
of O
the O
compact O
cardiac O
muscles. O
The O
PEI1.8-DA O
conjugates O
formed O
stable O
nanocomplexes O
with O
SHP-1 B-GENE-Y
siRNA O
via O
electrostatic O
and O
hydrophobic O
interactions. O
The O
PEI1.8-DA/SHP-1 B-GENE-Y
siRNA O
polyplexes O
effectively O
silenced O
SHP-1 B-GENE-Y
gene O
expression O
in O
cardiomyocytes, O
leading O
to O
a O
significant O
inhibition O
of O
cardiomyocyte O
apoptosis O
under O
hypoxia. O
In O
comparison O
to O
conventional O
gene O
carriers, O
relatively O
large O
amounts O
of O
siRNA O
molecules O
remained O
after O
treatment O

with O
the O
PEI1.8-DA/SHP-1 B-GENE-Y
siRNA O
polyplexes. O
Cardiac O
administration O
of O
the O
PEI1.8-DA/SHP-1 B-GENE-Y
siRNA O
polyplexes O
resulted O
in O
substantial O
improvement O
in O
SHP-1 B-GENE-Y
gene O
silencing, O
which O
can O
be O
explained O
by O
the O
enhancement O
of O
cardiac O
delivery O
efficiency O
of O
the O
PEI1.8-DA O
conjugates. O
In O
addition, O
in O
vivo O
treatment O
with O
the O
PEI1.8-DA/SHP-1 B-GENE-Y
siRNA O
polyplexes O
induced O
a O
highly O
significant O
reduction O
in O
myocardial O

apoptosis O
and O
infarct O
size O
in O
rat O
MI O
models. O
These O
results O
demonstrate O
that O
the O
PEI1.8-DA/SHP-1 B-GENE-Y
siRNA O
polyplex O
formulation O
is O
a O
useful O
system O
for O
efficient O
gene O
delivery O
into O
the O
compact O
myocardium O
that O
provides O
a O
fundamental O
advantage O
in O
treating O
ischemic-reperfused O
MI. O
Synthesis O
of O
C17-OH-north B-CHEMICAL
unit O
of O
ritterazine B-CHEMICAL
G I-CHEMICAL
via O
"Red-Ox" O
modifications O
of O
hecogenin B-CHEMICAL
acetate. I-CHEMICAL
The O
C17-OH-north B-CHEMICAL
unit O
of O
ritterazine B-CHEMICAL
G I-CHEMICAL
was O
prepared O
in O
13 O
steps O
from O
hecogenin B-CHEMICAL

acetate. I-CHEMICAL
This O
synthesis O
features O
a O
highly O
efficient O
and O
stereoselective O
introduction O
of O
the O
C17-OH B-CHEMICAL
via O
E-ring O
cleavage/F-ring O
formation, O
D-ring O
oxidation, O
and O
F-ring O
cleavage/E-ring O
formation. O
Inhibitory O
effects O
of O
in O
vivo O
oxidized B-GENE-N
high-density I-GENE-N
lipoproteins I-GENE-N
on O
platelet O
aggregation: O
evidence O
from O
patients O
with O
abetalipoproteinemia. O
There O
is O
evidence O
that O
high-density B-GENE-N
lipoproteins I-GENE-N
(HDLs) B-GENE-N
may O
regulate O
platelet O
function, O
but O
disparate O
results O
exist O
regarding O
the O
effects O
of O
oxidized O

HDLs B-GENE-N
on O
platelets. O
The O
objective O
of O
our O
study O
was O
to O
determine O
the O
role O
of O
in O
vivo O
oxidized B-GENE-N
HDLs I-GENE-N
on O
platelet O
aggregation. O
Platelet O
aggregation O
and O
redox O
status O
were O
investigated O
in O
5 O
patients O
with O
abetalipoproteinemia O
(ABLP) O
or O
homozygous O
hypobetalipoproteinemia, O
two O
rare O
metabolic O
diseases O
characterized O
by O
the O
absence O
of O
apolipoprotein B-GENE-Y
B-containing I-GENE-Y
lipoproteins, B-GENE-N
compared O
to O
5 O
control O
subjects. O
Platelets O
isolated O
from O
plasma O
of O
patients O
with O
ABLP O
aggregated O
4 O
to O
10 O
times O
more O
than O
control O
platelets, O

depending O
on O
the O
agonist. O
By O
contrast, O
no O
differences O
in O
the O
extent O
of O
platelet O
aggregation O
were O
observed O
between O
ABLP O
platelet-rich O
plasma O
(PRP) O
and O
control O
PRP, O
suggesting O
the O
presence O
of O
a O
protective O
factor O
in O
ABLP O
plasma. O
ABLP O
HDLs B-GENE-N
inhibited O
agonist-induced O
platelet O
aggregation O
by O
binding O
to O
SR-BI, B-GENE-Y
while O
control O
HDLs B-GENE-N
had O
no O
effect. O
On O
the O
other O
hand, O
lipoprotein-deficient B-GENE-N
plasma O
from O
patients O
with O
ABLP O
did O
not O
inhibit O
platelet O
aggregation. O
Severe O
oxidative O
stress O
was O
evidenced O
in O
patients O
with O

ABLP. O
Compared O
to O
control O
HDLs, B-GENE-N
ABLP O
HDLs B-GENE-N
showed O
a O
40% O
decrease O
of O
-tocopherol B-CHEMICAL
and O
an O
11-fold O
increased O
malondialdehyde B-CHEMICAL
concentration. O
These O
results O
demonstrate O
that O
in O
vivo O
oxidized B-GENE-N
HDLs I-GENE-N
do O
not O
lose O
their O
antiaggregatory O
properties O
despite O
oxidation.-Calzada, O
C., O
Vricel, O
E., O
Colas, O
R., O
Guillot, O
N., O
El O
Khoury, O
G., O
Drai, O
J., O
Sassolas, O
A., O
Peretti, O
N., O

Ponsin, O
G., O
Lagarde, O
M., O
Moulin, O
P. O
Inhibitory O
effects O
of O
in O
vivo O
oxidized B-GENE-N
high-density I-GENE-N
lipoproteins I-GENE-N
on O
platelet O
aggregation: O
evidence O
from O
patients O
with O
abetalipoproteinemia. O
Derivatives O
of O
Dictyostelium O
discoideum O
differentiation-inducing O
factor-3 O
suppress O
the O
activities O
of O
Trypanosoma O
cruzi O
in O
vitro O
and O
in O
vivo. O
Chagas O
disease O
(human O
American O
trypanosomiasis), O
which O
is O
caused O
by O
the O
protozoan O
parasite O
Trypanosoma O
cruzi, O

is O
responsible O
for O
numerous O
deaths O
each O
year; O
however, O
established O
treatments O
for O
the O
disease O
are O
limited. O
Differentiation-inducing O
factor-1 O
(DIF-1) O
and O
DIF-3 O
are O
chlorinated O
alkylphenones B-CHEMICAL
originally O
found O
in O
the O
cellular O
slime O
mold O
Dictyostelium O
discoideum O
that O
have O
been O
shown O
to O
possess O
pharmacological O
activities. O
Here, O
we O
investigated O
the O
effects O
of O
DIF-3 O
derivatives O
on O
the O
infection O
rate O
and O
growth O
of O
T. O
cruzi O
by O
using O
an O
in O
vitro O
assay O
system O
utilizing O
host O
human O
fibrosarcoma O
HT1080 O
cells. O
Certain O

DIF-3 O
derivatives, O
such O
as O
butoxy-DIF-3 B-CHEMICAL
(Bu-DIF-3), O
at O
micro-molar O
levels O
strongly O
suppressed O
both O
the O
infection O
rate O
and O
growth O
of O
T. O
cruzi O
in O
HT1080 O
cells O
and O
exhibited O
little O
toxicity O
for O
HT1080 O
cells. O
For O
example, O
the O
IC50 O
of O
DIF-3 O
and O
Bu-DIF-3 O
versus O
the O
growth O
of O
T. O
cruzi O
in O
HT1080 O
cells O
were O
3.95 O
and O
0.72M, O
respectively, O
and O
the O
LD50 O
of O
the O
two O
compounds O
versus O
HT1080 O
cells O

were O
both O
greater O
than O
100M. O
We O
also O
examined O
the O
effects O
of O
DIF-3 O
and O
Bu-DIF-3 O
on O
T. O
cruzi O
activity O
in O
C57BL/6 O
mice. O
Intraperitoneally O
administered O
Bu-DIF-3 O
(50mg/kg) O
significantly O
suppressed O
the O
number O
of O
trypomastigotes O
in O
blood O
with O
no O
apparent O
adverse O
effects. O
These O
results O
strongly O
suggest O
that O
DIF-3 O
derivatives O
could O
be O
new O
lead O
compounds O
in O
the O
development O
of O
anti-trypanosomiasis O
drugs. O
Neuroprotective O
Effects O
of O
Puerarin B-CHEMICAL
on O

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine B-CHEMICAL
induced O
Parkinson's O
Disease O
Model O
in O
Mice. O
Puerarin, B-CHEMICAL
an O
active O
component O
of O
Pueraria O
montana O
var. O
lobata O
(Willd.) O
Sanjappa O
& O
Pradeep O
is O
well-known O
for O
its O
anti-oxidative O
and O
neuroprotective O
activities. O
Although O
anti-Parkinson's O
disease O
activity O
of O
puerarin B-CHEMICAL
was O
reported O
in O
both O
of O
in O
vivo O
and O
in O
vitro O
model, O
detailed O
mechanisms O
are O
not O
clarified. O
In O
this O
study, O
we O
addressed O

that O
puerarin B-CHEMICAL
attenuated O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine B-CHEMICAL
(MPTP)-induced B-CHEMICAL
behavioral O
deficits, O
dopaminergic O
neuronal O
degeneration O
and O
dopamine B-CHEMICAL
depletion. O
Puerarin B-CHEMICAL
administration O
enhanced O
glutathione B-CHEMICAL
(GSH) B-CHEMICAL
activity, O
glial B-GENE-Y
cell I-GENE-Y
line-derived I-GENE-Y
neurotrophic I-GENE-Y
factor I-GENE-Y
(GDNF) B-GENE-Y
expression O
and O
PI3K/Akt B-GENE-N
pathway O
activation, O
which O
might O
ameliorate O
MPTP B-CHEMICAL
injection-induced O
progressive O
elevation O
of O
reactive O
oxygen B-CHEMICAL
species O

(ROS) O
formation O
in O
mice. O
In O
addition O
to O
the O
effect O
on O
ROS, O
puerarin B-CHEMICAL
ameliorated O
MPTP-reduced B-CHEMICAL
lysosome-associated B-GENE-Y
membrane I-GENE-Y
protein I-GENE-Y
type I-GENE-Y
2A I-GENE-Y
(Lamp B-GENE-Y
2A) I-GENE-Y
expression. O
Taken O
together, O
our O
data O
demonstrate O
that O
puerarin B-CHEMICAL
attenuates O
MPTP-induced B-CHEMICAL
dopaminergic O
neuronal O
degeneration O
via O
modulating O
GDNF B-GENE-Y
expression, O
PI3K/Akt B-GENE-N
pathway O
and O
GSH B-CHEMICAL
activation, O
which O
subsequently O
ameliorate O
MPTP-induced B-CHEMICAL
ROS O
formation O
and O
decrease O
of O
Lamp B-GENE-Y
2A I-GENE-Y
expression. O
Copyright O
 O
2013 O
John O

Wiley O
& O
Sons, O
Ltd. O
Efficient O
induction O
of O
apoptosis O
in O
HeLa O
cells O
by O
a O
novel O
cationic O
porphycene B-CHEMICAL
photosensitizer. O
In O
the O
present O
study O
we O
analyze O
the O
photobiological O
properties O
of O
2,7,12-tris(-pyridinio-p-tolyl)-17-(p-(methoxymethyl)phenyl) B-CHEMICAL
porphycene I-CHEMICAL
(Py3MeO-TBPo) B-CHEMICAL
in O
Hela O
cells, O
in O
order O
to O
assess O
its O
potential O
as O
a O
new O
photosensitizer O
for O
photodynamic O
therapy O
of O

cultured O
tumor O
cells. O
Using O
0.5 O
M O
Py3MeO-TBPo, B-CHEMICAL
flow O
cytometry O
studies O
demonstrated O
an O
increase O
of O
intracellular O
drug O
levels O
related O
to O
the O
incubation O
time, O
reaching O
a O
maximum O
at O
18 O
h. O
LysoTracker() O
Green O
(LTG) O
and O
MitoTracker() O
Green O
(MTG) O
probes O
were O
used O
to O
identify O
the O
subcellular O
localization. O
Upon O
exposure O
to O
ultraviolet O
excitation, O
red O
porphycene B-CHEMICAL
fluorescence O
was O
detected O
as O
red O
granules O
in O
the O
cytoplasm O
that O

colocalized O
with O
LTG. O
No O
significant O
toxic O
effects O
were O
detected O
for O
Py3MeO-TBPo B-CHEMICAL
in O
the O
dark O
at O
concentrations O
below O
1 O
M. O
In O
contrast, O
Py3MeO-TBPo B-CHEMICAL
combined O
with O
red-light O
irradiation O
induced O
concentration- O
and O
fluence-dependent O
HeLa O
cells O
inactivation. O
Besides, O
all O
photodynamic O
protocols O
assayed O
induced O
a O
clear O
effect O
of O
cell O
detachment O
inhibition O
after O
trypsin B-GENE-N
treatment. O
Both O
apoptotic O
and O
necrotic O
cell O
death O
mechanisms O
can O
occur O
in O
HeLa O
cells O
depending O
on O
the O
experimental O
protocol. O
After O

18 O
h O
incubation O
with O
0.5 O
M O
Py3MeO-TBPo B-CHEMICAL
and O
subsequent O
red O
light O
irradiation O
(3.6 O
J/cm(2)), O
a O
high O
number O
of O
cells O
die O
by O
apoptosis, O
as O
evaluated O
by O
morphological O
alterations, O
immunofluorescent O
relocalization O
of O
Bax B-GENE-Y
from O
cytosol O
to O
mitochondria, O
and O
TUNEL O
assay. O
Likewise, O
immunofluorescence O
techniques O
showed O
that O
cytochrome B-GENE-Y
c I-GENE-Y
is O
released O
from O
mitochondria O
into O
cytosol O
in O
cells O
undergoing O

apoptosis, O
which O
occurs O
immediately O
after O
relocation O
of O
Bax B-GENE-Y
in O
mitochondria. O
The O
highest O
amount O
of O
apoptosis O
appeared O
24 O
h O
after O
treatment O
(70%) O
and O
this O
cell O
death O
occurred O
without O
cell O
detachment O
to O
the O
substrate. O
In O
contrast, O
with O
0.75 O
M O
Py3MeO-TBPo B-CHEMICAL
and O
3.6 O
J/cm(2) O
irradiation, O
morphological O
changes O
showed O
a O
preferential O
necrotic O
cell O
death. O
Singlet O
oxygen B-CHEMICAL
was O
identified O
as O
the O
cytotoxic O
agent O
involved O
in O
cell O
photoinactivation. O
Moreover, O
cell O
cultures O
pre-exposed O
to O
the O

singlet O
oxygen B-CHEMICAL
scavenger O
sodium B-CHEMICAL
azide I-CHEMICAL
showed O
pronounced O
protection O
against O
the O
loss O
of O
viability O
induced O
by O
Py3MeO-TBPo B-CHEMICAL
and O
light. O
Different O
changes O
in O
distribution O
and O
organization O
of O
cytoskeletal O
elements O
(microtubules B-GENE-N
and O
actin B-GENE-N
microfilaments) O
as O
well O
as O
the O
protein O
vinculin, B-GENE-Y
after O
apoptotic O
and O
necrotic O
photodynamic O
treatments O
have O
been O
analyzed. O
Neither O
of O
these O
two O
cell O
death O
mechanisms O
(apoptosis O
or O
necrosis) O
induced O
cell O
detachment. O
In O
summary, O
Py3MeO-TBPo B-CHEMICAL
appears O
to O
meet O
the O

requirements O
for O
further O
scrutiny O
as O
a O
very O
good O
photosensitizer O
for O
photodynamic O
therapy: O
it O
is O
water O
soluble, O
has O
a O
high O
absorption O
in O
the O
red O
spectral O
region O
(where O
light O
penetration O
in O
tissue O
is O
higher), O
and O
is O
able O
to O
induce O
effective O
high O
apoptotic O
rate O
(70%) O
related O
to O
the O
more O
widely O
studied O
photosensitizers. O
Addition O
of O
artificial O
salt O
bridge O
by O
Ile646Lys B-GENE-N
mutation O
in O
gp41 B-GENE-N
coiled-coil I-GENE-N
domain I-GENE-N
regulates O
6-helical O
bundle O
formation. O
HIV O
entry O
is O
mediated O
by O
the O
envelope B-GENE-Y
glycoproteins I-GENE-Y
gp120 I-GENE-Y
and O
gp41. B-GENE-Y
The O

gp41 B-GENE-Y
subunit O
contains O
several O
functional O
domains: O
the O
N-terminal B-GENE-N
heptad I-GENE-N
repeat I-GENE-N
(NHR) I-GENE-N
domains I-GENE-N
fold O
a O
triple O
stranded O
coiled-coil O
forming O
a O
meta-stable O
prefusion O
intermediate. O
C-terminal B-CHEMICAL
heptad O
repeat O
(CHR) O
subsequently O
folds O
onto O
the O
hydrophobic O
grooves O
of O
the O
NHR O
coiled-coil O
to O
form O
a O
stable O
6-helix O
bundle, O
which O
juxtaposes O
the O
viral O
and O
cellular O
membranes O
for O
fusion. O
The O
C34 O
which O
has O
34 O
amino B-CHEMICAL
acid I-CHEMICAL
residues O
is O
known O
as O
the O
core O
structure O
in O
CHR. O
A O
highly O
anti-HIV O
peptide O
inhibitor O
derived O
from O
C34 O
was O
designed. O

An O
artificial O
salt O
bridge O
was O
added O
in O
the O
6-helical O
bundle O
by O
substitution O
of O
lysine B-CHEMICAL
for O
Ile646. B-CHEMICAL
With O
a O
cholesterol B-CHEMICAL
modification O
at O
C-terminal, B-CHEMICAL
the O
inhibitor O
containing O
I646K B-GENE-N
mutation O
represented O
higher O
anti-viral O
activity O
than O
C34-cholesterol B-CHEMICAL
combination O
without O
mutation. O
Cytotoxic O
mechanism O
of O
Piper O
gaudichaudianum O
Kunth O
essential O
oil O
and O
its O
major O
compound O
nerolidol. B-CHEMICAL
Piper O
gaudichaudianum O
Kunth O
is O
used O
in O
popular O
medicine O
as O
anti-inflamatory O
and O
against O
liver O
disorders. O
One O
of O
the O
most O
studied O
components O
of O

the O
plant O
is O
the O
essential O
oil O
for O
which O
chemical O
analysis O
revealed O
(E)-nerolidol B-CHEMICAL
as O
major O
compound. O
Recently, O
we O
have O
shown O
that O
P. O
gaudichaudianum O
essential O
oil O
possesses O
strong O
cytotoxic O
effects O
in O
mammalian O
V79 O
cells. O
The O
aim O
of O
this O
study O
was O
to O
analyze O
the O
cytotoxicity O
and O
mutagenicity O
of O
P. O
gaudichaudianum O
essential O
oil O
and O
nerolidol B-CHEMICAL
using O
Saccharomyces O
cerevisiae O
as O
model O
study. O
Treatment O
of O
the O
XV185-14c O
and O
N123 O
strains O
with O
essential O
oil O
and O

nerolidol B-CHEMICAL
led O
to O
cytotoxicity O
but O
did O
not O
induce O
mutagenicity. O
Our O
results O
revealed O
an O
important O
role O
of O
base O
excision O
repair O
(BER) O
as O
the O
ntg1, B-GENE-Y
ntg2, B-GENE-Y
apn1 B-GENE-Y
and O
apn2 B-GENE-Y
mutants O
showed O
pronounced O
sensitivity O
to O
essential O
oil O
and O
nerolidol. B-CHEMICAL
In O
the O
absence O
of O
superoxide B-CHEMICAL
dismutase I-GENE-Y
(in O
sod1 B-GENE-Y
mutant O
strain) O
sensitivity O
to O
the O
essential O
oil O
and O
nerolidol B-CHEMICAL
increased O
indicating O
that O
this O
oil O
and O
nerolidol B-CHEMICAL
are O
generating O
reactive O
oxygen B-CHEMICAL
species O
(ROS). O
The O
ROS O
production O
was O
confirmed O
by O

DCF-DA B-CHEMICAL
probing O
assay O
in O
Sod-deficient B-GENE-Y
strains. O
From O
this, O
we O
conclude O
that O
the O
observed O
cytotoxicity O
to O
P. O
gaudichaudianum O
essential O
oil O
and O
nerolidol B-CHEMICAL
is O
mainly O
related O
to O
ROS O
and O
DNA O
single O
strand O
breaks O
generated O
by O
the O
presence O
of O
oxidative O
lesions. O
Synthesis O
and O
biological O
evaluation O
of O
novel O
pyrrolidine-2,5-dione B-CHEMICAL
derivatives O
as O
potential O
antidepressant O
agents. O
Part O
1. O
A O
series O
of O

3-(1H-indol-3-yl)pyrrolidine-2,5-dione B-CHEMICAL
derivatives O
was O
synthesized O
and O
their O
biological O
activity O
was O
evaluated. O
The O
chemical O
structures O
of O
the O
newly O
prepared O
compounds O
were O
confirmed O
by O
(1)H B-CHEMICAL
NMR, O
(13)C B-CHEMICAL
NMR O
and O
ESI-HRMS O
spectra O
data. O
All O
tested O
compounds O
proved O
to O
be O
potent O
5-HT1A B-GENE-Y
receptor O
and O
serotonin B-GENE-Y
transporter I-GENE-Y
protein I-GENE-Y
(SERT) B-GENE-Y
ligands. O
Among O
them, O
compounds O
15, O
18, O
19 O
and O
30 O
showed O
significant O
affinity O
for O
5-HT1A B-GENE-Y
and O

SERT. B-GENE-Y
Computer O
docking O
simulations O
carried O
out O
for O
compounds O
15, O
31 O
and O
32 O
to O
models O
of O
5-HT1A B-GENE-Y
receptor O
and O
SERT B-GENE-Y
confirm O
the O
results O
of O
biological O
tests. O
Due O
to O
high O
affinity O
for O
the O
5-HT1A B-GENE-Y
receptor O
and O
moderate O
affinity O
for O
SERT, B-GENE-Y
compounds O
31, O
32, O
35, O
and O
37 O
were O
evaluated O
for O
their O
affinity O
for O
D2L, B-GENE-Y
5-HT6, B-GENE-Y
5-HT7 B-GENE-Y
and O
5-HT2A B-GENE-Y
receptors. O
In O
vivo O
tests, O
in O
turn, O
resulted O
in O
determining O
the O
functional O
activity O
of O
compounds O
15, O
18, O
19 O
and O
30 O
to O
the O

5-HT1A B-GENE-Y
receptor. O
The O
results O
of O
these O
tests O
indicate O
that O
all O
of O
the O
ligands O
possess O
properties O
characteristic O
of O
5-HT1A B-GENE-Y
receptor O
agonists. O
Metabolism O
Studies O
of O
Unformulated O
Internally O
[3H]-labeled B-CHEMICAL
siRNAs O
in O
Mice. O
Absorption, O
distribution, O
metabolism, O
and O
excretion O
properties O
of O
two O
unformulated O
model O
siRNAs O
were O
determined O
using O
a O
single O
internal O
[(3)H]-radiolabeling B-CHEMICAL
procedure, O
where O
the O
full-length O
oligonucleotides O
were O
radiolabeled O
by O

Br/(3)H-exchange. B-CHEMICAL
Tissue O
distribution, O
excretion, O
and O
mass O
balance O
of O
radioactivity O
were O
investigated O
in O
male O
CD-1 O
mice, O
following O
a O
single O
intravenous O
administration O
of O
the O
[(3)H]-siRNAs, B-CHEMICAL
at O
a O
target O
dose O
level O
of O
5 O
mg/kg. O
Quantitative O
whole-body O
autoradiography O
(QWBA) O
and O
liquid O
scintillation O
counting O
techniques O
were O
used O
to O
determine O
tissue O
distribution. O
Radiochromatogram O
profiles O
were O
determined O
in O
plasma, O
tissue O
extracts O
and O
urine. O
Metabolites O
were O
separated O
by O
liquid O
chromatography O
and O

identified O
by O
radiodetection O
and O
high-resolution O
accurate O
mass O
spectrometry. O
In O
general, O
there O
was O
little O
difference O
in O
the O
distribution O
of O
total O
radiolabeled O
components O
after O
administration O
of O
the O
two O
unformulated O
[(3)H]-siRNAs. B-CHEMICAL
The O
radioactivity O
was O
rapidly O
and O
widely O
distributed O
throughout O
the O
body, O
and O
remained O
detectable O
in O
all O
tissues O
investigated O
at O
later O
time O
points O
(24 O
and O
48 O
hours O
for O
[(3)H]-MRP4 B-CHEMICAL
and O
[(3)H]-SSB B-CHEMICAL
siRNA, O
respectively). O
After O
an O
initial O
rapid O
decline, O
concentrations O
of O
total O
radiolabeled O
components O
in O
dried O

blood O
declined O
at O
a O
much O
slower O
rate. O
A O
nearly O
complete O
mass O
balance O
was O
obtained O
for O
the O
[(3)H]-SSB B-CHEMICAL
siRNA O
and O
renal O
excretion O
was O
the O
main O
route O
of O
elimination O
(38%). O
The O
metabolism O
of O
the O
two O
model O
siRNAs O
was O
rapid O
and O
extensive. O
Five O
minutes O
after O
administration, O
no O
parent O
compound O
could O
be O
detected O
in O
plasma. O
Instead, O
radiolabeled O
nucleosides B-CHEMICAL
resulting O
from O
nuclease B-GENE-N
hydrolysis O
were O
observed. O
In O
the O
metabolism O
profiles O
obtained O
from O
various O
tissues O
only O
radiolabeled O
nucleosides B-CHEMICAL
were O
found, O
suggesting O
that O
siRNAs O
are O
rapidly O

metabolized O
and O
that O
the O
distribution O
pattern O
of O
total O
radiolabeled O
components O
can O
be O
ascribed O
to O
small O
molecular O
weight O
metabolites. O
Chemical O
genetic O
analyses O
of O
quantitative O
changes O
in O
Cdk1 B-GENE-Y
activity O
during O
the O
human O
cell O
cycle. O
Cyclin-dependent B-GENE-Y
kinase I-GENE-Y
1 I-GENE-Y
(Cdk1) B-GENE-Y
controls O
cell O
proliferation O
and O
is O
inhibited O
by O
promising O
anticancer O
agents, O
but O
its O
mode O
of O
action O
and O
the O
consequences O
of O
its O
inhibition O
are O
incompletely O
understood. O
Cdk1 B-GENE-Y
promotes O
S- O
and O
M-phases O
during O
the O
cell-cycle O
but O
also O
suppresses O
endoreduplication, O
which O
is O
associated O
with O
polyploidy O
and O
genome O

instability. O
The O
complexity O
of O
Cdk1 B-GENE-Y
regulation O
has O
made O
it O
difficult O
to O
determine O
whether O
these O
different O
roles O
require O
different O
thresholds O
of O
kinase B-GENE-N
activity O
and O
whether O
the O
surge O
of O
activity O
as O
inhibitory O
phosphates B-CHEMICAL
are O
removed O
at O
mitotic O
onset O
is O
essential O
for O
cell O
proliferation. O
Here, O
we O
have O
used O
chemical O
genetics O
in O
a O
human O
cell O
line O
to O
address O
these O
issues. O
We O
rescued O
cells O
lethally O
depleted O
of O
endogenous O
Cdk1 B-GENE-Y
with O
an O
exogenous O
Cdk1 B-GENE-Y
conferring O
sensitivity O
to O
one O
ATP B-CHEMICAL
analogue O
inhibitor O
(1NMPP1) B-CHEMICAL
and O
resistance O
to O
another O
(RO3306). B-CHEMICAL
At O
no O
1NMPP1 B-CHEMICAL
concentration O

was O
mitosis O
in O
rescued O
clones O
prevented O
without O
also O
inducing O
endoreduplication, O
suggesting O
that O
these O
two O
key O
roles O
for O
Cdk1 B-GENE-Y
are O
not O
simply O
controlled O
by O
different O
Cdk1 B-GENE-Y
activity O
thresholds. O
We O
also O
rescued O
RO3306-resistant B-CHEMICAL
clones O
using O
exogenous O
Cdk1 B-GENE-Y
without O
inhibitory O
phosphorylation O
sites, O
indicating O
that O
the O
mitotic O
surge O
of O
Cdk1 B-GENE-Y
activity O
is O
dispensable O
for O
cell O
proliferation. O
These O
results O
suggest O
that O
the O
basic O
mammalian O
cycle O
requires O
at O
least O
some O
qualitative O
changes O
in O
Cdk1 B-GENE-Y
activity O
and O
that O
quantitative O
increases O
in O
activity O
need O
not O
be O

rapid. O
Furthermore, O
the O
viability O
of O
cells O
that O
are O
unable O
to O
undergo O
rapid O
Cdk1 B-GENE-Y
activation, O
and O
the O
strong O
association O
between O
endoreduplication O
and O
impaired O
proliferation, O
may O
place O
restrictions O
on O
the O
therapeutic O
use O
of O
a O
Cdk1 B-GENE-Y
inhibitors. O
Inhibition O
of O
Ebola O
Virus O
Infection: O
Identification O
of O
Niemann-Pick B-GENE-Y
C1 I-GENE-Y
as O
the O
Target O
by O
Optimization O
of O
a O
Chemical O
Probe. O
A O
high O
throughput O
screen O
identified O
adamantane B-CHEMICAL
dipeptide O
1 O
as O
an O
inhibitor O
of O
Ebola O
virus O
(EboV) O
infection. O
Hit-to-lead O
optimization O
to O
determine O
the O

structure-activity O
relationship O
(SAR) O
identified O
the O
more O
potent O
EboV O
inhibitor O
2 O
and O
a O
photoaffinity O
labeling O
agent O
3. O
These O
anti-viral O
compounds O
were O
employed O
to O
identify O
the O
target O
as O
Niemann-Pick B-GENE-Y
C1 I-GENE-Y
(NPC1), B-GENE-Y
a O
host O
protein O
that O
binds O
the O
EboV B-GENE-N
glycoprotein I-GENE-N
and O
is O
essential O
for O
infection. O
These O
studies O
establish O
NPC1 B-GENE-Y
as O
a O
promising O
target O
for O
anti-viral O
therapy. O
Exploring O
the O
effect O
of O
N-substitution B-CHEMICAL
in O
nor-lobelane B-CHEMICAL
on O
the O
interaction O
with O
VMAT2: B-GENE-Y
discovery O
of O
a O
potential O
clinical O
candidate O
for O
treatment O
of O
methamphetamine B-CHEMICAL

abuse. O
A O
series O
of O
N-substituted B-CHEMICAL
lobelane B-CHEMICAL
analogues O
was O
synthesized O
and O
evaluated O
for O
their O
[(3)H]dihydrotetrabenazine B-CHEMICAL
binding O
affinity O
at O
the O
vesicular B-GENE-N
monoamine B-CHEMICAL
transporter I-GENE-N
and O
for O
their O
inhibition O
of O
vesicular O
[(3)H]dopamine B-CHEMICAL
uptake. O
Compound O
19a, O
which O
contains O
an O
N-1,2(R)-dihydroxypropyl B-CHEMICAL
group, O
had O
been O
identified O
as O
a O
potential O
clinical O
candidate O
for O
the O
treatment O
of O
methamphetamine B-CHEMICAL
abuse. O
The O
pre-clinical O
absorption, O
distribution, O
metabolism O
and O
excretion O
properties O
of O

IPI-926, B-CHEMICAL
an O
orally O
bioavailable O
antagonist O
of O
the O
hedgehog O
signal O
transduction O
pathway. O
Abstract O
1. O
IPI-926 B-CHEMICAL
is O
a O
novel O
semisynthetic O
cyclopamine B-CHEMICAL
derivative O
that O
is O
a O
potent O
and O
selective O
Smoothened O
inhibitor O
that O
blocks O
the O
hedgehog O
signal O
transduction O
pathway. O
2. O
The O
in O
vivo O
clearance O
of O
IPI-926 B-CHEMICAL
is O
low O
in O
mouse O
and O
dog O
and O
moderate O
in O
monkey. O
The O
volume O
of O
distribution O
is O
high O
across O
species. O
Oral O
bioavailability O
ranges O
from O
moderate O
in O
monkey O
to O
high O
in O
mouse O
and O
dog. O
Predicted O
human O
clearance O
using O
simple O

allometry O
is O
low O
(24 O
L O
h(-1)), O
predicted O
volume O
of O
distribution O
is O
high O
(469 O
L) O
and O
predicted O
half-life O
is O
long O
(20 O
h). O
3. O
IPI-926 B-CHEMICAL
is O
highly O
bound O
to O
plasma O
proteins O
and O
has O
minimal O
interaction O
with O
human B-GENE-N
-1-acid I-GENE-N
glycoprotein. I-GENE-N
4. O
In O
vitro O
metabolic O
stability O
ranges O
from O
stable O
to O
moderately O
stable. O
Twelve O
oxidative O
metabolites O
were O
detected O
in O
mouse, O
rat, O
dog, O
monkey O
and O
human O
liver O
microsome O
incubations O
and O
none O
were O
unique O
to O
human. O
5. O
IPI-926 B-CHEMICAL
is O

not O
a O
potent O
reversible O
inhibitor O
of O
CYP1A2, B-GENE-N
2C8, I-GENE-N
2C9 I-GENE-N
or I-GENE-N
3A4 I-GENE-N
(testosterone). B-CHEMICAL
IPI-926 B-CHEMICAL
is O
a O
moderate O
inhibitor O
of O
CYP2C19, B-GENE-N
2D6 I-GENE-N
and I-GENE-N
3A4 I-GENE-N
(midazolam) B-CHEMICAL
with O
KI O
values O
of O
19, O
16 O
and O
4.5 O
M, O
respectively. O
IPI-926 B-CHEMICAL
is O
both O
a O
substrate O
and O
inhibitor O
(IC50 O
= O
1.9 O
M) O
of O
P-glycoprotein. B-GENE-N
6. O
In O
summary, O
IPI-926 B-CHEMICAL
has O
desirable O
pre-clinical O
absorption, O
distribution, O
metabolism O

and O
excretion O
properties. O
Protection O
of O
glycyrrhizic B-CHEMICAL
acid I-CHEMICAL
against O
AGEs-induced O
endothelial O
dysfunction O
through O
inhibiting O
RAGE/NF-B B-GENE-Y
pathway O
activation O
in O
human O
umbilical O
vein O
endothelial O
cells. O
ETHNOPHARMACOLOGICAL O
RELEVANCE: O
Licorice O
(Glycyrrhiza O
uralensis O
roots) O
is O
used O
as O
a O
traditional O
medicine O
for O
the O
treatment O
of O
diabetes O
mellitus O
and O
its O
vascular O
complications. O
Glycyrrhizic B-CHEMICAL
acid I-CHEMICAL
(GA, O
also O
known O
as O

Glycyrrhizin), B-CHEMICAL
a O
triterpenoid B-CHEMICAL
saponin I-CHEMICAL
glycoside, I-CHEMICAL
is O
considered O
to O
be O
a O
bioactive O
component O
in O
Licorice O
and O
is O
beneficial O
to O
diabetic O
vascular O
complications. O
AIM O
OF O
STUDY: O
The O
present O
study O
was O
conducted O
to O
evaluate O
the O
potential O
protective O
activities O
on O
AGEs-induced O
endothelial O
dysfunction, O
including O
anti-apoptosis, O
antioxidant O
stress O
and O
anti-proinflammatory O
responses, O
and O
explore O
the O
underlying O
mechanism. O
MATERIALS O
AND O
METHODS: O
Human O
umbilical O
vein O
endothelial O
cells O

(HUVECs) O
were O
incubated O
and O
pre-treated O
with O
GA O
(10(-9)-10(-6)M) O
or O
RAGE-Ab B-GENE-Y
(5g/ml) O
in O
the O
presence O
or O
absence O
of O
200g/ml O
AGEs. O
AO/EB O
fluorescence O
staining O
assay O
was O
performed O
to O
evaluate O
anti-apoptosis O
activity. O
The O
superoxide B-CHEMICAL
dismutase I-GENE-N
(SOD) B-GENE-N
activity O
and O
malondialdehyde B-CHEMICAL
(MDA) B-CHEMICAL
level O
in O
cell O
supernatant O
were O
detected O
by O
kits O
while O
the O
intracellular O
reactive O
oxygen B-CHEMICAL
species O

(ROS) O
generation O
was O
determined O
by O
2,7-dichlorodihydrofluorescin B-CHEMICAL
diacetate I-CHEMICAL
(DCFH-DA) B-CHEMICAL
kit. O
Immunocytochemistry O
analysis O
was O
designed O
to O
determine O
transforming B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
beta1(TGF-1) I-GENE-Y
protein O
expression O
while O
immunofluorescence O
analysis O
for O
RAGE B-GENE-Y
and O
NF-kB. B-GENE-N
The O
protein O
expressions O
of O
TGF-1, B-GENE-Y
RAGE B-GENE-Y
and O
NF-kB B-GENE-N
were O
analyzed O
by O
Western O
blot O
analysis. O
RESULTS: O
Pretreatment O
with O
GA O
at O
a O
concentration O
of O

10(-8)-10(-6)M O
significantly O
reduced O
the O
AGEs-induced O
apoptosis O
in O
HUVECs. O
GA O
significantly O
increased O
antioxidant O
enzyme O
SOD B-GENE-N
activity O
and O
decreased O
peroxide O
degradation O
product O
MDA B-CHEMICAL
level O
in O
a O
dose-dependent O
manner. O
Furthermore, O
GA O
also O
remarkably O
inhibited O
the O
overgeneration O
of O
AGEs-induced O
ROS. O
Both O
immunocytochemistry O
analysis O
and O
western O
blot O
analysis O
showed O
that O
GA O
significantly O
decreased O
the O
protein O
expression O
of O
poinflammatory O
cytokine B-GENE-N
TGF-1 B-GENE-Y
in O
a O
similar O
manner O
which O
RAGE-Ab B-GENE-Y
did. O

Additionally, O
AGEs-induced O
RAGE B-GENE-Y
and O
NF-kB B-GENE-N
protein O
expressions O
were O
down-regulated O
significantly O
by O
the O
pretreatment O
with O
GA O
or O
RAGE-Ab. B-GENE-Y
CONCLUSION: O
These O
findings O
provide O
evidences O
that O
GA O
possesses O
protective O
activity O
on O
AGEs-induced O
endothelial O
dysfunction, O
including O
anti-apoptosis, O
anti-inflammation O
and O
antioxidant O
stress, O
via O
inhibiting O
RAGE/NF-kB B-GENE-Y
pathway. O
GA O
might O
be O
an O
alternative O
for O
the O
prevention O
and O
treatment O
of O
diabetic O
vascular O
complications O
in O
an O
appropriate O
dosage. O
Evaluation O
of O
body O
weight, O
insulin B-GENE-Y
resistance, O

leptin B-GENE-N
and O
adiponectin B-GENE-N
levels O
in O
premenopausal O
women O
with O
hyperprolactinemia. O
The O
effects O
of O
hyperprolactinemia O
on O
metabolic O
parameters O
are O
not O
clear O
and O
a O
few O
data O
evaluating O
adiponectin B-GENE-Y
levels O
in O
prolactinoma O
and O
idiopathic O
hyperprolactinemia O
exist. O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
hyperprolactinemia O
on O
body O
weight, O
insulin O
resistance, O
beta O
cell O
function, O
and O
leptin B-GENE-Y
and O
adiponectin B-GENE-Y
levels O
in O
premenopausal O
women O
with O

hyperprolactinemia. O
Forty O
premenopausal O
women O
with O
prolactinoma O
or O
idiopathic O
hyperprolactinemia O
were O
compared O
to O
41 O
age-matched O
healthy O
premenopausal O
women O
with O
regard O
to O
body O
weight, O
body O
mass O
index, O
waist O
and O
hip O
circumferences, O
waist O
to O
hip O
ratio, O
fasting O
plasma O
glucose, B-CHEMICAL
insulin B-GENE-Y
levels, O
insulin B-GENE-Y
resistance O
measured O
by O
homeostasis O
model O
assessment O
(HOMA)-insulin B-GENE-Y
resistance O
index, O
beta O
cell O
function O
measured O
by O
HOMA- O
index, O
leptin B-GENE-Y
and O
adiponectin B-GENE-Y
levels. O
Plasma O
insulin B-GENE-Y
levels O
and O

HOMA O
indexes O
(both O
insulin B-GENE-Y
resistance O
and O
beta O
indexes) O
were O
significantly O
higher O
in O
hyperprolactinemic O
women. O
The O
other O
parameters O
were O
similar O
between O
both O
groups. O
There O
was O
a O
positive O
correlation O
between O
prolactin B-GENE-Y
levels O
and O
fasting O
plasma O
glucose B-CHEMICAL
in O
hyperprolactinemic O
women. O
The O
results O
of O
this O
study O
showed O
that O
high O
prolactin B-GENE-Y
levels O
may O
be O
associated O
with O
hyperinsulinemia O
and O
insulin B-GENE-Y
resistance O
in O
premenopausal O
women. O
This O
effect O
seems O
to O
be O
independent O
of O
body O
weight, O
leptin B-GENE-Y
and O
adiponectin B-GENE-Y
levels. O
High O
prolactin B-GENE-Y
levels O
may O
directly O
stimulate O
insulin B-GENE-Y

secretion O
from O
pancreas O
and O
directly O
cause O
hepatic O
and O
whole-body O
insulin B-GENE-Y
resistance. O
Lorcaserin: B-CHEMICAL
a O
review O
of O
its O
use O
in O
chronic O
weight O
management. O
Oral O
lorcaserin B-CHEMICAL
(BELVIQ()), B-CHEMICAL
a O
selective O
serotonin B-CHEMICAL
5-HT2C B-GENE-Y
receptor O
agonist, O
is O
indicated O
in O
the O
US O
as O
an O
adjunct O
to O
diet O
and O
exercise O
in O
the O
chronic O
weight O
management O
of O
obese O
adults, O
or O
overweight O
adults O
with O
at O
least O
one O
weight-related O
comorbidity O
(e.g. O
dyslipidaemia, O
hypertension, O
type O
2 O
diabetes). O
This O

article O
reviews O
the O
pharmacological O
properties, O
therapeutic O
efficacy O
and O
tolerability O
of O
oral O
lorcaserin B-CHEMICAL
in O
this O
patient O
population. O
In O
three O
large O
randomized, O
double-blind, O
multicentre O
studies, O
oral O
lorcaserin B-CHEMICAL
was O
more O
effective O
than O
placebo O
in O
the O
management O
of O
obese O
and O
overweight O
adults O
with O
or O
without O
type O
2 O
diabetes O
mellitus. O
Following O
12 O
months' O
therapy, O
significantly O
higher O
proportions O
of O
lorcaserin B-CHEMICAL
than O
placebo O
recipients O
achieved O
a O
5 O
and O
10 O
% O
reduction O
from O
baseline O
in O
their O
bodyweight O
and O
a O
significant O
between-group O
difference O
favouring O
lorcaserin B-CHEMICAL
over O
placebo O
was O
observed O
for O

the O
change O
from O
baseline O
in O
bodyweight. O
Moreover, O
among O
patients O
who O
had O
achieved O
a O
5 O
% O
reduction O
in O
their O
bodyweight O
after O
12 O
months' O
therapy O
with O
lorcaserin, B-CHEMICAL
a O
significantly O
higher O
proportion O
who O
received O
lorcaserin B-CHEMICAL
for O
a O
further O
12 O
months O
than O
those O
who O
switched O
to O
placebo O
maintained O
5 O
% O
weight O
loss O
at O
24 O
months. O
In O
general, O
oral O
lorcaserin B-CHEMICAL
was O
well O
tolerated O
in O
clinical O
studies, O
with O
hypoglycaemia O
and O
headache O
the O
most O
frequently O
reported O
adverse O
events O
in O
those O
with O
or O
without O
type O
2 O
diabetes, O
respectively. O
According O
to O
a O
pooled O
analysis, O
the O
risk O
of O
US-FDA-defined O

valvulopathy O
with O
lorcaserin B-CHEMICAL
is O
generally O
low O
and O
not O
statistically O
significantly O
different O
from O
placebo. O
From O
these O
and O
other O
data, O
the O
FDA O
has O
concluded O
that O
lorcaserin B-CHEMICAL
is O
unlikely O
to O
elevate O
the O
risk O
of O
valvulopathy. O
Design, O
Synthesis, O
Biological O
Evaluation, O
and O
Docking O
Studies O
of O
(S)-Phenylalanine B-CHEMICAL
Derivatives O
with O
a O
2-Cyanopyrrolidine B-CHEMICAL
Moiety O
as O
Potent O
Dipeptidyl B-GENE-Y
Peptidase I-GENE-Y
4 I-GENE-Y
Inhibitors. O
A O
novel O
series O
of O
(S)-phenylalanine B-CHEMICAL
derivatives O
with O
a O

2-cyanopyrrolidine B-CHEMICAL
moiety O
were O
designed O
and O
synthesized O
through O
a O
rational O
drug O
design O
strategy. O
Biological O
evaluation O
revealed O
that O
most O
tested O
compounds O
were O
potent O
dipeptidyl B-GENE-Y
peptidase I-GENE-Y
4 I-GENE-Y
(DPP-4) B-GENE-Y
inhibitors, O
among O
them, O
the O
cyclopropyl-substituted B-CHEMICAL
phenylalanine I-CHEMICAL
derivative O
11h O
displayed O
the O
most O
potent O
DPP-4 B-GENE-Y
inhibitory O
activity O
with O
an O
IC50 O
value O
of O
0.247 O
M. O
In O
addition, O
molecular O
docking O
analysis O
of O
the O
representative O
compounds O
11h, O
11k, O
and O
15a O
were O
performed, O
which O
not O
only O
revealed O
the O
impact O
of O
binding O
modes O
on O

DPP-4 B-GENE-Y
inhibitory O
activity, O
but O
also O
provided O
additional O
methodological O
values O
for O
design O
and O
optimization. O
 O
2013 O
John O
Wiley O
& O
Sons O
A/S. O
Bioimaging O
real-time O
PXR-dependent B-GENE-Y
mdr1a B-GENE-Y
gene O
regulation O
in O
mdr1a.fLUC B-GENE-Y
reporter O
mice. O
The O
MDR1 B-GENE-Y
gene O
encodes O
P-glycoprotein, B-GENE-Y
a O
transmembrane B-GENE-N
drug I-GENE-N
efflux I-GENE-N
transporter I-GENE-N
that O
confers O
multidrug O
resistance O
in O
cancer O
cells O
and O
affects O
drug O
pharmacokinetics O
by O
virtue O
of O
its O
expression O
in O
the O
liver, O
kidney, O
and O
colon. O
Nuclear B-GENE-N
receptors I-GENE-N
SXR B-GENE-Y

and O
CAR B-GENE-Y
are O
possible O
master O
regulators O
of O
xenobiotic-inducible O
MDR1 B-GENE-Y
expression O
in O
drug O
processing O
organs, O
but O
the O
mechanism O
of O
MDR1 B-GENE-Y
regulation O
has O
yet O
to O
be O
directly O
demonstrated O
in O
vivo. O
Moreover, O
it O
has O
previously O
been O
impossible O
to O
determine O
the O
sustained O
or O
cumulative O
effect O
of O
repeated O
doses O
of O
xenobiotics O
on O
in O
vivo O
MDR1 B-GENE-Y
expression. O
We O
previously O
reported O
a O
mouse O
model O
containing O
firefly O
luciferase O
(fLUC) O
knocked O
into O
the O
mdr1a B-GENE-Y
genomic O
locus, O
allowing O
non-invasive O
bioimaging O
of O
intestinal O
mdr1a B-GENE-Y
gene O
expression O
in O
live O
animals. O
In O

the O
current O
study, O
we O
crossed O
mdr1a.fLUC B-GENE-Y
mice O
into O
the O
pxr B-GENE-Y
knockout O
(pxr(-/-)) B-GENE-Y
genetic O
background O
and O
injected O
mice O
with O
pregnenolone-16-carbonitrile B-CHEMICAL
(PCN), B-CHEMICAL
a O
strong O
PXR B-GENE-Y
ligand, O
and O
two O
therapeutically O
relevant O
taxanes, B-CHEMICAL
paclitaxel B-CHEMICAL
and O
docetaxel. B-CHEMICAL
All O
three O
agents O
induced O
mdr1a.fLUC B-GENE-Y
expression O
(bioluminescence), O
but O
only O
PCN B-CHEMICAL
and O
docetaxel B-CHEMICAL
appeared O
to O
act O
primarily O
via O
PXR. B-GENE-Y
Luminescence O
returned O

to O
baseline O
by O
24-48 O
hrs O
after O
drug O
injection O
and O
was O
re-inducible O
over O
two O
additional O
rounds O
of O
drug O
dosing O
in O
pxr(+/+) B-GENE-Y
mice. O
TCPOBOP, B-CHEMICAL
a O
CAR B-GENE-Y
ligand, O
modestly O
induced O
mdr1a.fLUC B-GENE-Y
in O
pxr(+/+) B-GENE-Y
and O
pxr(-/-) B-GENE-Y
strains, O
consistent O
with O
CAR's B-GENE-Y
minor O
role O
in O
mdr1a B-GENE-Y
regulation. O
Collectively, O
these O
results O
demonstrate O
that O
the O
mdr1a.fLUC B-GENE-Y
bioimaging O
model O
can O
capture O
changes O
in O
mdr1 B-GENE-Y
gene O
expression O

under O
conditions O
of O
repeated O
xenobiotic O
treatment O
in O
vivo O
and O
that O
it O
can O
be O
used O
to O
probe O
the O
mechanism O
of O
gene O
regulation O
in O
response O
to O
different O
xenobiotic O
agents. O
Bioinformatics O
and O
Molecular O
Dynamics O
Simulation O
Study O
of O
L1 B-GENE-N
Stalk I-GENE-N
Non-Canonical I-GENE-N
rRNA I-GENE-N
Elements: I-GENE-N
Kink-Turns, B-GENE-N
Loops, O
and O
Tetraloops. O
The O
L1 B-GENE-N
stalk I-GENE-N
is O
a O
prominent O
mobile O
element O
of O
the O
large O
ribosomal O
subunit. O
We O
explore O
the O
structure O
and O
dynamics O
of O
its O
non-canonical O
rRNA O
elements, O
which O
include O
two O
kink-turns, B-GENE-N
an O
internal B-GENE-N
loop, I-GENE-N
and O
a O
tetraloop. B-GENE-N
We O
use O

bioinformatics O
to O
identify O
the O
L1 B-GENE-N
stalk I-GENE-N
RNA O
conservation O
patterns O
and O
carry O
out O
over O
11.5 O
s O
of O
MD O
simulations O
for O
a O
set O
of O
systems O
ranging O
from O
isolated O
RNA O
building O
blocks O
up O
to O
complexes O
of O
L1 B-GENE-N
stalk I-GENE-N
rRNA O
with O
the O
L1 B-GENE-Y
protein I-GENE-Y
and O
tRNA O
fragment. O
We O
show O
that O
the O
L1 B-GENE-N
stalk I-GENE-N
tetraloop I-GENE-N
has O
an O
unusual O
GNNA B-GENE-N
or O
UNNG B-GENE-N
conservation O
pattern O
deviating O
from O
major O
GNRA B-GENE-N
and O
YNMG B-GENE-N
RNA B-GENE-N
tetraloop I-GENE-N
families. O
We O
suggest O
that O
this O
deviation O
is O
related O
to O
a O
highly O
conserved O
tertiary O
contact O
within O
the O
L1 B-GENE-N
stalk. I-GENE-N
The O
available O
X-ray O
structures O
contain O
only O
UCCG B-GENE-N

tetraloops B-GENE-N
which O
in O
addition O
differ O
in O
orientation O
(anti O
vs O
syn) O
of O
the O
guanine. B-CHEMICAL
Our O
analysis O
suggests O
that O
the O
anti O
orientation O
might O
be O
a O
mis-refinement, O
although O
even O
the O
anti O
interaction O
would O
be O
compatible O
with O
the O
sequence O
pattern O
and O
observed O
tertiary O
interaction. O
Alternatively, O
the O
anti O
conformation O
may O
be O
a O
real O
substate O
whose O
population O
could O
be O
pH-dependent, O
since O
the O
guanine B-CHEMICAL
syn O
orientation O
requires O
protonation O
of O
cytosine B-CHEMICAL
in O
the O
tertiary O
contact. O
In O
absence O
of O
structural O
data, O
we O
use O
molecular O
modeling O
to O
explore O
the O
GCCA B-GENE-N
tetraloop B-GENE-N
that O
is O
dominant O
in O
bacteria O
and O
suggest O
that O
the O

GCCA B-GENE-N
tetraloop B-GENE-N
is O
structurally O
similar O
to O
the O
YNMG B-GENE-N
tetraloop. B-GENE-N
Kink-turn B-GENE-N
Kt-77 I-GENE-N
is O
unusual O
due O
to O
its O
11-nucleotide B-CHEMICAL
bulge. O
The O
simulations O
indicate O
that O
the O
long O
bulge O
is O
a O
stalk-specific O
eight-nucleotide B-CHEMICAL
insertion O
into O
consensual O
kink-turn B-GENE-N
only O
subtly O
modifying O
its O
structural O
dynamics. O
We O
discuss O
a O
possible O
evolutionary O
role O
of O
helix B-GENE-N
H78 I-GENE-N
and O
a O
mechanism O
of O
L1 B-GENE-N
stalk I-GENE-N
interaction O
with O
tRNA. O
We O
also O
assess O
the O
simulation O
methodology. O
The O
simulations O
provide O
a O
good O
description O
of O
the O
studied O
systems O
with O
the O
latest O

bsc0OL3 O
force O
field O
showing O
improved O
performance. O
Still, O
even O
bsc0OL3 O
is O
unable O
to O
fully O
stabilize O
an O
essential O
sugar-edge B-CHEMICAL
H-bond B-CHEMICAL
between O
the O
bulge O
and O
non-canonical O
stem O
of O
the O
kink-turn. B-GENE-N
Inclusion O
of O
Mg(2+) B-CHEMICAL
ions O
may O
deteriorate O
the O
simulations. O
On O
the O
other O
hand, O
monovalent O
ions O
can O
in O
simulations O
readily O
occupy O
experimental O
Mg(2+) B-CHEMICAL
binding O
sites. O
Galangin B-CHEMICAL
attenuates O
mast O
cell-mediated O
allergic O
inflammation. O
A O
great O
number O
of O
people O
are O
suffering O
from O
allergic O
inflammatory O
disease O
such O
as O

asthma, O
atopic O
dermatitis, O
and O
sinusitis. O
Therefore O
discovery O
of O
drugs O
for O
the O
treatment O
of O
these O
diseases O
is O
an O
important O
subject O
in O
human O
health. O
In O
this O
study, O
we O
investigated O
anti-allergic O
inflammatory O
effect O
of O
galangin B-CHEMICAL
and O
underlying O
mechanisms O
of O
action O
using O
in O
vitro O
and O
in O
vivo O
models. O
Galangin B-CHEMICAL
inhibited O
histamine B-CHEMICAL
release O
by O
the O
reduction O
of O
intracellular O
calcium B-CHEMICAL
in O
phorbol B-CHEMICAL
12-mystate I-CHEMICAL
13-acetate I-CHEMICAL
plus O
calcium B-CHEMICAL
ionophore O
A23187-stimulated O
human O
mast O
cells O
(HMC-1). O
Galangin B-CHEMICAL
decreased O
expression O
of O
pro-inflammatory O

cytokines, B-GENE-N
such O
as O
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
(TNF)-, I-GENE-Y
interleukin B-GENE-Y
(IL)-6, B-GENE-Y
IL-1, B-GENE-Y
and O
IL-8. B-GENE-Y
The O
inhibitory O
effect O
of O
galangin B-CHEMICAL
on O
theses O
pro-inflammatory O
cytokines B-GENE-N
was O
related O
with O
c-Jun B-GENE-Y
N-terminal B-GENE-N
kinases, I-GENE-N
and O
p38 B-GENE-N
mitogen-activated B-GENE-N
protein I-GENE-N
kinase, I-GENE-N
nuclear B-GENE-N
factor-B, I-GENE-N
and O
caspase-1. B-GENE-Y
Furthermore, O
galangin B-CHEMICAL
attenuated O
IgE-mediated B-GENE-N
passive O
cutaneous O
anaphylaxis O
and O
the O
expression O
of O
histamine B-GENE-Y
receptor I-GENE-Y
1 I-GENE-Y
at O
the O

inflamed O
tissue. O
The O
inhibitory O
effects O
of O
galangin B-CHEMICAL
were O
more O
potent O
than O
cromolyn, B-CHEMICAL
a O
known O
anti-allergic O
drug. O
Our O
results O
showed O
that O
galangin B-CHEMICAL
down-regulates O
mast O
cell-derived O
allergic O
inflammatory O
reactions O
by O
blocking O
histamine B-CHEMICAL
release O
and O
expression O
of O
pro-inflammatory O
cytokines. B-GENE-N
In O
light O
of O
in O
vitro O
and O
in O
vivo O
anti-allergic O
inflammatory O
effects, O
galangin B-CHEMICAL
could O
be O
a O
beneficial O
anti-allergic O
inflammatory O
agent. O
Aberrant O
activation O
of O
M B-GENE-N
phase I-GENE-N
proteins I-GENE-N
by O
cell O
proliferation-evoking O
carcinogens O
after O
28-day O
administration O
in O
rats. O
We O
have O

previously O
reported O
that O
hepatocarcinogens O
increase O
liver O
cells O
expressing O
p21(Cip1), B-GENE-Y
a O
G1 O
checkpoint O
protein O
and O
M B-GENE-N
phase I-GENE-N
proteins I-GENE-N
after O
28-day O
treatment O
in O
rats. O
This O
study O
aimed O
to O
identify O
early O
prediction O
markers O
of O
carcinogens O
available O
in O
many O
target O
organs O
after O
28-day O
treatment O
in O
rats. O
Immunohistochemical O
analysis O
was O
performed O
on O
Ki-67, B-GENE-Y
p21(Cip1) B-GENE-Y
and O
M B-GENE-N
phase I-GENE-N
proteins I-GENE-N
[nuclear O
Cdc2, B-GENE-Y
phospho-Histone B-GENE-N
H3 I-GENE-N
(p-Histone B-GENE-N
H3), I-GENE-N
Aurora B-GENE-Y
B I-GENE-Y
and O
heterochromatin B-GENE-Y
protein I-GENE-Y

1 I-GENE-Y
(HP1)] B-GENE-Y
with O
carcinogens O
targeting O
different O
organs. O
Carcinogens O
targeting O
thyroid O
(sulfadimethoxine; B-CHEMICAL
SDM), B-CHEMICAL
urinary O
bladder O
(phenylethyl B-CHEMICAL
isothiocyanate), I-CHEMICAL
forestomach O
(butylated B-CHEMICAL
hydroxyanisole; I-CHEMICAL
BHA), B-CHEMICAL
glandular O
stomach O
(catechol; B-CHEMICAL
CC), O
and O
colon O
(2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine B-CHEMICAL
and O
chenodeoxycholic B-CHEMICAL
acid) I-CHEMICAL

were O
examined O
using O
a O
non-carcinogenic O
toxicant O
(caprolactam) B-CHEMICAL
and O
carcinogens O
targeting O
other O
organs O
as O
negative O
controls. O
All O
carcinogens O
increased O
Ki-67(+), B-GENE-Y
nuclear O
Cdc2(+), B-GENE-Y
p-Histone B-GENE-N
H3(+) I-GENE-N
or O
Aurora B-GENE-Y
B(+) I-GENE-Y
carcinogenic O
target O
cells, O
except O
for O
both O
colon O
carcinogens, O
which O
did O
not O
increase O
cell O
proliferation. O
On O
the O
other O
hand, O
p21(Cip1+) B-GENE-Y
cells O
increased O
with O
SDM O
and O
CC. O
HP1 B-GENE-Y
responded O
only O
to O
BHA. B-CHEMICAL
Results O
revealed O
carcinogens O

evoking O
cell O
proliferation O
concurrently O
induced O
cell O
cycle O
arrest O
at O
M O
phase O
or O
showing O
chromosomal O
instability O
reflecting O
aberration O
in O
cell O
cycle O
regulation, O
irrespective O
of O
target O
organs, O
after O
28-day O
treatment. O
Therefore, O
M B-GENE-N
phase I-GENE-N
proteins I-GENE-N
may O
be O
early O
prediction O
markers O
of O
carcinogens O
evoking O
cell O
proliferation O
in O
many O
target O
organs. O
Nobiletin B-CHEMICAL
attenuates O
metastasis O
via O
both O
ERK B-GENE-N
and O
PI3K/Akt B-GENE-N
pathways O
in O
HGF-treated B-GENE-Y
liver O
cancer O
HepG2 O
cells. O
Hepatocyte B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(HGF), B-GENE-Y
and O
its O
receptor, O
c-Met B-GENE-Y
activation O
has O
recently O

been O
shown O
to O
play O
important O
roles O
in O
cancer O
invasion O
and O
metastasis O
in O
a O
wide O
variety O
of O
tumor O
cells. O
We O
use O
HGF B-GENE-Y
as O
an O
invasive O
inducer O
of O
human O
HepG2 O
cells O
to O
investigate O
the O
effect O
of O
four O
flavones O
including O
apigenin, B-CHEMICAL
tricetin, B-CHEMICAL
tangeretin, B-CHEMICAL
and O
nobiletin B-CHEMICAL
on O
HGF/c-Met-mediated B-GENE-Y
tumor O
invasion O
and O
metastasis. O
Among O
them, O
nobiletin B-CHEMICAL
markedly O
inhibited O
HGF-induced B-GENE-Y
the O
abilities O
of O
the O
adhesion, O
invasion, O
and O
migration O
by O
cell-matrix O
adhesion O
assay O
and O
transwell-chamber O

invasion/migration O
assay O
under O
non-cytotoxic O
concentrations. O
Data O
also O
showed O
nobiletin B-CHEMICAL
inhibited O
HGF-induced B-GENE-Y
cell O
scattering O
and O
cytoskeleton O
changed O
such O
as O
filopodia O
and O
lamellipodia. O
Furthermore, O
nobiletin B-CHEMICAL
could O
inhibit O
HGF-induced B-GENE-Y
the O
membrane O
localization O
of O
phosphorylated O
c-Met, B-GENE-Y
ERK2, B-GENE-Y
and O
Akt, B-GENE-N
but O
not O
phosphorylated B-GENE-N
JNK1/2 I-GENE-N
and O
p38. B-GENE-N
Next, O
nobiletin B-CHEMICAL
significantly O
decreased O
the O
levels O
of O
phospho-ERK2 B-GENE-Y
and O

phospho-Akt B-GENE-N
in O
ERK2 B-GENE-Y
or O
Akt B-GENE-N
siRNA-transfected O
cells O
concomitantly O
with O
a O
marked O
reduction O
on O
cell O
invasion O
and O
migration. O
In O
conclusion, O
nobiletin B-CHEMICAL
attenuates O
HGF-induced B-GENE-Y
HepG2 O
cells O
metastasis O
involving O
both O
ERK B-GENE-N
and O
PI3K/Akt B-GENE-N
pathways O
and O
are O
potentially O
useful O
as O
anti-metastatic O
agents O
for O
the O
treatment O
of O
hepatoma. O
Cardiac B-GENE-N
natriuretic I-GENE-N
Peptide I-GENE-N
gene O
expression O
and O
plasma O
concentrations O
during O
the O
first O
72 O
hours O
of O
life O
in O
piglets. O
Plasma O
measurement O
of O
cardiac B-GENE-N
natriuretic I-GENE-N

peptides I-GENE-N
constitutes O
promising O
markers O
of O
congenital O
heart O
disease. O
However, O
concentrations O
change O
rapidly O
and O
dramatically O
during O
the O
first O
days O
after O
delivery O
even O
in O
healthy O
neonates, O
which O
complicates O
clinical O
interpretation. O
It O
is O
unknown O
whether O
these O
changes O
in O
plasma O
concentrations O
are O
explained O
by O
corresponding O
changes O
in O
the O
cardiac O
gene O
expression. O
We O
quantified O
the O
chamber-specific O
mRNA O
levels O
of O
ANP B-GENE-Y
(A-type B-GENE-Y
natriuretic I-GENE-Y
peptide) I-GENE-Y
and O
BNP B-GENE-Y
(B-type B-GENE-N
natriuretic I-GENE-N
peptide) I-GENE-N
and O
plasma O
pro-ANP B-GENE-Y
and O
BNP-32 B-GENE-Y
concentrations O
in O
healthy O
piglets O
during O
the O
first O
72 O
hours O
of O
life O
(from O
2 O

litters, O
n O
= O
44). O
Chamber-specific O
ANP B-GENE-Y
and O
BNP B-GENE-Y
mRNA O
levels O
reflected O
hemodynamic O
neonate O
changes O
at O
birth O
but O
did O
not O
correlate O
with O
circulating O
natriuretic B-GENE-N
peptide I-GENE-N
concentrations. O
However, O
plasma O
pro-ANP B-GENE-Y
and O
creatinine B-CHEMICAL
concentrations O
were O
closely O
correlated O
(P O
< O
.0001; O
r O
= O
0.73). O
Plasma O
pro-ANP B-GENE-Y
levels O
were O
highest O
on O
the O
day O
of O
delivery O
(5580 O
pmol/L O
[4320-6786] O
decreasing O
to O
2484 O
pmol/L O
[1602-2898] O
after O
72 O
hours, O
P O
< O

.0001). O
During O
the O
72 O
hours, O
gel O
chromatography O
suggested O
that O
the O
translational O
products O
in O
circulation O
and O
in O
atrial O
tissue O
were O
immature, O
ie, O
unprocessed O
pro-ANP. B-GENE-Y
In O
contrast O
to O
pro-ANP, B-GENE-Y
BNP-32 B-GENE-Y
plasma O
concentrations O
were O
low O
at O
delivery O
and O
peaked O
after O
48 O
hours O
(12 O
[10.5-20.6] O
vs. O
88.8 O
[71.7-101.4] O
pmol/L, O
P O
< O
.0001). O
To O
conclude, O
ANP B-GENE-Y
and O
BNP B-GENE-Y
gene O
expression O
differs O
considerably O
between O
cardiac O
chambers O
in O
the O
first O
72 O
hours O
of O

life O
in O
healthy O
piglets, O
resembling O
the O
transition O
from O
fetal O
to O
neonate O
circulation. O
However, O
the O
cardiac O
gene O
expression O
does O
not O
explain O
plasma O
concentrations. O
T-Cells O
from O
HLA-B*57:01+ B-GENE-Y
Human O
Subjects O
Are O
Activated O
with O
Abacavir B-CHEMICAL
through O
Two O
Independent O
Pathways O
and O
Induce O
Cell O
Death O
by O
Multiple O
Mechanisms. O
Susceptibility O
to O
abacavir O
hypersensitivity O
has O
been O
attributed O
to O
possession O
of O
the O
specific O
human B-GENE-Y
leukocyte I-GENE-Y
antigen I-GENE-Y
allele I-GENE-Y
HLA-B*57:01. I-GENE-Y
HLA-B*57:01-restricted B-GENE-Y
activation O
of O

CD8+ O
T-cells O
provides O
a O
link O
between O
the O
genetic O
association O
and O
the O
iatrogenic O
disease. O
The O
objectives O
of O
this O
study O
were O
to O
characterize O
the O
functionality O
of O
drug-responsive O
CD8+ O
T-cell O
clones O
generated O
from O
HLA-B*57:01+ B-GENE-Y
drug-naive O
subjects O
and O
to O
explore O
the O
relationship O
between O
abacavir B-CHEMICAL
accumulation O
in O
antigen O
presenting O
cells O
and O
the O
T-cell O
response. O
Seventy-four O
CD8+ O
clones O
expressing O
different O
V B-GENE-N
receptors I-GENE-N
were O
shown O
to O
proliferate O
and O
kill O
target O
cells O
via O
different O
mechanisms O
when O
exposed O
to O
abacavir. B-CHEMICAL
Certain O
clones O
were O
activated O
with O

abacavir B-CHEMICAL
in O
the O
absence O
of O
antigen O
presenting O
cells. O
Analysis O
of O
the O
remaining O
clones O
revealed O
two O
pathways O
of O
drug-dependent O
T-cell O
activation. O
Overnight O
incubation O
of O
antigen O
presenting O
cells O
with O
abacavir, B-CHEMICAL
followed O
by O
repeated O
washing O
to O
remove O
soluble O
drug, O
activated O
approximately O
50% O
of O
the O
clones, O
and O
the O
response O
was O
blocked O
by O
glutaraldehyde B-CHEMICAL
fixation. O
In O
contrast, O
a O
1 O
h O
antigen O
presenting O
cell O
pulse O
did O
not O
activate O
any O
of O
the O
clones. O
Accumulation O
of O
abacavir B-CHEMICAL
in O
antigen O
presenting O
cells O
was O
rapid O
(less O
than O
1 O
h), O
and O
the O

intracellular O
concentrations O
were O
maintained O
for O
16 O
h. O
However, O
intracellular O
abacavir B-CHEMICAL
was O
not O
detectable O
by O
mass O
spectrometry O
after O
pulsing. O
These O
data O
suggest O
that O
T-cells O
can O
be O
activated O
by O
abacavir B-CHEMICAL
through O
a O
direct O
interaction O
with O
surface O
and O
intracellular O
major B-GENE-N
histocompatibility I-GENE-N
complex I-GENE-N
(MHC) B-GENE-N
molecules. O
With O
the O
former, O
abacavir B-CHEMICAL
seemingly O
participates O
in O
the O
MHC B-GENE-N
T-cell B-GENE-N
receptor I-GENE-N
binding O
interaction. O
In O
contrast, O
the O
latter O
pathway O
likely O
involves O
MHC B-GENE-N
binding O
peptides O
displayed O
as O
a O
consequence O
of O
abacavir B-CHEMICAL
exposure, O
but O
not O
abacavir B-CHEMICAL
itself. O

Potential O
diagnostic O
applications O
of O
side O
chain O
oxysterols B-CHEMICAL
analysis O
in O
plasma O
and O
cerebrospinal O
fluid. O
The O
neurospecific O
cholesterol B-CHEMICAL
24-hydroxylase O
converts O
excess O
brain O
cholesterol B-CHEMICAL
into O
24S-hydroxycholesterol B-CHEMICAL
(24OHC) B-CHEMICAL
which, O
via O
the O
liver B-GENE-N
X I-GENE-N
receptor I-GENE-N
(LXR), B-GENE-N
can O
increase O
the O
expression O
and O
synthesis O
of O
astrocyte O
ApoE. B-GENE-Y
24OHC B-CHEMICAL
effluxes O
directly O
from O
brain O
into O
plasma O
where O
it O
is O
considered O
an O
indicator O
of O
brain O
cholesterol B-CHEMICAL
turnover. O
It O
is O
reduced O
in O
neurodegenerative O
disease O

states O
proportionally O
to O
the O
severity O
of O
disease O
and O
the O
degree O
of O
brain O
atrophy. O
In O
the O
early O
phases O
of O
active O
disease, O
a O
higher O
rate O
of O
turnover O
may O
result O
in O
transitory O
increases O
in O
plasma O
24OHC. B-CHEMICAL
Less O
than O
1% O
of O
the O
total O
brain O
excretion O
of O
24OHC B-CHEMICAL
occurs O
via O
the O
cerebrospinal O
fluid O
(CSF) O
whereas O
almost O
all O
27-hydroxycholesterol B-CHEMICAL
(27OHC) B-CHEMICAL
excretion O
is O
dependent O
on O
the O
function O
of O
the O
blood-cerebrospinal O
fluid O
barrier. O
Iincreased O
CSF O
oxysterols B-CHEMICAL
were O
found O
in O
patients O
with O

neurodegenerative O
and O
neuroinflammatory O
diseases O
in O
the O
presence O
of O
barrier O
dysfunction. O
In O
neurodegeneration, O
free O
cholesterol B-CHEMICAL
released O
from O
dying O
cells O
may O
engulf O
neurons. O
Cholesterol B-CHEMICAL
also O
increases O
Amyloid B-GENE-Y
 I-GENE-Y
(A) B-GENE-Y
deposition O
and O
tau B-GENE-Y
pathology. O
ApoE, B-GENE-Y
24OHC, B-CHEMICAL
tau B-GENE-Y
and O
soluble B-GENE-Y
APP I-GENE-Y
were O
correlated O
in O
Alzheimer O
disease O
(AD) O
samples. O
Excess O
of O
cholesterol B-CHEMICAL
converted O
into O
24OHC B-CHEMICAL
may O
up-regulate O
ApoE B-GENE-Y
synthesis O
which O
is O
a O
scavenger O
for O
A B-GENE-Y
and O
Tau. B-GENE-Y
In O
AD O
this O

protective O
mechanism O
seems O
to O
be O
inefficient, O
probably O
due O
to O
the O
presence O
of O
high O
concentrations O
of O
27OHC, B-CHEMICAL
microvascular O
dysfunction O
and O
the O
decreased O
efficiency O
of O
ApoE4 B-GENE-Y
as O
lipid O
transporter O
and O
A B-GENE-Y
scavenger. O
24OHC B-CHEMICAL
itself O
was O
cytotoxic. O
Analysis O
of O
side O
chain O
oxysterols B-CHEMICAL
in O
the O
CSF O
is O
likely O
to O
provided O
useful O
information O
about O
cholesterol B-CHEMICAL
metabolism O
and O
ApoE B-GENE-Y
function O
in O
the O
pathogenesis O
of O
AD. O
Loss O
of O
Calcium/Calmodulin-Dependent B-GENE-N
Protein I-GENE-N
Kinase I-GENE-N
II I-GENE-N
Activity O
in O
Cortical O

Astrocytes O
Decreases O
Glutamate B-CHEMICAL
Uptake O
and O
Induces O
Neurotoxic O
Release O
of O
ATP. B-CHEMICAL
The O
extent O
of O
calcium/calmodulin-dependent B-CHEMICAL
protein I-GENE-N
kinase I-GENE-N
II I-GENE-N
(CaMKII) B-GENE-N
inactivation O
in O
the O
brain O
following O
ischemia O
correlates O
with O
the O
extent O
of O
damage. O
We O
have O
previously O
shown O
that O
a O
loss O
of O
CaMKII B-GENE-N
activity O
in O
neurons O
is O
detrimental O
to O
neuronal O
viability O
by O
inducing O
excitotoxic O
glutamate B-CHEMICAL
release. O
In O
the O
current O
study, O
we O
extend O
these O
findings O
to O
show O
that O
the O
ability O
of O
astrocytes O
to O

buffer O
extracellular O
glutamate B-CHEMICAL
is O
reduced O
when O
CaMKII B-GENE-N
is O
inhibited. O
Furthermore, O
CaMKII B-GENE-N
inhibition O
in O
astrocytes O
is O
associated O
with O
the O
rapid O
onset O
of O
intracellular O
calcium B-CHEMICAL
oscillations. O
Surprisingly, O
this O
rapid O
calcium B-CHEMICAL
influx O
is O
blocked O
by O
the O
N-type B-GENE-N
calcium I-GENE-N
channel I-GENE-N
antagonist, O
omega-conotoxin. B-GENE-N
While O
the O
function O
of O
N-type B-GENE-N
calcium I-GENE-N
channels I-GENE-N
within O
astrocytes O
is O
controversial, O
these O
voltage-gated B-GENE-N
calcium I-GENE-N
channels I-GENE-N
have O
been O
linked O
to O
calcium-dependent B-CHEMICAL
vesicular O
gliotransmitter O
release. O
When O
extracellular O

glutamate B-CHEMICAL
and O
ATP B-CHEMICAL
levels O
are O
measured O
following O
CaMKII B-GENE-N
inhibition O
within O
our O
enriched O
astrocyte O
cultures, O
no O
alterations O
in O
glutamate B-CHEMICAL
levels O
are O
observed, O
whereas O
ATP B-CHEMICAL
levels O
in O
the O
extracellular O
environment O
significantly O
increase. O
Extracellular O
ATP B-CHEMICAL
accumulation O
associated O
with O
CaMKII B-GENE-N
inhibition O
contributes O
both O
to O
calcium B-CHEMICAL
oscillations O
within O
astrocytes O
and O
ultimately O
cortical O
neuron O
toxicity. O
Thus, O
a O
loss O
of O
CaMKII B-GENE-N
signaling O
within O
astrocytes O
dysregulates O
glutamate B-CHEMICAL
uptake O
and O
supports O
ATP B-CHEMICAL
release, O
two O
processes O
that O
would O
compromise O
neuronal O
survival O

following O
ischemic/excitotoxic O
insults. O
Stable O
and O
high-rate O
overcharge O
protection O
for O
rechargeable O
lithium B-CHEMICAL
batteries. O
Rechargeable O
lithium B-CHEMICAL
or O
lithium-ion B-CHEMICAL
cells O
can O
be O
overcharge-protected O
by O
an O
electroactive O
polymer O
composite O
separator. O
The O
use O
of O
non-woven O
fibrous O
membranes O
instead O
of O
conventional O
microporous O
membranes O
as O
the O
composite O
substrates O
allowed O
better O
distribution O
of O
the O
electroactive O
polymer, O
which O
led O
to O
improved O
utilization O
and O
a O
40-fold O
increase O
in O
sustainable O
current O
density. O
For O
the O
first O
time, O
stable O
overcharge O
protection O
for O
hundreds O
of O
cycles O
was O

demonstrated O
in O
several O
cell O
chemistries, O
including O
LiNi1/3Co1/3Mn1/3O2, B-CHEMICAL
LiFePO4, B-CHEMICAL
and O
spinel O
Li1.05Mn1.95O4 B-CHEMICAL
half-cells. O
Protection O
at O
a O
charging O
rate O
as O
high O
as O
5 O
C O
was O
achieved O
at O
a O
steady O
state O
cell O
potential O
below O
4.85 O
V. O
3-Hydroxypyridin-2-thione B-CHEMICAL
as O
Novel O
Zinc B-CHEMICAL
Binding O
Group O
for O
Selective O
Histone B-GENE-N
Deacetylase I-GENE-N
Inhibition. O
Small O
molecules O
bearing O
hydroxamic O
acid O
as O
the O
zinc B-CHEMICAL
binding O
group O
(ZBG) O

have O
been O
the O
most O
effective O
histone B-GENE-N
deacetylase I-GENE-N
inhibitors O
(HDACi) B-GENE-N
to O
date. O
However, O
concerns O
about O
the O
pharmacokinetic O
liabilities O
of O
the O
hydroxamic B-CHEMICAL
acid I-CHEMICAL
moiety O
have O
stimulated O
research O
efforts O
aimed O
at O
finding O
alternative O
nonhydroxamate O
ZBGs. O
We O
have O
identified O
3-hydroxypyridin-2-thione B-CHEMICAL
(3-HPT) B-CHEMICAL
as O
a O
novel O
ZBG O
that O
is O
compatible O
with O
HDAC B-GENE-N
inhibition. O
3-HPT B-CHEMICAL
inhibits O
HDAC B-GENE-Y
6 I-GENE-Y
and O
HDAC B-GENE-Y
8 I-GENE-Y
with O
an O
IC50 O
of O
681 O
and O

3675 O
nM, O
respectively. O
Remarkably, O
3-HPT B-CHEMICAL
gives O
no O
inhibition O
of O
HDAC B-GENE-Y
1. I-GENE-Y
Subsequent O
optimization O
led O
to O
several O
novel O
3HPT-based B-CHEMICAL
HDACi B-GENE-N
that O
are O
selective O
for O
HDAC B-GENE-Y
6 I-GENE-Y
and O
HDAC B-GENE-Y
8. I-GENE-Y
Furthermore, O
a O
subset O
of O
these O
inhibitors O
induces O
apoptosis O
in O
various O
cancer O
cell O
lines. O
Histological, O
ultrastructural O
and O
immunohistochemical O
studies O
on O
the O
protective O
effect O
of O
ginger O
extract O
against O
cisplatin-induced B-CHEMICAL
nephrotoxicity O
in O
male O
rats. O
Cisplatin B-CHEMICAL
(CP) O
is O
a O
widely O
used O
anticancer O

drug; O
however, O
it O
has O
several O
side O
effects O
such O
as O
nephrotoxicity. O
Ginger, O
the O
rhizome O
of O
Zingiber O
officinale, O
consumed O
since O
ancient O
times O
has O
numerous O
health O
benefits. O
The O
objective O
of O
this O
work O
was O
to O
evaluate O
the O
protective O
effect O
of O
ginger O
extract O
(GE) O
against O
CP-induced O
nephrotoxicity. O
CP O
group O
displayed O
a O
marked O
renal O
failure O
characterized O
by O
a O
significant O
increase O
in O
serum O
creatinine B-CHEMICAL
and O
blood O
urea B-CHEMICAL
nitrogen B-CHEMICAL
(BUN) O
levels O
in O
addition O
to O
severe O
histopathological O
and O
ultrastructural O
renal O
alterations. O
Also, O
CP O
group O
showed O
an O
increase O
in O
the O

immunohistochemical O
expression O
of O
Bax B-GENE-Y
proapoptotic O
protein. O
In O
contrast, O
GE+CP O
group O
showed O
significant O
decrease O
in O
the O
elevated O
serum O
creatinine B-CHEMICAL
and O
BUN O
levels O
and O
an O
improvement O
in O
the O
histopathological O
and O
ultrastructural O
renal O
injury O
induced O
by O
CP. O
The O
overexpression O
of O
Bax B-GENE-Y
proapoptotic O
protein O
was O
significantly O
decreased O
in O
the O
GE+CP O
group. O
Hence, O
the O
present O
results O
indicated O
that O
GE O
has O
a O
protective O
effect O
against O
CP-induced O
renal O
damage O
in O
rats. O
Thereby, O
such O
findings O
recommended O
the O
usage O
of O
GE O
to O
prevent O
and/or O
decrease O
the O
renal O
damage O
induced O

by O
CP O
chemotherapeutic O
treatment. O
An O
analysis O
of O
skeletal O
development O
in O
osteoblast- O
and O
chondrocyte-specific O
Runx2 B-GENE-Y
knockout O
mice. O
Global O
gene O
deletion O
studies O
in O
mice O
and O
humans O
have O
established O
the O
pivotal O
role O
of O
runt B-GENE-Y
related I-GENE-Y
transcription I-GENE-Y
factor-2 I-GENE-Y
(Runx2) B-GENE-Y
in O
both O
intramembranous O
and O
endochondral O
ossification O
processes O
during O
skeletogenesis. O
In O
this O
study, O
we O
for O
the O
first O
time O
generated O
mice O
carrying O
a O
conditional O
Runx2 B-GENE-Y
allele O
with O
exon O
4, O
which O
encodes O
the O
Runt B-GENE-N
domain, I-GENE-N
flanked O
by O
loxP B-GENE-N
sites. I-GENE-N

These O
mice O
were O
crossed O
with O
1(I)-collagen-Cre B-GENE-Y
or O
1(II)-collagen-Cre B-GENE-Y
transgenic O
mice O
to O
obtain O
osteoblast- O
or O
chondrocyte-specific O
Runx2 B-GENE-Y
deficient O
mice, O
respectively. O
As O
seen O
in O
Runx2(-/-) B-GENE-Y
mice, O
perinatal O
lethality O
was O
observed O
in O
1(II)-Cre;Runx2(flox/flox) B-GENE-Y
mice, O
but O
this O
was O
not O
the O
case O
in O
animals O
in O
which O
1(I)-collagen-Cre B-GENE-Y
was O
used O
to O
delete O

Runx2. B-GENE-Y
When O
using O
double O
staining O
with O
Alizarin B-CHEMICAL
red I-CHEMICAL
for O
mineralized O
matrix O
and O
Alcian B-CHEMICAL
blue I-CHEMICAL
for O
cartilaginous O
matrix, O
we O
observed O
previously O
that O
mineralization O
was O
totally O
absent O
at O
embryonic O
day O
15.5 O
throughout O
the O
body O
in O
Runx2(-/-) B-GENE-Y
mice, O
but O
was O
found O
in O
areas O
undergoing O
intramembranous O
ossification O
such O
as O
skull O
and O
clavicles O
in O
1(II)-Cre;Runx2(flox/flox) B-GENE-Y
mice. O
In O
newborn O
1(II)-Cre;Runx2(flox/flox) B-GENE-Y

mice, O
mineralization O
impairment O
was O
restricted O
to O
skeletal O
areas O
undergoing O
endochondral O
ossification O
including O
long O
bones O
and O
vertebrae. O
In O
contrast, O
no O
apparent O
skeletal O
abnormalities O
were O
seen O
in O
mutant O
embryo, O
newborn, O
and O
3- O
to O
6-week O
old-mice O
in O
which O
Runx2 B-GENE-Y
had O
been O
deleted O
with O
the O
1(I)-collagen-Cre B-GENE-Y
driver. O
These O
results O
suggest O
that O
Runx2 B-GENE-Y
is O
absolutely O
required O
for O
endochondral O
ossification O
during O
embryonic O
and O
postnatal O
skeletogenesis, O
but O
that O
disrupting O
its O
expression O
in O
already O
committed O
osteoblasts O

as O
achieved O
here O
with O
the O
1(I)-collagen-Cre B-GENE-Y
driver O
does O
not O
affect O
overtly O
intramembranous O
and O
endochondral O
ossification. O
The O
Runx2 B-GENE-Y
floxed O
allele O
established O
here O
is O
undoubtedly O
useful O
for O
investigating O
the O
role O
of O
Runx2 B-GENE-Y
in O
particular O
cells. O
 O
2013 O
American O
Society O
for O
Bone O
and O
Mineral O
Research. O
A O
Mineral O
Extract O
from O
red O
Algae O
Ameliorates O
Chronic O
Spontaneous O
Colitis O
in O
IL-10 B-GENE-Y
Deficient O
Mice O
in O
a O
Mouse O
Strain O
Dependent O
Manner. O
Inflammatory O
bowel O
disease O
is O
an O
urgent O

public O
health O
problem O
with O
a O
high O
incidence O
in O
developed O
countries. O
Alterations O
of O
lifestyle O
or O
dietary O
interventions O
may O
attenuate O
the O
disease O
progression O
and O
increase O
the O
efficacy O
of O
current O
therapies. O
Here O
we O
tested O
the O
effect O
of O
chronic O
supplementation O
with O
a O
mineral O
extract O
from O
red O
marine O
algae O
- O
rich O
in O
calcium B-CHEMICAL
(34%), O
magnesium, B-CHEMICAL
phosphorus, B-CHEMICAL
selenium B-CHEMICAL
and O
other O
trace O
minerals O
- O
in O
a O
clinically O
relevant O
model O
of O
spontaneous O
enterocolitis, O
interleukin B-GENE-Y
(IL)-10(-/-) I-GENE-Y
mice. O
The O
mineral O
extract O
was O
administered O
in O
the O
drinking O
water O
of O
Il10(-/-) B-GENE-Y
mice O
on O

C57BL/6 O
J O
and O
BALB/c O
strain O
backgrounds O
for O
25 O
weeks O
commencing O
from O
3 O
to O
4 O
weeks O
of O
age. O
The O
mineral O
extract O
ameliorated O
the O
spontaneous O
development O
of O
colitis O
and O
severity O
of O
disease O
in O
Il10(-/-) B-GENE-Y
mice O
on O
a O
C57BL/6 O
J O
background. O
Mineral O
extract-treated O
Il10(-/-) B-GENE-Y
C57BL/6 O
J O
strain O
mice O
had O
significantly O
reduced O
mortality, O
circulating O
levels O
of O
serum B-GENE-N
Amyloid I-GENE-N
A I-GENE-N
and O
reduced O
colonic O
tissue O
damage. O
In O
contrast, O
comparable O
treatment O
of O
Il10(-/-) B-GENE-Y
mice O
on O
a O

BALB/c O
background O
with O
the O
mineral O
extract O
did O
not O
alter O
the O
course O
of O
colitis. O
These O
data O
demonstrate O
that O
chronic O
supplementation O
with O
a O
natural O
mineral O
extract O
selectively O
ameliorates O
spontaneous O
mild-moderate O
colitis O
in O
Il10(-/-) B-GENE-Y
mice O
on O
a O
C57BL/6 O
J, O
but O
does O
not O
attenuate O
more O
moderate-severe O
colitis O
in O
BALB/c O
strain O
animals. O
Copyright O
 O
2013 O
John O
Wiley O
& O
Sons, O
Ltd. O
Neuronal O
expression O
of O
glucosylceramide B-CHEMICAL
synthase I-GENE-Y
in O
central O
nervous O
system O
regulates O
body O
weight O
and O
energy O
homeostasis. O

Hypothalamic O
neurons O
are O
main O
regulators O
of O
energy O
homeostasis. O
Neuronal O
function O
essentially O
depends O
on O
plasma O
membrane-located O
gangliosides. O
The O
present O
work O
demonstrates O
that O
hypothalamic O
integration O
of O
metabolic O
signals O
requires O
neuronal O
expression O
of O
glucosylceramide B-GENE-Y
synthase I-GENE-Y
(GCS; B-GENE-Y
UDP-glucose:ceramide B-CHEMICAL
glucosyltransferase). I-GENE-Y
As O
a O
major O
mechanism O
of O
central O
nervous O
system O
(CNS) O
metabolic O
control, O
we O
demonstrate O
that O
GCS-derived B-GENE-Y
gangliosides O
interacting O
with O
leptin B-GENE-Y
receptors I-GENE-Y
(ObR) B-GENE-Y
in O
the O

neuronal O
membrane O
modulate O
leptin-stimulated B-GENE-Y
formation O
of O
signaling O
metabolites O
in O
hypothalamic O
neurons. O
Furthermore, O
ganglioside-depleted O
hypothalamic O
neurons O
fail O
to O
adapt O
their O
activity O
(c-Fos) B-GENE-Y
in O
response O
to O
alterations O
in O
peripheral O
energy O
signals. O
Consequently, O
mice O
with O
inducible O
forebrain O
neuron-specific O
deletion O
of O
the O
UDP-glucose:ceramide B-CHEMICAL
glucosyltransferase I-GENE-Y
gene O
(Ugcg) B-GENE-Y
display O
obesity, O
hypothermia, O
and O
lower O
sympathetic O
activity. O
Recombinant O
adeno-associated O

virus O
(rAAV)-mediated O
Ugcg B-GENE-Y
delivery O
to O
the O
arcuate O
nucleus O
(Arc) O
significantly O
ameliorated O
obesity, O
specifying O
gangliosides O
as O
seminal O
components O
for O
hypothalamic O
regulation O
of O
body O
energy O
homeostasis. O
Environmental O
pesticide O
exposure O
modulates O
cytokines, B-GENE-N
arginase B-GENE-N
and O
ornithine B-CHEMICAL
decarboxylase I-GENE-Y
expression O
in O
human O
placenta. O
To O
evaluate O
the O
cytokine B-GENE-N
balance O
and O
enzymatic O
alterations O
induced O
by O
environmental O
pesticide O
exposure O
during O
pregnancy, O
this O
transversal O
study O
explored O
placentas O
derived O
from O
non-exposed O
women O
(control O

group-CG), O
and O
from O
women O
living O
in O
a O
rural O
area O
(rural O
group-RG), O
collected O
during O
intensive O
organophosphate B-CHEMICAL
(OP) O
pesticide O
spraying O
season O
(RG-SS) O
and O
during O
non-spraying O
season O
(RG-NSS). O
The O
exposure O
biomarkers O
blood O
cholinesterase B-GENE-Y
and O
placental O
carboxylesterase B-GENE-N
(CaE) B-GENE-N
were O
significantly O
decreased O
in O
RG-SS. O
Among O
the O
cytokines B-GENE-N
studied O
IL-8, B-GENE-Y
IL-6, B-GENE-Y
TNF, B-GENE-Y
IL-10, B-GENE-Y
TGF B-GENE-Y
and O
IL-13, B-GENE-Y
the O
expression O

frequency O
of O
IL-13 B-GENE-Y
increased O
in O
RG-SS. O
Arginase B-GENE-N
and O
ornithine B-CHEMICAL
decarboxylase I-GENE-Y
(ODC) B-GENE-Y
enzymes O
were O
induced O
in O
syncytiotrophoblast O
and O
endothelial O
cells. O
Interestingly, O
the O
decrease O
in O
CaE B-GENE-N
activity O
was O
associated O
with O
arginase O
and O
ODC B-GENE-Y
activity O
induction. O
These O
findings O
suggest O
that O
environmental O
pesticide O
exposure O
impacts O
the O
placenta O
by O
increasing O
the O
expression O
frequency O
of O
the O
anti-inflammatory O
cytokine B-GENE-N
IL-13, B-GENE-Y
which O
may O
be O
related O
to O
the O
up-regulation O
of O
enzymes O
implicated O
in O
tissue O
repair. O
Lixisenatide: O
first O
global O

approval. O
The O
selective O
once-daily O
prandial O
glucagon-like B-GENE-Y
peptide-1 I-GENE-Y
(GLP-1) I-GENE-Y
receptor I-GENE-Y
agonist O
lixisenatide O
(Lyxumia()) O
is O
under O
development O
with O
Sanofi O
for O
the O
treatment O
of O
type O
2 O
diabetes O
mellitus. O
Lixisenatide O
belongs O
to O
a O
class O
of O
GLP-1 B-GENE-Y
compounds O
designed O
to O
mimic O
the O
endogenous O
hormone O
GLP-1. B-GENE-Y
Native O
GLP-1 B-GENE-Y
stimulates O
insulin B-GENE-Y
secretion O
in O
a O
glucose-dependent B-CHEMICAL
manner, O
as O
well O
as O
suppressing O
glucagon B-GENE-Y
production O
and O
slowing O
gastric O
emptying. O
A O

once-daily O
subcutaneous O
formulation O
of O
lixisenatide O
has O
been O
approved O
in O
the O
EU, O
Iceland, O
Liechtenstein, O
Norway O
and O
Mexico O
for O
the O
treatment O
of O
type O
2 O
diabetes, O
and O
is O
under O
regulatory O
review O
in O
the O
USA, O
Switzerland, O
Brazil, O
Canada, O
Ukraine, O
South O
Africa, O
Japan O
and O
Australia. O
This O
article O
summarizes O
the O
milestones O
in O
the O
development O
of O
lixisenatide, O
leading O
to O
this O
first O
approval O
for O
use O
in O
adults O
with O
type O
2 O
diabetes. O
Maqui O
berry O
(Aristotelia O
chilensis) O
and O
the O
constituent O
delphinidin B-CHEMICAL
glycoside I-CHEMICAL
inhibit O
photoreceptor B-GENE-N
cell O
death O
induced O
by O
visible O

light. O
The O
protective O
effects O
of O
maqui O
berry O
(Aristotelia O
chilensis) O
extract O
(MBE) O
and O
its O
major O
anthocyanins B-CHEMICAL
[delphinidin B-CHEMICAL
3,5-O-diglucoside I-CHEMICAL
(D3G5G) B-CHEMICAL
and O
delphinidin B-CHEMICAL
3-O-sambubioside-5-O-glucoside I-CHEMICAL
(D3S5G)] B-CHEMICAL
against O
light-induced O
murine O
photoreceptor O
cells O
(661W) O
death O
were O
evaluated. O
Viability O
of O
661W O
after O
light O
treatment O
for O
24h, O
assessed O
by O
the O
tetrazolium B-CHEMICAL
salt O

(WST-8) O
assay O
and O
Hoechst B-CHEMICAL
33342 I-CHEMICAL
nuclear O
staining, O
was O
improved O
by O
addition O
of O
MBE, O
D3G5G, B-CHEMICAL
and O
D3S5G. B-CHEMICAL
Intracellular O
radical O
activation O
in O
661W, O
evaluated O
using O
the O
reactive O
oxygen B-CHEMICAL
species O
(ROS)-sensitive O
probe O
5-(and-6)-chloromethyl-2,7-dichlorodihydro B-CHEMICAL
fluorescein I-CHEMICAL
diacetate I-CHEMICAL
acetyl I-CHEMICAL
ester I-CHEMICAL
(CM-H2DCFDA), B-CHEMICAL
was O
reduced O
by O
MBE O
and O
its O
anthocyanins. B-CHEMICAL
The O
anti-apoptosis O

mechanism O
of O
MBE O
was O
evaluated O
by O
light-induced O
phosphorylation O
of O
p38. B-GENE-N
MBE O
significantly O
suppressed O
the O
light-induced O
phosphorylation O
of O
p38. B-GENE-N
These O
findings O
indicate O
that O
MBE O
and O
its O
anthocyanidins B-CHEMICAL
suppress O
the O
light-induced O
photoreceptor O
cell O
death O
by O
inhibiting O
ROS O
production, O
suggesting O
that O
the O
inhibition O
of O
phosphorylated-p38 B-GENE-N
may O
be O
involved O
in O
the O
underlying O
mechanism. O
Influence O
of O
triterpenoids B-CHEMICAL
present O
in O
apple O
peel O
on O
inflammatory O
gene O
expression O
associated O
with O
inflammatory O
bowel O
disease O
(IBD). O
Various O
ursanic, B-CHEMICAL
oleanic I-CHEMICAL

and I-CHEMICAL
lupanic I-CHEMICAL
pentacyclic I-CHEMICAL
triterpenoids I-CHEMICAL
found O
in O
apple O
peel O
were O
studied O
for O
anti-inflammatory O
effects O
in O
vitro O
using O
T84 O
colon O
carcinoma O
cells. O
After O
pretreatment O
with O
single O
triterpenoids, B-CHEMICAL
cells O
were O
stimulated O
with O
pro-inflammatory O
cytokines B-GENE-N
(TNF-, B-GENE-Y
INF-, B-GENE-Y
IL-1). B-GENE-Y
Regulation O
of O
mRNA O
expression O
was O
analysed O
for O
three O
specific O
inflammation-associated O
marker O
genes O
(TNF-, B-GENE-Y
IL-8, B-GENE-Y
IP-10) B-GENE-Y
using O
qRT-PCR. O
Furthermore, O
the O
effects O

of O
ursolic B-CHEMICAL
acid I-CHEMICAL
(UA) O
and O
oleanolic B-CHEMICAL
acid I-CHEMICAL
(OA) O
on O
the O
synthesis O
of O
certain O
pro-inflammatory O
proteins O
were O
examined. O
IP-10 B-GENE-Y
expression O
was O
inhibited O
in O
a O
dose-dependent O
manner O
by O
all O
the O
tested O
compounds O
at O
concentrations O
25M. O
The O
mRNA O
expression O
of O
TNF- B-GENE-Y
was O
slightly O
affected O
and O
the O
IL-8 B-GENE-Y
level O
was O
increased. O
At O
the O
protein O
level, O
UA O
and O
OA O
(25M) O
reduced O
the O
synthesis O
of O
IP-10; B-GENE-Y
sICAM-1, B-GENE-Y
IL-23 B-GENE-Y
and O
GRO B-GENE-Y
were O
slightly O
repressed. O
The O
TNF- B-GENE-Y
level O
was O
not O

modulated, O
whereas O
induction O
of O
IL-8 B-GENE-Y
was O
increased. O
UA O
also O
enhanced O
the O
synthesis O
of O
IL-1ra, B-GENE-Y
while O
OA O
suppressed O
the O
level O
of O
I-TAC. B-GENE-Y
The O
present O
study O
confirms O
that O
triterpenoids B-CHEMICAL
present O
in O
apple O
peel O
and O
-damascone B-CHEMICAL
may O
be O
implicated O
in O
the O
anti-inflammatory O
properties O
of O
apple O
constituents, O
suggesting O
that O
these O
substances O
might O
be O
helpful O
in O
the O
treatment O
of O
IBD O
as O
nutrient O
supplements. O
Curcumin B-CHEMICAL
inhibits O
invasion O
and O
metastasis O
in O
K1 O
papillary O
thyroid O
cancer O
cells. O
Curcumin, B-CHEMICAL
the O
active O
constituent O
of O
dietary O

spice O
turmeric, O
possesses O
a O
strong O
potential O
for O
cancer O
prevention O
and O
treatment. O
However, O
there O
is O
no O
study O
to O
address O
the O
effects O
of O
curcumin B-CHEMICAL
on O
invasion O
and O
metastasis O
of O
thyroid O
cancers. O
Thyroid O
cancer O
is O
the O
most O
common O
malignancy O
of O
endocrine O
organs, O
and O
its O
incidence O
rates O
have O
steadily O
increased O
over O
recent O
decades. O
Although O
most O
indolent O
tumours O
can O
be O
effectively O
managed, O
metastatic O
tumours O
at O
distant O
secondary O
sites O
behave O
aggressively O
and O
currently O
there O
is O
no O
effective O
form O
of O
treatment. O
Here, O
for O
the O
first O
time O
it O
has O
been O
reported O
that O
curcumin B-CHEMICAL
inhibit O
multiple O

metastasis O
steps O
of O
K1 O
papillary O
thyroid O
cancer O
cells. O
Curcumin B-CHEMICAL
dose-dependently O
suppressed O
viability O
of O
K1 O
cells O
as O
well O
as O
its O
cell O
attachment, O
spreading, O
migration O
and O
invasion O
abilities. O
Moreover, O
curcumin B-CHEMICAL
could O
also O
down-regulate O
the O
expression O
and O
activity O
of O
matrix B-GENE-Y
metalloproteinase-9 I-GENE-Y
(MMP-9). B-GENE-Y
The O
findings O
showed O
that O
curcumin B-CHEMICAL
might O
be O
an O
effective O
tumouristatic O
agent O
for O
the O
treatment O
of O
aggressive O
papillary O
thyroid O
carcinomas. O
Lignans B-CHEMICAL
extracted O
from O
Vitex O
negundo O
possess O
cytotoxic O

activity O
by O
G2/M O
phase O
cell O
cycle O
arrest O
and O
apoptosis O
induction. O
Evn-50 B-CHEMICAL
is O
a O
lignan B-CHEMICAL
compounds O
mixture O
extracted O
from O
Vitex O
negundo, O
a O
widely O
used O
herb O
in O
traditional O
Chinese O
medicine. O
This O
study O
is O
aimed O
to O
define O
the O
spectrum O
of O
cytotoxic O
activity O
of O
EVn-50, B-CHEMICAL
and O
also O
to O
investigate O
mechanisms O
underlying O
the O
anticancer O
actions O
via O
assessing O
the O
influence O
on O
cell O
cycle O
using O
EVn-50, B-CHEMICAL
and O
the O
lignan B-CHEMICAL
compound O
VB1 B-CHEMICAL
purified O
from O
EVn-50. B-CHEMICAL
The O
cytotoxic O
effect O
of O
EVn-50 B-CHEMICAL
and O

VB1 B-CHEMICAL
was O
determined O
with O
SRB O
assay O
using O
a O
panel O
of O
cancer O
cell O
lines. O
Breast O
cancer O
cell O
line O
MDA-MB-435 O
and O
liver O
cancer O
cell O
line O
SMMC-7721 O
were O
selected O
for O
further O
evaluating O
the O
effect O
of O
EVn-50 B-CHEMICAL
or O
VB1 B-CHEMICAL
on O
cell O
cycle O
by O
flow O
cytometric O
analysis. O
Apoptosis O
exerted O
by O
EVn-50 B-CHEMICAL
or O
VB1 B-CHEMICAL
was O
measured O
by O
TUNEL O
assay O
and O
DAPI O
staining, O
and O
Western O
blot O
analysis O
was O
utilized O
to O
assess O
the O
influence O
on O
expression O
and O
phosphorylation O
of O
proteins O
which O
are O
closely O
related O
to O
cell O
cycle O

and O
apoptosis. O
EVn-50 B-CHEMICAL
possessed O
a O
broad O
spectrum O
of O
in O
vitro O
anticancer O
activity O
for O
those O
tested O
cancer O
cells, O
especially O
sensitive O
to O
MDA-MB-435, O
SKOV-3, O
BXPC-3, O
SMMC-7721, O
MCF-7, O
HO-8910, O
SGC-7901, O
BEL-7402, O
HCT-116, O
and O
786-O, O
with O
the O
respective O
IC50 O
below O
10g/ml. O
Treatment O
with O
EVn-50 B-CHEMICAL
or O
VB1 B-CHEMICAL
resulted O
in O
arresting O
the O

MDA-MB-435 O
and O
SMMC-7721 O
cells O
at O
G2/M O
phase, O
which O
was O
further O
supported O
by O
observations O
of O
increased O
phosphorylation O
of O
Histone B-GENE-N
3 I-GENE-N
at O
Ser10, B-CHEMICAL
phosphorylation O
of O
Cdk1 B-GENE-Y
at O
Tyr15, B-CHEMICAL
expression O
of O
cyclin B-GENE-Y
B1, I-GENE-Y
and O
decreased O
expression O
of O
Cdc25c. B-GENE-Y
Moreover, O
we O
found O
that O
exposure O
of O
MDA-MB-435 O
cells O
to O
EVn-50 B-CHEMICAL
or O
VB1 B-CHEMICAL
caused O
obvious O
apoptosis O
of O
MDA-MB-435 O
cells. O
Our O
data O
show O
that O
EVn-50, B-CHEMICAL
lignan B-CHEMICAL

compounds O
extracted O
from O
Vitex O
negundo, O
possesses O
a O
broad O
spectrum O
cytotoxic O
effect O
via O
arresting O
cancer O
cells O
at O
G2/M O
phase O
cell O
cycle O
and O
subsequently O
inducing O
apoptosis. O
TRP B-GENE-N
and I-GENE-N
ASIC I-GENE-N
channels I-GENE-N
mediate O
the O
antinociceptive O
effect O
of O
citronellyl B-CHEMICAL
acetate. I-CHEMICAL
Background O
Citronellyl B-CHEMICAL
acetate I-CHEMICAL
(CAT), B-CHEMICAL
a O
monoterpene B-CHEMICAL
product O
of O
the O
secondary O
metabolism O
of O
plants, O
has O
been O
shown O
in O
the O
literature O
to O
possess O
several O
different O
biological O
activities. O
However, O
no O
antinociceptive O
abilities O
have O
yet O
been O
discussed. O
Here, O
we O
used O
acute O
pain O
animal O
models O
to O
describe O

the O
antinociceptive O
action O
of O
CAT. B-CHEMICAL
Methods O
The O
acetic B-CHEMICAL
acid-induced I-CHEMICAL
writhing O
test O
and O
the O
paw-licking O
test, O
in O
which O
paw O
licking O
was O
induced O
by O
glutamate B-CHEMICAL
and O
formalin, B-CHEMICAL
were O
performed O
to O
evaluate O
the O
antinociceptive O
action O
of O
CAT B-CHEMICAL
and O
to O
determine O
the O
involvement O
of O
PKC, B-GENE-N
PKA, B-GENE-N
TRPV1, B-GENE-Y
TRPA1, B-GENE-Y
TRPM8 B-GENE-Y
and O
ASIC B-GENE-N
in O
its O
antinociceptive O
mechanism. O
To O
do O
so, O
we O
induced O
paw-linking O
using O
agonists. O
Results O
CAT B-CHEMICAL
was O
administered O
intragastrically O
(25, O

50, O
75, O
100 O
and O
200mg/kg), O
and O
the O
two O
higher O
doses O
caused O
antinociceptive O
effects O
in O
the O
acetic B-CHEMICAL
acid I-CHEMICAL
model; O
the O
highest O
dose O
reduced O
pain O
for O
4h O
after O
it O
was O
administered O
(200mg/kg). O
In O
the O
formalin B-CHEMICAL
test, O
two O
doses O
of O
CAT B-CHEMICAL
promoted O
antinociception O
in O
both O
the O
early O
and O
later O
phases O
of O
the O
test. O
The O
glutamate B-CHEMICAL
test O
showed O
that O
its O
receptors O
are O
involved O
in O
the O
antinociceptive O
mechanism O
of O
CAT. B-CHEMICAL
Pretreatment O
with O
CAT B-CHEMICAL
did O
not O
alter O
locomotor O
activity O
or O
motor O
coordination. O
In O
an O
investigation O
into O
the O
participation O

of O
TRP B-GENE-N
channels I-GENE-N
and O
ASICs B-GENE-N
in O
CAT's B-CHEMICAL
antinociceptive O
mechanism, O
we O
used O
capsaicin B-CHEMICAL
(2.2g/paw), O
cinnamaldehyde B-CHEMICAL
(10mmol/paw), O
menthol B-CHEMICAL
(1.2mmol/paw) O
and O
acidified O
saline O
(2% O
acetic B-CHEMICAL
acid, I-CHEMICAL
pH O
1.98). O
The O
results O
showed O
that O
TRPV1, B-GENE-Y
TRPM8 B-GENE-Y
and O
ASIC, B-GENE-N
but O
not O
TRPA1, B-GENE-Y
are O
involved O
in O
the O
antinociceptive O
mechanism. O
Finally, O
the O
involvement O
of O
PKC B-GENE-N
and O
PKA B-GENE-N

was O
also O
studied, O
and O
we O
showed O
that O
both O
play O
a O
role O
in O
the O
antinociceptive O
mechanism O
of O
CAT. B-CHEMICAL
Conclusion O
The O
results O
of O
this O
work O
contribute O
information O
regarding O
the O
antinociceptive O
properties O
of O
CAT B-CHEMICAL
on O
acute O
pain O
and O
show O
that, O
at O
least O
in O
part, O
TRPV1, B-GENE-Y
TRPM8, B-GENE-Y
ASIC, B-GENE-N
glutamate B-GENE-N
receptors, I-GENE-N
PKC B-GENE-N
and O
PKA B-GENE-N
participate O
in O
CAT's B-CHEMICAL
antinociceptive O
mechanism. O
2-Hydroxychalcone B-CHEMICAL
and O
xanthohumol B-CHEMICAL
inhibit O
invasion O
of O
triple O
negative O
breast O
cancer O
cells. O
Breast O
cancer O
is O
estimated O
as O
one O
of O
the O

most O
common O
causes O
of O
cancer O
death O
among O
women. O
In O
particular, O
triple O
negative O
breast O
cancers O
(TNBCs), O
which O
do O
not O
express O
the O
genes O
for O
estrogen/progesterone B-GENE-Y
receptors I-GENE-Y
(ER/PR) B-GENE-Y
and O
human B-GENE-Y
epidermal I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
2 I-GENE-Y
(HER2), B-GENE-Y
have O
been O
associated O
with O
poor O
prognosis O
and O
metastasis. O
Chalcones, B-CHEMICAL
the O
biosynthetic O
precursors O
of O
flavonoids B-CHEMICAL
present O
in O
edible O
plants, O
exert O
cytotoxic O
and O
chemopreventive O
activities. O
Although O
mounting O
evidence O
suggests O
the O
anticancer O
properties O
of O
chalcones, B-CHEMICAL
limited O

information O
is O
available O
regarding O
the O
inhibitory O
effects O
of O
chalcones B-CHEMICAL
on O
the O
aggressiveness O
of O
breast O
cancer O
cells. O
The O
present O
study O
aimed O
to O
investigate O
the O
effects O
of O
chalcone B-CHEMICAL
and O
its O
derivatives O
on O
the O
growth O
and O
the O
invasiveness O
of O
TNBC O
cells. O
Here, O
we O
showed O
that O
treatment O
with O
chalcone, B-CHEMICAL
2-hydroxychalcone, B-CHEMICAL
and O
xanthohumol B-CHEMICAL
for O
24h O
inhibited O
the O
growth O
of O
MDA-MB-231cells O
with O
IC50 O
values O
of O
18.1, O
4.6, O
and O
6.7M, O
respectively. O
Similarly, O
Chalcone, B-CHEMICAL

2-hydroxychalcone, B-CHEMICAL
and O
xanthohumol B-CHEMICAL
also O
exerted O
cytotoxicity O
in O
another O
TNBC O
cell O
line, O
Hs578T. O
Neohesperidin B-CHEMICAL
dihydrochalcone, I-CHEMICAL
4-methoxychalcone, B-CHEMICAL
and O
hesperidin B-CHEMICAL
methylchalcone I-CHEMICAL
did O
not O
show O
the O
cytotoxicity O
on O
the O
MDA-MB-231cells. O
Xanthohumol B-CHEMICAL
and O
2-hydroxychalcone B-CHEMICAL
induced O
apoptosis O
by O
Bcl-2 B-GENE-Y
downregulation. O
Importantly, O

2-hydroxychalcone B-CHEMICAL
and O
xanthohumol B-CHEMICAL
exerted O
more O
potent O
inhibitory O
effects O
on O
the O
proliferation, O
MMP-9 B-GENE-Y
expression O
and O
invasive O
phenotype O
of O
MDA-MB-231 O
than O
chalcone. B-CHEMICAL
These O
results O
suggest O
a O
potential O
application O
of O
these O
chalcones B-CHEMICAL
as O
anticancer O
agents O
that O
can O
alleviate O
malignant O
progression O
of O
TNBC. O
4-Hydroxypyridazin-3(2H)-one B-CHEMICAL
Derivatives O
as O
Novel O
d-Amino B-GENE-Y
Acid I-GENE-Y
Oxidase I-GENE-Y
Inhibitors. O
d-Amino B-CHEMICAL
acid I-CHEMICAL
oxidase I-GENE-Y
(DAAO) B-GENE-Y

catalyzes O
the O
oxidation O
of O
d-amino B-CHEMICAL
acids I-CHEMICAL
including O
d-serine, B-CHEMICAL
a O
coagonist O
of O
the O
N-methyl-d-aspartate B-CHEMICAL
receptor. I-GENE-N
We O
identified O
a O
series O
of O
4-hydroxypyridazin-3(2H)-one B-CHEMICAL
derivatives O
as O
novel O
DAAO B-GENE-Y
inhibitors O
with O
high O
potency O
and O
substantial O
cell O
permeability O
using O
fragment-based O
drug O
design. O
Comparisons O
of O
complex O
structures O
deposited O
in O
the O
Protein O
Data O
Bank O
as O
well O
as O
those O
determined O
with O
in-house O
fragment O
hits O
revealed O
that O
a O
hydrophobic O
subpocket O
was O
formed O
perpendicular O
to O
the O
flavin O
ring O
by O
flipping O

Tyr224 B-CHEMICAL
in O
a O
ligand-dependent O
manner. O
We O
investigated O
the O
ability O
of O
the O
initial O
fragment O
hit, O
3-hydroxy-pyridine-2(1H)-one, B-CHEMICAL
to O
fill O
this O
subpocket O
with O
the O
aid O
of O
complex O
structure O
information. O
3-Hydroxy-5-(2-phenylethyl)pyridine-2(1H)-one B-CHEMICAL
exhibited O
the O
predicted O
binding O
mode O
and O
demonstrated O
high O
inhibitory O
activity O
for O
human B-GENE-Y
DAAO I-GENE-Y
in O
enzyme- O
and O
cell-based O
assays. O
We O
further O
designed O
and O
synthesized O

4-hydroxypyridazin-3(2H)-one B-CHEMICAL
derivatives, O
which O
are O
equivalent O
to O
the O
3-hydroxy-pyridine-2(1H)-one B-CHEMICAL
series O
but O
lack O
cell O
toxicity. O
6-[2-(3,5-Difluorophenyl)ethyl]-4-hydroxypyridazin-3(2H)-one B-CHEMICAL
was O
found O
to O
be O
effective O
against O
MK-801-induced B-CHEMICAL
cognitive O
deficit O
in O
the O
Y-maze. O
Comparative O
study O
on O
transcriptional O
activity O
of O
17 O
parabens B-CHEMICAL
mediated O
by O
estrogen B-GENE-N
receptor I-GENE-N
 I-GENE-N
and I-GENE-N
 I-GENE-N
and O

androgen B-GENE-Y
receptor. I-GENE-Y
The O
structure-activity O
relationships O
of O
parabens B-CHEMICAL
which O
are O
widely O
used O
as O
preservatives O
for O
transcriptional O
activities O
mediated O
by O
human B-GENE-Y
estrogen B-CHEMICAL
receptor I-GENE-Y
 I-GENE-Y
(hER), B-GENE-Y
hER B-GENE-Y
and O
androgen B-CHEMICAL
receptor I-GENE-Y
(hAR) B-GENE-Y
were O
investigated. O
Fourteen O
of O
17 O
parabens B-CHEMICAL
exhibited O
hER B-GENE-Y
and/or O
hER B-GENE-Y
agonistic O
activity O
at O
concentrations O
of O
110(-5)M, O
whereas O
none O
of O
the O
17 O
parabens B-CHEMICAL
showed O
AR B-GENE-Y
agonistic O
or O
antagonistic O
activity. O
Among O
12 O
parabens B-CHEMICAL
with O
linear O
alkyl B-CHEMICAL
chains O
ranging O
in O
length O
from O
C1 O
to O
C12, O

heptylparaben B-CHEMICAL
(C7) O
and O
pentylparaben B-CHEMICAL
(C5) O
showed O
the O
most O
potent O
ER B-GENE-Y
and O
ER B-GENE-Y
agonistic O
activity O
in O
the O
order O
of O
10(-7)M O
and O
10(-8)M, O
respectively, O
and O
the O
activities O
decreased O
in O
a O
stepwise O
manner O
as O
the O
alkyl O
chain O
was O
shortened O
to O
C1 O
or O
lengthened O
to O
C12. O
Most O
parabens B-CHEMICAL
showing O
estrogenic O
activity O
exhibited O
ER-agonistic B-GENE-Y
activity O
at O
lower O
concentrations O
than O
those O
inducing O
ER-agonistic B-GENE-Y
activity. O
The O
estrogenic O
activity O
of O
butylparaben B-CHEMICAL
was O

markedly O
decreased O
by O
incubation O
with O
rat O
liver O
microsomes, O
and O
the O
decrease O
of O
activity O
was O
blocked O
by O
a O
carboxylesterase B-GENE-N
inhibitor. O
These O
results O
indicate O
that O
parabens B-CHEMICAL
are O
selective O
agonists O
for O
ER B-GENE-Y
over O
ER; B-GENE-Y
their O
interactions O
with O
ER/ B-GENE-N
are O
dependent O
on O
the O
size O
and O
bulkiness O
of O
the O
alkyl B-CHEMICAL
groups; O
and O
they O
are O
metabolized O
by O
carboxylesterases, B-GENE-N
leading O
to O
attenuation O
of O
their O
estrogenic O
activity. O
The O
cyclin B-GENE-Y
D1 I-GENE-Y
(CCND1) B-GENE-Y
rs9344 B-GENE-N
G>A I-GENE-N
polymorphism O
predicts O
clinical O
outcome O
in O

colon O
cancer O
patients O
treated O
with O
adjuvant O
5-FU-based B-CHEMICAL
chemotherapy. O
Recent O
evidence O
indicates O
a O
potential O
prognostic O
and O
predictive O
value O
for O
germline O
polymorphisms O
in O
genes O
involved O
in O
cell O
cycle O
control. O
We O
investigated O
the O
effect O
of O
cyclin B-GENE-Y
D1 I-GENE-Y
(CCND1) B-GENE-Y
rs9344 B-GENE-N
G>A I-GENE-N
in O
stage O
II/III O
colon O
cancer O
patients O
and O
validated O
the O
findings O
in O
an O
independent O
study O
cohort. O
For O
evaluation O
and O
validation O
set, O
a O
total O
of O
264 O
and O
234 O
patients O
were O
included. O
Patients O
treated O
with O
5-fluorouracil-based B-CHEMICAL

chemotherapy, O
carrying O
the O
CCND1 B-GENE-Y
rs9344 B-GENE-N
A/A I-GENE-N
genotype O
had O
significantly O
decreased O
time-to-tumor O
recurrence O
(TTR) O
in O
univariate O
analysis O
and O
multivariate O
analysis O
(hazard O
ratio O
(HR) O
2.47; O
95% O
confidence O
interval O
(CI) O
1.16-5.29; O
P=0.019). O
There O
was O
no O
significant O
association O
between O
CCND1 B-GENE-Y
rs9344 B-GENE-N
G>A I-GENE-N
and O
TTR O
in O
patients O
with O
curative O
surgery O
alone. O
In O
the O
validation O
set, O
the O
A O
allele O
of O
CCND1 B-GENE-Y

rs9344 B-GENE-N
G>A I-GENE-N
remained O
significantly O
associated O
with O
decreased O
TTR O
in O
univariate O
and O
multivariate O
analyses O
(HR O
1.94; O
95% O
CI O
1.05-3.58; O
P=0.035). O
CCND1 B-GENE-Y
rs9344 B-GENE-N
G>A I-GENE-N
may O
be O
a O
predictive O
and/or O
prognostic O
biomarker O
in O
stage O
II/III O
colon O
cancer O
patients, O
however, O
prospective O
trials O
are O
warranted O
to O
confirm O
our O
findings.The O
Pharmacogenomics O
Journal O
advance O
online O
publication, O
9 O
April O
2013; O

doi:10.1038/tpj.2013.15. O
Evaluation O
of O
7-O-galloyl-d-sedoheptulose, B-CHEMICAL
isolated O
from O
Corni O
Fructus, O
in O
the O
adipose O
tissue O
of O
type O
2 O
diabetic O
db/db O
mice. O
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
beneficial O
effects O
of O
7-O-galloyl-d-sedoheptulose B-CHEMICAL
(GS), O
isolated O
from O
Corni O
Fructus, O
using O
type O
2 O
diabetic O
mice. O
GS O
was O
orally O
administered O
to O
db/db O
mice O

at O
doses O
of O
20 O
and O
100mg/kg O
body O
weight O
per O
day O
for O
6weeks, O
and O
the O
effects O
of O
GS O
on O
biochemical O
factors O
in O
serum O
and O
adipose O
tissue O
were O
investigated. O
To O
define O
the O
underlying O
mechanism O
of O
these O
effects, O
protein O
expressions O
related O
to O
lipid O
metabolism, O
inflammation, O
fibrosis, O
and O
apoptosis, O
were O
measured. O
The O
results O
showed O
that O
levels O
of O
glucose, B-CHEMICAL
leptin, B-GENE-Y
insulin, B-GENE-N
C-peptide, B-GENE-N
resistin, B-GENE-Y
tumor B-GENE-Y
necrosis I-GENE-Y
factor-, I-GENE-Y
interleukin-6, B-GENE-Y
triglycerides, B-CHEMICAL
total O
cholesterol, B-CHEMICAL
non-esterified O
fatty B-CHEMICAL

acids, I-CHEMICAL
high-density B-GENE-N
lipoprotein I-GENE-N
cholesterol, B-CHEMICAL
very O
low-density B-GENE-N
lipoprotein I-GENE-N
cholesterol/low-density B-CHEMICAL
lipoprotein I-GENE-N
cholesterol, B-CHEMICAL
reactive O
oxygen B-CHEMICAL
species O
(ROS), O
and O
thiobarbituric B-CHEMICAL
acid-reactive I-CHEMICAL
substance O
(TBARS) O
in O
serum O
were O
down-regulated, O
while O
adiponectin B-GENE-Y
was O
augmented O
by O
GS O
treatment. O
In O
addition, O
the O
elevated O
lipid, O
ROS, O
and O
TBARS O
contents O
in O
adipose O
tissue O
as O
well O
as O
serum O
levels O
in O
db/db O
mice O
were O
significantly O
decreased O
by O
the O
oral O
administration O
of O

GS. O
From O
protein O
analysis, O
the O
decreased O
expressions O
of O
peroxisome B-GENE-Y
proliferator I-GENE-Y
activated I-GENE-Y
receptor I-GENE-Y
(PPAR), I-GENE-Y
PPAR, B-GENE-Y
and O
B-cell B-GENE-Y
lymphoma I-GENE-Y
2 I-GENE-Y
were O
up-regulated O
in O
the O
adipose O
tissue O
of O
db/db O
mice. O
The O
administration O
of O
GS O
significantly O
decreased O
sterol B-CHEMICAL
regulatory I-GENE-Y
element I-GENE-Y
binding I-GENE-Y
protein-1, I-GENE-Y
nuclear B-GENE-N
factor-kappa I-GENE-N
?>Bp65, O
cyclooxygenase-2, B-GENE-Y
inducible B-GENE-Y
nitric B-CHEMICAL
oxide I-CHEMICAL
synthase, I-GENE-Y
monocyte B-GENE-Y
chemotactic I-GENE-Y
protein-1, I-GENE-Y
intracellular B-GENE-Y
adhesion I-GENE-Y
molecule-1, I-GENE-Y

phosphor B-GENE-Y
c-Jun I-GENE-Y
N-terminal B-CHEMICAL
kinase, B-GENE-N
activator B-GENE-Y
protein-1, I-GENE-Y
transforming B-GENE-Y
growth I-GENE-Y
factor-1, I-GENE-Y
Bax, B-GENE-Y
cytochrome B-GENE-Y
c, I-GENE-Y
and O
caspase-3 B-GENE-Y
expressions. O
These O
results O
suggest O
that O
GS O
acts O
as O
a O
regulator O
of O
oxidative O
stress, O
inflammation, O
fibrosis, O
and O
apoptosis O
in O
the O
adipose O
tissue O
of O
db/db O
mice. O
Extracellular B-GENE-N
Signal-Regulated I-GENE-N
Kinases I-GENE-N
(ERK) B-GENE-N
Inhibitors O
from O
Aristolochia O
yunnanensis. O
Six O
new O
sesquiterpenoids, B-CHEMICAL
aristoyunnolins B-CHEMICAL

A-F I-CHEMICAL
(1-6), O
an O
artifact O
of O
isolation O
[7-O-ethyl B-CHEMICAL
madolin I-CHEMICAL
W I-CHEMICAL
(7)], O
and O
12 O
known O
analogues O
were O
isolated O
from O
stems O
of O
Aristolochia O
yunnanensis. O
The O
structures O
were O
determined O
by O
combined O
chemical O
and O
spectral O
methods, O
and O
the O
absolute O
configurations O
of O
compounds O
2, O
3, O
5-7, O
9, O
14, O
and O
17 O
were O
determined O
by O
the O
modified O
Mosher's O
method O
and O
CD O
analysis. O
Compounds O
1-19 O
were O
screened O
using O
a O
bioassay O
system O
designed O
to O
evaluate O
the O
effect O
on O
mitogen-activated B-GENE-N
protein I-GENE-N
kinases I-GENE-N
(MAPKs) B-GENE-N
signaling O

pathways. O
Among O
three O
MAPKs B-GENE-N
(ERK1/2, B-GENE-N
JNK, B-GENE-N
and O
p38), B-GENE-N
compounds O
1, O
4, O
10-13, O
16, O
18, O
and O
19 O
exhibited O
selective O
inhibition O
of O
the O
phosphorylation O
of O
ERK1/2. B-GENE-N
Compounds O
16 O
and O
19 O
were O
more O
active O
than O
the O
positive O
control O
PD98059, B-CHEMICAL
a O
known O
inhibitor O
of O
the O
ERK1/2 B-GENE-N
signaling O
pathway. O
In O
vivo O
and O
in O
vitro O
anti-inflammatory O
potential O
of O
pentahydroxy-pregn-14-ol, B-CHEMICAL

20-one--d-thevetopyranoside I-CHEMICAL
in O
rats. O
Polyhydroxy B-CHEMICAL
pregnane I-CHEMICAL
glycoside I-CHEMICAL
(PPG), B-CHEMICAL
a O
steroidal B-CHEMICAL
glycoside I-CHEMICAL
was O
isolated O
from O
Wattakaka O
volubilis O
Linn. O
(Stap.f.). O
PPG B-CHEMICAL
was O
evaluated O
for O
in O
vivo O
and O
in O
vitro O
anti-inflammatory O
activity O
using O
acute O
inflammation O
and O
chronic O
model O
of O
inflammation O
in O
rats O
and O
LPS-induced O
RAW O
264.7 O
macrophage O
cells. O
PPG B-CHEMICAL
seemed O
to O
be O
responsible O
for O
the O
anti-inflammatory O
activity O
in O
the O
studied O
models. O
PPG B-CHEMICAL
at O
dose O
level O

of O
both O
5 O
and O
10mg/kg O
significantly O
reduced O
the O
edema O
induced O
by O
the O
carrageenan O
in O
acute O
model O
of O
inflammation. O
It O
also O
showed O
significant O
anti-proliferative O
effect O
(dry O
pellet O
weight O
basis) O
in O
chronic O
model O
of O
inflammation. O
Cellular O
content O
of O
granuloma O
was O
measured O
by O
assaying O
activity O
of O
N-acetyl B-CHEMICAL
glucosaminidase O
(NAG) O
and O
total O
nucleic O
acid O
content. O
PPG B-CHEMICAL
at O
5 O
and O
10mg/kg O
significantly O
suppressed O
the O
cellular O
infiltration O
measured O
by O
total O
nucleic O
acid O
content. O
In O
contrast, O
NAG O
activity O
decreased O
over O
a O
period O
of O
10 O

days O
resulting O
in O
inhibition O
of O
granuloma O
weight O
gain. O
PPG B-CHEMICAL
had O
a O
more O
effective O
response O
than O
the O
reference O
drug O
diclofenac B-CHEMICAL
sodium I-CHEMICAL
in O
both O
the O
models O
of O
inflammation. O
Wattakaka O
volubilis O
steroidal B-CHEMICAL
glycoside I-CHEMICAL
mixture O
(WVSM) O
and O
PPG B-CHEMICAL
(1-50M) O
significantly O
inhibited O
the O
COX-2 B-GENE-Y
and O
iNOS B-GENE-Y
enzymes O
resulting O
in O
low O
levels O
of O
PGE2 O
and O
NO O
in O
LPS-induced O
RAW O
264.7 O
macrophage O
cells. O
Hence O
the O
study O
supports O
the O
traditional O
use O
of O
Wattakaka O
volubilis O
and O
its O
constituent O
PPG B-CHEMICAL
in O
treatment O

of O
inflammatory O
disorders. O
Hypermethylation O
of O
P15, B-GENE-Y
P16, B-GENE-Y
and O
E-cadherin B-GENE-Y
genes O
in O
ovarian O
cancer. O
Both O
p16 B-GENE-Y
and O
p15 B-GENE-Y
proteins O
are O
inhibitors O
of O
cyclin-dependent B-GENE-N
kinases I-GENE-N
that O
prevent O
the O
cell O
going O
through O
the O
G1/S O
phase O
transaction. O
E-cadherin B-GENE-Y
is O
a O
transmembrane O
glycoprotein O
that O
mediates O
calcium-dependent B-CHEMICAL
interactions O
between O
adjacent O
epithelial O
cells. O
Two O
groups O
of O
patients O
were O
selected: O
the O
first O
group O
suffered O
from O
epithelial O
serous O
ovarian O
tumors O
and O
the O
second O
group O
suffered O
from O
benign O

ovarian O
lesions; O
ovarian O
tissue O
samples O
from O
all O
the O
subjects O
(benign O
and O
malignant) O
were O
subjected O
to O
methylation-specific O
polymerase O
chain O
reaction O
for O
methylated O
and O
unmethylated O
alleles O
of O
the O
genes O
(E-cadherin, B-GENE-Y
p15, B-GENE-Y
and O
p16). B-GENE-Y
Results O
obtained O
showed O
that O
aberrant O
methylation O
of O
p15 B-GENE-Y
and O
p16 B-GENE-Y
genes O
were O
detected O
in O
64.29 O
and O
50% O
of O
ovarian O
cancer O
patients, O
while O
E-cadherin B-GENE-Y
hypermethylation O
was O
detected O
in O
78.57% O
of O
ovarian O
cancer O
patients. O

Methylation O
of O
E-cadherin B-GENE-Y
was O
significantly O
correlated O
with O
different O
stage O
of O
disease O
(p O
< O
0.05). O
It O
was O
found O
that O
the O
risk O
of O
E-cadherin B-GENE-Y
hypermethylation O
was O
1.347-fold, O
while O
risk O
of O
p15 B-GENE-Y
hypermethylation O
was O
1.543-fold O
and O
p16 O
was O
1.2-fold O
among O
patients O
with O
ovarian O
cancer O
than O
that O
among O
patients O
with O
benign O
ovarian O
lesions. O
In O
conclusion, O
Dysfunction O
of O
the O
cell O
cycle O
and/or O
the O
cell-cell O
adhesion O
molecule O
plays O
a O
role O
in O
the O
pathogenesis O
of O

ovarian O
cancer O
and O
that O
the O
analysis O
of O
the O
methylation O
of O
p15 B-GENE-Y
and O
E-cadherin B-GENE-Y
genes O
can O
provide O
clinically O
important O
evidence O
on O
which O
to O
base O
the O
treatment. O
Circulating O
glucagon B-GENE-Y
to O
ghrelin B-GENE-Y
ratio O
as O
a O
determinant O
of O
insulin B-GENE-Y
resistance O
in O
hyperthyroidism. O
Due O
to O
stimulated O
overall O
metabolism, O
a O
state O
of O
nutritional O
inadequacy O
often O
ensues, O
during O
thyrotoxicosis. O
We O
aimed O
to O
investigate O
circulating O
levels O
of O
some O
major O
components O
of O
the O
system O
that O
regulates O
energy O
stores, O
glucose, B-CHEMICAL
and O
fat O
metabolism, O
during O
thyrotoxicosis O
compared O

to O
euthyroidism. O
Fasting O
serum O
ghrelin, B-GENE-Y
leptin, B-GENE-Y
adiponectin, B-GENE-Y
insulin, B-GENE-Y
glucagon, B-GENE-Y
glucose, B-CHEMICAL
as O
well O
as O
body O
fat O
composition O
were O
analyzed O
during O
thyrotoxicosis O
in O
40 O
hyperthyroid O
patients O
(50.5 O
 O
15.2 O
years O
old, O
22 O
females, O
31 O
with O
Graves O
disease, O
and O
9 O
with O
toxic O
nodular O
goiter). O
The O
same O
measurements O
were O
repeated O
an O
average O
3 O
months O
later, O
when O
all O
patients O
achieved O
euthyroidism. O
Compared O
to O
euthyroidism, O
in O
thyrotoxicosis, O
patients O
had O
lower O
ghrelin B-GENE-Y
and O

fat O
mass; O
had O
comparable O
insulin, B-GENE-Y
HOMA-IR, O
glucagon, B-GENE-Y
and O
leptin B-GENE-Y
levels; O
higher O
levels O
of O
circulating O
adiponectin. B-GENE-Y
Fasting O
serum O
glucose B-CHEMICAL
tended O
to O
be O
higher O
during O
thyrotoxicosis. O
The O
unique O
correlation O
of O
HOMA-IR O
was O
with O
the-glucagon B-GENE-Y
to O
ghrelin B-GENE-Y
ratio-(r O
= O
0.801, O
p O
< O
0.001) O
in O
hyperthyrodism, O
and O
with O
glucagon B-GENE-Y
itself O
in O
euthyroidism O
(r O
= O
-0.844, O
p O
< O
0.001). O

Circulating O
levels O
of O
ghrelin B-GENE-Y
are O
decreased; O
leptin, B-GENE-Y
insulin, B-GENE-Y
glucagon B-GENE-Y
are O
unchanged; O
adiponectin B-GENE-Y
are O
increased O
during O
hyperthyroidism. O
The O
fasting O
HOMA-IR O
tends O
to O
be O
higher, O
despite O
the O
decreased O
adiposity O
in O
hyperthyroidism. O
The-glucagon B-GENE-Y
to O
ghrelin B-GENE-Y
ratio-strongly O
correlates O
with O
fasting O
HOMA-IR O
in O
hyperthyroidism. O
Proposed O
diagnostic O
criteria O
for O
subclinical O
Cushing's O
syndrome O
associated O
with O
adrenal O
incidentaloma. O
Subclinical O

Cushing's O
syndrome O
(SCS) O
associated O
with O
adrenal O
incidentaloma O
is O
usually O
characterized O
by O
autonomous O
cortisol B-CHEMICAL
secretion O
without O
overt O
symptoms O
of O
Cushing's O
syndrome O
(CS). O
Although O
the O
diagnostic O
criteria O
for O
SCS O
differ O
among O
countries, O
the O
1 O
mg O
dexamethasone B-CHEMICAL
suppression O
test O
(DST) O
is O
essential O
to O
confirm O
the O
presence O
and O
the O
extent O
of O
cortisol B-CHEMICAL
overproduction. O
Since O
1995, O
SCS O
has O
been O
diagnosed O
in O
Japan O
based O
on O
serum O
cortisol B-CHEMICAL
levels O
3 O
g/dl O
(measured O
by O
radioimmunoassay O
[RIA]) O
after O

a O
1 O
mg O
DST. O
However, O
the O
increasing O
use O
of O
enzyme O
immunoassays O
(EIA) O
instead O
of O
RIA O
has O
hindered O
the O
diagnosis O
of O
SCS O
because O
of O
the O
differing O
sensitivities O
of O
commercially O
available O
assays, O
particularly O
for O
serum O
cortisol B-CHEMICAL
levels O
of O
around O
3 O
g/dl. O
One O
way O
to O
overcome O
this O
problem O
is O
to O
lower O
the O
cortisol B-CHEMICAL
threshold O
level O
after O
a O
1 O
mg O
DST. O
In O
the O
present O
study, O
we O
examined O
the O
clinical O
applicability O
of O
lowering O
the O
cortisol B-CHEMICAL
threshold O
to O
1.8 O
g/dl, O
similar O
to O
the O
American O
Endocrine O

Society's O
guidelines O
for O
CS, O
by O
reanalyzing O
119 O
patients O
with O
adrenal O
incidentaloma. O
Our O
findings O
indicate O
that O
serum O
cortisol B-CHEMICAL
levels O
1.8 O
g/dl O
after O
1 O
mg O
DST O
are O
useful O
to O
confirm O
the O
diagnosis O
of O
SCS O
if O
both O
of O
the O
following O
criteria O
are O
met: O
(1) O
basal O
ACTH B-GENE-Y
level O
<10 O
pg/ml O
(or O
poor O
plasma O
ACTH B-GENE-Y
response O
to O
corticotrophin-releasing B-GENE-Y
hormone) I-GENE-Y
and O
(2) O
serum O
cortisol B-CHEMICAL
5 O
g/dl O
at O
21:00 O
to O
23:00 O
h. O
If O
only O
one O
of O

(1) O
and O
(2) O
are O
met, O
we O
recommend O
that O
other O
clinical O
features O
are O
considered O
in O
the O
diagnosis O
of O
SCS, O
including O
serum O
dehydroepiandrosterone B-CHEMICAL
sulfate I-CHEMICAL
levels, O
urine O
free O
cortisol B-CHEMICAL
levels, O
adrenal O
scintigraphy, O
and O
clinical O
manifestation. O
Flexibly O
timed O
once-daily O
dosing O
with O
degludec: O
a O
new O
ultra-long-acting O
basal O
insulin. B-GENE-Y
Insulin B-GENE-Y
treatment O
in O
type O
1 O
and O
type O
2 O
diabetes O
(T1D O
and O
T2D) O
is O
highly O
efficacious, O
but O
in O
practice, O
non-adherence O
and O
ineffective O
dose O
titration O

limit O
its O
effectiveness. O
Barriers O
to O
more O
effective O
insulin B-GENE-Y
treatment O
are O
numerous, O
including O
hypoglycaemia, O
fear O
of O
hypoglycaemia O
and O
concern O
about O
weight O
gain. O
The O
regular O
treatment O
timing O
needed O
with O
conventional O
basal O
insulins B-GENE-Y
[neutral O
protamine O
Hagedorn O
(NPH) O
insulin B-GENE-Y
and O
the O
first-generation O
analogues O
glargine O
and O
detemir] O
may O
also O
make O
adherence O
to O
these O
treatments O
problematic O
for O
many O
patients. O
Indeed, O
surveys O
indicate O
that O
the O
rigidity O
of O
this O
schedule O
induces O
some O
patients O
with O
T1D O
and O
T2D O
to O
omit O
insulin B-GENE-Y
doses. O
Degludec O
is O
a O
novel, O

ultra-long-acting O
basal O
insulin B-GENE-Y
analogue O
that O
is O
as O
effective O
as O
insulin B-GENE-Y
glargine, O
but O
significantly O
reduces O
patients' O
risk O
of O
nocturnal O
hypoglycaemia. O
Because O
of O
its O
peakless, O
extended O
and O
highly O
predictable O
glucose-lowering B-CHEMICAL
effect, O
once-daily O
dosing O
on O
a O
flexible O
schedule O
may O
be O
feasible O
with O
degludec. O
Studies O
testing O
this O
possibility O
suggest O
that O
degludec O
tolerates O
day-to-day O
variation O
in O
dose O
timing O
while O
maintaining O
full O
efficacy O
and O
low O
risk O
of O
nocturnal O
hypoglycaemia. O
Degludec O
would O
appear O
to O
be O
an O
appropriate O
choice O
for O
patients O
being O
considered O
for O
a O
basal O
analogue, O

and O
it O
may O
be O
particularly O
well O
suited O
to O
patients O
with O
unpredictable O
social O
or O
work O
schedules, O
those O
who O
travel O
frequently O
and O
those O
who O
find O
rigid O
scheduling O
of O
their O
insulin B-GENE-Y
injections O
a O
burden O
or O
barrier O
to O
regular O
treatment. O
Evaluation O
of O
a O
predictive O
in O
vitro O
Leydig O
cell O
assay O
for O
anti-androgenicity O
of O
phthalate B-CHEMICAL
esters I-CHEMICAL
in O
the O
rat. O
An O
in O
vitro O
assay O
using O
the O
rat O
Leydig O
cell O
line O
R2C O
was O
evaluated O
for O
its O
ability O
to O
quantitatively O
predict O
inhibition O
of O
testosterone B-CHEMICAL
synthesis. O
Results O
obtained O
for O
endocrine O
active O
phthalates B-CHEMICAL
(MEHP, B-CHEMICAL
MBP), B-CHEMICAL
and O

inactive O
phthalates B-CHEMICAL
(MMP B-CHEMICAL
and O
MEP) B-CHEMICAL
were O
highly O
consistent O
with O
in O
vivo O
results O
based O
on O
tissue O
and O
media O
concentrations. O
Statistically O
significant O
inhibition O
of O
testosterone B-CHEMICAL
synthesis O
(p<0.05, O
1-way O
ANOVA) O
was O
observed O
at O
1M O
MBP B-CHEMICAL
and O
3M O
MEHP, B-CHEMICAL
while O
MEP B-CHEMICAL
and O
MMP B-CHEMICAL
did O
not O
affect O
inhibition O
of O
testosterone B-CHEMICAL
synthesis O
until O
much O
higher O
concentrations O
(100M). O
Concentrations O
causing O
50% O
inhibition O
of O
testosterone B-CHEMICAL
synthesis O
for O
MBP B-CHEMICAL
and O
MEHP B-CHEMICAL
(3 O
and O
6M O
respectively), O
were O
similar O
to O
in O
vivo O
values O
(3 O
and O

7M). O
The O
R2C O
assay O
was O
used O
to O
determine O
the O
relative O
potency O
of O
14 O
structurally O
diverse O
monoesters B-CHEMICAL
and O
oxidative O
metabolites O
of O
MEHP. B-CHEMICAL
Monoesters B-CHEMICAL
with O
alkyl O
chains O
4-5 O
carbons B-CHEMICAL
in O
length O
had O
the O
highest O
potency O
for O
testosterone B-CHEMICAL
inhibition, O
while O
0-2 O
carbon B-CHEMICAL
alkyl O
chains O
were O
least O
potent. O
Phase O
I O
metabolism O
did O
not O
completely O
inactivate O
MEHP, B-CHEMICAL
underscoring O
the O
need O
for O
metabolism O
data O
when O
interpreting O
in O
vitro O
pharmacodynamic O
data. O
This O
steroid B-CHEMICAL
inhibition O
assay O
provides O
a O
predictive O
in O

vitro O
alternative O
to O
expensive O
and O
timeconsuming O
developmental O
rat O
studies O
for O
phthalate-induced B-CHEMICAL
antiandrogenicity. O
Quercetin B-CHEMICAL
suppressed O
CYP2E1-dependent B-GENE-Y
ethanol B-CHEMICAL
hepatotoxicity O
via O
depleting O
heme O
pool O
and O
releasing O
CO. B-CHEMICAL
Naturally O
occuring O
quercetin B-CHEMICAL
protects O
hepatocytes O
from O
ethanol-induced B-CHEMICAL
oxidative O
stress, O
and O
heme B-GENE-Y
oxygenase-1 I-GENE-Y
(HO-1) B-GENE-Y
induction O
and O
carbon B-CHEMICAL
monoxide I-CHEMICAL
(CO) B-CHEMICAL
metabolite O
may O
be O
implicated O
in O
the O
beneficial O
effect. O
However, O
the O
precise O
mechanism O
by O
which O
quercetin B-CHEMICAL
counteracts O

CYP2E1-mediated B-GENE-Y
ethanol B-CHEMICAL
hepatotoxicity O
through O
HO-1 B-GENE-Y
system O
is O
still O
remained O
unclear. O
To O
explore O
the O
potential O
mechanism, O
herein, O
ethanol B-CHEMICAL
(4.0g/kg.bw.) O
was O
administrated O
to O
rats O
for O
90 O
days. O
Our O
data O
showed O
that O
chronic O
ethanol B-CHEMICAL
over-activated O
CYP2E1 B-GENE-Y
but O
suppressed O
HO-1 B-GENE-Y
with O
concurrent O
hepatic O
oxidative O
damage, O
which O
was O
partially O
normalized O
by O
quercetin B-CHEMICAL
(100mg/kg.bw.). O
Quercetin B-CHEMICAL
(100M) O
induced O
HO-1 B-GENE-Y
and O

depleted O
heme O
pool O
when O
incubated O
to O
human O
hepatocytes. O
Ethanol-stimulated B-CHEMICAL
(100mM) O
CYP2E1 B-GENE-Y
upregulation O
was O
suppressed O
by O
quercetin B-CHEMICAL
but O
further O
enhanced O
by O
HO-1 B-GENE-Y
inhibition O
with O
resultant O
heme B-CHEMICAL
accumulation. O
CO B-CHEMICAL
scavenging O
blocked O
the O
suppression O
of O
quercetin B-CHEMICAL
only O
on O
CYP2E1 B-GENE-Y
activity. O
CO B-CHEMICAL
donor O
dose-dependently O
inactivated O
CYP2E1 B-GENE-Y
of O
ethanol-incubated B-CHEMICAL
microsome, O
which O
was O
mimicked O
by O
HO-1 B-GENE-Y
substrate O
but O
abolished O
by O
CO B-CHEMICAL
scavenger. O
Thus, O

CYP2E1-mediated B-GENE-Y
ethanol B-CHEMICAL
hepatotoxicity O
was O
alleviated O
by O
quercetin B-CHEMICAL
through O
HO-1 B-GENE-Y
induction. O
Depleted O
heme O
pool O
and O
CO B-CHEMICAL
releasing O
limited O
protein O
synthesis O
and O
inhibited O
enzymatic O
activity O
of O
CYP2E1, B-GENE-Y
respectively. O
Novel O
racemic O
tetrahydrocurcuminoid B-CHEMICAL
dihydropyrimidinone I-CHEMICAL
analogues O
as O
potent O
acetylcholinesterase B-GENE-Y
inhibitors. O
The O
synthesis O
of O
racemic O
tetrahydrocurcumin- B-CHEMICAL
(THC-), B-CHEMICAL
tetrahydrodemethoxycurcumin- B-CHEMICAL

(THDC-) B-CHEMICAL
and O
tetrahydrobisdemethoxycurcumin- B-CHEMICAL
(THBDC-) B-CHEMICAL
dihydropyrimidinone B-CHEMICAL
(DHPM) B-CHEMICAL
analogues O
was O
achieved O
by O
utilizing O
the O
multi-component O
Biginelli O
reaction O
in O
the O
presence O
of O
copper B-CHEMICAL
sulphate I-CHEMICAL
as O
a O
catalyst. O
The O
evaluation O
of O
acetylcholinesterase B-GENE-Y
inhibitors O
for O
Alzheimer's O
disease O
of O
these O
compounds O
showed O
that O
they O
exhibited O
higher O
inhibitory O
activity O
than O
their O
parent O
analogues. O
THBDC-DHPM B-CHEMICAL
demonstrated O
the O
most O
potent O
inhibitory O
activity O
with O
an O
IC50 O
value O
of O

1.340.03M O
which O
was O
more O
active O
than O
the O
approved O
drug O
galanthamine B-CHEMICAL
(IC50=1.450.04M). O
Agonistic O
activity O
of O
ICI B-CHEMICAL
182 I-CHEMICAL
780 I-CHEMICAL
on O
activation O
of O
GSK B-GENE-Y
3/AKT I-GENE-Y
pathway O
in O
the O
rat O
uterus O
during O
the O
estrous O
cycle. O
We O
examined O
the O
ability O
of O
ICI B-CHEMICAL
182,780 I-CHEMICAL
(ICI) B-CHEMICAL
to O
block O
uterine O
cell O
proliferation O
via O
protein B-GENE-N
kinase I-GENE-N
b/AKT I-GENE-N
pathway O
in O
the O
uterus O
of O
the O
rat O
during O
the O
estrous O
cycle. O
Intact O
rats, O
with O
regular O
estrous O
cycles, O

received O
a O
subcutaneous O
(s.c.) O
injection O
of O
either O
vehicle O
or O
ICI B-CHEMICAL
at O
08:00h O
on O
the O
day O
of O
proestrus O
or O
at O
00:00h O
on O
the O
day O
of O
estrus O
and O
sacrificed O
at O
13:00h O
of O
metaestrus. O
Estradiol B-CHEMICAL
(E2) O
and O
progesterone B-CHEMICAL
(P4) O
plasma O
levels O
were O
measured O
by O
radioimmunoassay. O
Both O
ICI B-CHEMICAL
treatments, O
induced O
a O
significant O
decrease O
(p<0.01) O
in O
uterine O
estrogen B-GENE-Y
receptor I-GENE-Y
alpha I-GENE-Y
(ER) B-GENE-Y
content, O
had O
no O
effect O
on O
uterine O
progesterone B-GENE-Y
receptor I-GENE-Y

(PR) B-GENE-Y
protein O
expression O
and O
caused O
marked O
nuclear O
localization O
of O
cyclin B-GENE-Y
D1, I-GENE-Y
in O
both O
luminal O
and O
glandular O
uterine O
epithelium, O
as O
compared O
to O
vehicle-treated O
animals. O
Furthermore, O
we O
detected O
that O
ICI B-CHEMICAL
treatment O
induced O
glycogen B-GENE-N
synthase I-GENE-N
kinase I-GENE-N
(Gsk3-) B-GENE-Y
Ser O
9 O
phosphorylation, O
which O
correlates O
with O
cyclin B-GENE-Y
D1 I-GENE-Y
nuclear O
localization. O
However, O
some O
differences O
were O
observed O
between O
the O
two O
different O
time O
schedules O
of O
administration. O
We O
observed O
that O
the O
administration O
of O
ICI B-CHEMICAL
at O
08:00h O
on O
proestrus O
day O
produced O
a O

15% O
inhibition O
of O
luminal O
epithelial O
cell O
proliferation, O
reduced O
uterine O
wet O
weight O
by O
21% O
and O
caused O
reduction O
of O
Akt B-GENE-N
phosphorylation O
at O
Ser B-CHEMICAL
473 O
as O
compared O
to O
vehicle-treated O
animals, O
whereas O
ICI B-CHEMICAL
treatment O
at O
00:00h O
on O
estrus O
day O
had O
no O
effect O
on O
these O
parameters. O
The O
overall O
results O
indicate O
that O
ICI B-CHEMICAL
may O
exert O
agonistic O
and O
antagonistic O
effects O
on O
uterine O
cell O
proliferation O
through O
differential O
activation O
of O
the O
Akt B-GENE-N
pathway O
depending O
on O
the O
administration O
period O
during O
the O
estrous O
cycle, O
and O
indicates O
that O
the O
mechanism O
of O
cell O
proliferation O
during O
the O
physiological O
conditions O
of O
the O
estrous O

cycle, O
is O
under O
a O
different O
and O
more O
complex O
regulation O
than O
in O
the O
ovariectomized O
+E2 O
animal O
model. O
Aminopropylindenes B-CHEMICAL
derived O
from O
Grundmann's B-CHEMICAL
ketone I-CHEMICAL
as O
a O
novel O
chemotype O
of O
oxidosqualene B-GENE-Y
cyclase I-GENE-Y
inhibitors. O
A O
series O
of O
aminopropylindenes, B-CHEMICAL
designed O
as O
mimics O
of O
a O
cationic O
high O
energy O
intermediate O
in O
the O
oxidosqualene B-CHEMICAL
cyclase(1) I-GENE-Y
(OSC)-mediated B-GENE-Y
cyclization O
of O
2,3-oxidosqualen B-CHEMICAL
to O
lanosterol B-CHEMICAL

was O
prepared O
from O
Grundmann's B-CHEMICAL
ketone. I-CHEMICAL
Screening O
on O
OSCs B-GENE-N
from O
five O
different O
organisms O
revealed O
interesting O
activities O
and O
selectivities O
of O
some O
of O
the O
compounds. O
A O
N,N-dimethylaminopropyl B-CHEMICAL
derivative O
showed O
promising O
inhibition O
of O
Trypanosoma B-GENE-Y
cruzi I-GENE-Y
OSC I-GENE-Y
in O
combination O
with O
low O
cytotoxicity, O
and O
showed O
significant O
reduction O
of O
cholesterol B-CHEMICAL
biosynthesis O
in O
a O
human O
cell O
line. O
The O
ATP B-CHEMICAL
required O
for O
potentiation O
of O
skeletal O
muscle O
contraction O
is O
released O
via O
pannexin B-GENE-N
hemichannels. O
During O
repetitive O
stimulation O
of O
skeletal O
muscle, O
extracellular O
ATP B-CHEMICAL
levels O
raise, O

activating O
purinergic B-GENE-N
receptors, I-GENE-N
increasing O
Ca(2+) B-CHEMICAL
influx, O
and O
enhancing O
contractile O
force, O
a O
response O
called O
potentiation. O
We O
found O
that O
ATP B-CHEMICAL
appears O
to O
be O
released O
through O
pannexin1 B-GENE-Y
hemichannels O
(Panx1 B-GENE-Y
HCs). O
Immunocytochemical O
analyses O
and O
function O
were O
consistent O
with O
pannexin1 B-GENE-Y
localization O
to O
T-tubules O
intercalated O
with O
dihydropyridine B-CHEMICAL
and O
ryanodine B-GENE-N
receptors I-GENE-N
in O
slow O
(soleus) O
and O
fast O
(extensor O
digitorum O
longus, O
EDL) O
muscles. O
Isolated O
myofibers O
took O
up O

ethidium B-CHEMICAL
(Etd(+)) B-CHEMICAL
and O
released O
small O
molecules O
(as O
ATP) B-CHEMICAL
during O
electrical O
stimulation. O
Consistent O
with O
two O
glucose B-CHEMICAL
uptake O
pathways, O
induced O
uptake O
of O
2-NBDG, B-CHEMICAL
a O
fluorescent O
glucose B-CHEMICAL
derivative, O
was O
decreased O
by O
inhibition O
of O
HCs O
or O
glucose B-GENE-N
transporter I-GENE-N
(GLUT4), B-GENE-Y
and O
blocked O
by O
dual O
blockade. O
Adult O
skeletal O
muscles O
apparently O
do O
not O
express O
connexins, B-GENE-N
making O
it O
unlikely O
that O
connexin B-GENE-N
hemichannels O
contribute O
to O
the O
uptake O
and O
release O
of O
small O
molecules. O
ATP B-CHEMICAL
release, O
Etd(+) B-CHEMICAL
uptake, O
and O
potentiation O
induced O
by O
repetitive O
electrical O

stimulation O
were O
blocked O
by O
HC O
blockers O
and O
did O
not O
occur O
in O
muscles O
of O
pannexin1 B-GENE-Y
knockout O
mice. O
MRS2179, O
a O
P2Y1R B-GENE-Y
blocker, O
prevented O
potentiation O
in O
EDL, O
but O
not O
soleus O
muscles, O
suggesting O
that O
in O
fast O
muscles O
ATP B-CHEMICAL
activates O
P2Y1 B-GENE-Y
but O
not O
P2X B-GENE-N
receptors. I-GENE-N
Phosphorylation O
on O
Ser B-CHEMICAL
and O
Thr B-CHEMICAL
residues O
of O
pannexin1 B-GENE-Y
was O
increased O
during O
potentiation, O
possibly O
mediating O
HC O
opening. O
Opening O
of O
Panx1 B-GENE-Y
HCs O
during O
repetitive O
activation O
allows O
efflux O
of O
ATP, B-CHEMICAL
influx O
of O
glucose B-CHEMICAL
and O
possibly O
Ca(2+) B-CHEMICAL

too, O
which O
are O
required O
for O
potentiation O
of O
contraction. O
This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
'Connexin B-GENE-N
based O
channels'. O
tert-Butylhydroquinone B-CHEMICAL
reduces O
lipid O
accumulation O
in O
C57BL/6 O
mice O
with O
lower O
body O
weight O
gain. O
tert-Butylhydroquinone B-CHEMICAL
(tBHQ) B-CHEMICAL
is O
a O
commonly O
used O
antioxidant O
additive O
that O
is O
approved O
for O
human O
use O
by O
both O
the O
Food O
and O
Agriculture O
Organization O
and O
the O
World O
Health O
Organization O
(FAO/WHO). O
In O
this O
study, O
we O
examined O
the O
effect O
of O
tBHQ B-CHEMICAL
on O
body O
weight O
gain O
and O
found O

that O
food O
supplementation O
with O
0.001 O
% O
(w/w) O
tBHQ B-CHEMICAL
inhibited O
61.4 O
% O
(P O
< O
0.01) O
of O
body O
weight O
gain O
in O
high-fat O
diet O
(HFD)-induced O
C57BL/6 O
mice, O
and O
the O
oral O
administration O
of O
tBHQ B-CHEMICAL
(1.5 O
mg/kg) O
reduced O
47.5 O
% O
(P O
< O
0.05) O
of O
body O
weight O
gain O
in O
normal O
diet O
fed O
db/db O
mice. O
The O
HFD O
increased O
lipid O
deposit O
in O
adipocytes, O
but O
these O
were O
reduced O
significantly O
by O
tBHQ B-CHEMICAL
treatment O
in O

C57BL/6 O
mice. O
tBHQ B-CHEMICAL
supplementation O
significantly O
lowered O
the O
plasma O
triglyceride B-CHEMICAL
and O
total O
cholesterol, B-CHEMICAL
with O
reduced O
size O
of O
accumulated O
fat O
mass. O
The O
rate O
limiting O
enzyme O
of O
beta-oxidation O
(ACOX1) B-GENE-Y
was O
significantly O
over-expressed O
in O
the O
liver O
with O
tBHQ B-CHEMICAL
treatment. O
These O
results O
indicate O
that O
tBHQ B-CHEMICAL
suppresses O
body O
weight O
gain O
in O
mice, O
possibly O
at O
least O
related O
to O
the O
up-regulation O
of O
ACOX1 B-GENE-Y
gene O
expression. O
Dual O
Growth O
Factor O
Delivery O
Using O
Biocompatible O
Core-Shell O
Microcapsules O
for O
Angiogenesis. O
An O
optimized O

electrodropping O
system O
produces O
homogeneous O
core-shell O
microcapsules O
(C-S O
MCs) O
by O
using O
poly(L-lactic-co-glycolic B-CHEMICAL
acid) I-CHEMICAL
(PLGA) B-CHEMICAL
and O
alginate. O
Fluorescence O
imaging O
clearly O
shows O
the O
C-S O
domain O
in O
the O
MC. O
For O
release O
control, O
the O
use O
of O
high-molecular-weight O
PLGA B-CHEMICAL
(HMW O
270 O
000) O
restrains O
the O
initial O
burst O
release O
of O
protein O
compared O
to O
that O
of O
low-MW O
PLGA B-CHEMICAL
(LMW O
40 O
000). O
Layer-by-layer O
(LBL) O
assembly O
of O

chitosan O
and O
alginate O
on O
MCs O
is O
also O
useful O
in O
controlling O
the O
release O
profile O
of O
biomolecules. O
LBL O
(7-layer) O
treatment O
is O
effective O
in O
suppressing O
the O
initial O
burst O
release O
of O
protein O
compared O
to O
no O
LBL O
(0-layer). O
The O
difference O
of O
cumulative O
albumin O
release O
between O
HMW O
(7-layer O
LBL) O
and O
LMW O
(0-layer O
LBL) O
PLGA B-CHEMICAL
is O
determined O
to O
be O
more O
than O
40% O
on O
day O
5. O
When O
dual O
angiogenic O
growth O
factors O
(GFs), O
such O
as O
platelet-derived B-GENE-N
GF I-GENE-N
(PDGF) B-GENE-N
and O
vascular B-GENE-N

endothelial I-GENE-N
GF I-GENE-N
(VEGF), B-GENE-N
are O
encapsulated O
separately O
in O
the O
core O
and O
shell O
domains, O
respectively, O
the O
VEGF B-GENE-N
release O
rate O
is O
much O
greater O
than O
that O
of O
PDGF, B-GENE-N
and O
the O
difference O
of O
the O
cumulative O
release O
percentage O
between O
the O
two O
GFs O
is O
about O
30% O
on O
day O
7 O
with O
LMW O
core O
PLGA B-CHEMICAL
and O
more O
than O
45% O
with O
HMW O
core O
PLGA. B-CHEMICAL
As O
for O
the O
angiogenic O
potential O
of O
MC O
GFs O
with O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs), O
the O
fluorescence O
signal O
of O
CD31+ B-GENE-Y
suggests O
that O

the O
angiogenic O
sprout O
of O
ECs O
is O
more O
active O
in O
MC-mediated O
GF O
delivery O
than O
conventional O
GF O
delivery, O
and O
this O
difference O
is O
significant, O
based O
on O
the O
number O
of O
capillary O
branches O
in O
the O
unit O
area. O
This O
study O
demonstrates O
that O
the O
fabrication O
of O
biocompatible O
C-S O
MCs O
is O
possible, O
and O
that O
the O
release O
control O
of O
biomolecules O
is O
adjustable. O
Furthermore, O
MC-mediated O
GFs O
remain O
in O
an O
active O
form O
and O
can O
upregulate O
the O
angiogenic O
activity O
of O
ECs. O
Potency O
switch O
between O
CHK1 B-GENE-Y
and O
MK2: B-GENE-Y
Discovery O
of O

imidazo[1,2-a]pyrazine- B-CHEMICAL
and O
imidazo[1,2-c]pyrimidine-based B-CHEMICAL
kinase B-GENE-N
inhibitors. O
Chemistry O
has O
been O
developed O
to O
access O
both O
imidazo[1,2-a]pyrazines B-CHEMICAL
and O
imidazo[1,2-c]pyrimidines. B-CHEMICAL
Small O
structural O
modifications O
in O
both O
series O
led O
to O
a O
switch O
of O
potency O
between O
two O
kinases B-GENE-N
involved O
in O
mediating O
cell O
cycle O
checkpoint O
control, O
CHK1 B-GENE-Y
and O
MK2. B-GENE-Y
The O
Fer B-GENE-Y
tyrosine B-CHEMICAL
kinase I-GENE-N
is O
important O
for O
platelet-derived B-GENE-Y
growth I-GENE-Y

factor-BB-induced I-GENE-Y
Stat3 B-GENE-Y
phosphorylation, O
colony O
formation O
in O
soft O
agar O
and O
tumor O
growth O
in O
vivo. O
Fer B-GENE-Y
is O
a O
cytoplasmic O
tyrosine B-CHEMICAL
kinase I-GENE-N
that O
is O
activated O
in O
response O
to O
platelet-derived B-GENE-N
growth I-GENE-N
factor I-GENE-N
(PDGF) B-GENE-N
stimulation. O
In O
the O
present O
report, O
we O
show O
that O
Fer B-GENE-Y
associates O
with O
the O
activated O
PDGFbeta B-GENE-Y
receptor I-GENE-Y
(PDGFRbeta) B-GENE-Y
through O
multiple O
autophosphorylation O
sites, O
i.e. O
Tyr579, B-CHEMICAL
Tyr581, B-CHEMICAL
Tyr740 B-CHEMICAL
and O
Tyr1021. B-CHEMICAL
Using O

low O
molecular O
weight O
inhibitors, O
we O
found O
that O
PDGF-BB-induced B-GENE-Y
Fer B-GENE-Y
activation O
is O
dependent O
on O
PDGFRbeta B-GENE-Y
kinase B-GENE-N
activity, O
but O
not O
on O
the O
enzymatic O
activity O
of O
Src B-GENE-Y
or O
Jak B-GENE-N
kinases. B-GENE-N
In O
cells O
in O
which O
Fer B-GENE-Y
was O
downregulated O
using O
siRNA, O
PDGF-BB B-GENE-Y
was O
unable O
to O
induce O
phosphorylation O
of O
Stat3, B-GENE-Y
whereas O
phosphorylations O
of O
Stat5, B-GENE-N
Erk1/2 B-GENE-N
and O
Akt B-GENE-N
were O
unaffected. O
PDGF-BB-induced B-GENE-Y
activation O
of O
Stat3 B-GENE-Y
occurred O
also O
in O
cells O

expressing O
kinase-dead B-GENE-N
Fer, B-GENE-Y
suggesting O
a O
kinase-independent B-GENE-N
adaptor O
role O
of O
Fer. B-GENE-Y
Expression O
of O
Fer B-GENE-Y
was O
dispensable O
for O
PDGF-BB-induced B-GENE-Y
proliferation O
and O
migration, O
but O
essential O
for O
colony O
formation O
in O
soft O
agar. O
Tumor O
growth O
in O
vivo O
was O
delayed O
in O
cells O
depleted O
of O
Fer B-GENE-Y
expression. O
Our O
data O
suggests O
a O
critical O
role O
of O
Fer B-GENE-Y
in O
PDGF-BB-induced B-GENE-Y
Stat3 B-GENE-Y
activation O
and O
cell O
transformation. O
Discovery O
of O
aryl B-CHEMICAL
ureas I-CHEMICAL
and O
aryl B-CHEMICAL
amides I-CHEMICAL
as O
potent O
and O
selective O
histamine B-CHEMICAL
H3 I-GENE-Y
receptor I-GENE-Y
antagonists O
for O
the O
treatment O
of O
obesity O
(Part O

I). O
A O
series O
of O
structurally O
novel O
aryl B-CHEMICAL
ureas I-CHEMICAL
was O
derived O
from O
optimization O
of O
the O
HTS O
lead O
as O
selective O
histamine B-GENE-Y
H3 I-GENE-Y
receptor I-GENE-Y
(H3R) B-GENE-Y
antagonists. O
The O
SAR O
was O
explored O
and O
the O
data O
obtained O
set O
up O
the O
starting O
point O
and O
foundation O
for O
further O
optimization. O
The O
most O
potent O
tool O
compounds, O
as O
exemplified O
by O
compounds O
2l, O
5b, O
5d, O
and O
5e, O
displayed O
antagonism O
potencies O
in O
the O
subnanomolar O
range O
in O
in O
vitro O
human-H3R B-GENE-Y
FLIPR O
assays O
and O
rhesus B-GENE-Y
monkey I-GENE-Y
H3R I-GENE-Y
binding O
assays. O
Structure O
and O

energetics O
of O
gas O
phase O
halogen-bonding B-CHEMICAL
in O
mono-, B-GENE-N
bi-, I-GENE-N
and I-GENE-N
tri-dentate I-GENE-N
anion I-GENE-N
receptors I-GENE-N
as O
studied O
by O
BIRD. O
Complexes O
of O
mono-, B-GENE-N
bi- I-GENE-N
(RB), I-GENE-N
and I-GENE-N
tridentate I-GENE-N
(RT) I-GENE-N
receptors I-GENE-N
with O
a O
range O
of O
anions O
(Cl(-), B-CHEMICAL
Br(-), B-CHEMICAL
I(-), B-CHEMICAL
NO3(-), B-CHEMICAL
H2PO4(-), B-CHEMICAL
HSO4(-), B-CHEMICAL
and O
tosylate B-CHEMICAL
(TsO(-))) B-CHEMICAL
have O
been O
studied O
in O
the O
gas O
phase O
by O
both O
experimental O
and O

theoretical O
methods. O
Temperature O
dependent O
blackbody O
infrared O
radiative O
dissociation O
(BIRD) O
experiments O
were O
performed O
on O
complexes O
of O
C8F17I B-CHEMICAL
with O
Br(-) B-CHEMICAL
and O
I(-), B-CHEMICAL
RB O
with O
I(-), B-CHEMICAL
NO3(-), B-CHEMICAL
HSO4(-), B-CHEMICAL
H2PO4(-), B-CHEMICAL
and O
TsO(-), B-CHEMICAL
and O
RT O
with O
I(-), B-CHEMICAL
HSO4(-) B-CHEMICAL
and O
TsO(-) B-CHEMICAL
and O
the O
observed O
Arrhenius O
parameters O
are O
reported O
here. O
Master O
equation O
modeling O
of O
the O
BIRD O
kinetics O
data O
was O

carried O
out O
to O
determine O
threshold O
dissociation O
energies. O
Geometry O
optimizations O
and O
thermochemistry O
calculations O
were O
performed O
using O
the O
B3LYP/6-31+G(d,p) O
level O
of O
theory. O
Additional O
single O
point O
energies O
were O
calculated O
using O
MP2/6-311++G(2d,p). O
Results O
were O
examined O
in O
terms O
of O
the O
binding O
order O
of O
various O
anions O
as O
well O
as O
the O
added O
binding O
strength O
from O
additional O
halogen B-CHEMICAL
bonding O
(XB) O
interactions. O
The O
relative O
binding O
energies O
of O
ions O
were O
generally O
consistent O
with O
the O
ordering O
previously O
reported O
from O
solution O
phase O
experiments; O
however, O
the O
relatively O
strong O
binding O
of O

H2PO4(-) B-CHEMICAL
to O
the O
bidentate O
receptor O
contrasted O
the O
solution O
phase O
observation O
of O
oxoanions B-CHEMICAL
having O
weaker O
interactions O
when O
compared O
to O
halides. B-CHEMICAL
An O
increase O
in O
the O
energy O
required O
to O
remove O
the O
same O
anion O
from O
the O
tridentate B-GENE-N
receptor I-GENE-N
when O
compared O
to O
the O
bidentate B-GENE-N
and I-GENE-N
monodentate I-GENE-N
receptors I-GENE-N
is O
explained O
as O
being O
due O
to O
the O
increase O
in O
halogen B-CHEMICAL
bonding O
interactions. O
The O
possibility O
of O
mixed O
halogen B-CHEMICAL
and O
hydrogen B-CHEMICAL
bonded O
complexes O
were O
considered. O
Anandamide B-CHEMICAL
deficiency O
and O
heightened O
neuropathic O
pain O
in O
aged O
mice. O
Damaging O
of O
peripheral O
nerves O
may O
result O
in O
chronic O
neuropathic O
pain O
for O
which O
the O
likelihood O
is O

increased O
in O
the O
elderly. O
We O
assessed O
in O
mice O
if O
age-dependent O
alterations O
of O
endocannabinoids O
contributed O
to O
the O
heightened O
vulnerability O
to O
neuropathic O
pain O
at O
old O
age. O
We O
assessed O
nociception, O
endocannabinoids O
and O
the O
therapeutic O
efficacy O
of O
R-flurbiprofen B-CHEMICAL
in O
young O
and O
aged O
mice O
in O
the O
spared O
nerve O
injury O
model O
of O
neuropathic O
pain. O
R-flurbiprofen B-CHEMICAL
was O
used O
because O
it O
is O
able O
to O
reduce O
neuropathic O
pain O
in O
young O
mice O
in O
part O
by O
increasing O
anandamide. B-CHEMICAL
Aged O
mice O
developed O
stronger O
nociceptive O
hypersensitivity O
after O
sciatic O
nerve O
injury O
than O

young O
mice. O
This O
was O
associated O
with O
low O
anandamide B-CHEMICAL
levels O
in O
the O
dorsal O
root O
ganglia, O
spinal O
cord, O
thalamus O
and O
cortex, O
which O
further O
decreased O
after O
nerve O
injury. O
In O
aged O
mice, O
R-flurbiprofen B-CHEMICAL
had O
only O
weak O
antinociceptive O
efficacy O
and O
it O
failed O
to O
restore O
normal O
anandamide B-CHEMICAL
levels O
after O
nerve O
injury. O
In O
terms O
of O
the O
mechanisms, O
we O
found O
that O
fatty B-GENE-N
acid I-GENE-N
amide I-GENE-N
hydrolase I-GENE-N
(FAAH) B-GENE-N
which O
degrades O
anandamide, B-CHEMICAL
was O
upregulated O
after O
nerve O
injury O
at O
both O
ages, O
so O
that O
this O
upregulation O
likely O
did O
not O
account O
for O
the O

age-dependent O
differences. O
However, O
enzymes O
contributing O
to O
oxidative O
metabolism O
of O
anandamide, B-CHEMICAL
namely O
cyclooxygenase-1 B-GENE-Y
and O
Cyp2D6, B-GENE-N
were O
increased O
in O
the O
brain O
of O
aged O
mice, O
possibly O
enhancing O
the O
oxidative O
breakdown O
of O
anandamide. B-CHEMICAL
This O
may O
overwhelm O
the O
capacity O
of O
R-flurbiprofen B-CHEMICAL
to O
restore O
anandamide B-CHEMICAL
homeostasis O
and O
may O
contribute O
to O
the O
heightened O
risk O
for O
neuropathic O
pain O
at O
old O
age. O
Polymer-based O
protein O
engineering O
can O
rationally O
tune O
enzyme O
activity, O
pH-dependence, O
and O
stability. O
The O
attachment O

of O
inert O
polymers, O
such O
as O
polyethyleneglycol, B-CHEMICAL
to O
proteins O
has O
driven O
the O
emergence O
of O
a O
multibillion O
dollar O
biotechnology O
industry. O
In O
all O
cases, O
proteins O
have O
been O
stabilized O
or O
altered O
by O
covalently O
coupling O
the O
pre-existing O
polymer O
to O
the O
surface O
of O
the O
protein. O
This O
approach O
is O
inherently O
limited O
by O
a O
lack O
of O
exquisite O
control O
of O
polymer O
architecture, O
chain O
length, O
site O
and O
density O
of O
attachment. O
Using O
a O
novel O
water-soluble O
atom O
transfer O
radical O
polymerization O
initiator, O
we O
have O
grown O
temperature- O
and O
pH-responsive O
polymers O
from O
the O
surface O
of O
a O
model O
protein, O
the O
enzyme O

chymotrypsin. B-GENE-N
Poly(2-(dimethylamino)ethyl B-CHEMICAL
methacrylate) I-CHEMICAL
changes O
in O
conformation O
with O
altered O
temperature O
and O
pH. O
Growing O
the O
polymer O
from O
the O
surface O
of O
chymotrypsin B-GENE-N
we O
were O
able O
to O
demonstrate O
that O
changes O
in O
temperature O
or O
pH O
can O
change O
predictably O
the O
conformation O
of O
the O
polymer O
surrounding O
the O
enzyme, O
which O
in O
turn O
enabled O
the O
rational O
tailoring O
of O
enzyme O
activity O
and O
stability. O
Using O
what O
we O
now O
term O
"Polymer-Based O
Protein O
Engineering" O
we O
have O
increased O
the O
activity O
and O
stability O
of O
chymotrypsin B-GENE-N
by O
an O
order O
of O
magnitude O
at O

pH's O
where O
the O
enzyme O
is O
usually O
inactive O
or O
unstable. O
24(S)-hydroxycholesterol B-CHEMICAL
is O
actively O
eliminated O
from O
neuronal O
cells O
by O
ABCA1. B-GENE-Y
High O
cholesterol B-CHEMICAL
turnover O
catalyzed O
by O
cholesterol B-CHEMICAL
24-hydroxylase I-GENE-Y
is O
essential O
for O
neural O
functions, O
especially O
learning. O
Because O
24(S)-hydroxycholesterol B-CHEMICAL
(24-OHC), B-CHEMICAL
produced O
by O
24-hydroxylase, B-GENE-Y
induces O
apoptosis O
of O
neuronal O
cells, O
it O
is O
vital O
to O
eliminate O
it O
rapidly O
from O
cells. O
Here, O
using O
differentiated O
SH-SY5Y O

neuron-like O
cells O
as O
a O
model, O
we O
examined O
whether O
24-OHC B-CHEMICAL
is O
actively O
eliminated O
via O
transporters B-GENE-N
induced O
by O
its O
accumulation. O
The O
expression O
of O
ABCA1 B-GENE-Y
and O
ABCG1 B-GENE-Y
was O
induced O
by O
24-OHC, B-CHEMICAL
as O
well O
as O
TO901317 B-CHEMICAL
and O
retinoic B-CHEMICAL
acid, I-CHEMICAL
which O
are O
ligands O
of O
the O
nuclear B-GENE-N
receptors I-GENE-N
LXR/RXR. B-GENE-N
When O
the O
expression O
of O
ABCA1 B-GENE-Y
and O
ABCG1 B-GENE-Y
was O
induced, O
24-OHC B-CHEMICAL
efflux O
was O
stimulated O
in O
the O
presence O
of O
high B-GENE-N
density I-GENE-N
lipoprotein I-GENE-N
(HDL), B-GENE-N
whereas O
apolipoprotein B-GENE-Y
A-I I-GENE-Y
was O
not O
an O

efficient O
acceptor. O
The O
efflux O
was O
suppressed O
by O
the O
addition O
of O
siRNA O
against O
ABCA1, B-GENE-Y
but O
not O
by O
ABCG1 B-GENE-Y
siRNA. O
To O
confirm O
the O
role O
of O
each O
transporter, O
we O
analyzed O
HEK293 O
cells O
stably O
expressing O
human B-GENE-Y
ABCA1 I-GENE-Y
or O
ABCG1; B-GENE-Y
we O
clearly O
observed O
24-OHC B-CHEMICAL
efflux O
in O
the O
presence O
of O
HDL, B-GENE-N
whereas O
efflux O
in O
the O
presence O
of O
apolipoprotein B-GENE-Y
A-I I-GENE-Y
was O
marginal. O
Furthermore, O
the O
treatment O
of O
primary O
cerebral O
neurons O
with O
LXR/RXR B-GENE-N
ligands O
suppressed O
the O
toxicity O
of O
24-OHC. B-CHEMICAL
These O
results O
suggest O

that O
ABCA1 B-GENE-Y
actively O
eliminates O
24-OHC B-CHEMICAL
in O
the O
presence O
of O
HDL B-GENE-N
as O
a O
lipid O
acceptor O
and O
protects O
neuronal O
cells. O
This O
article O
is O
protected O
by O
copyright. O
All O
rights O
reserved. O
Design, O
Synthesis O
and O
biological O
evaluation O
of O
catecholamine B-CHEMICAL
vehicle O
for O
studying O
dopaminergic O
system. O
Catecholamine B-CHEMICAL
mimetic O
EDTA-bis(tyramide) B-CHEMICAL
was O
synthesized O
and O
characterized O
by O
various O
spectroscopic O
techniques O
(NMR, O
Mass O
spectroscopy) O
and O
em O
310 O
nm O
for O
the O
excitation O
at O
270 O
nm. O
Molecular O
docking O
studies O
were O
performed O
with O
Human B-GENE-Y

Serum I-GENE-Y
Albumin I-GENE-Y
(HSA: B-GENE-Y
PDB O
1E78), O
showing O
binding O
pattern O
with O
amino B-CHEMICAL
acid I-CHEMICAL
residues O
Arg218, B-CHEMICAL
Arg222 B-CHEMICAL
and O
Lys444, B-CHEMICAL
identifies O
the O
ligand-HSA B-GENE-Y
interaction O
for O
the O
transportation O
affinity O
of O
the O
ligand O
at O
the O
specific O
site O
of O
the O
target. O
Subsequently O
binding O
study O
with O
HSA O
at O
ex O
=350 O
nm O
found O
to O
be O
5.847x10(4) O
M(-1) O
shows O
effective O
quenching O
effect. O
Additionally O
to O
go O
more O
insight O
AChE O
binding O
affinity O
was O
investigated, O
which O
shows O
90% O
binding O
affinity O
for O
the O
10 O
mM O
concentration. O

IC50 O
value O
was O
was O
found O
18.60 O
M O
for O
MAO-B B-GENE-Y
inhibition. O
Finally, O
EDTA-bis(tyramide) B-CHEMICAL
labeled O
with O
(99m) B-CHEMICAL
Tc I-CHEMICAL
to O
investigate O
its O
in-vivo O
radiopharmaceutical O
efficiency, O
having O
97% O
binding O
affinity O
with O
98% O
radiochemical O
purity. O
In-vivo O
studies O
were O
carried O
out O
for O
(99m) B-CHEMICAL
Tc- I-CHEMICAL
EDTA-bis(tyramide) I-CHEMICAL
included O
blood O
kinetics O
showed O
a O
quick O
wash O
out O
from O
the O
circulation O
via O
renal O
route O
and O
biodistribution O
revealed O
that O
maximum%ID/g O
was O
found O
in O

kidney O
at O
1h O
and O
its O
scintigraphy O
image O
shows O
3.96% O
brain O
uptake O
with O
respect O
to O
whole O
body. O
This O
article O
is O
protected O
by O
copyright. O
All O
rights O
reserved. O
Synergistic O
enhancement O
of O
cancer O
therapy O
using O
a O
combination O
of O
heat B-GENE-N
shock I-GENE-N
protein I-GENE-N
targeted O
HPMA B-CHEMICAL
copolymer-drug O
conjugates O
and O
gold O
nanorod O
induced O
hyperthermia. O
In O
the O
field O
of O
nanomedicine, O
selective O
delivery O
to O
cancer O
cells O
is O
a O
common O
goal, O
where O
active O
targeting O
strategies O
are O
often O
employed O
to O
increase O
tumor O
accumulation. O
In O
this O
study, O
tumor O
hyperthermia O
was O
utilized O
as O
a O
means O
to O
increase O
the O
active O
delivery O

of O
heat B-GENE-N
shock I-GENE-N
protein I-GENE-N
(HSP) B-GENE-N
targeted O
N-(2-hydroxypropyl)methacrylamide B-CHEMICAL
(HPMA) B-CHEMICAL
copolymer-drug O
conjugates. O
Following O
hyperthermia, O
induced O
expression O
of O
cell O
surface O
heat B-GENE-N
shock I-GENE-N
protein I-GENE-N
(HSP) B-GENE-N
glucose B-CHEMICAL
regulated I-GENE-Y
protein I-GENE-Y
78kDa I-GENE-Y
(GRP78) B-GENE-Y
was O
utilized O
for O
targeted O
drug O
therapy. O
Conjugates O
bearing O
the O
anticancer O
agents O
aminohexylgeldanamycin B-CHEMICAL
(AHGDM), B-CHEMICAL
docetaxel B-CHEMICAL
(DOC), B-CHEMICAL
or O
cisplatin B-CHEMICAL
and O
the O
GRP78 B-GENE-Y

targeting O
peptide O
WDLAWMFRLPVG O
were O
synthesized O
and O
characterized. O
Binding O
to O
cell O
surface O
expressed O
heat B-GENE-N
shock I-GENE-N
protein I-GENE-N
GRP78 B-GENE-Y
on O
the O
surface O
of O
human O
prostate O
cancer O
DU145 O
cells O
was O
evaluated. O
HSP B-GENE-N
targeted O
AHGDM B-CHEMICAL
and O
DOC B-CHEMICAL
conjugates O
demonstrated O
active O
binding O
comparable O
to O
native O
targeting O
peptide. O
They O
were O
then O
assessed O
in O
vitro O
for O
the O
ability O
to O
synergistically O
induce O
cytotoxicity O
in O
combination O
with O
moderate O
hyperthermia O
(43C, O
30min). O
HSP B-GENE-N
targeted O
DOC B-CHEMICAL
conjugates O
exhibited O
high O
potency O
against O

DU145 O
cells O
with O
an O
IC50 O
of O
2.4nM. O
HSP B-GENE-N
targeted O
AHGDM B-CHEMICAL
and O
DOC B-CHEMICAL
conjugates O
demonstrated O
synergistic O
effects O
in O
combination O
with O
hyperthermia O
with O
combination O
index O
values O
of O
0.65 O
and O
0.45 O
respectively. O
Based O
on O
these O
results, O
HSP B-GENE-N
targeted O
DOC B-CHEMICAL
conjugates O
were O
selected O
for O
in O
vivo O
evaluation. O
In O
DU145 O
tumor O
bearing O
mice, O
a O
single O
treatment O
of O
tumor O
hyperthermia, O
induced O
via O
gold O
nanorod O
mediated O
plasmonic O
photothermal O
therapy, O
and O
intravenous O
administration O
of O
HSP B-GENE-N
targeted O
HPMA B-CHEMICAL

copolymer-docetaxel B-CHEMICAL
at O
10mg/kg O
resulted O
in O
maintained O
tumor O
regression O
for O
a O
period O
of O
30days. O
These O
results O
demonstrate O
the O
potential O
for O
tumor O
hyperthermia O
to O
increase O
the O
delivery O
of O
HSP B-GENE-N
targeted O
macromolecular O
chemotherapeutics. O
Presynaptic O
CaMKII B-GENE-Y
modulates O
dopamine B-GENE-Y
D3 I-GENE-Y
receptor I-GENE-Y
activation O
in O
striatonigral O
terminals O
of O
the O
rat O
brain O
in O
a O
Ca(2+) B-CHEMICAL
dependent O
manner. O
CaMKII B-GENE-Y
is O
expressed O
at O
high O
density O
in O
the O
nucleus O
accumbens O
where O
it O
binds O
to O

postsynaptic O
D3 B-GENE-Y
receptors I-GENE-Y
inhibiting O
their O
effects. O
In O
striatonigral O
projections, O
activation O
of O
presynaptic O
D3 B-GENE-Y
receptors I-GENE-Y
potentiates O
D1 B-GENE-Y
receptor-induced I-GENE-Y
stimulation O
of O
cAMP O
production O
and O
GABA O
release. O
In O
this O
study O
we O
examined O
whether O
the O
presynaptic O
effects O
of O
D3 B-GENE-Y
receptor I-GENE-Y
stimulation O
in O
the O
substantia O
nigra O
reticulata O
(SNr) O
are O
modulated O
by O
Ca(2+) B-CHEMICAL
activation O
of O
CaMKII. B-GENE-Y
In O
SNr O
synaptosomes O
two O
procedures O
that O
increase O
cytoplasmic O
Ca(2+), B-CHEMICAL

ionomycin B-CHEMICAL
and O
K(+)-depolarization, B-CHEMICAL
blocked O
the O
additional O
stimulation O
of O
cAMP B-CHEMICAL
accumulation O
produced O
by O
coactivating O
D3 B-GENE-N
and I-GENE-N
D1 I-GENE-N
dopamine I-GENE-N
receptors. I-GENE-N
The O
selective O
CaMKII B-GENE-Y
inhibitor O
KN-62 B-CHEMICAL
reversed O
the O
blockade O
produced O
by O
ionomycin B-CHEMICAL
and O
K(+)-depolarization. B-CHEMICAL
Incubation O
in O
either O
Ca(2) B-CHEMICAL
-free O
solutions O
or O
with O
the O
selective O
Ca(2+) B-CHEMICAL
blocker O
nifedipine, B-CHEMICAL
also O
reversed O
the O
blocking O
effects O
of O
K(+)-depolarization. B-CHEMICAL
Immunoblot O
studies O
showed O
that O

K(+)-depolarization B-CHEMICAL
increased O
CaMKII B-GENE-Y
phosphorylation O
in O
a O
KN-62 B-CHEMICAL
sensitive O
manner O
and O
promoted O
CaMKII B-GENE-Y
binding O
to O
D3 B-GENE-Y
receptors. I-GENE-Y
In O
K(+)-depolarized B-CHEMICAL
tissues, O
D3 B-GENE-Y
receptors I-GENE-Y
potentiated O
D1 B-GENE-N
receptor-induced I-GENE-N
stimulation O
of O
[(3)H]GABA B-CHEMICAL
release O
only O
when O
CaMKII B-GENE-Y
was O
blocked O
with O
KN-62. B-CHEMICAL
In O
the O
presence O
of O
this O
inhibitor, O
the O
selective O
D3 B-GENE-Y
agonist O
PD B-CHEMICAL
128,907 I-CHEMICAL
reduced O
the O
ED50 O
for O
the O
D1 B-GENE-Y
agonist O
SKF B-CHEMICAL
38393 I-CHEMICAL

from O
56 O
to O
4 O
nM. O
KN-62 B-CHEMICAL
also O
enhanced O
the O
effects O
of O
dopamine B-CHEMICAL
on O
depolarization O
induced O
[(3)H]GABA B-CHEMICAL
release. O
KN-62 B-CHEMICAL
changed O
ED50 O
for O
dopamine B-CHEMICAL
from O
584 O
to O
56 O
nM. O
KN-62 B-CHEMICAL
did O
not O
affect O
D1 B-GENE-N
and I-GENE-N
D4 I-GENE-N
receptor I-GENE-N
responses. O
These O
experiments O
show O
that O
in O
striatonigral O
projections, O
CaMKII B-GENE-Y
inhibits O
the O
action O
of O
D3 B-GENE-Y
receptors I-GENE-Y
in O
a O
Ca(2+) B-CHEMICAL
dependent O
manner O
blocking O
their O
modulatory O
effects O
on O
GABA B-CHEMICAL
release. O
These O
findings O
suggest O
a O
mechanism O
through O
which O
the O

frequency O
of O
action O
potential O
discharge O
in O
presynaptic O
terminals O
regulates O
dopamine B-CHEMICAL
effects. O
Ellagic B-CHEMICAL
acid I-CHEMICAL
attenuates O
bleomycin B-CHEMICAL
and O
cyclophosphamide-induced B-CHEMICAL
pulmonary O
toxicity O
in O
Wistar O
rats. O
Use O
of O
bleomycin B-CHEMICAL
(BLM) B-CHEMICAL
and O
cyclophosphamide B-CHEMICAL
(CP) O
as O
chemotherapeutic O
drugs O
is O
associated O
with O
side O
effects O
including O
toxicity O
to O
respiratory O
system. O
Their O
co-administration O
may O
enhance O
lung O
toxicity O
which O
may O
subsequently O
progress O
to O
the O
lung O
fibrosis. O
Natural O
compounds O
have O
shown O
mitigating O
effects O
against O
toxicity O
of O
anticancer O
drugs. O

Ellagic B-CHEMICAL
acid I-CHEMICAL
(EA), O
a O
polyphenolic O
compound O
present O
in O
many O
fruits O
and O
nuts O
in O
addition O
to O
walnut O
has O
shown O
promising O
protective O
effect O
against O
toxicity O
of O
drugs O
and O
chemicals. O
We O
studied O
the O
ameliorative O
effect O
of O
EA O
on O
lung O
toxicity O
in O
rats O
exposed O
to O
CP O
(150mg/kgb.w., O
i.p.) O
and O
BLM B-CHEMICAL
(10U/kgb.w., O
i.t.). O
EA O
(15mg/kgb.w., O
p.o.14days) O
treatment O
modulated O
enhanced O
hydroxyproline B-CHEMICAL
level, O

lipid O
peroxidation, O
myeloperoxidase B-GENE-Y
activity, O
nitric B-CHEMICAL
oxide I-CHEMICAL
production O
and O
protein O
carbonyl B-CHEMICAL
formation O
in O
lungs O
of O
rats O
exposed O
to O
toxic O
anticancer O
drugs. O
There O
was O
a O
marked O
decrease O
in O
GSH B-CHEMICAL
content O
and O
activities O
of O
antioxidant O
enzymes O
as O
a O
result O
of O
BLM B-CHEMICAL
and O
CP O
treatment. O
Bronchoalveolar O
lavage O
fluid O
showed O
increased O
level O
of O
cytotoxicity O
markers O
in O
drug O
treated O
animals. O
Treatment O
with O
EA O
attenuated O
these O
changes. O
Histopathological O
findings O
also O
showed O
protective O
effects O
of O
EA. O
In O
conclusion, O
EA O
emerged O
as O
a O
natural O
protectant O
with O
an O
ability O
to O
protect O
lungs O
from O

onslaught O
of O
pulmonary O
toxicity O
of O
anticancer O
drugs. O
Effects O
of O
High O
Iron B-CHEMICAL
and O
Glucose B-CHEMICAL
Concentrations O
over O
the O
Relative O
Expression O
of O
Bcl2, B-GENE-Y
Bax, B-GENE-Y
and O
Mfn2 B-GENE-Y
in O
MIN6 O
Cells. O
Type O
2 O
diabetes O
is O
characterized O
by O
hyperglycemia O
and O
oxidative O
stress. O
Hyperglycemia O
is O
linked O
to O
mitochondrial O
dysfunction O
and O
reduced O
-cell O
mass O
due O
to O
the O
reduced O
expression O
of O
genes O
such O
as O
Mfn2 B-GENE-Y
as O
well O
as O
the O
participation O
of O
the O
Bcl2 B-GENE-Y
gene O
family, O
responsible O
for O
increased O
apoptosis. O
The O
purpose O
of O
this O
study O

was O
to O
describe O
the O
effect O
of O
different O
iron B-CHEMICAL
and/or O
glucose B-CHEMICAL
concentrations O
over O
Mfn2, B-GENE-Y
Bax, B-GENE-Y
and O
Bcl2 B-GENE-Y
expressions O
in O
a O
-pancreatic O
cell O
line O
(MIN6 O
cells). O
MIN6 O
cells O
were O
pre-incubated O
with O
different O
iron B-CHEMICAL
and/or O
glucose B-CHEMICAL
concentrations, O
and O
the O
relative O
mRNA O
abundance O
of O
the O
Bcl2/Bax B-GENE-Y
ratio O
and O
of O
Mfn2 B-GENE-Y
genes O
was O
measured O
by O
qRT-PCR. O
Heme B-GENE-N
oxygenase I-GENE-N
(HO) B-GENE-N
activity, O
iron B-CHEMICAL
uptake, O
superoxide B-CHEMICAL
dismutase I-GENE-N
activity, O
and O
glutathione B-CHEMICAL
content O
were O
also O

determined. O
The O
Bcl2/Bax B-GENE-Y
ratio O
increased O
and O
Mfn2 B-GENE-Y
expression O
decreased O
in O
MIN6 O
cells O
after O
glucose B-CHEMICAL
stimulation. O
These O
effects O
were O
higher O
when O
glucose B-CHEMICAL
and O
iron B-CHEMICAL
were O
incubated O
together. O
Additionally, O
treatment O
with O
glucose/iron B-CHEMICAL
showed O
a O
higher O
HO B-GENE-N
activity. O
Our O
study O
revealed O
that O
high O
glucose/Fe B-CHEMICAL
concentrations O
in O
MIN6 O
cells O
induced O
an O
increase O
of O
the O
Bcl2/Bax B-GENE-Y
ratio, O
an O
indicator O
of O
increased O
cell O
apoptosis. O
Genetic O
Insights O
into O
Pyralomicin B-CHEMICAL
Biosynthesis O
in O
Nonomuraea O
spiralis O
IMC O
A-0156. O
The O

biosynthetic O
gene O
cluster O
for O
the O
pyralomicin B-CHEMICAL
antibiotics O
has O
been O
cloned O
and O
sequenced O
from O
Nonomuraea O
spiralis O
IMC O
A-0156. O
The O
41 O
kb O
gene O
cluster O
contains O
27 O
ORFs O
predicted O
to O
encode O
all O
of O
the O
functions O
for O
pyralomicin B-CHEMICAL
biosynthesis. O
This O
includes O
nonribosomal B-GENE-N
peptide I-GENE-N
synthetases I-GENE-N
(NRPS) B-GENE-N
and O
polyketide B-GENE-N
synthases I-GENE-N
(PKS) B-GENE-N
required O
for O
the O
formation O
of O
the O
benzopyranopyrrole B-CHEMICAL
core O
unit, O
as O
well O
as O
a O
suite O
of O
tailoring O
enzymes O

(e.g., O
four O
halogenases, B-GENE-N
an O
O-methyltransferase, B-CHEMICAL
and O
an O
N-glycosyltransferase) B-CHEMICAL
necessary O
for O
further O
modifications O
of O
the O
core O
structure. O
The O
N-glycosyltransferase B-CHEMICAL
is O
predicted O
to O
transfer O
either O
glucose B-CHEMICAL
or O
a O
pseudosugar O
(cyclitol) B-CHEMICAL
to O
the O
aglycone. O
A O
gene O
cassette O
encoding O
C7-cyclitol B-CHEMICAL
biosynthetic O
enzymes O
was O
identified O
upstream O
of O
the O
benzopyranopyrrole-specific B-CHEMICAL
ORFs. O
Targeted O
disruption O
of O
the O
gene O
encoding O
the O

N-glycosyltransferase, B-GENE-N
prlH, B-GENE-Y
abolished O
pyralomicin B-CHEMICAL
production, O
and O
recombinant O
expression O
of O
PrlA B-GENE-Y
confirms O
the O
activity O
of O
this O
enzyme O
as O
a O
sugar B-GENE-N
phosphate I-GENE-N
cyclase I-GENE-N
involved O
in O
the O
formation O
of O
the O
C7-cyclitol B-CHEMICAL
moiety. O
Synaptotagmin B-GENE-Y
1 I-GENE-Y
is O
required O
for O
vesicular O
Ca(2+) B-CHEMICAL
/H(+) B-CHEMICAL
-antiport O
activity. O
A O
low-affinity O
Ca(2+) B-CHEMICAL
/H(+) B-CHEMICAL
-antiport O
was O
described O
in O
the O
membrane O
of O
mammalian O
brain O
synaptic O

vesicles. O
Electrophysiological O
studies O
showed O
that O
this O
antiport O
contributes O
to O
the O
extreme O
brevity O
of O
excitation-release O
coupling O
in O
rapid O
synapses. O
Synaptotagmin-1, B-GENE-Y
a O
vesicular O
protein O
interacting O
with O
membranes O
upon O
low-affinity O
Ca(2+) B-CHEMICAL
-binding, O
plays O
a O
major O
role O
in O
excitation-release O
coupling, O
by O
synchronizing O
calcium B-CHEMICAL
entry O
with O
fast O
neurotransmitter O
release. O
Here, O
we O
report O
that O
synaptotagmin-1 B-GENE-Y
is O
necessary O
for O
expression O
of O
the O
vesicular O
Ca(2+) B-CHEMICAL

/H(+) B-CHEMICAL
-antiport. O
We O
measured O
Ca(2+) B-CHEMICAL
/H(+) B-CHEMICAL
-antiport O
activity O
in O
vesicles O
and O
granules O
of O
pheochromocytoma O
PC12 O
cells O
by O
three O
methods: O
(1) O
Ca(2+) B-CHEMICAL
-induced O
dissipation O
of O
the O
vesicular O
H(+) B-CHEMICAL
-gradient; O
(2) O
bafilomycin-sensitive B-CHEMICAL
calcium B-CHEMICAL
accumulation O
and O
(3) O
pH-jump-induced O
calcium B-CHEMICAL
accumulation. O
The O
results O
were O
congruent O
and O
highly O
significant: O
Ca(2+) B-CHEMICAL
/H(+) B-CHEMICAL
-antiport O
activity O
is O

detectable O
only O
in O
acidic O
organelles O
expressing O
functional O
synaptotagmin-1. B-GENE-Y
In O
contrast, O
synaptotagmin-1-deficient B-GENE-Y
cells O
- O
and O
cells O
where O
transgenically O
encoded O
synaptotagmin-1 B-GENE-Y
was O
acutely O
photo-inactivated O
- O
were O
devoid O
of O
any O
Ca(2+) B-CHEMICAL
/H(+) B-CHEMICAL
-antiport O
activity. O
Therefore, O
in O
addition O
to O
its O
previously O
described O
functions, O
synaptotagmin-1 B-GENE-Y
is O
involved O
in O
a O
rapid O
vesicular O
Ca(2+) B-CHEMICAL
sequestration O
through O
a O
Ca(2+) B-CHEMICAL
/H(+) B-CHEMICAL

antiport. O
This O
article O
is O
protected O
by O
copyright. O
All O
rights O
reserved. O
Estradiol B-CHEMICAL
replacement O
enhances O
cocaine-stimulated B-CHEMICAL
locomotion O
in O
female O
C57BL/6 O
mice O
through O
estrogen B-GENE-Y
receptor I-GENE-Y
alpha. I-GENE-Y
Psychostimulant O
effects O
are O
enhanced O
by O
ovarian O
hormones O
in O
women O
and O
female O
rodents. O
Estradiol B-CHEMICAL
increases O
behavioral O
responses O
to O
psychostimulants O
in O
women O
and O
female O
rats, O
although O
the O
underlying O
mechanism O
is O
unknown. O
This O
study O
utilized O
mice O
to O
investigate O
the O
time O
frame O
and O
receptor O
mediation O
of O
estradiol's B-CHEMICAL
enhancement O
of O
cocaine-induced B-CHEMICAL
behavior O
as O
mice O
enable O
parallel O
use O
of O
genetic, O

surgical O
and O
pharmacological O
methods. O
The O
spontaneous O
behavior O
of O
Sham O
and O
Ovariectomized O
(Ovx) O
female O
wildtype O
(WT) O
mice O
was O
determined O
during O
habituation O
to O
a O
novel O
environment O
and O
after O
cocaine B-CHEMICAL
administration. O
Ovx O
mice O
were O
replaced O
with O
vehicle O
(sesame O
oil) O
or O
17-estradiol B-CHEMICAL
(E2) O
for O
2 O
days O
or O
30 O
min O
prior O
to O
a O
cocaine B-CHEMICAL
challenge O
to O
investigate O
the O
time O
course O
of O
E2's O
effects. O
To O
examine O
receptor O
mediation O
of O
estradiol B-CHEMICAL
effects, O
Ovx O
mice O
replaced O
for O
2 O
days O
with O
either O
the O
ER-selective B-GENE-Y
agonist O
PPT B-CHEMICAL
or O

the O
ER-selective B-GENE-Y
agonist O
DPN B-CHEMICAL
were O
compared O
to O
Sham O
mice, O
and O
mice O
lacking O
either O
ER B-GENE-Y
(ERKO) B-GENE-Y
or O
ER B-GENE-Y
(ERKO) B-GENE-Y
were O
compared O
to O
WT O
littermates. O
Ovx O
mice O
exhibited O
fewer O
ambulations O
during O
habituation O
than O
Sham O
females. O
Cocaine-induced B-CHEMICAL
increases O
in O
behavioral O
ratings O
were O
greater O
in O
Sham O
than O
in O
Ovx O
mice. O
Two O
days O
but O
not O
30 O
min O
of O
E2 O
replacement O
in O
Ovx O
mice O
increased O
cocaine B-CHEMICAL
responses O
to O
Sham O
levels. O
PPT B-CHEMICAL
replacement O
also O
increased O
the O
cocaine B-CHEMICAL
response O
relative O
to O
vehicle- O
or O
DPN- B-CHEMICAL
treated O
Ovx O

mice. O
ERKO B-GENE-Y
mice O
displayed O
modestly O
attenuated O
behavioral O
responses O
to O
novelty O
and O
cocaine B-CHEMICAL
compared O
to O
WT O
littermates, O
but O
no O
behavioral O
differences O
were O
found O
between O
ERKO B-GENE-Y
and O
WT O
mice. O
These O
results O
suggest O
that O
E2 O
enhances O
cocaine-stimulated B-CHEMICAL
locomotion O
in O
mice O
predominantly O
through O
ER. B-GENE-Y
Dynamics O
and O
structural O
changes O
of O
small O
water O
clusters O
on O
ionization. O
Despite O
utmost O
importance O
in O
understanding O
water O
ionization O
process, O
reliable O
theoretical O
results O
of O
structural O
changes O
and O
molecular O
dynamics O
(MD) O
of O
water O
clusters O
on O
ionization O
have O
hardly O
been O
reported O
yet. O
Here, O
we O
investigate O
the O
water O
cations O
[(H2 B-CHEMICAL

O)n I-CHEMICAL
= O
2-6 O
(+) O
] O
with O
density O
functional O
theory O
(DFT), O
Mller-Plesset O
second-order O
perturbation O
theory O
(MP2), O
and O
coupled O
cluster O
theory O
with O
single, O
double, O
and O
perturbative O
triple O
excitations O
[CCSD(T)]. O
The O
complete O
basis O
set O
limits O
of O
interaction O
energies O
at O
the O
CCSD(T) O
level O
are O
reported, O
and O
the O
geometrical O
structures, O
electronic O
properties, O
and O
infrared O
spectra O
are O
investigated. O
The O
characteristics O
of O
structures O
and O
spectra O
of O
the O
water O
cluster O
cations O
reflect O
the O
formation O
of O
the O
hydronium B-CHEMICAL
cation O

moiety O
(H3 B-CHEMICAL
O(+) I-CHEMICAL
) O
and O
the O
hydroxyl B-CHEMICAL
radical. O
Although O
most O
density O
functionals O
fail O
to O
predict O
reasonable O
energetics O
of O
the O
water O
cations, O
some O
functionals O
are O
found O
to O
be O
reliable, O
in O
reasonable O
agreement O
with O
high-level O
ab O
initio O
results. O
To O
understand O
the O
ionization O
process O
of O
water O
clusters, O
DFT- O
and O
MP2-based O
Born-Oppenheimer O
MD O
(BOMD) O
simulations O
are O
performed O
on O
ionization. O
On O
ionization, O
the O
water O
clusters O
tend O
to O
have O
an O
Eigen-like O
form O
with O
the O
hydronium B-CHEMICAL
cation O
instead O
of O
a O

Zundel-like O
form, O
based O
on O
reliable O
BOMD O
simulations. O
For O
the O
vertically O
ionized O
water O
hexamer, O
the O
relatively O
stable O
(H2 B-CHEMICAL
O)5 I-CHEMICAL
(+) I-CHEMICAL
(5sL4A) O
cluster O
tends O
to O
form O
with O
a O
detached O
water O
molecule O
(H2 B-CHEMICAL
O). I-CHEMICAL
 O
2013 O
Wiley O
Periodicals, O
Inc. O
The O
Intermediate-conductance B-GENE-Y
Calcium-activated I-GENE-Y
Potassium I-GENE-Y
Channel I-GENE-Y
KCa3.1 I-GENE-Y
Regulates O
Vascular O
Smooth O
Muscle O
Cell O
Proliferation O
via O
Controlling O
Calcium-dependent B-CHEMICAL
Signaling. O
The O
intermediate-conductance B-GENE-Y
calcium-activated B-CHEMICAL
potassium B-CHEMICAL
channel I-GENE-Y

KCa3.1 I-GENE-Y
contributes O
to O
a O
variety O
of O
cell O
activation O
processes O
in O
pathologies O
such O
as O
inflammation, O
carcinogenesis O
and O
vascular O
remodeling. O
We O
examined O
the O
electrophysiological O
and O
transcriptional O
mechanisms O
by O
which O
KCa3.1 B-GENE-Y
regulates O
vascular O
smooth O
muscle O
cell O
(VSMC) O
proliferation. O
Platelet-derived B-GENE-Y
growth I-GENE-Y
factor-BB I-GENE-Y
(PDGF)-induced B-GENE-N
proliferation O
of O
human O
coronary O
artery O
VSMCs O
was O
attenuated O
by O
lowering O
intracellular O
Ca(2+) B-CHEMICAL
concentration O
([Ca(2+)]i) B-CHEMICAL
and O
was O
enhanced O
by O
elevating O

[Ca(2+)]i. B-CHEMICAL
KCa3.1 B-GENE-Y
blockade O
or O
knockdown O
inhibited O
proliferation O
by O
suppressing O
the O
rise O
in O
[Ca(2+)]i B-CHEMICAL
and O
attenuating O
the O
expression O
of O
phosphorylated B-GENE-N
cAMP B-CHEMICAL
response I-GENE-N
element I-GENE-N
binding I-GENE-N
protein I-GENE-N
(CREB), B-GENE-N
c-fos B-GENE-Y
and O
neuron-derived B-GENE-Y
orphan I-GENE-Y
receptor-1 I-GENE-Y
(NOR-1). B-GENE-Y
This O
anti-proliferative O
effect O
was O
abolished O
by O
elevating O
[Ca(2+)]i. B-CHEMICAL
KCa3.1 B-GENE-Y
overexpression O
induced O
VSMC O
proliferation, O
and O
potentiated O

PDGF-induced B-GENE-N
proliferation, O
by O
inducing O
CREB B-GENE-N
phosphorylation, O
c-fos B-GENE-Y
and O
NOR-1. B-GENE-Y
Pharmacological O
stimulation O
of O
KCa3.1 B-GENE-Y
unexpectedly O
suppressed O
proliferation O
by O
inhibiting O
the O
rise O
in O
[Ca(2+)]i B-CHEMICAL
and O
abolishing O
the O
expression O
and O
activity O
of O
KCa3.1 B-GENE-Y
and O
PDGF B-GENE-Y
-receptors. I-GENE-Y
The O
stimulation O
also O
attenuated O
the O
levels O
of O
phosphorylated B-GENE-N
CREB, I-GENE-N
c-fos B-GENE-Y
and O
cyclins B-GENE-N
expression. O
After O
KCa3.1 B-GENE-Y
blockade, O
the O
characteristic O
round O
shape O
of O
VSMCs O
expressing O

high O
l-caldesmon B-GENE-Y
and O
low O
calponin-1 B-GENE-Y
(dedifferentiation O
state) O
was O
maintained, O
whereas O
KCa3.1 B-GENE-Y
stimulation O
induced O
a O
spindle-shape O
cellular O
appearance, O
with O
low O
l-caldesmon B-GENE-Y
and O
high O
calponin-1. B-GENE-Y
In O
conclusion, O
KCa3.1 B-GENE-Y
plays O
an O
important O
role O
in O
VSMC O
proliferation O
via O
controlling O
Ca(2+)-dependent B-CHEMICAL
signaling O
pathways O
and O
its O
modulation O
may O
therefore O
constitute O
a O
new O
therapeutic O
target O
for O
cell O
proliferative O
diseases O
such O
as O
atherosclerosis. O
Reactive O
Metabolite O
Trapping O
Studies O
on O

Imidazo- B-CHEMICAL
and I-CHEMICAL
2-Methylimidazo[2,1-b]thiazole-based I-CHEMICAL
Inverse O
Agonists O
of O
the O
Ghrelin B-GENE-Y
Receptor. I-GENE-Y
The O
current O
study O
examined O
the O
bioactivation O
potential O
of O
ghrelin B-GENE-Y
receptor I-GENE-Y
inverse O
agonists, O

1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone B-CHEMICAL
(1) O
and O

1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone B-CHEMICAL
(2), O
containing O
a O
fused O
imidazo[2,1-b]thiazole B-CHEMICAL
motif O
in O
the O
core O
structure. O
Both O
compounds O
underwent O
oxidative O

metabolism O
in O
NADPH- B-CHEMICAL
and O
glutathione-supplemented B-CHEMICAL
human O
liver O
microsomes O
to O
yield O
glutathione B-CHEMICAL
conjugates, O
which O
was O
consistent O
with O
their O
bioactivation O
to O
reactive O
species. O
Mass O
spectral O
fragmentation O
and O
NMR O
analysis O
indicated O
that O
the O
site O
of O
attachment O
of O
the O
glutathionyl B-CHEMICAL
moiety O
in O
the O
thiol B-CHEMICAL
conjugates O
was O
on O
the O
thiazole B-CHEMICAL
ring O
within O
the O
bicycle. O
Two O
glutathione B-CHEMICAL
conjugates O
were O
discerned O
with O
the O
imidazo[2,1-b]thiazole B-CHEMICAL
derivative O
1. O
One O
adduct O
was O
derived O
from O
the O

Michael O
addition O
of O
glutathione B-CHEMICAL
to O
a O
putative O
S-oxide B-CHEMICAL
metabolite O
of O
1, O
whereas, O
the O
second O
adduct O
was O
formed O
via O
the O
reaction O
of O
a O
second O
glutathione B-CHEMICAL
molecule O
with O
the O
initial O
glutathione-S-oxide B-CHEMICAL
adduct. O
In O
the O
case O
of O
the O
2-methylimidazo[2,1-b]thiazole B-CHEMICAL
analog O
2, O
glutathione B-CHEMICAL
conjugation O
occurred O
via O
an O
oxidative O
desulfation O
mechanism, O
possibly O
involving O
thiazole B-CHEMICAL
ring O
epoxidation O
as O
the O
rate-limiting O
step. O
Additional O
insights O
into O
the O
mechanism O
were O
obtained O
via O

18O B-CHEMICAL
exchange O
and O
trapping O
studies O
with O
potassium B-CHEMICAL
cyanide. I-CHEMICAL
The O
mechanistic O
insights O
into O
the O
bioactivation O
pathways O
of O
1 O
and O
2 O
allowed O
the O
deployment O
of O
a O
rational O
chemical O
intervention O
strategy O
that O
involved O
replacement O
of O
the O
thiazole B-CHEMICAL
ring O
with O
a O
1,2,4-thiadiazole B-CHEMICAL
group O
to O
yield O

-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)ethanone B-CHEMICAL
(3). O
These O
structural O
changes O
not O
only O
abrogated O
the O
bioactivation O
liability O
but O
also O
retained O
the O
attractive O
pharmacological O
attributes O

of O
the O
prototype O
agents. O
Adenovirus-delivered O
angiopoietin-1 B-GENE-Y
treatment O
for O
phosgene-induced B-CHEMICAL
acute O
lung O
injury. O
Abstract O
Context: O
Exposure O
to O
phosgene B-CHEMICAL
can O
result O
in O
an O
acute O
lung O
injury, O
leading O
to O
pulmonary O
edema O
and O
even O
death. O
Angiopoietin-1 B-GENE-Y
(Ang1) B-GENE-Y
is O
a O
critical O
factor O
for O
vascular O
stabilization O
due O
to O
its O
ability O
to O
reduce O
endothelial O
permeability O
and O
inflammation. O
Objective: O
In O
this O
study, O
the O
histopathological O
changes O
of O
the O
lungs O
after O
exposure O
to O
phosgene B-CHEMICAL
and O
the O
effect O
of O
Ang1 B-GENE-Y
treatment O
were O
examined. O

Materials O
and O
methods: O
Rats O
were O
exposed O
to O
phosgene B-CHEMICAL
gas O
at O
8.33 O
g/m(3) O
for O
5 O
min. O
Ang1 O
overexpressing O
rats O
were O
established O
by O
an O
intravenous O
injection O
of O
adenovirus-Ang1 B-GENE-Y
(Ad/Ang1). B-GENE-Y
The O
histological O
changes O
of O
the O
lung O
were O
examined O
by O
Haematoxylin-Eosin B-CHEMICAL
(H&E) O
staining O
and O
fluorescence O
microscopy. O
The O
inferior O
lobe O
was O
used O
for O
the O
determination O
of O
the O
ratio O
of O
wet O
weight O
to O
dry O
weight O
of O
the O
lung. O
The O
concentration O
of O
cytokines B-GENE-N
in O
the O
serum O
and O

bronchoalveolar O
lavage O
fluid O
was O
determined O
by O
enzyme-linked O
immunosorbent O
assay. O
Results: O
The O
pathological O
analysis O
showed O
signs O
of O
inflammation O
and O
edema, O
evident O
from O
a O
significant O
increase O
in O
the O
number O
of O
leukocytes O
in O
bronchoalveolar O
lavage O
fluid O
and O
the O
ratio O
of O
wet O
to O
dry O
weight O
of O
the O
lungs. O
The O
lung O
injury O
induced O
by O
phosgene B-CHEMICAL
was O
markedly O
reduced O
after O
the O
injection O
of O
Ad/Ang1. B-GENE-Y
The O
increase O
of O
IL-1 B-GENE-Y
and O
IL-17 B-GENE-Y
and O
decrease O
of O
vascular B-GENE-Y
endothelial I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
in O
the O
serum O
and O
bronchoalveolar O
lavage O
fluid O

of O
phosgene-exposed B-CHEMICAL
animals O
were O
abolished O
by O
the O
administration O
of O
Ad/Ang1. B-GENE-Y
Discussion O
and O
conclusions: O
Ang1 B-GENE-Y
has O
the O
beneficial O
effects O
on O
phosgene-induced B-CHEMICAL
lung O
injury. O
The O
adenovirus-delivered O
Ang1 B-GENE-Y
may O
have O
the O
potential O
as O
a O
novel O
approach O
for O
the O
treatment O
of O
the O
acute O
lung O
injury O
caused O
by O
phosgene B-CHEMICAL
gas O
inhalation O
in O
humans. O
Probing O
the O
Role O
of O
the O
Vancomycin B-CHEMICAL
E-Ring O
Aryl B-CHEMICAL
Chloride: I-CHEMICAL
Selective O
Divergent O
Synthesis O
and O
Evaluation O
of O
Alternatively O
Substituted O
E-Ring O
Analogues. O
The O
selective O
functionalization O
of O
a O
vancomycin B-CHEMICAL

aglycon O
derivative O
through O
direct O
conversion O
of O
the O
E-ring O
aryl B-CHEMICAL
chloride I-CHEMICAL
to O
a O
reactive O
boronic B-CHEMICAL
acid, I-CHEMICAL
and O
its O
use O
in O
the O
synthesis O
of O
a O
systematic O
series O
of O
vancomycin B-CHEMICAL
E-ring O
analogues O
are O
described. O
The O
series O
of O
analogues O
was O
used O
to O
examine O
the O
impact O
of O
the O
E-ring O
chloride O
in O
binding O
D-Ala-D-Ala B-CHEMICAL
and O
on O
antimicrobial O
activity. O
In O
contrast O
to O
the O
reduced O
activity O
of O
the O
unsubstituted O
E-ring O
derivatives, O
hydrophobic O
and O
relatively O
non-polar O
substituents O
approach O
or O
match O
the O
chloro B-CHEMICAL
substituted I-CHEMICAL
vancomycin I-CHEMICAL

and O
was O
insensitive O
to O
the O
electronic O
character O
of O
the O
substituent O
(e.g. O
Cl B-CHEMICAL
vs O
CN B-CHEMICAL
or O
OMe), B-CHEMICAL
whereas O
highly O
polar O
substituents O
fail O
to O
provide O
the O
enhancements. O
Moreover, O
the O
active O
permethylated O
vancomycin B-CHEMICAL
aglycon O
derivatives O
examined O
exhibit O
VanB B-GENE-N
VRE O
antimicrobial O
activity O
at O
levels O
that O
approach O
(typically O
within O
2-fold) O
their O
activity O
against O
sensitive O
bacteria. O
The O
robust O
borylation O
reaction O
also O
enabled O
the O
selective O
functionalization O
of O
a O
minimally O
protected O
vancomycin B-CHEMICAL
aglycon O
(N-Boc B-CHEMICAL
vancomycin B-CHEMICAL

aglycon), O
and O
provides O
a O
direct O
method O
for O
the O
preparation O
of O
previously O
inaccessible O
analogues. O
Exposure O
to O
DEHP B-CHEMICAL
decreased O
four O
fatty B-CHEMICAL
acid I-CHEMICAL
levels O
in O
plasma O
of O
prepartum O
mice. O
Maternal O
exposure O
to O
di(2-ethylhexyl) B-CHEMICAL
phthalate I-CHEMICAL
(DEHP) B-CHEMICAL
decreased O
the O
plasma O
triglyceride B-CHEMICAL
in O
prepartum O
mice. O
To O
identify O
the O
fatty B-CHEMICAL
acid I-CHEMICAL
(FA) O
species O
involved O
and O
to O
understand O
the O
underlying O
mechanisms, O
pregnant O
Sv/129 O
wild-type O
(mPPAR), B-GENE-Y
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
-null I-GENE-Y

(Ppar-null) B-GENE-Y
and O
humanized B-GENE-Y
PPAR I-GENE-Y
(hPPAR) B-GENE-Y
mice O
were O
treated O
with O
diets O
containing O
0%, O
0.01%, O
0.05% O
or O
0.1% O
DEHP. B-CHEMICAL
Dams O
were O
dissected O
on O
gestational O
day O
18 O
together O
with O
fetuses, O
and O
on O
postnatal O
day O
2 O
together O
with O
newborns. O
n-3/n-6 B-CHEMICAL
polyunsaturated, I-CHEMICAL
saturated, I-CHEMICAL
and I-CHEMICAL
monounsaturated I-CHEMICAL
FAs I-CHEMICAL
in O
maternal O
plasma O
and O
in O
liver O
of O
wild-type O
offspring, O
and O
representative O
enzymes O
for O
FA O
desaturation O
and O
elongation O
in O

maternal O
liver, O
were O
measured. O
The O
plasma O
levels O
of O
linoleic B-CHEMICAL
acid, I-CHEMICAL
-linolenic B-CHEMICAL
acid, I-CHEMICAL
palmitic B-CHEMICAL
acid I-CHEMICAL
and O
oleic B-CHEMICAL
acid I-CHEMICAL
were O
higher O
in O
the O
pregnant O
control O
mPPARa B-GENE-Y
mice O
than O
in O
Ppara-null B-GENE-Y
and O
hPPARa B-GENE-Y
mice. O
DEHP B-CHEMICAL
exposure O
significantly O
decreased O
the O
levels O
of O
these O
four O
FAs O
only O
in O
pregnant O
mPPAR B-GENE-Y
mice. O
Plasma O
levels O
of O
many O
FAs O
were O
higher O
in O
pregnant O
mice O
than O
in O
postpartum O
ones O
in O
a O
genotype-independent O
manner, O
while O
it O
was O
lower O
in O
the O
livers O
of O
fetuses O
than O
pups. O
DEHP B-CHEMICAL
exposure O
slightly O

increased O
hepatic O
arachidonic B-CHEMICAL
acid, I-CHEMICAL
-linolenic B-CHEMICAL
acid, I-CHEMICAL
palmitoleic B-CHEMICAL
acid I-CHEMICAL
and O
oleic B-CHEMICAL
acid I-CHEMICAL
in O
fetuses, O
but O
not O
in O
pups. O
However, O
DEHP B-CHEMICAL
exposure O
did O
not O
clearly O
influence O
FA B-GENE-N
desaturase I-GENE-N
1 I-GENE-N
and I-GENE-N
2 I-GENE-N
nor O
elongase B-GENE-N
2 I-GENE-N
and I-GENE-N
5 I-GENE-N
expressions O
in O
the O
liver O
of O
all O
maternal O
mice. O
Taken O
together, O
the O
levels O
of O
plasma O
four O
FAs O
with O
shorter O
carbon B-CHEMICAL
chains O
were O
higher O
in O
pregnant O
mPPAR B-GENE-Y
mice O
than O
in O
other O
genotypes, O
and O
DEHP B-CHEMICAL
exposure O
decreased O
these O
specific O
FA O
concentrations O
only O
in O
mPPAR B-GENE-Y
mice, O
similarly O
to O

triglyceride B-CHEMICAL
levels. O
Soluble O
polysialylated B-GENE-Y
NCAM: I-GENE-Y
a O
novel O
player O
of O
the O
innate O
immune O
system O
in O
the O
lung. O
Posttranslational O
modification O
of O
the O
neural B-GENE-Y
cell I-GENE-Y
adhesion I-GENE-Y
molecule I-GENE-Y
(NCAM) B-GENE-Y
by O
polysialic B-CHEMICAL
acid I-CHEMICAL
(polySia) B-CHEMICAL
is O
well O
studied O
in O
the O
nervous O
system O
and O
described O
as O
a O
dynamic O
modulator O
of O
plastic O
processes O
like O
precursor O
cell O
migration, O
axon O
fasciculation, O
and O
synaptic O
plasticity. O
Here, O
we O
describe O
a O
novel O
function O
of O
polysialylated B-GENE-Y
NCAM I-GENE-Y
(polySia-NCAM) B-CHEMICAL
in O
innate O
immunity O

of O
the O
lung. O
In O
mature O
lung O
tissue O
of O
healthy O
donors, O
polySia B-CHEMICAL
was O
exclusively O
attached O
to O
the O
transmembrane O
isoform O
NCAM-140 B-GENE-Y
and O
located O
to O
intracellular O
compartments O
of O
epithelial O
cells. O
In O
patients O
with O
chronic O
obstructive O
pulmonary O
disease, O
however, O
increased O
polySia B-CHEMICAL
levels O
and O
processing O
of O
the O
NCAM B-GENE-Y
carrier O
were O
observed. O
Processing O
of O
polysialylated B-GENE-Y
NCAM I-GENE-Y
was O
reproduced O
in O
a O
mouse O
model O
by O
bleomycin B-CHEMICAL
administration O
leading O
to O
an O
activation O
of O
the O
inflammasome O
and O
secretion O
of O
interleukin B-GENE-Y
(IL)-1. I-GENE-Y
As O
shown O

in O
a O
cell O
culture O
model, O
polySia-NCAM-140 B-CHEMICAL
was O
kept O
in O
the O
late O
trans-Golgi O
apparatus O
of O
lung O
epithelial O
cells O
and O
stimulation O
by O
IL-1 B-GENE-Y
or O
lipopolysaccharide O
induced O
metalloprotease-mediated B-GENE-N
ectodomain B-GENE-N
shedding, O
resulting O
in O
the O
secretion O
of O
soluble O
polySia-NCAM. B-CHEMICAL
Interestingly, O
polySia B-CHEMICAL
chains O
of O
secreted O
NCAM B-GENE-Y
neutralized O
the O
cytotoxic O
activity O
of O
extracellular O
histones B-GENE-N
as O
well O
as O
DNA/histone-network-containing B-GENE-N
"neutrophil O
extracellular O
traps", O

which O
are O
formed O
during O
invasion O
of O
microorganisms. O
Thus, O
shedding O
of O
polySia-NCAM B-CHEMICAL
by O
lung O
epithelial O
cells O
may O
provide O
a O
host-protective O
mechanism O
to O
reduce O
tissue O
damage O
during O
inflammatory O
processes. O
Study O
of O
endothelial O
cell O
apoptosis O
using O
fluorescence O
resonance O
energy O
transfer O
(FRET) O
biosensor O
cell O
line O
with O
hemodynamic O
microfluidic O
chip O
system. O
To O
better O
understand O
how O
hyperglycemia O
induces O
endothelial O
cell O
dysfunction O
under O
the O
diabetic O
conditions, O
a O
hemodynamic O
microfluidic O
chip O
system O
was O
developed. O

The O
system O
combines O
a O
caspase-3-based B-GENE-Y
fluorescence O
resonance O
energy O
transfer O
(FRET) O
biosensor O
cell O
line O
which O
can O
detect O
endothelial O
cell O
apoptosis O
in O
real-time, O
post-treatment O
effect O
and O
with O
a O
limited O
cell O
sample, O
by O
using O
a O
microfluidic O
chip O
which O
can O
mimic O
the O
physiological O
pulsatile O
flow O
profile O
in O
the O
blood O
vessel. O
The O
caspase-3-based B-GENE-Y
FRET O
biosensor O
endothelial O
cell O
line O
(HUVEC-C3) O
can O
produce O
a O
FRET-based O
sensor O
protein O
capable O
of O
probing O

caspase-3 B-GENE-Y
activation. O
When O
the O
endothelial O
cells O
undergo O
apoptosis, O
the O
color O
of O
the O
sensor O
cells O
changes O
from O
green O
to O
blue, O
thus O
sensing O
apoptosis. O
A O
double-labeling O
fluorescent O
technique O
(yo B-CHEMICAL
pro-1 I-CHEMICAL
and O
propidium B-CHEMICAL
iodide) I-CHEMICAL
was O
used O
to O
validate O
the O
findings O
revealed O
by O
the O
FRET-based O
caspase B-GENE-N
sensor. O
The O
results O
show O
high O
rates O
of O
apoptosis O
and O
necrosis O
of O
endothelial O
cells O
when O
high O
glucose B-CHEMICAL
concentration O
was O
applied O
in O
our O
hemodynamic O
microfluidic O
chip O
combined O
with O
an O
exhaustive O
pulsatile O
flow O
profile. O

The O
two O
apoptosis O
detection O
techniques O
(fluorescent O
method O
and O
FRET O
biosensor) O
are O
comparable; O
but O
FRET O
biosensor O
offers O
more O
advantages O
such O
as O
real-time O
observation O
and O
a O
convenient O
operating O
process O
to O
generate O
more O
accurate O
and O
reliable O
data. O
Furthermore, O
the O
activation O
of O
the O
FRET O
biosensor O
also O
confirms O
the O
endothelial O
cell O
apoptosis O
induced O
by O
the O
abnormal O
pulsatile O
shear O
stress O
and O
high O
glucose B-CHEMICAL
concentration O
is O
through O
caspase-3 B-GENE-Y
pathway. O
A O
12% O
apoptotic O
rate O
(nearly O
a O
4-fold O
increase O
compared O
to O
the O
static O
condition) O
was O
observed O
when O
the O
endothelial O
cells O

were O
exposed O
to O
a O
high O
glucose B-CHEMICAL
concentration O
of O
20 O
mM O
under O
2 O
h O
exhaustive O
pulsatile O
shear O
stress O
of O
30 O
dyne O
cm(-2) O
and O
followed O
with O
another O
10 O
h O
normal O
pulsatile O
shear O
stress O
of O
15 O
dyne O
cm(-2). O
Therefore, O
the O
most O
important O
finding O
of O
this O
study O
is O
to O
develop O
a O
novel O
endothelial O
cell O
apoptosis O
detection O
method, O
which O
combines O
the O
microfluidic O
chip O
system O
and O
FRET O
biosensor. O
This O
finding O
may O
provide O
new O
insight O
into O
how O
glucose B-CHEMICAL
causes O
endothelial O
cell O
dysfunction, O
which O
is O
the O
major O
cause O
of O
diabetes-derived O

complications. O
High O
salt O
diets O
during O
pregnancy O
affected O
fetal O
and O
offspring O
renal O
renin-angiotensin B-GENE-Y
system. O
Intrauterine O
environments O
are O
linked O
to O
fetal O
renal O
development O
and O
postnatal O
health. O
Influence O
of O
salt O
diets O
during O
pregnancy O
on O
renal O
functions O
and O
renin-angiotensin B-GENE-Y
system O
(RAS) O
were O
determined O
in O
the O
ovine O
fetus O
and O
offspring. O
Pregnant O
ewes O
were O
fed O
high-salt O
diet O
(HSD) O
or O
normal-salt O
diet O
(NSD) O
for O
two O
months O
during O
middle-later O
gestation. O
Fetal O
renal O
functions, O
plasma O
hormones, O

mRNA O
and O
protein O
expressions O
of O
the O
key O
elements O
of O
renal O
RAS O
were O
measured O
in O
the O
fetus O
and O
offspring. O
Fetal O
renal O
excretion O
of O
sodium B-CHEMICAL
was O
increased O
while O
urine O
volume O
decreased O
in O
HSD O
group. O
Fetal O
blood O
urea B-CHEMICAL
nitrogen B-CHEMICAL
was O
increased, O
while O
kidney/body O
weight O
ratio O
decreased O
in O
HSD O
group. O
The O
altered O
ratio O
also O
was O
observed O
in O
the O
offspring O
at O
15-day-old O
and O
90-day-old. O
Maternal O
and O
fetal O
plasma O
antidiuretic B-GENE-Y
hormone I-GENE-Y
was O
elevated O
without O
change O
in O
plasma O
renin B-GENE-Y
activity O
and O
Ang B-GENE-Y
I I-GENE-Y
levels, O
while O
plasma O
Ang B-GENE-Y
II I-GENE-Y
was O
decreased. O
The O
key O
elements O
of O
local O
renal O

RAS, O
including O
angiotensinogen, B-GENE-Y
ACE, B-GENE-Y
ACE2, B-GENE-Y
AT1 B-GENE-Y
and O
AT2 B-GENE-Y
receptor I-GENE-Y
expression O
in O
both O
mRNA O
and O
protein, O
except O
renin, B-GENE-Y
were O
altered O
following O
maternal O
high O
salt O
intake. O
The O
results O
suggest O
that O
High O
intake O
of O
salt O
during O
pregnancy O
affected O
fetal O
renal O
development O
associated O
with O
an O
altered O
expression O
of O
the O
renal O
key O
elements O
of O
RAS, O
some O
alterations O
of O
fetal O
origins O
remained O
after O
birth O
as O
possible O
risks O
in O
developing O
renal O
or O
cardiovascular O
diseases. O
Synthesis O
of O
pyrazolo[1,5-a]pyrimidine B-CHEMICAL
linked O
aminobenzothiazole B-CHEMICAL
conjugates O

as O
potential O
anticancer O
agents. O
A O
series O
of O
pyrazolo[1,5-a]pyrimidine B-CHEMICAL
linked O
2-aminobenzothizole B-CHEMICAL
conjugates O
(6a-t) O
were O
synthesized O
and O
evaluated O
for O
their O
anticancer O
activity O
against O
five O
human O
cancer O
cell O
lines. O
Among O
them O
two O
compounds O
6p O
and O
6m O
showed O
significant O
anticancer O
activity O
with O
IC50 O
values O
ranging O
from O
2.01 O
to O
7.07 O
and O
1.94-3.46M, O
respectively. O
Moreover, O
cell O
cycle O
arrest O
in O
G2/M O
and O
reduction O
in O
Cdk1 B-GENE-Y
expression O
level O
were O
observed O
upon O

treatment O
of O
these O
compounds O
and O
they O
also O
induced O
caspase-3 B-GENE-Y
dependent O
apoptosis. O
This O
was O
further O
confirmed O
by O
staining O
as O
well O
as O
DNA O
fragmentation O
analysis. O
Evaluation O
of O
the O
positive O
effects O
on O
insulin-resistance B-GENE-Y
and O
-cell O
measurements O
of O
vildagliptin B-CHEMICAL
in O
addition O
to O
metformin B-CHEMICAL
in O
type O
2 O
diabetic O
patients. O
We O
evaluated O
the O
positive O
effects O
of O
vildagliptin B-CHEMICAL
in O
addition O
to O
metformin B-CHEMICAL
on O
glycemic O
control O
and O
-cell O
function O
in O
type O
2 O
diabetic O
patients. O
One O
hundred O
and O
seventy-one O
type O
2 O
diabetic O
patients O
were O
instructed O
to O
add O
vildaglipin B-CHEMICAL

50mg O
twice O
a O
day O
or O
placebo O
to O
metformin B-CHEMICAL
for O
12 O
months. O
Body O
mass O
index O
(BMI), O
glycemic O
control, O
fasting O
plasma O
insulin B-GENE-Y
(FPI), O
HOMA-IR, O
HOMA-, O
fasting O
plasma O
proinsulin B-GENE-Y
(FPPr), O
proinsulin/fasting B-GENE-Y
plasma O
insulin B-GENE-Y
ratio O
(Pr/FPI O
ratio), O
C-peptide, B-GENE-Y
glucagon, B-GENE-Y
vaspin, B-GENE-Y
visfatin, B-GENE-Y
and O
omentin-1 B-GENE-Y
were O
evaluated. O
Before, O
and O
after O
12 O
months O
since O
the O
addition O
of O

vildagliptin, B-CHEMICAL
patients O
underwent O
a O
combined O
euglycemic O
hyperinsulinemic O
and O
hyperglycemic O
clamp, O
with O
subsequent O
arginine B-CHEMICAL
stimulation. O
Vildagliptin+metformin B-CHEMICAL
were O
more O
effective O
than O
placebo+metformin B-CHEMICAL
in O
reducing O
body O
weight O
and O
BMI, O
glycemic O
control, O
HOMA-IR, O
glucagon B-GENE-Y
and O
insulin B-GENE-Y
resistance O
measurements. O
Vildagliptin+metformin B-CHEMICAL
gave O
also O
a O
better O
increase O
of O
HOMA-, O
and O
of O
all O
-cell O
parameters O
after O
the O
clamp. O
We O
also O
recorded O

a O
significant O
correlation O
between O
M O
value O
increase O
and O
the O
decrease O
of O
vaspin, B-GENE-Y
visfatin, B-GENE-Y
and O
omentin-1 B-GENE-Y
obtained O
with O
vildagliptin+metformin. B-CHEMICAL
Vildagliptin, B-CHEMICAL
in O
addition O
to O
metformin, B-CHEMICAL
proved O
to O
be O
effective O
in O
improving O
-cell O
function O
and O
in O
reducing O
insulin B-GENE-Y
resistance O
measurements. O
4-Hydroxytamoxifen-stimulated B-CHEMICAL
processing O
of O
cyclin B-GENE-Y
E I-GENE-Y
is O
mediated O
via O
G B-GENE-Y
protein-coupled I-GENE-Y
receptor I-GENE-Y
30 I-GENE-Y
(GPR30) B-GENE-Y
and O
accompanied O
by O
enhanced O
migration O
in O
MCF-7 O
breast O
cancer O
cells. O
Over-expression O
of O
cleaved O

cyclin B-GENE-Y
E I-GENE-Y
in O
breast O
tumors O
is O
closely O
associated O
with O
tumor O
progression O
and O
resistance O
to O
antiestrogens. O
17-Estradiol B-CHEMICAL
(E2) O
has O
been O
recently O
shown O
to O
induce O
cyclin B-GENE-Y
E I-GENE-Y
processing O
in O
breast O
cancer O
cells. O
Tamoxifen B-CHEMICAL
has O
been O
used O
in O
patients O
with O
estrogen-sensitive B-CHEMICAL
breast O
cancer, O
yet O
resistance O
to O
antiestrogens O
and O
recurrence O
will O
appear O
in O
some O
of O
the O
patients O
after O
its O
continued O
use. O
We O
therefore O
addressed O
possible O
effects O
of O
tamoxifen B-CHEMICAL
on O
the O
generation O
of O
cleaved O
cyclin B-GENE-Y
E I-GENE-Y
and O
its O
signal O
mechanism(s) O
in O

estrogen-responsive B-CHEMICAL
MCF-7 O
breast O
cancer O
cells O
that O
express O
both O
G B-GENE-Y
protein-coupled I-GENE-Y
protein I-GENE-Y
(GPR) I-GENE-Y
30 I-GENE-Y
and O
estrogen B-CHEMICAL
receptor I-GENE-Y
 I-GENE-Y
(ER). B-GENE-N
4-Hydroxytamoxifen B-CHEMICAL
(OHT, B-CHEMICAL
tamoxifen's B-CHEMICAL
active O
form) O
failed O
to O
prevent O
E2-induced O
proteolysis O
of O
cyclin B-GENE-Y
E I-GENE-Y
and O
migration, O
but O
rather O
triggered O
cyclin B-GENE-Y
E I-GENE-Y
cleavage O
coincident O
with O
augmented O
migration. O
OHT-induced B-CHEMICAL
cyclin B-GENE-Y
E I-GENE-Y
truncation O
also O
occurred O
in O
SK-BR-3 O
cells O
that O
express O
GPR30 B-GENE-Y
and O
lack O

ER, B-GENE-Y
but O
not O
in O
MDA-MB-231 O
cells O
that O
express O
neither O
GPR30 B-GENE-Y
nor O
ER. B-GENE-Y
G1, O
a O
specific O
GPR B-GENE-Y
30 I-GENE-Y
agonist, O
caused O
dramatic O
proteolysis O
of O
cyclin B-GENE-Y
E I-GENE-Y
and O
enhanced O
migration. O
Furthermore, O
OHT-stimulated B-CHEMICAL
cleavage O
of O
cyclin B-GENE-Y
E I-GENE-Y
and O
migration O
were O
tremendously O
attenuated O
by O
G15, O
a O
GPR30 B-GENE-Y
antagonist, O
or O
siRNA O
against O
GPR30. B-GENE-Y
In O
addition, O
inhibitors O
for O
EGFR B-GENE-Y
or O
ERK1/2 B-GENE-N
remarkably O
suppressed O
OHT-induced B-CHEMICAL
truncation O
of O
cyclin B-GENE-Y
E, I-GENE-Y
suggesting O
involvement O

of O
EGFR B-GENE-Y
signaling. O
Collectively, O
our O
data O
indicate O
that O
OHT B-CHEMICAL
contributes O
to O
the O
production O
of O
proteolyzed O
cyclin B-GENE-Y
E I-GENE-Y
via O
GPR30 B-GENE-Y
with O
augmented O
migration O
in O
MCF-7 O
cells. O
Mechanistic O
Aspects O
of O
hSOD1 B-GENE-Y
Maturation O
from O
the O
Solution O
Structure O
of O
Cu(I) B-CHEMICAL
-Loaded O
hCCS B-GENE-N
Domain I-GENE-N
1 I-GENE-N
and O
Analysis O
of O
Disulfide-Free B-CHEMICAL
hSOD1 B-GENE-Y
Mutants. O
Superoxide B-GENE-Y
dismutase I-GENE-Y
1 I-GENE-Y
(SOD1) B-GENE-Y
maturation O
within O
the O
cell O
is O
mainly O
accomplished O
with O
the O
SOD1-specific B-GENE-Y
chaperone, I-GENE-Y

CCS, B-GENE-Y
a O
dimeric O
protein O
with O
three O
distinct O
domains O
in O
each O
monomer. O
We O
recently O
showed O
that O
the O
first O
domain O
of O
human B-GENE-Y
CCS I-GENE-Y
(hCCSD1) B-GENE-N
is O
responsible O
for O
copper B-CHEMICAL
transfer O
to O
its O
protein O
partner, O
human B-GENE-Y
SOD1 I-GENE-Y
(hSOD1). B-GENE-Y
The O
NMR O
solution O
structure O
of O
the O
copper(I)-loaded B-CHEMICAL
form O
of O
hCCSD1 B-GENE-N
reported O
here O
contributes O
further O
to O
characterization O
of O
the O
copper-transfer O
mechanism O
to O
hSOD1. B-GENE-Y
NMR O
spectroscopy O
was O
also O
used O
to O
examine O
the O
hSOD1 B-GENE-Y
mutants O
C57A, B-GENE-N
C146A, B-GENE-N
and O

C57A/C146A, B-GENE-N
which O
are O
unable O
to O
form O
the O
structurally O
conserved O
disulfide B-CHEMICAL
bond O
in O
SOD1, B-GENE-Y
in O
order O
to O
investigate O
the O
role O
of O
these O
cysteines B-CHEMICAL
during O
hSOD1 B-GENE-Y
copper O
acquisition. O
Together, O
the O
information O
on O
both O
hCCS B-GENE-Y
and O
hSOD1, B-GENE-Y
along O
with O
a O
sequence O
analysis O
of O
eukaryotic O
CCSD1, B-GENE-N
allows O
us O
to O
propose O
important O
mechanistic O
aspects O
regarding O
the O
copper-transfer B-CHEMICAL
process O
from O
hCCS B-GENE-Y
to O
hSOD1. B-GENE-Y
Novel O
pentablock O
copolymer O
(PLA-PCL-PEG-PCL-PLA) B-CHEMICAL

based O
nanoparticles O
for O
controlled O
drug O
delivery: O
Effect O
of O
copolymer O
compositions O
on O
the O
crystallinity O
of O
copolymers O
and O
in O
vitro O
drug O
release O
profile O
from O
nanoparticles. O
The O
purpose O
of O
this O
investigation O
was O
to O
design O
novel O
pentablock O
copolymers O
(polylatide-polycaprolactone-polyethylene B-CHEMICAL
glycol- I-CHEMICAL
polycaprolactone-polylatide) B-CHEMICAL
(PLA-PCL-PEG-PCL-PLA) B-CHEMICAL
to O
prepare O
nanoparticle O
formulations O
which O
provide O
continuous O
delivery O
of O
steroids B-CHEMICAL
over O
a O
longer O

duration O
with O
minimal O
burst O
effect. O
Another O
purpose O
was O
to O
evaluate O
the O
effect O
of O
poly B-CHEMICAL
(L-lactide) I-CHEMICAL
(PLLA) B-CHEMICAL
or O
poly B-CHEMICAL
(D, I-CHEMICAL
L-lactide) I-CHEMICAL
(PDLLA) B-CHEMICAL
incorporation O
on O
crystallinity O
of O
pentablock O
copolymers O
and O
in O
vitro O
release O
profile O
of O
triamcinolone B-CHEMICAL
acetonide I-CHEMICAL
(selected O
as O
model O
drug) O
from O
nanoparticles. O
PLA-PCL-PEG-PCL-PLA B-CHEMICAL
copolymers O
with O
different O
block O
ratio O
of O
PCL/PLA B-CHEMICAL
segment O
were O
synthesized. O
Release O
of O
triamcinolone B-CHEMICAL

acetonide I-CHEMICAL
from O
nanoparticles O
was O
significantly O
affected O
by O
crystallinity O
of O
the O
copolymers. O
Burst O
release O
of O
triamcinolone B-CHEMICAL
acetonide I-CHEMICAL
from O
nanoparticles O
was O
significantly O
minimized O
with O
incorporation O
of O
proper O
ratio O
of O
PDLLA B-CHEMICAL
in O
the O
existing O
triblock O
(PCL-PEG-PCL) B-CHEMICAL
copolymer. O
Moreover, O
pentablock O
copolymer O
based O
nanoparticles O
exhibited O
continuous O
release O
of O
triamcinolone B-CHEMICAL
acetonide. I-CHEMICAL
Pentablock O
copolymer O
based O
nanoparticles O
can O
be O
utilized O
to O
achieve O
continuous O
near O
zero-order O
delivery O
of O

corticosteroids O
from O
nanoparticles O
without O
any O
burst O
effect. O
PICK1 B-GENE-Y
Deficiency O
Impairs O
Secretory O
Vesicle O
Biogenesis O
and O
Leads O
to O
Growth O
Retardation O
and O
Decreased O
Glucose B-CHEMICAL
Tolerance. O
Secretory O
vesicles O
in O
endocrine O
cells O
store O
hormones O
such O
as O
growth B-GENE-Y
hormone I-GENE-Y
(GH) B-GENE-Y
and O
insulin B-GENE-Y
before O
their O
release O
into O
the O
bloodstream. O
The O
molecular O
mechanisms O
governing O
budding O
of O
immature O
secretory O
vesicles O
from O
the O
trans-Golgi O
network O
(TGN) O
and O
their O
subsequent O
maturation O
remain O
unclear. O
Here, O
we O
identify O
the O

lipid B-GENE-N
binding I-GENE-N
BAR I-GENE-N
(Bin/amphiphysin/Rvs) I-GENE-N
domain I-GENE-N
protein I-GENE-N
PICK1 B-GENE-Y
(protein B-GENE-Y
interacting I-GENE-Y
with I-GENE-Y
C I-GENE-Y
kinase I-GENE-Y
1) I-GENE-Y
as O
a O
key O
component O
early O
in O
the O
biogenesis O
of O
secretory O
vesicles O
in O
GH-producing B-GENE-Y
cells. O
Both O
PICK1-deficient B-GENE-N
Drosophila O
and O
mice O
displayed O
somatic O
growth O
retardation. O
Growth O
retardation O
was O
rescued O
in O
flies O
by O
reintroducing O
PICK1 B-GENE-Y
in O
neurosecretory O
cells O
producing O
somatotropic O
peptides. O
PICK1-deficient B-GENE-Y
mice O
were O
characterized O
by O
decreased O
body O
weight O
and O
length, O

increased O
fat O
accumulation, O
impaired O
GH B-GENE-Y
secretion, O
and O
decreased O
storage O
of O
GH B-GENE-Y
in O
the O
pituitary. O
Decreased O
GH B-GENE-Y
storage O
was O
supported O
by O
electron O
microscopy O
showing O
prominent O
reduction O
in O
secretory O
vesicle O
number. O
Evidence O
was O
also O
obtained O
for O
impaired O
insulin O
secretion O
associated O
with O
decreased O
glucose B-CHEMICAL
tolerance. O
PICK1 B-GENE-Y
localized O
in O
cells O
to O
immature O
secretory O
vesicles, O
and O
the O
PICK1 B-GENE-N
BAR I-GENE-N
domain I-GENE-N
was O
shown O
by O
live O
imaging O
to O
associate O
with O
vesicles O
budding O
from O
the O
TGN O
and O
to O
possess O
membrane-sculpting O
properties O
in O
vitro. O
In O
mouse O

pituitary, O
PICK1 B-GENE-Y
co-localized O
with O
the O
BAR B-GENE-N
domain I-GENE-N
protein I-GENE-N
ICA69, B-GENE-Y
and O
PICK1 B-GENE-Y
deficiency O
abolished O
ICA69 B-GENE-Y
protein O
expression. O
In O
the O
Drosophila O
brain, O
PICK1 B-GENE-Y
and O
ICA69 B-GENE-Y
co-immunoprecipitated O
and O
showed O
mutually O
dependent O
expression. O
Finally, O
both O
in O
a O
Drosophila O
model O
of O
type O
2 O
diabetes O
and O
in O
high-fat-diet-induced O
obese O
mice, O
we O
observed O
up-regulation O
of O
PICK1 B-GENE-N
mRNA O
expression. O
Our O
findings O
suggest O
that O
PICK1, B-GENE-N
together O
with O

ICA69, B-GENE-N
is O
critical O
during O
budding O
of O
immature O
secretory O
vesicles O
from O
the O
TGN O
and O
thus O
for O
vesicular O
storage O
of O
GH B-GENE-N
and O
possibly O
other O
hormones. O
The O
data O
link O
two O
BAR B-GENE-N
domain I-GENE-N
proteins I-GENE-N
to O
membrane O
remodeling O
processes O
in O
the O
secretory O
pathway O
of O
peptidergic O
endocrine O
cells O
and O
support O
an O
important O
role O
of O
PICK1/ICA69 B-GENE-Y
in O
maintenance O
of O
metabolic O
homeostasis. O
Design, O
Synthesis O
and O
Biological O
Evaluation O
of O
Aminoalkylindole B-CHEMICAL
Derivatives O
as O
Cannabinoid B-GENE-Y
Receptor I-GENE-Y
Ligands O
with O
Potential O
for O
Treatment O
of O

Alcohol B-CHEMICAL
Abuse. O
Attenuation O
of O
increased O
endocannabinoid O
signaling O
with O
a O
CB1R B-GENE-Y
neutral O
antagonist O
might O
offer O
a O
new O
therapeutic O
direction O
for O
treatment O
of O
alcohol B-CHEMICAL
abuse. O
We O
have O
recently O
reported O
that O
a O
mono-hydroxylated O
metabolite O
of O
the O
synthetic O
aminoalkylindole B-CHEMICAL
cannabinoid O
JHW-073 B-CHEMICAL
(3) O
exhibits O
neutral O
antagonist O
activity O
at O
CB1Rs B-GENE-Y
and O
thus O
may O
serve O
as O
a O
promising O
lead O
for O
the O
development O
of O
novel O
alcohol B-CHEMICAL
abuse O
therapies. O
In O
the O
current O
study, O
we O
show O
that O
systematic O
modification O
of O
an O
aminoalkylindole B-CHEMICAL
scaffold O
identifies O
two O
new O
compounds O

with O
dual O
CB1R B-GENE-Y
antagonist/CB2R B-GENE-Y
agonist O
activity. O
Similar O
to O
the O
CB1R B-GENE-N
antagonist/inverse O
agonist O
rimonabant, O
analogues O
27 O
and O
30 O
decrease O
oral O
alcohol B-CHEMICAL
self-administration, O
without O
affecting O
total O
fluid O
intake O
and O
block O
the O
development O
of O
alcohol-conditioned B-CHEMICAL
place O
preference. O
Collectively, O
these O
initial O
findings O
suggest O
that O
design O
and O
systematic O
modification O
of O
aminoalkylindoles B-CHEMICAL
such O
as O
3 O
may O
lead O
to O
development O
of O
novel O
cannabinoid O
ligands O
with O
dual O
CB1R B-GENE-Y
antagonist/CB2R B-GENE-Y
agonist O
activity O
with O
potential O
for O
use O
as O
treatments O
of O
alcohol B-CHEMICAL
abuse. O
Immunoregulatory O
effects O
of O

Glycyrrhizic B-CHEMICAL
acid I-CHEMICAL
exerts O
anti-asthmatic O
effects O
via O
modulation O
of O
Th1/Th2 O
cytokines B-GENE-N
and O
enhancement O
of O
CD4(+)CD25(+)Foxp3(+) O
regulatory O
T O
cells O
in O
ovalbumin-sensitized B-GENE-Y
mice. O
ETHNOPHARMACOLOGICAL O
RELEVANCE: O
Glycyrrhizic B-CHEMICAL
acid I-CHEMICAL
(GA) O
is O
the O
main O
bioactive O
ingredient O
of O
licorice O
(Glycyrrhiza O
glabra), O
and O
has O
been O
found O
to O
be O

associated O
with O
multiple O
therapeutic O
properties. O
AIM O
OF O
THE O
STUDY: O
In O
this O
study, O
we O
investigated O
immunoregulatory O
effects O
of O
glycyrrhizic B-CHEMICAL
acid I-CHEMICAL
on O
anti-asthmatic O
effects O
and O
underlying O
mechanisms. O
MATERIALS O
AND O
METHODS: O
Asthma O
model O
was O
established O
by O
ovalbumin-induced. B-GENE-Y
A O
total O
of O
60 O
mice O
were O
randomly O
assigned O
to O
six O
experimental O
groups: O
control, O
model, O
dexamethasone B-CHEMICAL
(2mg/kg) O
and O
GA O
(10mg/kg, O
20mg/kg, O
40mg/kg). O
Airway O
resistance O

(Raw) O
were O
measured O
by O
the O
forced O
oscillation O
technique, O
histological O
studies O
were O
evaluated O
by O
The O
hematoxylin B-CHEMICAL
and O
eosin B-CHEMICAL
(HE) O
staining, O
Th1/Th2 O
and O
Th17 O
cytokines B-GENE-N
were O
evaluated O
by O
enzyme-linked O
immunosorbent O
assay O
(ELISA), O
and O
CD4(+)CD25(+)Foxp3(+) O
regulatory O
T O
cells O
(Tregs) O
was O
evaluated O
by O
Flow O
Cytometry O
(FCM), O
the O
forkhead/winged B-GENE-N
helix I-GENE-N
transcription I-GENE-N
factor I-GENE-N
(Foxp3) B-GENE-Y
was O
evaluated O

by O
western O
blotting. O
RESULTS: O
Our O
study O
demonstrated O
that, O
compared O
with O
model O
group, O
GA O
inhibited O
OVA-induced B-GENE-Y
increases O
in O
Raw O
and O
eosinophil O
count; O
interleukin B-GENE-Y
(IL)-4, I-GENE-Y
IL-5, B-GENE-Y
IL-13 B-GENE-Y
levels O
were O
recovered O
in O
bronchoalveolar O
lavage O
fluid O
compared; O
increased O
IFN-level B-GENE-Y
in O
bronchoalveolar O
lavage O
fluid; O
histological O
studies O
demonstrated O
that O
GA O
substantially O
inhibited O
OVA-induced B-GENE-Y
eosinophilia O
in O
lung O
tissue O
and O
airway O
tissue O
compared O
with O
model O
group. O
Flow O

cytometry O
studies O
demonstrated O
that O
GA O
substantially O
enhanced O
Tregs O
compared O
with O
model O
group. O
CONCLUSION: O
These O
findings O
suggest O
that O
GA O
may O
effectively O
ameliorate O
the O
progression O
of O
asthma O
and O
could O
be O
used O
as O
a O
therapy O
for O
patients O
with O
allergic O
asthma. O
Enhanced O
beta O
cell O
function O
and O
anti-inflammatory O
effect O
after O
chronic O
treatment O
with O
the O
dipeptidyl B-GENE-Y
peptidase-4 I-GENE-Y
inhibitor O
vildagliptin B-CHEMICAL
in O
an O
advanced-aged O
diet-induced O
obesity O
mouse O
model. O
AIMS/HYPOTHESIS: O
Studies O
have O
shown O
that O
dipeptidyl B-GENE-Y

peptidase-4 I-GENE-Y
(DPP4) B-GENE-Y
inhibitors O
stimulate O
insulin B-GENE-N
secretion O
and O
increase O
beta O
cell O
mass O
in O
rodents. O
However, O
in O
these O
models O
hyperglycaemia O
has O
been O
induced O
early O
on O
in O
life O
and O
the O
treatment O
periods O
have O
been O
short. O
To O
explore O
the O
long-term O
effects O
of O
DPP4 B-GENE-Y
inhibition O
on O
insulin B-GENE-N
secretion O
and O
beta O
cell O
mass, O
we O
have O
generated O
a O
high-fat O
diet O
(HFD)-induced-obesity O
model O
in O
mice O
of O
advanced O
age O
(10 O
months O
old). O
METHODS: O
After O
1 O
month O
of O
HFD O
alone, O
the O
mice O
were O
given O
the O
DPP4 B-GENE-Y
inhibitor O

vildagliptin B-CHEMICAL
for O
a O
further O
11 O
months. O
At O
multiple O
time O
points O
throughout O
the O
study, O
OGTTs O
were O
performed O
and O
beta O
cell O
area O
and O
long-term O
survival O
were O
evaluated. O
RESULTS: O
Beta O
cell O
function O
and O
glucose B-CHEMICAL
tolerance O
were O
significantly O
improved O
by O
vildagliptin B-CHEMICAL
with O
both O
diets. O
In O
contrast, O
in O
spite O
of O
the O
long O
treatment O
period, O
beta O
cell O
area O
was O
not O
significantly O
different O
between O
vildagliptin-treated B-CHEMICAL
mice O
and O
controls. O
Mice O
of O
advanced O
age O
chronically O
fed O
an O
HFD O
displayed O
clear O
and O
extensive O
pancreatic O
inflammation O
and O
peri-insulitis, O
mainly O
formed O

by O
CD3-positive O
T O
cells, O
which O
were O
completely O
prevented O
by O
vildagliptin B-CHEMICAL
treatment. O
Chronic O
vildagliptin B-CHEMICAL
treatment O
also O
improved O
survival O
rates O
for O
HFD-fed O
mice. O
CONCLUSIONS/INTERPRETATION: O
In O
a O
unique O
advanced-aged O
HFD-induced-obesity O
mouse O
model, O
insulin B-GENE-N
secretion O
was O
improved O
and O
the O
extensive O
peri-insulitis O
prevented O
by O
chronic O
DPP4 B-GENE-Y
inhibition. O
The O
improved O
survival O
rates O
for O
obese O
mice O
chronically O
treated O
with O
vildagliptin B-CHEMICAL
suggest O
that O
chronic O
DPP4 B-GENE-Y
inhibition O
potentially O
results O

in O
additional O
quality-adjusted O
life-years O
for O
individuals O
with O
type O
2 O
diabetes, O
which O
is O
the O
primary O
goal O
of O
any O
diabetes O
therapy. O
Amelioration O
of O
palmitate-induced B-CHEMICAL
insulin B-GENE-N
resistance O
in O
C2C12 O
muscle O
cells O
by O
rooibos O
(Aspalathus O
linearis). O
Increased O
levels O
of O
free B-CHEMICAL
fatty I-CHEMICAL
acids I-CHEMICAL
(FFAs), B-CHEMICAL
specifically O
saturated B-CHEMICAL
free I-CHEMICAL
fatty I-CHEMICAL
acids I-CHEMICAL
such O
as O
palmitate B-CHEMICAL
are O
associated O
with O
insulin B-GENE-Y
resistance O
of O
muscle, O
fat O
and O
liver. O
Skeletal O
muscle, O
responsible O
for O
up O
to O
80% O
of O
the O
glucose B-CHEMICAL
disposal O
from O
the O
peripheral O
circulation, O
is O
particularly O
vulnerable O
to O
increased O
levels O
of O
saturated O
FFAs. B-CHEMICAL
Rooibos O

(Aspalathus O
linearis) O
and O
its O
unique O
dihydrochalcone B-CHEMICAL
C-glucoside, I-CHEMICAL
aspalathin, B-CHEMICAL
shown O
to O
reduce O
hyperglycemia O
in O
diabetic O
rats, O
could O
play O
a O
role O
in O
preventing O
or O
ameliorating O
the O
development O
of O
insulin B-GENE-N
resistance. O
This O
study O
aims O
to O
establish O
whether O
rooibos O
can O
ameliorate O
experimentally-induced O
insulin-resistance B-GENE-N
in O
C2C12 O
skeletal O
muscle O
cells. O
Palmitate-induced B-CHEMICAL
insulin O
resistant O
C2C12 O
cells O
were O
treated O
with O
an O
aspalathin-enriched B-CHEMICAL
green O
(unfermented) O
rooibos O
extract O

(GRE), O
previously O
shown O
for O
its O
blood O
glucose B-CHEMICAL
lowering O
effect O
in O
vitro O
and O
in O
vivo O
or O
an O
aqueous O
extract O
of O
fermented O
rooibos O
(FRE). O
Glucose B-CHEMICAL
uptake O
and O
mitochondrial O
activity O
were O
measured O
using O
2-deoxy-[(3)H]-d-glucose, B-CHEMICAL
MTT B-CHEMICAL
and O
ATP B-CHEMICAL
assays, O
respectively. O
Expression O
of O
proteins O
relevant O
to O
glucose B-CHEMICAL
metabolism O
was O
analysed O
by O
Western O
blot. O
GRE O
contained O
higher O
levels O
of O
all O
compounds, O
except O
the O
enolic O
phenylpyruvic B-CHEMICAL
acid-2-O-glucoside I-CHEMICAL
and O

luteolin-7-O-glucoside. B-CHEMICAL
Both O
rooibos O
extracts O
increased O
glucose B-CHEMICAL
uptake, O
mitochondrial O
activity O
and O
ATP B-CHEMICAL
production. O
Compared O
to O
FRE, O
GRE O
was O
more O
effective O
at O
increasing O
glucose B-CHEMICAL
uptake O
and O
ATP B-CHEMICAL
production. O
At O
a O
mechanistic O
level O
both O
extracts O
down-regulated O
PKC B-GENE-Y
 I-GENE-Y
activation, O
which O
is O
associated O
with O
palmitate-induced B-CHEMICAL
insulin B-GENE-N
resistance. O
Furthermore, O
the O
extracts O
increased O
activation O
of O
key O
regulatory O
proteins O
(AKT B-GENE-Y
and O
AMPK) B-GENE-Y
involved O
in O
insulin-dependent B-GENE-N
and O
non-insulin B-GENE-N
regulated O
signalling O
pathways. O
Protein O
levels O
of O
the O
glucose B-GENE-N
transporter I-GENE-N
(GLUT4) B-GENE-Y
involved O

in O
glucose B-CHEMICAL
transport O
via O
these O
two O
pathways O
were O
also O
increased. O
This O
in O
vitro O
study O
therefore O
confirms O
that O
rooibos O
can O
ameliorate O
palmitate-induced B-CHEMICAL
insulin B-GENE-N
resistance O
in O
C2C12 O
skeletal O
muscle O
cells. O
Inhibition O
of O
PKC B-GENE-Y
 I-GENE-Y
activation O
and O
increased O
activation O
of O
AMPK B-GENE-Y
and O
AKT B-GENE-Y
offer O
a O
plausible O
mechanistic O
explanation O
for O
this O
ameliorative O
effect. O
Puerarin B-CHEMICAL
stimulates O
proliferation O
and O
differentiation O
and O
protects O
against O
cell O
death O
in O
human O
osteoblastic O
MG-63 O
cells O
via O
ER-dependent B-GENE-Y
MEK/ERK B-GENE-N
and O
PI3K/Akt B-GENE-N
activation. O
Puerarin, B-CHEMICAL
the O

main O
isoflavone B-CHEMICAL
glycoside I-CHEMICAL
found O
in O
the O
Chinese O
herb O
radix O
of O
Pueraria O
lobata O
(Willd.) O
Ohwi, O
has O
received O
increasing O
attention O
because O
of O
its O
possible O
role O
in O
the O
prevention O
of O
osteoporosis. O
Previously, O
we O
showed O
that O
puerarin B-CHEMICAL
could O
inhibit O
the O
bone O
absorption O
of O
osteoclasts O
and O
promote O
long O
bone O
growth O
in O
fetal O
mouse O
in O
vitro. O
Further O
study O
confirmed O
that O
puerarin B-CHEMICAL
stimulated O
proliferation O
and O
differentiation O
of O
osteoblasts O
in O
rat. O
However, O
the O
mechanisms O
underlying O
its O
actions O
on O
human O
bone O
cells O
have O
not O
been O
well O
defined. O
Here O
we O
show O

that O
puerarin B-CHEMICAL
increases O
proliferation O
and O
differentiation O
and O
opposes O
cisplatin-induced B-CHEMICAL
apoptosis O
in O
human O
osteoblastic O
MG-63 O
cells O
containing O
two O
estrogen B-GENE-Y
receptor I-GENE-Y
(ER) B-GENE-Y
isoforms. O
Puerarin B-CHEMICAL
promotes O
proliferation O
by O
altering O
cell O
cycle O
distribution O
whereas O
puerarin-mediated B-CHEMICAL
survival O
may O
be O
associated O
with O
up-regulation O
of O
Bcl-xL B-GENE-Y
expression. O
Treatment O
with O
the O
ER B-GENE-Y
antagonist O
ICI B-CHEMICAL
182,780 I-CHEMICAL
abolishes O
the O
above O
actions O
of O
puerarin B-CHEMICAL
on O
osteoblast-derived O
cells. O
Using O
small O
interfering O
double-stranded O
RNA O
technology, O
we O
further O
demonstrate O
that O
the O
effects O
of O
puerarin B-CHEMICAL

on O
proliferation, O
differentiation O
and O
survival O
are O
mediated O
by O
both O
ER B-GENE-Y
and O
ER. B-GENE-Y
Moreover, O
we O
also O
demonstrate O
that O
puerarin B-CHEMICAL
functions O
at O
least O
partially O
through O
activation O
of O
MEK/ERK B-GENE-N
and O
PI3K/Akt B-GENE-N
signaling. O
This O
agent O
also O
shows O
much O
weaker O
effect O
on O
breast O
epithelial O
cell O
growth O
than O
that O
of O
estrogen. B-CHEMICAL
Therefore, O
puerarin B-CHEMICAL
will O
be O
a O
promising O
agent O
that O
prevents O
or O
retards O
osteoporosis. O
Bone B-GENE-Y
Morphogenetic I-GENE-Y
Protein-7 I-GENE-Y
inhibits O
silica-induced B-CHEMICAL
pulmonary O
fibrosis O
in O
rats. O
Bone B-GENE-Y
morphogenetic I-GENE-Y
protein-7 I-GENE-Y

(BMP-7) B-GENE-Y
has O
been O
shown O
to O
inhibit O
liver O
and O
renal O
fibrosis O
in O
in O
vivo O
and O
in O
vitro O
studies. O
There O
is O
no O
study O
to O
investigate O
BMP-7's B-GENE-Y
role O
in O
the O
development O
of O
pulmonary O
fibrosis O
induced O
by O
silica. B-CHEMICAL
In O
the O
current O
study, O
we O
used O
the O
rat O
model O
to O
explore O
the O
potential O
antifibrotic O
role O
of O
BMP-7 B-GENE-Y
and O
its O
underlying O
mechanism O
in O
silica-induced B-CHEMICAL
pulmonary O
fibrosis. O
Sixty O
Wistar O
rats O
were O
randomly O
assigned O
into O
three O
groups. O
Control O
group O
received O
saline, O
silica B-CHEMICAL
group O
received O
silica B-CHEMICAL
and O
BMP-7 B-GENE-Y
treated O
group O

received O
silica B-CHEMICAL
and O
BMP-7. B-GENE-Y
BMP-7 B-GENE-Y
was O
administered O
to O
silica-treated B-CHEMICAL
rats O
intraperitoneally O
at O
a O
dose O
of O
300g/kg/injection O
from O
day O
8 O
to O
day O
30 O
every O
other O
day. O
After O
the O
animals O
were O
sacrificed O
on O
day O
15 O
and O
30, O
hydroxyproline B-CHEMICAL
levels, O
the O
protein O
expressions O
of O
BMP/Smad B-GENE-N
and O
TGF-/Smad B-GENE-Y
signaling, O
and O
histopathology O
in O
lung O
tissues O
were O
analyzed. O
The O
hydroxyproline B-CHEMICAL
contents O
in O
BMP-7 B-GENE-Y
treated O
groups O
were O
significantly O
lower O
than O
the O
silica B-CHEMICAL
groups O

(P<0.05). O
Histopathological O
results O
showed O
BMP-7 B-GENE-Y
could O
reduce O
the O
progression O
of O
silica B-CHEMICAL
induced O
fibrosis. O
Furthermore, O
the O
expression O
of O
p-Smad1/5/8, B-GENE-N
a O
marker O
of O
BMP/Smad B-GENE-N
signaling, O
was O
significantly O
up-regulated O
in O
BMP-7 B-GENE-Y
treated O
groups O
(P<0.05) O
compared O
with O
the O
silica B-CHEMICAL
groups. O
On O
the O
contrary, O
the O
expression O
of O
p-Smad2/3, B-GENE-N
a O
marker O
for O
TGF-/Smad B-GENE-Y
signaling, O
reduced O
significantly O
in O
BMP-7-treated B-GENE-Y
groups O
compared O
with O
silica B-CHEMICAL
groups O

(P<0.05). O
In O
conclusion, O
the O
pulmonary O
fibrosis O
induced O
by O
silica B-CHEMICAL
in O
rats O
was O
significantly O
reduced O
with O
the O
therapeutic O
treatment O
of O
BMP-7. B-GENE-Y
The O
antifibrotic O
effect O
of O
BMP-7 B-GENE-Y
could O
be O
related O
to O
the O
activation O
of O
BMP/Smad B-GENE-N
signaling O
and O
inhibition O
of O
TGF-/Smad B-GENE-Y
pathways. O
The O
preventive O
effect O
of O
uncarboxylated O
osteocalcin B-GENE-Y
against O
free B-CHEMICAL
fatty I-CHEMICAL
acid-induced I-CHEMICAL
endothelial O
apoptosis O
through O
the O
activation O
of O
phosphatidylinositol B-GENE-N
3-kinase/Akt I-GENE-N
signaling O
pathway: O

Uncarboxylated B-GENE-Y
osteocalcin I-GENE-Y
and O
endothelial O
apoptosis. O
OBJECTIVE: O
Increasing O
evidence O
suggests O
that O
osteocalcin B-GENE-Y
(OC), B-GENE-Y
one O
of O
the O
osteoblast-specific B-GENE-N
proteins, I-GENE-N
has O
been O
associated O
with O
atherosclerosis, O
but O
results O
are O
conflicting. O
The O
aim O
of O
this O
study O
was O
to O
elucidate O
the O
independent O
effect O
of O
uncarboxylated B-GENE-Y
osteocalcin I-GENE-Y
(ucOC), B-GENE-Y
an O
active O
form O
of O
osteocalcin B-GENE-Y
which O
has O
been O
suggested O
to O
have O
an O
insulin B-GENE-Y
sensitizing O
effect, O
on O
vascular O

endothelial O
cells. O
MATERIALS O
AND O
METHODS: O
We O
used O
human O
aortic O
endothelial O
cells O
and O
treated O
them O
with O
ucOC. B-GENE-Y
Linoleic B-CHEMICAL
acid I-CHEMICAL
(LA) O
was O
used O
as O
a O
representative O
free B-CHEMICAL
fatty I-CHEMICAL
acid. I-CHEMICAL
Apoptosis O
was O
evaluated O
using O
various O
methods O
including O
a O
terminal O
deoxyribonucleotide B-CHEMICAL
transferase-mediated I-GENE-Y
deoxyuridine B-CHEMICAL
triphosphate I-CHEMICAL
nick-end O
labeling O
analysis O
kit O
and O
Western O
blotting O
for O
cleaved O
caspase B-GENE-Y
3, I-GENE-Y
cleaved O
poly B-CHEMICAL
(ADP-ribose) I-CHEMICAL
polymerase I-GENE-N
and O

Bcl-xL. B-GENE-Y
The O
phosphorylations O
of O
Akt B-GENE-N
and O
endothelial B-GENE-Y
nitric B-CHEMICAL
oxide I-CHEMICAL
synthase I-GENE-Y
(eNOS) B-GENE-Y
as O
well O
as O
the O
level O
of O
NO B-CHEMICAL
were O
measured O
to O
confirm O
the O
effect O
of O
ucOC B-GENE-Y
on O
insulin B-GENE-Y
signaling O
pathway. O
RESULTS: O
Pretreatment O
of O
ucOC B-GENE-Y
(30ng/ml) O
prevented O
LA-induced O
apoptosis O
in O
insulin-stimulated B-GENE-Y
endothelial O
cells; O
effects O
were O
abolished O
by O
pretreatment O
with O
the O
phosphatidylinositol B-CHEMICAL
3-kinase I-GENE-N
(PI3-kinase) B-GENE-N
inhibitor, O

wortmannin. B-CHEMICAL
Treatment O
of O
ucOC B-GENE-Y
(ranged O
from O
0.3 O
to O
30ng/ml) O
significantly O
increased O
the O
phosphorylation O
of O
Akt B-GENE-N
and O
eNOS B-GENE-Y
and O
nitric B-CHEMICAL
oxide I-CHEMICAL
secretion O
from O
endothelial O
cells O
in O
a O
PI3-kinase B-GENE-N
dependent O
manner. O
CONCLUSIONS: O
Our O
study O
is O
the O
first O
to O
demonstrate O
the O
independent O
effect O
of O
ucOC B-GENE-Y
on O
vascular O
endothelial O
cells. O
Our O
results O
further O
suggest O
that O
ucOC B-GENE-Y
could O
have O
beneficial O
effects O
on O
atherosclerosis. O
Free O
volume O
in O
ionic O
liquids: O
a O
connection O
of O
experimentally O
accessible O

observables O
from O
PALS O
and O
PVT O
experiments O
with O
the O
molecular O
structure O
from O
XRD O
data. O
In O
the O
current O
work, O
free O
volume O
concepts, O
primarily O
applied O
to O
glass O
formers O
in O
the O
literature, O
were O
transferred O
to O
ionic O
liquids O
(ILs). O
A O
series O
of O
1-butyl-3-methylimidazolium B-CHEMICAL
([C4MIM](+)) B-CHEMICAL
based O
ILs O
was O
investigated O
by O
Positron O
Annihilation O
Lifetime O
Spectroscopy O
(PALS). O
The O
phase O
transition O
and O
dynamic O
properties O
of O
the O
ILs O
[C4MIM][X] B-CHEMICAL
with O

[X](-) O
= O
[Cl](-), B-CHEMICAL
[BF4](-), B-CHEMICAL
[PF6](-), B-CHEMICAL
[OTf](-), B-CHEMICAL
[NTf2](-) B-CHEMICAL
and O
[B(hfip)4](-) B-CHEMICAL
were O
reported O
recently O
(Yu O
et O
al., O
Phys. O
Chem. O
Chem. O
Phys., O
2012, O
14, O
6856-6868). O
In O
this O
subsequent O
work, O
attention O
was O
paid O
to O
the O
connection O
of O
the O
free O
volume O
from O
PALS O
(here O
the O
mean O
hole O
volume, O

vh) O
with O
the O
molecular O
structure, O
represented O
by O
volumes O
derived O
from O
X-ray O
diffraction O
(XRD) O
data. O
These O
were O
the O
scaled O
molecular O
volume O
Vm,scaled O
and O
the O
van O
der O
Waals O
volume O
Vvdw. O
Linear O
correlations O
of O
vh O
at O
the O
"knee" O
temperature O
(vh(Tk)) O
with O
Vm,scaled O
and O
Vvdw O
gave O
good O
results O
for O
the O
[C4MIM](+) B-CHEMICAL
series. O
Further O
relationships O
between O
volumes O
from O
XRD O
data O
with O
the O
occupied O
volume O
Vocc O
determined O
from O
PALS/PVT O

(Pressure O
Volume O
Temperature) O
measurements O
and O
from O
Sanchez-Lacombe O
Equation O
of O
State O
(SL-EOS) O
fits O
were O
elaborated O
(Vocc(SL-EOS) O
 O
1.63 O
Vvdw, O
R(2) O
= O
0.981 O
and O
Vocc(SL-EOS) O
 O
1.12 O
Vm,scaled, O
R(2) O
= O
0.980). O
Finally, O
the O
usability O
of O
Vm,scaled O
was O
justified O
in O
terms O
of O
the O
Cohen-Turnbull O
(CT) O
free O
volume O
theory. O
Empirical O
CT O
type O
plots O
of O
viscosity O

and O
electrical O
conductivity O
showed O
a O
systematic O
increase O
in O
the O
critical O
free O
volume O
with O
molecular O
size. O
Such O
correlations O
allow O
descriptions O
of O
IL O
properties O
with O
the O
easily O
accessible O
quantity O
Vm,scaled O
within O
the O
context O
of O
the O
free O
volume. O
Distinct O
role O
of O
PYK2 B-GENE-Y
in O
mediating O
thromboxane B-CHEMICAL
generation O
downstream O
of O
both O
G12/13 B-GENE-N
and O
integrin B-GENE-Y
iib I-GENE-Y
in O
platelets. O
Proline-rich B-CHEMICAL
tyrosine B-CHEMICAL
kinase I-GENE-Y
2 I-GENE-Y
(Pyk2) B-GENE-Y
is O
activated O
by O
various O
agonists O
in O
platelets. O
We O
evaluated O
the O
signaling O
mechanism O
and O
the O
functional O
role O
of O
Pyk2 B-GENE-Y
in O
platelets O
by O
using O

pharmacological O
inhibitors O
and O
Pyk2-deficient B-GENE-Y
platelets. O
We O
found O
that O
platelet O
aggregation O
and O
secretion O
in O
response O
to O
2-MeSADP B-CHEMICAL
and O
AYPGKF O
were O
diminished O
in O
the O
presence O
of O
Pyk2 B-GENE-Y
inhibitors O
or O
in O
Pyk2-deficient B-GENE-Y
platelets, O
suggesting O
that O
Pyk2 B-GENE-Y
plays O
a O
positive O
regulatory O
role O
in O
platelet O
functional O
responses. O
It O
has O
been O
shown O
that O
ADP-, B-CHEMICAL
but O
not O
thrombin-, B-GENE-Y
induced O
thromboxane B-CHEMICAL
(TxA2) B-CHEMICAL
generation O
depends O
on O
integrin B-GENE-N
signaling. O
Unlike O
ADP, B-CHEMICAL
thrombin B-GENE-Y
activates O

G12/13 B-GENE-N
pathways, O
and O
G12/13 B-GENE-N
pathways O
can O
substitute O
for O
integrin B-GENE-N
signaling O
for O
TxA2 B-CHEMICAL
generation. O
We O
found O
that O
Pyk2 B-GENE-Y
was O
activated O
downstream O
of O
both O
G12/13 B-GENE-N
and O
integrin-mediated B-GENE-N
pathways, O
and O
both O
2-MeSADP- B-CHEMICAL
and O
AYPGKF-induced O
TxA2 B-CHEMICAL
generation O
was O
significantly O
diminished O
in O
Pyk2-deficient B-GENE-Y
platelets. O
In O
addition, O
TxA2 B-CHEMICAL
generation O
induced O
by O
co-stimulation O
of O
Gi B-GENE-N
and O
Gz B-GENE-Y
pathways, O
which O
is O
dependent O
on O
integrin B-GENE-N
signaling, O
was O
inhibited O
by O
blocking O
Pyk2. B-GENE-Y

Furthermore, O
inhibition O
of O
2-MeSADP-induced B-CHEMICAL
TxA2 B-CHEMICAL
generation O
by O
fibrinogen B-GENE-Y
receptor I-GENE-Y
antagonist O
was O
not O
rescued O
by O
co-stimulation O
of O
G12/13 B-GENE-N
pathways O
in O
the O
presence O
of O
Pyk2 B-GENE-Y
inhibitor. O
We O
conclude O
that O
Pyk2 B-GENE-Y
is O
a O
common O
signaling O
effector O
downstream O
of O
both O
G12/13 B-GENE-N
and O
integrin B-GENE-Y
IIb3 I-GENE-Y
signaling O
which O
contributes O
to O
thromboxane B-CHEMICAL
generation. O
The O
use O
of O
antioxidant O
enzymes O
in O
freshwater O
biofilms: O
Temporal O
variability O
vs. O
toxicological O
responses. O
This O
study O
aims O
to O
investigate O
the O
potential O
of O
antioxidant O
enzyme O
activities O

(AEA) O
as O
biomarkers O
of O
oxidative O
stress O
in O
freshwater O
biofilms. O
Therefore, O
biofilms O
were O
grown O
in O
channels O
for O
38 O
days O
and O
then O
exposed O
to O
different O
concentrations O
(0-150gL(-1)) O
of O
the O
herbicide O
oxyfluorfen B-CHEMICAL
for O
5 O
more O
weeks. O
Under O
control O
conditions, O
the O
AEA O
of O
biofilms O
were O
found O
to O
change O
throughout O
time O
with O
a O
significant O
increase O
in O
ascorbate B-CHEMICAL
peroxidase I-GENE-N
(APX) B-GENE-N
activity O
during O
the O
exponential O
growth O
and O
a O
more O
important O
role O
of O
catalase B-GENE-N
(CAT) B-GENE-N
and O
glutathione B-CHEMICAL

reductase I-GENE-N
(GR) B-GENE-N
activities O
during O
the O
slow O
growth O
phase. O
Chronic O
exposure O
to O
oxyfluorfen B-CHEMICAL
led O
to O
slight O
variations O
in O
AEA, O
however, O
the O
ranges O
of O
variability O
of O
AEA O
in O
controls O
and O
exposed O
communities O
were O
similar, O
highlighting O
the O
difficulty O
of O
a O
direct O
interpretation O
of O
AEA O
values. O
After O
5 O
weeks O
of O
exposure O
to O
oxyfluorfen, B-CHEMICAL
no O
clear O
effects O
were O
observed O
on O
chl-a B-CHEMICAL
concentration O
or O
on O
the O
composition O
of O
other O
pigments O
suggesting O
that O
algal O
group O
composition O
was O
not O
affected. O
Eukaryotic O
communities O
were O
structured O
clearly O
by O
toxicant O
concentration O
and O
both O
eukaryotic O
and O
bacterial O
richness O

were O
reduced O
in O
communities O
exposed O
to O
the O
highest O
concentration. O
In O
addition, O
during O
acute O
exposure O
tests O
performed O
at O
the O
end O
of O
the O
chronic O
exposure, O
biofilms O
chronically O
exposed O
to O
75 O
and O
150gL(-1) O
oxyfluorfen B-CHEMICAL
showed O
a O
higher O
CAT B-GENE-N
activity O
than O
controls. O
Chronic O
exposure O
to O
oxyfluorfen B-CHEMICAL
provoked O
then O
structural O
changes O
but O
also O
functional O
changes O
in O
the O
capacity O
of O
biofilm O
CAT B-GENE-N
activity O
to O
respond O
to O
a O
sudden O
increase O
in O
concentration, O
suggesting O
a O
selection O
of O
species O
with O
higher O
antioxidant O
capacity. O
This O
study O
highlighted O
the O
difficulty O
of O
interpretation O
of O
AEA O
values O
due O
to O
their O
temporal O
variation O
and O
to O
the O

absence O
of O
absolute O
threshold O
value O
indicative O
of O
oxidative O
stress O
induced O
by O
contaminants. O
Nevertheless, O
the O
determination O
of O
AEA O
pattern O
throughout O
acute O
exposure O
test O
is O
of O
high O
interest O
to O
compare O
oxidative O
stress O
levels O
undergone O
by O
different O
biofilm O
communities O
and O
thus O
determine O
their O
antioxidant O
capacity. O
Pharmacological O
and O
genetic O
evidence O
for O
pre- O
and O
postsynaptic O
D2 B-GENE-Y
receptor I-GENE-Y
involvement O
in O
motor O
responses O
to O
nociceptin/orphanin B-GENE-Y
FQ I-GENE-Y
receptor I-GENE-Y
ligands. O
A O
combined O
pharmacological O
and O
genetic O
approach O
was O
undertaken O
to O
investigate O
the O
contribution O
of O
endogenous O
dopamine B-CHEMICAL
to O
the O
motor O
actions O
of O

nociceptin/orphanin B-GENE-Y
FQ I-GENE-Y
(N/OFQ) I-GENE-Y
receptor I-GENE-Y
(NOP B-GENE-Y
receptor) I-GENE-Y
ligands. O
Motor O
activity O
was O
evaluated O
by O
a O
battery O
of O
behavioural O
tests O
in O
mice. O
The O
involvement O
of O
the O
various O
DA B-GENE-N
receptor I-GENE-N
subtypes O
in O
the O
motor O
effects O
of O
N/OFQ B-GENE-Y
and O
NOP B-GENE-Y
receptor I-GENE-Y
antagonists O
was O
evaluated O
pharmacologically, O
using O
D1/D5 B-GENE-Y
(SCH23390), B-CHEMICAL
D2/D3 B-GENE-Y
(raclopride, B-CHEMICAL
amisulpride) B-CHEMICAL
and O
D3 B-GENE-Y
(S33084) B-CHEMICAL
receptor O
antagonists, O
and O
by O
using O
D2 B-GENE-Y
receptor I-GENE-Y
knockout O

mice. O
Low O
doses O
of O
N/OFQ B-GENE-Y
and O
NOP B-GENE-Y
receptor I-GENE-Y
antagonists O
promoted O
movement O
whereas O
higher O
doses O
inhibited O
it. O
Motor O
facilitation O
was O
selectively O
prevented O
by O
raclopride B-CHEMICAL
while O
motor O
inhibition O
was O
prevented O
by O
amisulpride. B-CHEMICAL
Amisulpride B-CHEMICAL
also O
attenuated O
the O
hypolocomotion O
induced O
by O
the O
D2/D3 B-GENE-N
receptor I-GENE-N
agonist O
pramipexole B-CHEMICAL
and O
dopamine B-CHEMICAL
precursor O
L-3,4-dihydroxyphenylalanine, B-CHEMICAL
whereas O
raclopride B-CHEMICAL
(and O
S33084) B-CHEMICAL
worsened O
it. O
To O
dissect O
out O

the O
contribution O
of O
pre- O
and O
postsynaptic O
D2 B-GENE-Y
receptors, I-GENE-Y
mice O
lacking O
the O
D2 B-GENE-Y
receptor I-GENE-Y
(D2R(-/-)) B-GENE-Y
or O
its O
long O
isoform O
(D2L(-/-)) B-GENE-Y
were O
used. O
Motor O
facilitation O
induced O
by O
N/OFQ B-GENE-Y
and O
NOP B-GENE-Y
receptor I-GENE-Y
antagonists O
was O
lost O
in O
D2R(-/-) B-GENE-Y
and O
D2L(-/-) B-GENE-Y
mice O
whereas O
motor O
inhibition O
induced O
by O
NOP B-GENE-Y
receptor I-GENE-Y
antagonists O
(and O
pramipexole) B-CHEMICAL
was O
lost O
in O
D2R(-/-) B-GENE-Y
but O
preserved O
in O

D2L(-/-) B-GENE-Y
mice. O
N/OFQ-induced B-GENE-Y
hypolocomotion O
was O
observed O
in O
both O
genotypes. O
We O
demonstrate O
that O
motor O
actions O
of O
NOP B-GENE-Y
receptor I-GENE-Y
ligands O
rely O
on O
the O
modulation O
of O
endogenous O
dopamine. B-CHEMICAL
Motor O
facilitation O
induced O
by O
NOP B-GENE-Y
receptor I-GENE-Y
antagonists O
as O
well O
as O
low O
dose O
N/OFQ B-GENE-Y
is O
mediated O
through O
D2L B-GENE-Y
postsynaptic O
receptors O
whereas O
motor O
inhibition O
observed O
with O
higher O
doses O
of O
N/OFQ B-GENE-Y
occurs O
by O
direct O
inhibition O
of O
mesencephalic O
DA O
neurons. O
Motor O
inhibition O
seen O
with O
high O
doses O
of O
NOP B-GENE-Y

receptor I-GENE-Y
antagonists O
appears O
to O
be O
mediated O
through O
the O
D2 B-GENE-Y
presynaptic I-GENE-Y
autoreceptors. I-GENE-Y
These O
data O
confirm O
that O
endogenous O
N/OFQ B-GENE-Y
is O
a O
powerful O
modulator O
of O
dopamine O
transmission O
in O
vivo O
and O
that O
the O
effects O
of O
NOP B-GENE-Y
receptor I-GENE-Y
antagonists O
on O
motor O
function O
reflect O
the O
blockade O
of O
this O
endogenous O
N/OFQ B-GENE-Y
tone. O
Haloperidol B-CHEMICAL
promotes O
mTORC1-dependent B-GENE-N
phosphorylation O
of O
ribosomal B-GENE-Y
protein I-GENE-Y
S6 I-GENE-Y
via O
dopamine- B-GENE-Y
and I-GENE-Y
cAMP-regulated I-GENE-Y
phosphoprotein I-GENE-Y
of I-GENE-Y
32 I-GENE-Y
kDa I-GENE-Y
and O
inhibition O
of O
protein B-GENE-N

phosphatase-1. I-GENE-N
The O
ribosomal B-GENE-Y
protein I-GENE-Y
S6 I-GENE-Y
(rpS6) B-GENE-Y
is O
a O
component O
of O
the O
small O
40S B-GENE-N
ribosomal I-GENE-N
subunit, I-GENE-N
involved O
in O
multiple O
physiological O
functions. O
Here, O
we O
examined O
the O
effects O
produced O
by O
haloperidol, B-CHEMICAL
a O
typical O
antipsychotic O
drug, O
on O
the O
phosphorylation O
of O
rpS6 B-GENE-Y
at O
Ser240/244 B-CHEMICAL
in O
the O
striatum, O
a O
brain O
region O
involved O
in O
neurodegenerative O
and O
neuropsychiatric O
disorders. O
Administration O
of O
haloperidol B-CHEMICAL
increased O
Ser240/244 B-CHEMICAL
phosphorylation O
in O
a O

subpopulation O
of O
GABA-ergic B-CHEMICAL
medium O
spiny O
neurons O
(MSNs), O
which O
express O
dopamine B-GENE-Y
D2 I-GENE-Y
receptors I-GENE-Y
(D2Rs). B-GENE-Y
This O
effect O
was O
prevented O
by O
rapamycin, B-CHEMICAL
an O
inhibitor O
of O
the O
mammalian B-GENE-N
target I-GENE-N
of I-GENE-N
rapamycin I-GENE-N
complex I-GENE-N
1 I-GENE-N
(mTORC1), B-GENE-N
or O
by O
PF470867, B-CHEMICAL
a O
selective O
inhibitor O
of O
the O
p70 B-GENE-Y
ribosomal I-GENE-Y
S6 I-GENE-Y
kinase I-GENE-Y
1 I-GENE-Y
(S6K1). B-GENE-N
We O
also O
found O
that O
the O
effect O
of O
haloperidol B-CHEMICAL
on O
Ser240/244 B-CHEMICAL
phosphorylation O
was O
prevented O
by O
functional O
inactivation O

of O
dopamine- B-GENE-Y
and I-GENE-Y
cAMP-regulated I-GENE-Y
phosphoprotein I-GENE-Y
of I-GENE-Y
32 I-GENE-Y
kDa I-GENE-Y
(DARPP-32), B-GENE-Y
an O
endogenous O
inhibitor O
of O
protein B-GENE-N
phosphatase-1 I-GENE-N
(PP-1). B-GENE-N
In O
line O
with O
this O
observation, O
incubation O
of O
striatal O
slices O
with O
okadaic B-CHEMICAL
acid I-CHEMICAL
and O
calyculin B-CHEMICAL
A, I-CHEMICAL
two O
inhibitors O
of O
PP-1, B-GENE-N
increased O
Ser240/244 B-CHEMICAL
phosphorylation. O
These O
results O
show O
that O
haloperidol B-CHEMICAL
promotes O
mTORC1- B-GENE-N
and O
S6K1-dependent B-GENE-N
phosphorylation O
of O

rpS6 B-GENE-Y
at O
Ser240/244, B-CHEMICAL
in O
a O
subpopulation O
of O
striatal O
MSNs O
expressing O
D2Rs. B-GENE-Y
They O
also O
indicate O
that O
this O
effect O
is O
exerted O
by O
suppressing O
dephosphorylation O
at O
Ser240/244, B-CHEMICAL
through O
PKA-dependent B-GENE-N
activation O
of O
DARPP-32 B-GENE-Y
and O
inhibition O
of O
PP-1. B-GENE-N
Designing, O
structural O
elucidation, O
comparison O
of O
DNA O
binding, O
cleavage, O
radical O
scavenging O
activity O
and O
anticancer O
activity O
of O
copper(I) B-CHEMICAL
complex O
with O

5-dimethyl-2-phenyl-4-[(pyridin-2-ylmethylene)-amino]-1,2-dihydro-pyrazol-3-one B-CHEMICAL
Schiff B-CHEMICAL
base I-CHEMICAL
ligand. O
A O
novel O
copper(I) B-CHEMICAL
Schiff I-CHEMICAL
base I-CHEMICAL
complex O
has O
been O
synthesized O
and O
fully O
characterized O
by O
spectral, O
analytical O
and O
structural O
modes. O
Single O
crystal O
X-ray O
diffraction O
studies O
revealed O
that O
the O
copper(I) B-CHEMICAL
complex O
[CuCl(PPh3)L] B-CHEMICAL
has O
a O
distorted O
tetrahedral O
geometry O
around O
the O
central O

copper(I) B-CHEMICAL
ion. O
The O
interaction O
of O
the O
ligand O
and O
the O
complex O
with O
CT-DNA O
has O
been O
explored O
by O
absorption O
titration O
method O
which O
revealed O
that O
the O
compounds O
could O
interact O
with O
CT-DNA O
through O
intercalation. O
A O
gel O
electrophoresis O
assay O
demonstrated O
the O
ability O
of O
the O
complex O
to O
cleave O
the O
pBR322 O
DNA. O
The O
antioxidative O
properties O
showed O
that O
the O
copper(I) B-CHEMICAL
complex O
has O
a O
strong O
radical-scavenging O
potency O
than O
ligands. O
Further O
the O
cytotoxic O
effect O
of O
the O
compounds O
examined O
on O
cancerous O
cell O
lines O
showed O
that O
the O
complex O
exhibited O
substantial O
anticancer O

activity. O
Low O
molecular O
weight O
dual O
inhibitors O
of O
factor B-GENE-Y
Xa I-GENE-Y
and O
fibrinogen B-GENE-N
binding O
to O
GPIIb/IIIa B-GENE-Y
with O
highly O
overlapped O
pharmacophores. O
Dual O
antithrombotic O
agents O
acting O
as O
anticoagulants O
and O
aggregation O
inhibitors O
could O
have O
substantial O
advantages O
over O
currently O
prescribed O
combinations O
of O
antithrombotic O
drugs. O
Herein, O
we O
report O
compounds O
with O
moderate O
inhibitory O
activity O
for O
factor B-GENE-Y
Xa I-GENE-Y
and O
fibrinogen B-GENE-N
GPIIb/IIIa B-GENE-Y
binding O
(both O
in O
the O
micromolar O
range). O
These O
compounds O
resulted O
from O
our O
efforts O
to O
merge O
the O
pharmacophores O
of O
selective O
factor B-GENE-Y

Xa I-GENE-Y
inhibitor O
rivaroxaban B-CHEMICAL
with O
a O
mimic O
of O
the O
Arg-Gly-Asp B-GENE-N
(RGD) B-GENE-N
sequence O
of O
fibrinogen B-GENE-N
to O
obtain O
designed O
multiple O
ligands O
with O
potential O
antithrombotic O
activity. O
Resulting O
from O
this O
study, O
a O
structurally O
novel O
class O
of O
submicromolar O
fibrinogen O
GPIIb/IIIa B-GENE-Y
binding O
inhibitor O
bearing O
1,2,4-oxadiazol-5(4H)-one B-CHEMICAL
moiety O
is O
also O
described. O
Role O
of O
quercetin B-CHEMICAL
in O
cadmium-induced B-CHEMICAL
oxidative O
stress, O
neuronal O

damage, O
and O
apoptosis O
in O
rats. O
The O
present O
study O
was O
carried O
out O
to O
evaluate O
the O
neuroprotective O
effect O
of O
quercetin B-CHEMICAL
(QE) O
in O
protecting O
the O
cadmium B-CHEMICAL
(Cd)-induced B-CHEMICAL
neuronal O
injury O
in O
frontal O
cortex O
of O
rats. O
A O
total O
of O
30 O
adult O
male O
Sprague-Dawley O
rats O
were O
randomly O
divided O
into O
three O
groups O
of O
10 O
animals O
each: O
control, O
Cd B-CHEMICAL
treated O
and O
Cd B-CHEMICAL
treated O
with O
QE. O
The O
Cd-treated B-CHEMICAL
group O
was O
injected O
subcutaneously O
with O
cadmium B-CHEMICAL
chloride I-CHEMICAL
(CdCl2) B-CHEMICAL
dissolved O
in O
saline O
at O
a O
dose O
of O
2 O

ml/kg/day O
for O
30 O
days, O
resulting O
in O
a O
dosage O
of O
1 O
mg/kg O
Cd. B-CHEMICAL
The O
rats O
in O
QE-treated O
groups O
were O
given O
QE O
(15 O
mg/kg O
body O
weight) O
once O
a O
day O
intraperitoneally O
starting O
2 O
days O
prior O
to O
Cd B-CHEMICAL
injection, O
during O
the O
study O
period. O
Rats O
were O
sacrificed O
at O
the O
end O
of O
the O
study O
and O
the O
frontal O
cortex O
tissues O
were O
removed O
for O
biochemical O
and O
histopathological O
investigation. O
To O
date, O
there O
is O
no O
available O
information O
on O
the O
effect O
of O
QE O
on O
neuronal O
injury O
after O
Cd B-CHEMICAL
exposure. O
Rats O
intoxicated O
with O
Cd B-CHEMICAL
for O

30 O
days, O
significantly O
increased O
tissue O
malondialdehyde B-CHEMICAL
(MDA) B-CHEMICAL
levels O
and O
significantly O
decreased O
enzymatic O
antioxidants O
superoxide B-GENE-N
dismutase, I-GENE-N
glutathione B-CHEMICAL
peroxidase I-GENE-N
and O
catalase B-GENE-Y
in O
the O
frontal O
cortex O
tissue. O
Administration O
of O
QE O
with O
Cd B-CHEMICAL
significantly O
diminished O
the O
levels O
of O
MDA B-CHEMICAL
and O
significantly O
elevated O
the O
levels O
of O
enzymatic O
antioxidants O
in O
the O
frontal O
cortex O
tissue. O
The O
histopathological O
studies O
in O
the O
brain O
of O
rats O
also O
supported O
that O
QE O
markedly O
reduced O
the O
Cd-induced B-CHEMICAL
histopathological O
changes O
and O
well O
preserved O
the O
normal O
histological O
architecture O
of O
the O
frontal O

cortex O
tissue. O
The O
caspase-3 B-GENE-Y
immunopositivity O
was O
increased O
in O
degenerating O
neurons O
of O
the O
Cd B-CHEMICAL
group. O
Treatment O
with O
QE O
markedly O
reduced O
the O
immunoreactivity O
of O
degenerating O
neurons. O
In O
conclusion, O
the O
results O
of O
the O
current O
study O
suggest O
that O
QE O
may O
be O
beneficial O
in O
combating O
the O
Cd-induced B-CHEMICAL
neurotoxicity O
in O
the O
brain O
of O
rats. O
We O
believe O
that O
further O
preclinical O
research O
into O
the O
utility O
of O
QE O
may O
indicate O
its O
usefulness O
as O
a O
potential O
treatment O
for O
neurodegeneration O
after O
Cd B-CHEMICAL
exposure O
in O
rats. O
Oestrogen B-CHEMICAL
action O
on O

thyroid O
progenitor O
cells: O
relevant O
for O
the O
pathogenesis O
of O
thyroid O
nodules? O
Benign O
and O
malignant O
thyroid O
nodules O
are O
more O
prevalent O
in O
females O
than O
in O
men. O
Experimental O
data O
suggest O
that O
the O
proliferative O
effect O
of O
oestrogen B-CHEMICAL
rather O
than O
polymorphisms O
is O
responsible O
for O
this O
gender O
difference. O
This O
study O
analysed O
whether O
both O
differentiated O
thyroid O
cells O
and O
thyroid O
stem O
and O
progenitor O
cells O
are O
a O
target O
of O
oestrogen B-CHEMICAL
action. O
In O
thyroid O
stem/progenitor O
cells O
derived O
from O
nodular O
goitres O
the O
ability O
of O
17beta-oestradiol B-CHEMICAL
to O
induce O
thyrosphere O

formation, O
the O
expression O
of O
oestrogen B-CHEMICAL
receptors I-GENE-Y
and O
the O
effect O
of O
17beta-oestradiol B-CHEMICAL
on O
growth, O
expression O
of O
marker O
of O
stem O
cells O
and O
thyroid O
differentiation O
(TSH B-GENE-Y
receptor, I-GENE-Y
thyroperoxidase, B-GENE-Y
thyroglobulin, B-GENE-Y
sodium B-GENE-Y
iodide I-GENE-Y
symporter I-GENE-Y
expression) O
were O
analysed. O
17beta-oestradiol B-CHEMICAL
induced O
thyrosphere O
formation, O
albeit O
to O
lower O
extent O
than O
other O
growth O
factors. O
Thyroid O
stem O
and O
progenitor O
cells O
expressed O
oestrogen B-GENE-N
receptor I-GENE-N
alpha I-GENE-N
and I-GENE-N
beta I-GENE-N
with O
an O
8 O
time O
higher O
expression O
level O
of O
oestrogen B-GENE-N
receptor I-GENE-N
alpha I-GENE-N
mRNA O
compared O
to O
differentiated O

thyrocytes. O
17beta-oestradiol B-CHEMICAL
was O
a O
potent O
stimulator O
of O
thyroid O
stem/ O
progenitor O
cell O
growth. O
In O
contrast, O
TSH-induced O
differentiation O
of O
progenitor O
cells, O
in O
particular O
the O
expression O
of O
the O
sodium B-CHEMICAL
iodide I-CHEMICAL
symporter, I-GENE-Y
was O
significantly O
inhibited O
by O
17beta-oestradiol.In B-CHEMICAL
conclusion, O
oestrogen B-CHEMICAL
stimulated O
growth O
and O
simultaneously O
inhibited O
differentiation O
of O
thyroid O
nodules O
derived O
stem/progenitor O
cells. O
From O
these O
data O
and O
based O
on O
the O
concept O
of O
cellular O
heterogeneity, O
we O
hypothesize O
a O

supportive O
role O
of O
oestrogen B-CHEMICAL
in O
the O
propagation O
of O
thyroid O
stem/progenitor O
cells O
leading O
to O
a O
selection O
of O
a O
progeny O
of O
growth-prone O
cells O
with O
a O
decreased O
differentiation. O
These O
cells O
may O
be O
the O
origin O
of O
hypo- O
or O
non-functioning O
thyroid O
nodules O
in O
females. O
Differential O
regulation O
of O
Arabidopsis B-GENE-N
plastid I-GENE-N
gene O
expression O
and O
RNA O
editing O
in O
non-photosynthetic O
tissues. O
RNA O
editing O
is O
one O
of O
the O
post-transcriptional O
processes O
that O
commonly O
occur O
in O
plant B-GENE-N
plastids I-GENE-N
and O
mitochondria. O
In O
Arabidopsis, O
34 O
C-to-U O
RNA O
editing O
events, O
affecting O
transcripts O
of O
18 O

plastid B-GENE-N
genes, O
have O
been O
identified. O
Here, O
we O
examined O
the O
editing O
and O
expression O
of O
these O
transcripts O
in O
different O
organs, O
and O
in O
green O
and O
non-green O
seedlings O
(etiolated, O
cia5-2, O
ispF O
and O
ispG O
albino O
mutants, O
lincomycin-, B-CHEMICAL
and O
norflurazon-treated). B-CHEMICAL
The O
editing O
efficiency O
of O
Arabidopsis B-GENE-N
plastid I-GENE-N
transcripts O
varies O
from O
site O
to O
site, O
and O
may O
be O
specifically O
regulated O
in O
different O
tissues. O
Steady O
state O
levels O
of O
plastid B-GENE-N
transcripts O
are O
low O
or O
undetectable O
in O
etiolated O
seedlings, O

but O
most O
editing O
sites O
are O
edited O
with O
efficiencies O
similar O
to O
those O
observed O
in O
green O
seedlings. O
By O
contrast, O
the O
editing O
of O
some O
sites O
is O
completely O
lost O
or O
significantly O
reduced O
in O
other O
non-green O
tissues; O
for O
instance, O
the O
editing O
of O
ndhB-149, B-GENE-N
ndhB-1255, B-GENE-N
and O
ndhD-2 B-GENE-N
is O
completely O
lost O
in O
roots O
and O
in O
lincomycin-treated B-CHEMICAL
seedlings. O
The O
editing O
of O
ndhD-2 B-GENE-N
is O
also O
completely O
lost O
in O
albino O
mutants O
and O
norflurazon-treated B-CHEMICAL
seedlings. O
However, O
matK-640 O
is O
completely O
edited, O
and O

accD-794, B-GENE-N
atpF-92, B-GENE-N
psbE-214, B-GENE-N
psbF-77, B-GENE-N
psbZ-50, B-GENE-N
and O
rps14-50 B-GENE-N
are O
completely O
or O
highly O
edited O
in O
both O
green O
and O
non-green O
tissues. O
In O
addition, O
the O
expression O
of O
nucleus-encoded O
RNA B-GENE-N
polymerase I-GENE-N
dependent O
transcripts O
is O
specifically O
induced O
by O
lincomycin, B-CHEMICAL
and O
the O
splicing O
of O
ndhB B-GENE-N
transcripts O
is O
significantly O
reduced O
in O
the O
albino O
mutants O
and O
inhibitor-treated O
seedlings. O
Our O
results O
indicate O
that O
plastid B-GENE-N
gene O
expression, O
and O
the O
splicing O
and O
editing O
of O
plastid B-GENE-N
transcripts O

are O
specifically O
and O
differentially O
regulated O
in O
various O
types O
of O
non-green O
tissues. O
Drug-drug O
interactions O
between O
HMG-CoA B-GENE-Y
reductase I-GENE-Y
inhibitors O
(statins) O
and O
antiviral O
protease B-GENE-N
inhibitors. O
The O
HMG-CoA B-GENE-Y
reductase I-GENE-Y
inhibitors O
are O
a O
class O
of O
drugs O
also O
known O
as O
statins. O
These O
drugs O
are O
effective O
and O
widely O
prescribed O
for O
the O
treatment O
of O
hypercholesterolemia O
and O
prevention O
of O
cardiovascular O
morbidity O
and O
mortality. O
Seven O
statins O
are O
currently O
available: O
atorvastatin, B-CHEMICAL
fluvastatin, B-CHEMICAL
lovastatin, B-CHEMICAL

pitavastatin, B-CHEMICAL
pravastatin, B-CHEMICAL
rosuvastatin B-CHEMICAL
and O
simvastatin. B-CHEMICAL
Although O
these O
drugs O
are O
generally O
well O
tolerated, O
skeletal O
muscle O
abnormalities O
from O
myalgia O
to O
severe O
lethal O
rhabdomyolysis O
can O
occur. O
Factors O
that O
increase O
statin O
concentrations O
such O
as O
drug-drug O
interactions O
can O
increase O
the O
risk O
of O
these O
adverse O
events. O
Drug-drug O
interactions O
are O
dependent O
on O
statins' O
pharmacokinetic O
profile: O
simvastatin, B-CHEMICAL
lovastatin B-CHEMICAL
and O
atorvastatin B-CHEMICAL
are O
metabolized O
through O
cytochrome B-GENE-N
P450 I-GENE-N
(CYP) I-GENE-N

3A, I-GENE-N
while O
the O
metabolism O
of O
the O
other O
statins O
is O
independent O
of O
this O
CYP. B-GENE-N
All O
statins O
are O
substrate O
of O
organic B-GENE-Y
anion I-GENE-Y
transporter I-GENE-Y
polypeptide I-GENE-Y
1B1, I-GENE-Y
an O
uptake O
transporter O
expressed O
in O
hepatocyte O
membrane O
that O
may O
also O
explain O
some O
drug-drug O
interactions. O
Many O
HIV-infected O
patients O
have O
dyslipidemia O
and O
comorbidities O
that O
may O
require O
statin O
treatment. O
HIV-protease B-GENE-N
inhibitors O
(HIV O
PIs) O
are O
part O
of O
recommended O
antiretroviral O
treatment O
in O
combination O
with O
two O
reverse B-GENE-N
transcriptase I-GENE-N
inhibitors. O
All O
HIV O
PIs O

except O
nelfinavir B-CHEMICAL
are O
coadministered O
with O
a O
low O
dose O
of O
ritonavir, B-CHEMICAL
a O
potent O
CYP3A B-GENE-N
inhibitor O
to O
improve O
their O
pharmacokinetic O
properties. O
Cobicistat O
is O
a O
new O
potent O
CYP3A B-GENE-N
inhibitor O
that O
is O
combined O
with O
elvitegravir O
and O
will O
be O
combined O
with O
HIV-PIs O
in O
the O
future. O
The O
HCV-PIs O
boceprevir B-CHEMICAL
and O
telaprevir B-CHEMICAL
are O
both, O
to O
different O
extents, O
inhibitors O
of O
CYP3A. B-GENE-N
This O
review O
summarizes O
the O
pharmacokinetic O
properties O
of O
statins O
and O

PIs O
with O
emphasis O
on O
their O
metabolic O
pathways O
explaining O
clinically O
important O
drug-drug O
interactions. O
Simvastatin B-CHEMICAL
and O
lovastatin B-CHEMICAL
metabolized O
through O
CYP3A B-GENE-N
have O
the O
highest O
potency O
for O
drug-drug O
interaction O
with O
potent O
CYP3A B-GENE-N
inhibitors O
such O
as O
ritonavir- B-CHEMICAL
or O
cobicistat-boosted B-CHEMICAL
HIV-PI O
or O
the O
hepatitis O
C O
virus O
(HCV) O
PI, O
telaprevir B-CHEMICAL
or O
boceprevir, B-CHEMICAL
and O
therefore O
their O
coadministration O
is O
contraindicated. O
Atorvastatin B-CHEMICAL
is O
also O
a O
CYP3A B-GENE-N

substrate, O
but O
less O
potent O
drug-drug O
interactions O
have O
been O
reported O
with O
CYP3A B-GENE-N
inhibitors. O
Non-CYP3A-dependent B-GENE-N
statin O
concentrations O
are O
also O
affected O
although O
to O
a O
lesser O
extent O
when O
coadministered O
with O
HIV O
or O
HCV O
PIs, O
mainly O
through O
interaction O
with O
OATP1B1, B-GENE-Y
and O
treatment O
should O
start O
with O
the O
lowest O
available O
statin O
dose. O
Effectiveness O
and O
occurrence O
of O
adverse O
effects O
should O
be O
monitored O
at O
regular O
time O
intervals. O
Synthesis, O
structure-activity O
relationships, O
and O
in O
vivo O
efficacy O
of O
the O
novel O
potent O
and O
selective O
anaplastic B-GENE-Y
lymphoma I-GENE-Y
kinase I-GENE-Y
(ALK) B-GENE-Y
inhibitor O

5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf B-CHEMICAL
onyl)phenyl)pyrimidine-2,4-diamine I-CHEMICAL
(LDK378) B-CHEMICAL
currently O
in O
phase O
1 O
and O
phase O
2 O
clinical O
trials. O
The O
synthesis, O
preclinical O
profile, O
and O
in O
vivo O
efficacy O
in O
rat O
xenograft O
models O
of O
the O
novel O
and O
selective O
anaplastic B-GENE-Y
lymphoma I-GENE-Y
kinase I-GENE-Y
inhibitor O
15b O

(LDK378) B-CHEMICAL
are O
described. O
In O
this O
initial O
report, O
preliminary O
structure-activity O
relationships O
(SARs) O
are O
described O
as O
well O
as O
the O
rational O
design O
strategy O
employed O
to O
overcome O
the O
development O
deficiencies O
of O
the O
first O
generation O
ALK B-GENE-Y
inhibitor O
4 O
(TAE684). B-CHEMICAL
Compound O
15b O
is O
currently O
in O
phase O
1 O
and O
phase O
2 O
clinical O
trials O
with O
substantial O
antitumor O
activity O
being O
observed O
in O
ALK-positive B-GENE-Y
cancer O
patients. O
Benzodiazepines, B-CHEMICAL
but O
not O
beta B-CHEMICAL
carbolines, I-CHEMICAL
limit O
high O
frequency O
repetitive O
firing O
of O
action O
potentials O
of O
spinal O
cord O
neurons O
in O
cell O
culture. O
Effects O
of O

benzodiazepines B-CHEMICAL
(BDZs) B-CHEMICAL
and O
beta B-CHEMICAL
carbolines I-CHEMICAL
(beta B-CHEMICAL
CCs) I-CHEMICAL
on O
sustained O
repetitive O
firing O
at O
high O
frequency O
(SRF) O
of O
action O
potentials O
of O
mouse O
spinal O
cord O
neurons O
in O
cell O
culture O
were O
examined O
using O
intracellular O
recording O
techniques. O
In O
control O
medium O
neurons O
responded O
to O
depolarizing O
current O
pulses O
with O
SRF. O
Limitation O
of O
SRF O
was O
produced O
by O
the O
anticonvulsant O
BDZs B-CHEMICAL
(diazepam, B-CHEMICAL
clonazepam, B-CHEMICAL
nitrazepam B-CHEMICAL
and O
lorazepam) B-CHEMICAL
at O
low O
to O
mid O
nanomolar O
concentrations, O
by O
a O

convulsant O
BDZ B-CHEMICAL
which O
does O
not O
bind O
to O
high O
affinity O
BDZ B-GENE-N
receptors I-GENE-N
(Ro B-CHEMICAL
5-4864) I-CHEMICAL
at O
high O
nanomolar O
concentrations O
and O
by O
a O
BDZ B-GENE-N
receptor I-GENE-N
weak O
partial O
agonist O
(Ro B-CHEMICAL
15-1788) I-CHEMICAL
at O
micromolar O
concentrations. O
The O
limitation O
of O
SRF O
was O
accompanied O
by O
use- O
and O
voltage-dependent O
reduction O
of O
maximal O
rate O
of O
rise O
(Vmax) O
of O
sodium-dependent B-CHEMICAL
action O
potentials. O
Partial O
agonist O
and O
inverse O
agonist O
beta O
CCs O
did O
not O
limit O
SRF O
at O
concentrations O
up O
to O
200 O
nM. O
The O
limitation O
of O
SRF O
by O
diazepam B-CHEMICAL
was O
not O

prevented O
by O
inverse O
or O
partial O
agonists O
at O
the O
BDZ B-GENE-N
receptor, I-GENE-N
including O
Ro B-CHEMICAL
15-1788 I-CHEMICAL
and O
the O
beta B-CHEMICAL
CCs. I-CHEMICAL
These O
findings O
suggest O
that O
limitation O
of O
SRF O
was O
produced O
by O
binding O
of O
BDZs, B-CHEMICAL
but O
not O
beta B-CHEMICAL
CCs, I-CHEMICAL
to O
voltage-dependent B-GENE-N
sodium B-CHEMICAL
channels I-GENE-N
and O
not O
to O
high O
affinity O
central O
BDZ B-CHEMICAL
receptors, I-GENE-N
and O
that O
BDZs B-CHEMICAL
limit O
SRF O
by O
slowing O
recovery O
of O
sodium B-GENE-N
channels I-GENE-N
from O
inactivation. O
We O
propose O
that O
the O
limitation O
of O
SRF O
may O
contribute O
to O
the O
efficacy O
of O
BDZs B-CHEMICAL
against O
generalized O
tonic-clonic O
seizures O
and O
status O
epilepticus. O
Androgens B-CHEMICAL

directly O
stimulate O
proliferation O
of O
bone O
cells O
in O
vitro. O
This O
report O
describes O
the O
first O
observation O
of O
a O
direct O
mitogenic O
effect O
of O
androgens B-CHEMICAL
on O
isolated O
osteoblastic O
cells O
in O
serum-free O
culture. O
[3H]thymidine B-CHEMICAL
incorporation O
into O
DNA O
and O
cell O
counts O
were O
used O
as O
measures O
of O
cell O
proliferation. O
The O
percentage O
of O
cells O
that O
stained O
for O
alkaline B-GENE-N
phosphatase I-GENE-N
was O
used O
as O
a O
measure O
of O
differentiation. O
Dihydrotestosterone B-CHEMICAL
(DHT) B-CHEMICAL
enhanced O
mouse O
osteoblastic O
cell O
proliferation O
in O
a O
dose O
dependent O
manner O
over O
a O
wide O
range O
of O
doses O
(10(-8) O
to O
10(-11) O

molar), O
and O
was O
maximally O
active O
at O
10(-9) O
M. O
DHT B-CHEMICAL
also O
stimulated O
proliferation O
in O
human O
osteoblast O
cell O
cultures O
and O
in O
cultures O
of O
the O
human O
osteosarcoma O
cell O
line, O
TE89. O
Testosterone, B-CHEMICAL
fluoxymesterone B-CHEMICAL
(a O
synthetic O
androgenic O
steroid) B-CHEMICAL
and O
methenolone B-CHEMICAL
(an O
anabolic O
steroid) B-CHEMICAL
were O
also O
mitogenic O
in O
the O
mouse O
bone O
cell O
system. O
The O
mitogenic O
effect O
of O
DHT B-CHEMICAL
on O
bone O
cells O
was O
inhibited O
by O
antiandrogens O
(hydroxyflutamide B-CHEMICAL
and O

cyproterone B-CHEMICAL
acetate) I-CHEMICAL
which O
compete O
for O
binding O
to O
the O
androgen B-GENE-N
receptor. I-GENE-N
In O
addition O
to O
effects O
on O
cell O
proliferation, O
DHT B-CHEMICAL
increased O
the O
percentage O
of O
alkaline B-GENE-N
phosphatase I-GENE-N
(ALP) B-GENE-N
positive O
cells O
in O
all O
three O
bone O
cell O
systems O
tested, O
and O
this O
effect O
was O
inhibited O
by O
antiandrogens. O
We O
conclude O
that O
androgens B-CHEMICAL
can O
stimulate O
human O
and O
murine O
osteoblastic O
cell O
proliferation O
in O
vitro, O
and O
induce O
expression O
of O
the O
osteoblast-line B-GENE-N
differentiation I-GENE-N
marker I-GENE-N
ALP, B-GENE-N
presumably O
by O
an O
androgen B-CHEMICAL
receptor I-GENE-N
mediated O
mechanism. O
The O
effect O
of O
histamine-H1 B-GENE-Y
receptor I-GENE-Y

antagonism O
with O
terfenadine B-CHEMICAL
on O
concentration-related O
AMP-induced B-CHEMICAL
bronchoconstriction O
in O
asthma. O
Selective O
histamine-H1 B-CHEMICAL
receptor I-GENE-Y
antagonists O
inhibit O
adenosine B-CHEMICAL
5'-monophosphate I-CHEMICAL
(AMP)-induced B-CHEMICAL
bronchoconstriction O
by O
greater O
than O
80% O
when O
expressed O
as O
a O
percentage O
inhibition O
of O
the O
FEV1 O
time-response O
curve O
following O
inhalation O
of O
the O
provocation O
concentration O
of O
AMP B-CHEMICAL
required O
to O
produce O
a O
20% O
decrease O
in O
FEV1 O
from O
baseline O
(PC20). O
To O
investigate O
this O
further O
we O
have O
determined O

that, O
in O
eight O
mild O
atopic O
asthmatic O
subjects, O
terfenadine B-CHEMICAL
(180 O
mg), O
administered O
3 O
hr O
pre-challenge, O
increases O
the O
geometric O
mean O
PC20 O
for O
histamine B-CHEMICAL
from O
0.4 O
(range O
0.03-3) O
mg/ml O
after O
placebo, O
to O
20.2 O
(range O
0.6-64) O
mg/ml O
following O
active O
treatment O
(P O
less O
than O
0.0001). O
For O
AMP, B-CHEMICAL
the O
PC20 O
increased O
from O
9.3 O
(range O
1.0-113.3) O
mg/ml O
after O
placebo, O
to O
150.2 O
(range O

32.1-1177.7) O
mg/ml O
with O
terfenadine B-CHEMICAL
(P O
less O
than O
0.0001). O
This O
16.2-fold O
(range, O
5.5-47.9) O
displacement O
to O
the O
right O
of O
the O
AMP B-CHEMICAL
concentration-response O
curve O
by O
a O
selective O
histamine-H1 B-GENE-Y
receptor I-GENE-Y
antagonist O
emphasizes O
the O
central O
role O
of O
histamine B-CHEMICAL
in O
the O
airways O
response O
to O
this O
nucleotide. O
Ibrutinib: B-CHEMICAL
a O
review O
of O
its O
use O
in O
patients O
with O
mantle O
cell O
lymphoma O
or O
chronic O
lymphocytic O
leukaemia. O
Ibrutinib B-CHEMICAL

(Imbruvica(R)) B-CHEMICAL
is O
a O
first-in-class, O
potent, O
orally O
administered, O
covalent O
inhibitor O
of O
Bruton's B-GENE-Y
tyrosine B-CHEMICAL
kinase I-GENE-Y
(BTK) B-GENE-Y
that O
inhibits O
B-cell B-GENE-N
antigen I-GENE-N
receptor I-GENE-N
signalling O
downstream O
of O
BTK. B-GENE-Y
Oral O
ibrutinib B-CHEMICAL
is O
indicated O
for O
the O
treatment O
of O
patients O
with O
relapsed/refractory O
mantle O
cell O
lymphoma O
(MCL) O
or O
chronic O
lymphocytic O
leukaemia O
(CLL) O
and O
for O
the O
treatment O
of O
patients O
with O
CLL O
and O
a O
chromosome O
17 O
deletion O
(del O
17p) O
or O

TP53 B-GENE-Y
mutation. O
This O
article O
summarizes O
pharmacological, O
efficacy O
and O
tolerability O
data O
relevant O
to O
the O
use O
of O
ibrutinib B-CHEMICAL
in O
these O
indications. O
In O
clinical O
studies, O
ibrutinib B-CHEMICAL
induced O
a O
high O
overall O
response O
rate O
in O
patients O
with O
relapsed/refractory O
MCL O
(phase O
II O
study). O
In O
addition, O
ibrutinib B-CHEMICAL
significantly O
prolonged O
progression-free O
survival O
and O
significantly O
improved O
the O
partial O
response O
rate O
and O
overall O
survival O
in O
patients O
with O
relapsed/refractory O
CLL O
(RESONATE O
study), O
including O
in O
those O
with O
del O
17p, O
a O
subgroup O

with O
a O
poor O
prognosis. O
Ibrutinib B-CHEMICAL
had O
an O
acceptable O
tolerability O
profile O
in O
these O
studies O
with O
<10% O
of O
patients O
discontinuing O
treatment O
because O
of O
adverse O
events. O
Given O
its O
efficacy O
and O
tolerability, O
once-daily, O
oral O
ibrutinib B-CHEMICAL
is O
an O
emerging O
treatment O
option O
for O
patients O
with O
relapsed/refractory O
MCL O
or O
CLL O
and O
CLL O
patients O
with O
del O
17p O
or O
TP53 B-GENE-Y
mutation. O
Effects O
of O
beta-adrenoceptor B-GENE-N
antagonist O
administration O
on O
beta B-GENE-Y
2-adrenoceptor I-GENE-Y
density O
in O
human O
lymphocytes. O
The O
role O
of O
the O
"intrinsic O

sympathomimetic O
activity". O
Abrupt O
withdrawal O
of O
beta-adrenoceptor B-GENE-N
antagonists O
may O
lead O
to O
"rebound-effects". O
To O
study O
the O
mechanism O
underlying O
this O
phenomenon, O
the O
effects O
of O
the O
nonselective O
beta-adrenoceptor B-GENE-N
antagonists O
propranolol B-CHEMICAL
[no O
intrinsic O
sympathomimetic O
activity O
(ISA)], O
alprenolol B-CHEMICAL
(weak O
ISA) O
and O
mepindolol B-CHEMICAL
(strong O
ISA) O
on O
lymphocyte O
beta B-GENE-Y
2-adrenoceptor I-GENE-Y
density--assessed O
by O

(+/-)-[125I]-iodocyanopindolol B-CHEMICAL
(ICYP) B-CHEMICAL
binding--and O
plasma O
renin B-GENE-Y
activity O
(PRA) O
were O
investigated O
in O
male O
healthy O
volunteers O
aged O
23-35 O
years. O
Propranolol B-CHEMICAL
treatment O
(4 O
X O
40 O
mg/day) O
increased O
the O
density O
of O
beta B-GENE-Y
2-adrenoceptors I-GENE-Y
by O
25% O
after O
2 O
days; O
concomitantly O
PRA O
and O
heart O
rate O
were O
reduced. O
During O
treatment O
beta B-GENE-Y
2-adrenoceptor I-GENE-Y
density O
remained O
elevated. O
After O
withdrawal O
of O
propranolol B-CHEMICAL
PRA O
reached O
pre-drug O
levels O
rapidly, O
while O
heart O
rate O

was O
significantly O
enhanced. O
Beta B-GENE-Y
2-Adrenoceptor I-GENE-Y
density, O
however, O
declined O
slowly O
being O
still O
significantly O
increased O
after O
3 O
days, O
although O
propranolol B-CHEMICAL
was O
not O
detectable O
in O
plasma O
after O
24 O
h. O
The O
affinity O
of O
ICYP B-CHEMICAL
to O
beta B-GENE-Y
2-adrenoceptors I-GENE-Y
was O
not O
changed O
during O
or O
after O
treatment. O
Mepindolol B-CHEMICAL
treatment O
(2 O
X O
5 O
mg/day) O
caused O
a O
30% O
decrease O
of O
beta B-GENE-Y
2-adrenoceptor I-GENE-Y
density O
and O
PRA O
after O
2 O
days; O
both O
parameters O
remained O
reduced O
during O
treatment. O
After O
withdrawal, O
PRA O
reached O
rapidly O
pre-drug O
levels, O
whereas O
beta B-GENE-Y

2-adrenoceptor I-GENE-Y
density O
was O
still O
after O
4 O
days O
significantly O
diminished. O
The O
KD-values O
for O
ICYP, B-CHEMICAL
however, O
were O
not O
changed. O
During O
and O
after O
treatment O
heart O
rate O
was O
not O
affected. O
Alprenolol B-CHEMICAL
treatment O
(4 O
X O
100 O
mg/day) O
led O
to O
a O
rapid O
fall O
in O
PRA, O
but O
did O
not O
significantly O
affect O
beta B-GENE-Y
2-adrenoceptor I-GENE-Y
density. O
It O
is O
concluded, O
that O
the O
ISA O
may O
play O
an O
important O
role O
in O
modulating O
beta B-GENE-Y
2-adrenoceptor I-GENE-Y
density O
and O
hence O
tissue O
responsiveness O
to O
beta-adrenoceptor B-GENE-N

stimulation.(ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS) O
Inhibition O
of O
5-lipoxygenase B-GENE-Y
pathway O
of O
arachidonic B-CHEMICAL
acid I-CHEMICAL
metabolism O
in O
human O
neutrophils O
by O
sulfasalazine B-CHEMICAL
and O
5-aminosalicylic B-CHEMICAL
acid. I-CHEMICAL
The O
possible O
effect O
of O
sulfasalazine, B-CHEMICAL
5-aminosalicylic B-CHEMICAL
acid, I-CHEMICAL
and O
acetyl-5-aminosalicylic B-CHEMICAL
acid I-CHEMICAL
on O
endogenous O
arachidonic B-CHEMICAL
acid I-CHEMICAL
release O
and O
metabolism O
was O
studied O
in O
human O
polymorphonuclear O
leukocytes O
(PMNs). O

A O
new O
in O
vitro O
assay O
was O
used O
by O
which O
[1-14C]arachidonic B-CHEMICAL
acid I-CHEMICAL
is O
incorporated O
by O
purified O
peripheral O
PMNs O
until O
steady O
state O
was O
obtained O
(5 O
hr). O
After O
preincubation O
with O
the O
test O
drugs O
prior O
to O
activation O
with O
calcium B-CHEMICAL
ionophore I-CHEMICAL
A23187, I-CHEMICAL
the O
released O
eicosanoids B-CHEMICAL
were O
isolated O
by O
extraction O
and O
thin-layer O
chromatography O
(TLC) O
and O
quantitated O
by O
autoradiography O
and O
laser O
densitometry. O
Median O
drug O
concentrations O
needed O
for O
50% O
inhibition O
of O
leukotriene B-CHEMICAL
B4 I-CHEMICAL
and O

5-hydroxyeicosatetraenoic B-CHEMICAL
acid I-CHEMICAL
(5-HETE) B-CHEMICAL
release O
was O
4-5 O
mM O
(range O
1-9 O
mM) O
for O
both O
sulfasalazine B-CHEMICAL
and O
5-aminosalicylic B-CHEMICAL
acid. I-CHEMICAL
The O
acetylated B-CHEMICAL
derivative I-CHEMICAL
of I-CHEMICAL
5-aminosalicylic I-CHEMICAL
acid I-CHEMICAL
was O
ineffective. O
The O
present O
data O
suggest O
that O
inhibition O
of O
arachidonic B-CHEMICAL
acid I-CHEMICAL
lipoxygenation O
may O
be O
an O
essential O
action O
of O
sulfasalazine B-CHEMICAL
and O
its O
active O
metabolite, O
5-aminosalicylic B-CHEMICAL
acid. I-CHEMICAL
Interference O
with O
lipoxygenase B-GENE-N
enzymes, O
rather O
than O

a O
steroid-like B-CHEMICAL
inhibition O
of O
arachidonic B-CHEMICAL
acid I-CHEMICAL
release O
from O
intracellular O
phospholipids, O
seems O
to O
be O
the O
mode O
of O
action. O
Bevantolol: B-CHEMICAL
a O
beta-1 B-GENE-Y
adrenoceptor I-GENE-Y
antagonist O
with O
unique O
additional O
actions. O
UNLABELLED: O
Bevantolol B-CHEMICAL
is O
a O
beta-1 B-GENE-Y
adrenoceptor I-GENE-Y
antagonist O
that O
has O
been O
shown O
to O
be O
as O
effective O
as O
other O
beta O
blockers O
for O
the O
treatment O
of O
angina O
pectoris O
and O
hypertension. O
Some O
interesting O
additional O
properties, O
such O
as O
the O
absence O
of O
the O
side O
effect O
of O
cold O
extremities, O
required O

investigation, O
and O
a O
great O
deal O
of O
new O
evidence O
has O
been O
accumulated O
during O
the O
last O
three O
years. O
This O
new O
data O
is O
consistent O
with O
the O
proposal O
put O
forward O
a O
couple O
of O
years O
ago O
that O
bevantolol O
interacts O
with O
alpha-adrenoceptors. B-GENE-N
All O
the O
available O
evidence, O
published O
and O
unpublished, O
has O
been O
reviewed O
and O
fits O
into O
a O
coherent O
pattern, O
here O
arranged O
into O
five O
sections. O
Chemistry: O
affinity O
for O
alpha-adrenoceptors. B-GENE-N
Animal O
experiments O
confirm O
both O
agonist O
and O
antagonist O
effects O
on O
alpha-receptors, O
in O
addition O
to O
antagonist O
activity O
at O
beta-1 B-GENE-N
receptors. I-GENE-N
In O
addition, O
bevantolol B-CHEMICAL
has O
electrophysiologic O
effects, O

including O
bradycardia O
by O
a O
direct O
action O
on O
the O
sinus O
node O
and O
a O
class O
1 O
antiarrhythmic O
action. O
Investigations O
in O
humans O
have O
shown O
that O
although O
bevantolol B-CHEMICAL
has O
a O
short O
half-life, O
good O
control O
of O
hypertension O
can O
be O
achieved O
on O
once-a-day O
dosing. O
SAFETY: O
bevantolol B-CHEMICAL
has O
remarkably O
few O
side O
effects, O
does O
not O
cause O
cold O
extremities, O
and O
does O
not O
significantly O
affect O
glomerular O
filtration O
rate O
in O
patients O
with O
renal O
impairment. O
Evidence O
has O
been O
obtained O
in O
man O
for O
interaction O
with O
alpha-adrenoceptors B-GENE-N
in O

the O
brain; O
and O
in O
the O
peripheral O
circulation O
bevantolol B-CHEMICAL
does O
not, O
as O
do O
other O
beta O
blockers, O
increase O
peripheral O
vascular O
resistance, O
but O
reduces O
it. O
It O
is O
suggested O
that O
all O
the O
additional O
actions O
of O
bevantolol B-CHEMICAL
can O
be O
attributed O
to O
a O
partial O
agonist O
action O
on O
alpha-adrenoceptors. B-GENE-N
Benzodiazepine B-GENE-N
receptor I-GENE-N
binding O
of O
triazolobenzodiazepines B-CHEMICAL
in O
vivo: O
increased O
receptor O
number O
with O
low-dose O
alprazolam. B-CHEMICAL
Triazolobenzodiazepines B-CHEMICAL
are O
in O
clinical O
use O
as O
hypnotics O
and O
anxiolytics. O
We O
analyzed O
in O
vivo O

receptor O
binding O
and O
brain O
concentrations O
of O
alprazolam, B-CHEMICAL
triazolam, B-CHEMICAL
and O
estazolam. B-CHEMICAL
Drug O
concentrations O
measured O
in O
the O
cerebral O
cortex O
1 O
h O
after O
administration O
were O
directly O
proportional O
to O
dose O
for O
all O
three O
compounds. O
In O
vivo O
receptor O
binding, O
as O
defined O
by O
the O
specific O
uptake O
of O
[3H]Ro15-1788, B-CHEMICAL
decreased O
with O
increasing O
doses O
of O
estazolam B-CHEMICAL
and O
triazolam, B-CHEMICAL
a O
finding O
indicating O
dose-related O
increases O
in O
receptor O
occupancy O
due O
to O
these O
compounds. O
Triazolam B-CHEMICAL
was O
substantially O
more O
potent, O
with O
an O
IC50 O
value O
of O
16 O
ng/g, O
compared O
with O
117 O

ng/g O
for O
estazolam. B-CHEMICAL
At O
higher O
doses O
of O
alprazolam B-CHEMICAL
(greater O
than O
0.2 O
mg/kg), O
receptor O
binding O
by O
[3H]Ro15-1788, B-CHEMICAL
likewise O
decreased O
with O
increasing O
dose O
of O
the O
former O
drug. O
However, O
at O
lower O
doses O
of O
alprazolam B-CHEMICAL
(0.02-0.05 O
mg/kg), O
which O
resulted O
in O
cortex O
concentrations O
of O
2-7 O
ng/g, O
receptor O
binding O
was O
increased O
above O
control O
values O
in O
cortex, O
hypothalamus, O
and O
hippocampus O
but O
not O
in O
several O
other O
brain O
regions. O
Binding O
returned O
to O
control O
values O
at O
doses O
of O
greater O

than O
or O
equal O
to O
0.01 O
mg/kg. O
Similar O
results O
were O
obtained O
in O
time O
course O
studies. O
At O
8 O
and O
10 O
h O
after O
a O
dose O
of O
1 O
mg/kg O
i.p., O
corresponding O
to O
cortex O
concentrations O
of O
2.7-7 O
ng/g, O
receptor O
binding O
was O
increased O
compared O
with O
controls. O
Similarly, O
at O
1, O
2, O
and O
3 O
h O
after O
a O
single O
dose O
of O
0.05 O
mg/kg, O
corresponding O
to O
cortex O
concentrations O
of O
3.7-5.8 O
ng/g, O
receptor O
binding O
was O
also O
increased. O
The O
apparent O
affinity O
of O
benzodiazepine B-CHEMICAL
receptors I-GENE-N
for O
clonazepam B-CHEMICAL
in O
mice O
receiving O

alprazolam B-CHEMICAL
(0.05 O
mg/kg) O
was O
unchanged O
from O
that O
in O
untreated O
control O
mice, O
an O
observation O
suggesting O
that O
low O
doses O
of O
alprazolam B-CHEMICAL
increased O
receptor O
number.(ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS) O
Muscarinic O
cholinergic O
and O
histamine B-GENE-Y
H1 I-GENE-Y
receptor I-GENE-Y
binding O
of O
phenothiazine B-CHEMICAL
drug O
metabolites. O
In O
vitro O
binding O
affinities O
of O
chlorpromazine, B-CHEMICAL
fluphenazine, B-CHEMICAL
levomepromazine, B-CHEMICAL
perphenazine B-CHEMICAL
and O
some O
of O
their O
metabolites O
for O
dopamine B-CHEMICAL
D2 I-GENE-Y
receptors, I-GENE-Y

alpha B-GENE-N
1- I-GENE-N
and I-GENE-N
alpha I-GENE-N
2 I-GENE-N
adrenoceptors I-GENE-N
in O
rat O
brain O
were O
previously O
reported O
from O
our O
laboratories. O
The O
present O
study O
reports O
the O
in O
vitro O
binding O
affinities O
of O
the O
same O
compounds O
for O
muscarinic B-GENE-N
cholinergic I-GENE-N
receptors I-GENE-N
and O
for O
histamine B-CHEMICAL
H1 I-GENE-Y
receptors I-GENE-Y
in O
rat O
brain, O
using O
3H-quinuclidinyl B-CHEMICAL
benzilate I-CHEMICAL
and O
3H-mepyramine B-CHEMICAL
as O
radioligands. O
Chlorpromazine, B-CHEMICAL
levomepromazine, B-CHEMICAL
and O
their O
metabolites O
had O
5-30 O
times O
higher O
binding O
affinities O
for O
muscarinic B-GENE-N
cholinergic I-GENE-N
receptors I-GENE-N
than O

fluphenazine, B-CHEMICAL
perphenazine B-CHEMICAL
and O
their O
metabolites. O
Levomepromazine B-CHEMICAL
was O
the O
most O
potent O
and O
fluphenazine B-CHEMICAL
the O
least O
potent O
of O
the O
four O
drugs O
in O
histamine B-GENE-Y
H1 I-GENE-Y
receptor I-GENE-Y
binding. O
7-Hydroxy B-CHEMICAL
levomepromazine, I-CHEMICAL
3-hydroxy B-CHEMICAL
levomepromazine I-CHEMICAL
and O
7-hydroxy B-CHEMICAL
fluphenazine I-CHEMICAL
had O
only O
10% O
of O
the O
potency O
of O
the O
parent O
drug O
in O
histamine B-GENE-Y
H1 I-GENE-Y
receptor I-GENE-Y
binding, O
while O
the O
7-hydroxy-metabolites B-CHEMICAL
of O
chlorpromazine B-CHEMICAL
and O
perphenazine B-CHEMICAL
had O
about O
75% O
of O
the O

potency O
of O
the O
parent O
drug O
in O
this O
binding O
system. O
Their O
histamine B-GENE-Y
H1 I-GENE-Y
receptor I-GENE-Y
binding O
affinities O
indicate O
that O
metabolites O
may O
contribute O
to O
the O
sedative O
effects O
of O
chlorpromazine B-CHEMICAL
and O
levomepromazine. B-CHEMICAL
Retinoid-induced B-CHEMICAL
hemorrhaging O
and O
bone O
toxicity O
in O
rats O
fed O
diets O
deficient O
in O
vitamin B-CHEMICAL
K. I-CHEMICAL
The O
recent O
increase O
in O
the O
clinical O
use O
of O
synthetic O
vitamin B-CHEMICAL
A I-CHEMICAL
compounds O
has O
led O
to O
concern O
of O
possible O
side O
effects. O
Some O
of O
these O
effects O
are O
known O
to O
be O
influenced O
by O
dietary O
levels O
of O
vitamin B-CHEMICAL
K. I-CHEMICAL
We O
therefore O
compared O
the O
toxic O
effects O
of O
13-cis-retinoic B-CHEMICAL
acid I-CHEMICAL

(13cisRA), B-CHEMICAL
retinyl B-CHEMICAL
acetate I-CHEMICAL
(ROAc), B-CHEMICAL
and O
N-(4-hydroxyphenyl)retinamide B-CHEMICAL
(4HPR) B-CHEMICAL
in O
male O
Sprague-Dawley O
rats O
maintained O
on O
diets O
containing O
different O
levels O
of O
vitamin B-CHEMICAL
K. I-CHEMICAL
Animals O
were O
fed O
either O
an O
NIH-07 O
diet O
supplemented O
with O
menadione B-CHEMICAL
(3.1 O
ppm O
vitamin B-CHEMICAL
K3), I-CHEMICAL
an O
NIH-07 O
diet O
not O
supplemented O
with O
menadione, B-CHEMICAL
or O
an O
AIN-076 O
purified O
diet O
devoid O
of O
vitamin B-CHEMICAL
K. I-CHEMICAL
The O
retinoids B-CHEMICAL
had O
no O
effect O
on O

prothrombin B-GENE-Y
times O
of O
animals O
fed O
the O
supplemented O
diet. O
When O
menadione B-CHEMICAL
was O
omitted O
from O
the O
diet, O
however, O
4HPR-dosed B-CHEMICAL
animals O
had O
elevated O
prothrombin B-GENE-Y
times. O
This O
effect O
was O
observed O
as O
early O
as O
Day O
7 O
and O
was O
accompanied O
by O
one O
confirmed O
hemorrhagic O
death. O
13cisRA-dosed B-CHEMICAL
animals O
showed O
no O
change O
in O
prothrombin B-GENE-Y
times. O
In O
the O
high-dose O
ROAc B-CHEMICAL
group, O
there O
was O
a O
twofold O
increase O
in O
prothrombin B-GENE-Y
times O
but O
only O
after O
prolonged O
dosing. O
In O
animals O
fed O
the O
NIH-07 O
diets, O
13cisRA B-CHEMICAL
and O
ROAc B-CHEMICAL

induced O
multiple O
bone O
fractures O
at O
all O
dose O
levels. O
In O
contrast, O
4HPR B-CHEMICAL
administered O
at O
the O
highest O
dose O
induced O
only O
one O
fracture O
in O
one O
animal. O
Animals O
fed O
the O
purified O
diet O
lost O
weight O
faster O
and O
diet O
sooner O
than O
those O
maintained O
on O
the O
other O
diets. O
Bone O
fractures O
were O
not O
observed O
in O
these O
animals O
because O
of O
early O
deaths O
resulting O
from O
hemorrhaging. O
For O
all O
retinoid-dosed B-CHEMICAL
groups O
maintained O
on O
the O
purified O
diet, O
changes O
in O
prothrombin B-GENE-Y
times O
occured O
as O
early O
as O
1 O
week. O
The O
order O
of O
effect O
was O
4HPR B-CHEMICAL
greater O
than O
ROAc B-CHEMICAL
greater O
than O
13cisRA, B-CHEMICAL
with O
increases O
in O

prothrombin B-GENE-Y
times O
correlating O
with O
increases O
in O
hemorrhagic O
deaths. O
Hence, O
the O
degree O
of O
retinoid-induced B-CHEMICAL
hemorrhage, O
but O
not O
the O
incidence O
of O
bone O
fractures, O
was O
inversely O
related O
to O
vitamin B-CHEMICAL
K I-CHEMICAL
levels O
in O
the O
diet. O
13cisRA B-CHEMICAL
and O
ROAc, B-CHEMICAL
but O
not O
4HPR, B-CHEMICAL
caused O
a O
dose-dependent O
reduction O
in O
plasma O
osteocalcin, B-GENE-Y
an O
effect O
that O
correlated O
with O
retinoid-induced B-CHEMICAL
bone O
effects. O
In O
contrast, O
serum O
alkaline B-GENE-N
phosphatase I-GENE-N
was O
elevated O
in O
animals O
dosed O
with O
13cisRA B-CHEMICAL
or O
4HPR B-CHEMICAL
but O
not O
in O
those O
dose O
with O

ROAc. B-CHEMICAL
For O
this O
enzyme, O
the O
electrophoretic O
pattern O
on O
agarose O
gel O
showed O
a O
decrease, O
compared O
to O
controls, O
in O
the O
major O
isozyme O
in O
serum O
of O
ROAc-dosed B-CHEMICAL
animals. O
Hence, O
plasma O
osteocalcin B-GENE-Y
is O
a O
better O
predictor O
of O
retinoid-induced B-CHEMICAL
bone O
effects O
than O
serum O
alkaline B-GENE-N
phosphatase. I-GENE-N
Multiple O
affinity O
states O
of O
opiate B-GENE-N
receptor I-GENE-N
in O
neuroblastoma O
x O
glioma O
NG108-15 O
hybrid O
cells. O
Opiate O
agonist O
association O
rate O
is O
a O
function O
of O
receptor O
occupancy. O
The O
existence O
of O
multiple O
affinity O
states O
for O
the O
opiate O

receptor O
in O
neuroblastoma O
x O
glioma O
NG108-15 O
hybrid O
cells O
has O
been O
demonstrated O
by O
competition O
binding O
studies O
with O
tritiated B-CHEMICAL
diprenorphine I-CHEMICAL
and O
[D-Ala2, B-CHEMICAL
D-Leu5]enkephalin I-CHEMICAL
(DADLE). B-CHEMICAL
In O
the O
presence O
of O
10 O
mM O
Mg2+, B-CHEMICAL
all O
receptors O
exist O
in O
a O
high O
affinity O
state O
with O
Kd O
= O
1.88 O
+/- O
0.16 O
nM. O
Addition O
of O
10 O
microM O
guanyl-5'-yl B-CHEMICAL
imidodiphosphate I-CHEMICAL
(Gpp(NH)p) B-CHEMICAL
decreased O
the O
affinity O
of O

DADLE B-CHEMICAL
to O
Kd O
= O
8.08 O
+/- O
0.93 O
nM. O
However, O
in O
the O
presence O
of O
100 O
mM O
Na+, B-CHEMICAL
which O
is O
required O
for O
opiate O
inhibition O
of O
adenylate B-GENE-N
cyclase I-GENE-N
activity, O
analysis O
of O
competition O
binding O
data O
revealed O
three O
sites: O
the O
first, O
consisting O
of O
17.5% O
of O
total O
receptor O
population O
has O
a O
Kd O
= O
0.38 O
+/- O
0.18 O
nM; O
the O
second, O
50.6% O
of O
the O
population, O
has O
a O
Kd O
= O
6.8 O
+/- O
2.2 O
nM; O
and O
the O
third, O
31.9% O
of O

the O
population, O
has O
a O
Kd O
of O
410 O
+/- O
110 O
nM. O
Thus, O
in O
the O
presence O
of O
sodium, B-CHEMICAL
a O
high O
affinity O
complex O
between O
receptor O
(R), O
GTP B-CHEMICAL
binding O
component O
(Ni), O
and O
ligand O
(L) O
was O
formed O
which O
was O
different O
from O
that O
formed O
in O
the O
absence O
of O
sodium. B-CHEMICAL
These O
multiple O
affinity O
states O
of O
receptor O
in O
the O
hybrid O
cells O
are O
agonist-specific, O
and O
the O
percentage O
of O
total O
opiate B-GENE-N
receptor I-GENE-N
in O
high O
affinity O
state O
is O
relatively O
constant O
in O
various O
concentrations O
of O
Na+. B-CHEMICAL
Multiple O
affinity O
states O
of O
opiate B-GENE-N
receptor I-GENE-N
can O
be O
demonstrated O
further O
by O
Scatchard O
analysis O
of O
saturation O
binding O
studies O
with O

[3H]DADLE. B-CHEMICAL
In O
the O
presence O
of O
Mg2+, B-CHEMICAL
or O
Gpp(NH)p, B-CHEMICAL
analysis O
of O
[3H]DADLE B-CHEMICAL
binding O
demonstrates O
that O
opiate O
receptor O
can O
exist O
in O
a O
single O
affinity O
state, O
with O
apparent O
Kd O
values O
of O
[3H]DADLE B-CHEMICAL
in O
10 O
mM O
Mg2+ O
= O
1.75 O
+/- O
0.28 O
nM O
and O
in O
10 O
microM O
Gpp(NH)p B-CHEMICAL
= O
0.85 O
+/- O
0.12 O
nM. O
There O
is O
a O
reduction O
of O
Bmax O
value O
from O
0.19 O
+/- O
0.02 O
nM O
in O

the O
presence O
of O
Mg2+ B-CHEMICAL
to O
0.14 O
+/- O
0.03 O
nM O
in O
the O
presence O
of O
Gpp(NH)p. B-CHEMICAL
In O
the O
presence O
of O
100 O
mM O
Na+, B-CHEMICAL
Scatchard O
analysis O
of O
saturation O
binding O
of O
[3H]DADLE B-CHEMICAL
reveals O
nonlinear O
plots; O
two-site O
analysis O
of O
the O
curves O
yields O
Kd O
= O
0.43 O
+/- O
0.09 O
and O
7.9 O
+/- O
3.2 O
nM. O
These O
Kd O
values O
are O
analogous O
to O
that O
obtained O
with O
competition O
binding O
studies. O
Again, O
this O
conversion O
of O
single O
site O
binding O
Scatchard O
plots O
to O
multiple O
sites O
binding O
plots O
in O

the O
presence O
of O
Na+ B-CHEMICAL
is O
restricted O
to O
3H-agonist B-CHEMICAL
binding O
only.(ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS) O
Inhibition O
of O
the O
leukotriene B-GENE-N
synthetase I-GENE-N
of O
rat O
basophil O
leukemia O
cells O
by O
diethylcarbamazine, B-CHEMICAL
and O
synergism O
between O
diethylcarbamazine B-CHEMICAL
and O
piriprost, B-CHEMICAL
a O
5-lipoxygenase B-GENE-Y
inhibitor. O
Diethylcarbamazine B-CHEMICAL
inhibited O
the O
formation O
of O
sulfidopeptide B-CHEMICAL
leukotrienes I-CHEMICAL
in O
rat O
basophil O
leukemia O

(RBL) O
cells O
(50% O
inhibitory O
concentration, O
EC50, O
3 O
mM). O
Similar O
concentrations O
also O
inhibited O
the O
formation O
of O
leukotriene B-CHEMICAL
C4 I-CHEMICAL
(LTC4) B-CHEMICAL
by O
LTC B-GENE-Y
synthetase, I-GENE-Y
a O
detergent-solubilized O
cell O
free O
particulate O
enzyme O
from O
RBL O
cells O
which O
is O
capable O
of O
coupling O
LTA4 B-CHEMICAL
to O
glutathione. B-CHEMICAL
By O
contrast, O
the O
conversion O
of O
LTA4 B-CHEMICAL
to O
LTC4 B-CHEMICAL
using O
enzymes O
from O
rat O
liver O
was O
at O
least O
ten O
times O
less O
sensitive O
to O
this O
inhibitor. O
The O
EC50 O
for O
inhibition O
of O
the O
leukotriene B-GENE-Y
C I-GENE-Y

synthetase I-GENE-Y
of O
RBL O
cells O
was O
directly O
proportional O
to O
the O
LTA4 B-CHEMICAL
concentration O
in O
the O
incubations, O
ranging O
from O
1.5 O
mM O
at O
10 O
microM O
LTA4 B-CHEMICAL
to O
over O
40 O
mM O
at O
500 O
microM O
LTA4. B-CHEMICAL
Kinetic O
analysis O
revealed O
that O
the O
inhibition O
of O
the O
leukotriene B-GENE-Y
C I-GENE-Y
synthetase I-GENE-Y
reaction O
by O
diethylcarbamazine B-CHEMICAL
was O
competitive O
with O
respect O
to O
LTA4. B-CHEMICAL
In O
contrast O
to O
diethylcarbamazine, B-CHEMICAL
piriprost B-CHEMICAL
(U-60,257; B-CHEMICAL

6,9-deepoxy-6,9-(phenylimino)-delta B-CHEMICAL
6,8-prostaglandin I-CHEMICAL
I1), I-CHEMICAL
which O
inhibits O
the O
formation O
of O
sulfidopeptide B-CHEMICAL
leuktrienes I-CHEMICAL
in O
RBL O
cells O
at O
the O
5-lipoxygenase B-GENE-Y
step O
(EC50 O
5 O
microM), O
did O
not O
inhibit O
the O
leukotriene B-CHEMICAL
synthetase I-GENE-N
of O
these O
cells. O
On O
the O
other O
hand, O
low O
concentrations O
of O
piriprost, B-CHEMICAL
which O
had O
no O
demonstrable O
inhibitory O
activity O
on O
leukotriene B-CHEMICAL
formation O
by O
themselves, O

markedly O
synergized O
the O
inhibitory O
activity O
of O
diethylcarbamazine. B-CHEMICAL
These O
results O
are O
consistent O
with O
the O
interpretation O
that O
both O
piriprost B-CHEMICAL
and O
diethylcarbamazine B-CHEMICAL
inhibit O
leukotriene B-CHEMICAL
formation O
but O
that O
they O
act O
on O
sequential O
steps O
in O
the O
biosynthetic O
pathway O
in O
such O
a O
manner O
as O
to O
synergistically O
interfere O
with O
the O
availability O
or O
utilization O
of O
LTA4 B-CHEMICAL
in O
the O
leukotriene B-GENE-Y
C I-GENE-Y
synthetase I-GENE-Y
reaction. O
Intestinal O
permeability O
and O
lactose B-CHEMICAL
hydrolysis O
in O
human O
rotaviral O
gastroenteritis O
assessed O
simultaneously O
by O

non-invasive O
differential O
sugar O
permeation. O
Changes O
in O
intestinal O
permeability O
and O
lactose B-CHEMICAL
hydrolysis O
have O
been O
investigated O
in O
three O
adults O
and O
fifteen O
infants O
with O
acute O
rotaviral O
gastroenteritis O
by O
differential O
sugar O
absorption. O
The O
method O
involves O
chromatographic O
measurement O
of O
urinary O
lactose, B-CHEMICAL
lactulose B-CHEMICAL
and O
L-rhamnose B-CHEMICAL
excretion O
following O
combined O
ingestion O
in O
an O
iso-osmolar O
test O
solution. O
All O
patients O
had O
abnormal O
intestinal O
permeability O
indicated O
by O
raised O
urine O
lactulose/L-rhamnose B-CHEMICAL
excretion, O
ratio O
of O
percentages O
recovered O
in O

5 O
h, O
of O
0.462 O
(0.100-1.227) O
mean O
and O
range, O
compared O
with O
0.027 O
(0.008-0.052) O
for O
healthy O
controls O
(P O
less O
than O
0.001). O
Ten O
patients O
also O
had O
urinary O
lactose/lactulose B-CHEMICAL
excretion O
ratios O
raised O
above O
the O
normal O
range O
(0.014-0.41, O
mean O
0.258) O
during O
their O
acute O
illness, O
indicating O
impaired O
intestinal O
lactose B-CHEMICAL
hydrolysis. O
Both O
indices O
had O
become O
normal O
4 O
weeks O
after O
the O
acute O
illness, O
serial O
investigation O
of O
five O
patients O
showing O

that O
improvement O
was O
complete O
much O
earlier. O
Except O
for O
the O
short O
duration O
these O
changes O
are O
similar O
to O
those O
associated O
with O
villous O
atrophy O
in O
coeliac O
disease. O
The O
test O
procedure O
was O
verified O
with O
respect O
to O
intestinal O
lactose B-CHEMICAL
hydrolysis O
by O
demonstrating O
a O
linear O
relationship O
between O
lactose/lactulose B-CHEMICAL
excretion O
and O
log O
jejunal O
mucosal O
lactase B-GENE-Y
activity O
by O
in O
vitro O
assay O
(R2 O
= O
0.95) O
in O
a O
further O
group O
of O
subjects. O
Differential O
lactose/lactulose/L-rhamnose B-CHEMICAL
absorption O
provides O
a O
non-invasive O
and O
sensitive O

index O
of O
small O
intestinal O
integrity O
of O
value O
for O
the O
interpretation O
of O
prolonged O
or O
otherwise O
complicated O
enteritis O
and O
the O
distinction O
of O
primary O
secondary O
intestinal O
lactase B-GENE-Y
deficiency. O
Characteristics O
of O
the O
binding O
of O
phenoxybenzamine B-CHEMICAL
to O
calmodulin. B-GENE-N
To O
determine O
the O
factors O
that O
influence O
the O
interaction O
between O
phenoxybenzamine B-CHEMICAL
and O
calmodulin, B-GENE-N
the O
binding O
of O
phenoxybenzamine B-CHEMICAL
to O
calmodulin B-GENE-N
was O
determined O
by O
equilibrium O
dialysis O
under O
a O
variety O
of O
experimental O
conditions. O
This O
interaction O
was O
found O
to O
be O
similar O
in O
some O
respects O
to O
the O
interaction O
between O
phenothiazines B-CHEMICAL
and O
calmodulin. B-GENE-N

It O
was O
saturable, O
with O
between O
1 O
and O
2 O
mol O
of O
phenoxybenzamine B-CHEMICAL
bound O
to O
1 O
mol O
of O
calmodulin. B-GENE-N
It O
was O
also O
dependent O
upon O
temperature, O
the O
presence O
of O
a O
divalent O
cation O
such O
as O
calcium, B-CHEMICAL
and O
on O
pH, O
showing O
maximum O
binding O
at O
pH O
6.5 O
with O
little O
binding O
at O
pH O
values O
below O
4.2 O
or O
above O
8.0. O
The O
site O
at O
which O
phenoxybenzamine B-CHEMICAL
bound O
to O
calmodulin B-GENE-N
appears O
to O
be O
similar O
to O
that O
at O
which O
certain O
antipsychotic O
agents O
bind, O
since O
several O
of O
them, O
including O
penfluridol, B-CHEMICAL
pimozide B-CHEMICAL
and O

spiroperidol, B-CHEMICAL
prevented O
the O
binding O
of O
phenoxybenzamine B-CHEMICAL
to O
calmodulin. B-GENE-N
However, O
in O
contrast O
to O
the O
reversible O
binding O
of O
most O
phenothiazines B-CHEMICAL
to O
calmodulin, B-GENE-N
phenoxybenzamine B-CHEMICAL
bound O
to O
calmodulin B-GENE-N
irreversibly. O
The O
binding O
of O
phenoxybenzamine B-CHEMICAL
to O
calmodulin B-GENE-N
was O
fairly O
selective O
in O
that O
other O
alpha-adrenergic B-GENE-N
agents O
such O
as O
prazosin, B-CHEMICAL
yohimbine B-CHEMICAL
and O
clonidine B-CHEMICAL
failed O
to O
bind O
to O
calmodulin B-GENE-N
when O
examined O
under O
the O
same O
experimental O
conditions. O
In O
addition, O

phenoxybenzamine B-CHEMICAL
showed O
little O
or O
no O
calcium-dependent B-CHEMICAL
binding O
to O
the O
S-100 B-GENE-N
protein, I-GENE-N
bovine B-GENE-Y
serum I-GENE-Y
albumin I-GENE-Y
or O
cytochrome B-GENE-Y
c. I-GENE-Y
The O
irreversible O
complex O
between O
phenoxybenzamine B-CHEMICAL
and O
calmodulin B-GENE-N
may O
be O
useful O
for O
inhibiting O
certain O
calmodulin-dependent B-GENE-N
reactions O
and O
for O
studying O
the O
various O
biological O
functions O
of O
calmodulin. B-GENE-N
Pharmacological O
and O
clinical O
studies O
of O
the O
antiandrogen O
Anandron. B-CHEMICAL
This O
paper O
summarizes O
the O
animal O
and O
human O
studies O
with O
Anandron B-CHEMICAL
available O
at O
the O
time O
of O
the O
meeting. O
The O
following O
was O
demonstrated O
in O
the O
rat O
and O
confirmed O
in O
man: O
interaction O

of O
Anandron B-CHEMICAL
with O
the O
prostatic B-GENE-N
androgen I-GENE-N
receptor, I-GENE-N
antiandrogen O
activity O
against O
testosterone B-CHEMICAL
(in O
particular O
against O
the O
early O
transient O
rise O
induced O
by O
LHRH B-GENE-N
analogs) O
and O
adrenal O
androgens. B-CHEMICAL
Thus, O
as O
shown O
in O
4 O
different O
double O
blind O
studies O
performed O
in O
stage O
D2 O
prostrate O
cancer O
patients, O
the O
combination O
of O
Anandron B-CHEMICAL
with O
surgical O
or O
chemical O
castration O
enhanced O
the O
beneficial O
effects O
of O
castration O
alone O
and O
thus O
seems O
a O
step O
forward O
in O
the O
hormonal O
treatment O
of O
prostatic O
carcinoma. O
Adenosine B-GENE-N
receptors: I-GENE-N
development O
of O
selective O
agonists O
and O
antagonists. O
Adenosine B-CHEMICAL
modulates O
a O
variety O

of O
physiological O
functions O
through O
interaction O
with O
A1 B-GENE-N
and I-GENE-N
A2 I-GENE-N
adenosine I-GENE-N
receptors, I-GENE-N
where O
agonists O
mediate O
inhibition O
and O
stimulation, O
respectively, O
of O
adenylate B-GENE-N
cyclase. I-GENE-N
In O
the O
cardiovascular O
system, O
A2 B-GENE-N
receptors I-GENE-N
mediate O
vasodilation O
and O
reduction O
in O
blood O
pressure, O
while O
A1 B-GENE-Y
receptors I-GENE-Y
mediate O
cardiac O
depression. O
The O
involvement O
of O
adenylate B-GENE-N
cyclase I-GENE-N
in O
these O
responses O
remains O
unresolved. O
Adenosine B-CHEMICAL
analogs O
in O
particular O
the O
N6-substituted B-CHEMICAL
compounds O
are O
more O
potent O
at O
A1 B-GENE-Y
receptors I-GENE-Y
than O
at O
A2 B-GENE-N
receptors. I-GENE-N
The O
subregion O
of O
the O
adenosine B-GENE-N
receptor I-GENE-N
that O
interacts O
with O
the O

N6-substituent B-CHEMICAL
is O
different O
for O
A1 B-GENE-N
and I-GENE-N
A2 I-GENE-N
receptors, I-GENE-N
particularly O
with O
respect O
to O
phenyl B-CHEMICAL
interactions, O
bulk O
tolerance O
and O
stereoselectivity. O
A O
series O
of O
para-substituted O
N6-phenyladenosines B-CHEMICAL
have O
been O
synthesized O
based O
on O
a O
"functionalized O
congener" O
approach O
in O
which O
a O
chemically O
reactive O
group, O
such O
as O
an O
amine B-CHEMICAL
or O
carboxylic B-CHEMICAL
acid, I-CHEMICAL
is O
introduced O
at O
the O
terminus O
of O
a O
chain. O
From O
the O
"functionalized O
congener" O
are O
synthesized O
a O
variety O
of O
conjugates O
each O
containing O
a O
common O
pharmacophore. O
Certain O
of O
the O

adenosine B-CHEMICAL
conjugates O
are O
highly O
selective O
for O
A1 B-GENE-Y
receptors. I-GENE-Y
Xanthines B-CHEMICAL
are O
classical O
antagonists O
for O
adenosine B-CHEMICAL
receptors I-GENE-N
for O
many O
of O
their O
pharmacological O
actions O
may O
be O
due O
to O
blockade O
of O
adenosine B-CHEMICAL
receptors. I-GENE-N
Caffeine B-CHEMICAL
and O
theophylline B-CHEMICAL
are O
virtually O
non-selective O
for O
A2 B-GENE-N
and I-GENE-N
A2 I-GENE-N
receptors. I-GENE-N
Replacement O
of O
the O
methyl B-CHEMICAL
groups O
of O
theophylline B-CHEMICAL
with O
n-propyl B-CHEMICAL
or O
larger O
alkyl B-CHEMICAL
groups O
yields O
xanthines B-CHEMICAL
with O
selectivity O
for O
A1 B-GENE-Y
receptors, I-GENE-Y
particularly O
when O
combined O
with O
an O
8-phenyl B-CHEMICAL
moiety. O
Most O

1,3-dialkyl-8-phenyl B-CHEMICAL
xanthines I-CHEMICAL
are O
very O
insoluble, O
but O
incorporation O
of O
polar O
aryl B-CHEMICAL
substituents, O
such O
as O
sulfo B-CHEMICAL
or O
carboxy B-CHEMICAL
to O
increase O
solubility, O
results O
in O
marked O
reduction O
in O
potency O
and O
selectivity. O
A O
new O
series O
of O
more O
hydrophilic O
1,3-dipropyl-8-phenylxanthines B-CHEMICAL
has O
been O
synthesized O
using O
the O
"functionalized O
congener" O
approach. O
Certain O
conjugates O
of O
8-[4-(carboxymethyloxy)phenyl B-CHEMICAL

1]1,3-dipropylxanthine I-CHEMICAL
display O
A1 O
selectivity O
in O
biochemical O
and O
cardiovascular O
models. O
Certain O
analogs O
of O
caffeine B-CHEMICAL
in O
which O
the O
methyl B-CHEMICAL
group O
at O
the O
1- O
or O
7-position O
is O
replaced O
with O
a O
propargyl O
or O
propyl B-CHEMICAL
group O
display O
selectivity O
for O
A2 B-GENE-N
receptors. I-GENE-N
The O
profile O
of O
a O
series O
of O
adenosine B-CHEMICAL
analogs O
or O
of O
xanthine B-CHEMICAL
antagonists O
can O
be O
used O
to O
define O
the O
nature O
of O
adenosine B-GENE-N
receptors. I-GENE-N
Inhibition O
of O
testicular O
LDH-X B-GENE-N
from O
laboratory O
animals O
and O
man O
by O
gossypol B-CHEMICAL
and O
its O
isomers. O
The O
inhibitory O
effect O

of O
(+)-, B-CHEMICAL
(-)-, I-CHEMICAL
(+/-)-gossypol I-CHEMICAL
and O
(+/-)-gossypol B-CHEMICAL
acetic I-CHEMICAL
acid I-CHEMICAL
upon O
testicular O
cytosolic O
LDH-X B-GENE-Y
was O
measured O
in O
vitro. O
Gossypol B-CHEMICAL
acetic I-CHEMICAL
acid I-CHEMICAL
(0-100 O
mumol/l) O
inhibited O
LDH-X B-GENE-N
prepared O
from O
the O
testes O
of O
the O
mouse O
greater O
than O
rabbit O
greater O
than O
human O
greater O
than O
rat O
greater O
than O
hamster. O
There O
was O
no O
relationship O
between O
inhibition O
and O
in-vivo O
antifertility O
activity. O
LDH B-GENE-N
activity O
measured O
in O
vitro O
in O
serum O

of O
men O
and O
hamsters O
was O
unaffected O
by O
gossypol. B-CHEMICAL
Gossypol B-CHEMICAL
and O
its O
isomers O
were O
non-competitive O
inhibitors O
of O
human B-GENE-N
and I-GENE-N
hamster I-GENE-N
LDH-X I-GENE-N
with O
respect O
to O
the O
coenzyme O
NADH, B-CHEMICAL
competitive O
inhibitors O
of O
human B-GENE-Y
LDH-X I-GENE-Y
and O
noncompetitive-competitive O
inhibitors O
of O
hamster B-GENE-Y
LDH-X I-GENE-Y
with O
respect O
to O
the O
substrate O
alpha-ketobutyrate. B-CHEMICAL
Co-incubation O
with O
human B-GENE-Y
serum I-GENE-Y
albumin I-GENE-Y
or O
poly-L-lysine B-CHEMICAL
but O
not O
lysine B-CHEMICAL
protected O
human B-GENE-N
and I-GENE-N
hamster I-GENE-N

LDH-X I-GENE-N
from O
gossypol. B-CHEMICAL
Inactivation O
of O
prostaglandin B-GENE-N
H I-GENE-N
synthase I-GENE-N
and O
prostacyclin B-GENE-Y
synthase I-GENE-Y
by O
phenylbutazone. B-CHEMICAL
Requirement O
for O
peroxidative O
metabolism. O
Phenylbutazone B-CHEMICAL
(PB), B-CHEMICAL
a O
nonsteroidal O
anti-inflammatory O
drug, O
is O
an O
efficient O
reducing O
cofactor O
for O
the O
peroxidase O
activity O
of O
prostaglandin B-CHEMICAL
H I-CHEMICAL
synthase I-GENE-N
(PHS). B-GENE-N
Most O
reducing O
cofactors O
for O
the O
peroxidase O
protect O
PHS B-GENE-N
and O
prostacyclin B-GENE-Y
synthase I-GENE-Y
from O

inactivation O
by O
hydroperoxides. B-CHEMICAL
PB, B-CHEMICAL
however, O
does O
not O
protect O
these O
enzymes, O
but O
rather O
augments O
their O
hydroperoxide-dependent B-CHEMICAL
inactivation. O
Using O
ram O
seminal O
vesicle O
microsomes O
as O
a O
source O
of O
PHS B-GENE-N
and O
prostacyclin B-GENE-Y
synthase, I-GENE-Y
we O
have O
examined O
the O
interaction O
of O
PB B-CHEMICAL
and O
exogenous O
hydroperoxides. B-CHEMICAL
Chromatographic O
analysis O
of O
the O
metabolism O
of O
14C-labeled B-CHEMICAL
arachidonic I-CHEMICAL
acid I-CHEMICAL
in O
this O
system O
revealed O
that O
PB-dependent B-CHEMICAL
inactivation O
of O
PHS B-GENE-N
is O
markedly O
increased O
in O
the O
presence O
of O
100 O
microM O

H2O2. B-CHEMICAL
This O
inactivation O
is O
a O
linear O
function O
of O
PB B-CHEMICAL
concentration O
between O
10 O
and O
250 O
microM, O
with O
a O
half-maximal O
effect O
in O
this O
range O
at O
about O
100 O
microM O
PB. O
Prostacyclin B-GENE-Y
synthase I-GENE-Y
is O
even O
more O
sensitive O
to O
inactivation O
by O
the O
combined O
PB B-CHEMICAL
and O
H2O2 B-CHEMICAL
treatment, O
with O
a O
corresponding O
half-maximal O
effect O
at O
PB B-CHEMICAL
concentrations O
near O
25 O
microM. O
This O
PB- B-CHEMICAL
and O
H2O2-dependent B-CHEMICAL
inactivation O
is O
demonstrable O
whether O
PGH2 B-CHEMICAL
is O
generated O
in O
situ O
from O
arachidonic B-CHEMICAL
acid I-CHEMICAL
or O
is O
added O

exogenously, O
supporting O
a O
direct O
effect O
of O
the O
treatment O
on O
prostacyclin B-CHEMICAL
synthase. I-GENE-Y
As O
PB B-CHEMICAL
undergoes O
peroxide-dependent B-CHEMICAL
co-oxygenation O
catalyzed O
by O
PHS, B-GENE-N
we O
propose O
that O
it O
is O
an O
oxygenated O
derivative O
of O
PB, B-CHEMICAL
rather O
than O
the O
parent O
compound, O
which O
is O
responsible O
for O
the O
inactivation O
of O
PHS B-GENE-N
and O
prostacyclin B-GENE-Y
synthase. I-GENE-Y
Nafazatrom, B-CHEMICAL
a O
competitive O
inhibitor O
of O
PB B-CHEMICAL
co-oxygenation, O
blocks O
the O
effects O
of O
the O
PB B-CHEMICAL
and O
H2O2 B-CHEMICAL
treatment, O
supporting O
our O
proposal. O
Drug-protein O
interactions: O
isolation O
and O
characterization O
of O
covalent O

adducts O
of O
phenoxybenzamine B-CHEMICAL
and O
calmodulin. B-GENE-Y
Phenoxybenzamine, B-CHEMICAL
an O
alpha-adrenergic O
antagonist O
containing O
a O
(chloroethyl)amine B-CHEMICAL
group, O
labels O
calmodulin B-GENE-Y
in O
the O
presence O
of O
calcium. B-CHEMICAL
The O
covalent O
interaction O
is O
inhibited O
by O
chlorpromazine B-CHEMICAL
in O
a O
concentration-dependent O
manner. O
Adducts O
of O
calmodulin B-GENE-Y
and O
phenoxybenzamine B-CHEMICAL
were O
separated O
by O
high-performance O
liquid O
chromatography O
into O
four O
major O
fractions: O
two O
containing O
0.6 O
and O
1.2 O
mol O
of O
drug O
per O
mol O
of O
protein O
and O
two O

different O
fractions O
each O
containing O
2.0 O
mol/mol. O
Each O
adduct O
had O
a O
reduced O
ability O
to O
activate O
cyclic B-CHEMICAL
nucleotide I-CHEMICAL
phosphodiesterase I-GENE-N
and O
myosin B-GENE-Y
light I-GENE-Y
chain I-GENE-Y
kinase, I-GENE-Y
and O
the O
chlorpromazine B-CHEMICAL
binding O
capacities O
of O
the O
phenoxybenzamine-calmodulin B-CHEMICAL
adducts O
were O
diminished O
to O
the O
extent O
of O
phenoxybenzamine B-CHEMICAL
incorporation O
into O
each O
adduct. O
Isolation O
and O
characterization O
of O
labeled O
peptides O
from O
phenoxybenzamine-modified B-CHEMICAL
calmodulins B-GENE-Y
indicated O
that O
peptides O
encompassing O
residues O
38-75, O

107-126, O
and O
127-148 O
contained O
phenoxybenzamine B-CHEMICAL
label. O
These O
studies O
directly O
demonstrate O
the O
relatedness O
between O
the O
binding O
activities O
of O
two O
structurally O
dissimilar O
calmodulin B-GENE-Y
antagonists, O
demonstrate O
that O
covalent O
adducts O
of O
calmodulin B-GENE-Y
and O
drugs O
with O
equal O
stoichiometries O
of O
labeling O
can O
have O
quantitative O
differences O
in O
activity O
and O
sites O
of O
modification, O
and O
provide O
direct O
evidence O
of O
distinct O
drug O
binding O
regions O
in O
calmodulin B-GENE-Y
located O
in O
the O
amphipathic O
alpha-helical O
regions O
of O
the O
second O
and O
fourth O
domains. O
Amine B-GENE-N
oxidase I-GENE-N
activities O
in O
brown O
adipose O
tissue O
of O
the O
rat: O

identification O
of O
semicarbazide-sensitive B-CHEMICAL
(clorgyline-resistant) B-CHEMICAL
activity O
at O
the O
fat O
cell O
membrane. O
Amine B-CHEMICAL
oxidase I-GENE-N
activity, O
previously O
described O
in O
homogenates O
of O
brown O
adipose O
tissue O
of O
the O
rat, O
has O
now O
been O
investigated O
in O
preparations O
of O
isolated O
fat O
cells. O
It O
was O
found O
that O
the O
specific O
activities O
of O
both O
monoamine B-CHEMICAL
oxidase I-GENE-Y
A I-GENE-Y
(MAO) B-GENE-N
and O
of O
the O
semicarbazide-sensitive B-CHEMICAL
clorgyline-resistant B-CHEMICAL
amine I-GENE-Y
oxidase I-GENE-Y
(SSAO) B-GENE-Y
were O
higher O
in O
isolated O
fat O
cells O
than O
in O
the O
original O
whole O
tissue. O
Brown O
adipocytes O
therefore O

represent O
a O
major O
source O
of O
both O
these O
enzymes. O
In O
plasma O
membranes O
prepared O
from O
these O
isolated O
brown O
fat O
cells O
by O
borate B-CHEMICAL
extraction O
there O
was O
a O
similar O
enrichment O
of O
activity O
of O
SSAO B-GENE-Y
and O
of O
the O
plasma O
membrane O
marker O
enzyme, O
phosphodiesterase B-GENE-N
I. I-GENE-N
However O
in O
preparations O
of O
cell O
membranes O
made O
by O
binding O
the O
cells O
to O
polycation-coated O
beads, O
enrichment O
of O
phosphodiesterase B-GENE-N
I I-GENE-N
activity O
was O
much O
greater O
than O
that O
of O
SSAO. B-GENE-Y
It O
is O
suggested O
that O
the O
disposition O
of O
the O
enzyme O
within O
the O
cell O
membrane O
may O
account O
for O
the O
discrepancy O
in O
these O
results, O
i.e. O
the O

sidedness O
of O
the O
membrane O
may O
be O
important. O
Histochemical O
visualization O
of O
enzyme O
activity O
in O
whole O
tissue O
at O
the O
ultrastructural O
level O
was O
undertaken. O
Positive O
staining O
of O
mitochondria O
was O
achieved O
in O
the O
presence O
of O
the O
MAO B-GENE-N
substrate, O
tryptamine. B-CHEMICAL
Staining O
around O
the O
edges O
of O
the O
brown O
fat O
cells O
was O
observed O
with O
the O
SSAO B-GENE-Y
substrates, O
tyramine B-CHEMICAL
and O
benzylamine. B-CHEMICAL
Staining O
was O
largely O
absent O
when O
substrate O
was O
omitted O
or O
after O
pretreatment O
with O
the O
irreversible O
SSAO B-GENE-Y
inhibitor, O
hydralazine B-CHEMICAL
and O
the O
slowly O
reversible O
inhibitor, O
semicarbazide. B-CHEMICAL

It O
is O
not O
definitely O
proven O
that O
this O
staining O
represents O
sites O
of O
enzyme O
activity O
but O
the O
results O
are O
consistent O
with O
evidence O
from O
other O
studies O
indicating O
that O
SSAO B-GENE-Y
in O
brown O
adipose O
tissue O
of O
the O
rat O
may O
be O
found O
predominantly O
at O
the O
fat O
cell O
surface.(ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS) O
Penicillin-binding B-GENE-N
proteins I-GENE-N
and O
role O
of O
amdinocillin B-CHEMICAL
in O
causing O
bacterial O
cell O
death. O
The O
activity O
of O
penicillins B-CHEMICAL
against O
bacteria O
is O
in O
large O
part O
related O
to O
binding O
to O
specific O
receptor O
proteins O
involved O
in O
cell O
wall O
biosynthesis. O
These O
proteins O
have O
been O
designated O
penicillin-binding B-GENE-N
proteins. I-GENE-N

They O
can O
be O
separated O
into O
distinct O
entities O
through O
the O
use O
of O
acrylamide B-CHEMICAL
gel O
electrophoresis O
and O
binding O
of O
radioactive O
14C-labeled B-CHEMICAL
penicillin I-CHEMICAL
G. I-CHEMICAL
Six O
major O
proteins O
have O
been O
defined O
in O
the O
Enterobacteriaceae, O
penicillin-binding B-GENE-N
proteins I-GENE-N
1 I-GENE-N
to I-GENE-N
6. I-GENE-N
Selection O
of O
mutants O
has O
shown O
that O
there O
are O
three O
essential O
proteins: O
penicillin-binding B-GENE-N
protein I-GENE-N
1, I-GENE-N
which O
is O
divided O
into O
penicillin-binding B-GENE-N
protein I-GENE-N
1Bs, I-GENE-N
a O
peptidoglycan B-GENE-N
transpeptidase, I-GENE-N
and O
penicillin-binding B-GENE-N
protein I-GENE-N
1A, I-GENE-N
which O
acts O
as O
a O
replacement O
for O
penicillin-binding B-GENE-N

protein I-GENE-N
1Bs. I-GENE-N
Penicillin-binding B-GENE-N
protein I-GENE-N
2 I-GENE-N
is O
a O
murein-elongation B-GENE-N
initiating O
enzyme O
and O
penicillin-binding B-GENE-N
protein I-GENE-N
3 I-GENE-N
is O
a O
septal O
murein-synthesizing B-GENE-N
enzyme. O
Penicillin-binding B-GENE-N
proteins I-GENE-N
4, I-GENE-N
5, I-GENE-N
and I-GENE-N
6 I-GENE-N
are O
not O
essential O
for O
bacterial O
survival. O
Binding O
of O
penicillins B-CHEMICAL
to O
penicillin-binding B-GENE-N
protein I-GENE-N
1Bs I-GENE-N
produces O
lysis, O
binding O
to O
penicillin-binding B-GENE-N
protein I-GENE-N
2 I-GENE-N
produces O
round O
cells, O
and O
binding O
to O
penicillin-binding B-GENE-N
protein I-GENE-N
3 I-GENE-N
produces O
long O
filaments. O
Amdinocillin B-CHEMICAL
is O
a O

beta-amidino B-CHEMICAL
penicillanic I-CHEMICAL
acid I-CHEMICAL
derivative O
that O
binds O
specifically O
to O
penicillin-binding B-CHEMICAL
protein I-GENE-N
2. I-GENE-N
The O
compound O
is O
more O
beta-lactamase B-GENE-N
stable O
than O
ampicillin B-CHEMICAL
and O
has O
no O
major O
delay O
in O
entry O
into O
the O
periplasmic O
space O
as O
do O
some O
penicillins. B-CHEMICAL
Amdinocillin B-CHEMICAL
inhibits O
most O
of O
the O
Enterobacteriaceae, O
with O
the O
exception O
of O
some O
indole-positive B-CHEMICAL
Proteus O
species, O
but O
it O
does O
not O
inhibit O
gram-positive O
cocci O
or O
Pseudomonas O
aeruginosa. O
Amdinocillin B-CHEMICAL
produces O
spherical O
bacterial O
cells O
that O

eventually O
lyse. O
Its O
activity O
in O
vitro O
is O
markedly O
affected O
by O
ionic O
content O
of O
media. O
This O
agent O
acts O
synergistically O
with O
many O
penicillins, B-CHEMICAL
such O
as O
ampicillin, B-CHEMICAL
carbenicillin, B-CHEMICAL
and O
the O
like, O
and O
with O
cephalosporins, B-CHEMICAL
cefazolin, B-CHEMICAL
cefamandole, B-CHEMICAL
or O
cefoxitin B-CHEMICAL
to O
inhibit O
gram-negative O
bacilli, O
probably O
on O
the O
basis O
of O
binding O
to O
different O
proteins O
needed O
for O
the O
production O
of O
the O
peptidoglycan B-GENE-N
of O
the O
bacterial O
cell O
wall. O
Amdinocillin B-CHEMICAL
possesses O
a O
number O
of O
the O

essentials O
for O
effective O
antimicrobial O
activity O
and, O
by O
virtue O
of O
its O
enhancement O
of O
the O
activity O
of O
other O
beta-lactams, B-CHEMICAL
may O
prove O
to O
be O
a O
useful O
agent O
in O
the O
chemotherapy O
of O
certain O
infections. O
Loss O
of O
alpha B-GENE-Y
2-macroglobulin I-GENE-Y
and O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
surface O
binding O
induced O
by O
phenothiazines B-CHEMICAL
and O
naphthalene B-CHEMICAL
sulfonamides. I-CHEMICAL
We O
have O
found O
that O
certain O
naphthalenesulfonamides B-CHEMICAL
[e.g., O

N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide B-CHEMICAL
(W-7)] B-CHEMICAL
and O
phenothiazines B-CHEMICAL
[e.g., O
trifluoperazine B-CHEMICAL
(TFP)] B-CHEMICAL
induce O
a O
loss O
of O
cell-surface O
receptors O
for O
alpha B-GENE-Y
2-macroglobulin, I-GENE-Y
and O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(EGF) B-GENE-Y
in O
fibroblasts. O
The O
loss O
of O
alpha B-GENE-Y
2-macroglobulin I-GENE-Y
receptors I-GENE-Y
is O
independent O
of O
receptor O
occupancy O
and O
is O
rapidly O
reversed O
upon O
removal O
of O
these O
agents O
from O
the O
culture O

medium. O
The O
extent O
of O
EGF B-GENE-Y
receptor I-GENE-Y
loss O
is O
less O
than O
for O
alpha B-GENE-Y
2-macroglobulin, I-GENE-Y
and O
the O
EGF B-GENE-Y
receptors I-GENE-Y
do O
not O
reappear O
at O
the O
surface O
when O
W-7 B-CHEMICAL
is O
removed. O
Receptor O
loss O
was O
measured O
as O
a O
change O
in O
the O
capacity O
for O
binding O
iodinated O
ligands; O
no O
change O
in O
affinity O
of O
binding O
was O
observed. O
This O
receptor O
loss O
could O
reflect O
inactivation O
of O
receptors O
or O
internalization. O
W-7 B-CHEMICAL
did O
not O
induce O
a O
loss O
of O
cell O
surface O
beta B-GENE-Y
2-microglobulin, I-GENE-Y
a O
membrane O
protein O
which O
is O
excluded O
from O
coated O
pits O
and O
which O
is O
not O
internalized, O
indicating O
that O
the O

effect O
of O
W-7 B-CHEMICAL
was O
specific O
for O
membrane O
receptors O
and O
not O
a O
result O
of O
bulk O
depletion O
of O
plasma O
membrane. O
The O
loss O
of O
alpha B-GENE-Y
2-macroglobulin I-GENE-Y
and O
EGF B-GENE-Y
receptors I-GENE-Y
occurs O
at O
concentrations O
which O
do O
not O
cause O
an O
increase O
in O
the O
pH O
of O
endocytic O
vesicles O
or O
the O
cytoplasm, O
indicating O
that O
these O
agents O
act O
by O
a O
mechanism O
distinct O
from O
the O
effect O
of O
other O
weak O
bases. O
Since O
both O
TFP B-CHEMICAL
and O
W-7 B-CHEMICAL
are O
potent O
inhibitors O
of O
calmodulin, B-GENE-N
we O
investigated O
the O
possibility O
that O
inhibition O
of O
calmodulin B-GENE-N
was O
responsible O
for O
the O
loss O
of O
receptors. O
Three O
lines O
of O
evidence O
suggest O
that O

calmodulin B-GENE-N
inhibition O
is O
not O
responsible O
for O
the O
inhibition O
of O
binding O
and O
endocytosis: O
1) O
Promethazine, B-CHEMICAL
a O
phenothiazine B-CHEMICAL
that O
is O
a O
poor O
inhibitor O
of O
calmodulin, O
is O
nearly O
as O
effective O
as O
TFP B-CHEMICAL
at O
inhibiting O
endocytosis; O
calmidazolium, O
a O
potent O
inhibitor O
of O
several O
calmodulin B-GENE-N
functions, O
did O
not O
cause O
a O
loss O
of O
binding; O
2) O
the O
microinjection O
of O
calmodulin B-GENE-N
into O
cells O
did O
not O
reverse O
the O
effects O
of O
W-7; B-CHEMICAL
using O
pressure O
microinjection, O
we O
introduced O
up O
to O
a O
100-fold O
excess O
of O
calmodulin B-GENE-N
over O
native O
levels O

into O
individual O
gerbil O
fibroma O
cells; O
using O
rhodamine-labeled B-CHEMICAL
alpha B-GENE-Y
2-macroglobulin, I-GENE-Y
we O
saw O
that O
the O
W-7 B-CHEMICAL
induced O
inhibition O
of O
receptor-mediated O
endocytosis O
was O
the O
same O
in O
injected O
and O
uninjected O
cells; O
3) O
we O
injected O
calcineurin, B-GENE-N
a O
calmodulin-binding B-GENE-N
protein, I-GENE-N
into O
cells O
(1-3 O
pg/cell) O
and O
observed O
no O
effect O
on O
the O
receptor-mediated O
endocytosis O
of O
rhodamine-labeled B-CHEMICAL
alpha B-GENE-Y
2-macroglobulin. I-GENE-Y
These O
data O
indicated O
that O
cell O
surface O
receptor O
numbers O
can O
be O
regulated O
by O
a O

cellular O
component O
that O
is O
not O
cytoplasmic B-GENE-N
calmodulin I-GENE-N
but O
that O
shares O
some O
drug O
sensitivities O
with O
calmodulin. B-GENE-N
The O
effect O
of O
various O
amino B-CHEMICAL
acids I-CHEMICAL
and O
drugs O
on O
the O
para- B-CHEMICAL
and I-CHEMICAL
meta-hydroxyphenylacetic I-CHEMICAL
acid I-CHEMICAL
concentrations O
in O
the O
mouse O
caudate O
nucleus. O
Injection O
of O
L-p-tyrosine B-CHEMICAL
(800 O
mg/kg, O
2 O
h) O
increased O
the O
mouse O
striatal O
para-hydroxyphenylacetic B-CHEMICAL
acid I-CHEMICAL
(p-HPAA) B-CHEMICAL
concentrations. O
A O
smaller O
dose O
of O
D,L-m-tyrosine B-CHEMICAL
(20 O
mg/kg, O
2 O

h) O
produced O
a O
larger O
increase O
in O
mouse O
striatal O
meta-hydroxyphenylacetic B-CHEMICAL
acid I-CHEMICAL
(m-HPAA) B-CHEMICAL
concentrations. O
The O
administration O
of O
L-phenylalanine B-CHEMICAL
to O
mice O
caused O
a O
slight O
increase O
in O
the O
p-HPAA B-CHEMICAL
concentration O
in O
the O
corpus O
striatum O
after O
2 O
h O
while O
a O
larger O
dose O
of O
L-phenylalanine B-CHEMICAL
(800 O
mg/kg) O
produced O
a O
greater O
increase. O
Eight O
hours O
following O
L-phenylalanine B-CHEMICAL
injection, O
p-HPAA B-CHEMICAL
concentrations O
were O
still O
elevated. O
With O
D-phenylalanine B-CHEMICAL
a O
significant O
increase O
was O
observed O
at O
eight O
hours O
after O
drug O

administration. O
Two O
drugs O
which O
reduce O
dopamine B-CHEMICAL
synthesis, O
alpha-methyl-para-tyrosine B-CHEMICAL
and O
apomorphine, B-CHEMICAL
decreased O
m-HPAA B-CHEMICAL
striatal O
concentrations O
without O
affecting O
p-HPAA B-CHEMICAL
concentrations. O
From O
these O
results, O
it O
is O
proposed O
that O
tyrosine B-GENE-Y
hydroxylase I-GENE-Y
activity O
determines O
p-HPAA B-CHEMICAL
concentrations O
by O
regulating O
p-tyrosine B-CHEMICAL
availability. O
This O
enzyme O
may O
also O
synthesize O
m-tyrosine B-CHEMICAL
which O
is O
subsequently O
decarboxylated O
to O
form O
m-tyramine B-CHEMICAL
and O
then O
oxidatively O
deaminated O
to O
form O
m-HPAA. B-CHEMICAL

Demonstration O
of O
histamine B-CHEMICAL
receptors I-GENE-N
on O
human O
platelets O
by O
flow O
cytometry. O
Fluoresceinated B-GENE-Y
human I-GENE-Y
albumin I-GENE-Y
conjugated O
with O
histamine B-CHEMICAL
(FHA-HIS) B-GENE-Y
has O
been O
used O
for O
the O
demonstration O
of O
histamine B-CHEMICAL
receptors I-GENE-N
on O
human O
platelets. O
Such O
receptors O
were O
demonstrated O
on O
40-63% O
of O
peripheral O
blood O
platelets O
in O
4 O
healthy O
donors. O
The O
binding O
of O
FHA-HIS B-GENE-Y
was O
inhibited O
on O
35-79% O
of O
the O
platelets O
by O
the O
histamine B-CHEMICAL
H1 I-GENE-Y
receptor I-GENE-Y
antagonists O
diphenhydramine B-CHEMICAL
and O
clemastine. B-CHEMICAL
The O
histamine B-CHEMICAL
H2 I-GENE-Y
receptor I-GENE-Y
antagonist O
cimetidine B-CHEMICAL
blocked O
the O

FHA-HIS B-GENE-Y
binding O
on O
14-37% O
of O
the O
platelets. O
It O
is O
concluded O
that O
histamine B-CHEMICAL
H1 I-GENE-Y
as O
well O
as O
H2 B-GENE-Y
receptors I-GENE-Y
occur O
on O
human O
platelets O
but O
the O
receptors O
are O
not O
equally O
distributed O
in O
the O
platelet O
population. O
The O
effect O
of O
vitamin B-CHEMICAL
B6 I-CHEMICAL
deficiency O
on O
alanine: B-GENE-N
glyoxylate I-GENE-N
aminotransferase I-GENE-N
isoenzymes O
in O
rat O
liver. O
Endogenous O
synthesis O
of O
oxalate B-CHEMICAL
has O
been O
reported O
to O
increase O
in O
vitamin B-CHEMICAL
B6 I-CHEMICAL
deficiency O
probably O
due O
to O
defective O
transamination O
of O
glyoxylate, B-CHEMICAL
the O
direct O
source O
of O
oxalate, B-CHEMICAL
to O
glycine. B-CHEMICAL

Alanine:glyoxylate B-CHEMICAL
aminotransferase I-GENE-N
(AGT) B-GENE-N
in O
the O
liver O
catalyzes O
most O
of O
the O
glyoxylate B-CHEMICAL
transamination O
in O
mammalian O
tissues O
(E. O
V. O
Rowsell, O
K. O
Snell, O
J. O
A. O
Carnie, O
and O
K. O
V. O
Rowsell O
(1972) O
Biochem. O
J. O
127, O
155-165). O
The O
effects O
of O
vitamin B-CHEMICAL
B6 I-CHEMICAL
deficiency O
on O
hepatic O
AGT B-GENE-N
isoenzymes, O
designated O
AGT B-GENE-Y
1 I-GENE-Y
and O
AGT B-GENE-Y
2, I-GENE-Y
respectively, O
were O
examined O
with O
male O
rats; O
AGT B-GENE-Y
1 I-GENE-Y
is O
located O

both O
in O
the O
peroxisomes O
and O
in O
the O
mitochondria, O
and O
AGT B-GENE-Y
2 I-GENE-Y
only O
in O
the O
mitochondria. O
The O
holo O
activity O
of O
combined O
peroxisomal O
and O
mitochondrial O
AGT B-GENE-Y
1 I-GENE-Y
with O
a O
low O
Km O
for O
L-alanine B-CHEMICAL
rapidly O
decreased O
after O
a O
lag O
time O
of O
about O
2 O
days O
during O
feeding O
of O
the O
vitamin B-CHEMICAL
B6-deficient I-CHEMICAL
diet O
(by O
50% O
in O
5 O
days, O
by O
86% O
in O
14 O
days). O
Peroxisomal O
AGT B-GENE-Y
1 I-GENE-Y
activity O
was O
more O
affected O
than O
the O
mitochondrial. O
The O
holo O
activity O
of O
AGT B-GENE-Y
2 I-GENE-Y
with O
a O
high O
Km O
for O

L-alanine B-CHEMICAL
decreased O
more O
slowly O
than O
AGT B-GENE-Y
1 I-GENE-Y
(by O
33% O
in O
14 O
days, O
by O
60% O
in O
28 O
days). O
Urinary O
excretion O
of O
oxalate B-CHEMICAL
began O
to O
increase O
in O
8-9 O
days, O
when O
AGT B-GENE-Y
2 I-GENE-Y
remained O
intact O
but O
most O
of O
AGT B-GENE-Y
1 I-GENE-Y
is O
depleted. O
When O
the O
defect O
in O
the O
glyoxylate B-CHEMICAL
transamination O
in O
vivo O
in O
vitamin B-CHEMICAL
B6 I-CHEMICAL
deficiency O
is O
considered, O
these O
findings O
suggest O
that O
it O
is O
due O
to O
the O
deficiency O
of O
AGT B-GENE-Y
1. I-GENE-Y
The O
importance O
of O
peroxisomal O
AGT B-GENE-Y
1 I-GENE-Y
is O
discussed, O
since O
peroxisomes O
have O
been O
described O
to O
be O

probably O
the O
major O
site O
of O
glyoxylate B-CHEMICAL
formation. O
How O
do O
volatile O
anesthetics O
inhibit O
Ca(2+)-ATPases? B-GENE-N
Volatile O
anesthetics O
at O
concentrations O
that O
are O
used O
in O
clinical O
practice O
to O
induce O
anesthesia O
selectively O
inhibit O
activity O
of O
the O
plasma O
membrane O
Ca(2+)-transport B-CHEMICAL
ATPase I-GENE-N
(Kosk-Kosicka, O
D., O
and O
Roszczynska, O
G. O
(1993) O
Anesthesiology O
79, O
774-780). O
We O
have O
investigated O
the O
mechanism O
of O
the O
inhibitory O
action O
of O
several O
anesthetics O
on O
the O

purified O
erythrocyte O
Ca(2+)-ATPase B-CHEMICAL
by O
employing O
fluorescence O
spectroscopy O
measurements O
that O
report O
changes O
in O
the O
environment O
of O
intrinsic O
tryptophans B-CHEMICAL
and O
of O
an O
extrinsic O
probe O
attached O
in O
the O
active O
site O
of O
the O
enzyme. O
We O
have O
shown O
that O
the O
observed O
inhibition O
of O
the O
Ca(2+)-dependent B-CHEMICAL
activation O
of O
the O
enzyme O
correlates O
well O
with O
the O
elimination O
of O
the O
Ca(2+)-induced B-CHEMICAL
conformation O
change O
that O
is O
important O
for O
the O
proper O
function O
of O
the O
enzyme. O
Analysis O
of O
the O
anesthetics O
effects O
on O
the O
total O
tryptophan B-CHEMICAL

fluorescence O
indicates O
a O
significant O
effect O
on O
enzyme O
conformation. O
Similar O
changes O
have O
been O
observed O
in O
the O
sarcoplasmic B-GENE-N
reticulum I-GENE-N
Ca(2+)-ATPase. B-CHEMICAL
We O
propose O
that O
volatile O
anesthetics O
inhibit O
Ca(2+)-ATPase B-CHEMICAL
by O
interacting O
with O
nonpolar O
sites O
in O
protein O
interior, O
in O
analogy O
to O
the O
binding O
demonstrated O
for O
myoglobin, B-GENE-Y
hemoglobin, B-GENE-N
and O
adenylate B-CHEMICAL
kinase I-GENE-N
(Schoenborn, O
B. O
P., O
and O
Featherstone, O
R. O
M. O
(1967) O
Adv. O
Pharmacol. O
5, O

1-17; O
Tilton, O
R. O
F., O
Kuntz, O
I. O
D., O
and O
Petsko, O
G. O
A. O
(1984) O
Biochemistry O
23, O
2849-2857). O
Such O
binding O
is O
expected O
to O
modify O
conformational O
substate(s) O
of O
the O
enzyme O
and O
perturb O
its O
function. O
We O
view O
this O
process O
as O
an O
example O
of O
a O
general O
phenomena O
of O
interaction O
of O
small O
molecules O
with O
internal O
sites O
in O
proteins. O
The O
effect O
of O
triclosan B-CHEMICAL
on O
mediators O
of O
gingival O
inflammation. O
Triclosan B-CHEMICAL

(2,4,4',-trichloro-2'-hydroxydiphenylether) B-CHEMICAL
is O
a O
well-known O
and O
widely O
used O
nonionic O
antibacterial O
agent O
which O
has O
recently O
been O
introduced O
in O
toothpastes O
and O
mouthrinses. O
The O
efficacy O
of O
triclosan-containing B-CHEMICAL
toothpaste O
and O
mouthrinse O
to O
reduce O
both O
plaque O
and O
gingivitis O
in O
long-term O
clinical O
trials O
has O
been O
well O
documented. O
Until O
recently, O
it O
was O
generally O
assumed O
that O
triclosan's O
effect O
on O
gingival O
inflammation O
was O
due O
to O
its O
antimicrobial O
and O
anti-plaque O
effect. O

It O
has O
now O
become O
apparent O
that O
triclosan B-CHEMICAL
may O
have O
a O
direct O
anti-inflammatory O
effect O
on O
the O
gingival O
tissues. O
Several O
in O
vitro O
studies O
were O
conducted O
to O
evaluate O
the O
effect O
of O
triclosan B-CHEMICAL
on O
4 O
primary O
enzymes O
of O
the O
pathways O
of O
arachidonic B-CHEMICAL
acid I-CHEMICAL
metabolism, O
cyclo-oxygenase B-GENE-Y
1, I-GENE-Y
cyclo-oxygenase B-GENE-Y
2, I-GENE-Y
5-lipoxygenase B-GENE-Y
and O
15-lipoxygenase. B-GENE-Y
These O
pathways O
lead O
to O
the O
production O
of O
known O
mediators O
of O
inflammation O
such O
as O
the O
prostaglandins, B-CHEMICAL
leukotrienes B-CHEMICAL
and O
lipoxins. B-CHEMICAL

Triclosan B-CHEMICAL
inhibited O
both O
cyclooxygenase B-GENE-Y
1 I-GENE-Y
and O
cyclo-oxygenase B-GENE-Y
2 I-GENE-Y
with O
IC-50 O
values O
of O
43 O
microM O
and O
227 O
microM, O
respectively. O
Triclosan B-CHEMICAL
also O
inhibited O
5-lipoxygenase B-GENE-Y
with O
an O
IC-50 O
of O
43 O
microM. O
The O
15-lipoxygenase B-GENE-Y
was O
similarly O
inhibited O
by O
triclosan B-CHEMICAL
with O
an O
IC-50 O
of O
61 O
microM. O
Hence, O
triclosan B-CHEMICAL
has O
the O
ability O
to O
inhibit O
both O
the O
cyclo-oxygenase B-GENE-N
and O
lipoxygenase B-GENE-N
pathways O

of O
arachidonic B-CHEMICAL
acid I-CHEMICAL
metabolism O
with O
similar O
efficacy. O
In O
cell O
culture O
experiments, O
it O
was O
found O
that O
triclosan B-CHEMICAL
inhibited O
IL-1 B-GENE-Y
beta I-GENE-Y
induced O
prostaglandin B-CHEMICAL
E2 I-CHEMICAL
production O
by O
human O
gingival O
fibroblasts O
in O
a O
concentration O
dependent O
manner, O
and O
at O
relatively O
low O
concentrations. O
These O
data, O
taken O
together, O
indicate O
that O
triclosan B-CHEMICAL
can O
inhibit O
formation O
of O
several O
important O
mediators O
of O
gingival O
inflammation.(ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS) O
The O
dynamics O
of O
cobalamin B-CHEMICAL
utilization O
in O
L-1210 O
mouse O
leukemia O

cells: O
a O
model O
of O
cellular O
cobalamin B-CHEMICAL
metabolism. O
The O
uptake O
and O
metabolism O
of O
cobalamin B-CHEMICAL
(Cbl) B-CHEMICAL
has O
been O
studied O
in O
L-1210 O
murine O
leukemia O
cells O
propagating O
in O
vitro. O
Extracellular O
Cbl B-CHEMICAL
(protein O
bound O
and O
free) O
and O
intracellular O
Cbl B-CHEMICAL
(protein O
bound O
and O
free) O
were O
determined O
after O
culturing O
L-1210 O
cells O
in O
the O
presence O
of O
[57Co]cyanocobalamin B-CHEMICAL
(CN-Cbl) B-CHEMICAL
bound O
to O
transcobalamin B-GENE-Y
II I-GENE-Y
(transcobalamin, B-GENE-N
TC). B-GENE-N

The O
intracellular O
pool O
of O
free O
[57Co]Cbl B-CHEMICAL
increased O
during O
the O
first O
24 O
h O
of O
culture O
and O
a O
substantial O
fraction O
of O
this O
free O
pool O
was O
effluxed O
from O
the O
cell O
to O
the O
medium. O
Upon O
depletion O
of O
extracellular O
TC-[57Co]CN-Cbl, B-CHEMICAL
the O
intracellular O
concentration O
of O
free O
Cbl B-CHEMICAL
decreased O
as O
did O
the O
efflux O
of O
Cbl B-CHEMICAL
to O
the O
medium. O
Internalized O
[57Co]CN-Cbl B-CHEMICAL
was O
converted O
to O
hydroxocobalamin B-CHEMICAL
(OH-Cbl), B-CHEMICAL

methylcobalamin B-CHEMICAL
(Me-Cbl) B-CHEMICAL
and O
5'-deoxyadenosylcobalamin. B-CHEMICAL
These O
Cbl B-CHEMICAL
forms O
were O
found O
in O
both O
soluble O
(cytoplasmic) O
and O
insoluble O
(membrane) O
fractions. O
Intracellular O
protein-bound O
[57Co]Cbl B-CHEMICAL
fractionated O
with O
methionine B-GENE-Y
synthase I-GENE-Y
(MS) B-GENE-Y
and O
methylmalonyl-CoA B-GENE-Y
mutase I-GENE-Y
(MU) B-GENE-Y
activity. O
The O
major O
form O
of O
Cbl B-CHEMICAL
associated O
with O
the O
two O
enzymes O
was O
OH-Cbl. B-CHEMICAL
Cells O
propagated O
in O

medium O
containing O
N5-methyltetrahydrofolate B-CHEMICAL
and O
homocysteine B-CHEMICAL
showed O
a O
substantial O
increase O
in O
MS B-GENE-Y
activity O
which O
paralleled O
the O
increase O
in O
the O
intracellular O
concentration O
of O
Me-Cbl B-CHEMICAL
and O
the O
Cbl B-CHEMICAL
bound O
to O
the O
enzyme. O
Ergovaline B-CHEMICAL
binding O
and O
activation O
of O
D2 B-GENE-Y
dopamine I-GENE-Y
receptors I-GENE-Y
in O
GH4ZR7 O
cells. O
Ergovaline B-CHEMICAL
inhibition O
of O
radioligand O
binding O
to O
the O
D2 B-GENE-Y
dopamine I-GENE-Y
receptor I-GENE-Y
and O
ergot B-CHEMICAL
alkaloid I-CHEMICAL
inhibition O
of O
vasoactive B-GENE-Y
intestinal I-GENE-Y
peptide I-GENE-Y
(VIP)-stimulated B-GENE-Y
cyclic B-CHEMICAL
AMP I-CHEMICAL
production O
in O

GH4ZR7 O
cells, O
stably O
transfected O
with O
a O
rat B-GENE-Y
D2 I-GENE-Y
dopamine B-CHEMICAL
receptor, I-GENE-Y
were O
evaluated. O
Ergovaline B-CHEMICAL
inhibition O
of O
the O
binding O
of O
the O
D2-specific B-GENE-Y
radioligand, O
[3H]YM-09151-2, B-CHEMICAL
exhibited O
a O
KI O
(inhibition O
constant) O
of O
6.9 O
+/- O
2.6 O
nM, O
whereas O
dopamine B-CHEMICAL
was O
much O
less O
potent O
(370 O
+/- O
160 O
nM). O
Ergot B-CHEMICAL
alkaloids I-CHEMICAL
were O
also O
effective O
in O
inhibiting O
VIP-stimulated B-GENE-Y
cyclic B-CHEMICAL
AMP I-CHEMICAL
production, O
with O
EC50 O
values O
for O

ergovaline, B-CHEMICAL
ergonovine, B-CHEMICAL
alpha-ergocryptine, B-CHEMICAL
ergotamine, B-CHEMICAL
and O
dopamine B-CHEMICAL
of O
8 O
+/- O
2, O
47 O
+/- O
2, O
28 O
+/- O
2, O
2 O
+/- O
1, O
and O
8 O
+/- O
1 O
nM, O
respectively. O
Inhibition O
of O
cyclic B-CHEMICAL
AMP I-CHEMICAL
production O
by O
ergovaline B-CHEMICAL
was O
blocked O
by O
the O
dopamine B-GENE-N
receptor I-GENE-N
antagonist, O
(-)-sulpiride B-CHEMICAL
(IC50, O
300 O
+/- O
150 O
nM). O
Our O
results O
indicate O
that O
ergot O
compounds, O
especially O
ergovaline, B-CHEMICAL
bind O
to O
D2 B-GENE-Y

dopamine I-GENE-Y
receptors I-GENE-Y
and O
elicit O
second O
messenger O
responses O
similar O
to O
that O
of O
dopamine. B-CHEMICAL
These O
findings O
suggest O
that O
some O
of O
the O
deleterious O
effects O
of O
consumption O
of O
endophyte-infected O
tall O
fescue, O
which O
contains O
several O
ergot B-CHEMICAL
alkaloids I-CHEMICAL
including O
ergovaline, B-CHEMICAL
may O
be O
due O
to O
D2 B-GENE-Y
dopamine B-CHEMICAL
receptor I-GENE-Y
activation. O
Binding O
of O
antipsychotic O
drugs O
at O
alpha B-GENE-N
1A- I-GENE-N
and I-GENE-N
alpha I-GENE-N
1B-adrenoceptors: I-GENE-N
risperidone B-CHEMICAL
is O
selective O
for O
the O
alpha B-GENE-Y
1B-adrenoceptors. I-GENE-Y
The O
binding O
of O
the O
antipsychotic O
drugs O
risperidone, B-CHEMICAL

(+)-butaclamol, B-CHEMICAL
clozapine, B-CHEMICAL
haloperidol, B-CHEMICAL
spiperone, B-CHEMICAL
thioridazine B-CHEMICAL
and O
YM-09151-2 B-CHEMICAL
was O
studied O
at O
the O
subtypes O
of O
the O
alpha B-GENE-N
1-adrenoceptor. I-GENE-N
Saturation O
experiments O
showed O
that O
[3H]prazosin B-CHEMICAL
labelled O
a O
single O
population O
of O
binding O
sites O
in O
the O
spleen O
(alpha B-GENE-Y
1B) I-GENE-Y
and O
hippocampus O
(alpha B-GENE-Y
1A I-GENE-Y
and O
alpha B-GENE-Y
1B) I-GENE-Y
(dissociation O
constants O
(KD): O
0.26 O
nM O
and O
0.14 O
nM O
respectively). O

Prazosin B-CHEMICAL
displaced O
the O
radioligand O
in O
a O
monophasic O
manner O
in O
both O
the O
spleen O
and O
hippocampus O
whereas O
5-methyl-urapidil, B-CHEMICAL
phentolamine B-CHEMICAL
and O
WB B-CHEMICAL
4101 I-CHEMICAL
displaced O
the O
radioligand O
in O
a O
monophasic O
manner O
in O
the O
spleen O
but O
in O
a O
biphasic O
manner O
in O
the O
hippocampus. O
The O
affinity O
of O
these O
three O
compounds O
for O
the O
low O
affinity O
site O
in O
the O
hippocampus O
was O
similar O
to O
that O
observed O
in O
the O
spleen, O
suggesting O
that O
all O
three O
were O
selective O
for O
the O
alpha B-GENE-Y
1A-adrenoceptor. I-GENE-Y

Furthermore, O
the O
affinities O
for O
the O
alpha B-GENE-N
1A- I-GENE-N
and I-GENE-N
alpha I-GENE-N
1B-adrenoceptors I-GENE-N
calculated O
in O
this O
manner O
were O
in O
agreement O
with O
literature O
values. O
With O
the O
exception O
of O
risperidone, B-CHEMICAL
all O
the O
antipsychotic O
drugs O
tested O
failed O
to O
show O
selectivity O
for O
either O
of O
the O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
subtypes. O
Risperidone B-CHEMICAL
was O
120-fold O
more O
selective O
for O
the O
alpha B-GENE-Y
1B-adrenoceptor I-GENE-Y
with O
respect O
to O
the O
alpha B-GENE-Y
1A-adrenoceptor I-GENE-Y
(Ki O
values: O
2.3 O
+/- O
1.2 O
nM O
and O
283.6 O

+/- O
174.1 O
nM O
respectively). O
Mediation O
of O
noradrenaline-induced B-CHEMICAL
contractions O
of O
rat O
aorta O
by O
the O
alpha B-GENE-Y
1B-adrenoceptor I-GENE-Y
subtype. O
1. O
The O
subtypes O
of O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
mediating O
contractions O
to O
exogenous O
noradrenaline B-CHEMICAL
(NA) B-CHEMICAL
in O
rat O
aorta O
have O
been O
examined O
in O
both O
biochemical O
and O
functional O
studies. O
2. O
Incubation O
of O
rat O
aortic O
membranes O
with O
the O
irreversible O
alpha B-GENE-Y
1B-adrenoceptor I-GENE-Y
antagonist, O
chloroethylclonidine B-CHEMICAL

(CEC: B-CHEMICAL
10 O
microM) O
did O
not O
change O
the O
KD O
of O
[3H]-prazosin B-CHEMICAL
binding O
in O
comparison O
to O
untreated O
membranes, O
but O
reduced O
by O
88% O
the O
total O
number O
of O
binding O
sites O
(Bmax). O
3. O
Contractions O
of O
rat O
aortic O
strips O
to O
NA B-CHEMICAL
after O
CEC B-CHEMICAL
(50 O
microM O
for O
30 O
min) O
incubation O
followed O
by O
repetitive O
washing, O
showed O
a O
marked O
shift O
in O
the O
potency O
of O
NA B-CHEMICAL
and O
a O
partial O
reduction O
in O
the O
maximum O
response. O
The O
residual O
contractions O
to O
NA B-CHEMICAL
after O
CEC B-CHEMICAL
incubation O
were O
not O
affected O
by O
prazosin B-CHEMICAL
(10 O

nM). O
4. O
The O
competitive O
antagonists O
prazosin, B-CHEMICAL
terazosin, B-CHEMICAL
(R)-YM-12617, B-CHEMICAL
phentolamine, B-CHEMICAL
5-methylurapidil B-CHEMICAL
and O
spiperone B-CHEMICAL
inhibited O
contractions O
to O
NA B-CHEMICAL
with O
estimated O
pA2 O
values O
of O
9.85, O
8.54, O
9.34, O
7.71, O
7.64 O
and O
8.41, O
respectively. O
5. O
The O
affinity O
of O
the O
same O
antagonists O
for O
the O
alpha B-GENE-N
1A- I-GENE-N
and I-GENE-N
alpha I-GENE-N
1B- I-GENE-N
adrenoceptors I-GENE-N
was O
evaluated O
by O
utilizing O
membranes O
from O
rat O
hippocampus O

pretreated O
with O
CEC, B-CHEMICAL
and O
rat O
liver, O
respectively. O
5-Methylurapidil B-CHEMICAL
and O
phentolamine B-CHEMICAL
were O
confirmed O
as O
selective O
for O
the O
alpha B-GENE-Y
1A-adrenoceptors, I-GENE-Y
whereas O
spiperone B-CHEMICAL
was O
alpha O
1B-selective. O
6. O
A O
significant O
correlation O
was O
found O
between O
the O
pA2 O
values O
of O
the O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
antagonists O
tested O
and O
their O
affinity O
for O
the O
alpha B-GENE-Y
1B-adrenoceptor I-GENE-Y
subtype, O
but O
not O
for O
the O
alpha O
1A-subtype. O
7. O
In O
conclusion, O
these O
findings O
indicate O
that O
in O
rat O
aorta O
most O
of O
the O
contraction O
is O
mediated O
by O

alpha B-GENE-Y
1B-adrenoceptors, I-GENE-Y
and O
that O
the O
potency O
(pA2) O
of O
an O
antagonist O
in O
this O
tissue O
should O
be O
related O
to O
its O
antagonistic O
effect O
on O
this O
subtype O
of O
the O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
population. O
Beta O
2- O
but O
not O
beta B-GENE-Y
1-adrenoceptors I-GENE-Y
are O
involved O
in O
desipramine B-CHEMICAL
enhancement O
of O
aggressive O
behavior O
in O
long-term O
isolated O
mice. O
The O
effects O
of O
several O
beta-adrenoceptor B-GENE-N
antagonists O
on O
the O
desipramine-induced B-CHEMICAL
increase O
in O
aggressive O
behavior O
in O
long-term O
isolated O
mice O
were O
examined. O
Desipramine B-CHEMICAL
HCl I-CHEMICAL
(10 O

mg/kg, O
IP) O
significantly O
increased O
the O
duration O
of O
aggressive O
behavior O
in O
isolated O
mice O
but O
did O
not O
significantly O
change O
the O
latency O
to O
the O
first O
attack O
consistent O
with O
our O
previous O
reports. O
Intraperitoneal O
administration O
of O
(+/- B-CHEMICAL
)propranolol I-CHEMICAL
HCl I-CHEMICAL
(2.5-10 O
mg/kg), O
a O
nonselective O
beta-adrenoceptor B-GENE-N
antagonist, O
dose O
dependently O
attenuated O
the O
desipramine-induced B-CHEMICAL
enhancement O
of O
aggressive O
behavior O
without O
significantly O
affecting O
the O
basal O
aggressive O
responses. O
ICI118,551 B-CHEMICAL
HCl I-CHEMICAL
(1.25-5 O
mg/kg, O
IP), O

a O
selective O
beta B-GENE-Y
2-adrenoceptor I-GENE-Y
antagonist, O
also O
blocked O
the O
desipramine-induced O
enhancement O
of O
aggressive O
behavior O
in O
a O
dose-dependent O
manner, O
whereas O
metoprolol B-CHEMICAL
tartrate I-CHEMICAL
(5-20 O
mg/kg, O
IP), O
a O
selective O
beta B-GENE-Y
1-adrenoceptor I-GENE-Y
antagonist, O
did O
not O
affect O
it. O
Moreover, O
clenbuterol B-CHEMICAL
HCl I-CHEMICAL
(0.1-0.5 O
mg/kg, O
IP), O
a O
lipophilic O
beta B-GENE-Y
2-adrenoceptor I-GENE-Y
agonist, O
significantly O
increased O
the O
duration O
of O
basal O
aggressive O
behavior. O
Taken O
together O
with O
our O
previous O
finding O
that O

the O
desipramine-induced B-CHEMICAL
enhancement O
of O
aggressive O
behavior O
can O
be O
blocked O
by O
yohimbine, B-CHEMICAL
an O
alpha B-GENE-N
2-adrenoceptor I-GENE-N
antagonist, O
the O
present O
results O
indicate O
that O
not O
only O
alpha O
2- O
but O
also O
beta B-GENE-Y
2-adrenoceptor I-GENE-Y
stimulation O
plays O
important O
roles O
in O
modulation O
of O
aggressive O
behavior O
in O
long-term O
isolated O
mice. O
Alpha B-GENE-N
1-adrenoceptor I-GENE-N
subtypes O
mediating O
the O
regulation O
and O
modulation O
of O
Ca2+ B-CHEMICAL
sensitization O
in O
rabbit O
thoracic O
aorta. O
Norepinephrine B-CHEMICAL
(10 O
microM), O
methoxamine B-CHEMICAL
(100 O

microM) O
and O
clonidine B-CHEMICAL
(100 O
microM) O
with O
guanosine B-CHEMICAL
5'-triphosphate I-CHEMICAL
(GTP, O
50 O
microM) O
or O
guanosine B-CHEMICAL
5'-O-(3-thiotriphosphate) I-CHEMICAL
(GTP B-CHEMICAL
gamma-S, I-CHEMICAL
10 O
microM) O
all O
significantly O
enhanced O
the O
contraction O
induced O
by O
0.3 O
microM O
Ca2+ B-CHEMICAL
(pCa6.5) O
in O
beta-escin-skinned O
smooth O
muscle O
of O
rabbit O
thoracic O
aorta. O
The O
enhancement O
of O
Ca2+ B-CHEMICAL
contraction O
produced O
by O
norepinephrine B-CHEMICAL
was O
greater O
than O
that O
produced O

by O
methoxamine B-CHEMICAL
or O
clonidine. B-CHEMICAL
In O
beta-escin-skinned O
strips O
of O
chloroethylclonidine-pretreated B-CHEMICAL
smooth O
muscle, O
the O
enhancement O
of O
Ca2+ B-CHEMICAL
contraction O
produced O
by O
norepinephrine B-CHEMICAL
was O
significantly O
decreased, O
whereas O
the O
amplitude O
was O
the O
same O
as O
that O
produced O
by O
methoxamine B-CHEMICAL
or O
clonidine; B-CHEMICAL
this O
enhancement O
was O
inhibited O
by O
the O
selective O
alpha B-GENE-Y
1A-adrenoceptor I-GENE-Y
antagonist O
WB B-CHEMICAL
4101 I-CHEMICAL
(100 O
nM). O
The O
enhancement O
of O
Ca2+ B-CHEMICAL
contraction O
produced O
by O
methoxamine B-CHEMICAL
and O
clonidine B-CHEMICAL
was O

not O
affected O
by O
chloroethylclonidine B-CHEMICAL
pretreatment. O
The O
effects O
of O
methoxamine, B-CHEMICAL
clonidine B-CHEMICAL
and O
norepinephrine B-CHEMICAL
in O
the O
chloroethylclonidine-pretreated B-CHEMICAL
tissue O
were O
all O
inhibited O
by O
guanosine B-CHEMICAL
5'-O-(2-thiodiphosphate) I-CHEMICAL
(GDP B-CHEMICAL
beta-S, I-CHEMICAL
1 O
mM) O
and O
1-(5-isoquinolinylsulfonyl)-methylpiperazine B-CHEMICAL
(H-7, O
20 O
microM). O
Furthermore, O
the O
phosphorylation O

of O
myosin B-GENE-N
light I-GENE-N
chain I-GENE-N
produced O
by O
norepinephrine B-CHEMICAL
was O
greater O
than O
that O
produced O
by O
clonidine. B-CHEMICAL
These O
results O
suggest O
that O
both O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
subtypes I-GENE-N
(alpha I-GENE-N
1A I-GENE-N
and I-GENE-N
alpha I-GENE-N
1B) I-GENE-N
increase O
the O
Ca2+ B-CHEMICAL
sensitivity O
of O
contractile O
elements, O
and O
that O
the O
Ca2+ B-CHEMICAL
sensitization O
produced O
by O
alpha B-GENE-Y
1A-subtype I-GENE-Y
receptors I-GENE-Y
is O
mediated O
through O
G-protein B-GENE-N
and O
protein B-GENE-N
kinase I-GENE-N
C, I-GENE-N
and O
plays O
an O
important O
role O
in O
contraction O
of O
smooth O
muscle O
of O
rabbit O
thoracic O
aorta. O
STZ O
transport O
and O
cytotoxicity. O
Specific O
enhancement O
in O

GLUT2-expressing B-GENE-Y
cells. O
The O
glucose B-CHEMICAL
analog O
streptozotocin B-CHEMICAL
(STZ) B-CHEMICAL
has O
long O
been O
used O
as O
a O
tool O
for O
creating O
experimental O
diabetes O
because O
of O
its O
relatively O
specific O
beta-cell O
cytotoxic O
effect, O
but O
the O
mechanism O
by O
which O
systemic O
injection O
of O
STZ B-CHEMICAL
causes O
beta-cell O
destruction O
is O
not O
well O
understood. O
In O
the O
current O
study, O
we O
have O
used O
insulinoma O
(RIN) O
and O
AtT-20ins O
cell O
lines O
engineered O
for O
overexpression O
of O
GLUT2 B-GENE-Y
or O
GLUT1 B-GENE-Y
to O
investigate O
the O
role O
of O
glucose B-CHEMICAL
transporter I-GENE-N
isoforms O
in O
mediating O
STZ B-CHEMICAL

cytotoxicity. O
The O
in O
vivo O
effects O
of O
STZ B-CHEMICAL
were O
evaluated O
by O
implantation O
of O
RIN O
cells O
expressing O
or O
lacking O
GLUT2 B-GENE-Y
into O
athymic O
nude O
rats. O
The O
drug O
had O
a O
potent O
cytotoxic O
effect O
on O
RIN O
cells O
expressing O
GLUT2, B-GENE-Y
but O
had O
no O
effect O
on O
cells O
lacking O
GLUT2 B-GENE-Y
expression, O
as O
indicated O
by O
histological O
analysis O
and O
measurement O
of O
the O
blood O
glucose B-CHEMICAL
levels O
of O
treated O
animals. O
The O
preferential O
cytotoxic O
effect O
of O
STZ B-CHEMICAL
on O
GLUT2-expressing B-GENE-Y
cell O
lines O
was O
confirmed O
by O
in O
vitro O
analysis O
of O
GLUT2-expressing B-GENE-Y

and O
untransfected O
RIN O
cells, O
as O
well O
as O
GLUT2- B-GENE-Y
and O
GLUT1-overexpressing B-GENE-Y
AtT-20ins O
cells. O
Consistent O
with O
these O
data, O
only O
GLUT2-expressing B-GENE-Y
RIN O
or O
AtT-20ins O
cells O
transported O
STZ B-CHEMICAL
efficiently. O
We O
conclude O
that O
expression O
of O
GLUT2 B-GENE-Y
is O
required O
for O
efficient O
killing O
of O
neuroendocrine O
cells O
by O
STZ, B-CHEMICAL
and O
this O
effect O
is O
related O
to O
specific O
recognition O
of O
the O
drug O
as O
a O
transported O
substrate O
by O
GLUT2 B-GENE-Y
but O
not O
GLUT1. B-GENE-Y
Annexin B-GENE-Y
1 I-GENE-Y
regulation O
in O
human O
epidermal O
cells. O

Annexin B-GENE-Y
1 I-GENE-Y
(named O
p35, B-GENE-Y
lipocortin B-GENE-Y
I I-GENE-Y
or O
calpactin B-GENE-Y
II), I-GENE-Y
initially O
described O
as O
a O
glucocorticoid O
induced O
protein, O
belongs O
to O
a O
new O
characterized O
family O
of O
intracellular O
proteins. O
In O
the O
skin, O
the O
role O
of O
annexins B-GENE-N
has O
still O
not O
been O
elucidated. O
In O
a O
previous O
study, O
we O
reported O
the O
localization O
of O
annexin B-GENE-Y
1 I-GENE-Y
in O
both O
freshly O
isolated O
human O
epidermal O
cells O
and O
in O
cultured O
keratinocytes O
using O
immunofluorescence, O
FACS O
analysis O
and O
immunoblotting O
techniques. O
The O
protein O
was O
characterized O
by O
Western O

blot O
and O
immunoprecipitation O
as O
a O
35 O
kDa O
protein. O
Results O
from O
in O
vivo O
studies O
confirmed O
the O
presence O
of O
annexin B-GENE-Y
1 I-GENE-Y
in O
basal O
and O
suprabasal O
layers O
of O
normal O
human O
skin O
with O
modified O
reactivity O
patterns O
in O
hyperproliferative O
lesions. O
In O
the O
present O
study, O
the O
role O
of O
glucocorticoids O
in O
annexin B-GENE-Y
1 I-GENE-Y
regulation O
was O
investigated O
in O
epidermal O
cells O
by O
Western O
blot O
and O
immunoprecipation O
assays. O
In O
contrast O
to O
other O
studies, O
we O
found O
that O
glucocorticoid O
treatment O
of O
epidermal O
cells O
led O
to O

a O
decrease O
in O
annexin B-GENE-Y
1 I-GENE-Y
content O
in O
the O
cytoplasm O
and O
the O
membranes O
of O
cells. O
As O
annexin B-GENE-Y
1 I-GENE-Y
was O
not O
detected O
in O
the O
nucleus O
of O
cells, O
we O
conclude O
that O
there O
was O
a O
down O
regulation O
of O
annexin B-GENE-Y
1 I-GENE-Y
after O
glucocorticoid O
treatments O
rather O
than O
a O
translocation O
of O
the O
protein O
to O
the O
nucleus. O
Despite O
the O
absence O
of O
the O
signal O
peptide O
sequence O
necessary O
for O
protein O
secretion, O
annexin B-GENE-Y
1 I-GENE-Y
was O
released O
in O
the O
keratinocyte O
culture O
medium. O
We O
found O
that O
the O
protein O
was O
secreted O
only O
in O
low O
Ca2+ B-CHEMICAL
medium O
(0.15 O
mM), O
this O
process O

required O
an O
active O
metabolism. O
Inhibitory O
effects O
of O
lysine B-CHEMICAL
analogues O
on O
t-PA B-GENE-Y
induced O
whole O
blood O
clot O
lysis. O
The O
lysine B-CHEMICAL
analogues O
epsilon-aminocaproic B-CHEMICAL
acid I-CHEMICAL
(EACA) B-CHEMICAL
and O
trans-4-amino-methyl B-CHEMICAL
cyclohexane I-CHEMICAL
carboxylic I-CHEMICAL
acid I-CHEMICAL
(AMCA) B-CHEMICAL
are O
used O
to O
prevent O
excessive O
bleeding O
in O
patients O
with O
coagulopathies, O
such O
as O
hemophilia O
and O
thrombocytopenia, O
or O
in O
those O
who O
have O
received O
tissue B-GENE-Y
plasminogen I-GENE-Y
activator I-GENE-Y
(t-PA). B-GENE-Y
However, O
their O
relative O
efficacy O

in O
inhibiting O
lysis O
of O
clots O
that O
have O
been O
formed O
in O
the O
presence O
of O
exogenous O
t-PA B-GENE-Y
or O
that O
have O
been O
formed O
and O
then O
exposed O
to O
exogenous O
t-PA B-GENE-Y
has O
not O
been O
well O
characterized. O
The O
present O
study O
utilized O
blood O
from O
normal O
volunteers O
and O
125I-fibrinogen B-CHEMICAL
in O
a O
dilute O
whole O
blood O
clot O
assay O
to O
determine O
the O
relative O
concentrations O
of O
lysine B-CHEMICAL
analogues O
required O
for O
inhibition O
of O
clot O
lysis O
induced O
by O
exogenous O
t-PA. B-GENE-Y
AMCA B-CHEMICAL
(0.06 O
mM) O
and O
EACA B-CHEMICAL
(0.6 O
mM) O
were O
effective O
in O

prolonging O
clot O
lysis O
if O
(1) O
whole O
blood O
clots O
were O
formed O
and O
then O
exposed O
to O
a O
lysine B-CHEMICAL
analogue O
and O
exogenous O
t-PA B-GENE-Y
or O
if O
(2) O
whole O
blood O
clots O
were O
formed O
in O
the O
presence O
of O
exogenous O
t-PA B-GENE-Y
and O
a O
lysine B-CHEMICAL
analogue. O
However, O
their O
inhibitory O
effect O
was O
markedly O
reduced O
if O
clots O
were O
formed O
in O
the O
presence O
of O
t-PA B-GENE-Y
and O
then O
exposed O
to O
either O
of O
the O
lysine B-CHEMICAL
analogues. O
The O
analogues O
did O
not O
inhibit O
the O
initial O
binding O
of O
t-PA B-GENE-Y
to O
fibrin. B-GENE-N
They O
did O
inhibit O
binding O
of O

plasminogen B-GENE-Y
to O
fibrin B-GENE-N
as O
well O
as O
the O
activation O
of O
plasminogen B-GENE-Y
by O
t-PA B-GENE-Y
in O
the O
absence O
of O
fibrin. B-GENE-N
The O
data O
suggest O
that O
lysine B-CHEMICAL
analogues, O
even O
at O
low O
concentrations, O
reduce O
the O
rate O
of O
t-PA B-GENE-Y
induced O
whole O
blood O
clot O
lysis O
by O
several O
mechanisms. O
Histamine B-CHEMICAL
enhances O
the O
depolarizing O
afterpotential O
of O
immunohistochemically O
identified O
vasopressin B-CHEMICAL
neurons O
in O
the O
rat O
supraoptic O
nucleus O
via O
H1-receptor B-GENE-Y
activation. O
Previous O
studies O
have O
demonstrated O
that O
histamine B-CHEMICAL
primarily O
excites O
unidentified O
neurons O
in O
the O
rat O
supraoptic O

nucleus. O
We O
investigated O
the O
neuromodulatory O
effects O
of O
histamine B-CHEMICAL
on O
immunohistochemically O
identified O
vasopressin B-CHEMICAL
neurons O
in O
the O
rat O
supraoptic O
nucleus O
using O
intracellular O
recording O
techniques O
from O
the O
hypothalamo-neurohypophysial O
explant. O
Exogenous O
application O
of O
histamine B-CHEMICAL
(0.1-100 O
microM) O
to O
vasopressinergic O
neurons O
produced O
a O
small O
membrane O
depolarization O
accompanied O
by O
an O
increase O
of O
up O
to O
100% O
in O
the O
amplitude O
of O
the O
depolarizing O
afterpotential O
that O
follows O
current-evoked O
trains O
of O
action O

potentials. O
The O
enhancement O
of O
the O
depolarizing O
afterpotential O
by O
histamine B-CHEMICAL
did O
not O
depend O
upon O
the O
depolarization. O
Further, O
histamine B-CHEMICAL
enhanced O
the O
amplitude O
of O
the O
depolarizing O
afterpotential O
when O
blocking O
the O
afterhyperpolarizing O
potential O
with O
d-tubocurarine B-CHEMICAL
or O
apamin, O
and O
in O
the O
presence O
of O
tetrodotoxin B-CHEMICAL
and O
d-tubocurarine B-CHEMICAL
or O
apamin, O
indicating O
a O
postsynaptic O
action O
of O
histamine B-CHEMICAL
on O
the O
depolarizing O
afterpotential O
that O
is O
not O
simply O
a O
reflection O
of O
a O
decrease O
in O
the O
afterhyperpolarizing O
potential. O
These O

toxins O
also O
had O
no O
effect O
on O
the O
histamine-induced B-CHEMICAL
depolarization. O
The O
enhancement O
of O
the O
depolarizing O
afterpotential O
by O
histamine B-CHEMICAL
was O
mimicked O
by O
the O
histamine B-CHEMICAL
H1-receptor I-GENE-Y
agonist O
2-thiazolylethylamine B-CHEMICAL
and O
was O
reduced O
or O
blocked O
by O
the O
H1-receptor B-GENE-Y
antagonist O
promethazine, B-CHEMICAL
but O
was O
not O
blocked O
or O
reduced O
in O
the O
presence O
of O
the O
histamine B-CHEMICAL
H2-receptor I-GENE-Y
antagonist, O
cimetidine. B-CHEMICAL
In O
summary, O
these O
results O
show O
that O
the O
excitatory O
effect O
of O
histamine B-CHEMICAL
on O
immunohistochemically O
identified O
vasopressin B-CHEMICAL

neurons O
in O
the O
supraoptic O
nucleus O
is O
due O
in O
part O
to O
the O
H1-receptor-mediated B-GENE-Y
enhancement O
of O
the O
depolarizing O
afterpotential O
independent O
of O
any O
change O
in O
the O
afterhyperpolarizing O
potential O
or O
membrane O
potential. O
Adapalene, B-CHEMICAL
a O
new O
chemical O
entity O
with O
retinoid B-CHEMICAL
activity. O
Adapalene B-CHEMICAL
is O
a O
novel O
chemical O
entity O
which, O
in O
terms O
of O
pharmacology, O
behaves O
similar O
to O
tretinoin, B-CHEMICAL
but O
is O
chemically O
and O
photochemically O
stable. O
It O
has O
a O
particular O
selectivity O
profile O
for O
the O
known O
nuclear O
retinoic B-CHEMICAL
acid I-CHEMICAL
receptors I-GENE-N
with O
low O
affinity O
for O
RAR B-GENE-Y
alpha I-GENE-Y
and O
no O

transactivating O
potential O
for O
RXR B-GENE-Y
alpha. I-GENE-Y
This O
receptor O
profile O
could O
imply O
that O
adapalene, B-CHEMICAL
in O
contrast O
to O
tretinoin, B-CHEMICAL
affects O
the O
terminal O
differentiation O
pathway O
of O
epidermal O
cells O
rather O
than O
their O
proliferation. O
Furthermore, O
adapalene B-CHEMICAL
does O
not O
bind O
to O
members O
of O
the O
cellular O
retinoic B-CHEMICAL
acid I-CHEMICAL
binding I-GENE-N
protein I-GENE-N
family. O
Adapalene B-CHEMICAL
has O
comedolytic O
activity O
in O
the O
topical O
rhino O
mouse O
model. O
It O
exerts O
a O
moderate-to-potent O
anti-inflammatory O
effect O
in O
a O
series O
of O
in O
vitro O
and O
in O
vivo O
models. O
In O
comparative O
clinical O
studies O
involving O
72 O
acne O
patients, O
the O
efficacy O
of O

adapalene B-CHEMICAL
was O
comparable, O
if O
not O
superior, O
to O
tretinoin, B-CHEMICAL
but O
adapalene B-CHEMICAL
was O
better O
tolerated. O
The O
data O
reviewed O
in O
this O
paper O
indicate O
that O
adapalene B-CHEMICAL
should O
be O
particularly O
beneficial O
in O
the O
treatment O
of O
acne. O
Comparative O
effects O
of O
three O
different O
potent O
renin B-GENE-N
inhibitors O
in O
primates. O
The O
goal O
of O
the O
present O
study O
was O
to O
compare O
the O
effects O
of O
three O
potent O
reference O
renin B-GENE-Y
inhibitors O
(remikiren, B-CHEMICAL
CGP B-CHEMICAL
38560A, I-CHEMICAL
and O
enalkiren) B-CHEMICAL
in O
sodium-depleted B-CHEMICAL
normotensive O
squirrel O
monkeys. O
In O
these O
monkeys, O
arterial O
pressure O
was O
measured O
in O
the O
conscious O
state O
with O
a O

telemetry O
system. O
Oral O
and O
intravenous O
maximal O
effective O
doses O
of O
the O
three O
renin B-GENE-Y
inhibitors O
were O
compared O
in O
parallel O
groups O
of O
monkeys. O
In O
additional O
experiments, O
remikiren O
was O
given O
on O
top O
of O
either O
CGP B-CHEMICAL
38560A I-CHEMICAL
or O
enalkiren B-CHEMICAL
in O
the O
same O
animals. O
Finally, O
the O
three O
drugs O
were O
compared O
with O
the O
angiotensin B-GENE-Y
converting I-GENE-Y
enzyme I-GENE-Y
inhibitor O
cilazapril. B-CHEMICAL
The O
effects O
of O
the O
three O
drugs O
on O
the O
plasma O
components O
of O
the O
renin-angiotensin B-GENE-Y
system O
(plasma O
renin B-GENE-Y
activity, O
immunoreactive O
renin, B-GENE-Y
and O
immunoreactive O
angiotensin B-GENE-Y

II I-GENE-Y
concentrations) O
were O
also O
measured. O
Our O
results O
show O
that O
remikiren B-CHEMICAL
was O
as O
effective O
as O
cilazapril B-CHEMICAL
and O
markedly O
more O
effective O
than O
CGP B-CHEMICAL
38560A I-CHEMICAL
or O
enalkiren B-CHEMICAL
in O
reducing O
arterial O
pressure O
in O
our O
monkey O
model. O
Interestingly, O
these O
differences O
in O
arterial O
pressure O
could O
not O
be O
explained O
by O
differences O
of O
in O
vitro O
potency O
or O
different O
biochemical O
changes O
of O
the O
plasma O
components O
of O
the O
renin-angiotensin B-GENE-Y
system, O
because O
the O
inhibitors O
all O
reduced O
immunoreactive O
angiotensin B-GENE-Y
II I-GENE-Y
to O
similarly O
low O
levels. O
One O
possible O
explanation O
is O
that, O
in O
our O
model, O

remikiren B-CHEMICAL
in O
contrast O
to O
CGP B-CHEMICAL
38560A I-CHEMICAL
and O
enalkiren B-CHEMICAL
is O
able O
to O
inhibit O
renin B-GENE-Y
in O
a O
functionally O
important O
extraplasmatic O
compartment. O
Inhibition O
of O
cytokine-primed B-GENE-N
eosinophil O
chemotaxis O
by O
nedocromil B-CHEMICAL
sodium. I-CHEMICAL
BACKGROUND: O
Eosinophil O
influx O
into O
the O
lung O
tissue O
is O
considered O
to O
be O
relevant O
for O
the O
pathogenesis O
of O
asthma. O
Various O
chemotactic O
factors O
may O
be O
responsible O
for O
this O
influx. O
Recently O
it O
has O
been O
demonstrated O
that O
the O
cytokines B-GENE-N

granulocyte-macrophage B-GENE-Y
colony-stimulating I-GENE-Y
factor I-GENE-Y
(GM-CSF), B-GENE-Y
interleukin-3 B-GENE-Y
(IL-3), B-GENE-Y
and O
interleukin-5 B-GENE-Y
(IL-5) B-GENE-Y
are O
present O
in O
the O
circulation O
of O
individuals O
with O
allergic O
asthma. O
These O
cytokines B-GENE-N
have O
the O
capacity O
to O
modulate O
chemotactic O
responses O
of O
eosinophils O
toward O
platelet-activating O
factor, O
formyl-methionyl-leucyl-phenylalanine, B-CHEMICAL
(FMLP) B-CHEMICAL
and O
neutrophil-activating B-GENE-Y
factor I-GENE-Y

(NAF)/IL-8, B-GENE-Y
but O
not O
toward O
complement B-GENE-Y
fragment I-GENE-Y
C5a I-GENE-Y
(C5a). B-GENE-Y
Here O
the O
effect O
of O
nedocromil B-CHEMICAL
sodium I-CHEMICAL
on O
the O
chemotactic O
response O
of O
eosinophils O
from O
allergic O
asthmatic O
individuals O
and O
from O
normal O
donors O
preincubated O
with O
GM-CSF B-GENE-Y
or O
IL-3 B-GENE-N
toward O
FMLP, O
NAF/IL-8 B-GENE-Y
was O
evaluated. O
RESULTS: O
Nedocromil B-CHEMICAL
sodium I-CHEMICAL
inhibited O
the O
chemotactic O
response O
toward O
FMLP B-CHEMICAL
and O
NAF/IL-8 B-GENE-Y
of O
GM-CSF B-GENE-Y
primed O
eosinophils O

approximately O
60% O
(inhibitory O
concentration O
of O
50% O
[IC50] O
approximately O
1 O
to O
10 O
nmol/L), O
whereas O
these O
responses O
of O
IL-3 B-GENE-Y
primed O
eosinophils O
was O
completely O
inhibited O
(IC50 O
approximately O
1 O
nmol/L). O
CONCLUSIONS: O
The O
chemotactic O
responses O
toward O
C5a B-GENE-Y
were O
inhibited O
by O
nedocromil B-CHEMICAL
sodium I-CHEMICAL
at O
higher O
concentrations O
than O
were O
required O
in O
the O
priming O
studies O
(IC50 O
approximately O
10 O
to O
100 O
nmol/L). O
Nedocromil B-CHEMICAL
sodium I-CHEMICAL
(0.1 O
mumol/L) O
was O
also O

effective O
in O
inhibiting O
the O
chemotactic O
response O
toward O
FMLP B-CHEMICAL
(10 O
nmol/L) O
of O
eosinophils O
isolated O
from O
the O
circulation O
of O
patients O
with O
allergic O
asthma O
3 O
hours O
after O
allergen O
challenge. O
These O
findings O
might O
explain O
in O
part O
the O
antiinflammatory O
action O
of O
nedocromil B-CHEMICAL
sodium. I-CHEMICAL
Dominant O
expression O
of O
mRNA O
for O
prostaglandin B-CHEMICAL
D I-CHEMICAL
synthase I-GENE-Y
in O
leptomeninges, O
choroid O
plexus, O
and O
oligodendrocytes O
of O
the O
adult O
rat O
brain. O
Glutathione-independent B-CHEMICAL
prostaglandin B-GENE-Y
D I-GENE-Y

synthase I-GENE-Y
[prostaglandin-H2 B-CHEMICAL
D-isomerase; I-GENE-Y
(5Z,13E)-(15S)-9 B-CHEMICAL
alpha,11 I-CHEMICAL
alpha-epidioxy-15-hydroxyprosta-5,13-dienoate I-CHEMICAL
D-isomerase, I-GENE-Y
EC B-GENE-Y
5.3.99.2] I-GENE-Y
is O
an O
enzyme O
responsible O
for O
biosynthesis O
of O
prostaglandin B-CHEMICAL
D2 I-CHEMICAL
in O
the O
central O
nervous O
system. O
In O
situ O
hybridization O
with O
antisense O
RNA O
for O
the O
enzyme O
indicated O
that O
mRNA O
for O
the O
enzyme O
was O
predominantly O
expressed O
in O
the O

leptomeninges, O
choroid O
plexus, O
and O
oligodendrocytes O
of O
the O
adult O
rat O
brain. O
The O
findings O
agree O
with O
those O
obtained O
by O
immunohistochemical O
staining O
with O
antibodies O
against O
the O
enzyme. O
It O
was O
further O
revealed O
that O
prostaglandin B-CHEMICAL
D I-CHEMICAL
synthase I-GENE-Y
activity O
was O
considerably O
greater O
in O
the O
isolated O
leptomeninges O
(14.2 O
nmol O
per O
min O
per O
mg O
of O
protein) O
and O
choroid O
plexus O
(7.0 O
nmol O
per O
min O
per O
mg O
of O
protein) O
than O
the O
activity O
in O
the O
whole O
brain O
(2.0 O
nmol O
per O
min O
per O
mg O
of O

protein). O
These O
results, O
taken O
together, O
indicate O
that O
the O
enzyme O
is O
mainly O
synthesized O
and O
located O
in O
the O
leptomeninges, O
choroid O
plexus, O
and O
oligodendrocytes O
in O
the O
brain. O
cDNA O
cloning O
and O
functional O
properties O
of O
human B-GENE-N
glutamate I-GENE-N
receptor I-GENE-N
EAA3 B-GENE-Y
(GluR5) B-GENE-Y
in O
homomeric O
and O
heteromeric O
configuration. O
We O
have O
isolated O
a O
new O
member O
of O
the O
human B-GENE-N
glutamate I-GENE-N
receptor I-GENE-N
family O
from O
a O
fetal O
brain O
cDNA O
library. O
This O
cDNA O
clone, O
designated O
EAA3a, B-GENE-Y
shares O
a O
90% O
nucleotide B-CHEMICAL

identity O
with O
the O
previously O
reported O
rat B-GENE-Y
GluR5-2b I-GENE-Y
cDNA O
splice O
variant O
and O
differed O
from O
human B-GENE-Y
GluR5-1d I-GENE-Y
in O
the O
amino B-CHEMICAL
and O
carboxy B-CHEMICAL
terminal O
regions. O
Cell O
lines O
stably O
expressing O
EAA3a B-GENE-Y
protein O
formed O
homomeric O
ligand-gated B-GENE-N
ion I-GENE-N
channels I-GENE-N
responsive, O
in O
order O
of O
decreasing O
affinity O
to O
domoate, O
kainate, B-CHEMICAL
L-glutamate B-CHEMICAL
and O
(RS)-alpha-amino-3-hydroxy-5- B-CHEMICAL
methylisoxazole-propionate I-CHEMICAL
(AMPA). B-CHEMICAL
Kainate-evoked B-CHEMICAL
currents O

showed O
partial O
desensitization O
that O
was O
reduced O
on O
incubation O
with O
concanavalin B-GENE-N
A I-GENE-N
(conA) B-GENE-N
but O
not O
cyclothiazide B-CHEMICAL
and O
were O
attenuated O
by O
the O
non-N-methyl-D-aspartate B-CHEMICAL
(NMDA) I-GENE-N
receptor I-GENE-N
antagonist O
CNQX B-CHEMICAL
(6-cyano-7-nitro-quinoxalinedione). B-CHEMICAL
Coexpression O
of O
EAA3a B-GENE-Y
and O
human B-GENE-Y
EAA1 I-GENE-Y
cDNAs O
in O
HEK O
293 O
cells O
formed O
a O
heteromeric O
channel O
with O
unique O
properties. O
Kainate B-CHEMICAL
and O
AMPA B-CHEMICAL
activated O
the O

heteromeric O
channel O
with O
significantly O
higher O
affinities O
than O
observed O
for O
EAA3a B-GENE-Y
alone. O
Ligand O
binding O
studies O
with O
the O
recombinant O
EAA3a B-GENE-Y
receptor O
expressed O
in O
mammalian O
cells O
indicated O
a O
high O
affinity O
kainate B-CHEMICAL
binding O
site O
(Kd O
= O
120 O
+/- O
15.0 O
nM). O
The O
relative O
potency O
of O
compounds O
in O
displacing O
[3H]-kainate B-CHEMICAL
binding O
to O
EAA3a B-GENE-Y
receptor O
was: O
domoate O
> O
kainate B-CHEMICAL
> O
L-glutamate B-CHEMICAL
= O
quisqualate B-CHEMICAL
> O

6,7-dinitroquinoxaline-2,3-dione B-CHEMICAL
(DNQX) B-CHEMICAL
= O
CNQX B-CHEMICAL
> O
AMPA B-CHEMICAL
> O
dihydrokainate B-CHEMICAL
> O
NMDA. B-CHEMICAL
Leukotrienes B-CHEMICAL
in O
the O
pathogenesis O
of O
pulmonary O
blast O
injury. O
Our O
previous O
studies O
demonstrate O
a O
significant O
increase O
of O
sulfidopeptide O
leukotriene B-CHEMICAL
concentrations O
in O
animals O
exposed O
to O
a O
free O
air O
blast. O
The O
aim O
of O
this O
study O
was O
to O
analyze O
the O
role O
of O
leukotrienes B-CHEMICAL
in O
the O
local O
response O
of O
lung O
tissue O
as O
well O
as O
in O
the O
general O
response O
of O
organisms O
to O
blast O
overpressure. O
The O

study O
was O
conducted O
on O
adult O
rabbits O
exposed O
to O
moderate O
blast O
overpressure O
(four O
pulmonary O
contusions O
characterized O
as O
confluent O
ecchymoses O
involving O
30 O
to O
60% O
of O
the O
lungs), O
generated O
in O
laboratory O
conditions. O
One O
group O
of O
experimental O
animals O
was O
treated O
with O
5-lipoxygenase B-GENE-Y
(5-LO) B-GENE-Y
inhibitor, O
diethylcarbamazine B-CHEMICAL
(DEC, B-CHEMICAL
Sigma, O
St. O
Louis, O
Missouri) O
(50 O
mg/kg, O
i.v.), O
immediately O
before O
blast. O
The O
early O
posttraumatic O
period O
was O
observed O
(30 O
minutes O
after O
blast). O
Hemodynamic O
parameters O
(mean O
arterial O

pressure, O
heart O
rate, O
blood O
gases) O
as O
well O
as O
arterial O
plasma O
levels O
of O
conjugated O
dienes O
were O
observed. O
The O
myeloperoxidase B-GENE-Y
activity, O
lipid O
peroxidation O
products O
levels, O
and O
water O
contents O
were O
measured O
in O
the O
lung O
tissue O
of O
injured O
rabbits. O
We O
observed O
that O
5-LO B-GENE-Y
inhibition O
reduced O
edema O
formation, O
accumulation O
of O
neutrophils, O
and O
generation O
of O
lipid O
peroxidation O
products O
in O
injured O
lungs. O
In O
this O
study, O
we O
demonstrated O
that O
treatment O
with O
DEC B-CHEMICAL
inhibits O
the O
increased O
systemic O
generation O
of O
conjugated O
dienes O
after O
blast O
injury. O
Although O
DEC B-CHEMICAL
exerts O
local O

antioxidant O
activity O
with O
beneficial O
effects O
on O
lung O
tissue, O
this O
5-LO B-GENE-Y
inhibitor O
intensifies O
the O
blast O
overpressure O
caused O
hemodynamic O
insufficiency. O
Tamsulosin, B-CHEMICAL
the O
first O
prostate-selective O
alpha B-GENE-Y
1A-adrenoceptor I-GENE-Y
antagonist. O
A O
meta-analysis O
of O
two O
randomized, O
placebo-controlled, O
multicentre O
studies O
in O
patients O
with O
benign O
prostatic O
obstruction O
(symptomatic O
BPH). O
European O
Tamsulosin B-CHEMICAL
Study O
Group. O
OBJECTIVE: O
This O
meta-analysis O
of O
two O
European O
studies O
evaluated O
the O
efficacy O
and O
safety O
of O
modified-release O

tamsulosin B-CHEMICAL
0.4 O
mg O
once O
daily O
compared O
with O
placebo O
in O
patients O
with O
benign O
prostatic O
enlargement, O
lower O
urinary O
tract O
symptoms O
and O
prostatic O
obstruction O
(symptomatic O
BPH). O
METHODS: O
Patients O
entered O
a O
2-week O
placebo O
run-in O
period, O
followed O
by O
randomization O
to O
treatment O
with O
tamsulosin B-CHEMICAL
(382 O
patients) O
or O
placebo O
(193 O
patients) O
once O
daily O
for O
12 O
weeks. O
RESULTS: O
Maximum O
urinary O
flow O
rate O
improved O
to O
a O
greater O
extent O
in O
the O
tamsulosin B-CHEMICAL
group O
(1.6 O

ml/s, O
16%) O
than O
the O
placebo O
group O
(0.6 O
ml/s, O
6%) O
(p O
= O
0.002). O
Total O
Boyarsky O
symptom O
score O
also O
improved O
to O
a O
greater O
extent O
in O
the O
tamsulosin B-CHEMICAL
group O
(3.3 O
points, O
35.1% O
reduction) O
than O
the O
placebo O
group O
(2.4 O
points, O
25.5% O
reduction) O
(p O
= O
0.002). O
Significantly O
more O
tamsulosin B-CHEMICAL
patients O
(66%) O
than O
placebo O
patients O
(49%) O
had O
a O
> O
or O
= O
25% O
decrease O
in O
total O

symptom O
score O
at O
endpoint O
(p O
< O
0.001). O
Twelve O
weeks O
of O
treatment O
with O
tamsulosin B-CHEMICAL
also O
produced O
significant O
improvements O
in O
average O
urinary O
flow O
rate O
(p O
= O
0.005) O
and O
voiding O
or O
"obstructive" O
(p O
= O
0.008) O
and O
storage O
or O
"irritative' O
(p O
= O
0.017) O
symptom O
scores. O
The O
incidence O
of O
drug-related O
adverse O
events O
was O
comparable O
for O
the O
tamsulosin B-CHEMICAL
and O
placebo O
groups O
(13 O
and O
12% O
respectively, O
p O
= O
0.802). O
The O
same O
applies O
to O
the O
incidence O
of O

adverse O
events O
commonly O
attributed O
to O
alpha B-GENE-Y
1-adrenoceptor I-GENE-Y
antagonists, O
such O
as O
dizziness, O
headache, O
postural O
hypotension, O
syncope, O
asthenia, O
somnolence O
and O
rhinitis. O
There O
were O
no O
clinically O
significant O
changes O
in O
blood O
pressure O
or O
pulse O
rate O
in O
tamsulosin B-CHEMICAL
patients O
compared O
with O
placebo O
patients O
both O
in O
hypertensive O
and O
normotensive O
BPH O
patients. O
CONCLUSION: O
Tamsulosin B-CHEMICAL
0.4 O
mg O
once O
daily O
is O
safe, O
well-tolerated O
and O
improves O
both O
the O
symptoms O
and O
urinary O
flow O
rate O
in O
patients O
with O

benign O
prostatic O
obstruction O
(symptomatic O
BPH). O
Human B-GENE-Y
prohormone I-GENE-Y
convertase I-GENE-Y
3 I-GENE-Y
gene: O
exon-intron O
organization O
and O
molecular O
scanning O
for O
mutations O
in O
Japanese O
subjects O
with O
NIDDM. O
Proinsulin B-GENE-Y
is O
converted O
to O
insulin B-GENE-Y
by O
the O
concerted O
action O
of O
two O
sequence-specific O
subtilisin-like B-GENE-N
proteases I-GENE-N
termed O
prohormone B-GENE-Y
convertase I-GENE-Y
2 I-GENE-Y
(PC2) B-GENE-Y
and O
prohormone B-GENE-Y
convertase I-GENE-Y
3 I-GENE-Y
(PC3). B-GENE-Y
PC3 B-GENE-Y
is O
a O
type B-GENE-N
I I-GENE-N
proinsulin-processing I-GENE-N
enzyme I-GENE-N
that O
initiates O
the O
sequential O
processing O
of O
proinsulin B-GENE-Y
to O
insulin B-GENE-Y
by O
cleaving O

the O
proinsulin B-GENE-Y
molecule O
on O
the O
COOH-terminal B-CHEMICAL
side O
of O
the O
dibasic O
peptide, O
Arg31-Arg32, O
joining O
the O
B-chain O
and O
C-peptide. B-CHEMICAL
Thus, O
PC3 B-GENE-Y
plays O
a O
key O
role O
in O
regulating O
insulin B-GENE-Y
biosynthesis. O
Expressions O
of O
insulin B-GENE-Y
and O
PC3, B-GENE-Y
but O
not O
PC2, B-GENE-Y
are O
coordinately O
regulated O
by O
glucose, B-CHEMICAL
consistent O
with O
the O
important O
role O
of O
PC3 B-GENE-Y
in O
regulating O
proinsulin B-GENE-Y
processing. O
NIDDM O
is O
associated O
with O
increased O
secretion O
of O
proinsulin B-GENE-Y
and O
proinsulin-like B-GENE-Y
molecules, O
suggesting O
that O
mutations O
in O
the O
PC3 B-GENE-Y
gene O
may O
be O
involved O
in O
the O
development O
of O

this O
disorder. O
To O
examine O
this O
hypothesis, O
we O
have O
isolated O
and O
characterized O
the O
human B-GENE-Y
PC3 I-GENE-Y
gene O
and O
screened O
it O
for O
mutations O
in O
a O
group O
of O
Japanese O
subjects O
with O
NIDDM. O
The O
PC3 B-GENE-Y
gene O
consists O
of O
14 O
exons O
spanning O
more O
than O
35 O
kb. O
The O
exon-intron O
organization O
of O
PC2 B-GENE-Y
and O
PC3 B-GENE-Y
genes O
are O
conserved, O
consistent O
with O
a O
common O
evolutionary O
origin O
for O
the O
prohormone B-GENE-N
convertase I-GENE-N
gene O
family. O
Single-strand O
conformational O
analysis O
and O
nucleotide B-CHEMICAL
sequencing O
of O
the O
entire O
coding O
region O
of O
the O
PC3 B-GENE-Y
gene O
in O
102 O
Japanese O
subjects O
with O
NIDDM O
revealed O
missense O
mutations O
in O
exons O
2 O

(Arg/Gln53) B-GENE-N
and O
14 O
(Gln/Glu638), B-GENE-N
neither O
of O
which O
was O
associated O
with O
NIDDM O
in O
this O
population. O
These O
data O
suggest O
that O
genetic O
variation O
in O
the O
PC3 B-GENE-Y
gene O
is O
unlikely O
to O
be O
a O
major O
contributor O
to O
NIDDM O
susceptibility O
in O
Japanese. O
Desipramine B-CHEMICAL
administration O
in O
the O
olfactory O
bulbectomized O
rat: O
changes O
in O
brain O
beta-adrenoceptor B-GENE-N
and O
5-HT2A B-GENE-Y
binding O
sites O
and O
their O
relationship O
to O
behaviour. O
1. O
The O
effects O
of O
repeated O
administration O
of O
the O
tricyclic B-CHEMICAL
antidepressant O
drug, O

desipramine B-CHEMICAL
(DMI), B-CHEMICAL
on O
behaviour O
(locomotor O
activity O
and O
rearing) O
and O
the O
number O
and O
affinity O
of O
brain O
beta-adrenoceptor B-GENE-N
and O
5-HT2A B-GENE-Y
receptor O
binding O
sites O
were O
examined O
in O
olfactory O
bulbectomized O
(OB) O
and O
sham-operated O
control O
rats. O
2. O
Locomotor O
activity O
and O
rearing O
were O
increased O
in O
OB O
rats O
compared O
to O
sham-operated O
controls. O
The O
effect O
of O
various O
doses O
of O
DMI B-CHEMICAL
(administered O
orally O
twice O
daily O
for O
21 O
days) O
on O
these O
behavioural O
measures O
was O
examined. O
A O
dose O
of O
7.5 O
mg O

kg-1 O
provided O
optimal O
reversal O
of O
hyperlocomotion O
and O
increased O
rearing O
in O
OB O
rats, O
without O
changing O
these O
measures O
in O
sham-operated O
controls. O
3. O
The O
time O
course O
of O
DMI B-CHEMICAL
(7.5 O
mg O
kg-1) O
on O
behavioural O
and O
neurochemical O
measures O
was O
examined. O
locomotion O
and O
rearing O
in O
OB O
rats O
were O
not O
significantly O
altered O
after O
7 O
days, O
were O
significantly O
attenuated O
after O
14 O
days O
and O
were O
normalized O
after O
21 O
days. O
4. O
After O
7 O
days O
of O
DMI B-CHEMICAL
administration O
the O
number O
of O
beta-adrenoceptors B-GENE-N
was O
lower O
in O
frontal O
and O
occipital O
cortex O
and O

hippocampus. O
This O
reduction O
was O
largely O
restricted O
to O
the O
beta B-GENE-Y
1-adrenoceptor I-GENE-Y
subtype. O
Administration O
of O
DMI B-CHEMICAL
for O
14 O
or O
21 O
days O
did O
not O
further O
reduce O
the O
number O
of O
beta-adrenoceptors. B-GENE-N
The O
DMI B-CHEMICAL
induced O
reduction O
in O
beta-adrenoceptors B-GENE-N
did O
not O
differ O
in O
OB O
and O
sham-operated O
control O
rats. O
5. O
DMI B-CHEMICAL
administration O
for O
up O
to O
21 O
days O
produced O
a O
progressive O
reduction O
in O
the O
number O
of O
5-HT2A B-GENE-Y
receptors O
in O
frontal O
cortex, O
without O
significant O
alterations O
in O
occipital O
cortex. O
6. O
The O
time O
course O
of O
the O
reduction O
in O
the O
number O
of O

5-HT2A B-GENE-Y
receptors O
was O
similar O
to O
that O
of O
the O
DMI-induced B-CHEMICAL
behavioural O
changes O
whereas O
that O
for O
the O
reduction O
in O
beta-adrenoceptors B-GENE-N
was O
clearly O
different. O
7. O
The O
present O
results O
suggest O
that O
the O
action O
of O
DMI B-CHEMICAL
in O
this O
animal O
model O
is O
unlikely O
to O
be O
directly O
related O
to O
a O
reduction O
in O
beta-adrenoceptors B-GENE-N
but O
may O
be O
related O
to O
a O
reduction O
in O
frontal O
cortical O
5-HT2A B-GENE-Y
receptors. O
Binding O
of O
thalidomide B-CHEMICAL
to O
alpha1-acid B-GENE-N
glycoprotein I-GENE-N
may O
be O
involved O
in O
its O
inhibition O
of O
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
alpha I-GENE-Y
production. O
In O
addition O

to O
its O
well O
known O
sedative O
and O
teratogenic O
effects, O
thalidomide O
also O
possesses O
potent O
immunomodulatory O
and O
antiinflammatory O
activities, O
being O
most O
effective O
against O
leprosy O
and O
chronic O
graft-versus-host O
disease. O
The O
immunomodulatory O
activity O
of O
thalidomide B-CHEMICAL
has O
been O
ascribed O
to O
the O
selective O
inhibition O
of O
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
alpha I-GENE-Y
from O
monocytes. O
The O
molecular O
mechanism O
for O
the O
immunomodulatory O
effect O
of O
thalidomide B-CHEMICAL
remains O
unknown. O
To O
elucidate O
this O
mechanism, O
we O
synthesized O
an O
active O
photoaffinity O
label O
of O

thalidomide B-CHEMICAL
as O
a O
probe O
to O
identify O
the O
molecular O
target O
of O
the O
drug. O
Using O
the O
probe, O
we O
specifically O
labeled O
a O
pair O
of O
proteins O
of O
43-45 O
kDa O
with O
high O
acidity O
from O
bovine O
thymus O
extract. O
Purification O
of O
these O
proteins O
and O
partial O
peptide O
sequence O
determination O
revealed O
them O
to O
be O
alpha1-acid B-GENE-Y
glycoprotein I-GENE-Y
(AGP). B-GENE-Y
We O
show O
that O
the O
binding O
of O
thalidomide B-CHEMICAL
photoaffinity O
label O
to O
authentic O
human B-GENE-N
AGP I-GENE-N
is O
competed O
with O
both O
thalidomide B-CHEMICAL
and O
the O
nonradioactive O
photoaffinity O
label O
at O
concentrations O
comparable O
to O
those O
required O
for O
inhibition O
of O
production O
of O

tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
alpha I-GENE-Y
from O
human O
monocytes, O
suggesting O
that O
AGP B-GENE-N
may O
be O
involved O
in O
the O
immunomodulatory O
activity O
of O
thalidomide. B-CHEMICAL
AMPA B-GENE-N
receptor I-GENE-N
heterogeneity O
in O
rat O
hippocampal O
neurons O
revealed O
by O
differential O
sensitivity O
to O
cyclothiazide. B-CHEMICAL
1. O
The O
kinetics O
of O
onset O
of O
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic B-CHEMICAL
acid I-CHEMICAL
(AMPA) B-GENE-N
receptor I-GENE-N
desensitization O
by O
glutamate, B-CHEMICAL
and O
the O
extent O
of O
attenuation O
of O
AMPA B-CHEMICAL
receptor I-GENE-N
desensitization O
by O

cyclothiazide, B-CHEMICAL
showed O
pronounced O
cell-to-cell O
variation O
in O
cultures O
of O
rat O
hippocampal O
neurons. O
Cultures O
prepared O
from O
area O
CA1 O
stratum O
radiatum O
tended O
to O
show O
weaker O
modulation O
by O
cyclothiazide B-CHEMICAL
than O
cultures O
prepared O
from O
the O
whole O
hippocampus. O
2. O
Kinetic O
analysis O
of O
concentration O
jump O
responses O
to O
glutamate B-CHEMICAL
revealed O
multiple O
populations O
of O
receptors O
with O
fast O
(approximately O
400 O
ms), O
intermediate O
(approximately O
2-4 O
s), O
and O
slow O
(> O
20 O
s) O
time O
constants O
for O
recovery O
from O
modulation O
by O
cyclothiazide. B-CHEMICAL
The O

amplitudes O
of O
these O
components O
varied O
widely O
between O
cells, O
suggesting O
the O
existence O
of O
at O
least O
three O
populations O
of O
AMPA B-GENE-N
receptor I-GENE-N
subtypes, O
the O
relative O
density O
of O
which O
varied O
from O
cell O
to O
cell. O
3. O
The O
complex O
patterns O
of O
sensitivity O
to O
cyclothiazide B-CHEMICAL
seen O
in O
hippocampal O
neurons O
could O
be O
reconstituted O
by O
assembly O
of O
recombinant O
AMPA B-GENE-N
receptor I-GENE-N
subunits O
generated O
from O
cDNAs O
encoding O
the O
flip O
(i) O
and O
flop O
(o) O
splice O
variants O
of O
the O
GluR-A B-GENE-Y
and O
GluR-B B-GENE-Y
subunits. O
Recovery O
from O
modulation O
by O
cyclothiazide B-CHEMICAL
was O

slower O
for O
GluR-AiBi B-GENE-N
and O
GluR-AoBi B-GENE-N
than O
for O
GluR-AiBo B-GENE-N
and O
GluR-AoBo. B-GENE-N
4. O
Coexpression O
of O
the O
flip O
and O
flop O
splice O
variants O
of O
GluR-A, B-GENE-Y
in O
the O
absence O
of O
GluR-B, B-GENE-Y
revealed O
that O
heteromeric O
AMPA B-CHEMICAL
receptors I-GENE-N
with O
intermediate O
sensitivity O
to O
cyclothiazide, B-CHEMICAL
similar O
to O
responses O
observed O
for O
the O
combinations O
GluR-AoBi B-GENE-N
or O
GluR-AiBo, B-GENE-N
could O
be O
generated O
independently O
of O
the O
presence O
of O
the O

GluR-B B-GENE-Y
subunit. O
However, O
recovery O
from O
modulation O
by O
cyclothiazide B-CHEMICAL
was O
twofold O
slower O
for O
GluR-AiBi B-GENE-N
than O
for O
homomeric O
GluR-Ai, B-GENE-N
indicating O
that O
the O
GluR-A B-GENE-Y
and O
GluR-B B-GENE-Y
subunits O
are O
not O
functionally O
equivalent O
in O
controlling O
sensitivity O
to O
cyclothiazide. B-CHEMICAL
5. O
These O
results O
demonstrate O
that O
AMPA B-CHEMICAL
receptors I-GENE-N
expressed O
in O
hippocampal O
neurons O
are O
assembled O
in O
a O
variety O
of O
subunit O
and O
splice O
variant O
combinations O
that O
might O
serve O
as O
a O
mechanism O
to O
fine-tune O
the O
kinetics O
of O
synaptic O
transmission. O

Striatal O
dopamine, B-CHEMICAL
dopamine B-GENE-Y
transporter, I-GENE-Y
and O
vesicular B-GENE-Y
monoamine I-GENE-Y
transporter I-GENE-Y
in O
chronic O
cocaine B-CHEMICAL
users. O
Depletion O
of O
striatal O
dopamine B-CHEMICAL
(DA) B-CHEMICAL
has O
been O
hypothesized O
to O
explain O
some O
of O
the O
neurological O
and O
psychiatric O
complications O
of O
chronic O
use O
of O
cocaine, B-CHEMICAL
including O
increased O
risk O
for O
neuroleptic-precipitated O
movement O
disorders. O
We O
measured O
levels O
of O
DA, B-CHEMICAL
as O
well O
as O
two O
DA B-CHEMICAL
nerve O
terminal O
indices, O
namely, O
the O
DA B-CHEMICAL
transporter I-GENE-Y
(DAT) B-GENE-Y
and O
the O
vesicular B-GENE-Y
monoamine B-CHEMICAL
transporter I-GENE-Y

(VMAT2) B-GENE-Y
in O
autopsied O
brain O
of O
12 O
chronic O
cocaine B-CHEMICAL
users. O
Mean O
DA B-CHEMICAL
levels O
were O
normal O
in O
the O
putamen, O
the O
motor O
component O
of O
the O
striatum; O
however O
4 O
of O
the O
12 O
subjects O
had O
DA B-CHEMICAL
values O
below O
the O
lower O
limit O
of O
the O
control O
range. O
DA B-CHEMICAL
concentrations O
were O
significantly O
reduced O
in O
the O
caudate O
head O
(head, O
-33%; O
tail, O
-39%) O
with O
a O
trend O
for O
reduction O
in O
nucleus O
accumbens O
(-27%). O
Striatal O
DAT B-GENE-Y
protein O
(-25 O
to O
-46%) O
and O
VMAT2 B-GENE-Y
(-17 O
to O

-22%) O
were O
reduced, O
whereas O
DAT B-GENE-Y
determined O
by O
[3H]WIN B-CHEMICAL
35,428 I-CHEMICAL
binding O
was O
normal. O
In O
conclusion, O
our O
data O
suggest O
that O
chronic O
cocaine B-CHEMICAL
use O
is O
associated O
with O
modestly O
reduced O
levels O
of O
striatal O
DA B-CHEMICAL
and O
the O
DA B-GENE-Y
transporter I-GENE-Y
in O
some O
subjects O
and O
that O
these O
changes O
might O
contribute O
to O
the O
neurological O
and O
psychiatric O
effects O
of O
the O
drug. O
Purification O
and O
characterization O
of O
a O
novel O
hyaluronan-binding B-GENE-N
protein I-GENE-N
(PHBP) B-GENE-Y
from O
human O
plasma: O
it O
has O
three O
EGF, O
a O
kringle O
and O
a O
serine B-CHEMICAL
protease I-GENE-N
domain, I-GENE-N
similar O
to O

hepatocyte O
growth O
factor O
activator. O
A O
novel O
hyaluronan-binding B-GENE-N
protein I-GENE-N
(PHBP) B-GENE-Y
was O
purified O
from O
human O
plasma O
by O
affinity O
chromatography O
on O
hyaluronan-conjugated O
Sepharose. O
The O
contaminating O
IgM B-GENE-N
and O
albumin B-GENE-N
in O
the O
partially O
purified O
preparation O
were O
removed O
with O
anti-IgG B-GENE-N
antibody-conjugated O
Sepharose O
and O
anti-albumin B-GENE-N
antibody-conjugated O
Sepharose, O
respectively, O
and O
no O
other O
contaminant O
was O
observed. O
Finally, O
800 O
micrograms O
of O
PHBP B-GENE-Y
was O
isolated O
from O
500 O

ml O
of O
human O
plasma. O
PHBP B-GENE-Y
gave O
a O
single O
70-kDa O
band O
on O
SDS-PAGE O
under O
non-reducing O
conditions, O
and O
50-kDa O
and O
17-kDa O
bands O
under O
reducing O
conditions. O
Thus, O
PHBP B-GENE-Y
was O
a O
heterodimer O
composed O
of O
50-kDa O
and O
17-kDa O
subunits, O
bridged O
by O
a O
disulfide B-CHEMICAL
linkage. O
Both O
subunits O
had O
novel O
N-terminal B-CHEMICAL
amino I-CHEMICAL
acid I-CHEMICAL
sequences, O
indicating O
that O
PHBP B-GENE-Y
was O
a O
novel O
hyaluronan-binding O
protein O
in O
human O
plasma. O
The O
amino B-CHEMICAL
acid I-CHEMICAL
sequence O
deduced O
from O

the O
nucleotide B-CHEMICAL
sequence O
of O
the O
cloned O
PHBP B-GENE-Y
cDNA O
exhibited O
significant O
homology O
to O
that O
of O
hepatocyte B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
activator I-GENE-Y
(HGFA). B-GENE-Y
The O
results O
of O
Northern O
blot O
analysis O
indicated O
that O
liver, O
kidney, O
and O
pancreas O
expressed O
PHBP B-GENE-Y
mRNA. O
The O
predicted O
structure O
of O
PHBP B-GENE-Y
showed O
three O
epidermal B-GENE-N
growth I-GENE-N
factor I-GENE-N
(EGF) I-GENE-N
domains, I-GENE-N
a O
kringle B-GENE-N
domain I-GENE-N
and O
a O
serine B-CHEMICAL
protease I-GENE-N
domain, I-GENE-N
from O
its O
N-terminus, B-CHEMICAL
although O
HGFA B-GENE-Y
has O
a O
fibronectin B-GENE-N
type I-GENE-N
II I-GENE-N
domain, I-GENE-N
an O
EGF B-GENE-N

domain, I-GENE-N
a O
fibronectin B-GENE-N
type I-GENE-N
I I-GENE-N
domain, I-GENE-N
an O
EGF B-GENE-N
domain, I-GENE-N
a O
kringle B-GENE-N
domain, I-GENE-N
and O
a O
serine B-CHEMICAL
protease I-GENE-N
domain, I-GENE-N
from O
its O
N-terminus. B-CHEMICAL
Hypoxemia O
associated O
with O
cimetidine B-CHEMICAL
therapy O
in O
a O
newborn O
infant. O
Cimetidine B-CHEMICAL
therapy O
used O
for O
the O
treatment O
of O
gastric O
bleeding O
due O
to O
tolazoline B-CHEMICAL
therapy O
in O
a O
newborn O
infant O
was O
temporally O
associated O
with O
episodes O
of O
severe O
hypoxemia. O
It O
appears O
likely O
that O
the O
histamine B-GENE-Y
H2 I-GENE-Y
receptor I-GENE-Y
blocked O
by O
cimetidine B-CHEMICAL
obviated O
the O
pulmonary O
vasodilator O
effect O
of O
tolazoline B-CHEMICAL
therapy. O

Interactions O
of O
2,3-benzodiazepines B-CHEMICAL
and O
cyclothiazide B-CHEMICAL
at O
AMPA B-GENE-N
receptors: I-GENE-N
patch O
clamp O
recordings O
in O
cultured O
neurones O
and O
area O
CA1 O
in O
hippocampal O
slices. O
1. O
The O
2,3-benzodiazepines B-CHEMICAL
GYKI B-CHEMICAL
52466, I-CHEMICAL
GYKI B-CHEMICAL
53405 I-CHEMICAL
and O
GYKI B-CHEMICAL
53655 I-CHEMICAL
antagonized O
AMPA-induced B-CHEMICAL
currents O
in O
cultured O
superior O
colliculus O
neurones O
in O
a O
non O
use-dependent O
manner O
(steady O
state O
IC50s: O
GYKI B-CHEMICAL
52466 I-CHEMICAL
9.8 O

+/- O
0.6 O
microM; O
GYKI B-CHEMICAL
53405 I-CHEMICAL
3.1 O
+/- O
0.6 O
microM; O
GYKI B-CHEMICAL
53655 I-CHEMICAL
0.8 O
+/- O
0.1 O
microM). O
2. O
Higher O
concentrations O
of O
all O
three O
antagonists O
slowed O
the O
onset O
kinetics O
and O
quickened O
the O
offset O
kinetics O
of O
AMPA-induced B-CHEMICAL
currents O
indicative O
of O
an O
allosteric O
interaction O
with O
the O
AMPA B-CHEMICAL
recognition O
site. O
3. O
Cyclothiazide B-CHEMICAL
(3-300 O
microM) O
dramatically O
slowed O
desensitization O
of O
AMPA-induced B-CHEMICAL
currents O
and O
potentiated O
steady O
state O
currents O
(EC50 O

10.0 O
+/- O
2.5 O
microM) O
to O
a O
much O
greater O
degree O
than O
peak O
currents. O
Both O
tau O
on O
and O
tau O
off O
were O
also O
increased O
by O
cyclothiazide B-CHEMICAL
in O
a O
concentration-dependent O
manner O
(EC50: O
tau O
on O
42.1 O
+/- O
4.5 O
microM; O
tau O
off O
31.6 O
+/- O
6.6 O
microM). O
4. O
Cyclothiazide B-CHEMICAL
(10-100 O
microM) O
shifted O
the O
concentration-response O
curves O
of O
the O
2,3-benzodiazepines B-CHEMICAL
to O
the O
right. O
For O
example, O
with O
10 O
microM O

cyclothiazide B-CHEMICAL
the O
IC50s O
of O
GYKI B-CHEMICAL
52466 I-CHEMICAL
and O
GYKI B-CHEMICAL
53405 I-CHEMICAL
on O
steady-state O
AMPA-induced B-CHEMICAL
currents O
were O
57.9 O
+/- O
9.5 O
and O
41.6 O
+/- O
1.5 O
microM, O
respectively. O
5. O
GYKI B-CHEMICAL
53405 I-CHEMICAL
and O
GYKI B-CHEMICAL
52466 I-CHEMICAL
concentration-dependently O
reversed O
the O
effects O
of O
cyclothiazide B-CHEMICAL
(100 O
microM) O
on O
offset O
kinetics O
(GYKI B-CHEMICAL
53405 I-CHEMICAL
IC50 O
16.6 O
+/- O
4.2 O
microM). O

However, O
the O
2,3-benzodiazepines B-CHEMICAL
were O
unable O
to O
reintroduce O
desensitization O
in O
the O
presence O
of O
cyclothiazide B-CHEMICAL
and O
even O
concentration-dependently O
slowed O
the O
onset O
kinetics O
of O
AMPA B-CHEMICAL
responses O
further O
(GYKI B-CHEMICAL
53405 I-CHEMICAL
EC50 O
8.0 O
+/- O
2.8 O
microM). O
6. O
GYKI B-CHEMICAL
52466 I-CHEMICAL
decreased O
the O
peak O
amplitude O
of O
hippocampal O
area O
CA1 O
AMPA B-GENE-N
receptor-mediated I-GENE-N
excitatory O
postsynaptic O
currents O
(e.p.s.cs) O
(IC50 O
10.8 O

+/- O
0.8 O
microM) O
with O
no O
apparent O
effect O
on O
response O
kinetics. O
Cyclothiazide B-CHEMICAL
prolonged O
the O
decay O
time O
constant O
of O
AMPA B-GENE-N
receptor-mediated I-GENE-N
e.p.s.cs O
(EC50 O
35.7 O
+/- O
6.5 O
microM) O
with O
less O
pronounced O
effects O
in O
slowing O
e.p.s.c. O
onset O
kinetics O
and O
increasing O
e.p.s.c. O
amplitude. O
7. O
Cyclothiazide B-CHEMICAL
(330 O
microM) O
shifted O
the O
concentration-response O
curve O
for O
the O
effects O
of O
GYKI B-CHEMICAL
52466 I-CHEMICAL
on O
AMPA B-GENE-N
receptor-mediated I-GENE-N

e.p.s.c. O
peak O
amplitude O
to O
the O
right O
(GYKI B-CHEMICAL
52466 I-CHEMICAL
IC50 O
26.9 O
+/- O
9.4 O
microM). O
Likewise, O
GYKI B-CHEMICAL
52466 I-CHEMICAL
(30-100 O
microM)) O
shifted O
the O
concentration-response O
curve O
for O
the O
effects O
of O
cyclothiazide B-CHEMICAL
on O
AMPA B-GENE-N
receptor-mediated I-GENE-N
e.p.s.c. O
decay O
time O
constants O
to O
the O
right. O
8. O
In O
conclusion, O
cyclothiazide B-CHEMICAL
and O
the O
2,3-benzodiazepines B-CHEMICAL
seem O
to O
bind O
to O
different O
sites O
on O
AMPA B-GENE-N
receptors I-GENE-N
but O

exert O
strong O
allosteric O
interactions O
with O
one O
another O
and O
with O
other O
domains O
such O
as O
the O
agonist O
recognition O
site. O
The O
interactions O
of O
GYKI B-CHEMICAL
52466 I-CHEMICAL
and O
cyclothiazide B-CHEMICAL
on O
AMPA B-GENE-N
receptor-mediated I-GENE-N
e.p.s.cs O
in O
area O
CA1 O
of O
hippocampal O
slices O
provide O
evidence O
that O
the O
decay O
time O
constant O
of O
these O
synaptic O
events O
are O
not O
governed O
by O
desensitization. O
Comparison O
of O
ligand O
binding O
affinities O
at O
human B-GENE-N
I1-imidazoline I-GENE-N
binding I-GENE-N
sites I-GENE-N
and O
the O
high O
affinity O
state O
of O
alpha-2 B-GENE-N
adrenoceptor I-GENE-N

subtypes. O
To O
identify O
selective O
compounds O
for O
nonadrenergic O
I1-imidazoline B-GENE-Y
receptors I-GENE-Y
(I1), B-GENE-Y
the O
affinities O
of O
22 O
ligands O
for O
[125I]p-iodoclonidine B-CHEMICAL
binding O
have O
been O
compared O
at O
human B-GENE-N
platelet I-GENE-N
I1-imidazoline I-GENE-N
binding I-GENE-N
sites I-GENE-N
(analyzed O
under O
norepinephrine B-CHEMICAL
mask O
of O
alpha-2 B-GENE-N
AR) I-GENE-N
and O
at O
human B-GENE-Y
alpha-2A, I-GENE-Y
alpha-2B B-GENE-Y
and O
alpha-2C B-GENE-Y
adrenoceptors I-GENE-Y
stably O
expressed O
on O
transfected O
Chinese O
hamster O
ovary O
cells. O
Competition O
curves O
at O
the O
platelet O

I1-imidazoline B-GENE-N
binding I-GENE-N
site I-GENE-N
were O
biphasic O
for O
most O
compounds. O
Only O
tizanidine B-CHEMICAL
and O
BDF,6143 B-CHEMICAL
displayed O
monophasic O
I1 O
competition O
curves. O
Agmatine, B-CHEMICAL
an O
endogenous O
neurotransmitter O
candidate O
for O
the O
I1-imidazoline B-GENE-Y
receptor, I-GENE-Y
was O
identified O
as O
the O
most O
selective O
agent O
for O
a O
subcomponent O
of O
platelet O
I1 B-GENE-N
sites. I-GENE-N
The O
affinity O
of O
agmatine B-CHEMICAL
at O
the O
high O
affinity O
component O
of O
platelet O
I1 B-GENE-N
sites I-GENE-N
was O
1400-fold O
selective O
over O
alpha-2A B-GENE-Y
adrenoceptors, I-GENE-Y
5000-fold O
selective O
over O

alpha-2B B-GENE-Y
adrenoceptors I-GENE-Y
and O
800-fold O
selective O
over O
alpha-2C B-GENE-Y
adrenoceptors. I-GENE-Y
Moxonidine B-CHEMICAL
and O
tizanidine B-CHEMICAL
also O
displayed O
selectivities O
for O
a O
high O
affinity O
component O
of O
the O
platelet O
I1 B-GENE-N
binding I-GENE-N
sites I-GENE-N
over O
alpha-2 B-GENE-N
adrenoceptors. I-GENE-N
Naphazoline B-CHEMICAL
was O
the O
most O
selective O
compound O
for O
the O
high O
affinity O
state O
of O
the O
alpha-2A B-GENE-Y
adrenoceptor, I-GENE-Y
displaying O
7-, O
23- O
and O
9-fold O
higher O
affinity O
than O
alpha-2B, B-GENE-Y
alpha-2C B-GENE-Y
and O
platelet O
I1-midazoline B-GENE-N
binding I-GENE-N
sites, I-GENE-N
respectively. O
No O

single O
selective O
compound O
was O
identified O
for O
the O
alpha-2B B-GENE-Y
adrenoceptor. I-GENE-Y
Norepinephrine B-CHEMICAL
displayed, O
respectively, O
18- O
and O
31-fold O
selectivity O
for O
the O
high O
affinity O
state O
of O
the O
alpha-2C B-GENE-Y
adrenoceptor I-GENE-Y
as O
compared O
to O
alpha-2A- B-GENE-Y
or O
alpha-2B B-GENE-Y
adrenoceptors, I-GENE-Y
and O
was O
> O
100,000- O
fold O
selective O
over O
platelet O
I1-imidazoline B-GENE-N
sites. I-GENE-N
Thus, O
human B-GENE-N
alpha-2 I-GENE-N
adrenoceptors I-GENE-N
and O
the O
platelet O
I1-imidazoline B-GENE-N
binding I-GENE-N
site I-GENE-N
can O
be O
clearly O
discriminated O
based O
on O
their O
affinities O

for O
certain O
compounds. O
Activation O
of O
cytoprotective O
prostaglandin B-GENE-Y
synthase-1 I-GENE-Y
by O
minoxidil B-CHEMICAL
as O
a O
possible O
explanation O
for O
its O
hair O
growth-stimulating O
effect. O
Data O
from O
the O
literature O
indicate O
that O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs), O
such O
as O
indomethacin, B-CHEMICAL
naproxen, B-CHEMICAL
piroxicam, B-CHEMICAL
or O
ibuprofen, B-CHEMICAL
induce O
hair O
loss O
in O
vivo. O
These O
NSAIDs O
are O
well-known O
inhibitors O
of O
both O
the O
cytoprotective O
isoform O
of O
prostaglandin B-CHEMICAL
endoperoxide I-GENE-Y

synthase-1 I-GENE-Y
(PGHS-1) B-GENE-Y
and O
of O
the O
inducible O
form O
(PGHS-2). B-GENE-Y
By O
immunohistochemical O
staining, O
we O
found O
that O
PGHS-1 B-GENE-Y
is O
the O
main O
isoform O
present O
in O
the O
dermal O
papilla O
from O
normal O
human O
hair O
follicle O
(either O
anagen O
or O
catagen), O
whereas O
PGHS-2 B-GENE-Y
was O
only O
faintly O
and O
exclusively O
expressed O
in O
anagen O
dermal O
papilla. O
Thus, O
PGHS-1 B-GENE-Y
might O
be O
the O
primary O
target O
of O
the O
hair O
growth-inhibitory O
effects O
of O
NSAIDs. O
We O
thus O

speculated O
that O
activation O
of O
PGHS-1 B-GENE-Y
might O
be O
a O
mechanism O
by O
which O
minoxidil B-CHEMICAL
(2,4-diamino-6-piperidinopyrimidine-3-oxyde) B-CHEMICAL
stimulates O
hair O
growth O
in O
vivo. O
We O
demonstrate O
here O
that O
minoxidil B-CHEMICAL
is O
a O
potent O
activator O
of O
purified O
PGHS-1 B-GENE-Y
(AC50 O
= O
80 O
microM), O
as O
assayed O
by O
oxygen B-CHEMICAL
consumption O
and O
PGE2 O
production. O
This O
activation O
was O
also O
evidenced O
by O
increased O
PGE2 O
production O
by O
BALB/c O
3T3 O
fibroblasts O
and O
by O
human O
dermal O

papilla O
fibroblasts O
in O
culture. O
Our O
findings O
suggest O
that O
minoxidil B-CHEMICAL
and O
its O
derivatives O
may O
have O
a O
cytoprotective O
activity O
in O
vivo O
and O
that O
more O
potent O
second-generation O
hair O
growth-promoting O
drugs O
might O
be O
designed, O
based O
on O
this O
mechanism. O
Clonal O
CD8+ O
and O
CD52- O
T O
cells O
are O
induced O
in O
responding O
B O
cell O
lymphoma O
patients O
treated O
with O
Campath-1H O
(anti-CD52). B-GENE-Y
Five O
patients O
with O
non-Hodgkin's O
lymphoma O
(NHL) O
and O
4 O
patients O
with O
chronic O
lymphocytic O
leukaemia O
(CLL) O
were O

treated O
with O
the O
CDR-grafted O
(rat O
x O
human) O
monoclonal O
antibody O
(mAb) O
Campath-1H O
(anti-CD52). B-GENE-Y
Tumour O
regression O
was O
noted O
preferentially O
in O
peripheral O
blood O
and O
in O
the O
bone O
marrow O
but O
lymph O
nodes O
were O
less O
affected. O
Normal O
blood O
B O
and O
T O
cells O
were O
profoundly O
reduced O
in O
all O
patients O
whereas O
CD16+ O
NK O
cells O
and O
CD14+ O
monocytes O
decreased O
marginally. O
In O
all O
responding O
CLL O
patients O
CD52-negative B-GENE-Y
T O
but O
not O
B O
cells O
appeared O
during O
treatment O
and O
persisted O
for O
several O
months O
(4-19+) O
during O

unmaintained O
follow-up. O
Clonal O
T O
cells O
defined O
as O
a O
predominance O
of O
a O
single O
T B-GENE-N
cell I-GENE-N
receptor I-GENE-N
(TCR) I-GENE-N
V I-GENE-N
gene O
usage, O
in O
one O
case O
verified O
by O
TCR B-GENE-N
CDR3 O
fragment O
analysis O
and O
nucleotide B-CHEMICAL
sequencing, O
emerged O
within O
the O
CD52-/CD8+ O
cell O
population O
during O
Campath-1H O
therapy O
in O
2 O
CLL O
patients, O
both O
achieving O
a O
long-lasting O
remission. O
The O
increase O
in O
CD8+ O
T O
cell O
expansions O
(up O
to O
23-fold) O
during O
unmaintained O
remission O
and O
follow-up O
suggest O
that O
the O
clonal O

CD8+ O
cells O
may O
represent O
regulatory O
T O
cells O
controlling O
the O
growth O
of O
the O
tumour O
B O
cell O
clone. O
Clonal O
T O
cells O
might O
thus O
be O
a O
target O
for O
an O
immune O
therapeutic O
intervention O
in O
B O
cell O
tumours. O
Clinical O
manifestations O
of O
genetic O
defects O
affecting O
gonadotrophins B-GENE-N
and O
their O
receptors. O
Raised O
activity O
of O
the O
LH B-GENE-N
axis O
caused O
by O
activating O
mutations O
of O
LH B-GENE-Y
receptor I-GENE-Y
gene O
presents O
with O
precocious O
puberty O
in O
boys, O
analogous O
to O
the O
presentation O
of O
LH B-GENE-N
secreting O
pituitary O
adenomas O
(Faggiano O
et O
al., O
1983; O
Ambrosi O
et O
al., O
1990). O
LH B-GENE-N

"hyperactivity' O
in O
females O
appears O
to O
have O
no O
effect. O
Hyperactivity O
of O
the O
FSH B-GENE-N
axis O
caused O
by O
activating O
mutations O
of O
the O
FSH B-GENE-Y
receptor I-GENE-Y
gene O
might O
parallel O
the O
presentation O
of O
FSH B-GENE-N
secreting O
pituitary O
adenomas O
with O
Sertoli O
cell O
hypertrophy O
in O
men O
(Heseltine O
et O
al., O
1989) O
or O
reversible O
premature O
ovarian O
failure O
in O
women O
(Moses O
et O
al., O
1986; O
Okuda O
et O
al., O
1989). O
Indeed O
the O
first O
such O
case O
to O
be O
described O
is O
a O
male O
who O
maintained O
testicular O
volume O
and O
fertility O
in O
the O
absence O
of O

gonadotrophins B-GENE-N
(Gromoll O
et O
al., O
1996). O
Female O
precocious O
puberty O
may O
require O
hyperactivity O
of O
both O
gonadotrophin B-GENE-N
axes O
because O
of O
the O
"two-cell' O
arrangement O
required O
for O
ovarian O
oestrogen B-CHEMICAL
production. O
Mutations O
of O
the O
Gs B-GENE-N
alpha-subunit I-GENE-N
gene O
can O
mimic O
this O
situation O
in O
some O
women O
with O
the O
McCune-Albright O
syndrome O
(Malchoff O
et O
al., O
1994). O
Lack O
of O
LH B-GENE-N
activity O
caused O
by O
defects O
in O
the O
LH B-GENE-Y
beta I-GENE-Y
molecule O
causes O
infertility O
in O
men O
and O
that O
resulting O
from O
inactivating O
mutations O
of O
the O
LH B-GENE-Y

receptor I-GENE-Y
gene O
causes O
Leydig O
cell O
agenesis O
in O
men O
while O
ovarian O
development O
in O
females O
is O
relatively O
normal. O
Lack O
of O
FSH B-GENE-N
activity O
caused O
by O
defects O
in O
the O
FSH B-GENE-Y
beta I-GENE-Y
caused O
infertility O
in O
a O
female, O
and O
that O
caused O
by O
inactivating O
mutations O
of O
the O
FSH B-GENE-Y
receptor I-GENE-Y
gene O
causes O
ovarian O
dysgenesis O
in O
women O
but O
only O
variable O
depression O
of O
spermatogenesis O
in O
men. O
Incidentally, O
this O
categorization O
of O
reproductive O
disorders O
may O
also O
be O
applied O
to O
the O
TSH B-GENE-N
axis. O
Pituitary O
adenomas O
and O
activating O
mutations O
of O
the O
TSH B-GENE-Y
receptor I-GENE-Y
gene O
(Parma O
et O

al., O
1993) O
cause O
hyperthyroidism O
and O
TSH B-GENE-Y
beta I-GENE-Y
gene O
defects O
(Hayashizaki O
et O
al., O
1989) O
and O
inactivating O
mutations O
of O
the O
TSH B-GENE-Y
receptor I-GENE-Y
gene O
(Sunthornthepvarakul O
et O
al., O
1995) O
cause O
hypothyroidism. O
To O
complete O
the O
analogy O
with O
thyroid O
disorders, O
it O
is O
curious O
that O
despite O
structural O
similarities O
with O
the O
TSH B-GENE-Y
receptor, I-GENE-Y
neither O
LH B-GENE-N
nor I-GENE-N
FSH I-GENE-N
receptor I-GENE-N
autoantibodies O
have O
a O
prominent O
role O
in O
ovarian O
pathophysiology O
(Moncayo O
et O
al., O
1989; O
Van O

Weissenbruch O
et O
al., O
1991; O
Simoni O
et O
al., O
1993). O
Complete O
gonadotrophin B-GENE-N
resistance O
is O
likely O
to O
be O
very O
rare, O
however, O
so O
what O
are O
we O
likely O
to O
find O
in O
partial O
gonadotrophin B-GENE-N
resistance? O
Might O
the O
"resistant O
ovary O
syndrome' O
come O
right O
in O
the O
end, O
with O
corresponding O
minor O
FSH B-GENE-Y
receptor I-GENE-Y
mutations? O
Experience O
with O
insulin B-GENE-Y
and O
androgen O
resistance O
syndromes O
suggests O
that O
such O
a O
scenario O
is O
unlikely. O
Insulin B-GENE-Y
receptor I-GENE-Y
gene O
mutations O
are O
found O
in O
extreme O
Type O
A O
insulin B-GENE-Y
resistance O
but O
not O
in O
moderate O
forms O
of O
insulin B-GENE-Y
resistance O
(O'Rahilly O
et O
al., O

1991). O
Androgen B-GENE-Y
receptor I-GENE-Y
gene O
mutations O
are O
found O
in O
nearly O
all O
cases O
of O
complete O
androgen O
insensitivity O
but O
rarely O
in O
partial O
forms O
(Patterson O
et O
al., O
1994). O
Mild O
resistance O
to O
hormone O
action O
is O
rarely O
detectable O
in O
relatives O
who O
are O
heterozygous O
for O
receptor O
mutations O
which O
are O
inherited O
in O
a O
recessive O
pattern. O
It O
seems O
unlikely O
therefore, O
that O
individuals O
heterozygous O
for O
inactivating O
receptor O
mutations O
will O
manifest O
symptoms O
of O
reproductive O
disorders O
and O
account O
for O
common O
conditions. O
Thus, O
while O
mutation O
analysis O
provides O
new O
insights O
into O
the O
gender O
specific O
role O
of O
the O
gonadotrophins B-GENE-N
the O
cause O
of O
early O
gonadal O
failure O

in O
the O
majority O
of O
individuals O
remains O
a O
mystery. O
Evolution O
of O
the O
aminoacyl-tRNA B-CHEMICAL
synthetase I-GENE-N
family O
and O
the O
organization O
of O
the O
Drosophila O
glutamyl-prolyl-tRNA B-CHEMICAL
synthetase I-GENE-Y
gene. O
Intron/exon O
structure O
of O
the O
gene, O
control O
of O
expression O
of O
the O
two O
mRNAs, O
selective O
advantage O
of O
the O
multienzyme O
complex. O
In O
Drosophila, O
glutamyl-prolyl-tRNA B-CHEMICAL
synthetase I-GENE-Y
is O
a O
multifunctional O
synthetase O
encoded O
by O
a O
unique O
gene O
and O
composed O
of O
three O
domains: O
the O
amino- B-CHEMICAL
and O

carboxy-terminal B-CHEMICAL
domains O
catalyze O
the O
aminoacylation O
of O
glutamic B-CHEMICAL
acid I-CHEMICAL
and O
proline O
tRNA O
species, O
respectively, O
and O
the O
central O
domain O
is O
made O
of O
75 O
amino B-CHEMICAL
acids I-CHEMICAL
repeated O
six O
times O
amongst O
which O
46 O
are O
highly O
conserved O
and O
constitute O
the O
repeated O
motifs O
[Cerini, O
C., O
Kerjan, O
P., O
Astier, O
M., O
Gratecos, O
D., O
Mirande, O
M. O
& O
Semeriva, O
M. O
(1991) O
EMBO O
J. O
10, O
4267-4277]. O
The O
intron/exon O
organization O
of O
the O
Drosophila O
gene O
reveals O
the O

presence O
of O
six O
exons O
among O
which O
four O
are O
in O
the O
5'-end O
encoding O
glutamic B-CHEMICAL
acid I-CHEMICAL
activity. O
Only O
one O
exon O
encodes O
the O
repeated O
motifs. O
A O
comparison O
of O
introns O
positions, O
intron O
classes O
and O
intron/exon O
boundaries O
in O
the O
Drosophila O
gene O
and O
in O
its O
human O
counterpart O
is O
compatible O
with O
the O
intron-early O
hypothesis O
presiding, O
at O
least O
in O
part, O
to O
the O
evolution O
of O
the O
synthetases. B-GENE-N
The O
full-length O
fly O
protein O
is O
encoded O
by O
a O
6.1-kb O
mRNA O
which O
is O
expressed O
throughout O
development. O
In O
addition, O
a O
shorter O
transcript O
encompasses O
the O
3'-end O
of O

the O
cDNA O
and O
it O
is O
especially O
abundant O
in O
5-10-h O
embryos O
until O
the O
first O
larval O
stage. O
Expression O
of O
these O
two O
mRNAs O
seems O
to O
be O
controlled O
by O
two O
independent O
promoters. O
The O
6.1-kb O
mRNA O
promoter O
is O
probably O
localized O
in O
the O
5'-end O
of O
the O
gene. O
The O
small O
mRNA O
promoter O
resides O
in O
the O
4th O
intron O
and O
evidence O
is O
provided O
that O
the O
mRNA O
encodes O
only O
the O
domain O
corresponding O
to O
prolyl-tRNA B-CHEMICAL
synthetase I-GENE-Y
and O
is O
functional O
in O
vivo. O
Finally, O
transgenic O
flies O
have O
been O
established O
by O
using O
constructs O
corresponding O
to O
the O

three O
domains O
of O
the O
protein. O
Overexpression O
of O
the O
repeated O
motifs O
leads O
to O
a O
sterility O
of O
the O
flies O
that O
suggests O
a O
role O
of O
these O
motifs O
in O
linking O
the O
multienzyme O
complex O
to O
an, O
as O
yet, O
unknown O
structure O
of O
the O
protein O
synthesis O
apparatus. O
Pharmacology O
and O
chemistry O
of O
adapalene. B-CHEMICAL
BACKGROUND: O
Retinoid B-CHEMICAL
research O
in O
the O
field O
of O
dermatology O
has O
been O
influenced O
by O
the O
clinical O
success O
of O
topical O
tretinoin B-CHEMICAL
and O
oral O
isotretinoin B-CHEMICAL
in O
the O
treatment O
of O
acne, O
and O
by O
the O
discovery O
of O
high-affinity O
binding O
proteins O
for O
retinoic B-CHEMICAL
acid I-CHEMICAL

mediating O
its O
action O
and O
interaction O
with O
other O
vitamins B-CHEMICAL
and O
hormones. O
OBJECTIVE: O
We O
sought O
molecules O
with O
an O
optimal O
balance O
between O
stability, O
efficacy, O
and O
local O
tolerance O
for O
topical O
acne O
therapy. O
METHODS: O
In O
vitro O
and O
in O
vivo O
bioassay O
systems O
were O
used O
to O
test O
the O
ability O
of O
retinoids B-CHEMICAL
to O
modulate O
cell O
proliferation O
and O
differentiation. O
In O
addition, O
antiinflammatory O
properties O
were O
assessed. O
Binding O
and O
transactivation O
assays O
were O
used O
to O
compare O
affinities O
and O
transcriptional O
activities O
of O
adapalene B-CHEMICAL
and O
tretinoin B-CHEMICAL
for O
the O
nuclear B-GENE-N
transcription I-GENE-N
factors, I-GENE-N

retinoic B-GENE-N
acid I-GENE-N
receptors I-GENE-N
(RARs). B-GENE-N
RESULTS O
AND O
CONCLUSION: O
Adapalene B-CHEMICAL
is O
a O
stable O
naphthoic B-CHEMICAL
acid I-CHEMICAL
derivative O
with O
potent O
retinoid B-CHEMICAL
pharmacology, O
controlling O
cell O
proliferation O
and O
differentiation. O
In O
addition O
it O
has O
significant O
antiinflammatory O
action. O
The O
nuclear B-GENE-N
gene I-GENE-N
transcription I-GENE-N
factors I-GENE-N
RAR B-GENE-Y
beta I-GENE-Y
and O
RAR B-GENE-Y
gamma I-GENE-Y
mediate O
the O
retinoid B-CHEMICAL
activity O
of O
adapalene. B-CHEMICAL
Cinitapride B-CHEMICAL
protects O
against O
ethanol-induced B-CHEMICAL
gastric O
mucosal O
injury O
in O
rats: O
role O
of O
5-hydroxytryptamine, B-CHEMICAL
prostaglandins B-CHEMICAL
and O

sulfhydryl B-CHEMICAL
compounds. O
This O
study O
was O
designed O
to O
determine O
the O
gastroprotective O
properties O
of O
cinitapride B-CHEMICAL
(CNT), B-CHEMICAL
a O
novel O
prokinetic O
benzamide B-CHEMICAL
derivative O
agonist O
of O
5-HT4 B-GENE-Y
and O
5-HT1 B-GENE-N
receptors O
and O
5-HT2 B-GENE-N
antagonist, O
on O
mucosal O
injury O
produced O
by O
50% O
(v/v) O
ethanol. B-CHEMICAL
Results O
were O
compared O
with O
those O
for O
5-hydroxytryptamine B-CHEMICAL
(5-HT: B-CHEMICAL
10 O
mg O
kg-1). O
The O
possible O
involvements O
of O
gastric O
mucus O
secretion, O
endogenous O

prostaglandins B-CHEMICAL
(PGs) B-CHEMICAL
and O
sulfhydryl B-CHEMICAL
compounds O
(SH) B-CHEMICAL
in O
the O
protection O
mediated O
by O
CNT B-CHEMICAL
were O
also O
examined. O
Intraperitoneal O
administration O
of O
CNT B-CHEMICAL
(0.50 O
and O
1 O
mg O
kg-1), O
30 O
min O
before O
ethanol, B-CHEMICAL
significantly O
prevented O
gastric O
ulceration O
and O
increased O
the O
hexosamine B-CHEMICAL
content O
of O
gastric O
mucus. O
CNT B-CHEMICAL
(1 O
mg O
kg-1) O
also O
produced O
a O
significant O
increase O
in O
gastric O
mucosal O
levels O
of O
PGE2, B-CHEMICAL
but O
did O
not O
induce O
any O
significant O
changes O
in O
SH B-CHEMICAL
values. O
On O
the O
contrary, O
pretreatment O

with O
5-HT B-CHEMICAL
worsened O
ethanol-induced B-CHEMICAL
erosions, O
however, O
did O
not O
affect O
gastric O
mucus O
secretion, O
glycoprotein B-GENE-N
content O
or O
PGE2 B-CHEMICAL
levels, O
although O
the O
non-protein O
SH B-CHEMICAL
fraction O
was O
significantly O
decreased. O
The O
present O
results O
demonstrate O
that O
the O
gastroprotective O
effects O
of O
CNT B-CHEMICAL
could O
be O
partly O
explained O
by O
a O
complex O
PG B-CHEMICAL
dependent O
mechanism. O
We O
suggest O
that O
5-HT B-CHEMICAL
dependent O
mechanisms O
through O
5-HT2 B-GENE-N
receptor O
blockade O
and O
5-HT1 B-GENE-N
receptor O
activation O
could O
be O
also O
involved. O
Cloning, O
characterization, O
and O
expression O
of O
a O
calcitonin B-GENE-Y
receptor I-GENE-Y
from O

guinea O
pig O
brain. O
A O
calcitonin B-GENE-Y
receptor I-GENE-Y
was O
cloned O
from O
guinea O
pig O
brain O
by O
using O
a O
degenerate O
reverse O
transcription-polymerase O
chain O
reaction O
(RT-PCR) O
strategy. O
When O
the O
cloned O
guinea B-GENE-Y
pig I-GENE-Y
calcitonin I-GENE-Y
receptor I-GENE-Y
was O
transfected O
into O
COS O
1 O
cells, O
salmon B-GENE-N
calcitonin I-GENE-N
stimulated O
intracellular O
cyclic B-CHEMICAL
AMP I-CHEMICAL
accumulation O
with O
an O
EC50 O
of O
0.1 O
nM, O
whereas O
human B-GENE-Y
calcitonin I-GENE-Y
was O
>250-fold O
less O
potent O
(EC50 O
27.6 O
nM). O
Related O
neuropeptides O
rat B-GENE-Y

alphaCGRP I-GENE-Y
and O
rat B-GENE-Y
amylin I-GENE-Y
did O
not O
activate O
the O
guinea B-GENE-Y
pig I-GENE-Y
calcitonin I-GENE-Y
receptor I-GENE-Y
at O
physiologic O
concentrations. O
Stimulation O
of O
the O
transfected O
guinea B-GENE-Y
pig I-GENE-Y
calcitonin I-GENE-Y
receptor I-GENE-Y
by O
salmon O
calcitonin O
also O
resulted O
in O
phosphatidylinositol B-CHEMICAL
hydrolysis O
with O
an O
EC50 O
of O
2.5 O
nM. O
Expression O
of O
the O
calcitonin B-GENE-Y
receptor I-GENE-Y
was O
mapped O
by O
a O
combination O
of O
RT-PCR, O
northern O
analysis, O
and O
expression O
in O
Xenopus O
oocytes. O
The O
guinea B-GENE-Y
pig I-GENE-Y
calcitonin I-GENE-Y
receptor I-GENE-Y

was O
most O
highly O
expressed O
in O
diencephalon O
and O
a O
single O
subtype O
was O
detected. O
Adenosine B-CHEMICAL
deaminase I-GENE-Y
is O
a O
specific O
partner O
for O
the O
Grb2 B-GENE-Y
isoform O
Grb3-3. B-GENE-Y
Grb3-3 B-GENE-Y
is O
an O
isoform O
of O
Grb2, B-GENE-Y
thought O
to O
arise O
by O
alternative O
splicing, O
that O
lacks O
a O
functional O
SH2 B-GENE-N
domain I-GENE-N
but O
retains O
functional O
SH3 B-GENE-N
domains, I-GENE-N
which O
allow O
interaction O
with O
other O
proteins O
through O
binding O
to O
prolinerich O
sequences. O
Several O
evidences O
suggest O
that O
besides O
common O
partners O
for O
Grb2 B-GENE-Y
and O
Grb3-3, B-GENE-Y
specific O
targets O
could O
exist. O
In O
order O
to O
find O
specific O
partners O
for O

Grb3-3, B-GENE-Y
we O
have O
screened O
a O
human O
cDNA O
library O
by O
the O
yeast O
two-hybrid O
system O
with O
Grb3-3 B-GENE-Y
as O
a O
bait. O
We O
have O
identified O
adenosine B-CHEMICAL
deaminase, I-GENE-Y
an O
enzyme O
involved O
in O
purine B-CHEMICAL
metabolism O
whose O
deficiency O
is O
associated O
with O
severe O
combined O
immunodeficiency, O
as O
a O
Grb3-3 B-GENE-Y
binding O
protein O
that O
is O
not O
able O
to O
bind O
to O
Grb2. B-GENE-Y
This O
interaction O
has O
been O
confirmed O
in O
vitro O
with O
GST B-GENE-N
fusion O
proteins O
and O
in O
vivo O
by O
coimmunoprecipitation O
experiments O
in O
NIH3T3 O
cells O
stably O
transfected O
with O

Grb3-3. B-GENE-Y
The O
functional O
significance O
of O
this O
finding O
is O
discussed. O
Alendronate B-CHEMICAL
inhibition O
of O
protein-tyrosine-phosphatase-meg1. B-GENE-Y
Alendronate B-CHEMICAL
(4-amino-1-hydroxybutylidene-1,1-bisphosphonate) B-CHEMICAL
is O
a O
potent O
bisphosphonate B-CHEMICAL
that O
inhibits O
osteoclastic O
bone O
resorption O
and O
has O
proven O
effective O
for O
the O
treatment O
of O
osteoporosis. O
Its O
molecular O
mechanism O
of O
action, O
however, O
has O
not O
been O
defined O
precisely. O
Here O
we O
report O
that O
alendronate B-CHEMICAL
is O
a O
potent O

inhibitor O
of O
the O
protein-tyrosine-phosphatase-meg1 B-GENE-Y
(PTPmeg1). B-GENE-Y
Two O
substrates O
were O
employed O
in O
this O
study: O
fluorescein O
diphosphate B-CHEMICAL
and O
the O
phosphotyrosyl O
peptide O
src-pY527. B-GENE-Y
With O
either O
substrate, O
alendronate B-CHEMICAL
was O
a O
slow O
binding O
inhibitor O
of O
PTPmeg1. B-GENE-Y
Among O
the O
other O
bisphosphonates B-CHEMICAL
studied, O
alendronate B-CHEMICAL
was O
more O
potent O
and O
selective O
for O
PTPmeg1. B-GENE-Y
The O
hydrolysis O
of O
fluorescein O
diphosphate B-CHEMICAL
by O
PTP B-GENE-Y
epsilon I-GENE-Y
and O

PTPmeg1 B-GENE-Y
was O
sensitive O
to O
alendronate, B-CHEMICAL
with O
IC50 O
values O
of O
less O
than O
1 O
microM; O
PTPsigma, B-GENE-Y
however, O
under O
the O
same O
conditions, O
was O
inhibited O
by O
only O
50% O
with O
141 O
microM O
alendronate. B-CHEMICAL
Similarly, O
with O
the O
src-pY527 B-GENE-Y
substrate, O
alendronate B-CHEMICAL
inhibition O
was O
also O
PTP B-GENE-N
dependent. O
Alendronate B-CHEMICAL
inhibited O
PTPmeg1 B-GENE-Y
with O
an O
IC50 O
value O
of O
23 O
microM, O
PTPsigma B-GENE-Y
with O
an O
IC50 O
value O
of O
2 O
microM, O
and O
did O
not O
inhibit O
PTP B-GENE-Y
epsilon I-GENE-Y
at O

concentrations O
up O
to O
1 O
mM. O
The O
alendronate B-CHEMICAL
inhibition O
of O
these O
three O
PTPs B-GENE-N
and O
two O
substrates O
is O
consistent O
with O
the O
formation O
of O
a O
ternary O
complex O
comprised O
of O
enzyme, O
substrate, O
and O
inhibitor. O
PTP B-GENE-N
inhibition O
by O
hisphosphonates B-CHEMICAL
or O
vanadate B-CHEMICAL
was O
diminished O
by O
the O
metal O
chelating O
agent O
EDTA, B-CHEMICAL
or O
by O
the O
reducing O
agent O
dithiothreitol, B-CHEMICAL
suggesting O
that O
a O
metal O
ion O
and O
the O
oxidation O
of O
a O
cysteine B-CHEMICAL
residue O
are O
required O
for O
full O
inhibition. O
These O
observations O
show O
substrate- O
and O
enzyme-specific O
PTP B-GENE-N
inhibition O
by O
alendronate B-CHEMICAL
and O
support O
the O
possibility O
that O

a O
certain O
PTP(s) B-GENE-N
may O
be O
the O
molecular O
target O
for O
alendronate B-CHEMICAL
action. O
Ligand O
binding O
specificities O
of O
the O
eight O
types O
and O
subtypes O
of O
the O
mouse B-GENE-N
prostanoid B-CHEMICAL
receptors I-GENE-N
expressed O
in O
Chinese O
hamster O
ovary O
cells. O
1. O
Eight O
types O
and O
subtypes O
of O
the O
mouse B-GENE-N
prostanoid B-CHEMICAL
receptor, I-GENE-N
the O
prostaglandin B-CHEMICAL
D I-CHEMICAL
(DP) I-GENE-Y
receptor, I-GENE-Y
the O
prostaglandin B-GENE-Y
F I-GENE-Y
(FP) I-GENE-Y
receptor, I-GENE-Y
the O
prostaglandin B-GENE-Y
I I-GENE-Y
(IP) I-GENE-Y
receptor, I-GENE-Y
the O
thromboxane B-GENE-Y
A I-GENE-Y
(TP) I-GENE-Y
receptor I-GENE-Y
and O
the O
EP1, B-GENE-Y
EP2, B-GENE-Y
EP3 B-GENE-Y
and O

EP4 B-GENE-Y
subtypes O
of O
the O
prostaglandin B-CHEMICAL
E I-CHEMICAL
receptor, I-GENE-N
were O
stably O
expressed O
in O
Chinese O
hamster O
ovary O
cells. O
Their O
ligand O
binding O
characteristics O
were O
examined O
with O
thirty O
two O
prostanoids B-CHEMICAL
and O
their O
analogues O
by O
determining O
the O
Ki O
values O
from O
the O
displacement O
curves O
of O
radioligand O
binding O
to O
the O
respective O
receptors. O
2. O
The O
DP, B-CHEMICAL
IP B-CHEMICAL
and O
TP B-CHEMICAL
receptors I-GENE-Y
showed O
high O
ligand O
binding O
specificity O
and O
only O
bound O
their O
own O
putative O
ligands O
with O
high O
affinity O
such O
as O
PGD2, B-CHEMICAL
BW245C B-CHEMICAL
and O
BW868C B-CHEMICAL
for O
DP, B-CHEMICAL
cicaprost, B-CHEMICAL

iloprost B-CHEMICAL
and O
isocabacyclin B-CHEMICAL
for O
IP, B-CHEMICAL
and O
S-145, B-CHEMICAL
I-BOP B-CHEMICAL
and O
GR B-CHEMICAL
32191 I-CHEMICAL
for O
TP. B-CHEMICAL
3. O
The O
FP B-CHEMICAL
receptor I-GENE-Y
bound O
PGF2 B-CHEMICAL
alpha O
and O
fluprostenol B-CHEMICAL
with O
Ki O
values O
of O
3-4 O
nM. O
In O
addition, O
PGD2, B-CHEMICAL
17-phenyl-PGE2, B-CHEMICAL
STA2, B-CHEMICAL
I-BOP, B-CHEMICAL
PGE2 B-CHEMICAL
and O
M&B-28767 B-CHEMICAL
bound O
to O
this O
receptor O
with O
Ki O
values O
less O
than O
100 O
nM. O
4. O
The O
EP1 B-GENE-Y
receptor O
bound O

17-phenyl-PGE2, B-CHEMICAL
sulprostone B-CHEMICAL
and O
iloprost B-CHEMICAL
in O
addition O
to O
PGE2 B-CHEMICAL
and O
PGE1, B-CHEMICAL
with O
Ki O
values O
of O
14-36 O
nM. O
16,16-dimethyl-PGE2 B-CHEMICAL
and O
two O
putative O
EP1 B-GENE-Y
antagonists, O
AH6809 B-CHEMICAL
and O
SC-19220, B-CHEMICAL
did O
not O
show O
any O
significant O
binding O
to O
this O
receptor. O
M&B-28767, B-CHEMICAL
a O
putative O
EP3 B-GENE-Y
agonist, O
and O
misoprostol, B-CHEMICAL
a O
putative O
EP2/EP3 B-GENE-Y
agonist, O
also O
bound O
to O
this O
receptor O
with O
Ki O
values O
of O

120 O
nM. O
5. O
The O
EP2 B-GENE-Y
and O
EP4 B-GENE-Y
receptors O
showed O
similar O
binding O
profiles. O
They O
bound O
16,16-dimethyl B-CHEMICAL
PGE2 I-CHEMICAL
and O
11-deoxy-PGE1 B-CHEMICAL
in O
addition O
to O
PGE2 B-CHEMICAL
and O
PGE1. B-CHEMICAL
The O
two O
receptors O
were O
discriminated O
by O
butaprost, B-CHEMICAL
AH-13205 B-CHEMICAL
and O
AH-6809 B-CHEMICAL
that O
bound O
to O
the O
EP2 B-GENE-Y
receptor O
but O
not O
to O
the O
EP4 B-GENE-Y
receptor, O
and O
by O
1-OH-PGE1 B-CHEMICAL
that O
bound O
to O
the O
EP4 B-GENE-Y
but O
not O
to O
the O
EP2 B-GENE-Y
receptor. O
6. O
The O
EP3 B-GENE-Y
receptor O
showed O
the O
broadest O
binding O

profile, O
and O
bound O
sulprostone, B-CHEMICAL
M&B-28767, B-CHEMICAL
GR63799X, B-CHEMICAL
11-deoxy-PGE1, B-CHEMICAL
16,16-dimethyl-PGE2 B-CHEMICAL
and O
17-phenyl-PGE2, B-CHEMICAL
in O
addition O
to O
PGE2 B-CHEMICAL
and O
PGE1, B-CHEMICAL
with O
Ki O
values O
of O
0.6-3.7 O
nM. O
In O
addition, O
three O
IP B-GENE-Y
ligands, O
iloprost, B-CHEMICAL
carbacyclin B-CHEMICAL
and O
isocarbacyclin, B-CHEMICAL
and O
one O
TP B-GENE-Y
ligand, O
STA2, B-CHEMICAL
bound O
to O
this O

receptor O
with O
Ki O
values O
comparable O
to O
the O
Ki O
values O
of O
these O
compounds O
for O
the O
IP B-GENE-Y
and O
TP B-GENE-Y
receptors, I-GENE-Y
respectively. O
7. B-CHEMICAL
8-Epi-PGF2 I-CHEMICAL
alpha O
showed O
only O
weak O
binding O
to O
the O
IP, B-GENE-Y
TP, B-GENE-Y
FP, B-GENE-Y
EP2 B-GENE-Y
and O
EP3 B-GENE-Y
receptor O
at O
10 O
microM O
concentration. O
The O
structures O
of O
thymidine B-GENE-Y
kinase I-GENE-Y
from O
herpes O
simplex O
virus O
type O
1 O
in O
complex O
with O
substrates O
and O
a O
substrate O
analogue. O
Thymidine B-GENE-Y
kinase I-GENE-Y
from O
Herpes O
simplex O
virus O
type O
1 O
(TK) B-GENE-Y
was O
crystallized O
in O
an O
N-terminally B-CHEMICAL
truncated O
but O
fully O
active O
form. O
The O
structures O
of O
TK B-GENE-Y
complexed O
with O

ADP B-CHEMICAL
at O
the O
ATP-site B-CHEMICAL
and O
deoxythymidine-5'-monophosphate B-CHEMICAL
(dTMP), B-CHEMICAL
deoxythymidine B-CHEMICAL
(dT), B-CHEMICAL
or O
idoxuridine-5'-phosphate B-CHEMICAL
(5-iodo-dUMP) B-CHEMICAL
at O
the O
substrate-site O
were O
refined O
to O
2.75 O
A, O
2.8 O
A, O
and O
3.0 O
A O
resolution, O
respectively. O
TK B-GENE-Y
catalyzes O
the O
phosphorylation O
of O
dT B-CHEMICAL
resulting O
in O
an O
ester, B-CHEMICAL
and O
the O
phosphorylation O
of O
dTMP B-CHEMICAL
giving O
rise O
to O
an O

anhydride. B-CHEMICAL
The O
presented O
TK B-GENE-Y
structures O
indicate O
that O
there O
are O
only O
small O
differences O
between O
these O
two O
modes O
of O
action. O
Glu83 O
serves O
as O
a O
general O
base O
in O
the O
ester B-CHEMICAL
reaction. O
Arg163 O
parks O
at O
an O
internal O
aspartate B-CHEMICAL
during O
ester B-CHEMICAL
formation O
and O
binds O
the O
alpha-phosphate B-CHEMICAL
of O
dTMP B-CHEMICAL
during O
anhydride B-CHEMICAL
formation. O
The O
bound O
deoxythymidine B-CHEMICAL
leaves O
a O
35 O
A3 O
cavity O
at O
position O
5 O
of O
the O
base O
and O
two O
sequestered O
water O
molecules O
at O
position O
2. O
Cavity O
and O
water O
molecules O
reduce O
the O
substrate O
specificity O
to O
such O
an O
extent O
that O
TK B-GENE-Y
can O
phosphorylate B-CHEMICAL

various O
substrate O
analogues O
useful O
in O
pharmaceutical O
applications. O
TK B-CHEMICAL
is O
structurally O
homologous O
to O
the O
well-known O
nucleoside B-CHEMICAL
monophosphate I-CHEMICAL
kinases I-GENE-N
but O
contains O
large O
additional O
peptide O
segments. O
Blockage O
of O
the O
HERG B-GENE-Y
human I-GENE-Y
cardiac I-GENE-Y
K+ I-GENE-Y
channel I-GENE-Y
by O
the O
gastrointestinal O
prokinetic O
agent O
cisapride. B-CHEMICAL
Cisapride, B-CHEMICAL
a O
gastrointestinal O
prokinetic O
agent, O
is O
known O
to O
cause O
long O
Q-T O
syndrome O
and O
ventricular O
arrhythmias. O
The O
cellular O
mechanism O
is O
not O
known. O
The O
human B-GENE-Y
ether-a-go-go-related I-GENE-Y
gene I-GENE-Y

(HERG), B-GENE-Y
which O
encodes O
the O
rapidly O
activating O
delayed O
rectifier O
K+ B-CHEMICAL
current O
and O
is O
important O
in O
cardiac O
repolarization, O
may O
serve O
as O
a O
target O
for O
the O
action O
of O
cisapride. B-CHEMICAL
We O
tested O
the O
hypothesis O
that O
cisapride B-CHEMICAL
blocks O
HERG. B-GENE-Y
The O
whole O
cell O
patch-clamp O
recording O
technique O
was O
used O
to O
study O
HERG B-GENE-Y
channels O
stably O
expressed O
heterologously O
in O
HEK293 O
cells. O
Under O
voltage-clamp O
conditions, O
cisapride B-CHEMICAL
block O
of O
HERG B-GENE-Y
is O
dose O
dependent O
with O
a O
half-maximal O
inhibitory O
concentration O
of O
6.5 O
nM O
at O
22 O

degrees O
C O
(n O
= O
25 O
cells). O
Currents O
rapidly O
recovered O
with O
drug O
washout. O
The O
onset O
of O
block O
by O
cisapride B-CHEMICAL
required O
channel O
activation O
indicative O
of O
open O
or O
inactivated O
state O
blockage. O
Block O
of O
HERG B-GENE-Y
with O
cisapride B-CHEMICAL
after O
channel O
activation O
was O
voltage O
dependent. O
At O
-20 O
mV, O
10 O
nM O
cisapride B-CHEMICAL
reduced O
HERG B-GENE-Y
tail-current O
amplitude O
by O
5%, O
whereas, O
at O
+ O
20 O
mV, O
the O
tail-current O
amplitude O
was O
reduced O
by O
45% O
(n O
= O
4 O
cells). O
At O
-20 O
and O
+ O
20 O
mV, O
100 O
nM O
cisapride B-CHEMICAL
reduced O

tail-current O
amplitude O
by O
66 O
and O
90%, O
respectively. O
We O
conclude O
that O
cisapride B-CHEMICAL
is O
a O
potent O
blocker O
of O
HERG B-GENE-Y
channels O
expressed O
in O
HEK293 O
cells. O
This O
effect O
may O
account O
for O
the O
clinical O
occurrence O
of O
Q-T O
prolongation O
and O
ventricular O
arrhythmias O
observed O
with O
cisapride. B-CHEMICAL
Analysis O
of O
NMDA B-GENE-N
receptors I-GENE-N
in O
the O
human O
spinal O
cord. O
NMDA B-CHEMICAL
receptors I-GENE-N
in O
postmortem O
human O
spinal O
cord O
were O
analyzed O
using O
[3H]MK-801 B-CHEMICAL
ligand O
binding O
and O
immunoblotting O
with O
NMDA B-CHEMICAL
receptor I-GENE-N
subunit-specific O
antibodies. O
The O

average O
KD O
for O
[3H]MK-801 B-CHEMICAL
binding O
was O
1.77 O
nM O
with O
a O
Bmax O
of O
0.103 O
pmol/mg. O
The O
EC50 O
for O
stimulation O
of O
-3H-MK-801 B-CHEMICAL
binding O
with O
L-glutamate B-CHEMICAL
was O
0.34 O
microM. O
None O
of O
these O
parameters O
were O
affected O
by O
postmortem O
intervals O
up O
to O
72 O
h. O
Immunoblotting O
of O
native O
NMDA B-CHEMICAL
receptors I-GENE-N
showed O
that O
NR1, B-GENE-Y
NR2A, B-GENE-Y
NR2C, B-GENE-N
and O
NR2D B-GENE-Y
subunits O
could O
all O
be O
found O
in O
the O
human O
spinal O
cord O
of O
which O

NR1 B-GENE-Y
was O
preferentially O
located O
to O
the O
dorsal O
half. O
Immunoprecipitation O
of O
solubilized O
receptors O
revealed O
that O
NR1, B-GENE-Y
NR2C, B-GENE-N
and O
NR2D B-GENE-Y
subunits O
coprecipitated O
with O
the O
NR2A B-GENE-Y
subunit, O
indicating O
that O
native O
human O
spinal O
cord O
NMDA B-CHEMICAL
receptors I-GENE-N
are O
heteroligimeric B-CHEMICAL
receptors I-GENE-N
assembled O
by O
at O
least O
three O
different O
receptor O
subunits. O
These O
results O
provide O
a O
basis O
for O
the O
development O
of O
drugs O
selectively O
aimed O
at O
spinal O
cord O
NMDA B-GENE-N
receptors I-GENE-N
for O
the O
future O
treatment O
of O
spinal O
cord O
disorders. O
Monoamine B-GENE-N
transporter I-GENE-N
and O
sodium B-GENE-N
channel I-GENE-N
mechanisms O
in O
the O
rapid O

pressor O
response O
to O
cocaine. B-CHEMICAL
Intravenous O
(I.V.) O
cocaine B-CHEMICAL
(0.03-3 O
mg/kg) O
produced O
dose-dependent, O
rapid, O
and O
brief O
increases O
in O
blood O
pressure O
(BP) O
in O
conscious O
rats O
pretreated O
with O
the O
dopamine B-GENE-N
receptor I-GENE-N
antagonist, O
SCH B-CHEMICAL
23390. I-CHEMICAL
Monoamine B-CHEMICAL
uptake O
inhibitors O
structurally O
analogous O
to O
cocaine B-CHEMICAL
(cocaethylene, B-CHEMICAL
CFT, B-CHEMICAL
betaCIT, B-CHEMICAL
CPT, B-CHEMICAL
(+)-cocaine, B-CHEMICAL
norcocaine, B-CHEMICAL
and O
benztropine) B-CHEMICAL
also O
produced O
this O
rapid O
pressor O
response, O
whereas O
structurally O
unrelated O
uptake O
inhibitors O
with O
diverse O

monoamine B-GENE-N
transporter I-GENE-N
selectivities O
(BTCP, B-CHEMICAL
indatraline, B-CHEMICAL
GBR B-CHEMICAL
12935, I-CHEMICAL
mazindol, B-CHEMICAL
nomifensine, B-CHEMICAL
and O
zimeldine) B-CHEMICAL
either O
did O
not O
produce O
a O
rapid O
pressor O
response O
or O
produced O
only O
a O
small O
pressor O
response. O
At O
nonconvulsant O
doses, O
the O
sodium B-GENE-N
channel I-GENE-N
blockers O
acetylprocainamide, B-CHEMICAL
dibucaine, B-CHEMICAL
dyclonine, B-CHEMICAL
prilocaine, B-CHEMICAL
proparacaine, B-CHEMICAL
quinidine, B-CHEMICAL
and O
tetracaine B-CHEMICAL
produced O
a O
small O
pressor O
response O
or O
no O
increase O
in O
BP. O
In O
rats O

implanted O
with O
telemetric O
devices, O
cocaine B-CHEMICAL
and O
its O
analog, O
CFT, B-CHEMICAL
produced O
a O
biphasic O
pharmacological O
response O
that O
consisted O
of O
an O
initial O
brief O
and O
abrupt O
behavioral O
arousal O
associated O
with O
a O
rapid, O
large O
increase O
in O
BP O
followed O
by O
prolonged, O
parallel O
increases O
in O
BP O
and O
locomotor O
activity. O
Pretreatment O
with O
SCH B-CHEMICAL
23390 I-CHEMICAL
prevented O
the O
prolonged O
but O
not O
the O
initial O
rapid O
and O
brief O
pressor O
and O
activity O
responses O
to O
both O
cocaine B-CHEMICAL
and O
CFT B-CHEMICAL
administration. O
The O
present O
data O
suggest O
that O
the O
inhibition O
of O
dopamine, B-CHEMICAL
norepinephrine, B-CHEMICAL
or I-GENE-N
serotonin B-CHEMICAL
transporter I-GENE-N
functions, O
either O
alone O
or O
in O

combination, O
does O
not O
mediate O
the O
rapid O
pressor O
response O
to O
cocaine. B-CHEMICAL
The O
sodium B-CHEMICAL
channel-blocking I-GENE-N
action O
of O
cocaine B-CHEMICAL
per O
se O
does O
not O
appear O
to O
be O
involved O
in O
the O
rapid O
pressor O
response O
to O
cocaine. B-CHEMICAL
Finally, O
the O
present O
results O
confirm O
previous O
findings O
that O
dopaminergic O
mechanisms O
mediate O
the O
prolonged O
increases O
in O
BP O
and O
locomotor O
activity O
produced O
by O
cocaine. B-CHEMICAL
Identification O
of O
cDNAs O
encoding O
two O
human B-GENE-N
alpha I-GENE-N
class I-GENE-N
glutathione B-CHEMICAL
transferases I-GENE-N
(GSTA3 B-GENE-Y
and O
GSTA4) B-GENE-Y
and O
the O
heterologous O
expression O
of O
GSTA4-4. B-GENE-Y
The O
Expressed O
Sequence O
Tag O
database O
has O
been O
searched O

for O
examples O
of O
previously O
undescribed O
human B-GENE-N
Alpha I-GENE-N
class I-GENE-N
glutathione B-CHEMICAL
transferases. I-GENE-N
An O
incomplete O
transcript O
of O
the O
previously O
described O
GSTA3 B-GENE-Y
gene O
was O
identified O
in O
a O
cDNA O
library O
derived O
from O
8-9 O
week O
placenta. O
This O
indicates O
that O
the O
GSTA3 B-GENE-Y
gene O
is O
functional O
and O
is O
possibly O
under O
specific O
developmental O
regulation. O
A O
second O
cDNA, O
termed O
GSTA4, B-GENE-Y
was O
identified O
in O
a O
brain O
cDNA O
library. O
The O
encoded O
GSTA4-4 B-GENE-Y
enzyme O
was O
expressed O
in O
Escherichia O
coli O
and O
was O
found O
to O
be O
immunologically O
distinct O
from O
GSTA1-1 B-GENE-Y
and O
to O
have O

high O
activity O
with O
alk-2-enals. O
Although O
GSTA4-4 B-GENE-Y
appears O
to O
be O
functionally O
similar O
to O
the O
mouse B-GENE-Y
GST5.7 I-GENE-Y
and O
rat B-GENE-Y
GST8-8 I-GENE-Y
Alpha O
class O
enzymes, O
sequence O
comparisons O
and O
phylogenetic O
analysis O
suggest O
that O
GSTA4-4 B-GENE-Y
may O
be O
a O
member O
of O
a O
distinct O
Alpha O
class O
subgroup. O
Characterization O
of O
binding O
sites O
of O
a O
new O
neurotensin B-GENE-N
receptor I-GENE-N
antagonist, O
[3H]SR B-CHEMICAL
142948A, I-CHEMICAL
in O
the O
rat O
brain. O
The O
present O
study O
describes O
the O
characterization O
of O
the O
binding O
properties O
and O
autoradiographic O
distribution O
of O
a O
new O
nonpeptide O
antagonist O
of O
neurotensin B-CHEMICAL

receptors, I-GENE-N
[3H]SR B-CHEMICAL
142948A I-CHEMICAL
(2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl B-CHEMICAL
carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad I-CHEMICAL
amantane-2-carboxylic I-CHEMICAL
acid, I-CHEMICAL
hydrochloride), I-CHEMICAL
in O
the O
rat O
brain. O
The O
binding O
of O
[3H]SR B-CHEMICAL

142948A I-CHEMICAL
in O
brain O
membrane O
homogenates O
was O
specific, O
time-dependent, O
reversible O
and O
saturable. O
[3H]SR B-CHEMICAL
142948A I-CHEMICAL
bound O
to O
an O
apparently O
homogeneous O
population O
of O
sites, O
with O
a O
Kd O
of O
3.5 O
nM O
and O
a O
Bmax O
value O
of O
508 O
fmol/mg O
of O
protein, O
which O
was O
80% O
higher O
than O
that O
observed O
in O
saturation O
experiments O
with O
[3H]neurotensin. B-CHEMICAL
[3H]SR B-CHEMICAL
142948A I-CHEMICAL
binding O
was O
inhibited O
by O
SR B-CHEMICAL
142948A, I-CHEMICAL
the O
related O
nonpeptide O
receptor O
antagonist, O
SR B-CHEMICAL
48692 I-CHEMICAL

(2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole B-CHEMICAL
-3-carbonyl]amino]-adamantane-2-carboxylic I-CHEMICAL
acid) I-CHEMICAL
and O
neurotensin. B-GENE-Y
Saturation O
and O
competition O
studies O
in O
the O
presence O
or O
absence O
of O
the O
histamine B-GENE-Y
H1 I-GENE-Y
receptor I-GENE-Y
antagonist, O
levocabastine, B-CHEMICAL
revealed O
that O
[3H]SR B-CHEMICAL
142948A I-CHEMICAL
bound O
with O
similar O
affinities O
to O
both O
the O

levocabastine-insensitive B-CHEMICAL
neurotensin B-CHEMICAL
NT1 I-GENE-Y
receptors I-GENE-Y
(20% O
of O
the O
total O
binding O
population) O
and O
the O
recently O
cloned O
levocabastine-sensitive B-CHEMICAL
neurotensin B-GENE-Y
NT2 I-GENE-Y
receptors I-GENE-Y
(80% O
of O
the O
receptors) O
(Kd O
= O
6.8 O
and O
4.8 O
nM, O
respectively). O
The O
regional O
distribution O
of O
[3H]SR B-CHEMICAL
142948A I-CHEMICAL
binding O
in O
the O
rat O
brain O
closely O
matched O
the O
distribution O
of O
[125I]neurotensin B-CHEMICAL
binding. O
In O
conclusion, O
these O
findings O
indicate O
that O
[3H]SR B-CHEMICAL
142948A I-CHEMICAL
is O
a O
new O
potent O
antagonist O

radioligand O
which O
recognizes O
with O
high O
affinity O
both O
neurotensin B-GENE-Y
NT1 I-GENE-Y
and O
NT2 B-GENE-Y
receptors I-GENE-Y
and O
represents O
thus O
an O
excellent O
tool O
to O
study O
neurotensin B-GENE-N
receptors I-GENE-N
in O
the O
rat O
brain. O
A O
new O
concept O
of O
drug O
delivery O
for O
acne. O
Adapalene B-CHEMICAL
is O
a O
stable O
naphthoic B-CHEMICAL
acid I-CHEMICAL
derivative O
that O
displays O
a O
strong O
retinoid B-CHEMICAL
agonist O
pharmacology. O
This O
drug O
controls O
cell O
proliferation O
and O
differentiation, O
and O
possesses O
significant O
anti-inflammatory O
action. O
The O
retinoid B-CHEMICAL
action O
of O
adapalene B-CHEMICAL
are O
mediated O
by O
the O
ligand-activated B-GENE-N
gene I-GENE-N
transcription I-GENE-N
factors I-GENE-N
retinoic B-GENE-N
acid I-GENE-N
receptors I-GENE-N
RAR B-GENE-Y
beta I-GENE-Y
and O
RAR B-GENE-Y
gamma. I-GENE-Y

We O
describe O
here O
how O
an O
aqueous O
gel O
containing O
adapalene B-CHEMICAL
was O
selected O
for O
the O
topical O
treatment O
of O
acne. O
Isoform-specific O
inhibition O
of O
L-type B-GENE-N
calcium I-GENE-N
channels I-GENE-N
by O
dihydropyridines B-CHEMICAL
is O
independent O
of O
isoform-specific O
gating O
properties. O
Dihydropyridines B-CHEMICAL
(DHPs) B-CHEMICAL
block O
L-type B-GENE-N
Ca2+ B-CHEMICAL
channels I-GENE-N
more O
potently O
at O
depolarized O
membrane O
potentials, O
consistent O
with O
high O
affinity O
binding O
to O
the O
inactivated O
state. O
Nisoldipine B-CHEMICAL
(a O
DHP B-CHEMICAL
antagonist) O
blocks O
the O
smooth B-GENE-N
muscle I-GENE-N
channel I-GENE-N
more O
potently O
than O
the O
cardiac O
one, O
a O
phenomenon O
observed O
not O

only O
in O
native O
channels O
but O
also O
in O
expressed O
channels. O
We O
examined O
whether O
this O
tissue O
specificity O
was O
attributable O
to O
differences O
of O
inactivation O
in O
the O
two O
channel O
types. O
We O
expressed O
cardiac O
or O
smooth B-GENE-Y
muscle I-GENE-Y
alpha1C I-GENE-Y
subunits O
in O
combination O
with O
beta2a O
and O
alpha2/delta O
subunits O
in O
human O
embryonic O
kidney O
cells, O
and O
used O
2 O
mM O
Ca2+ B-CHEMICAL
as O
the O
permeant O
ion. O
This O
system O
thus O
reproduces O
the O
in O
vivo O
topology O
and O
charge O
carrier O
of O
the O
channels O
while O
facilitating O
comparison O
of O
the O
two O
alpha1C O
splice O
variants. O
Both O
voltage-dependent O
and O
isoform-specific O
sensitivity O

of O
10 O
nM O
nisoldipine B-CHEMICAL
inhibition O
of O
the O
channel O
were O
demonstrated, O
with O
the O
use O
of O
-100 O
mV O
as O
the O
holding O
potential O
for O
fully O
reprimed O
channels O
and O
-65 O
mV O
to O
populate O
the O
inactivated O
state. O
Under O
drug-free O
conditions, O
we O
characterized O
fast O
inactivation O
(1-sec O
prepulses) O
and O
slow O
inactivation O
(3 O
min O
prepulses) O
in O
the O
two O
isoforms. O
Inactivation O
parameters O
were O
not O
statistically O
different O
in O
the O
two O
channel O
isoforms; O
if O
anything, O
cardiac B-GENE-N
channels I-GENE-N
tended O
to O
inactivate O
more O
than O
the O
smooth B-GENE-N
muscle I-GENE-N
channels I-GENE-N
at O
relevant O

voltages. O
Likewise, O
the O
voltage-dependent O
activation O
was O
identical O
in O
the O
two O
isoforms. O
We O
thus O
conclude O
that O
the O
more O
potent O
nisoldipine B-CHEMICAL
inhibition O
of O
smooth O
muscle O
versus O
cardiac B-GENE-N
L-type I-GENE-N
Ca2+ B-CHEMICAL
channels I-GENE-N
is O
not O
attributable O
to O
differences O
in O
channel O
inactivation O
or O
activation. O
Intrinsic, O
gating-independent O
DHP B-CHEMICAL
receptor I-GENE-N
binding O
affinity O
differences O
must O
be O
invoked O
to O
explain O
the O
isoform-specific O
sensitivity O
of O
the O
DHP B-CHEMICAL
block. O
Remethylation O
defects: O
guidelines O
for O
clinical O
diagnosis O
and O
treatment. O
The O
main O
remethylation O
defects O
include O
disorders O
which O
all O
have O
defective O
methionine B-CHEMICAL

synthesis O
in O
common. O
Methylenetetrahydrofolate B-CHEMICAL
reductase I-GENE-Y
deficiency O
impairs O
methyltetrahydrofolate B-CHEMICAL
synthesis, O
defects O
in O
cytosolic O
reduction O
of O
hydroxocobalamin B-CHEMICAL
(CblC/D) O
impair O
the O
synthesis O
of O
both O
methyl- B-CHEMICAL
and O
adenosyl B-CHEMICAL
cobalamin I-CHEMICAL
and O
deficiencies O
of O
methionine B-CHEMICAL
synthase I-GENE-Y
(CblE/G) O
are O
associated O
with O
defective O
methyl B-CHEMICAL
cobalamin I-CHEMICAL
synthesis. O
The O
clinical O
presentation O
is O
characterized O
by O
acute O
neurological O
distress O
in O
early O
infancy. O
In O
childhood, O
patients O
present O
with O
progressive O

encephalopathy O
with O
an O
end-stage O
which O
has O
many O
signs O
in O
common O
with O
the O
adult O
onset O
form. O
In O
fact, O
both O
have O
more O
or O
less O
severe O
signs O
of O
subacute O
degeneration O
of O
the O
cord. O
Cobalamin B-CHEMICAL
defective O
patients O
must O
be O
treated O
with O
parenteral O
supplementation O
of O
hydroxocobalamin B-CHEMICAL
(1-2 O
mg O
per O
dose). O
Some O
methylenetetrahydrofolate B-CHEMICAL
patients O
could O
be O
folate B-CHEMICAL
responsive O
and O
must O
have O
a O
high-dosage O
folate O
trial. O
In O
addition, O
oral O
betaine B-CHEMICAL
supplementation O
(2-9 O
g O
per O
day O
depending O
on O
age) O
appears O

an O
effective O
means O
to O
prevent O
further O
neurological O
deterioration. O
Increased O
Cat3-mediated B-GENE-Y
cationic O
amino B-CHEMICAL
acid I-CHEMICAL
transport O
functionally O
compensates O
in O
Cat1 B-GENE-Y
knockout O
cell O
lines. O
Arginine B-CHEMICAL
transport O
is O
important O
for O
a O
number O
of O
biological O
processes O
in O
vertebrates, O
and O
its O
transport O
may O
be O
rate-limiting O
for O
the O
production O
of O
nitric B-CHEMICAL
oxide. I-CHEMICAL
The O
majority O
of O
L-Arg B-CHEMICAL
transport O
is O
mediated O
by O
System B-GENE-N
y+, I-GENE-N
although O
several O
other O
carriers O
have O
been O
kinetically O
defined. O
System B-GENE-N
y+ I-GENE-N
cationic O
amino B-CHEMICAL
acid I-CHEMICAL
transport O
is O
mediated O
by O
proteins O
encoded O
by O
a O
family O
of O
genes, O
Cat1, B-GENE-Y
Cat2, B-GENE-Y
and O

Cat3. B-GENE-Y
High O
affinity O
L-arginine B-CHEMICAL
transport O
was O
investigated O
in O
embryonic O
fibroblast O
cells O
derived O
from O
Cat1 B-GENE-Y
knockout O
mice O
that O
lack O
functional O
Cat1. B-GENE-Y
Both O
wild O
type O
and O
knockout O
cells O
transport O
arginine B-CHEMICAL
with O
comparable O
Km O
and O
Vmax. O
However, O
the O
apparent O
affinity O
for O
lysine B-CHEMICAL
transport O
was O
2.4 O
times O
lower O
in O
Cat1(-/-) B-GENE-Y
cells O
when O
compared O
with O
wild O
type O
cells, O
a O
property O
characteristic O
of O
Cat3-mediated B-GENE-Y
transport. O
Northern O
analysis-documented O
Cat2 B-GENE-Y
mRNA O
increased O
2-fold, O
whereas O
Cat3 B-GENE-Y
mRNA O
levels O
increased O
11-fold O
in O

Cat1(-/-) B-GENE-Y
relative O
to O
Cat1(+/+) B-GENE-Y
cells. O
The O
low O
affinity O
Cat2a B-GENE-N
mRNA O
was O
not O
detectably O
expressed O
in O
these O
cells. O
Even O
though O
Cat3 B-GENE-Y
expression O
is O
normally O
limited O
to O
adult O
brain, O
there O
was O
a O
large O
increase O
in O
the O
amount O
of O
Cat3 B-GENE-Y
protein O
present O
at O
the O
plasma O
membrane O
of O
Cat1(-/-) B-GENE-Y
embryonic O
fibroblast O
cells. O
These O
results O
suggest O
that O
Cat3 B-GENE-Y
compensates O
for O
the O
loss O
of O
functional O
Cat1 B-GENE-Y
in O
cells O
derived O
from O
Cat1 B-GENE-Y
knockout O
mice O
and O
mediates O
the O
majority O
of O
high O
affinity O
arginine B-CHEMICAL
transport. O
Effect O
of O
lintitript, B-CHEMICAL

a O
new O
CCK-A B-GENE-Y
receptor I-GENE-Y
antagonist, O
on O
gastric O
emptying O
of O
a O
solid-liquid O
meal O
in O
humans. O
The O
role O
of O
cholecystokinin B-GENE-Y
(CCK) B-GENE-Y
in O
the O
regulation O
of O
gastric O
emptying O
of O
physiological O
meals O
containing O
solids O
and O
liquids O
in O
humans O
remains O
controversial. O
We O
studied O
the O
role O
of O
endogenous O
CCK B-GENE-Y
in O
the O
emptying O
of O
a O
solid/liquid O
meal O
administering O
the O
new, O
highly O
specific O
and O
potent O
CCK-A B-GENE-Y
receptor I-GENE-Y
antagonist O
lintitript. B-CHEMICAL
Gastric O
emptying O
was O
assessed O
in O
nine O
healthy O
male O
volunteers O
using O
a O
randomized, O
double O
blind, O
two-period O
crossover O
design O
with O
oral O

lintitript B-CHEMICAL
(15 O
mg O
1 O
h O
prior O
to O
meal O
intake) O
or O
placebo O
on O
two O
different O
days. O
After O
ingestion O
of O
a O
pancake O
(570 O
kcal) O
labelled O
with O
500 O
microCi O
of O
99mTc-sulfur B-CHEMICAL
colloid O
and O
500 O
ml O
10% O
dextrose O
containing O
80 O
microCi. O
111In-DTPA, B-CHEMICAL
subjects O
were O
studied O
in O
a O
sitting O
position, O
using O
a O
dual-headed O
gamma O
camera. O
Plasma O
CCK B-GENE-Y
and O
pancreatic B-GENE-Y
polypeptide I-GENE-Y
(PP) B-GENE-Y
were O
measured O
by O
a O
specific O
RIA. O
Lintitript B-CHEMICAL
distinctly O
accelerated O
gastric O

emptying O
of O
solids, O
while O
gastric O
emptying O
of O
liquids O
was O
not O
significantly O
altered. O
The O
lag O
period O
was O
shortened O
by O
20% O
(P<0.05), O
AUC O
and O
half O
emptying O
time O
of O
solid O
emptying O
were O
lowered O
by O
12% O
and O
13%, O
respectively O
(P<0.03). O
Lintitript B-CHEMICAL
markedly O
increased O
postprandial O
plasma O
CCK B-GENE-Y
release O
(P<0.001) O
while O
distinctly O
reducing O
postprandial O
PP B-GENE-Y
levels O
(P<0.01) O
as O
compared O
to O
placebo. O
These O
data O
provide O
further O
evidence O
for O
a O
significant O
role O
of O
CCK B-GENE-Y
in O
the O
regulation O
of O

gastric O
emptying O
of O
solids. O
The O
study O
demonstrates O
for O
the O
first O
time O
the O
marked O
gastrokinetic O
properties O
of O
the O
new O
CCK-A B-GENE-Y
receptor I-GENE-Y
antagonist O
lintitript B-CHEMICAL
in O
humans. O
Beta-adrenoceptor-mediated B-GENE-N
inhibition O
of O
IFN-gamma, B-GENE-Y
IL-3, B-GENE-Y
and O
GM-CSF B-GENE-Y
mRNA O
accumulation O
in O
activated O
human O
T O
lymphocytes O
is O
solely O
mediated O
by O
the O
beta2-adrenoceptor B-GENE-Y
subtype. O
Cytokine B-GENE-N
gene O
expression O
in O
T O
lymphocytes O
is O
a O
strictly O
regulated O
process, O
involving O
both O
stimulatory O
and O
inhibitory O
signals. O
beta-Adrenoceptor B-GENE-N

(betaAR) B-GENE-N
agonists O
are O
widely O
used O
in O
the O
treatment O
of O
asthma O
and O
are O
able O
to O
induce O
an O
inhibitory O
signal O
on O
immunological O
responses O
after O
binding O
to O
their O
specific O
receptors. O
In O
this O
study, O
the O
characterization O
of O
betaAR B-GENE-N
subtype(s) O
(beta1, O
beta2, O
and O
beta3) O
involved O
in O
the O
regulation O
of O
interleukin B-GENE-Y
(IL)-3, I-GENE-Y
IL-4, B-GENE-Y
granulocyte-macrophage B-GENE-Y
colony-stimulating I-GENE-Y
factor I-GENE-Y
(GM-CSF), B-GENE-Y
and O
interferon-gamma B-GENE-Y
(IFN-gamma) B-GENE-Y
mRNA O
accumulation O
was O
studied O
by O
using O
various O
betaAR B-GENE-N

agonists O
and O
antagonists. O
Concanavalin B-GENE-N
A I-GENE-N
(Con B-GENE-N
A)-induced I-GENE-N
IFN-gamma, B-GENE-Y
GM-CSF, B-GENE-Y
and O
IL-3 B-GENE-Y
mRNAs O
are O
dose-dependently O
inhibited O
by O
the O
nonselective O
betaAR B-GENE-N
agonist O
isoproterenol B-CHEMICAL
and O
by O
the O
selective O
beta2AR B-GENE-Y
agonist O
fenoterol. B-CHEMICAL
IL-4 B-GENE-Y
mRNA O
accumulation O
was O
not O
susceptible O
to O
betaAR B-GENE-N
stimulation. O
The O
observed O
inhibition O
on O
IFN-gamma, B-GENE-Y
GM-CSF, B-GENE-Y
and O
IL-3 B-GENE-Y
mRNA O
was O
blocked O
by O
the O
selective O
beta2AR B-GENE-Y
antagonist O
ICI B-CHEMICAL
118,551 I-CHEMICAL

(10(-6) O
M) O
and O
by O
timolol B-CHEMICAL
(10(-6) O
M), O
a O
nonselective O
antagonist. O
The O
selective O
beta1AR B-GENE-Y
antagonist O
atenolol B-CHEMICAL
(0.3 O
x O
10(-6) O
M) O
did O
not O
have O
any O
effect. O
Secretion O
of O
GM-CSF B-GENE-Y
protein O
in O
the O
presence O
of O
increasing O
concentrations O
of O
isoproterenol B-CHEMICAL
followed O
a O
similar O
pattern O
as O
observed O
for O
GM-CSF B-GENE-Y
mRNA. O
In O
addition, O
the O
betaAR-mediated B-GENE-N
inhibition O
of O
IFN-gamma, B-GENE-Y
GM-CSF, B-GENE-Y
and O
IL-3 B-GENE-Y
mRNA O
accumulation O
and O
GM-CSF B-GENE-Y
protein O

secretion O
were O
related O
to O
the O
accumulation O
of O
intracellular O
cyclic B-CHEMICAL
adenosine I-CHEMICAL
monophosphate I-CHEMICAL
(cAMP) B-CHEMICAL
levels. O
Although O
beta3AR B-GENE-Y
mRNA O
was O
detectable O
in O
Con B-GENE-N
A-activated I-GENE-N
T O
lymphocytes, O
we O
could O
not O
demonstrate O
a O
functional O
activity O
in O
the O
regulation O
of O
cytokine B-GENE-N
expression: O
the O
beta3AR B-GENE-Y
agonist O
BRL B-CHEMICAL
37344 I-CHEMICAL
had O
no O
effect O
on O
the O
accumulation O
of O
the O
studied O
cytokine B-GENE-N
mRNAs, O
and O
did O
not O
significantly O
affect O
cellular O
cAMP B-CHEMICAL
levels. O
These O
data O
demonstrate O
that O
beta-agonist-induced O
inhibition O
of O
IFN-gamma, B-GENE-Y
GM-CSF, B-GENE-Y

and O
IL-3 B-GENE-Y
mRNA O
accumulation O
is O
solely O
mediated O
by O
beta2-adrenoceptors. B-GENE-Y
Oxytocin B-GENE-Y
receptor I-GENE-Y
binding O
and O
uterotonic O
activity O
of O
carbetocin B-CHEMICAL
and O
its O
metabolites O
following O
enzymatic O
degradation. O
Metabolites O
of O
the O
analogue O
1-deamino-1-carba-2-tyrosine(O-methyl)-oxytocin B-CHEMICAL
(carbetocin) B-CHEMICAL
following O
incubation O
with O
a O
rat O
kidney O
homogenate O
were O
isolated O
and O
their O
pharmacodynamic O
properties O
investigated. O
Apart O
from O
the O
parent O
compound O
two O
metabolites O
were O
identified O
namely O

desGlyNH2-carbetocin B-CHEMICAL
(carbetocin B-CHEMICAL
metabolite O
I) O
and O
desLeuGlyNH2-carbetocin B-CHEMICAL
(carbetocin B-CHEMICAL
metabolite O
II). O
Both O
carbetocin, B-CHEMICAL
carbetocin B-CHEMICAL
metabolite O
I O
and O
carbetocin B-CHEMICAL
metabolite O
II O
displayed O
binding O
affinities O
to O
the O
myometrial O
oxytocin B-GENE-Y
receptor I-GENE-Y
of O
a O
similar O
magnitude O
as O
oxytocin. B-GENE-Y
Carbetocin B-CHEMICAL
was O
found O
to O
have O
agonistic O
properties O
on O
isolated O
myometrial O
strips O
and O
it O
was O
found O
to O
exert O
this O
effect O
through O
generation O
of O

inositol B-CHEMICAL
phosphates, I-CHEMICAL
as O
is O
the O
case O
for O
oxytocin. B-GENE-Y
However, O
maximal O
contractile O
effect O
of O
carbetocin B-CHEMICAL
was O
approximately O
50% O
lower O
than O
that O
of O
oxytocin B-GENE-Y
(2.70 O
+/- O
0.12 O
g O
compared O
to O
5.22 O
+/- O
0.26 O
g) O
and O
EC50 O
was O
approximately O
ten O
times O
higher O
(48.0 O
+/- O
8.20 O
nM O
compared O
to O
5.62 O
+/- O
1.22 O
nM). O
Neither O
carbetocin B-CHEMICAL
metabolite O
I O
nor O
carbetocin B-CHEMICAL
metabolite O
II O
were O
able O
to O
contract O
isolated O

myometrial O
tissue. O
All O
three O
compounds O
displayed O
antagonistic O
properties O
against O
oxytocin B-GENE-Y
in O
vitro, O
with O
carbetocin B-CHEMICAL
being O
the O
strongest O
inhibitor O
(pA2 O
= O
8.21) O
and O
carbetocin B-CHEMICAL
metabolite O
II O
(pA2 O
= O
8.01) O
being O
stronger O
than O
carbetocin B-CHEMICAL
metabolite O
I O
(pA2 O
= O
7.81). O
These O
results O
indicate O
that O
carbetocin B-CHEMICAL
is O
a O
partial O
agonist/antagonist O
to O
the O
oxytocin B-CHEMICAL
receptor I-GENE-Y
while O
the O
two O
metabolites O
carbetocin B-CHEMICAL
metabolite O
I O
and O
carbetocin B-CHEMICAL
metabolite O
II O
are O

pure O
antagonists. O
All O
three O
analogues O
bound O
to O
the O
myometrial O
vasopressin B-GENE-N
V1 I-GENE-N
receptor, I-GENE-N
albeit O
with O
much O
lower O
affinities O
than O
to O
the O
oxytocin B-GENE-Y
receptor. I-GENE-Y
Carbetocin B-CHEMICAL
metabolite O
II O
showed O
the O
weakest O
binding O
affinity O
of O
33.7 O
+/- O
7.34 O
nM O
compared O
to O
7.24 O
+/- O
0.29 O
nM O
for O
carbetocin B-CHEMICAL
and O
9.89 O
+ O
2.80 O
nM O
for O
carbetocin B-CHEMICAL
metabolite O
I. O
Only O
carbetocin B-CHEMICAL
bound O
to O
the O
renal O
vasopressin B-GENE-Y
V2 I-GENE-Y
receptor I-GENE-Y
though O
the O
binding O
affinity O

was O
very O
low O
(61.3 O
+/- O
14.6 O
nM). O
Crystallographic O
analysis O
of O
the O
human B-GENE-N
phenylalanine I-GENE-N
hydroxylase I-GENE-N
catalytic I-GENE-N
domain I-GENE-N
with O
bound O
catechol B-CHEMICAL
inhibitors O
at O
2.0 O
A O
resolution. O
The O
aromatic B-GENE-N
amino I-GENE-N
acid I-GENE-N
hydroxylases I-GENE-N
represent O
a O
superfamily O
of O
structurally O
and O
functionally O
closely O
related O
enzymes, O
one O
of O
those O
functions O
being O
reversible O
inhibition O
by O
catechol B-CHEMICAL
derivatives. O
Here O
we O
present O
the O
crystal O
structure O
of O
the O
dimeric O
catalytic O
domain O
(residues O
117-424) O
of O
human B-GENE-Y
phenylalanine B-CHEMICAL
hydroxylase I-GENE-Y

(hPheOH), B-GENE-Y
cocrystallized O
with O
various O
potent O
and O
well-known O
catechol B-CHEMICAL
inhibitors O
and O
refined O
at O
a O
resolution O
of O
2.0 O
A. O
The O
catechols B-CHEMICAL
bind O
by O
bidentate O
coordination O
to O
each O
iron B-CHEMICAL
in O
both O
subunits O
of O
the O
dimer O
through O
the O
catechol B-CHEMICAL
hydroxyl I-CHEMICAL
groups, O
forming O
a O
blue-green O
colored O
ligand-to-metal O
charge-transfer O
complex. O
In O
addition, O
Glu330 O
and O
Tyr325 O
are O
identified O
as O
determinant O
residues O
in O
the O
recognition O
of O
the O
inhibitors. O
In O
particular, O
the O
interaction O
with O
Glu330 O
conforms O

to O
the O
structural O
explanation O
for O
the O
pH O
dependence O
of O
catecholamine B-CHEMICAL
binding O
to O
PheOH, B-CHEMICAL
with O
a O
pKa O
value O
of O
5.1 O
(20 O
degreesC). O
The O
overall O
structure O
of O
the O
catechol-bound B-CHEMICAL
enzyme O
is O
very O
similar O
to O
that O
of O
the O
uncomplexed O
enzyme O
(rms O
difference O
of O
0.2 O
A O
for O
the O
Calpha O
atoms). O
Most O
striking O
is O
the O
replacement O
of O
two O
iron-bound O
water O
molecules O
with O
catechol B-CHEMICAL
hydroxyl I-CHEMICAL
groups. O
This O
change O
is O
consistent O
with O
a O
change O
in O
the O
ligand O
field O
symmetry O
of O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O

from O
a O
rhombic O
to O
a O
nearly O
axial O
ligand O
field O
symmetry O
as O
seen O
upon O
noradrenaline B-CHEMICAL
binding O
using O
EPR O
spectroscopy O
[Martinez, O
A., O
Andersson, O
K. O
K., O
Haavik, O
J., O
and O
Flatmark, O
T. O
(1991) O
Eur. O
J. O
Biochem. O
198, O
675-682]. O
Crystallographic O
comparison O
with O
the O
structurally O
related O
rat B-GENE-Y
tyrosine B-CHEMICAL
hydroxylase I-GENE-Y
binary O
complex O
with O
the O
oxidized O
cofactor O
7,8-dihydrobiopterin B-CHEMICAL
revealed O
overlapping O
binding O
sites O
for O
the O

catechols B-CHEMICAL
and O
the O
cofactor, O
compatible O
with O
a O
competitive O
type O
of O
inhibition O
of O
the O
catechols B-CHEMICAL
versus O
BH4. O
The O
comparison O
demonstrates O
some O
structural O
differences O
at O
the O
active O
site O
as O
the O
potential O
basis O
for O
the O
different O
substrate O
specificity O
of O
the O
two O
enzymes. O
Various O
glucocorticoids O
differ O
in O
their O
ability O
to O
induce O
gene O
expression, O
apoptosis O
and O
to O
repress O
NF-kappaB-dependent B-GENE-N
transcription. O
Glucocorticoids O
(GCs) O
influence O
a O
great O
variety O
of O
cellular O
functions O
by O
at O
least O
three O
important O
modes O
of O
action: O
the O
activation O
(or O
repression) O
of O
genes O
controlled O
by O
binding O
sites O
for O
the O

glucocorticoid B-GENE-Y
receptor I-GENE-Y
(GR), B-GENE-Y
the O
induction O
of O
apoptosis O
in O
lymphocytes O
and O
the O
recently O
discovered O
cross-talk O
to O
other O
transcription O
factors O
such O
as O
NF-kappaB. B-GENE-N
In O
this O
study O
we O
systematically O
compared O
various O
natural O
and O
synthetic O
steroid B-CHEMICAL
hormones O
frequently O
used O
as O
therapeutic O
agents O
on O
their O
ability O
to O
mediate O
these O
three O
modes O
of O
action. O
Betamethasone, B-CHEMICAL
triamcinolone, B-CHEMICAL
dexamethasone B-CHEMICAL
and O
clobetasol B-CHEMICAL
turned O
out O
to O
be O
the O
best O
inducers O
of O
gene O
expression O
and O
apoptosis. O
All O
GCs O
including O
the O
antagonistic O
compound O
RU486 B-CHEMICAL
efficiently O
reduced O

NF-kappaB-mediated B-GENE-N
transactivation O
to O
comparable O
extents, O
suggesting O
that O
ligand-induced O
nuclear O
localization O
of O
the O
GR B-GENE-Y
is O
sufficient O
for O
transrepression. O
Glucocorticoid O
treatment O
of O
cells O
did O
not O
result O
in O
elevated O
IkappaB-alpha B-GENE-Y
expression, O
but O
impaired O
the O
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
(TNF)-alpha-induced I-GENE-Y
degradation O
of O
IkappaB-alpha B-GENE-Y
without O
affecting O
DNA O
binding O
of O
NF-kappaB. B-GENE-N
The O
structural O
requirements O
for O
the O
various O
functions O
of O
glucocorticoids O
are O
discussed. O
Cooperative O
binding O
of O
ATP B-CHEMICAL
and O
MgADP B-CHEMICAL
in O
the O

sulfonylurea B-GENE-N
receptor I-GENE-N
is O
modulated O
by O
glibenclamide. B-CHEMICAL
The O
ATP-sensitive B-GENE-N
potassium I-GENE-N
(KATP) I-GENE-N
channels I-GENE-N
in O
pancreatic O
beta O
cells O
are O
critical O
in O
the O
regulation O
of O
glucose-induced B-CHEMICAL
insulin B-GENE-Y
secretion. O
Although O
electrophysiological O
studies O
provide O
clues O
to O
the O
complex O
control O
of O
KATP B-GENE-N
channels I-GENE-N
by O
ATP, B-CHEMICAL
MgADP, B-CHEMICAL
and O
pharmacological O
agents, O
the O
molecular O
mechanism O
of O
KATP-channel B-GENE-N
regulation O
remains O
unclear. O
The O
KATP B-GENE-N
channel I-GENE-N
is O
a O
heterooligomeric O
complex O
of O
SUR1 B-GENE-Y
subunits O
of O
the O
ATP-binding-cassette B-CHEMICAL
superfamily O
with O
two O

nucleotide-binding B-GENE-N
folds I-GENE-N
(NBF1 B-GENE-N
and O
NBF2) B-GENE-N
and O
the O
pore-forming O
Kir6.2 B-GENE-Y
subunits. O
Here, O
we O
report O
that O
MgATP B-CHEMICAL
and O
MgADP, B-CHEMICAL
but O
not O
the O
Mg B-CHEMICAL
salt O
of O
gamma-thio-ATP, B-CHEMICAL
stabilize O
the O
binding O
of O
prebound O
8-azido-[alpha-32P]ATP B-CHEMICAL
to O
SUR1. B-GENE-Y
Mutation O
in O
the O
Walker B-GENE-N
A I-GENE-N
and I-GENE-N
B I-GENE-N
motifs I-GENE-N
of O
NBF2 B-GENE-N
of O
SUR1 B-GENE-Y
abolished O
this O
stabilizing O
effect O
of O
MgADP. B-CHEMICAL
These O
results O
suggest O
that O
SUR1 B-GENE-Y
binds O

8-azido-ATP B-CHEMICAL
strongly O
at O
NBF1 B-GENE-N
and O
that O
MgADP, B-CHEMICAL
either O
by O
direct O
binding O
to O
NBF2 B-GENE-N
or O
by O
hydrolysis O
of O
bound O
MgATP B-CHEMICAL
at O
NBF2, B-GENE-N
stabilizes O
prebound O
8-azido-ATP B-CHEMICAL
binding O
at O
NBF1. B-GENE-N
The O
sulfonylurea B-CHEMICAL
glibenclamide I-CHEMICAL
caused O
release O
of O
prebound O
8-azido-[alpha-32P]ATP B-CHEMICAL
from O
SUR1 B-GENE-Y
in O
the O
presence O
of O
MgADP B-CHEMICAL
or O
MgATP B-CHEMICAL
in O
a O
concentration-dependent O
manner. O
This O
direct O
biochemical O
evidence O
of O
cooperative O
interaction O
in O

nucleotide B-CHEMICAL
binding O
of O
the O
two O
NBFs B-GENE-N
of O
SUR1 B-GENE-Y
suggests O
that O
glibenclamide B-CHEMICAL
both O
blocks O
this O
cooperative O
binding O
of O
ATP B-CHEMICAL
and O
MgADP B-CHEMICAL
and, O
in O
cooperation O
with O
the O
MgADP B-CHEMICAL
bound O
at O
NBF2, B-GENE-N
causes O
ATP B-CHEMICAL
to O
be O
released O
from O
NBF1. B-GENE-N
